﻿

   Table of Contents
Title Page
About this Book
Introduction
BASIC SCIENCE AND PHARMACOLOGY
A closer look at generic drugs | S Gavura
Generic Drugs: Are they Equivalent? | S Gavura
Generic Drugs: Are they different? | S Gavura
Are generic drugs equivalent to brand-name drugs? | S Gavura
What’s all that other stuff in my medicine? | S Gavura
Binders, fillers and more? What’s all that other stuff in my medicine? | S Gavura
Are those “inactive” ingredients in my medicine really inactive? | S Gavura
R&D and the High Cost of Drugs | J Thomas
Drug Interactions, Polypharmacy, and Science-Based Medicine | S Gavura
Reducing the Risk of Adverse Drug Events | H Hall
What does a new drug cost? Part II: The productivity problem | S Gavura
When Drugs Cost Too Much | H Hall
Gold mine or dumpster dive? A closer look at adverse event reports | S Gavura
The drug expiry date: A necessary safety measure, or yet another Big Pharma conspiracy? | S Gavura
Are drug expiry dates really a myth? | S Gavura
Adherence: The difference between what is, and what ought to be | S Gavura
More drugs, more supplements, and potentially more problems | S Gavura
Herbal Remedies, Street Drugs, and Pharmacology. Harriet Hall.
The Plant vs Pharmaceutical False Dichotomy. Steven Novella 
Diet Supplements or Nutritional Supplements: A Ruse by Any Other Name is Still a Ruse. Harriet Hall.
Supplements and cancer prevention | D Gorski
Weak drug regulation and patient tragedies: We’ve seen this story before | S Gavura
Natural Health Products: Loosely regulated, little evidence of benefit, and an industry intent on preserving the status quo | S Gavura
Side effects may include liver failure | S Gavura
We’re a drug-taking, supplement-taking nation. So how do we do so safely? | S Gavura
The Growing Problem of Supplement–Drug Interactions in Seniors | Science-Based Medicine
“Safe” dietary supplements can land you in the emergency room | D Gorski
What are health professionals telling consumers about dietary supplements? | S Gavura
Should you try a “natural alternative” before medication? | S Gavura
Beware the Integrative Pharmacy | S Gavura
The Elephant in the Compounding Pharmacy | H Hall
Pharmacists Selling Snakeoil | S Novella
What are “Adaptogens”? | S Novella
Alpha Brain – What’s Wrong with the Supplement Industry.Steven Novella 
A natural product of his environment. David J Kroll
Natural is not innocuous: the case of Angel’s Trumpet and tropane alkaloid intoxication. David J Kroll.
Patient Beware: Off-label drug promotion by pharmaceutical companies | J Bellamy
Commercial deception: undeclared drugs in herbs and other dietary supplements. David J Kroll
A Pattern of Deceptive Video Ads for Supplements | H Hall
Quality differences of supplements vs. drugs | S. Gavura
How to Interrogate an Herbal Medicine: Thunder God Vine. David J Kroll.
Why we don’t prescribe bark for cancer. David J Kroll
The risks of CAM: How much do we know? Scott Gavura.
What’s in your supplement? | S Gavura
Economically-Motivated Herb Adulteration David Kroll
Adulteration of Herbal Supplements Continues | S. Novella
Searching for the supplement in your supplement | S Gavura
Audit reveals supplement regulation and oversight is lacking | S Gavura
Who takes dietary supplements, and why? | S Gavura
Questions about DNA Barcoding | S Gavura
Adverse Effects from Dietary Supplements: A survey of the US Military | S Gavura
Liver Failure From Alternative Medicines | S Novella
What’s really in that sports supplement? | S Gavura
Who’s to Blame for Drug Shortages?
Drug shortages are worsening, and there are no simple solutions | S Gavura
More drug shortages due to COVID-19 | S Gavura
Yes, drug companies do pay attention to herbal medicine. David J. Kroll.
Supplements with Multiple Ingredients, Many with No Apparent Rationale | H Hall
Drugs in your supplements | S Gavura
Amazon goes where the FDA does not | S Gavura
Do pill organizers help or hurt? | S Gavura
Can DNA testing predict your response to drugs? | S Gavura
Antioxidants and Exercise: More Harm Than Good? | S Gavura
What’s in your Traditional Chinese Medicine? | S Gavura
Herbs, Supplements & Vitamins
The Supplement Con | S Novella
Widespread Use of Dietary Supplements Linked to Liver Damage | S Gavura
Andrew Weil’s Seasonal Supplements | H Hall
Dietary supplement industry says “no” to more information for consumers (again) | J Bellamy
New concerns about the safety and quality of herbal supplements | S Gavura
Where science meets supplements | S Gavura
Supplements: Still popular despite little evidence they’re useful | S Gavura
Billions on herbal remedies – and for what? | S Gavura
About Herbs: an app to avoid | M Crislip
No, the Nobel Prize does not validate naturopathy or herbalism | S Gavura
Garden of Healing | M Crislip
Vitamins and Mortality | S Novella
More evidence that routine multivitamin use should be avoided | S Gavura
US Preventive Services Task Force Recommends Against Multivitamins | S Novella
Another Negative Study of Vitamins. Steven Novella
No Benefit to Daily Multivitamin Use | S Gavura
Routine Vitamin Supplementation Mostly Useless | S Novella
Transdermal Vitamin and Wellness Patches: Hype versus Evidence | S Gavura
At Your Own Risk | J Bellamy
A closer look at vitamin injections | Science-Based Medicine
The consumer lab rat: More questions about supplement safety | S Gavura
More Trouble for Antioxidants | S Novella
Multivitamins and Vascular Disease | S Novella
Vitamins and Mortality. Steven Novella
Study of Multivitamin Use and Memory | S Novella
Prenatal Multivitamins and Iron: Not Evidence-Based | H Hall
Do vitamins prevent cancer and heart disease? | S Gavura
Cancer, vitamin supplements, and unexpected consequences | S Gavura
Vitamins and Cancer Risk | S Novella
Herbal Products and Cancer Treatment | S Novella
Do dietary supplements affect the survival of cancer patients? | S Gavura
Presidential candidate Ben Carson: Shilling for Mannatech with his very own alternative cancer cure testimonial? | D Gorsko
Supplements for Osteoarthritis – Evaluating the Evidence | S Gavura
Supplement vendors make unfounded cancer treatment claims | S Gavura
Isagenix Study Is Not Convincing | H Hall
Puritan’s Pride Vitamin Advisor Gives Questionable Advice | H Hall
Can supplements improve memory and cognition? | S Gavura
AARP report: Insufficient evidence that dietary supplements benefit brain health | J Bellamy
Do dietary supplements improve heart health? | S Gavura
Fixing the supplement market for consumers | S Gavura
A Call for Caution on Antioxidant Supplementation | J Quiles
Increase In Supplement Poisonings | S Novella
SUPPLEMENTS AND HERBS
A “Natural Cure” for Eczema Leaves a Young Child in Agony….. | C Jones
High dose vitamin C and cancer: Has Linus Pauling been vindicated? David Gorski
Vitamin C strikes (out) again. David Gorski
The effectiveness of zinc and vitamin C on the duration of COVID-19 infections | S Gavura
Vitamin E and Stroke. Steven Novella.
Vitamin E for Alzheimer’s | H Hall
Vitamin D: To Screen or Not to Screen? | H Hall
Are guidelines for calcium and vitamin D rooted in evidence, or vested interests? | S Gavura
Vitamin D shows no efficacy against moderate to severe COVID-19 infections | S Gavura
Vitamin D supplements do not reduce the risk of depression | S Gavura
Should You Take Vitamin D Supplements? | H Hall
The effects of vitamin D supplementation on major cardiac events | S Gavura
Does Vitamin D Prevent Autoimmune Disease? | H Hall
Vitamin D for the prevention of COVID-19: A randomized controlled trial | S Gavura
Vitamin D and Diabetes: Another Case Where Supplementation Sounded Like a Good Idea But Wasn’t | H Hall
Vitamin D supplements do not reduce the risk of cancer or cardiovascular disease | S Gavura
Vitamin D and the relationship to colon cancer | S Gavura
The rise and inevitable fall of Vitamin D | S Gavura
Should You Take Vitamin K With Your Vitamin D? 
If you don’t buy this supplement for your child, you’re a terrible parent | S Gavura
Vitamin K Refusal – The New Anti-Vax | S Novella
Update on Vitamin K Refusal | S Novella
K2: The Vitamin, Not the Mountain | H Hall
Vitamins are not for vaping | S Gavura
The benefits and risks of folic acid supplementation. Scott Gavura 
Faith and Supplements – B17 | S Novella
Vitamin B12 – The Energy Panacea? | S Gavura
New Cautions About Vitamin B6 and Peripheral Neuropathy | S Gavura
Macular Degeneration and AREDS 2 Supplements | H Hall
VacciShield: Pixie dust for an imaginary threat | J Snyder
Short Attention Span SBM. Mark Crislip.
Echinacea for Cold and Flu. Steven Novella.
Belief in Echinacea. Harriet Hall
Aloe Vera | H Hall
Zinc and COVID | S Gavura
Zinc for the prevention or treatment of respiratory tract infections: A new systematic review | S Gavura
Calcium supplements and heart attacks: More data, more questions | S Gavura
Magnesium: The cure to all disease? | S Gavura
Is Magnesium the Underlying Cause and Treatment for Everything? | H Hall
Magnesium oil: Not so magical | S Gavura
Maternal Fluoride and IQ – The Scientific Community Pushes Back | G Richey
Fluroide and IQ S. Novella
Maternal Fluoride and IQ | S Novella
Chromium and Fluoride – What an ‘Interesting’ Combination | C Pearcey
The Fluoride Dragon Cometh! Or does he? | C Pearcey
Iron supplements for fatigue | S Gavura
Pink Himalayan Sea Salt: An Update | H Hall
Zapping a Cold with Copper | S Novella
GLUCOSAMINE
Knee Osteoarthritis: Thumbs Down for Acupuncture and Glucosamine | H Hall
Glucosamine Update | H Hall
Does Glucosamine Really Work? Harriet Hall
Glucosamine Update: A New Study and a New Product Harriet Hall 
Glucosamine: The Unsinkable Rubber Duck. Harriet Hall.
Hyaluronic Acid Adulteration | S Gavura
Collagen: An implausible supplement for joint pain | S Gavura
Collagen Supplementation: Hype and Hope | S Gavura
New Evidence for Chondroitin | H Hall
Liver damage associate with turmeric ingestion | S Gavura
Herbal Medicine and Aristolochic Acid Nephropathy | S Novella
Bad advertising for UPGRAID | H Hall
The Hormone Myth | H Hall
Lipogen for Premenstrual Syndrome (PMS) | H Hall
Bioidentical Hormones. Harriet Hall.
Hormone Replacement Therapy. Harriet Hall
Expert review warns against compounded bioidentical hormone therapies | Science-Based Medicine
Herbal Products and Pregnancy | S Novella
Lactation cookies feed on breastfeeding anxieties | S Gavura
“Low T”: The triumph of marketing over science | D Gorski
Testing Testosterone Treatments | H Hall
Update on Testosterone Supplementation | H Hall
Testosterone: Not an Anti-Aging Panacea. Harriet Hall.
James Ray and testosterone replacement therapy (TRT). David J Kroll
What do mRNA vaccines, Synthroid, and pharmaceuticals have in common (according to MAHA)? | D Gorski
Viotren and Other Dietary Supplements for Erectile Dysfunction: Buyer Beware | H Hall
Black Cohosh and Hot Flashes. Steven Novella. 
Black Salve Still Thriving Online | S Novella
Does marshmallow root tea have medicinal benefits? | S Gavura
Scientific evidence for synergy in a botanical product. David J Kroll 
Nugenix Total T | H Hall
Stupid Videos Meet Penis Growth Scams | S Hall
The Prostate Placebo. Mark Crislip
SARMs Harms | S Gavura
MELATONIN
Melatonin for sleep disorders – Safe and effective? | S Gavura
Melatonin: What’s on the label isn’t in the bottle | S Gavura
Melatonin | H Hall
Melatonin quality varies widely | S Gavura
Melatonin poisonings in children are increasing | S Gavura
Despite safety and quality questions, melatonin use growing in children | S Gavura
An Herbal Cure for Peanut Allergy? Harriet Hall
Ginkgo biloba – No Effect. Steven Novella
St. John’s Wort for depression – A herbal remedy that works? | S Gavura
Cranberry, the alt-med zombie | S Gavura
Cranberry Juice, Revisited | S Gavura
Cinnamon for diabetes? The consequences of “natural alternatives” | S Gavura
Pycnogenol – Does maritime pine bark extract live up to the hype? | S Gavura
Biotin: Haircuts Plus Health Advice? | H Hall
Coenzyme Q10 for heart failure: The hype and the science | S Gavura
Is Kava Safe? Harriet Hall
Kava and Liver Damage | S Novella
Black Cumin – Be Skeptical | S Novella
How effectively does cinnamon treat diabetes? | S Gavura
Elderberry Elixir for the Common Cold | H Hall
Phenibut Is Neither Proven Nor Safe As A Prosocial Wonder Drug | A Campbell
Turmeric: Tasty in Curry, Questionable as Medicine | H Hall
Bee Stings for Arthritis | H Hall
Bee Venom Therapy – Grassroots Medicine. Steven Novella 
Bee Venom Therapy Update | S Novella
Bee Pollen Supplements – Not Safe or Effective | S Novella
The Beekeeper: Sentinel Chicken? | M Crislip
Honey Boo Boo | M Crislip
Honey. Mark Crislip
Are Berries the New Snake Oil? | Science-Based Medicine
A Popular Home Remedy Causes Severe Burns in Pediatric Patients | C Jones
The Annals of Internal Medicine Qualifies for Fail Blog. Mark Crislip
Testing a Chinese Herbal Flu Remedy. Harriet Hall
How To Listen to Chi | H Hall
Do calcium supplements cause heart attacks? Scott Gavura.
The latest chapter in the seemingly never-ending saga of dichloroacetate as a cancer treatment. David Gorski.
Dr. Seeds’ Chill Pills | H Hall
Product B: Here We Go Again | H Hall
Brief Update: Protandim | H Hall
Systemic Enzyme Therapy | S Gavura
MARIJUANA AND CBD
Medical Marijuana: Where is the evidence? | S Gavura
Medical marijuana as the new herbalism, part 1: Science versus the politics of weed in New York and beyond | D Gorski
Medical marijuana as the new herbalism, part 2: Cannabis does not cure cancer | D Gorski
Medical marijuana as the new herbalism, part 3: A “cannabis cures cancer” testimonial | D Gorski
Medical marijuana as the new herbalism, part 4: Cannabis for autism | D Gorski
Medical marijuana as the new herbalism, part 5: Turning herbalism into science-based medicine | D Gorski
Cannabis use and cardiovascular disease | S Gavura
Did cannabis oil save Deryn Blackwell, the “boy in seven billion,” when his bone marrow transplant for two cancers was failing? | D Gorski
Hash Oil for Gliomas? What Would You Do? Harriet Hall.
The Parasympathetic State | H Hall
CBD Oil: The new miracle cure | S Gavura
Where Are We With CBD | S Novella
How Safe is CBD? | S Novella
Cannabinoids for Acute Pain | S Novella
Avemar: Wheat Germ for Cancer | H Hall
Can it get any worse?: industrial bleach as cancer and HIV cure. David J Kroll.
Lorenzo’s Oil: Hollywood versus science | S Novella
COFFEE AND CAFFEINE
This stimulant can kill, yet you can legally buy it online. Why? | S Gavura
Caffeine Overdose Death Raises Question of Weak Regulations Across the Pond | C Jones
Go ahead, have that coffee | S Gavura
Healthy Habits Global: Spreading False Information about an MLM Coffee with Herbal Additives | H Hall
Caffeine for ADHD. Scott Gavura
The Decaf Wars | S Novella
Caffeine Withdrawal Headaches | H Hall
Ask the (Science-Based) Pharmacist: What are the benefits of coffee enemas? | S Gavura
How do you like your coffee? Rectally? | S Gavura
Lessons from the dubious rise and inevitable fall of green coffee beans | S Gavura
Dr. Oz and Green Coffee Beans – More Weight Loss Pseudoscience | S Gavura
Dr. Oz Doubles Down on Green Coffee Bean with a Made-for-TV Clinical Trial | S Gavura
The Great and Powerful Oz versus science and research ethics | D Gorski
5-hour Energy | H Hall
Lies, fraud, conflicts of interest, and bogus science: The real Dr. Oz effect | S Gavura
Kombucha: A symbiotic mix of yeast, bacteria and the naturalistic fallacy | S Gavura
Kratom – An Emerging Herbal Drug | S Novella
POM: Not So Wonderful | J Bellamy
Teenager? Anxious? Yes, there’s a supplement for that, too. | S Gavura
Fake Treatments for Fake Illnesses. Steven Novella
Help – My Doctor is a Crank! Steven Novella.
The Great Sunscreen Cover Up. Scott Gavura.
Steven Fowkes (Part 1 of 2): How to Cure Alzheimer’s and Herpes. Harriet Hall
Milk Thistle and Mushroom Poisoning. David Kroll.
Red Yeast Rice and Cholesterol | H Hall
Are “keto supplements” necessary? | S Gavura
Should Protein Powder Have a Warning Label? | C Jones
TikTok driving chlorophyll supplement fad | S Gavura
Ashwagandha – An Herbal TikTok Sensation | S Novella
Balm of Gilead | H Hall
Tag Away | H Hall
Tonaki Tinnitus Protocol | H Hall
Rightful for Pain: Deceptive Advertising and a Dangerous Ingredient | H Hall
NAD Therapy | S Gavura
Nada for NADA: “acudetox” not effective in addiction treatment | J Bellamy
Khat and Muguka Use in East Africa | S Novella
Mayim Bialik’s Neuriva Commercials Make Questionable Claims | H Hall
Procera AVH: A Pill to Restore Memory | H Hall
Bad Documentary Review: The Great Culling | B MacBeth
Another In a Pattern of Really Stupid Marketing Videos, This One Claiming Tinnitus Has Nothing to Do with the Ear and Is 100% Curable. | H Hall
Gut Check. Probiotics and Metabiome. | M Crislip
The Species in the Feces: Probiotics and the Microbiome | M Crislip
Probiotics Online | S Novella
Probiotics, revisited | S Gavura
The Trans Fat 51-Day Half-Life Myth | H Hall
dōTERRA: Multilevel Marketing of Essential Oils | H Hall
The Dr. Oz Red Palm Oil (non-) Miracle | S Gavura
No Benefit from Fish Oil | S Novella
Fish Oil Doesn’t Help Dry Eyes | S Gavura
Fake News about Fish Oil | H Hall
Essential Oils in the Ambulance | S Novella
Activated charcoal, the wellness scam | S Gavura
Green Tea: Panacea or Poison? | H Hall
Chaga Tea | H Hall
Lipo-Flavonoid for Tinnitus | H Hall
On Guard, DōTERRA, Essential Oils, and a Lesson in Reading Research Studies | H Hall
Neuriva: Clinically Proven? | H Hall
“Healthy Directions” Is a Double Misnomer | H Hall
Ellura: A Supplement Backed By Evidence | H Hall
“SuperMannan Cures Bladder Infections!” Really? | H Hall
SeroVital: Dubious Anti-Aging Claims | H Hall
The “Evidence” for Prodovite Is Junk Science | H Hall
Herbalife or Herbadeath? | H Hall
Reader’s Digest Promotes Prevagen | H Hall
Nope, Quenepa Has No Health Benefits. | A Campbell
Liver cancer, naturally | S Gavura
ASEA
ASEA: Another Expensive Way to Buy Water | H Hall
Fan Mail from an ASEA Supporter | H Hall
Accused of Lying about ASEA: Not Guilty | H Hall
ASEA, ORMUS, and Alchemy | H Hall
ASEA – Still Selling Snake Oil | S Novella
Protandim: Another Kind of Antioxidant | H Hall
Pursued by Protandim Proselytizers | H Hall
Update on ASEA, Protandim, and dōTERRA | H Hall
I Was Wrong about Protandim | H Hall
Vital Stem: Affordable Stem Cell Treatments for Everyone? Anti-Aging Breakthrough? | H Hall
Turpentine, the Fountain of Youth According to Dr. Jennifer Daniels | H Hall
Elderberry (What is it good for) | S Gavura
Plavinol and Other Natural Remedies for Diabetes: “Condimentary Medicine”? | H Hall
Natural Remedies for Diabetes: Plavinol, Glucopure | H Hall
AllerVarx: A Questionable Remedy for Allergic Rhinitis | H Hall
BrainPlus IQ: Lying with Advertising | H Hall
“Glyconutrients,” Mannatech, and Ambrotose: Marketing, Not Science | H Hall
Diatomaceous Earth? No Thank You! | H Hall
Is there a natural treatment for tinnitus? | S Gavura
Not natural, not safe: Grapefruit Seed Extract | S Gavura
The THRIVE Experience: Masterful Marketing, Short on Substance | H Hall
Medicine doesn’t come from the hardware store: Don’t drink turpentine | S Gavura
Beetroots Don’t Cure Cancer | S Novella
DMAA: Efficacious but is it Safe? | A Pavlov
Amish Farmer Jailed for Selling Snakeoil | S Novella
Oregano Snake Oil | S Novella
Creatine Supplements for Brain Function | S Novella
The peptide craze sweeping America has a fan in RFK Jr | P Knoepfler
LAW AND REGULATION
The Congressional Dietary Supplement Caucus | J Bellamy
Supplements, Lies, and a Lengthy Transcript | J Bellamy
US Department of Justice Goes After Supplements | S Novella
Don’t supplement users deserve consumer protection, too? | S Gavura
The Amarin case: off-label promotion and a double standard for prescription drugs vs. dietary supplements | J Bellamy
FDA poised to reshape the cold remedy aisle | S Gavura
FDA v. Jack3d: Round 2 | J Bellamy
FDA issues new CBD safety warnings, calls for more research to guide regulation | J Bellamy
FDA: No CBD in dietary supplements or foods for now, but let’s talk | J Bellamy
FDA promises industry-friendly “modernization” of dietary supplement regulation | J Bellamy
The FDA under MAHA control: Weakening the quack Miranda warning on supplements | D Gorski
Consumer and public health groups push for cancer warning on alcoholic beverages | J Bellamy
Utah Senator Orrin Hatch: A pit bull in defense of the supplement industry. David Gorski.
The Dietary Supplement Safety Act of 2010: A long overdue correction to the DSHEA of 1994? David Gorski
The GAO Report on Supplement Regulation. Steven Novella
CAM and the Law Part 4: Regulation of Supplements and Homeopathic Remedies. Brennen McKenzie 
Supplements are the Wild West of health. One Attorney General is out to change that. | S Gavura
Supplement Regulation: Be Careful What You Wish For. Scott Gavura.
Holding the supplement industry to account: Can we learn from tobacco regulation? | S Gavura
CAM Docket: Kardashian Diet Products Klass Action | J Bellamy
European Union “Ban” On Herbal Products. Steven Novella. 
FDA Decision on Oleandra | S Novella
Airborne Settles Case On False Advertising. Steven Novella 
FDA Zicam Warning. Steven Novella.
What does a new drug cost? Scott Gavura.
Chelation: Compounding Pharmacy’s Problems. Scott Gavura.
The Truth vs. Alex Jones: How the DSHEA of 1994 gave conspiracy mongers the means to fund their empires | D Gorski
Pandemic drives huge surge in herbal remedy sales | S Gavura
Facebook promoting dangerous and even banned supplements | S Gavura
Science-Based Medicine Reviews: Herbs, Supplements and Vitamins
A Critical Guide for the Health Practitioner and Consumer 
2025 Edition

Executive Editor Steven Novella MD
Managing Editor David Gorski MD PhD
Series Editor Mark Crislip MD

About This Book

As of 2025, there are over 5000 essays on the Science Based Medicine website. I do no know about you, but I find it difficult to find any post I wrote, much less one written by another contributor. 

So I have updated the books and include almost all the articles through 2025. The volumes are

CAM Concepts
Chiropractic
COVID 
Critical Thinking
Diet and Nutrition
Ethics and CAM
Herbs, Supplements, and Diet
Homeopathy
Infections and Immunity
Law and CAM
Media and Internet
Medicine, Public Health, Dentistry and Pediatrics
Miscellaneous CAM
Naturopathy
Neurology and Psychiatry
Placebo
Quackademic Medicine
Regulation. FDA and FTC
SBM or EBM
Stem Cells, Genetics, AI and Gender
Supplements, Vitamins and Herbs
Vaccine & Anivax
Vaccines and Autism
Vaccines and Preventable Infections
The articles are roughly organized by publication date and topic. Many articles will be in multiple volumes as an essay of, for example, chiropractic and law will be found in both the chiropractic volume and the law volume.
You may find the organization a bit odd. I do. But 5000 plus articles are difficult to organize and I have more to do in my retirement than work of these volumes.
Still, if you find I have missed a nentry or some glaring error, drop me a note and I will fix it for the next edition.

About the authors
Steven P. Novella, MD – Founder and Executive Editor Science Based Medicine.
Founder and currently Executive Editor of Science-Based Medicine Steven Novella, MD.
David H. Gorski, MD, PhD – Managing Editor. Science Based Medicine.
Mark A. Crislip, MD. Editor, Science Based Medicine Guides. 
He did he editing of all the volumes so is to blame for any mistakes.
As to all the other contributors, if you are interested click on the ‘Link’ at top of each essay to go the SBM site, where further information about each author can be found.
A Note On References
The chapters in this book were originally blog entries at ScienceBasedMedicine.org.
Blog and web pages lend themselves to hyperlinks to sources and references that are tedious to translate into footnotes for this ebook.
Under the title of each essay is a hyperlink, cleverly titled ‘Link’, to the original blog entry with all the hyperlinks and references, as well as the comments to the blogs, which often have interesting and thoughtful insights by our readers, as well as some curious comments by the not so thoughtful.
Graphs, tables and links to videos are not in included these essays due to issues of copyright and permission. However, thanks to the ‘Link’, the graphics are a click away.
Thanks for reading the site.
Mark Crislip 


   Introduction 
Steven Novella
The world of health care is becoming an increasingly complex and challenging place. The internet is changing the way we generate and access information, and health information is one of the most popular uses of the internet. It represents an unprecedented democratization of information and opinion. 
While there are many advantages and benefits to such information access, there are also many challenges to health professionals, regulators, academics, and consumers. There is a proliferation of health related products and services, with many provocative health claims. Regulations are generally not keeping up, and often have been watered down, in the face of this onslaught of claims and products. 
The consumer is left with an overwhelming array of health claims, many of which challenge and even directly oppose the traditional experts and institutions. 
The mission of Science-Based Medicine (SBM) is to be a source of reliable information and analysis to help navigate the wild west of health information on the internet and elsewhere. The authors who contribute to this series of e-books are all physicians and other health care professionals who have a great deal of experience educating the public about complex medical issues. We especially take on controversial issues and try to expose pseudoscience and fraud wherever possible.
The Philosophy of Science-Based Medicine
The philosophy of SBM, at its core, is simple: Safe and effective health care is critical to everyone’s quality of life; so much so that it is generally considered a basic human right. Therefore, health care products and services that work and are safe are better than those that do not work or are unsafe. 
The best method for determining which interventions and health products are safe and effective is, without question, good science. Therefore it is in everyone’s best interest for health care to be systematically evaluated by the best science available.
Too often the nature of science itself is misunderstood or misrepresented to the public. Science is not an arcane and privileged discipline. By its very nature it is meant to be transparent and public. Science is nothing more than a systematic and careful use of evidence and logic to evaluate factual claims. And good science possesses certain virtues that are not unique to science but generic to all intellectual endeavors: fairly accounting for all available evidence, using valid and internally consistent logic, using unambiguous concepts and language, proper use of statistics, being quantitatively precise and accurate, and above all being honest.
And yet there are numerous and powerful influences in society that strongly appose the scientific basis of medicine. Driven by some combination of ideology or the desire for profit they wish to eliminate standards of science in health care, or (often under the guise of “health care freedom”) create a double standard in which unscientific methods and products can thrive unchecked. Others simply lack the training or knowledge to achieve minimal standards of quality for scientific medicine. And even the best traditions of scientific medicine can benefit from more critical analysis.
Recognition of the need for careful scientific analysis in medicine partly stems from a recognition that it is very difficult (almost impossible) to reliably assess treatments anecdotally. Human perception, memory, and cognition are prone to a host of flaws, weaknesses, and biases that will tend to mislead us, especially towards conclusions that we wish to be true. Placebo effects, confirmation bias, and simple statistics can make any intervention seem effective, even when they are worthless or harmful. 
Science-Based Medicine vs Evidence-Based Medicine
Within the practice of medicine there is already a recognition of the need to raise the standards of evidence and the availability of the best evidence to the practitioner and the consumer – formalized in the movement known as evidence-based medicine (EBM). 
EBM is a vital and positive influence on the practice of medicine, but it has its limitations. EBM tends to focus on clinical trial results to the exclusion of scientific plausibility. The focus on trial results (which, in the EBM lexicon, is what is meant by “evidence”) has its utility, but fails to properly deal with medical modalities that are highly implausible, or seem to defy well-established findings in science.
All of science describes the same reality, and therefore it must (if it is functioning properly) all be mutually compatible. Collectively, science builds one cumulative model of the natural world. This means we can make rational judgments about what is likely to be true based upon what is already well established. This does not necessarily equate to rejecting new ideas out-of-hand, but rather to adjusting the threshold of evidence required to establish a new claim based upon the prior scientific plausibility of the new claim. Failure to do so leads to conclusions and recommendations that are not reliable, and therefore medical practices that are probably not safe and effective.
The SBM Series
This is why the authors of this series strongly advocate for science based medicine – the use of the best scientific evidence available, in the light of our cumulative scientific knowledge from all relevant disciplines, in evaluating health claims, practices, and products. 
Some of the articles here will analyze individual studies, and explore the strengths and weaknesses of their methods, separating what the study really tells us from how it may be represented in the media. Other articles will summarize what many studies tell us about a specific medical question. 
We will also explore health information on the internet, separating out which information is reliable from that which is misleading, erroneous, or possibly even fraudulent. Likewise we will critique mainstream media coverage of health topics, giving the reader specific tools for to critically analyze health information for themselves.
Other articles will explore topics related to health regulation and academia. Regulations have struggled to keep up with the rapidly changing health care market place, with critical gaps that leave the health care consumer responsible for their own protection. Academic institutions themselves, long the defenders of high standards of scholarship in all fields, including medicine, have been infiltrated by promoters of pseudoscientific belief systems. The result is that there is no longer any single reliable guarantee of scientific integrity. 
The SBM series of e-books is organized by topic, such as acupuncture, chiropractic, homeopathy, and many others. The books are collections of essays, not intended to be a systematic reference, but rather to explore the various scientific issues related to each topic. The goal is to give the reader critical thinking skills and a deeper understanding of, not just the current findings of science, but the process of science, specifically how it relates to health care and the topic of each book. 
Science-based medicine can serve as your pocket guide through the wilderness of health information..

   Basic Science and Pharmacology

A closer look at generic drugs
In the struggle to contain growing healthcare costs, generic drugs have the potential to save millions. What gives us confidence they are equivalent to brand-name drugs?
Scott Gavura om June 1, 2017
Link
While Scott Gavura’s taking a break from blogging, here’s a slightly refreshed old post from 2012 many of you may not have seen.
With healthcare costs continuing to rise, generic drugs are looking more attractive than ever. The prospect of getting the same drug at a lower cost is tempting to anyone with a large drug bill — patient or insurer alike. The savings to insurers and individuals are massive: prices can drop by 90% or more, almost overnight. In 2012, Plavix and Seroquel, two other blockbusters, lost patent protection too — with just two drugs, it was estimated there would be $10 billion in health care savings created. A “patent cliff” that existed several years ago was expected to shrivel about $255 billion in worldwide patented drug sales over the following five years. If you’re taking a prescription drug and not already on a generic version, you may be in the future.
Pharmacists are responsible for most of the prescription switches from brand to generic drugs. It depends on the state or province, but in some cases generics may be automatically substituted — that is, switched without patient or prescriber consent. Misconceptions are common, ranging from manufacturing standards (“lax standards!”) to efficacy (“the drugs don’t work!”). So today’s post is an overview of the science of evaluating generic drugs. Specifically, I want to review the concept of bioequivalence, the confirmation of which assures us of the interchangeability of different drugs — that is, one can be substituted for another.
What is a generic drug?
What is referred to as a “generic” drug may vary by country, and be influenced by both medical practice and by regulatory requirements. The most common definition is that used by the World Health Organization:
A generic drug is a pharmaceutical product, usually intended to be interchangeable with an innovator product, that is manufactured without a licence from the innovator company and marketed after the expiry date of the patent or other exclusive rights.
Generic products may also be called “multisource” products. And you’ll often see a drug’s chemical name referred to as the “generic name” or the “non-proprietary” name, which as I’ve described can lead to confusion among consumers who may only know their prescription by the brand name alone.
The active pharmaceutical ingredient
To understand the scientific basis of generic drug evaluations, it’s necessary to understand some key concepts. The first one is the active pharmaceutical ingredient or API. In Lipitor, for example, the API is atorvastatin, or to use its full chemical name, (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate. The API is the chemical that has the desired biological effect. There may be a dozen ingredients in a tablet, for example, but the API is the ingredient we’re interested in. It’s the API that will allow us to generalize data and studies with the drug, linking the original bench science and preclinical research, to the tablet dispensed by the pharmacy — it’s the same chemical. The fact that drugs have an API allows generic drugs to be marketed, because when we compare generics, the API is the same. In contrast, consider the scenario of an herbal remedy. A single tablet of 100mg of a raw herb might contain hundreds of different chemicals. If there is no known API or standardized active ingredient, we cannot compare between brands, or assume that clinical trials with one brand are relevant to any other product, because we have no idea which ingredient is actually having an effect, and if any other version has that same ingredient (or combination of ingredients.) That’s why understanding the active components in herbal medicines is so important.
Bioavailability
Most dosage forms (e.g., tablets and capsules) are designed to deliver the API to the site of action. Unless it’s a drug that acts directly on the lining of the gastrointestinal tract, we rely on the circulatory system to carry the drug to the site of action in the body. Bioavailability refers to the amount of drug that, once ingested, reaches the bloodstream. Bioavailability is evaluated based on two measures — the rate of absorption, and the extent of absorption:

(source)
Look at this graph carefully. Let’s assume a dose of a drug is taken by mouth at time=0. A dosage form, such as a tablet, needs to disintegrate, and then the API needs to dissolve. It then must be absorbed through the gastrointestinal tract, where it will move into in the blood. Sequential blood samples are taken (say, every 30 minutes) and measured for the concentration of the drug. The point measurements are then connected, resulting in the smooth line you see. At first, the drug is absorbed rapidly, peaking at concentration Cmax at time tmax. The drug then starts to be eliminated from the blood — it could be metabolized, perhaps by the liver, and/or be filtered out of the circulation, by the kidneys. We’re then able to calculate the rate of absorption, described by Cmax/tmax, and the total extent of absorption and exposure in the body, which is the area under the curve (AUC).
Studying the physiological actions of the API, and relating it to the concentration time profile allows us to understand if there is a maximum tolerated concentration (MTC) and if there’s a certain blood concentration where the drug’s action seems to start and wear off, termed the minimum effective concentration (MEC). These values are estimates, based on the understanding that there is a relationship between the drug’s concentration in the bloodstream, and the amount of that same drug at the site of action in the body. These measures will guide how the drug is eventually manufactured: We want each dose to predictably and reliably follow the same curve. That means standard production methods, and the use of fillers, diluents and other excipients, all of which serve to ensure that there is little to no variation tablet-to-tablet or dose-to-dose. This is done with the intention of also minimizing interpatient variability, which is the variation seen between different patients given the same dosage form.
There may be other ways that the formulation can be varied. When the MEC is very close to the MTC, greater precision in per-tablet accuracy may be necessary. Further, we can vary shape of the curve, by doing things like enteric-coating the tablet, or making a sustained-release version that releases the API more slowly. The final absorption curve of any pharmaceutical preparation will be a product of both the physical characteristics of the drug (i.e., its intrinsic chemical properties) and the dosage form (i.e., the pharmaceutical properties).
Generic manufacturers that want to duplicate a drug coming off patent then have a few challenges. First, manufacture the complicate chemical structure that is the API (or find someone else who can make it for you). Second, package it in a dosage form that resembles the patented drug. Third, show that the new generic shares the same absorption curve as the branded version. That is, they must show that two product are bioequivalent.
Bioequivalence
We now want to compare a branded drug, one that’s been on the market for years, with a new generic. There is a single fundamental assumption that underlies the comparison:
Two products are considered equivalent when the rate and extent of absorption of the generic drug does not show a significant different from the rate and extent of absorption of the brand drug, when administered at the same dose under similar experimental conditions.
So let’s unpack this. We don’t need to know if the tablets look alike, or have different fillers. We also don’t need to do clinical trials with the generic drug. If we can demonstrate that the API is absorbed at the same rate and extent as the brand drug, then we can declare two products to be bioequivalent. That is, taking one or the other results in the same “body exposure” to the same drug. Assume we want to compare Drug A and Drug B. We will take a group of normal, healthy adults and put them in standardized conditions — usually fasting overnight and then giving a drug on an empty stomach or with a standardized meal. We’ll give Drug A to a patient, take serial blood samples, and then calculate Cmax/tmax and AUC. Later, after the drug has been fully eliminated from the body, we’ll repeat the process in the same patient, under the same conditions, with drug B. This may be done in 20+ patients. We’ll get a graph that looks like this:

(source)
Are the two curves super-imposable? Not quite, in this example. There are slight differences in the extent of absorption. Are these two drugs bioequivalent? Here’s where the statistics come in. We apply statistics to evaluate if the curves are meaningfully different. To do this, we need to make some assumptions about what we will accept as a meaningful difference. Does a slight difference in the rate or extent of absorption make a clinical difference? Most regulators worldwide have decided that a 20% variation is generally not clinically significant.
Two versions of a drug are generally said to be bioequivalent if the 90% confidence intervals for the ratios of the geometric means (brand vs. generic) of the AUC and Cmax fall within 80% and 125%. The tmax (brand vs. generic) must also be comparable — and there should not be any significant differences between different patients.
For practical purposes, generic versions of branded drugs have AUC and Cmax ratios that are very close to one. With significant variation in either value, it would be unlikely for the confidence intervals to lie within the 80% to 125% range. For the sake of keeping this post short I’ll leave a more detailed discussion of the statistics to the interested reader.
Myths, misconceptions, and controversies
Generic drugs are manufactured differently from branded drugs, and branded drug manufacturers use better processes
If the dosage form releases the same drug with the same concentration/time profile, then any minor manufacturing differences are irrelevant to the pharmacological activity. Regulators have established standardized manufacturing practices and standards, termed good manufacturing practices, that all manufacturers, brand or generic, must adhere to. Final products must meet the same product quality standards as well.
Biosimilars aren’t generics
Biosimilars refers to follow-on versions of antibodies, proteins and other patented biological drugs, like growth hormones. Biological drugs are very large molecules that are structurally more complex that the relatively simple, smaller molecules in most tablets and injections. Their complexity means that a simple bioequivalence evaluations may be insufficient to fully describe a drug’s action. Manufacturing processes may involve recombinant DNA technology, and can take place inside living cells, leading to a final dosage form which cannot be fully characterized as a single defined API. As some of the biologic drugs approved over the past few decades have lost patent protection, the act of verifying both pharmaceutical but also clinical equivalence of “generic” biologicals has become an evaluation challenge for regulators. So if they’re not completely bioequivalent, do they have the same effects in patients? That is, are they clinically and therapeutically equivalent? While approaches between countries may vary, many are being cautious and requiring more detailed comparisons, including clinical safety and efficacy trials to demonstrate that biosimilars have the same end effects. As regulators gain more experience evaluating these products, expect the testing standards to evolve. (There’s good information for health professionals and consumers prepared by the Canadian Agency for Drugs and Technologies in Health which provides more detail on the current evaluation process.)
Bioequivalence studies are always necessary to establish interchangeability
For some dosage forms, bioequivalence studies may be inappropriate or impractical. Consider ophthalmic eyedrops. These products are administered at the site of action, and don’t rely on systemic absorption. It may be more appropriate to verify equivalence by comparing physicochemical properties including pH, viscosity, and osmolarity/osmolality. Where all relevant parameters are evaluated to be comparable, regulators will deem generic versions interchangeable based on these parameters alone.
Generics need to be tested in sick patients, not healthy volunteers
The intent of a bioequivalence comparison is to determine the differences in formulation between two drug products. Healthy standardized volunteers are used in bioequivalence studies to control for patient differences, meaning that any differences in bioavailability will be the result of drug formulation issues, not patient issues. In order to isolate drug formulation effects, it is necessary to hold everything else as constant as possible. If formulations are consistent, the rate and extent of drug absorption will not differ, and consequently there should be no differences in the pharmacologic effects of the drugs.
I absolutely can’t take a generic version of my prescription
Patented drug manufacturers usually aren’t willing to sacrifice their entire market share to generic competitors. Some will start producing “generic” versions of their own drug, selling them to a partner or subsidiary who will sell them as an “ultrageneric”. So in many cases, at least one of the generic versions that’s marketed will be truly identical (except perhaps for markings) to the branded products. Now if you think this means people won’t occasionally identify the switch as the source of efficacy issues or side effects, my anecdotal experience says otherwise.
I had a negative reaction (e.g., more side effects) to the generic
There are no requirements for generic drugs to contain the same non-medicinal ingredients as the brand-name drug, so allergic reactions to generic versions of drugs are possible. Most of the excipients are generally inert but there have been suggestions that serious allergies may rarely affect some patients. However, complaints about intolerance in the absence of a true allergic response or documented allergy could also be nocebo effects, negative symptoms elicited by negative expectations from the patient.
Bioequivalence testing isn’t an accepted evaluation method
It’s not just generic companies that must do bioequivalence studies. The company that owns the patent may need to do the same studies. Any changes to the dosage form either during development, or after marketing the product, may necessitate bioequivalence studies to demonstrate that changes do not meaningfully alter the concentration-time curve. So if the clinical trial was with a capsule, and the final marketed product is a tablet, a bioequivalence study comparing the two may be necessary. This reassures regulators that the clinical trials continue to be relevant and applicable to the new dosage form.
I don’t care what you say, the drugs are not equivalent in the real world
The Medical Letter recently summarized some studies that have evaluated the clinical effects of generic substitution:
    • A systematic review of 47 studies that compared cardiovascular drugs found no evidence that brand-name drugs were superior with respect to clinical outcomes.
    • An RCT comparing a brand antibiotic vs. a generic antibiotic found no differences in clinical effects.
    • The FDA conducted its own evaluation of proton pump inhibitors (e.g., Prilosec/Losec). All five generics met dissolution standards.
    • Levothyroxine as an API is unstable, and the FDA recently tightened manufacturing standards for all versions. There are no well-documented cases of therapeutic inequivalence between brands deemed to be bioequivalent. Most health professionals still recommend using a consistent brand, however.
    • Retrospective case-control studies with anti-epileptic drugs have yielded some data suggestive of therapeutic inequivalence. Given the limits of these studies (patients who have switched brands may differ in some way from those that did not switch), the data are not conclusive. Clinically, most health professionals are cautious when switching to generic antiepileptic drugs.
Conclusion: Bioequivalence testing ensures safe, effective generics
The science of bioequivalence evaluations for generics has been in place in most countries for more than 20 years with an established track record of therapeutic equivalence. These evaluation methods have been so successful in establishing generic drug standards that they are largely consistent between all of the major drug regulators worldwide. Consumers and health professionals alike can be reassured that generic drugs approved under these regulatory frameworks are indeed bioequivalent, and therefore, interchangeable with brand name products.

Generic Drugs: Are they Equivalent?
Scott Gavura on January 5, 2012
Link
With healthcare costs continuing to rise, generic drugs are looking more attractive than ever. The prospect of getting the same drug at a lower cost is tempting to anyone with a large drug bill — patient or insurer alike. The savings are massive: Lipitor lost patent protection last month — it was a $10 billion drug, and the generic versions are priced at a fraction of the original cost. In 2012, Plavix and Seroquel, two other blockbusters, will lose patent protection too — that’s another $10 billion in drug costs that will shrink. This “patent cliff” will shrivel about $255 billion in worldwide patented drug sales over the next five years. If you’re taking a prescription drug and not already on a generic, you probably will be soon. And depending on where you live, you may be automatically switched to a generic version of your prescription drug as soon as it’s available.
Pharmacists are responsible for most of the switches from brand to generic drugs. In Ontario, where I work, regulations specify which drugs and brands may be automatically substituted — that is, without patient or prescriber consent. This doesn’t mean a lack of transparency, however, so I spend a lot of time speaking with patients about generic drugs. Misconceptions are common, ranging from manufacturing standards (“they’re weaker!”) to efficacy (“the drugs don’t work!”). I’ve seen a number of questions and comments about generic drugs in the comments section here at SBM as well. So today’s post is an overview of the science of evaluating generic drugs. Specifically, I want to review the concept of bioequivalence, the confirmation of which assures us of the interchangeability of different drugs — that is, one can be substituted for another.
What is a generic drug?
What is referred to as a “generic” drug may vary by country, and be influenced by both medical practice and by regulatory requirements. The most common definition is that used by the World Health Organization:
A generic drug is a pharmaceutical product, usually intended to be interchangeable with an innovator product, that is manufactured without a licence from the innovator company and marketed after the expiry date of the patent or other exclusive rights.
Generic products may also be called “multisource” products. And you’ll often see a drug’s chemical name referred to as the “generic name” or the “non-proprietary” name, which I’ve described can lead to confusion among consumers who may only know their prescription by the brand name alone.
The Active Pharmaceutical Ingredient
To understand the scientific basis of generic drug evaluations, it’s necessary to understand some key concepts. The first one is the active pharmaceutical ingredient or API. In Lipitor, for example, the API is atorvastatin, or to use its full chemical name, (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate. The API is the chemical that has the desired biological effect. There may be a dozen ingredients in a tablet, for example, but the API is the ingredient we’re interested in. It’s the API that will allow us to generalize data and studies with the drug, linking the original bench science and preclinical research, to the tablet dispensed by the pharmacy — it’s the same chemical. The fact that drugs have an API allows generic drugs to be marketed, because when we compare generics, the API is the same. In contrast, consider the scenario of an herbal remedy. A single tablet of 100mg of a raw herb might contain hundreds of different chemicals. If there is no known API or standardized active ingredient, we cannot compare between brands, or assume that clinical trials with one brand are relevant to any other product, because we have no idea which ingredient is actually having an effect, and if any other version has that same ingredient (or combination of ingredients.)
Bioavailability
Most dosage forms (e.g., tablets and capsules) are designed to deliver the API to the site of action. Unless it’s a drug that acts directly on the lining of the gastrointestinal tract, we rely on the circulatory system to carry the drug to the site of action in the body. Bioavailability refers to the amount of drug that, once ingested, reaches the bloodstream. Bioavailability is evaluated based on two measures — the rate of absorption, and the extent of absorption:

(source)
Look at this graph carefully. Let’s assume a dose of a drug is taken by mouth at time=0. A dosage form, such as a tablet, needs to disintegrate, and then the API needs to dissolve. It then must be absorbed through the gastrointestinal tract, where it will move into in the blood. Sequential blood samples are taken (say, every 30 minutes) and measured for the concentration of the drug. The point measurements are then connected, resulting in the smooth line you see. At first, the drug is absorbed rapidly, peaking at concentration Cmax at time tmax. The drug then starts to be eliminated from the blood — it could be metabolized, perhaps by the liver, and/or be filtered out of the circulation, by the kidneys. We’re then able to calculate the rate of absorption, described by Cmax/tmax, and the total extent of absorption, which is the area under the curve (AUC), calculated using integral calculus.
Studying the physiological actions of the API, and relating it to the concentration time profile allows us to understand if there is a maximum tolerated concentration (MTC) and if there’s a certain blood concentration where the drug’s action seems to start and wear off, termed the minimum effective concentration (MEC). These values are estimates, based on the understanding that there is a relationship between the drug’s concentration in the bloodstream, and the amount of that same drug at the site of action in the body. These measures will guide how the drug is eventually manufactured: We want each dose to predictably and reliably follow the same curve. That means standard production methods, and the use of fillers, diluents and other excipients, all of which serve to ensure that there is little to no variation tablet-to-tablet or dose-to-dose. This is done with the intention of also minimizing interpatient variability, which is the variation seen between different patients given the same dosage form.
There may be other ways that the formulation can be varied. When the MEC is very close to the MTC, greater precision in per-tablet accuracy may be necessary. Further, we can vary shape of the curve, by doing things like enteric-coating the tablet, or making a sustained-release version that releases the API more slowly. The final absorption curve of any pharmaceutical preparation will be a product of both the physical characteristics of the drug (i.e., the intrinsic chemical properties) and the dosage form (i.e., the pharmaceutical properties).
Generic manufacturers that want to duplicate a drug coming off patent then have a few challenges. First, manufacture the complicate chemical structure that is the API (or find someone else who can make it for you). Second, package it in a dosage form that resembles the patented drug. Third, show that the new generic shares the same absorption curve as the branded version. That is, they must show that two product are bioequivalent.
Bioequivalence
We now want to compare a branded drug, one that’s been on the market for years, with a new generic. There is a single fundamental assumption that underlies the comparison:
Two products are considered equivalent when the rate and extent of absorption of the generic drug does not show a significant different from the rate and extent of absorption of the brand drug, when administered at the same dose under similar experimental conditions.
So let’s unpack this. We don’t need to know if the tablets look alike, or have different fillers. We also don’t need to do clinical trials with the generic drug. If we can demonstrate that the API is absorbed at the same rate and extent as the brand drug, then we can declare two products to be bioequivalent. That is, taking one or the other results in the same “body exposure” to the same drug. Assume we want to compare Drug A and Drug B. We will take a group of normal, healthy adults and put them in standardized conditions — usually fasting overnight and then giving a drug on a empty stomach or with a standardized meal. We’ll give Drug A to a patient, take serial blood samples, and then calculate Cmax/tmax and AUC. Later, after the drug has been fully eliminated from the body, we’ll repeat the process in the same patient, under the same conditions, with drug B. This may be done in 20+ patients. We’ll get a graph that looks like this:

(source)
Are the two curves super-imposable? Not quite, in this example. There are slight differences in the extent of absorption. Are these two drugs bioequivalent? Here’s where the statistics come in. We apply statistics to evaluate if the curves are meaningfully different. To do this, we need to make some assumptions about what we will accept as a meaningful difference. Does a slight difference in the rate or extent of absorption make a clinical difference? Most regulators worldwide have decided that a 20% variation is generally not clinically significant.
Two versions of a drug are generally said to be bioequivalent if the 90% confidence intervals for the ratios of the geometric means (brand vs. generic) of the AUC and Cmax fall within 80% and 125%. The tmax (brand vs. generic) must also be comparable — and there should not be any significant differences between different patients.
For practical purposes, generic versions of branded drugs have AUC and Cmax ratios that are very close to one. With significant variation in either value, it would be unlikely for the confidence intervals to lie withing the 80% to 125% range. For the sake of keeping this post short I’ll leave a more detailed discussion of the statistics to the interested reader.
Myths, Misconceptions, and Controversies
Generic drugs are manufactured differently from branded drugs, and branded drug manufacturers use better processes
If the dosage form releases the same drug with the same concentration/time profile, then any minor manufacturing differences are irrelevant to the pharmacological activity. Regulators have established standardized manufacturing practices and standards, termed good manufacturing practices, that all manufacturers, brand or generic, must adhere to. Final products must meet the same product quality standards as well.
Biosimilars are bioequivalent
Biosimilars refers to follow-on versions of antibodies, proteins and other patented biological drugs, like growth hormones. Biological drugs are very large molecules that are structurally more complex that the relatively simple, smaller molecules in most tablets and injections. Their complexity means that a simple bioequivalence evaluations may be insufficient to fully describe a drug’s action. Manufacturing processes may involve recombinant DNA technology, and can take place inside living cells, leading to a final dosage form which cannot be fully characterized as a single defined API. As some of the biologic drugs approved over the past few decades have lost patent protection, the challenge of verifying both pharmaceutical but also clinical equivalence of “generic” biologicals has become an evaluation challenge for regulators. So if they’re not completely bioequivalent, do they have the same effects in patients? That is, are they clinically and therapeutically equivalent? While approaches between countries may vary, many are being cautious and requiring more detailed comparisons, including clinical safety and efficacy trials to adequately demonstrate that “generic” versions of biologic drugs have the same end effects. As regulators gain more experience evaluating these products, expect the testing standards to evolve.
Bioequivalence studies are always necessary to establish interchangeability
For some dosage forms, bioequivalence studies may be inappropriate or impractical. Consider ophthalmic eyedrops. These products are administered at the site of action, and don’t rely on systemic absorption. It may be more appropriate to verify equivalence by comparing physicochemical properties including pH, viscosity, and osmolarity/osmolality. Where all relevant parameters are evaluated to be comparable, regulators will deem generic versions interchangeable based on these parameter alone.
Generics need to be tested in sick patients, not healthy volunteers
The intent of a bioequivalence comparison is to determine the differences in formulation between two drug products. Healthy standardized volunteers are used in bioequivalence studies to control for patient differences, meaning that any differences in bioavailability will be the result of drug formulation issues, not patient issues. In order to isolate drug formulation effects, it is necessary to hold everything else as constant as possible. If formulations are consistent, the rate and extent of drug absorption will not differ, and consequently there should be no differences in the pharmacologic effects of the drugs.
I absolutely can’t take a generic version of my prescription
Patented drug manufacturers usually aren’t willing to sacrifice their entire market share to generic competitors. Some will start producing “generic” versions of their own drug, selling them to a partner or subsidiary who will sell them as an “ultrageneric”. So in many cases, at least one of the generic versions that’s marketed will be truly identical (except perhaps for markings) to the branded products. Now if you think this means people won’t occasionally identify the switch as the source of efficacy issues or side effects, my anecdotal experience says otherwise.
I had a negative reaction (e.g., more side effects) to the generic
There are no requirements for generic drugs to contain the same non-medicinal ingredients as the brand-name drug, so allergic reactions are not impossible. Most of the excipients are generally inert but there have been suggestions that serious allergies may rarely affect some patients. However, complaints about intolerance in the absence of a true allergic response or documented allergy could also be nocebo effects, negative symptoms elicited by negative expectations from the patient.
Bioequivalence testing isn’t an accepted evaluation method
It’s not just generic companies that must do bioequivalence studies. The company that owns the patent may need to do the same studies. Any changes to the dosage form either during development, or after marketing the product, may necessitate bioequivalence studies to demonstrate that changes do not meaningfully alter the concentration-time curve. So if the clinical trial was with a capsule, and the final marketed product is a tablet, a bioequivalence study comparing the two may be necessary. This reassures regulators that the clinical trials continue to be relevant and applicable to the new dosage form.
I don’t care what you say, the drugs are not equivalent in the real world
The Medical Letter recently summarized some studies that have evaluated the clinical effects of generic substitution:
    • A systematic review of 47 studies that compared cardiovascular drugs found no evidence that brand-name drugs were superior with respect to clinical outcomes.
    • An RCT comparing a brand antibiotic vs. a generic antibiotic found no differences in clinical effects.
    • The FDA conducted its own evaluation of proton pump inhibitors (e.g., Prilosec/Losec). All five generics met dissolution standards.
    • Levothyroxine as an API is unstable, and the FDA recently tightened manufacturing standards for all versions. There are no well-documented cases of therapeutic inequivalence between brands deemed to be bioequivalent. Most health professionals still recommend using a consistent brand, however.
    • Retrospective case-control studies with anti-epileptic drugs have yielded some data suggestive of therapeutic inequivalence. Given the limits of these studies (patients who have switched brands may differ in some way from those that did not switch), the data are not conclusive. Clinically, most health professionals are cautious when switching to generic antiepileptic drugs.
Conclusion
The science of bioequivalence evaluations for generics has been in place in most countries for more that 20 years with an established track record of therapeutic equivalence. These evaluation methods have been so successful in establishing generic drug standards that they are largely consistent between all of the major drug regulators worldwide. Consumers and health professionals alike can be reassured that generic drugs approved under these regulatory frameworks are indeed bioequivalent, and therefore, interchangeable with brand name products.

Generic Drugs: Are they different?
Standards in place for generic drugs should give consumers confidence that these products are just as effective as their brand-name equivalent.
Scott Gavura on May 23, 2024
Link

The following is a post lightly updated from 2011. If you’ve seen it before, then thank you for following the blog for so long! New posts are coming soon!
With healthcare costs continuing to rise, generic drugs look attractive to anyone with a large drug bill. The savings can be massive: When Liptor, a cardiovascular drug, lost patent protection, it was $10 billion drug – and generic versions emerged, priced at a fraction of the original cost. If you’re taking an oral prescription drug and not already on a generic, you may be in the future. And depending on where you live, and the type of drug plan you have, you may be automatically switched to a generic version of your prescription drug as soon as it’s available.
Pharmacists are responsible for most of the switches from brand to generic drugs. Regulations generally specify which drugs and brands may be automatically substituted — that is, without patient or prescriber consent. Many patients can be understandably concerned about switching to a generic, especially if they are doing well on a brand-name drug and have been stable for some time. Misconceptions are common, ranging from manufacturing standards (“they’re weaker!”) to efficacy (“the drugs don’t work!”). Today’s post is a short summary of the science of evaluating generic drugs. Specifically, I want to review the concept of bioequivalence, the confirmation of which assures us of the interchangeability of different drugs — that is, one can be substituted for another.
What is a generic drug?
What is referred to as a “generic” drug may vary by country, and be influenced by both medical practice and by regulatory requirements. A common definition is that used by the World Health Organization:
A generic drug is a pharmaceutical product, usually intended to be interchangeable with an innovator product, that is manufactured without a licence from the innovator company and marketed after the expiry date of the patent or other exclusive rights.
Generic products may also be called “multisource” products. And you’ll often see a drug’s chemical name referred to as the “generic name” or the “non-proprietary” name, which I’ve described can lead to confusion among consumers who may only know their prescription by the brand name alone.
The Active Pharmaceutical Ingredient
To understand the scientific basis of generic drug evaluations, it’s necessary to understand some key concepts. The first one is the active pharmaceutical ingredient or API. In Lipitor, for example, the API is atorvastatin, or to use its full chemical name, (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate. The API is the chemical that has the desired biological effect. There may be a dozen ingredients in a tablet, for example, but the API is the ingredient we’re interested in. It’s the API that will allow us to generalize data and studies with the drug, linking the original bench science and preclinical research, to the tablet dispensed by the pharmacy — it’s the same chemical. The fact that drugs have an API allows generic drugs to be marketed, because when we compare generics, the API is the same. In contrast, consider the scenario of an herbal remedy. A single tablet of 100mg of a raw herb might contain hundreds of different chemicals. If there is no known API or standardized active ingredient, we cannot compare between brands, or assume that clinical trials with one brand are relevant to any other product, because we have no idea which ingredient is actually having an effect, and if any other version has that same ingredient (or combination of ingredients.)
Bioavailability
Most dosage forms (e.g., tablets and capsules) are designed to deliver the API to the site of action. Unless it’s a drug that acts directly on the lining of the gastrointestinal tract, we rely on the circulatory system to carry the drug to the site of action in the body. Bioavailability refers to the amount of drug that, once ingested, reaches the bloodstream. Bioavailability is evaluated based on two measures — the rate of absorption, and the extent of absorption:
Blood plasma level curve for a typical single dose of an oral drug;
Source
Let’s assume a dose of a drug is taken by mouth at time=0. A dosage form, such as a tablet, needs to disintegrate, and then the API needs to dissolve. It then must be absorbed through the gastrointestinal tract (absorption phase), where it will move into in the blood. Sequential blood samples are taken (say, every 30 minutes) and measured for the concentration of the drug. The point measurements are then connected, resulting in the smooth line you see. At first, the drug is absorbed rapidly, peaking at concentration Cmax at time tmax. The drug then starts to be eliminated from the blood — it could be metabolized, perhaps by the liver, and/or be filtered out of the circulation, by the kidneys. We’re then able to calculate the rate of absorption, described by Cmax/tmax, and the total extent of absorption, which is the area under the curve (AUC), calculated using integral calculus.
Studying the physiological actions of the API, and relating it to the concentration time profile allows us to understand if there is a maximum tolerated concentration (MTC) and if there’s a certain blood concentration where the drug’s action seems to start and wear off, termed the minimum effective concentration (MEC). These values are estimates, based on the understanding that there is a relationship between the drug’s concentration in the bloodstream, and the amount of that same drug at the site of action in the body. These measures will guide how the drug is eventually manufactured: We want each dose to predictably and reliably follow the same curve. That means standard production methods, and the use of fillers, diluents and other excipients, all of which serve to ensure that there is little to no variation tablet-to-tablet or dose-to-dose. This is done with the intention of also minimizing interpatient variability, which is the variation seen between different patients given the same dosage form.
There may be other ways that the formulation can be varied. When the MEC is very close to the MTC, greater precision in per-tablet accuracy may be necessary. Further, we can vary shape of the curve, by doing things like enteric-coating the tablet, or making a sustained-release version that releases the API more slowly. The final absorption curve of any pharmaceutical preparation will be a product of both the physical characteristics of the drug (i.e., the intrinsic chemical properties) and the dosage form (i.e., the pharmaceutical properties).
Generic manufacturers that want to duplicate a drug coming off patent then have a few challenges. First, manufacture the complicate chemical structure that is the API (or find someone else who can make it for you). Second, package it in a dosage form that resembles the patented drug. Third, show that the new generic shares the same absorption curve as the branded version. That is, they must show that two product are bioequivalent.
Bioequivalence
We now want to compare a branded drug, one that’s been on the market for years, with a new generic. There is a single fundamental assumption that underlies the comparison:
Two products are considered equivalent when the rate and extent of absorption of the generic drug does not show a significant different from the rate and extent of absorption of the brand drug, when administered at the same dose under similar experimental conditions.
So let’s unpack this. We don’t need to know if the tablets look alike, or have different fillers. We also don’t need to do clinical trials with the generic drug. If we can demonstrate that the API is absorbed at the same rate and extent as the brand drug, then we can declare two products to be bioequivalent. That is, taking one or the other results in the same “body exposure” to the same drug. Assume we want to compare Drug A and Drug B. We will take a group of normal, healthy adults and put them in standardized conditions — usually fasting overnight and then giving a drug on a empty stomach or with a standardized meal. We’ll give Drug A to a patient, take serial blood samples, and then calculate Cmax/tmax and AUC. Later, after the drug has been fully eliminated from the body, we’ll repeat the process in the same patient, under the same conditions, with drug B. This may be done in 20+ patients. We’ll get a graph that looks like this:
Typical concentration-time graph for two drug products
Typical concentration-time graph for two drug products
(source)
Are the two curves super-imposable? Not quite, in this example. There are slight differences in the extent of absorption. Are these two drugs bioequivalent? Here’s where the statistics come in. We apply statistics to evaluate if the curves are meaningfully different. To do this, we need to make some assumptions about what we will accept as a meaningful difference. Does a slight difference in the rate or extent of absorption make a clinical difference? Most regulators worldwide have decided that a 20% variation is generally not clinically significant.
Two versions of a drug are generally said to be bioequivalent if the 90% confidence intervals for the ratios of the geometric means (brand vs. generic) of the AUC and Cmax fall within 80% and 125%. The tmax (brand vs. generic) must also be comparable — and there should not be any significant differences between different patients.
For practical purposes, generic versions of branded drugs have AUC and Cmax ratios that are very close to one. With significant variation in either value, it would be unlikely for the confidence intervals to lie withing the 80% to 125% range. For the sake of keeping this post short I’ll leave a more detailed discussion of the statistics to the interested reader.
Myths, Misconceptions, and Controversies
Generic drugs are manufactured differently from branded drugs, and branded drug manufacturers use better processes
If the dosage form releases the same drug with the same concentration/time profile, then any minor manufacturing differences are irrelevant to the pharmacological activity. Regulators have established standardized manufacturing practices and standards, termed good manufacturing practices, that all manufacturers, brand or generic, are required to adhere to. Final products must meet the same product quality standards as well.
Bioequivalence studies are always necessary to establish interchangeability
For some dosage forms, bioequivalence studies may be inappropriate or impractical. Consider ophthalmic eyedrops. These products are administered at the site of action, and don’t rely on systemic absorption. It may be more appropriate to verify equivalence by comparing physicochemical properties including pH, viscosity, and osmolarity/osmolality. Where all relevant parameters are evaluated to be comparable, regulators will deem generic versions interchangeable based on these parameter alone.
Generics need to be tested in sick patients, not healthy volunteers
The intent of a bioequivalence comparison is to determine the differences in formulation between two drug products. Healthy standardized volunteers are used in bioequivalence studies to control for patient differences, meaning that any differences in bioavailability will be the result of drug formulation issues, not patient issues. In order to isolate drug formulation effects, it is necessary to hold everything else as constant as possible. If formulations are consistent, the rate and extent of drug absorption will not differ, and consequently there should be no differences in the pharmacologic effects of the drugs.
I absolutely can’t take a generic version of my prescription
Patented drug manufacturers usually aren’t willing to sacrifice their entire market share to generic competitors. Some will start producing “generic” versions of their own drug, selling them to a partner or subsidiary who will sell them as an “ultrageneric”. So in many cases, at least one of the generic versions that’s marketed will be truly identical (except perhaps for markings) to the branded products. Now if you think this means people won’t occasionally identify the switch as the source of efficacy issues or side effects, my anecdotal experience says otherwise.
I had a negative reaction (e.g., a new side effect) to the generic
There are no requirements for generic drugs to contain the same non-medicinal ingredients as the brand-name drug, so allergic reactions are rare, but possible. Most of the excipients are generally inert but there have been suggestions that serious allergies may rarely affect some patients. However, complaints about intolerance in the absence of a true allergic response or documented allergy could also be nocebo effects, negative symptoms elicited by negative expectations from the patient.
Bioequivalence testing isn’t an accepted evaluation method
It’s not just generic companies that must do bioequivalence studies. The company that owns the patent may need to do the same studies. Any changes to the dosage form either during development, or after marketing the product, may necessitate bioequivalence studies to demonstrate that changes do not meaningfully alter the concentration-time curve. So if the clinical trial was with a capsule, and the final marketed product is a tablet, a bioequivalence study – just as described above – may be necessary. This reassures regulators that the clinical trials continue to be relevant and applicable to the new dosage form.
I don’t care what you say, the drugs are not equivalent in the real world
The Medical Letter (now behind a paywall) summarized some studies that have evaluated the clinical effects of generic substitution:
    • A systematic review of 47 studies that compared cardiovascular drugs found no evidence that brand-name drugs were superior with respect to clinical outcomes.
    • An RCT comparing a brand antibiotic vs. a generic antibiotic found no differences in clinical effects.
    • The FDA conducted its own evaluation of proton pump inhibitors (e.g., Prilosec/Losec). All five generics met dissolution standards.
    • Levothyroxine as an API is unstable, and the FDA recently tightened manufacturing standards for all versions. There are no well-documented cases of therapeutic inequivalence between brands deemed to be bioequivalent. Most health professionals still recommend using a consistent brand, however.
    • Retrospective case-control studies with anti-epileptic drugs have yielded some data suggestive of therapeutic inequivalence. Given the limits of these studies (patients who have switched brands may differ in some way from those that did not switch), the data are not conclusive. Clinically, most health professionals are cautious when switching to generic antiepileptic drugs.
Conclusion
        ◦ The science of bioequivalence evaluations for generics has been in place in most countries for more that 30 years with an established track record of therapeutic equivalence. These evaluation methods have been so successful in establishing generic drug standards that they are largely consistent between all of the major drug regulators worldwide. Consumers and health professionals alike can be reassured that generic drugs approved under these regulatory frameworks are indeed bioequivalent, and therefore, interchangeable with brand name products.

Are generic drugs equivalent to brand-name drugs?
Generic drugs cost a fraction of brand-name drugs. What gives us confidence they are equivalent? Science.
Scott Gavura on May 31, 2018
Link

[Note: In the absence of a new post today, here’s an updated, old post, that you may not have seen.]
With healthcare costs continuing to rise, generic drugs are looking more attractive than ever. The prospect of getting the same drug at a lower cost is tempting to anyone with a large drug bill — patient or insurer alike. The savings to insurers and individuals are massive: prices can drop by 90% or more, almost overnight. In 2012, Plavix and Seroquel, two other blockbusters, lost patent protection too — with just two drugs, it was estimated there would be $10 billion in health care savings created. A “patent cliff” that existed several years ago was expected to shrivel about $255 billion in worldwide patented drug sales over the following five years. If you’re taking a prescription drug and not already on a generic version, you may be in the future.
Pharmacists are responsible for most of the prescription switches from brand to generic drugs. It depends on the state or province, but in some cases generics may be automatically substituted — that is, switched without patient or prescriber consent. Misconceptions are common, ranging from manufacturing standards (“lax standards!”) to efficacy (“the drugs don’t work!”). So today’s post is an overview of the science of evaluating generic drugs. Specifically, I want to review the concept of bioequivalence, the confirmation of which assures us of the interchangeability of different drugs — that is, one can be substituted for another.
What is a generic drug?
What is referred to as a “generic” drug may vary by country, and be influenced by both medical practice and by regulatory requirements. The most common definition is that used by the World Health Organization:
A generic drug is a pharmaceutical product, usually intended to be interchangeable with an innovator product, that is manufactured without a licence from the innovator company and marketed after the expiry date of the patent or other exclusive rights.
Generic products may also be called “multisource” products. And you’ll often see a drug’s chemical name referred to as the “generic name” or the “non-proprietary” name, which as I’ve described can lead to confusion among consumers who may only know their prescription by the brand name alone.
The active pharmaceutical ingredient
To understand the scientific basis of generic drug evaluations, it’s necessary to understand some key concepts. The first one is the active pharmaceutical ingredient or API. In Lipitor, for example, the API is atorvastatin, or to use its full chemical name, (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate. The API is the chemical that has the desired biological effect. There may be a dozen ingredients in a tablet, for example, but the API is the ingredient we’re interested in. It’s the API that will allow us to generalize data and studies with the drug, linking the original bench science and preclinical research, to the tablet dispensed by the pharmacy — it’s the same chemical. The fact that drugs have an API allows generic drugs to be marketed, because when we compare generics, the API is the same. In contrast, consider the scenario of an herbal remedy. A single tablet of 100mg of a raw herb might contain hundreds of different chemicals. If there is no known API or standardized active ingredient, we cannot compare between brands, or assume that clinical trials with one brand are relevant to any other product, because we have no idea which ingredient is actually having an effect, and if any other version has that same ingredient (or combination of ingredients.) That’s why understanding the active components in herbal medicines is so important.
Bioavailability
Most dosage forms (e.g., tablets and capsules) are designed to deliver the API to the site of action. Unless it’s a drug that acts directly on the lining of the gastrointestinal tract, we rely on the circulatory system to carry the drug to the site of action in the body. Bioavailability refers to the amount of drug that, once ingested, reaches the bloodstream. Bioavailability is evaluated based on two measures — the rate of absorption, and the extent of absorption:
Look at this graph carefully. Let’s assume a dose of a drug is taken by mouth at time=0. A dosage form, such as a tablet, needs to disintegrate, and then the API needs to dissolve. It then must be absorbed through the gastrointestinal tract, where it will move into in the blood. Sequential blood samples are taken (say, every 30 minutes) and measured for the concentration of the drug. The point measurements are then connected, resulting in the smooth line you see. At first, the drug is absorbed rapidly, peaking at concentration Cmax at time tmax. The drug then starts to be eliminated from the blood — it could be metabolized, perhaps by the liver, and/or be filtered out of the circulation, by the kidneys. We’re then able to calculate the rate of absorption, described by Cmax/tmax, and the total extent of absorption and exposure in the body, which is the area under the curve (AUC).
Studying the physiological actions of the API, and relating it to the concentration time profile allows us to understand if there is a maximum tolerated concentration (MTC) and if there’s a certain blood concentration where the drug’s action seems to start and wear off, termed the minimum effective concentration (MEC). These values are estimates, based on the understanding that there is a relationship between the drug’s concentration in the bloodstream, and the amount of that same drug at the site of action in the body. These measures will guide how the drug is eventually manufactured: We want each dose to predictably and reliably follow the same curve. That means standard production methods, and the use of fillers, diluents and other excipients, all of which serve to ensure that there is little to no variation tablet-to-tablet or dose-to-dose. This is done with the intention of also minimizing interpatient variability, which is the variation seen between different patients given the same dosage form.
There may be other ways that the formulation can be varied. When the MEC is very close to the MTC, greater precision in per-tablet accuracy may be necessary. Further, we can vary shape of the curve, by doing things like enteric-coating the tablet, or making a sustained-release version that releases the API more slowly. The final absorption curve of any pharmaceutical preparation will be a product of both the physical characteristics of the drug (i.e., its intrinsic chemical properties) and the dosage form (i.e., the pharmaceutical properties).
Generic manufacturers that want to duplicate a drug coming off patent then have a few challenges. First, manufacture the complicate chemical structure that is the API (or find someone else who can make it for you). Second, package it in a dosage form that resembles the patented drug. Third, show that the new generic shares the same absorption curve as the branded version. That is, they must show that two product are bioequivalent.
Bioequivalence
We now want to compare a branded drug, one that’s been on the market for years, with a new generic. There is a single fundamental assumption that underlies the comparison:
Two products are considered equivalent when the rate and extent of absorption of the generic drug does not show a significant different from the rate and extent of absorption of the brand drug, when administered at the same dose under similar experimental conditions.
So let’s unpack this. We don’t need to know if the tablets look alike, or have different fillers. We also don’t need to do clinical trials with the generic drug. If we can demonstrate that the API is absorbed at the same rate and extent as the brand drug, then we can declare two products to be bioequivalent. That is, taking one or the other results in the same “body exposure” to the same drug. Assume we want to compare Drug A and Drug B. We will take a group of normal, healthy adults and put them in standardized conditions — usually fasting overnight and then giving a drug on an empty stomach or with a standardized meal. We’ll give Drug A to a patient, take serial blood samples, and then calculate Cmax/tmax and AUC. Later, after the drug has been fully eliminated from the body, we’ll repeat the process in the same patient, under the same conditions, with drug B. This may be done in 20+ patients. We’ll get a graph that looks like this:

(source)
Are the two curves super-imposable? Not quite, in this example. There are slight differences in the extent of absorption. Are these two drugs bioequivalent? Here’s where the statistics come in. We apply statistics to evaluate if the curves are meaningfully different. To do this, we need to make some assumptions about what we will accept as a meaningful difference. Does a slight difference in the rate or extent of absorption make a clinical difference? Most regulators worldwide have decided that a 20% variation is generally not clinically significant.
Two versions of a drug are generally said to be bioequivalent if the 90% confidence intervals for the ratios of the geometric means (brand vs. generic) of the AUC and Cmax fall within 80% and 125%. The tmax (brand vs. generic) must also be comparable — and there should not be any significant differences between different patients.
For practical purposes, generic versions of branded drugs have AUC and Cmax ratios that are very close to one. With significant variation in either value, it would be unlikely for the confidence intervals to lie within the 80% to 125% range. For the sake of keeping this post short I’ll leave a more detailed discussion of the statistics to the interested reader.
Myths, misconceptions, and controversies
Generic drugs are manufactured differently from branded drugs, and branded drug manufacturers use better processes
If the dosage form releases the same drug with the same concentration/time profile, then any minor manufacturing differences are irrelevant to the pharmacological activity. Regulators have established standardized manufacturing practices and standards, termed good manufacturing practices, that all manufacturers, brand or generic, must adhere to. Final products must meet the same product quality standards as well.
Biosimilars aren’t generics
Biosimilars refers to follow-on versions of antibodies, proteins and other patented biological drugs, like growth hormones. Biological drugs are very large molecules that are structurally more complex that the relatively simple, smaller molecules in most tablets and injections. Their complexity means that a simple bioequivalence evaluations may be insufficient to fully describe a drug’s action. Manufacturing processes may involve recombinant DNA technology, and can take place inside living cells, leading to a final dosage form which cannot be fully characterized as a single defined API. As some of the biologic drugs approved over the past few decades have lost patent protection, the act of verifying both pharmaceutical but also clinical equivalence of “generic” biologicals has become an evaluation challenge for regulators. So if they’re not completely bioequivalent, do they have the same effects in patients? That is, are they clinically and therapeutically equivalent? While approaches between countries may vary, many are being cautious and requiring more detailed comparisons, including clinical safety and efficacy trials to demonstrate that biosimilars have the same end effects. As regulators gain more experience evaluating these products, expect the testing standards to evolve. (There’s good information for health professionals and consumers prepared by the Canadian Agency for Drugs and Technologies in Health which provides more detail on the current evaluation process.)
Bioequivalence studies are always necessary to establish interchangeability
For some dosage forms, bioequivalence studies may be inappropriate or impractical. Consider ophthalmic eyedrops. These products are administered at the site of action, and don’t rely on systemic absorption. It may be more appropriate to verify equivalence by comparing physicochemical properties including pH, viscosity, and osmolarity/osmolality. Where all relevant parameters are evaluated to be comparable, regulators will deem generic versions interchangeable based on these parameters alone.
Generics need to be tested in sick patients, not healthy volunteers
The intent of a bioequivalence comparison is to determine the differences in formulation between two drug products. Healthy standardized volunteers are used in bioequivalence studies to control for patient differences, meaning that any differences in bioavailability will be the result of drug formulation issues, not patient issues. In order to isolate drug formulation effects, it is necessary to hold everything else as constant as possible. If formulations are consistent, the rate and extent of drug absorption will not differ, and consequently there should be no differences in the pharmacologic effects of the drugs.
I absolutely can’t take a generic version of my prescription
Patented drug manufacturers usually aren’t willing to sacrifice their entire market share to generic competitors. Some will start producing “generic” versions of their own drug, selling them to a partner or subsidiary who will sell them as an “ultrageneric”. So in many cases, at least one of the generic versions that’s marketed will be truly identical (except perhaps for markings) to the branded products. Now if you think this means people won’t occasionally identify the switch as the source of efficacy issues or side effects, my anecdotal experience says otherwise.
I had a negative reaction (e.g., more side effects) to the generic
There are no requirements for generic drugs to contain the same non-medicinal ingredients as the brand-name drug, so allergic reactions to generic versions of drugs are possible. Most of the excipients are generally inert but there have been suggestions that serious allergies may rarely affect some patients. However, complaints about intolerance in the absence of a true allergic response or documented allergy could also be nocebo effects, negative symptoms elicited by negative expectations from the patient.
Bioequivalence testing isn’t an accepted evaluation method
It’s not just generic companies that must do bioequivalence studies. The company that owns the patent may need to do the same studies. Any changes to the dosage form either during development, or after marketing the product, may necessitate bioequivalence studies to demonstrate that changes do not meaningfully alter the concentration-time curve. So if the clinical trial was with a capsule, and the final marketed product is a tablet, a bioequivalence study comparing the two may be necessary. This reassures regulators that the clinical trials continue to be relevant and applicable to the new dosage form.
I don’t care what you say, the drugs are not equivalent in the real world
The Medical Letter summarized some studies that have evaluated the clinical effects of generic substitution:
    • A systematic review of 47 studies that compared cardiovascular drugs found no evidence that brand-name drugs were superior with respect to clinical outcomes.
    • An RCT comparing a brand antibiotic vs. a generic antibiotic found no differences in clinical effects.
    • The FDA conducted its own evaluation of proton pump inhibitors (e.g., Prilosec/Losec). All five generics met dissolution standards.
    • Levothyroxine as an API is unstable, and the FDA recently tightened manufacturing standards for all versions. There are no well-documented cases of therapeutic inequivalence between brands deemed to be bioequivalent. Most health professionals still recommend using a consistent brand, however.
    • Retrospective case-control studies with anti-epileptic drugs have yielded some data suggestive of therapeutic inequivalence. Given the limits of these studies (patients who have switched brands may differ in some way from those that did not switch), the data are not conclusive. Clinically, most health professionals are cautious when switching to generic antiepileptic drugs.
Conclusion: Bioequivalence testing ensures safe, effective generics
        ◦ The science of bioequivalence evaluations for generics has been in place in most countries for more than 20 years with an established track record of therapeutic equivalence. These evaluation methods have been so successful in establishing generic drug standards that they are largely consistent between all of the major drug regulators worldwide. Consumers and health professionals alike can be reassured that generic drugs approved under these regulatory frameworks are indeed bioequivalent, and therefore, interchangeable with brand name products.

What’s all that other stuff in my medicine?
Scott Gavura on October 13, 2011
Link

If you read enough supplement advertisements, like I do, you’ll often see the purity of  a product often cited as one of its merits. It’s usually some phrase like:
Contains no binders! No fillers! No colours! No excipients! No starch! No gluten! No coatings! No flow agents!
It’s a point of pride for supplement manufacturers to advertise that their product contains nothing but the labelled ingredient. And that’s also seen as an important benefit to many that purchase supplements. The perception from many consumers (based on my personal experience) seems to be that products are inferior if they contain non-drug ingredients. By this measure, drug products are problematic. Pharmaceuticals all contain an array of binders, coatings, supplements and fillers.  Even (gasp) artificial ingredients and sweeteners! And they’re often, though not always, disclosed on the package label.
But rather than being a negative feature, these supplementary, non-medicinal ingredients play a critical role in ensuring that drug products are of consistent and reproducible quality. Without them, we’d have products that are potentially unstable, we’d be unclear if they were actually being absorbed, and we wouldn’t know if they actually delivered any active ingredients into the body. In short, we’d be in the same situation we’re currently in with many herbal remedies and other types of supplements.
Standard pharmaceutical products are evaluated in both clinical trials (to measure efficacy) but also more basic tests – such as whether a drug that is ingested is actually absorbed into the bloodstream.  A promising drug won’t work if it doesn’t reach the desired site of action. And to do that, we use a variety of tools and processes to ensure that a drug is reliably and predictably absorbed when we use it, whether by ingesting it, rubbing it on our skin, or injecting it. Excipients can be described as any components of a drug product that are not the “API”, the active pharmaceutical ingredient. Excipients serve to keep the API stable, help its absorption, and simplify the manufacturing process.They help ensure that products are consistent – batch to batch and bottle to bottle. Excipients also help improve consumer acceptance and usage.
It took me some time as a pharmacist before I realized why  supplement manufacturers strive to minimize the use of excipents in their products. It’s because the consistency, absorption and effectiveness of most products hasn’t been measured, and doesn’t need to be evaluated. That is, there’s no testing done to see if the product is absorbed consistently. You can’t control what you don’t know, and with the majority of herbal products, there’s no standardization of  the active ingredient – because it may not even be clear what the active ingredients actually are. So any attempt to produce a consistent product is complicated by the lack of an API, and not knowing what type of product consistency is needed.
I’m asked about excipients regularly. There are hundreds in use, and their presence can be confusing to consumers, who may not understand their role. Patients may also have personal concerns about a specific type of excipient, or may need to avoid specific substances due to allergies. Here are some of the inactive ingredients you may see listed on on a package’s label – and why they’re there:
Fillers/Diluents/Bulk Materials
To make dosage forms a reasonable size, bulk materials are added to give size to finished products. (Imagine the size of a 100 microgram tablet without any fillers). Bulk materials also ease processing and manufacturing. They may influence the flow of the material during manufacturing, and can impact on the final product’s stability.  Typical fillers for tablets and capsules include starch, calcium salts, and sugars like lactose.  In liquid formulations, materials like glycerine and water are used to dissolve (or suspend) active ingredients and simplify dose measurements.  Alcohol, a historically popular diluent, is now rarely used. Topical products like creams and lotions use fillers like mineral oil, petrolatum, lanolin and various waxes.
Lactose is a common filler and sweetener (see below) in many prescription and non-prescription drugs. While intolerance is possible, the small amounts in most drugs makes the risk minimal.
Coatings and Disintegrants
Once the dosage form is consumed, we want it to dissolve in a consistent manner. Products that don’t dissolve are not absorbed. Disintegrants break up a tablet or capsule at the appropriate time.  Most orally consumed APIs are stable in stomach acid and disintegrate within a few minutes of ingestion. Some can be absorbed under the tongue, so disintegrating agents ensure that products like nitroglycerine dissolve immediately upon contact with saliva.   Common disintegrating agents include alginic acid, microcrystalline cellulose, and various forms of starch.
Coatings provide protection of the final product from light, oxygen, and moisture. Coatings can include gluten, (food grade) shellac, and gelatin. Some drugs are destroyed by stomach acid, so a combination of coatings and disintegrants ensure they dissolve late, after the intact tablet has passed into the small intestine, a less acidic environement. Acid-resistant (“enteric”) coatings, like cellulose acetate phthalate, work this way. That’s why some products must not be crushed or chewed before swallowing: The active ingredient would otherwise be destroyed by stomach acid.
Lubricants
Lubricants are incorporated into dosage forms to support the manufacturing process. They can reduce static charges, and ease the flow of the powder form, ensuring products will have a consistent content of the API per unit. Lubricants impact on the dissolution of the final dosage form, affecting the absorbtion rate and extent. Lubricants include calcium and magnesium stearate, polyethylene glycol, stearic acid, and talc.
Sweeteners and Flavoring Agents
Sweetener products and flavoring agents make final products palatable. If you’ve ever tried to give a child a foul-tasting medication, you already have an appreciation of palatability.  Palatability means that people will take their medication – a basic yet critical component of science-based medicine. In solid oral products, like tablets, sweeteners and flavors may coat tablets. In liquid products, like syrups and suspensions, sweeteners include sugars, artificial sweeteners, and products like corn syrup. Natural sweeteners are generally less popular from a manufacturing perspective, because of their association with dental caries, and possible impact on diabetics.  Flavoring agents can be naturally-sourced or synthetically created. There is no intrinsic advantage to a natural sweetener or flavoring agent – it’s the physical characteristics that are important, not its origin.
Coloring Agents
Colours help with product identification and are also used for consistency with flavors, particularly in children’s formulations. (Though I truly didn’t appreciate the “dye-free” versions until I had a mouthful of a medication sprayed on me by an unhappy child.)  In general, children and adults have no problems with the tiny amounts of dyes and colors in pharmaceutical products, though reactions have been reported, particularly with  the product tartrazine.
Preservatives
Preservatives can stabilize the active ingredient or ensure a product remains sterile, which is a concern with all injectables and aqueous (water-based) products. Thimerosal needs no introduction to SBM readers. It’s a vaccine preservative. Benzalkonium chloride is a common preservative in contact lens products.
Allergies to Excipients
Adverse reactions and allergies can occur to both medicinal and non-medicinal ingredients. Severe allergic reactions have been attributed to trace amounts of corn in a dosage form [PDF], for example.  The management of allergic reactions involves closely checking all excipients (and their sources), and isolating the causative agent (if possible). It can take a lot of digging, and sometimes even specialized pharmacy compounding, to deal with severe allergies and intolerances to commonly-used excipients.
The Product Expiry DateExpiry dates for products are based on when a product’s finished quality standards (e.g., strength, quality, purity) are no longer met. That is, when product degradation progresses to a point where the product either lacks the labelled potency (most cases) or in some cases, has degraded into compounds that may be toxic. Chemicals can deteriorate for reasons that include chemical reactions, such as oxidation (usually from exposure to air or moisture), physical changes (e.g., separation of a suspension), photochemical reactions (i.e., light exposure) and even chemical reactions with the product packaging. Quantitative analysis of newly prepared products is done, usually in the final packaging, to understand how quickly a product will deteriorate, and the expiry date is established based on this information. This can be an iterative process – the final product formulation may change to make a product more stable. Or the packaging may change to give the finished product a longer shelf-life. Multiple factors can play a role.
Conclusion
Excipients play an important role in ensuring that medications are consistently absorbed and reproducible in their effects. Consumers should be reassured that their inclusion actually improves, rather than detracts from, the quality of the finished product.

Binders, fillers and more? What’s all that other stuff in my medicine?
Non-medicinal products in your medicine are there for a reason.
Scott Gavura on May 9, 2024
Link

If you read enough supplement advertisements, you’ll often see the purity of a product often cited as one of its merits. It’s usually some phrase like:
Contains no binders! No fillers! No colors! No excipients! No starch! No gluten! No coatings! No flow agents!
It’s a point of pride for supplement manufacturers to advertise that their product contains nothing but the labelled ingredient. And that’s often seen as an important benefit to many that purchase supplements. The perception from some consumers (presumably shaped by marketing) seems to be that products are inferior if they contain non-drug ingredients. By this measure, drug products are problematic. Pharmaceuticals all contain an array of binders, coatings, supplements and fillers. 
But rather than being a negative feature, these supplementary, non-medicinal ingredients play a critical role in ensuring that drug products are of consistent and reproducible quality. Without them, we’d have products that are potentially unstable, we’d be unclear if they were actually being absorbed, and we wouldn’t know if they actually delivered any active ingredients into the body. In short, we’d be in the same situation we’re currently in with many dietary supplements and herbal remedies.
What is an excipient?
Standard pharmaceutical products are evaluated in both clinical trials (to measure efficacy) but also more basic tests – such as whether a drug that is ingested dissolves in the stomach, and is actually absorbed into the bloodstream. A promising drug won’t work if it doesn’t reach the desired site of action. And to do that, we use a variety of tools and processes to ensure that a drug is reliably and predictably absorbed when we use it, whether by ingesting it, rubbing it on our skin, or injecting it. Excipients can be described as any components of a drug product that are not the “API”, the active pharmaceutical ingredient. Excipients serve to keep the API stable, help its absorption, and simplify the manufacturing process.They help ensure that products are consistent – batch to batch and bottle to bottle. Excipients also help improve consumer acceptance and usage.
It took me some time as a pharmacist before I realized why supplement manufacturers minimize the use of excipients in their products. It’s because the consistency, absorption and effectiveness of most products hasn’t been measured, and doesn’t need to be evaluated. That is, there’s no testing done to see if the product is absorbed consistently. You can’t control what you don’t know, and with the majority of herbal products, there’s no standardization of the active ingredient – because it may not even be clear what the active ingredients actually are. So any attempt to produce a consistent product is complicated by the lack of an API, and not knowing just what type of product consistency is needed.
There are hundreds of excipients in use, and their presence can be confusing. Patients may also have personal concerns about a specific type of excipient, or may need to avoid specific substances due to allergies. Here are some of the inactive ingredients you may see listed on on a package’s label – and why they’re there:
Fillers/Diluents/Bulk Materials
To make dosage forms a reasonable size, bulk materials are added to give size to finished products. (Imagine the size of a 100 microgram tablet without any fillers). Bulk materials also ease processing and manufacturing. They may influence the flow of the material during manufacturing, and can impact on the final product’s stability. Typical fillers for tablets and capsules include starch, calcium salts, and sugars like lactose. In liquid formulations, materials like glycerine and water are used to dissolve (or suspend) active ingredients and simplify dose measurements. Alcohol, a historically popular diluent, is now rarely used. Topical products like creams and lotions use fillers like mineral oil, petrolatum, lanolin and various waxes.
Lactose is a common filler and sweetener (see below) in many prescription and non-prescription drugs. While intolerance is possible, the small amounts in most drugs makes the risk minimal.
Coatings and Disintegrants
Once the dosage form is consumed, we want it to dissolve in a consistent manner. Products that don’t dissolve are not absorbed. Disintegrants break up a tablet or capsule at the appropriate time. Most orally consumed APIs are stable in stomach acid and disintegrate within a few minutes of ingestion. Some can be absorbed under the tongue, so disintegrating agents ensure that products like nitroglycerine dissolve immediately upon contact with saliva. Common disintegrating agents include alginic acid, microcrystalline cellulose, and various forms of starch.
Coatings provide protection of the final product from light, oxygen, and moisture. Coatings can include gluten, (food grade) shellac, and gelatin. Some drugs are destroyed by stomach acid, so a combination of coatings and disintegrants ensure they dissolve late, after the intact tablet has passed into the small intestine, a less acidic environment. Acid-resistant (“enteric”) coatings, like cellulose acetate phthalate, work this way. That’s why some products must not be crushed or chewed before swallowing: The active ingredient would otherwise be destroyed by stomach acid.
Lubricants
Lubricants are incorporated into dosage forms to support the manufacturing process. They can reduce static charges, and ease the flow of the powder form, ensuring products will have a consistent content of the API per unit. Lubricants impact on the dissolution of the final dosage form, affecting the absorbtion rate and extent. Lubricants include calcium and magnesium stearate, polyethylene glycol, stearic acid, and talc.
Sweeteners and Flavoring Agents
Sweetener products and flavoring agents make final products palatable. If you’ve ever tried to give a child a foul-tasting medication, you already have an appreciation of palatability. Palatability means that people will take their medication – a basic yet critical component getting medicine to work. In solid oral products, like tablets, sweeteners and flavors may coat tablets. In liquid products, like syrups and suspensions, sweeteners include sugars, artificial sweeteners, and products like corn syrup. Natural sweeteners are generally less popular from a manufacturing perspective, because of their association with dental caries, and possible impact on diabetics. Flavoring agents can be naturally-sourced or synthetically created. There is no intrinsic advantage to a natural sweetener or flavoring agent – it’s the physical characteristics that are important, not its origin.
Coloring Agents
Colours help with product identification and are also used for consistency with flavors, particularly in children’s formulations. (Though I truly didn’t appreciate the “dye-free” versions until I had a mouthful of a medication sprayed on me by an unhappy child.) In general, children and adults have no problems with the tiny amounts of dyes and colors in pharmaceutical products, though reactions have been reported, particularly with the product tartrazine.
Preservatives
Preservatives can stabilize the active ingredient or ensure a product remains sterile, which is a concern with all injectables and aqueous (water-based) products. Thimerosal needs no introduction to SBM readers. It’s a vaccine preservative. Benzalkonium chloride is a common preservative in contact lens products.
Allergies to Excipients
Adverse reactions and allergies can occur to both medicinal and non-medicinal ingredients. Severe allergic reactions have been attributed to trace amounts of ingredients in medicines. The management of allergic reactions involves closely checking all excipients (and their sources), and isolating the causative agent (if possible). It can take a lot of digging, and sometimes even specialized pharmacy compounding, to deal with severe allergies and intolerances to commonly-used excipients.
The Product Expiry Date
Expiry dates for products are based on when a product’s finished quality standards (e.g., strength, quality, purity) are no longer met. That is, when product degradation progresses to a point where the product either lacks the labelled potency (most cases) or in some cases, has degraded into compounds that may be toxic. Chemicals can deteriorate for reasons that include chemical reactions, such as oxidation (usually from exposure to air or moisture), physical changes (e.g., separation of a suspension), photochemical reactions (i.e., light exposure) and even chemical reactions with the product packaging. Quantitative analysis of newly prepared products is done, usually in the final packaging, to understand how quickly a product will deteriorate, and the expiry date is established based on this information. This can be an iterative process – the final product formulation may change to make a product more stable. Or the packaging may change to give the finished product a longer shelf-life. Multiple factors can play a role.
Conclusion: Don’t fear the “filler”
Excipients play an important role in ensuring that medications are consistently absorbed and reproducible in their effects. Their inclusion actually improves, rather than detracts from, the quality of pharmaceutical products.
(Today’s post is an update to a 2010 post.)r

Are those “inactive” ingredients in my medicine really inactive?
Drugs and supplements contain dozens of inactive ingredients. Is this a concern to those with allergies and sensitivities?
Scott Gavura on March 21, 2019
Link


Several years ago I wrote a post on pharmaceutical excipients – the substances that are used to make the tablets, capsules, creams, ointments and liquid dosage forms of supplements and drugs. Excipients have traditionally been defined as “inert” ingredients, used to package and deliver the active pharmaceutical ingredient (the “API”) into the body in a consistent, reproducible, and sometime palatable manner. Excipients are commonly described in disparaging terms, like “fillers” and “additives” but they actually play a critical role in ensuring that the medications (or supplements) we take are stable and consistent. There are hundreds of ingredients that are approved excipients that can be used in formulating a dosage form.
Recently a paper caught my eye that’s led me to revisit this topic and do a bit of a deeper dive into excipients. Entitled “‘Inactive’ ingredients in oral medications”, it’s from Daniel Reker and colleagues, and was published in Science Translational Medicine. The authors seem to get worked up about drug manufacturing characteristics that are not themselves controversial or even problematic, yet may be surprising to non-pharmacists who don’t understand the science, art and practice of pharmaceutics – the science of dosage form design. Pharmaceutics was of those courses that in pharmacy school we rolled our eyes at (when would we ever make acetaminophen tablets?) but the principles of pharmaceutics are largely immutable, even as we’ve reached a point where a single tablet or capsule can cost $500. So I want to touch on a few of the issues that this paper raises as a complement and addition to my 2011 post, and discuss how excipients can sometimes be the cause of adverse reactions.
What are excipients and why do medicines contain them?
Can you remember the last time you took any medication? It was probably a tablet, as tablets are the most commonly prescribed form of medication. The vast majority of each tablet (in terms of mass) is excipients, not active ingredient. The ratio of active pharmaceutical ingredient (API) to excipient varies based on the dosage and the characteristics that are necessary to ensure the dosage form is stable and acceptable, and is delivered into the body (usually the bloodstream) in a predictable manner. If you consider that doses of some medications can be measured in micrograms and miligrams, then it’s clear the tablet will need some additional mass to the tablet just to make a single dose possible to handle. You also need to ensure that each dose is precise, and fillers allow the dose to be distributed consistently in a production batch. You then need binders, which actually hold the tablet together after the doses are manufactured in a press, and ensure they don’t crumble in the bottle or vial. But since you’ve compressed the material, a disintengrant may also be required to rapidly break the tablet apart once it reaches the right part of the digestive system. Other ingredients may be added to help the material flow properly in the production process. Finally, some excipients are added to help tablet identification (colours, shapes, and imprints), to protect the API from light or moisture, or to control the release of the product (e.g., enteric coating). The table below, reproduced from the Australian Prescriber, describes the most common excipients that are present in tablets – and why they are there.

It’s conceivable that patients taking several different drugs per day (not uncommon in the elderly) could end up taking a few grams of excipients each day. In most people, excipients are not a problem. In some people, they can be. A small but sizeable proportion (1%-10%) of the population report some form of food allergy or intolerance. Whether or not those reactions are real or simply perceived, they mandate a closer look at the excipients in medications.
Allergies, intolerances, and adverse reactions to excipients
The perfect excipient has no biological effects other than the desired one, is non-toxic, and does not interact with the API or any other ingredient. For many people, excipients are invisible. But some people cannot tolerate specific excipients, and may attribute any untoward effects to the drug itself, not even recognizing that an excipient may be to blame. Importantly, generic versions of drugs may contain different excipients. Some excipients that have been described to cause negative reactions include:
    • Starch can be used as a binder, diluent or disintegrant. When starch is extracted from wheat, it can contain trace amounts of gluten. These trace amounts are considered acceptable for those with celiac disease, though some may want to choose other products, regardless of the lack of risk.
    • Lactose is a common ingredient in medicines. Some people are lactose intolerant, or may avoid all fermentable oligosaccharides (FODMAPs) (including lactose) to manage symptoms of irritable bowel syndrome. Generally, the amount of lactose is so small in any dosage form that it is unlikely to cause any symptoms or discomfort at all. In those with severe intolerance, other dosage forms or medications may be preferred.
    • Eggs can cause allergic reactions and may be present in some vaccines. However, vaccines do not always have to be avoided in the presence of an egg allergy, and local public health units can advise on the acceptability and best practices with respect to specific vaccines.
    • Peanuts can cause anaphylactic allergies, and while no medications contain peanuts, some (e.g., intramuscular injections, ear drops, enemas, and topical preparations) contain peanut oil (arachis oil). While pharmaceutical-grade peanut oil should be free of peanut protein, patients with severe peanut allergies should not use products that contain peanut oil. Because of the similarities between peanuts and soy, those with severe allergies to soy should also avoid peanut oil-containing products.
    • Shellfish may not be something you think of in medication, but some forms of glucosamine supplements are produced from shellfish shells. There’s no compelling reason to take glucosamine supplements, but if you do, use caution if you have a shellfish allergy. While the allergy is caused by a reaction to the flesh of shellfish, not the shell itself, manufacturers recommend avoidance in the case of severe allergies.
    • Colourants like tartrazine are used in medications and have been attributed (though not conclusively linked to) activity and attention issues in children. The is no compelling reason for approved colourants to be avoided, but some may prefer products without these ingredients.
    • Some preservatives, like benzalkonium chloride, may be present in dosage forms like eye drops and cause irritation or other allergic reactions.
    • Sodium may be an ingredient in products like antacids, which could be taken in large amounts. If necessary for dietary reasons, it may be possible to identify low- or sodium-free alternatives.
    • Some ingredients may not cause specific intolerances but may simply be avoided for religious or dietary reasons. Gelatin is an ingredient that is routinely used in capsule dosage forms but comes from animal sources. In some cases, the manufacturer may need to be consulted to verify the source of any ingredients.
    • Sweeteners like sorbitol can cause diarrhea if taken in large amounts.
    • Ethanol may be found in some liquid dosage forms, but is typically avoided in anything intended for children. Doses are typically small, but in excess, even homeopathy can get you loaded. Alcohol can also react negatively with some prescription drugs.
Conclusion
Medicines and supplements contain a variety of ingredients that are included as part of the manufacturing process to ensure stability, consistency and quality. While these excipients are by definition “inert”, they have the potential to cause adverse reactions in rare circumstances in sensitive individuals. Importantly, excipients can vary between brands of the same product. Detailed information is not always easily accessible. When in doubt, ask your pharmacist or phone the manufacturer directly (ask for “medical information”), who will tell you what excipients are present, or can confirm the presence or absence of any excipient in question.

R&D and the High Cost of Drugs
James Thomas on October 15, 2016
Link

Until a year ago very few people had ever heard of Martin Shkreli. In 2015 the then-32-year-old CEO of Turing Pharmaceuticals LLC became the poster boy for Big Pharma eXXXcesses when Turing acquired rights to Daraprim, an antiparasitic drug used widely to treat toxoplasmosis. The acquisition itself wasn’t particularly controversial. Raising the price of Daraprim from $13.50 per pill to $750 per pill was.
And so another round of hand-wringing and teeth-gnashing over health care costs began. There was a Congressional hearing where Shkreli preened and smirked and refused to answer questions, later asserting that he had been subpoenaed “unethically” and that it is, “hard to accept that these imbeciles represent the people in our government.” Benjamin Brafman, Shkreli’s attorney, clarified afterward that, “he meant no disrespect…” He wouldn’t want to leave the wrong impression.
Turing later halved the effective price to $375 per pill but that still represented a 2,700% increase over the original $13.50. Daraprim is on the World Health Organization’s List of Essential Medicines by its generic name (pyrimethamine) for its use in treating toxoplasmosis, a killer of pregnant women and those with compromised immune systems. It is “the leading cause of focal central nervous system (CNS) disease in AIDS.”
Indeed, Turing is not the only company to raise drug prices astronomically. Anyone prone to anaphylaxis knows the EpiPen®, a product of Mylan Pharmaceuticals. The EpiPen® can be carried in a pocket or purse and in an emergency, jabbed into a thigh to deliver a metered dose of life-saving epinephrine. A decade ago a two-pack cost about $94. Today it averages $608. And EpiPens® expire. The manufacturer states that “Each new EpiPen® should have a minimum of 12 months before expiry.” That works out to about $50 per month. Epinephrine is cheap. The epinephrine in an EpiPen® costs at most $0.045 in wholesale quantities, less than a nickel.
Hepatits C “is a serious disease that can result in long-term health problems, including liver damage, liver failure, liver cancer, or even death.” Gilead Science, maker of the Hepatitis C drug Sovaldi (sofosbuvir), sells a typical 12 week course of treatment for $84,000. The drug has an impressive cure rate; perhaps as high as 90%. Manufacturing costs are estimated to be $1,400.
These extraordinary prices can be explained, of course. Merck CEO Kenneth Frazier says, “There’s a huge challenge we face between trying to optimize access to our drugs in whatever pricing we establish, and trying to ensure that you have the resources to continue to pursue the next generation of drugs.” The Washington Post quotes Turning spokesman Craig Rothenberg as saying that Turing “will use the money from the sales to further research treatments for toxoplasmosis.” The Post continues, “the firm had plans to invest in marketing and education tools to raise awareness of the disease.” And Heather Bresch, CEO of Mylan, the company that makes the EpiPen® is quoted by CNBC as noting that Mylan’s costs include, “manufacturing the product, distributing the product, enhancing the product, investing.” Apparently Ms. Bresch believes that other manufacturing companies don’t have those costs. Ms. Bresch was earning subsistence compensation of $2,453,456 in 2007 when she engineered the acquisition of EpiPen® from Merck and jacked the product price 600%. In 2015 she earned $18,931,068, ensuring that she would be able to afford EpiPens® for her own children should they need them. The bottom line for all of them? R&D is, like, really expensive.
Not getting what you pay for
In the August 23 issue of JAMA, Kesselheim et al., find that per capita prescription drug spending in the United States exceeds that in all other countries, largely driven by brand-name drug prices that have been increasing in recent years at rates far beyond the consumer price index. In 2013, annual per capita spending on prescription drugs was $858 compared with an average of $400 for 19 other industrialized nations.
Indeed, health care costs in general are much higher in the United States than in other OECD nations. Using World Bank numbers from 2014, the OECD average per capita health care expenditure was $4,741. In the United States we spent $9,403. Spending so much more than other industrialized nations, the US must have the finest health care in the world, right? According to the Commonwealth Fund, the US ranks last among 11 industrialized nations studied, pulled down by, among other factors, high cost and dismal efficiency. The US did not score first in any of the components measured. The UK, which spends about 40% per capita of what the US spends, ranked first in most of the measures.
This level of spending matters. There are roughly 320 million Americans. The difference between spending $9,403 versus $4,741 on each of them is $4,662 per person. In total that is $1,491,840,000,000 in excess spending and given the poor performance of US health care that $1.5 trillion dollars can only be seen as waste. To put that number in perspective, the United States 2014 defense budget was $526.6 billion, $615.1 billion including the Overseas Contingency Operations “slush fund.” Looked at from another perspective, it would cost the government a mere $62.6 billion to provide free public university education. That is to say, if we spent the OECD per capita average, we could double the defense budget, provide free public university education to all, and have the combined GDPs of Florida and Minnesota left over to spend on new drapes for the Clinton White House.
Focusing on pharmaceuticals, Kesselheim identifies two factors:
Drug prices are higher in the United States than in the rest of the industrialized world because, unlike that in nearly every other advanced nation, the US health care system allows manufacturers to set their own price for a given product.
Drug companies’ ability to maintain high prices in the United States is based on 2 market forces: protection from competition and negotiating power.
The first observation that the United States differs from the rest of the industrialized world in letting pharmaceutical companies set their own prices may surprise some American readers for whom the primacy of free markets is an article of faith. The fundamental concept is that the tension between supply and demand and the competition between various suppliers will result in low prices and high quality. David Halberstam celebrated this in The Reckoning, where he described the impact of high quality, low cost Japanese vehicles on the US automobile industry.
But, but, but, we spend lots on research and development
But drugs are not automobiles and medical markets are in no sense free. Pharmaceuticals are perhaps the most tightly regulated products in existence. Medicinet estimates that it takes 12 years on average for a new drug to move from laboratory to pharmacy shelves. A potential new drug spends several years in preclinical testing, then an Investigational New Drug Application is filed with the Food and Drug Administration (FDA), followed by three iterations of clinical studies. If all goes well the result is a New Drug Application (NDA) filed with FDA. The General Accounting Office reports that as of 2011, 96% of NDA submissions were reviewed within 10 months, the decision interval goal set by the FDA.
The costs related to this regulatory gauntlet are considerable. DiMasi et al. report the average capitalized cost including Phase IV post-approval costs for each approved compound to be $2.87 billion. Forbes magazine evaluated R&D spending over a 15 year period for a dozen pharmaceutical companies and found per approved drug costs ranging from $3.7 billion to a staggering $11.8 billion. The variation in cost reflects the variation in success. The Forbes authors divided each company’s R&D spending by the number of drugs approved. Those with more drugs failing to transit the pipeline consequently have higher costs associated with the drugs that do.
All of this seems to suggest that the cost of drugs only appears to be high, that in fact given the high development costs and long lead times, consumers are lucky that pharmaceutical companies are willing to take the risks associated with new drug development.
Kesselheim counters:
First, important innovation that leads to new drug products is often performed in academic institutions and supported by investment from public sources such as the National Institutes of Health. A recent analysis of the most transformative drugs of the last 25 years found that more than half of the 26 products or product classes identified had their origins in publicly funded research in such nonprofit centers. Other analyses have highlighted the importance of small companies, many funded by venture capital. These biotech startups frequently take early-stage drug development research that may have its origins in academic laboratories and continue it until the product and the company can be acquired by a large manufacturer, as occurred with sofosbuvir.Arguments in defense of maintaining high drug prices to protect the strength of the drug industry misstate its vulnerability. The biotechnology and pharmaceutical sectors have for years been among the very best-performing sectors in the US economy. The proportion of revenue of large pharmaceutical companies that is invested in research and development is just 10% to 20% (Table 4); if only innovative product development is considered, that proportion is considerably lower. The contention that high prescription drug spending in the United States is required to spur domestic innovation has not been borne out in several analyses. A more relevant policy opportunity would be to address the stringency of congressional funding for the National Institutes of Health, such that its budget has barely kept up with inflation for most of the last decade. Given the evidence of the central role played by publicly funded research in generating discoveries that lead to new therapeutic approaches, this is one obvious area of potential intervention to address concerns about threats to innovation in drug discovery.
Americans invest over $32 billion annually in medical research through the National Institutes of Health (NIH) alone. To put that in perspective Pfizer’s entire 2014 R&D budget was about $7.2 billion. But even this doesn’t tell the whole story because R&D means research and development. While NIH funding is almost entirely for basic research, the sort of fundamental research that fuels new understandings, opens new avenues and leads to new drugs and therapies, Big Pharma spends most of its R&D money on the development end – clinical trials.

So of Pfizer’s $7.2 billion R&D budget, perhaps 1.5 billion goes to basic research. Even there much of pharmaceutical companies’ R&D feeds on publicly-funded research. In a study published in Health Affairs, Kesselheim et al. note:
Perhaps the most common pattern of interaction involved academic scientists’ conceptualizing a therapeutic approach based on basic research about disease mechanisms and then demonstrating the proof of concept for a given molecule. Industry collaborators then developed the product for more extensive clinical testing.
The point here is that pharmaceutical companies are increasingly in the business of running clinical trials and marketing drugs rather than plowing the hard ground for new discoveries. In this sense the basic research costs are socialized while the profits, increasingly breathtaking profits, are privatized.
This is not to ignore the very high costs associated with clinical trials. As the Statistica chart above shows, half of pharmaceutical company R&D spending goes to clinical trials. The curious can find a brief explanation of clinical trial phases on the NIH website. The Biotechnology Innovation Organization, a trade association, states that less than 10% of new drugs make it through clinical trials and are ultimately approved.

This high attrition rate magnifies the cost per drug approved. So why is the attrition rate so high? Part of the problem is the misuse and misinterpretation of p-values. Friend of SBM David Colquhoun explored this problem at some depth concluding that, “if you use p=0.05 as a criterion for claiming that you have discovered an effect you will make a fool of yourself at least 30% of the time.” When the consequences are measured in tens or hundreds of millions of dollars, foolishness is to be discouraged. David Granger used Professor Colquhoun’s approach to examine the impact of p=0.05 idolatry and misinterpretation specifically as it applies to drug trials and concluded that fewer than “2 out of every three positive trial results were real.”
This would seem to demand rigorous replication of foundational laboratory and pre-clinical results. As Errington, Nosek, et al. note, “Despite being a defining feature of science, reproducibility is more an assumption than a practice in the present scientific ecosystem.” Without careful vetting at the earliest stages of investigation, hundreds of millions of dollars can be wasted chasing a false premise through the gauntlet of clinical trial. Garbage in will never produce gospel out regardless of the amount of cash squandered in the effort. The important point here is that this is not a failure of science and not a failure of regulatory overreach, it is a failure of basic due diligence. Some of this procedural elision may owe to competitive pressures. Patent law is a winner-take-all system that places absolute value on being first.
This and other market forces have driven changes in the industry. For a while the industry went through a period of “swinging for the fences” where every company chased blockbuster drugs. That model is changing with drug companies now trying to produce more drugs for smaller markets and then trying to expand the indications for which the drug is used. This is sometimes successful as it was with Novartis’ Afinitor (everolimus). First approved for patients with advanced renal cancers, everolimus was later approved for subependymal giant cell astrocytoma (SEGA), then for pancreatic neuroendocrine tumors, then for non-cancerous kidney tumors in patients with tuberous sclerosis complex, then for women with ER-postive, HER2-negative breast cancer, then for certain lung and gastrointestinal tumors. In essence this model tries to squeeze ever more toothpaste out of the same tube. Sometimes this is tried without the niceties of clinical trials and formal approvals by promoting off-label uses. Many of Big Pharma’s biggest players have been hit with fines running into the hundreds of millions and even the billions of dollars for promoting drugs for unapproved indications. The judgment can be (but isn’t always) made that gambling on clinical trials for expanded use is less expensive than attracting the ire of regulatory authorities.
Finally, an increasing amount of pharmaceutical innovation is done in the offices of investment bankers where merger and acquisition (M&A) deals are cobbled together. Small startups raise venture capital to develop an idea that often grew from the academic research of one or more of the founders. As the concept matures one of the multinational Pharma giants steps in, offers a deal that allows the venture capitalists and founders to cash out, and carries the product through the final stages of approval and marketing. Or a company like Turing or Mylan acquires a legacy product from another manufacturer and jacks up the price without, in fact, doing much of anything else. This model is very much closer to merchandising than to traditional pharmaceutical research and development. It is a particularly egregious form of what economists call ‘rent-seeking’, where resources are employed to obtain economic gain without the concomitant reciprocal benefit to society of wealth creation. The significant regulatory burden associated with pharmaceutical products make this sort of rent-seeking particularly easy. And the case can be made that industry-wide rent-seeking explains the legal prohibition of federal negotiation of drug prices. The US alone allows drug companies to charge whatever the market will bear.
The very bottom line
The bottom line is that industry claims that highly inflated drug prices are necessary to fuel new drug research doesn’t bear close scrutiny. Much of the fundamental research is done in academic settings using public money. The regulatory expense of bringing entirely new drugs to market is high but much of that cost owes to a high attrition rate during clinical trialing which itself owes to fundamental errors in choosing promising candidates. And a growing trend is for pharmaceutical companies to specialize in sales and marketing rather than research and development.
So why then are pharmaceutical companies charging so much? Marcia Angell, former editor-in-chief of The New England Journal of Medicine examined this issue in a recent Washington Post editorial and concluded, “Because they can.”

Drug Interactions, Polypharmacy, and Science-Based Medicine
Scott Gavura on February 16, 2012
Link
As I write this, the American news cycle is firmly focused on the issue of drug harms. It’s in the headlines not because of the thousands of cases of drug toxicity, hospitalizations, and even deaths that are documented each year, but because of the untimely death of singer Whitney Houston. While the cause of Houston’s death has not yet been identified,prescription drugs and alcohol are suspected to have played a role. If that’s the case, she’ll join a long list of celebrities whose deaths have been attributed to the abuse of prescription drugs. Over at Natural News, Mike Adams has already added her name to the list of “celebrities killed by Big Pharma“. He elaborated on drug-related deaths back in 2009 when actor Brittany Murphy died, deeming her death to be due to “Acute Pharmaceutical Toxicity“:
As you already guessed, there’s a fatal flaw in this pharmaceutical approach to sick care: Pharmaceuticals have never been tested in combination with other drugs. So all the so-called “gold standard science” is absolutely worthless at knowing what might happen when half a dozen pharmaceutical drugs are combined in a patient’s body. Brittany Murphy may have been on as many as TEN drugs!
Despite the fact that no combination testing has ever been done on pharmaceuticals, they are regularly prescribed in combination. Obviously, this creates a whole new realm of unknown risk based on the way multiple drugs might chemically interact in the human body.
The more pharmaceuticals you take, the more dangerous they become. While one pharmaceutical chemical may at first seem harmless (even though just one drug can actually kill you), when you start adding a second, third, fourth and fifth prescription on top of that, you’re dealing with Acute Pharmaceutical Toxicity (APT) that’s never even been tested in clinical trials.
Pharmacists are trained to help people avoid the most toxic two-drug combinations, but they rarely have any real knowledge about what happens when you combine three, four, five or more drugs. No one does. The science has simply never been done on that question. It’s no wonder: With all the possible combinations and permutations of pharmaceutical toxicity, it would take literally trillions of clinical trials to test them all.
Adams’ ignorance of medicine is obvious here. Combinations of drugs are studied in clinical trials all the time. You can start with the HIV treatments, move on to cancer drugs, and then chronic illnesses to see studies examining two, three and more in combination. But if a particular combination hasn’t been studied, are we still in the realm of science-based medicine? Alternative health proponents, sensitive to the lack of evidence supporting their preferred treatments, see drug combinations as just one example ofSBM hypocrisy. We’re told that “only 10–35% of medical practice is based on randomized controlled trials” as a justification for unproven or disproven treatment strategies.While this particular statistic has been repeatedly examined and debunked, and the risks of polypharmacy have been discussed at SBM, a science-based approach to combining drugs, even in situations when they haven’t been directly studied in clinical trials, hasn’t gotten as much attention.
It’s important to acknowledge that adverse reactions from prescription drugs are a major cause of harms and death. In 2008 poisonings caused more deaths than car accidents, and many of these poisonings were from prescription, not illegal, drugs. It’s been estimated that adverse reactions may cause 2-6% of hospital admissions, and that proportion may be even higher in specific age groups. Each case of drug-related harm has its own set of contributors, which may include health professional culpability, a lack of proper education, and patient factors (including situations of deliberate abuse). The tragedy is not just their absolute numbers, but the fact that many of these events are both predictable and avoidable — particularly those that result from combining prescription drugs, or mixing prescription drugs and alcohol. As Harriet Hall has noted before, it’s misleading to say that combining drugs can’t be evidence-based. How different drugs interact when combined in the body isn’t a scientific black box: An understanding of drug kinetics and of molecular biology allows us to predict with fair accuracy how drugs will behave when combined. So while we cannot anticipate all idiosyncratic reactions to drugs, there already exists the knowledge and tools to be doing a much better job preventing drug-related harms.
There are two main types of drug interactions:
Pharmodynamic interactions change the effect of a drug, without changing the amount of drug in the body. The celebrity overdose is a common example: combining multiple drugs that can depress and impair the central nervous system can lead to significant sedation and even death. These outcomes are not a surprise — they are a direct extension of their pharmacologic action. We can use pharmacodynamic interactions in more positive ways, too: Different types of antihypertensives work in different ways, so a combination of drugs may be effective in lowering blood pressure when raising the dose of a single drug is ineffective or causes unwanted side effects. But not in all cases. Combining drugs like ACE-inhibitors with potassium-sparing diuretics may lower blood pressure, but both drugs also elevate potassium levels, sometimes to life-threatening levels. Another example of pharmacodynamics is the treatment of pain with a narcotic such as codeine, plus an anti-inflammatory,such as naproxen. Both provide pain relief, albeit by different mechanisms of action.
Pharmacokinetic interactions are the result of one drug affecting another drug’s action by modifying its concentration at the site of action. This can be accomplished in four different ways:
1. A change in drug absorption
Unless it’s injected, a drug needs to be absorbed (usually from our gastrointestinal tract). Modifying the environment (say, reducing stomach acidity with a proton pump inhibitor like Prilosec) can modify how extensively some drugs are absorbed, if that absorption is dependent on an acidic environment. Or we can influence absorption by slowing down or speeding up the motility of your gastrointestinal tract: Change transit time, and you can change the extent of absorption. Or kill off some bacteria in your colon antibiotics, and it may reduce the circulation of drugs that are secreted in the bile and then reabsorbed. It doesn’t have to be the stomach, either. Drugs administered via the skin can have their absorption affected by solvents like DMSO.
Cellular pumps allow drugs and other chemicals to cross otherwise impermeable barriers. P-glycoprotein is a cellular pump located in the intestine, kidney, liver and blood-brain and blood-testes barrier. Loperamide (Imodium) is an anti-diarrheal that is structurally similar to narcotics, but lacks the usual narcotic effects on the brain, because p-glycoprotein blocks it from crossing the blood-brain barrier. When the function of one drug depends p-glycoprotein, and another drug modifies its action, unpredictable effects can results.
2. A change in drug distribution
Drug molecules don’t just float along in the bloodstream — they may hitch a ride on proteins, binding to them and effectively decreasing the amount available for activity at the site of action, or in the liver, when the drugs will be transformed (and eliminated). The impact of one drug on the protein binding of another can modify a drug’s action. If one drug displaces another from its protein binding, this can raise the effective or “free” levels in the blood, potentially causing a toxic effect.
3. A change in drug metabolism
Drug metabolism is the process that convert drugs (and other chemicals) into molecules that can more easily be excreted from the body, usually by way of the kidneys. These transformations are catalyzed by enzymes, and some drugs act to inhibit or induce enzyme action. In particular, a group of enzymes called cytochrome P450, or CYP enzymes, are the main metabolic pathway for many drug products. While there are dozens of different CYP enzymes, only a handful act on drugs. Consequently, if we know a specific drug is metabolized by, inhibits, or induces a particular CYP enzyme, it becomes easier to predict the possible effects on other drugs — without the need for direct evidence to verify the interaction.
Many drugs are well absorbed from the gastrointestinal tract, yet fail to appear in high levels in the blood circulation. It’s the liver at work, causing what’s called the “first pass” effect — metabolizing drugs as they first pass through the liver, before they circulate in the body. Inhibition of certain enzymes, particularly CYP3A4, can dramatically suppress this first pass effect, potentially changing usual doses into overdoses.
4. A change in drug elimination
Drugs can induce elimination of other drugs, reducing peak levels and duration of effect, possibly to an extent that efficacy is compromised. Or they can inhibit elimination, raising peak levels and the duration of effect, possibly to toxic levels.
Drug-Food Interactions
We tend to separate drug-drug interactions from drug-food interactions, but from a biochemical perspective, it doesn’t matter: foods are just combinations of chemicals, some of which may interact with drugs. And the mechanisms for these are the same:
    • pharmacodynamic effects: alcohol can increase the sedating effects of narcotics, antihistamines, and sedatives like benzodiazepines
    • absorption issues: calcium and iron can reduce drug absorption, while some drugs are absorbed more extensively in the presence of food.
    • drug kinetic issues: vitamin-K containing foods can antagonize the effects of warfarin; tyramine-containing foods combined with the (now rarely used) monoamineoxidase (MAO) inhibitors can cause a massive increase in blood pressure and even stroke. Grapefruit juice has been identified as a significant cause of drug interactions, through inhibition of CYP enzymes.
Drug-Herb Interaction
Herbal products can be a nightmare from a drug interaction perspective. In general, herbs raise the level of therapeutic uncertainty and risk, compared to drug-drug interactions. Compared to the relative straightforward data on drugs with known pharmacokinetics and predictable interactions, herbs can contain many different chemicals, of which the “active” ingredient(s) may not even be known. Combine the lack of standardization, and the possibility of poor quality control standards, and you’ll see most pharmacists wince when you ask about drug-herb interactions: the unknowns make combining herbs and drugs potentially risky, especially in situations where the drugs have a narrow “therapeutic index“, or when the stakes are high, such as cancer chemotherapy.
While we don’t have good estimates of their true prevalence, we know that some herbs are demonstrably problematic: St. John’s Wort (Hypericum perforatum) (SJW) can cause significant drug-drug interactions, including HIV drugs and transplant therapies. There are multiple cases of transpanted organ rejection linked to initiation of SJW. Why? SJW is a powerful inducer of CYP3A4 enzyme, which increases the metabolism of immunosuppressants, decreasing their effects.
What’s most frustrating about drug-herb interactions is that the natural products industry seems determined to keep consumers in the dark about the potential harms, as Mother Jones outlined this week, in a column entitled What the Supplement Industry Isn’t Telling You About St. John’s Wort:
The real problem here lies in transparency to consumers—a problem that goes directly back to the supplement’s manufacturers. In a 2008 study published in BMC Complementary and Alternative Medicine that tested 74 different SJW brands, less than a quarter of the product labels identified possible interactions with antidepressants. Even more disturbing was that only 8 percent identified possible interactions with birth control.
Many groups, like the Center for Science in the Public Interest, have tried to push the FDA to standardize SJW labels to properly reflect possible dangers. But since supplement makers are not required by law to warn consumer about health risks associated with their products, it hasn’t been easy. “These companies fight warning labels like the dickens, and whether they intend it or not, that affirms the belief that natural products are unequivocally good for you,” says Stephen Gardner, litigation director at CSPI.
And that’s the issue. It’s not that drugs are inherently harmful, and herbs are wonderful and safe panaceas. Any product, whether it’s a herb or a synthetic drug, has the potential to harm, and to interact negatively. And unless the potential for interactions is well understood, we need to approach the combination of herbs and drugs with caution. Part of the solution is ensuring that health professionals and consumers alike are asking the right questions about their safety and efficacy.
Pharmacogenomics
One of the most interesting areas in drug interactions and drug safety is our evolving knowledge of pharmacogenomics: how genetic factors can influence drug behavior. The vision for pharmacogenomics is to maximize efficacy and to avoid adverse drug reactions. The reality is that we’re not there yet, but the science is progressing. For example, the dosing of warfarin (Coumadin), a drug associated with a significant bleeding risk, can be modified to minimize toxicity based in part on testing for the genes CYP2C9 and VKORC1. While it doesn’t eliminate the dosing uncertainty, and the clinical usefulness of testing remains limited, it’s a promising sign of what may become a more predictable way of selecting and dosing drugs. Over time, our accuracy at drug selection and dosing may become much more personalized than it is today.
Where do we go from here?
Harms associated from combining prescription drugs neither validates alternative medicine, nor invalidates science-based medicine. Celebrity or otherwise, many of the harms attributed to prescription drugs are predictable and avoidable. Every treatment decision boils down to an individual evaluation of risk versus benefit, and we can combine therapies with a great degree of confidence based on our understanding of how they will (or will not) interact. Drug-related injuries and toxicity are a real issues, one that medical systems could be doing a much better job of addressing. But when it comes to understanding how these harms are occurring, and preventing them, it’s not just the drugs we need to look at: we already have the information, technology, and capacity to significantly reduce the occurrence of drug-related harms.

Reducing the Risk of Adverse Drug Events
Harriet Hall on January 3, 2012
Link
Critics of mainstream medicine often point to the dangers of drugs. I previously wrote about “Death by Medicine,” where I explained the fallacy of fixating on harmful effects of drugs without putting them into perspective with all the good drugs do. Yes, patients have died from severe allergic reactions to penicillin, but penicillin has also saved countless lives.
A recent article in The New England Journal of Medicine looks at emergency hospitalizations for adverse drug events in elderly Americans. It confirms that adverse reactions are a serious problem, but some of its findings are surprising.
The elderly are seven times as likely as younger people to have adverse drug events. They are more susceptible because of physiologic changes with aging, frailty, coexisting conditions, and polypharmacy. Forty percent of people over 65 take 5-9 medications, and 18% take 10 or more. Combinations of medications can cause unexpected problems.
Among adults age 65 and older, they estimate nearly 100,000 emergency hospitalizations every year in the U.S. for adverse drug events. Half of those were in those over age 80. And most of them were entirely preventable. If you tried to guess which drugs were most often to blame, you might guess NSAIDs or psychoactive drugs, but you would be wrong. Drugs previously recognized as “high-risk” in this age group were responsible for only 1.2% of these hospitalizations. Four medications were implicated in 67% of cases:
    • Warfarin 33.3%
    • Insulin 13.9%
    • Oral antiplatelet agents 13.3%
    • Oral hypoglycemic agents 10.7%
Further down the list are opioid analgesics, antibiotics, digoxin, and chemotherapy drugs. Even further down: sedatives, blood pressure meds, and anti-seizure medications. And nearly two thirds of hospitalizations were for unintentional overdoses. They concluded that simply improving management of commonly used antithrombotic and antidiabetic drugs could have a big impact, both in reducing harm and in reducing health care costs.
Warfarin, or Coumadin, is by far the biggest offender. Appropriate dosage varies with the individual and over time; adjusting it requires frequent blood tests to measure the INR (international normalized ratio of prothrombin time compared to a standard). It may be necessary to monitor the INR every day or two at first when readings tend to fluctuate markedly, and when the readings become stable the frequency of testing can drop down to monthly. Bleeding complications are more likely to occur when the INR goes above the target range. One specialist told me he had never seen a complication in a patient on Coumadin whose INR was in the target range.
It is conceivable that the biggest problem drug could entirely drop off the list and 33% of drug-related hospitalizations could be prevented if only doctors managed Coumadin dosing more effectively and if patients complied better with instructions about medication and diet. At my local hospital (Madigan Army Medical Center), all patients on anticoagulation are managed by a Coumadin Clinic run by an experienced clinical pharmacologist using rigorous procedures and guidelines; I don’t have any figures, but I think that approach is much better than having individual doctors manage their own patients.
A pharmacist, Robert Steven Gold, has written a book with specific proposals for reducing medication risks. The title is Are Your Meds Making You Sick? The title led me to expect a typical anti-establishment rant about evil Big Pharma poisons. It is anything but. The format is engaging: it presents a series of mini-mystery case reports and challenges the reader to detect which drug is the culprit.
Gold provides 16 rules for reducing the risk from drugs:
     1.  Learn which medications are sending people to emergency rooms
     2.  Know your kidney lab values
     3.  Know your liver lab values
     4.  Be aware that the elderly are different from younger people
     5.  Take your meds as your doctor prescribed
     6.  Know your lab-test schedule
     7.  Know your medication’s monitoring parameters
     8.  Don’t hesitate to call your doctor
     9.  Be aware of drug interactions
     10.  Understand that OTC meds, herbals, and alcohols are drugs too
     11.  If your health changes after you add a new drug, think drug-induced disease
     12.  Know that most adverse drug reactions are due to dosage issues
     13.  Insist on medication reconciliation
     14.  Don’t stop taking a medication without talking to your doctor
     15.  Remember that elderly individuals should be on lower doses
     16.  Ads don’t warn of incidence of adverse events – don’t believe them.
He explains each of these in detail, and refers to them as he goes through each mini-mystery. He adds “above all, record and report,” pointing out that the majority of drug reactions go unreported.
Just one mini-mystery example: a woman experiences weight loss, heartburn, nausea, weakness and dizziness. She is on medicines for high blood pressure and osteoporosis (Fosamax) and takes an over-the-counter non-steroidal anti-inflammatory drug (naproxen) for back pain. Endoscopy finds ulcers in her esophagus and stomach. Yes, we know NSAIDs cause GI bleeding, but in this case naproxen was only an accomplice. The real culprit was Fosamax, and the patient was to blame because she had failed to follow the instructions to take it with plain water and remain upright for 30 minutes after taking it. She had been taking it with orange juice and reclining in a chair for 30 minutes. She had also ignored the package insert for Fosamax that warns against combining it with NSAIDs. She had violated rules 5, 9, 10, and 16.
In 1860, Oliver Wendell Holmes famously said,
I firmly believe that if the whole materia medica could be sunk to the bottom of the sea, it would be all the better for mankind and all the worse for the fishes.
He wouldn’t say that today. We have come a long way since 1860. Modern science has developed effective medications that can save lives, control diseases, and relieve symptoms; but anything that has effects is likely to also have side effects, and these medications can also harm. Drugs can be hazardous to your health. Of course, not taking them can be even more hazardous: insulin reactions occur and can even sometimes kill patients, but if diabetics stopped taking insulin they would be certain to suffer unnecessarily and die prematurely. Both this article and this book are great examples of how science-based medicine is constantly striving to improve itself, in stark contrast to so-called “alternative” medicine: we recognize problems, confront them head-on, and try to reduce risks. Replacing medicine with “alternative” medicine because of drug reactions would be as foolish as replacing cars with walking barefoot because of automobile accidents.
Gold’s book contains essential information that anyone taking medications should know for their own safety, and that doctors should be more aware of. As a doctor, I already had a grasp of the basic principles, but reading this information taught me more about the details. Almost every mini-mystery case in Gold’s book could have been prevented by following his 16 rules. Both health professionals and consumers can do much better than we have been doing.

What does a new drug cost? Part II: The productivity problem
Scott Gavura on December 5, 2012
Link
A few weeks ago I reviewed Ben Goldacre’s new book, Bad Pharma, an examination of the pharmaceutical industry, and more broadly, of the way new drugs are discovered, developed and brought to market. As I have noted before, despite the very different health systems that exist around the world, we all rely on private, for-profit, pharmaceutical companies to supply drug products and also to bring newer, better therapies to market. It’s great when there are lots of new drugs appearing, and they’re affordable for consumers and health systems. But that doesn’t seem to be the case. Pipelines seem to be drying up, and the cost of new drugs is climbing. Manufacturers refer to the costs of drug development when explaining high drug prices: New drugs are expensive, we’re told, because developing drugs is a risky, costly, time consuming endeavor. The high prices for new treatments are the price of innovative new treatments, both now and in the future. Research and development (R&D) costs are used to argue against strategies that could reduce company profitability (and presumably, future R&D), be it hospitals refusing to pay high drug costs, or changing patent laws that will determine when a generic drug will be marketed.
The overall costs of R&D are not the focus in Goldacre’s book, receiving only a short mention in the afterword, where he refers to the estimate of £500 million to bring a drug to market as “mythical and overstated.” He’s not alone in his skepticism. There’s a fair number of papers and analyses that have attempted to come up with a “true” estimate, and some authors argue the industry does not describe the true costs accurately or transparently enough to allow for objective evaluations. Some develop models independently, based on publicly available data. All models, however, must incorporate a range of assumptions that can influence the output. Over a year ago I reviewed at a study by Light and Warburton, entitled Demythologizing the high costs of pharmaceutical research, which estimated R&D costs at a tiny $43.4 million per drug – not £500 million, or the $1 billion you may see quoted. Their estimates, however, were based on a sequence of highly implausible assumptions, meaning the “average” drug development costs are almost certainly higher in the real world. But how much higher isn’t clear. There have been at least eleven different studies published that estimate costs. Methods used range from direct data collection to aggregate industry estimates. Given the higher costs of new drugs, having an understanding of the drivers of development costs can help us understand just how efficiently this industry is performing. There are good reasons to be critical of the pharmaceutical industry. Are R&D costs one of them?
Is the low-hanging fruit gone?
A growing concern with the pharmaceutical industry is its overall productivity in delivering new drugs. There’s a relationship assumed between what what’s spent (R&D) and the number of new drugs that get approved. Ignoring the fact that quantity is a poor guide to quality, let’s look at the crude values: It does appear that the number of new drugs approved is dropping. Here’s a European snapshot [PDF]:
And FDA approvals show the same downward trend:
At the same time, the amount spent on R&D, both in Europe and the US, has steadily climbed during most of this period:
Here’s another view with a even longer timeframe, from a paper on R&D efficiency published in March 2012 in Nature Reviews Drug Discovery:

The number of new drugs approved FDA per billion US dollars has halved about every 9 years. Remember Moore’s law, suggesting the number of transistors on integrated circuts doubles every 18 months? The authors of this paper introduce Eroom’s law – Moore spelled backwards:
Eroom’s Law indicates that powerful forces have outweighed scientific, technical and managerial improvements over the past 60 years, and/or that some of the improvements have been less ‘improving’ than commonly thought. The more positive anyone is about the past several decades of progress, the more negative they should be about the strength of countervailing forces. If someone is optimistic about the prospects for R&D today, they presumably believe the countervailing forces — whatever they are — are starting to abate, or that there has been a sudden and unprecedented acceleration in scientific, technological or managerial progress that will soon become visible in new drug approvals.
Spending is up, productivity down. The data suggest the decline is real, which may mean claims drugs are becoming more expensive to develop are real. Matthew Herper did some rough calculations earlier this year in Forbes using publicly available data. He pulled R&D spending for companies over 15 years, and divided that by the number of new drugs developed per company during that time. He estimated the costs per drug per company ranged from $4 billion to $11 billion. A crude estimate, yes, and one that doesn’t account for the time lag in developments. But as a rough yardstick, it suggests that the costs per approved drug are more likely to be measured in billions and not millions.
Let the finger pointing begin. Here’s where you’ll see the blame split – some say it’s a regulatory issue and a consequence of of FDA stringency, while others point to industry as engineering its own misfortune. Setting aside blame (for now), let’s look at the drivers and the productivity issue. There’s also a new R&D estimate out from the Office of Health Economics, a UK-based consultancy and research group. The paper, entitled The R&D Cost of a New Medicine, is the latest academic attempt to quantify the “average” cost of developing a new drug.. I’ll first note that this analysis was “partially funded by an unrestricted research grant” from AstraZeneca. Keeping that potential bias in mind, let’s start with their bottom line:
Published estimates of the mean (average) cost of researching and developing a successful new medicine suggest an increased over the last decade—from the estimate of US$802m by DiMasi et al (2003) at 2000 prices (US$1,031m at 2011 prices) to the estimate by Paul et al (2010) of US$1,867m at 2011 prices. In this study, we present a new estimate, US$1,506m (at 2011 prices), which lies within this range. Our analysis explores how these costs have been evolving and for what reasons.
First, a review. Drug development isn’t a sequential process. It only looks that way in hindsight when you have a successful drug. R&D may be better thought of as maze, with countless dead ends. And in some cases, no solution at all. Given we can’t accurately forecast the future, drug development becomes a series of decisions under uncertainty: Looking at the evidence collected to date, estimating probabilities, and factoring in costs. Every potential new drug passes through countless “go/no go” decisions – first identifying molecules and biological pathways of interest, then developing potential compounds, and possibly testing them in increasingly rigorous studies that start in test tubes, proceed to animals, and ultimately may end up in human trials. This diagram shows the steps:
This complicated diagram illustrates the attrition risk, and the approximate time involved at each step. Importantly, what’s called “basic research” and then “discovery research” component is the “research” part of the R&D. What follows, through trials is actually considered the “development” component. The authors argue that there are four key variables that influence overall R&D cost estimates:
1. Out-of-Pocket Costs
These are the direct costs spent on trials, recognizing that not all trials make it all the way through all three phases. The most recent estimates suggest that mean costs now likely exceed $200 million for all three phases, and these costs have been increasing over time, up 600% since the 1970’s. The factors that can influence OOP costs include:
    • The cost of each patient (recruitment, treatment, etc.)
    • The number of patients in the trial.
    • The complexity of the trial, including its duration. Complexity could be driven by regulatory demands for better evidence, or simply treatment of more challenging conditions. For example, studying a treatment for urinary track infections, is quite a bit simpler than studying a drug that treats Alzheimer’s disease.
    • Where the trial is done. Outsourcing the trial to Asia is much cheaper than conducting studies in North America. As other costs rise, companies have been shifting
2. Success Rates
The first goal is finding a possible drug. This is an area where there’s a vast difference of opinion between those that work on drug development, and those that criticize it. (If you’re interested in the development perspective, Derek Lowe’s blog can’t be beat.) Assuming we’ve identified a potential drug (which can take years and years), we’ll move into clinical trials. Throughout the development process, cold calculations are applied to the results: Should development continue? The chance of proceeding past each phase was estimated based on literature that looked at different samples of drugs:
Passing Phase I: 49% to 75% of drug candidates move forward
Passing Phase II: 30% to 48% of remaining drug candidates move forward
Passing Phase III: 50% to 71% of remaining drug candidates will go on to
The authors refer to different estimates and conclude that rates have increased over time. Whether this is due to more stringent standards established by risk averse regulators, or because finding effective drugs is getting harder is difficult to say. Failure rates could also reflect more effective scrutiny by industry, killing off weaker drug candidates, earlier. As the costs of new drugs continues to be scrutinized, research termination could also include economic reasons. When we consider this trend in the context of missing or unpublished data, it would suggest that these may be overestimates of what the true success rates should be. Based on this analysis, the authors estimate it takes between 4 and 14 drugs to enter phase I trial for a single drug to make it through to final registration.
3. Development Times
Based on estimates taken from other papers on development, the authors noted the time from phase I to phase III has been fairly consistent – about 6.5 years. So if trials are getting more complicated, and the regulatory review is more intense, this hasn’t shown up in the past. This is a positive sign, as longer development times delay potentially useful drugs but also eat into overall profits, given a fixed patent expiry date.
4. The Cost of Capital
The cost of capital enrages pharmaceutical industry critics, who don’t seem to understand that it’s a real cost. The cost of capital is the rate of return a company is expected to generate for its owners. That is, if investors are making bets (and that’s essentially what this is) on the future payoff of a potential drugs, they need to factor in the revenue they could generate by investing elsewhere in a project of similar risk. It’s true that the cost of capital doesn’t reflect a cash outlay. It’s also true that R&D costs receive preferential tax treatment. However this only changes who ultimately covers the cost. Taking risks like the pharmaceutical industry does means massive bets, with payoffs that might stretch decades in the future, or might disappear suddenly if a safety or efficacy problem is identified in the future. These authors use a cost of capital of 11%, which sounds excessive considering what your bank account may be paying in interest, but may represent a fair estimate for pharma given investing in drug development looks riskier and riskier.
The Critics
As I’ve pointed out before, there are considerable criticisms of R&D estimates that have appeared in the literature. One outspoken critic is Marcia Angell, former editor of the New England Journal of Medicine who has argued that R&D costs are only a fraction of published estimates. Specific criticisms include the confidential nature of the data analyzed – the transparency issue again. Selection bias is also cited, suggesting that companies that have shared data may have only included more expensive drugs, and not drugs that represent slight variations of existing drugs (“me-toos”) which presumably are significantly less expensive to develop. She has also criticized using the cost of capital in these estimates. Other critics, like Merrill Goozner have argued that much of the development costs are borne by the public sector (i.e., NIH). He also points to the competitive nature of drug development which creates waste through duplicative effort at different companies. Other criticisms in the literature include the complexity of estimating the costs of drugs that are discovered by small companies, and then licensed to larger companies to complete the registration process. There are fair points in many of these criticisms. However, none do an adequate job of explaining the current state: fewer drugs approved, and higher costs incurred.
The New Estimate
For this new analysis the authors gathered data on costs from 97 development products provided by confidential surveys of pharmaceutical companies. They aggregated costs and then averaged costs for each component of research and development, estimating the overall probability of success of any single drug at 7%. The authors noted the average overall development timelines were 11.5 years. On balance, the estimated out-of-pocket costs were estimated at $899 million (2011 values). Factoring in time and cost of capital, this becomes an estimate of $1.5 billion. It’s a number within the range of other published estimates, and again, it suffers from a lack of transparency in some of the estimates it uses. Set against the industry-wide trends I noted above, this number fits into that range.
Conclusion
Criticism of the pharmaceutical industry is justified when it’s done for the right reasons. Being skeptical of R&D estimates is wise. Data on individual drugs is not transparent, and estimates must incorporate a number of assumptions which have the potential to bias the conclusions. This lack of transparency fuel suspicion of the process. But we should also be equally skeptical of arguments that dismiss or diminish the growing problems with R&D. There is good evidence to suggest that drug development is a risky, expensive endeavor, and that this work is getting harder. There’s also good evidence to suggest that the productivity of this process is declining. As consumers, this may mean fewer new drugs, and higher per-drug costs. Finally, average drugs costs are just that – averages. They’re good for talking points, but don’t diagnose the problem. Is it possible to fix the productivity decline in the pharmaceutical industry? I’ll save that discussion for a future post.

When Drugs Cost Too Much
Our ability to develop new drugs is fast outstripping our ability to pay for them; some are exorbitantly expensive and not very effective. Funds are limited, and as a society we need to have a serious discussion about how they are to be allocated.
Harriet Hall on June 6, 2017
Link

How much is it reasonable to pay for a drug? If I have a headache, I would gladly pay a dollar for a dose of Motrin, but if it cost $500 I think I would rather endure the headache and save my hard-earned money for other things. If I had a history of life-threatening anaphylactic reactions to bee stings, I would gladly pay a lot for an Epi-Pen; but where would I draw the line? What if it cost so much I would have to skimp on food and forgo other budget items to pay for it? If insurance is paying, we may not worry about cost; but if insurance covers exorbitantly expensive drugs for some, that will raise premiums for all.
Some new drugs offer a small benefit at a high price
I subscribe to The Medical Letter and I am frequently shocked by the cost of some of the new drugs they review, especially the cancer drugs. We’re talking tens of thousands or even hundreds of thousands of dollars a year for drugs that may or may not help individual patients; and if they do help, they may only extend their lives by a few weeks and they may cause worrisome side effects. And drugs for other, non-cancer indications bring small benefits at a high price. Here are some examples from just one recent issue:
Evolocumab (Repatha) is given by injection every 2-4 weeks to reduce cardiovascular risk in patients whose LDL cholesterol levels have not dropped to acceptable levels with maximally-tolerated doses of statins. In a large double-blind placebo-controlled trial, it reduced the incidence of heart attacks from 4.6% to 3.4%, reduced the need for revascularization surgery from 7.0% to 5.5%, and reduced the incidence of ischemic strokes from 1.9% to 1.5%. These reductions were statistically significant, but it did not significantly reduce cardiovascular mortality or all-cause mortality. Treatment for one year costs $14,563. The authors of the study estimated that 74 patients would have to be treated for two years to prevent one cardiovascular event (death, heart attack, or stroke). It would cost $2,149,400 for one patient to benefit while treating 73 patients who would not benefit.
Dupilumab (Dupixent) is an injected human monoclonal antibody approved to treat adults with moderate to severe atopic dermatitis (eczema) that has not responded to topical therapies. Several placebo-controlled trials have shown it to be safe and effective. Around 40% of patients on dupilumab had complete or almost complete clearing of skin lesions compared to 7-12% of patients on placebo. One pre-filled syringe costs $1,423; a year’s supply costs around $37,000.
Plecanatide (Trulance) treats chronic idiopathic constipation. In the 20% of patients who responded, it increased the rate of complete spontaneous bowel movements by one a week, which was statistically significant. At a cost of $353.50 a month, or $4,242 a year. That’s $88 for one complete spontaneous bowel movement; if insurance didn’t cover it, how many patients would be willing to pay that much out of pocket for a single BM, even if they could afford it?
The challenges of the accelerated approval program
A recent article in The New England Journal of Medicine (NEJM) discussed the challenging combination of accelerated approval and expensive drugs. The FDA’s accelerated approval program was started in the early 1990s in response to the demand for faster drug development to meet the AIDS crisis. It allows the approval of drugs on the basis of surrogate end points that are “reasonably likely to predict clinical benefit.” Accelerated approval currently accounts for about 10% of new drug approvals. It requires manufacturers to conduct post-approval trials and to label the drugs with a statement that clinical benefits have not been established.
Eteplirsen (Exondys 51) was approved for muscular dystrophy on the basis of very small increases in the production of dystrophin protein. After approval, the manufacturer announced an estimated cost of $300,000 a year, a lot to pay for a drug when the clinical effectiveness is unknown. Private insurers have either declined to cover it or have imposed restrictions. Medicaid is required to cover nearly all FDA-approved drugs. Medicare is required to cover drugs that are “reasonable and necessary,” with protected classes for which all or nearly all FDA-approved drugs must be covered; one of those protected classes is cancer drugs, a class that qualifies for accelerated approval.
Some other drug costs are listed in a table in the NEJM article:
    • Crizotinib for certain cancers: $14,353 a month
    • Bedaquiline for drug-resistant tuberculosis: $6,000 a month
    • Pomalidomide for refractory multiple myeloma: $14,165 a month
    • Blinatumomab for refractory lymphoblastic leukemia: $56,262 a month
    • Pembrolizumab for unresectable melanoma: $9,252 a month
    • Ceritinib for advanced non-small-cell lung cancer: $14,628 a month
    • Panobinostat for resistant multiple myeloma: $10,625 a month
    • Palbociclib for certain advanced breast cancers: $11,224 a month
    • Eteplirsen for Duchenne’s muscular dystrophy: $7,600 a month
The authors propose several policy options to address this challenge.
The challenge of hepatitis C
Around 3.5 million people in the US are infected with hepatitis C virus. It is more common in people who have had blood transfusions, have injected drugs, have HIV, have been on long-term kidney dialysis, or were born between 1945 and 1965. 75-85% of infected patients develop chronic hepatitis C, which can lead to liver cancer and cirrhosis; it is one of the top reasons people get liver transplants. Highly effective drug treatments have recently become available, but they are expensive, as much as $84,000 to $94,500 for a course of treatment. If everyone in the US with hepatitis C virus were treated, it would cost $331 billion, more than the total drug spending in 2013. For Medicare, treating one patient with Harvoni costs as much as the total annual health care costs for 29 enrollees.
State Medicaid programs have been sued for limiting access to hepatitis C treatments. The suits claim the restrictions are illegal and violate standard medical care. In Washington State, a federal court judge ordered the state Medicaid program to lift coverage restrictions.
The lessons of kidney dialysis
When kidney dialysis was first introduced in the early 1960s, funds were not available to treat everyone who needed it. So-called “God panels” were established to allocate treatment based on perceived social worth. The ethics of that practice were questionable. In 1972 the federal government stepped in to provide lifelong subsidies for eligible patients with end-stage renal disease. At the time, there were 10,000 patients on dialysis with an annual cost of $280 million, but by 2008 there were 382,000 patients on dialysis for a total cost of $39.5 billion, 8% of total Medicare costs. The God panels gave priority to the patients they thought would benefit society by returning to work, but 71% of dialysis patients are unemployed.
Dialysis is not a panacea. It only performs about 10 percent of the work of a healthy kidney, and can cause problems like anemia, bone disease, and high blood pressure. Patients who have a kidney transplant live longer than patients on dialysis, but kidney transplants are expensive, involve risks, and require lifelong immunosuppressant medications at an annual cost of $10-14,000. For the sickest patients, the average cost of one additional quality-adjusted year of life (QALY) was $488,000. For many patients, dialysis has an adverse effect on quality of life. In patients older than 75 with comorbidities, dialysis does not improve survival compared to nonaggressive, conservative renal care. And technological advances in dialysis over the last two decades have not resulted in any improvement in mortality.
Conclusion: Drug prices are a dilemma for society
Our ability to develop new medical treatments is fast outstripping our ability to pay for them. An article in the AMA Journal of Ethics argues that we are already in the era of health care rationing. Funds are not unlimited. As the present trend of ever-more-expensive medical treatments continues, something will have to give. As a society, we will have some difficult decisions to make. How much are we willing to spend? Can we put a price on a human life or on quality of life? What can be done to cut costs? These issues deserve serious discussion, especially now with President Trump’s proposed budget cuts and the pending revision of the American Health Care Act.

Gold mine or dumpster dive? A closer look at adverse event reports
Scott Gavura on April 26, 2012
Link
All informed health decisions are based on an evaluation of expected risks and known benefits. Nothing is without risk. Drugs can provide an enormous benefit, but they all have the potential to harm. Whether it’s to guide therapy choices or to ensure patients are aware of the risks of their prescription drugs, I spend a lot of time discussing the potential negative consequences of treatments. It’s part of my dialogue with consumers: You cannot have an effect without the possibility of an adverse effect. And even when used in a science-based way, there is always the possibility of a drug causing either predictable or idiosyncratic harm.
An “adverse event” is an undesirable outcome related to the provision of healthcare. It may be a natural consequence of the underlying illness, or it could be related to a treatment provided. The use of the term “event” is deliberate, as it does not imply a cause: it is simply associated with an intervention. The term “adverse reaction,” or more specifically “adverse drug reaction,” is used where a causal relationship is strongly suspected. Not all adverse events can be be causally linked to health interventions. Consequently, many adverse events associated with drug treatments can only be considered “suspected” adverse drug reactions until more information emerges to suggest the relationship is likely to be true.
Correlation fallacies can be hard to identify, even for health professionals. You take a drug (or, say, are given a vaccine). Soon after, some event occurs. Was the event caused by the treatment? It’s one of the most common questions I receive: “Does drug ‘X’ cause reaction ‘Y’?” We know correlation doesn’t equal causation. But we can do better than dismissing the relationship as anecdotal, as it could be real. Consider an adverse event that is a believed to be related to drug therapy:
    • First, is the event an extension of the drug’s pharmacology? Is it predictable, based on how the drug works? For example, narcotics predictably cause constipation and cognitive impairment. Oral antibiotics cause diarrhea because they kill the normal flora in our colon.
    • Secondly, what was observed in clinical trials? The product monograph or prescribing information usually summarizes which adverse events were reported in trials, and which were more frequently observed than in the placebo group.
Neither of the two approaches is comprehensive. If the suspected event is rare, it may not have shown up simply by chance alone, in the clinical trial. Or the event may develop slowly: clinical trials have a fixed duration, while treatments in the real world can last decades. The patient population in clinical trials is usually healthier and on fewer other medications than those in the real world. So to truly understand the adverse event profile, we need to look at real world data. We could turn to epidemiological studies that evaluate safety in real-world settings, often using massive treatment databases. While not as robust as data from a randomized controlled trial, and prone to misuse, epidemiological studies can answer questions about vaccine safety or identify subtle effects of drugs on common events, like heart attacks.
If the event in question doesn’t show up in any other data source, but is suspicious, it might be appropriate to submit a report to the manufacturer or to the national drug regulator. Importantly, this is a suspected reaction — we cannot be certain the event was caused by a drug based on a single observation. But multiple reports, sent independently, could “signal” the need for more investigation. Consequently, countries with robust regulatory systems have all established systems for collecting spontaneous reports of harms. Systems generally include:
    • mandatory reporting from drug manufacturers of any adverse event reported to the company
    • optional or mandatory reporting from health professionals who become aware of possible adverse events
    • the option for consumers to report harms directly to regulators (bypassing manufacturers or health professionals)
    • collaboration with other countries to share information on adverse events that are collected.
There are four essential elements to any adverse event report:
    • An identifiable patient: there must be a specific patient known to be involved, and adequate information is necessary (gender, age, etc.).
    • An identifiable reporter.
    • A suspected drug: the drug should be known. If a patient is on multiple drugs, they all need to be described in the report.
    • A suspected adverse event or fatal outcome: specific signs and symptoms are required, and ideally a diagnosis as well (e.g.,”rash” isn’t specific enough to compare between reports).
Multiple reports are typically required to generate the safety “signal”, a flag that an association merits further investigation. The FDA compiles all adverse event reports it collects in the Adverse Event Reporting System (AERS), and continually analyzes that database, publishing possible signals that it has identified. While consumers and health professionals can submit reports to the FDA directly, the overwhelming majority of adverse events are reported by pharmaceutical manufacturers, who are required by law to forward all adverse events they identify. If an event described is serious and not already listed in the prescribing information, it must be forwarded to the FDA within 15 days. Here are the statistics from its Adverse Events Reporting System (AERS):
The blue bars are direct reports, submitted by health professionals or the public — about 4% of the total submitted in 2010. The remainder are submitted by manufacturers. Even massive numbers like these may not be sufficient to identify potential signals of adverse events related to treatments, so countries collaborate and share information: a bigger net can catch more safety signals, it seems. The Uppsala Monitoring Centre is an international collaboration, combining reports submitted by over 100 countries. It has amassed a database of over 7 million reports. Adverse event databases are great resources for identifying safety signals — albeit with some significant limitations.
The Trouble with (V)AERS
The misuse of vaccine-related adverse event reports — called VAERS, for Vaccine Adverse Event Reporting System — is a common tactic of antivaccine groups who believe that vaccines are unsafe and cause significant harms. And a database of suspected harms is a gold mine to those seeking anecdotes. Antivaccine groups have been known to mine the VAERS database, and draw causal relationships where none have been established.
There is no question that adverse effect databases can serve as a valuable resource as part of an overall program to monitor the safety and efficacy of a drug or vaccine. However, in isolation, these databases have limited utility. Patterns or “signals” are recurrent events observed in the data. They are hypothesis-generating — not hypothesis-answering. Most importantly, these databases cannot estimate the incidence of any adverse event. In order to estimate the incidence of an event, we need to know how many times it has occurred in a specified population size: the denominator, which is the total number of patients that have taken the drug (or vaccine, as the case may be). No denominator, no incidence. AERS cannot provide that information, given reporting is spontaneous, incomplete, and the size of the population taking the drug isn’t known. The FDA makes this very, very clear:
AERS data do have limitations. First, there is no certainty that the reported event was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. Further, FDA does not receive all adverse event reports that occur with a product. Many factors can influence whether or not an event will be reported, such as the time a product has been marketed and publicity about an event. Therefore, AERS cannot be used to calculate the incidence of an adverse event in the U.S. population. [emphasis added]
The old adage that garbage in = garbage out holds true with adverse event databases. The quality of reporting is as important as, if not more important than, the quantity of these reports. Low quality reports, with incomplete data have the potential to increase the challenge of finding true safety signals. Trends in AERS and VAERS reports may also be subject to external pressures unrelated to drug effects. Relationships have been established between H1N1 media stories and VAERS reports. Vaccine litigation can do the same thing. Neither are real, but you need to look beyond the databases to answer the question. It would be interesting to see if some of the current medical-legal drug controversies (e.g., oral contraceptives, antipsychotics, and antidepressants) also have identifiable litigation-related trends in AERS databases.
The Power of Nocebo
Are all reported side effects real effects? Probably not. Any double-blind clinical trial will describe the side effects reported with both the active treatment, and the placebo. And adverse events from placebos can be so significant that they lead to treatment discontinuation. A systematic review of trials in patients with fibromyalgia noted that 67% of patients reported adverse events in the placebo arms, and 10% discontinued “treatment” with the placebo due to adverse effects. In a study of allergy treatments, 27% of participants reported allergic symptoms to a placebo challenge. And in a study that compared ASA (aspirin) versus placebo, describing potential adverse effects of therapy led to a “sixfold increase in the number of subjects withdrawing from the study because of subjective, minor, gastrointestinal symptoms” compared to study sites that did not provide that caution.
The recognition of nocebo effects is another consideration when evaluating individual adverse event reports.
Free the data!
While collecting and analyzing adverse event reports has been standard practice since the thalidomide disaster, the data only became publicly available more recently. Several years ago, the Canadian Broadcasting Corporation (CBC) used access-to-information laws to obtain access to Health Canada’s entire adverse event database, and posted the data online. Health Canada subsequently made the data available directly. The FDA makes similar data available, which you can query directly. But given the limitations described above, the utility of these databases to the public or health professionals isn’t clear.
It seems clear to a new company, adverseevents.com, which aims to make AERS data more easily accessible, and to make money while doing so as the CMAJ described last week. Brian Overstreet, CEO, made the following comments:
We live in an information age, and there is an overwhelming pool of potential information for consumers to look at online. What’s lacking is a real statistical overview. We can come in and say, listen it’s nice that 200 people on this discussion board say they got an upset stomach, but we have 50 000 case reports, and from those we know 27% have an upset stomach. Having hard data to back up the real world perception I think is very, very valuable.
The FDA, and even they don’t know for sure, but they estimate maybe 10% of the serious adverse events are reported. But as much as we’re talking about a limited data set, three million case reports in the last seven years, it’s not a small data set. It’s a pretty robust data set. The data’s never going to be perfect, but it’s better than nothing, and so long as we’re treating it properly, the end result should be valuable.
The obvious problem with this approach, as I’ve pointed out above, is that it ignores the significant limitations of the data itself. You cannot estimate incidence without a denominator. And there is no denominator in the AERS data. These data limitations don’t stop the company from comparing within classes of drugs based on reported events, or even identifying which drugs are most likely to be associated with death.
Another group that recently announced a query service for adverse events reports is headed by Dr. David Healy, psychiatrist and author of the book Pharmageddon. He has launched an independent adverse event collection site, Rxrisk.org, which states:
There comes a point where, even if the clinical trial data says otherwise, it is just not reasonable to say the problem can’t be happening in at least some people. You and your healthcare team have been handed a megaphone!
It appears that Rxrisk.org will both analyze FDA-reported adverse events, as well as collect reports directly, and facilitate their submission. In an interview, Healy made the following comment:
People need to wake up and stop thinking that clinical trials have provided all the answers. We need to get back to believing the evidence of our own eyes. The key thing is to get the data. There isn’t anyone else getting data like this.
Given the dangers of drawing conclusions from spontaneous reports, and considering how the VAERS databases have been misused to make erroneous inferences about vaccine safety, I’m somewhat skeptical of what rxrisk.org and adverseeevents.com will contribute to our understanding of drug safety. The sites are not yet fully operational, so this may be a topic I’ll revisit in a future post.
Improving our drug safety monitoring systems
We all share the goal of wanting to understand the true risks of drug treatments. Part of supporting informed evaluations of risk and benefit means regulators must continuously monitor the real-world safety profile of licensed drugs. Adverse event databases perform a critical role in identifying possible safety signals and generating hypotheses that require additional analysis. The significant challenge is to differentiate between the useful signals and the noise, and recognize biases in our observations and in the way we collect this data. Otherwise we may well assign causality where none may exist — another sort of poor outcome.
Adverse effect reporting systems are designed to enhance patient safety. They are one tool, unquestionably useful, but limited in utility. If we don’t keep these limitations in mind, we run the risk of worsening, not improving, our understanding of a treatment’s risk and benefit.

The drug expiry date: A necessary safety measure, or yet another Big Pharma conspiracy?
Scott Gavura on May 10, 2012
Link
Consider this scenario: You’re in good health and take no prescription drugs. You use the following remedies occasionally:
    • Excedrin for the rare migraine
    • Arnica 30CH for bumps and bruises
    • Echinacea capsules, when you feel a cold coming on
Today you look in your cupboard, and notice all three products expired last year. Would you still consider taking any of them? Why or why not?
Your answer is probably influenced by a number of factors, including perceptions of risk and benefit. I’ve encountered patients who believe that drugs are less active as they near the expiration date, and others who see expiry dates solely as marketing ploy from Big Pharma. Few understand how they’re calculated.
Over the past few months I’ve written several posts on different aspects of drug development and testing, including drug interactions, fillers and excipients in drug products, the equivalence testing of generic drugs, and the management of drug allergies. I’ve done this for two reasons. The first is to develop a SBM-oriented resource for common questions and misconceptions about the mechanics of modern medicines. The second, less obvious reason for these posts has been to illustrate the serious credibility gaps with CAM therapies. Largely because of a lax regulatory framework, the CAM industry has ballooned into a multi-billion dollar market without answering basic questions that should be asked of any supplement or drug, “alternative” or otherwise. What’s not well known to consumers, but is glaringly obvious to SBM advocates, is that CAM largely ignores issues of pharmacology: understanding how a chemical substance, once consumed, behaves in the body. It’s critical to scientific medicine, but an unnecessary step for CAM, where there’s no need to determine if a product has a beneficial biological effect before selling it. Fundamental tests in medicine, like the identification and isolation of an active ingredient, or understanding dose-effect relationships, are simply ignored. As David Gorski and Mark Crislip have pointed out over the past week, we have a reality bias at SBM. And this bias is equally jarring when it comes to considering expiry dates for products: real drugs, and also CAM.
Expiry dates are the source of a lot of questions to pharmacists. Not only is the pharmacy legally responsible for ensuring your prescription is filled with “in-date” stock, we’re regularly confronted with dealing with expired drugs. Because of expiry dates, an enormous quantity of drugs are manufactured and sold or dispensed, but never consumed. This creates a significant wastage issue: Last month, the U.S. Drug Enforcement Administration’s National Prescription Drug Take-Back Day collected 552,161 pounds (that’s 276 tons) of unwanted or expired drugs. Those are drugs that someone paid for, and are now being incinerated. If expiry dates are nonsense, extending them could have considerable economic and environmental benefits. So where does the expiry date come from? For drugs, they’re based on the chemical characteristics of the product itself.
Calculating the expiry date
At some point after major clinical trials are concluded, but before FDA approval, a series of quality standards are established for each new drug. These are the manufacturing and testing specifications, which includes upper and lower limits for the amount of the Active Pharmaceutical Ingredient (API) in each dose unit (e.g., 500mg per tablet). The final dosage form may be a mix of the API as well as fillers, binders, and other ingredients to ensure the API is delivered to the body in a reliable and predictable manner. But what certainty do we have that this new dosage form will maintain all of these properties over time? What happens after it sits on a shelf for two or three years, or more? Few companies have the patience to wait, so drug products are put through accelerated degradation testing, or “stress” testing, to estimate how quickly a drug will deteriorate. Depending on the dosage form, stress testing may include short-term exposure to extremes of heat, light, oxidation, and humidity. After exposure over different time periods, the quantity of the API, and the other product characteristics, will be assayed again. Not only does this help us understand how stable a drug is, it illustrates the degradation pathways – what chemical reactions that could be expected to occur over time. For liquid and injectable drugs, there will be additional tests for bacterial purity and chemical stability. All of these tests predict the overall stability of the dosage form – not just the amount of drug, but how that drug will be absorbed into the body. All of this is used to estimate what the expiry date should be: the date to which the manufacturer warrants the original product characteristics will be retained.
Expiry dates for drugs can vary dramatically. One of the shortest for a drug in common use is injectable epinephrine known as the “Epipen”, carried by those with severe allergies. Epinephrine for injection is notoriously unstable, and you’re lucky to find a product that expires longer than 18 months after you get it. Other drug products are highly sensitive to moisture, requiring dispensing in specialized containers with dessicants to trap moisture and enhance stability. Many liquid antibiotics have very poor stability, so they must be prepared in the pharmacy at the time of dispensing. Refrigeration is necessary for other drugs, ranging from vaccines to eyedrops, which keeps the dosage form stable.
It is important to keep in mind that the expiry date of a drug is based on testing of previously unopened products, stored in its original container, and maintained under typical conditions. Once you open a bottle, or transfer it to another container (like a prescription vial), the manufacturer’s expiry date is no longer reliable. That doesn’t mean a drug will become ineffective rapidly, but the stability could be compromised once it has been introduced to light, heat, and humidity. Humidity’s effects are frequently noticable with old bottles of Aspirin (acetylsalicylic acid) which breaks down via hydrolysis to salicylic acid and acetic acid giving old bottles a characteristic vinegar odour.
Are expired drugs still safe?
The first concern related to expired drugs is whether they are potentially harmful if consumed. Reassuringly, there is no published data to suggest harms from use of drug formulations after their expiry data. The example of degraded tetracycline causing kidney damage in cases dating back to the 1960’s, is drilled into every pharmacist’s brain. Reassuringly, this occurred with a version of the drug that is no longer available. While recognizing that case reports are an inaccurate and imprecise way of identifying harms, the lack of documented harms suggests that degradation of useful chemicals into toxic compounds is rare, if it occurs at all. Additionally, current requirements for stability testing of drugs should identify if expired products pose a safety risk – and there do not seem to be any other documented cases.
Are expired drugs still effective?
Again, the evidence is reassuring – with some caveats. The best way to verify long-term stability would be to stockpile supplies, let them sit for years, and even decades, and then test them. My American colleagues can thank their government for doing just such testing- the Department of Defense/FDA Shelf Life Extension Program has been in place for over 20 years. It tested 122 different products, stored unopened and in their original containers, and found that about 88% are stable for at least one year after expiry with an average of 5 years after the expiry date. However, this was under ideal conditions – not typical use consumer use, where bottles are usually partially consumed, and partially exposed to moisture and light. Stability isn’t always a given. Epipen’s active ingredient degrades consistently after the expiration. So I’d never suggest people carry an expired Epi-Pen – but I wouldn’t hesitate to recommend its use in life-threatening anaphylactic situations where no other alternatives existed. Similarly, you may be less concerned about drug potency if you’re taking something like Excedrin for a headache, versus medication to treat epilepsy, where small changes in the dose delivered could affect drug levels. Because of sterility concerns, you should throw out an eye drop that has been open for several months, even if the expiry date still says it’s OK to use – that expiry date was for unopened drug. And if you leave your prescriptions to cook on the dash of your car in the hot sun (I have encountered this) speak with a pharmacist who may be able to get drug-specific stability data.
Disposing of expired drugs
I was surprised to see that the FDA suggests some drugs can be safely disposed of by flushing down the toilet. I could not find similar guidance in Canada, where medication return programs are common and many pharmacies participate. Return program incinerate the drug, eliminating secondary environmental exposure. This method also minimizes the risk of diversion or accidental poisoning.
Revisiting our vignette
Excedrin is a combination of acetaminiophen (Tylenol), acetylsalicylic acid (Aspirin) and caffeine. Excedrin may be effective after expiration – but sniff for the vinegar odour, which indicates the ASA has deteriorated. Expired Excedrin is unlikely to be harmful, but has the potential for degradation over time.
Arnica 30CH is a homeopathic product. It has no active ingredients, and no meaningful therapeutic effects, so there’s nothing to “expire”. However, regulators like Health Canada insist that an expiry date must be assigned:
Expiry date: The earlier of:
the date, expressed at minimum as a year and month, up to and including which a NHP [Natural Health Product] maintains its purity and physical characteristics and its medicinal ingredients maintain their quantity per dosage unit and their potency; andthe date, expressed at minimum as a year and month, after which the manufacturer recommends that the NHP should not be used.
Given homeopathy, once diluted to typical concentrations, contains zero active ingredients, I’m curious why Health Canada allowed language like “medicinal ingredients” and “quantity per dosage unit” for establishing standards for what are quite literally sugar pills. The FDA, to its credit, recognizes that the non-ingredients of homeopathy can’t be measured and can’t expire:
1. Section 211.137 (Expiration dating) specifically exempts homeopathic drug products from expiration dating requirements.
There’s no good evidence to demonstrate echinacea is effective for preventing or treating colds. The active ingredients, if any exist, have not been identified and isolated. Capsules of echinacea usually contain pieces of the root or rhizome. Given the active ingredient isn’t known, there’s no way to test for its presence. And if you can’t verify the amount of active ingredient in each capsule, you can’t verify its stability over time. So for herbal products without standardized active ingredients, any expiry date is going to be arbitrary – unrelated to product quality or safety. Not surprisingly, the FDA does not require expiry dates to be placed on dietary supplements, an acknowledgement that you can’t verify what you haven’t found. In contrast to the FDA, Health Canada requires an expiry date to be assigned for herbal products.
Conclusion
There’s no single rule for expired drugs and supplements, owing to the variety of products, regulatory requirements, and other factors that can influence a product’s safety and efficacy. In general, expiry dates are conservative, and consumers can have confidence that drug labeling claims will be accurate up to, and in some cases well beyond, the labelled expiry date. The reality is that we don’t store drugs under ideal circumstances. So when absolute certainty is required, stick to drug products that are not expired. When absolutely necessary, expired drugs are probably safe, however, the potency may be compromised. And when you’re talking about supplements, herbals, and homeopathy, keep in mind that any expiry dates are usually arbitrary. And before you flush or toss those expired drugs, find ways to dispose of them in a way that minimizes the environmental impact and potential for harm.

Are drug expiry dates really a myth?
Are drug expiry dates just an industry ploy to keep you buying new bottles of medicine?
Scott Gavura on July 27, 2017
Link
Drug expiry dates have been in the news following a ProPublica report on July 18. While Scott is taking a blogging break, here’s an update of his post on expiry dates from 2012.
Imagine that’s the contents of your medicine cabinet above. All of the products are expired. Would you still consider taking any of them? Why or why not?
Your answer is probably influenced by a number of factors, including perceptions of risk and benefit. Some feel the expiry date is purely a plot of Big Pharma to sell more drugs. Others believe that drugs start deteriorating long before the expiry date. Few understand how and why they’re calculated.
Expiry dates are the source of a lot of questions to pharmacists. Not only is the pharmacy legally responsible for ensuring your prescription is filled with “in-date” stock, we’re regularly confronted with dealing with expired drugs, both prescription and non-prescription. Because of expiry dates, an enormous quantity of drugs are manufactured and sold or dispensed, but never consumed. This creates a significant wastage issue: In April 2017, the U.S. Drug Enforcement Administration’s National Prescription Drug Take-Back Day collected 900,386 pounds (that’s 450 tons) of unwanted or expired drugs. Those are drugs that someone paid for, and are now being incinerated. If expiry dates are nonsense, extending them could have considerable economic and environmental benefits. So where does the expiry date come from? They’re based on the chemical characteristics of the product itself.
Calculating the expiry date
At some point after major clinical trials are concluded, but before FDA approval, a series of quality standards are established for each new drug. These are the manufacturing and testing specifications, which includes upper and lower limits for the amount of the Active Pharmaceutical Ingredient (API) in each dose unit (e.g., 500mg per tablet). The final dosage form may be a mix of the API as well as fillers, binders, and other ingredients to ensure the API is delivered to the body in a reliable and predictable manner. But what certainty do we have that this new dosage form will maintain all of these properties over time? What happens after it sits on a shelf for two or three years, or more? Few companies have the patience to wait, so drug products are put through accelerated degradation testing, or “stress” testing, to estimate how quickly a drug will deteriorate. Depending on the dosage form, stress testing may include short-term exposure to extremes of heat, light, oxidation, and humidity. After exposure over different time periods, the quantity of the API, and the other product characteristics, will be assayed again. Not only does this help us understand how stable a drug is, it illustrates the degradation pathways – what chemical reactions could be expected to occur over time. For liquid and injectable drugs, there will be additional tests for bacterial purity and chemical stability. All of these tests predict the overall stability of the dosage form – not just the amount of drug, but how that drug will be absorbed into the body. All of this is used to estimate what the expiry date should be: the date to which the manufacturer warrants the original product characteristics will be retained.
Expiry dates for drugs can vary dramatically. One of the shortest for a drug in common use is injectable epinephrine known as the “Epipen”, carried by those with severe allergies. Epinephrine for injection is unstable, and you’re lucky to find a product that expires more than 18 months after you get it. (The ProPublica article points out that this may, in fact, be overstated.) Other drug products are highly sensitive to moisture, requiring dispensing in specialized containers with dessicants to trap moisture and enhance stability. Many liquid antibiotics have very poor stability, so they must be prepared in the pharmacy at the time of dispensing. Refrigeration is necessary for other drugs, ranging from vaccines to eyedrops, which keeps the dosage form stable.
It is important to keep in mind that the expiry date of a drug is based on testing of previously unopened products, stored in its original container, and maintained under typical conditions. Once you open a bottle, or transfer it to another container (like a prescription vial), the manufacturer’s expiry date is no longer reliable. That doesn’t mean a drug will become ineffective rapidly, but the stability could be compromised once it has been introduced to light, heat, and humidity. Humidity’s effects are frequently noticeable with old bottles of Aspirin (acetylsalicylic acid) which breaks down via hydrolysis to salicylic acid and acetic acid giving old bottles a characteristic vinegar odour.
Are expired drugs still safe?
The first concern related to expired drugs is whether they are potentially harmful if consumed. Reassuringly, there is no published data to suggest harms from use of drug formulations after their expiry data. The example of degraded tetracycline causing kidney damage in cases dating back to the 1960’s, is drilled into every pharmacist’s brain. Reassuringly, this occurred with a version of the drug that is no longer available. While recognizing that case reports are an inaccurate and imprecise way of identifying harms, the lack of documented harms suggests that degradation of useful chemicals into toxic compounds is rare, if it occurs at all. Additionally, current requirements for stability testing of drugs should identify if expired products pose a safety risk – and there do not seem to be any other documented cases.
Are expired drugs still effective?
Again, the evidence is reassuring – with some caveats. The best way to verify long-term stability would be to stockpile supplies, let them sit for years, and even decades, and then test them. Americans can thank their government for doing just such testing – the Department of Defense/FDA Shelf Life Extension Program has been in place for over 20 years. It tested 122 different products, stored unopened and in their original containers, and found that about 88% are stable for at least one year after expiry with an average of 5 years after the expiry date. However, this was under ideal conditions – not typical use consumer use, where bottles are usually partially consumed, and partially exposed to moisture and light. Stability isn’t always a given. Epipen’s active ingredient degrades consistently after the expiration. (Though ProPublica points to a newer paper that suggests better stability.) So I’d never suggest people carry an expired Epi-Pen – but I wouldn’t hesitate to recommend its use in life-threatening anaphylactic situations where no other alternatives existed. Similarly, you may be less concerned about drug potency if you’re taking something like Excedrin for a headache, versus medication to treat epilepsy, where small changes in the dose delivered could affect drug levels. Because of sterility concerns, you should throw out an eye drop that has been open for several months, even if the expiry date still says it’s OK to use – that expiry date was for the unopened drug, not a bottle that’s been used. And if you leave your prescriptions to cook on the dash of your car in the hot sun, or freeze in the winter, (I have encountered both) speak with a pharmacist who may be able to get drug-specific stability data.
Conclusion: Drug expiration dates exist for a reason
There’s no single rule for expired drugs and supplements, owing to the variety of products, regulatory requirements, and other factors that can influence a product’s safety and efficacy. In general, expiry dates are conservative, and consumers can have confidence that drug labeling claims will be accurate up to, and in some cases well beyond, the labelled expiry date. But the reality is that we don’t store drugs under ideal circumstances. So when absolute certainty is required, stick to drug products that are not expired. When absolutely necessary, expired drugs are probably safe, however, the potency may be compromised. And before you flush or toss those expired drugs, find ways to dispose of them in a way that minimizes the environmental impact and potential for harm.

Adherence: The difference between what is, and what ought to be
Scott Gavura on March 15, 2012
Link
One of the most interesting aspects of working as a community-based pharmacist is the insight you gain into the actual effectiveness of the different health interventions. You can see the most elaborate medication regimens developed, and then see what happens when the “rubber really hits the road”: when patients are expected to manage their own treatment plan. Not only do we get feedback from patients, there’s a semi-objective measure we can use — the prescription refill history.
The clinical trial, from where we derive much of our evidence on treatments, is very much an idealized environment. The relationship to the “real world” may be tenuous. Patients in trials are usually highly selected, typically those that are able to comply with the intervention planned. They may need to be free of any other diseases which could complicate evaluation. Patients that qualify for enrollment enter an environment where active monitoring is the norm, and may be far more intense than normal clinical practice. All of these factors mean that trial results may be meaningful, but not completely generalizable to the patient that may eventually be given the intervention. It’s for this reason we use the term “efficacy” to describe clinical trial results, while “effectiveness” is what we’re more interested in: those real-word effects that are far more relevant, yet more elusive to our decision-making. Efficacy measures a drug’s effect on an endpoint, and estimates risk and benefit in a particular setting. Effectiveness adds in real-world tolerance, the ability to tolerate the regimen, and all the other factors that are present when real patients take a drugs under less-than-ideal conditions. Consequently, effectiveness is a much more useful predictor of outcome than efficacy. Unfortunately, measurements of real-world effectiveness, possibly as a “phase 4” or real-world trial, are rarely conducted.
But the gap between clinical trials and the real world is obvious: medications just aren’t taken regularly. The extent of non-compliance with prescribed therapy varies between reviews, but an estimate of about 25% is probably fair. Patient with HIV, arthritis, gastrointestinal disorders and cancer tend to be the most adherent to therapy — not surprising, perhaps because of the seriousness of the condition, or perhaps the responsiveness of symptoms to treatment. Least compliant are patients for treatments of lung disease, diabetes, and sleep disorders. In general, it’s safe to assume that if symptoms are mild or non-existent (e.g., high blood pressure or high cholesterol), compliance will be poor, compared to more symptomatic diseases.
Failing to adhere to a prescribed medication course is a significant challenge — after all, you won’t get the outcome you want if the medication isn’t taken. Or will you? The relationship between the two that has always been considered to be causal, but there is some evidence to suggest that adherence to a medication schedule may be a proxy for healthy lifestyles and generally healthy behaviours. I wanted to look closer into adherence after reading a paper highlighted by Mark Crislip a few weeks ago: Adherence to placebo and mortality in the Beta Blocker Evaluation of Survival Trial (BEST). This post-hoc analysis studied the placebo group of a double-blind, placebo-control trial that evaluated the drug bucindolol versus placebo. Those deemed “adherent” to their placebo (taking >75% of doses) were compared to the non-compliant (who took <75% of doses). The authors adjusted for all known modifiable, non-modifiable and psychosocial variables. The surprising result?
Adherent participants had a significantly lower total mortality compared to less-adherent participants (HR = 0.61, 95% Confidence Interval: 0.46–0.82). Adjusting for available confounders did not change the magnitude or significance of the estimates. When considering cause-specific mortality, CVD and pump failure showed similar associations.
Those are impressive gains, apparently from a placebo. So what’s the cause? It’s not any confounding factor already explored by the authors. And we know the placebo has no meaningful physiologic effects. So by increasing adherence to prescribed medications, are we getting therapeutic effects from the intervention, or simply by modifying some other factor that affects outcomes? Or are there other factors at play? In the absence of a prospective randomized trial, we can’t say with any certainty.
While the correlation may not be understood yet, it seems reasonable to continue to promote adherence, given the relationship with improved outcomes. Surprisingly, despite the widespread nature of the problem, the literature base on interventions to improve adherence don’t paint a clear picture on how to change the situation. Well designed trials that evaluate interventions are rare. Probably the most comprehensive summary of the literature is from the Cochrane review, which concludes that even more effective interventions don’t lead to significant improvements in clinical outcomes. Before we get into what works, we should be clear on the terminology [PDF], as it can be source of confusion:
Adherence or Compliance refers to the act of following recommendations made by health professionals, with respect to drug, dose, and medication schedule. The ideal means of measuring adherence is with electronic devices that measure daily dosing. As these are usually not available, the prescription refill frequency is a useful, if imperfect, proxy.
Concordance is a related term used to describe a shared agreement between a health professional and a patient about therapeutic goals. It’s less a measure, and more a philosophical approach to implementing treatment plans.
Persistence refers to the duration of conformance to a particular treatment plan, and is usually defined by the interval between when therapy is started, and when it is discontinued. Adherence to the exact dosing schedule is not necessary in a measure of adherence.
Most research on adherence evaluates the effect of a specific intervention on some measure of medication-taking. In a few studies there are also evaluations of clinical outcomes that are a consequence of (non)adherence — which is far more relevant, but unfortunately, less frequently evaluated:
Technical interventions simplify dosing by modifying how medications are actually taken. You could reduce the number of daily doses (e.g., the extended-release tablet) or give a tablet or dosage form which contains two or more different drugs (e.g., many HIV medications). Technical interventions also include pharmacy-driven services like bubble-packing tablets, or by filling specialized pill “medication reminder” devices.
Technical interventions have been evaluated in multiple reviews. Obviously, blinding is a problem in these circumstances. In general, simplifying medication regimens helps with adherence: Taking one pill per day is easier and more acceptable than one pill every six hours.
Behavioural interventions prompt medication use through the use of memory aids, reminders (manual or electronic), monitoring, feedback and rewards. These types of interventions seem to have beneficial effects, an observation that’s been made in several different studies. There’s a lot of potential to use mobile technology to support medication use, now that smart phones are becoming ubiquitous.
Education interventions are the pharmacist’s bread and butter: patient teaching and knowledge. In general, there’s a positive correlation between patient knowledge, medication adherence, and outcomes, although the effects don’t seem as impressive as technical and behavioural interventions.
Social support interventions offer practical or emotional support to patients. While it sounds attractive, there’s less data available to describe which interventions are the most effective.
Structural interventions are more extensive tactics usually used to manage chronic disease. Workplace specialty care programs (e.g., hypertension) or disease management programs (e.g., diabetes) are examples of this intervention.
There are several caveats to keep in mind. Studies that have prospectively looked at adherence typically enroll patients that again, may not be fully representative of the general medication-taking population. In addition, studies that have looked at adherence suggest that many interventions that work can be time consuming and expensive. Finally, the relevance to long-term medication use is unclear in some cases.
Conclusion
Adherence to therapy is a medical challenge, where the root causes are not always well understood. While the idea of a healthy patient effect seems real enough, the factors that lead to better outcomes in those that adhere to therapy isn’t clear. Given the importance of adherence to the treatment of most chronic diseases, it’s a unfortunate that strategies to improve adherence have not been more thoroughly evaluated. In the absence of good data, interventions to simplify medication schedules, provide education on the importance of adherence, and provide reminders on dosing make sense. When the “rubber hits the road” when planning treatments, it’s important to recognize that adherence may be one of the biggest influences on health outcomes.

More drugs, more supplements, and potentially more problems
Scott Gavura on March 24, 2016
Link

Early in my career I was fortunate to be offered a role as a hospital pharmacist, working on an inpatient ward along with physicians, nurses, and a number of other health professionals. My responsibilities included conducting a detailed medication review with each newly admitted patient. We would sit together, often with family members, going through what was sometimes a literal garbage bag full of medications, and documenting the drug, the dose, and the reason for use. I can’t remember the most medications I ever counted, but a dozen or more was normal. Some were taking medications four or five times per day, every day. Were all these drugs necessary? In many cases, no. They’d been started at different times, often by different physicians. Some drugs treated the side effects of other medications. Few had ever had a health professional document them all in a single list. There had rarely been an overall review for safety and appropriateness. Few patients knew the treatment goals of their medications. Often, they’d never been asked about their treatment preferences.
In addition to auditing every prescribed medication, I asked about vitamins, supplements and over-the-counter drugs. I usually encountered the same scenario – multiple products, often without any clear medical need. There were vitamins for “eyes”, tonics for “the blood”, and supplements believed to treat or prevent illness. There was regular (and sometimes dangerous) over-the-counter painkiller consumption. Sometimes all of these combinations were clearly antagonistic: concurrent laxatives and treatments for diarrhea, or sleeping pills taken along with stimulants. Worryingly, few had disclosed the use of many of these products to their physician beforehand.
Medication reviews were a tremendous amount of work – but enormously rewarding. It was not difficult to find one or more cases of drugs potentially causing harm, or situations with clear drug-drug or drug-supplement interaction. In some cases, it was the medications that had put them in the hospital in the first place. Working with the residents and medical staff we could usually find ways to simplify their regimen, often discontinuing one or more drugs, reducing the doses of others, and suggesting ways to cut their supplement and over-the-counter drug use – or at a minimum, reduce the risk that these products could cause problems. Not only did patients end up with simpler medication schedules, we were helping them feel better, too. Before every patient was discharged, they’d get a follow-up visit from me. I’d provide a detailed list of current medications with a simplified schedule designed to make medication use easier. We’d provide copies for them to take to the pharmacy and to any specialist. In many cases, patients were still on a long list of drugs. But we’d cleaved away the most harmful and unnecessary, trying to leave only the medications that were appropriate.
What is polypharmacy?
As medication reviews became part of my job, I grew familiar with the term “polypharmacy”. Polypharmacy describes the concurrent (and usually inappropriate) use of multiple medications. As I have written many times before, all drugs have expected benefits and potential risks. A decision to take any drug needs to consider both. Polypharmacy complicates matters. There is good evidence to demonstrate that the total number of medications you take concurrently is a strong risk factor for medication-related harms. The higher the number, the greater the likelihood of inappropriate use, and the greater the risk of medication-induced problems, like drug interactions. Making matters worse, the growing use of supplements means more people using drugs and supplements concurrently. The consequence may be more medication- and supplement-induced harms.
Polypharmacy is common among seniors
Seniors are at the biggest risk of polypharmacy. Chronic medical conditions are more common, and each may require medical therapy. And despite how frequently we use medications in the elderly, there’s often less information available about their relative risks and benefits. Kidney and liver function can decline as you age, leading to changes in how the body eliminates drugs (and supplements). New side effects can emerge and be mistaken for new medical conditions, and treated with more drugs (or supplements). The consequences can be severe: cognitive impairment, falls, and overall increases in the risk of injury or death.
Two new papers published this week in the Journal of the American Medical Association give some new statistics on the trends in polypharmacy among seniors.
Trends in polypharmacy – both drugs and supplements
The first paper is from Dima M. Quato and colleagues and is entitled “Changes in Prescription and Over-the-Counter Medication and Dietary Supplement Use Among Older Adults in the United States, 2005 vs 2011.” This is a survey of older Americans (aged 62 to 85) who consented to in-home interviews and direct audits of medication, supplement, and over-the-counter drug use. One group was audited in 2005, and the other in 2011. There were over 2,000 participants in each group, with few differences between them from a demographic perspective. If a drug or supplement was taken on a “regular schedule”, they were included. The researchers subsequently compared the medication audits of the two groups, and that data is summarized in this paper. Considering 2005 versus 2011, there were several significant findings:
    • The overall prevalence of prescription medication use increased slightly from 84.1% to 87.7%
    • The concurrent use of more than five prescription medications increased from 53.4% to 67.1%
    • The use of over-the-counter medications decreased from 44.4% to 37.9%
    • The use of dietary supplements increased from 51.8% to 63.7%
    • The concurrent use of two or more dietary supplements increased from 31.6% to 47.0%
Because these audits captured the names of every product taken, it allowed for some interesting observations beyond the numbers. There was an increase in the overall use of statins, anti-platelet drugs, anti-inflammatory medications, and stomach-acid-suppressing proton pump inhibitors. Other categories, like drugs for hypertension, were relatively consistent between the periods. Among supplements, multivitamins, minerals, and calcium supplements remained the most commonly used. There were increases in the use of omega-3 fish oils, vitamin D, and coenzyme Q10. The use of vitamin E and folic acid, conversely, declined.
The audits also identified the possibility of drug-drug and drug-supplement interactions. 15.1% of all older adults were taking medication combinations with the potential for a major interaction. This was an increase from 8.4% just six years earlier. In an ideal world, each of these interactions would have been reviewed carefully for appropriateness. But the review found that potentially serious interactions (like simvastatin and amlodipine) were increasing.
Interactions – drug/supplement, but also patient/doctor
Drug-drug interactions and drug-supplement interactions can be serious, and it’s difficult for patients and health professionals to avoid them without the cooperation and participation of patients who are ultimately making their own decisions about what products (prescription or otherwise) that they decide to take. This leads to the second paper I want to highlight, which also appeared in JAMA this week. It’s a research letter entitled “Nondisclosure of Complementary and Alternative Medicine Use to Primary Care Physicians: Findings From the 2012 National Health Interview Survey.” The authors are Judy Jou and Pamela Jo Johnston, who introduce their work with an odd defense of CAM and a plea for “integration”:
Although one-third of US adults report using complementary and alternative medicine (CAM), integration of CAM into the conventional medical system is inconsistent. Patients have shown a desire for their primary care physicians to inquire about CAM and refer to CAM practitioners (acupuncturist, massage therapists, etc), but primary care physicians rarely initiate conversations with patients about their use of CAM. Patients have also expressed concerns about discussing the use of CAM with their physicians, fearing disapproval. These communication barriers may prevent CAM from becoming fully integrated into patients’ treatment and self-care routines, especially if patients do not disclose their use of CAM to their primary care physicians.
It seems this paper was funded by the University of Minnesota’s “Integrative Health and Wellbeing Program” at the “Center for Spirituality and Healing”. That program offers (among other courses) university credits on topics like aromatherapy, Ayurveda, reiki, acupressure, and “healing imagery”, which may explain the pro-CAM perspective. Having said that, their analysis is quite interesting and complements the Quato paper’s findings on the growing presence of polypharmacy.
The authors analyzed the National Health Interview Survey, an annual survey conducted by the National Center for Health Statistics. That survey contains an “Adult Alternative Medicine” supplemental questionnaire. The sample studied included civilian adults who voluntarily completed the CAM questionnaire, had used some form of CAM during the past 12 months (more on this below), and indicated that they had a family physician.
In the questionnaire, respondents were asked to indicate the nature of their CAM use, and indicate if they had told their family physician about the CAM they felt was “most important to their health in the previous year”. This table summarizes the overall findings, and the disclosure rate by type of CAM:
There were 34,525 adults who completed the CAM questionnaire in 2012. Of those, 29.6% reporting using CAM at least once in the past year, and 66.3% had a primary care physician, resulting in 7,493 adults who met both criteria. In this group, 42.3% did not disclose the use of CAM. This sounds concerning, but the details are somewhat more reassuring.
From a polypharmacy perspective, the objective is to reduce the risk of drug- or supplement-induced harm. Reassuringly, the products with the greatest likelihood of causing interactions with drug (supplements and herbs) were noted as being disclosed to the physician 75% of the time. That’s not ideal, but it’s much better than the 42.3% in the overall findings. One reason for the very low reporting rate might have been influenced by what was considered CAM. This questionnaire included yoga as CAM, and non-disclosure was highest with yoga, at about 65%. I don’t find this surprising. I do yoga occasionally, and I’ve always thought of it as exercise, not medicine, and definitely not CAM. It would never occur to me to mention this to a physician if asked about CAM usage. Similarly, only about half of the people using homeopathy were disclosing it to their physician. Partial disclosure isn’t ideal, but there’s no real risk of incremental polypharmacy harms with homeopathy, given homeopathy is an elaborate placebo system where many remedies don’t contain a single molecule of any medicinal ingredient. What is important, however, is a shared understanding about why CAM products like supplements and even homeopathy are being used, so that there can be a candid discussion about the best therapeutic approach.
If respondents said they hadn’t disclosed their CAM use, they were asked why.
I found this finding reassuring, to some extent. It’s rare that participants were worried about their physician’s reaction or knowledge. Not disclosing was more likely due to the physician not asking, or the patient not thinking that the physician needed to know. The reasons for this lack of disclosure can be rectified fairly easily: health professionals need to ask, and they need to create an environment of trust where patients feel comfortable talking about their own approaches and preferences. In particular, identifying CAM with the greatest potential to cause supplement-drug interactions is essential. An open dialogue, with specific questions about supplement and CAM use, may help address this issue.
The risks of polypharmacy and supplements
The biggest concern about concurrent supplement use with medication goes beyond their lack of efficacy. As I have written before, because the quality standards for supplements and other “natural health products” are not as rigorous as they are for drug products. Not only is there (in most cases) little information to support routine supplement use, there is evidence to show that CAM (like herbal remedies) products can be adulterated or even lack the ingredient that’s listed on the label – a state of affairs that is virtually unheard of when it comes to drug products approved by regulators like the FDA.
Polypharmacy can absolutely be harmful, but it can also be justified. My time as a hospital pharmacist showed me that while medications can cause harms, they can also be essential. Some seniors would be much better off if we discontinued several of their medications. Others would be dead. The absolute numbers of medications, supplements and over-the-counter drugs taken isn’t the problem – but it is a big red flag to proceed cautiously. Polypharmacy is growing and so are the risks of harms. Health professionals, particularly physicians and pharmacist, need to do more. We need to ask more questions, and ensure our patients treat supplements and over-the-counter drugs just like medicines. We need to ensure our advice and decisions are guided by the evidence – what works, and what’s best for a patient given the circumstances and the treatment goals. The patient as partner in these discussions, whenever possible, is critical. It’s only with a patient-centred discussion, with the health professional giving treatment advice and recommendations that considers a patient’s own preferences, that we can be confident that we’re managing medications appropriately.

   Herbal Remedies, Street Drugs, and Pharmacology
Harriet Hall
Link
David Kroll’s recent article on thunder god vine is a great example of what can be learned by using science to study plants identified by herbalists as therapeutic. The herbalists’ arsenal can be a rich source of potential knowledge. But Kroll’s article is also a reminder that blindly trusting herbalists’ recommendations for treatment can be risky.
Herbal medicine has always fascinated me. How did early humans determine which plants worked? They had no record-keeping, no scientific methods, only trial and error and word of mouth. How many intrepid investigators poisoned themselves and died in the quest? Imagine yourself in the jungle: which plants would you be willing to try? How would you decide whether to use the leaf or the root? How would you decide whether to chew the raw leaf or brew an infusion? It is truly remarkable that our forbears were able to identify useful natural medicines and pass the knowledge down to us.
It is equally remarkable that modern humans with all the advantages of science are willing to put useless and potentially dangerous plant products into their bodies based on nothing better than prescientific hearsay.
Ancient Sumerians used willow, a salicylate-rich plant that foreshadowed modern aspirin. Digitalis was used by the ancient Romans long before William Withering wrote about its use for heart failure. South American natives discovered that chinchona bark, a source of quinine, was an effective treatment for malaria. These early herbal remedies pointed the way to modern pharmaceuticals. How many other early remedies fell by the wayside? What else did the Sumerians, the Romans, and the natives use that did more harm than good? If “ancient wisdom” exists, so does “ancient stupidity.”
Plants undeniably produce lots of good stuff. Today researchers are finding useful medicines in plants that have no tradition of use. Taxol, the cancer-fighting product of Pacific yew trees, was discovered by the National Cancer Institute only by screening compounds from thousands of plants.
There is a reason pharmacology abandoned whole plant extracts in favor of isolated active ingredients. The amount of active ingredient in a plant can vary with factors like the variety, the geographic location, the weather, the season, the time of harvest, soil conditions, storage conditions, and the method of preparation. Foxglove contains a mixture of digitalis-type active ingredients but it is difficult to control the dosage. The therapeutic dose of digitalis is very close to the toxic dose. Pharmacologists succeeded in preparing a synthetic version: now the dosage can be controlled, the blood levels can be measured, and an antibody is even available to reverse the drug’s effects if needed.
“Ancient wisdom” argues that if an herbal remedy has been used for centuries, it must be both effective and safe. That’s a fallacy. Bloodletting was used for centuries but it wasn’t effective and it did more harm than good. If a serious side effect occurred in one in a thousand recipients of an herb, or even one in a hundred, no individual herbalist would be likely to detect it. If a patient died, they would be more likely to attribute the cause to other factors than to herbs that they believed were safe. Even with prescription drugs, widespread use regularly uncovers problems that were not detected with pre-marketing studies.
Arguments in favor of herbal remedies include:
    • They’re natural. (So what? Strychnine is natural.)
    • They’re safer than prescription drugs. (Maybe some are, some aren’t; how would you know?)
    • They’re milder than prescription drugs. (That would depend on the dosage of active ingredient.)
    • They’re less likely to cause side effects. (When they have been as well studied as prescription drugs, they may turn out to have just as many or more side effects. All effective drugs have side effects, and if an herbal medicine has fewer side effects it might have fewer therapeutic effects too. Formal systems for reporting adverse effects have long been in place for prescription drugs; not so for herbal remedies.)
    • They’re different from prescription drugs. (Some are identical to prescription drugs, like red yeast rice which contains the same ingredient as prescription lovastatin; and some herbal products have been found contaminated with prescription drugs.)
    • They’re less expensive. (True, but is a cheaper, inferior product a good bargain?)
    • They’re easier to obtain. (True, you don’t have to make an appointment with a doctor; but that means you don’t get the benefit of a doctor’s knowledge.)
    • The mixture of ingredients in a plant can have synergistic effects. (This is widely claimed but almost never substantiated. The other ingredients are just as likely to counteract the desired effect or to cause unwanted adverse effects.)
    • For every disease, God has provided a natural remedy. (Perhaps this is a comforting thought for believers, but it is not based on any evidence and is not convincing to atheists and agnostics. And it doesn’t help us find that natural remedy.)
Even when an herbal remedy works, finding a safe and reliable source is problematic. Horror stories abound:
    • Contaminants (such as heavy metals, pesticides, carcinogens, toxic herbs, and insect parts).
    • Wild variation in content (from no active ingredient to many times the amount on the label).
    • Mislabeled products that contain an entirely different herb.
I won’t list specific examples here; they are easy enough to find. I’ll just say that natural medicines are not regulated the way prescription drugs are, thanks to the infamous Diet Supplement and Health Education Act (DSHEA) of 1994.
When you take an herbal remedy, you are taking
    • An active ingredient that usually has not been adequately tested,
    • Other components that have not even been identified, much less tested,
    • An uncertain amount, and
    • Possible contaminants.
The term “street drugs” comes to mind: you don’t really know what you’re getting.

   The Plant vs Pharmaceutical False Dichotomy
Steven Novella 
Link
A recent web feature produced by the New York Times tells the story of Chris Kilham, “The Medicine Hunter.” Specifically it recounts his thoughts on the use of maca, a root native to South America, “said to have energy and libido enhancing properties,” according to the piece. The brief piece reflects the current attitudes popular in the public and promoted by mainstream media reflecting a false dichotomy between medicinal plants and pharmaceuticals. This false dichotomy is extremely counterproductive and ultimately harmful to consumers.
Kilham represents this false dichotomy when he says:
“My goal is to have more people using safe, effective, proven, healthful herbs, and fewer people using toxic, overly expensive, marginally effective, potentially lethal pharmaceutical drugs.”
There are many unwarranted assumptions in this statement. It seems to be implying that herbs are inherently more safe, less toxic, and more healthful than pharmaceuticals. It also assumes that there is a real difference between the two. Therefore Kilham seems to be saying something meaningful when he is actually just reflecting biased assumptions. This is made clear if we simply reverse his statement. Most people, for example, would agree if I said that “My goal is to have more people using safe, effective, proven, healthful pharmaceuticals, and fewer people using toxic, overly expensive, marginally effective, potentially lethal herbs.”
The most meaningful statement is also the one that is most obvious and hardly needs to be pointed out. Any rational person would rather use safe and effective treatments of any kind than toxic and marginally effective (or ineffective) treatments of any kind. Because everyone is likely to agree with this, Kilham is creating a forced choice in which any rational person would choose herbs over pharmaceuticals. But Kilham’s unstated assumptions are completely unwarranted.
First and foremost, herbs and plants that are used for medicinal purposes are drugs – they are as much drugs as any manufactured pharmaceutical. A drug is any chemical or combination of chemicals that has biological activity within the body above and beyond their purely nutritional value. Herbs have little to no nutritional value, but they do contain various chemicals, some with biological activity. Herbs are drugs. The distinction between herbs and pharmaceuticals is therefore a false dichotomy.
It is critical for effective health care and consumer protection that practitioners, educators, the industry, and regulations focus on that which is important – evidence for safety and effectiveness. Here there is a clear distinction between substances marketed under the regulations for drugs and those under the far looser regulations for herbs and supplements. Drugs typically have far greater evidence for both safety and effectiveness. Herbs, on the other hands, are typically marketed based upon tradition and anecdote with insufficient scientific evidence for safety or efficacy.
So what Kilham should be advocating is for higher and more uniform standards of scientific evidence for all pharmaceuticals, whether they are plant based or not.
Ironically, the focus of the New York Times piece and advocated by Kilham, maca, is almost completely without scientific from human trials. A recent study of maca in humans (the first, as far as I can tell) states, referring to maca:
There are however no published data on their toxicity and safety in humans.
The study, which should be considered preliminary, showed that maca may have some benefits for lipid metabolism. There are a number of studies looking at sperm count in rats showing that maca may increase sperm count, or counteract the effect of high altitude on decreasing sperm count, but this line of research is still in the early stages and has not been replicated in humans.
So Kilham, while stating that he is advocating the use of “proven” herbs, is in fact promoting the use of a plant-derived drug with almost no evidence for safety or effectiveness. This, in my opinion, is what happens when ideology trumps logic and science. Kilham clearly is a strong advocate for the use of botanicals. This appears to have become an ideology that has caused him, and many others, to take their eyes off the ball. The only thing that truly matters is evidence for safety and effectiveness – everything else is a costly and hazardous distraction.
To be fair, I think Kilham has a more nuanced and reasonable position than what was presented on the New York Times piece. In this article by Kilham, for example, he writes:
Some of the criticism aimed at the botanical industry is well founded. For as long as companies borrow science to make marketing claims for their own untested products, the market will be awash with second-rate or wholly ineffective botanicals. Very few companies engage in rigorous science to ensure that their products deliver the health benefits for which they are used. The marketing of untested, ineffective botanicals erodes consumer confidence and leaves the botanical industry wide open to heavy handed regulation.
I completely agree. I think where Kilham and I disagree is in what constitutes good science and adequate evidence for safety and effectiveness. I think he is too soft on botanicals and too harsh on the pharmaceutical industry. This appears to be driven, again, by the ideology of the false dichotomy between plants and “drugs.”
To be clear, I have nothing against plant-derived pharmaceuticals. Plants represent a vast reservoir of biologically interesting chemicals – an evolutionary science lab. I also strongly support efforts to survey the world’s plant life (and animal life, for that matter) looking for potentially useful substances. But in so doing, in order to achieve the maximal benefit for the health of the public, we need to apply adequate and uniform standards of scientific evidence for safety of all pharmacologically active substances, and we should fairly regulate the health claims made for any such products. This means purging ourselves of the sloppy thinking represented by the false dichotomies between natural and synthetic (something which has no bearing on safety or efficacy) and of herbs vs drugs.
There is also, incidentally, a false dichotomy between the pharmaceutical industry and the supplement industry. The two are increasingly merging over time, as the large companies are being drawn to the easy profits of selling supplements without having to pay for expensive clinical trials.
These are myths and fictions perpetrated, unfortunately, by those who would be the strongest advocates for plant-based medicinals – like Kilham, abetted by a mainstream media constrained by established talking points, which includes these fictions. These myths are extremely counterproductive. Once we dispense with them we can most effectively work together toward the common goal of providing the most safe and effective medicinal products to the public, based upon adequate scientific evidence.

   Diet Supplements or Nutritional Supplements: A Ruse by Any Other Name is Still a Ruse
Harriet Hall
Link
I was surprised to get this e-mail from a reader:
Surely, Dr. Hall, the public mania for nutritional supplements is baseless. All the alleged nutrients in supplements are contained in the food we eat. And what governmental agency has oversight responsibility regarding the production of these so-call nutritional supplements? Even if one believes that such pills have value, how can the consumer be assured that the product actually contains what the label signifies? I have yet to find a comment on this subject on your otherwise informative website.
My co-bloggers and I have addressed these issues repeatedly. Peter Lipson covered DSHEA (The Diet Supplement Health and Education Act) nicely. It’s all been said before, but perhaps it needs to be said again; and maybe by writing this post I can make it easier for new readers to find the information.
Food, Medicine, or Something In Between?
The FDA regulates foods and has been instrumental in improving the safety of our food supply. It regulates prescription and over-the-counter medications, requiring evidence of effectiveness and safety before marketing. Surveys have shown that most people falsely assume these protections extend to everything on the shelves including diet supplements, but they don’t.
Under the 1994 Diet Supplement Health and Education Act (DSHEA), a variety of products such as vitamins, minerals, herbs and botanicals, amino acids, enzymes, organ tissues, and hormones can evade the usual controls if they are sold as diet supplements. Under the DSHEA, the manufacturer doesn’t have to prove to the FDA that a product is safe and effective; it is up to the FDA to prove that it isn’t safe, and until recently there was no systematic method of reporting adverse effects (required reporting is still limited to serious effects like death).
So far the FDA has only managed to ban one substance, ephedra, and it took the death of a prominent sports figure and considerable skirmishing with the courts to accomplish that. Independent lab tests of diet supplements have found a high rate of contamination (with things like heavy metals and prescription drugs) and dosages wildly varying from the label. A striking example was Gary Null’s recent poisoning with vitamin D from one of his own products which contained 1000 times the intended amount.
The FDA has issued rules on good manufacturing practices, but standardization is not required and it remains to be seen whether the new rules will effectively improve product quality.
Rational Supplementation
It makes sense to supplement the diet with essential nutrients if the food in the diet is deficient in those nutrients or if the patient is not able to absorb nutrients normally. There are specific situations where that applies, such as providing folic acid to women to prevent birth defects or providing vitamins and minerals to bariatric surgery patients whose digestive functions are compromised. There are FDA-approved sources of nutrients for indications like these.
It is commonly claimed that “food is medicine” but there are very few situations where the evidence shows that specific nutrients are useful as medicine. Niacin for treatment of hyperlipidemia comes to mind.
The following (taken from a supplement website) are not rational reasons for supplements and are not supported by evidence:
    • We can’t get all the nutrients we need from food.
    • Supplements boost the immune system.
    • Supplements help get rid of toxins.
    • Even if you feel well, your health will only be optimal if you take supplements.
The Big Lie
DSHEA is based on a fiction. It prohibits claims that diet supplements prevent or treat any disease and only allows structure/function claims alleging that they “support” health in various ways. DSHEA is a stealth weapon that allows the sale of unproven medicines just as long as you pretend they are not medicines. It allows the sale of products that are not intended to prevent or treat disease so people can buy them with the intent of preventing or treating diseases. People don’t buy St. John’s wort to correct a deficiency of SJW in their diet or in their bloodstream; they don’t buy it to “support” brain function; they buy it to treat depression. People don’t buy glucosamine to “support joint health” but to treat their arthritis pain. People don’t buy saw palmetto to “support prostate health” or correct a saw palmetto deficiency, but to relieve symptoms of benign prostatic hyperplasia or to prevent prostate cancer. The FDA’s “Quack Miranda warnings” are routinely ignored even by those few who actually read the fine print.
DHEA (dehydroepiandrosterone) is a hormone that was once approved by the FDA as a prescription drug; then it was taken off the market because the FDA decided it was unsafe. Now it’s available as a diet supplement without a prescription. When the FDA later saw evidence that DHEA was effective for a rare adrenal condition, they re-approved it with orphan drug status. Now the people with that rare disease, and only those with that disease, can get a prescription for the drug, while their perfect healthy neighbor can buy it at any health food store. Does that make any sense at all?
Advocates of CAM complain about “Big Pharma.” What about “Big Supplement” (“Big Suppla”?)? The diet supplement industry is a very profitable multibillion dollar industry that was able to lobby effectively to get the DSHEA passed. BP generates huge profits but it also saves lives. BS (double entendre intentional) has generated huge profits for its investors but hasn’t produced any measurable health benefits to those who use its products.
Yes, Some of Them Work
Some of them do work, but do they work better than prescription alternatives or FDA-approved over-the-counter products with more trustworthy, regulated sources? Are they as safe? They are admittedly cheaper and more convenient than prescription drugs, but is there any other reason to prefer them? One argument is that they are safer, but it isn’t safe to assume that—not until proper large-scale studies are done. Just think of all the prescription drugs that appeared to be safe until careful post-marketing surveillance revealed unexpected problems.
What are the chances that a diet supplement picked at random will turn out to be safe and effective when proper studies are done? Not high. Promising drugs that pharmaceutical companies submit to clinical trials only have about a 5% chance of making it to the market. A few years ago, I went through all the entries in the Natural Medicines Comprehensive Database and tabulated their effectiveness ratings. Only 5% were rated “effective” and almost all of those were vitamins, minerals, and medicines that are also available as prescription or over-the-counter products approved by the FDA.
There are many products on the diet supplement market that combine multiple ingredients in a kitchen-sink mixture that has no rationale and has not undergone any testing. Maybe the ingredients act synergistically; maybe they interfere with each other. How would we know? Taking such products is a crap-shoot and is like being a guinea pig in an uncontrolled experiment. Many supplement mixtures are sold by multilevel marketing programs and improve health only to the extent that they improve the health of the promoters’ wallets.
Supplements can also harm. Kava has been associated with fatal liver damage. An herbal weight-loss remedy caused kidney failure in dozens of women in Belgium. One fifth of Ayurvedic remedies have unacceptable levels of arsenic, lead and mercury. Most trials of antioxidant vitamin supplements have shown that patients taking them either do no better or do worse than those taking placebos. Vitamin A supplementation increases the risk of fractures in post-menopausal women.
Conclusions
    • As my correspondent put it, “the public mania for nutritional supplements is baseless.”
    • In general, all our nutritional needs can be supplied by an adequate diet.
    • Supplements are beneficial for a few specific evidence-based indications; otherwise, they offer no benefits and may even be risky.
    • Diet supplements are not medicines, but are being used as medicines.
    • DSHEA should be repealed.

Supplements and cancer prevention
David Gorski on April 30, 2012
Link
The bloggers here have been very critical of a law passed nearly 20 years ago, commonly referred to as the DSHEA of 1994. The abbreviation DSHEA stands for about as Orwellian a name for a law as I can imagine: the Dietary Supplement Health and Education Act. Of course, as we’ve pointed out time and time again, the DSHEA is not about health, and it’s certainly not about education. Indeed, perhaps my favorite description of this law comes from our very own Peter Lipson, who refers to it as a “travesty of a mockery of a sham.” Rather, it’s about allowing supplement manufacturers and promoters of so-called “complementary and alternative medicine” (CAM, with or without a preceding “s,” depending on your taste) who do not want pesky things like government laws and regulations to interfere with their selling of pseudoscience to market various compounds as “dietary supplements” with near-impunity. As Harriet Hall put it so accurately, the DSHEA is “a stealth weapon that allows the sale of unproven medicines just as long as you pretend they are not medicines.”
The DSHEA accomplishes this by making a seemingly reasonable distinction between food and medicine and twisting it in such a way that allows manufacturers to label all sorts of botanicals and various other compounds, many of which have substances in them with pharmacological activity, and sell them as “supplements” without prior approval by the FDA before marketing. As long as the manufacturer is careful enough not to make health claims that are too specific, namely that the supplement can diagnose or treat any specific disease, and sticks to “structure-function” statements (“it boosts the immune system!”), almost anything goes, particularly if a Quack Miranda Warning is included.
Not surprisingly, given what a big business supplements have become in this country largely due to the DSHEA, manufacturers and CAM advocates fight tooth and nail against any attempt to update the DSHEA to correct some of its more unfortunate consequences. Led by Utah Senator Orrin Hatch and Iowa Senator Tom Harkin, who together make up a bipartisan tag-team in defense of the supplement industry and do their best to block any effort to increase its regulation by the FDA. We saw that most recently when Arizona Senator John McCain, of all people, introduced a bill in 2010 to try to tighten up the DSHEA and was thoroughly slapped down by Orrin Hatch. More recently, not satisfied with how good things are for the supplement industry, another Utah Representative Jason Chaffetz reached across the aisle to Jared Polis, teaming up to introduce the Free Speech About Science Act, which basically seeks to allow the supplement industry to make more liberal claims about its products. All it will need is a “peer-reviewed” paper to support it (Mark and David Geier would do!), and you can claim almost anything. Anything to grow the supplement industry, which is currently around $30 billion a year.
That’s why it’s critical, from time to time, to look at actual evidence, and just last week Maria Elena Martinez, PhD, of the University of California San Diego, and co-authors did in a commentary published online in the Journal of the National Cancer Institute entitled Dietary Supplements and Cancer Prevention: Balancing Potential Benefits Against Proven Harms.\
As several of us have pointed out before, there are science-based roles for supplementation. For instance, in the case of nutritional deficiencies, and Martinez et al point out the very same thing:
Clearly, dietary supplements are useful for the treatment of nutrient deficiencies; however, with the exception of select subgroups (2,3), such deficiencies are relatively uncommon in the United States and most industrialized countries today.
Of course, if you listen to CAM promoters and supplement manufacturers, you’d think that supplements are absolutely essential to preventing cancer. While it is true that there is increasing evidence that diet has a significant effect on our risk for various cancers, this evidence is nothing new. We’ve simply concentrated on it more in recent years, and a new generation of “natural health” advocates, such as Dean Ornish, have attributed near magical powers to diet as a tool for preventing cancer. As a byproduct of increasing evidence that cancer risk is influenced by lifestyle choices, it is understandably tempting to think that we could somehow “bottle” what’s in various foods as supplements that could reverse or ameliorate diet-associated cancer risks. Ironically, although CAM advocates would never concede it, this sort of thinking is the sort of thinking they themselves decry in conventional medicine when they make the exaggerated charge that all doctors do (or want to do) is to prescribe a pill to deal with health issues. Think about it: Even is supplement did what is claimed for them, is there any real difference between just prescribing a supplement to decrease cancer risk rather than recommending much harder lifestyle interventions and prescribing a statin to prevent heart disease rather than recommending much harder lifestyle interventions?
Martinez et al then go on to summarize the state of evidence as it currently exists for the use of supplements to prevent cancer. They conclude that there is precious little evidence for efficacy and existing evidence for harm. Their assessment of the evidence for antioxidants is particularly withering:
Several early observational studies (10–13) found that diets high in fruit and vegetables were associated with diminished risk of several cancers, including respiratory and gastrointestinal cancers. The importance of β-carotene and other carotenoids was suggested by both retrospective and prospective studies showing that low levels of β-carotene in the serum were associated with higher subsequent risk for lung cancer (14). At one point, research focused on retinoid supplementation, in light of the finding that β-carotene is converted to retinol (13). It was hypothesized that the lower risk associated with consumption of these foods, and with β-carotene, α-tocopherol, and vitamin C intake, might be attributable to the activity of antioxidants. In vitro and in vivo studies suggested that these compounds encourage growth of normal tissue and block growth of abnormal tissue (2). However, human experimental studies have uncovered the following: β-carotene does not prevent non-melanoma skin cancer recurrence (15); β-carotene and α-tocopherol with vitamin C do not protect against adenoma recurrence (16); β-carotene and vitamin A do not protect against lung cancer incidence (17); α-tocopherol and β-carotene do not prevent lung cancer (18); β-carotene does not prevent lung cancer (19); vitamins C and E do not protect against total cancer incidence (20); and α-tocopherol, vitamin C, and β-carotene do not protect against total cancer or cancer mortality (21). Based on a review of trial data, a Cochrane report (22) concluded that there was no convincing evidence that β-carotene, vitamin A, vitamin C, or vitamin E supplements, given singly or in combination, prevent gastrointestinal cancers.
That’s not all, though. An article such as this can’t go without mentioning the Selenium and Vitamin E Cancer Prevention Trial (SELECT), which was resoundingly negative. Selenium and vitamin E showed no evidence of decreasing the risk of prostate cancer, leading to the trial being halted after approximately 5.5 years of followup. Consistent with the results of SELECT, a Southwest Oncology Group (SWOG) trial showed that selenium supplementation in men with a premalignant precursor of prostate cancer showed no benefit, and another trial showed that selenized yeast does not prevent recurrence of stage I non-small cell lung cancer. As Martinez et al put it, “organic selenium appears to provide no cancer prevention benefit.”
Not every trial was negative. One exception noted by Martinez et al is a 20 year old prevention trial in China consisting of 30,000 subjects. This study showed a 13% reduction in cancer mortality, including a 21% reduction in gastric cancer mortality, compared to placebo controls in a randomized trial testing a combination of β-carotene, vitamin E, and selenium. This is, at best, a modest effect. However, similar studies looking at such cocktails were even less convincing, including a companion study of 3,000 subjects examining a supplement that contained 14 vitamins and 12 minerals, including β-carotene, vitamin E, and selenium. No statistically significant effect on cancer incidence was observed.
The counterweight to the weight of existing high quality evidence looking at antioxidants and cancer, which suggests no benefit in the vast majority of cancers studied this far and equivocal evidence even in the handful of studies that suggest a benefit is a cohort of studies that suggests the real possibility of harm due to antioxidant use:
Several antioxidant trials (17,18,30,31) have actually reported increased risks with supplementation. The most prominent example, β-carotene and lung cancer, was tested in two RCTs (17,18) in high-risk populations of heavy smokers and asbestos-exposed individuals. Individuals randomly assigned to β-carotene in the Beta-Carotene and Retinol Efficacy Trial (CARET) trial had a 39% increase in lung cancer incidence compared with those in the placebo arm (17); the ATBC trial found a 16% increase in risk of lung cancer associated with β-carotene (18). With prolonged follow-up, NPC investigators found that selenium supplementation statistically significantly increased the risk of squamous cell skin cancer by 25% and total non-melanoma skin cancer by 17% (30). The increased risk was particularly marked among individuals in the highest tertile of circulating selenium levels just before the start of the trial. The most recent illustration of the possibility that pharmacological doses of antioxidants may not have the intended effect comes from the extended follow-up in the SELECT trial, which reported that α-tocopherol increased risk of prostate cancer by a statistically significant 17%; these results led the authors to conclude that consumers should be skeptical of health claims related to unregulated over-the-counter products (31).
The authors then looked at folate supplementation. The state of the evidence for whether folate can prevent cancer is similarly disappointing. In fact, it can be described as largely negative. Worse, like the case with antioxidants, contrary to the hypothesized benefit of folic acid supplementation, there is evidence that it can contribute to some cancers. For instance, there is one trial that showed that long-term supplementation with folic acid increases the risk of advanced colorectal adenomas (relative risk = 1.67) and the risk of developing three or more such adenomas (RR = 2.32). An elevated risk of prostate cancer was also observed. These results are consistent with preclinical studies in animals suggesting that folic acid can increase the risk of cancer, as well as observational studies that have linked higher dietary intake with an increased risk of prostate and breast cancer. Ironically, in the U.S. and other countries, the government has mandated folic-acid fortification of the food supply, which makes the question of whether folic acid supplementation is doing more harm than good particularly pertinent. True, there’s strong evidence that folic acid supplementation of the diet in pregnant women can decrease the risk of birth defects, particularly neural tube defects, but that is short term supplementation compared to long term supplementation. The question, then, is, as always: Is the balance of benefit versus risk due to folate supplementation favorable? There’s enough evidence out there to be concerned that the answer to that question might very well be no, except for pregnant women.
Finally, Martinez et al take on the case of vitamin D and calcium. Anyone who’s been reading CAM-friendly websites these days probably knows that vitamin D is currently viewed by many in the alternative medicine world as some sort of panacea that prevents all cancer. Heck, to listen to some CAM advocates tell it, vitamin D is supposedly so awesome that it prevents influenza more effectively than the influenza vaccine. Of course, as has been discussed on this very blog, the picture is, as is usually the case, more complicated than that, and Martinez et al try to communicate that complexity, referencing the Institute of Medicine’s recent recommendations for vitamin D and calcium intake published in 2011, in which the IOM concluded that there is insufficient evidence to conclude that there is a causal association between low vitamin D intake or low blood 25 hydroxy (OH) vitamin D [25(OH)D] levels and cancer. Martinez et al sum up this data thusly:
There have been many epidemiological investigations of blood 25 hydroxy (OH) vitamin D [25(OH)D] concentrations and cancer-related endpoints (45–49), and meta-analyses of these have shown statistically significant inverse associations between serum 25(OH)D and colorectal adenoma (46,49) and colorectal cancer (45), whereas the results for prostate cancer have largely been null (45,48). For breast cancer, the relationship with serum 25(OH)D levels varies by study design; case-control studies generally demonstrate inverse associations, and prospective studies have been null (45,47,50); because blood levels are collected after the onset of cancer in case-control studies, the potential for bias in these studies must be considered (47,50). Clearly, clinical trials are needed to elucidate any preventive effect of vitamin D (51,52). To date, three short-term RCTs of vitamin D and cancer endpoints (52–55) have been completed; one showed no direct effect of vitamin D supplementation on cancer mortality (53), the second showed no reduction in breast or colorectal cancer incidence by a vitamin D/calcium combination (54,55), and the third showed a reduction in total cancer incidence by a calcium/vitamin D combination vs placebo (56). As concluded in a recent meta-analysis, because of the potential confounding inherent in observational studies and the limited data from clinical trials, evidence is currently insufficient to draw conclusions about the efficacy of vitamin D supplementation for cancer prevention (57).
As far as cancer is concerned, there just isn’t a whole lot of data from well-designed randomized clinical trials testing the effect of vitamin D supplementation on cancer risk to hang one’s hat on. The same is true of calcium supplementation, only more so. Observational studies have, as Martinez et al almost drolly characterize it, “yielded diverse results.” In any case some of the diverse results with respect to vitamin D suggest a correlation between high vitamin D concentrations and pancreatic cancer, while a recent meta-analysis suggests a reduction in risk. In the case of prostate cancer, however, a recently published study suggests a statistically significantly increased risk of prostate cancer (RR = 1.56 for men in the highest quintile) among men who have the highest levels of 25(OH)D, a finding that was more striking for aggressive disease, leading the authors of the study to advise caution in recommending vitamin D for cancer prevention. Puzzlingly, these results are in contrast to a lot of basic science research that supports a beneficial role for vitamin D compounds in prostate cell proliferation and differentiation, prostate cancer cell growth and invasion, and tumorigenesis.
To say that the state of evidence in support of the use of various dietary supplements as cancer preventatives is unsettled is a gross understatement. Martinez et al discussed supplements that have been studied the most and, let’s be frank, that involve the purest supplements, most of which contain only a single ingredient, and they found little evidence of efficacy in preventing cancer but some evidence of potential harm. That’s not even counting the near innumerable supplements now being sold that are not pure substances but some form of extract from plant, fungi, yeast, or even animal origin. As I’ve said before time and time again, supplements that “work” (i.e., have some sort of biological effect) are drugs. They’re impure, adulterated drugs with highly variable potency because of their highly variable content of active ingredient. Obviously, supplements that don’t have such a biological effect are worthless (except for lining the pockets of supplement manufacturers). That’s why supplement manufacturers very much want consumers to believe that their supplements have a whole range of beneficial biological effects, and the DSHEA allows them to imply that, as long as they don’t do it too explicitly.
Martinez et al put the blame squarely where it belongs: On the DSHEA and another law. They also explain how supplement manufacturers get around even the weak prohibitions in the DSHEA:
Even without such direct statements, anticancer effects can be implied. For example, even though the manufacturers of Pill X cannot openly advertise that it prevents prostate cancer, they can create an advertisement that states that prostate cancer is a major health problem, that Pill X has a role to “support prostate health,” and that a particular study found that the compounds in Pill X reduced the growth of prostate cells in culture. Their website can then be accompanied by advertisements for Pill X and can contain links to testimonials that are free to expound the benefits of Pill X as experienced by real people. The absence of credible scientific evidence that taking Pill X confers anti-prostate cancer properties in men can be easily obscured by this constellation of claims that collectively suggest anticancer effects. As a result of limited regulatory authority, manufacturers who cannot overtly claim anticancer benefits of supplements without scientific proof are nonetheless free to imply those benefits in ways that make it difficult for the consumer to discern innuendo from scientific fact (82).
Indeed. Another recent review concluded that, with the possible exceptions of vitamin D and omega-3 fatty acids, there are no data to support the widespread use of dietary supplements in Westernized populations and that such supplements can even be harmful. Another recent study finds no effect from supplements on all-cause mortality and even found a negative effect from folic acid supplementation, consistent with yet another study. The bottom line is that, at present, it is quite probable that most supplements probably do more harm than good.
So why do so many people take supplements? Martinez et al also quite correctly point out:
Undoubtedly, use is driven by a common belief that supplements can improve health and protect against disease, and that at worst, they are harmless. However, the assumption that any dietary supplement is safe under all circumstances and in all quantities is no longer empirically reasonable. Believers in supplements are sometimes quick to discredit caution over supplement use, as they suggest that the tendency of mainstream science to ignore nonconventional evidence is tainted or that mainstream science is somehow corrupted by its link to a medical–industrial complex that seeks to protect profits rather than prevent disease.
Right on cue, our favorite quack apologist and supplement hawker, Joe Mercola, chimed in with an article entitled Over 60 Billion Doses a Year and Not ONE Death, But Still Not Safe? In it, Mercola in his usual frothing-at-the-mouth style (although not nearly as frothy as another favorite quack apologist Mike Adams) rants that a recent survey from the American Association of Poison Control Centers’ National Poison Data System reveals, there were zero deaths linked to nutritional supplements in 2010, amusingly citing the Orthomolecular Medicine News Service as its source. Orthomolecular medicine, you might recall, is a form of supplement quackery originally embraced by Linus Pauling when he concluded that high dose vitamin C was the cure for the common cold and cancer.
Never let it be said that Mercola isn’t good at intentionally confusing short term toxicity with long term effects in his eagerness to attack a straw man. He seems to think that when scientists point out that supplements can be hazardous that they are claiming that supplements will kill you fast when in reality most potential problems with supplements are long term health effects, although, I would point out, certain supplements can certainly cause serious problems more acutely. In any case, when Mercola asks, “Where are the bodies?” I’d answer that if a supplement increases the risk of a common cancer by 25%, that’s a lot of potential bodies. They just won’t be directly linked to supplements. Particularly amusing is Mercola’s outrage that the FDA is trying to impose the same limits on supplements as on aspartame, monosodium glutamate, and sodium nitrate.
What is infuriating Mercola and the supplement industry are draft guidelines from the FDA designed to assess new ingredients in supplements using safety standards similar to what are required for the approval of new food additives, as described in this recent New England Journal of Medicine commentary:
The proposed guidance clarifies the level of evidence the FDA would use to assess safety. Specifically, the safety of supplements would be evaluated according to three key factors: documented history of use (e.g., in foods or in supplements or herbal medicines sold outside the United States), formulation and proposed daily dose (e.g., more or less than was formerly consumed), and the recommended duration of use (e.g., intermittent or long-term). The FDA’s guidance provides a thoughtful framework for evaluating the safety of new ingredients (see table Required Safety Testing for New Dietary Ingredients Labeled for Intermittent Use.), and if implemented it would lead to substantial improvement in safety. For example, the FDA would require in vitro, animal, and tolerability testing for products that would be marketed for consumption at doses greater than those historically ingested.
In actuality, however, even these draft guidelines do not go far enough, and the supplement industry is vigorously opposing them, even though they strike me as an eminently reasonable strategy for trying to address at least one of the shortcomings of the DSHEA. After all, don’t supplement manufacturers themselves claim that their supplements are food, not medicine? Then why not require that new supplement ingredients without documented historical usage be subject to the same requirements for safety as any other food additive?
It’s important to remember that, in the end, supplements that have biological activity are functioning as drugs. As Martinez et al and a number of other studies strongly suggest, there is very little, if any, evidence that supplements improve health, at least in an already well-fed population, with a precious few possible exceptions that are far more narrow than anything CAM advocates or supplement manufacturers claim. Worse, at least as it stands right now, for most supplements, it is disturbingly likely that the harms probably outweigh the benefits for most people. This is one area where we probably do need more studies, but they need to be “strategically designed” studies, as Martinez et al put it, set up in light of existing evidence from previous studies that have been largely negative.

Weak drug regulation and patient tragedies: We’ve seen this story before
Scott Gavura on October 25, 2012
Link
Plenty of new drugs, but few that are truly innovative. Growing costs from their use. Physicians deemed “Dupes of Big Pharma” for their interactions with the pharmaceutical industry. A call to produce better information on which drugs work best. Finally, shoddy drug manufacturing is injuring and even killing patients. These stories could be lifted from today’s headlines — but they’re actually from 1962. Problems with the behavior of the pharmaceutical manufacturing industry, and our relationship with it, are not new. Nor are they restricted to one country. Every developed country’s health-care system is different, but one feature is near-universal: none have a public pharmaceutical industry. Ever nation relies on for-profit, private companies to supply its population with drug products.
Blog posts here can get pretty wonkish about health policy, as many of the substantial challenges to science-based medicine have their roots in regulation — whether it’s DSHEA which implemented a regulatory double-standard for supplements, or the state-by-state legislative alchemy that Jann Bellamy has documented, which transforms magical thinking and pseudoscientific practices into registered and regulated health practitioners. Federal food and drug regulations have also come under some scrutiny (and praise). The FDA’s under fire again; this time over its responsibility to oversee pharmaceutical manufacturing. But in this case, it’s not Big Pharma that’s the villan — it’s pharmacies.
Pharmacies rarely makes the headlines, and that’s probably a good thing. Safe and effective is boring. But my Google Alert for pharmacy news has been pinging me nonstop. The catastrophe of fungal meningitis that continues to emerge across America may be the worst drug manufacturing disaster since the 1930’s when the S.E. Massengill company inadvertently mixed the antibiotic sulfanilamide with antifreeze, killing over 100 people. It was the Massengill fatalities that led to the Food, Drugs and Cosmetics Act (1938). They were a good first start, focusing on the requirement to for manufacturers to document that their products were safe. But they didn’t go far enough.
From today’s perspective, the FD&C Act (1938) was pretty basic. There was no requirement for manufacturers to demonstrate good manufacturing practices. And if the FDA didn’t move to block a sale within 60 days, a product could be sold. By the 1950’s, it was clear that the Act wasn’t fully effective. Concerns of excessive pricing and questionable evidence statements from manufacturers eventually led to hearings led by Senator Estes Kefauver. Over 18 months an array of new amendments emerged: efficacy claims would be reviewed and approved. Side effects must be reported. Drugs must be approved for sale before any sales could begin. Good drug manufacturing standards would be mandatory, and would be FDA-inspected. Advertising would be monitored. Drugs would have clear generic names, in addition to trade names. All of these proposals made it into the final wording. What’s pretty interesting is what they cut:
    • Compulsory licensing of generics after 3 years to allow competitive markets
    • Banning so-called “me-too” drugs — new drugs which failed to offer substantial improvements over existing drugs — would be forbidden, as well as minor modifications to existing chemicals that didn’t offer any therapeutic improvements (hello, Nexium)
    • Patent approval only where a new drug offered advantages over the current standard treatment — not just demonstrating superiority over placebo
Why did they get cut? As expected, there was strong opposition from pharmaceutical companies. But the American Medical Association also objected, particularly against a greater role for the FDA in evaluating efficacy. The bill was on life support until the thalidomide disaster in 1962 that secured its passage, now called the Kefauver-Harris Amendments to the Federal Food, Drug and Cosmetics Act. It effectively set the template for modern-day regulation which has been subsequently emulated around the world. Without these amendments, the requirements for pre-licensing clinical trials probably would not exist. Nor would longer patents, granted in 1984 based on appeals for longer patent protection due to the barriers established before drugs can be sold.
So how did we end up with a meningitis outbreak this year? Through a loophole in the Act. The contamination of injectable steroids is one of a long string of medical harms caused by “compounding pharmacies” — pharmacies that skirt FDA regulations by acting as chameleons. To hospitals and physicians, they’re businesses selling drug products, just like any other pharmaceutical company. But to the FDA, they claim to be pharmacies, not pharmaceutical companies, which put them under the jurisdiction of state pharmacy regulators. Why the loophole? Until fairly recently, all pharmacies used to be compounding pharmacies. Each store made its own dosage forms like creams and capsules. Everything could be personalized. Today, compounding in the pharmacy has dwindled for most products, as Pharma can do it faster, cheaper, and more accurately. But compounding is a legitimate part of pharmacy practice, and can fill real patient care needs. And in an era of regular drug shortages, they can manufacture drug product – but without any of the quality standards mandatory for pharmaceutical companies. Unlike federal requirements which are uniform across the USA and around the world, regulations for pharmacies are determined at the state level, by pharmacy regulators. The same degree of oversight simply does not exist.
It should not be surprising that compounding pharmacies have fought all attempts by the FDA to impose more rigorous manufacturing standards, which would make it harder to sell products. To lawmakers, advocates position it as an access and “right to choose” argument especially for “natural” products like “bioidentical” hormones which are often made by compounding pharmacies. These are the same pharmacies preparing chelation infusions, and they used autistic children to argue for their right to continue to manufacture these products, despite the fact that they are clinically useless for autism. But they seem to work well as a lobbying tool. They’ve successfully killed legislation proposed in 1997, 2003 and again in 2007. This lobbying success is remarkable given there have been no shortage of problems: Since 1990 the Institute for Safe Medication Practice has documented 22 significant pharmacy compounding errors involving 71 different drugs resulting in over 200 adverse events — some fatal.
But is FDA oversight required to keep fungal contamination out of injectable drugs? It shouldn’t be. The United States Pharmacopeia Chapter <797> establishes sterile manufacturing standards which are expected to be adhered to by pharmacies that make these products. Tightening of requirements <797> in 2008 had the effect of causing more outsourcing to larger pharmacies, as smaller centres could not meet the requirements. Probably most concerning is that the requirement to follow <797> isn’t uniform across states — five boards don’t mandate it, and the others don’t audit consistently. That seems to be the case in Massachusetts , where the New England Compounding Center (NECC), has now been closed permanently as it’s revealed that basic safety and manufacturing standards, including <797> requirements were not being followed when it manufactured preservative-free methylprednisolone acetate. The two lots of drug contaminated with black mold have reached 14,000 patients in 23 states. This is no small operation. Furthermore, NECC was flouting state pharmacy law by failing to act as a pharmacy: it shipped product out without a prescription, or labelled for an individual patient.
Conclusion
Regulatory frameworks evolve over time. Regrettably, it sometimes takes a public health catastrophe to give lawmakers the motivation to ignore vested interests and act in the interest of public health. Like the Massengil deaths in the 1930’s, and the thalidomide birth defects in the 1960’s, the New England Compounding Centre may prove to be the impetus for the appropriate regulation of compounding pharmacies. Products manufactured by facilities like NECC should receive the same regulatory oversight, and meet the same manufacturing standards as any other bulk manufactured drug product. What’s clear is that this responsibility cannot be left to the pharmacy profession to manage itself. As I pointed out back in 2010, pharmacy regulators have repeatedly failed to act on the ethical and safety problems with compounding pharmacies. That their inertia has resulted in another public health tragedy is shameful to the profession of pharmacy, and patients across America are quite literally paying the price.

Natural Health Products: Loosely regulated, little evidence of benefit, and an industry intent on preserving the status quo
Scott Gavura on October 20, 2016
Link


This week’s post will revisit a topic I recently covered, but it’s time-sensitive and needs your input. Health Canada, the Canadian equivalent to the US Food and Drugs Administration, is considering revisions to the way in which it regulates dietary supplements, which are called “natural health products” in Canada. It is rare that a regulator acknowledges that a regulatory system isn’t working, and publicly expresses a commitment to being more science-based. There is a time-limited opportunity for the public (including all of you non-Canadians!) to provide comment on how supplement regulation could be more closely aligned around scientific principles, rather than the supplement industry’s priorities. Whether you take dietary supplements or not, we can probably all agree that consumers should have access to safe products as well as credible, relevant information about these products, in order to make informed health decisions. It will likely not surprise you that these ideas are seen as threats to supplement manufacturers, who benefit from little regulatory oversight and few restrictions on what can currently be claimed about any product’s effectiveness. Since my last post, there have been some new reactions to the consultation that are worth discussing.
What’s the problem in Canada?
Regular readers to the blog, especially the American readers, will likely be familiar with the Dietary Supplement Health and Education Act of 1994 (DSHEA). DSHEA was an amendment to the U.S. Federal Food, Drug and Cosmetic Act that established the regulatory framework for dietary supplements. It effectively excludes manufacturers of these products from virtually all regulations that are in place for prescription and over-the-counter drugs. DSHEA attempts to distinguish supplements from drugs in a puzzling way, even going as far as defining therapeutic and pharmacologically-active products (e.g., herbs, botanicals, some hormones) to be categorized as foods, and therefore eligible for DSHEA exemptions from the FDA’s drug regulations. Manufacturers can put virtually any claim on a supplement, without any requirement to provide persuasive clinical evidence, as long as it’s accompanied by the Quack Miranda Warning: “These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.” Disease treatment claims are not permitted, but are typically restated as permissible “structure/function” claims, implying an ability to improve the structure or function of the body. There’s a lack of prospective manufacturing oversight of these products, and there are no effectively no pre-marketing requirements. The FDA can only block the sale dietary supplements only after significant problems have been identified. DSHEA overall has been a win for manufacturers, and for sales, but a disaster for giving consumers quality products, who today cannot trust that what’s on the label is actually in the bottle, or that the products they buy are safe or effective.
When Canada decided to regulate supplements, it took a slightly different path. Instead of calling products “foods” or “drugs” it created a new category: so-called “natural health products”. This category includes nutritional supplements, probiotics, traditional Chinese medicine, vitamins, herbal products, and homeopathy – many of the same products that would be considered “dietary supplements” under DSHEA. These regulations were a compromise: they introduced some manufacturing quality and safety standards, while effectively eliminating the requirement to provide clinical evidence to substantiate efficacy claims. But in Canada, all products are assessed and approved by the regulator. Today, homeopathy is a “natural health product” that is “approved” by Health Canada. While homeopathy is effectively an elaborate placebo system, Health Canada assigns distinct registration numbers, dosages, and even “recommended use” to hundreds of physically indistinguishable brands of sugar pills.
What’s in the consultation?
Health Canada has a nice summary of what the consultation is about:
Health Canada has different ways of overseeing the safety, efficacy, and quality of cosmetics, natural health products, and non-prescription drugs. By safety, we mean that the product will not be harmful or toxic when you use it according to the directions and warnings on the label. Efficacy refers to what the product is meant to do and is usually represented by a claim, e.g., “relieves headache”. A health claim is a description on the product about what it does in relation to someone’s health. Finally, quality means that the product is manufactured under controlled conditions and will be made properly.
While all of these products fall under one law in Canada – the Food and Drugs Act – they are regulated under three separate sets of regulations:
    • Cosmetics sold in Canada must meet the Cosmetic Regulations;
    • Natural health products sold in Canada must meet the Natural Health Products Regulations; and
    • Non-prescription drugs sold in Canada must meet the Food and Drug Regulations.
Regulations, along with related policy and guidance documents, set the rules that companies have to follow so that their products can be sold in Canada. These rules set out how products are evaluated and approved by Health Canada (including what claims can be made); how products should be manufactured, labelled and packaged; how safety and compliance will be monitored once products are on the market; and, what the consequences are for companies if they do not follow the rules.
Even though all three sets of regulations fall under the same Act, they do not set out the same rules for bringing self-care products to market. For example, not all self-care products currently require that the company provide scientific evidence to Health Canada to support the claims made on the label. Similarly, some products undergo a lot of scrutiny before coming to market, while others do not. This means that products could appear almost identical on a store shelf, even though the rules for bringing them to market are quite different. For a consumer weighing the options between similar-looking products, both claiming to treat the same symptom or condition, the differences in the approval process are not apparent. This means that consumers may be choosing a product without the information required to make an informed choice.
Health Canada is examining new approaches to the regulation of self-care products, including refocusing the approval of health claims to those based on scientific proof. A new approach will continue to allow for a wide range of products to be available for Canadian consumers, while, at the same time, taking a more consistent approach to the oversight of self-care products that will ultimately better support consumers’ ability to make an informed decision.
Emphasis added.
Health Canada is proposing regulations based on risk. Low risk products would be subject to few regulatory requirements, and high-risk products would receive a more rigorous review. Risk will be determined by (1) the underlying safety of the product, and (2) the consequences if a product fails to do what it claims. Whether or not a product is “natural” will have no bearing on this assessment. This image illustrates how the scrutiny and regulation could vary:
In short, if you want to sell homeopathic sugar pills, you can continue to do so. However, you will not be permitted to make any claims that your product can diagnose, treat, prevent, cure or mitigate any condition. You will also need to state on the label that Health Canada has not reviewed your product for effectiveness (which is effectively Canada’s own Quack Miranda). If you want to sell a product with a specific claim that it has a medicinal effect, then you must provide scientific evidence to substantiate that claim. The rule will apply if your product is a pharmaceutical drug, or a dietary supplement. The evidence standard and expectation will be exactly the same.
Industry spin: Health Canada is coming after your supplements!
The new requirements will not automatically force any existing product off the market. It will simply change the claims that can be made about them. If you want to claim effectiveness, then you have to substantiate your claim. The intent of the regulation is to move towards consistent standards of evidence and accuracy in label claims. This is a hard position to argue against, so the Canadian supplement industry is describing this move as one that will limit consumers. From one trade publication:
So what does the industry think about such changes? Cheryl Kos, ND, regulatory affairs research analyst at Metagenics, said that the tone and content of Health Canada’s proposal are of concern, “as is the lack of detail regarding how ingredients such as probiotics and botanicals are meant to be regulated under the proposed format and how the over 100,000 existing NHPs with NPNs and approved claims will be treated.
“The proposals appear to seek to upend a system upon which industry has spent many millions of dollars seeking to comply with, and intends to replace it with a vaguely-described new one that promises to cost more while restricting claims and product availability,” he said.
“The proposal states that consumers may believe that products situated in proximity in stores are equally effective, and seems to critique NHPs repeatedly because a lower percentage of consumers consider themselves well-informed when buying NHPs as compared to ‘other’ self-care products (OTCs and cosmetics). Neither shelf proximity nor percentage considering themselves well-informed seems a reasonable basis for determining that NHPs need to be regulated in any different way (to which they refer, in further diminution of NNHPD, as ‘modernization’),” noted Holmes.
Manufacturers are worried about losing the credibility that Health Canada’s current approval process implies. From a Canadian company that sells naturopathic shakes and homeopathy:
Health Canada’s proposal represents a marked departure from the way it has regulated NHPs for the last 12 years. The erosion of consumer confidence in NHPs may be an unfortunate outcome of the proposed new changes. The health agency’s proposed new regulation regime for NHPs is likely to result in much less choice for consumers at a time when health concerns are rising and health awareness is growing.
Health Canada would do well to consider increasing its support of NHPs in an effort to reduce rising health care costs, particularly when NHPs have a long history of traditional use, as well as being safe and effective. The government’s complete reversal on accepting as evidence a wide range of documentation to support NHP claims means health-aware consumers will be that much less informed by product labels. People make better-informed choices about their health when they have access to adequate and accurate information.
What’s more, the cost of NHPs could be driven up as manufacturers may face increased regulatory fees, additional labelling and advertising amendments, and perhaps even product reformulations.
Note how the restriction on manufacturer claims of “efficacy”, which I’ve pointed out are based on no credible scientific standards at all, are being spun to suggest that this is a negative for consumers. Consumers are absolutely are in a better position to make informed decisions about their heath when they have access to accurate information. But you can see that a company that sells homeopathy for acne, bedwetting, appetite, insect bites and more might not want to see the regulations changed if they are asked to substantiate their claims with credible scientific evidence.
Pro-science comments on the consultation
Bad Science Watch, a science advocacy group in Canada has publicly posted its own comprehensive response to the consultation [PDF]. It’s excellent and worth reading, and delves into details of the consultation I haven’t covered here. You can review their response to each question of the of the consultation. A sample:
What are your thoughts on the proposal to require scientific data to support a health claim? If you do not support, please explain why.
Health claims should of course be supported by scientific evidence. What else would a science-based regulatory body otherwise allow? An example of concern is homeopathic products that have been allowed to make specific health claims on the basis of “traditional use” despite having no scientific plausibility for efficacy and relying on generally very poorly designed (i.e., often small and/or not properly blinded) clinical research studies (Linde and Melchart, 1998, Shang et al.,2005). Traditional use should be abolished and an objective threshold of research quality and/or quantity should be included in the proposal to better define how products are able to prove efficacy prior to approval. We also argue that a requirement be set that a majority of documentation allowed to support health claims be peer-reviewed: Peer-review has been set as the international requirement for assessing validity of statements and experimental hypotheses, and as such this minimum standard should also apply to the use of scientific evidence as it applies here (Voight, 2012). Additionally, the use of scientific evidence is vital so that health providers are informed and able to discuss the safe use of health care products with patients. As an additional example, in one study health care providers were consulted about the use of echinacea-a commonly used NHP during pregnancy. Many suggested the product is safe and unlikely to be a concern, though studies do not exist to support these claims (Gallo et al., 2000).
The mandate of the Health Protection and Foods Branch can only be accomplished by use of a rigorous scientific approach.
There’s also an excellent summary of the issue in the health policy blog, Healthy Debate:
Currently, natural products are permitted to make health claims based on homeopathic textbooks, anecdotal information or the historical use to treat a condition. They’re not required to show their products have demonstrated effectiveness in controlled, scientific studies, as prescription and over-the-counter pharmaceutical drugs are.
The current regime has come under scrutiny in recent years. Last year, for example, CBC Marketplace was able to get a fake natural product licensed as an effective treatment by Health Canada. Submitting only a 1902 homeopathic reference book, the bogus children’s medication was approved to claim “effective relief from fever, pain and inflammation” on the label.
Ubaka Ogbogu, a professor of law and pharmacy at the University of Alberta, says more rigorous standards are long overdue, as there are serious dangers to taking natural health products that make unproven claims. “There’s the danger people will forgo actual treatments in favour of things that don’t work, and there’s the danger that natural health products can interact with other drugs a person may be taking,” he says. For example, the herb St. John’s Wort can interact with a variety of drugs, including blood thinners and some painkillers. (The herb can exaggerate or reduce the effects of certain pharmaceuticals). There’s also “the financial danger.” If Canadians buy an ineffective product they’ve been misled to think works, they’re wasting their money.
Canada needs you
The consultation is open for comment until October 24. Science-based comments, the more the better, are essential to add weight to support rational changes to natural health product regulations in Canada. Please consider taking a few minutes in the next several days to complete the online consultation and add your own perspectives.

Side effects may include liver failure
Scott Gavura on September 11, 2014
Link
“Safe and natural.” It’s a marketing phrase attached to dietary supplements that’s often accepted as self-evident. The marketing works. Supplements have a strong health halo. But evidence suggests that this reputation may be undeserved. Not only are there continued questions about whether most supplements have any health benefits whatsoever, there is also evidence that they can be harmful. We can’t even be confident that what’s on the label is actually in the bottle. Just two days ago I was notified of another long list of supplements and remedies that the FDA had identified that were contaminated with prescription drugs. These warnings about products sold as supplements appear regularly. Some time ago I asked, “What’s in your supplement?“, and noted that contamination and poor product quality standards continue to raise questions about whether supplements can be used safely at all, because the harms, when they occur, can be catastrophic. No matter how you feel about their efficacy, we can probably all agree no consumer should lose an organ from taking a health supplement. But it can happen.
Like any other drug products, supplements have chemical ingredients that, once absorbed, are processed (metabolized) by the body. Our liver’s an amazing organ. Millions of years of evolution have given us the capacity to metabolize and detoxify pretty much everything we can eat. But sometimes we’ll encounter something that our liver can’t respond to. And sometimes those products cause organ damage, in the form of liver failure. It may be the labelled ingredient, or it could be something else – a contaminant that causes the harm. Unless there’s a lot of cases, it may be difficult to spot, or link harms to a specific product.
Supplements are popular – and growing in their popularity. We’re in the midst of a 40-year trend of increasing supplement use that shows no likelihood of slowing down. This is big business, a $30-billion-per-year (USD, 2011) industry with little regulatory oversight. Importantly, dietary supplements are not held and inspected to the same manufacturing and quality standards as pharmaceutical drugs – hence the persistent and worrying questions about their quality. The driver of this loose regulation is the legislation called DSHEA, which removed the onus of demonstrating safety and efficacy from the manufacturer, and put the requirement to demonstrate harm on the FDA. Yet calling a product a supplement doesn’t make it harmless. Those ingredients can harm, just like drug products. Do they deserve the same regulation? I’d argue yes – we should not have two different efficacy and safety standards, just because something is “natural” or deemed a “supplement”. The supplement industry would disagree. They may cite a lack of evidence of harms. And from one perspective, that is true. Despite their widespread use, surveillance of supplements (the limited amount that occurs) reveals generally few adverse events. It could be that many products simply don’t do anything at all – either positive or negative.
Now a new analysis from the US-based Drug-Induced Liver Injury Network gives some cautionary statistics on the harms related to dietary supplements. The study looked at data from eight referral centres, and captured data on any case of liver injury attributed to herbal and dietary supplements. Importantly, this analysis excluded cases of liver injury from acetaminophen (Tylenol). Acetaminophen poisonings, whether intentional or not, cause harms that dwarf anything else – even dietary supplements. In the USA, poisonings from this drug alone result in 56,000 emergency room visits, 26,000 hospitalizations, and 458 deaths per year. [PDF] Acetaminophen is responsible for more overdoses, and overdose deaths [PDF], than any other pharmaceutical product. In this latest report, patients were followed if they had documented liver toxicity that was suspected as being either medication- or supplement-related. A standardized protocol was used to determine the relationship and assess causality. Cases were only included if the likelihood of a causal relationship was at least probable. Other causes of liver damage were ruled out. Rates of hospitalization, and outcomes like liver transplant or death were also followed. The analysis divided the cases into two groups: those with injuries attributed to bodybuilding supplements, and those from other supplements. Given the statistics, one of the best ways to avoid liver damage from supplements seems to be to avoid anything related to bodybuilding, as they are the most common cause of supplement-induced liver damage. These injuries occur predominantly in younger men and they tend (according to the authors) to cause a similar injury: prolonged jaundice and eventual recovery. Liver injury caused by other supplements is more varied, and has different outcomes, including a greater risk of liver transplant or death.
Between 2004 and 2013 the researchers found 839 cases of liver injury eligible for consideration: 709 were from drugs, and 130 from supplements. In the pool of 130 injuries linked to supplements, 45 (35%) were from bodybuilding supplements and 85 (65%) were from other supplements. The analysis found no patient that took bodybuilding supplements died or required a liver transplant. In the non-bodybuilding group, 13 patients died or required a transplant. Interestingly, the severity of the reaction to supplements was greater than the liver toxicity from conventional meds, though conventional med reactions were associated with a greater risk of death (7% vs. 4%, respectively.) Here’s the list of the products that caused death or led to a liver transplant, and the full list of all implicated supplements may be downloaded here:
What’s surprising? There’s a lot of products on the full list that should not be associated with liver problems at all, like multivitamins. It’s highly unlikely that a product like a multivitamin would cause liver damage. What’s also possible (and probably more likely) is product contamination. The authors note that the pattern of liver damage associated with bodybuilding products is consistent with what might be expected if the products were contaminated with anabolic steroids. But we don’t know for sure – to truly identify the cause, it would be necessary to assay and test every single product associated with liver damage, in order to determine the actual ingredients and the most likely cause. In this survey, 217 products were associated with the 130 cases of liver injury. Amazingly and frighteningly, only about 80% had identifiable ingredients according to the label. And given the product quality concerns that continue to plague the supplement industry, determining which products and ingredients are the real risk factors is all-but impossible, as we can’t trust the labels to be accurate.
Tip of the harms iceberg?
Liver damage and liver failure is both catastrophic and fairly easily identified. Other harms may not be immediately attributed to supplements, which may mean that harms from supplements may be under-reported. I’ve mentioned several factors before, which include:
    • The belief that supplements are harmless, accentuated by beliefs that “natural” substances don’t harm, so the link is never suspected.
    • The lack of routine health professional monitoring.
    • The reluctance to disclose harms and side effects to a health professional, in part because they may not want to disclose they’re taking a supplement at all.
    • Not knowing that adverse events should be reported, or how to report them.
    • Use may be driven through consultation with “alternative” medicine providers, and those experiencing harm may be reluctant to report experiences to “conventional” health providers like physicians or pharmacists.
    • Concern about the risk of additional regulation, leading to a reluctance to report harms.
    • Supplements may be used short intervals for self-limiting conditions, and long-term harms may not appear (or be detectable).
Reducing the risk
If you don’t look for it, you won’t find it. And if you set the system up to minimize the likelihood of finding harm, it should be no surprise that supplements are not associated with a lot of safety concerns or reports. Given the way this data was assembled, it’s not possible to estimate a relative risk of harm, or even assess the any change in incidence of liver damage associated with supplements. But it should put to rest any claims that supplements are without harm. Even more troubling, it doesn’t look like there’s any way to avoid the risk of supplement harms, unless you decide to avoid them completely. There’s no question that drugs can cause liver problems, and they do so with more frequency than supplements. But these harms are not related to widespread product contamination – a risk that is very real, and difficult to avoid, with any dietary supplements sold today. Until regulations are tightened, I don’t expect manufacturers to do much to improve the quality of their products. Which is unfortunate, because until we can consistently trust what’s on the label, it’s going to continue to be hard to accept dietary supplements as either safe or effective.
Reference
Navarro V.J., Herbert L. Bonkovsky, Timothy Davern, Robert J. Fontana, Lafaine Grant, K. Rajender Reddy, Leonard B. Seeff, Jose Serrano, Averell H. Sherker & Andrew Stolz & (2014). Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network, Hepatology, n/a-n/a. DOI: http://dx.doi.org/10.1002/hep.27317

We’re a drug-taking, supplement-taking nation. So how do we do so safely?
Scott Gavura on May 8, 2014
Link

Do you take a vitamin or dietary supplement? It’s increasingly likely that you do, as over half of all American adults took some sort of supplement over the past 30 days. Now there’s evidence to suggest that about one-third of all Americans are taking supplements and prescription drug at the same time, which is renewing questions about risks and benefits. The same study reveals that combining supplements and prescription drugs is more common among those with certain medical conditions, compared to those without.
Many of us supplement in the absence of evidence of benefit, or even medical need. For example, there is little persuasive evidence to suggest that routine supplementation with products like multivitamins is necessary. There are exceptions of course: Those potentially becoming pregnant, those on dietary restrictions (e.g., vegans), and those with demonstrable medical need are among the cases where there is a clear benefit to vitamin supplementation, for example. The majority of us take supplements, like multivitamins, for “insurance” rather than because we have a deficiency or medical need. The evidence for non-vitamin supplements, like herbal products, is just as questionable as it is for vitamins, with few products showing meaningful health benefits. Ultimately decisions about supplements come down to evaluations of risk and benefits. Since I started working as a pharmacist, I’ve always cautioned consumers about the quality concerns and efficacy with herbal products and supplements, and the resultant risks that make me very hesitant to suggest their routine use – especially when they’re combined with prescription drugs. Yet the evidence suggests that it’s occurring – with increasing frequency.
The supplement trend
I’ve covered this in a past post, but it’s worth reflecting on the growing habit of consuming dietary supplements – 40 years of data from the National Health and Nutrition Examination Survey (NHANES) shows a doubling of use since the 1970’s:
Source: Council for Responsible Nutrition
With these numbers, it should be no surprise that supplements are now big business: this is a $30-billion-per-year (USD, 2011) industry with little regulatory oversight. The current marketplace is now rife with exaggerated claims and few products backed by credible evidence. And importantly, dietary supplements are not held and inspected to the same manufacturing and quality standards as pharmaceutical drugs – so there are persistent and worrying questions about the quality of products sold as supplements.
The quality question
Surveys suggest the vast majority of Americans are confident in the safety, quality, and effectiveness of these products. Is that fair? I have noted before that the absence of good product quality standards for dietary supplements is a persistent barrier to the use in science-based ways. Drugs have a rigorous standard that requires the products sold to be equivalent to the versions studied in clinical trials. With supplements, there is no similar quality standard. Weaker regulations and weaker standards mean less confidence for health professionals (and consumers) that what’s on the label is actually in the bottle.
The lack of confidence in quality seems justified. I recently described a disturbing study that suggested that in a sample of 44 supplements purchased off-the-shelf, only 48% were authentic and 59% of products contained species not listed on the label. Only two of the 12 companies in the sample had products without any substitution, contaminants and fillers.
The contamination concerns are among the most concerning – from lead in Ayurvedic remedies to shark cartilage supplements that contain mercury and neurotoxins and ironically, supplements contaminated with actual drugs. As long as there are poor quality standards, it’s difficult to see how supplements can be used safely in combination with prescription drugs, where an unlabelled ingredient could cause unanticipated harm.
The study
In light of the demonstrable quality problems with supplements, combining supplements and prescription drugs raises questions about safety. This new analysis, titled “Concomitant Dietary Supplement and Prescription Medication Use Is Prevalent among US Adults with Doctor-Informed Medical Conditions”, was published in the Journal of Academy of Nutrition and Dietetics in April 2014. The data comes from the NHANES database, which is supposed to be representative of your typical civilian, non-institutionalized adults. This survey excluded all pregnant women and participants were information was missing. The sample size was almost 10,000 adults.
NHANES assessed supplement use through personal interviews. Supplements were divided into 18 categories of products. Interestingly, multivitamins were divided into “standard” multivitamins (no minerals/botanicals) versus other forms of multivitamins, some of which also contained herbals. This makes sense, as there’s a big difference in ingredients between a cheap drugstore multivitamin and something like this which claims to be a detoxifying multivitamin. Prescription medication use was evaluated using the same process, as well as any “doctor informed medical conditions” (DIMC) which included:
    • asthma
    • arthritis
    • congestive heart failure
    • coronary heart disease
    • angina
    • angian pectoris
    • heart attack
    • stroke
    • high blood pressure
    • high cholesterol
    • emphysema
    • chronic bronchitis
    • any liver condition
    • thyroid problem
    • cancer
    • kidney dysfunction/dialysis
    • osteoporosis
Both the term DIMC and the list of chronic illnesses included under this label seem to have been made up solely for this study – I could not find any other mention of it. Having said that, it is a reasonably good list of chronic medical conditions that require medical management and supervision.
The results
Those that used supplements and prescription drugs tended to be females >60 years old, college graduates, and hold higher income levels, which is consistent with what we’d expect with supplement users. Half of all adults used supplements, and more than half reported prescription drug use. And one third reported simultaneous supplement and prescription drug use. This would mean approximately 72 million Americans are taking prescription drugs and supplements together. The use of supplements or prescription drugs was higher among those with a DIMC – specifically osteoporosis, where almost everyone surveyed was taking supplements and prescription drugs:
Supplement use in oseteoporosis is not surprising, as the researchers categorized calcium as a “drug” if it was prescribed but as a “supplement” if it was purchased directly by the consumer without a prescription. A closer look at the supplements being used reveals some interesting data:
Notice how multivitamins and their variants make up the vast majority of supplement use. “Multivitamin plus other” (at least 3 vitamins and at least one other ingredient, but not a botanical) is the most prevalent, followed by antacids, and then multivitamin/botanical combinations. The use of products like single-ingredient botanicals was actually small – less than 1% of consumers. Looking at the relationship the other way, those taking cardiovascular drugs were the most likely to also be taking supplements, followed by those on central nervous system agents, then hormones, and so on:
What this study tells me is that the most common supplement that’s combined with a prescription drug is usually a vitamin – but that vitamin may contain ingredients that go beyond the usual basic multi. (This isn’t the first survey that shows multivitamin use dominates supplement use.) The combination of botanicals into multi-vitamins is concerning, as it’s botanicals like herbs that can induce or impair liver enzymes and have dramatic effects on prescription drugs. Supplements like St. John’s Wort are the bane of pharmacists as they can cause an array of significant and severe drug interactions.
Conclusion
The concurrent use of supplements and prescription drugs is very common, even among those with major medical conditions. Yet there is limited data to suggest that supplements offer meaningful health benefits. Given the uncertain and unreliable quality of dietary supplements that are currently marketed, the risks and benefits of combining supplements with prescription drugs are not clear. Not only are there the potential harms from adverse effects from supplements, there is the additional risk of supplements interacting or interfering with the effectiveness of prescription drugs. Both consumers and health professionals need to understand that the decision to take supplements should not be made lightly – they may not be innocuous, and they may antagonize the effects of any concurrent prescription drugs. And even a multivitamin may contain ingredients that can antagonize medication. The exploding sales and use of supplements may be good business but the health effects are less clear. Mixing supplements and drugs is a type of health roulette – you simply can’t predict the effects.
Reference
Farina E.K., Austin K.G. & Lieberman H.R. (2014). Concomitant Dietary Supplement and Prescription Medication Use Is Prevalent among US Adults with Doctor-Informed Medical Conditions, Journal of the Academy of Nutrition and Dietetics, DOI: 10.1016/j.jand.2014.01.016

The Growing Problem of Supplement–Drug Interactions in Seniors
Many people take supplements alongside prescription drugs without realizing the risks.
Scott Gavura on October 9, 2025
Link
As a pharmacist, I’ve done a lot of medication reviews with patients over the years. I always ask about supplements, and because of my many years of practice (and blogging) I’ve heard of many of them. Patients are sometimes reluctant to disclose, possibly fearing disapproval or judgment. A nonjudgmental attitude is essential.
I’ve sometimes found myself staring at long lists of supplements alongside equally long lists of prescription drugs. Many consumers, especially older adults, genuinely believe dietary supplement products are (at worst) harmless, taking a “can’t hurt” perspective to combining “natural” supplements with prescribed medications. But supplements cannot always be taken safely with medications: It’s not uncommon to find combinations that might blunt a prescribed drug’s effect, raise one’s bleeding risk, or cause other unintended consequences. A medication history that doesn’t include dietary supplements is an incomplete one.
Recent reviews have underscored just how common and under-recognized these interactions are. Surveys of older adults report that many take multiple prescription drugs along with one or more dietary supplements, yet few report this use to their healthcare providers. The result is a growing potential for supplement–drug interactions—some theoretical, others well-documented. A newly published review in Cureus, (h/t Edzard Ernst) for example, documents the extent of this issue, with many examples.
Despite all my past posts, this is a topic I haven’t covered enough: How often supplement-drug interactions occur, which combinations are most concerning, the likelihood of harm, and what kinds of evidence support these concerns. Understanding the scope of the problem, and the evidence base, can support better, safer use of supplements alongside prescription drugs.
Understanding how drugs and supplements interact
When we use the term “drug interaction” we’re describing situations where one substance changes the way another works in the body. That can mean a change in how a drug is absorbed, distributed, metabolized, or eliminated (a pharmacokinetic interaction), or a change in how it acts on its target (a pharmacodynamic interaction).
Supplements can influence drugs in the same ways. Some herbal products, for instance, affect the same liver enzymes that also metabolize many medications, either speeding them up (which can then make a drug less effective) or slowing them down (which reduces the body’s ability to eliminate the drug, potentially causing side effects or toxicity). Others may have additive or opposing effects on the body’s systems. For example, combining ginkgo or fish oil with blood “thinners” like warfarin have the potential to increase bleeding risk, while taking St. John’s wort can lower levels of several prescription drugs by boosting the metabolism of the drugs and reducing blood levels.
Not every supplement–drug combination causes problems, and not every reported or anticipated interaction causes meaningful effects. But understanding how and why these interactions occur helps explain why they’re so important to identify—especially in older adults who may take plenty of both.
Frequency of Interactions
Interactions between supplements and medications are more common than many people realize. Studies suggest that among adults who take prescription drugs, anywhere from 15% to over 30% also use dietary supplements—often several at once. The more products someone takes, the greater the chance of an interaction. Older adults are particularly at risk because they tend to take more medications and may be more sensitive to their effects. Yet many of these combinations go unnoticed, since supplements are often viewed as “natural” and not mentioned to doctors or pharmacists.
Commonly-identified drug-supplement interactions
Some supplement–drug interactions are well established and supported by strong clinical evidence. St. John’s wort is one of the most studied examples: It induces cytochrome P450 enzymes (particularly CYP3A4), which can reduce blood levels and effectiveness of many drugs, including oral contraceptives, antidepressants, transplant anti-rejection drugs, and HIV medications. Ginkgo biloba and garlic supplements can increase bleeding risk when combined with anticoagulants or antiplatelet drugs such as warfarin or aspirin. Ginseng may interfere with blood sugar control, potentially counteracting diabetes medications or increasing hypoglycemia risk. Calcium, magnesium, and iron supplements can reduce the absorption of thyroid medication and some antibiotics if taken together.
Fish oil, while widely consumed and generally safe, may also enhance the effects of “blood-thinning” drugs when taken in high doses. I have blogged the story of the grapefruit juice interaction before. It can inhibit CYP3A4 and cause dangerously high blood levels of certain medications like statins and calcium channel blockers.
While some of these risks are small, the point is that “natural” doesn’t always mean “inert.” The potential for real pharmacologic effects (and therefore interactions) is very real. As I and others have pointed out, many dietary supplements, particularly herbal remedies, can be viewed as unrefined, unpurified, and unstandardized drugs. That lack of consistency increases the risk to patients, because we can’t count on supplements to meet the same quality standards as medicines, or to interact with them in predictable ways.
A new review paper
A newly published review in Cureus, entitled Pharmacological Interactions Between Nutritional Supplements and Prescription Medications in Older Adults: A Comprehensive Review sets out to summarize what’s known about supplement-drug interactions in the older adult population. The authors conducted a literature search ultimately including 16 studies (original research and review articles) that describe clinically relevant interactions. While the authors describe their search and review as comprehensive, the review was narrative in nature, with limited assessment of study quality. Still, it identified some consistent themes. The authors note the following:
The findings from these 16 primary and secondary sources identify three themes in the use of nutritional supplements in older adults: the high prevalence of use and polypharmacy, the identification of common supplement-drug interactions and high-risk patient groups, and the critical role of communication gaps in exacerbating these risks.
The findings are both familiar and concerning. The supplements most often implicated were herbal products, particularly St. John’s wort, ginkgo biloba, garlic, ginseng, and echinacea. The most frequently affected medication classes were anticoagulants, antihypertensives, antidepressants, and antidiabetic drugs. Reported effects ranged from reduced therapeutic efficacy (for example, St. John’s wort lowering blood levels of some drugs) to increased bleeding risk with ginkgo or garlic when combined with warfarin or aspirin. The authors also noted that up to one-third of older adults in various studies were taking at least one supplement–drug combination with potential for harm. The review highlights the need for awareness among healthcare providers and patients regarding these interactions, and the need for health professionals to screen for supplement use. The authors recommend enhanced education and communication strategies to mitigate risks, as well as further research to better understand the science of supplement-drug combinations.
What isn’t known
Not all potential interactions cause real-world harm. The actual incidence of serious clinical harm seems to be far lower than what a paper analysis of potential interactions would suggest. Many identified interactions are theoretical, based on known pharmacologic mechanisms or lab data, rather than direct evidence of harm. Others are reported in case studies, and whether or not they can be generalized is unclear. On one hand, this could be a consequence of poor supplement quality – where we don’t know if what’s on the label is in the bottle. This makes risk assessment, and evidence-based advice nearly impossible. Or it may be that the clinical consequence of supplement-drug interactions may be limited to specific combinations of products. Given the lack of regulation in the supplement market and the poor (overall) data, it is difficult to say.
The end result is a knowledge gap for patients and health professionals: we can identify plausible mechanisms and credible signals of risk, but it’s much harder to know how often real-world harm occurs. For clinicians, this uncertainty reinforces the need to understand if supplement use is occurring, open dialogue with patients, and a healthy skepticism toward assumptions that supplements can only provide benefit. Given the risks, you can see why health professionals are generally leery of combining supplements with drugs.
Conclusion
The first step in reducing the risk of supplement–drug interactions is simple awareness. Supplements need to be treated like medicines: products with drug-like potential that can have risks and can interfere with other treatments. Every medication review must include a discussion about vitamins, minerals, and herbal products—not just prescription and over-the-counter drugs.
Patients can reduce their own risk by being transparent with their health care providers. Keeping an up-to-date list of products and doses for your physician and pharmacist is so helpful. Pharmacists can use evidence-based tools to assess risks, and can put reported interactions into perspective. In some cases, separating doses by a few hours may be enough to prevent any problems. In others, a supplement may need to be avoided completely.
People generally take supplements with good intentions: To improve their health or address gaps in their diet. But when supplements are combined with prescription drugs, good intentions alone will not be enough to prevent problems.The safest approach is one that’s transparent, informed, and guided by good evidence.


“Safe” dietary supplements can land you in the emergency room
David Gorski on October 18, 2015
Link

If there’s one thing I’ve been consistent about, it’s that, however ridiculous all the other woo I routinely discuss here is—homeopathy, reiki, reflexology, I’m talking to you and your friends—herbal medicine and supplements might have value because they might have a physiological effect that is beneficial in treating or preventing disease. Of course, if that’s the case, it’s because the herb or supplement contains chemicals that act as drugs. They’re “dirty” drugs in that they are mixed with all sorts of other substances in the herb or supplement that might or might not have effects, which means that different lots of the herbs or supplements often have different activity, but they are drugs nonetheless. That’s why, for instance, doctors don’t tell patients to chew on foxglove leaves when they want a patient to get digoxin. Digoxin is a powerful drug with a relatively narrow “therapeutic window,” meaning that the difference between the levels of the drug in the blood needed for therapeutic effect are not very far from toxic levels; so predictable, reliable drug content is essential. I just learned a while ago that within the living memory of some older physicians digoxin actually was prescribed as crude extracts, which was very difficult and dangerous, hence the necessity of purification. In other cases, (such as Artemisinin, for which Youyou Tu was recently awarded the Nobel Prize in Physiology or Medicine), crude plant extracts do not contain sufficient quantities of the active component, necessitating its isolation, purification, and, in some cases, chemical modification to increase its absorption, stability, or activity.
One thing that proponents of herbal medicine and supplements often forget, though, is that if herbs or supplements can have potentially beneficial effects (albeit difficult to regulate effects due to the crude, impure nature of the extracts often used) because they contain drugs, then herbs and supplements can also produce adverse events, again, because they contain drugs. You can overdose on herbs and supplements. This point was recently reinforced by a new study by Geller et al. published last week in the New England Journal of Medicine (NEJM), entitled “Emergency Department Visits for Adverse Events Related to Dietary Supplements.” It was carried out by investigators from the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, and Chenega Government Consulting; and the Center for Food Safety and Applied Nutrition and the Division of Public Health Informatics and Analytics and the Division of Dietary Supplement Programs, Food and Drug Administration. The title pretty much tells you what the study is about, and what the study is about is that dietary supplements cause a lot of visits to the emergency room every year; 23,005 (95% confidence interval [CI], 18,611 to 27,398) emergency department visits per year can be attributed to adverse events related to dietary supplements.
Let’s back it up a minute before I get into the study more. In the US, dietary supplements are regulated by the FDA (or, more appropriately, barely regulated by the FDA) under the Dietary Supplement Health and Education Act of 1994 (DSHEA), which is one of the worst laws ever passed or, as Peter Lipson called it right here, a travesty of a mockery of a sham. Basically, supplements are considered more food than medicine and regulated as such. They can’t be marketed for the treatment or prevention of disease (i.e. drug claims), but can make so-called “structure-function” claims (i.e., “boosts the immune system”). The problem is, what constitutes a “drug claim” compared to a “structure-function” claim remains fairly vague. Even after the FDA issued rules in 2000 that banned explicit claims that a product treats or prevents disease, there’s still considerable wiggle room, and enforcement isn’t exactly what I would call robust. In the meantime, supplement hawkers have cleverly used the Internet to circulate claims for these products that aren’t necessarily on the packages or in the package inserts. As Geller et al. note:
Although supplements cannot be marketed for the treatment or prevention of disease, they are often taken to address symptoms or illnesses, as well as to maintain or improve overall health. The estimated number of supplement products increased from 4000 in 19943 to more than 55,000 in 2012 (the most recent year for which data are publicly available), and approximately half of all adults in the United States report having used at least one dietary supplement in the past month.5 In 2007, out-of-pocket expenditures for herbal or complementary nutritional products reached $14.8 billion, one third of the out-of-pocket expenditures for prescription drugs.6
We know supplements are big industry here in the US. Indeed, for whatever reason, Utah has become the state where the supplement industry is most concentrated, and as a result its politicians strongly support supplements. Senator Orrin Hatch (R-UT) has long been in the pocket of the supplement industry and is its most friendly lapdog and powerful defender. Rising star Representative Jason Chaffetz (R-UT) is a long shot candidate for Speaker of the House in the wake of John Boehner’s resignation and the implosion of Kevin McCarthy’s (R-CA) candidacy, and Chaffetz has over the last few years been vying to outdo Hatch in demonstrating his fealty to the supplement industry. It’s not just Utah politicians, though. There is the Congressional Dietary Supplement Caucus, which is bipartisan and has members from all over the country. It includes the aforementioned Chaffetz and Hatch, as well as Sen. Darrell Issa (R-CA), Rep. Frank Pallone (D-NJ), and Rep. Tom Cotton (R-AR). Thanks to the power of the supplement industry, thus far every attempt to tighten regulation of supplements since 1994 has failed. For example, in 2010, facing a primary challenge from the Tea Party, after having championed a bill to give the FDA more power to regulate dietary supplements, Sen. John McCain (R-AZ) caved because he decided that he couldn’t be perceived as being in favor of more government regulation.
As a result of the lack of regulation of dietary supplements, manufacturers and advocates make all sorts of de facto health claims for supplements such as that they can prevent or treat cancer and the like. FDA enforcement is sporadic and directed at only the most egregious, most immediately dangerous cases. Meanwhile, advocates, using the exaggeration of “food as medicine,” continue to sell their products, and many supplements are scary substances manufactured under scary conditions, even though there is a distinct paucity of evidence for their usefulness.
The result is what we see in this study. Postmarketing reporting of adverse events from supplements by manufacturers is only required for the most serious events (e.g., those resulting in hospitalization, significant disability, or death), while voluntary reporting almost certainly greatly underestimates the incidence of adverse events. So Geller et al. decided to use a national surveillance database to estimate the number of adverse events attributable to supplements that result in visits to the emergency room. They used the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance (NEISS-CADES) project conducted by the CDC, the FDA, and the Consumer Product Safety Commission. There are 63 hospitals participating in the project that make up a nationally-representative probability sample drawn from all hospitals with at least six beds and 24-hour emergency departments with four strata based on hospital size and a fifth stratum for pediatric hospitals. Cases were identified thusly:
Trained abstractors at each hospital reviewed the clinical records of every emergency department visit to identify physician-diagnosed adverse events and reported up to 2 implicated products and 10 concomitant products, as described previously. Abstractors also recorded narrative descriptions of the event, including preceding circumstances, physician diagnoses, testing, treatments administered in the emergency department or by emergency medical services, and patient outcome. Narrative data were coded with the use of the Medical Dictionary for Regulatory Activities (MedDRA), version 9.1.
Geller et al. looked at a ten year period from 2004 to 2013 for cases:
Cases were defined as emergency department visits for problems that the treating clinician explicitly attributed to the use of dietary supplements. This analysis included orally administered herbal or complementary nutritional products (including botanicals, microbial additives, and amino acids) and micronutrients (vitamins and minerals) but excluded products that are typically considered to be foods or drinks (e.g., energy drinks, herbal tea beverages). Additional products that are often used by consumers for complementary health but do not fall under the regulatory definition of dietary supplements (e.g., topically administered herbal or homeopathic products) were also included in the analysis. Herbal or complementary nutritional products were categorized according to common reasons for use…
Adverse events were categorized as adverse reactions, allergic reactions, excess doses, unsupervised ingestion by children, or other events (e.g., choking). Cases involving death on the way to the emergency department or after arrival were excluded because death registration practices vary among participating hospitals, and details about event circumstances are often lacking. Visits involving intentional self-harm, drug abuse, therapeutic failures, nonadherence, or withdrawal were also excluded. The categorization of symptoms was based on MedDRA-coded narratives.
When the analysis was done, on the basis of 3.667 cases identified in the database, Geller et al. calculated an average of 23,005 emergency room visits for adverse events related to supplements and further estimated a 2,154 yearly hospitalizations. In the vast majority of these cases (88.3%), doctors attributed the adverse event to only one supplement, and the mean age of patients was 32 years, with more than a quarter of the visits due to patients between 20 and 34 years of age. Not surprisingly, people older than 65 were nearly twice as likely to be hospitalized. One-fifth of the visits involved unsupervised ingestion of supplements by children. (So, parents, lock your supplements up the way you do with your prescription and over-the-counter drugs.) There’s a nice graph in the article that boils down a lot of information in a very compact package, including age of patients and what the product category was:

Not surprisingly, in younger patients weight loss supplements were by far the largest category of supplements that caused adverse events. Similarly, not surprisingly, cardiac symptoms were the most common symptom associated with weight-loss products (42.9% of patients), and weight-loss or energy products were implicated in 71.8% of all ER visits for supplement-related adverse events involving palpitations, chest pain, or tachycardia. These were young people, too, the vast majority between 20 and 34 years old. Interestingly, among patients under 6 and 65 or older, swallowing problems caused a significant number of the ER visits. I don’t find that too surprising, given the horse pill-sized capsules many supplements are often sold in. Calcium supplements were the worst offenders.
It’s rather an odd coincidence that a couple of days before this study was published, the story of NBA star Lamar Odom’s fight for his life after taking large quantities of “herbal Viagra” in a Nevada brothel hit the news in a big way. It should be noted, however, that Odom had also apparently been using cocaine and drinking Cognac, so it’s difficult to know what the cause of his collapse was for sure, although it certainly could have been a combination of whatever was in the herbal product plus the cocaine, plus whatever else he was taking (and, according to E! News, he was taking a lot). Whatever the case, Odom is, by many reports, in bad shape, with TMZ.com reporting the failure of four organs, is on dialysis, and has suffered multiple small strokes. How many of these medical reports are true (considering the source) or not, the prognosis of multiorgan failure is very, very bad.
Whether the ten or more tablets of “herbal Viagra” that Odom took had anything to do with his condition or it was the cocaine, Cognac, and other drugs he was doing that landed him hear death, this NEJM study is yet more evidence that there are real consequences to the DSHEA and letting supplements be sold with, in essence, almost no regulation. Odom, if the herbs were the main reason for his collapse, would just be an extreme case.

What are health professionals telling consumers about dietary supplements?
Scott Gavura on November 17, 2016
Link

The popularity of dietary supplements continues to grow. A few weeks ago I described how dietary supplements have become a $34 billion industry, despite the fact that there’s very little evidence to support their use. While there are absolutely some medical circumstances where specific supplements may be warranted, the vast majority of supplements are taken for general purposes, such as “wellness” or to prevent perceived deficiencies. There’s also the belief that “more is better”, a sentiment that seems unique to supplements (compared with drugs), perhaps because supplements are widely believed to be safe, effective and yet simultaneously free of any adverse effects. While none of these assumptions are inherent to any “supplement”, this thinking has had a clear influence on regulators and consumers:
    • Regulatory frameworks for supplements or “natural health products” (the regulatory term in Canada) are weak, and favour manufacturer interests over the need for consumers to be informed about the products they buy, or to have access to products that have been shown to be safe and effective. Regulations like the US Dietary Supplement Health and Education Act of 1994 (DSHEA) effectively exclude manufacturers from most of the regulations that are in place for prescription and over-the-counter drugs, and puts the requirement to demonstrate harm on the FDA, rather than the onus on the manufacturer to show a product is safe and effective.In part because there are no requirements for manufacturers to actually demonstrate their products are effective, there is relatively little research conducted by manufacturers on the products they sell. There’s also no routine collection of adverse event (side effect) information. The consequence is that we’re effectively conducting a massive, uncontrolled, unmonitored clinical trial in millions, with products of unknown quality. Only when products kill (e.g., ephedra) or harm in a unique way (e.g., aristolochia) is the link more obvious.
    • Despite the lack of credible information to support the routine sale and use of dietary supplements, and weak regulation which disadvantages consumers, pharmacies have become major providers of these products. Seemingly every pharmacy I visit in Canada or the US has an aisle (or two) now dedicated to supplements ranging from homeopathy to vitamins to herbal remedies and “detox” kits. Pharmacy is a self-regulated profession, and while state and provincial regulations vary, pharmacists are generally expected to provide information on supplements that factual, and supports consumers who wish to make their own self-care decisions. Dietary supplements can also cause drug interactions with prescription drugs, so pharmacists must have sufficient knowledge in order to identify and resolve any drug-supplement problems.
Trusted health professionals such as pharmacists are in a unique position to guide the use of dietary supplements. The extent to which pharmacists effectively guide the selection and use of dietary supplements hasn’t been previously studied. Now a new paper by Ubaka Ogbogo and Candace Necyk sheds some light on this question. Entitled “Community Pharmacists’ Views and Practices Regarding Natural Health Products Sold in Community Pharmacies” and published in PLOS One, this is a survey of 403 community pharmacists in the Canadian province of Alberta. The results are interesting and worth discussing when we think about the broader goal of improving the rational use of supplements. What is the best way to get accurate information to consumers in order to help them make informed decisions about supplement use? This paper gives some hints. For clarity, this survey called supplements “Natural Health Products” (NHPs) which in Canada include vitamins, minerals, herbal remedies, homeopathy, Traditional Chinese Medicine, and Ayurveda.
The entire survey is online [PDF] and was made up of 15 questions. There are about 4,000 pharmacists in Alberta, so a 10% response rate to an electronic survey isn’t bad. In terms of who responded, the sample was made up mainly of retail (community) pharmacists: They provided patient care an average of 33 hours per week. 85% indicated that they had spent some time learning about natural health products (NHPs), with 14% indicating no time learning about NHPs. The key observations were as follows:
Frequency of recommendations
Most pharmacists indicated they recommend NHPs “sometimes” (45%) or “rarely” (28%). Only 18% recommend NHPs often, and 6% “very often”. Just 3% of pharmacists never recommend NHPs.
Which products?
Vitamin D is the most recommended NHP, followed by calcium, then multivitamins, probiotics, and fish oils, iron, and melatonin. At the bottom of the list are weight loss/”detox” products (hurray!) and St. John’s wort, which pharmacists loathe because of its demonstrated ability to interfere with the action of what seems like every other drug.The full table is here:

Why were NHPs recommended at all?
The most common reason for recommendation of an NHP cited was an identified vitamin and/or mineral deficiency, which is surprising, given actual deficiencies are very rare. Bone and musculoskeletal disorders followed (likely calcium and vitamin D) followed by gastrointestinal disorders (probiotics?) and then pregnancy (folic acid, most likely). Thankfully there were relatively few recommendations for dubious purposes like food “intolerances” or “weight loss/detoxification”:

What products were recommended?
There’s some good news here. Most pharmacist relied on review articles in publications like the Pharmacist’s Letter and the Canadian Pharmacists Journal as their primary evidence source (35%) with relatively few relying on Health Canada’s approval (12%) or manufacturer information (3%), likely because neither are credible sources for this type of information. (Recall that Health Canada has a homeopathic evidence bar for determining if a NHP may be sold.) Looking at the primary literature itself is the ideal approach, but it’s also time consuming, so pharmacists cited researching the primary literature only 14% of the time. Most pharmacists (58%) noted that they do not recommend products that haven’t been reviewed and approved by Health Canada. I’m surprised this isn’t higher, because pharmacies really shouldn’t be selling any supplements that haven’t been reviewed and approved by Health Canada.
Where did pharmacists obtain efficacy and safety information?
Almost all pharmacists (90%) responded that they provide patient information upon request when they receive an inquiry. While the Natural Medicines Comprehensive Database was the most commonly cited source of information about efficacy and safety reported (70%), it was nice to see the Science-Based Medicine blog among the references used by a minority pharmacists, as well as “respected authors of evidence based medicine [such as] Dr. Edzard Ernst.” They like us! They really like us!
Do pharmacists influence NHP use?
Pharmacists are routinely involved in providing information about dietary supplements or natural health products to consumers. Most pharmacists in this survey (68%) routinely or occasionally recommend NHPs. Given the lack of good information to support the use of most NHPs, it is somewhat reassuring to see that pharmacists make positive recommendations for products for which there is relatively more evidence to support their use. This doesn’t mean that use is science-based however. Moreover, pharmacists seem to be using reasonable references to guide their recommendations. While we don’t know if the specific recommendations they are making are themselves evidence-based, the survey gives some signals of appropriateness. Only 7% of respondents cited homeopathy as their most-recommended NHPs, which I’d argue is still too high, given there’s zero convincing evidence that homeopathy is anything other than an elaborate placebo system.
Conclusion: Good news, but…
Community pharmacists are key providers of information on NHPs, and may have an opportunity to discourage inappropriate use. But will they? These products are widely used despite a lack of good evidence showing they offer much benefit. While pharmacists are ethically expected to put the consumer interests ahead of business interests, there’s an inherent conflict of interest when the pharmacy stands to profit from the sale of a supplement. And just the act of selling a supplement in a pharmacy may give it a veneer of legitimacy that it may not have in if sold at the local health food store. In order to ensure that pharmacists’ recommendations are based on the best evidence, pharmacists and other health professionals need access to credible, critical, science-based resources. As advocates for the rational use of these products by consumers, we need to find more ways to get the right information to both consumers and health professionals to help support informed decision-making and wise choices about supplements.

Should you try a “natural alternative” before medication?
Scott Gavura on July 14, 2016
Link


The idea of taking medication can be frightening. And as consumers and patients that want to make our own informed health decisions, it’s understandable and even appropriate to question our physicians when they recommend drug treatments. We need to understand the rationale for any medication that’s recommended or prescribed, the benefits of therapy, the side effects, and if there are any other approaches that might be more appropriate. Dietary supplements and natural health products are widely marketed as being safe and effective, and are occupying more and more shelf space in pharmacies, usually right beside the pharmacy counter. Many of my patient encounters in the pharmacy have included a discussion on the merits of drug therapy, versus the supplements that may have flashy packaging and impressive claims of effectiveness.
One encounter from my time working at a local pharmacy still sticks with me. I met a new patient who was anxious and eager to get my advice. He’d been cautioned by his family doctor that he was on the borderline of being diagnosed with diabetes. He had come to the pharmacy seeking a supplement that could help him avoid diabetes and medication. Rather than recommend any supplement, I suggested that the best approach he could probably take would be to lose some weight and get some exercise – it could be more effective than any supplement or drug, and would definitely help his health. He agreed, and then asked me what supplement he could take that could help him with some weight loss.
This type of discussion occurs all the time, and seems more common when there’s a lack of trust in the physician, or when the goals of treatment aren’t understood. The patient, reluctant to accept the physician’s recommendation, heads to the pharmacy for what they believe is a second opinion. In some cases, the patient may question the physician’s advice: “All my physician wants to do is prescribe drugs,” is a statement I’ve heard more than once. In those that are reluctant to accept medical treatment, there’s often a willingness to consider anything that’s available without a prescription – particularly if it’s perceived as “natural.” Natural products and dietary supplements are thought to be gentle, safe, and effective, while medicine may be felt to be unnatural, harsh, and potentially dangerous. Yet when I explain to patients that there’s actually little evidence to suggest most supplements offer any meaningful health benefits, I am sometimes met with puzzled or dismissive looks. The supplement industry’s marketing has been remarkably effective, glossing over the fact that the research done on dietary supplements is overall unconvincing and largely negative when it comes to having anything useful to offer for health.
Given I want to ensure patients are making informed health decisions based on good scientific evidence, I was eager to read a post that naturopath Reuben Dinsmore recently posted on the website of the British Columbia Naturopaths Association (BCNA). Entitled “The Top Five Medications You Shouldn’t Take Without Trying a Natural Alternative First,” Dinsmore states that supplements can offer all the benefits yet none of the side effects of prescription drugs:
Natural supplements, or nutraceuticals, have been given a bad rap lately—which, in some cases, has been absolutely warranted. But natural formulas that actually contain what they claim on the label, and that are formulated to have maximal efficacy, can be equal to their pharmaceutical counterparts. Better yet, they can be just as effective without the laundry list of side effects.
I approached the article with curiosity. Are supplements an appropriate therapy before medication? I have no bias against supplements, but I do have a bias against unsubstantiated claims. I want to know what works, supplement, drug or otherwise. I looked at each recommendation as if it was given to me by a patient in the pharmacy, and evaluate it against the scientific evidence.
Understanding the naturopathic approach
I’ve written multiple posts in the past about treatment claims by naturopaths, and how they stack up against the scientific evidence. Naturopaths offer an array of unconventional health practices like homeopathy, acupuncture and herbalism that are linked philosophically by a belief in vitalism – the prescientific idea we have a “life force”. From this philosophy can sometimes emerge sensible health advice, but it can also be illogical and even potentially harmful. In past posts I’ve looked at the naturopathic perspectives on fake diseases, infertility, autism, prenatal vitamins, vaccinations, allergies, and even scientific facts themselves. As long as a treatment is viewed as being congruent with the naturopathic belief system, it’s acceptably “naturopathic” – no matter what the scientific evidence says. Despite this obvious disconnect from science-based medicine, naturopaths present themselves as primary care providers, just like medical doctors. The BCNA’s own marketing campaign describes naturopaths as “medically trained”:
Britt Hermes is a former naturopath and has written extensively about naturopathy, and her perspective is clear: There are no naturopathic standards of care and naturopathic training is very different than what naturopaths claim. She argues is that naturopathy has too much quackery and that what actually makes naturopathy unique is its embrace of pseudoscience.
So let’s examine the five categories of drugs that Dinsmore says have equally effective natural remedies. He lists statins, antacids, SSRIs (selective serotonin reuptake inhibitors), antihypertensives, and benzodiazepines.
Statins for high cholesterol
Why do we treat it?
High cholesterol has no symptoms. We treat high cholesterol to lower the risk of heart disease: heart attacks, strokes, and death. One’s risk of heart disease goes up with the LDL cholesterol level, along with the total number of heart disease risk factors.
When is drug treatment appropriate?
High cholesterol doesn’t mean that drug treatment is mandatory. An assessment will include age, family history, and other health conditions such as diabetes, heart disease, or a prior heart attack or stroke. Lifestyle changes are important: A healthy diet, an appropriate weight, regular physical exercise, and quitting smoking can also reduce your risk of heart disease. In those at low risk, drug therapy many not be necessary. “Statins” are a class of drugs that reduce LDL cholesterol. In those with a prior heart attack or stroke, the benefits of treatment with drugs like statins are well documented.
What benefits have drugs been shown to offer?
There’s two general uses for statin therapy: primary prevention (avoiding a first heart attack or stroke), and secondary prevention (using a statin in someone that has already had a heart attack or stroke) to reduce the risk of another cardiovascular event. There is good evidence that statins reduce the risk of heart attacks and strokes, when used for both primary and secondary prevention. Much of the debate on the usefulness of statins has focused on the net benefit when used in lower-risk groups. This is a fair question, and one that I’ve discussed at length previously. But what is not in question is that statins have been proven to reduce the risk of heart attacks, stroke, and death.
What does naturopathy suggest?
As per Dinsmore:
High cholesterol is blamed for heart attacks and strokes via formation of arterial plaques. But the real culprit is inflammation, without which the plaques wouldn’t form in the first place. Bottom line: You can lower cholesterol all you want, but as long as there is inflammation present, plaques can still form.
Some common side effects of statins include muscle pain, cognitive impairment, sexual dysfunction, and increased risk of cancer and diabetes.
Nutraceuticals are an alternative to statins. These include: Omega-3 fatty acids (best sourced from wild-caught fish oils) and curcumin (the active component in turmeric). Both are excellent supplements to lower inflammation. Garlic extracts have been proven to improve cholesterol levels as well. Another option I discuss with patients is red rice yeast extract, which is the natural compound statins were derived from in the first place, and works in a similar manner. This product may have side effects; I find that it can be beneficial for some patients, but not all, something I deal with on a patient by patient basis.
What evidence supports the use of naturopathic treatments?
The reason we use drug therapy to treat high cholesterol is to lower the risk of heart attacks, stroke, and death. Consequently, that’s the benefit we want to see when we consider taking any treatment – naturopathic or drug. Statins are proven effective, so that’s the effectiveness we should be looking for if we’re going to use supplements as an alternative. There is no published evidence to demonstrate that garlic extracts or curcurmin supplements can prevent heart attacks and stroke, or reduce the risk of death. The data are a bit more encouraging with omega-3 fatty acids (which, incidentally, exist as both a drug and a supplement with different regulatory standards for each), but whether or not these products actually produce a real survival advantage is not clear. There is a Cochrane review on dietary modifications for the treatment of high cholesterol, in which the authors conclude:
No conclusions can be made about the effectiveness of a cholesterol-lowering diet, or any of the other dietary interventions suggested for familial hypercholesterolaemia, for the primary outcomes: evidence and incidence of ischaemic heart disease, number of deaths and age at death, due to the lack of data on these. Large, parallel, randomised controlled trials are needed to investigate the effectiveness of a cholesterol-lowering diet and the addition of omega-3 fatty acids, plant sterols or stanols, soya protein, dietary fibers to a cholesterol-lowering diet.
Red rice yeast extract is effectively a natural but crude source of the statin drug lovastatin (the active molecules are identical). There are questions about its safety that are exclusive to red yeast rice, but not present with prescription drugs. Why red rice yeast extract would be preferred over a drug product is unclear, unless one puts a priority on something “natural” over something that’s standardized, predictable, and demonstrated to be effective.
What approach has the best evidence?
Statins provide proven benefits, reducing heart attacks, strokes, and the risk of death. Even if a supplement reduces cholesterol levels, real benefits haven’t been established. There’s no obvious reason to use supplements for high cholesterol.
“Antacids” (anti-ulcer medications for gastro-esophageal reflux)
Why do we treat it?
The reflux of stomach contents, often called “heartburn” requires medical attention when there is damage to the esophagus, or there are unpleasant symptoms. The objective of treatment is to repair any tissue damage and/or to reduce the symptoms of heartburn.
When is drug treatment appropriate?
So called “lifestyle” modifications are usually recommended first, and they aren’t always effective. Weight loss (if appropriate) can provide relief, as can elevating the head of the bed for those with heartburn at night. Minimizing specific foods or “triggers” is usually not necessary, but some find this approach helpful. Drug treatment with medications like proton pump inhibitors (PPIs), which suppress stomach acid production, are usually appropriate when symptoms are severe, or where there’s esophageal damage.
What benefits have drugs been shown to offer?
PPIs are among the most effective drugs to treat heartburn and heal esophagitis. PPIs are well tolerated over the short term. When acid production is suppressed for long-term periods (months to years), there are concerns this may predispose people to infections and malabsorption conditions. Whether or not PPIs raise the risk of osteoporosis or hip fractures isn’t clear. Many people find these medications highly effective, but some stay on therapy far longer than necessary. Current guidance suggests the lowest dose should be used for the shortest duration possible to minimize these risks.
What does naturopathy suggest?
As per Dinsmore:
It’s said that five million Canadians suffer from heartburn symptoms weekly. Prescriptions for the acid-blocking drugs PPIs (proton pump inhibitors) accounted for $24 million in BC alone in 2013. Risks of taking these mostly involve nutrient deficiencies from poor absorption DUE TO LOW STOMACH ACID (see the problem here?). Examples include bone fractures from poor calcium absorption or anemia from decreased levels of vitamin B12 or iron. B12 deficiency can also cause dementia and neurological damage. There has also been a correlation shown between PPI use and C. difficile infection, which causes life-threatening diarrhea.
Nutraceuticals: Long story short, most people don’t have too much stomach acid. The problem is the acid they have is getting into the wrong place (the lower esophagus) where it burns. This can be from the muscle between the esophagus and the stomach not closing properly, either from poor tone or insufficient stomach acid, which is the signal for the sphincter to close. Limonene (an extract from citrus peel) helps strengthen this muscle and promotes movement of food downward to the stomach. DGL (an extract from licorice root) stimulates mucus production in the stomach, which acts to coat and protect the sensitive lining of the esophagus.
What evidence supports the use of naturopathic treatments?
Limonene is an ingredient in citrus oils, and is considered “possibly safe” as a supplement by the Natural Medicines database. I could locate no published evidence in PubMed it has been studied for heartburn or GERD. I did find a reference to clinical trials in Alternative Medicine Review, but there’s not a lot of information to review: one trial had 19 adults and had no control group. The other had just 13 participants but was randomized and blinded, noting improvements in heartburn symptoms with limonene. There’s not much safety information on limonene, and it appears to have multiple interactions with drugs. How limonene might work isn’t clear. Long-term effects haven’t been reported.
Deglycyrrhizinated licorice (DGL) is licorice processed to remove the glycyrrhizic acid, which can cause steroid-like side effects when consumed in excess. Short term use of licorice as a supplement is considered “possibly safe” and long-term use is considered “possibly unsafe”. Some branded supplements combining licorice with other herbal ingredients have been studied for the treatment of acid reflux, stomach pain and cramping. How DGL might work isn’t clear. There’s a lack of evidence to suggest DGL is effective.
What approach has the best evidence?
There’s good evidence to show PPIs work, and they work quickly. There are some concerns when used for long-term purposes. The effectiveness of the remedies suggested by Dinsmore is unclear, as is their long-term safety. Given the lack of good evidence showing they work, I wouldn’t recommend the products, but if someone wanted to try them for mild heartburn, they appear to be low risk when used for short-term use.
SSRIs (selective serotonin reuptake inhibitors) for depression
Why do we treat it?
Depression is the most common psychiatric disorder and a major public health issue. It is associated with functional disability and greater risk of death. It frequently recurs.
When is drug treatment appropriate?
We treat depression to put symptoms into remission and to restore baseline (pre-depression) levels of function. The usual initial treatment of depression can include drug therapy or psychotherapy. Psychotherapy alone appears to be just as effective as drug therapy alone. There’s some evidence the combination may be more effective than either approach alone.
What benefits have drugs been shown to offer?
Antidepressants can help with depression, but the magnitude of that benefit has been questioned. The overall advantage of antidepressants over placebo can be modest for mild-to-moderate depression. Selective publication of trials may have led to an overestimate of the efficacy of antidepressants. SSRI’s or selective serotonin reuptake inhibitors are a popular class of antidepressant medications. No particular SSRI is dramatically and consistently superior to any other antidepressant drug in terms of effectiveness, but the side effects can vary. In severe cases of depression, drug therapy is combined with psychotherapy.
What does naturopathy suggest?
As per Dinsmore:
SSRIs (selective serotonin reuptake inhibitors) are the most common class of anti-depressant drugs. One in twelve Canadians will experience major depression in their lifetime, but it’s still one of the most misunderstood conditions. Standard treatment protocols typically target neurotransmitter activity (most commonly serotonin). However, new research indicates the underlying cause may actually be inflammation. Either way, natural medicine has you covered.
Some nutraceuticals to consider are 5-HTP, which is used to make serotonin, with the help of vitamin B6. The herb St. John’s Wort has been studied extensively and appears to work in the same way as SSRIs. Both 5-HTP and St. John’s wort have shown similar efficacy to SSRIs when given for mild to moderate depression. And as I mentioned earlier, omega-3 fatty acids and curcumin decrease inflammation throughout the body, including the brain.
Side effects of SSRIs include sexual dysfunction, weight gain, and worsened/chronic depression. St. John’s wort also has a side effect which should be considered if taking other medications—it impacts liver function, which can result in either higher or lower blood medication levels.
What evidence supports the use of naturopathic treatments?
5-HTP is considered “possibly effective” for the treatment of depression by the Natural Medicines database. It notes:
Overall, despite the preliminary beneficial effects shown in clinical research, the trials to date are generally small and have methodological problems or a lack of generalizability to mixed populations of depressed people. More higher-quality studies in larger patient populations are needed to confirm these result.
St. John’s Wort is considered to be “likely effective” for the treatment of depression by the Natural Medicines database. It’s an interesting natural product that is used widely for antidepressant effects. Trials have many limitations, but the data suggest that SJW may be as effective as SSRIs, but the evidence is less consistent. However, it’s not recommended in most treatment guidelines for many of the reasons discussed before at this blog: preparations of the product are often not standardized, supplement manufacturing quality is not clear, and the dosing may consequently not be predictable. Moreover, St. John’s Wort causes a wide array of drug interactions with other medications, making it difficult to use safely.
What approach has the best evidence?
Overall, there’s better evidence with the SSRIs compared to 5-HTP and St. John’s Wort. However, a decision to use St. John’s Wort is effectively a decision to use medicine, so unsupervised, unmonitored use, when treating depression, should be avoided.
Anti-hypertensives for the treatment of high blood pressure
Why do we treat it?
Untreated high blood pressure, or hypertension, can increase your risk of heart attack, stroke, heart failure, and kidney disease. We treat hypertension to reduce these risks.
When is drug treatment appropriate?
Non-drug treatments are usually considered before drug therapy, and can reduce the need for medication. Weight reduction (when necessary), quitting smoking, avoiding excessive alcohol, a healthy, reduced-salt diet, and regular exercise are all low-risk strategies that can be beneficial. Drug therapy can have side effects. People are usually unwilling to tolerate side effects for a symptomless condition, unless there is a good reason to take medication. There is good evidence that drug therapy provides real benefits to those with hypertension that can’t be controlled by lifestyle changes.
What benefits have drugs been shown to offer?
When drug treatment is considered appropriate (usually when blood pressure exceeds 140/90), there are multiple treatment options that may be appropriate. From Up-to-Date:
In large-scale randomized trials, antihypertensive therapy produces a nearly 50 percent relative risk reduction in the incidence of heart failure, a 30 to 40 percent relative risk reduction in stroke, and a 20 to 25 percent relative risk reduction in myocardial infarction.
The absolute benefit is less impressive, but still real: There’s an approximate 2% reduction in heart attacks and strokes. The benefits of medical treatment are not as clear in those with mild hypertension, those with few risk factors, or the frail elderly.
What does naturopathy suggest?
As per Dinsmore:
Hypertension (i.e., high blood pressure) affects 6 million Canadians, and is responsible for approximately 13 per cent of all deaths. Various classes of anti-hypertensives include diuretics, ACE inhibitors, angiotensin II receptor blockers (ARBs). Diuretics increase urine output, which can negatively affect sodium and potassium levels, which can cause muscle cramps. ACEIs and ARBs may both cause a chronic dry cough. All anti-hypertensives can cause dizziness, headache and low blood pressure.
Again, there are many nutraceutical options for patients to consider, such as CoQ10, magnesium, garlic extracts, omega-3 fatty acids, L-arginine and vitamin C. All of these have all been shown to lower high blood pressure by various means. Dandelion leaf is an effective diuretic that doesn’t lower potassium levels.
What evidence supports the use of naturopathic treatments?
I could find no published evidence that coenzyme-q10, magnesium, garlic, omega-3 fatty acids, l-arginine, or vitamin C supplements reduce the risk of heart attacks, stroke, heart failure, or kidney disease. There is some evidence to show that eating fatty fish (a source of omega-3 fatty acids) can reduce the risk of heart disease or stroke. Omega-3 supplements (also discussed above for hypercholesterolemia) may modestly reduce blood pressure. None of the products listed are considered both safe and effective for treatment of hypertension by the Natural Medicines database. I could find no published evidence that demonstrates dandelion leaf is an effective hypertension treatment.
What approach has the best evidence?
The only reason to treat hypertension with a drug or supplement is to reduce the risk of a future catastrophic event. If medicine is necessary, there’s little reason to choose a “natural” remedy first, as the real-world benefits of supplements have not been proven.
Benzodiazepines for anxiety and insomnia
Why do we treat it?
The term “anxiety” describes worries and fears that are difficult to control and can cause debilitating effects. Insomnia describes difficulty falling asleep or staying asleep. We treat both to reduce the consequences of these conditions, and to restore normal functioning.
When is drug treatment appropriate?
After a workup for underlying causes of anxiety or insomnia, drug therapy might be considered after options like lifestyle changes and cognitive behavioral therapy have been attempted. Benzodiazepines are a class of drugs that can be useful treatments for anxiety and insomnia, though they are usually not the first choice for either condition. There are justified concerns about dependence and tolerance with benzodiazepines, reinforcing the importance of using these medications cautiously and when the benefits are expected to outweigh the risks.
What benefits have drugs been shown to offer?
Benzodiazepines can work quickly and can be effective in anxiety where there’s a poor response to other medications. They are also effective insomnia treatments, with some taking effect within minutes.
What does naturopathy suggest?
As per Dinsmore:
Benzodiazepines are a class of drugs most often prescribed for anxiety disorders and insomnia. They work by binding to receptors for GABA, a neurotransmitter in the brain that calms activity of the nervous system. Interestingly, this is the same mechanism by which alcohol acts in the brain. One obvious effect of benzodiazepines is sedation—great when the treatment target is insomnia. Not so great when you just want to decrease your anxiety but still function. Other side effects include dizziness, loss of balance, and even cognitive impairment at higher doses. They also have a significant risk of developing physical or psychological dependence and rebound anxiety when discontinued.
This is an area where you should have a thorough workup with your naturopathic doctor and consider the options that are right for you. You can take GABA as an alternative (but there’s mixed evidence on whether or not it actually gets into the brain), or herbs such as passionflower (which has the same mechanism of action as benzodiazepines). Other herbs include valerian, chamomile, kava, and many others.
What evidence supports the use of naturopathic treatments?
Up-to-Date has a nice summary:
A variety of herbal products are purported to be useful for insomnia. There is little evidence from randomized controlled trials about the efficacy of many herbals, however, and for those that have been well studied (eg, valerian), there is little evidence of benefit. A meta-analysis that included 14 randomized trials in over 1600 patients found no significant difference between any herbal medicine and placebo on any of 13 clinical efficacy measures of insomnia [94]. The majority of the trials (11 out of 14) studied valerian; chamomile, kava, and wuling were studied in one trial each. Unlike the other herbals studied, valerian was associated with a greater number of adverse events per person compared with placebo. Valerian may also produce hepatotoxic effects [1]. Contamination with undesirable substances poses a problem for many such natural remedies.
And for natural treatments of anxiety, Up-to-Date notes:
None of the herbal remedies described here been shown in clinical trials to be clearly effective or ineffective for anxiety symptoms or disorders. Trials suggest that kava and chamomile may reduce anxiety in some people with generalized anxiety disorder (GAD). Findings from trials of valerian, passion flower, and St. John’s wort are either mixed or negative. Patients may wrongly equate “herbal” with terms such as “good,” “weak,” or “healthy” in evaluating these remedies. These perspectives underestimate their potential risks; some herbs can be potent, poisonous, or addictive. Potentially serious adverse effects of herbal remedies discussed here include hepatotoxicity with kava and anticoagulation with chamomile. It is not known if these remedies are safe or unsafe during pregnancy.
What approach has the best evidence?
It’s understandable to want to avoid benzodiazepines, but they can provide real and demonstrated benefit in select circumstances with close monitoring from a physician. There’s a lack of evidence to demonstrate the efficacy and safety of any of the herbal remedies recommended for the treatment of anxiety or insomnia.
Conclusion: The evidence simply doesn’t support these natural treatments
Naturopaths claim that they can effectively manage medical conditions with “natural” approaches, but the evidence supporting these recommendations has been consistently shown to be absent or weak. It may be that the treatment goals are not understood, which may explain why therapies without any demonstrated benefit are being recommended before proven therapies. In some cases, avoiding drug therapy and using natural remedies may be harmful. In light of the recommendations above, it seems prudent to discuss any naturopathic advice with a health professional like a pharmacist or physician before making any decision to delay medically-recommended drug therapy, or substitute a natural remedy or dietary supplement.

Beware the Integrative Pharmacy
Scott Gavura on May 22, 2014
Link

Imagine a retail pharmacy where some of the medicines on the shelves have been replaced with similar-looking packages that contain no active ingredients at all. There is no easy way to distinguish between the real and the fake.
Another section of the store offers a number of remedies with fantastic claims, such as “boosting” the immune system, “detoxifying” the body, or “cleansing” you of microscopic Candida. They look sciencey, unless you realize that they treat imaginary medical conditions.
A corner of the store offers unpurified drugs supplied as tinctures and teas. The active ingredients aren’t known, and the batch-to-batch consistency of the product is unclear. The store will suggest products for you based on your symptoms.
Walk past the enormous wall of vitamins and other supplements and you’ll find a nutritionist who will tell you what products you should be taking. You’ll also find a weight loss section. From a science-based perspective, this shouldn’t even exist, given no product has been shown to offer any meaningful benefit. But there are dozens of products for sale.
At the back of the store you’ll finally find the pharmacist. A sign on the counter offers blood- and saliva-based tests for food “intolerance” and adrenal “fatigue”, claiming to test for medical conditions that actually don’t exist or lack an evidence base. The pharmacy also offers a large compounding practice, advertising what it calls “personalized” approaches to hormone replacement with “bioidentical” hormones.
Welcome to the “integrative” pharmacy.
You may not see all these features in your local drug store, but they’re coming: claims of a new “integrative” way to provide health care that is changing the face of retail pharmacy. Unfortunately, it’s harkening back to the era of patent medicines and snake oil. It’s not good for the pharmacists and the profession of pharmacy, and it’s even worse for patients.
As the blog’s only pharmacist, I like to think I bring a different but (cough) complementary perspective to the contributions. Naturally I like to write about drug-related issues, and I’ll occasionally scrutinize the profession itself. One trend in the profession seems to be accelerating: It’s the increasing volume of scientifically-questionable products on pharmacy shelves. It hit home the other day when I found yet another local pharmacy that proudly advertises that it will sell you sugar pills and call it medicine. A twitter discussion ensued, with one pharmacist commenting that his own retail pharmacy looks behind-the-times simply because he puts patient care and ethics ahead of revenue, and refuses to sell products like homeopathy. Pharmacy is a health profession, but retail pharmacy is also a for-profit business. This is a continual conflict, and I fear the professional side may be losing ground in the drive to increase revenue.
While I don’t personally work regularly in retail pharmacy, I think of myself as a strong advocate for the community-based pharmacist’s role – and for their potential to do much more. Not only are pharmacists among the most accessible health professionals, they can also have close, supportive relationships with their patients. And pharmacists are well-positioned to do much more to enhance the safe and appropriate use of drugs – from managing doses and side effects, to simplifying regimens, and by ensuring that prescribed medications are being taken safely and appropriately. If you’re generally healthy and don’t need medication, you may not even know a pharmacist. But those with high medication needs tend to know their pharmacist well, and many rely on their pharmacist as a key member of their health care team. I know the impact a good pharmacist can have on the health of a patient. But I’m increasingly dismayed at retail pharmacy practices that call the credibility and good intentions of the pharmacist into question.
Old whine in a new bottle
Integrative medicine is ascendant. Terms like “alternative” and “complementary” are falling out of favor, in part because it’s increasingly recognized that these terms carry a stigma – they are not part of mainstream medicine. Integrative medicine seeks to explicitly embed complementary and alternative medical practices into conventional, science-based medical care. It purports to take a “best of both worlds” approach, mixing science-based treatments with a variety of unconventional treatments. The fundamental challenge with integrative medicine is that “integrative” products and services don’t have scientific evidence to support them: if they did, they’d simply be called “medicine”. Instead of evidence, promoters of integrative medicine rely on other standards – many are grounded in belief systems, such as the idea of “vitalism“. While ideas like vitalism are long-discarded from science-based medicine, they live on in the philosophies of practices like homeopathy, naturopathy, and chiropractic. And the retail part of the pharmacy profession sees an opportunity, like this advertisement seems to suggest. Never mind the evidence, you pharmacy has sugar pills to sell:

Misleading patients and selling them inert, ineffective products is unethical medical practice. But under an “integrative” framework, pharmacies are simply offering homeopathy – after all, it’s trusted by millions. Basing your medical advice on pre-scientific ideas is incompetence from a conventional, science-based perspective. But integrative medicine seems to mean the freedom to simply make up diseases, and then to sell treatments for them. Scientific evidence is no longer the basis for your practice – it’s become more holistic, embracing “different ways of knowing.” I’ve written before about the harms to hospitals and academic settings from the embrace of “integrative medicine”. In short, there is no medical standard with integrative medicine – and that’s why “integration” is so problematic. The bandwagon is growing, however. On Monday, David Gorski noted that the National Center for Complementary and Alternative Medicine is jumping on board, with a proposal to change its name to the National Center for Research on Complementary and Integrative Health (NCRCI). Change the standard of practice, and what was ethically verboten is now acceptable – and that’s what integrative medicine proponents are explicitly trying to do in health care.
The integrative pharmacy
If you integrate unproven remedies with proven medicine in your pharmacy, it does not improve pharmacy practice or patient care – it makes that care worse.
– (paraphrasing Mark Crislip)
A HuffPo column a few years back was a call-to-action to pharmacies to embrace integrative medicine – it was a depressing read to anyone that advocates for science-based principles. Entitled “Who Will Own the Brand of Integrative Medicine? “, the column described integrative medicine as a business opportunity:
There is a revolution happening in North American medicine. If successful, it will educate and empower consumers, introduce us to a world of new cures, and leave most of us wondering, ‘Why didn’t we do this 50 years ago?’
It profiled the Pharmaca chain of pharmacies in the US. The CEO of Pharmaca was quoted:
The common US model is one pharmacist, and a bunch of clerks stocking shelves. In our case, we have the highly trained pharmacist, but also highly skilled practitioners with homeopathic or naturopathic backgrounds. No one expert has the full answer. Instead, we collaborate to offer our customers a more holistic approach to managing their health.
Not surprisingly, Pharmaca advertises a wide array of ineffective treatments, from products that claim to offer adrenal “support” to homeopathy, detox kits and a weight loss selection that Dr. Oz would approve of. To their credit, they also offer important pharmacy services such as vaccines, including the whooping cough vaccine. It’s a shame they’re also actively promoting and profiting from selling pseudoscience.
Another integrative pharmacy that was profiled in the same column was Vancouver’s Pure Integrative Pharmacy:
Up to now, there’s been a polarization between advocates of traditional and conventional pharmacy. We believe the way forward lies in using treatments that are backed by evidence, regardless of their origin.
and the CEO continued:
I want to get rid of the whole east meets west stereotype. This isn’t about east meets west. It’s about getting the best product, or combination of products, for our customers. And those products come with proof of efficacy.
No argument there. It could have come from the authors at SBM – we have long argued that products need to be evaluated on their own merits, instead of a lower bar for products deemed “natural”, “herbal”, “alternative”, “complementary” or “integrative”. Science is science, and that doesn’t change if you’re in North America or Asia. So what kinds of products does Pure Pharmacy believe come with “proof of efficacy”? I didn’t have to search long to find homeopathic remedies, and products to treat adrenal fatigue, suggesting that “proof” seems to be a subjective term when it comes to “integrative” pharmacy practice.
Calls for pharmacy to change
The challenge to the profession and the ethically-troubling issue of “integrative” pharmacy practice hasn’t gone unnoticed. The recent publication of another comprehensive review of homeopathy is renewing questions about what pharmacies sell, and urging the profession to clean up its practice. The Australian National Health and Medical Research Council (NHMRC) report on the effectiveness of homeopathy for treating health conditions was recently reviewed by Steven Novella, so I’ll just touch on the highlights. The NHMRC is the Australian organization that promotes and maintains health standards, both by supporting health research and by creating evidence-based health guidelines. Part of its mandate includes the requirement to “advise the community”. In this case, the review set out to answer the following question:
Is homeopathy an effective treatment for health conditions, compared with no homeopathy, or compared to other treatments?
There were three sources of information assessed to answer this question:
    • published systematic reviews – a structured approach to filter out low-quality evidence and while analyzing all available published high-quality data
    • information provided by homeopaths and homeopathy-supporting groups and organizations – from the information submitted, only the highest-quality evidence was subsequently considered.
    • clinical practice guidelines and government reports published in other countries
To support the credibility of the data evaluation process, the NHMRC asked the Australasian Cochrane Centre to verify the processes used were rigorous, transparent, and consistently applied.
Cutting to the chase, the review concludes the following:
NHMRC concludes that the assessment of the evidence from research in humans does not show that homeopathy is effective for treating the range of health conditions considered.
Case closed, one would hope. Homeopathy has no place in modern pharmacy practice, except perhaps as a case study in history, ethics or perhaps most appropriately, critical thinking. Yet despite the ethical and medical problems that exist with homeopathy, I’m unaware of any pharmacy regulator, worldwide, every taking voluntary action to limit or restrict the sale of homeopathy in pharmacies. The impetus to change only seems to be coming from outside the profession:
Pressure is mounting on pharmacists to stop selling homeopathic products after a major review found there was no credible scientific evidence to support the alternative medicines.
Despite scepticism about homeopathy among pharmacists, many pharmacies sell homeopathic products that are marketed for illnesses including migraine headaches, bleeding, persistent nausea and vomiting, coughs and colds, insomnia and arthritic pain.
But there are now increasing calls for them to abandon the products after a major National Health and Medical Research Council review of homeopathy concluded there was no reliable evidence it could treat health conditions.
The review, released earlier this month, also stated: ”People who choose homeopathy, instead of proven conventional treatment, may put their health at risk if safe and evidence-based treatments are rejected or delayed in favour of homeopathic treatment.”
While the review has been criticised by homeopaths who are appealing the finding, some doctors and pharmacists say it should make it unethical for pharmacists to continue stocking and selling homeopathic products.
Under the Pharmacy Board of Australia code of conduct, pharmacists are required to practice ”in accordance with the current and accepted evidence base of the health profession, including clinical outcomes” and by ”facilitating the quality use of therapeutic products based on the best available evidence and the patient or client’s needs”.
While the professional bodies of pharmacy seem supportive, the retail arm of the profession is ignoring the advice:
Grant Kardachi, president of the Pharmaceutical Society of Australia, the professional body representing 18,000 pharmacists, said he planned to inform members about the review council’s report because homeopathy did not sit well with their aim for pharmacies to become more professional ”health hubs”.’
‘I think we’d be saying you should seriously consider, if you are stocking these products in your pharmacy, what that actually means, and you should be looking at other products in your pharmacy to treat patients’ health conditions where you know there is more evidence,” he said.
Greg Turnbull, from the Pharmacy Guild of Australia, which represents pharmacy owners, said it did not plan to do anything with the review.
The continued practice of ignoring the ethical responsibilities of the profession reminds me of this classic XKCD cartoon on “alternative literature”:
Alt-text: I just noticed CVS has started stocking homeopathic pills on the same shelves with–and labeled similarly to–their actual medicine. Telling someone who trusts you that you’re giving them medicine, when you know you’re not, because you want their money, isn’t just lying–it’s like an example you’d make up if you had to illustrate for a child why lying is wrong.
Conclusion
The idea that pharmacy practice is at a crossroads is a tired cliché in the profession, but I’m seeing the retail component of the profession deciding between one of two paths: One path will involve retail pharmacists, supported by pharmacy regulators, taking greater responsibility for their own profession and professional standards. In doing so, pharmacists will recommit to a professional service model that puts patient care responsibilities first. On this path, professional ethics trump retail pressures, and the practice of retail pharmacy changes to a new equilibrium, where products and services offered are focused on optimizing health, based on the best scientific evidence. There is no more question about the motivation of pharmacists, or the profession. It has happened before. Canadian pharmacies fought moves to ban cigarette sales. The bans prevailed – and pharmacy practice continued. The same can happen with “alternative” medicine and “integrative” practices, starting with the most egregious practices, like homeopathy.
The alternative path for pharmacy is quite different than the other. It’s the “anything for a buck” model, otherwise known as the “integrative” pharmacy. In this model, the retail practice of pharmacy becomes a loss-leader to get customers into stores, and there is a growing disconnect between the practice of dispensing and selling prescription drugs, and the rest of a pharmacy’s offerings. The pharmacy is a retailer first, and abandons any scientific standards or justification for products and services offered. Customers may be pleased, but they won’t be well-served. Pharmacists and pharmacies may profit in the short-term, but this self-sabotage will effectively and ultimately ostracize the retail pharmacy from science-based medicine.
Personally, I see only one path that is tenable. First, the profession needs to stop embarrassing itself, and get the most egregious quackery, like homeopathy, out of the pharmacy. Second, it needs to stop confusing and misleading customers into the sloppy (and potentially dangerous) thinking that underlies “integrative” care. Finally, it needs to recommit to putting the patient at the center of its practice – and to start making choices about the products and services the profession will profit from. As a pharmacist I want retail pharmacy to thrive – but in a framework that is grounded in the best science and the best medical care. “Integrative” pharmacy isn’t that path.

The Elephant in the Compounding Pharmacy
Contaminated products from compounding pharmacies have harmed and even killed patients. Quality control measures are being implemented, but there is a bigger problem: the injudicious use of untested and potentially dangerous treatments.
Harriet Hall on January 16, 2018
Link

Compounding pharmacies create medicines specifically designed for the needs of an individual patient when those needs are not met by products available on the market. They may eliminate an ingredient the patient is allergic to, they may prepare a liquid version of a pill for patients who have difficulty swallowing, they may alter the taste or texture of a medication, they may offer a different dosage, etc. Recently this kind of individual or “traditional” compounding has been augmented by large-scale operations to provide a specific formulation in bulk. There have been illnesses and deaths associated with drugs from compounding pharmacies. The FDA has investigated and issued warnings, and in 2013 the Drug Quality and Security Act was passed to give the FDA more authority.
A selenium overdose
In their safety bulletin, the Institute for Safe Medication Practices (ISMP) Canada recently reported a death associated with an IV compounding error in a naturopathic center (not the first we have discussed). They begin by saying “patients with a diagnosis of cancer may choose to use complementary and alternative medicine, such as naturopathy, to support conventional medical therapies.” [They may indeed, but it may not be a wise choice.]
The case
A patient was discharged from hospital after surgical excision of a cancerous tumour and was further treated, in a collaborative arrangement, by a conventional medical team and a naturopathic doctor at a CCC [Complementary Care Centre]. The naturopathic doctor prescribed a complex tissue- and wound-healing formulation, which included selenium, for twice-weekly IV administration. The selenium solution was prepared by a compounding pharmacy and was added to the formulation on site at the CCC.
During the 13th infusion, she became nauseated and sweaty. The infusion was stopped and she was treated with homeopathic remedies. When that didn’t help, she was eventually taken to the emergency room; she died in the hospital. Investigation showed that the selenium concentration in the infusion was 1,000 times greater than intended.
The recommendations
The ISMP made numerous recommendations to reduce the chances of a similar catastrophe in future. For the compounding pharmacy, they recommended various quality control, standardization, and safety measures, including particular care with abbreviations or inconsistent units of measure that might lead to dosage errors. One of their recommendations was to have pharmacy staff take photographs of the containers used and the weight readings, and attach the photographs to the compounding record.
For the Complementary Care Centre, they recommended detailed protocols to be followed in emergency situations. They didn’t accuse the naturopath of malpractice in this case, but they did comment that “there may have been a lack of appropriate supervision…which may have contributed to the delay in transferring the patient,” and they commented that the homeopathic remedies “did not produce any clinical improvement.” (Surprise, surprise!) They made further recommendations about the preparation, storage, and administration of admixtures.
And they additionally recommended requiring specific accreditation for compounding pharmacies.
The New England Journal report
Only a week earlier, The New England Journal of Medicine (NEJM) had published a “Perspective” article titled “Toward Better-Quality Compounded Drugs – An Update from the FDA.”
In 2012, an outbreak of fungal meningitis was traced to fungal contamination of epidural steroid injections prepared in a compounding pharmacy. More than 750 patients were infected and at least 64 died.
The FDA has investigated and issued warnings, and in 2013 the Drug Quality and Security Act was passed to give the FDA more authority. As a result of that bill, the FDA took the following actions in fiscal years 2014-17:
    • 428 routine inspections (findings included dead insects in sterile compounding areas, visible mold on ceilings, and dog beds and dog hairs in close proximity to compounding areas)
    • 136 for-cause inspections in response to complaints or adverse events
    • 162 warning letters
    • 61 state referral letters
    • 144 recalls
Despite the FDA’s surveillance efforts, serious adverse events continue to occur:
    • 43 patients had diminished visual function after a compounded steroid/anti-infective drug was injected into their eyes.
    • 2 patients had hypersensitivity reactions and one died, after IV infusions of a compounded curcumin product.
    • 3 infants had serious adverse events after receiving a compounded morphine preparation that was 2,500% as potent as the label indicated.
    • 15 patients developed bacterial bloodstream infections and 2 died, after receiving contaminated infusions of compounded calcium gluconate.
    • 7 patients developed thyrotoxicosis after receiving superpotent compounded liothyronine; 3 were admitted to the ICU.
The NEJM article lists a total of 16 such events between 2012 and 2017, and the FDA says the vast majority of compounding facilities do not report adverse events to the FDA, so their records probably include only a small proportion of the events that actually occur.
The FDA is working on draft guidance and updated standards. They are most concerned about the outsourcing-facility sector, which produces sterile drugs in large quantities and ships them throughout the US.
The elephant in the room
While the concerns about quality control in compounding pharmacies are clearly important, there is an elephant in the room that neither the ISMP nor the NEJM noticed. Both David Gorski and Scott Gavura have seen the elephant clearly, and written about it here.
The elephant in the room is the fact that compounding pharmacies are often used injudiciously by naturopaths, “integrative medicine” doctors, “functional medicine” doctors, and other providers who prescribe treatments that are not supported by credible evidence and that often involve risky IV administration. The elephant is that many of those using compounding pharmacies are guided by speculation and belief rather than by acceptable scientific evidence. They are endangering their patients because they fail to understand that science is the only reliable guide to safe and effective treatments.
The outbreak of fungal meningitis was due to steroid injections for back and joint pain, a controversial treatment that is not supported by high quality evidence and that can occasionally cause serious side effects. Even if you think it is an effective treatment, you will acknowledge that it is being overused.
The IV curcumin fatality was a result of a naturopath injecting an herbal compound intravenously to treat a skin condition, a treatment not supported by evidence.
The case reported by the ISMP was particularly egregious. A naturopath prescribed a twice-weekly intravenous injection of “a complex tissue- and wound-healing formulation” which has never been tested. There is no evidence that it has any benefit for cancer patients. And the medical doctors collaborating with the naturopath let it happen.
Some of the incidents involved a compounded version of a drug that is available in standard versions approved by the FDA.
Conclusion: Science based medicine matters
When health care providers fail to understand the importance of basing treatments on adequate evidence, when they accept low-quality evidence, when they use a different standard for alternative medicine, disaster can ensue. When providers depart from science-based medicine, they free themselves to rely on testimonials and to speculate based on pre-clinical studies. They free themselves to make things up as they go along, to experiment with trial and error. And because many conditions improve naturally over time, and because of human psychology, it is easy for them to convince themselves that bogus treatments work.
Quality control for compounding pharmacies is important. But quality control in medical decision-making is also important.

Pharmacists Selling Snakeoil
Steven Novella on July 20, 2016
Link

Edzard Ernst published an excellent editorial today addressing the question of why pharmacists sell bogus products. Our own resident pharmacist, Scott Gavura, expressed similar points here on SBM a year ago. Their points are worth emphasizing and expanding upon.
Professional ethics
The explicit premise of both editorials is that pharmacists, like physicians, are health care professionals. Being a professional means adhering to certain professional standard of quality control and ethical behavior. A profession is essentially a contract with society – the profession gets exclusive rights to certain commercial behaviors, and in return promises to maintain adequate quality control and to act in the best interests of society and their individual clients.
When a profession puts their own commercial interests ahead of society or their individual customers, they have violated that contract.
There are multiple layers of regulation to maintain quality and ethical standards in the health care professions. Once a profession is licensed, they basically self-regulate, with members of the profession establishing the standard of care. Standardized testing designed by the profession is used to establish competence or specialized expertise.
In the US, the states largely have the power to license and regulate professionals. States have boards of health that set ethical standards and will investigate professionals who may have violated either the standard of care or those ethical standards.
Institutions also provide a layer of quality control, by hiring or granting privileges to professionals. The last line of defense is the law; when all the other layers fail a patient or customer can always sue for malpractice.
Some professionals are salaried and work for an institution or the government, but in the US many are private, which means they are essentially shopkeepers as well as professionals. Many pharmacists fall into this category. Often pharmacists work for large chains and so they do not have direct control over what their shop sells, but that does not alleviate them of their professional responsibilities.
Selling snakeoil
For over-the-counter (OTC) products, the pharmacist is the only professional with whom a client may interact. By definition you do not need a prescription or to have seen a doctor in order to obtain an OTC drug or health product. In this case the pharmacist might be the primary or only source of health care advice.
The American Pharmacist Association (APA) recognizes this role:
You should also check with your pharmacist before taking any nonprescription medication. Even though they do not require a physician’s prescription, nonprescription medicines are powerful and can, if taken improperly, adversely interact with your prescription medications or badly affect another health condition.
The unfortunate fact is that the FDA does not have the power, or in some cases the desire, to properly regulate all health care products. Homeopathic products are sold as drugs. Supplements are sold with implied health claims but without any requirement for evidence of efficacy or even safety. There are also a large number of non-ingested products, like magnetic insoles or copper bracelets, that are sold in pharmacies with health claims.
The APA code of conduct states:
A pharmacist has a duty to tell the truth and to act with conviction of conscience. A pharmacist avoids discriminatory practices, behavior or work conditions that impair professional judgment, and actions that compromise dedication to the best interests of patients.
They do not specifically address selling products that do not work, but I think that is implied in the above statement. The Pharmaceutical Society of Australia is more explicit:
Our position is that pharmacists must use their professional judgement to prevent the supply of products with evidence of no effect.
And the Chief Scientist of the UK Royal Pharmaceutical Society, Professor Jayne Lawrence, was also more direct:
The public have a right to expect pharmacists and other health professionals to be open and honest about the effectiveness and limitations of treatments. Surely it is now the time for pharmacists to cast homeopathy from the shelves and focus on scientifically based treatments backed by clear clinical evidence.
The APA should add to their code of conduct a similar statement, specifically stating that it is their duty not to sell ineffective products with false health claims.
What is clear, regardless of the specific language used, is that selling snake oil or bogus products is a violation of the pharmacist professional ethics. Homeopathic and herbal product sales in the US reached $6.4 billion in 2013.
Edzard provided an excellent review of why pharmacists might knowingly sell ineffective products – they believe the products work (unlikely given their expertise), they defer to client autonomy, they use their sale as an opportunity to educate their customers, they do not have control over their corporate masters, and they are putting profits ahead of ethics. All but the last reason does not hold up to scrutiny.
Call to action
Clearly the pharmacist profession needs a wake-up call. That is why I would like to add my voice (and I’m sure I am joined by all my SBM colleagues) to Edzard and Scott in detailing the professional failure of pharmacists, as a group, to meet their own ethical standards of putting their patients and society before their own commercial interests.
This problem exists in all professions, and I do not mean to imply that it is unique to pharmacists or to unfairly single them out. We are equally critical of the failure of any health care professions to meet standards of quality and ethics. It’s just the pharmacists’ turn today.
For pharmacists there is also a very simple and clear course of action that they can take. Just stop selling health care products that have no evidence of efficacy or evidence of lack of efficacy. Stop selling products that don’t work, can’t work, or are unproven to work.
This means a refusal to sell any homeopathic product. If you work for a large corporate pharmacy chain, that still does not obligate you to violate your professional ethics, and you should express your position up the corporate chain. If pharmacists as a profession refused to sell homeopathy, big pharmacy chains would have no choice but to drop the products.
Failure to take such a stand is interpreted by the public as endorsement. Most people believe that pharmacists would not be selling homeopathic products alongside actual drugs if they were nothing but snake oil. Failure to oppose the sale of snake oil is implicit acceptance.
This would also send a huge message to the public. Professionals and academics need to take a stand for a high standard of science within health care. Otherwise we are just shopkeepers, or worse, witchdoctors.

What are “Adaptogens”?
Steven Novella on June 5, 2024
Link

The multi-billion dollar “snake oil” industry is nothing if not good at marketing. This is probably because this is not one or even a small number of companies, but likely thousands of companies and millions of individuals crowdsourcing many different marketing strategies. Those that work tend to prosper and proliferate, spawning variations. The rhetoric has been evolving in this way for at least hundreds of years.
There are several common themes that are frequently used to sell dubious treatments, which can be summarized as something like, “Modern science meets ancient wisdom to discover how this natural product works gently with your body to achieve healing.”
Interestingly, this evolving marketing language is often used to sell the same products, some of which have been sold by snake oil salesmen for over a hundred years. Take echinacea, which as I wrote about in 2010:
“It was first popularized by a dubious physician and snake-oil salesman called H.C.F. Meyer. In the late 1800s he sold Echinacea as a panacea, claiming it cured everything, including cancer. He also heavily marketed the Native American connection, which was popular at the time.”
Such products were marketed as native, as all natural, as herbs, supplements, then “neutraceuticals”. How do they work? That always seems to be a mystery, but it must have something to do with toxins, or perhaps boosting the immune system. They could be a “superfood” providing preternatural nutrition. On the more magical end of the spectrum they may harmonize your vibrational frequencies, or facilitate the flow of chi.
Some herbs, of course, are actual drugs. Most of the useful ones have already been purified as pharmaceuticals (there is an entire discipline dedicated to identifying active ingredients, purifying, and testing them). But they are strangely rarely markets as drug-like, even when the putative mechanism of action is pharmacological. No one says – take echinacea, it’s a naturally-occurring drug with variable constituents of unknown dose and bioavailability, but probably in too low a dose to cause serious side effects (or any actual effect).
Now we have another term to add to the lexicon of dubious health claims – the “adaptogen”. The most common definition out there is similar to this one by Dr. Hunnes from UCLA Health: “The claim is that adaptogens reduce our body’s reaction to stress and help us adapt to stressors better.”
How do they allegedly do that? Well – “Experts believe that adaptogens interact with the hypothalamic-pituitary-adrenal (HPA) axis, which initiates your body’s stress response and plays a big role in keeping your body in balance.” The evidence for this is virtually non-existent, which is why it is stated as a “belief”. Other proposed mechanisms include boosting the immune system, reducing oxidative stress, and balancing the body (such as balancing hormones). These are familiar vague claims already part of the snake oil canon.
Another one is the claim that adaptogens can fight fatigue through their “ergogenic” effects. This is yet another sciencey-sounding term for something nonspecific, in this case increasing energy and stamina or reducing fatigue.
Even researchers who promote herbal remedies have found the term frustrating vague:
“The term “adaptogen,” which has not been well defined scientifically, undermines the need for increased inquiry and research into the many promising effects of this herb.”
One of the hallmarks of good science is that it uses precise terminology and definitions. Words are the place-keepers for our ideas, and we literally cannot think precisely without precise language. Vague words betray vague and sloppy thinking. When it comes to the supplement industry, and the alternative medicine industry more broadly, vague terminology is not a bug, it’s a feature.
Vagueness allows for general marketing vibes without being tied to a specific scientific claim that can be proven false. The supplement industry has even managed to have this approach codified into law in the US, in the form of the Dietary Supplement Health and Education Act (DSHEA). This act created the “structure-function” category of marketing claims that can be made for herbs and supplements – things like boosting the immune system, increasing energy, supporting a positive outlook. These are basically the same claims made for “adaptogens”. It’s the same con with a new label.
Actually the term “adaptogen” was coined in 1947 by Soviet toxicologist Nikolai Lazarev. He failed, however, to discover anything specific to back up the concept, as did later research. The term has never been accepted as a genuine scientific concept, and is not recognized by the FDA as a legitimate claim (which is why you have to back up the label by saying it “boosts the immune system” or some other structure-function claim).
Now the term has a second life as just another marketing buzzword for snake oil products. It’s a perfect vague marketing term for a society that has a vague faith in science without really understanding it – get your neutraceutical ergogenic adaptogen.

   Alpha Brain – What’s Wrong with the Supplement Industry
Steven Novella 
Link
There is an endless stream of supplement products on the market that are of questionable value. They tend to follow a similar pattern: put an essentially random assortment of vitamins, minerals, perhaps herbs and nutritional elements into a pill and then make whatever pseudo-health claims you want. Usually the claim is implied in the name of the product itself – sleepwell, or brainboost. The popular product Airborne fits this mold. It is essentially a multivitamin with the unfounded claim that it will prevent infection by boosting the immune system.
In the US, regulations (under DSHEA) specifically allow “structure/function” claims without any requirement for evidence to back up the claims. In other words, as long as you don’t mention a disease by name, you can make pretty much whatever claim you want. This was supposed to be good for the consumer, when in fact it is springtime for industry at the expense of the consumer. If your claims are outrageous enough the FTC can still go after you, but they are playing a game of whack-a-mole and losing.
Another pattern that is common is for a supplement product to contain specific components that are claimed to have specific benefits. Often these claims are based upon evidence – just the wrong kind of evidence. Basic science evidence is used inappropriately to support clinical claims. This strategy is more insidious, as it gives the public the sense that the product is science-based when it isn’t.
Recently a product came to my attention which fits this mold perfectly – Alpha Brain. This is a supplement that claims to “enhance” mental function, sleep, creativity, and athletic performance. Their website includes a section called “The science behind alpha-brain.” I always find it amusing to following the links for promised evidence on such sites. What they never seem to contain is links or references to primary sources that actually demonstrate the claims they are making.
The site reviews all of the ingredients in Alpha-Brain explaining the science behind the claims – let’s look in detail at just one example, GPC choline, which is an essential nutrient and a precursor for the neurotransmitter acetylcholine. The site claims:
There is scientific evidence that proves that increased levels of acetylcholine in the body can dramatically increase memory and cognitive ability of men and women of all ages[1]
The reference given is not to a peer-reviewed study, but to another promotional site that simply makes more claims about the benefits of choline. The concept here is not implausible, but also cannot be assumed, and is very common in the supplement industry. The idea is that a precursor of an important molecule in the body will increase the availability and therefore function of that molecule. That could be true, if availability of the precursor is the rate-limiting-step in the production and function of the molecule. Specifically in this case, is the nutritional availability of choline limiting the production and function of acetylcholine?
Choline is an essential nutrient, so (as is true with all nutrients) in someone who is undernourished or with specific deficits in their diet, supplementing will help. But in someone with an adequate diet, there is no reason to assume that more will be better. Supplements treat deficiencies – but there is no reason to think that taking additional nutrients beyond the minimum necessary will have functional benefits.
They then report:
A study performed by Sangiorgi Barbagallo at the University of Palermo studied 2044 candidates who suffered from recent stroke or transient ischemic attack. The study concluded that administration of GPC choline confirmed its therapeutic role in improving cognitive ability in this group of study subjects.
They don’t give the reference, but I tracked in down. This is an excellent example of how a company can cite studies to make is seem as if their claims are evidence-based when they are not. The question is – how relevant is this study to Alpha-Brain? There are two major problems: The first is that the study (which was not blinded, but even if we take its results at face value) used 1000mg IM (intramuscular) for 28 days, followed by 400mg orally daily. Alpha-Brain contains 100mg of GPC choline. IM administration likely has a completely different bioavailability than an oral dose. And of course the dosing for 28 days was 10 times that in the supplement.
A bigger problem, however, is the study population – those recovering from a stroke or TIA. When the body is under physiological stress demand for nutrients are likely to become a limiting factor in the rate of recovery, even when those same nutrients are not a limiting factor in a healthy individual. You therefore cannot extrapolate from a disease population to a healthy population – just because a nutrient helps recovery does not mean it will enhance normal function.
The same is true for Alzheimer’s disease. There is evidence that choline supplements may improve the symptoms of dementia. But this does not mean they will enhance mental function in a healthy individual.
Conclusion
I am presenting just one illustrative example of the types of deceptive marketing practice by the supplement industry, specifically with their use of scientific evidence. They use the evidence as a marketing tool, not as a way to determine the net clinical effects of a product. Several types of deceptive use of evidence are common: using basic science studies to support clinical claims, using studies in ill subjects to make claims about enhancing normal function, referencing secondary sources or sources that do not support the claims being made, and making inappropriate comparisons to different doses and routes of administration.
The goal is to create the impression that the supplement being marketed has health benefits that are backed by science – but the devil is always in the details. What they never seem to provide is rigorous studies of their actual product published in the peer-reviewed literature showing the specific benefits they are claiming when used as directed.

   A natural product of his environment
David J Kroll
Link
I’m delighted to have the opportunity to join this outstanding group of medical professional bloggers in adding my natural products angle to the application of science-based medicine. With the exception of Dr. Gorski, who holds MD and PhD degrees, I believe I am the first “only a PhD” to be invited to SBM. However, I have spent much of my career training, and training with, physician-scientists; so enthusiastic am I about the special qualities of the physician-scientist that I married one (or, rather, she chose to marry me, truth be told.). Conversely, I view the invitation to write here as a responsibility in representing what my fellow basic scientists bring to bear on discussions of the scientific arguments for and against modalities classified broadly as complementary and alternative medicine or integrative medicine.
Why write about herbal medicines and natural products?
I have long been interested in bringing objective scientific information to the public, perhaps as early as my college years in bars while visiting my working-class hometown of Wallington, NJ, or while shooting darts with Philadelphia cops across from my undergrad apartment. Any chat I’d have with an old buddy or bartender about drugs, cancer, or drugs and cancer would invariably draw some interest from fellow patrons overhearing my discussions. These were usually followed by, “Hey, aren’t you Frankie Kroll’s boy?,” or “I’ve heard the government is hiding the cure for cancer – do you have any inside dope on that?”
Why I mention this story on a somewhat more scholarly blog than which I am accustomed is because I am convinced that regular people without letters after their names are starved for authentic scientific and medical information that affects their lives. But all too often, people other than health professionals are the ones providing that information, many of whom are trying to hawk some dubious health and wellness product. This is why I write for the public and have been engaged in public science education since my first faculty appointment at the University of Colorado School of Pharmacy in 1992.
But let’s step back a moment and introduce ourselves properly: I am a PhD cancer pharmacologist who has been studying chemotherapeutic drugs derived from natural sources since beginning graduate school in 1985. Cancer chemotherapy is particularly rich in the application of natural products to therapeutics. Plants have given us the microtubule polymerization inhibitor, vincristine, as well as the microtubule depolymerization inhibitor, Taxol/paclitaxel. Marine organisms have given us the precursor to cytosine arabinoside, or ara-C, to treat leukemias. The underappreciated world of microorganisms has been an exceptionally rich source of chemotherapeutics including doxorubicin and daunorubicin, bleomycin, mitomycin C, and even the antileukemic asparagine-degrading enzyme, L-asparaginase. These naturally-occurring compounds have then in many cases been subjected to medicinal chemistry manipulations to produce semi-synthetic derivatives with improved potency and selectivity, longer duration of action, lack of tumor cell cross-resistance with similar compounds, and better solubility for parenteral dosing.
With this background, I came into medical and pharmacy education with a deep appreciation of nature as a source of chemical diversity for targets not just in cancer, but in other therapeutic areas as well. But in 1994-1995, my pharmacy students became notably more vocal in asking questions in our Pharmacology & Therapeutics class about these herbal medicines that were increasingly marketed in retail pharmacies where many were doing their internships. Since I already knew a bit about naturally-sourced prescription pharmaceuticals, they asked if I could start adding some lecture content on this topic. Unappreciated by me at the time was the fact that these requests coincided with passage of the 1994 Dietary Supplement Health and Education Act (DSHEA) which many of you know permits herbal supplements to be sold in the U.S. without proof of safety or efficacy as long as direct disease treatment claims were not made. Pharmacoeconomics colleagues told me that herbal medicines and non-botanical dietary supplements were the biggest product growth area in retail pharmacy during those mid-1990s.
How does a conventionally-trained scientist become versed in herbal medicines?
I certainly knew about natural products outside of cancer and one can usually kick off a lively lecture of natural products talking with young college students about CNS-active recreational plants like marijuana, hallucinogenic mushrooms, and the art and practice of toad-licking. But herbal medicines were a bit out of my bailiwick although I was in fact hired in place of Colorado’s then recently-retired herbal medicine and pharmacology professor, Dr. Glenn Appelt, who together with his wife, Jennifer, authored several treatises on the Hispanic folk medicines of the San Luis Valley in the southcentral part of the state.
So as not to trouble the Appelts in their retirement to the Alabama Gulf Coast, I was lucky to be able to turn Dr. Ara DerMarderosian, Professor of Pharmacognosy, at my alma mater, the then-Philadelphia College of Pharmacy and Science. Dr. DerMarderosian has been studying herbal medicines for over four decades and joined the PCP&S faculty during the year of my birth. His pharmacognosy course never fit into my curriculum when I was there but when I contacted him, he was extremely generous with articles, books, and other resources. Hence, I began my self-education on the pharmacology of herbal medicines: the fact and fiction behind the therapeutic potential of complex plant mixtures.
Do we wish to turn back the clock 200 years?
Readers should keep in mind that herbal medicines take us back to a scientific period that precedes the 1800s. Most physicians are well-aware of the story of British doctor and botanist, William Withering, who adopted a country remedy for dropsy (pulmonary edema due to congestive heart failure) composed of 20 herbs including the foxglove, Digitalis purpurea and other species. Depending on the time of year that foxglove was harvested, it could act as a remedy or induce significant nausea and vomiting. We now know the plant contains the cardiac glycosides, digoxin and digitoxin, whose abundance varies under growth conditions and time of harvest. Pure digitoxin was not isolated until about 1875 by the German scientist, Oswald Schmiedeberg, regarded as the father of pharmacology and mentor of John Jacob Abel, the so-called American father of pharmacology.
However, the concept of reproducible and predictable treatment with an herbal medicine really began in 1805 when the German pharmacist and chemist, Friedrich Wilhelm Sertürner, made similar observations about opium extract from the poppy, Papaver somniferum. Sertürner believed that the “active principle” could be isolated from the crude latex of ripe flower heads and was the first to isolate the alkaloid he called morphine, after Morpheus, the Greek god of sleep. Opium extract also contains other active compounds such as codeine and papaverine.
I mention all of this background not because I am simply an enthusiast of the history of my discipline. Instead, I wish to stress that today’s practice and marketing of herbal medicine takes us backwards over 200 years. When plant medicines were all we had, underdosing and overdosing were common because we had not yet achieved the scientific skills or knowledge to effectively isolate known quantities of physiologically-active constituents.
Today’s herbalists and purveyors of alternative medicines will frequently argue that 1) whole herbs possess a synergy that is missing when one isolates and uses pure constituents, or that 2) the mixture is safer than pure compounds because one compound can reduce the side effects of another without compromising its therapeutic efficacy. In the former case, synergy has actually be described in the scientific literature but the cases are extremely rare. These few cases are scientifically fascinating and worthy of discussion in future SBM posts. The safety attributed to herbal mixtures is more likely due to the fact that any active constituent lacks the abundance or oral bioavailability to have any effect, pharmacological or toxicological. I have yet to see any convincing peer-reviewed publication that convincingly demonstrates efficacy and reduced side effects in the same herbal mixture.
In fact, as I learned more about herbal medicines as used today, I became increasingly disappointed that so few of them were actually backed up by clinical trials. But among these disappointments are a few gems that hold promise for therapeutics that I will discuss in future posts.
From newbie to expert?
But what I was not prepared for was the rapidity with which I became an “expert” in herbal medicines once I began teaching this information to my pharmacy and medical students in 1995. Offers for speaking engagements came in from around the state and then around the country for pharmacy, nursing, and medical continuing education; media requests began to pile up from local radio to national television. I was taken aback because I had spent at least ten years in my area of cancer research without being even mistaken for an expert. Yet within two years of teaching about herbal medicines I was suddenly a widely sought speaker and commentator. Because I did not trust even myself with the title of “expert,” I developed a degree of mistrust for, or at least a cautious eye toward, anyone the media considers a medical expert. In fact, these experiences and concerns seeded my current interests and involvement with the University of North Carolina at Chapel Hill’s MS Program in Medical & Science Journalism.
I’ve since worked quite hard to develop and refine my interests in herbal medicine education and have even progressed to the point of including this work in my NIH-funded research. I’ll speak more later about my subsequent experiences in other posts but I was fortunate most recently to work with the late Dr. Monroe Wall and now-83-year-old Dr. Mansukh Wani who first isolated Taxol/paclitaxel from the Pacific yew tree, Taxus brevifolia. Using the technology available almost 40 years ago, they solved the chemical structure of this complex molecule comprised of 11 chiral centers, a tremendous accomplishment even with today’s tools. Their lesser-known discovery, camptothecin from the Chinese tree of joy, Camptotheca acuminata, gave rise to two semi-synthetic derivatives that have become FDA-approved chemotherapeutic drugs. When I co-authored my first peer-reviewed publication in 1987 on the use of camptothecin to map sites of transcriptional activation in the Drosophila hsp70 gene promoter, little did I know that I would one day have the honor of working beside the co-discoverers of this compound.
There are many other areas I hope to address as my tenure at SBM proceeds. The drug interaction potential of herbal products is a major issue of public safety, especially with St. John’s wort. The cherrypicking of in vitro studies by herbal marketers as “scientific proof” for their remedy’s effectiveness is so rampant that even a paper from our research group is used to improperly promote a milk thistle product. Finally, I also hope to combat the misperception that natural products cannot be patented so there is no financial incentive for them to ever be developed as drugs.
I’ve had the pleasure and accidental good fortune of interacting with some tremendous leaders in the area of natural products chemistry and pharmacology to the point that I sometimes feel a bit like Forrest Gump. I am grateful that their encouragement and mentoring has brought me to a position where I can periodically discuss these issues with the engaging contributors and readership of Science-Based Medicine.

   Natural is not innocuous: the case of Angel’s Trumpet and tropane alkaloid intoxication
David J Kroll
Link
With this post, I’m happy to return to Science-Based Medicine on a regular basis, at least monthly and perhaps more depending upon how often commentary is required on natural products, whether they be herbal medicines or single-agent pharmaceuticals derived from natural sources. Next week, I’ll be attending the 2010 Annual Meeting of the American Society of Pharmacognosy being held jointly with the Phytochemical Society of North America in St. Petersburg, Florida. I hope to bring back the latest on novel natural products in preclinical development.
But today, I bring recent news that revisits a timeworn folly of the young (and some older folks): recreational use of toxic plants for the purpose of hallucination.
Toxicity reports are re-emerging in southern California this week after a dozen hospitalizations of kids using teas made from a fragrant flowering plant called Angel’s Trumpet. The tea is used to produce hallucinations, but they can progress to extremely unpleasant experiences. Moreover, Angel’s Trumpet can be deadly, accelerating the heart rate and causing fatal cardiac rhythmic disturbances and bronchoconstriction that can trigger asthma attacks in sensitive individuals.
220px-Atropine.svg.pngAngel’s Trumpet is one of a series of plants in the Brugmansia genus that make a variety of muscarinic cholinergic antagonists such as atropine (dl-hyoscyamine, pictured to the right) and scopolamine (l-hyoscine). These compounds are also known chemically as tropane alkaloids or belladonna alkaloids, the latter derived from their classical isolation from Atropa belladonna. The belladonna name derives from the use of eye drops made from the plants that prevent constriction of the pupils (mydriasis), back when the size of a woman’s pupils was a sign of beauty and arousal.
The tropane alkaloids are ubiquitous in plants and fungi and act as classic hallucinogens when used in high doses. Their legend goes back to witches brews and beyond. A wonderfully colorful history of tropane alkaloids by Robert S. Holzman of Children’s Hospital and Harvard Medical School was offered in this free 1998 paper in the journal, Anesthesiology (1998; 89:241-249).
However, the aftermath of Angel’s Trumpet use is far from colorful. In cases like these, I like to turn to the Erowid site, a respected, user-supported site that offers non-judgmental information on plant-derived and synthetic psychoactive agents. The Erowid Experience Vault has several descriptions of the use of Angel’s Trumpet but this one is the most detailed and representative of the downsides of this plant. (Note that the colloquial term for Angel’s Trumpet in Australia is sometimes “Tree Datura,” although Brugmansia is a closely-related but distinct genus from Datura within the Solanaceae family.)
I also came across a poorly-documented 2003 news article cited a German teenager cutting off his penis and tongue with garden shears after using Angel’s Trumpet.
While I’m NOT a physician, emergency personnel stumbling upon this post would do well to note that physostigmine or pilocarpine are typical antidotes for anticholinergic poisonings with Angel’s Trumpet, Atropa, Datura, and other similar plants that cause dilated pupils with loss of accommodation, xerostomia (dry mouth), and tachycardia. Click on this paragraph to access the Medscape poisoning article with more details on when and where specific treatments should be employed.
From the eMedicine article linked to in the above paragraph:
Remember common signs and symptoms with the mnemonic, “red as a beet, dry as a bone, blind as a bat, mad as a hatter, and hot as a hare.” The mnemonic refers to the symptoms of flushing, dry skin and mucous membranes, mydriasis with loss of accommodation, altered mental status (AMS), and fever, respectively.
I encourage all clinicians to be vigilant about anticholinergic poisonings in the weeks to come. In some cases in the past, I have found that reports such as these from southern California will often give rise to attempts to use the hallucinatory plant elsewhere despite the risks detailed.

Patient Beware: Off-label drug promotion by pharmaceutical companies
Jann Bellamy on March 3, 2016
Link


Pharmaceutical companies and their sales reps can distribute information, such as medical journal articles, about unapproved (“off-label“) uses of their drugs as long as they adhere to FDA guidelines. However, the FDA takes the position that this information must be distributed separately from information that is “promotional in nature,” i.e., for marketing purposes, a position that is now open to question.
Off-label promotion of a drug for a use that has not been approved by the FDA is, in the FDA’s view, a violation of the federal Food, Drug & Cosmetic Act (FDC Act). It is subject to criminal prosecution, because promoting a drug for new, unapproved uses is evidence of an intent that the drug be used before it has gone through the extensive process of clinical trials and a review of the evidence of safety and efficacy by a panel of experts, as required by law before a drug can be marketed. Thus, off-label promotion is seen as an end-run around the approval process that perverts the purpose of the FDC Act, which is to protect the public from ineffective and unsafe drugs.
Studies show that personal sales visits to physicians by pharmaceutical reps (called “detailing”) drives prescriptions in favor of the drugs being promoted. This is true even though physicians’ view of detailing ranges from neutral to highly negative, a “necessary evil,” and physicians are aware of potential conflicts of interest these visits precipitate.
While there are restrictions on off-label promotion, off-label prescribing by a physician is not illegal. Physician practice is regulated by the states and not within the jurisdiction of the FDA. In fact, off-label prescribing is considered both ethical and within the standard of care in appropriate circumstances. (I am currently taking a drug for an off-label use, and was informed of this, plus the risks and benefits, by my physician prior to his prescribing it.) It is also common, according to an article by law professors Ryan Abbot and Ian Ayers in the Duke Law Journal, which is well worth reading:
for the 3 leading drugs in each of the 15 leading drug classes, off-label use accounts for approximately 21% of prescriptions. Moreover, off-label uses may be the norm in some areas of practice, such as oncology, pain management, and palliative care, and in some patient populations, such as children, the elderly, and the severely ill. For example, about 80 percent of all drug prescriptions for children are off-label, and between 80 and 90 percent of all drug prescriptions for rare diseases are off-label. [Footnotes omitted.]
As Abbott and Ayers explain, and as one might expect, evidence of safety and efficacy for off-label use is sometimes lacking. One estimate is that about 15% of all off-label drug uses lack scientific support for efficacy and over 70% lack significant scientific support. A 2008 study estimated that 67% of children treated with antipsychotic drugs were prescribed off-label treatments with an “uncertain” evidence base.
Patients do not seem to be aware of these facts. In a 2006 poll of the American public, about half of the respondents believed doctors were allowed to prescribe only for approved uses, and about half believed doctors should be prohibited from off-label prescribing.
In particular cases, an off-label drug may be the patient’s only option. Some drugs have a long history of safe and effective use and are supported by good evidence, including controlled clinical trials. And there are resources available to physicians that evaluate and disseminate evidence supporting off-label use, such as the American Hospital Formulary Service Drug Information. However, one review of compendia governing off-label oncological uses concluded that they were “lacking in consistency, quality, transparency and timeliness.”
In sum, FDA prohibitions on off-label promotion attempt to preserve the original purpose of the FDC Act, which is to protect the public health by requiring good evidence of safety and efficacy before a drug can be marketed for a particular use. Distribution of journal articles and like information to physicians by pharmaceutical companies is permitted, with the realization that off-label prescribing can be beneficial to patients, as long as the companies refrain from actively selling the physician on an off-label use.
The Caronia case
Into this somewhat delicate balance, the U.S. Court of Appeals for the Second Circuit dropped a bombshell of a decision that threatens to undermine the entire drug regulatory scheme, United States v. Caronia. Or maybe not so much, depending upon whom you ask. What is certain is that the effect of the decision is still being sorted out, with the FDA yet to issue new guidance on off-label promotion. The decision is also an exemplar of the expanding First Amendment protection of commercial speech by the federal courts.
Orphan Medical sales representative Alfred Caronia promoted the brand-name drug Xyrem to physicians. Xyrem is sodium oxybate. The active ingredient is gamma hydrooxybutyrate (GHB), also known as the “date rape” recreational drug. Xyrem was approved by the FDA in 2002 for use in narcolepsy with severe cataplexy, a rare clinical condition.
Another Orphan sales rep told the government that the company decided to start promoting Xyrem off-label to increase revenue and encouraged reps to market off-label uses to physicians, including those who were unlikely to see patients with narcolepsy. The U.S. Department of Justice began an investigation. A physician cooperating in the investigation wore a wire and recorded Caronia suggesting, without any prompting, that Xyrem was effective for a range of conditions, including insomnia, fibromyalgia, restless leg syndrome, chronic pain, Parkinson’s disease, and MS. Caronia also told the physician that the drug could safely be used in elderly and pediatric patients, although the FDA-approved labeling stated the drug had not been tested in these patients.
Caronia, Orphan Medical and a psychiatrist, who was assisting the company in this scheme, were prosecuted for conspiracy to introduce a misbranded drug into interstate commerce. The company pled guilty and paid civil and criminal fines of about $27 million. Caronia, however, did not enter a plea, went to trial, and was convicted.
Drug promotion is protected “commercial speech” under the First Amendment, as interpreted by the Supreme Court. (More on this later.) Thus, the implications of convicting Caronia for what was assumed to be truthful speech (more on that later also) were considered by the trial judge and rejected. The judge reasoned that
constraining the marketing options of manufacturers is one of the ‘few mechanisms available’ to the FDA to ensure that manufacturers will not seek approval for only certain limited uses of drugs, then promote that same drug for off-label uses, effectively circumventing the FDA’s new drug requirements. [citation omitted.]
The court looked at whether the FDA could employ non-speech restrictions that would serve the same purpose of ensuring the integrity of the new drug process and found that no such alternatives could be identified.
On appeal, Caronia argued that the government could not criminalize his speech, as long as his promotion of Xyrem was truthful and non-misleading. The U.S. Court of Appeals for the Second Circuit agreed, in a 2-1 decision. The government argued that it wasn’t prosecuting Caronia for his speech at all, rather it was merely using his speech as evidence of his intent to commit a crime, but that view was rejected by the appellate court.
At this point, some high-priced legal talent stepped in to assist Caronia’s criminal defense attorney on appeal. The Medical Information Working Group, a coalition of drug manufacturers represented by both Ropes & Gray and Sidley Austin, filed an amicus brief on behalf of Coronia. The Washington Legal Foundation, founded, in part, to “fight activist lawyers, regulators, and intrusive government agencies at the federal and state levels, in the courts and regulatory agencies across the country” also filed an amicus brief, represented by Jones Day. Obviously, it would be worth a great deal to the pharmaceutical industry to be rid of the prohibition on off-label promotion.
As mentioned, Albert Caronia’s speech (that is, his sales pitch) was protected by the First Amendment as “commercial speech,” an interesting concept. For about 200 years of First Amendment jurisprudence, commercial speech, such as advertising and sales promotion, was not considered protected at all. It was not until the 1970s that the Supreme Court decided commercial speech deserved some level of First Amendment protection, although not at the same level as political or social speech. In a 1980 case, Central Hudson, the Supreme Court developed a framework for evaluating commercial speech restrictions under the First Amendment. This framework is succinctly explained in an excellent article discussing Caronia authored by Aaron S. Kesselheim, M.D., J.D., M.P.H., and Michelle M. Mello, J.D., Ph.D., appearing in the North Carolina Law Review.
First, was the speech false or misleading, or did it concern unlawful activity? If so, the speech deserves no protection. Second, is the government’s interest in regulating the speech substantial? Third, does the regulation directly and materially advance the government’s interest? Finally, is the regulation narrowly tailored, meaning, no more extensive than necessary to serve that interest?
Unfortunately, because the government was using Caronia’s speech only as evidence of intent (even though the court said it wasn’t), it had no incentive to put on any evidence regarding the truthfulness of his speech at trial. (Although I have not researched the issue, I tend to doubt there is good evidence that Xyrem is safe and effective for all of the uses and all of the patient populations he claimed during his recorded conversation with the physician.)
Thus, on appeal, the court assumed the information was truthful. However, it noted, correctly, that the First Amendment protects only truthful and non-misleading speech, leaving open the possibility that, in future cases, the government could, in the court’s view, constitutionally prosecute a sales rep’s off-label promotion if it could show that the information given the physician was untruthful or misleading. A remaining question is whether off-label promotion is per se illegal anymore, even if the government makes it absolutely clear at trial that the rep’s speech is only being used as evidence of intent. We’ll return to that question at the end of this post.
The court recognized that the FDA certainly had a substantial interest in preventing off-label promotion: “preserving the efficacy and integrity of the FDA’s drug approval process and reducing patient exposure to unsafe and ineffective drugs.” The court then turned to the third and fourth prongs of the Central Hudson test and found that the FDA failed on both. It is here that the ruling is most disturbing.
The court decided that, far from advancing the FDA’s interest in public protection, the FDA was “paternalistically” interfering with information being given to physicians, a skilled and sophisticated audience, in the court’s view, who could more than adequately determine the usefulness of the sales rep’s information. With this information in hand, the court opined, physicians could actually serve the public interest by making sure “that decisions about the use of prescription drugs, including off-label usage, are intelligent and well-informed.”
As to the fourth Central Hudson prong, the court determined that restricting off-label promotion was overly broad because other means could achieve the same goal without interfering with protected speech. How? By educating physicians and patients to distinguish between “misleading and false promotion, exaggerations and embellishments, and truthful or non-misleading information,” require off-label use disclaimers, limit the number of off-label prescriptions, and warn physicians about tort liability from adverse outcomes due to off-label uses.
The government did not ask for a rehearing in front of the full Second Circuit Court of Appeals, nor did it petition the U.S. Supreme Court to hear the case, perhaps because it wanted to contain the damage and not risk, in the case of an adverse Supreme Court decision, nationwide impact.
One of the cases the court relied on in reaching its decision was Thompson v. Western States Medical Center, a case that should serve as a cautionary tale for courts looking to second guess the FDA’s regulatory scheme. In 2002, in Western States, the Supreme Court struck down a prohibition on advertising by compounding pharmacies. The FDA viewed the prohibition as recognition of the useful services compounding pharmacies could provide in local communities, regulated by the states and without federal oversight. At the same time, by prohibiting advertising, these pharmacies would be restrained from growing too big and essentially turning themselves into unregulated large-scale drug manufacturers.
With FDA regulation out of the way, that is exactly what happened. Many compounding pharmacies scaled up. One of these was a Massachusetts compounding pharmacy that manufactured, and extensively advertised, steroid injections. A decade after the Western States decision, these injections ended up sickening hundreds and killing dozens of people from fungal infections due to unsafe compounding practices.
Criticism of Caronia
The Caronia decision has garnered a good deal of criticism, according to an essay by law professor Christopher Robertson, J.D., Ph.D.:
Opinion leaders and scientific journal editors have expressed concern about the Caronia decision and the trend that it extends, as the latest in a wave of litigation and scholarship calling into question the constitutionality of FDA’s regulatory regime. The head of the Cleveland Clinic called the legitimation of off-label promotion ‘a potential catastrophe for patients.’ . . . Scholars are already predicting that, if it gets such a case, ‘the Supreme Court will find the FDA’s current regulatory scheme unconstitutional.’
This criticism starts in the case itself, in the dissent of one member of the three-judge panel, Judge Debra Ann Livingston. She viewed the majority’s opinion as “call[ing] into question the very foundations of our century-old system of drug regulation.” The majority, she said, would allow “any substance that may be legally sold for some purpose [to] be promoted by its manufacturer for any purpose – so long as the manufacturer’s statements are merely unsubstantiated, rather than demonstrably false or misleading.”
Kesselheim and Mello echo this criticism:
The decision appears to pave the way for medical product companies to conduct poor-quality studies for the purpose of showing products’ utility for unapproved indications. There is no need for companies to design these studies to meet the FDA’s standards for methodological rigor if the companies have no intention of submitting an application for approval of the new use but rather intend to use the study findings only in marketing communications. Companies can design studies in ways that maximize the chances of obtaining a desired result and select which studies to emphasize in promotional communications, ignoring others that do not support their promotional message.
Indeed, pharmaceutical companies would do well to borrow from the CAM playbook in constructing and interpreting studies. Here at SBM, we’ve documented the numerous ways one can play with the evidence to produce a desired result. For example, one can bury the damning results in a lot of noise. The study can be spun to suit one’s purposes. One can twist a negative study into a positive one by moving the goalposts on the study’s objectives and using fetching charts calibrated to make the results look good. Or, just do bad studies, as has been demonstrated time and again with acupuncture. And, as a last resort, there is always outright fraud, Andrew Wakefield-style.
With all due respect, I wouldn’t be so sanguine about physicians’ abilities to sort out all the evidence and come to the right conclusion. First, who has the time? Second, again turning to CAM as an example, the embrace of “integrative medicine” leaves one wondering if evaluating the evidence is within the skill set of a certain number of physicians. Although for entirely different reasons, Kesselheim and Mello are with me on this one: “courts have had greater confidence than is warranted in physicians’ ability to evaluate claims about off-label uses.”
Finally, in light of our experience with dietary supplements, it is wishful thinking to assume that educating physicians and patients to distinguish between “misleading and false promotion, exaggerations and embellishments, and truthful or non-misleading information,” is an achievable goal, or that disclaimers will protect the public.
Patient beware
The FDA has not officially changed its position that off-label promotion is a violation of the FDC Act, although the pharmaceutical industry is trying mightily to push it in that direction. The government is still prosecuting off-label promotion cases. Perhaps the FDA does not agree with critics of the Caronia decision that its ability to regulate drugs has been seriously undermined. At least one law firm representing drug companies warns against a hasty interpretation that Caronia is a get-out-of-jail-free card. It will likely take several years to sort all of this out.
In the meantime, patients should be aware that off-label prescribing is not unusual and that it is sometimes based on insufficient evidence, a problem that some experts think could be exacerbated by more liberal sales promotion practices. Patients have every right to ask their physicians the circumstances of his or her prescribing a drug and the evidence for doing so.

   Commercial deception: undeclared drugs in herbs and other dietary supplements
David J Kroll
Link
Back in February, an acupuncturist in Key West, Florida, was arrested on charges of using a physician’s credentials to obtain controlled substances and other prescription drugs. While some of these drugs were for the individual’s personal use, the Key West Citizen reported from arrest records that the acupuncturist had obtained other drugs for her patients, including anxiolytics, a muscle relaxant, and sedative sleep aids.
While it is not clear if the individual in question specifically mixed those drugs with herbal or homeopathic remedies available at her practice, the demographics of her clientele are likely to be inconsistent with the use of prescription drugs.
Why do I propose this hypothesis and where would a practitioner get the idea to mix prescription drugs with herbal products to make them appear effective?
Why, the dietary supplement industry, of course.
In fact, adulterating commercial herbal products with prescription drugs is so common that the US FDA is keeping a running tally of actions against companies selling supplements containing “undeclared drugs”: the polite regulatory term for deceptive doping of a useless product with a real drug.
Most-common approaches have been to dope weight-loss supplements with sibutramine, a prescription amphetamine-like, serotonin/norepinephrine reuptake inhibitor sold in the US and Canada as Meridia. The US FDA list on this class of deception has increased from 28 to 69 products since 22 Dec 2008. Regular SBM readers may have heard, for example, of weight loss claims made for apple cider vinegar capsules. You may be surprised to know that such a product might have efficacy – if it contains sibutramine – as the FDA found in 2007 for a product manufactured by Confidence, Inc.
Another common adulteration tactic is for erectile dysfunction supplement manufacturers to boost their products with prescription phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil (Viagra) or related compounds. So popular is this approach that the same manufacturer cited above for sibutramine-adulteration of apple cider vinegar products has also been found guilty of adding PDE5 inhibitors to their aptly named “Long Weekend” product.
At least their business model is consistent.
In fact, a recent FDA investigation of such supplements sold online revealed that up to one-third of products are so adulterated.
Most concerning is when these adulterants might interact with other medications a patient is taking (in the case of PDE5 inhibitors and antihypertensive vasodilators) or, worse, have inherent harmful effects. There is at least one case in the literature where supplement doping has been associated with unusual cases of prostate cancer (Clin Cancer Res 2008:607-11). In this case, the bodybuilding supplement Teston-6 was found to contain testosterone and other compounds more potent than testosterone in promoting prostate cancer cell growth in vitro.
As a natural products pharmacologist, I am all for researching botanical and non-botanical supplements that may intrinsically contain useful therapeutic molecules – that is the cornerstone of my field. Indeed, some traditional herbal medicines have been used as sources for modern pharmaceuticals.
But to dope supplement products with effective drugs is to admit that one is selling garbage: a deceptive practice to prey upon those who choose to seek out “alternative” medical approaches and keep them coming back. I wonder how many consumers of “green” or “alternative” products (paid for out-of-pocket, mind you) would be pleased to know that their apparent health benefits were due to prescription drugs present therein that could have been obtained in a consistent, reproducible dosage form for a small co-pay.
This practice also makes one wonder how many anecdotal cases of “success” with herbal products could be attributed to adulteration with prescription drugs.
For this reason, I recommend that grant reviewers and journal editors insist that any dietary supplement used in a clinical trial be subjected to extensive chemical analysis as a condition of funding or publication, respectively, including screening for pharmaceutical compounds capable of exerting the therapeutic effect under investigation.

A Pattern of Deceptive Video Ads for Supplements
I’ve been seeing a pattern of deceptive videos that promise to reveal a secret but make you watch the entire video to learn what it is. They feature alarmist stories, emotional language, and testimonials, but no actual science. They make claims that can’t be believed.
Harriet Hall on February 9, 2021
Link


I’ve been seeing a lot of video ads with “click-bait” promises that are very enticing. They fall into a pattern of despicable marketing ploys. They promise to tell you about a quick fix, something you can do in only a few seconds in the morning that will cure an illness or solve an annoying problem. But you have to sit through almost the entire video before they finally get around to revealing the secret, which usually turns out to be a pill with a mixture of dietary supplements and no science to back up the claims.
I will walk you through a typical example, so you needn’t waste your time suffering through the video like I did. This one is an advertisement for ReVision, a mixture of dietary supplements that is said to prevent all kinds of eye conditions and other ills, and specifically to restore deteriorating eyesight and allow you to throw your glasses away.
The presenter in this video is Larry Stephenson, a 55-year-old man who is not a doctor, but who recently retired after a 30-year career as a medicinal chemist.
These videos always start with an alarmist, emotional, exaggerated story meant to get your attention and tug at your heartstrings. Stephenson begins his story with “my wife was behind the wheel that horrible night. She had a terrible accident that wasn’t even her fault: it was because of deteriorating vision that her doctors were unable to fix, despite assuring them that their over-priced, multi-thousand dollar treatments worked.” He felt terrible that he had not been able to protect his wife. He realized that vision loss could be deadly and that the doctors had been telling big fat lies. (But had they? He doesn’t tell us what her visual acuity was with her glasses or show that impaired vision caused her accident. Already, he is making unsubstantiated accusations against her doctors and exaggerating the cost of getting glasses.)
When his wife’s vision began to deteriorate, she was embarrassed because couldn’t recognize her friends. Her eye doctor prescribed two pairs of glasses, for near and distant vision. She hated them. (But didn’t they correct her vision?) Her eyes got tired, and she thought the glasses made her look ugly. It was inconvenient to have to carry glasses everywhere, clean them, and store them properly to protect them from breaking. The whole thing cost $2,000. (The typical cost of an eye exam and glasses is much less.) He wanted to know why “this alienating disease” was happening to her. They spent thousands of dollars on products they found on the internet. They didn’t work. She started isolating herself, refusing invitations. (Most people don’t react that negatively to needing glasses.) One night, while driving home from work, she saw two teenagers crossing the street; she saw them too late and crashed into a tree. The tree fell on the car. She had a broken leg and a concussion and required many stitches. He was furious with himself, with eye doctors, and with the whole eye-care industry that promised their darn treatments would restore her vision: how could they have let her drive, knowing she couldn’t see well? (Presumably because she could see well with her glasses.) When she woke up in the hospital, she started crying her eyes out and said she couldn’t live with herself any more, she was no use to anyone, and it was getting harder and harder for her to get around. He couldn’t stand seeing her suffer, being lied to that the eye industry’s treatments worked. (But he doesn’t give any evidence that they didn’t work.) He searched the internet for a solution that didn’t involve glasses or surgery, because they were “draining the life out of her” and hurting her eyes, with no guarantees that she wouldn’t go completely blind eventually. He wondered why some people lose vision when there is nothing physically wrong with them. (Not true.)
He promises that the video will reveal a simple, 6-second solution, but he won’t tell you what it is until near the end of his spiel. He says “It’s important to watch the entire video to the end.” Because “This information could save your life or the life of someone you love.”
We are told the video may be removed due to powerful forces in the vision industry controlled by Big Pharma. (These videos always say this, but they are never removed.) He says they are scared that his new dirt-cheap method will put them out of business. “These fat-cats are perfectly happy to shatter your physical and mental health, forcing their overpriced lenses down your throat and becoming obscenely rich in the process…they don’t want you to have perfect eyesight, they need to keep you a customer for life.” (Such claims are common in these videos, but have no basis in reality.)
He exaggerates the inconvenience of corrective lenses. Glasses are fragile and easily broken, contact lenses are uncomfortable. He wants viewers to “break free from the prison”. (These scaremongering videos always make the standard treatment sound much worse than it is. Most of us wear glasses and don’t think of it as prison.)
He offers several video testimonials with no documentation and with details that don’t make medical sense. (Testimonials are notoriously unreliable and not acceptable as scientific evidence of efficacy.)
He tells us 67,000 Americans have already experienced the benefits. (Argument from popularity is a logical fallacy.)
He searched for the root cause. (Root cause is a popular meme of alternative medicine.) He explains how vision works and says vision starts to deteriorate when the electro-chemical impulses start dying. But WHY do they start dying, he asks? You can’t just blame old age. (Anyway, no cells are dying when cataracts impair vision.) In 2018, he claims that researchers found a whole new system that allows the retina to communicate directly with the brain, a new type of cell in the retina that decodes images. We don’t see with our eyes, we see with our brain, with the brain neurons situated on the retina. (I couldn’t find the research he mentions, and he provides no citations.)
This may explain why people with poor eyesight also suffer from fatigue, anxiety, depression, and migraines. (So do people with good eyesight.) They have a problem with signals not reaching their destination in the brain. (And he knows this how?) He consulted a friend, a renowned Swedish ophthalmologist, who refused to discuss it on the phone. (Why? Part of the conspiracy?)
He told his wife’s ophthalmologist about his discovery, but he said if it were true, the experts would have discovered it by now.
A friend introduced him to a Japanese doctor, Kenji Kanamaro. (There is no such doctor listed in PubMed, and K. Kanmaru is listed but has not published any relevant research.) Why isn’t there a treatment available to connect the eyes and the brain? It’s suppressed by the vision industry. They want you to keep purchasing fancy lenses every 3 months (Do you know anyone who needs new glasses every 3 months?), eye drops, artificial tears, etc. They want you to keep getting surgeries and having headaches. They want to keep taking your money for your entire lifetime. (The ones I know sincerely want to help you see better.)
Every time a natural treatment is proven to work, they ban it from future testing, claiming it’s dangerous or “homeopathic nonsense”. The eye industry would rather have people go blind, or die, as in the case of his wife, instead of looking for an efficient, cost-effective cure. As well as profit-hungry, he calls them “Godless”. (A complete distortion of reality.)
New research has shown that the only solution is to greatly reduce the enzyme Arginase2 in your body. That prevents the death of neurons from your retina and prevents the decay of fiber-links that connect neurons to each other and to the brain. A study in Sweden examined 93 subjects with all kinds of different eye problems and found they could reduce their levels of Arginase2 with Huperzine A (which inhibits the arginase enzyme). All 93 patients reportedly noticed improvement or even complete resolution of their vision problems, and they also experienced a great decrease in all bodily inflammation, including the kind of damage in the back of the eye caused by hypertension and diabetes. He “felt like jumping up and down with joy, like a 5-year-old”. But his friend warned him that Big Pharma would never allow this information to be made public. They would get the ingredients banned, claiming they were dangerous or homeopathic nonsense. He was willing to take a risk, knowing he might save the lives of people like his wife. He couldn’t wait for millions of Americans to go blind while everything was crumbling.
They developed a product using only pure ingredients sourced from local growers who let plants naturally reach their full maturity without the use of herbicides. They worked constantly to find the most effective doses and combinations, and to put them into a small pill. They came up with a mixture of Huperzine A to inhibit the arginase enzyme, Alpha GPC (which increases blood flow to the brain), Phosphatidylserine (food for your nerve cells), niacin, and some other “special plants to increase the effects”. (There may be some preclinical evidence for some of the ingredients, from animal studies and perhaps a small human pilot study with no control group. But the mixture in ReVision itself has never been tested in a controlled study.) He finally had a pill that would restore his wife’s vision and bring their lives back. He invested everything he had in the project. His wife noticed no changes in the first few days, and she asked him if he was going to help her look for a decent nursing home. After a few more days, something amazing happened: he asked her to check their electricity bill and she did it without glasses! And she could read for more than an hour without her eyes getting tired. Her headaches were gone, and she could recognize people from the other side of the street. She was the first to see her neighbor’s lost dog – at a distance, in the dark. They thought that was doggone impressive (pun intended). They rejoiced and threw her glasses in the river.
They found 54 other people to try it: all reported dramatic improvement, as well as bursts of energy and restful sleep, with no anxiety or headaches. He claims it has been “clinically tested” (apparently on the basis of this one unpublished study with no control group!). It is called ReVision. It is carefully manufactured with sterile precautions and contains no GMOs. He says it can be more powerful than any lenses or surgery on the planet. It boosts the health of your eyes and brain, helps you see great at night, keeps your focus clear and your vision detailed and sharp. It gives you triple protection against glaucoma, cataracts, and macular degeneration. You’ll notice yourself thinking better, feeling sharper and more relaxed. Your headaches and migraines might disappear. (Or they might not. With no evidence from controlled studies, why should you believe these claims?)
He’s not interested in money. (Yeah, sure!) He keeps remembering how helpless he felt when Lucy had her accident and when she said there was no point in living any more. He may have to increase the price soon, (a common warning in these videos) but for now he is offering a 30 day supply for only $69, a 90-day supply for $59 a bottle, and a 180 day supply for only $49 a bottle. It comes with a 60-day money-back guarantee.
You should buy now, because supplies are running low and if they run out it will take several months to make a new supply. (Again, a common theme in these videos, and one that is hard to believe). ReVision is available only through his page and can’t be found anywhere else. He says he is dealing with threats from eyewear moguls and risking the safety of his family for YOUR safety. (He says, without evidence. Do you believe him?).
Conclusion: Not credible
Videos like this are available for many different products. They seem to be following the same formula, which a clever marketer may have devised and which may be good for sales, but it’s far from convincing. It is an appeal to emotion with no credible claims based on science.
We often wonder whether people selling dietary supplements actually believe their products work or are just cynically out to make a buck. I think there is good reason to assume these videos are examples of the latter. I have been sucked into sitting through several of these in my curiosity to figure out what they were selling, and I regret it. I hope you don’t get sucked in by similar clickbait.

Quality differences of supplements vs. drugs
Scott Gavura on February 29, 2024
Link

Bottle of galantamine available on Amazon.com
When it comes to drugs or dietary supplements, accuracy should be a given. What’s on the label should accurately describe what’s in the bottle. No exceptions. When it comes to ensuring the products we buy are of high quality, we’re all effectively reliant on regulation to protect us. As a pharmacist, I can’t personally verify that each tablet in your prescription contains the active ingredient on the label. I am dependent on a supply chain that may stretch around the world. While the product manufacturer may be reputable, it’s only a regulator that can realistically verify and enforce production to strict quality standards.
The same cannot be said for products like supplements and herbs which are regulated differently than drugs, and held to different, and in some cases, weaker standards. A weak regulatory framework, which doesn’t hold manufacturers to account, would be expected to result in a product of lower quality. And that’s exactly what you see in this most recent paper.
Two versions of galantamine
In this small but effective paper, Peter A. Cohen and colleagues set out to determine if label accuracy differs between prescription drugs and dietary supplements. They chose a chemical which is both. Galantamine, which can be naturally sourced from plants, is available in the United States as either a dietary supplement or as a prescription medication. As a drug, galantamine is approved by the FDA for the treatment of mild to moderate Alzheimer dementia. It is also sold as a dietary supplement marketed for cognitive conditions and “memory enhancement.” Other than some vitamins, I’m not sure what other products straddle both categories. So this was an ideal product to test.
In June 2023, all galantamine dietary supplements on Amazon.com labeled with both galantamine as an ingredient that also had Supplement Facts panel were purchased online. (The Supplement Facts panel was required to ensure the product was actually being marketed as a dietary supplement.) In September 2023, versions of all generic immediate-release prescription versions of galantamine were purchased.
Products were then analyzed for the presence of galantamine, and the amount was quantified. Contamination with microorganisms was tested for as well.
The results
Drugs first:
Eleven brands of generic galantamine were purchased and tested, in various strengths. The actual content of galantamine in the generic drugs ranged from 97.5% to 104.2% of the labeled content. This is better than the United States Pharmacopeia standard, which specifies 90% to 110%. None of the products were contaminated with bacteria.
Supplements were much, much worse:
The actual quantity of galantamine in the supplements ranged from less than 2% to 110% of the labeled quantity. Only one product contained galantamine within 10% of the label. Three of the ten products tested were also contaminated, with Bacillus cereus sensu stricto– enterotoxin genes.
Here’s the product-by-product breakdown:
Drug vs. Supplement matters – but should it?
This small study showed that galantamine, when sold as a generic drug, was accurately labeled and free from contamination. This is not the case with galantamine sold as dietary supplements, where the consumer may be purchasing contaminated products that contain a fraction of the galantamine promised.
The dietary supplement industry has exploded in size over the past few decades, with much of that credit owed to the lack of regulatory oversight. But it’s left a marketplace where consumers cannot trust that what is on the label is accurate, or that their supplement was manufactured to high quality standards. This double-standard has made it harder, rather than easier, for consumers to use supplements safely. Until a single, rigorous standard is applied across all consumer health products, there will continue to be uncertainty and even safety risks for users of dietary supplements.
We benefit from regulation, if only to ensure we’re getting what we’re paying for. Weak regulation that doesn’t require manufacturers to demonstrate quality before products are sold, or fails to hold manufacturers accountable for quality, might be expected to result in poor-quality products. And that’s the reality we see today.

   How to Interrogate an Herbal Medicine: Thunder God Vine
David J Kroll
Link
ResearchBlogging.orgThunder god vine may not be a useful herbal medicine but the compounds isolated from it are fascinating – if not as medicines, then most certainly as laboratory tools. Nature Chemical Biology recently published an article where a research team from Johns Hopkins, the University of Colorado at Boulder, and Drew University in New Jersey, has determined the molecular mechanism of action of triptolide, an unusual triepoxide compound from the plant.
Tripterygium wilfordii Hook F, or thunder god vine, is known as lei gong teng in Chinese traditional medicine and has a history of use as an anti-inflammatory herb. As with many traditional medicines, usage patterns do not necessarily indicate scientific validity. In fact, a Cochrane review published just last month on herbal therapies for rheumatoid arthritis indicated that the efficacy of thunder god vine was mixed. More concerning is that the herb had significant adverse effects in some trials, from hair loss to one case of aplastic anemia.
Nevertheless, the herb’s components have been studied since the 1970s for since they also appears to kill tumor cells in culture with nanomolar potency and have immunosuppresant activity in animal models. The group of the late natural products chemist at the University of Virginia, S. Morris Kupchan, first identified the unusual structures of triptolide and tripdiolide from Tripterygium wilfordii as described in this 1972 paper from the Journal of the American Chemical Society. Cytotoxic activity toward tumor cells in culture was used to guide the chemical fractionation of extracts. The unusual presence of three consecutive epoxides in the structures of both compounds led Kupchan to hypothesize later in Science that they target leukemia cells by covalent binding to cellular targets involved in cellular growth.
As an aside: Epoxides are chemically reactive groups composed of an oxygen atom bonded to two carbons; the constraints of this triangular structure and the electrons on the oxygen favor the opening of this ring and attack of other atoms such as sulfur, often present in regulatory regions of enzymes. The Wikipedia entry gives a pretty nice primer. The reactivity of epoxides also makes these compounds highly useful intermediates in industry, particularly in the manufacture of ethylene glycol antifreeze and industrial paints and adhesives (e.g. epoxy resins).
Conventional wisdom would drive most scientists to take one look at triptolide and say that this stuff is a royal mess – so chemically reactive that it couldn’t possible have a specific cellular target. It’s probably too “dirty” – so promiscuous in its binding that it probably attacks all manner of sulfhydryl-containing enzymes and blows the cells to smithereens.
However, several groups have shown over the last 10 or 15 years that some epoxide-containing natural products have very specific cellular targets. Epoxides are not so wildly reactive that they bind everything in their midst. Instead, the environment in which the epoxide exists seems to provide some binding specificity. For example, the group of Jun O. Liu, then at MIT, showed in 1998 that another epoxide-containing natural product, fumagillin, exerted its antiangiogenic activity by binding to a protein called methionine aminopeptidase 2 (MetAP2). Similarly, Brent Stockwell at Columbia University and the Howard Hughes Medical Institute recently published a tour de force in another Nature Chemical Biology paper showing that a reactive 2-chloromethylketone compound specifically targets protein disulfide isomerase, preventing neuronal cell death from misfolded proteins with potential use in Alzheimer’s or Huntington’s diseases.
Jun Liu was again at the helm in the current thunder god vine study in Nature Chemical Biology. The group started with a simple approach to narrow down the target of triptolide from thunder god vine: they treated the venerable HeLa cervical carcinoma cell line with the drug and examined the incorporation of the building blocks of DNA, RNA, or protein. Triptolide was several orders of magnitude more potent in rapidly inhibiting RNA synthesis.
In an elegant series of experiments, the researchers progressively dissected the modulation of RNA synthesis – first identifying the multiprotein complex of RNA polymerase II (RNAPII) as the target but acting via a mechanism different from known RNAPII inhibitors such as the mushroom toxin, α-amanitin.
Further experiments revealed that triptolide bound to a transcription factor component of the RNAPII complex called TFIIH. Then, finally, the investigators demonstrated that triptolide specifically attacked a component of TFIIH called XPB. XPB is a type of DNA unwinding enzyme called a helicase and is involved in DNA repair. The group then made semi-synthetic chemical analogs of triptolide to determine how inhibition of the ATP hydrolyzing activity of XPB correlated with potency in killing HeLa cells. While the rank order of potency of the compounds correlated, the drugs were less potent in attacking the enzyme activity of the XPB protein than in killing HeLa cells. So, it’s unclear as to exactly how binding to XPB is leading to cell killing. The investigators do note that triptolide may have other cellular targets that are less abundant than XPB that contribute to its activity.
Of course, we can’t tell right now if triptolide selectively kills tumor cells relative to normal cells. Again, conventional wisdom would argue that a drug that hits such a crucial target as a transcription factor is unlikely to have selective activity. After all, the classic RNAPII inhibitor α-amanitin is well-known as a lethal toxin responsible for legendary poisonings by the death cap mushroom, Amanita phalloides. However, low concentrations of such a compound might indeed have some selectivity when given together with a DNA-damaging anticancer drug. But that’s a very fine tightrope to walk.
In the end, triptolide may end up “just” being a useful laboratory tool for understanding the basics of gene transcription and DNA repair. But if normally disregarded epoxides do indeed have some specificity in their action on cellular targets, perhaps analogs can be made with selective action against tumor cells. Many triptolide analogs have been synthesized over the years and should certainly be revisited in the context of cancer treatment. But this finding should also serve to warn us that the indiscriminate use of the herb as an anti-inflammatory should be revisited, particularly if the dose of the herb gives variable concentrations of compounds with a very low margin of safety.
Reference
Titov, D., Gilman, B., He, Q., Bhat, S., Low, W., Dang, Y., Smeaton, M., Demain, A., Miller, P., Kugel, J., Goodrich, J., & Liu, J. (2011). XPB, a subunit of TFIIH, is a target of the natural product triptolide Nature Chemical Biology, 7 (3), 182-188 DOI: 10.1038/nchembio.522

   Why we don’t prescribe bark for cancer
David J Kroll
Link
My valued colleague, Dr. Antonio Baines, recently invited me to speak for his graduate course in Toxicology. Dr. Baines’ course is one of the most highly-regarded graduate classes at North Carolina Central University for M.S. students in Biology and Pharmaceutical Sciences. Antonio asked that I discuss the pharmacology and toxicology of herbal and non-botanical dietary supplements but pretty much gave me free reign as to the mechanism by which I would do so.
In the past, I have often introduced herbal supplements to students who already know a bit about drug and toxicant action by taking the example of the anticancer drug, taxol (Note: Little “t” taxol was the name originally given to this chemical by its co-discovers but the corporate sponsor used it as a registered trademark for the brand name, big “t” Taxol, and the USAN proposed the use of the cumbersome paclitaxel as the generic name.). As I noted in my previous post, taxol is an anticancer drug isolated from the bark of the Pacific yew tree, Taxus brevifolia, and was the first compound shown to kill cancer cells by promoting microtubule polymerization (and preventing depolymerization).
As a teaching tool in demonstrating how far we’ve come since Sertürner first isolated codeine and morphine from the opium poppy, I ask students to answer a rather simple, seemingly flippant, but highly informative question:
If taxol is an anticancer drug with known clinical activity against ovarian, lung, and breast cancer, why don’t we prescribe Taxus bark for cancer?
Similarly, why doesn’t the dietary supplement industry promote ground Taxus bark as an oral dosage form, herbal remedy to promote well-being for cancer patients?
These questions get to the heart of why we have come over 200 years from Sertürner’s day: to purify and concentrate pharmacologically-active constituents from natural products:
1. Drug metabolism and lack of oral bioavailability: Orally adminstered drugs are subject to first-pass metabolism when absorbed in the gut. The mesenteric blood supply collects into the hepatic portal vein and must get through the liver before being distributed to the rest of the body. The primary Phase I drug oxidizing enzymes and Phase II drug conjugating enzymes are in their highest concentrations in the liver and many compounds are metabolized to inactive compounds before they even reach the systemic circulation. (N.B., The intestinal mucosa also contains some cytochrome P450 isozymes, so metabolism starts even earlier than that.) As a result, many drugs, like taxol, must be given intravenously to preclude first-pass metabolism.
2. Influence of bark composition: Lignans and cellulosic compounds might interfere with the absorption of taxol by preventing its dissolution. In fact, any change in the amount or composition of inactive excipients in a prescription drug can dramatically influence dissolution and drug absorption. Other components of the bark might as as competitive inhibitors of taxol’s binding to tubulin or, in a broader sense, have some other adverse influence on drug pharmacodynamics. In addition, other components of the bark might enhance the metabolism of taxol. This leads us into:
3. What is the appropriate dose of bark?: This is a major stumbling point with herbal medicines. Indeed, botanical products may contain physiologically-active compounds, but these may be at concentrations too low to achieve relevant plasma concentrations. Taxus bark contains 0.05 to 0.005% taxol. Even if taxol were orally-active, the amount of bark one would have to ingest would be so large as to present a patient compliance issue (or at least severe gastrointestinal discomfort).
4. Reproducibility: If a tumor response was observed, how would one know how much bark to give the patient for the next dose? The environment (weather, soil composition, water, sun) in which the trees are grown can all influence the abundance of secondary metabolites present in crude plant material. Hence, there are significant lot-to-lot variations in the chemical composition of botanical products. Even if all of the above issues were circumvented, the reproducibility of subsequent doses might have unpredictable biological effects.
5. Toxicological issues: Again related to growth environment, many plants are bioaccumulators of heavy metals from the soil, especially cadmium. With many recent reports of heavy metal contamination of herbal remedies, companies are only now beginning to test their raw materials for heavy metals. Plant materials could also be contaminated with pesticides, insecticides, or harmful microorganisms that would also be removed if the active principle were purified. Moreover, there have been several cases of botanical products intentionally or accidentally adulterated with other prescription drugs (called ‘undeclared drugs’ by the US FDA) in the attempt to produce a biological effect that the plant medicine is incapable of having itself.
There are certainly more issues that readers are welcome to add in the comments. The point of this exercise was to demonstrate to students the distinctions between the safety and efficacy of crude plant products relative to pure drugs isolated from such natural sources. This discussion and list was compiled in a fraction of the time it took me to type it.
I wish to acknowledge the students of Dr. Antonio Baines’ BIOG 5140 – Toxicology class at North Carolina Central University for their individual contributions to this post:
Onize (Ony) Aiyede, Lavita Anderson, Chantal Bodkin-Clarke, Jamila Broadway, Shailendra Devota, Chang Hun Lee, and Roketa Sloan.

   The risks of CAM: How much do we know?
Scott Gavura
Link
Working in pharmacies where supplements are sold alongside traditional (over-the-counter) medications, I’m regularly astonished at the different perceptions consumers can have about the relative efficacy and safety of different types of products. Once, speaking with a customer about a medical condition she wanted to treat, I indicated that there were no effective non-prescription therapies — she needed to see a physician for access to an effective treatment by prescription — and I gestured behind the counter. “Back there?!” she pointed. “That’s where you keep the stuff that kills people! I want something natural!” Suggesting that my patients with heart disease or HIV had a somewhat different perspective, I tried (unsuccessfully) to talk her out of a questionable-looking supplement (Hint: avoid anything from a company with a P.O. box as a mailing address.) This appeal to nature, combined with a perception that natural products are safe, and conventional drugs are unsafe, is pervasive.
One of the responses regularly tossed at health professionals who argue for higher regulatory standards for supplements, CAM, and other natural health products is that conventional medicine kills, and prescription drugs are its preferred weapon. In contrast, they argue, supplements are safe. Any credible health professional will agree that conventional medicine can cause harms. David Gorski has examined SBM and patient safety before. The number of preventable adverse events from medical treatments is far too high. And even the idiosyncratic events — freak accidents, basically — mean we must always consider the rare but possible harms of the therapies we use. But as Harriet Hall has pointed out, we cannot look at drug harms in isolation: the variable perpetually ignored by critics of mainstream medicine is the benefits associated with those drugs, which can make the risks seem quite acceptable. Both expected benefits and possible harms need to be incorporated into our decision-making process.
When it comes to drug (or supplement) safety monitoring, causality assessment is the evaluation of the odds that a particular treatment is associated with a particular adverse event. A single adverse event may have characteristics that suggest the relationship to a treatment is highly probable. But because correlation may well not equal causation, data are usually rolled up an analyzed in aggregate, by national and world-wide agencies to help identify the rare but serious adverse events. What this means is, if data are not collected, we have an incomplete picture of a product’s adverse event profile. Yet when it comes to supplements, good data on safety and efficacy are often lacking.
How Safe is the ‘Alternative’?
One of the recurrent themes of science-based medicine is that any medical intervention that can plausibly cause physiological benefit can also plausibly cause physiological harm.
— Steven Novella, Vitamin E and Stroke
Despite the widespread perception that supplements are safe, some do have undesirable biological and pharmacological activity. There is no inherent safety to any product, natural or not. There is both anecdotal and more systematically-captured information to suggest harms can be associated with supplements. So how do we gather good data to inform decision making?
The primary challenge we face when evaluating the risk profile of supplements is the lack of good quality clinical trial evidence. When these data do exist, studies are typically of short duration with small sample sizes. Without clinical trials that systematically measure and report adverse events, there’s no harms profile, and the “Side Effects” section of the monograph stays nice and short. In contrast to supplements, new drugs undergo extensive clinical trials and adverse events are actively monitored, collated, and eventually are summarized in the product monograph. It should surprise no-one that the list of adverse events is longer, when you actually go out an systematically look for them.
As regulators worldwide generally don’t require any meaningful pre-sale testing of supplements for safety or efficacy, there’s typically little data available when any product becomes marketed. (Some regulators will approved products based on a history of “traditional use”, which offers little insight into a products safety profile, as that data have never been systematically collected.) Instead, regulators worldwide (e.g., Canada and the USA) rely almost entirely passive surveillance to monitor the safety of marketed products.
Passive surveillance depends on the spontaneous reporting of adverse events from health professionals, alternative medicine purveyors, manufacturers, and even consumers directly. Passive surveillance is the key method of collecting safety data on drugs and supplements once they have been licensed for sale.
However, passive surveillance is an imperfect means of collecting safety data. It is much more effective at identifying rare and infrequent adverse events (e.g., liver toxicity) than incremental increases in the risks of common medical conditions (e.g., heart attacks). While the true denominator cannot be know with certainty, it’s generally accepted that only a fraction of adverse events are identified, and only a fraction of these are actually reported. Despite these limitations, the Institute for Safe Medication Practices reports that in 2009, the FDA received 19,551 reports of patient deaths associated with drug therapy. Is this the smoking gun that Big Pharma is killing us? Not quite. Causation has not been established, and even then, we need to consider harms in the context of the benefits a therapy may offer. The system isn’t perfect, but it is producing data that may be helpful for decision making, and understanding the evolving risk profile of licensed products.
Despite their widespread use, surveillance of supplements reveals generally few adverse events. It could be that many products lack meaningful pharmacologic activity — either positive or negative. An adverse event is probably less likely in drugs without any meaningful beneficial effects. But beyond efficacy, there are several other factors, unique to supplement use, that may contribute to even less frequent adverse event reporting. These were identified in a series of qualitative semi-structured interviews conducted by Rishma Walji in 2010, and summarized in the paper Consumers of Natural Health Products: natural born pharmacovigilantes?:
    • Consumers believe supplements are safe, because they are “natural.” Therefore they’re less likely to associate adverse events with supplement use.
    • Supplements don’t require a prescription. No health professional may be involved in monitoring response to therapy, who might be able to identify adverse events as part of a monitoring plan.
    • Because consumers may not involve health professionals in their decisions to take a supplement, they may feel obliged to deal with it on their own, and not involve health professionals. Perceptions about how their health professional will react to their use of supplements may come into play.
    • Consumers may not know how to manage and adverse event, and who to report an adverse event to. They didn’t get it from a doctor, so they don’t report the outcome to a doctor.
    • Even if they do contemplate reporting an adverse event, the process can be complex, especially for consumers.
    • Users may have a distrust of “conventional” medicine which drove their initial use of the product. When adverse events were identified, there were reluctant to consult “conventional” health care providers for assistance.
    • Some surveyed stated a fear of losing access to supplements, driving a reluctance to report adverse events.
From my own practice, I’d add few additional factors to the list. Supplements are commonly used for short durations, and for self-limiting conditions, in comparison to prescription drugs that may be used chronically. Prescription drug manufacturers are required by law to report to regulators any actual or potential adverse events that they learn of. This requirement was recently implemented in the USA for supplement manufacturers — however, contact information may not yet appear on supplement labels.
Disappointingly, consumers surveyed reported a preference to discuss adverse with health food store personnel, family or friends, which appears to be a factor of both comfort and convenience. Enablers to reporting adverse events included knowledge and importance of adverse event reporting, and personal comfort with their health care provider.
Real World Harms
People often ask “what’s the harm” of supplements and other forms of alternative medicine. This question can be answered, if incompletely. Considering the numerous case reports of harm helps us understand patterns, look at causality, and guide the safe use of these products. A recent case series of adverse events supports some of the observations that Walji made in her paper, and expands on the possible consequence of CAM use. The paper, Adverse events associated with the use of complementary and alternative medicine in children, is from Lim et al., and appears in the Archives of Disease in Childhood.
Monthly surveillance reports of CAM-associated adverse events in Australian children were collated over a three year period. This active surveillance program (pediatricians are asked monthly to report any rare disorders that have been observed) followed adverse event reports with detailed questionnaires, evaluating causality, severity, and whether the adverse event was potentially related to a failure to use “conventional” therapy. The program identified 39 adverse events, with 64% considered severe, life threatening, or fatal. Thirty cases (77%) were considered to be related to CAM, and 17 cases (44%) were felt to be due to a failure to use conventional medicine. Four deaths were documented, all attributed to a failure to use conventional medicine in favour of CAM. One of the deaths, from seizure, was attributed to a decision to use CAM rather than drugs, with the aim of avoiding the side effects of drugs.
The authors make the following observations on CAM use and adverse events:
    • Reporting can be complicated because information on the product may not be available.
    • Products can be contaminated or adulterated with therapeutic, undisclosed drugs, complicating evaluations of causality.
    • Because CAM products are perceived as safe, they may not be stored properly in the home.
    • CAM use may be accompanied by dietary advice that is dangerous, and not based on good evidence. Two of the fatalities associated with CAM occurred in children on marked dietary restrictions prescribed by a CAM practitioner.
It’s a small case series, and we know neither the actual numerator or denominator. Still the severity of some of the reactions is concerning, and the author’s comments point to additional factors that may influence the incidence of adverse events reported.
Information is Beautiful … But Incomplete
As a pharmacist, I constantly need to contextualize data directly for patients, translating trial results into more understandable figures like numbers needed to treat and numbers needed to harm. I’m always searching for better ways of communicating the understanding of risks and benefit. Information is Beautiful is one of my favourite blogs, as the authors highlight innovative and effective ways of graphically presenting data. So I was initially excited about their attempt to summarize the data for supplements — click on the image to view the data on the IiB website:
Clicking each bubble will link you to the supporting clinical data. But there’s a crucial element missing in their presentation: harms. You cannot evaluate the value of a treatment based on efficacy alone. For example, selenium is ranked very highly for colorectal cancer prevention based on this study. Not only is there evidence to the contrary, selenium consumption is associated with a significant increase in the risk of type 2 diabetes. The risks actually seem more compelling and relevant than the potential benefits. Or look at red yeast rice, another supplement rated highly. While RYR does seem effective, is less effective and more dangerous than drugs derived from it. I like the IiB visual approach, but it fails in communicating meaningful data on risk and benefit, both of which are essential for decision-making.
Supporting Science-Based Decision Making
Whether one is considering a “conventional” drug or a supplement, the questions we should be asking are the same:
    • What benefits can I expect given my own condition? What data exist to support this? How much more effective is this treatment than a placebo?
    • What harms with this treatment have been documented? Has the product been studied extensively enough to understand the potential risk profile?
    • In how many patients has this product been studied? How closely do they match my situation?
    • What alternatives exist, and what are their risk-benefit profiles? What are the risks of no treatment at all?
    • What are the economic consequences of the treatment strategy I decide upon? How much “bang for the buck” should I expect?
Conclusion
Any active treatment can have harms, yet robust safety data can be hard to come by for supplements and natural health products, painting a skewed picture of their risks and benefits. Our passive system of collecting safety information isn’t likely to remedy this situation. While regulators may have created different standards for supplements and CAM, permitting sale in the absence of good safety and efficacy data, our decision-making should make no such exceptions. Evaluating what we know about efficacy and safety, and what we don’t know, and the limitations of both, are critical to science-based decision making.
References
Lim A, Cranswick N, & South M (2010). Adverse events associated with the use of complementary and alternative medicine in children. Archives of disease in childhood PMID: 21178176
Walji, R., Boon, H., Barnes, J., Austin, Z., Welsh, S., & Baker, G. (2010). Consumers of natural health products: natural-born pharmacovigilantes? BMC Complementary and Alternative Medicine, 10 (1) DOI: 10.1186/1472-6882-10-8

What’s in your supplement?
It could be the ingredients on the bottle. It could be drugs. It could be ground-up snails!
Scott Gavura on April 25, 2013
Link
When you pick up a bottle of supplements, should you trust what the label says?  While there is the perception that supplements are effective and inherently safe, there are good reasons to be skeptical. Few supplements are backed by good evidence that show they work as claimed. The risks of supplements are often not well understood. And importantly, the entire process of manufacturing, distributing, and marketing supplements is subject to a completely different set of rules than for drugs.  These products may sit on pharmacy shelves, side-by-side with bottles of Tylenol, but they are held to significantly lower safety and efficacy standards. So while the number of products for sale has grown dramatically, so has the challenge to identify supplements that are truly safe and effective.
It’s been covered in depth before, but is worth repeating, that the Dietary Supplement Health and Education Act of 1994 (DSHEA) was an amendment to the U.S. Federal Food, Drug and Cosmetic Act that established the American regulatory framework for dietary supplements. It effectively excludes manufacturers of these products from virtually all regulations that are in place for prescription and over-the-counter drugs, and puts the requirement to demonstrate harm on the FDA, rather than the onus on the manufacturer to show a product is safe and effective. The goal was to eliminate barriers to sale, and it worked: Within four years of the DSHEA, supplement sales grew from $4 billion to $12 billion. In Canada, the Natural Health Product regulations have had a similar effect at creating a manufacturer-friendly market: Pretty much anything goes, and today even homeopathic rabbit anus is deemed “safe and effective” by the Canadian regulator, Health Canada.
Notwithstanding the lack of good efficacy data for many products, the absence of good product quality standards is a persistent barrier to the science-based use of supplements. With drugs, the standards are rigorous: Any drug product that is approved for sale must be shown to be equivalent to the product studied in the clinical trials that established its efficacy. This allows us to extrapolate the findings from research into expected effects in patients. And manufacturers must meet stringent quality standards for their products, including verifying the consistency and quality of everything they produce. The same can’t be said for supplements. Even if there is promising data from studies, we can’t make the same inference about the expected effects. Lax regulations translate into lax product standards, and more questions about quality standards, safety, and expected effects. So even if I believe a supplement isn’t expected to interfere with someone’s prescription drugs, I’m basing this on the assumption the manufacturer is actually providing a product that delivers what the label says. And the different regulations mean we must have less confidence this is the case.
One of the more troubling signs that there are serious problems with the supplement market are the continued recalls and warnings from regulators. Just last week, Health Canada warned consumers about the following supplements with unlabelled contaminants (among many others):
    • Snake Powder Capsule (for rheumatism) – actually contain piroxicam (an anti-inflammatory), dexamethasone (a steroid), hydrochlorothiazine (a diuretic) and cimetidine (used to treat ulcers). No snake though.
    • Jia Rong Zhuang Gu Tong Bi Jiaonang (for joint pain) – actually contains indomethacin, piroxicam and diclofenac (all anti-inflammatories), prednisone (a steroid), hydrochlorothiazide, metoclopramide, theophylline (used to be used for asthma), trimethoprim (an antibiotic) and phenylbutazone (a now-banned anti-inflammatory which is associated with bone marrow suppression).
    • Long Ren Tang Fu She Gu Rang Jiao Nang (for joint pain) – actually contains indomethacin, piroxicam, diclofenac, naproxen (yep, four NSAIDs), hydrochlorothiazide, cimetidine, metoclopramide and dipyrimadamole.
If you wanted to create supplements that not only had an irrational combination of ingredients, but also maximized the odds of potentially fatal adverse effect, you would have trouble topping the ingredients in these adulterated products.
The FDA maintains its own list, which has warnings that are equally frightening:
FDA continues to warn the public about Reumofan Plus—a product promoted as a dietary supplement for the treatment of arthritis, osteoporosis, bone cancer and other conditions. The product contains hidden prescription drug ingredients that can cause potentially fatal side effects. It could be labeled in Spanish and sold in some retail outlets, at flea markets and on the Internet.
Since June 2012, when FDA first warned the public about the dangers of Reumofan Plus and Reumofan Plus Premium, the agency has received reports of fatalities, stroke, dizziness, difficulty sleeping, high blood sugar levels, problems with liver and kidney functions, and severe bleeding in the esophagus, stomach and intestines, as well as corticosteroid (an anti-inflammatory drug) withdrawal syndrome.
Turns out after the recall, the manufacturer just relabeled it – it’s now called WOW, and still contains three undeclared prescription drugs: dexamethasone, diclofenac, and methocarbamol.
How frequently are supplements adulterated with real drugs? It’s a difficult question to answer given the lack of regulation of this market. The best signal may be regulator-initiated recalls. A systematic search was recently published by Ziv Harel and colleagues in JAMA Internal Medicine entitled The Frequency and Characteristics of Dietary Supplement Recalls in the United States, it’s a fairly simple review – a descriptive summary of all drug products listed as dietary supplements with class I (dangerous or defective product) recalls. While supplements are not drugs, once they’re identified to contain unapproved ingredients, they’re treated as unapproved drugs for the purpose of a recall. From the perspective of the supplement industry, the results should be concerning:
    • Between 2004 and 2012, 465 products were subject to a class I recall. 51% were supplements – the balance were drugs.
    • Most of the recalls occurred after 2008
    • Every supplement recall was because of unapproved ingredients
    • The majority of the recalled products were manufactured in the United States. Only 24% were imported.
    • Supplements marketed for sexual enhancement were the most commonly recalled product, followed by bodybuilding supplements, and then weight loss products.
Remarkably, the authors noted that the FDA does not have accurate manufacturer contact information on file for 20% of all supplement manufacturers. What’s further, the FDA has found Good Manufacturing Practice violations to be present in nearly half of the firms it has actually inspected. So in light of the lack of regulatory oversight, it’s reasonable to think this list captures only a fraction of the total number of mislabelled and adulterated supplements on the market today.
There are few signals that can guide consumers. Sexual enhancement, weight loss, and body building supplements seem more likely to be adulterated. Given the lack of good evidence to suggest supplements are useful for these purposes, extra caution is warranted. While no harms were noted in the recall notices posted by the FDA, harms from adulterated supplements have been reported. Pai You Guo was a Chinese-manufactured weight loss supplement adulterated with two banned drug products, sibutramine and phenolphthalein. Despite warnings from the FDA, sales continued. In a survey, almost all users (85%) reported side effects from use.
Conclusion: Let’s help consumers, not manufacturers
A lowered regulatory bar for supplements and natural health products has been a boon to manufacturers, but the same can’t be said for consumer protection. In the absence of regulation that puts safety ahead of manufacturer interests, we shouldn’t expect to see any meaningful improvements in product quality, and the list of adulterated supplements will continue to grow. This double-standard has made it harder, rather than easier, for consumers to use supplements safely. Until a single, rigorous standard is applied across all consumer health products, there will continue to be uncertainty about the safety and quality of supplements.
Reference
Harel Z., Harel S., Wald R., Mamdani M. & Bell C.M. (2013). The Frequency and Characteristics of Dietary Supplement Recalls in the United States. JAMA internal medicine, PMID: 23589151

   Economically-Motivated Herb Adulteration
David J Kroll 
Link
As early as 2006, I used to be able to write monthly about US FDA warnings on erectile dysfunction supplements being found adulterated with prescription drugs such as sildenafil, the phosphodiesterase-5 inhibitor found in Viagra. These adulteration episodes raised the question of how many anecdotal reports of herbal products “working” had to do with them containing approved medicines.
So common was this practice that FDA created a site in 2008 that was dedicated to this problem: Hidden Risks of Erectile Dysfunction “Treatments” Sold Online. Indeed, these products were more commonly encountered from online retailers and not in health food stores. Other similar practices include bodybuilding supplement being spiked with anabolic steroids and weight loss supplements being adulterated with sibutramine (formerly Meridia), an anorectant removed from the market last year after showing increased incidence of heart attacks and stroke in patients with preexisting cardiovascular disease.
The herbal industry, led by the American Herbal Products Association (AHPA), aimed to clean up this problem and launched an initiative called, KeepSupplementsClean.org. Spurred by an FDA letter to the industry on 15 December 2010 of increased scrutiny on the adulteration problem, AHPA actually encouraged FDA to root out manufacturers who adulterated their products or failed to qualify suppliers of their raw materials
AHPA has publicly expressed its support for FDA actions against marketers of products that masquerade as dietary supplements but contain illegal ingredients. AHPA encourages FDA to use its regulatory authority to hold accountable those who violate the law and jeopardize the public confidence, including all legal means to enforce the law.
The initiative seems to have been effective. This week, the independent testing organization ConsumerLab.com reported that testing of 11 “sexual enhancement” products revealed no adulteration with prescription drugs. On the other hand, the organization showed that, “[f]our products contained less of a key ingredient than claimed on the label, one product was contaminated with an unacceptable level of lead, and two products lacked FDA-required information on their labeling.”
Economically-Motivated Adulteration
This week also saw increased attention on another problem: herbal supplements containing less-expensive plant materials, some of which can cause liver damage. A US Department of Agriculture group has published an analytical method to detect adulteration of Scutellaria lateriflora L. (American skullcap) with two species of germander, a plant well known to contain compounds bioactivated by cytochrome P450 to reactive chemicals that damage the liver. The group of Vanderbilt University biochemist Larry Marnett showed in an elegant 2007 Chemical Research in Toxicology paper how the germander compound teucrin A is activated and identified key proteins in the liver that are chemically attacked by the reactive metabolite.
Skullcap supplements are normally taken to relieve anxiety and do indeed contain flavone compounds that bind to the benzodiazepine site on GABAA receptors like some prescription drugs. However, the herb hasn’t fared well in clinical trials for anti-anxiety activity.
Well, how’s this for increasing anxiety: In the current USDA study, 13 Scutellaria lateriflora products were tested using the new method and four were found to contain teucrin A, indicating that the products contained germander.
But this is apparently old news. In a NutraIngredients USA article that discussed the paper’s findings, American Botanical Council founder and Executive Director Mark Blumenthal called the finding, “disappointing, but by no means surprising,” noting that,
Many experts in the herb community have known about this misidentification for many years, he said. “ABC published an article by botanist Steven Foster about this problem in HerbalGram in the fall of 1985! Foster cited this problem as having been around for decades.
Indeed, one can find on the ABC website a nice monograph by Gayle Engles on the history of skullcap use and the cases of human hepatotoxicity from the 1980s.
The use of cheaper materials in drug and supplement products came to light with melamine used to artificially boost apparent protein content in pet food and infant formula products in China. In 2009, the Council for Responsible Nutrition released a statement on the problem of economically-motivated adulteration in the supplement industry. While the new Good Manufacturing Practice guidelines for the industry were intended to address this issue, the current USDA analytical paper tells us that more stringent enforcement of the rules is necessary.
Until then, be careful when taking herbs for anxiety. Because that’s exactly what you might get.

Adulteration of Herbal Supplements Continues
The supplement industry continues to be plagued by deliberate adulteration of products.
Steven Novella on January 31, 2024
Link

There is a lot of money to be made selling people products with claimed medical benefits. Prior to the FDA in the US was the age of patent medicine, when literally anyone could put whatever they wanted into a bottle and then market it as a cure for anything. This thriving snake-oil industry took a hit when the government decided to impose some standards, requiring evidence for safety and effectiveness, regulating what could be said to the public in marketing, and requiring physician supervision for the more complicated or serious drugs.
But by then the snake-oil grift was well established, highly profitable, and skilled at parting the public from their money. They weren’t going away quietly. This resulted in a constant battle to find ways around regulations, to weaken those regulations, and continue to make billions selling dubious medical products to the public.
Regular readers here will know that the snake oil peddlers have been largely successful. They have successfully lobbied state and federal government to loosen regulations and carve out exceptions. If nothing else, they have their political champions who do everything they can to make sure the regulatory agencies are underfunded and unable to adequately do their job.
Further, they have been very creative in trying to legitimize their snake oil. Perhaps their biggest victory was DSHEA – the Dietary Supplement Health and Education Act of 1994, which created a separate category for herbal supplements, allowing “structure function” claims (a deliberate back door to unregulated health claims). The industry exploded, and essentially became a major front for what is really a new patent medicine industry. That may sound harsh, but that is only because snake oil has been normalized through decades of lobbying and marketing.
I offer as evidence the well documented fact that the herbal supplement industry (just like the patent medicine industry before it) uses all the same tricks, including adulteration, substitution, and contamination.
There are several recent reports, including this one from Australia, indicating that adulteration, the deliberate inclusion of pharmaceutical drugs in products marketed as “supplements”, is still happening on a large scale. They found that many herbal product marketed for male erection, including Tantra Jelly, Bullblood tablets and Throb herbal supplements, contained regulated pharmaceuticals, including sildenafil, tadalafil or vardenafil (better known as Viagra and Cialis). This was more prevalent when purchased online from overseas companies.
This represents a serious health risk. These are essentially unregulated drugs, which have the potential for serious side effects and interactions. Also, many of the adulterants are not the pharmaceutical grade drugs, but analogues made in unregulated labs, sometimes they an analogue that have been pulled from the market for being unsafe.
The most common product found to be adulterated are for weight loss and erectile dysfunction, with one review finding 81% of the latter to contain at least one adulterated drug.
Far from improving, adulteration is described by researchers as a “growing trend”: that is getting harder to regulate. The FDA has found that between 2007 and 2019, 1068 unique herbal products were found to be deliberately adulterated with drugs. Online sales is exacerbating this trend as foreign companies are much harder to regulate. Often the FDA, for example, will just send out a public notice warning about an adulteration (you get all those notices, right?).
There is a reason that many herbal supplements cheat by including actual drugs – because there is precious little evidence that herbal supplements generally work for anything. Most are thinly studied, if at all, with low quality studies. Those with high quality research generally show they don’t work. (A thorough review is beyond the scope of this article, but see here, here, here, here and here.)
This is not surprising. Herbal products are not purified, contain dozens or hundred of ingredients, generally have low doses and even lower bioavailability, with highly variable properties. If there is anything in a particular herb that is pharmacologically active it would be near impossible to effectively regulate dosing, timing, and interactions, without knowledge of half-life, absorption, protein binding, route of elimination, and drug-drug interactions. If you did the research to purify active ingredients and know all those things, you would have a drug on your hands.
But why bother, when you can sell useless products with any claims you wish”? Or if you want to get a leg up on the competition, throw in some actual unregulated drugs, but pretend it’s the proprietary blend of herbs that are actually working.
Snake oil peddlers have literally been doing this since at least the 19th century. They are just experiencing a renaissance because they are currently beating attempts at consumer protection and regulation.

Searching for the supplement in your supplement
While the supplement market continues to grow, it’s becoming harder to identify products that are truly safe and effective. We need better regulation and product quality to ensure there’s a market where consumers can purchase supplements with confidence and use them safely.
Scott GavuraonFebruary 12, 2015
Link


Most of us are fortunate to live in countries where we don’t have to worry about counterfeit drugs. We can be confident that the prescription we receive, or the drugs we purchase from the pharmacy, are of high quality and contain exactly what’s on the label. But in these same countries, there’s another group of products where the risks of counterfeits are very real – it’s among the dietary supplements that are often found on the same shelves. Dietary supplements are not regulated in the same way as drug products. The American supplement industry is a multi-billion dollar free-for-all with little meaningful safety or quality regulation. Supplement quality and safety issues are in the media regularly as a result. The most recent example comes from the New York State attorney general’s office. It has accused four large retailers of selling supplements that failed to contain labelled ingredients. Testing the products with a technology called “DNA barcoding”, the AG’s office concluded that most of the products contained little to none of the labelled ingredient. And they also found ingredients that were not disclosed on the label. The AG’s office has demanded these products be removed from store shelves, and the stores stand accused of fraud.
It’s rare that I recommend dietary supplements. I have no particular bias against supplements, but I follow the evidence. A supplement worth taking is backed by good evidence, and is unlikely to cause harm. Most supplements fail this test – usually because they lack good evidence to show they work. But even where the evidence is promising (and the risks appear acceptable), there’s an additional consideration with dietary supplements – supplement quality is unclear. And there’s no easy way for a health professional or a consumer to independently verify that a product is of high quality. Regulatory structures leave a lot to be desired, resulting in a “buyer beware” marketplace for consumers.
Both users and critics of dietary supplements should all agree that these products need to be manufactured to high quality standards. We need regulation from a consumer protection perspective, if only to ensure we’re getting what we’re paying for. Weak regulation that doesn’t require manufacturers to demonstrate quality before products are sold, or fails to hold manufacturers to account when things go wrong, might be expected to result in products that satisfy a low standard. And that’s the reality with supplements today.
The term “supplement” describes a wide array of products. Many are herbs or other plant materials. As I’ve written before, a surprising number of drugs are based on natural ingredients. Acetylsalicylic acid (aspirin) is derived from salicin found in the bark of the willow tree. The antimalarial quinine is found in the bark of the Cinchona tree. The benefit of drugs over herbs is that their effects are more predictable and reliable: the active ingredient is identified, isolated, and then manufactured in a dosage form that can be absorbed by the body. The same can’t be said for products sold in their raw form, as herbs. Herbs are essentially unpurified drugs. One herb may have several different active chemical ingredients, several of which may have medicinal effects. The content in the plant sample may vary based on factors like growing conditions, harvesting conditions, and what portion is consumed. Some herbal products do “standardize” and verify one or more chemical constituents, where the active ingredient is measured, but this is rare. Without standardization, we have no idea if a herbal product contains some – or any – purported active ingredient. We may have the right species of plant, but we have no easy way to verify it contains the right amounts of the right active ingredients necessary to create some sort of effect.
So what did the New York attorney general find? In four of five cases, the herb wasn’t even found in the sample. The AG used the same DNA barcoding technology that I have described before. In this most recent study, the following were tested, with dismal results:
GNC (Herbal Plus brand):
    • Gingko biloba: None found, detected garlic, rice, spruce, asparagus
    • St. John’s wort: None found, detected garlic, rice, and dracaena (a houseplant)
    • Ginseng: None found, detected rice, dracaena, pine, wheat, grass and citrus
    • Echinacea: None found, detected rice
    • Saw palmetto: One sample had the product
    • Garlic: Contained garlic!
Target (Up and Up brand)
    • Gingko biloba: None found, detected rice, garlic and mung bean
    • St. John’s wort: None found, detected garlic, rice and dracaena
    • Garlic: Contained garlic! (one test detected no product)
    • Echinacea: Found in most samples
    • Saw palmetto: Found in most but not all samples
    • Valerian: None detected, found allium, bean, asparagus, pea family, rice, wild carrot and saw palmetto
Walgreens (Finest Nutrition brand)
    • Gingko biloba: None found, detected rice
    • St. John’s wort: None found, detected garlic, rice and dracaena
    • Ginseng: None found, detected garlic and rice
    • Garlic: None found, detected palm, dracaena, wheat and rice
    • Echinacea: None found, detected garlic, rice and daisy
    • Saw palmetto: contained saw palmetto!
Walmart (Spring Valley brand)
    • Gingko biloba: None found, detected rice, dracaena, mustard, wheat, radish
    • St. John’s wort: None found, detected garlic, rice and cassava
    • Ginseng: None found, detected rice, dracaena, pine, wheat/grass and citrus
    • Garlic: One sample had product
    • Echinacea: None found
    • Saw palmetto: Some samples contained small amounts. Also found garlic and rice
This sounds another slam dunk for prosecutors and represents the worst possible scenario: fraudulent marketing and shoddy manufacturing with ingredients missing, and other ingredients included, but not disclosed. It’s simply not possible to use supplements safely under these circumstances. But there’s been an interesting twist: One manufacturer and other critics are challenging the AG’s methodology, claiming that DNA barcoding is inappropriate and insufficient to detect ingredients. They stated that the DNA may not survive processing, but that doesn’t mean the original product isn’t there. They also claim that the “contaminants” may be acceptable fillers. But this doesn’t explain the fact that some tests found product, and others didn’t – even within the same brand. The AG, in response, is pointing to data suggesting that this methodology has been validated. Given the testing was done by a private organization and is unpublished, there’s insufficient information to say. However, even critics of the supplement industry that have looked at the AG’s analysis agree that DNA bardcoding, by itself, may be insufficient. Without more data, and the assessment of experts, it’s impossible to draw firm conclusions. The root cause here is that there is no evidence these products have any medicinal effects. Without proof they do anything medicinal, we can’t identify any specific active ingredient, nor can we test for it. DNA barcoding can’t do any of this – it can only identify if the raw (source) material is present. And that alone may be insufficient.
David Kroll, writing in Forbes today, describes another problem we often find with supplements: adulterants. He describes the case of INSANE bee pollen and EDGE Amplified Weight Loss, both of which have been spiked with the antidepressant drug fluoxetine (Prozac). Kroll points out the product label claims these supplements meet Good Manufacturing Practice (GMP) standards, a laughable claim given the findings. This finding in the supplement industry is not uncommon. The FDA posts all recalls and you’re regularly find products marketed as supplements that are recalled for containing undeclared drugs. This month (so far) the FDA has issued new warnings for Reumofan Plus and Maxiloss Weight Advanced. It’s important to note that DNA barcoding alone won’t detect drug adulterants, owing to the lack of DNA.
Conclusion
Without reliable, consistent supplements, consumers don’t get what they pay for, and health professionals can’t advise on their safe use. Given the limited evidence of efficacy for supplements, and the repeated concerns about product quality, I continue to advise that consumers approach supplements with great caution. The potential benefits need to be pretty compelling to justify their use. There’s a lack of good evidence to suggest most supplements offer any meaningful health benefits. While the supplement market continues to grow, it’s becoming harder to identify products that are truly safe and effective. We need better regulation and product quality standards to ensure the consumers that purchase supplements can do so with confidence, and use them safely.


Audit reveals supplement regulation and oversight is lacking
A Canadian audit of dietary supplements shows serious problems with the quality and safety of the products you may be buying.
Scott Gavura on May 13, 2021
Link


Health regulations are generally established to protect patients and consumers. When it comes to dietary supplements, they have long favored the supplement industry at the expense of the consumer. When written and enforced appropriately, regulation can give consumers access to safe products that are labelled correctly and give reassurance that what is on the label is actually in the bottle. That is exactly what we have in countries with rigorous regulation of the pharmaceutical drug industry. But the natural products industry has consistently fought oversight in the United States, Canada, and other countries, in order to reduce the regulatory requirements and the burden to ensure their products are safe, effective, and manufactured to a high quality standard. While this undoubtedly is useful to manufacturers, the benefits to consumers have been less clear. Yes, there are a lot of products available to buy. But can you trust them? Most countries have chosen to take a “light touch” with these products, exempting them from most of the requirements placed on over-the-counter or prescription drugs. Now a new audit, from Canada, gives a sort of report card to consumers on the health consequences of a “hands off” regulatory approach.
American vs. Canadian regulations: Two approaches
In the United States, the Dietary Supplement Health and Education Act of 1994 (DSHEA) established the regulatory framework for dietary supplements. It effectively excludes manufacturers of these products from virtually all regulations that are in place for prescription and over-the-counter drugs. The FDA can only intervene to pull products off the market if they are adulterated or misbranded. It notes:
Manufacturers and distributors of dietary supplements and dietary ingredients are prohibited from marketing products that are adulterated or misbranded. That means that these firms are responsible for evaluating the safety and labeling of their products before marketing to ensure that they meet all the requirements of DSHEA and FDA regulations.
DSHEA draws a crude distinction between food and drugs meaning that many product can be considered “supplements” when they are more appropriately categorized as drugs. In addition, manufacturers can put virtually any claim on a supplement, without any requirement to provide evidence it works, as long as it’s accompanied by what’s called the Quack Miranda Warning: “These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease“. The regulation of marketing claims is effectively left to the Federal Trade Commission (FTC), which can prosecute manufacturers for fraud. There is also a lack of rigorous oversight of manufacturing practices, nor is there industry standardization of ingredients, or even purity guarantees. It is truly a manufacturer’s market.
Canada took a slightly different approach when regulating supplements. Like the American approach, the Natural Health Product Regulations were a compromise – not requiring pharmaceutical-level oversight and regulation, but establishing basic expectations and standards. Canada defines a “natural health product” as one of:
    • vitamins, minerals, and probiotics
    • herbal remedies
    • homeopathic remedies
    • traditional medicines e.g., (Chinese and Ayurvedic)
    • amino acids and essential fatty acids
In contrast with the United States, natural health products must be licensed by Health Canada in order to be sold. To obtain a license, manufacturers must submit evidence of efficacy. While this sounds reasonable, the evidence standards are laughable. The TV show CBC Marketplace decided to test Health Canada’s standards several years ago. They applied for approval to market a homeopathic remedy they named “Nighton” (an anagram of “nothing”) to be used to treat fever and pain in infants and children. For evidence, they submitted a few pages photocopied from an old homeopathy textbook. No trials were conducted and no safety data was provided. Without any questions, their product was approved and licensed as a “natural health product”, and for a time, was listed in the national database of health products Health Canada declared were “safe, effective, and of high quality.” This isn’t exceptional. You will find hundreds homeopathic remedies on store shelves in Canada that have been approved for sale by Health Canada. Since 2004, 91,000 licenses have been granted for natural health products. Frustratingly, these products are sold alongside over-the-counter drugs, which are regulated to much stricter standards. Only a close inspection of the label can tell an informed consumer if a product was approved under this licensing framework.
The other major component of the Canadian regulations is site certification. Health Canada not only approves products, it approves the sites that manufacture them. Manufacturers must provide information demonstrating that it meets Good Manufacturing Practices (GMP). GMP are manufacturing standards to ensure accuracy, precision, and safety of products. GMP includes processes and people that are fully trained and qualified. Unlike drug manufacturers, Health Canada does not pre-inspect facilities that manufacture natural health products – it relies on attestations and documentation.
On paper, these requirement look to be modestly more rigorous than the American approach. But do they work? The Office of the Auditor General of Canada recently completed an audit of Health Canada’s approach to natural health products to determine if these products are safe and accurately represented to Canadians. The results give some clues to the consequences of light regulation, which may hint at what is occurring in other countries.
Safe? Effective? Health Canada can’t say
The Office of the Auditor General of Canada is independent of Health Canada (and the federal government) and is responsible for providing information and advice to the Canadian Parliament. This audit was intended to determine if natural health products available to Canadians are safe and properly labelled. To do so, they examined the licensing process for both products and manufacturing sites, verifying if Health Canada obtained sufficient information before a product was sold. It also examined if Health Canada took action after a product was licensed to manage any health risks related to these products.
Safety and efficacy assurances lacking
Health Canada requires supplement manufacturers provide a written attestation that they follow good manufacturing practices. They do not inspect facilities before products enter the market. Here is what the auditors found:
    • The auditors pulled a sample of 25 site licenses. In 13/25 licenses, Health Canada relied on inspections from other countries. In 10/13, there was no assurance these inspections included natural health product manufacturing processes.
    • For the remaining 12 sites, Health Canada failed to verify one or more components that would demonstrate GMP.
    • The audit noted that good manufacturing practices cannot be verified until after production has started. However, when products are manufactured and sold is not disclosed to Health Canada, so it could not verify that health products sold were manufactured in sites that met GMP requirements.
Health Canada failed to respond to serious product issues after they entered the market
The auditors found that Health Canada would react to complaints about labeling and advertising, but did little to actively prevent misleading or inaccurate information from being given to consumers by manufacturers. Even when it took action, it was not always successful in addressing the issue.
88% of products were advertised with misleading information
Here I think I’ll just quote from the report:
We found that Health Canada did not sufficiently monitor whether product label information and advertisements met the product-licence conditions. We found that the department monitored product labels and advertisements in response to complaints instead of monitoring the market using a risk-based approach. To gain an understanding of the market, we examined a sample of 75 licensed products for sale on Canadian websites. We found that 88% of these products were advertised with misleading product information. Also, 56% of the products we examined were marketed with misleading label information—label information that included one or more of the following problems:
    • health claims not authorized by Health Canada because they might not have been proven, such as claims to relieve fatigue, enhance endurance, or burn fat
    • an erroneous statement that the product was recommended for children of ages 3 and older when it was authorized only for adolescents and adults
    • an incomplete list of risks and authorized ingredients
    • the wrong dosage of medicinal ingredients
    • product label information, such as safety warnings, printed very small (that is, in a 4-point font); on paper, font sizes under 8 points are difficult to read without magnification; according to Health Canada, poor readability of the printed label information contributes to incorrect product use
Limited monitoring of products and manufacturers
Regulators in Australia and Europe inspect all supplement/natural health product manufacturers on an established cycle (e.g., once every four years). Health Canada has no program for routine on-site inspections. Because of the sheer number of products approved (91,000 since 2004) it has been unable to monitor licensed products and their manufacturers. Many products have been approved by Health Canada but never sold (like the CBC’s product described above). This may be due in part to the fact that Health Canada does not charge licensing fees for these products, unlike any other health product it regulates. Consumers are bearing the entire cost of this ineffective regulatory framework, and manufacturers pay nothing.
Incredibly, Health Canada doesn’t know where approved products are actually manufactured: Fewer than 5% of licence holders actually disclosed this information to the regulator.
Health Canada started to inspect manufacturers in 2016. The audit found:
    • Health Canada inspected 6% of active licensed companies between 2017 and 2019. Sites were chosen because of high-risk products (e.g., sterile products) or because they had a poor compliance history.
    • In almost half of the sites it inspected, it took regulatory action because of significant health issues. Seven site licenses were cancelled, and five product licenses were cancelled.
    • In some cases, site licenses were eventually renewed, but without verifying companies met other GMP requirements.
    • In the case of license renewals, 22 of a sample of 25 were renewed without verifying sites were following GMP requirements.
Additional activities revealed poor patterns of compliance. This statement, buried in the audit report, was remarkable:
Health Canada conducted other activities to gather compliance information, which also exposed quality problems with certain manufacturers. For example, in 2019, the department reviewed 35 companies’ testing results for 2 products that each company had recently released for sale. The department found problems at all sites, including the use of expired raw materials, unacceptable amounts of contaminants, and product tests that did not confirm the product expiry date. For half of the 35 companies, Health Canada took regulatory action, such as issuing a notice of intent to suspend the site licence, because the problems were serious.
Limited monitoring of unlicensed products
Health Canada is expected to monitor regulators like the FDA to identify high-risk products that may be available in Canada. The auditors found no program to actively monitor this. Despite the ease of accessing products online, Health Canada did little monitoring of non-compliant products. Importantly, the auditors found dozens of products advertised to treat or prevent cancer, a claim which is forbidden for these products.
Regulation that favor manufacturers also hurt consumers
One of the most pervasive yet appealing health myths is the idea that “natural” equals “safe”. It’s a statement that has repeated constantly by manufacturers of supplements and “natural” health products. And this argument has been used successfully, in Canada and elsewhere, to give these products completely different regulatory structures than exist for drug products. Weaker regulation of supplements and natural health products has been a boon to manufacturers, but the same can’t be said for consumer protection. This Canadian audit reveals a sad consequence of weak regulation. Canadians can’t trust that what is on the label is actually in the bottle, and Health Canada isn’t ensuring that these products is safe and effective. Health Canada agrees with the audit findings. Time will tell if things change for the better. Until then, this is buyer-beware marketplace, and consumers are quite literally paying for it.

Who takes dietary supplements, and why?
Scott Gavura on February 14, 2013
Link
If you’re a regular reader of this blog, I’ll bet you’re not a regular consumer of vitamins or supplements. I’m in that group. Aside from sporadic vitamin D in winter, I don’t take any vitamins or supplements routinely, nor do I give any to my children. Your reasons may be close to mine: There is little to no evidence suggesting that dietary deficiencies are widespread, nor is there good evidence to suggest that vitamin supplements are beneficial in the absence of deficiency. I don’t have any need for an other supplements, nor am I confident in the scientific evidence for many of them.This position of “no supplements” is a cautious and conservative one, but is based on a consideration of the scientific evidence. I view decisions about healthcare as evaluations of risk and benefit, and then cost if necessary. Given supplementation (with some exceptions) has no demonstrable benefits and, in some cases, a little risk, the odds favour not supplementing in most cases. Add in costs, and it’s even less attractive as a routine health strategy.
Yet a decision not to take vitamins or supplements regularly is becoming a minority position. Supplement use has grown over the past 40 years among Americans, with the National Health and Nutrition Examination Survey (NHANES) showing steadily increasing utilization among younger and older adults:

Supplement makers promote an image of being small, ethical, and natural — the exact opposite of evil Big Pharma. Yet the numbers show this is big business: a $30 billion (USD, 2011) industry which (as has been noted regularly at this blog) has limited regulatory oversight. The result is a marketplace with products listing exaggerated claims that aren’t supported by credible evidence. Yet industry surveys suggest 85% of Americans are confident in the safety, quality, and effectiveness of these products.
Given the (lack of) good evidence showing benefit, why are consumers so fond of these products that they willingly shed out $30 billion per year for supplements? It’s a question I regularly ask myself when consulting with patients who enquire about supplements as a complement to, or as a substitute for, more conventional treatments. It’s a testament to the marketing of these products that they are (from my own observations) perceived as being safe and effective, in contrast to drug products. The reason that I’m not promoting them, I’m sometimes told, is because I’m not trained in “botanicals” or “herbals,” unlike the friendly neighbourhood naturopath, who routinely recommends a long list of supplements, in contrast with my typical advice to see a medical doctor, or to make basic lifestyle and dietary changes first.
As a pharmacist I have a simple goal with my patients: improve health by improving medication use. I don’t distinguish between drugs, vitamins, and supplements. If they’re being taken for a therapeutic use, they’re fair game. I do this in part by interpreting the scientific evidence to support patient self-care decisions. So as an advocate for science-based medicine, I admit to finding the surging popularity of supplement use a bit frustrating. I’ve seen people spend $100 or more per month on a variety of supplements, most of which are either unproven, or proven ineffective. At the same time, they may reject or defer strategies backed by better evidence. Now $30 billion could likely be used much more effectively for health care if redirected towards the strategies that offer more health “bang for the buck”. So if the goal is to change behaviors, the motivations need to be understood. And I can’t rely on my own biased sample — I need a more systematic analysis.
Happily, consumer patterns and motivations have been studied. Published earlier this month in what used to be called the Archives of Internal Medicine (now called JAMA Internal Medicine) was Why US Adults Use Dietary Supplements by Reagan L. Bailey and colleagues from the Office of Dietary Supplements at the National Institutes of Health. It also relies on the NHANES dataset, a representative survey of US civilians which began collecting specific information on reasons for supplement use in 2007. Data are collected through interviews, and a Dietary Supplement Questionnaire was used to gather detailed information on each participant’s use of vitamins and other supplements. This survey reports the results from 11,956 adults (children, young adults (< 20 years), and all pregnant and lactating women were excluded from analysis). Here’s the snapshot of the participants:
    • 49% of adults used a supplement of some kind in the prior 30 days: 54% of women, 43% of men.
    • Supplement use increased with age: 34% aged 20-39, 50% age 40-59, and 67% over age 60
    • Non-Hispanic whites use more supplements (54%) than Non-Hispanic blacks (38%) or Hispanics (33%)
    • Supplement use is greater in “never” (51%) or “former” (59%) smokers compared to current smokers (30-36%)
    • Supplement use is much more common in those with health insurance (53%) than those without (31%)
    • Supplement use parallels reported exercise, from “low” (43%) to “moderate” (54%) to “high” (56%).
    • Supplement use was higher among those that reported “excellent” or “very good” health (55%) versus “good” (47%) or fair/poor (44%)
So far this is as expected: supplement users tend to be wealthier and healthier than non-users. It’s the “healthy user” effect which shows up throughout epidemiological studies, confounding evaluations of outcomes. That is, we shouldn’t assume supplement use make you healthier, any more than assuming that supplement use makes you wealthier.
Here are the most common reasons for taking supplements:
The most common motivations for taking supplements were to “improve” (45%) or to “maintain” (33%) health, consistently reported between men and women. Bone health is next, with a large gender split between men (11%) and women (36%). Most of the other reasons given are equally common, with significant differences in only a few categories: Men reported more interest in supplements for heart health (18% vs. 13%) while women reported more supplementation for sleep, skin, and hair health, as well as anemia. The frustrating (and fallacious) “to boost immunity” came in at 15%, revealing just how widespread the perception is that our immunity can be “boosted” and that it can be accomplished with supplements. Motivation for site-specific use (vision, heart, bones) increased with age of the user.
The “enhanced energy” rationale for supplements was cited only 11% of the time — less common than I expected.
Knowing the motivations, let’s take a look at the types of supplements comsumed, reported in Table 3. It’s a distribution with a long tail: multivitamins/minerals are tops, with an overall prevalence of 32%. Calcium is next, at 12%, followed by omega-3 supplements/fish oils (10%), then “botanicals” (a category of herbals, probiotics, melatonin, and coenzyme q10) and the individual supplements and other categories.
The authors note that 23% of the supplements reported as being used were recommended by a health professional (not defined), whose top recommendations matched the top supplements reported overall. This suggests that over 75% of supplement decisions are being made without (or despite) the recommendation of a health professional.
Other studies
A related survey, also recently published in JAMA Internal Medicine, Users’ Views of Dietary Supplements, gives additional insight to the NHANES survey on motivations for use of supplements. Blendon and colleagues at the Harvard School of Public Health conducted a telephone survey of 1579 people aged 18 or older. This survey asked specifically about dietary supplements but not vitamins or mineral, and identified 584 supplement users. 38% reported taking any supplement in the past two years, and 13% reported taking a supplement regularly — which appears in the ballpark of the NHANES study, if you pull out vitamins. Fish oil/omega-3 oils were the most common consumed (again, consistent with NHANES) with 24% consuming the product in the past two years. Reasons reported for taking supplements included:
    • “to feel better” (41%)
    • “to improve your overall energy levels” (41%)
    • “to boost your immune system” (36%)
    • “digestive issues” (28%)
    • “lower cholesterol” (21%)
Over 80% reported it was important to have access to supplements. Interestingly, users were asked how government-sponsored efficacy studies would influence their decision to take a supplement. Amazingly, only 25% of users said they would stop using a supplement if it was evaluated to be ineffective. Also interesting: 36% of supplement users had not told their physician about their supplement use, while 31% reported a physician or nurse had recommended their supplement use.
A third study reveals largely consistent information on popularity. From the Military Nutrition Division of the US Army, it’s entitled, Confidence in the efficacy and safety of dietary supplements among United States active duty army personnel, and was published in BMC Complementary and Alternative Medicine in 2012. This was a survey of 990 soldiers in 2006-07 at 11 military bases that focused on motivations, not specific products taken. A dietician or other health professional administered the questionnaire directly and asked for usage of supplements as defined by DSHEA. The sample group was mainly male (87%), white (70%), and young (41% were aged 18-24). Just over half (53%) reported using supplements at least once per week during the prior 6 weeks. Usage was observed to be highest among those older in age, better educated, and holding higher ranks, and reporting good/excellent health.
Here’s the evaluation of efficacy:

Two-thirds (67%) of all participants were somewhat confident or extremely/very confident in the efficacy of supplements, which increased to 86% among users. The majority of non-users (62% were not at all confident in supplement efficacy. Those who reported excellent fitness or dietary habits were much more likely to be very/extremely confident in supplement efficacy.
Here’s the evaluation of safety:

The patterns are largely similar. 71% of all respondents were somewhat or extremely/very confident in supplement safety, increasing to 88% among users. Again, the majority of non-users (55%) lacked confidence in the safety of supplements. The same patterns with self-reported excellent fitness/dietary habits and confidence in safety were also observed.
When asked about regulation, few understood the current regulatory structure, with nearly half indicating they didn’t know if there were requirements the supplements work as advertised. Belief that supplements must be safe for consumption was more common among users (38%) than non-users (25%).
On balance, the survey reveals that soldiers that use supplements are confident in their efficacy and safety, and that this confidence is highest among those that believe current regulations require supplements to be both safe and effective.
What does it mean?
Survey on supplement consumption report widespread use, which seems to be based on perceptions that these products are both safe and effective. While supplement use of all kinds is common, it’s multivitamin/minerals that really push the overall consumption rates up. Take that away, and regular usage of other kinds of supplements drops down to just over 10% of the population. When looked at over longer time frames, however, the Harvard survey suggests that 40% do take some form of non-vitamin supplement at least intermittently.
The reasons for taking supplements varies. In the case of multivitamins, it seems to be based around the belief that their consumption will offer meaningful benefits. Yet on balance, there is little evidence to support general supplementation, and in the absence of a deficiency, no evidence multivitamins will boost mood or energy levels. For the most common reasons cited for supplements, expectations are generalized and fairly non-specific. Many may be taking multivitamins as an insurance policy — not a strategy that I’d routinely endorse, given the evidence, but one that is not uncommon. And certainly there is some vitamin and supplement use that is appropriate and evidence-based.
Most of the decision-making around vitamin and supplement use appears to occur without the input of a health professional, raising questions about the rationale for use. And perhaps not surprisingly, few subsequently tell their health professionals about their supplement use. Medical evidence may not be a factor in decisions to take these products. Instead they may be based on perceptions or attitudes that they’re beneficial, perhaps because of confidence in regulations that allow their sale, or the resulting marketing that exaggerates expected benefits. What’s most surprising is that the scientific evidence may not matter at all. It’s said that you can’t reason people out of a decision they didn’t reason themselves into. Perhaps that’s the case with supplements. Certainly it illustrates the need for a more thoughtful (and yes, science-based) approach to promoting health behavior change in individuals. For health professionals interested in improving the safe and appropriate use of vitamins and supplements, and reducing unnecessary or inappropriate use, we need better strategies to promote change.
References
Bailey R.L. Why US Adults Use Dietary Supplements, JAMA Internal Medicine, 1. DOI: 10.1001/jamainternmed.2013.2299
Blendon R.J. (2013). Users’ Views of Dietary Supplements, JAMA Internal Medicine, 173 (1) 74. DOI: 10.1001/2013.jamainternmed.311
Carvey C.E., Farina E.K. & Lieberman H.R. (2012). Confidence in the efficacy and safety of dietary supplements among United States active duty army personnel, BMC Complementary and Alternative Medicine, 12 (1) 182. DOI: 10.1186/1472-6882-12-182

Questions about DNA Barcoding
The author of a 2013 paper on supplement quality is now facing serious allegations of scientific misconduct.
Scott Gavura on June 23, 2022
Link

The herbal supplement market is lightly regulated in many countries. A consequence is often quality assurance: With no mandatory testing for quality and consistency, consumers and health professionals alike are largely at the mercy of a manufacturer’s claims. Unlike prescription pharmaceuticals and over-the-counter drugs, which are more tightly regulated, there could be (depending on the country) no requirement for supplement manufacturers to make products that are uniform, standardized, and of consistent quality. While third-party testing can provide consumers with some degree of assurance, it is limited and not routine. Strengthening the quality and safety standards for supplements should be a win for consumers and arguably beneficial for the industry itself.
Earlier this week I was listening to a podcast about a Canadian scientist who had published papers that utilized a technology called “DNA barcoding” and whose work was now being called into question. The research sounded familiar. I checked the SBM archives and sure enough, I blogged about DNA barcoding and the work of this scientist way back in 2013. Give the current investigations I thought it would be worthwhile to summarize the current controversy.
A “DNA barcode” is short DNA sequence that can uniquely identify a specific species of any living thing. About 700 nucleotides in length, the “barcode” is a portion of DNA that varies significantly between different species. Beyond the obvious biology benefits of helping to identify new species, DNA barcodes have commercial applications, such as being used to detect fraud in foods (e.g., sushi) and other products. What DNA barcoding cannot do is quantify the content (in terms of milligrams of active ingredient) or confirm the presence (or absence) of any active ingredients.
I will draw heavily on the writing from the journal Science, who have written several articles on this controversy:
In 2013, a team led by Steven Newmaster, a botanist at the University of Guelph (UG), took a hard look at popular herbal products such as echinacea, ginkgo biloba, and St. John’s wort. The team published a study that used DNA barcoding—a system to identify species using small, unique snippets of genetic material—to test whether the bottles really contained what was printed on the label.
The results were troubling. Most of the tested products contained different plants, were larded with inert fillers, or were tainted with contaminants that could cause liver and colon damage, skin tumors, and other serious health problems. The paper, published in BMC Medicine, received prominent attention from The New York Times, CBC, and many other media outlets. The findings “pissed me off,” Newmaster told PBS’s Frontline. “I go in to buy a product that I believe in, that I care about and I pay a lot of money for, and it’s not even in the bottle? Are you kidding me?”
His work inspired then–New York Attorney General Eric Schneiderman to sponsor a similar study conducted by James Schulte, then at Clarkson University, who confirmed that consumers were often misled. At Schneiderman’s request, major retailers such as GNC, Walgreens, and Walmart pledged to pull suspect products from the shelves or take other measures.
In that 2013 paper, the authors describe authenticity testing of 44 herbal products. They found that only 48% of the tested products were authentic, with 59% of the products containing species not listed on the label, and one-third contained a substitute product with none of the labelled ingredient. These results were surprising, but not inconsistent with concerns about the quality of dietary supplements that had been identified (and blogged about) before. Importantly, other DNA barcoding analyses (by other, unaffiliated authors) had found similar concerns with herbal tea ingredients, or with the actual components of black cohosh supplements.
Science continues:
Almost overnight, Newmaster became an authority on the verification of food and supplement ingredients. He quickly went from industry adversary to ally, as major supplementmakers hired companies he created to certify their products as authentic. In 2017, Newmaster also founded the Natural Health Products Research Alliance (NHPRA), a venture within UG that aims to improve certification technologies for supplements. It raised millions of dollars from herbal suppliers, boosting UG’s finances and prestige.
But in an ironic twist, eight experts in DNA barcoding and related fields now charge that the 2013 paper that indicted an entire industry and launched a new phase in Newmaster’s career is itself a fraud. In a 43-page allegation letter, sent to UG in June 2021 and obtained by Science, the researchers—from UG, the University of Toronto, the University of British Columbia, and Stanford University—cited major problems in the study and two others by Newmaster and collaborators. “The data which underpin [the papers] are missing, fraudulent, or plagiarized,” the letter flatly stated. The group also charged that Newmaster “recurrently failed to disclose competing financial interests” in his papers.
There was subsequently considerable criticism of the 2013 paper.
In the 2013 supplement paper, Newmaster, Ragupathy, and collaborators describe how they derived DNA barcodes for 44 popular herbal products and compared them with barcodes from validated sources. The explosive results—most of the products had DNA from herbs not on the label, and many contained plants with “known toxicity”—alarmed experts. “This suggests that the problems are widespread and that quality control for many companies, whether through ignorance, incompetence or dishonesty, is unacceptable,” nutritionist David Schardt, then with the Center for Science in the Public Interest, told The New York Times.
The paper drew criticism as well. A stinging 2013 analysis in HerbalEGram—a journal of the American Botanical Council, a nonprofit research group—claimed many egregious errors and called for a retraction. The analysis accused Newmaster of not understanding that supplements use benign inactive substances such as rice powder as “carriers,” and that DNA can be destroyed during processing without altering a supplement’s effects.
When I blogged about the paper in 2013, I noted the authors stated that they had no conflicts of interest. However, there was activity, that if not a conflict of interest, is certainly surprising:
Although the paper claimed “no competing interests,” Newmaster and UG geneticist Robert Hanner in 2012 had created Biological ID Technologies Inc., which conducted DNA barcoding for foods and herbal products and offered purity certifications for product labels. On 11 July 2013, about 1 week after the paper was submitted, Newmaster and Hanner incorporated a second company, named Tru-ID, which apparently assumed the business initiated by Biological ID Technologies. (Tru-ID folded in 2020, under “financial hardship during the pandemic,” Newmaster said in his response to the misconduct complaint. Hanner would not provide any comment for this article.)
When the New York attorney general’s probe triggered by Newmaster’s paper pressured companies to validate their ingredients, Tru-ID was ready to help, says Stefan Gafner, chief science officer at the American Botanical Council and co-author of the HerbalEGram critique. At least three major supplementmakers [sic], Nature’s Way, Herbalife Nutrition, and Jamieson, hired Tru-ID and adopted its certifications.
The Science paper goes on to document some astonishing activity from Newmaster, including plagiarism, presenting research from other authors as his own, and unbelievably, presenting “magnetic resonance profiles” for three cannabis strains using a graphic that identical to one showing arrest data for 50 U.S. states. He is also on record of describing working on COVID-19 tests in the summer and fall of 2019 (i.e., pre-pandemic) at the behest of the CDC. Science notes, “A CDC spokesperson could not locate information about working with Newmaster”.
Newmaster has denied all charges of misconduct, Science reports. It should also be noted that a University of Guelph investigation committee has recently reviewed complaints against Newmaster and concluded that he did not engage in scientific misconduct:
Newmaster “displayed a pattern of poor judgement and failed to apply the standards reasonably expected in research activity in his discipline,” panel chairman John Walsh wrote today in a letter to the eight scientists who lodged a complaint against Newmaster last year. Yet despite “many shortcomings” in his work, the panel said there was “insufficient evidence” to find Newmaster guilty of misconduct in three studies that his accusers had singled out.
The university has yet to reach a final conclusion. In the meantime, there are cautions on the 2013 herbal supplement paper, another paper has been retracted, and another is now appended with an “expression of concern“.
What does this say about supplement quality?
Without reliable, consistent products, consumers can’t use commercially packaged herbal remedies safely. Health professionals are in a similar bind, where product quality concerns may limit their confidence in making treatment recommendations. When regulators do not enforce quality assurance processes or standardized products, testing and quality assurance is often left in the hands of third parties. In the case of DNA barcoding, serious questions have been raised about work coming from the lab of one researcher. Allegations were made about product quality, that manufacturers struggled to respond to. In a world where supplements were subject to routine quality assurance and were standardized, the findings should have been easily refuted. Despite the allegations made against a particular researcher, there may yet be utility in DNA barcoding in the quality assurance of supplement manufacturing. But the larger issues of quality assurance and product quality remain.

Adverse Effects from Dietary Supplements: A survey of the US Military
Over 26,000 US Service members completed a survey on the adverse effects associated with dietary supplements. Some categories of supplements are associated with substantial adverse events.
Scott Gavura on September 15, 2022
Link

It is a triumph of marketing over evidence that so many people believe dietary supplements are natural, safe, and effective. Supplements actually cause a significant amount of harm, and are associated with at least 23,000 emergency department visits and 2,000 hospitalizations per year. Supplements are consumed by 50% of Americans and incredibly, 70% of United States military service members. As they are widely sold and are subject to weak regulation, the routine collection of evidence and reports of the harms of supplements is hard to come by. The FDA relies on passive reporting, including collecting adverse event reports and consumer complaints, inspecting manufacturing facilities, and monitoring imported ingredients. In exceptional circumstances, the FDA can take supplements off the market by issuing a recall. In a new survey, over 26,000 US service members provide reports on adverse effects of dietary supplements. The report highlights which supplements are associated with the most adverse effects.
Evidence of harms
Dietary supplements encompass an array of products that include vitamins, minerals, herbal remedies, and other products. As I’ve discussed over the past several years here at the blog (and also discussed by others), there is little assurance provided by regulators that consumers can trust that what’s on the label of a dietary supplement is actually in the bottle. Quality standards are not enforced in the same way as for prescription or over-the-counter drugs, and consequently there are greater risk of contamination or dose variation owing to a weak regulatory framework that doesn’t mandate review before a product can be sold. Even if the label is 100% accurate, and the dose itself is standardized, there is also nothing intrinsic to a dietary supplement or natural product that it cannot cause harm in some way. If a substance can have beneficial effects, then it can have negative effects. You may recall that the amphetamine-line 1,3–dimethylamylamine (DMAA) was a popular dietary supplement that had the rare but unfortunate side effect of death. It was eventually forced from the market by the FDA.
This paper discusses the US Military Dietary Supplement Use Study which was a random sample of military service members who completed a survey on supplement use and adverse effects experienced. Recruitment began in 2018 and surveys continued through August 2019. The questionnaire listed 96 generic dietary supplements (e.g., multivitamins, individual vitamins, proteins/amino acids, herbals products) as well as 67 named products. The branded products were identified by looking at dietary supplements sales directly to service members (via the military’s Exchange service) and also by surveying General Nutrition Centre stores on or near military installations. There were also open text fields where supplements not otherwise listed could be added.
The survey asked service members if they had used a particular dietary supplement in the past six months and if they believed they had experienced a particular “side effect” from using that supplement. A list of side effects were presented (e.g., palpitations, abdominal pain, nausea/vomiting, etc.) as well an “other” category with the opportunity to describe the effect.
The 96+ dietary supplements were grouped into the following categories:

For each dietary supplement and for each category, the total number of users and the number of users reporting at least one adverse event where counted. The proportion of users reporting adverse events were then calculated, along with the standard error. For dietary supplements associated with at least 25% of user reporting adverse events, each individual event was also compiled with frequency and standard error.
Results
Of the 200,000 service members identified, 73% were contacted successfully, and 126,681 (18.2%) signed the consent and completed the survey. Here are the proportion of service members reports that included at least one adverse event.
The combination product category (which included body building, fat/weight loss and pre/post workout products) had the highest adverse event prevalence. Joint health products had the least. Additional tables show the adverse event for individual ingredients and products. Vitamins were generally well tolerated, either as multivitamins or individual ingredient products. Some branded multivitamins were associated with greater reports of adverse events. Not surprisingly, niacin, which can cause face flushing, was the poorest-tolerated individual vitamin.
Products marketed for weight and fat loss were associated with considerable side effects:
The same can be said for pre/post workout supplements (below) as well as products sold as “prohormones”:
Turning to herbals and remedies for “joint health”, side effects were reported for most products, at varying degrees of frequency:
Finally, here is the prevalence of specific adverse effects reported for specific products. The reported rates of heart palpitations are quite high with some of these products.
Conclusion: More evidence against supplement safety
In this large sample of US service members, the overall proportion of reported adverse effects was generally low, with notable exceptions in some categories and with some products. Over 10% of users reported adverse effects for 89% of weight loss products, 83% of pre/post workout products, and 53% of “prohormone” products. Adverse effects were most commonly reported with combination (“muscle building”) products and related products also had high adverse effect report rates. This could be due to the ingredients in these products or possibly a consequence of multi-ingredient supplements causing additive side effects.
There were several limitations to this trial. This was self-reported data, based on recall. It could have potentially biased toward those that do associate adverse effects with supplements, as those not identifying any effects may not have been as willing to do the survey. The survey did not measure dosages, so we do not know if the products were being used “as labelled” or some other way. Because not every dietary supplement could be listed, it is possible the products were missed. It was also not possible to identify users taking multiple dietary supplements at one time, and determine how adverse effects were associated with a particular product. This survey did not look at the medical consequences of the reported adverse effects.
This survey provides new information to show that specific categories of dietary supplements (weight loss, pre/post workout, and body building products and prohormones) are more likely than other supplements to be associated with adverse effects. Consumers that want to reduce their risk of adverse effects from dietary supplements may want to avoid these categories of products.

Liver Failure From Alternative Medicines
Steven Novella on March 18, 2026
Link

One of the persistent themes we confront at SBM is the evolving double-standard in clinical medicine. On the one hand, in mainstream medicine there is a push for higher standards of science and evidence and more effective regulation. At the same time proponents of “alternative medicine” are constantly seeking ways to water down scientific standards and loosen regulations. This is sold to the public as “health care freedom“, with alternative products and services shrouded in the appeal to nature fallacy.
It is therefore useful to do what we can to inform and remind the public that alternative treatments do not exist in a separate magical world where the laws of nature are suspended, rules of scholarship and quality science do not matter, and being “natural” is enough to guarantee safety and effectiveness. Snake oil peddlers do not have your best interest in mind, only your wallet. And these fanciful treatments are not always harmless (as David pointed out earlier this week).
I myself have pointed out numerous times that herbs are drugs. They are not supplements, and are not taken for their (negligible) nutritional value. They are drugs, taken for their pharmaceutical effects. They are poorly regulated, often contaminated, adulterated, and substituted drugs, with variable dosing, and poorly understood interactions and toxicity. And yet, in the US (under DSHEA) they are essentially regulated like food, or cleared under the principle of GRAS (generally regarded as safe). The public is lead to believe they are safe because they are “natural”, even though the deadliest substances known to science occur in nature.
A recent study highlights once again the fallacy of assuming that alternative or “natural” remedies are automatically safe, and that effective regulation is essential. The study comes from India, but it should be noted that 25% of herbal products produced in India are exported to the US, amounting to $688 million per year. Many products are also imported from China. The supplement industry is global, and we cannot assume good manufacturing practice. In fact, the evidence shows an industry rife with problems.
The study focused on liver toxicity (hepatotoxicity), and specifically acute on chronic live failure (ACLF). They looked at 386 alternative products in 91 consecutive patients presenting with side effects and receiving alternative treatments. They found:
“ACLF occurred in 39.6% of all patients (36/91) and 41.9% of those with hepatic adverse events (36/86), with associated mortality of 38.9% (14/36) compared to 10.9% (6/55) in non-ACLF presentations (OR 5.20, P = 0.004). Heavy metals exceeded WHO limits in many products: mercury (34%), cadmium (25%), arsenic (21%), and lead (14%). Cadmium exposure exceeding WHO limits showed a strong association with ACLF (75.9% vs 22.6%, P<0.001, FDR q<0.001). The association with mortality did not reach statistical significance after correction for multiple comparisons (34.5% vs 16.1%, uncorrected P = 0.061, FDR q=0.24). Undeclared pharmaceutical adulteration (at least one adulterant found in 27.7% of products; exposure to at least one adulterated product in 46.2% of patients) and animal-derived content (31.3%) were prevalent. Notably, unlabeled product consumption significantly predicted mortality (P = 0.025).”
Liver toxicity is a common problem with any potential pharmaceutical, as the liver is one of the main organs that metabolizes drugs. During drug development, 20% of promising new candidates fail due to liver toxicity. But imagine if such testing were not even required.
What the study found is not surprising, given prior research. It confirmed a high level of contamination (unintentional inclusion of a substance), mostly with heavy metals, It also found adulteration, which is the deliberate inclusion of an unlabeled pharmaceutical or animal product. It also found substitution, replacing the labeled ingredient with something else. If the product causing ACLF included an unlabeled ingredient, that significantly correlated with death from liver injury.
This is not surprising, because herbs are drugs, and many drugs cause liver toxicity. This is about what we would expect from exposing the public to untested and/or unlabeled drugs, often contaminated with heavy metals. Just being unlabeled is a significant risk, because consumers don’t know what they are taking, and may have reasons to avoid any product which is stressful to the liver. This is combined with the false “natural” health halo, giving consumers an unwarranted sense of safety.
The remedy for this situation is obvious, but we simply lack the political will to take the necessary steps. Senator Dick Durbin has just reintroduced the Dietary Supplement Listing Act, legislation to require dietary supplement manufacturers to register their products with the Food and Drug Administration (FDA). This has already failed in the Senate twice – this is the most basic regulation, requiring a minimum of transparency, and cannot get passed into law.
Such a listing act would only be the beginning of truly effective regulation. Right now manufacturers are trusted to regulate themselves, and are not required to prove their products are safe. The FDA has the burden of showing there is a problem with any product, and when they do it typically results in a warning letter, most of which result in no change.
The manufacture and marketing of health products, especially those intended to be taken orally as a pharmaceutical, should be carefully regulated. Industry should have to prove good manufacturing practice, and that their products do not contain any significant contamination, adulteration, or substitution. Product labels should also be completely transparent, with appropriate warnings of interactions and side effects – just like other drugs. Imported herbal drugs should meet the same standards.
This is especially true because the majority of the public already thinks that these products are regulated, even though they aren’t (another source of false security). Surveys show that most people using herbal products have chronic illness, making them more susceptible to toxicity, side effects, and drug-drug interactions. Many use them first line, before or instead of regulated drugs, on the marketed promise that they are safer.
This anti-consumer and pro-industry situation is partly due to the intense lobbying by the supplement industry to keep effective regulations at bay. They complain about “big pharma”, an industry not without its issues, but which is highly regulated. Meanwhile “big supplement” is largely unregulated, uses demonstrably poor manufacturing practices, deceptive marketing, while providing very little in the way of demonstrable health benefit. Looking at the totality of evidence, it is reasonable to conclude that the supplement industry is a net negative on consumer health, while annually taking in $210-$250 billion globally (about $63 billion in the US).
It’s time for some common sense regulation.

What’s really in that sports supplement?
A new analysis of sports supplements shows that you cannot trust the label to tell you what’s actually in the bottle.
Scott Gavura on August 3, 2023
Link


Most of the readers of this blog are fortunate to live in countries where we don’t have to worry about counterfeit drugs, as long as we’re shopping at regulated pharmacies. We can be confident that the prescription we receive, or the over-the-counter drugs we purchase from a pharmacy are of high quality and contain exactly what’s on the label. But in these same countries (and sometimes in these same pharmacies), there’s another group of products where the risks of mislabeled or contaminated products is significant – it’s among the dietary supplements that are often found on the same shelves. In many countries, the manufacturing, distributing, and marketing of dietary supplements is subject to a completely different set of regulations than what is in place for drugs. 
Looking specifically at the United States, it is worth repeating that this weakly-regulate marketplace is here by design. The Dietary Supplement Health and Education Act of 1994 (DSHEA) was an amendment to the U.S. Federal Food, Drug and Cosmetic Act that established the American regulatory framework for dietary supplements. It effectively excludes manufacturers of these products from virtually all regulations that are in place for prescription and over-the-counter drugs, and puts the requirement to demonstrate harm on the FDA, rather than the onus on the manufacturer to show a product is safe and effective. The goal was to eliminate barriers to sale, and it worked: Within four years of the DSHEA, supplement sales grew from $4 billion to $12 billion, and is now estimated at over $55 billion per year.
The absence of good product quality standards is a persistent barrier to the science-based use of supplements. With drugs, the standards are rigorous and largely consistent across countries: Drugs are approved after clinical trials are conducted to show they have meaningful effects. These clinical trials are scrutinized by regulators. Products that are approved for sale must be shown to be equivalent to the product studied in the clinical trials. This allows us to extrapolate the findings from research into expected effects in patients. And manufacturers must meet stringent quality standards for their products, including verifying the consistency and quality of what they produce. The same can’t be said for supplements. Even if there is promising data from clinical trials, we can’t make the same inference about the expected effects, because there is not guarantee that a supplement for sale is identical to (or even closely similar to) another product.
A new research letter in JAMA Network Open adds more data to other studies that have raised questions about supplement manufacturing quality. From Pieter Cohen and colleagues, the paper is titled Presence and Quantity of Botanical Ingredients With Purported Performance-Enhancing Properties in Sports Supplements and was published on July 17, 2023. The authors explain that since the FDA banned ephedra from dietary supplements in 2004, manufacturers have tried to come up with a variety of supplements to provide stimulant or anabolic effects all while remaining classified as “supplements” and not drugs. The specifically sought to determine the accuracy of products that were said to contain Rauwolfia vomitoria, methylliberine, the halostachine, turkesterone, and octopamine. All of these ingredients can be naturally sourced and are promoted for sports stimulant effects.
Sixty-three products were purchased online. Six of these products did not list one of the five ingredients above, so 57 products remained to be analyzed. Twenty-three of the 57 products (40%) did not contain any detectable amount of the labeled ingredient. Among the other products, the actual content ranged from 0.02% to 334% of the label’s stated quantity. Only six products (11%) contained ingredients within 10% of the stated labelled standard. Seven of the 57 products were found to contain at least one FDA-prohibited ingredient, an unapproved drug available legally only in Russia (omberacetam), three drugs formerly available in Europe (ioctodrine, oxilofrine, and deterenol), and incredibly, one drug that has never been approved in any country (1,4-dimethylamylamine). The full table of analysis can be found here.
An analysis that I wrote about back in 2018 identified that supplement adulteration (with prescription drugs) seemed to be concentrated in products like erectile dysfunction supplements, weight loss supplements, and muscle building/bodybuilder supplements. This analysis provides new data that shows that dietary supplements marketed as sports supplements appear to be manufactured to terrible quality control standards.
Buyer Beware
Both users and critics of dietary supplements should agree that products need to be manufactured to high quality standards. We need regulation from a consumer protection perspective, if only to ensure we’re getting what we’re paying for. Weak regulation that doesn’t require manufacturers to demonstrate quality before products are sold, or fails to hold manufacturers to account when things go wrong, might be expected to result in poor-quality products. And that’s the reality with supplements today.
A lowered regulatory bar for dietary supplements has been a boon to the industry, but the same can’t be said for consumer protection. In the absence of regulation that puts safety ahead of manufacturer interests, we shouldn’t expect to see any meaningful improvements in product quality. This double-standard has made it harder, rather than easier, for consumers to use supplements safely. Until a single, rigorous standard is applied across all consumer health products, there will continue to be uncertainty and even safety risks for users of dietary supplements.

   Who’s to Blame for Drug Shortages?
Scott Gavura
Link
All the best effort to practice science-based medicine are for naught when the optimal treatment is unavailable. And that’s increasingly the case – even for life-threatening illnesses. Shortages of prescription drugs, including cancer drugs, seem more frequent and more significant than at any time in the past. Just recently manufacturing deficiencies at a large U.S.-based contract drug manufacturer meant that over a dozen drugs stopped being produced. This lead to extensive media coverage, speculating on the causes and implications of what seems like a growing problem. So who’s to blame?
First, some perspective. Drug shortages are not a new problem. I’m a pharmacist who has worked in almost every healthcare setting – and dealing with shortages is a time-consuming and frustrating part of the the profession. However, the perception, even among health professionals, is that this situation is worsening. Statistics back this up. U.S. sources accurately track the prevalence of drug shortages and it hit a record high in the first half of 2011, with over 180 drugs reported to be in short supply. Before you blame the dysfunctional American health care system – it’s not just there. The same issues are occurring in Canada, and the United Kingdom, an some are worldwide. Managing shortages is a problem that affects all aspects of a patient’s treatment. Consider the impact of a cancer drug that disappears suddenly from the market, which looks to the be the case with the chemotherapy drug Doxil:
    • Pharmacists struggle to ensure inventory levels are in place to meet treatment demands. Managing supplies can be a daily crisis.
    • Cancer centres and hospitals struggle to coordinate treatment plans, unsure if necessary drugs will be available. In some cases, substitutes may be necessary. So called “grey market” vendors may take advantage of the shortage, buying up dwindling stock and then reselling it, at tremendously inflated prices [PDF].
    • Insurance plans need to confirm payment of alternative treatments and elevated prices.
    • Physicians are concerned about the impact on treatment regimens and the consequences of substitutions and delays on treatment plans.
    • Cancer patients, already dealing with a cancer diagnosis, may be concerned about access to their treatments, and the possible health consequences of delays and changes. They’re at a greater risk of medication errors due to switches in drugs and doses.
The shortage is so bad with Doxil that new patients may not start therapy – the dwindling supplies are restricted only to patients already on treatment. While not all shortages are this bad, sterile injectable drugs seem to have the biggest supply problems problem. And when generic versions don’t exist, there’s no exact substitute. So where are these shortages coming from?
Causes
Drugs can be in short supply for two main reasons. Demand can grow and outpace supply, or the supply can be reduced, and there’s an inability to meed demand. All signs point to current shortages being a consequence of supply problems.
There is no single cause to supply interruptions. One of the biggest factors is changes in the generic drug industry. (Generic drug manufacturer can produce a product after it losses patent protection). Consolidation in the industry means there are fewer companies that will produce any product. And the manufacturers may outsource their production to contract organizations, due to the technical requirements involved. (Take a look at this Health Canada advisory which notes that one plant manufactures drugs for several different companies) .
What causes manufacturing issues? Problems emerge throughout the supply chain. In many cases, it’s regulatory agencies like the Food and Drug Association that identify quality or safety issues, interrupting production. With manufacturing increasingly becoming a global endeavor, the FDA now sends inspectors to plants in China and India where all or part of the supply may originate. It may be difficult to obtain or process raw materials that meet FDA quality standards. When problems emerge, manufacturers may decide that supporting production for low-profit or low-volume products doesn’t make economic sense. Combined with industry consolidation, the result is a dwindling number of companies willing to produce a product – and no excess capacity when there are interruptions with one supplier. A survey conducted [PDF] by the American Society of Health-System Pharmacists identified that product quality issues were the most common reason for interruptions, followed by discontinuations, capacity issues and delays, and raw material issues.
Some have attributed shortages to being a consequence of generic drug reimbursement policies. That’s what Ezekiel J. Emanuel argued in a recent New York Times op-ed. He argues that (U.S.) Medicare pricing policies have made selling generic drugs unprofitable, driving companies from the market. But given shortages are are nothing new, sometimes involuntary, and exist worldwide, there’s no persuasive evidence that directly links reimbursement rates to supply issues. Tendering and bulk purchasing of pharmaceuticals, another common approach to purchasing, have the potential to impact supply, if a manufacturer given market exclusivity is suddenly unable to meet demands. But again, there’s no direct evidence that’s been the case, either in Canada or the USA.
A drug shortages summit in 2010 [like it already does for other drugs.
But these approaches don’t affect underlying challenge: No-one “owns” the supply issue. And there is no single cause of shortages. That’s the challenge: Building accountability for drug supply throughout this complex pathway. There are other complicated supply chains in the world – perhaps there’s something that can leveraged from other industries and transplanted into healthcare. Because we all need to stay focused on who is at the receiving end of the supply chain: The patient, wondering if they’re going to get their medicine.

Drug shortages are worsening, and there are no simple solutions
Drug shortages, which worsen medical care and patient outcomes, are becoming more and more common. A new Task Force report from the FDA offers a potential way forward.
Scott Gavura on October 31, 2019
Tweet


Prescription drug shortages are occurring everyday and seem more frequent than even. As I write this post there is a critical shortage of vincristine in the United States, a drug which has a critical role in the treatment of pediatric cancers. Vincristine production was discontinued in June 2019 by Teva Pharmaceuticals for “business reasons“, leaving Pfizer as the only company producing vincristine in the country. Pfizer is now struggling to meet demand. In Canada and also in Ireland, there are critical shortages of the oral cancer drug tamoxifen, leaving pharmacists, oncologists and patients scrambling to track down limited supplies. These two shortages alone affect thousands of patients around the world. And that is just a sample of what’s current this week. The FDA lists hundreds of drugs currently in shortage, a trend that can be observed in countries like Canada and also the United Kingdom. Many countries maintain standing lists of drugs that are in short supply. Numerous survey show that pharmacists, physicians and other health care workers spend a considerable amount of their time tracking down drugs that are in short supply, or in making adjustments to treatments, sometimes forced to substitute inferior drugs, that may cost more.
I blogged about drug shortages back in 2011 and that post could have been written yesterday, with perhaps even more urgency, as the problem seems to be getting worse, not better, despite efforts to reduce them. In 2018, FDA Commissioner Scott Gottlieb established the Agency Drug Shortages Task Force to determine the root causes of drug shortages, and propose recommendations to address them. That report was released this week, and it identifies three root causes to drug shortages, with and proposes strategies to address them.
Shortages 101
What exactly is a drug shortage?
A drug shortage is a situation where the demand for a drug exceeds the supply for that drug. Shortages can be caused by a surge in demand or a reduction in supply. The primary cause of almost all drug shortages is a reduction in supply, which can sometimes cause secondary shortages through surges in demand for other products.
Why are shortages such a significant problem?
Most of the prescription drugs used in the United States, and worldwide, are generic drugs. Generic drugs have no patent protection and may have one or more manufacturers. Many generic drugs were formerly patented, with usage dating back decades. Old does not mean inferior, however, and many generic drugs that have gone into shortage are critically important and in some cases, truly lifesaving.
When the most appropriate drug for a given situation is not available, the ramifications can be severe. Surgeries can be delayed, treatments can be interrupted, and alternate therapies, potentially less effective or more expensive, may have to be used. Resolving shortages consumes the time of patients, pharmacists, physicians, and other health professionals, and can be enormously distressing to patients who simply want the appropriate therapy. Switching therapies from the preferred drug increase the risk of errors in prescribing, as well as the possibility of adverse effects, such as side effects to the substitute therapy. The full impact on patients and health systems is not well defined, but it is substantial. And to those that sit outside the healthcare system (and to many of us inside the system, too) shortages don’t make any economic sense. Why aren’t the basic rules of supply and demand working when it comes to prescriptions drugs? This is what the FDA report tries to answer.
What did the FDA’s Task Force find?
The prescription drug market is not like other markets, based on an analysis by the FDA of shortages from 2013 through 2017. While economic factors are the major reasons that shortages are occurring, the way in which drugs are manufactured and purchased today are making drug shortages more prevalent:
     1.  Lack of incentives to produce. Manufacturers of generic drugs face substantial barriers to entry, substantial price competition, and uncertain revenue.
        ◦ Manufacturing drugs to FDA standards, particularly sterile injectable drugs, requires an enormous up-front investment, with manufacturing sites costing over USD$100 million and taking years to build and certify.
        ◦ Manufacturing cannot be scaled up or down easily, and manufacturers do not want to invest in redundant or idle equipment. Firms may choose to make more profitable drugs on the same equipment as lower-cost products.
        ◦ Purchaser consolidation, through group purchasing organizations and other buying groups, have increased negotiation power or purchasers, resulting in very low prices for generic drugs.
        ◦ Manufacturers compete almost completely on price, with a “race to the bottom”. Purchasers cannot easily assess other possible quality factors (such as reliability of manufacturing) so they are exquisitely price sensitive.
        ◦ The “costs” of drug shortages may not be borne by those that make purchasing decisions, leading to decisions that will prioritize price over manufacturing production reliability.
        ◦ The nature of bulk purchasing means that future sales are not certain, leading to challenges in forecasting revenue and profit margins, which are already low.
     2.  The market is not rewarding manufacturers for mature quality management systems. There is little incentive for manufacturers to invest in processes and systems which reduce the risk of shortages.
        ◦ Quality management systems are business practices designed around consistency and reliability.
        ◦ Good Manufacturing Practice (GMP) assessments measure compliance with requirements, but don’t assess the resilience of manufacturing against supply and manufacturing issues.
        ◦ Supply chains are opaque, and purchasers don’t know what companies are involved in product manufacturing, from the active pharmaceutical ingredient (API) creation through final product fabrication and packaging. This complicates any “quality” assessment.
        ◦ With limited information available to purchasers, purchasers cannot assess value-added manufacturing investments, nor can they easily penalize manufacturers that fail to supply product consistently. “Failure to supply” clauses that may be in purchasing contracts are thought to be weak and ineffective, causing mainly reputational risk to manufacturers.
     3.  Logistical and regulatory challenges make it difficult for systems to recover after disruptions
        ◦ With a smaller number of manufacturers at every stage of the pharmaceutical drug fabrication process, there are fewer competitors to step in when one manufacturer falters.
        ◦ Regulatory barriers make it difficult for new manufacturers to enter markets.
        ◦ As noted above, manufacturing facilities typically operate near capacity and cannot quickly adapt to rapid swings in demand caused by shortages.
        ◦ Almost all changes to the manufacturing process (e.g., changing API supplier) require FDA approval. As most manufacturers supply global markets, minor changes may require the approval of multiple regulators, further slowing down responsiveness.
        ◦ The costs to seek approval to market a generic drug are considerable, costing USD$1 – 5 million and taking up to give years.
The table below shows the extent to which manufacturing of APIs is today, largely done outside North America. Even the majority of final dosage forms are now manufactured outside the U.S.:
Common questions about drug shortages
Are drug shortages caused by Obamacare/Medicare/Brexit/Government Price Controls/Group Purchasing Organizations or [insert policy here]?
No. Drug shortages are often global and are a significant problem in vastly different pharmaceutical markets (e.g., Canada vs. U.S. vs. Europe).
Would drug shortages be solved if we only had Medicare-for-all/Brexit/Pharmacare/Government Price Negotiations/More Group Purchasing or [insert policy here]?
No. With a global marketplace, global manufacturing chains, and a common reliance on cheap generic drugs to help compensate for high-cost new drugs, there is no single policy solution that can resolve drug shortages. This is a global problem.
Is Big Pharma creating the shortage so they can profit when the prices rise?
No. Almost all drugs that go into shortage situations are generic drugs, meaning there are no patents protecting them. The FDA report notes that drugs that go into shortage situations are often small components of any manufacturer’s revenue. There does not appear to be a strong financial incentive to produce these products, in some circumstances, leading to decisions to discontinue to supply them – sometimes with massive repercussions.
If that’s the case, then why do multiple manufacturers report shortages at the same time?
The recent recalls and warnings about of ranitidine (Zantac) products and valsartan (Diovan) being contaminated with N-nitrosodimethylamine (NDMA), a probable carcinogen, illustrate that just one company may produce the active pharmaceutical ingredient (API) for multiple companies. Zhejiang Huahai Pharmaceutical Co. Ltd. isn’t a name that is familiar to many, but this Chinese firm manufactured most of the valsartan chemical compound for other generic drug manufacturers, resulting in multiple brands all being found to be contaminated. For companies that didn’t have problems with the valsartan API, they couldn’t easily scale-up to address the shifting demand as contaminated products were pulled from pharmacy shelves, and a shortage situation was created.
What are the causes of most shortages?
By far, the biggest cause is quality issues, as the agency notes in its report. Frustratingly, even the FDA couldn’t identify the cause in 1/5 of shortages.
What can be done about drug shortages?
The FDA’s Task Force made the following recommendations:
1. Do more to understand the impact of shortages, and how contracting may contribute to them: Collect better data on the frequency, persistence, intensity and harms of shortages, as well as the impact on patients and costs to health systems. As part of this, get better transparency on the private sector contracting practices (e.g., group-purchasing agreements with low price clauses that put contract certainty in question.)
2. Create a rating system for manufacturers to invest in quality management systems: A standardized rating system based on objective indicators could inform purchasers about a manufacturer’s commitment to processes that reduce the likelihood of shortages. This could become a consideration in purchasing, giving a competitive advantage and potential reward to companies that are more resilient and reliable.
3. Promote sustainable private sector contracting: Contracts need to provide reasonable returns to manufacturers, particularly for drugs which are of critical importance. Contracts should reward quality management systems.
Conclusion: No simple solution to drug shortages
While economic factors lie behind many of the factors that cause drug shortages, there is no easy way to address drug shortages. The FDA’s proposal to assess quality management systems is a good one, and something that realistically only the FDA could undertake. But other solutions require a fundamental rethink about our approach to buying and using generic drugs. Ultimately, without more stability and certainty in the market for manufacturers, there is likely to be continued uncertainty and instability in the marketplace for patients and consumers.

More drug shortages due to COVID-19
COVID-19 is worsening a long-standing problem: Drug shortages
Scott Gavura on April 16, 2020
Link

As the blog’s resident pharmacist I’ve taken on the topic of drug shortages a few times over the past several years, an issue that may sometimes be invisible to patients but something that most pharmacists grapple with every day of their working lives. Prescription drugs routinely go into shortage situations, and all evidence suggests that the problem has been worsening, not improving, over the past several years. Even before the COVID-19 pandemic emerged, the FDA listed hundreds of drugs currently in shortage, a situation also observed in countries like Canada and also the United Kingdom. Many countries maintain standing lists of drugs that are in short supply. In general, most of these shortages have traditionally been generic drugs, not brand-name products. All health systems rely heavily on lower-priced generics to help offset the cost of new, patented, high-cost drugs. There are substantial barriers for manufacturers to enter the generic drug manufacturing market, and there is significant competition that drives prices down low. The result has been the gradual outsourcing and consolidation of manufacturing, with supply chains that may stretch across continents. There are far fewer shortages of brand name drugs but they can occur when manufacturers experience problems with manufacturing or changes in demand.
I first blogged about drug shortages back in 2011 and the post could have been written yesterday, with perhaps even more urgency, as the problems seems to be getting worse, not better, despite efforts to reduce them. In 2018, FDA Commissioner Scott Gottlieb established the Agency Drug Shortages Task Force to determine the root causes of drug shortages, and propose recommendations to address them. And that was pre-COVID. While access to personal protective equipment, intensive care units and ventilators have grabbed headlines, there is increasing concern about access to prescription drugs – not just to treat COVID patients, but longer-term effects on access to many prescription drugs.
Initial worries
The first concerns about COVID-related drug shortages emerged shortly after Wuhan, China was locked down in early January. As China is a major supplier of active pharmaceutical ingredients (APIs) to the rest of the world, there were concerns that the lockdown would threaten shipments of APIs out of Wuhan to the rest of the world, disrupting the manufacture of drugs worldwide. The table below (from the FDA’s Task Force on shortages) shows the distribution of manufacturing of APIs and finished products (e.g., tablets/capsules/vials) in 2019: largely done outside North America. Just 12% of APIs used in American drugs were manufactured in the USA, and only 37% of finished products were actually manufactured domestically:As you can see, 14% of APIs come to the US from China and, the first COVID-related drug shortage was reported by the FDA on February 27. The drug and manufacturer were not named. At that time, the FDA noted:
Also, as part of our efforts, the FDA has identified about 20 other drugs, which solely source their active pharmaceutical ingredients or finished drug products from China. We have been in contact with those firms to assess whether they face any drug shortage risks due to the outbreak. None of these firms have reported any shortage to date. Also, these drugs are considered non-critical drugs.
The second wave of shortages
This attention to APIs coming out of China was the focus of regulators and the broader health care market for several weeks. In mid-February, the scrutiny remained on China. Even as late as mid-March, European regulators seemingly were focusing on supply chains and travel restrictions. It was only after the COVID started to spread outside China, and case numbers exploded in Europe did broader recognition start of what I’ll call the second wave of drug shortages – the treatments essential to keep patients intubated, ventilated, and alive in intensive care units. By late March and early April, it was apparent that existing supplies of these medications were insufficient to treat the thousands of new patients that required hospitalization. On April 6, the European Union noted:
Some EU Member States have indicated that they are starting to see shortages of certain medicines used for patients with COVID-19 or are expecting such shortages to occur very soon. These include medicines used in intensive care units such as certain anaesthetics, antibiotics and muscle relaxants as well as medicines used off-label for COVID-19. EU authorities are therefore putting in place additional measures to mitigate the impact of the pandemic on the supply chain of medicines in a coordinated manner.
It’s worth reiterating that drug “shortage” is just an imbalance between supply and demand. These can be local, regional, national, and international. While primary concerns were about supplies of drugs, from China, treating COVID patients was causing shortages through surges of demand. And as the pandemic has taken hold in United States, the same surges in demand occurred. By late March, demand was surging and outstripping supply:
Demand for drugs given to patients on ventilators is outstripping supply, according to Vizient Inc., a pharmaceutical-purchasing group that works with more than half of U.S. hospitals and health systems. Hospital orders for sedatives, analgesics and neuromuscular blockers increased 58% overall in March compared with January, Vizient said. Those medicines are used to prevent movement, manage pain and soothe patients who can’t breathe without the assistance of a machine.
On April 2, The New York Times reported:
Across the country, as hospitals confront a harrowing surge in coronavirus cases, they are also beginning to report shortages of critical medications — especially those desperately needed to ease the disease’s assault on patients’ respiratory systems.The most commonly reported shortages include drugs that are used to keep patients’ airways open, antibiotics, antivirals and sedatives. They are all part of a standard cocktail of medications that help patients on mechanical ventilators, control secondary lung infections, reduce fevers, manage pain and resuscitate those who go into cardiac arrest.Demand for these drugs significantly increased in March as the pandemic took hold in the United States. Orders for antibiotics like azithromycin and antiviral medicines like ribavirin nearly tripled. Medicines used for sedation and pain management, including fentanyl, midazolam and propofol, increased by 100 percent, 70 percent and 60 percent respectively.Demand for albuterol, a common asthma inhaler medication, has also risen significantly, given its importance in easing the breathing of patients with severe infection.
While not all of these drugs are currently in a shortage situation, their rising use are raising concerns that shortages are far more likely. This is being observed across North America. From a Canadian hospital:
Even though ICUs have yet to be overrun with a feared surge of coronavirus cases, the drugs are being administered at a far higher rate than usual, say doctors and pharmacists. “Some hospitals have reported they’re essentially using a 30-day supply of certain medications in just one day,” said Dr. Michael Warner, ICU head at Toronto’s Michael Garron Hospital. “Overall, our consumption of these drugs could increase by an order of magnitude.”
Importantly, none of these drugs can be easily manufactured. Most of them are sterile injectable drugs, which are more difficult and complex to manufacture, compared to oral products like liquids, tablets, and capsules. In the case of brand-name drugs, there may be only a small number of manufacturing sites worldwide. It’s not known if supplies and reserves exist for these drugs, or how quickly manufacturers can ramp up manufacturing to cope with worldwide surges in demand. Wholesalers in the U.S. reported difficulties meeting orders, particularly in New York, at the end of March:
Using its comprehensive data on purchasing patterns and current fill rates, Premier found that these products experienced the greatest spikes in demand during the month of March but were also unable to be supplied in the requested quantities – two early warning signals for shortages. Drugs include antimalarials and antivirals that may be an effective COVID-19 treatment, as well as antibiotics used to cure infections. Other products at risk of shortages include bronchodilators for keeping airways open, as well as sedatives and neuromuscular blockers used to intubate patients. Demand for these products was even higher in COVID-19 hotspots like New York, suggesting that products could move from regional shortages into national shortages as the disease spreads to additional communities.
Drugs have now moved into true shortage situations.
In the past few days (April 13), the FDA has continued to report new shortages of drugs for patients that require ventilation and intensive care:
Increasing demand for sedatives used to help put COVID-19 patients onto ventilators means the US Food and Drug Administration (FDA) added two more – this time the injectables propofol and dexmedetomidine – to its list of drug shortages.
The propofol shortage was also previously listed by the American Society for Health-System Pharmacists (ASHP) earlier this month, with manufacturers noting increased demand. Michael Ganio, senior director of pharmacy practice and quality at ASHP, previously told Focus via email: “We have multiple reports of increases in purchases and utilization of sedatives like midazolam, fentanyl, and propofol to treat COVID-19 patients who require mechanical ventilation.”
And:
A Pfizer spokesperson told Focus via email: “As of today, Pfizer’s manufacturing and distribution network continues to operate at high performance with no operational disruptions due to COVID-19. Historically, Pfizer has had a market share of approximately 15% for Propofol. We recently have observed an unprecedented surge in demand for Propofol beyond Pfizer’s historical demand which is limiting our ability to fully satisfy customer orders in the short-term. We are making every effort to advance the ordering of additional materials, increase our production, reduce lead times and expedite orders to customers, especially those in high-impact areas.”
As we see the pandemic spread across countries and around the world, time will tell if we have “flattened the curve” enough for manufacturing and supplies to match the needs of hospitalized patients who needs these drugs to stay alive.
Treating COVID: The third wave of shortages
I don’t want to spend time in this post talking about possible COVID treatments, as the data are evolving quickly. Earlier this week David Gorski discussed the weak evidence to support the use of hydroxychloroquine and azithromycin to treat COVID-19. While current treatment guidelines (as of April 14) do not recommend the use of either product outside of a clinical trial, the hype around these products has caused surges in demand that have led to concerns of shortages for non-COVID patients that rely on these medications to treat their illness. From April 10, in The Journal of the American Medical Association:
Hydroxychloroquine is recommended for all patients with lupus, especially those with no contraindication such as pregnancy. It relieves constitutional, musculoskeletal, and mucocutaneous manifestations and decreases thrombotic events, organ damage, and mortality. Hydroxychloroquine helps maintain disease remission and prevent flares. Among patients with lupus that is not organ threatening, 80% achieve remission with hydroxychloroquine and may sustain it with this therapy for long periods.2Although there is no rigorous scientific evidence supporting the use of hydroxychloroquine in COVID-19 as of early April 2020, consumers are stockpiling the drug not only for treatment but also prophylaxis prompted by media reports of possible efficacy. A rationale for hydroxychloroquine use in COVID-19 is based on in vitro studies showing that chloroquine inhibits virus replication.3 Because hydroxychloroquine and chloroquine may have in vivo antiviral and anti-inflammatory effects, they offer a potential means to mitigate COVID-19.A recent small (n = 36), open-label nonrandomized trial in France suggested that therapy with hydroxychloroquine and azithromycin decreased viral load and replication,4 garnering significant media attention. However, randomized clinical trials are required to assess the efficacy and safety of hydroxychloroquine as prophylaxis or treatment for COVID-19. The FDA has authorized its use for treatment of patients hospitalized with COVID-19 but not for prophylaxis. President Trump has touted hydroxychloroquine therapy, despite very limited evidence of efficacy.5,6Since being prominently featured in the press and on social media as a potential COVID-19 therapy, demand for hydroxychloroquine has exploded and a shortage has ensued. Some physicians are prescribing it for prophylaxis as well as outpatient treatment of COVID-19, often along with azithromycin. Some health care workers are taking it as prophylaxis without any evidence to support this use.
Azithromycin is a common treatment used for adult and pediatric infections, including pneumonia. A shortage of azithromycin may mean selecting inferior products or challenges in treating these infections. Given these are both oral drugs, it’s hoped that shortages will be short-lived without causing harm to patients that need them.
Hydroxychloroquine and azithromycin are the most well-known products that are being used to treat COVID-19. There are a number of products being utilized and/or investigated in clinical trials, with new drugs likely to be added over the coming weeks and months. From the British Columbia Centre for Disease Control is a list of “unproven” products as of April 12:
    • lopinavir/ritonavir (Kaletra®)
    • remdesivir
    • oseltamivir
    • ribavirin and interferon
    • colchicine
    • tocilizumab/sarilumab
    • corticosteroids
    • antibiotics
As “old” drugs are repurposed and investigated, it is possible that we will see unpredictable surges in demand for products, raising the risk of additional shortages, with effects beyond COVID. Like patients with lupus are already experiencing, a drug can move from stable into shortage in a matter of a few weeks, and manufacturing supply chains may struggle to adapt. What we have now in the USA and other countries is a growing list of drug shortages – the number of drugs that are short in the USA due to COVID now numbers 23 at my last count.
A fourth wave of shortages?
I’ve described these shortages as waves and I’m not sure if that’s the right analogy, as the different drivers of shortages are going to have overlapping effects for some time. The fourth category or wave of shortage that I want to discuss is the manifestation and exacerbation of what we have been experiencing for years, in a new world where supply chains may be more tentative. As I have noted in past posts, problems in manufacturing and distribution of prescription drugs can emerge throughout the supply chain. In some cases, it is regulatory agencies like the FDA that identify quality or safety issues, interrupting production. In other cases it may be difficult to obtain or process raw materials that meet FDA quality standards. When these problems emerge, manufacturers may decide that supporting production for low-profit or low-volume products doesn’t make economic sense, leading to discontinuation, and yes, more shortages. While this is outside my area of expertise, I am skeptical that shifting manufacturing of APIs from China or India is something that can occur quickly, or can be done without additional supply chain interruptions. My sense is that manufacturing hundreds of different drug products to high standards may be more difficult that manufacturing PPE. It is unlikely that manufacturers who may derive little profit from these products will be willing (or able) to do this. Consequently, massive changes cannot (or will not) occur without significant intervention and direction from governments and regulators. Price hikes for low cost generics may be inevitable, as more countries insist on domestic manufacturing. Whether or not this shift in manufacturing can (or should) occur is something that we will observe over the coming months and years as we find out what the new normal looks like.
The COVID-19 pandemic has exacerbated and made apparent the long-standing challenges with pharmaceutical drug manufacturing and supply. It’s possible this could lead to the changes that are essential to address long-standing problems that have become worse over the past decade. The supply chain has been brittle and vastly too opaque for years. Some countries, like New Zealand, mandate a level of manufacturing transparency that is unavailable in other countries. Group purchasing organizations, wholesalers, manufacturers, regulators, health systems, and insurers need to find new ways to collaborate and share information in order to fix these fragile supply chains and to reduce the impact of shortages on patients. More transparency will help. Leadership is essential. I’ve noted before that no single organization “owns” drug shortages. Health systems need to act now, decisively, to fix these problems.

   Yes, drug companies do pay attention to herbal medicine
David J Kroll
Link
I’m only a monthly contributor here but between being a SBM reader and having my own blogs, I often grow weary of the blind criticism that researchers and drug companies couldn’t care less about traditional folk medicines as drug products. My laboratory spends every single day working on natural product extracts in the search for compounds that may have selective effectiveness against cancer. So, this is a bit of a sore spot for me.
Two papers this week from Cancer Prevention Research on the potential anticancer effects of a diabetes drug (Nathan Seppa story here) remind me to tell the story of a Middle Ages European herbal medicine used to treat polyuria that gave rise to one of the most widely prescribed drugs in the world, metformin (Glucophage in the US). Metformin, known chemically as a biguanide, dimethylguanide to be precise, traces its roots to the plant Galega officinalis. Known as goat’s rue, French lilac, or professor weed, this plant was shown to be a rich source of guanidine and a less toxic compound later called galegin or galegine (isoamyline guanidine).
Although used as an herbal medicine in Europe for centuries, especially in France, this classic 1918 paper (free PDF) in the Journal of Biological Chemistry was perhaps the first widely-recognized report of the hypoglycemic effect of guanidine. The study was conducted in rabbits by CK Watanabe at Yale University. (P.S. Thank you, JBC, for making your archives freely available – the JBC was founded in 1909 by my blog nymsake, pharmacologist John Jacob Abel.)
While guanidine was to toxic for use in humans, pre-World War II researchers in Germany began synthesizing analogs called synthelins, biguanides with long carbon chains between the guanide moieties. A Parisian physician and clinical pharmacologist, Jean Sterne, probably played the most pivotal role in getting this class of compounds into clinical use. In the 1950s he held both academic and pharmaceutical industry positions, the latter at Aron Laboratories.
While there, Sterne’s group investigated a series of biguanidines that included metformin, a deceptively simple molecule. and they published a crucial paper in 1957 where he coined the name Glucophage for metformin, “glucose eater.” The paper was written in French and appeared in the less-widely read Maroc Medical journal. A paper that appeared later that year in Proceedings of the Society for Experimental Biology and Medicine on a related compound, phenformin, is more widely cited – the authors were then at the US Vitamin Corporation.
A long series of clinical studies with the biguanides ensued over decades but it was the acquisition of Aron Laboratories by Lipha Pharmaceuticals in 1995 that led metformin to come to the US market. It’s a fascinating story that gave rise to a multi-billion dollar market of Glucophage and related dosage forms. And that’s without even getting into studies this week on the potential anticancer effects of metformin – that story is for another day.
There are two superb papers you must read if you want more details on the history of metformin. An unparalleled, short, and free-access history of metformin written by Clifford Bailey and Caroline Day at the Aston University diabetes research group in Birmingham, UK, can be found here (PDF). Much of the historical information I’ve provided here comes from that paper. Second, to accompany the two papers in this month’s issue of Cancer Prevention Research Michael Pollack at McGill University in Montreal wrote an excellent overview of metformin and the critical gaps in our knowledge to investigate and potentially implement the use of the compound in cancer prevention and, possibly, treatment.

Supplements with Multiple Ingredients, Many with No Apparent Rationale
Dietary. supplements frequently have multiple ingredients, often mixtures of vitamins, minerals, and herbs. The rationale for including each ingredient is questionable, to say the least.
Harriet Hall on December 10, 2019
Link

Whenever I evaluate the evidence for a dietary supplement, one of my first questions is “What is it?” I remember many years ago, when I first started doing this, I looked up the ingredients for a product advertised to cause weight loss. One of the ingredients was listed in the Natural Medicines Comprehensive Database as causing weight gain! Ever since, I have been very suspicious of the reasoning for including ingredients in a multi-ingredient product.
I recently wrote about SeroVital, a dietary supplement advertised to boost the body’s own production of human growth hormone (HGH). I found that Dr. Oz had recommended supplements with these four amino acids: glycine, ornithine, arginine, and lysine. SeroVital only contains two of these. And in addition, SeroVital contains the powdered herb Japanese catnip (Schizonepeta tenuifolia). Why did they pick different amino acids than Dr. Oz did? And why on earth did they add the herb? It “appears to have some selective anti-inflammatory effects”, but no other scientifically supported uses. An article on Chinese herbs says it is useful for treating colds and flu and dispelling “wind”. I found no evidence that it increases HGH or has any anti-aging effects. How do you suppose the designers of SeroVital imagine that it adds to the effectiveness of their product?
I also came across a product on PatchMD that makes anti-aging claims for vitamins A, C, D, B3, B6, B9, curcumin, clove extract, ginger root extract, Indian gooseberry extract, L-carnitine, CoQ10, resveratrol, choline, glutathione, NAC, and alpha-lipoic acid. It combines all of these in a convenient Anti-Aging Topical Skin Patch, supplying the nutrients via the skin. They claim all these ingredients are backed by science for their anti-aging effects, but that’s a real stretch, based mainly on their antioxidant and anti-inflammatory properties. At least they provided a proposed (pseudo-)scientific rationale.
Why do the makers of Lipo-Flavonoid imagine their mixture will cure tinnitus? It contains lemon bioflavonoid complex, vitamins, choline, inositol, and melatonin. There’s no scientific evidence; did they rely on unreliable testimonials from friends and family?
Then there’s Super Brain Renew, a nootropic designed to improve memory, focus, clarity, and mood. It contains the “essential 5” brain supporting nutrients (DHA Omega 3, Huperzine A, Phosphatidylserine, Bacopa Extract, and N- Acetyl L-tyrosine). But essential isn’t enough for them. They add vitamins A, C, D, E, B-1, 2,3,5, and 6, folic acid, biotin, calcium, iron, magnesium, zinc, selenomethionine, copper, manganese, chromium, molybdenum, potassium, and 692 mg of a proprietary blend of 19(!) other ingredients (herbs, minerals, green tea extract and much more). Another product, Mind Lab Pro, contains only a few of these nutrients but contains several others, including citicoline, lion’s mane mushroom, maritime pine bark extract, Vitamin B12, and others. Are they going by the principle “more is better?” Do they think the sheer number of ingredients will impress customers? How do you suppose different nootropics intended for the same purpose came up with such different lists of ingredients?
How do they decide?
I see this kind of thing everywhere. Actually, most dietary supplements contain single active ingredients; but a great many of them are a potpourri of vitamins, minerals, and herbs. I can’t understand how they choose which ingredients to put in their products. My imagination runs wild. Did they throw in some vitamin B9 just because they needed to use up an overstock they had left over from a previous product? Did they ask unqualified people to brainstorm, put all suggestions on a dartboard and throw darts at it? Did they rely on intuition or dreams? Did they use a pendulum or dowsing rod? Did they disagree and ask the janitor to arbitrate? Did they go by the cost of each ingredient (“That one’s cheap, and it wouldn’t hurt to throw some in”)? Did they consider side effects or interactions with other medicines? If they want antioxidants, why did they pick those specific ones and not others? I can imagine all kinds of bizarre scenarios, and I’m sure you can too.
I don’t for an instant imagine that these decisions are based on good scientific evidence, but people seldom do things for no reason at all. They probably have some rationale to justify their choices in their own minds. I wish I knew what that rationale is. I would dearly love to understand their thinking. Oh, to be a fly on the wall during their planning sessions! While it would be unlikely to impart any useful information about the ingredients themselves, it could be highly entertaining and could give insight into human behavior. And it might reveal which companies actually believe in their products and which are made up of crooks who deliberately sell products for the sole purpose of making money by deceiving the public.
Multiple ingredients are sometimes reasonable
That’s not to say multiple ingredients are never justified. Here are some of the reasons science-based doctors might want to combine drugs:
    • One might not be very effective, and two might have an additive effect (2 + 2 = 4).
    • There might be a synergistic effect where 2 + 2 = 5, but synergy is nowhere near as common as proponents of natural medicines seem to believe. When a mixture of ingredients or a plant extract is tested head-to-head against a single active ingredient, the single active ingredient usually works just as well. And it might even work better because of unwanted ingredients in the plants.
    • If drugs have toxic side effects, combining drugs might allow a reduction of the dose of each to avoid toxicity.
    • If a patient is deficient in a nutrient, the treatment might be more effective after correction of the deficiency. But there would be no benefit to adding more of the nutrient for patients who were not deficient.
    • Drugs can be prescribed separately, but combining them to reduce the number of pills can improve convenience and compliance.
When ingredients are combined, there is no guarantee that the combination will work better, and there is always a possibility that the combination might have unexpected effects. If there is an adverse reaction to a combination, it can be difficult to identify which ingredient is responsible.
Conclusion: Buyer beware
We should always think critically about claims for any treatment, and we should always ask for the evidence; but dietary supplements that combine multiple ingredients are particularly suspect. The only reliable way to find out if a treatment is safe and effective is to test it in controlled clinical studies. Scientific testing is expensive; but it might lead to FDA approval, so the products could be marketed as drugs rather than as dietary supplements. In the absence of adequate evidence, taking dietary supplements is a gamble, especially since some products have been found to contain contaminants like heavy metals, toxins, and even prescription drugs.
I can’t stop wondering why they chose each ingredient. I would dearly love to be that fly on the wall! But then a fly couldn’t tell anyone what it heard.

Drugs in your supplements
Supplements are a billion-dollar business, but quality control is questionable. A new study shows that supplements may be adulterated with unlabelled prescription drugs.
Scott Gavura on October 18, 2018
Link


There can be many reasons why someone may choose to buy a dietary supplement. Some prefer supplements over prescription drugs, believing them to be more “natural” and possibly more gentle than prescription drugs. While there is a lack of good evidence showing most dietary supplements have any meaningful benefit, there is one effective way to make a supplement “work”: Add an active ingredient. Juicing up a supplement with actual prescription drugs isn’t uncommon – it happens routinely, and there is little that the Food and Drug Administration can really do about it. While supplements are often packaged like pharmaceuticals, and may be sold alongside over-the-counter drugs, anything considered a dietary supplement is subject to completely different regulatory standards than is in place for prescription drugs. And that’s created a marketplace where consumers are ill-served and may even be at risk of harming themselves.
Supplements are not drugs (according to regulators)
It’s been covered in depth before, but is worth repeating, that the Dietary Supplement Health and Education Act of 1994 (DSHEA) was an amendment to the U.S. Federal Food, Drug and Cosmetic Act that established the American regulatory framework for dietary supplements. It effectively excludes manufacturers of these products from virtually all regulations that are in place for prescription and over-the-counter drugs, and puts the requirement to demonstrate harm on the FDA, rather than the onus on the manufacturer to show a product is safe and effective. The goal was to eliminate barriers to sale, and it worked: Within four years of the DSHEA, supplement sales grew from $4 billion to $12 billion. Today, dietary supplements are a $35 billion industry.
Because there is no pre-market or post-market product testing in place, the FDA relies on other forms of monitoring in an attempt to ensure that supplements are safe. This includes collecting adverse event reports and consumer complaints, inspecting manufacturing facilities, and monitoring imported ingredients. In exceptional circumstances, the FDA can take supplements off the market by issuing a recall.
Despite the perception that supplements are safe, natural, and effective, they continue to cause a significant amount of harm, associated with 23,000 emergency department visits and 2,000 hospitalizations per year. This number may in fact be an underestimate, as assessing causality is challenging, and erroneous perceptions about supplements may mean fewer people even suspect a supplement of causing harm.
The FDA maintains a Tainted Products Marketed as Dietary Supplements database, which was the data set used for a recent study I will be discussing below. Adulterated dietary supplements are particularly problematic for consumers, because it is impossible to safely take a prescription drug if you don’t know you’re taking it at all. And if you have medical conditions, or take other prescription drugs, your risk of harm from adulterated supplements is even greater.
Counting the adulterated supplements
The study was a straightforward analysis of FDA data. Jenna Tucker and colleagues examined adulterated supplements, defined as supplements containing unapproved ingredients (e.g., prescription drugs). The paper is entitled “Unapproved Pharmaceutical Ingredients Included in Dietary Supplements Associated With US Food and Drug Administration Warnings,” published in JAMA Network Open last week. The objective was to summarize trends observed in adulterated supplements associated with an FDA warning, between 2007 and 2016. 776 supplements were in the data set, and the majority of them were products marketed for sexual enhancement (46%), weight loss (41%), and muscle building (12%), with only 2% of products marketed for other purposes. (See table)
While most products had only one unlabelled prescription drug as an adulterant, just over 20% contained two or more. Two products (one marketed for arthritis and one for sexual enhancement) contained six different unlabelled drugs.
Among the warnings, 96% of products were associated with a single warning. Amazingly, 28 products were found to repeatedly contain adulterants, with 19 (67%) of these product being laced with DIFFERENT prescription drugs the second or third time around.
Just under half of the products in this sample were associated with a voluntary recall from the manufacturer. Surprisingly, in 44% of cases, there was a public notification only, and no recall.
Key highlights of the findings
Supplements for sexual enhancement: Among the adulterants, sildanafil, (the active ingredient in Viagra) was the most common, with 81% of the sexual enhancement supplements containing it or a close chemical analogue.
Supplements for weight loss: The most common adulterant in weight loss supplements was the weight loss drug silbutramine (or an analogue) along with the laxative phenolphthalein, both of which have been removed from the US market. Silbutramine was found in 85% of weight loss products in the dataset, and phenolphthalein was in 24% of these products. Some weight loss supplements were also found to contain the prescription drug fluoxetine (Prozac).
Supplements for muscle building: 73 of the 92 supplements had undeclared anabolic steroids (or steroid-like analogues). In what could be described as a form of honesty in supplement advertising, nine products did disclose that the supplement actually contained anabolic steroids. Ten products disclosed that they contained a class of anti-cancer drugs call aromatase inhibitors, which are used to block estrogen.
Other supplements: While marketed for a variety of conditions including pain, cancer, sleep issues, gout and prostate health, half of the products (7 of 14) contained diclofenac (an anti-inflammatory drug) and five contained dexamethasone (a steroid).
What does it mean for me, the consumer?
When supplements are tainted with prescription drugs, they’re no longer dietary supplements – they’re unlabelled drugs. Consumers should be entitled to dietary supplements that at minimum, honestly and accurately describe what’s inside the bottle (meaning not just lacking adulterants, but including the purported active ingredient). This analysis show that unapproved drugs are regularly sold in the United States as dietary supplements, and there are no signs that regulation will change this fact. However, it is possible to greatly reduce your risk of purchasing adulterated supplements. If you stay away from erectile dysfunction supplements, weight loss supplements, and muscle building/bodybuilder supplements, there’s a much better chance that you won’t be getting any prescription drug surprises in your dietary supplement. Until there is better, more effective regulation of dietary supplements, consumers will continue to put their health at risk with each supplement they consume.

Amazon goes where the FDA does not
Amazon has implemented new quality standards for some dietary supplements.
Scott Gavura on June 20, 2024
Link

Amazon sells more dietary supplements that Walmart or Target. It’s one of the largest dietary supplement vendors in the US. And, like other industries where Amazon operates, it has enormous market power.
Recently Amazon announced new rules for supplement vendors that want to distribute their products through its website. These new requirements go where the federal regulator, the Food and Drug Administration (FDA), won’t go – or more accurately, can’t go. Amazon is now forcing manufacturers to submit their products to third-party testing, something that isn’t currently required for for dietary supplements sold in the country.

The low quality bar for American supplements
Before discussing the implications of Amazon’s new rules, it’s worth recalling the current standards that exist. Products labelled as dietary supplements in the United States are not subject to prescription drug manufacturing standards. The Dietary Supplement Health and Education Act of 1994 (DSHEA) established the regulatory framework for dietary supplements. It effectively excludes manufacturers of these products from virtually all regulations that are in place for prescription and over-the-counter drugs. Under DSHEA, the FDA may not approve dietary supplements for safety and effectiveness before they are marketed. The FDA can only intervene to pull products off the market, after they are marketed, and only if they are adulterated or misbranded. The goal was to eliminate barriers to sale, and it worked: Within four years of the DSHEA, supplement sales grew from $4 billion to $12 billion, and is now estimated at over $55 billion per year.
In many past posts I have identified the consequences of this legislation – ongoing reports of quality concerns with marketed dietary supplements. The absence of good product quality and labelling standards is a barrier to the science-based use of supplements. With conventional drugs, standards are rigorous and largely consistent across countries: Clinical trials are conducted to determine if a drug has meaningful effects. These clinical trials are scrutinized by regulators. Products approved are considered safe and effective based on that evaluation. Marketing claims related to drugs are permitted only as they are consistent with the evidence that supported their approval. And the manufacturing standards for any product sold must be shown to be the same as the product studied in the clinical trial. Importantly, you can trust that what’s on the label is what’s in the bottle.
Amazon’s past problems
Earlier this year I blogged about the drug galantamine, which can be extracted from plants, or synthesized in a lab. Because it can be naturally sourced, it’s available in the United States as either a dietary supplement or as a prescription medication. As a drug, galantamine is approved by the FDA for the treatment of mild to moderate Alzheimer dementia. It is also sold as a dietary supplement marketed for cognitive conditions and “memory enhancement.” In a study, researchers purchased a number of galantamine supplements from Amazon.com and compared their quality to the prescription versions of the drug. While the prescription versions all met good quality standards, the quantity of galantamine in the supplements ranged from less than 2% to more than 110% of the labeled quantity. Only one product contained galantamine within 10% of what the label stated. Frighteningly, 3 of the 10 products tested were also contaminated with Bacillus cereus sensu stricto– enterotoxin genes.
This past December, the FDA wrote to Amazon about adulterated supplements available on its website:
The United States Food and Drug Administration (FDA) purchased on your website, www.amazon.com, products that are labeled as energy enhancing supplements or food, but laboratory analyses confirmed that they contained undeclared and potentially harmful active pharmaceutical ingredients. As discussed further below, your firm is responsible for introducing or delivering for introduction into interstate commerce products that are unapproved new drugs under section 505(a) of the FD&C Act, 21 U.S.C. 355(a).
This and other investigations have led to headlines articles like this:
and
so it is perhaps understandable (and good business sense) that Amazon was forced to act.
Amazon’s new requirements
In April 2024, Amazon.com announced that some dietary supplement products now need to be verified through a third-party Testing, Inspection, and Certification (TIC) organization. It identified three organizations that that sellers can work with: Eurofins, UL and NSF International. Manufacturers that use other labs to test their products must submit these test results to Eurofins, UL or NSF International who will evaluate the results. These rules cover weight management, sexual enhancement and sports nutrition products. This is not a surprise as these categories of supplements are routinely contaminated.
Previously, vendors were required to submit Certificates of Analysis (CoAs) from an accredited laboratory or show enrollment in an independent quality certification program. That is no longer sufficient. NSF says the following about its testing standards:
NSF evaluates the composition of dietary supplements and ingredients. The assessment includes testing for vitamins, minerals, herbs, botanicals, amino acids, sports supplements, concentrates, metabolites, constituents and extracts to verify the supplement facts panel reflects the product’s contents or that the certificate of analysis for the ingredient accurately depicts its identity and purity specifications.
To ensure that a safer product reaches consumers, we assess products and ingredients for the presence of contaminants that impact health, including the toxic elements lead, mercury, arsenic, cadmium and chromium (VI). We test for the presence of aerobic microorganisms, yeast and molds, and Enterobacteriaceae, and specifically for the potential pathogens Salmonella spp., Escherichia coli and Staphylococcus aureus. We analyze for mycotoxins, which are released by fungi and are hepatotoxic. We assess items that contain botanical materials for the presence of pesticides.
Amazon raises the (quality) bar?
With these new requirements, Amazon has put in place requirements that go beyond what the FDA current requires, given these quality standards must be independently verified as a condition of selling on the platform. While the third-party certification standards currently only apply to three categories of supplements, this is expected to expand to other categories (and perhaps all supplements) sold on the website over time.
This is a significant “raising of the bar” for supplements for US consumers. While there are still significant issues (like efficacy concerns) with the vast majority of dietary supplements, these new rules should provide consumers with more assurance that what is on the label is what’s actually in the bottle, and the product is free of contaminants and adulterants. Still not a great market for consumers, but it is an improvement over the current state.

Do pill organizers help or hurt?
Scott Gavura on August 25, 2016
Link


In order for medication to work, getting a prescription filled isn’t enough. You have to actually take the medication. And that’s where you (the patient) come in. Estimates vary based on the population and the medication, but a reasonable assumption is that 50% of people given a prescription don’t take their medication as prescribed. In pharmacy terminology we usually call this medication compliance, but because that sounds a bit paternalistic, the term medication adherence is also used. People forget doses, deliberately skip doses, and sometimes even take more than directed. Often, the prescription isn’t finished completely. Perhaps not surprisingly, people are less likely to adhere to their prescribed medication schedule when the condition they are treating has no symptoms. All things being equal, you’re more likely to take your pain control medicine than your hypertensive medications: Pain medications have side effects, but should help you feel better right now. Hypertension medications can only make you feel worse. Statins (as a group of medications) are another good example. We treat high cholesterol to lower the risk of heart disease: heart attacks, strokes, and death. It has no obvious benefit now, nor will we ever be able to point to the benefit we received. We’re taking the medication to reduce the risk of something happening in the future. If the drug isn’t taken regularly (or at all) then you’re not going to get the expected benefits of statin therapy. The “value” that treatment delivers is reduced (or eliminated). And if you stop a medication periodically, then restart it, you might get more side effects than you would have if you just took it regularly.
Why proper dosing is important
When medications are licensed and approved for sale, the suggested schedule for use isn’t made up out of thin air. It’s based on the accumulated scientific evidence which showed it to be effective. Bioavailability studies and clinical trials guide decisions about what an appropriate dose should be. If your antibiotic is 500mg twice a day for 10 days, that’s because that specific dosage has been shown to provide the necessary blood or tissue concentrations in order to treat the illness. If your statin medication is 10mg once per day, that dosage has been studied in clinical trials and presumably been shown to produce a benefit (e.g., a reduction in the risk of heart attack or stroke). When a medication isn’t taken as directed, there can be negative consequences. And with more and more medications being introduced that can be taken orally (e.g., about half of the newer cancer drugs are oral, not intravenous), it’s essential to find ways to ensure that people take medications safely and accurately.
Because many people forget to take their medications as directed, and may also be on multiple medications, the idea of a multi-medication compliance pack or “pill organizer” has grown. They are enormously popular among seniors who may be on several medications, each with their own dosing schedule. Some of the benefits include:
    • They can automatically manage complicated dosing schedules.
    • They streamline medication schedules and reduce the risk of errors (they eliminate the question “Did I take my medications today?”)
    • They can reduce wastage of medication
    • They can help people stay in their own homes longer, maintaining autonomy and independence
What pill organizers do, really effectively, is they monitor medication use. When an organizer is used properly, any missed doses are obvious. I have worked in many pharmacies and pill organizers are very common – not just for those in long-term care, but for anyone that is on one (or several) chronic medications and needs a tool to simplify use and help them to remember to take their medication. To be frank, I’ve never even considered the thought that they may not always be helpful, as the answer always seemed self-evident.
The study
Given my own assumptions about pill organizers, I was surprised to see recent headlines like “Pill organizers could put seniors at risk” and “Pill organizers could cause adverse effects among elderly.” The story being reported is research by Debi Bhattacharya and colleagues at the University of East Anglia. The title is long and a bit confusing: “The feasibility of determining the effectiveness and cost-effectiveness of medication organisation devices compared with usual care for older people in a community setting: systematic review, stakeholder focus groups and feasibility randomised controlled trial.”
There were multiple components to the study. Initial work looked at the best way to evaluate medication organization devices (MODs), and included a literature search as well as discussions with patients and health care professionals.
This work informed the trial design. They used a “2 × 2 factorial design” to compare MODs with usual prescription drug packaging. They also simultaneously compared providing drugs on a weekly or a monthly basis. Because of the design, there was no blinding possible.
The actual intervention went as follows:
    • Potential participants were found in six medical practices. They had to be over the age of 72 and prescribed 3 or more medications.
    • One third of the 288 potential participants already used a pill organizer. One quarter were deliberately not taking their medication as prescribed. These patients were excluded. There were several other rules for exclusion.
    • Of the remaining 80 patients, about half were inadvertently not taking their medication as prescribed. These were included in the trial, with some exclusions.
    • The researchers were left with 29 patients, half of whom were given pill organizers and half to continue as per normal.
The findings were a bit surprising. There’s actually a lack of good evidence showing that MODs improve health outcomes or quality of life. While there’s some evidence showing MODs improve adherence, there’s also some evidence showing they may increase hospitalizations.
Based on an analysis of recruited patients, the prevalence of intentional non-adherence was 24.7%. In the remaining patients, the rate of unintentional non-adherence (pre-study) was 46.1%. This was the group then randomized to pill organizers versus normal prescription packaging.
This comment from the researchers didn’t surprise me at all:
Some medications were neatly presented with the correct blisters in their original packaging in an organised fashion and others appeared to have been randomly tossed into buckets, bags and boxes. One participant, who was subsequently withdrawn from the study, had very poor eyesight and used the colours and sizes of his medicine boxes to distinguish one from another. This participant had incorrect blisters inside boxes. Many patients had medicines surplus to reasonable requirement in their possession, as summarised in Table 17. As an extreme example, one participant presented 17 unused tubes of Ovestin cream and seven unopened boxes of codeine phosphate. Many participants had excessive numbers of surplus prescribed painkillers. No patients reported any discomfort with or declined the removal from use of their old medicine stocks.
Many patients had a large excess of medications on hand:

So what were the results of being randomized to a pill organizer? Overall compliance between all groups was very good. However, in the MOD groups, there were five adverse events, including three falls, one diabetic low blood sugar event, and one event where a patient was so ill they were “trapped in a bathtub for 12 hours”. There were no adverse events in the group that had continued to take their medication as per their normal processes. The difference was calculated to be statistically significant. How could this occur? It was likely because participants were not previously taking their medication exactly as prescribed, so the MOD meant a change (and possibly an increase) in their regular dose. With the sudden changes, some experienced adverse events.
Conclusion: A little surprise
This was a small trial with surprising results, but identified a risk that could be quite real to the hundreds of thousands of people who struggle to manage their medications. While medications are prescribed with certain expectations about usage, the patient experience can be very different. It’s essential for health professionals, physicians and pharmacists alike, to understand our patient’s perspective and their habits. MODs themselves, or any other forms of pill organizers, aren’t harmful or problematic on their own. This research does show, not surprisingly, that changes in medication doses and schedules, brought on by an MOD, could raise the risk of a medication-related adverse event. We see compliance aids as a tool to help improve outcomes and patient satisfaction in the absence of evidence to show they actually do so. What I learned from this study is that any decision to use an MOD requires a collaborative discussion with the patient to carefully understand their perspectives on medication use, and ideally, some documentation of non-compliance with the prescribed schedule. Used properly, an MOD can support independence or autonomy. Used without careful planning, these devices may be inadvertently be causing harm.

Can DNA testing predict your response to drugs?
Can your genes really predict how you will metabolize certain medications? The FDA has approved the first direct-to-consumer test that claims to do this. How meaningful are the findings?
Scott Gavura on November 29, 2018
Link

A few years ago I looked at the burgeoning market for direct-to-consumer (DTC) genetic testing that was being rolled out in pharmacies. Pharmacogenomics, as it’s called, is claimed to provide valuable information that can help in prescription drug selection. And it’s true that over 100 drugs are approved by the FDA that reference genetic variation in response. At the time of my original post, I commented that genomics was promising, but that its overall effectiveness had yet to be proven. Fast forward to 2018, and the FDA has now announced that the company 23andme has had a DTC genetic test approved for detecting variations in how certain medications may behave in your body. Has the science caught up to the marketing and hype?
What did the FDA approve?
The FDA made the following announcement:
Today, the U.S. Food and Drug Administration permitted marketing, with special controls, of the 23andMe Personal Genome Service Pharmacogenetic Reports test as a direct-to-consumer test for providing information about genetic variants that may be associated with a patient’s ability to metabolize some medications to help inform discussions with a health care provider. The FDA is authorizing the test to detect 33 variants for multiple genes.
It sounds promising, but the FDA is very limited in endorsing the test itself:
The 23andMe Personal Genome Service Pharmacogenetic Reports test is not intended to provide information on a patient’s ability to respond to any specific medication. The test does not describe an association between the detected variants and any specific drug nor whether a person will or will not respond to a particular drug. Furthermore, health care providers should not use the test to make any treatment decisions. Results from this test should be confirmed with independent pharmacogenetic testing before making any medical decisions.
This seems hardly like a ringing endorsement of DTC testing. It also notes:
The FDA’s review of the test determined, among other things, that the company provided data to show that the test is accurate (i.e., can correctly identify the genetic variants in saliva samples) and that it can provide reproducible results. The company submitted data on user comprehension studies that demonstrated that the test instructions and reports were understood by consumers. The test report provides information describing what the results might mean, what the test does not do and how to interpret results.
Reading between the lines, my sense is that the FDA seems to simultaneously feel it’s reasonable to make this information available, while simultaneously cautioning that actual medical decisions, including using it to select or adjust medications, is not appropriate without confirmatory testing. Which seems like a pretty weak endorsement for sales. Interestingly, the FDA issued a warning about unapproved tests the following day, on November 1, 2018:
The FDA has become aware of genetic tests with claims to predict how a person will respond to specific medications in cases where the relationship between genetic (DNA) variations and the medication’s effects has not been determined. These genetic tests might be offered through health care providers or advertised directly to consumers and claim to provide information on how a patient will respond to medications used to treat conditions such as, depression, heart conditions, acid reflux, and others. They might claim to predict which medication should be used or that a specific medication may be less effective or have an increased chance of side effects compared to other medications due to genetic variations. Results from these tests may also indicate that the health care provider can or should change a patient’s medication based on results from these tests. The FDA is also aware of software programs that interpret genetic information from a separate source that claim to provide this same type of information. However, sufficient clinical evidence is not currently available for these genetic tests or software programs and, therefore, these claims are not supported for most medications.
It continued:
There are a limited number of cases for which at least some evidence does exist to support a correlation between a genetic variant and drug levels within the body, and this is described in the labeling of FDA cleared or approved genetic tests and FDA approved medications. The FDA authorized labels for these medical products may provide general information on how DNA variations may impact the levels of a medication in a person’s body, or they may describe how genetic information can be used in determining therapeutic treatment, depending on the available evidence.
The bottom line from the FDA seems to be, if the correlation between test result and drug effect isn’t already in the product’s marketing and use information, then the result should not be considered useful for clinical decision-making. The FDA gives that warning to manufacturers in the same warning:
If your test claims to predict a patient’s response to specific medications, confirm that the FDA-approved drug labels for medications included in your test labeling describe how genetic information can be used in determining therapeutic treatment.
Hype vs. science
When genetic testing gives results that have not been show to be definitively useful, then problems can occur. Changing or avoiding drugs based on unvalidated testing has the potential to worsen your care, not improve it. For example, numerous tests claim to give results which can help in antidepressant selection. However the relationship between genetic tests and the effectiveness of antidepressants has not been proven. Yet that’s exactly what the myDNA test does, as noted in a report by the CBC:
The CBC report on DTC testing is cautiously positive, profiling a pharmacy that sells the test, but also sharing some criticisms and concerns, including pointing to a statement from the Canadian Medical Association that cautions physicians about DTC genetic testing:
DTC genetic tests are not regulated in Canada. The clinical validity and reliability of these tests varies widely, but DTC genetic testing companies make them available to consumers without distinguishing between those that may be useful to the management of one’s health, those that have some limited health value, and those that are meant purely for recreational use.
It continues,
The CMA believes that patients have the right to be fully informed about what a DTC genetic test can and cannot say about their health and that the scientific evidence on which a test is based should be clearly stated and easy to understand.
The 23andme test is the only pharmacogenomic test approved by the FDA. None are approved in Canada at all. A paper published in March 2018 by Stefany Tandy-Connors and colleagues, entitled “False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care” highlights some of the quality concerns with DTC test. The researchers looked at 49 patient samples where DTC testing had identified genetic variants. They reported:
Our analyses indicated that 40% of variants in a variety of genes reported in DTC raw data were false positives. In addition, some variants designated with the “increased risk” classification in DTC raw data or by a third-party interpretation service were classified as benign at Ambry Genetics as well as several other clinical laboratories, and are noted to be common variants in publicly available population frequency databases.
Purchasing a test? Proceed with caution
DTC genetic testing is promising but, like many new medical technologies, the hype is outpacing the actual science, as the relevance of these tests, even when they are accurate, is often unclear. While the marketing paints an optimistic picture of how these tests may be useful, the opposite is equally likely to be the case. The FDA’s regulation and approval of the 23andme test is a cautious first step in regulating this “wild west” of healthcare.

Antioxidants and Exercise: More Harm Than Good?
Scott Gavura on November 24, 2011
Link

Multivitamin supplementation has been getting a rough ride in the literature, as evidence emerges that routine supplementation for most is, at best, unnecessary. Some individual vitamins are earning their own unattractive risk/benefit profiles: Products like folic acid, calcium, and beta-carotene all seem inadvisable for routine supplementation in the absence of deficiency or medical indication. Vitamin E, already on the watch list, looks increasingly problematic, with data recently published confirming the suspected association of supplementation with an elevated risk of prostate cancer.
Reading through the vitamin posts here at SBM, one issue comes through repeatedly: The danger of assuming therapeutic benefits in the absence of confirmatory evidence. Vitamin supplement have the patina of safety and of health, a feature that’s reinforced when you purchase them: You don’t need a prescription, you don’t get counseled on their use, and there isn’t a long list of frightening potential side effects to accompany the product. You can pull a bottle off the shelf, and take any dose you want. After all, how harmful can vitamins be when you can buy 5 pounds of vitamin C at a time, or vitamin E capsules in a 1000-pack? But the research signals seem to be getting stronger, and most are pointing in the same direction: what we though we knew about antioxidants was based on simplistic hypotheses about nutrition and health. And while we thought we were doing ourselves good with antioxidant supplements, we may have been doing harm.
I have vitamin confession to make, like Harriet Hall did a few years ago. I too was a panacea-seeking antioxidant-taker. As background, I’m a marathon runner and occasional triathlete. Several years ago, I was training for an Ironman triathlon, and banking 20+ hours of intense exercise per week. That may sound absurd to many (it does to me, now that I have kids) but that kind of training is necessary for the long races. So what did the pharmacist-wannabe-triathlete with access to discounts do? He stocked up on the fancy bottles of multivitamins, the “endurance” version, of course — with extra antioxidants. Why did I supplement? I wanted to maximize my workouts, speed recovery, and minimize downtime and the risk of injury. Oxidation sounds bad — like a rusting car. Anti-oxidants sounded like the ultimate in preventative medicine. My workouts may have been more extreme, but the practice of supplementing if you exercise is common among athletes.
As it turns out, not only were the antioxidants likely ineffective, they may have compromised some of the gains I was seeking with all that training. That I didn’t evaluate the evidence at the time was my critical-thinking blind spot. Over the the past several years, more data on antioxidants and exercise have emerged. A recent review article, profiled by sports & science blogger Alex Hutchinson at his blog Sweat Science, was an opportunity to get caught up on the evidence. And there’s a lot, nicely summarized by Tina-Tinkari Peternelj and Jeff S. Coombes in this month’s Sports Medicine: Antioxidant Supplementation during Exercise Training: Beneficial or Detrimental?
Let me address the biggest limitation of the paper first. This is just a review paper — not a systematic review. While the authors describe using systematic search strategy, there’s no methodology described for the articles selected, nor is there a systematic appraisal of the literature selected. And as Travis Saunders at the excellent Obesity Panacea blog recently pointed out, a review article with the right amount of cherry picking can be used to support even the most implausible hypothesis, such as the potential benefits of smoking to distance runners. I couldn’t locate any published systematic reviews on this topic, so perhaps it’s more appropriate to consider the paper as a launching point for a review, but not a definitive statement on the evidence.
Why antioxidants?
There’s good epidemiologic data to suggest that a diet rich in foods that are naturally high in antioxidants is associated with better health outcomes. So if some antioxidants are good, more might be better, right? At a minimum, supplements might allow the kale-haters to get all the health benefits their cruciferous-vegetable-loving friends could be enjoying.
Oxidation (electron loss) and reduction (electron gains) are ubiquitous in biochemical reactions. While oxygen is essential to life, the outputs of respiration have the potential to do cellular damage in the form of “reactive oxygen species” or ROS. The ROS can damage cell membranes and other components. The imbalance is sometimes called “oxidative stress.” Antioxidants work to eliminate the oxidative stress by neutralizing ROS when they develop, preventing cell damage. We have evolved complex systems to produce several antioxidants (e.g., glutathione, uric acid, coenzyme q-10) endogenously — the process is too critical to rely solely on the consumption of dietary antioxidants like vitamin C, vitamin E, and beta-carotene, which also play a role in managing ROS.
The antioxidant-exercise hypothesis is simple: exercise more, breathe more, oxidize more. Exercise can also damage muscle tissue. So the idea of boosting the antioxidant reserves to offset the perceived negative effects of exercise emerged. The expected results: better workouts and faster recovery. But like the t-shirt says, it’s a bit more complicated than that.
So let’s look at the data in the paper. The authors found 150 studies, but most were small and had weak methodologies:
As commonly found in sports nutrition research, the vast majority do not adhere to all the accepted features of a high-quality trial (e.g. placebo-controlled, double-blind, randomized design with an intent-to-treat analysis). Indeed, most studies fail to provide sufficient detail regarding inclusion and exclusion criteria, justification of sample size, adverse events, data gathering and reporting, randomization, allocation and concealment methods, and an assessment of blinding success. The poor quality of the majority of studies in this field increases the possibility for bias and needs to be always considered when evaluating the findings.
Summarizing the data is complicated by different supplements, different endpoints, varied durations and doses, and a lack of hard outcomes. The most common endpoint was some measure of oxidative stress, and on balance (though not always consistently) the data suggest that antioxidants do reduce this parameter. It’s been shown with vitamin C, vitamin E, beta carotene, and other antioxidants. Good news? Not really. It’s an endpoint without any demonstrated relationship to something meaningful — like performance or recovery.
Evaluations of the effects of antioxidant supplements on exercise-induced muscle damage are disappointing. The usual research approach is to look at measures of muscle damage in the bloodstream — enzymes like creatine kinase, which are a indicator of cell rupture. But the evidence is mixed — there’s no strong evidence to suggest supplements have any meaningful effect on muscle damage. What’s more concerning is that some studies have suggested that supplements may induce muscle injury and actually delay recovery.
So do antioxidants have any acute benefits on exercise? Should I be selecting the energy bar with extra vitamins? The data are more consistent here — there does not appear to be strong evidence of a performance-enhancing effect when antioxidants are consumed during exercise. With some exceptions, single ingredient and multiple-product supplements including vitamins E, C, coenzyme Q10, quercetin and polyphenol resveratrol have generally failed to demonstrate consistent effects in animal and human studies. Again, the quality of the studies and the lack of reproduction of many of the trials precludes firm conclusions.
Let’s consider the post-workout period now, and it’s here where we get to the most concerning data. Antioxidant supplements seem to be working against the beneficial cardiovascular effects of exercise. Mechanisms could include:
    • Promoting, rather than reducing, oxidative stress: In some cases, supplements appear to raise indicators of inflammation, rather than reduce them.
    • Reducing the ability to adapt to exercise-induced oxidative stress: Cells will naturally adapt to increases in ROS by upregulating endogenous enzyme systems. Supplements may inhibit this endogenous adaptation.
    • Affecting physiologic processes like muscle contraction and insulin sensitivity: Supplementation, by affecting the concentration of ROS, may interfere with muscle function and recovery from the effects of exercise. A study by Ristow identified that supplementation with vitamins E and C inhibited the usual insulin-sensitizing effects of exercise. The result, for diabetics that exercise and take antioxidants, could mean an elimination of the expected benefits.
So what does the science say about antioxidants and exercise?
Simple solutions can be the wrong ones. Surrogate endpoints, like those that measure oxidative stress, can’t be extrapolated to infer positive health effects in the absence of confirmatory data. Like other areas of CAM, our ability to draw conclusions is limited by a lack of good data. The evidence is inconsistent and generally unimpressive when it comes to the effects of antioxidant supplements on exercise. So we’re challenged to make decisions based on incomplete information. In light of what we know about antioxidants and exercise, the trend in the data is strongly suggestive of zero benefit, at best, with the real possibility that there may be negative consequences to supplementation. Overlay the epidemiologic evidence that looks at mortality, cancer, and other outcomes, and the attractiveness of antioxidant supplements drops even further. The best advice for those that exercise seems to be to focus on consuming a diet rich in fruits and vegetables, and leaving the antioxidant bottles on the shelf. There appears to be little that is complementary about them.
Reference
Peternelj TT, & Coombes JS (2011). Antioxidant Supplementation during Exercise Training: Beneficial or Detrimental? Sports medicine (Auckland, N.Z.), 41 (12), 1043-69 PMID: 22060178

What’s in your Traditional Chinese Medicine?
What’s in your Traditional Chinese Medicine? An Australian analysis of 26 products found 92% were contaminated with heavy metals, undeclared plants, pharmaceuticals, or even animals like the endangered snow leopard, cat, dog, rat and pit viper.
Scott Gavura on December 17, 2015
Link


Two weeks ago I detailed the pervasive problem of poor quality supplements. The main reason for this seems to be weak regulatory standards that prioritize the rights of manufacturers to sell supplements over the rights of consumers to buy safe, high quality, properly-labelled products. Call it “health freedom“, where the freedom belongs to producers, who in many countries are largely freed from most of the quality and safety regulations that are in place for licensed prescription and non-prescription pharmaceuticals. The result of weak regulation is that few supplements sold on the market today have been properly tested for safety or effectiveness, and there are few quality standards for the production of these products.
Not surprisingly, there are persistent signs that consumers may face real risks to their health from using these products. Now a new study from Australia confirms what past studies have already shown: adulterated and contaminated herbal remedies are the rule, rather than the exception. They often contain undeclared ingredients ranging from potential allergens to heavy metals to endangered species.
At a minimum, we should expect supplements to be labelled properly. Consumers should know what they are paying for, and get what they pay for — anything else is fraudulent and potentially very dangerous.
So how does a consumer know that the label on a bottle of supplements is accurate? It’s almost impossible. With drug products, drug regulators inspect manufacturing facilities, verify production standards, and enforce the quality and consistency of the final product. When it comes to supplements such as herbal remedies, none of this may occur. Not only must the source material be verified, but a lack of contaminants must be verified. Herbals and botanicals are plant-based products that are natural concoctions of chemicals which are rarely purified or standardized to contain a predictable amount of any single active ingredient. Unless the manufacturer tests rigorously for specific additives, chemical adulterants, or toxic substances (like heavy metals), there is no way to know for certain that a herbal remedy is pure and uncontaminated. There is no routinely-conducted quality testing, so consumers are completely at the mercy of the manufacturer’s own quality assurance process that must confirm the presence of the desired substance and also the absence of contaminating substances. And there is no evidence that this is taking place.
Endangered species, pharmaceuticals, and heavy metals in your herbal remedies
A group of Australian researchers recently published a study of legally purchased Traditional Chinese Medicine (TCM). They used a series of molecular tests to see if what was on the label was actually in the bottle, and then further tested the products for pharmaceuticals, heavy metals, and other contaminants. What they found was a startling lack of product quality, and in some cases, what appears to be the deliberate adulteration of TCM with prescription and non-prescription drugs.
The researchers purchased 26 TCM products from retail stores in Australia, and directly from Australian TCM practitioners. Samples included tablets/capsules, teas, and one liquid sample. They first attempted to do a DNA analysis, and found sufficient DNA in 22 of the samples. There was so much plant contamination that the authors noted the number of ingredients were often “too numerous to list” and so they highlighted the most concerning ingredients. For instance, one product contained Asarum (TCM1) which contains aristolochic acid, a strongly carcinogenic (and natural) substance which has been banned worldwide.
Half of the products they purchased were not even legally approved by the Therapeutic Goods Administration (TGA), yet even that approval was no mark of quality: contamination was found in products whether they were approved or not. Plants and animals not listed on the label were found in most products, including:
    • the snow leopard (an endangered species)
    • cat
    • dog
    • rat
    • shrub frog
    • pit viper
    • a variety of bovids (such as goats)
The contamination doesn’t end there. A wide array of pharmaceutical contaminants was also found in the samples including:
    • analgesics like acetaminophen
    • antihistamines
    • steroids
    • anti-inflammatories like ibuprofen
    • erectile dysfunction drugs like sildenafil (Viagra)
    • antibiotics
    • stimulants
    • The anticoagulant (“blood thinner”) warfarin, used in rat poison
    • Most spectacularly, clinically significant amounts of two neurotoxins, brucine and strychnine
Twenty-five samples were screened for the heavy metals arsenic, cadmium, and lead. Twenty contained at least one heavy metal. Eleven contained all three metals. In many cases the amount consumed per day, if the product dose instructions were followed, would result in heavy metal consumption that exceeded safe levels.
The bottom line? Only two of 26 products tested were not found to contain any undeclared substances:
Manufacturing mistakes? Unlikely!
Is sloppy manufacturing and cross-contamination between different products to blame? Unlikely, given the pattern of contamination observed.
    • One sample (TCM18) was sold as weight-gain promoting product. It was adulterated with both cyproheptadine and the steroid dexamethasone, both of which are drugs that can increase appetite.
    • Another (TCM2) sold as product for “reducing hay fever” and “nasal secretions” contain a stimulant/decongestant, ephedrine, an analgesic, salicylic acid, an antibiotic, amoxicillin, and a blood thinner, warfarin. It is frightening that none of these ingredients were actually disclosed, creating a real risk of harm.
    • Finally, TCM8, marketed for “arthritis” and “pain” contained traces of the endangered snow panther, as well as tiger. Tigers have a long history of use in TCM, a prescientific belief that is driving the poaching of these animals, risking their extinction.
Who is happy with the status quo? Manufacturers.
Loose regulatory structures in Australia (and worldwide) have resulted in TCM remedies that largely fail to meet even basic quality standards for medicines. There is no acceptable reason for contamination (and adulteration) of TCM, yet this appears to be commonplace based on the sample studied. Perhaps not surprisingly, the Chinese Medicine Society in Australia feels the status quo is acceptable, and warns against anything that might result in products that meet basic health and quality standards:
The Federation of Chinese Medicine Society of Australia said the study provides no cause for concern, saying contamination would not be widespread in Australia. The society’s president, Professor Lin Tzi Chiang, acknowledged that some manufacturers might not be complying with standards set by the TGA, but said by and large most manufacturers would be doing the right thing.
“Unfortunately for sure, there might be one or two products that it might happen like that, but it cannot be blamed on the whole profession,” he told SBS World News.
He warned against over-regulation of traditional Chinese medicines, saying it would place an unfair burden on the industry and profession.
The evidence demonstrates otherwise. 92% of products tested failed to meet quality standards. A single adulterated or contaminated pharmaceutical product in a country like Australia would trigger a national recall and quite likely legal repercussions for the manufacturer. Yet contamination and adulteration appear to be business as usual in the TCM industry, where advocates are oblivious to the possibility of harm, and don’t even mention the right of consumers to purchase products that don’t contain unlabelled Viagra, dog, endangered species, or neurotoxins.
Still no evidence of effectiveness
All of the problems with TCM products found in this study need to be considered in the context of what we know about their efficacy, because ultimately a decision to take any product to improve our health needs to balance expected benefits against known risks. With TCM, any benefits we can expect are unclear. While the specific products studied in this analysis are not named, I’m not aware of any TCM product that is backed by good evidence of efficacy or safety. Even if it was effective, how could we be confident that it wasn’t due to the inclusion of prescription drugs?
Given the lack of any established benefits, and the almost certain likelihood that any given TCM product (in Australia, at least) is probably contaminated or adulterated, consumers are in the worst possible situation. I can’t think of any circumstances where the benefits might be clear enough to outweigh the risks.
Regulation of the supplement industry has been approached with a light touch, and now the consequences are being documented. The idea that herbal remedies including TCM are safe and effective is a marketing strategy based on a fallacy. Consumers may risk their own health when they buy products that are quite likely to be adulterated and contaminated. The industry’s unwillingness to recognize the problem and to clean up its own act is telling — these companies prioritize profits over consumer safety. And as long as consumers keep buying their products, and regulators do nothing, there’s little reason for the situation to change. At Science-Based Medicine we continue to advocate for more rigorous standards for supplements, herbal products and TCM — standards that are equivalent to drug products, where products are tested for quality and where claims of effectiveness must be backed by evidence. Until standards improve, or unless you don’t mind some endangered species or heavy metals in your remedy, you’re better off steering clear of TCM.

   Herbs, Supplements & Vitamins

The Supplement Con
A new article in Business Insider challenges the major narrative promoted by the supplement industry – that supplements are safe, effective, natural, and actually in the bottle. If we are lucky, this may mark a the start of a sea change in how Americans see supplements.
Steven Novella on August 16, 2017
Link


A recent article in Business Insider is an encouraging sign that skepticism about the supplement industry is starting to go mainstream. The article hits all the main points – the supplement industry in the US is now $37 billion, is largely unregulated, and their products are largely worthless, make unfounded claims, and may even be harmful.
They correctly point out the key factor that made the supplement industry go from bad to terrible:
In 1994, about 600 supplement companies were producing about 4,000 products for a total revenue of about $4 billion. But that market has since ballooned — today, close to 6,000 companies pump out about 75,000 products.
“We’re regulating that with 26 people and a budget of $5 million,” [FDA spokesperson] Tave said.
The change dates to the 1994 Dietary Supplement Health and Education Act (DSHEA). This law did a few things. First, it greatly expanded the definition of “supplement” to include herbs and other products that are not, in fact, taken as a nutritional supplement but for their pharmacological activity (i.e. drugs). Second, it allowed supplement makers to make “structure-function” health claims for their products without FDA oversight. This means a supplement maker can claim their product supports your body’s immune system so it can fight off cancer, even though it can’t directly claim to treat cancer – a subtle and ultimately meaningless difference.
Essentially the supplement industry was given the ability to sell unregulated snake oil, so they did, ballooning from a $4 billion to a $37 billion industry.
A review of all available evidence, which we have done over the years at SBM, suggests that this entire industry is largely worthless, providing scant health benefits to consumers. Further, they present measurable risk.
Only a tiny slice of the industry appears to be legitimate – actual vitamin and mineral supplements used for targeted evidence-based supplementation. Pregnant women need supplemental folic acid, vitamin D insufficiency is common (though controversial), certain illnesses require specific supplementation, and some people have specific nutritional deficits for various reasons. Some people also require more complete nutritional supplementation because they can’t get enough from eating regular food.
That, however, is it. There is no evidence that routine supplementation with a multi-vitamin or specific vitamin is of any health benefit, and it doesn’t replace eating a well-rounded nutritionally complete diet. Antioxidants are useless and may, in fact, be harmful.
Herbal products fair no better. They are offered for a variety of common health conditions, based largely on anecdotes or very thin reasoning. By the time large clinical trials are done, the supplement industry has already created the belief in the general public that their herbal products work. One by one rigorous clinical trials have shown that the most popular herbal remedies do not work as advertised: ginkgo biloba for memory and dementia, echinacea for cold and flu, glucosamine and chondroitin for arthritis, black cohosh for hot flashes, and saw palmetto for the prostate and urinary tract.
Other herbs may have a marginal benefit, but also significant risks. St. John’s Wort, for example, does have a small effect on mild to moderate depression, but also has a long list of drug-drug interactions. In the end it is clear that St. John’s Wort is just a terrible drug, with a poor risk to benefit ratio.
The industry also has huge problems with quality control. Reviews have shown that herbal products are commonly adulterated with actual drugs, contaminated with heavy metals and other toxins, and substituted with cheaper ingredients like alfalfa. Even if there is a marginal benefit to some herb in a clinical trial, where they use DNA barcoding to verify the content and measure the amount of active ingredients, this does not translate to the store shelf.
The result of all this is a $37 billion con on the American public. How did we arrive at this scandalous situation? Again, it mostly stems from DSHEA, which was a blatant pro-industry and anti-consumer law. The deeper problem is the anti-science and anti-intellectual narrative that promoters of supplements and alternative medicine have sold to the public over the last few decades. There has been a self-reinforcing feedback loop in which snake oil salesmen used the money they made from selling their wares in order to market their narrative to the public and to lobby politicians. This led to favorable laws which increased their profits, and subsequently increased their marketing and lobbying might.
The end result is a public who largely believes the lies told to them by an industry trying to sell them worthless and possibly harmful products, often with outrageous claims. All cons begin with a compelling story, and the supplement-alternative medicine industry have theirs – natural is magically safe and effective, health product regulations are about limiting consumer choice (rather than protecting consumers from fraud), doctors are trying to keep you sick, and the pharmaceutical industry is evil.
“Natural” has been marketed as a lifestyle. Consumers are encouraged to just feel good about the health halo surrounding anything “natural” and to forgo actually thinking critically about plausibility and evidence.
Anyone who bothers to point this out is dismissed as a shill. Conspiracy theories are a convenient way to fend off any logic or evidence.
There is a clear and obvious solution to this problem – get rid of DSHEA and pass legislation for effective regulation of the supplement industry. The industry will use all of their might to fight such efforts (and have done so in the past), which means it will require political will to pass any effective legislation. Unfortunately, industry marketing has been highly effective in sapping the public of just the political will necessary to properly regulate the industry. This is similar to tactics used by the tobacco and oil industries.
It is further unfortunate that there is no major political party on the side of science and reason on this issue. Both major parties are equally anti-science when it comes to snake oil.
Hopefully more articles like the one in Business Insider will start to turn the tide of public opinion, but that will take a herculean effort.

Widespread Use of Dietary Supplements Linked to Liver Damage
Millions of Americans are taking herbal remedies that may be toxic to the liver.
Scott Gavura on October 24, 2024
Link
Dietary supplements are enormously popular. With an economic impact of $159 billion (2023), it is somewhat (but not much) smaller than Big Pharma at $800 billion (2022). The category includes thousands of products, generally consumed with the aim of health improvement or maintenance. Some supplements have defined ingredients that have been well studied, where the risk of toxicity is understood. Other supplements may be sourced from plants (e.g., herbs) and by definition will be multi-ingredient – after all, herbal remedies with medicinal effects are effectively unrefined drugs. Toxicity risks with herbal remedies may be less clear, owing to their different and varying constituents. Because there is generally less regulation of supplements versus prescription or over-the-counter drugs, there may also be discrepancies between what’s on the label compared to what’s actually in the bottle, increasing the uncertainty about what you’re actually buying when you buy a herbal remedy.
Liver harms from herbal remedies are increasing
The US-based Drug Induced Liver Injury Network (DILIN) collects and and analyzes cases of severe liver injury caused by prescription drugs, over-the-counter drugs, and alternative medicines/dietary supplements, including herbal remedies. It has previously reported that the proportion of drug-induced liver injury cases from dietary supplements nearly tripled from 7% in 2004-05 to 20% in 2013-14, with the most commonly implicated products including turmeric, kratom, green tea extract, and Garcinia cambogia. A similar trend was identified by the Acute Liver Failure Study Group, noting an increasing proportion of drug-induced liver injury attributed to dietary supplements, from 12.4% in 1998-2007 to 21.1% in 2007-15.
I have written about the National Health and Nutrition Examination Survey (NHANES) before which is a seemingly endless source of data on dietary supplement use. Surveys have been conducted every two years since 1999, and were only interrupted by the COVID-19 pandemic. In a recent study, entitled Estimated Exposure to 6 Potentially Hepatotoxic Botanicals in US Adults published in JAMA Network Open, the proportion of NHANES participants who reported consumption of six potentially hepatotoxic botanicals—turmeric or curcumin, green tea, Garcinia cambogia, black cohosh, red yeast rice, and ashwagandha—were identified. These were chosen because they are the most commonly implicated causes of supplement-induced liver injury based on the DILIN. Importantly while previous research has shown that supplements that can cause liver damage are frequently mislabeled, this study sought to better understand the frequency of use among Americans.
The NHANES survey collect a large amount of information, including detailed demographics, medical history, lifestyle factors, and dietary supplement, prescription and non-prescription drug use. This analysis looked at data collected between 2017 and March 2020. In this analysis, researchers looked for consumption of the six products listed above. Notably, doses were not assessed, nor was a direct confirmation of the ingredients in the supplements done. This was solely based on reporting of use, based on the brand name of the product reported.
In addition to the survey, about 95% of adults 18 years or older provided blood samples, which were tested with standard protocols. Participant’s livers were examined by Vibration-Controlled Transient Elastography which is a non-invasive method of evaluating the liver for damage.
Results
In a cohort of 9,685 adults, the mean age was 47.5 years, 52% female and 48% male. Racially, the participants included 16% Hispanic, 6% non-Hispanic Asian, 12% non-Hispanic Black, 62% non-Hispanic White, and 4% other races. Overall, 58% of adults reported using at least one herbal dietary supplement product in the past 30 days. (See below) Herbal dietary supplement users were generally older (mean age 51.9 vs 41.5 years), more likely to be female, non-Hispanic White, married, and had higher education levels compared to non-users. They were less likely to smoke, less likely to be below the poverty line, but had similar body mass index and alcohol use patterns compared to non-users. They were more likely to have conditions like hypertension, diabetes, coronary heart disease, stroke, arthritis, thyroid disorders, cancer, and liver issues compared to non-users. The median number of herbal dietary products used in 30 days was 1, with some using up to 22 products concurrently. Herbal dietary supplement users were also more likely to take prescription medications (70.1% vs 42.2%). They had had higher hemoglobin A1C and total cholesterol levels, consistent with their higher diabetes prevalence, but lower triglyceride levels. They also had lower serum alanine aminotransferase and alkaline phosphatase levels. Notably and importantly, no significant differences were observed between the groups for liver attenuation or stiffness scores.
Potentially Hepatotoxic Herbal Use
In this analysis, 8% of those surveyed used a botanical-containing dietary product in the past 30 days with 5% (350) used at least one of six potentially hepatotoxic botanicals, with turmeric/curcumin (236 users) and green tea (92 users) being the most common. Most botanical users (291) used only one of the six products, while a few (8) used three or more:
The majority of potentially hepatotoxic botanical users were self-medicating, with most not following healthcare provider recommendations. This included 88% for turmeric users, 80% for green tea, 63% for black cohosh, 40% for red yeast rice, 96% for ashwagandha and 100% for Garcinia cambogia users. Common reasons cited for using the products included improving or maintaining health, preventing health issues, or boosting immunity. Specific motivations included joint health or arthritis (27% of turmeric users), energy improvement (27% of green tea users), and weight loss (70% of Garcinia cambogia users). Black cohosh users (84%) mainly used it for hot flashes, and most users were women (88%). Red yeast rice was primarily used for heart health (90%) by older individuals with a high incidence of diabetes. (It is worth noting that there is little evidence to support these uses, and in some cases there are safer and more effective prescription drug alternatives available.)
The prevalence of using these potentially hepatotoxic botanical products was compared to the use of known hepatotoxic prescription medications. About 14.8 million US adults used prescription NSAIDs, commonly for similar reasons as turmeric (pain or arthritis). Simvastatin, used for cardiovascular disease like red yeast rice, was used by around 14 million people. Additionally, 7.7 million individuals used sertraline, primarily prescribed for depression but also other mental health issues. Here is how usage of these herbal remedies compares, based on extrapolating the numbers from this survey. The numbers are non-trivial:
Widespread use of Potentially Hepatotoxic Herbal Remedies
Based on the results of this survey, it’s estimated that about 15 million US adults used at least one of these six potentially hepatotoxic herbal supplements in the past 30 days, a figure comparable to the number of people prescribed NSAIDs or simvastatin. Are there recorded harms from supplements? Yes: About 23,000 annual emergency visits and an increasing incidence of supplement-related liver injuries, which has led to severe outcomes such as liver transplants and deaths.
Just because a product is “natural” doesn’t mean it’s safe, especially when consumed regularly or in supplement format. For example, turmeric had few reports of association with liver damage until formulations were developed that were more easily absorbed – or combined with black pepper which also increases absorption. Reports of hepatic damage subsequently increased as this form of use became more popular.
Consumers are often hesitant (or may forget) to disclose their use of dietary supplements to health professionals, or they may not even view them as potential medicines that can have adverse effects. To support the identification and possible mitigation of liver injury from supplements, it’s essential that users understand that there are potential adverse effects with supplements, and, as well as potential negative interactions between herbs and medications. Given their frequency of use, unreported herbal remedy use should clearly be considered as a potential cause of otherwise-unexplained liver injury.

Andrew Weil’s Seasonal Supplements
Harriet Hall on August 28, 2012
Link
Dr. Andrew Weil has teamed with Innate Response Formulas to develop a series of seminars and a line of products for “seasonally appropriate integrative strategies.” Seasonal Therapeutics is a system for adjusting diet supplement recommendations according to the season of the year. To kick off the program, a one-day seminar was presented by Weil’s colleague Tierona Low Dog in Boston on August 25, 2012. It was approved for 8 CEU credits for DCs and NDs through the University of Bridgeport, a school that has ties to Sun Myung Moon’s Unification Church and offers degrees in naturopathy, chiropractic, and acupuncture. It cost $129 to attend the seminar, but participants were given a product credit of $129 so they could apply their newfound knowledge by buying Innate products. 
In a video, Dr. Weil acknowledges that the best nutrition is obtained through diet but says it is essential to take supplements as insurance against gaps in the diet. He recommends Innate Response products because they are formulated with whole foods and contain accessory compounds that have health benefits. They are claimed to be “food, not chemicals” and “potent healing solutions.” They describe their seminars as “research based programs.” 
A series of seminar programs will address seasonal issues:
    • Autumn: Season of Harvest: focuses on liver and GI
    • Winter: Season of Reflection: focuses on immune and mood
    • Spring: Season of Renewal: focuses on purification and allergy
    • Summer: Season of Vitality: focuses on cardio and joint health.
For the Autumn seminar:
Autumn explores the inter-relationship of the gastrointestinal, immune and neurological systems. By understanding how the GI system impacts immune surveillance and brain health, you will be able to help guide your patients to better health, starting at the core. Autumn is the ideal time to focus on the body’s natural detoxification mechanisms and improve gastrointestinal function in order to prime the immune system and shore up the body’s reserves. The best time to prepare the body for the rigors of winter is not during the winter season, but before. The Seasonal Therapeutics program will teach you how to:
    • Use evidence-based, targeted nutritional supplementation to restore integrity to the gastrointestinal mucosa, enhance digestive function, repopulate the microbiome, and optimize immune function
    • Utilize seasonal changes in the diet to assist the body’s detoxification mechanisms
    • Integrate stress management strategies that encourage the exploration of gratitude and meditation
The lectures cover:
    • Chronobiology: the connection between the autumn season and health
    • An overview of the multi-directional communication between the gastrointestinal, immune and nervous systems and how this impacts health
    • The multiple faces of the human microbiome
    • Nutrient and botanical support for optimal gut/immune/brain function
    • Clinical application of pre and probiotics
    • Differential use of bitters, hepatics, demulcents, and nervines
    • Nutritional support for phase I and II detoxification
    • Putting it all together: clinical pearls
Innate Response Products
Innate Response is working with Dr. Weil to formulate a new line of products, but these will not carry Weil’s name. Innate Response calls itself “the unwavering leader of whole food nutrition.” It uses the freshest raw foods, low temperature drying, meticulous juicing, technology for rapid nutrient delivery, and vigorous quality assurance. It currently offers well over a hundred different products.
Its Cholesterol Response formula offers:
a superior union of nutrients providing a broad range of nutraceuticals and botanicals that research has implicated to be effective in helping to maintain HDL levels already within a normal range and support cardiovascular health.
Um, if your HDL levels are already within a normal range, who says they need help staying there? And who says this particular mixture of herbs would do the job?
Other claims are similarly vague and meaningless. With over a hundred products, how are you to choose among so many offerings? For women alone, they offer Women Over 40, Women’s Flora, Women’s Greens, Women’s Daily, Women’s One Daily, Women +40 Greens, and Women’s Multi. And shouldn’t these women also be taking Cholesterol, Thyroid, Adrenal and other products? And which ones go with which seasons? I guess you have to attend the seminars for guidance.
The method of sales is confusing. The Innate Response website apparently sells only to medical professionals, but the same products are sold direct to the consumer on various other websites. I tried to compare prices, but the Innate Response site won’t let me even see prices unless I fax them a copy of my medical license, which I chose not to do.
Adrenal Response
Let’s look at the first product on their list in more detail: Adrenal Response
A botanical formula targeted at helping to support biochemical imbalances, cortisol levels in particular related to alterations in adrenal function. The use of non-stimulant plant adaptogens is a safe and effective method of modulating an individual’s stress response or hormonal perturbations. Crafted from a synergistic combination of botanicals, including Sensoril®, a patented extract of ashwagandha root and leaf, and rhodiola, an adaptogen.
For additional nutritional support of the adrenal gland, take in conjunction with Cortisol Response®.
    • clinically shown to strengthen the body from the deleterious effects of chronic stress
    • documented to help normalize the manner in which the body responds to stress triggers
    • maintains equilibrium within the hypothalamic-pituitary-adrenal axis (HPA)
What’s in it? Ashgawanda root, rhodiola extract, astragalus, American ginseng, sacred basil, and schizandra berry.
What research supports it? One flawed study from India in a nutraceutical journal (JANA) that only looked at one of the ingredients, ashgawanda. JANA was a publication of the American Nutraceutical Association that was published irregularly for a few years and discontinued in 2009. I looked for more information about the 6 active ingredients in the Natural Medicines Comprehensive Database. It says “insufficient reliable information.”
A Rockwell Nutrition website also sells this product, and it has a research tab. Under that tab, they don’t even mention the JANA study. Their idea of “research” apparently is “add to cart” options and testimonials.
They offer two customer reviews that damn it with such faint praise that they made me laugh out loud:
     1.  Has not had a positive impact onmy health, but maybe it is somethin I have to take for more than just a few months.
     2.  I am taking this supplement per my physician’s order. I am taking many supplements so not sure of the exact effect of this particular one, but I have no problem with the taste, size of the tablets, etc., so will give it a good review.
Weil: Science vs. Intuition
Dr. Weil is not a reliable source of health information. It’s unfortunate, because so much of his information is good, but he promiscuously interleaves science-based facts with belief-based opinions in such a way that laymen have no chance of distinguishing his wheat from his chaff.
He got his MD at Harvard but, instead of doing a residency, he dropped out, experimented with drugs, and went to live on an Indian reservation to study with a Sioux medicine man. Then he went on to become “the father of integrative medicine” and establish an empire. He has openly promoted “stoned thinking,” alleging that thoughts experienced while under the influence of psychedelic drugs or in altered states of consciousness are as valid as, or more valid than, scientific evidence. Arnold Relman explains all this and more in his article, “A Trip to Stonesville: Some Notes on Andrew Weil (1998),” available online and well worth reading. 
Weil thinks his intuition trumps the results of clinical trials. For instance, he has seen improvement in children with ear infections after osteopathic manipulation (not surprising, since most ear infections resolve without treatment) and he continues to believe that cranial manipulation cures ear infections and to recommend that treatment to his followers even though there is no scientific evidence to support either its clinical usefulness or its fanciful underpinnings. 
He rejects much of conventional medicine. He has written:
I would look elsewhere than conventional medicine for help if I contracted a severe viral disease like hepatitis or polio, or a metabolic disease like diabetes. I would not seek allopathic treatment for cancer, except for a few varieties, or for such chronic ailments as arthritis, asthma, hypertension (high blood pressure), multiple sclerosis, or for many other chronic diseases….
I find it absolutely astounding that these words could come out of the mouth of a Harvard trained MD who is both highly intelligent and educated about medical science.
Some of his advice is frankly dangerous. For rheumatoid arthritis, he has recommended that patients avoid prescription drugs and experiment with a series of natural remedies to see what works best for them. Patients who do this miss out on the proven benefits of DMARDs (disease-modifying anti-rheumatic drugs) that can prevent permanent joint deformities and disabilities when taken early in the course of the disease.
Weil has become famous and popular, so much so that the American Academy of Family Physicians has invited him to be the keynote speaker at their upcoming annual assembly. I wrote a letter of protest to the AAFP and other protests are in the works, from as far afield as the Dutch Society Against Quackery.
Weil and Supplements
Weil has been in the supplement business for a long time. He had an earlier partnership with drugstore.com to sell his branded products. That didn’t work out too well. In 2005 they sued him for breach of contract. 
In 2009, the FDA sent Dr. Weil a warning letter for FDA and FTC violations involving one of his diet supplement products, Immune Support Formula. 
He sells supplements on his website, where a handy “Vitamin Advisor” questionnaire generates individual vitamin recommendations (without regard to the season). It uses the word “vitamin” loosely to include all kinds of unproven supplements. Rather than just an “advisor,” it is a marketing scheme with links to put each recommended product into a shopping cart.
My daughter and I answered the questionnaire. My daughter is 27 and in excellent health yet it recommended she take a daily multivitamin, a daily antioxidant, a calcium/magnesium pill, evening primrose oil, milk thistle, omega 3, and 1000mg vitamin C, at a total monthly cost of $99.90. I’m 67 and have several diagnoses, yet it recommended considerably less for me: a daily multivitamin, calcium/ magnesium, glucosamine, and Weil Juvenon, at a monthly cost of $65. We both cried caveat emptor and declined the shopping cart option.
As I explained in a previous post, I stopped taking a multivitamin years ago.
The Medical Letter summarized current science-based vitamin requirements as follows:
Supplements are necessary to assure adequate intake of folic acid in young women and possibly of vitamins D and B12 in the elderly. There is no convincing evidence that taking supplements of vitamin C prevents any disease except scurvy. Women should not take vitamin A supplements during pregnancy or after menopause. No one should take high dose beta carotene supplements. A balanced diet rich in fruits and vegetables may be safer than taking vitamin supplements. No biologically active substance taken for a long term can be assumed to be free of risk.
I trust The Medical Letter’s unbiased panel of experts far more than I trust Dr. Weil’s intuition.
Conclusion 
Does the new Seasonal Therapeutics program offer any improvement on the old Vitamin Advisor? Where did the idea of different seasonal supplement requirements come from? None of this is good science. It is, however, very creative and savvy marketing. Will it improve the health of customers? Possibly. But without clinical testing, we can’t know: it’s a gamble. Will it improve the health of Weil’s and Innate Response’s bank accounts? That’s no gamble: that’s a certainty.

Dietary supplement industry says “no” to more information for consumers (again)
Jann Bellamy on October 3, 2013
Link
Once again, the dietary supplement industry is fighting efforts to give consumers more information about the safety and effectiveness of dietary supplements.
Big Supp is very clever. It sells consumers on the phony idea that they need dietary supplements for good health. Even as the evidence continues to mount that consumers don’t need supplements and shouldn’t take them, the industry continues to convince the public otherwise. And in 2011 they raked in $30 billion.
The state and federal governments have served as handmaidens to the industry in this clever marketing strategy. Congress’s gift to the supplement industry, the Orwellian-named Dietary Supplement Health and Education Act (DSHEA) “effectively excludes manufacturers of these products from virtually all regulations that are in place for prescription and over-the-counter drugs, and puts the requirement to demonstrate harm on the FDA, rather than the onus on the manufacturer to show a product is safe and effective,” as SBM’s Scott Gavura pointed out. DSHEA allows supplements to make “structure and function” claims, although no one seems to know what that means, including the FDA.
States have done their part in granting chiropractors and naturopaths the authority to give “nutritional” advice and recommend dietary supplements, sometimes on the basis of dubious diagnostic testing purporting to reveal imagined nutritional deficiencies. This gives them carte blanche to sell supplements to their patients, a clear conflict of interest.
And when proposed regulation threatens their profits, the dietary supplement industry and its surrogates enlist the very public it duped to join the battle. The industry convinces the public that someone is trying to take away their access to supplements they never needed in the first place. This threat is dressed up in terms designed to push all the buttons of a public already primed to be leery of “the government” – their “health freedom” may be taken away. Actually, freedom to choose among health care practices is most threatened by withholding readily-available information which would adequately inform health care decisions.
Sen. Durbin wants more information for consumers
Sen. Dick Durbin (D-IL) has (once again) introduced legislation with some perfectly reasonable requirements designed to help consumers make informed choices about whether to use supplements. (The Dietary Supplement Labeling Act, S. 1425) Sen. Richard Blumenthal (D-CT) joins him in this effort. I’ve criticized Sen. Blumenthal for his support of a Connecticut law forcing recognition of a disease that does not exist – Chronic Lyme Disease. I don’t know if he’s seen the scientific light and now wants to protect consumers or simply doesn’t realize that the dietary supplement industry and “Lyme literate” doctors are employing variations of the same marketing strategy: selling the public on a need and then selling the public products or services to fulfill that illusory need.
In support of the bill, Sen. Durbin refers to yet another government report on the health risks of supplements. A recent Government Accounting Office report noted that between 2008 and 2011, the FDA received 2,100 reports of health problems associated with dietary supplements. However, the GAO suspects underreporting of adverse events because most consumers call poison control centers, not the FDA. (To be fair, a reported adverse event may or may not be caused by taking a dietary supplement.)
The latest report is just one of many warnings about the dangers of supplements and pleas for adequate regulation. Recently, the American College of Medical Toxicology and the American Academy of Clinical Toxicology had this to say in a joint statement:
There is a lack of stringent quality control of the ingredients present in many herbal and dietary supplements. Reliable evidence that these products are effective is often lacking, but substantial evidence exists that they may produce harm. Indirect health risks also occur when these products delay or replace more effective forms of treatment or when they compromise the efficacy of conventional medicines.
Sen. Durbin’s bill would at least partially address some of these problems. Here’s what the bill would do:
     1.  Beef up the registration requirements for supplement manufacturers. In addition to registering, manufacturers would be required to provide the FDA with a description of each dietary supplement they make, a list of its ingredients and a copy of the label. The companies already have all of this information – at least, I certainly hope they do. This information would be available to the public.
     2.  Require the FDA to compile a list of dietary supplement ingredients (or blends of ingredients) it determines could cause potentially serious adverse events, drug interactions, contraindications or risks to subgroups such as children and pregnant or breastfeeding women. (But not to the general public.) The Institute of Medicine would evaluate dietary supplement ingredients and provide this information, at no cost to the supplement companies.
     3.  Require dietary supplement manufacturers to provide substantiation for their claims of health benefits, such as “structure and function” claims. Currently, manufacturers are supposed to have substantiation but need not give it to the FDA. Again, information the companies already have in their records, or should have.
     4.  Give the FDA authority to clear up the distinction between dietary supplements and food and beverages with additives.
Big Supp doesn’t want them to have it
In sum, the bill would give consumers some of the tools necessary to do a proper risk-benefit analysis in deciding whether to take a dietary supplement. It accomplishes this with information the companies already have or which the government will provide free of charge. But the supplement industry (once again) does not want consumers to have this information. Here’s what Michael McGuffin of the American Herbal Products Association (AHPA), an industry trade group, has to say about the bill:
There are numerous authoritative references already available to provide safety information on dietary ingredients, including AHPA’s Botanical Safety Handbook for herbal ingredients . . . Instead of using taxpayer funds to reinvent the wheel, the existing resources should be recognized.
Of course, consumers would need a paid subscription to access much of this research, if it exists, including the AHPA’s Handbook, which provides information only on botanicals. As pointed out by the toxicology experts, many of these supplements have never been fully researched. And one would need a background in pharmacy or medicine to fully understand the information provided in the Handbook.
Personally (if I took supplements, which I don’t) I’d rather have the Institute of Medicine doing my research instead of a trade organization. For example, let’s compare what the AHPA says about St. John’s wort to the analysis of St. John’s wort available from Natural Medicines Comprehensive Database, which also requires a subscription. (For brevity’s sake, I’ve omitted the references.)
AHPA Handbook:
Pregnancy and Lactation
Studies on the effect of prenatal consumption of St. John’s wort on pregnancy in mice and rats were generally associated with normal gestation and offspring development. A limited number of human case reports indicated healthy pregnancies and infants when St. John’s wort was used prenatally.
In studies of nursing mothers, the compound hyperforin was detected in low concentrations in mother’s milk while the compound hypericin was not detected in milk.
Natural Medicines Comprehensive Database:
PREGNANCY: POSSIBLY UNSAFE …when used orally. Anecdotal evidence suggests that St. John’s wort might be safe for use during pregnancy; however, animal model research has produced contradictory findings. Other preliminary research suggests that constituents of St. John’s wort might have teratogenic effects. Until more is known, St. John’s wort should not be taken during pregnancy.
LACTATION: POSSIBLY UNSAFE …when used orally. Nursing infants of mothers who take St. John’s wort can experience colic, drowsiness, and lethargy; avoid using.
Whose advice would you follow?
According to Steve Mister, from another industry trade group the Council for Responsible Nutrition, the supplement industry does not support legislation
that directs FDA to require warning labels for products or ingredients that ‘could cause’ adverse events or potential risks as this is a case of the precautionary principle run amok. While the premise may be well intentioned, in practice this requirement would lead to confusing and unnecessary label instructions likely to deter consumers from using beneficial dietary supplements based on uncommon or miniscule risks.
But that’s not what this legislation says. It plainly states that labels would have to warn only of “potentially serious adverse events, drug interactions, or contraindications, or potential risks to subgroups” like pregnant women and children. And “beneficial”? If the industry has good evidence that using dietary supplements is beneficial why not share it with the public?
In other statements, Mister seems to want to shift the focus to supplement manufacturers and sellers who aren’t complying with DSHEA and urges more resources for the FDA to address those problems. I certainly agree with giving the agency more resources, but that doesn’t really address the issues raised by this legislation: insufficient information about health benefit claims all manufacturers are touting and knowing the health risks of taking any dietary supplement, not just those sold by companies who are out of line.
Sen. Durbin’s bill has been referred to the Senate Committee on Health, Education, Labor and Pensions. Unfortunately, according to GovTrack, it has zero chance of passing.

New concerns about the safety and quality of herbal supplements
Scott Gavura on November 7, 2013
Link
If there is one aspect of “alternative” medicine that both critics and fans should agree on, it’s that products should be manufactured to high standards. What’s on the label should accurately describe what’s in the bottle. Product quality standards are essential, whether you’re using herbs or drugs. And when it comes to ensuring the products we buy are of high quality, we’re all effectively reliant on regulation to protect us. As a pharmacist, I can’t personally verify that each tablet in your prescription contains the active ingredient on the label. I am dependent on a supply chain that may stretch around the world. While the product manufacturer may be reputable, it’s only a regulator that can realistically verify and enforce production to strict quality standards. The same cannot be said for products like supplements and herbs which are regulated differently than drugs, and held to different, and in some cases, weaker standards. A weak regulatory framework, which doesn’t hold manufacturers to account, would be expected to result in a product of lower quality. And that’s exactly what you see when you look at supplements on the market today.
A new study paints a disturbing picture of the quality standards of herbal products commercially sold in Canada and North America. Entitled “DNA barcoding detects contamination and substitution in North American herbal products”, Steven G. Newmaster and colleagues from the University of Guelph in Ontario conducted authenticity testing of 44 herbal products. The authors have no personal bias against herbal medicines – the study was funded by non-commercial interests, and none of the authors reported any conflicts of interest. They’re actually quite positive about the therapeutic effects of herbal medicines, noting “there is considerable evidence of the health benefits of herbal medicine,” a statement that most at SBM would take issue with. The authors note a significant problem in the way these products are produced and distributed:
There are currently no best practices in place for identifying the species of the various ingredients used in herbal products. This is because the diagnostic morphological features of the plants on which the current Linnaean taxonomic system is based cannot typically be assessed from powdered or otherwise processed biomaterials. As a result, the marketplace is prone to contamination and possible product substitution, which dilute the effectiveness of otherwise useful remedies, lowering the perceived value of all related products because of a lack of consumer confidence in them. Herbal product substitution has been documented for many individual medicinal plant species, teas, and ‘nutraceuticals’. Although there is limited research available, the frequency of product mislabeling in herbal products has been estimated at 14% to 33% from previous studies. There are legitimate health concerns for consumers which results in a lack of confidence in safe, high quality herbal products.
Before we go into the study, it’s worth distinguishing between the physical characteristics of drug products and medicinal herbs. A surprising number of drugs we use today are derived from, or based on, chemicals originally found in nature. Acetylsalicylic acid (aspirin) is derived from salicin found in the bark of the willow tree. The antimalarial quinine is found in the bark of the Cinchona tree. Atropine was found in nightshade, and digitalis (digoxin) is what makes consuming the foxglove plant toxic. All had their origins as natural remedies. The benefit of drug products over herbs is the reproducibility of effects, which starts with isolating and purifying the active ingredient. The next step is manufacturing a dosage that results in consistency in absorption and standard and predictable dosages. Clinical trials establish if the drug has meaningful effects. So when I’m speaking with a patient about their new prescription drug, I know there’s a traceable relationship between the characteristics of product they’ve been dispensed and the drug product that was studied in the clinical trials. Consequently, it’s reasonable to expect the same outcomes and effects, based on this linkage. Even doing something as simple as changing the product from a tablet to a capsule may result in a regulator requiring bioequivalence study to confirm the effects are the same.
The rigorous controls in place for drug products don’t carry over to supplements. Many herbal products that are sold as “medicinal” contain a variety of chemical ingredients, several of which may have medicinal effects. If there was a clinical trial conducted, there is no simple way to verify that other versions of the plant contain the same combination of ingredients that produced the effects. Some herbal products do “standardize” one or more chemical constituents, where the suspected active ingredient is measured and verified in production. But even this isn’t an assurance of quality. Feverfew is a herb used to prevent and treat migraine, which is usually standardized to its content of the chemical parthenolide , the suspected actual ingredient. Yet there are dozens of chemical components in the feverfew leaf, and even standardized products cannot demonstrate effectiveness, which could mean that the active ingredient isn’t the parthenolide. Or it could be that feverfew simply doesn’t work. Without the purification and standardization offered by finding, isolating, and then testing the active ingredient, herbal products will always be at a disadvantage when it comes to quality, consistency, and predictability of effect.
Once we swallow a substance, be it a herb or a drug, our body can’t distinguish the difference. Chemicals are absorbed into the bloodstream, circulate in the body, and presumably reach the site of action and then have some sort of biological effect. They are eventually excreted, sometimes only after being transformed in the liver. The more consistent the original product, the more predictable the response in the body. Given the similarities of how herbs and drugs behave in the body, it’s hard to understand the rationale for a completely different regulatory standard for herbs. In the USA, it’s the Dietary Supplement Health and Education Act (DSHEA) that creates a double standard. In Canada, it’s the Natural Health Products Regulations. They are similar in that they implement some manufacturing and safety standards, while essentially eliminating the requirement to demonstrate that the product actually does anything useful. DSHEA goes so far as to put the requirement to demonstrate harm on the FDA, instead of requiring the manufacturer to demonstrate that a product is safe and effective. Canada regulates differently, but to an equally low standard. As I’ve pointed out before, the Natural Health Product Regulations have had a similar effect at creating a manufacturer-friendly market: Pretty much anything goes, and even homeopathic cancer, homeopathic corn, and homeopathic water (think about that one) have been approved by Health Canada as “safe and effective”. And when it comes to herbs, Health Canada approves products that are said to “tonify the kidney and fortify the yan“.
The separate regulatory systems for natural products, supplements and herbs in Canada and the United States have led to a boon in the development and sale of these products. The barriers to establishing a business are trivial compared to drugs. Importantly, there’s no requirement to actually demonstrate your product works. There’s not even a requirement to show your product is consistent batch-to-batch, because to show that you’d first need to demonstrate some objective and measurable effects. Finally and most importantly, there’s really no simple way for a regulator to actually test to see if what you’re putting in the capsule (for herbs) is actually what you say. Until now, and the technology used by Newmaster. It’s called DNA barcoding, which essentially treats DNA strands like UPC codes, examining and distinguishing between different species.
The researchers purchased herbal products for sale in Toronto, Canada and via mail order from the United States. Twelve manufacturers were involved, representing 44 products (41 capsules, 2 powders, 1 tablet). They also obtained 50 samples of known products from greenhouses. Both were studied in a blinded fashion. In total there were 30 herbal species, and these were studied against a barcoded “library” of over 100 species. Their definitions were as follows:
    • Authentic: a product contained the DNA barcode for a species that was the main ingredient on the label.
    • Contaminated: contains labelled ingredient and also the DNA barcode for a species not on the label.
    • Substitution: a product contained the DNA barcode for a species not on the label, and there was no trace of the labelled ingredient.
Here were the results:
The findings are dismal and quite discouraging for consumers and health professionals alike. Only 48% of products were authentic. 59% of the products contained species not listed on the label. One-third contained fillers and contaminants that were not labeled. Amazingly, another third of products tested contained a substituted ingredient – and none of the labeled ingredient. Of the 12 companies sampled, only two had authentic products without any substitution, contaminants, and fillers. Unlabelled fillers including wheat, soy, and rice, were found in 20% of products. Three companies had products for which no products could be authenticated:
Some of the products were of such poor quality that harms could be expected. One sample was labelled as containing St. John’s wort (used to treat depression) but actually only contained senna, a laxative. Several products were contaminated with feverfew, which has chemical ingredients that can cause side effects, including withdrawal syndromes. Feverfew may also interfere with the elimination of some prescription drugs, and needs to be avoided in pregnancy. Another product was contaminated with black walnut, which has a nasty side effect profile. And there’s also the undisclosed wheat in some products, which would be harmful to those with Celiac disease or a wheat allergy.
This is far from the first sign that there are issues with supplement quality standards. Earlier this year I wrote about the frequency and characteristics of dietary supplement recalls in the USA. That study noted that every supplement recalled between 2004 and 2012 was due to unapproved ingredients. But recalls don’t give us a comprehensive summary based on sampling – which is where this study excels. Other studies have raised similar concerns:
    • A study of 131 herbal teas revealed only 58% of products could be authenticated, and 33% were contaminated.
    • A study of 40 “black cohosh” supplements noted that 25% were substituted with related species.
    • Half of the ginseng products examined in one study contained other forms of ginseng than the labelled Panax ginseng.
    • A 2005 survey of 230 Ayurvedic medicines found that 20% were contaminated with heavy metals such as lead, mercury and arsenic.
The implications
Without reliable, consistent products, consumers can’t use herbs safely, or even assume they might work as expected. Health professionals are in a similar bind, and can’t make recommendations without high-quality products to rely on. For my entire career I’ve cautioned consumers about the quality concerns with herbal products and supplements, and the resultant risks that make me very hesitant about their use. And in the absence of good evidence of benefit, the potential risks take on more importance. There’s no question that legislation like DSHEA has created a tremendous business opportunity for manufacturers. The market is comparatively easier for manufacturers to enter. Combine this with little requirement to test products, or substantiate claims they even work, and you get a market where product contamination and substitution appears commonplace. It’s exactly what you’d predict if you loosened or eliminated the regulation of prescription drugs. Supplements do share one key feature with prescription drugs: this is big business, a $28 billion market in the US in 2010, with year-over-year growth exceeding 5% annually for the past several years. And the industry is actively behaving in ways that don’t favor consumers, such as fighting moves to give consumers more information about their products.
Perhaps not surprisingly, the supplement industry rejects this latest study, raising some minor criticisms (e.g., asking for reproducibility) but also handwaving away the overall conclusions, with no acknowledgment of the serious nature of these findings. If herbs actually have medicinal effects, then contamination of this nature and scale should be unacceptable within the industry. It’s a disappointing response, because if there’s a single issue that threatens true science-based use of herbs and supplements, it’s product contamination and adulteration worries. And that’s exactly what’s starting to occur. Last month the Children’s Hospital of Philadelphia announced it was no longer supplying supplements, and would discourage patients’ families from their use. Why?
’Because vitamins and dietary supplements are essentially unregulated, there is no sound information about adverse side effects, drug interactions, or even standard dosing for the vast majority of them,” said Sarah Erush, CHOP Pharmacy Clinical Manager and a member of the hospital’s Therapeutic Standards Committee, which recommended the policy change that was rolled out over the summer. “Administering these medications — particularly to children with serious health complications — is unethical when the risks are unknown, and when there are alternative treatments that have been proven in clinical trials to be safe and effective,” Erush said.
Conclusion
This new study joins several others in pointing out serious quality concerns with herbal products sold today. Substantive improvements are necessary to bring the quality of herbal products in line with conventional drug products. And until supplements demonstrate reliable and consistent quality, they cannot be counted on to actually deliver any predictable health effects. Yet without effective regulation to mandate and enforce better standards, there is no external pressure for change. Lax regulation has been a boon to manufacturers, and the supplement industry has exploded. It’s unfortunate that the same conditions actually make it harder to find products that are safe and effective. Until these products are held to more rigorous quality standards, consumers will continue to pay a form of health roulette each time they purchase a herbal supplement.
Reference
Newmaster S.G., Grguric M., Shanmughanandhan D., Ramalingam S. & Ragupathy S. (2013). DNA barcoding detects contamination and substitution in North American herbal products, BMC Medicine, 11 (1) 222. DOI: 10.1186/1741-7015-11-222

Where science meets supplements
The use of supplements is, for most people, not supported by science. There is little consumer protection, even less evidence of benefit, and even some evidence of harm.
Scott Gavura on May 19, 2016
Link

For those of you that missed the Science-Based Medicine day at NECSS last week, I’ve put the highlights in the following post:
The supplement industry is big business, and the popularity of these products seems to keep growing. I once worked at a small independent pharmacy that specialized in supplements, homeopathy and “alternative medicine” as way to differentiate itself from the big chain pharmacies. A lot has changed in a decade. Today, even national chain pharmacies have aisles and aisles of herbal remedies, dietary supplements, and even homeopathy. Yet despite the preponderance of products on store shelves, there is little evidence to suggest that supplements are necessary or even improve health (and may even cause harm). The right for consumers to buy products for themselves, and make their own self-care decisions, is an important one that respects individual autonomy. Regrettably, the regulations of these products are so weak and ineffective that the sale of these products quite possibly harms, rather than helps, the average consumer. The system is rigged against consumers, and it prevents the use of supplements in an evidence-based way.
What exactly is a supplement?
The idea of a risk-free magic bullet that improves our health seems irresistible. Especially when you can choose a product that allows you to avoid what are assumed to be toxic, unnatural, chemical drugs. Supplements are marketed as safe, natural and effective, and there is no question that messaging has been effective. But whether or not a product is considered a drug or supplement may be less clear than you think. But the difference is important, as the distinction can mean:
    • Whether there is an evidence to justify their sale
    • The presence of any safety studies
    • What manufacturers can claim about their products
    • The overall quality of the product
Recognizing consumer demand for supplements, and the insistence that these products were self-evidently both safe and effective, many national health/drug regulators have sought to distinguish supplements from “drug products” in some way. The FDA defines supplements as:
A dietary supplement is a product intended for ingestion that contains a “dietary ingredient” intended to add further nutritional value to (supplement) the diet. A “dietary ingredient” may be one, or any combination, of the following substances:
    • a vitamin
    • a mineral
    • an amino acid
    • a dietary substance for use by people to supplement the diet by increasing the total dietary intake
    • a concentrate, metabolite, constituent, or extract
The FDA’s own definition is problematic. This is a disparate group of products. Some supplements are completely synthetically manufactured, such as certain vitamins. These products are probably the closest to drug products (and in some cases, are considered drugs). They can have specific and genuine, established uses (e.g., folic acid in prenatal vitamins for preventing neural tube defects). These products can be easily manufactured to the same standard as conventional drug products. But the category of “supplement” also includes herbal remedies – which I would argue shouldn’t be “supplements” at all. There is no routine need to supplement the diet with any “herb or other botanical”. Outside of cooking, these products are consumed for what are believed to be medicinal effects. Yet an herbal remedy has very different regulatory oversight than if we purified the same herb, isolated the active ingredient, and manufactured it. Then it would be a drug, not an herb. Herbal remedies are effectively crude, unpurified drugs – possibly with hundreds of ingredients, and unclear product standards. Many drugs sold today have botanical origins, but are not considered supplements. Acetylsalicylic acid (aspirin) is derived from salicin, found in the bark of the willow tree. Atropine was found in nightshade, and digitalis (digoxin) is what makes the foxglove plant toxic. Yet they’re drugs, not supplement.
If the US approach to regulation sounds artificial, you’re right. For more information on the Dietary Supplement Health and Education Act of 1994 (DSHEA) that regulates supplements, there are multiple other posts that explain it in more detail.
When is a supplement not a supplement?
In general, supplements are considered safe until proven unsafe. Regulation is light, as mandated by DSHEA. In contrast, drugs are strictly regulated and must be shown to be both safe and effective before they are allowed for sale. But is the line really that clear? Consider these two examples.
    • Vitamin A is sold as both a supplement and a prescription drug, depending on the formulation and the dose. A routine ingredient in multivitamins, it’s also used as a drug to treat acne, cancer and anemia. Vitamin A is not innocuous, either. Side effects can include birth defects and liver toxicity.
    • Melatonin is a naturally-produced hormone that’s also found in some foods. Supplements are typically manufactured synthetically (and are safer in that form) and are the only hormone available without a prescription in the United States. There’s some evidence for effectiveness with jet lag, but it’s used for a variety of sleep/wake disorders. The long-term effects, particularly in children, are not well understood.
Drug or supplement, there are some common goals
Regardless of whether you’re taking a drug or a supplement, you typically want the following to occur:
    • The product to be absorbed in the body
    • That substance to get to where it needs to in the body
    • That substance to have some sort of a beneficial or positive effect
    • That substance to not be harmful to us, meaning minimal side-effects or other toxicity
In order for any of this to occur, we need to consider the science of pharmacokinetics. It’s not necessary to understand the intricacies, but a general understanding of the four factors that influence how a substance behaves in the body when we ingest it can help us evaluate the plausibility of efficacy claims. The shorthand is ADME, for absorption, distribution, metabolism and elimination (more here, for you pharmacokinetics nerds):
     1.  Absorption: What you swallow does not automatically equal what your body will absorb. Whether or not a drug or supplement is absorbed depends on the route of administration, the formulation (capsule/tablet/liquid/raw material), the chemical properties of the substance, and other factors (like food in the stomach). It needs to survive being dispersed in stomach acids and digestive enzymes. It must then dissolve fully into gastric juices (particulate matter is not absorbed by the body), and then the substance must cross cell membranes – just to enter bloodstream. Not all substances are absorbed. Drugs like insulin must be injected because they are destroyed in the stomach. Even if it makes it as far as absorption, a substance then needs to survive the “first pass effect“, which is passage of blood through the liver before it reaches the rest of the body. In the liver, enzymes attempt to eliminate and metabolize molecules, deactivating anything foreign or unwanted.
     2.  Distribution: Once a substance is absorbed, it then has to be distributed in the body to the location where it will have its presumed effect. You cannot simply assume a substance will reach any part of the body to any significant degree. A substance may adhere to proteins in the blood, reducing the “free” amount that is available for distribution to other cells. Not all chemicals, (drugs and supplements alike) are distributed equally to all parts of the body – some may deposit more readily in fat tissue, for example. The blood-brain barrier blocks most foreign molecules from reaching the brain.
     3.  Metabolism: Foreign or waste substances are typically excreted by the kidneys in the urine, but can also be secreted in the bile. Molecules may undergo chemical changes, facilitated by enzymes in the liver (and elsewhere) to make them easier for the body to eliminate. This transformation or “metabolism” is true detoxification (not the fake detox). As your ability to metabolize a substance can vary based on factors like age and genetics, drugs (and supplements) can also have their effects modified. Importantly, drugs and supplements can be metabolized by common pathways, which can lead to a drug-supplement “interaction” where the action of one substance is modified by another.
     4.  Elimination/Excretion: Foreign substances need to be eliminated from the body, otherwise blood concentrations could potentially rise to dangerous levels. The kidneys are the main organs of excretion, but secondary roots can include the stool, lungs, skin, and even breast milk.
The net effect can be illustrated in the classic concentration/time graph: Note the gradual onset (due to absorption), the peak level in the bloodstream, and then the effects of metabolism and elimination, as the concentration drops off again:
The same kinetics rules apply
The concentration-time graph is equally applicable to drugs and supplements. Consider vitamin D, which is considered to have a wide “therapeutic window”, meaning it’s nearly impossible to overdose on the vitamin to the point where you’d have side effects. Supplement seller Gary Null found a way, however, when he was poisoned by his own brand of supplements which was later found to contain excessive amounts of vitamin D.
Another example I like to cite is oil of oregano. Reading the marketing, you might think this oil has magical healing properties, from toenail fungus to skin infections, to what are claimed to be simultaneous antiviral, antibacterial and antiparisitic effects. And there are in vitro (test tube) studies showing that this product may have some medicinal properties. But in order for oil of oregano to have an effect in the body, it must be absorbed and distributed to the site of action where it must be present in sufficient quantity (and for an adequate duration) to have an effect. As a corollary, consider how you clean your hands: Alcohol hand gel is also antiviral and antibacterial, but no matter how many maragaritas you may drink, you will never be able to raise your blood alcohol level high enough to kill bacteria or viruses- without killing yourself first. The dose matters. So considering the claims about oil of oregano, claims such as “disinfectant” or even “skin infection treatment” are far more plausible than claims it’s effective for internal infections. There’s simply no evidence to suggest that the chemical constituents of oil of oregano are absorbed and available in the body to have any effect at all.
Drugs can have interactions with each other, and drug-supplement interactions are also common. Supplements can affect the ADME of drugs, leading to potentially harmful effects:
    • Calcium supplements can bind to drugs in the gastrointestinal tract and reduce overall absorption.
    • Quercitin can displace the protein binding of “blood thinners” like warfarin, potentially increasing bleeding risk.
    • Ginseng is among many supplements that can modify the way liver enzymes work, interfering with the way drugs work.
There’s also the risk of additive effects, where a drug and a supplement may have similar effects: concurrent use of vitamin E, ginkgo biloba, warfarin and aspirin can increase the risk of bleeding over drug therapy alone.
Supplements have unique risks
Now that we’ve established the common chemical and biological properties that apply to drugs and supplements, it’s worthwhile noting that there can be important differences in their characteristics as well. One of the most important limitations of supplements, in particular with the herbal and botanical-based remedies, is that there may not be any identified active ingredients. This may not initially sound concerning, but it has dramatic implications on how we assess efficacy, and the relevance of different clinical trials. If there has been no basic research that’s identified the one (or more) active chemicals among the hundreds of chemical that may be in a herb or plant supplement, it is simply impossible to apply basic quality control standards. Are you getting a leaf, a stem, the flower, or the root? When was it harvested? How was the product prepared? Without a known active ingredient, measuring blood concentrations can’t be done – because you won’t’ know what to measure. Consequently, herbs and botanicals could potentially vary in their chemical makeup from brand to brand and even batch to batch of the same product.
Contrast the herbal remedy with the typical drug product, such as a new chemical in development. Because drugs must be tested before they are allowed for sale, the chemical characteristics (ADME) must be known and well understood before any tests of efficacy. The quantity per tablet or capsule is measured precisely, and can be verified. When any clinical trial is conducted, the same formulation (e.g., capsule or tablet) is used. If that drug is among the molecules that eventually makes its way to a pharmacy near you, the manufacturer must demonstrate that the version that is sold behaves identically in the body as the formulation that was tested in the clinical trial. This gives your physician, your pharmacist, and you the confidence that the clinical trials that established a drug’s efficacy are relevant to the product you have been prescribed. None of this is possible with herbal remedies. Quality manufacturing standards are rare, and standardization is uncommon. Is a clinical trial with a supplement relevant to the product you’re considering buying? There’s simply no way to know.
Safety concerns are significant as well. Few supplements are actually subjected to rigorous clinical trials where safety can be measured. Harms are rarely reported to regulators – if they are even detected. The story of Aristolochia is cautionary and telling. Aristolochia is a plant that has been considered to have medicinal properties for hundreds, perhaps thousands of years. Owing to its resemblance to a uterus it has been thought to be effective for childbirth and has been used as part of traditional Chinese medicine for a number of conditions, (none of which were supported by any evidence). When a cluster of Belgian women developed kidney disease and urinary cancers after taking Aristolochia-containing diet pills, the catastrophic harms from this product were revealed. Aristolochia promotes cancer formation through DNA mutations. It’s now classified as a type 1 carcinogen, alongside asbestos and solar radiation. Are other botanicals or supplements causing other harms? There’s no routine data collection, so it’s impossible to say for sure. And even if there was, drawing associations is exceptionally difficult: The appearance of an effect like cancer may lag for years, or decades. The harms of a product like Aristolochia are so widespread and diffuse that it’s notable that it took a cluster of cases in Belgium to finally bring this toxicity to light. We may see elevated number of urinary cancer cases in some Asian countries, possibly for decades. Aristolochia is an example of the challenge we face in identifying and monitoring for adverse effects from herbal products. We simply have no clear understanding of the potential for harms, which is magnified when we can’t even be confident that what’s on the label is actually in the bottle.
Identity, purity, potency and stability questions
To ensure product consistency, we need to be assured that the main ingredient has been tested and is in fact present in a consistent dose. We need the assurance that there are no contaminants present. We need to be sure that the potency hasn’t decreased over time due to the preparation of the dosage form. Finally, we need to be sure that the supplement is stable when it’s stored. It’s notable that the FDA doesn’t mandate expiry date studies with supplements – because with herbals and botanicals, it’s not even clear how you’d establish a product is no longer potent. This is much easier with multivitamins and minerals.
Is your supplement manufactured to high quality standards?
While supplement manufacturers are expected to meet the FDA’s Good Manufacturing Practices (GMP) standards, there’s little evidence that supplement manufacturers consistently do this. FDA inspections repeatedly show that few companies are doing everything they can to ensure products are of high quality. Consider the following statements, with emphasis added.
From 2012, Trine Tsouderos noted in The Chicago Tribune:
Federal inspections of companies that make dietary supplements — from multivitamins and calcium chews to capsules of echinacea and bodybuilding powders — reveal serious and widespread manufacturing problems in a $28 billion industry that sells products consumed by half of all Americans. In the last four years, the U.S. Food and Drug Administration has found violations of manufacturing rules in half of the nearly 450 dietary supplement firms it has inspected, according to agency officials. The inspection reports portray an industry struggling to meet basic manufacturing standards, from verifying the identity of the ingredients that go into its products to inspecting finished batches of supplements.
From May 2013, from Naturalproductsinsider.com, an industry publication:
During a three-year period, federal inspectors have cited seven out of 10 facilities that make dietary supplements for violating regulations intended to ensure products are safe and contain the ingredients that are listed on the labels.
And:
“Unlike traditional foods, when it’s rotten, the consumer will often know by taste or smell, [but] with supplements we’re swallowing them based on blind faith in the manufacturer,” noted Pieter Cohen, M.D., a general internist at Cambridge Health Alliance and assistant professor of medicine at Harvard Medical School, who has studied supplement safety and reviewed the FDA data. “But FDA inspections appear to reveal a different story: when we take a look behind closed doors, less than a third of companies are doing everything they can to ensure top-notch products.”
From March 2016, also from Naturalproductsinsider.com, the problems don’t appear to be resolved, based on FDA inspections:
The reinspection data still reflects continuing areas of concern for the industry. Fifteen dietary supplement reinspections—or nearly one-quarter of all of them—resulted in citations for failure to establish product specifications. Setting product specs, cGMP consultants have noted, is a basic requirement. Around 17 percent of reinspected firms were cited for having inadequate batch production records.
“Largely, it’s the same problem … that systematic issue with GMP compliance,” FDA’s Welch said, citing the most common violations in the reinspection data.
“As we’ve seen, the industry knows we need to move much further beyond cGMPs to have a product that consumers can trust,” said Pieter Cohen, M.D., an assistant professor of medicine at Harvard Medical School who has researched a number of sports products that are tainted with illegal substances. “So the fact that 60 percent of firms inspected aren’t even making this incredibly low bar of cGMP is frankly embarrassing and poses serious risks to consumers.”
And also:
Joy Joseph, a cGMP consultant to dietary supplement firms, said many new companies have emerged in the dietary supplement industry. She still encounters firms that aren’t even aware of the FDA regulations in spite of the fact that they were adopted nine years ago.
“We still have a lot of companies that have never been inspected, and still today, most dietary supplement companies don’t have laboratories, and they don’t have qualified people to establish the correct specifications and do the testing,” said Joseph, principal consultant with Joy’s Quality Management Systems, in a phone interview.
“And at the end of the day,” she added later, “it is the consumer who is being harmed by these products being manufactured by companies who don’t know anything about GMPs.”
What we’re left with, as health professionals and consumers, is an industry without the ability to manufacture products that meet the basic standards in place for pharmaceuticals. Moreover, the evidence suggests that some of these companies are not even aware of the expectations to make products that meet basic standards for identity, purity, potency, and stability.
Adulteration is not uncommon
I and others have blogged multiple times about what appears to be the routine adulteration of supplements. Vox has a great website where you can check if your supplement may have drug contaminants:
These pills are barely regulated. Supplement makers don’t need to prove their products are safe or even effective before putting them on store shelves. And while supplements are supposed to be accurately labeled, a Vox review of government databases, court documents, and scientific studies uncovered more than 850 products that contained illegal and/or hidden ingredients — including banned drugs, pharmaceuticals like antidepressants, and other synthetic chemicals that have never been tested on humans.
We found examples of weight loss supplements spiked with cancer-causing drugs that had been pulled from the US market, and brain enhancers laced with chemicals that have never been approved for sale in the US. More than 100 products contained DMAA, a drug that’s been banned in the US, UK, and several other countries because it is linked to strokes, heart failure, and sudden death.
Several months ago I described an analysis of 26 traditional Chinese medicine products that found 92% were contaminated with pharmaceuticals, heavy metals, or the DNA of animals, including traces of cat, dog, rat, or pit viper. I’ve also described actions of the New York State Attorney General’s office. It accused four large retailers of selling supplements that failed to contain labelled ingredients. Testing the products with a technology called “DNA barcoding”, the AG’s office concluded that most of the products contained little to none of the labelled ingredient. They also found ingredients that were not disclosed on the label. While this testing technology was criticized (fairly) for its technical accuracy, it’s notable that vitamin retailing giant GNC has agreed to implement its own DNA barcoding testing technology for its products, and will be setting a higher quality standard that what is required of the industry.
How can we select and use supplements safely?
A supplement worth taking is backed by good evidence, and is unlikely to cause harm. Most supplements fail this test – usually because they lack good evidence to show they work. But even where the evidence is promising (and the risks appear acceptable), there’s an additional consideration with dietary supplements – supplement quality is unclear. When you consider the different products that are considered supplements, multivitamins and minerals are probably the safest product – the ingredients are known, they can be measured, and the manufacturing can be standardized. There’s more risk with the herbal and botanical remedies. Not only is there a lack of consistency, there’s a much greater risk of adulteration and contamination. Finally, sexual enhancement, weight loss, and body building supplements seem most likely to be adulterated (and there’s no reason at all to take these products). When it comes to dietary supplements, there’s no easy way for a health professional or a consumer to independently verify that a product is of high quality. Regulatory structures leave a lot to be desired, resulting in a “buyer beware” marketplace for consumers. Until something changes, it will continue to be nearly impossible to have confidence in the quality of supplements, or to use them in science-based ways.

Supplements: Still popular despite little evidence they’re useful
Scott Gavura on November 3, 2016
Link


As healthcare systems struggle to cope with growing and aging populations, there is renewed interest in eliminating wasteful, and possibly harmful, care. The Choosing Wisely campaign suggests that up to 30% of health care services may be unnecessary. Driven by the medical profession itself, Choosing Wisely is challenging both patients and health care providers to have an honest dialogue about the appropriateness of care. What is increasingly obvious is that ineffective and inappropriate medical care can’t be counted on to disappear naturally, even when the evidence is clear and is acknowledged by health professionals.
Dietary supplements are an enormously popular category of consumer products (I hesitate to call them health products), usually taken with the objective of promoting or supporting health. In the US alone, supplements are a $34 billion dollar industry. I’ve posted several times about trends in supplement use, looking at some of the larger studies to understand who takes supplements, and why. As a pharmacist who has worked in both community (retail) and hospital pharmacy practice, my own observations seem in line with what the evidence shows. The extent to which some consumers embrace supplements as part of their health activities is remarkable. I have seen people spend hundreds of dollars per month on dietary supplements based solely on the advice of a naturopath or other alternative medicine provider. And as a former hospital pharmacist responsible for doing medication histories with new patients, I would regularly encounter seniors taking dozens of different types of vitamins, over-the-counter medications, supplements and tonics, often with contradictory purposes: the “natural” laxatives with the anti-diarrheal medicine, or combinations of products for a single use, like melatonin and diphenhydramine for sleep. Cleaning up the supplement schedules to something rational (or at least safe) was one of the more challenging aspects of my role. Like medication, consumers can get very attached to their supplements, sometimes attributing beneficial effects to them that were highly implausible, and more likely reflected placebo effects. Convincing people that the supplements they’re taking are unnecessary, and even potentially harmful, can be difficult. Some have been so convinced of the merits of their (usually self-driven) supplement strategy that they would take suggestions very personally, as if I were questioning their own judgement. Such is the nature of the supplement industry: A triumph of marketing and an unquestioned boon for manufacturers, but billions in spending with little evidence that supplements have any real health benefits whatsoever.
We didn’t become widespread consumers of dietary supplements by accident. The growth in supplement consumption has been driven by highly effective marketing based around the invented idea that dietary supplements are necessary for good health. This message was given tacit approval by regulators who have traditionally used a light hand when it comes to holding supplement companies accountable for marketing products that are safe and effective. The Dietary Supplement Health and Education Act of 1994 (DSHEA) was an amendment to the U.S. Federal Food, Drug and Cosmetic Act that established the American regulatory framework for dietary supplements. It effectively excludes manufacturers of these products from virtually all regulations that are in place for prescription and over-the-counter drugs, and puts the requirement to demonstrate harm on the FDA, rather than the onus on the manufacturer to show a product is safe and effective. The goal was to eliminate barriers to sale, and it worked: Within four years of the DSHEA, supplement sales grew from $4 billion to $12 billion. And the market has almost tripled since then.
A new study looks at trends in supplement use over a thirteen year period. Published last month in the Journal of the American Medical Association (JAMA), “Trends in Dietary Supplement Use Among US Adults From 1999-2012” is from Elizabeth D. Kantor and colleagues at the Memorial Sloan Kettering Cancer Center. This is a cross-sectional study of National Health and Nutrition Examination Survey (NHANES) collected between 1999 and 2012, which examined American residents who were not in a nursing home. Data was collected via in-home interviews, and participants were asked about any supplement use in the past 30 days. Given the thousands of products sold as “supplements”, the investigators sought to categorize products in a similar way. Multivitamins and mineral supplements were defined as a product with >9 vitamins and/or minerals. There were also queries about individual vitamins as well as non-vitamins supplements. Consequently, an ingredient like vitamin C could be considered a multivitamin or a specific vitamin supplement, depending on how it was packaged. For each type of vitamin or supplement, the usage over time was examined and statistical significance was calculated. Data collected was also stratified by age, race/ethnicity, and education level.
Results
This was a large study, with almost 38,000 participants in total, or over 5,000 participants per two-year cycle. The mean age was 46 and the sample was 52% women. In 2011/12, 52% of adults reported using a supplement in the past 30 days. When looking at the stratified data, there are some interesting (but perhaps not surprising) observations. Older adults use more supplements. Women use more supplements than men. White adults use the most supplements. Those with the most formal education used the most supplements. And those with the highest-reported health status used the most supplements:
When you examine usage over time, it’s a bit like a time machine, where you can see changing trends which appear to have been driven by hype, but also (let’s hope) influenced by scientific evidence. There are tables and tables of data, and I’ve pulled out a few highlights. For example:
    • Consumption of multivitamins had decreased overall (37% to 31%, comparing 1999/2000 vs. 2011/12), possibly driven by studies showing they are largely unnecessary and offer no meaningful benefit.
    • Vitamin D usage as a single ingredient supplement has increased over time (5% to 19%), likely influenced by science, but also hype and buzz.
    • Omega-3 fatty acids consumption has grown over time (1.9% vs. 13%, respectively), possibly influenced by greater awareness of expected benefits of fatty fish consumption, which has been translated by the supplement industry into marketable products.
    • Decreases in the use of Echinacea, garlic, Ginkgo biloba and ginseng, likely influenced by studies which have shown these supplements have no real health benefits.
Trends in usage were also described, which shows some interesting features. For example, usage of supplements is decreasing among younger adults:

Implications
A “glass-half-empty” perspective on this evidence would point to the widespread use, billions in expenditures, and no objective benefits, and question the effectiveness of health professionals’ efforts to help consumers choose more wisely. A more optimistic perspective might point to the flat overall usage and the declining usage in many categories of products, some of which may have been influenced by broader consumer uptake of the scientific evidence that has emerged. If it weren’t for growing usage of products like vitamin D and fish oil supplements (which are at least less likely to be harmful that many other supplements), the overall trend in usage might even be negative. This is what we should expect, given the state of the evidence for dietary supplements: There is little information to suggest that routine supplementation is necessary in most cases. There is also growing evidence to show that supplementation may be harmful, whether it’s acute supplement toxicity, or harms from chronic use. But this is still a $34 billion industry, and there are many areas were we could probably direct that health spending more effectively. Moreover there are choices we can all make that will be demonstrably more effective than any supplement ever marketed, and cost nothing, like getting more exercise.
An editorial that accompanies this study asks why usage is still so high, despite the evidence:
One factor may simply be that consumers are not aware of these negative results, and so continue to use the products they have been using for years. In these cases, the onus is on clinicians to inform patients when the evidence has changed. Other consumers might not have faith in the scientific process, in which case counseling is unlikely to result in significant changes in supplement use.
Another factor may be that these findings are counter-intuitive: avoiding a multivitamin seems to run counter to everything patients have been taught about the importance of consuming enough vitamins and minerals. Physicians can help remind patients that there is no benefit of obtaining vitamins from a pill rather than from conventional food.
A third factor is that the law affords manufacturers significant leeway to advertise supplements for a broad spectrum of conditions. DSHEA permits the promotion of supplements using “structure/function claims.” For example, claims such as “supplement X will preserve heart health” or “supplement Y will maintain mental alertness” are permitted without premarketing authorization from the FDA. Such claims must be accompanied by a disclaimer: “These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.” However, the disclaimer appears to have minimal effect on consumer understanding of the advertised claim.
Moreover, even after high-quality studies that show no meaningful clinical differences between supplements and placebos are published, the law provides manufacturers latitude to continue advertising their products based on earlier, low-quality data. For example, Ginkgo biloba continues to be sold “to support mental sharpness” despite a large, high-quality NIH-funded study that found evidence to the contrary. In the study by Kantor et al, when the consumption of some products declined over time, consumption of other products increased and made up for the deficit. It might be that companies refocused advertising from one supplement to another. In response to research findings showing no substantial benefit for garlic and glucosamine, for example, manufacturers may have turned to preliminary findings to promote coenzyme Q10 for heart health or methylsulfonylmethane for joint health.
Rx: Better education and more effective regulation
What are the key takeaways from this study? The first is that supplement use is very common and needs to be considered alongside prescription medications as products that can potentially be causing drug-related harms, or drug-supplement interactions. The second is that evidence seems to be having an effect, but doing the research and publishing it isn’t enough. We need better communication about the lack of benefits and the risks, recognizing that we’re up against a powerful marketing machine. To help, we need to create a more transparent market for consumers. We need better regulation to ensure that consumers can easily access and understand the scientific facts supporting any particular supplement. Moreover, we need health professionals (like pharmacists) to actively advocate for patient interests above the desire to sell anything, and to stop giving supplements a veneer of health legitimacy. There is a place for, and even a need for, dietary supplements as part of good health. But widespread access and a lack of good advice is contributing to billions in waste.


Billions on herbal remedies – and for what?
Consumers spend billions each year on herbal remedies, with little to show for it.
Scott Gavura on November 1, 2018
Link


How does this business opportunity sound? A retail market that is lightly regulated with few barriers to entry. No meaningful limits on what you can say about your product, and no responsibility to actually prove your product does what it says. And this market has experienced year-over-year of growth, doubling since 2004 to almost $8 billion per year with its biggest growth ever, 8.5%, in the past year. The recently released report from the American Botanical Council paints an impressive picture of the overwhelming financial success of the natural products industry. Who wouldn’t be impressed with a sales growth chart like this?
We didn’t become widespread consumers of herbal remedies by accident. The growth in consumption has been driven by highly effective marketing based around the invented idea that these products are necessary for good health. This idea has been given credibility by regulators who have traditionally used a light hand when it comes to holding manufacturers accountable for marketing products that are safe and effective. The Dietary Supplement Health and Education Act of 1994 (DSHEA) was an amendment to the U.S. Federal Food, Drug and Cosmetic Act that established the American regulatory framework for dietary supplements such as herbal remedies. It effectively excludes manufacturers of these products from virtually all regulations that are in place for prescription and over-the-counter drugs, and puts the requirement to demonstrate harm on the FDA, rather than the onus on the manufacturer to show a product is safe and effective. The goal was to eliminate barriers to sale, and clearly, it has worked dramatically.
While many people buy their herbal products from retail outlets like health food stores and pharmacies, the strongest growth in herbal sales was direct sales, via the internet and multi-level-marketing. Direct sales accounts for a staggering half ($4 billion) of all herbal sales.
A closer look at the top 5
The report gives a detailed breakdown of sales and trends of individual ingredients. The top five selling products in mainstream outlets were as follows:
    • Horehound (Marrubium vulgare) was the top-selling supplement ingredient in 2017 (and for the previous four years), with sales exceeding $140 million. This ingredient may not be familiar to you (it wasn’t to me) but you are probably familiar with Ricola cough lozenges, where it’s one of the several herbal ingredients. Horehound has a long history of use, and is popularly believed to have both expectorant and cough-suppressant properties (though how it could do both, simultaneously, seems implausible). There is no evidence to suggest that it in fact has these properties, or any other medicinal properties, but given the long history of use, regulators have given horehound a pass. It’s a common ingredient in “herbal” cough and cold remedies, which likely accounts for its chart-topping success.
    • Echinacea comes in at #2, with $84 million in sales. Echinacea is promoted as a remedy to both prevent and treat colds and influenza. Echinacea has studied in clinical trials, using different variants of the plant, as well as different parts of the plant, and in some cases without any standardized ingredients or dosing schedules, resulting in conflicting findings that are sometimes supportive of an effect, and others that suggest no effectiveness. Overall, the strongest evidence points to the conclusion that Echinacea is likely no more effective than a comparable placebo for preventing or treating colds.
    • Cranberry is a zombie of alternative medicine. There was $68 million in sales of cranberry, and it’s usually taken to prevent or treat urinary tract infections. Rigorous testing shows that it does neither. Unless you like the taste of cranberry juice, or like me, put it on your Thanksgiving turkey, there is no compelling reason to consume cranberries.
    • Ivy leaf (Hedera helix) comes in at #4 with $32 million in sales. English ivy is both a groundcover and also popular supplement, and is thought to be effective for respiratory illness and infections. Ivy has been studied as a cough product for children, and there is no convincing evidence it actually has any meaningful effects.
    • Turmeric rounds out the top five, with $32 million in sales and year-over-year growth of 46%. Turmeric is hot. We’ve blogged about it several times. It’s seen as some sort of magical spice, with growth fueled more by hype than any actual evidence of effectiveness. This may be due in part to the properties of the chemicals itself – it is not well absorbed and doesn’t reach any meaningful levels in the blood. But don’t think about getting an intravenous injection from a naturopath – there’s even less evidence for that, and side-effects can be fatal.
I didn’t have the time or patience to work my way through the entire list. Skimming the remainder, I could only spot a few products for which there may be reasonable scientific evidence of effectiveness, such as Senna as a laxative, or St. John’s Wort as an antidepressant.
The report notes that three herbal remedies experienced sales drops of more than 30%:
    • Green coffee bean, which I have blogged about extensively was an elaborate scam promoted by credulous people like Dr. Oz. After Dr. Oz was grilled by a Senate subcommittee, which focused on his promotion of green coffee bean, the facts seem to be resonating. Green coffee bean has no useful medicinal properties.
    • Coconut oil seems to have lost its time in the sun. It was initially sold as some kind of cure-all, but the evidence seems more likely that it is one of the worst oils you can consume. That advice may be resonating with consumers, thankfully.
    • Green tea has been a favourite herbal remedy for decade and is a popular beverage worldwide. There is no good evidence to show it has any meaningful health benefits, but it’s considered a safe beverage to drink which is arguably much healthier than sugar-laden drinks like pop. Concentrated extracts are less clear however. Why its sales have dropped is not clear – it could be that consumers have simply moved on to other beverages that are believed to support weight loss.
What’s hot in herbals?
Glancing at the big movers gives a hint of what we might expect to see more of in the future:
    • Cannabidiol (CBD), a non-intoxicating compound in Cannabis species grew in sales by over 300%. As has been blogged before, the use of medical marijuana seems to be more hype that fact at this point. With legalization (in Canada) and greater interest in actual science, I’m optimistically hoping more evidence will emerge to guide health professionals and consumers on the medicinal properties of this chemical.
    • Nigella (Nigella sativa), also called black cumin or black seed, grew in sales by over 200%. It’s touted as a herbal remedy and used in Ayurvedic medicine. There are claims that can treat asthma, diabetes, digestive issues, hypertension, and more. Evidence is lacking to support use for any of these conditions.
    • Moringa (Moringa oleifera) is another herbal remedy with roots in Ayurvedic medicine. It experienced sales growth of 30% and seems to be sold regularly as a powder. The report suggests that consumers may be attracted to Moringa for “general wellness and nutrition benefits”. As a food product, Moringa has been used to support nutrition programs. As a medicine, evidence is lacking it has any specific benefits or even effects./
Marketing triumphs over evidence
With herbal remedies, it’s all about the marketing, and the evidence is usually weak and occasionally nonexistent. If consumers had access to better information on efficacy and safety, would it matter? While there are signs that clear evidence of harm or non-effectiveness can resonate with consumer the overall trends in sales of this category of products suggests that evidence may not be a primary consideration to consumers. Regrettably, there is little evidence that consumers are getting much in the way of health benefit for the billions they are spending on herbal remedies annually.

About Herbs: an app to avoid
Mark Crislip on June 24, 2016
Link


Medicine has an intellectual hierarchy. Supposedly the best and the brightest are in the academic medical centers and are the thought leaders in their field.
Those of us lower in the hierarchy are well aware of some of the warts present on our betters, but I would expect those at the top would adhere to the highest intellectual and ethical standards. People being, well, people, expecting exceptional standards is admittedly an unrealistic expectation.
It would appear that many academic centers are doing their best to avoid meeting my expectations, attempting to abandon all standards.
I mentioned over at SfSBM that Dana-Farber is spending 2 million dollars on a renovation to, in part, offer the unmitigated steer manure that is reiki and reflexology to their cancer patients. Yes. Reiki. Reflexology.
Those are not fracking earthquakes in Kentucky, those tremors are the result of the tremendous kinetic energy of Flexner spinning in his grave as his life’s work becomes a farce.
Dana-Farber is just one of many academic medical centers who are putting their imprimatur on nonsense.
Memorial Sloan Kettering Cancer Integrative has released “About Herbs”, an iPad/iPhone guide to Botanicals, Supplements, Complementary Therapies and More. Spoiler alert: the ‘More’ does not include critical thinking. This guide is not anywhere as ludicrous as offering reeky, sorry, reiki, but at times it comes close.
Let’s take a look at our first contestant
My bias does kick in looking at the Sloan Kettering guide. I have my own compendium of infectious diseases, so I have strong opinions about what does and does not make for a good medical guide.
In my opinion a good medical guide should take a complex topic and interpret the evidence. A given study is often within the context of a broader literature and needs to be understood in context.
The “About Herbs” approach to evidence seems to be if there is any evidence, good, bad or indifferent, then mention and reference it. But don’t explain or advise. The approach renders the guide next to useless.
For example, Zhong Jie Feng.
It is a traditional Chinese-pseudo-medicine used for:
bruises, bone fractures, arthritis, nausea, internal pain, and cough.
Those are six processes with similar physiologies. I can see how Zhong Jie Feng would work for all six. That, btw, is sarcasm.
But Zhong Jie Feng is “hepatoprotective and cytotoxic.”
Hmm. It protects cells and it kills cells. What exactly are they referring to?
The hepatoprotective is:
against D-galactosamine-induced toxicity in WB-F#44 rat hepatic epithelial stem like cells
And the cytotoxicity was:
some of the new isolates exhibit significant cytotoxicities when tested against a small panel of tumor cell lines.
But probably not liver tumor.
So for a patient, or a clinician, a fundamentally useless hodgepodge of unrelated information once the references are reviewed.
Zhong Jie Feng is perhaps useful for idiopathic thrombocytopenia purpura AND protective against viral pneumonia. In mice.
And Zhong Jie Feng relieves fatigue in cancer patients AND decreases mucositis. In non-blinded, non-placebo controlled trial with a p of <0.05 if you hunt down the reference. Hardly impressive data.
It sounds like Zhong Jie Feng is the wonder drug that works wonders from the text until a look at the supportive literature yields an unimpressive result.
It seems they just throw whatever material is available at the wall and see what sticks. But if you go to the references the ‘evidence’ is not impressive and my interpretation of Zhong Jie Feng is that if it contains bioactive compounds the evidence to support its effects in vivo are minimal and in vitro even less.
That is all from the “Professional” side of the app, as if patients are not going to go through this laundry list of poorly reported information. The “Consumer” side is not referenced, but gives similar, if watered down, information on its purported uses with no final recommendations.
I would tell patients to save their money on Zhong Jie Feng, but “About Herbs” is no Consumers Reports.
But I knew nothing going in about Zhong Jie Feng. How about the entries for products about which I know something?
And behind doors number two through four?
Shark cartilage? “About Herbs” suggests shark cartilage has no effect on any process for which it has been tested. Yet nowhere do they explicitly say don’t take it, it is leading to the decimation of shark populations.
Echinacea? It doesn’t prevent colds and it doesn’t have any clinically relevant effects on cold symptoms. Sure, patients had their cold symptoms shortened by 0.16 days, or 3 hours, 50 minutes, and 24 seconds. Anyone besides me think this is noise in the data? Not the authors of “About Herbs”.
Saw palmetto? The best study and meta-analysis shows no benefit for the symptoms of benign prostatic hypertrophy, a result echoed in the Cochrane Reviews.
Of course, that’s if you look at all the data. If you a cherry pickin’ daddy, like “About Herbs”, you report on some data, as is disingenuously noted in:
Several clinical trials and meta-analyses have shown that saw palmetto improves urinary tract symptoms associated with BPH
And, of course, several have not. That the better quality studies and meta-analysis point to lack of efficacy isn’t mentioned.
All three of these products have a “Mechanism of Action” section. But the products don’t do anything, so how can they have a mechanism of action? I suppose the title is shorter and more to the point than the more descriptive “Random Results of Pointless Studies by Those Who Use Why Most Published Research Findings Are False as a ‘How To’ Rather Than a Warning.”
Besides herbs they also report on a hodgepodge of other SCAMS.
The rest of the doors all go into the basement…
Magnets? They recognize as bunkum.
The Gonzalez Metabolic Therapy is noted to be dangerous and useless. Which is nice. As in many of the analyses inside, “About Herbs” itself offers no recommendations or analysis. Instead they note:
The American Cancer Society urges cancer patients not to seek treatment with metabolic therapies.
But not “About Herbs”? I would wonder if those who mistrust modern medicine could construe these weasel words as, if not an implicit approval, then at least a ‘do as you want, you will anyway’ shrug.
Vitamin O? They note it to be nonsense.
Qigong?
Proponents of Traditional Chinese Medicine contend that qigong works to promote a healthy, balanced flow of energy – called “qi” – within the body. Many believe that a disturbed or blocked flow of qi produces discomfort and illness within an individual; conversely, with a balanced, free flow of qi, one is believed to be in better health.
“About Herbs” is nonjudgemental, failing to suggest this explanation is gibberish.
Acupuncture?
They repeat every canard about this useless theatrical placebo. For every assertion about acupuncture, there is probably an SBM article that refutes it. They ignore the vast contradictory literature on acupuncture as well:
There is evidence that acupuncture can reduce symptoms such as depression, facial pain, headache, peripheral neuropathy, lower back pain, nausea and vomiting, neck pain, postoperative pain, shortness of breath, chronic fatigue, hot flashes and side effects caused by radiotherapy and/or chemotherapy. It may also assist with lifestyle changes such as smoking cessation.
Not mentioned is the evidence is all biased and of poor quality whose efficacy vanishes as the quality of the study improves.
It is as if the entire acupuncture literature were put into a Nutri-Matic machine and it produced an analysis of acupuncture that that is almost, but not quite, entirely unlike the truth.
Unlike other interventions, they downplay acupuncture complications with only three references, unlike other entries were every complication is often noted.
And then.
Then?
…And the basement is flooded
There is the entry on homeopathy.
There is some evidence that homeopathy may benefit individuals with chronic conditions.
Homeopathy, developed more than 200 years ago, is based on the Law of Similars, or “like cures like.”
Clinical studies have been conducted to evaluate benefits of homeopathy, but data are limited and results, inconclusive. More research is needed.
No, no a thousand times no. Maybe I should have started with homeopathy, as any guide that finds homeopathy even remotely reasonable is produced by those who evidently have no understanding of reality-based medicine. And that the Australians and English both have produced extensive analysis that demonstrate the worthlessness of homeopathy is somehow not mentioned.
If you judge a article by the company it keeps, these articles hang out with medical unicorn tears.
I looked at the Sloan Kettering Integrative Medicine website. They offer acupuncture, reflexology and reiki, what I would consider fraudulent magic. They charge a pretty penny for the acupuncture. I can’t see it in their interest to be critical of the practice.
Conclusion: “About Herbs” is a mixed bag
Some good information, some sketchy, some positively BS. And if you do not have the background in medicine, critical thinking, and SCAM, how are you going to know which is which? Much of the information is presented in a shruggie’s Gish Gallop of often-cherry picked information and the occasional lie by omission.
For consumers? It isn’t worth the price. Look elsewhere.
For health care professionals? “About Herbs” does not contain enough explanation to allow you to separate the good from the bad from the ugly. Every referenced statement needs to be evaluated for veracity and context as they can’t be trusted or even understood.
For SBM advocates? It is an excellent example of how not to present pseudo-medical information. Or any information for that matter.
“About Herbs” will appeal most to true believers in pseudo-medicine who wish for the patina of scientific validation without the need for a real understanding and who cannot or will not apply Feynman’s admonition. That would be Integrative Medicine practitioners and Naturopaths I suppose.

No, the Nobel Prize does not validate naturopathy or herbalism
This year’s Nobel prize is an excellent case study that illustrates the problems with alternative medicine and proving just what science-based medicine can deliver.
Scott Gavura on October 8, 2015
Link

The 2015 Nobel Prize in Physiology or Medicine was awarded Monday, acknowledging the developers behind two drugs used to treat parasite infections. In a shared award, William C. Campbell and Satoshi Ōmura won for the discovery of avermectin, and Youyou Tu won for the discovery of artemisinin. Given both of these products are derived from natural substances, and “natural” remedies are used in different alternative medicine philosophies, it is perhaps not surprising that advocates claimed that this somehow validates practices like Traditional Chinese Medicine (TCM) and naturopathy. The Association of Accredited Naturopathic Medical Colleges (AANMC) made the following announcement on their Facebook page:Which if you follow the link to the CNN story and actually read it, is surprising. It doesn’t mention naturopathy at all. In fact, when you look closer at the two drugs and their development, this year’s Nobel Prize is actually an excellent case study that illustrates the inherent limitations and weaknesses in alternative medicine systems like naturopathy, herbalism or TCM, while reinforcing just what science-based medicine is capable of delivering.
The problem with “natural” remedies
We’ve turned to the substances around us to serve as medicine well before we even knew what medicine was. Herbs and plant substances were probably our species’ first drugs. Philosophically, some believe that herbs and plant substances exist (or were placed) on earth expressly to cure our illnesses, and the challenge is simply to match the right plant to the right disease (sometimes based on ludicrous principles). The reality is much more interesting. Plants are amazing chemical factories that produce substances which may or may not have biological effects in humans. And Mother Nature is utterly indifferent to our health and survival: Some of the most toxic substances on earth are natural substances. As the study and use of herbs and plants moved from belief- and anecdote-based herbalism toward more the more rigorous and scientific study of their therapeutic use, the science specialization called pharmacognosy emerged. Unlike herbalism, naturopathy, or Traditional Chinese Medicine, pharmacognosy is the scientific study of drugs of natural origins (see some examples of pharmacognosy on SBM in these discussions of the Angel’s trumpet mushroom and the Thunder God vine). Research focuses on identifying biologically-active chemicals, isolating them, and turning them into useful medicines. It’s pharmacognosy that’s changed pharmacies from stocking jars of raw herbs into dispensing pharmaceutical dosage forms like tablets, creams, and injections, with predictable effects and standardized quality. In medicine, we don’t use raw substances that contain ingredients like opium, digitalis, and belladonna. Very few natural products are in active medical use, because in most cases the natural substances have some negative or inferior properties – such as unpredictable amounts of active ingredients. Once the active chemical substance has been identified and isolated, chemists go to work to synthesize it, standardize it, and even improve upon it. And that’s exactly what happened with the two drug products the Nobel committee cited.
Malaria, killer for millennia
Malaria has killed millions over the thousands of years we have coexisted with it. We’re lucky today as we may think of it only when we travel. I live in Canada and was amazed to learn that malaria was killing Canadians where I live in the 1800s and wasn’t actually eliminated from Canada until 1950. Worldwide, malaria remains a formidable killer. The World Health Organization estimates that 3.3 billion people in 97 countries are at risk of malaria – over half of the world’s population – and it continues to kill almost 500,000 people per year. Malaria is caused by the parasite Plasmodium, which is carried by mosquitoes and transmitted by bites.
Artemisinin (and related drugs) are without question the most effective malaria treatments ever created. Its discovery came just as existing treatments for malaria were beginning to fail due to drug resistance: Chinese soldiers were dying in Vietnam from drug-resistant infections. While the Cultural Revolution was putting many scientists and intellectuals into labour camps, Mao directed the army to identify new treatments. Hundreds of scientists were apparently recruited, and the early research focused on screening thousands and thousands of chemicals for efficacy. But it also looked to traditional medicine for clues, searching for fever “cures”. Dr. Tu found a reference to quinghao (artemisinin) in old texts that made references to fevers. She is credited by the Nobel committee as the first to investigate the substance scientifically and showed that aretemisinin was effective against the malaria parasite. Amazingly, she’s noted to have referred back to old texts as guides:
Also, after rereading a manuscript by Ge Hong, a fourth-century healer, prescribing qinghao steeped in cold water for fever, she realized that boiling, the typical extraction method, was destroying the active ingredient. She switched to ether, and qinghao became the first plant extract 100 percent effective at killing malaria in mice.
A host of factors stalled further research and development over the following years, but slowly published evidence began to emerge, and in 1982 The Lancet published an article from Chinese researchers. (Orac’s post on the Nobel Prize has more.) Alone, artemisinin isn’t effective as a treatment – it is eliminated too quickly from the body. What finally turned artemisinin into a useful drug and brought this treatment to patients was in fact Big Pharma:
A Swiss company, Novartis, finally broke the logjam. It bought a new Chinese patent on a mix of artemether, an artemisinin derivative, and lumefantrine, another Chinese drug, and took out Western patents, planning to sell it under the name Riamet at high prices to tourists and militaries; in 2001, it agreed to sell it nearly at cost to the W.H.O. under the name Coartem. The money to buy the drug on a large scale became available with the creation of the Global Fund to Fight AIDS, Tuberculosis and Malaria in 2002 and the Bush administration’s introduction of the President’s Malaria Initiative in 2005. Now, about 150 million doses of several combinations are bought for poor countries each year.
In part through the discovery of artemisinin, it’s estimated that malaria infections have been cut by 40% over the past few years, and mortality from malaria has been reduced by about 50%. There are likely few other drug discoveries that have produced (or will produce) this magnitude and extent of benefit.
The misery of roundworm
For many of us, the only worm infection we may ever recall is a case of pinworms as a child. But parasite worm infections cause catastrophic harms worldwide. The worms called Onchocerca volvulus are carried and transmitted by blackflies, causing the tropical disease river blindness which leads to skin and eye inflammation and sometimes blindness. Lymphatic filariasis or elephantiasis is an infection caused by Filariodidea roundworms and spread by mosquitos to hundreds of millions around the world. Infections cause abnormal swelling of different body parts, leading to pain, swelling and social stigma.
The discovery of avermectin also illustrates how applied science can improve upon natural substances. Satoshi Omura, a Japanese microbiologist, was a researcher of natural products who focused on identifying new Streptomyces bacteria, which produced substances known to have antibacterial properties. In 1974 some of the most promising Streptomyces bacterial cultures were acquired by (yep, Big Pharma again) Merck in the USA.
William C. Campbell, an American expert in parasite biology at Merck, worked with Omura’s cultures and demonstrated that one isolate was effective against parasite infections. That product was isolated, purified, and named avermectin. This product was subsequently chemically modified to be less toxic to humans and more effective against parasites. This new drug was named ivermectin. It is so effective that it only needs to be taken once or twice a year to clear Filariodidea infections. It should be noted that significant credit for the benefit of ivermectin needs to be given to Merck’s CEO at the time, Roy Vagelos, who brought the drug to market and then made it freely available to countries that needed it. As of 2012, over 200 million people have received the drug.
Beyond herbalism: Science-based practice
So what do these discoveries have to do with naturopathy? Nothing, really. Naturopathy is an alternative medicine philosophy based on pre-scientific principles. The central belief of naturopathy is “vitalism”, which posits that living beings have a “life force” not found in inanimate objects. Naturopathic treatment ideas are all grounded in the idea of restoring this “energy”, which may explain the enthusiasm for treatments based on “natural” remedies rather than being driven by looking at what actually works. Yet despite rejecting foundational issues essential to science-based medicine, naturopathy constantly seeks the credibility that science implies. Hence the declaration that this year’s Nobel winners are somehow naturopathic.
The histories of ivermectin and artemisinin are testaments to the power that science can bring to natural substances remedies and traditional medicines. Traditional practices of herbalism or natural medicine could never have turned either of these discoveries into life-saving medications. They wouldn’t even have been identified. Natural sources (and in the case of artemisinin, traditional medicine practices) helped identify candidate substances. But with each, there was a long and laborious development process that followed, from isolation, to testing, to trials and finally, manufacturing and distribution. Science delivered. And millions are alive, or live without disability, as a result.

Garden of Healing
As I read the plaques in the Garden of Healing, I thought it would be a fun project to compare the content with reality.
Mark Crislip on July 15, 2025
Link
My wife is a Master gardener and would rather spend time in the garden than do just about anything else. I just do the heavy lifting and digging, but take all the credit when the garden is complemented. A holdover from my working days: when things go well, take full credit, when things go south, blame nursing. I am uncertain just what she is going to do with the 3 by 6 by 6-foot hole she is digging in the back. A water feature? Dunno. She has been tight lipped about it.
Anyhoo.
When we travel, we usually check out any botanical gardens, and I find them fascinating. The variation in plants is remarkable, the best of DEI. Although I wish they had more on the why’s of the plants. What was the environmental pressure that led the plants to evolve to look like that?
When we were in Adelaide, we went to the Adelaide Botanic Garden, one of the better botanic gardens we have seen. As we wandered about, we came across the Garden of Healing:
The Garden of Healing conceptualizes the use of medicinal plants from eastern and western cultures.
Species from the Middle East and Northern African regions, China, India, Indigenous Australia and North and South America have been gathered to form a collection rich in diversity that specializes in healing properties. Themed garden beds have been designed to represent these cultures, as well as western culture, represented by a themed garden bed incorporating medicinal plants from Europe.
The Garden of Healing demonstrates the historical contributions of plants for over 60,000 years, as well as the importance of plants in pharmaceutical discovery and modern medicine. The Garden of Healing is also a necessary platform to aid the understanding of defensive and remedial plant properties for the future.
As I read the plaques in the Garden of Healing, I thought it would be a fun project to compare the content with reality, as they struck me as a bit… gullible? Although it is admitted that they are constrained by space. You can’t put a whole SBM analysis on a small plaque. Can’t make a plaque big enough for a Gorski, which really should be a unit of measurement. As an example, this essay is a quarter Gorski. Let’s not go into what unit of measurement a Crislip would be. Wouldn’t be prudent.
Of course I recognize there is nothing intrinsically unreasonable about plants as a source of efficacious medications. My career was based on giving modified bacterial and fungal products to people. Many a valuable medication originated in plants. However, in the past, treating mostly self-limited diseases with various plants makes causality suspect.
I do not know if I managed to photograph all the plaques. Darkness and rain were heading out way. I was in a bit of a rush, so I likely missed a few and at least one, liverwort, was obscured by the liverwort. Or is that a weed?
So what liverwort, the plant with the coolest name, was alleged to treat is unknown. Anyone wants to send be back to Adelaide to see, let me know. Do you think it is a good reason for a Go Fund Me? It looks to be Hepatica nobilis. While I can’t read the plaque, a search suggests it is used for liver/gallbladder problems, hence the name. Nothing, however , on the Pubmeds for clinical trials.
A review suggests
Medicinal use of bryophytes dates to ancient times, but it has always been marginal due to their small size, difficult identification, lack of conspicuous organs, which would attract attention (flowers, fruits) and insipid taste of the herb
Insipid taste. I guess it is why I never had a liverwort sandwich.
Nature’s Earliest Medicine … People all over the world have developed herbal medicine, along with rituals and philosophies that seek to explain what plants work and why.
But, of course, not IF the plants work. That is the tricky part.
Many ancient remedies have been backed up by modern science, which others have been debunked. There are herbs that heal, but science cannot yet explain how they work.
I do not think I would use debunk. That, for me, is reserved for bat shit crazy divorced from reality, like acupuncture, homeopathy, and tariffs.
Science cannot yet explain how they work.
Yes, it can. If it, indeed, works. Usually such a statement means the intervention does not work and there is nothing to explain. Like homeopathy.
The botanical world still holds many secrets for us to discover
No argument there. Lots of potential treatments likely in plants soon to vanish.
Does it really work?
In many traditional medical practices, ritual and the spiritual powers of the healer are a major part of the treatment.
While some herbal medicines have been found to have a scientific basis, others seem to have no effect in clinical trials.
Seem to have no effect in clinical trials? So they don’t work, simple enough. Do you think the Garden of Health will go to the trouble of identifying which plants have potential and which have been shown as worthless? A vital piece of information, I would think. But you know the answer. Of course not.
Perhaps it is not the chemical compounds in the plant, but the belief in the treatment process itself that heals? This type of healing is well known to medical science and is called the placebo effect. Modern clinical trials take the placebo effect into account by comparing test drugs to an inactive version with the patient not knowing which one they’re taking.
A placebo might not have any pharmacological basis, but its effects are no less real for those who is cured. The person may well ask, if it works, does it matter?
Then why have a garden of healing at all? Such a lack of understanding of placebo. And it matters if you are treating anything serious or paying for it.
Drugs are not always necessary, but belief in recovery always is. Norman Cousins.
It is one of those aphorisms that sounds good until you think about it. I cured many an infection and belief in recovery played no role nor did lack of belief result in treatment failure.
Explore the Garden of Health to discover the amazing stories of plants that heal
In the Garden of Healing, wake a walk through 60,000 years of plant-based medicine. See how different cultures use plants to treat and prevent illness and how modern medicine can benefit from this knowledge.
Plants have been part of our lives and our health since earliest time. They’ve relieved pain, enhanced desire, altered out minds and lifted out spirits.
Oddly, they have neither hops nor barley, the two most important plants that when combined relieve pain, enhance desire, alter the mind and lift the spirit.
Treating the Whole Body
From head to toe , inside and out, there is a plant for every part of the body.
That is not how biology works. Plants target physiology, not anatomy. I know. It’s an artful simplification for the sake of limited space, but misleading. Just bugs me.
In these beds you will find plants that help with all kinds of body functions, from sharpening the mind, to improving digestion; helping the heart to soothing the skin.
We will see, won’t we?
While most of these plants have been used since antiquity, science is getting to know them afresh and finding new applications for time-honoured remedies.
We probably know barley (Hordeum vulgare) best known as a cereal grain used in soups, stews and brewing. It’s also had a long reputation as a general promoter of good health. Scientists now hope that compounds in barley will turn out to be effective cancer treatments.
There are a few in vitro studies to suggest barley has effects on colon cancer, but it has yet to reach clinical utility. And always remember Cells. And I love the hover-over comment.
The art of healing comes from nature, not from the physician, Therefore, the physician must start from nature, with an open mind,
But not so open that your brain falls out. I will also note, given the mortality from some infectious diseases, nature ain’t doing such a great job.
Plants are the pharmacy of 8o% of the world’s people who depend on traditional medicine for their main form of health care. Many of them are featured in the garden.
I guess that in part explains the low life expectancy of so much of the world through history. I am glad I have not needed to depend on traditional medicine for the three processes that would have killed me in the good old days.
20,000 BCE
Ice-age cave paintings in Europe show the use of plants as healing agent
If so, I can’t find the example. Perhaps my Googe-fu is lacking, and I spent a long time looking.
One review says,
Of the 5786 depictions identified across 113 European Paleolithic caves, only 0.07% featured plants. Animals and abstract symbols appeared more frequently, 53.7% and 43.3% respectively. The identification of plants from drawings was somewhat ambiguous due to a lack of detail in some images, making interpretation of images difficult in some cases.
Interestingly, the underrepresentation of plants in cave art during the Paleolithic has been reported from other sites outside Europe.
And how do they know that the ice-age cave painting, if it exists, actually shows plants being used for medicinal purposes? Ever since the ludicrous idea that Otzi the Iceman used acupuncture I have been skeptical of ice age interpretations. Hallucinatory conclusions predate AI.
Rosemary, Rosnarinus officinalis, has probably been used medicinally since prehistoric times, As well as treating headaches and indigestion, rosemary extracts have shown promising anti-cancer properties in the lab
On Pubmed, zero hits for clinical trials of rosemary and either headache or indigestion.
For cancer, many chemicals from Rosemary have effects on a wide variety of cancers in the lab.
Rosmarinic acid (RA) and carnosic acid (CA) are potent polyphenolic compounds found in rosemary (Rosmarinus officinalis) extract. They have been extensively studied for their biological properties, which include anti-diabetic, anti-inflammatory, antioxidant, and anticancer activities. In addition, RA and CA have demonstrated effective anti-proliferative properties against various cancers, making them promising targets for extensive research to develop candidate or leading compounds for cancer treatment.
Although as of this writing, no Rosemary product has moved to clinical trials for cancer unless it was the author’s first name.
1500 BCE
The Vedas, four sacred Hindu texts, document the underlying philosophies of Ayurvedic healing.
Philosophy, not reality, mind you.
Forskolin, from the Ayurvedic herb Plectranthus forskohlii, has wide-ranging medicinal benefits owing to its ability to lower blood pressure and reduce inflammation.
As to blood pressure, there are few clinical studies. One, Cardiovascular effects of colforsin daropate hydrochloride for acute heart failure after open heart surgery showed
After 2 or 3 hours from administration of COL, heart rate and cardiac index increased, and pulmonary artery pressure and central venous pressure decreased significantly, but blood pressure and systemic venous oxygen saturation did not show significant change.
And another study in obese diabetic men, compared Forskolin to placebo:
Systolic blood pressure changes were not shown to be statistically significant across time, and there were no significant differences among groups at either initial, mid-, or final measurements. In fact, within both groups, a trend toward a significant reduction in systolic blood pressure was shown (p = 0.079 for forskolin vs. p = 0.077 for placebo). No significant difference or trends toward significance were observed for diastolic blood pressure or in the actual change in diastolic blood pressure at any time-point.
So not impressed. Although forskolin and derivatives do appear to have a variety of other effects on the cardiovascular system, none appear to have made it to clinical use. And if circumcised? Could not resist. Sorry.
Reduced inflammation is a tough one, as that can mean damn near anything. In variety of models, it has effects on a variety of inflammatory endpoints. Take your pick. However, I could find no clinical utility.
1492 AD
Columbus voyaged across the Atlantic. New plants became known to the West.
Echinacea purpura was used for centuries by Native Americans for a range of afflictions, ranging from snakebite to toothache.
Used Echinacea? Yes. Did it help a snake bite? Doubt it; the Pubmeds are unsurprisingly not helpful for clinical trials. Who would enter such a study, much less organize one? A huge number of herbs are supposed to have effects on snake bites; boy, our forebears got snakebit a lot. Do they work? Who knows? Deadmen tell no tales.
And there are no clinical trials for toothache. Could it help? Maybe. But in an often self-limited process, single tales of efficacy are useless. As has been said many times, the plural of anecdote is anecdotes, not data.
1545 AD
Padua’s Botanical Garden opens as part of its medical school in 1545.
Sweet tooth’s favorite licorice, Glycyrrhiza glabra, was found uses in herbal medicines the world over. Research has shown licorice has antiviral and antibacterial properties.
There are multiple studies to show various compounds from licorice inhibit bacteria and viri in the test tube. Whether as an antibiotic (i.e., inhibits a specific metabolic pathway) or an antiseptic (kills non-specifically, like alcohol) I cannot tell.
One review says
The probable mechanism behind these action is the inhibition of the protein synthesis, DNA gyrase, and dihydrofolate reductase.
Which to my mind suggests a nonspecific effect. Like tea tree oil. Oh, and licorice is a dietary abomination second only to walnuts. It is no sweet tooths favorite. That is enough to to discredit the plaque unless Swedish.
1776 AD
Australian and indigenous medicine and heating plants start to become known to the rest of the world.
Melaleuca alternifolia is the source of tea tree oil, antibacterial and antifungal agents used in antiseptic creams and medicated shampoos.
One review notes
In contrast, contemporary data clearly show that the broad-spectrum activity of TTO includes antibacterial, antifungal, antiviral, and antiprotozoal activities. Not all of the activity has been characterized well in vitro, and in the few cases where clinical work has been done, data are promising but thus far inadequate.
Anything that kills that many microbial families is an antiseptic and melaleuca is an antiseptic, it just rips cell walls apart.
Lavandula angusifois
Used in Tibet to treat mental illness.
One study found
Our study showed that M. officinalis and L. angustifolia effect similar to fluoxetine in mild to moderate depression. (F = 0.131, df = 2,42, p = 0.877).
But
Conclusion: Due to some restrictions in this study, including absence of placebo group, large-scale trials are needed to investigate the anti-depressant effect of these two herbs with more details.
And a meta-analysis said
Lavender is beneficial, tolerable, and safe in treating depression. Despite obtaining promising results, they are not enough to recommend prescribing lavender to depressed patients. Further high-quality, large-scale studies for rectifying the shortcomings of existing studies are recommended.
Of course, there are more mental illnesses than depression. The Garden of Health is not all that specific as to what mental illness is being treated. But maybe.
Crassula arborescents
In South Africa it is used in the treatment of epilepsy.
As well as diarrhoea, corns, and as a purgative. All diseases that have the same pathophysiology. Not.
A huge number of plants are used to treat seizures.
It may work in mice, but I could find nothing in humans except it is a toxic succulent.
Aloe zebrina
A powder from the stem of leaf bases is taken twice a day by women after childbirth.
But why? They do not say. The web suggests it is to “cleanse the system.“
No idea what that means.
Dodonaea viscosa v. spatulata
Widely found in the valleys and gullys across central and eastern Australian, it is used to relieve the pain of snake bite.
Of course, no clinical trials. So who knows?
Withania somnifera
Used as a stress reliever and a calming tonic, Withania strengthens the immune system and helps the body cope with stress
What is a tonic? Dunno. We will go with the definition: A tonic is something, sometimes a medicine, that makes you feel better or restores you to health.
But in one review
Recent systematic reviews showed that supplementing stressed adults with Ashwagandha can decrease morning cortisol levels, indicating stress-relieving properties. Several studies presented benefits of Ashwagandha e.g., in fertility problems , anxiety, metabolic disorders such as dyslipidaemia, insulin resistance and diabetes, cognitive function, and obsessive-compulsive disorders.
And I have written several times on the silliness that is boosting the immune system. Basically, find the herb causing an inflammatory response, which is usually a bad thing if not infected.
Artemisia absinthium
A nerve tonic, traditionally used to treat indigestion & stomach pain.
A nerve tonic? That is “believed to calm, soothe, or strengthen the nerves. It’s used to address symptoms like nervousness, anxiety, and irritability, aiming to restore balance and promote relaxation.”
Of course, as indigestion is, I suppose, due to nerves? I used to get the worst dyspepsia around midnight when on call as an intern. Cimetidine was released just in time to get me through the night. Perhaps I should have tried Artemisia absinthium.
As to the literature, I cannot find anything on Artemisia absinthium and clinical trials for either symptom on Pubmed, but a lot of other alleged uses. Which is common for a number of the plants. Each plant has TNTC potential uses, including treating broiler chicken coccidiosis.
Juniperus chinensis ‘Pyramidalis’
A liquor brewed from fresh juniper leaves is used as a tonic.
Gin and tonic? Gin as tonic? Works for me. Wait. Gin has juniper berries, not leaves. Never mind. But a Pubmed search finds nothing on using Juniperus chinensis ‘Pyramidalis’ in a way that would be called a tonic.
Myrtus communis
In India, used in the treatment of affliction of the mind. Externally, it is used in the treatment of acne, wounds, gum infections and haemorrhoids.
Whatever an affliction of the mind might be. Heather Nova might need it? Truly a wonder drug that works wonders,:
A pharmacological investigation revealed that M. communis possessed anti-inflammatory, analgesic, antimicrobial, antiparasitic, antioxidant, antidiabetic, anticancer, antimutagenic, immunomodulatory, dermatological, cardiovascular, central nervous system, and gastrointestinal protective effects, among numerous other biological effects.
Although I could find nothing that could be considered an affliction of the mind. But I do admire the way their plants can treat a diverse number of ailments that have nothing in common anatomically or physiologically. The opposite of the magic bullet of antibiotics. The early quote should have read.
From head to toe, inside and out, every plant for every part of the body.
But it may have efficacy against haemorrhoids. I will note that two of the three references in the updated review have nothing to do with haemorrhoids that I can find. It is always interesting to go back to the original material.
As to gum infections, wounds and acne, nothing on the Pubmeds.
Thymus vulgaris
Pliny the elder noted its use to treat melancholy and “aberrations of the mind.”
Perhaps
CONCLUSIONS: Thymus vulgaris leaves, a traditional food source, demonstrate potential for enhancing both prospective and retrospective memory, alleviating anxiety and depression, and improving sleep quality in university students.
But there is but the one study
Melissa officinalis (Lemon Balm)
Uses
Medicinal – sedative, enema, eyewash, fevers, colds, antiviral, antiseptic, stomach cramps, bruises, ulcers, wounds, toothache.
As well as its multiple culinary and cosmetics
This is a widely studied product for multiple physiologic processes: herpes, depression, metabolic diseases as examples. No really compelling studies I could find and the meta-analyses all point to multiple methodologic flaws. So it may have effects, with ‘may’ being the most popular word in the conclusions.
But there was little in the Pubmeds for the uses listed in the Garden of Healing.
But at least the Garden of Healting were not totally gullible.
Deadly Doses and Killer Combinations
Natural doesn’t mean safe. Plants can cure, but they can also kill~ and sometimes the same plant does both!
Digitalis, also known as foxglove, can be used to treat heart failure. But the plant itself is very poisonous ~ get the dose only a little wrong and the consequences are deadly.
Like all drugs, some plants are dangerous in certain combinations, or when mixed with other medicines, For instance, St John’s Wort, a common herbal antidepressant, interferes with the action of several prescription drugs, including the contraceptive pill.
Treat plant-based medicine like you would any drug and watch the doses and combinations you take.
Conclusion? I was not overly impressed with the scientific rigor that went into the signs (for some reason I find the word signage annoying) at the Garden of Health. Most of plants had were either debunked or unsupported by reality, er, science, for their putative uses. I know they had limitations for space, but their results were just sad: vague, gullible, misleading and often unsupported by reality. I would have suspected the content was generated by AI.
However, it is a wonderful botanical garden to wander look at and marvel at the beauty and diversity of plants, even if the explanatory signs are blech.

Vitamins and Mortality
Steven Novella on October 12, 2011
Link
The discovery of various vitamins – essential micronutrients that cause disease when deficient – was one of the great advances of modern scientific medicine. This knowledge also led to several highly successful public health campaigns, such as vitamin-D supplementation to prevent rickets.
Today vitamins have a deserved reputation for being an important part of overall health. However, their reputation has gone beyond the science and taken on almost mythical proportions. Perhaps it is due to aggressive marketing from the supplement industry, perhaps recent generations have grown up being told by their parents thousands of times how important it is to take their vitamins, or eat vitamin-rich food. Culture also plays a role – Popeye eating spinach to make himself super strong is an example this pervasive message.
Regardless of the cause, the general feeling is that vitamins are all good – they are not only important for health, they promote health. Many people take vitamin supplements on the idea that more is better, or for nutritional “insurance” to make sure they are getting enough of every vitamin.
The problem with deeply embedded cultural beliefs is that people make decisions based upon assumptions that everyone “knows,” rather than making evidence-based risk vs benefit decisions. This phenomenon is exacerbated when the industry is able to make aggressive health claims without requiring any scientific evidence to back up those claims (as is the case in the US since DSHEA was passed in 1994).
It is therefore important to shatter the pedestal on which vitamins have been placed, to bring them down to the level of scientific evidence. The good news is, there is a ton of research on vitamins, which continue to be the subject of much new research. Each year, therefore, the risks and benefits of vitamins become more clear. One recent study which is getting much press adds to this body of knowledge about vitamins.
In the latest issue of The Archives of Internal Medicine is a population based observational study looking at health outcomes and vitamin use as part of the larger Iowa Women’s Health Study. The authors looked at 38,772 older women and asked them to self-report their vitamin use. This is a long term study and their vitamin use was reports in 1986, 1997, and 2004, and mortality was followed through 2008. They found a small but statistically significant increase in mortality for those taking multivitamins, B6, folic acid, iron, copper, magnesium and zinc. There was also a small decrease in mortality for those taking calcium.
The strength of this study is that it is large with a long term follow up. There are many weaknesses, however. Vitamin use was self-reported. Further, this is a correlational study only. Therefore possible confounding factors could not be controlled for. For example, it is possible that women who have an underlying health issue that increases their mortality were more likely to take vitamins or to report taking vitamins.In fact, other studies suggest there is such a “sick-user effect” with vitamins.
It is therefore not possible from this study to draw any conclusions about cause and effect – that vitamin use increases mortality. But it does provide a cautionary reminder that it is not reasonable to assume that vitamin supplementation is without any risk. We still need to follow the evidence for the use of specific vitamins at specific doses for specific conditions and outcomes.
Conclusion
As is typical of observational studies, the results are somewhat mixed, depending upon the details of how such studies are conducted. There are also many variables to consider – which vitamins and which doses in which populations with what health conditions. There is therefore a great deal of noise in the data. I do not think we can conclude that the vitamins listed above actually increase risk of mortality. But neither can we conclude that there is any health benefit for routine supplementation. Years of research have failed to provide such evidence, and the mixed results we are seeing is consistent with there being no or only a small effect.
Based upon the totality of evidence the best current recommendation is to have a well-rounded diet with sufficient fruits and vegetables, which should be able to provide most people with all the micronutrients they require. There is no evidence to support routine supplementation. There is also reason to avoid taking megadoses of vitamins, as this can cause toxicity, and even short of toxicity the evidence becomes more compelling at higher doses of the risks of supplementation.
But there are also many situations in which targeted supplementation is evidence-based and appropriate. There is increasing evidence to support the use of vitamin D supplementation for many populations. Many elderly have borderline or  low B12 levels, which correlates with dementia. Pregnant women should take prenanatal vitamins. (To give just a few examples.)
Vitamins are just like any other health care intervention – they have potential risks and benefits and it is best to follow the evidence. For most people the best advice is to ask your primary health care provider which supplements, if any, you should take. Recommendations should be based upon specific health conditions and blood tests to measure levels of vitamins, so that specific deficiencies can be appropriately targeted.

More evidence that routine multivitamin use should be avoided
Scott Gavura on December 19, 2013
Link
If scientific evidence guides our health decisions, we will look back at the vitamin craze of the last few decades with disbelief. Indiscriminate use is, in most cases, probably useless and potentially harmful. We are collectively throwing away billions of dollars into supplements, chasing the idea of benefits that have never materialized. Multivitamins are marketed with a veneer of science but that image is a mirage – rigorous testing doesn’t support the health claims. But I don’t think the routine use of vitamins will disappear anytime soon. It’s a skillfully-marketed panacea that about half of us buy into.
Not all vitamin and mineral supplementation is useless. They can be used appropriately, when our decisions are informed by scientific evidence: Folic acid prevents neural tube defects in the developing fetus. Vitamin B12 can reverse anemia. Vitamin D is recommended for breastfeeding babies to prevent deficiency. Vitamin K injections in newborns prevent potentially catastrophic bleeding events. But the most common reason for taking vitamins isn’t a clear need, but rather our desire to “improve overall health”. It’s deemed “primary prevention” – the belief that we’re just filling in the gaps in our diet. Others may believe that if vitamins are good, then more vitamins must be better. And there is no debate that we need dietary vitamins to live. The case for indiscriminate supplementation, however, has never been established. We’ve been led to believe, through very effective marketing, that taking vitamins is beneficial to our overall health – even if our health status is reasonably good. So if supplements truly provide real benefits, then we should be able to verify this claim by studying health effects in populations of people that consume vitamins for years at a time. Those studies have been done. Different endpoints, different study populations, and different combinations of vitamins. The evidence is clear. Routine multivitamin supplementation doesn’t offer any meaningful health benefits. The parrot is dead.
This week’s Annals of Internal Medicine published three papers on multivitamins, with a frankly written editorial that should not surprise regular readers of this blog: Enough Is Enough: Stop Wasting Money on Vitamin and Mineral Supplements:
The large body of accumulated evidence has important public health and clinical implications. Evidence is sufﬁcient to advise against routine supplementation, and we should translate null and negative ﬁndings into action. The message is simple: Most supplements do not prevent chronic disease or death, their use is not justiﬁed, and they should be avoided. This message is especially true for the general population with no clear evidence of micronutrient deﬁciencies, who represent most supplement users in the United States and in other countries.
While these papers have generated a lot of press, the findings are not surprising. They are consistent with what the accumulated scientific evidence already tells us: there is no compelling reason for most people to take regular vitamin supplements. At best there are an expensive placebo. At worst, they may be harmful.
The U.S. Preventive Services Task Force (USPSTF) Systematic Review
One of the three papers isn’t actually new, as I reviewed it last month. Briefly, it’s the U.S. Preventive Services Task Force Report update to its 2003 guidance on the use of multivitamins, entitled “Vitamin and Mineral Supplements in the Primary Prevention of Cardiovascular Disease and Cancer: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force“. The intent of this review was to examine the evidence for vitamin and mineral supplementation in community-dwelling, nutrient-sufficient adults. They studied the effect of supplementation on two major killers: cardiovascular disease (CVD) and cancer. Thousands of papers were searched and those of the highest quality were compiled:
    • Multivitamin supplements: 4 trials and 1 cohort study
    • For individual or paired supplements: 18 trials and 5 cohort studies
Overall, multivitamins were found to have no effect on cardiovascular disease or cancer risk. If there is an actual effect, it’s too small to measure in these trials, and too small to be meaningful. From a risk perspective – there was no clear signal of harms from multivitamin supplementation.
Individual supplements also lacked a sound evidence base. There was no evidence of harm or benefit from vitamins A, C, or D, folic acid, calcium (with or without Vitamin D), or selenium. There was more data with beta-carotene, enough to demonstrate that it clearly has no meaningful effects, except in high-risk groups, where it is associated with an increase (yes, an increase) in cancer risk. The evidence for vitamin E was also clear – there were no beneficial effects. The takeaways from this review were stark. Multivitamins have no established role to play in the prevention of cardiovascular disease and cancer. There is currently no persuasive evidence to suggest that routine supplementation offers any meaningful benefits. The USPSTF review joins a long list of studies (1,2,3,4,5,6,7,8,9,10) that have come to similar conclusions.
The Physicians’ Health Study II (PHS II)
The PHS II was a massive study designed to study the effects of vitamins on a number of chronic diseases. This paper reported on the effects of a daily multivitamin on cognition, a secondary outcome in the study. This is another area where the evidence for vitamins has been unimpressive – mainly negative findings albeit with some positive results. The PHS II recruited 5947 male physicians, aged 65 or older. Patients were randomized to beta-carotene or placebo; synthetic vitamin E (400IU) on alternate days, or placebo; vitamin C 500mg daily, or placebo; or a multivitamin (Centrum Silver) or placebo. Patients were assessed through telephone interviews that measured cognition ever 3 years, and followed for a total of 12 years. The reports for beta carotene and vitamins C and E (for cardiovascular disease and for cancer) have been previously reported, with no meaningful benefits shown. This study looked at the multivitamin treatment with Centrum Silver – about 2 900 were randomized to each group.
There was good follow-up with participants and the adherence rate was high, with about 84% of each group taking at least 2/3 of their doses. The findings were also clear – there were no differences between the groups for any outcome at any evaluation, starting with the first cognitive assessment right through to the final assessment about a decade later. The same was observed for verbal memory: no differences between the groups at any assessment. With a very large study of such high quality, we can draw clear conclusions: supplementation with a multivitamin in a generally healthy group of older males appears to have no benefit. If multivitamins have any effect on cognition, then it was too small to be detectable.
The Trial to Assess Chelation Therapy (TACT)
The last trial is the most infamous of all, one that SBM editor Kimball Atwood argued was “unethical, dangerous, pointless, and wasteful.” TACT was a $30 million NCCAM-funded phase 3 trial that assessed chelation therapy versus placebo and high-dose vitamins versus placebo, for the treatment of patients that recently had a heart attack. Both chelation and high-dose vitamins are the darlings of alternative medicine providers who believe these therapies can treat coronary artery disease: not just modestly, but dramatically. The scientific evidence says otherwise: outside of treating heavy metal toxicity, chelation is quackery. There are several posts at Science-Based Medicine on the myriad of problems with the TACT trial, including its ethical issues, its misleading consent process, and the fact that some of the investigators were convicted felons. Few academic research centers participated in this trial. Instead, investigators (who appeared to be advocates of chelation) relied on recruiting from a network of over 130 small centers, some of which already administered chelation treatments and other pseudoscientific treatments. Sites included the “Institute of Integrative Medicine” in New Jersey, an “Integrated Wellness” center in Maine and the “Center for Complementary Medicine” in New York. While designed to be double-blind, there were questions as to whether this blinding could have been maintained effectively. Overall, 1 708 patients aged 50 or over were recruited, all of whom had a heart attack at least six months previously. The vitamin intervention was a massive 28 ingredient supplement – 3 caplets, twice daily, which according to the trial authors, was “designed to reflect the vitamin regimen commonly used by chelation practitioners” giving doses that were in some cases significantly higher than the recommended daily value:
There were significant problems during the study period. Recruitment was difficult and consequently the target number was reduced. What was expected to take three years to enroll, took seven. In total, 853 patients were randomized to vitamins, 855 to placebo. The endpoint studied was the time to the next major cardiac event (e.g., heart attack) or death. Subjects were followed for a median of about 5 years. The problems didn’t end with recruitment. The lead investigators had to plead with site investigators to spend more time actually tracking and following patients, as they noted as recently as 2007 [PDF]:
Over the last year, the number of patients that have stopped their infusions and vitamins has increased dangerously. If our patients do not receive their treatments, then there is no chance that we could show a difference between groups.
And in what looks like some sort of grade school homework assignment, the investigators even published a list of “Helpful Websites for Finding Patients” to encourage investigators to track patients down that had dropped out of the study. Despite their efforts, the discontinuation rates were indeed dismal: 46% of participants stopped therapy, with no difference between the placebo and the vitamin arms (Perhaps it was the burden of taking six caplets per day.) In the final analysis, no significant difference was found between the high-dose vitamins and placebo for any of the endpoints, including death, or any cardiovascular event. On the positive side, however, the high-dose vitamins were well tolerated and no obvious harms were found. This time, the design and implementation was defined by alternative medicine proponents – and vitamins still failed to deliver any meaningful benefits.
The response from vitamin advocates
As expected, vitamin purveyors don’t take criticism of their product lightly:
The editorial demonstrates a close-minded, one-sided approach that attempts to dismiss even the proven benefits of vitamins and minerals. It’s a shame for consumers that the authors refuse to recognize the real-life need for vitamin and mineral supplementation, living in a fairy-tale world that makes the inaccurate assumption that we’re all eating healthy diets and getting everything we need from food alone. We would not suggest that vitamin supplements are a panacea for preventing chronic disease, but we hope the authors would agree that there is an appropriate place for supplements. Given that government research repeatedly demonstrates that the typical consumer diet is falling short on critical nutrients, vitamin supplements are an appropriate option to meet those needs.
– Steve Mister, President and CEO of the Council for Responsible Nutrition (CRN)
The intention of supplements is to supplement the diet. Don’t expect supplements to cure the common cold or prevent cancer, but they are part of the puzzle of a healthy lifestyle.
– Cara Welch, Sr VP of Scientific & Regulatory Affairs for Natural Products Association (NPA)
It’s telling that advocates won’t directly address the elephant in the room: these products, when studied, demonstrably offer no meaningful health benefits. What the evidence does say is that there is no established role for indiscriminate supplementation, and that they appear to contribute nothing to a healthy lifestyle.
But when it comes to making excuses for supplements, no-one can bring the hysterics like Mike Adams of Natural News:
To make sure these multivitamin studies fail to produce positive results, these studies are universally structured so that they are based on cheap, low-grade, synthetic vitamins and inorganic minerals. Not coincidentally, these brands of low-grade multivitamins are actually manufactured by companies owned by pharmaceutical interests. They really do have a financial incentive to make multivitamins look bad, and so their multivitamin formulations are intentionally designed to fail.
It’s clear Adams didn’t really read the studies at all. If he did, he’d see that Pfizer actually does sell the supplement used in the PHS II study – it’s called Centrum Silver, and a negative trial is probably not what Pfizer is looking for. And guess who designed the supplement used in the TACT study? The TACT authors note:
…complementary and alternative medicine practitioners rather than clinical researchers or supplement companies designed the specific components of the oral treatment regimen, leading to a unique high dose mixture.
TACT was a close as we will probably ever get to seeing a vitamin trial designed by alternative medicine proponents. Furthermore, none of the studies were driven by, or sponsored by, the pharmaceutical industry. The TACT study was sponsored by NCCAM, a regulator with a long history of boosting and supporting supplement use. And why does Adams think these trials repeatedly show that routine supplementation has no meaningful effects? He doesn’t actually refute with actual data. Cue the conspiracy music:
Let’s get down to the real motivation in all this, however. The Annals of Internal Medicine and the scientists behind this extremely deceptive junk science all share the same intention: they want you to trust in drugs, not multivitamins.
Which is an odd statement to make, as I don’t see the Annals or any “scientist” suggesting we should substitute vitamins with drugs for any of the conditions studied. The science is in fact very clear on this point: The healthiest approach, and the science-based approach, is to obtain your vitamins from your food – not from supplements.
Conclusion
Three new papers published in the Annals of Internal Medicine add to an accumulated body of research that has studied the health effects of routine vitamin and mineral supplements in healthy populations. The best available evidence gives us good, reliable information to conclude that multivitamins offer no meaningful health benefits to the generally healthy consumer. It’s time to bring an end to the era of indiscriminate multivitamin use.
References
Guallar E., Stranges S., Mulrow C., Appel L.J. & Miller E.R. (2013). Enough Is Enough: Stop Wasting Money on Vitamin and Mineral Supplements, Annals of Internal Medicine, 159 (12) 850-851. DOI: 10.7326/0003-4819-159-12-201312170-00011
Grodstein F., O’Brien J., Kang J.H., Dushkes R., Cook N.R., Okereke O., Manson J.E., Glynn R.J., Buring J.E. & Gaziano J.M. & (2013). Long-Term Multivitamin Supplementation and Cognitive Function in Men, Annals of Internal Medicine, 159 (12) 806-814. DOI: 10.7326/0003-4819-159-12-201312170-00006
(2013). High-Dose Multivitamins and Minerals After a Heart Attack, Annals of Internal Medicine, 159 (12) I-20. DOI: 10.7326/0003-4819-159-12-201312170-00001
Fortmann S.P., Burda B.U., Senger C.A., Lin J.S. & Whitlock E.P. (2013). Vitamin and Mineral Supplements in the Primary Prevention of Cardiovascular Disease and Cancer: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force, Annals of Internal Medicine, 159 (12) 824-834. DOI: 10.7326/0003-4819-159-12-201312170-00729

US Preventive Services Task Force Recommends Against Multivitamins
An updated review of the evidence reinforces that routine vitamin use is mostly worthless.
Steven Novella on June 22, 2022
Tweet

One of the most common questions I get as an advocate of SBM is – should I take a multivitamin? On the one hand it makes superficial sense. Vitamins and minerals are micronutrients necessary for optimal health, we may not be getting all we need from our Western Industrialized diet, so supplementing is just nutritional insurance. On the other hand, there is a huge marketing campaign selling vitamins, they are mostly pushed by gurus, and the claims for them seem overblown. Where does the truth lie?
We have been answering this question since at least 2008 – multivitamins are mostly useless. This conclusion is now supported by the US Preventive Services Task Force (USPSTF) final recommendation statement, discussed in a recent editorial in JAMA. The USPSTF makes three basic recommendations:
    • The USPSTF recommends against the use of beta carotene or vitamin E supplements for the prevention of cardiovascular disease or cancer.
    • The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of the use of multivitamin supplements for the prevention of cardiovascular disease or cancer.
    • The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of the use of single or paired nutrient supplements (other than beta carotene and vitamin E) for the prevention of cardiovascular disease or cancer.
These recommendations are for non-pregnant healthy adults. Pregnant women should take folic acid and iron, and should be under the care of their OB. Individuals may also have specific nutritional needs, need to treat a nutritional deficiency, or may have an illness which can benefit from specific supplementation. Targeted supplementation in these situations should be based on measurements of blood levels of the specific nutrients and occur under the guidance of a physician.
But for healthy non-pregnant adults, there is essentially no convincing evidence that routine supplementation, of individual vitamins or multivitamins, is of any health benefit. The USPSTF specifically recommends against beta carotene and vitamin E supplementation because there is evidence that such supplementation increases the risk of overall mortality, cardiovascular mortality, or lung cancer.
This brings up a very important point – vitamins are not necessarily benign. The supplement industry spend about $900 million a year (to support a $50 billion industry). Vitamins are marketed as “natural” and harmless, but they not harmless. Every vitamin is associated with toxicity if the dose is too high. Further, vitamin use, especially beta carotene and vitamin E, may actually increase the risk of major disease, like cancer. While we don’t know the precise mechanism, one theory is that vitamins can feed the metabolically-demanding cancer cells. Regardless, it is an easy recommendation to make to avoid high doses or “megadoses” of any vitamins or supplements, as the potential for harm increases dramatically.
For multivitamins and vitamins other than beta carotene or vitamin E the USPSTF simply says that there is “insufficient evidence” to recommend their routine use, but let’s dive into the details. This does not mean that we don’t have studies – there are multiple large studies. The problem is essentially two-fold. First, it is difficult to do large, controlled studies with vitamins. This does occasionally happen, but most of the data is ecologically, correlating vitamin use with health outcomes. The problem with ecological data is that it is correlational only, with many possible confounding factors.
For example, there are potentially both healthy user and sick user effects. People who take vitamins may also do other things to support their health, such as exercise and eat well. If they have better outcomes, what is causing it, the vitamins or the exercise? On the other hand, people who are sick may be more likely to take vitamins because they think they will help, causing an association between negative health outcomes and vitamins. It’s like the association between dieting and being overweight – dieting results from, and does not cause, being overweight. How do these two opposing confounding factors sort out? We don’t know.
But there is a second and important cause of the insufficient evidence to know what the net health effect of supplementation is – there is likely no large effect. If there were a large benefit from vitamins, we would be able to see it in the data. The signal would be strong. While proving a negative (a lack of an association) is impossible with outcome data, even high-quality data, the evidence can set statistical limits on the possible size of any remaining effect. So while we can’t say there is zero benefit, or zero harm, for that matter, we can say that any possible effect is extremely small. We can chase that tiny effect with increasingly powerful and rigorous studies, but as a public health measure it’s likely to be insignificant.
And this brings us to an important conclusion of the USPSTF and JAMA editorial recommendations – routine vitamin supplementation is not an effective public health intervention. Even worse, it is likely a costly distraction from more effective measures. More than half of Americans take routine supplementation, for no demonstrable benefit (and in some cases possible harm). This accomplishes nothing but feeding supplement industry profits.
Rather, the evidence clearly shows that there are health benefits to having a well-balanced diet with plenty of fruits and vegetables. Taking a supplement as “insurance” may result in a false sense of security, giving people permission to not spend as much effort on their diet. This will have negative health outcomes. Exercise is also a proven lifestyle intervention with a host of health benefits. Good sleep, not smoking, and using alcohol with moderation are other proven lifestyle choices with health benefits, and there is generally no need to complicate things beyond this basic advice.
These are the big five – diet, exercise, sleep, and avoiding smoking and excessive alcohol use. These factors all have big signals in the evidence, they have proven substantial benefit. Yet many people focus on the margins, on possible tiny benefits that may not even be there. Multivitamins are also just part of a much larger problem – a self-help and “wellness” industry that focuses people’s attention mostly on the wrong things. They may pay lip service to the proven lifestyle factors above (that’s low hanging fruit), but for them their real “value added” is being “experts” (sorry for the excessive scare quotes use) in natural medicine, bogus nutritional advice, and pushing fashionable trends like organic food, avoiding GMOs, and “processed” foods.
The wellness industry is really an industry of expensive distraction. This is because the answer to a healthful lifestyle is already out there, and already part of mainstream medicine – diet, exercise, good sleep, avoid smoking and drinking. For most healthy adults, that’s all they need. The info can fit on a pamphlet. That’s the 95%.
In terms of public health, we need to focus on making healthy choices easier and more affordable. Healthy food tends to be more expensive, and many people live in “food deserts” where fresh produce is not available. Meanwhile bad food choices are cheap and abundant. Cities can also be redesigned to facilitate walking and riding bikes. Workplaces can encourage movement and exercise, rather than sitting at a desk all day. Public education can help improve overall sleep hygiene.
These measures can have a large proven health benefit. Multivitamins are an expensive and largely worthless distraction.s

   Another Negative Study of Vitamins
Steven Novella
Link
Perhaps one of the most common questions I receive from those who wish to utilize science-based medicine for their own health is what I think about vitamins. Even among hard-nosed skeptics, this question is often perplexing. On the one hand, vitamins themselves were discovered by medical and biological science, they play a vital role (by definition) in the healthy functioning of our bodies, and deficiencies of vitamins can cause disease. So they seem perfectly legitimate. On the other hand the market is full of exaggerated and even magical claims about the cure-all power of vitamins.
It’s difficult for people to come to a bottom-line conclusion – should they take vitamin supplements or not. Is it woo or not woo?
Well – it’s complicated. But there is large body of research to help inform our decisions about vitamins. Now, the largest study to date has been published (Multivitamin Use and Risk of Cancer and Cardiovascular Disease in the Women’s Health Initiative Cohorts) looking at 161,808 post-menopausal women over 8 years and finding no benefit for heart disease, cancer risk, or overall survival. This study comes on the heels of other recent studies showing no benefit from routine supplementation.
The recent study
There were two components of this new study. The first pooled data from several trials where multivitamin use was tracked, and also randomized patients to dietary modification, hormonal therapy, and calcium and vitamin D supplementation. The second component of the study was an observational study – which means that multivitamin use was tracked but subjects were not randomized. The study found:
After a median follow-up of 8.0 and 7.9 years in the clinical trial and observational study cohorts, respectively, the Women’s Health Initiative study provided convincing evidence that multivitamin use has little or no influence on the risk of common cancers, CVD, or total mortality in postmenopausal women.
The strengths of this study are its size and duration. Essentially the study had enough power to detect even a modest effect if present. The weaknesses are that the observational part of the study was not controlled. This opens the door to multiple factors that could influence the results.
Some have also charged that 8 years is no sufficient, as benefit from supplementation may manifest only over decades. This is true, but is a generic criticism that can be leveled against any negative study. It doesn’t change the fact that there is still a lack of evidence for routine supplementation. Also, I think that 8 years is a substantial follow up, so if there were a measurable benefit from vitamins this study was probably powerful enough to see it.
On another point, the study’s lead author, Marian Neuhouser, is quoted as saying:
“Get nutrients from food. Whole foods are better than dietary supplements.”
This may be true, but this is not something that can be concluded from this study. Advocates for the preventive benefits of nutrition often make this claim – that nutrition from food is better than nutrition from vitamins. This is partly based on other observational studies that link a diet rich in fruits and vegetables with lower risk of heart disease and certain cancers. However, another way to interpret this discrepancy is not that vitamins from food are better than vitamins from pills but rather that vitamins are not what is healthy about such diets. For example, a diet rich in fruits and vegetables may be healthy because it is not full of animal fat. Or, people who take care to eat such diets may also generally take better care of themselves.
The weakness of observational studies cuts both ways.
Routine Supplementation
To back up a bit – let me say that I am a strong believer in good nutrition. From a basic science point of view, it just makes sense. We need specific nutrients for various biochemical reactions in our bodies. Deficiencies are clearly related to specific diseases. Further, in areas where nutrition is poor overall development is also poor. The connection is clear.
The question of routine supplementation, however, goes further. It asks whether or not taking vitamin supplements are necessary or helpful for someone who has a reasonable diet and does not have any specific disease or condition that would impact their demand for specific vitamins – i.e. routine. In most wealthy industrialized nations lack of quality food is not a problem for most people. Also, modern methods of growing, preserving, and shipping food means that more people have access to a wider variety of foods all year round.
Supplement sellers have tried to perpetuate a myth that foods grown today lack key nutrients. There is just no evidence for this, however. The foods we have access to today have, if anything, superior nutrition to those of the past. Further, botique organically grown crops have only a minor advantage in nutritional content that is not likely to be meaningful.
In short, lack of nutrition does not appear to be a problem for the industrialized west. The modern nutritional scourge is, rather, too much of the wrong kinds of food. This gets back to the point about diets rich in fruits and vegetables – their benefits may be more in what they do not contain than what they do.
Right now the evidence supports the conclusion that for most people who have a reasonable diet there is no benefit from routine supplementation. Of course, what’s a “reasonable” diet? This opens the door for those who wish to take a multivitamin as “insurance” because they feel their diet is not very good. The evidence suggests that they would be better off having a healthy diet rather than living on steak and vitamin pills.
While lacking evidence, the “insurance” argument is not entirely unreasonable. The advice I give my own patients who ask my opinion is this. If you feel you need a supplement because your diet is lacking than go ahead. But – do not take megadoses of vitamins, do not go broke on fancy expensive supplements, and do not use vitamins as an excuse to otherwise have an unhealthy lifestyle. And, in the end your are probably better off working on having a better diet.
Targeted Supplementation
None of what I said above has anything to do with targeted supplementation. I prescribe vitamins almost every day – for those with conditions known to be improved or prevented by specific vitamins or co-factors, and for those with a documented deficiency. For example, many patients with certain neurological diseases have low folate or vitamin B12 levels. So I check these frequently and supplement them if the levels are low.
There is evidence that vitamin B2 may improve migraines in some patients – so that is an option I offer migraine patients. B6 may improve recovery from nerve damage (but only at proper doses, megadoses actually causes nerve damage). And folate has been shown to reduce the risk of spinal cord defects, and so should be taken by any woman who might become pregnant (once you find out you are pregnant it’s too late).
Also, there has been much evidence recently about the value of vitamin D in preventing certain cancers and neurological disorders. It may be that the recommended daily allowances of vitamin D were too low, and they are being increased as new evidence comes in.
Targeted supplementation is evidence-based and specific.
Conclusion
There is a clear trend in the evidence we have to date. The benefits of routine supplementation are unproven. High doses of vitamins probably cause more harm than good. If you are concerned about your nutrition then improve your diet.
Further, as with good science-based medicine in general, questions must be specific. We should not ask – do vitamins work. Rather we need to consider specific supplementation in specific situations and conditions.
What may surprise members of the public who have been exposed for years to the propaganda of a supplement industry eager to take their money, or CAM proponents eager to appear legitimate – is that vitamins have always been part of mainstream science-based medicine. There is a tremendous amount of quality research to inform our conclusions about vitamins, and they are part of everyday practice.

No Benefit to Daily Multivitamin Use
A 20-year analysis of almost 400,000 generally healthy adults shows that vitamins do not help you live longer.
Scott Gavura on July 4, 2024
Tweet

Nearly one in three Americans takes a daily multivitamins, with the primary motivation being maintaining or improving health. Studying the effectiveness of multivitamins in the “real world” is complicated by the healthy user effect – those that take vitamins typically eat healthier, exercise more, and smoke less. There is also the sick user effect which may play a factor – in that patients with a diagnosed disease may increase their multivitamin intake because of the perceived benefits.
A new study looks at mortality risk with daily multivitamin use by analyzing three different US populations where there were repeat assessments of use over an extended period, with the tracking of health-related outcomes. This is a massive study of over 390,000 adults where 164,000 deaths were reported.

The Study
This was not a new clinical trial. It was led by Erikka Loftfield and researchers at the National Institutes of Health’s National Cancer Institute and was published on June 26, 2024, in JAMA Network Open. Participants in this analysis were drawn from the National Institutes of Health–AARP Diet and Health Study (NIH-AARP) cohort (initially, 550,596 AARP members aged 50-71); the PLCO Cancer Screening Trial cohort (65,577 participants, aged 55-74); and the Agricultural Health Study (AHS) cohort (57,333 participants aged 18+). After data quality exclusions, other exclusions included those with extreme calorie intake or those with chronic diseases. The final population available for the analysis was 390,124 adults, with trial entry as early as 1993! The median age was 61 and the cohort was 55% male.
In all three trials, participants were asked at initiation and in follow-up about their supplement use. Those that answered “Yes” were asked about frequency of multivitamin use using predefined categories. Categories of multivitamin use were harmonized into three groups: nonusers, non-daily users, and daily users of multivitamins.
As I noted above, there are many potential confounders which the authors attempted to harmonize across studies, including age, sex, race/ethnicity, education levels, smoking status/intensity, BMI, marital status, physical activity, alcohol intake, coffee intake, other supplement use, Healthy Eating Index and family history of cancer.
Participants were followed from baseline until date of death, loss to follow-up, or the closure of the study period. Cause specific mortality was determined from death certificates. Baseline results from the three different studies were similar, so the pooled analysis formed the basis of the overall conclusions. While confounding was minimized, because this was observational data, it’s possible that there are unmeasured/unadjusted confounders that where not addressed.
Results
In the three cohorts, multivitamin daily users vs nonusers were comparable with a few differences:
Participants who used multivitamins were more likely to use individual supplements, have lower BMI and better diets compared to non-users. Multivitamin use didn’t vary significantly by race/ethnicity or family history of cancer.
As for the effectiveness? Daily multivitamin use was associated with a higher mortality risk compared to non-users (Hazard ratio 1.04, 95% confidence interval 1.02-1.07). That is, mortality was 4% higher among multivitamin users. There were no differences in mortality when looking at heart disease, cancer, and cerebrovascular mortality:
No Justification for Daily Multivitamins
There’s no question that vitamins play a critical role in health. Supplementation is justified and evidence-based is some circumstances, such as folate supplementation in pregnancy. Supplementation is not always beneficial though – look to the harms caused by beta-carotene supplements or vitamin E supplements. The benefits of multivitamin supplements have also been questioned for years. While many take multivitamins as “insurance” against a diet which may not be optimal, there is a lack of evidence showing that general multivitamins provide any meaningful benefits.
Given how regularly Americans take multivitamins, it’s important to understand their health effects. This massive study with over 20 years of follow-up has showed that there is no clear justification for routine use of multivitamins in healthy adults. Rather, multivitamins users appear to be slightly more likely to die than their non-user counterparts. An accompanying editorial points out that mortality effects, like this research studied, may miss other health-related benefits such as age-related macular degeneration with specific supplements. While this is true, it reinforces the need for targeted, science-based supplementation when the evidence supports it, rather than indiscriminate multivitamins.
The supplement industry has put a tremendous con over consumers, promoting the idea that vitamin and mineral supplements are beneficial to your health, and that more=better. None of this has been shown definitively to be true when it comes to longevity. It is now very evident that multivitamins as form of dietary “insurance” is a strategy that is at best, useless, and at at worst, causing reducing life expectancy.

Routine Vitamin Supplementation Mostly Useless
A new meta-analysis shows no benefit from multivitamins or routine supplementation. These results should motivate users to take a fresh look at their supplementation.
Steven Novella on May 30, 2018
Link

For decades the vitamin industry has been promoting their products as generally good for health, and as a result 90% of the general public think taking vitamins is a good idea (although in the same survey 80% recognize that vitamins do not replace a healthful diet). A 2016 study found that 52% of the population take some form of supplementation. Use of multivitamins (MVI) did decrease a bit from 37% to 31% from 2000-2012.
Still, that is a huge portion of the general population. The supplement industry continues to grow every year, reaching $36.1 billion a year in the US in 2017. How much health benefit are we getting from that $36.1 billion? A new meta-analysis suggests – not much if any at all, and maybe even some harm. The new study, published in the Journal of the American College of Cardiology, is a meta-analysis of randomized controlled trials looking at a variety of vitamins, both multivitamins and specific vitamins, and their relationship to cardiovascular disease, stroke, and all-cause mortality. Because this is a recap of prior research, the results are not surprising to anyone familiar with that research.
What they found is that:
    • Multivitamins, vitamins D, C, A, B6, E, calcium, β-carotene, zinc, iron, magnesium, and selenium had no benefit or harm for vascular disease or all-cause mortality.
    • Folic acid and B-complex (Folic acid, B6 and B12) reduced stroke risk
    • Antioxidants and niacin increased all-cause mortality.
Or to show this visually:All of these findings were supported by moderate level evidence. The most dramatic result was the reduction in stroke risk by folic acid (20%), however there is an important caveat to this finding. These results were largely driven by CSPPT (China Stroke Primary Prevention Trial). In most areas China does not fortify any food with folic acid, and therefore the population may be generally deficient. This benefit, therefore, may not translate to Western countries with fortification.
I have written about antioxidants before – the evidence shows that, not only are they of no routine benefit, they may cause harm by disrupting the natural mechanisms of internal homeostasis. The authors also note that while there was a clear benefit to folic acid, some studies show a potential increase in cancer risk (specifically prostate cancer, but this may extend to other cancers).
There are limits to this data. The quality of evidence was mostly moderate. Also, one could argue that longer term studies and larger studies might detect a smaller benefit. However, this data does set limits on the magnitude of any possible remaining benefit. Further, the exact same argument can be made about potential harms.
This meta-analysis is a good opportunity to step back and reconsider our basic approach to vitamins and supplements, in terms of both practical implications and underlying philosophy. In terms of philosophy, there are various assumptions (encouraged by the supplement industry, who stands to gain from these assumptions) that do not make sense when analyzed, and have not been supported by the evidence.
The first is that vitamins are all good. This stems further from the more fundamental approach to nutrition that there are good foods you should eat and bad foods you should avoid. Vitamins, in this view, are healthful in-and-of themselves. This leads to two further beliefs: that if some is good, more is better, and that vitamins can do no harm. In this view there is little downside and no risk to taking vitamins “as insurance,” even if they are not strictly needed.
This heavily marketed approach runs contrary to standard clinical logic, which recognizes that dose is everything, and all interventions should be looked at from the perspective of risk vs benefit.
Every vitamin has a toxic dose. Further, there is likely a ceiling effect, meaning that there is a level of intake that is sufficient and anything beyond that is of no further benefit. In this view, maximal nutritional benefit comes from taking the appropriate amount of each vitamin, rather than simply taking more. Most vitamins do have a very large range over which they are essentially harmless, which creates the false impression that all vitamins are completely harmless. Some vitamins have a narrower range, and it is possible to experience toxic effects from routine supplementation, or even from an extreme diet. Vitamins A and B6 toxicity are not rare. I have diagnosed B6 toxicity myself, which can cause nerve damage. There is also good reason to conclude that large doses of antioxidants can be harmful, supported further by the current study.
Aside from direct harm, there is the potential for even greater indirect harm. The $36 billion and growing supplement industry represents a massive opportunity cost for health care. Some people might forgo needed medications, or better nutrition, because they are spending some of their limited budget on vitamins and supplements they think will help them, but won’t.
Further, there is the potential of using supplementation as an excuse for an otherwise poor diet. The evidence clearly shows that vitamins do not replace a well-rounded and nutritious diet.
The bottom line message for the average person is this:
There is essentially no benefit to routine supplementation, and there may be some risks. You are far better off saving your money, and spending it on fresh produce. Have a varied diet with plenty of fruits and vegetables and you are overwhelmingly likely to get all the nutrition you need.
For those with special needs or if you have any questions, simply consult your physician. Targeted supplementation based on specific needs and measured blood levels is the way to go. You probably should be taking prenatal vitamins if you are trying to get pregnant, and should be under the care of an OB. If you are trying to reduce your stroke and vascular risk, again you should be doing this under the supervision of an appropriate physician. This may include folic acid supplementation.
Also, while we are at it – do not believe supplement hype (antioxidant or otherwise), do not believe nutrition gurus, do not take megadoses, and there is no such thing as a “superfood.”

Transdermal Vitamin and Wellness Patches: Hype versus Evidence
Wellness patches lack plausibility and evidence to demonstrate effectiveness
Scott Gavura on September 24, 2026
Link

Do you remember the Power Balance Bracelet craze? Circa 2010, Shaquille O’Neal and other athletes were wearing silicone bracelets that had a “hologram” (a sticker) that was claimed to “resonate with the body’s natural energy field”, improving balance, strength, and flexibility. They were enormously popular until regulators and science caught up. Independent testing couldn’t find any meaningful performance benefits beyond placebo effects. The manufacturer subsequently faced lawsuits in the United States and filed for bankruptcy after agreeing to a settlement of approximately $57 million in 2011.
I was reminded of the Power Balance fad when I saw wellness patches on social media. I’ve previously blogged about “GLP-1 Patches,” but some products go well beyond weight loss. For example, the website for Restelle offers “Sleep” patches, “Weightless” patches, “NAD+” patches, “Energy” patches, “Focus” patches, and “Period” patches. Each patch is said to contain several different ingredients. For example, the “Sleep” patches are stated to contain magnesium glycinate 3mg, valerian root 5mg, hops 3mg, 5-HTP 1 mg, L-tryptophan 5 mg, and melatonin 5mg. The “Weightless” patches are said to contain Berberine extract 5mg, Fucoxanthin extract 3mg, Green tea extract 2mg, Pomegranate oil 2mg, Vitamin C 2mg, African mango seed extract 1mg, Vitamin B1 1mg, B2 1mg, B3 1mg, B5 1mg, and B6 0.5mg. Now I could do a deep dive on each of these ingredients in each patch, looking for direct evidence of efficacy when applied transdermally. But that would be a very long post. Instead, I’ll explain transdermal absorption and show the key challenges faced in transdermal drug delivery that illustrate why we should look at these efficacy claims for non-prescription wellness “patches” very skeptically.
Delivering drugs through the skin
Our skin is both a protective barrier and, under the right circumstances, a route for drug delivery. The outermost layer, the stratum corneum, consists of flattened, keratin-rich cells embedded in lipids and is remarkably effective at keeping water in and foreign substances out. That is a very good thing. Chemicals that do penetrate intact skin generally do so by passive diffusion, moving from an area of higher concentration on the skin surface to lower concentration in the tissues and blood beneath it. Small molecules, especially ones that have the right balance of water and lipid solubility, penetrate most readily. Conversely, large, highly water-soluble or charged molecules cannot cross the skin’s layers easily. And absorption is critical for drug delivery. It’s only after a substance passes through the stratum corneum, into the epidermis and dermis, that it can enter the capillaries and subsequently be delivered to the rest of the body.
Recognizing the potential to deliver drugs this way led to transdermal drug delivery research, with the intent of delivering medicine through intact skin. Although medicinal substances have been applied to skin for centuries, modern transdermal patches have arrived relatively late in the history of medicine. They really only reached widespread use in the late 20th century as advances in polymers, adhesives, and membrane technology made predictable delivery possible. Because that’s critical with transdermal drug delivery—you need predictable delivery in order to promise predictable, consistent effects. Patches can be very effective and useful as a means of getting drug through the skin. They can provide relatively steady drug concentrations over hours or even days. Importantly, delivery this way will bypass the gastrointestinal tract and the “first-pass” metabolism by the liver after gastrointestinal absorption, which can make oral use infeasible. The major limitation for transdermal drugs is that relatively few drugs have the physicochemical properties and potency needed to cross the skin in useful amounts.
The common transdermal patches that are licensed and sold today share some common characteristics. Nicotine is a small molecule, at about 162 Daltons (Da), and readily crosses biological membranes, making it suitable for patches that provide sustained nicotine exposure during smoking cessation. Nitroglycerin, about 227 Da, is small and lipophilic (fat-soluble) and is effective at very low systemic concentrations. Transdermal administration also avoids the extensive first-pass metabolism that follows oral administration (which is why we see sublingual tablets and sprays and not long-acting tablets). Estradiol is about 272 Da, and is a potent, lipophilic steroid hormone and therefore an excellent candidate for delivery through the skin. Fentanyl, an opioid narcotic, is about 336 Da, is larger but extremely potent and highly lipophilic, so only microgram quantities need to cross the skin each hour to produce an effect.
The existence and licensing of transdermal drug delivery patches isn’t evidence that this mechanism is a good mechanism to deliver drugs. Rather, the relatively few approved products illustrate the significant commercial and chemical barriers that exist to using this approach to drug delivery. It isn’t as simple as thinking “small molecule” = “good candidate for transdermal”. The ideal transdermal drug candidate is:
    • small enough to cross the skin’s barrier
    • lipophilic enough to pass through the skin, but not so lipophilic that it stays trapped in the skin’s outer layers
    • potent enough so that a small amount of absorption can produce a systemic effect
How to test if patches work
Skin absorption can be studied both in the laboratory and in people. After laboratory testing with human or animal skin to prove feasibility, successful candidate drugs may move to human trials. Transdermal drug products are tested similarly to oral medicines, by measuring drug concentrations in the blood at multiple time points after the patch is applied. From the resulting concentration-time curve, researchers can then calculate standard pharmacokinetic measures including Cmax (the highest observed blood concentration) and AUC (area under the curve), which represents the body’s total systemic exposure to the drug over a defined period. They also measure Tmax, the time required to reach the maximum concentration. Unlike an immediate-release oral drug, which often produces a relatively sharp, quick peak followed by rapidly declining concentrations, a patch is generally designed to produce a slower rise and a flatter, more sustained delivery. After a patch is removed, concentrations may also decline relatively slowly because drug may remain in the skin’s outer layers and continue to enter the circulation.
Melatonin is an interesting candidate for transdermal delivery. It’s a hormone, about 232 Da, and is in the range of size for drugs that can be delivered transdermally. And there are small human studies that show that patches can produce measurable blood levels. However, absorption is slow and variable: peaks (Tmax) occur over 8-13 hours after application. There is evidence that melatonin accumulates in the skin and continues to enter the bloodstream for some time, even after the patch is removed. This makes a patch technically feasible for prolonged exposure, but not really suitable for supporting sleep. I was not able to find any studies that demonstrate reliable clinical effectiveness of melatonin administered in a patch. The challenges with manufacturing and dosing are likely the reason I couldn’t find any evidence that any health regulator has approved a melatonin transdermal patch.
Not every ingredient in a wellness patch is implausible for the same reason. The “Sleep Patch” I referenced above is said to contain magnesium glycinate, 5-HTP (about 220 Da), and L-tryptophan (about 204 Da), all of which are small enough that molecular weight alone does not rule out transdermal delivery. But molecular weight is only one factor. Magnesium presents a more fundamental problem: magnesium exists in the body as the charged Mg²⁺ ion, rather than as a small, neutral, lipid-soluble molecule that can readily diffuse through the stratum corneum. 5-HTP and L-tryptophan present a different challenge. Like other amino acids, they are predominantly zwitterionic at physiological pH, meaning they carry both positive and negative charges. That makes them highly polar and poorly suited to diffusing into the stratum corneum. So although their molecular weights are small, their chemical properties make substantial passive transdermal delivery through intact skin highly unlikely, without some means of enhancing penetration.
Vitamin C in the “Weightless” patch illustrates the same point. Ascorbic acid is tiny, about 176 Da, comparable in molecular size to drugs that can be delivered transdermally, yet it is water-soluble and readily ionized. Research on topical vitamin C has found that meaningful penetration depends strongly on factors such as concentration and pH; one study found (in a widely cited pig-skin study) that L-ascorbic acid had to be formulated below pH 3.5 to penetrate skin effectively. If you’ve seen vitamin C in cosmetics, you may notice that manufacturers are using specialized formulations and delivery technologies—and this is just to deliver it to the skin itself, not attempt systemic absorption. So the fact that the vitamin C molecule is small, at 176 Da, does not mean that putting it into an adhesive patch will produce meaningful systemic absorption. There are too many practical barriers to expect that there would be any absorption.
Finally, let’s look at examples where additional technologies are required for transdermal delivery. There’s published research into B12 that we can look at that is informative. Cyanocobalamin, the form typically found in supplements, weighs about 1,355 Da, several times larger than anything else we’ve discussed, and beyond what we can anticipate could be passively absorbed. Real, patented transdermal B12 delivery systems exist, and the patents themselves are explicit about what it takes: “physical methods” such as iontophoresis or stripping of the stratum corneum, or chemical penetration enhancers, because passive diffusion alone doesn’t move a molecule this size across intact skin. A 2026 study out of Aston University, published in the Journal of Pharmaceutical Sciences, delivered B12 across excised murine skin using dissolving microneedles, tiny needles that create temporary microchannels and then dissolve. So getting B12 into the bloodstream through the skin, but this molecule needs specific technology to deliver it. So if a wellness patch doesn’t have specific technology, it’s not likely able to surpass these barriers. Especially in a product combined with several other ingredients, each with its own physicochemical requirements.
Other ingredients in some of these patches aren’t even single compounds at all: valerian root, hops, berberine, green tea extract, pomegranate oil, African mango seed extract, etc. They aren’t single molecules at all. They’re whole plant extracts with no defined molecular weight—if we wanted to measure if it’s absorbed, we’d need to know what chemical to look for in the bloodstream.
Conclusion
Transdermal patches can be an effective drug delivery mechanism. Nicotine, fentanyl, estradiol, and nitroglycerin work as patches and as licensed pharmaceuticals because they share similar features: small, lipophilic, uncharged, and potent enough that a tiny absorbed dose still matters. When we look at the ingredients in wellness patches, you’ll find several red flags. Among the different ingredients that I reviewed, melatonin is the most plausible, but there is no published data that I could find that this works effectively to support sleep. Other ingredients, like magnesium, 5-HTP, L-tryptophan, and vitamin C, are small enough but are not expected to cross the skin because of their properties. B12 is too large and difficult to cross through the skin without product-specific enhancements like microneedles. And plant extracts aren’t single molecules with a defined size that would even allow someone to evaluate absorption. Leveraging real science to sell health and wellness products isn’t a new strategy. But in the case of wellness patches, there are so many scientific holes that it’s reasonable to ask if these products actually do anything at all. And in the absence of published evidence to show they are effective, that’s what the cautious consumer should conclude.
    • 

At Your Own Risk
Jann Bellamy on March 21, 2013
Link
In 2011, Americans spent some $30 billion on dietary supplements. Yet, except for the industry itself and a few politicians and “health freedom” advocates, you’d be hard pressed to find anyone (who’s given it some thought) of the opinion that dietary supplement regulation is adequate. Three recent reports, two from the government and one from a newspaper, demonstrate why this near-universal conclusion is warranted.
Another government report on lax supplement regulation
Here’s how an October, 2012, Department of Health and Human Services Office of Inspector General’s (OIG) report described the FDA’s regulatory authority:
DSHEA [Dietary Supplement Health and Education Act] does not require manufacturers to submit dietary supplements to FDA for safety or approval prior to sale. As a result, FDA has no comprehensive list of dietary supplements on the market. Dietary supplement manufacturers must ensure that their products are safe, they have evidence to substantiate structure/function claims, and that product labels are truthful and not misleading.
In other words, the fox guards the henhouse.
Because there is much confusion about structure/function claims, here is a somewhat lengthy explanation from the report about what they are and how they are different from disease claims, which dietary supplement manufacturers aren’t supposed to make. (Citations omitted.)
In general, structure/function claims describe the role of a dietary supplement in the structure and function of human bodies, but the claims may not explicitly or implicitly claim to prevent, treat, mitigate, cure, or diagnose a disease. A structure/function claim may also:
• claim a benefit related to a classical nutrient deficiency disease (e.g., scurvy) and disclose the prevalence of such disease in the United States,
• characterize the documented mechanism by which a nutrient or dietary ingredient acts to maintain such structure or function, or
• describe general well-being from consumption of a nutrient or dietary ingredient.
For example, a supplement may claim that it “curbs appetite to help with weight loss,” but it may not claim to “aid weight loss to treat obesity” because obesity is a disease. Similarly, a supplement may claim to “support immunity,” but may not claim to “boost the immune system against colds and flu” because the latter references specific diseases. Although FDA has issued regulations and published guidance describing the difference between structure/function claims and disease claims, it acknowledges the challenge of distinguishing between the two.
If the FDA has trouble interpreting DSHEA and its own regulations, imagine the problems everyone else has with “the challenge of distinguishing between the two.” The report continues:
DSHEA requires manufacturers to meet three requirements for placing a structure/function claim on a supplement label: (1) substantiation that the claim is truthful and not misleading, (2) notification to FDA within 30 days of marketing the supplement with the claim, and (3) a disclaimer on the supplement label.
“Substantiation of structure/function claims” means:
Manufacturers must have substantiation for the structure/function claims on their products’ labels to ensure that they are truthful and not misleading. . . .
However, this substantiation requirement is, shall we say, substantially limited by the fact that:
In any legal proceeding concerning structure/function claims, FDA must prove that the claim is false or misleading.
A further limitation is:
DSHEA does not require manufacturers to submit the substantiation requirement to FDA to determine its adequacy and FDA may not compel manufacturers to produce substantial upon request.
So, let’s see. DSHEA requires substantiation of structure/ function claims but manufacturers are under no legal obligation share that information with the FDA even if the FDA asks for it. All the manufacturer has to do is notify the FDA of the structure/function claim and slap the Quack Miranda Warning on the label. Then it’s off to market. The burden is on the FDA to identify risky supplements, of which there are about 85,000, according to a recent New York Times story. And if the FDA takes a manufacturer to court it is up to the FDA to prove the lack of substantiation. In a classic case of bureaucratic understatement, this caused the OIG to conclude that the FDA “has limited authority to enforce the substantiation requirement.” Indeed.
And how is industry doing with that substantiation?
Even with these slack requirements, a sampling of 127 supplements marketed for weight loss and “immune system support” revealed manufacturers did not fully comply with FDA guidance on proper substantiation of claims. A wide variety of brands were selected from various locations across the country and the internet. A truly random sample was not possible because “no comprehensive list of dietary supplements or manufacturers exists.” The OIG would have looked at more supplements but only 61% of the manufacturers complied with its request for information. Here’s a sampling of structure/function claims from the report:
Based on its review, the OIG concluded:
    • Most substantiation was not derived from human studies. 56% would be considered background information (e.g., in vitro and animal studies), which are not primary sources of evidence and therefore may not be sufficient to support claims.
    • None of the human studies met all of the FDA’s recommendations for competent and reliable evidence.
    • Human studies rarely showed a direct relationship to the claim. For example, evidence submitted to support a supplement claim that it burns fat because it contains a green tea extract was actually a study of drinking green tea.
    • Most human studies did not appear to represent the totality of the evidence. In this conclusion, the OIG relied on NCCAM staff, who told them that a large body of evidence contradicts structure/function claims. But a whopping 96% of human studies the OIG received were favorable to the supplement’s claim.
    • Most studies were not consistent with FDA guidance on quality. Another whopping figure here – 85% were not randomized, double-blind, parallel group, placebo-controlled trials.
    • About a third were not consistent with FDA guidance on the meaning of the claim made.
    • 10% did not qualify as substantiation at all.
As an example of this last deficiency, the OIG noted:
One company submitted a 30-year-old handwritten college term paper . . . while others included articles from trade newsletters; press releases; advertisements; and links to Web pages, such as Wikipedia or an online dictionary.
Only drugs can legally make disease claims, yet 20% of the supplements made such claims. Another chart from the study:
The manufacturers couldn’t even get the bonehead requirements right. A majority of notification letters were missing required information. And 7% didn’t have the Quack Miranda Warning on the label.
In response to the report, the FDA said it would improve its notification system for structure/function claims, expand market surveillance to detect disease claims and enforce inclusion of the Quack Miranda Warning. However, as to the OIG’s recommendation that the FDA seek legislation requiring approval for all structure/function claims in labeling, the FDA would only commit to considering the possibility. Small wonder, given the fact that Congress has a conniption fit every time attempts are made to beef up regulation.
In addition to this report, the OIG issued another on dietary supplement regulation at the same time. Here, the title says it all:
Dietary Supplements: Companies May Be Difficult to Locate in an Emergency
True. When the government doesn’t know what products are out there or who makes them it would indeed be difficult to find the companies under the best of circumstances, much less in an emergency.
Putting a human face on the problem
Now to a feature story from Sunday’s New York Times, which recounts the heart-breaking tale of a body-building supplement and the death of a soldier.
In June of 2011, Michael Lee Sparling, a 22-year-old Army private stationed at Fort Bliss, Texas, collapsed after running in formation for about 10 minutes in 75 degree weather. He went into cardiac arrest and died later that day. Before the exercise, he had taken the recommended dose of Jack3d (pronounced “jacked”), a supplement sold by, among others, GNC, the retail dietary supplement chain, who advertised it as producing “ultra-intense muscle-gorging strength, energy, power and endurance.” Pvt. Sparling, who by all accounts was in excellent physical condition, purchased his Jack3d at an on-base GNC store.
Pvt. Sparling’s untimely death has once again ignited criticism of lax dietary supplement regulation in the United States, a subject we have addressed many times at SBM. Now joining the chorus of calls for reform are his parents, Leanne and Michael Sparling. Last month, the Sparlings filed a wrongful death lawsuit against GNC and Jack3d’s manufacturer, USPlabs. Ms. Sparling, who still wears her son’s dog tags, told the Times:
They just think they are too big and everybody’s afraid of them. They think I will just go away. Unfortunately for them, I won’t go away.
According to the Times, DMAA (dimethylamylamine), started out as an inhaled drug for nasal congestion. Because of potential side effects – tremors, headaches and nervousness – Eli Lilly withdrew it from the market voluntarily. In 2005, it reappeared as a dietary supplement based on the disputed claim that it can be found in a geranium grown in China. This doesn’t mean that any of the DMAA on the market actually comes from this plant, but such is the logic of the DSHEA.
Last April, the FDA sent warning letters to several supplement manufacturers saying it had no evidence DMAA is a legitimate dietary ingredient and citing its risks. (Health regulators in other countries, such as Sweden and Denmark, have actually banned DMAA-containing supplements.) Heart attacks, heart failure, kidney failure and liver failure were among the health problems reported to the FDA, as well as 5 deaths. GNC responded that it was “completely opposed to this unilateral, factually and legally unfounded action by the FDA.”
The Times story said that other organizations are also taking action. The World Anti-Doping Agency and Major League Baseball have banned methylhexaneamine, which is the same thing. The military removed supplements containing DMAA from base stores, including GNC. Col. Erin P. Edgar, a command surgeon with the U.S. Central Command, thinks the military, which sells “truckloads” of body-building supplements at its bases, should not be selling them at all.
And how did the industry respond?
Part of the problem is lack of any pre-market requirement of proof of safety and part of the problem is retailers like GNC, who aren’t regulated at all. As reported in the Times, both had predictable responses to the lawsuit and unfavorable publicity, as did the supplement industry.
The attorney for USPlabs said the company is “unaware” of any deaths from the proper use of Jack3d and that there is no evidence the reported deaths were caused by the product. Various spokespersons for GNC, which had about $4.2 billion in revenue last year, said the company had no reason to believe that DMAA is unsafe, that GNC sells legal products widely available from other retailers, and that it complies with all relevant regulatory guidelines. A spokesperson for the Council for Responsible Nutrition, an industry trade group, said that a majority of supplements are safe.
Unfortunately, all of these speakers are well within their rights. Manufacturers are under no obligation to test their supplements to see if they are fatal before they market them and they must report any deaths only if someone happens to complain. Even then, they are free to say there is no proven causal relationship. And if the FDA wants to challenge that, the FDA has the burden of proof. No doubt GNC does comply with all regulatory guidelines as there aren’t any regulations requiring retailers to inquire into safety or effectiveness. The Council spokesperson is probably right when he says that a majority of supplements are safe. We just don’t know which ones aren’t until we find out the hard way, when injury and death reaches a threshold that spurs further investigation. Or, as Dr. Amy Eichner, a special adviser to the anti-doping association for American Olympic athletes, told the Times:
No consumer can ever know what’s inside a bottle. We advise our athletes that all supplement use is at their own risk.
Great advice for all consumers, whether athletes or not. In fact, what we need instead of the Quack Miranda Warning on supplement labels is a more accurate disclaimer of FDA involvement in dietary supplement regulation:
FDA WARNING: Safety and effectiveness unknown. Use at your own risk.

A closer look at vitamin injections
Scott Gavura on May 24, 2013
Link
Vitamins are magic. Especially when they’re injected. Roll up the sleeve, find a vein, insert a needle and watch that colourful concoction flow directly into the bloodstream. It may sound somewhat illicit, but that person infusing it is wearing a white coat, and you’re sitting in a chic clinic. There must be something to it, right? Intravenous vitamin injections are popular with celebrities and have even been described by Dr. Oz as “cutting edge”. Advocates claim vitamin injections can benefit serious conditions like cancer, Parkinson’s disease, macular degeneration, fibromyalgia, depression, and that modern-day obsession, “detoxification”. And vitamin infusions aren’t just for the ill. They’re also touted as helpful for preventing illness, too. A search for vitamin injections brings up millions of hits and dozens of advertisements. There is no question that vitamin injections are popular. But despite all the hype and all the endorsements, there is no credible evidence to suggest that routine vitamin infusions are necessary or offer any meaningful health benefit. Vitamin infusions are a marketing creation, giving the illusion you’re doing something for your health, but lacking any demonstrable efficacy. What’s more concerning, providers of vitamin therapies target their marketing at those fighting life-threatening illnesses like cancer, selling unproven treatments in the absence of good scientific evidence that they are beneficial.
The intravenous vitamin industry is a sideshow to science-based health care. Yes, there is an established medical role for injectable vitamins, though it’s no energy-boosting cure-all – they’re used to replace what we should obtain in our diet. As a hospital-based pharmacist I used to prepare sterile bags of total parenteral nutrition (TPN), a mixture of vitamins, carbohydrate, protein and fat that completely replaced the requirement to eat. TPN is effective, but not without risks, and far less preferable than getting your nutrients the old fashioned way – by eating them. There’s also the routine use of injectable vitamins like B12, or iron, all of which can be science-based when used to address true deficiencies, or to manage specific drug toxicities. And there is the therapeutic use of high-dose minerals like intravenous magnesium for acute asthma attacks. But there is no medical justification to infuse vitamins into a vein when you can more appropriately obtain those nutrients in your diet.
So if they’re not necessary, where does the demand come from? A review in the Globe and Mail illustrates the hype and the promise:
Alison Dantas, chief executive officer of the Ontario Association of Naturopathic Doctors, says people’s fast-paced, frenetic lives are what is prompting more interest in naturopathic medicine and IVMT [intravenous micronutrient therapy]. While underscoring the difference between a recreational boost like caffeine and the injections, which must be given by trained professionals, she takes no issue with their trendy turn. “It raises awareness about complement therapies and medicines that assist people in staying healthy,” she says.
Of the 867 practising naturopaths in her province, Dantas says, 156 are intravenous-certified. She expects that number to increase. “We see a growing need because of the lifestyle of the population; it’s very effective in mitigating the risks of chronic disease but also managing chronic disease,” she says of Myers’ cocktail.
A 2011 survey by Caulfield and Rachul observed that that IV therapies are among the most popular services advertised by naturopaths. If it’s not “Myers’ cocktail”, (the intravenous version of a multivitamin pill), it’s high-dose vitamin C, which is explicitly marketed to cancer patients (One naturopath even recommends a video “Vitamin C better for cancer than chemo“.) Nothing subtle about it. Like Myers’ cocktail, vitamin C infusions are also touted as a panacea for the prevention or treatment of pretty much everything. As noted above, naturopathy organizations explicitly endorse the practice, and have even created a certification for the service. Given naturopaths argue that naturopathy is scientific and that the services they offer are science-based, I took a closer look at the scientific evidence supporting these services.
The PremiseBlame Linus Pauling. Actually, to be fair, the idea of injectable vitamins precedes Pauling. But Pauling, with two Nobel Prizes, brought attention and interest to vitamin C far beyond what any evidence suggested. He seized on the observation that many species can produce their own vitamin C, while humans, apes and some other species lack this ability. Pauling surmised that some disease may be due to vitamin C deficiency, which could be addressed with massive supplements. Linus moved from vitamin C for colds and on to vitamin C for cancer, teaming up with surgeon Ewan Cameron to conduct a clinical “trial” which claimed efficacy, but was so poorly designed no conclusions could be drawn. He continued to tout the potential of vitamin C, wrote a few books on the subject, and founded the Linus Pauling Institute of Medicine, creating the foundation for the entire “orthomolecular” pseudoscience you see today. (Orac has more.) Unfortunately it seems Pauling was a victim of Nobel disease, where prize-winning scientists subsequently become enamored with scientifically unsound ideas. At the time of his death in 1994, Pauling’s vitamin C theories were considered quackery within the scientific community, but those ideas had gone on to be embraced and widely promoted by complementary and alternative medicine (CAM) purveyors.
Fast forward to today, and not much has changed. Pauling’s theories on the efficacy of vitamin C have never been substantiated. Despite the lack of evidence, the routine use of vitamins has continued to expand in popularity over the years. With the growth in sales of vitamin pills, there seems to be a similar rise (though admittedly hard to quantify) of intravenous vitamin injections. The most popular seems to be Myers’ cocktail, an arbitrary concoction of vitamins and minerals including magnesium and calcium. It’s named after Baltimore physician Dr. John Myers who apparently administered injectable vitamins to his patients regularly. After he died in 1984, the practice was taken on by another physician, Dr. Alan Gaby. Gaby admits that he doesn’t know what was in the original Myers’ cocktail, so he made up his own recipe and took on the practice of offering multivitamin injections for the treatment of various maladies. The use of Myer’s cocktail seems to have gained more prominence after an article by Gaby appeared in Alternative Medicine Review which is essentially a collection of anecdotal claims of benefit for conditions that include asthma, migraine, fatigue, fibromyalgia, depression, cardiovascular disease, upper respiratory tract infections, allergies, urticaria, narcotic withdrawal, athletic performance and hyperthyroidism.
The advertisements you’ll find online above make it clear – it’s not what vitamins are good for – they’re clearly good for everyone. Infusions run from $50 to $250 for a few pennies worth of vitamins delivered intravenously. You’ll find no shortage of explanations from providers as to why intravenous injections are superior to dietary sources, from food sensitivities and “intolerance”, to greater demand by the body in times of disease or recovery. There are even claims the higher levels in the bloodstream “coax” vitamins into the cells and mitochondria, where presumably they’re beneficial. It sounds impressive, but these claims betray a profound ignorance of physiology and biochemistry. Strangely missing from these descriptions is an explanation why pushing megadoses of vitamins directly into a vein (and bypassing the liver’s first pass metabolism) is somehow still considered a “natural” treatment.
The VillainsAs expected, being a pharmacist, I’m blamed (along with other health professionals) with standing in the way of the widespread use of intravenous vitamins. Apparently it’s our bias against nutritional treatments of illness. Oh, and blame Big Pharma too – apparently you’ll never see research on a vitamin (unless you do) or on products you can’t patent (unless you do) or on cancer treatments that aren’t industry funded (unless you do). We love the prescription pad too much – but just for drugs, not for vitamins. (Never mind that it’s pharmaceutical companies manufacturing the injectable vitamins in question.) The fact that conspiracies are often cited should tell you all you need to know about the veracity of these statements. But I’ll risk the wrath of the Pharmaceutical-Industrial Complex™ and tell you the real reason science-based health professionals don’t recommend or use vitamin injections in routine practice. It’s because there’s no convincing evidence they are useful.
The Evidence CheckI looked in PubMed for evidence with injectable vitamins that would demonstrate a therapeutic or preventative effect. With respect to Myers’ cocktail, there is no published evidence to substantiate claims of efficacy for the prevention or treatment of any condition. The only paper in the medical literature is the review paper by Gaby (which collates impressive anecdotes, but no trials). Shrader published a study examining injectable vitamins for the use in asthma, but the study was unblinded with no placebo group. There is also a randomized trial by David Katz examining efficacy for fibromyalgia, which failed to show any efficacy. (Katz discusses this on Dr. Oz, and admits there’s a lack of efficacy). And that’s it for published evidence.
Looking specifically at vitamin C, there are hundreds of citations – there’s no question that vitamin C has been extensively studied. Advocates for vitamin C always find reasons to criticize the negative trials, so let’s look at the most positive trials only. Some of the “evidence” proponents of vitamin C like to cite includes the following papers:
    • Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues. Discussed and critiqued here and here in detail. Preliminary data that hasn’t been substantiated in human studies.
    • Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Discussed here. Showed high-dose injectable vitamin C can be well tolerated, but also showed a lack of any efficacy for advanced cancer.
    • Intravenously administered vitamin C as cancer therapy: three cases. Discussed here. These are case studies, and even the authors acknowledge that these reports increase plausibility, but don’t provide conclusive evidence given other factors could have contributed to the positive observed effects. The accompanying commentary is appropriately cautious.
    • Effect of high-dose intravenous vitamin C on inflammation in cancer patients. Unblinded. Doesn’t measure relevant clinical outcomes.
    • Vitamin C reduces fatigue in breast cancer. Unrandomized and unblinded. Is it any surprise the patients who accepted vitamin C felt better subjectively?
On balance, the data supporting the use of vitamin C are unimpressive – it’s no wonder that few scientists are advocating for more use or even more research. An optimistic review article from 2009 reluctantly admitted that the evidence supporting efficacy is still lacking despite 50 years of research. When we look at current clinical trials, it’s equally unimpressive. Notably, two trials (NCT00441207 and NCT00626444) have concluded in the past few years but have still not reported any results, suggesting the results were negative.
Overall, the evidence for vitamin C seems to suggest that if there really is an anticancer effect, it is so modest that it’s not detectable in clinical trials. While there are lots of anecdotes claiming benefit, there are also ones claiming it’s useless:
Celebrated physicist Sir Paul Callaghan has ended his experimental intravenous vitamin-C treatment for cancer, saying there is “absolutely no evidence” it worked. He is concerned that alternative medicine advocates are now using his “unusual experiment” to promote the controversial treatment in a misleading way. The New Zealander of the Year, who has terminal colon cancer, began receiving high-dose intravenous infusions of vitamin C in June last year, along with several alternative herbal remedies. The 64-year-old began the treatment during a six-month break from chemotherapy, tracking its effectiveness through a blood test for protein carcinoembryonic antigen (CEA), which indicates cancer levels. Yesterday, he told The Dominion Post he had ended his experiment after analysing data from six months of blood test results. “I have, as a result, learned enough to say that there is absolutely no evidence of any beneficial effect of high-dose intravenous vitamin C in my case.”
(Callaghan died in 2012.)
Given the lack of efficacy, my take on the efficacy of vitamin C for cancer is along the lines of what the American Cancer Society recommends – get your vitamin C from your food. When it comes to the use of injectable vitamin C for other conditions, no obvious benefit has been shown. There is no evidence to support the use vitamin C infusions for the prevention of disease, or for general “wellness.” In light of the lack of documented benefit, vitamin C infusions should really only be offered (or accepted) as part of a research study, and only in situations where its use is not expect to delay the use of more effective treatments. For any other conditions, the science-based approach would be the same: maximize the consumption of vitamin C-containing foods like fruits and vegetables, rather than relying on supplements – injectable or otherwise.
The RisksIf you trust the sterile technique of vitamin infusion purveyors, and are willing to chance the small risk of infection, then the risks associated with the different vitamin infusions appear to be quite low. You generally don’t get adverse effects when there’s no effect, which may be why these products are well tolerated. While good data have not been compiled, there are also few case reports that document harms. Based on the ingredients themselves, that’s what we’d expect. Vitamin C infusions are generally well tolerated though the osmotic load (fluid shifts) from huge doses may be problematic. There are also case reports of kidney stones from intravenous infusions, an association also seen with vitamin C oral supplements. Of course there are the cases compiled at What’s the Harm?, but reassuringly, most of the documented harms seem to be the result of avoiding appropriate treatments, rather than due directly to IV vitamin therapy. There is some evidence suggesting high dose vitamin C may reduce the effectiveness of chemotherapy (reviewed in detail here). There are also specific concerns about concurrent use with bortezomib (Velcade). Given there is no demonstrable benefit to vitamin C infusions for cancer, it’s probably safest for cancer patients to avoid vitamin C infusions entirely.
The Bottom LineWith so many purveyors of vitamin infusions, one would hope the practice was grounded in good science. But it isn’t, and that shouldn’t be a surprise. Despite the lack of good evidence, there is a near-obsessive devotion to touting the benefits of intravenous vitamins while railing against the mysterious entities which are blocking The Truth. But the reality is more mundane. In the absence of a deficiency, vitamin infusions don’t do much of anything. To the worried well, intravenous vitamins are going to be a harmless panacea that just succeed in enriching the revenues of the purveyor. Just as That Mitchell and Web Look said of the homeopath, “Bottle of basically just water in one hand, and a huge invoice in the other.” So if you value health theater over health care, and don’t mind paying mightily for the illusion, vitamin infusions may be your thing.
I have a much different opinion when these products are promoted to patients fighting for their lives, particularly with illnesses like cancer. There is good evidence to show that delaying treatment or substituting CAM for established cancer treatments dramatically worsens outcomes. Touting unproven treatments and then profiting from their administration is appallingly opportunistic. Real diseases require real treatments, not fake ones. They may look sciencey, but the reality is that intravenous vitamin injections are modern-day snake oil.

The consumer lab rat: More questions about supplement safety
Scott Gavura on January 28, 2016
Link
Do you take a vitamin or dietary supplement? Over half of all American adults do, making this a $30 billion dollar business. Many of us even take supplements in the absence of any clear medical or health need. I’m often told it’s a form of nutritional “insurance” or it’s being taken for some presumed beneficial effect – like Steven Novella outlined in yesterday’s post on antioxidants. We love the idea of a risk-free magic bullet that improves our health and wellness. Especially one that avoids what are presumed to be toxic, unnatural drugs. Supplements are marketed as safe, natural and effective, and there is no question that messaging has been effective.
I used to take supplements. For me it was multivitamins. But as I’ve taken a closer look at the evidence for supplementation, my personal behaviors changed. The primary reason is a lack of evidence. There is no evidence to suggest that vitamins offer any health benefits in the absence of deficiency. The balance of evidence suggests that routine multivitamins are unnecessary for most people. Vitamins should come from your food, not from supplements. More generally, looking at the broader category of supplements that range from probiotics to herbal remedies, there is little evidence to support most of them. With a few exceptions, the research done on dietary supplements is unconvincing and largely negative. If you don’t supplement, you don’t seem to be missing out on any tremendous health benefits.
Going beyond the lack of evidence, there’s an even more compelling need for consumers to be wary of them. The safety of supplements is increasingly being called into question. Evidence has emerged demonstrating that quality standards for supplements sold in many countries are erratic and unpredictable. The root cause seems to be regulatory systems that prioritize manufacturer interests ahead of consumer protection. With supplements, products are effectively being tested for safety after they are marketed, and the consumer is the unwitting research subject. 
Regardless of your personal position on supplements, I have yet to find someone that doesn’t want all supplements to be manufactured to high quality standards. What’s on the label should accurately describe what’s in the bottle, and there should be no exceptions to this. As a pharmacist, I can’t personally verify that each tablet in your prescription contains the active ingredient on the label. I am totally dependent on a supply chain that may stretch around the world, and tight regulatory standards that mandate quality testing of every batch of drugs. But none of these assurances are in place for dietary supplements. Only a regulator that can realistically verify and enforce production of drugs (or supplements) to strict quality standards. But with supplements, regulators are given different standard to apply.
Federal legislation enshrines your access to untested, dubious supplements
While the US Food and Drug Administration (FDA) is respected worldwide for pharmaceutical policy (few countries are as rigorous and as transparent), the same cannot be said for its regulation of supplements. Audits and recalls suggest that there is a small but persistent trend of poor manufacturing standards for American products. Adulteration, virtually unheard of with prescription drugs, seems to be a regular occurrence with supplements – Vox recently published a long table of adulterated supplements. Poor quality should not be a surprise. It’s a consequence of legislation deliberately designed to weaken the FDA’s ability to regulate and provide oversight of supplements. The Dietary Supplement Health and Education Act of 1994 (DSHEA) was an amendment to the US Federal Food, Drug and Cosmetic Act that established the American regulatory framework for dietary supplements. It effectively excludes manufacturers of these products from many of the requirements that are in place for prescription and over-the-counter drugs. Amazingly, it puts the requirement to demonstrate harm on the FDA, rather than the onus on the manufacturer to show a product is safe and effective. A weak regulatory framework, which doesn’t require pre-sale testing of product quality and finished product specifications, might be expected to result in a weaker commitment to quality. And that might be expected to result in erratic product quality, and possibly bad behavior from some manufacturers. And that’s exactly what we find when you look at supplement sales today. Happily, these effects are being reported to regulators, who are starting to act. Sadly, it’s been driven by a series of catastrophic harms suffered by consumers.
PBS Frontline describes the consequences of weak regulation
Last week the PBS television show Frontline focused on supplement safety. I strongly recommend listening or watching, as it paints a disturbing picture of how consumers continue to be harmed as a consequence of weak regulation and poor quality standards. A few highlights I picked up:
    • The FDA does not review dietary supplements before they are sold in the market. There is no formal registration process for manufacturers. Consequently, the FDA doesn’t know how many companies produce supplements in the US. (This is probably because the entire division dedicated to dietary supplements has just 25 people.)
    • In 2013 Purity First vitamins were found to be laced with two anabolic steroids. Even after this was identified, it took the FDA six months to finally have the product removed from the market.
    • Suspected harms and adverse events from supplements can be reported to the FDA. However, physicians interviewed reported difficulty in reporting problems, and in getting the FDA to take complaints seriously.
    • The Children’s Hospital of Philadelphia, faced with patients bringing in supplements, took steps to validate their safety and quality. They decided to ask supplement manufacturers for certificates of analysis, which are documents which demonstrate that what’s on the label of a supplement is actually verified to be in the supplement, and that the supplement meets stated quality manufacturing standards. 90% never responded and of the 10% that did respond, most couldn’t demonstrate their products were manufactured to acceptable standards.
    • Manufacturers fought the withdrawal of the stimulant supplement ephedra for over a decade. By the time it was finally withdrawn, over 160 deaths were linked to its consumption. The ban has effectively eliminated deaths and poisonings.
    • Another supplement, OxyElite Pro caused an outbreak of hepatitis leading to liver failures, transplants, and deaths in some circumstances. The US Department of Justice recently announced it is pursuing civil and criminal charges against the manufacturer, USPLabs.
    • Despite criticism from the industry about DNA barcoding, some manufacturers are starting to accept that this type of testing is essential if they’re going to address concerns about product quality. So they’re adopting these methods.
Frontline suggests you ask the following five questions before taking a supplement:
    • Has the product triggered any health warnings or sanctions? Searching the FDA’s website for a list of all recalls will identify if the product in question has been flagged. But given the few resources put into monitoring supplement safety issues, a lack of warnings is no assurance of quality or safety.
    • Has the product been tested by independent labs? This is currently very difficult to verify. Frontline mentions ConsumerLab.com and LabDoor as independent testing services with data available to the public. However even independent testing can be problematic, as you’ll see below.
    • Is the product too good to be true? While supplement makers are legally prohibited from making unfounded claims of efficacy, it’s not hard to find these claims on products. It’s important to note that there are no magic bullets out there. Outlandish claims (particularly common with products marketed for dieting) should not be believed.
    • Is there evidence that the supplement does what it promises? Look to reputable sources that summarize the evidence without bias. If there’s no good evidence supporting any efficacy claims, it’s a giant red flag that the product is probably bogus. Frontline notes:
Thousands of studies have been conducted on the effect of various substances on the human body. The National Institutes of Health has summarized what is known about the most commonly consumed supplements — vitamins and minerals — in a series of fact sheets. These explain how each vitamin or mineral behaves in the body, and the scientific evidence behind its health impacts. The US National Library of Medicine’s MedlinePlus has similar information about other drugs, herbs and supplements. For a deeper dive into the science behind a specific supplement, explore the Library of Medicine’s PubMed Dietary Supplement Subset. The database includes scientific literature on vitamin, mineral, phytochemical, ergogenic, botanical, traditional Chinese medicine, and herbal supplements in humans and animal models.
Resources are also available for certain groups: The Department of Defense offers information about the safety of specific supplements to service members. Older adults can find resources aimed at them created by the FDA, the Federal Trade Commission, National Institute on Aging, and NSF International.
    • Do I really need supplements? If so, am I taking the right amount? This is the key question, which is easier to answer after you’ve answered the questions above. There are some circumstances where specific supplementation is advisable. In other cases, it may not be essential. If you do need it, understand what the evidence says about the dosing, and ensure you’re taking a safe amount.
CBC Marketplace tested several supplements – and got it wrong
In a post on supplement safety and quality, I think it’s important to discuss how one group tested supplements – and how they got it wrong. Last week the Canadian consumer advocacy television show CBC Marketplace published a lengthy apology on its website. Its own analysis of supplements, which it had broadcast last fall, was faulty – and they were retracting the episode and apologizing:
Last fall, Marketplace commissioned lab testing for samples of fish oil, vitamin C and protein powder supplements to see if consumers are actually getting what they pay for. Based on those test results, Marketplace reported that Emergen-C and two protein powders: GNC Lean Shake 25 and Cytosport Muscle Milk failed to live up to label claims. However, subsequent re-testing of the samples has found that the lab results and analysis provided to Marketplace were incorrect, and that there is no evidence of problems with those products. The original lab tests were performed by an independent lab in Michigan, which is ISO-17025 accredited, registered with the US Food and Drug Administration, and used by the supplement industry. The lab was recommended by Neil Thanedar, co-founder and CEO of LabDoor, a company that has products tested and makes those results public to help guide consumers about vitamins and supplements.
LabDoor’s investors and partners include Rock Health, a San Francisco-based venture fund that invests in health-care research, and the Mayo Clinic. Thanedar agreed to analyze the test results for Marketplace. The supplement companies strongly disputed those results. When Marketplace learned there might be a problem with one of the tests, CBC re-tested some of the products at other independent, accredited labs. None of them found problems with the samples.
So what happened here? Marketplace seemed to take all the right steps. It sought out what it thought was a reputable organization, Labdoor, to help with testing, which claimed the requisite expertise in evaluating product quality. The testing itself was done at an independent facility. Yet secondary testing refuted the original testing, and ultimately vindicated these three products – there were no problems, after all. What seems clear is that quality testing is not an easy matter. And Marketplace was testing fairly straightforward products. Imagine the complexity of testing herbal products – not only do you need to verify the raw material is present, but you must also verify the absence of adulterants like prescription drugs. In December I asked “What’s in your Traditional Chinese Medicine” after an analysis found dog, cat, snake, prescription drugs and heavy metals in products sold by retailers in Australia. What the CBC’s retraction says to me is that verifying supplement quality and standards may be even more difficult than we thought.
The supplement market is a massive, uncontrolled, unmonitored clinical trial
While they may look like medicine, and be sold alongside medicines in the pharmacy, supplements are very different. With supplements, the testing may not begin until you start taking the product. A weak regulatory structure has resulted in a marketplace with thousands and thousands of products, but little assurance to consumers that these products are safe and effective. Consumers want safe products that work, but they are effectively research subjects in massive uncontrolled experiments. Manufacturers want to sell products, and will continue to push for the weakest, lightest regulation possible. The result will continue to be a marketplace where there is little assurance that any product label can be trusted. Until these quality and safety gaps are addressed with the appropriate incentives, penalties and regulations, it’s difficult to conceive how we can use supplements safely, and in a science-based manner.

More Trouble for Antioxidants
Steven Novella on January 27, 2016
Link


Antioxidants are now an iconic example of premature hype making its way into marketing and the public consciousness long before the science is adequately understood. There are multiple lessons to be learned in this story, and a new study just emphasizes those lessons further.
A brief history of antioxidants
One of the unavoidable consequences of metabolism (burning food for energy) is the creation of oxygen free radicals, or reactive oxygen species (ROS). These are molecules that are highly reactive. They essentially contain oxygen with an extra electron, which can react with another molecule, breaking bonds and causing damage.
As you might expect, the body has natural antioxidants which react with ROS to form benign molecules.
In the 1990s it became increasingly apparent that oxidative stress was playing an important role in cell damage, even sometimes triggering apoptosis, or programmed cell death. Many degenerative diseases, like Alzheimer’s disease, were shown to be driven in part by oxidative stress. In addition, it seemed that ROS play a role in aging.
The implications of this realization are clear – if oxidative stress is causing aging and disease, then antioxidants should help slow aging and disease progression, maybe even stop it. This was a reasonable hypothesis in the 1990s. A quarter of a century later, however, we realize that the story is much more complicated.
Before scientists could even follow up on their hypotheses, however, the supplement industry seized upon the notion of antioxidants. The prospect of slowing aging was a perfect match for the typical hype of the supplement industry, and the fact there was actual science to back up those claims (even if it was preliminary without any clinical findings to back them up) sweetened the deal.
Marketing of the alleged health benefits of antioxidants has been at saturation levels ever since. The result is that antioxidants have a powerful health halo, one that they did not earn through scientific study.
Reality sets in
While the supplement industry was very satisfied with the preliminary science of the 1990s, scientists did not stop their investigations. It was soon discovered that ROS also play many positive and important roles in the body. The immune system uses ROS to attack and destroy bacteria or cancer cells, for example. They are also important signaling molecules, telling cells to ramp up protective pathways.
Further, organisms already possess powerful antioxidants (more powerful than any supplement) that keep the ROS in balance. Evolution is very efficient at optimizing systems. It therefore makes sense that we would have evolved an optimal balance between ROS and antioxidants. If there were a clear health benefit to additional antioxidants, our bodies would just make more.
We do, however, need some exogenous antioxidants (like vitamin C and vitamin E). They are a part of the system too, and work with the endogenous antioxidants to keep the system in balance. As with supplements in general, it makes sense to make sure one is getting sufficient nutrients to avoid deficiency. However, there is no rationale for taking large doses, or thinking that more is always better.
In retrospect it was naïve to think that taking extra exogenous antioxidants would make the system function better, even to the point of slowing aging. It was reasonable to think that in certain disease states the balance of ROS and antioxidants was abnormal, and this could be fixed with exogenous antioxidants.
There are some specific diseases where this is the case, such as one form of familial ALS, which is a genetic mutation in superoxide dismutase, an important antioxidant. However, even this story is more complex as the mutated protein not only does not do its job as an antioxidant but is also directly toxic to proteins.
A recent review of antioxidants concluded:
The balance between oxidation and antioxidation (redox balance) is critical in maintaining a healthy biological system. In cellular redox state, the double-edged effect does not only concern ROS, but also antioxidants. Physiologic doses of exogenous antioxidants are required to maintain or re-establish redox homeostasis. However, high doses of exogenous antioxidants may disrupt redox balance.
In other words – eat your fruits and vegetables, but don’t bother with supplements.
The new study
With this background, a recent study published in Nature [PDF, full article temporarily available here] concerning antioxidants and metastatic cancer should not be a surprise.
The study is based on the observation that with solid tumors, like melanoma, there is frequent dissemination of cancer cells through the blood (metastasis) but these cells are very inefficient at establishing a metastatic tumor. One reason for this is the immune system using ROS to essentially kill metastatic cells before they can be established. They found that cancer cells that do establish tumors tend to have mutations that make them resistant to oxidative stress.
Most relevant to this topic, however, they found that in mice exogenous antioxidants promoted distant metastasis. This suggests that if you have cancer and you take antioxidants, your chance of developing metastases is greater. Keep in mind most solid tumor are usually present for 2-3 years before they are diagnosed, so the risk potentially exists even for those who have not yet been diagnosed with cancer.
This has alarming implications given the popularity of antioxidant supplements.
Lessons
To emphasize the lessons from this iconic story of supplement industry misadventure:
    • The body is complex, and we should be skeptical of any simplistic notions of the effects of our interventions
    • We need to respect the natural homeostatic mechanisms that evolved and not think that we can easily improve them
    • More is not always better
    • Be skeptical of clinical claims based on pre-clinical or basic science; until we study an intervention’s net health effects, we cannot really know what they will be
    • We have yet more evidence that for the average person the best advice is to eat a well-rounded diet with plenty of fruits and vegetables, but extra supplements (and especially high dose supplements) are likely unnecessary and even counterproductive.

Multivitamins and Vascular Disease
Yet another massive meta-analysis shows no health benefit to routine supplementation with vitamins or minerals.
Steven Novella on July 11, 2018
Link

One of the more common questions I get as a physician, and as a proponent of science-based medicine, regards whether or not it is helpful to take a multivitamin/mineral supplement (MVM) routinely for general health. Part of the reason this question is so common is because there has been a great deal of marketing trying to convince the public that this is a good idea.
In the US alone the vitamin and supplement industry was worth $36.1 billion in 2017. The industry also continues to grow and is expected to reach $278 billion worldwide by 2024. About half of Americans take vitamins regularly. This is perhaps the most iconic example of health marketing getting ahead of the science.
Vitamins, by definition, are necessary for health – they are substances that the body needs to carry out its biochemical functions, but cannot manufacture itself from other substances. You have to eat vitamins to get them. Minerals refer to trace minerals that also need to be consumed, since they are elements and cannot be manufactured. Since the discovery of specific vitamins and minerals, what they do, the diseases that result from their deficiency, and which foods contain them, the standard recommendation has been to get enough vitamins from food. This means having a varied diet with plenty of fruits and vegetables. This is still unequivocally the best advice.
Specific individuals or populations, however, may be insufficient or deficient in specific vitamins or have a greater need for a specific vitamin, and in such cases supplementation may be necessary. There have even been programs of fortification – adding specific supplements (like vitamin D to milk) to increase levels in the general population. Why, then, don’t we just fortify the drinking water with multivitamins to reduce the incidence of all vitamin deficiencies? (You might argue that, to a degree, we do, given the popularity of vitamin water and other fortified food products.) Would the expense and risk of such a program yield worthwhile health benefits?
Multivitamin use and vascular disease
The question of routine vitamin and mineral supplementation (meaning, in the general population, without a specific indication) is a difficult one to answer. Researchers would have to look at very large numbers of subjects over years, evaluating many possible supplements, diet, and a host of possible health outcomes. We could also look at subpopulations (sex, race, age, socioeconomic status, duration of supplementation, etc.) further multiplying the number of possible questions to be researched.
A recently published meta-analysis looking at MVM use in vascular disease takes a huge bite out of this massive set of questions. The researchers looked at: “Eighteen studies with 2,019,862 participants and 18,363,326 person-years of follow-up were included in the analysis.” Two million participants is a pretty powerful study. Here is what they found:
Overall, there was no association between MVM supplementation and CVD mortality (relative risk [RR], 1.00; 95% confidence interval [CI], 0.97–1.04), CHD mortality (RR, 1.02; 95% CI, 0.92–1.13), stroke mortality (RR, 0.95; 95% CI, 0.82–1.09), or stroke incidence (RR, 0.98; 95% CI, 0.91–1.05). There was no association between MVM supplements and CVD or CHD mortality in prespecified subgroups categorized by mean follow-up period, mean age, period of MVM use, sex, type of population, exclusion of patients with history of CHD, and adjustment for diet, adjustment for smoking, adjustment for physical activity, and study site.
CVD is cardiovascular disease, while CHD is coronary heart disease. Incidence is simply the number of people who develop the condition, while mortality is the number who die from it. So MVM use was not associated with any decrease in vascular mortality, or with stroke incidence. There was a slight decrease in CHD incidence, but this did not remain significant when they did a “pooled subgroup analysis of randomized controlled trials”.
The authors conclude:
Our meta-analysis of clinical trials and prospective cohort studies demonstrates that MVM supplementation does not improve cardiovascular outcomes in the general population.
About three months ago I wrote about another meta-analysis of vitamin use that came to the same conclusion. This review also looked at specific vitamins and looked at all-cause mortality as an outcome. This review found:
    • Multivitamins, vitamins D, C, A, B6, E, calcium, β-carotene, zinc, iron, magnesium, and selenium had no benefit or harm for vascular disease or all-cause mortality.
    • Folic acid and B-complex (Folic acid, B6 and B12) reduced stroke risk.
    • Antioxidants and niacin increased all-cause mortality.
The data showing a reduced stroke risk, however, had problems. Specifically this finding was driven by a large study in China which does not fortify foods with folic acid so the population may be generally deficient, and therefore these results may not translate to other countries. This new meta-analysis shows that multivitamins (which include folic acid) were not associated with a reduction in stroke incidence or mortality.
What’s the harm?
In a 2015 survey 90% of the public thought it was a good idea to take a multivitamin. (In the same survey 80% of the public also said that taking a multivitamin does not replace a good diet.) This shows that the marketing has worked, despite the evidence. We can now say with a high degree of confidence that there is essentially no health benefit to routine supplementation. (I always have to emphasize that this does not include pregnant women or other special populations – consult your doctor.)
What most physicians practice is better termed targeted supplementation. We check vitamin levels and then make dietary advice or prescribe specific doses of supplements to address specific deficiencies, and follow up.
Many people, however, think of vitamin supplementation as “insurance”. Sure, have a healthful diet, eat your fruits and vegetable, but just in case a multivitamin can’t hurt. But everything in medicine should be viewed from the perspective of risk vs benefit. Spending collectively billions of dollars on unnecessary supplements is an opportunity cost that should not be ignored. In extreme cases I have seen patients who cannot afford needed prescriptions because they are spending hundreds of dollars a month on unneeded supplements.
There is also the well-known “false sense of security” factor. People may think they can get away with a less-than-ideal diet because they take MVM as insurance – but we know that vitamins do not compensate for a poor diet. They may even neglect other aspects of health care partly because of the false assurance of taking supplements.
There is also the small risk of toxicity from oversupplementing. This is not as rare as you might think. There is also the possibility of more subtle direct negative effects, suggested in the previous study showing increased all-cause mortality from taking anti-oxidants.
So the hype (as opposed to the science) surrounding vitamin supplements and supporting a massive industry likely provide no health benefit may cause some harm, can cause a false sense of security, and diverts resources and attention from other effective interventions. None of this implies that vitamins are not necessary for health, they are, but rather that in developed nations vitamin deficiency is not a problem for the general population.
I also seem to conclude articles on vitamins and supplements with the same nugget of advice, because that advice is still true and has not changed over decades of scientific research – eat your fruits and vegetables.

   Vitamins and Mortality
Steven Novella
Link
The discovery of various vitamins – essential micronutrients that cause disease when deficient – was one of the great advances of modern scientific medicine. This knowledge also led to several highly successful public health campaigns, such as vitamin-D supplementation to prevent rickets.
Today vitamins have a deserved reputation for being an important part of overall health. However, their reputation has gone beyond the science and taken on almost mythical proportions. Perhaps it is due to aggressive marketing from the supplement industry, perhaps recent generations have grown up being told by their parents thousands of times how important it is to take their vitamins, or eat vitamin-rich food. Culture also plays a role – Popeye eating spinach to make himself super strong is an example this pervasive message.
Regardless of the cause, the general feeling is that vitamins are all good – they are not only important for health, they promote health. Many people take vitamin supplements on the idea that more is better, or for nutritional “insurance” to make sure they are getting enough of every vitamin.
The problem with deeply embedded cultural beliefs is that people make decisions based upon assumptions that everyone “knows,” rather than making evidence-based risk vs benefit decisions. This phenomenon is exacerbated when the industry is able to make aggressive health claims without requiring any scientific evidence to back up those claims (as is the case in the US since DSHEA was passed in 1994).
It is therefore important to shatter the pedestal on which vitamins have been placed, to bring them down to the level of scientific evidence. The good news is, there is a ton of research on vitamins, which continue to be the subject of much new research. Each year, therefore, the risks and benefits of vitamins become more clear. One recent study which is getting much press adds to this body of knowledge about vitamins.
In the latest issue of The Archives of Internal Medicine is a population based observational study looking at health outcomes and vitamin use as part of the larger Iowa Women’s Health Study. The authors looked at 38,772 older women and asked them to self-report their vitamin use. This is a long term study and their vitamin use was reports in 1986, 1997, and 2004, and mortality was followed through 2008. They found a small but statistically significant increase in mortality for those taking multivitamins, B6, folic acid, iron, copper, magnesium and zinc. There was also a small decrease in mortality for those taking calcium.
The strength of this study is that it is large with a long term follow up. There are many weaknesses, however. Vitamin use was self-reported. Further, this is a correlational study only. Therefore possible confounding factors could not be controlled for. For example, it is possible that women who have an underlying health issue that increases their mortality were more likely to take vitamins or to report taking vitamins.In fact, other studies suggest there is such a “sick-user effect” with vitamins.
It is therefore not possible from this study to draw any conclusions about cause and effect – that vitamin use increases mortality. But it does provide a cautionary reminder that it is not reasonable to assume that vitamin supplementation is without any risk. We still need to follow the evidence for the use of specific vitamins at specific doses for specific conditions and outcomes.
Conclusion
As is typical of observational studies, the results are somewhat mixed, depending upon the details of how such studies are conducted. There are also many variables to consider – which vitamins and which doses in which populations with what health conditions. There is therefore a great deal of noise in the data. I do not think we can conclude that the vitamins listed above actually increase risk of mortality. But neither can we conclude that there is any health benefit for routine supplementation. Years of research have failed to provide such evidence, and the mixed results we are seeing is consistent with there being no or only a small effect.
Based upon the totality of evidence the best current recommendation is to have a well-rounded diet with sufficient fruits and vegetables, which should be able to provide most people with all the micronutrients they require. There is no evidence to support routine supplementation. There is also reason to avoid taking megadoses of vitamins, as this can cause toxicity, and even short of toxicity the evidence becomes more compelling at higher doses of the risks of supplementation.
But there are also many situations in which targeted supplementation is evidence-based and appropriate. There is increasing evidence to support the use of vitamin D supplementation for many populations. Many elderly have borderline or low B12 levels, which correlates with dementia. Pregnant women should take prenanatal vitamins. (To give just a few examples.)
Vitamins are just like any other health care intervention – they have potential risks and benefits and it is best to follow the evidence. For most people the best advice is to ask your primary health care provider which supplements, if any, you should take. Recommendations should be based upon specific health conditions and blood tests to measure levels of vitamins, so that specific deficiencies can be appropriately targeted.

Study of Multivitamin Use and Memory
Routine multivitamins are likely not the best strategy for cognitive effects.
Steven Novella on September 21, 2022
Link

A recent study of multivitamin use and memory in older adults is getting a lot of press and definitely needs to be put into perspective. Let’s begin with a quick review of the literature so far.
The clinical question is whether or not vitamin supplementation can improve memory or decrease the decline in memory as we age. Obviously there are a lot of subquestions here – if so, in which subpopulations, supplementing with which vitamins, and at what dose? There are also many possible outcomes to measure – attention, immediate recall, long term recall, verbal performance, and prevention of a diagnosis of dementia. There is an incredible amount of permutations. However, we can start with the most basic question and then try to drill down from there – is there any cognitive benefit to taking a multivitamin (MVM) in the general population or the general older population?
This question is actually hard to answer in the literature, as there are many study differences, overall study quality is generally low, and the findings are mixed. This 2021 systematic review specifically looked at B-vitamins and cognitive decline. B-vitamins are of special interest because they can decrease a metabolic product in the blood known as homocysteine. High levels of homocysteine are linked to poor vascular health and can increase the risk of blood clots and contribute to dementia and cognitive decline. The review found that B-vitamins specifically can delay cognitive decline in older adults, but larger and more rigorous clinical trials are needed to confirm this benefit.
Of note, a 2016 review looking specifically at different trials of B-vitamins in dementia found:
Most homocysteine-lowering trials with folate and vitamins B6 and/or B12 tested as protective agents against cognitive decline were poorly designed by including subjects unlikely to benefit during the trial period. In contrast, trials in high-risk subjects, which have taken into account the baseline B vitamin status, show a slowing of cognitive decline and of atrophy in critical brain regions, results that are consistent with modification of the Alzheimer’s disease process.
In other words, the protective effect of B-vitamins may only occur in those with baseline low B-vitamin levels and/or high homocysteine levels.
Other systematic reviews of MVM use in the general population find either no benefit or limited benefit. For example, the linked review found small benefit for immediate recall only, with no benefit for delayed recall or other cognitive functions measured. And also, the reviews generally conclude that the existing data is insufficient to adequately address the question. So there is definitively room for a larger and more rigorous study, and that is exactly the hole the current study seeks to fill.
The researchers in the current study actually had four treatment groups – cocoa extract plus placebo, MVM plus placebo, cocoa extract plus MVM, and just placebo. There were 2,262 subjects total enrolled in the study and evenly divided among the four groups. This was a three-year study, and so is larger and longer than other studies of MVM use and cognition. The assessment of the subjects was done over the phone, which is actually fine as the various cognitive exams can be done entirely verbally.
They found that all groups improved on all measures over the three years. This was expected and is due to the practice effect – subjects get better at the cognitive tasks with practice. They also generally plateaued between year 2 and 3 – also an expected pattern with the practice effect. So comparisons to baseline were essentially meaningless. All that mattered was comparison to placebo. There was a pretty high drop out rate:
Of enrolled participants, 2082 (92%) completed the cognitive assessment at Year 1, 1906 (84%) at Year 2, 1790 (79%) at Year 3, and 1732 (77%) in all 3 years of follow-up.
It’s hard to know the effects of this on the outcome, but such high dropout rates are a problem. That aside, the results showed a benefit for cognitive performance in the MVM vs placebo. There was no benefit for the cocoa extract vs placebo, and no addition benefit for adding cocoa extract to MVM. However, the authors also did a pre-planned subgroup analysis, looking at subject with baseline cardiovascular disease (CVD) and without. Those with CVD had a greater benefit from MVM use, and were the only subgroup that had a cognitive decline in the placebo group (as I stated, all other groups improved throughout the study). There was still a benefit for the non-CVD group, however, just not as dramatic.
For me, there is one glaring omission in this study – they did not evaluate baseline vitamin level or homocysteine levels. It is therefore possible that the entire effect seen in this study comes from the effect of B-vitamins on lowering homocysteine levels, which is consistent with the fact that the group who seemed to benefit the most from MVM use had baseline CVD. Also, I just want to emphasize that CVD is a major risk factor for dementia and cognitive decline.
This may all seem pedantic, but messaging to the public is critical. First, there is no evidence that MVM use improved cognition, as many mainstream outlets are reporting. It is far more likely, as the authors acknowledge, that MVM use simply decreased the decline in cognition in this older population. Therefore young healthy people should not expect any cognitive benefit to MVM use.
Further, it seems likely that the observed benefit here may be due to simply treating low B-vitamin and/or high homocysteine levels in this population, something which is already fairly well established. It is far better for people to have regular medical care in this age group, which includes measuring vitamin and metabolic levels and targeted supplementation, with monitoring, when appropriate. We would like to know, for example, which vitamins levels in particular are low. Also, not everyone responds to oral B12 supplementation and may require B12 injections. Thinking that a daily MVM will have you covered, therefore, may be counterproductive.
Also, this study only looked at cognition. Large reviews of hundreds of thousands of subjects have found not only is there no benefit to routine MVM use, some vitamins (like vitamin E) may be harmful in high doses. Routine MVM use, therefore, appears to be a harmful strategy, wasting money for most people and potentially resulting in excess supplementation with harmful effects. The proper messaging, in my opinion, is that older patients should be getting regular health visits, part of which will include monitoring nutritional factors which may lead to targeted evidence-based supplementation.

Prenatal Multivitamins and Iron: Not Evidence-Based
Harriet Hall on February 2, 2016
Link

When I was pregnant, I obediently took the iron pills and prenatal vitamins prescribed by my obstetrician. And I prescribed them for every pregnant patient I took care of as a family physician. I never questioned the practice. It seemed intuitively obvious that it was a good thing; we know pregnancy makes extra nutritional demands and depletes iron stores. It never occurred to me to question what I had been taught, because it seemed perfectly logical. I did question other things I was taught that didn’t seem so logical. In my internship, we were ordered to do episiotomies on every patient (the rationale was that it made birth less traumatic for the baby and prevented uncontrolled perineal tearing in the mother). I was severely chastised for omitting an episiotomy on a patient who begged me not to do one. She had had several babies and was stretchy enough to deliver easily without an episiotomy. In this case, my common-sense clinical judgment was vindicated by further research in the years after my internship; new evidence showed that routine episiotomies were of no benefit, practice changed in response to the new evidence, and episiotomies are no longer done routinely.
That was a long time ago. I have long since learned that even the most reasonable assumptions can be wrong. I happened to be right about episiotomies, but I might just as well have been wrong; and the only way to know whether a belief is true is to test it in controlled scientific trials. As Will Rogers said, “It isn’t what we don’t know that gives us trouble, it’s what we know that ain’t so.” It turns out that routine multivitamin and iron supplementation is not supported by any convincing evidence from scientific studies. And practice is changing. Recently, when one woman asked her OB what she should do about prenatal vitamins he pulled his wastebasket out from under his desk and said “put them there.”
The evidence for folic acid

Folic acid prevents serious congenital abnormalities, neural tube defects like spina bifida and anencephaly. It is recommended for any woman who might become pregnant, because the damage occurs early, sometimes before she knows she is pregnant. The United States Preventive Services Task Force (USPSTF) found high quality (Grade A) evidence to support their recommendation that “All women planning or capable of pregnancy take a daily supplement containing 0.4 to 0.8 mg of folic acid.”
The American Academy of Family Physicians seconds that recommendation and recommends folic acid supplementation be continued for the first 6-12 weeks of pregnancy. But it points out that many other elements of routine prenatal care are based on tradition and lack a firm evidence base. It makes recommendations about healthy diet, but it doesn’t make specific recommendations about prenatal multivitamins. It doesn’t recommend iron supplements for all pregnant women, only for those with iron deficiency anemia.
The evidence for iron
The USPSTF found insufficient evidence to recommend for or against routine iron supplementation in pregnancy. In summary, it said:
routine iron supplementation during pregnancy may improve maternal hematologic indices and reduce the incidence of iron deficiency and iron deficiency anemia (IDA) in the short term. However, there is no clear or consistent evidence that prenatal iron supplementation has a beneficial clinical impact on maternal or infant health. In addition, no trials are available on the effect of prenatal screening for IDA on clinical outcomes despite routine screening practices in many high-income countries. Rigorous studies are needed to fully understand the short- and long-term effect of routine iron supplementation and screening during pregnancy on women and infants, including the effects on rates of cesarean delivery, small size for gestational age, and low birthweight. Until then, the evidence on routine iron supplementation and screening in prenatal care will remain unclear at best.
The evidence for multivitamins
The American Congress of Obstetricians and Gynecologists (ACOG) recommends a multivitamin with folic acid.
A review of the literature found evidence to support routine folic acid supplementation but not supplementation of omega-3 fatty acids, vitamin D, or iron. It found evidence of harm from supplementation with large doses of vitamins A, C, and E. As for multivitamins, it concluded:
Vitamin and mineral supplements cannot replace a healthy diet, and there are not enough high-quality data to recommend multivitamin supplements for all American women.
The Skeptical OB, Amy Tuteur, says:
Folic acid does prevent neural tube defects like spina bifida. The rest of the vitamins in prenatal vitamin preparations probably don’t provide any benefit for women who are well nourished.
Evidence of harm?
There is little evidence of harm from routine supplementation with multivitamins and iron. Some women have trouble swallowing pills, especially when they suffer from morning sickness. Allergic reactions to components in the pill can occur, but they are rare. Some patients report constipation, diarrhea, and nausea, which can often be relieved by switching to a different formulation.
Diet instead of pills?
There’s no reason to think that the nutritional needs of pregnancy can’t be adequately met through diet alone. There are published dietary guidelines for pregnant women. In addition to the general nutritional advice that is applicable to everyone, specific advice for pregnant women includes:
    • Minimize intake of food and drinks containing saccharin (other artificial sweeteners are probably OK).
    • Limit consumption of caffeine (possible association of high caffeine intake with spontaneous abortion and low birth weight; moderate amounts are probably safe).
    • Most pregnant women require an additional 300-400 calories a day beyond what would normally be required to maintain their weight when not pregnant.
    • Avoid unpasteurized dairy products, delicatessen foods, pâtés, and meat spreads (risk of Toxoplasma and Listeria contamination, based on case reports).
    • Avoid raw eggs (risk of Salmonella contamination, based on case reports).
    • Fruits and vegetables: wash before eating.
    • Avoid certain herbal teas that have been associated with adverse outcomes, like chamomile, licorice, peppermint, or raspberry leaf; teas containing ginger, citrus peel, lemon balm, and rose hips are probably safe in moderation.
    • Reheat leftover foods thoroughly before eating.
    • Avoid undercooked meat; cutting boards, utensils, and hands should be washed with hot, soapy water after contact with uncooked meat.
    • Liver and liver products should be eaten in moderation (risk of vitamin A toxicity).
    • Avoid shark, swordfish, mackerel, tilefish, and tuna steaks and limit intake of other fish (to minimize mercury intake).
    • Avoid refrigerated smoked seafood, raw fish, and shellfish; eat farmed salmon in moderation.
Dietary sources of iron include fruits, vegetables, meat, and poultry. The non-heme iron in vegetarian diets is not as well absorbed as the heme iron from meat, so vegetarians have almost double the requirement for iron compared to women who eat meat.
“It seemed like a good idea at the time”
One of my husband’s friends was shocked to hear that he had finally married at age 41; everyone thought of him as a confirmed bachelor. My husband explained, “Yes, I got married. It seemed like a good idea at the time.” Thirty-four years later, after raising two daughters, he still thinks it was a good idea. Routine prescription of prenatal vitamins and iron seemed like a good idea at the time, and it might still be a good idea, at least for women who are at risk of anemia or inadequate diet. The lack of evidence of benefit doesn’t necessarily mean the practice should be abandoned. The chance of harm is minimal.
Conclusion: There are no absolutes regarding prenatal vitamins
There is compelling evidence to support the use of folic acid supplements before pregnancy and during the first trimester. There is no good evidence to support the routine use of multivitamins or iron, but there is no good reason not to use them. If doctors recommend them, they should be honest about the uncertainty of the evidence and let their patients participate in the decision. Our own Scott Gavura has provided some guidance on selecting a prenatal multivitamin. Whether or not patients choose to take multivitamins and iron, they should be given guidance about a healthy diet that meets the nutritional needs of mother and child.
Incidentally, this is a good example of how mainstream medicine is willing to re-examine its own practices and change course. Something alternative medicine never seems to do.

Do vitamins prevent cancer and heart disease?
The US Preventive Services Task Force has released an update on vitamin and mineral supplements to prevent heart disease and cancer. The evidence was not good and did not support taking vitamins as “nutritional insurance.”
Scott Gavura on November 21, 2013
Link
It is a triumph of marketing over evidence that millions take supplements every day. There is no question we need vitamins in our diet to live. But do we need vitamin supplements? It’s not so clear. There is evidence that our diets, even in developed countries, can be deficient in some micronutrients. But there’s also a lack of evidence to demonstrate that routine supplementation is beneficial. And there’s no convincing evidence that supplementing vitamins in the absence of deficiency is beneficial. Studies of supplements suggest that most vitamins are useless at best and harmful at worst. Yet the sales of vitamins seem completely immune to negative publicity. One negative clinical trial can kill a drug, but vitamins retain an aura of wellness, even as the evidence accumulates that they may not offer any meaningful health benefits. So why do so many buy supplements? As I’ve said before, vitamins are magic. Or more accurately, we believe this to be the case.
There can be many reasons for taking vitamins but one of the most popular I hear is “insurance” which is effectively primary prevention – taking a supplement in the absence of a confirmed deficiency or medical need with the belief we’re better off for taking it. A survey backs this up – 48% reported “to improve overall health” as the primary reason for taking vitamins. Yes, there is some vitamin and supplement use that is appropriate and science-based: Vitamin D deficiencies can occur, particularly in northern climates. Folic acid supplements during pregnancy can reduce the risk of neural tube defects. Vitamin B12 supplementation is often justified in the elderly. But what about in the absence of any clear medical need?
The question many have is a straightforward one: Is taking a multivitamin going to do more harm than good? To answer this, we should look at all the evidence in a systematic way, evaluate risks and benefits, estimate the overall odds of a good outcome, and then make a decision that would weigh these factors against considerations like cost. Happily, an updated analysis summarizes the evidence for vitamins to treat two of the biggest killers: cardiovascular disease, and cancer.
The U.S. Preventive Services Task Force Report
The USPSTF has released a revision and update to its 2003 guidance on the use of multivitamins based on an updated systematic review of the evidence. The review was published last week in the Annals of Internal Medicine and is entitled “Vitamin and Mineral Supplements in the Primary Prevention of Cardiovascular Disease and Cancer: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force“. The objective was to systematically review and summarize the evidence for vitamin and mineral supplements in community-dwelling, nutrient-sufficient adults for the primary prevention of cardiovascular disease (CVD) and cancer. Like any systematic review, the process involved a thorough search of the literature, followed by a ranking based on each study’s quality. From an initial screen of thousands of papers, the final review was whittled down to the following:
    • Multivitamin supplements: 4 trials and 1 cohort study
    • For individual or paired supplements: 18 trials and 5 cohort studies
Here’s the data for multivitamins, summarized (click to enlarge):
Some of these were huge trials with long durations, which should have been able to detect a difference if any existed. And some studies detected small differences in some groups. But overall, multivitamins were found to have no effect on cardiovascular disease or cancer risk. If multivitamins are beneficial, the effect is too small to detect. Reassuringly, there was no consistent pattern of harms, though subgroup analysis and some individual studies identified elevated cancer or cardiovascular risks.
With individual and paired supplements, there was a lack of good evidence for several vitamins. Overall, there was no strong evidence of either a beneficial or detrimental effect with vitamins A, C, or D, folic acid, selenium, or calcium. The evidence for beta-carotene was more clear: it had no effect on cardiovascular disease, cancer, and mortality. In high-risk subgroups, beta-carotene was associated with an increased cancer risk. The evidence for vitamin E was also clear – it has no beneficial effects.
I’ve blogged about the risks and benefits of calcium and vitamin D before so I was interested in the findings with this combination. Calcium, with or without vitamin D, seems to have no meaningful effects on cancer or cardiovascular disease. However, there was also no clear evidence of harms, either.
The authors point out in their discussion that their review isn’t the first to identify a lack of benefit from vitamin supplements, there are at least ten others that have drawn similar conclusions. They also point out the challenge of studies of this kind – you need thousands of participants and must follow participants for several years, which makes for a very costly trial. However, given the continued interest (and spending) on multivitamins, this might be a worthwhile investment. But given the perennial popularity of multivitamins, would a negative trial actually make a difference?
The thing to do with [these reports] is just ride them out…we see no impact on our business.
– Joseph Fortunato, Chief Executive of General Nutrition Centers, quoted in Do You Believe in Magic? by Paul Offit
The USPSTF’s recommendations
In light of the systematic review, the USPSTF has issued the following draft recommendations:
    • The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of the use of multivitamins for the prevention of cardiovascular disease or cancer.
    • The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of the use of single- or paired-nutrient supplements (with the exception of beta-carotene and vitamin E) for the prevention of cardiovascular disease or cancer.
So there is insufficient evidence to establish a clear benefit or harm. Both recommendations are given an “I” rating which means that if the product is offered/suggested, patients should understand the uncertainty about risk and benefit.
Beta-carotene and vitamin E get their own recommendation:
    • The USPSTF recommends against the use of beta-carotene or vitamin E supplements for the prevention of cardiovascular disease or cancer.
This is a “D” recommendation, which means use should be discouraged.
Conclusion: Few reasons to take a multivitamin
Without demonstrated benefit, there’s currently no clear rationale to justify multivitamin supplements or individual vitamins to prevent cardiovascular disease or cancer. Taking vitamins for “insurance” doesn’t appear to be harmful, but the evidence isn’t conclusive. It’s concerning that the two individual supplements for which we do have good evidence also have the least attractive risk/benefit profiles. While the risk of harms do seem low, (especially if you avoid vitamin E and beta-carotene), there’s also no evidence supplementation offers any upside. I’m a believer in the hypothesis that supplement consumption may actually worsen dietary intake, so my advice remains unchanged: If you believe your diet is unhealthy or insufficient to meet your nutritional requirements, then change your diet instead of adding supplements. Supplements should be reserved for when there’s an actual dietary deficiency or medical need that cannot be met through diet. You won’t see this message advertised anytime soon by the supplement industry.
The USPSTF’s recommendations are open for comment until December 8.
Reference
Fortmann S.P., Burda B.U., Senger C.A., Lin J.S. & Whitlock E.P. Vitamin and Mineral Supplements in the Primary Prevention of Cardiovascular Disease and Cancer: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force, Annals of Internal Medicine, DOI: 10.7326/0003-4819-159-12-201312170-00729

Cancer, vitamin supplements, and unexpected consequences
Not only do B-vitamin supplements not protect you from lung cancer, they may significantly raise your risk of cancer.
Scott Gavura on September 7, 2017
Link


Vitamin supplements have been successfully marketed for decades, despite the lack of good evidence that they are necessary or beneficial for the vast majority of people that take them. While frank deficiencies of vitamins are generally rare (you don’t see scurvy much anymore), dietary restrictions, pregnancy, and even socio-economic status may increase the possibility of a deficiency and an evidence-based recommendation to supplement. It’s more of an open question if supplementation in the absence of any clear medical need is advisable or necessary. As a pharmacist I’ve spent a lot of time over the years speaking with patients about vitamin supplementation. Many seem to take the view of vitamins as a reasonable “insurance policy” for their diet, and a net positive thing they can do to support healthy living. Early in my career, I viewed vitamin supplementation without any clear medical clear need as producing “expensive urine” for the user, but unlikely to cause much harm. But over the past 25 years, evidence has emerged to change my view. I am much more skeptical now of the net benefit of vitamin supplementation. That position is based on the results of multiple studies that have shown that vitamin supplementation is not always harmless – in some cases it appears to be harmful, and should be discouraged. 
Many of the problems with vitamin supplementation have emerged when we have assumed that isolated vitamins are an appropriate or equivalent substitute for foods that contain those same vitamins. Compound this with the equally bad idea that more=better, and you have supplement doses much higher than would be consumed in diet alone. Antioxidants are the most representative example. The idea for antioxidants emerged from observations about oxidative stress and their contribution to illness and aging, and the hypothesis that antioxidant supplements could minimize these effects. Yet trials have failed to show that antioxidant supplements have the same effects as antioxidant-rich foods. Over time it became clear that beta-carotene supplements could raise your risk of cancer. Vitamin E supplements also appears to raise, rather than lower, prostate cancer risk. Steven Novella’s post from 2015 summarizes the evidence on vitamins and cancer risk, and provides the backdrop to the study I want to review today that illustrates the cautious, deliberate approach we should take to supplementation.
Studying the effect of B-vitamin supplementation
Any pharmacy that you walk through will likely have several shelves of different combinations of vitamins all touted with specific purposes. “Stresstabs” are a popular vitamin brand sold around the world that are essentially a multivitamin with added B vitamins. Presumably created based on some idea that stress depleted B-vitamins, or could be relieved with B-vitamins, Stresstabs were very popular in the local pharmacy where I worked where patients thought they could get a “quick fix” from the stress in their lives. There’s also B12 supplements which continue to be marketed as some kind of energy panacea despite the lack of any evidence they do anything useful if you’re not deficient.
This new study from Brasky and colleagues is entitled “Long-Term, Supplemental, One-Carbon Metabolism–Related Vitamin B Use in Relation to Lung Cancer Risk in the Vitamins and Lifestyle (VITAL) Cohort” and was published in the Journal of Clinical Oncology. This is a focused analysis of the B-vitamins (B6, B9 (folate), and B12) on lung cancer risk. The paper is behind a paywall, so regrettably the detail may not be easily accessible to you.
The authors start out by noting that the results from previous studies of B-vitamins and lung cancer have been unclear, yet there have been hints of the risk of harm. The authors hypothesized that doses of B-vitamins in excess of the Recommended Daily Allowance (RDA) might be cancer-promoting through effects on the cellular environment. This analysis draws on data collected from the VITamins And Lifestyle cohort study, initiated in 2000 to study the association of vitamin supplements with cancer risk. Over 77,000 men and women aged 50-76 years living in Washington state were enrolled, with the objective of tracking cancer and deaths. As part of the study, participants reported their regular consumption of vitamins (individual products and multivitamins) over the prior 10 years. The 10-year average daily dose of vitamins B6, B9, and B12 were calculated, and participants were stratified by doses consumed, ranging from multivitamin-level-doses (small) to what would be considered high doses.
In addition to supplementation habits, dietary habits were assessed using standardized questionnaires, and multiple health-related risk factors (e.g., smoking history) were also collected.
Patients were followed for the incidence of lung cancer from baseline (2000-2002) through December 31, 2007. The incidence of cancer was determined through linkage to the SEER cancer registry. 808 cases of invasive lung cancer were identified in the cohort.
The statistical analysis is complex and used models to estimate hazard ratios and confidence intervals for the association between doses of B-vitamins and the risk of lung cancer. They tried to identify and control for as many confounders as possible (e.g., adjusting for smoking rates, or adjusting B-vitamin intake based on caloric intake).
The findings were pretty striking. Based on information collected when participants enrolled in the study, former use of individual supplements of vitamin B6 or B12 was associated with an increase in lung cancer risk in men, but not women. Compared to no supplementation, vitamin B6 increased the risk of lung cancer by 84%, and vitamin B12 was observed to more than double risk. Looking at the 10-year average daily dose, the increase in cancer risk was associated with the highest levels of supplementation: more that 20mg/day of B6 and more than 55mcg/day of B12. No association was found between folate (folic acid) and lung cancer risk. The trend was most significant in smokers. There were no beneficial effects of supplementation seen in any group.
Implications
This study gives fairly compelling evidence that consumption of high doses of vitamins B6 and B12 are associated with an increased lung cancer risk. This association was found in men only, and was stronger in smokers. No association was found in women, and no association was found with the consumption of B-vitamins in the low doses contained in multivitamins. The authors suggest that doses of B6 and B12 that are taken in excess of dietary requirements may be causing pro-cancer effects.
Key considerations
Perhaps not surprisingly, industry advocates have moved quickly to question or dismiss the findings (“Statistical chance” says one) and criticizing the coverage of the trial. But what’s arguably just as important as the elevated risk of lung cancer observed is the fact that there was no evidence found to suggest that B-vitamin supplementation offers any meaningful benefit, either.
Despite that marketing that vitamin-or-supplement-de-jour can prevent cancer or help you live longer/better, there is actually little evidence that any vitamin or mineral supplement has any meaningful or beneficial effects in the absence of a true deficiency. Vitamin supplementation remains exceptionally popular, and this new study should be considered in the context of other studies that have raised concerns that these products may be causing harm. Vitamin supplementation can be medically appropriate, but we should not view indiscriminate supplementation as a panacea or as harmless insurance against dietary deficiencies. And if we elect to take a vitamin supplement, isolated vitamin supplements may deliver the higher doses that appear to be associated with more risk. Probably the best advice that can come from studies like this is that we don’t fully understand the consequences of our vitamin supplement habit. Focusing on a healthy, balanced diet to meet our vitamin needs is the approach that appears to offer the best benefits and the fewest risks.

Vitamins and Cancer Risk
Vitamins have been promoted as a general panacea, as well as a means of preventing cancer. In reality, high doses of vitamins may even cause cancer.
Steven Novella on May 6, 2015
Link
One of the greatest triumphs of marketing over evidence was the incredible rise of vitamin supplement use in the 20th century. Supplement makers successfully created a “health halo” around vitamins, and taking your vitamins became a virtue, something mothers told their children to do. The evidence, however, does not tell such a simple story.
In recent years it has become increasingly apparent that there are unintended consequences to taking vitamin supplements, and in fact there may be a net negative health effect. This is especially true for those who are healthy and don’t need vitamins, and for those who exceed the recommend dosages.
A recent review of the last 20 years of literature on the subject, presented at the American Association for Cancer Research 2015 meeting, found an overall increased risk of cancer among vitamin users. Dr. Tim Byers presented the study, which echoes the result of a 2012 review that he and others published. He specifically refers to two famous studies showing an increased risk of cancer from vitamins.
The 2011 SELECT trial found an overall increased risk of prostate cancer among men taking vitamin E. 
It has also been shown, first in a 1994 NEJM study, that high doses of beta carotene increase the risk of lung cancer in smokers and those exposed to asbestos.
In fact, antioxidants in general lack evidence for an overall health benefit and in high doses may increase cancer and overall mortality.
Folic acid and cancer risk is a more complex topic. There is evidence that taking folate reduces the risk of breast and possibly colon cancer. There is a “U” shaped relationship between dose and cancer risk, however:
Women with daily dietary folate intake between 153 and 400 μg showed a significant reduced breast cancer risk compared with those <153 μg, but not for those >400 μg.
There is preliminary evidence that higher doses of folate may increase cancer risk.
There are several possible mechanisms by which excess vitamin intake may promote cancer. Cancer cells are metabolically very active. Taking more vitamins than is necessary for healthy cells may only serve to feed cancerous cells, promoting their growth. Elevated levels of vitamins, exceeding what the body need for normal metabolism, may also result in the creation of alternate downstream metabolites that have negative health consequences. Further, taking megadoses of a vitamin may alter the body’s natural homeostasis with negative consequence. This is likely true with antioxidants – oxidative compounds are used by the immune system and act as signals for the creation of protective proteins. There is a balance between oxidants and anti-oxidants, and shifting that balance is not beneficial.
There are also possible unintended consequences. The evidence is fairly clear that having a healthful and well-rounded diet has health benefits. Taking vitamins does not replace having a good diet. However, taking vitamins may lead to a false sense of security, justifying a less healthful diet with net negative health consequences.
Conclusion
Dr. Byers gave a reasonable summation of the evidence:
This is not to say that people need to be afraid of taking vitamins and minerals. If taken at the correct dosage multivitamins can be good for you. But there is no substitute for good food.
My reading of the evidence leads to several specific recommendations:
    • Do not use vitamins as a substitute for an overall healthful diet. Try to get your vitamins and minerals through a well-rounded diet with sufficient fruits and vegetables.
    • Routine supplementation in healthy individuals is unnecessary.
    • Do not take megadoses or even exceed recommended doses of vitamins or minerals. The evidence suggests this can be harmful.
    • Targeted supplementation of specific vitamins at correct doses in specific individuals or populations can be beneficial.
    • For targeted supplementation (such as folic acid in women of child-bearing age) follow accepted guidelines, or the advice of your physician. Often physicians will directly measure the blood level of specific vitamins and supplement accordingly.
Perhaps the greatest harm of the supplement industry over the last half-century has been the cultivation of the idea that vitamin and mineral supplements are harmless, that if some is good then more is better, and that the public can determine their own supplement needs based on industry marketing and magazine articles (and now websites).
It turns out that none of these assumptions are true. There is a risk to excess vitamin use. Determining who should receive what dose of which vitamin is also a bit complex and nuanced, and perhaps a little professional guidance is in order. It’s quite possible that vitamin supplement use, in addition to costing billions of dollar per year, has been a net health negative. We can save money and ensure that it is a net health positive with more rational and evidence-based supplementation.

Herbal Products and Cancer Treatment
Oncologists increasingly are warning their patients away from alternative herbal treatments, and with good reason.
Steven Novella on November 20, 2019
Link
In 2017 David Gorski discussed a study that showed that cancer patients who rely on alternative treatments had a worse survival. He wrote:
…alternative medicine use was associated with a 2.5-fold increased risk of death for combined breast, prostate, lung, or colorectal cancer patients, and a whopping 5.7-fold increased risk of death for breast cancer patients.
Essentially this study suggests that alternative treatments do not work, or at least they do not work as well as conventional treatment. But what about patients who use both conventional and alternative treatments? This David covered in 2018, reporting on another study that showed that cancer patients who use alternative medicine in addition to standard medicine also have worse survival.
When the authors looked at specific cancer types, they noted that the use of CM was associated with poorer five-year survival for breast cancer (84.8% vs 90.4%) and colorectal cancer (81.8% vs 84.4%). However, they did not note any statistically significant differences seen in 5-year survival for patients with prostate or lung cancer.
More data on different kinds of cancer and patient uses would be helpful, but the evidence we have shows that relying on alternative treatments is extremely dangerous, and complementing with alternative treatments does not help, may hurt, and is associated with a higher risk of refusing standard treatment. One aspect of this net negative effect from alternative cancer treatments is the potential drug-drug interactions between over-the-counter (OTC) herbal products and cancer treatments. Oncologists are starting to push back against this trend, warning their patients about possible interactions. Speaking at the Advanced Breast Cancer Fifth International Consensus Conference, Surgeon Prof Maria Joao Cardoso warned about some possible interactions and emphasized the importance of doctors being proactive in asking their patients about herbal product use.
Notice that I referred to these interactions as “drug-drug” interactions. That is because herbal supplements are drugs – they are taken for the pharmacological activity of their constituents. And just like any drug, they can have effects on other drugs and how the body handles other drugs.
Cardoso gives as an example of one type of interaction, herbal products that can potentially cause blood thinning. She lists: green chiretta, feverfew, garlic, ginkgo, ginseng, hawthorn, horse chestnut, and turmeric. Often cancer patients are given blood thinners in careful doses based on the best evidence available. A blood thinner is a great example of the core concept in medicine of risk vs benefit – thinning the blood reduces the risk of blood clots, but also increases the risk of bleeding. Cancer patients often have increased blood clotting and can get complications like deep vein thrombosis (DVT). Blood thinners are used to compensate – but they have to be carefully dosed. Too much blood thinner can increase the healing time of skin lesions and increase scarring. They also increase the risk of hematoma.
Other cancer researchers have also warned about other possible interactions. Antioxidants, for example, are especially problematic. They represent another balancing act critical to cancer therapy – balancing toxicity with efficacy. Chemotherapy is essentially the strategy of giving powerful poisons to patients that kill cells, but they kill cancer cells more than healthy cells. The idea is to shoot for a sweet spot in which the probability of killing all the cancer cells is maximal with the least amount of toxicity to healthy cells. This balancing act is carefully researched and calibrated.
Some chemotherapy drugs work by causing oxidative stress that kills the rapidly dividing cancer cells. This, by the way, is also one mechanism by which your immune cells kill invaders. If a patient takes a high dose of an anti-oxidant in order to reduce the side effects of chemotherapy, they may also be reducing the effects of the chemotherapy. They are adjusting the toxicity-efficacy balance, likely moving away from the carefully researched sweet spot. Add to this the fact that the doses of herbal products are highly variable and poorly regulated, and it becomes impossible to predict what effect such products will have.
Some herbal products may affect the absorption of oral chemotherapy drugs, or affect their metabolism. All of the standard drug-drug interactions are in play.
Another interaction that may be specific to some cancers are hormonal effects:
Botanicals such as red clover and soy products are known to have mild estrogenic effects and may stimulate the growth of hormone-sensitive cancers.
Such products could literally stimulate the cancer to grow, and interfere with standard treatment which is designed to block that very stimulation.
One fairly complicated area of biological activity from herbal drugs is immune function. Many herbal products claim to be either anti-inflammatory (which by definition is immunosuppressive) or to “boost the immune system“. These claims are often vague or even untrue, but the extent to which they are true is likely to be problematic. Immune activity, again, can be a delicate balancing act, even in a healthy individual. The immune system is our body’s army that goes out and kills invaders, but the killing activity often has serious side effects, and healthy cells can get caught in the cross-fire.
There are two contexts here. The first is healthy immune function, in which the immune activity is properly targeted against either infection, foreign bodies, or unhealthy or cancerous host cells. This immune activity is beneficial and we don’t want to interfere with it. However, it can cause unpleasant side effects, such as fever, redness, or pain. How much we can reduce the side effects of inflammation before we reduce the effectiveness of the immune system is a complicated calculation and the focus of much research. For example, the best evidence currently suggests that we should not treat mild fevers, but rather tolerate them as our immune systems do their job. Of course, there are limits – a high fever can be dangerous – and special populations, for example children with fever-induced epilepsy. So complex individual decisions are often required.
On the flip side are “immune boosters”. This does not really exist as a scientific medical concept, because it implies that the treatment is improving the function of the immune system. It is more accurate, rather, to view such effects as shifting the balance toward greater immune activity. In healthy individuals, the balance has been carefully tweaked over millions of years of evolution, so I probably wouldn’t mess with it without good reason and good evidence. In disease states, doing anything to affect the immune system is complicated and even experts guess the net effects of interventions incorrectly. Clinical research has made experts humble about such predictions.
All this does not mesh well with a system in which untrained individuals can treat themselves with OTC drugs making broad and vague claims and that actually affect their immune function. With cancer, we don’t want to impair the body’s ability to fight off cancer cells. With auto-immune diseases, we don’t want to stimulate the immune system further, as it is already overactive. In fact standard treatment is immunosuppressive, again with careful monitoring and balancing beneficial effects from side effects (like increased susceptibility to infections).
One thing to keep in mind is that when manipulating a complex dynamic homeostatic system, such as the body, in either a healthy or disease state, figuring out the net effects of any intervention is extremely difficult. It takes decades of research by experts thinking very carefully to calibrate the proper balance, and then individualizing that information to each specific patient. While doing this, it is generally not helpful for the patient to be interfering with the whole process by taking poorly regulated products often with unknown ingredients, of highly dubious quality control, and in doses that are essentially anyone’s guess.
Further, in medicine there is rarely any free lunch, meaning that any significant medical intervention is a compromise between desired effects and unwanted side effects. We always have to take a careful risk vs benefit approach to any intervention. But herbal products, especially for things like cancer, are often sold with the myth that they are magically free of the compromises that real medicine faces. They are often claimed to magically target cancer cells while leaving healthy cells alone, or “improving” some function when actually they are just pushing a homeostatic system out of balance.
They are also often marketed as “natural” as if that means they operate in some way other than their drug-like effects.
Don’t be conned. Don’t fall for DIY cancer treatment with dubious poorly-studied drugs.

Do dietary supplements affect the survival of cancer patients?
Do dietary supplements offer advantages or risks to breast cancer patients undergoing chemotherapy?
Scott Gavura on January 9, 2020
Link

If you’re a regular reader of this blog, you’ve probably observed that we as a group of contributors tend to be pretty critical of dietary supplements. These concerns include:
    • The manufacturing quality of supplements is inconsistent, meaning consumers can’t trust that what is on the label is actually in the bottle.
    • Marketing claims go well beyond proven science.
    • There is little convincing evidence that most dietary supplements do anything useful or beneficial. Sometimes supplements are adulterated with actual drugs to give them the appearance of efficacy.
For the past several years there has been increasing concern that dietary supplements may not simply be useless, but that taking supplements could actually be harmful. This question is especially pertinent for those undergoing treatment for cancer. Cancer treatment can be debilitating and maintaining good dietary health can be difficult. Vitamin supplements may be viewed as a prudent way of supporting dietary intake. More generally, supplements are routinely promoted as treatments for cancer, and cancer patients may be drawn to products promoted as offering “natural” effectives. But because the mechanism of some cancer chemotherapies is to generate reactive oxygen species, there is concern that supplements such as anti-oxidants may actually reduce the effectiveness of treatment. And given the quality control standards of dietary supplements is questionable, there could be unpredictable and unanticipated interactions with chemotherapies that could have negative effects. As I have written on this topic before, there is a lot we do not understand about the effects of supplements on cancer survival. Now a new paper examines the effect of dietary supplements on survival in breast cancer patients.
What did the researchers set out to answer?
This was called the Diet, Exercise, Lifestyle and Cancer Prognosis (DELCaP) study, and the findings were published in the Journal of Clinical Oncology on December 18, 2019. The lead author is Christine Ambrosone, and the study was funded through a number of grants from government and other organizations, with no industry funding (supplement, pharmaceutical, or otherwise). Because of ongoing concerns about the effects of supplements on the effectiveness of cancer chemotherapy, the investigators set out to prospectively evaluate the relationship between the two.
What approach did they take?
This study ran concurrently with a phase 3 clinical trial (S0221) that studied different breast cancer chemotherapy treatment schedules. 80% of participants in that trial agreed to participate in the DELCaP trial, completing a baseline set of questions which asked about regular (at least 1x/week) use of supplements before beginning chemotherapy. A second survey was sent to participants about 6 months later, as chemotherapy was concluding. Among patients alive and without disease recurrent at that six-month point, patients were followed from that point until death from any cause. The median follow-up was 8.1 years.
Patients were then stratified into four categories and analyzed.
    • YN – took supplements at baseline but not during chemotherapy
    • YY – took supplements at baseline and during chemotherapy
    • NY – no supplements at baseline but taken during chemotherapy
    • NN – no supplements consumed before or during chemotherapy
What types of patients were enrolled?
A total of 1,340 patients completed questionnaire one and 1,134 completed both questionnaires. Participants were female, in their fifties, and predominantly white. Overall there were 251 recurrences and 181 deaths. Patients who experienced recurrence were more likely to be older, postmenopausal, and to have a higher BMI.
The overall prevalence of supplement use, compared to other literature reports, was low:
    • Vitamin C was used by 20.5% of patients before treatment and just 12.2% during treatment.
    • Vitamins E and A were taken by <10% of participants.
    • Antioxidant (Vitamins C, A, E, carotenoids, coenzyme Q10) were taken by 17.5% of participants.
    • In contrast, 44% of patients took multivitamins.
What did the researchers find?
    • Patients who used any antioxidant both before and during treatment were at increased hazard of recurrence. The hazard ratio was 1.41, with a confidence interval of 0.98 to 2.04, meaning it wasn’t statistically significant (P=0.06). There was also a suggestion of a negative effect on the risk of death (HR=1.4, confidence intervals 0.9 to 2.18) which was also not significant. There was no relationship found between antioxidants and these outcomes if taken only before chemotherapy or only during chemotherapy.
    • There were no associations found for the single antioxidants, multivitamins, and vitamin D at any point.
    • Vitamin B12 both before and during treatment was associated with poorer disease free survival (HR 1.95, confidence intervals 1.15 to 2.92) and overall survival (HR 2.04, confidence intervals 1.22 to 3.40).
    • Similar findings were made for iron with respect to disease free survival during treatment (HR 1.79, confidence intervals 1.20 to 2.67) and, non significantly, DFS with use before and during treatment (HR 1.91, confidence intervals 0.98 to 3.70).
    • Use of omega-3 fatty acids before and during treatment were associated with poorer disease-free survival (HR 1.67, confidence intervals 1.12 to 2.49) but no effect on overall survival.
What conclusions can we draw from this study?
Dietary supplements appear to be, at best, neutral with respect to cancer survival, and there is no indication that they offer advantages or benefits to those that take them. While this was a small trial with low levels of supplement use, we have the benefit of a concurrent cancer treatment trial that ensured that all patients received standardized chemotherapy regimens. There is a strong suggestion that some dietary supplements may have a negative impact on disease-free survival and overall survival. Notably, the use of any antioxidant was associated with a 41% increase in the hazard of recurrence in this study (albeit, this was statistically non-significant.) However, there were significant negative findings with B12 and iron. The results of this study should provide additional information to cancer patients and their clinicians when discussing the potential risks and benefit of dietary supplements during the course of cancer chemotherapy.

Presidential candidate Ben Carson: Shilling for Mannatech with his very own alternative cancer cure testimonial?
David Gorski on October 11, 2015
Link


Over the years, mainly at my not-so-super-secret other blog, I’ve frequently made the points that the vast majority of physicians are not scientists and, in fact, that many of them suffer from a severe case of Dunning-Kruger when it comes to science outside of biomedical sciences—or even biomedical sciences outside of their medical field of expertise. The most common science I’ve seen physicians embarrass themselves attacking has generally been evolution, with a disturbingly high number of physicians denying evolution and embracing creationism. Of these, the doctor I wrote about most frequently back in the day was the creationist neurosurgeon Michael Egnor, but with the onset of the 2016 Presidential race there’s been a new creationist neurosurgeon in town with arguably even more ignorant attacks on evolution. I’m referring, of course, to noted neurosurgeon Ben Carson, whose creationist stylings have been so bad that I had to use him as a poster child to demonstrate how the vast majority of physicians are not scientists and all too many of us have an inordinate and unjustified confidence in medicine as a “check on BS.”
Over the last couple of weeks since my post on the second Republican debate, in which Donald Trump spewed antivaccine nonsense and Ben Carson pandered to antivaccine views, even though past statements by him demonstrate that he knows better, unfortunately Carson has continued to spew statements that are nothing but downright embarrassing, be they his statement in the wake of the Oregon mass shooting that it would be better to attack an armed gunman during a mass shooting “because he can’t get us all” (complete with a seeming attitude that those who died were cowardly), his doubling down on that by claiming that if the Jews had been armed maybe things would have turned out differently in the Holocaust (neglecting the fact that Jews did resist), or his many other statements that make me wonder how someone with so little critical thinking skills could get through medical school and a neurosurgery residency to become such a respected surgeon.
While I knew Dr. Carson shows an uncanny lack of critical thinking when it comes to most issues outside of medicine, I had never in general doubted his medical judgment. Oh, sure, I was disturbed and disappointed when during the second Republican debate, instead of repeating his previous full-throated defense of vaccines and school vaccine mandates, he waffled and pandered to the G.O.P. base regarding Trump’s antivaccine views, but I didn’t think that was because he truly thought vaccines cause autism but rather because he was too cowardly to speak out as clearly as he had in the past. I expected behavior like this from Rand Paul, the other physician running for office, but not from Ben Carson, at least not based on his history.
Ben Carson – company shill
Then, last weekend, while I was away at the American College of Surgeons meeting, there was an article in the Wall Street Journal entitled “Ben Carson Has Had Ties to Dietary Supplement Firm That Faced Legal Challenge.” Unfortunately I’m not a WSJ subscriber, so I can’t read the whole article. Fortunately, there’s enough of it excerpted out there in various blogs and other news outlets that I can get the gist of the story and what he said. Actually, you and I can experience everything he said by watching this 2004 YouTube clip of Ben Carson shilling for Mannatech:
The video is 1:19 hr. long, so I admit that I haven’t had time to watch the entire thing; however, most of the relevant statements are in the early part of the video. What I have seen in it is quite disturbing. A bit of background was in order. Over ten years ago, Ben Carson faced prostate cancer at a relatively young age, his early 50s, and he went to an unexpected source for help:
Faced with a prostate-cancer diagnosis more than a decade ago, Ben Carson, the Republican presidential hopeful and retired surgeon, consulted an unusual source: the medical director of a Texas company that sells nutritional supplements made of substances such as larch-tree bark and aloe vera extract.
The company doctor “prescribed a regimen” of supplements, Mr. Carson told its sales associates in a 2004 speech.
The video above is basically an infomercial for Mannatech. The video was taken down from the company’s website, apparently after the WSJ made inquiries about it, but the Internet never forgets, and so the video is still around, allowing me to embed it above.
The prostate cancer cure that wasn’t
According to Carson, a couple of years before his talk, he was diagnosed with prostate cancer. He described himself as an individual who underwent routine medical screenings and annual physicals and had his PSA checked. However, he noticed that when he was in the operating room for long periods of time he became very interested in the clock because, unlike in the past, he couldn’t go many hours without having to go to the bathroom. So he went to see the chief of urology at Johns Hopkins, who thought at first that he had some prostatitis and gave him antibiotics. The symptoms, however, didn’t go away. So the urologist suggested that maybe he had some prostatic hypertrophy and gave him some Flomax, but the symptoms still didn’t resolve. His PSA was checked again, and it was somewhat elevated so a biopsy was recommended. Now, I have to admit, Carson is a very folksy and engaging speaker, particularly the part where he described undergoing his prostate biopsy. I can see why Mannatech would want him to shill for it: A famous neurosurgeon who is a very likable speaker (or at least was, as I don’t find much of Carson’s schtick that likable any more) makes for great PR.
In any case, he related getting the news in the operating room that he had high grade cancer. Now, personally, if I were in the operating room and received news like that, I’m not entirely sure that I could “put it out of my mind” the way Dr. Carson relates, and continue with the operation. On the other hand, that’s what surgeons do; patients must not be abandoned just because of our own personal traumas. Be that as it may, next Carson described getting an MRI and having a copy given to him without a radiologist’s reading. Looking at it, he saw “lesions up and down my spine.”
So how did his association with Mannatech begin? Basically, somehow the news got out that Carson had some sort of cancer, and as a result people started sending him products from all over the world. (Even at that time, Carson was pretty famous.) The father of one of Carson’s patients also apparently heard the news and asked him if he had ever heard of glyconutrients. This recommendation from his patient’s father led Carson to contact Mannatech and a “Dr. Reg,” who I can only assume must have been Dr. “Reg” McDaniel, who was at that time medical director of Mannatech and is now Director of Research at Wellness Quest, LLC, who doesn’t appear to be particularly science-based. Let’s just say that “Dr. Reg” is proud of having been awarded the “Discovery of the Year Award” by the American Naturopathic Medical Association in 1996 for his glyconutrient work and claims and that he’s still selling dubious dietary supplements. In any case, Carson described how Dr. Reg sent him some products and prescribed a regimen. He began to take it, and “within about three weeks my symptoms went away, and I was really quite amazed.” Carson even stated that “I actually toyed with the idea of not having surgery done, because it was recommended that I undergo surgery.”
Let’s stop right there for a second. According to his story, Dr. Carson was diagnosed with high grade prostate cancer. He apparently thought it had metastasized to his spine based on reading his own MRI scan. That’s a terminal diagnosis, although prostate cancer can be fairly indolent and even at stage IV take a long time to kill. Yet, surgery was still being recommended to remove the prostate? Something about this story didn’t quite add up to me, because usually the treatment for metastatic prostate cancer is not surgery, but castration, as most prostate cancers are androgen-dependent. In the old days (back when I was a resident), that would have been surgical castration, but these days chemical castration is the treatment, usually with a drug like Lupron. Castration can often give a long period of palliation before the prostate cancer inevitably becomes androgen-independent and starts growing again. As I listened to Carson’s speech, all I could think was that Carson’s surgeon must have thought that the cancer was still localized and therefore potentially curable. Otherwise, it’s doubtful he would have offered radical prostatectomy, which, even if done laparoscopically, is an operation not without risk and the potential for significant morbidity.
In any case, Carson continued on about how he read up on the “theory behind” Mannatech, the “bolstering of the immune system,” saying “this makes an awful lot of sense,” and thought about whether the cancer could just be controlled. The very fact that Carson thought Mannatech’s “theories” were ones that “made and awful lot of sense” was depressing because, whatever Carson’s shortcomings in critical thinking in non-medical areas, this was the first time I had seen evidence of a similar lack in an actual medicine topic. Indeed, his whole story by this point had turned into an alternative medicine cancer cure testimonial, starring Mannatech, complete with his discovery of the cure and his having actually been cured by surgery rather than the alternative cancer treatment. That’s right. Carson did, fortunately for him, ultimately undergo surgery, making his story in essence no different than that of, for example, Suzanne Somers beating cancer or Chris Wark curing his own cancer, except that he doesn’t credit the alternative medicine supplements for his good fortune as pointedly as they do.
Excuses, excuses, backpedaling, and more excuses
Here’s why he decided not to rely solely on Mannatech:
Then I began to realize that, having a high profile, if I did that, a lot of other people might follow that example too, but they might not be quite as diligent as I was about taking the product, and there might be a lot of needless deaths, and I didn’t feel as though I could have that on my conscience. So I went ahead and had the surgery done.
So let me get this straight. He thought that Mannatech’s product would work but that others would die if they followed his example because they wouldn’t be as awesomely diligent as Dr. Carson at following the regimen? Yes, Dr. Carson’s rationale for undergoing the surgery was, apparently, that he might be able to cure himself with Mannatech’s supplements but others would die because they wouldn’t follow the protocol closely enough. How many times have I discussed this victim-blaming explanation for the failure of alternative cancer cures? More times than I can remember. It’s a common thread in alternative cancer cure advocacy, that if you don’t follow the protocol to the letter it will fail and it will be your fault. So, awesomely selfless guy that Carson was, he underwent major surgery in order to save people from that fate. Or perhaps he didn’t believe quite as strongly as he made it sound in his speech. Probably the latter. No, strike that. Almost certainly the latter. Darth Vader Mannatech would find his lack of faith…disturbing.
Whatever the case, Carson underwent a nerve-sparing prostatectomy, which is designed to spare the nerves responsible for sexual and bladder function whose damage was a common complication of radical prostatectomy, later to discover that the MRI findings in his spine were a congenital abnormality of the bone marrow and not metastatic cancer at all. The cancer was within 1 mm of the capsule of the prostate, but still confined to the prostate, meaning that the surgery was potentially curative. (A urologist pointed out to me that this close margin could well be due more to the aggressiveness of the surgeon in sparing the nerves than the true margin of the tumor.) Given that it’s something like 12 years later and Carson is still alive and kicking, the surgery was just curative. In his talk, Carson attributed his good fortune to prayers more than Mannatech, but he was still basically shilling for Mannatech. In fairness, Carson also pointed out that, although people have told him that it was the glyconutrients that cured him—an odd thing to say, given that he still had cancer in his prostate that was almost to the capsule—he does advocate what might be called “integrative” medicine, at least with respect to Mannatech:
Now some people have concluded that I was cured without surgery and that I was just cured by the glyconutrients. Maybe it would have happened, maybe it would not have. I do not advocate abandoning traditional medical cures that have been shown to work. What I would, however, advocate is using natural products to supplement what’s done by traditional medicine. The two things do not have to be adversarial. In fact, they can be extremely complementary.
Oddly enough, he then said that he was not a Mannatech associate, because he didn’t think that would be appropriate, nor was he a Mannatech spokesman, because he didn’t think that would be appropriate either. Really? He just gave what amounts to a Mannatech cancer cure testimonial to an auditorium full of Mannatech associates! He might not have been an associate, but he was definitely at least an unpaid spokesman. He has also denied knowing anything about Mannatech’s business practices while boasting how “I’ve been taking them [Mannatech supplements] for more than a decade” and how “since I’ve been taking them, I almost never get sick anymore. I used to get sick a lot.” There is, however, this non-denial denial by his own business manager:
“I don’t know that he’s ever had a compensated relationship with Mannatech,” says Armstrong Williams, Carson’s business manager, when asked about those appearances. “All we know is that the Washington Speaker’s Bureau, which booked hundreds of speaking engagements for him through the year, booked these engagements. He had no idea who these people are. They’re booked through the speakers’ bureau. The question should be asked to the Washington Speakers Bureau, when did they have a relationship with Mannatech, because Dr. Carson never had one.” (At Washington Speakers Bureau, Carson is listed as a level-6 speaker, meaning his fee is more than $40,000 per speech.)
Carson even pointed out how he set up a system in his office to direct people asking him about Mannatech to the “right people” and described how he and his wife were still taking Mannatech glyconutrient supplements every day and later said in a promotional video:
The wonderful thing about a company like Mannatech is that they recognize that when God made us, He gave us the right fuel. And that fuel was the right kind of healthy food. You know we live in a society that is very sophisticated, and sometimes we’re not able to achieve the original diet. And we have to alter our diet to fit our lifestyle. Many of the natural things are not included in our diet. Basically what the company is doing is trying to find a way to restore natural diet as a medicine or as a mechanism for maintaining health.
Fast forwarding in time, it turns out that this wasn’t the only time Carson promoted Mannatech. He spoke at Mannatech conferences in 2011 and 2013 and spoke about glyconutrients for a PBS special just last year. His relationship with Mannatech thus went on for at least a decade, apparently only to be severed when he decided he wanted to run for President.
Mannatech is a really dubious company
Before I conclude, it must be emphasized just how dubious Mannatech is. As this National Review article points out:
Mannatech has a long, checkered past, stretching back to its founding more than a decade before Carson began touting the company’s supplements. It was started by businessman Samuel L. Caster in late 1993, mere “months,” the Wall Street Journal later noted, before Congress passed the Dietary Supplement Health and Education Act of 1994, which greatly loosened restrictions on how supplement makers could market their products. Within a few years of its inception, the company was marketing a wide variety of “glyconutrient” products using many of the same tactics previously described in lawsuits against Eagle Shield, Caster’s first company.
In November 2004, the mother of a child with Tay-Sachs disease who died after being treated with Mannatech products filed suit against the company in Los Angeles Superior Court, seeking damages for intentional infliction of emotional distress, negligent misrepresentation, and conspiracy to commit fraud. The suit alleged that the Mannatech sales associate who “treated” the three-year-old had shared naked photos of the boy — provided by his mother as evidence of weight gain, with an understanding that they’d be kept confidential — with hundreds of people at a Mannatech demonstration seminar. The sales associate was further accused of authoring an article, in the Journal of the American Nutraceutical Association in August 1997, explicitly claiming that Mannatech’s supplements had improved the boy’s condition, even though the boy had, by that time, died. The suit also presented evidence that Mannatech was still using photographs of the boy in promotional materials on its website in March 2004, “with the clear inference that [the boy] was alive and doing well some seven years after his actual death.”
I also note that Mannatech’s associates hawk one of its products, Ambrotose, as a near cure-all for everything from cancer to multiple sclerosis to AIDS. It’s even been described as a sham in a journal article. I might have to do a separate post on Mannatech one day, but in the meantime if you doubt the dubious nature of the company and its products, Quackwatch has a resource.
As disturbing as Dr. Carson’s advocacy of pseudoscience like creationism is, I find this revelation about his longstanding relationship with Mannatech to be far more disturbing, striking as it does at the heart of his strength, his reputation as an excellent physician and neurosurgeon. It turns out that Carson’s lack of critical thinking skills goes beyond just evolution, the Big Bang Theory, geology, history, and physics. As great a neurosurgeon as he was, he was so easily persuaded by pseudoscience that he was willing to promote nonsense like Mannatech as a treatment for prostate cancer. This is not a trait I want in a physician or a political leader.

Supplements for Osteoarthritis – Evaluating the Evidence
A new review evaluates the evidence for supplements to treat osteoarthris
Scott Gavura on July 12, 2018
Link

I’ve reached the age in my life where my joints have started making odd noises – all of a sudden my knees sound like Rice Krispies, which WebMD reassures me is clearly imminent osteoarthritis. At least I’ll have company, as osteoarthritis (OA) affects nearly everyone, once you get old enough. It’s the most common form of arthritis, and treatments are focused on reducing symptoms, as osteoarthritis is incurable. Anti-inflammatory drugs like ibuprofen and naproxen are commonly used to treat the pain associated with OA. They can be effective, but there are also safety concerns with the use of anti-inflammatory drugs. Non-steroidal anti-inflammatory drugs (NSAIDS) have been linked to about 30% of drug-related hospital admissions, and it’s estimated that 12,000-16,000 Americans die annually as a result of gastrointestinal bleeding caused by NSAIDs. They can also cause significant kidney damage in up to 5% of users. Drugs like acetaminophen (Tylenol) are also used commonly but the efficacy of acetaminophen has been questioned, and this drug can be fatal in overdose. With questions about the safety and efficacy of commonly-used drugs to treat OA, there is persistent interest in the use of supplements and other forms of alternative medicine, perhaps based on the perception that these products are safer and potentially as or more effective than “conventional” therapies. A recent paper in the journal Rheumatology summarizes the conclusions of systematic reviews and randomized controlled trials of a variety of herbal products and dietary supplements, and is a helpful guide to inform self-selection and decision-making.
Understanding osteoarthritis
Osteoarthritis is a common debilitating condition of synovial joints. These joints make up most of the movable articulations of the body and are characterised by an articular capsule and synovial lining that surrounds the fluid-filled synovial cavity. This fluid functions somewhat like motor oil, acting as the joint’s lubricant. The opposing ends of the two articulating bones are lined by cartilage which acts like a shock absorber and reduces friction between bones. If you sample a piece of cartilage and observe it under a microscope, you’d see cells called chondrocytes bathing in a matrix composed of collagen fibers, a substance rich in proteoglycans and elastin fibers. Now these proteoglycans are themselves composed of a protein bound to glycoaminoglycans (GAG) – a chain of repeating carbohydrates compound (e.g., hyaluronan). The role of proteoglycans is to act as binding force in articular tissue. GAGs include chondroitin, heparin, and keratan.

Although its cause is not well understood, osteoarthritis seems to be caused mostly by articulation “wear and tear”, such that nearly everyone by age 70 has some degree of OA. Other factors for OA include genetic inheritance, behavior influences, and obesity. Chronic pain in the knee, hip, fingers and of the lower back are typical symptoms of osteoarthritis. After injury (e.g., trauma or repetitive joint overuse), changes start to occur in the joint itself. First, cartilage cells start to change their metabolism and cause an overall depletion in proteoglycan that leads to damage to the collagen matrix. Then the cartilage swells and loses its ability to absorb joint pressure. As a consequence of cartilage loss, the bone surfaces of the articulation start to wear off which result in deformed bone structures of the joint. Pain from OA is activity-related, with onset during or just after joint use, and then gradual resolution. In the early phase of the condition, pain is episodic and happens after a day or two of overuse of the affected articulation. In severe OA, pain can be continuous. Occasionally, morning stiffness can occur, typically resolving within 30 minutes. While some patients may have physical changes in the joint – particularly joint space narrowing – that can be seen on x-rays, a diagnosis of mild to moderate OA is usually based on a physical examination only. If you’re older than 25, have persistent joint pain in a few joints, and morning stiffness, it’s probably osteoarthritis.
The important and measurable outcomes in OA are global pain as measured by a visual analog scale (VAS), pain function as measured by the WOMAC or the Lequesne Index, and occasionally, joint space narrowing (JSN) as measured using x-ray imaging. As the physical changes seen on x-rays do not accurately predict the severity of symptoms, most trials use pain outcomes as clinically important outcomes to evaluate.
A new review of the evidence
This new paper, published in Rheumatology and entitled “Which supplements can I recommend to my osteoarthritis patients?, is from Xiaoqian Liu and colleagues. The researchers sought out randomized controlled clinical trials and systematic reviews for commonly recommended supplements and “complementary” medicines. Eight systematic reviews and nine RCTs were identified, meaning a total of 16 products were included in the review. The researchers estimated the treatment effect size based on the standardized mean difference where an SMD of up to 0.3 was considered small, 0.3 to 0.8 was moderate, and >0.8 was considered large. The minimum clinically relevant difference was estimated at 0.37 which correlates with a difference of about 9mm on a 100mm pain scale. We use the terms “clinically important” or “clinically relevant” to try to distinguish between changes that are meaningful to patients, and those that are likely not. For example, if you rate your pain a 70 today and a 66 tomorrow, that’s not likely to be clinically meaningful.

The researchers also utilized the Grading of Recommendations Assessment, Development and Evaluation (GRADE) to rate the quality and strength of the evidence, which you’ll see below. A bubble diagram provides a simplified summary of the evidence suggesting which products may be effective and which should be avoided. The bigger the bubble, the higher the rating.
The results
Here’s a summary of what the review found.
Marine omega-3 fatty acids
Fish oils (e.g., cod liver oil), krill oil and products like green-lipped mussel extract have been studied for 6-26 weeks with no evidence of effectiveness, based on low-quality evidence.
Glucosamine
Harriet Hall has written about glucosamine regularly. Despite extensive investigation, glucosamine hasn’t been shown to have any convincing meaningful effects, a finding made by this review team as well. This non-effectiveness is consistent across the different forms of glucosamine (sulfate vs. hydrochloride). Glucosamine, however, appears safe.
Chondroitin sulfate
This is another supplement that Harriet Hall recently revisited. This review noted that a Cochrane review found superiority to placebo, but the clinical significance was unclear. Another, subsequent systematic review concluded that chondroitin had no clinically important effects. It was found to be safe, however. The review also noted that combination glucosamine + chondroitin is also ineffective in terms of reducing joint pain or functional impairment in knee pain over six months.
Vitamins D and E
Four studies have evaluated vitamin D supplementation for treating OA. The durations ranged from 1-3 years with doses ranging from 800-2000IU per day to 50-60000IU per month. No clinically meaningful effect on pain or function has been shown.
Vitamin E has also been evaluated at doses of 500IU for 6 months to 2 years, with no effect on symptoms but it was associated with a higher risk of bleeding.
Collagen
Collagen is a protein, and it’s claimed that consuming it will decrease cartilage degeneration by promoting collage synthesis. When we consume collagen, usually in the form of food, the long chain proteins are broken down during digestion to their original amino acids. There are inconsistent signs of benefit and of unclear clinical importance with collage hydrolysate. Undenatured collagen (derived from chicken sternum cartilage) has been evaluated in two clinical trials for 90-180 days and has been shown to be more effective than glucosamine + chondroitin, or placebo.
Willow bark extract
This is akin to impure, raw aspirin (acetylsalicylic acid) as the raw ingredient of willow bark (salicin) was later used to develop ASA and other anti-inflammatory drugs. A systematic review gave conflicting results in OA, and other trials have shown no effect. (Whether or not this is due to the inconsistent presence of active ingredients is always a question I have with these products.) Adverse effects include gastrointestinal effects, and if this is truly just a raw, unstandardized NSAID, we should expect the same cardiovascular side effects as well.
MSM (Methylsulfonylmethane)
While in-vitro testing suggests that MSM may have inflammatory effects, and MSM is very popular as a supplement, the treatment effects are promising, but not convincing. One systematic review found positive “but not definitive” evidence of a treatment effect compared to placebo. A second systematic review found modest to large treatment effects when used for 12 weeks, though the quality of the evidence was low. Optimal dosing isn’t clear, and the product can cause mild gastrointestinal discomfort.
Avocado and soybean extracts
Avocado/soybean unsaponifiables (ASU) (i.e. extracts) are made of one-third avocado oil and two-thirds soybean oil. Low quality evidence suggests that ASU might have moderate effects in the short-term, but these effects were not observed with more rigorous evaluations. ASU seems to be as well tolerated as a comparable placebo.
Turmeric /curcumin
I’ve written about this product before, which has promising anti-inflammatory effects. The main pharmacological challenge with curcumin seems to be that the product is poorly absorbed. Manufacturers have come up with several different formulations (e.g., nanoparticles, liposomes) but there’s not a lot of high-quality evidence to go on. Like other supplements, what appear to be large treatment effects are complicated by overall poor quality evidence. While curcumin seems to be well tolerated, this is one supplement that may cause interactions with prescription drugs like anticoagulants (“blood thinners”).
Boswellia serrata
Boswellia is a gum resin extract from the frankincense tree. Several potentially active ingredients have been identified with anti-inflammatory effects. Three studies have evaluated two different Boswellia products in knee OA that found clinically meaningful treatment effects on pain and disability improvement. However, the quality of that evidence was evaluated to be low. While it appears to be well tolerated, it has been reported to cause abdominal pain, fever, and weakness.
Pycnogenol
Pycnogenol is an extract of the maritime pine made up of a concentrate of plant polyphenols, and is claimed to have anti-inflammatory effects. Three studies (of moderate quality) that have evaluated the supplement have found large and clinically meaningful effects for pain and disability. No serious side effects have been reported.
Rose hip
Rose hip is another herbal remedy which has anti-inflammatory properties. It has been studied against placebo in three studies with a duration of 3-4 months. A meta-analysis found small to moderate short-term effects for pain reduction, and a subsequent RCT found no effects. Rose hip was as well tolerated as placebo.
Making sense of the studies
Based on their review, the authors do not recommend omega-3 fatty acids, vitamins D and E, willow bark extract, collagen hydrolysate, glucosamine, chondroitin, combinations of glucosamine and chondroitin, and rose hip. Based on the review, Boswellia serrata extract and pycnogenol appear to demonstrate the most clinically important effects. They also note that while curcumin and MSM demonstrated clinically important effects, the quality of that evidence was low. The authors comment that the overall evidence base remains limited by poor-quality studies, often of short duration, with many sponsored by manufacturers (particularly small studies that showed large effects), noting the following priorities for future research:
They summarize the evidence, and their overall evaluation, in this figure:
The authors conclude that in those with osteoarthritis who are enthusiastic about using supplements, short-term trials of the pycnogenol, curcumin, Boswellia serrata extract, or MSM could be attempted, and should be discontinued after 4-6 weeks if no obvious benefits are noted. Importantly, drug-supplement interactions are not always well understood or well documented, and any supplement should be used with caution (and preferably, consultation with their pharmacist) if being combined with prescription or non-prescription drugs. There are also the very real concerns about supplement quality and batch-to-batch consistency, which complicates evaluations of risk and determining whether or not they work.
Making sense of supplements for osteoarthritis
Given the ubiquity of osteoarthritis and the lack of really good treatment options, it’s worth noting what has been shown to work: Ongoing exercise and weight loss (where appropriate) is backed by moderate-to-high quality evidence and a moderate effect size. This is a benefit that is comparable to anti-inflammatory drugs, but without the cost or the side effects. There are also topical anti-inflammatory drugs, which appear to provide meaningful benefits without the typical NSAID-related side effects.
For those who have exhausted the established options, supplements may look appealing and some may be worth a short-term trial. It’s important to remember that with studies of supplements and drugs alike, as the quality of evidence improves, the treatment effects often diminish or disappear. Still, based on the existing evidence, for your own evaluation it seems reasonable to try products for which there is the best evidence. This is an area where the evidence continues to emerge, so if you’re experiencing OA, cautious skepticism about the “latest and greatest” supplement seems to be reasonable.

Supplement vendors make unfounded cancer treatment claims
A new analysis shows widespread marketing of natural health products for the prevention or treatment of cancer.
Scott Gavura on March 5, 2020
Link

Fear is a powerful motivator. And few events may be as frightening as a cancer diagnosis. It shouldn’t be surprising that the unscrupulous may try to take advantage of your fear in order to sell you something.
While the specifics vary by country, dietary supplements tend to be subject to weaker regulations than those for prescription and over-the-counter drugs. This includes the claims that can be made about a product. While drugs are subject to very specific marketing requirements, there may be more latitude given to manufacturers of dietary supplements. Even where regulations and requirements for these products exist, they may not be routinely enforced. In the United States, supplement vendors can make “structure/function” claims (e.g., “Helps maintain proper joint function”) but cannot make specific statements (e.g., “Relieves joint pain”). However, regular readers of this blog may recall many products promoted with claims that are not based on any credible evidence, or would be considered to meet regulatory requirements.
Canada has a similar, though not identical approach. Notably, prescription drugs cannot be advertised to the public in Canada, but “natural health products” can be advertised. Health Canada (Canada’s equivalent to the Food and Drug Administration) forbids treatment claims for natural health products for conditions like cancer, but does permit preventative claims, but only if those claims are approved by Health Canada. It’s a narrow window, that, if enforced to a science-based standard, could balance the desire to provide information on products while making sure statements are supported by evidence.
Recently the Canadian science advocacy group Bad Science Watch undertook a review of the online marketing of Canadian natural health products. Specifically, they looked at statements made regarding cancer, and whether or not those claims were appropriate and authorized by Health Canada. The results will not surprise you.
The approach
The overall intent of this survey was to develop and evaluate a methodology towards assessment of whether Canadian online retailers of natural health products were marketing their products in alignment with the authorization provided by Health Canada. The specific condition examined was cancer. Content from Canadian retailers was collected based on the keyword “cancer” (and related terms, like tumor or metastasis) and each statement was examined for accuracy. Both direct and indirect claims were identified:
Direct: e.g., “It is also important in the prevention and treatment of breast and colon cancer.”
Indirect: e.g., “”Bloodroot extracts have also been promoted by some supplement companies as a treatment or cure for cancer.”
The specific websites themselves were identified from a convenience sample from the Canadian Health Food Association Retailer Directory.
Twenty-three trained volunteers evaluated the claims for each page identified. Overall, 31,686 web pages were identified and ultimately 2,324 were screened. (Full methodology is here.) In the end, 558 unique web pages were identified, and this was what was found:
    • 20% (113) of web pages made a direct claim of treatment or cure
    • 30% (166) made an indirect claim of treatment or cure
    • Only 3 out of the 558 pages had claims that were Health-Canada-approved.
There’s an infographic of all of the results.
What this means
This isn’t the first post to remind you to be skeptical of what you read on the internet. Consumers facing frightening conditions like cancer may be tempted to try these products, despite the lack of evidence to substantiate these claims. As I have blogged before, dietary supplements appear to be, at best, neutral with respect to cancer survival, and there is no indication that they offer advantages or benefits to those that take them. We also know that cancer patients that opt for alternative medicine have higher rates of cancer death than those that use conventional therapies. It’s for these reasons that consumers deserve robust regulation, and enforcement of those regulations, to prevent these forms of opportunistic marketing.

Isagenix Study Is Not Convincing
Harriet Hall on December 11, 2012
Link
Isagenix is a wellness system sold by multilevel marketing. It consists of a suite of products to be used in various combinations for “nutritional cleansing,” detoxification, and supplementation to aid in weight loss, improve energy and performance, and support healthy aging. It allegedly burns fat while supporting lean muscle, maintains healthy cholesterol levels, supports telomeres, improves resistance to illness, reduces cravings, improves body composition, and slows the aging process. And makes millions for distributors who got on the bandwagon early and are high on the pyramid.
I have written about it before and have been roundly criticized by its proponents. It generated my all-time favorite insult: “Dr Harriet Hall is a refrigerator with a head.”
My biggest concern with Isagenix was that it had not been clinically tested. They claimed that clinical tests were in progress (funded by Isagenix). An e-mail correspondent recently told me I should take another look at Isagenix, since a clinical study had been completed. It had not yet been published, and I asked her to get back to me when it was. Ask and you shall receive (but you may be sorry!). She contacted me when the study by Kroeger et al. was published in the journal Nutrition and Metabolism. The full study is available online and I urge readers to click on the link and look at Table 2, which I will be referring to later. The journal is peer-reviewed but, as will become painfully obvious, the peer reviewers did not do a competent job. It is an open-access online journal with a low impact factor. The authors had to pay to get their article published: it cost them $1805.
Methods
Now, if you were going to design a clinical study of Isagenix, how would you go about it? You probably wouldn’t want to study telomere support or “improved energy” first, or try to establish that “detoxification” had occurred. Since the most common use of Isagenix is for weight loss, it seems to me the logical place to start would be to study weight loss on the Isagenix program compared to weight loss with a diet providing an equal number of calories, ideally a nutritious diet with a similar proportion of fat, carbs and protein.
For some inscrutable reason, these researchers elected to study 54 obese women age 35-65 (no men or younger women or overweight but non-obese women) on a one-day-a-week intermittent fasting (IF) program. They compared a calorie-restricted diet with a liquid meal replacement for 2 meals a day (using only one component of the Isagenix system, Isalean shakes) to a diet with the same number of calories provided by regular food. For the first two weeks, they established a baseline by having patients simply try to maintain their weight. Then for weeks 3-10 they were randomized to the liquid meal replacement Isalean group or the regular food group; and weight, intake, lipids, adipokines, and other factors were measured at weeks 3 and 10.
Why intermittent fasting? In their Introduction, they say that IF has been growing in popularity and that it “may” be effective for weight loss and coronary risk reduction. The references they provide do not show that intermittent fasting offers any advantage over constant calorie restriction. And IF is not a part of the Isagenix program. Why did they choose to incorporate it into their study? Doesn’t it just add another unnecessary complication?
The researchers themselves pointed out a serious limitation of their study. It did not control for food intake. The dinner meal for the Isalean group and all meals for the food group were left up to the subjects after instruction by a dietitian. The goal was to limit breakfast and lunch to 240 calories each and dinner to 400-600 calories, with <35% calories from fat and 50-60% from carbohydrate. Actual intake was self-reported via telephone: subjects were interviewed and asked to recall what they had eaten in the previous 24 hours.
Results
The results were positive, but far from impressive. Over 8 weeks, subjects using Isalean lost 4 kg compared to 3 kg in the control group (1.1 and 0.8 pounds a week, respectively). The Isalean group reportedly reduced their total daily calorie intake from 1708 to 1255, and we can calculate that a reduction of 500 calories a day should result in a weight loss of one pound a week without any need for fasting days, meal replacements, or supplements. The control group reduced their total calorie intake by less than 500 calories a day, so of course they lost less weight.
There were favorable changes in lipids and adipokines, so the researchers argued that that the liquid meal replacement might confer protection against coronary heart disease. That is nothing but speculation, since they didn’t assess actual CHD. We know that measuring changes in risk factors is not enough. For instance, intervention producing favorable changes in the cardiac risk factor homocysteine does not translate to any decrease in cardiac events.
Possible Bias
We know that studies of pharmaceuticals are more likely to generate positive results when funded by the manufacturer. This study was funded by the Isagenix company, and at least one investigator had links to the company.
The Numbers Don’t Add Up
The researchers said that:
Energy intake decreased (P < 0.05) in both the IFCR-L and IFCR-F groups between week 3 and 10. There were no changes in fat, protein, carbohydrate, cholesterol, or fiber intake from the beginning to the end of the study in either group.
I puzzled over the numbers reported in table 2. They just don’t add up. For instance, the total calorie intake for the Isalean group at week 10 was 1255, but if you add up the calories from the reported intake of fat, carbohydrates and protein (9, 4 and 4 calories per gram respectively), you get 1655. Similarly, the total calorie intake for the food group was reported as 1444, but adding up the calories from fat, carbs and protein gives 1279. The Isalean group reportedly ingested more fat, more protein, and more carbohydrates than the regular food group, which would have to mean they got more total calories, not less. I asked my correspondent, who answered:
Our team did notice the inconsistency. They asked the lead investigator who replied that the kcal value for IFCR-L week 10 comes from the 24-h recalls that were analyzed and not from the macronutrient values. It’s unclear why the numbers don’t match up. However, the kcal value for IFCR-L week 10 does make sense in terms of weight loss.
She asked if that answered my question. I replied:
No. Where did the macronutrient values come from? If it is “unclear why the numbers don’t match up,” why were they reported that way, and why can’t the researchers make it clear? What do you mean when you say the kcal value for IFCR-L week 10 does make sense in terms of weight loss? If the calculated values are questionable, how can any conclusions be drawn?
So far, I haven’t received any answer. Apparently her “team” was pacified by the researcher who managed to baffle them with bullshit. When you want to believe, you may be easily convinced that the researcher knows what he’s doing.
More Problems
The subjects in the Isalean group supposedly got 240 calories from each of two Isalean shakes and then ate a 400-600 calorie dinner. That would add up to a daily total of 880 to 1080 calories, not the 1255 calories reported. The food group was intended to ingest the same number of calories, not the 1444 reported.
In the Isalean group, the fat intake was listed as 51 grams (459 calories); but according to the product label, each Isalean serving provides 50 calories from fat, and the goal of <35% calories from fat in the evening meal would give up to 35% of 600 calories or 210 calories from fat. That adds up to a maximum of 310 calories from fat, not an average of 459. If the food group was getting 1444 calories a day and their diet contained 50-60% calories from carbs, their carbohydrate intake ought to be between 722 and 866 calories, not the 696 calories from the 174 grams that were reported.
The more I looked, the more problems I found. Eventually my brain started to melt and I gave up. There’s no way to make sense of the results as reported.
Their Conclusion
Taken together, our results suggest that IFCR (intermittent fasting/ calorie restriction) with liquid meals is an effective diet therapy to reduce body weight, visceral fat mass, and lipid indicators of CHD risk. Our findings also demonstrate that the beneficial modulations in vascular disease risk by IFCR may be mediated, in part, by reductions in visceral fat mass and pro-atherogenic adipokines. This study is an important first step to understanding the underlying mechanisms that mediate the cardio-protective effects of this novel diet regimen.
My Conclusion
The results are uninterpretable. This study does nothing to suggest that the Isagenix system has any advantage over other calorie-restricted diets. Neither does it tell us anything about the possible benefits of intermittent fasting. And the study is not “an important first step to understanding the underlying mechanisms that mediate the cardio-protective effects of this novel diet” since it has not been established that there are any cardio-protective effects to understand.

Puritan’s Pride Vitamin Advisor Gives Questionable Advice
Harriet Hall on February 9, 2016
Link
The Puritan’s Pride website has a Vitamin Advisor that claims to provide a personalized supplement plan, with expert recommendations chosen just for you. In my opinion it is deceptive, designed not to provide evidence-based personalized health advice, but to sell their products; and one can only wonder what kind of “experts” would support such ill-advised recommendations. Stephen Barrett and I have just co-authored an article on the Quackwatch site analyzing the Vitamin Advisor’s advice. I wanted to share what we found with our SBM readers, with some further comments.
Their recommendations are based on a series of questions like age, sex, health concerns, whether you are exposed to cigarette smoke, etc. The full list can be found in our Quackwatch article. The one-size-fits-all questions are useless because “eye concerns” might mean anything from needing glasses to glaucoma.
$100 worth of stuff I don’t need
I filled out the questionnaire honestly, and it advised I take these 6 products (links are to SBM posts on these topics):
     1.  UltraWoman 50 Plus Multivitamins
     2.  CoQ10 100 mg
     3.  Omega fish oil 1000 mg
     4.  Absorb calcium 1200 mg with vitamin D 1000 IU
     5.  Triple strength glucosamine, chondroitin, MSM Joint Soother
     6.  Vitamin D 2000 IU
The total price of these six products is $99.90. In my informed opinion, this advice is wrong. There is no credible scientific evidence that I would benefit from any of these. Dr. Barrett was also advised to take six products, none of which he needed. I stopped taking multivitamins many years ago and explained my reasoning why.
My Puritan’s Pride Vitamin Advisor recommendations add up to a total of 8000 IU vitamin D and 2044 mg of calcium. The tolerable upper intake level of vitamin D is 4000 IU; of calcium, 2000 mg. For women my age, the recommended amount (from all sources) is 800 IU of vitamin D and 1200 mg of calcium. The benefits of calcium and vitamin D supplementation remain uncertain, and calcium supplementation has been associated with increased cardiovascular risks.
Deciphering the algorithm
Dr. Barrett and I were curious, so we had fun doing a little detective work. We tried putting different answers into the questionnaire, posing as a man or woman of various ages. The algorithm it uses was easy to figure out:
    • If you are a teenager, it asks no further questions and recommends Mega Vita Min Multivitamins for Teenagers
    • EVERYONE gets a multivitamin: If you are a woman under 50, you get UltraWoman; if you are over 50 you get Ultrawoman 50 Plus; if you are trying to get pregnant, you get Pre-Natal Complex
    • If a woman checks poor emotional wellbeing, she gets UltraWoman, B-50, Omega, vitamin D
    • If you are tired, you get vitamin B12 1000 mg
    • If you are a woman with PMS: B-50 complex, magnesium, calcium/D
    • If you are a woman with menopausal symptoms: B-50 vitamin complex, Estrobalance, and magnesium (Estrobalance contains phytonutrients found in soy and black cohosh, vitamins and minerals including E, folic acid and calcium)
    • Eye concerns: lutein/zeaxanthin
    • Joint concerns: glucosamine/chondroitin/MSM
    • Air pollution: Vitamin C, selenium 200 mcg, vitamin E 400 IU
    • Cigarette smoke exposure: Vitamin C with bioflavonoids and rose hips
    • Urinary tract concerns: Cranberry fruit concentrate with C and E
    • Stress, tired, poor emotional well-being: Vitamin B complex, vitamin C/bioflavonoids/rose hips, vitamin B12 1000 mcg, omega, vitamin D
    • Digestive concerns: Probiotic 10
    • Blood sugar concerns: Cinnamon/chromium, magnesium
    • No sun exposure: Vitamin D 2000 IU
    • If you’re a vegetarian: B12, fish oil, calcium/D
    • If you’re concerned about heart health and BP: CoQ10, omega fish oil 1000 mg, magnesium 250 mg
    • If you have concerns about bone density: Calcium/D, magnesium 250 mg, and an additional vitamin D pill with 2000 IU
    • If you are a man who wakes up to urinate during the night, you get a saw palmetto product
In our judgment, none of these recommendations are based on good scientific evidence. You can read our critique of each recommendation, explaining why we thought it was wrong.
Who needs supplements?
Obviously, customers would not consult a Vitamin Advisor unless they were already convinced they needed supplements. But most people don’t need supplements; their nutritional needs are met by their diet. If it can be determined that their diet is inadequate, the obvious remedy is to improve the diet. Taking pills is a poor second best, and money spent on supplements could be better spent on healthy foods. Many people take a multivitamin out of insecurity, as “insurance” to allay their fears that they may not be eating right. Others take them in the false belief that they will improve their energy or for other reasons that are not supported by evidence.
In most cases a multivitamin is harmless, even though it may accomplish nothing more than creating expensive urine. But every vitamin and mineral can be harmful in high doses. There is growing concern that taking high doses of antioxidant supplements such as beta-carotene might do more harm than good. You may remember how Gary Null almost killed himself with his own brand of supplement that happened to be inadvertently overloaded with vitamin D. And there is even some evidence that a daily multivitamin is associated with an increased rate of death in older people. (Admittedly, this is correlation, not causation; a causal link has not been established.)
According to The Medical Letter, 47 (1213):
Supplements are necessary to assure adequate intake of folic acid in young women and possibly of vitamins D and B12 in the elderly. There is no convincing evidence that taking supplements of vitamin C prevents any disease except scurvy. Women should not take vitamin A supplements during pregnancy or after menopause. No one should take high dose beta carotene supplements. A balanced diet rich in fruits and vegetables may be safer than taking vitamin supplements. No biologically active substance taken for a long term can be assumed to be free of risk.
According to the American Academy of Family Physicians at the time I wrote my SBM article about multivitamins:
The decision to provide special dietary intervention or nutrient supplementation must be on an individual basis using the family physician’s best judgment based on evidence of benefit as well as lack of harmful effects. Megadoses of certain vitamins and minerals have been proven to be harmful.
Their current advice about vitamin and mineral supplementation for various specific indications either recommends against supplementation or states there is insufficient evidence to assess the balance of benefits and harms.
The disclaimers
And while poor diet might be a rationale for vitamin and mineral supplements, most of the diet supplements on the market are not intended to supply dietary deficiencies but to provide some kind of alleged preventive or therapeutic effects. Under the DSHEA, sellers are not allowed to make claims about such effects. Puritan’s Pride includes the usual disclaimer, and they comply with FDA regulations by only mentioning vague function/support claims. For example, for the lutein/zexanthin supplement that they recommend for everyone with “eye concerns,” they say:
Lutein helps to improve vision in low contrast situations, which is essential for night driving. Lutein Lutigold™ plays a role in the maintenance of eye health and is the principal Carotenoid found in the central area of the retina called the macula. Carotenoids are fat-soluble antioxidants found in fruits, vegetables, marigolds and other plants.…Nutrients such as lutein, zeaxanthan, and EPA may support eye health.
For eye health, in addition to the lutein/zeaxanthin supplement recommended by the Vitamin Advisor, the company sells 35 other products to support healthy eyes, including various combinations of antioxidants, some of which contain up to 25,000 IU of beta carotene. The Medical Letter has said no one should take high doses of beta carotene.
The only evidence-based use of supplements for eye health is that a specific mixture has been shown to slow the progression of moderate-to-advanced macular degeneration. Puritan’s Pride does not sell this mixture. There is no evidence that supplements offer any benefit for prevention of macular degeneration or for treatment of early disease, and there is no evidence that they benefit any other eye conditions.
Stephen Barrett “translated” Puritan’s Pride’s disclaimer thusly:
We’d like to sell you products, so here is a questionnaire that will recommend something no matter how you answer it. Our information is not necessarily derived from sources that are trustworthy or even relevant to humans. When ingredients are included in more than one product, the combined amounts can exceed safe levels, but our recommendations won’t take this into account. We would like you to believe that our products are useful. However, our words are not intended to suggest that they can help treat, cure, or prevent any disease. They are merely “informational.” We say that you should not consume any product we recommend without discussing it with your doctor. However, we really don’t mean this, because most doctors will advise you not to take the products. We just say it as part of our effort to avoid legal responsibility for any harm caused by our advice or products.
Conclusion: Puritan’s Pride wants your money, not your health
Most people don’t need vitamin supplements. There are specific indications for supplementation in specific circumstances. All women who might become pregnant should take a folic acid supplement. Otherwise, it is best to consult a doctor who can provide truly individualized advice based on detailed knowledge about the patient. Relying on an online questionnaire for medical advice is foolhardy. Your physician wants to do what’s best for your health; the Puritan’s Pride company wants to sell you stuff. Buyer beware!

Can supplements improve memory and cognition?
Can you reduce the risk of cognitive decline with dietary supplements?
Scott Gavura on September 1, 2022
Link

We all have days when we feel “sharp” and others where everything seems a bit foggy. As we age, those foggy periods may feel more frequent. Small changes in cognition are common with aging, but many see this as sign of impending cognitive decline and even dementia. And dementia is an unfortunate reality for millions – Alzheimer Disease alone affects 6 million Americans. With no really effective prescription medications for the treatment or prevention of cognitive decline, many consumers turn to vitamins and dietary supplements. I recently spotted advertisements for a product called “Clear Brain” which is marketed to “enhance cognitive function and memory in adults”. This isn’t the only product marketed for cognition – there are many products with a huge array of ingredients. Is there evidence to suggest that you can reduce the risk of cognitive decline with dietary supplements?
A product marketed to enhance cognitive function should be backed by clinical trials, because it’s not practically possible for an individual to objectively assess any benefits themselves. Clear Brain contains a variety of ingredients which I’ll go through in order to evaluate the evidence.
Pomegranate fruit extract (75 mg) – Pomegranate is usually eaten raw or consumed as juice. The juice may have a minor effect on blood pressure. There is no published information to demonstrate that fruit extract has any meaningful effects on cognition. However, it’s considered safe to consume.
Green tea leaf extract (75 mg) – Green tea is widely consumed. Heralded for cardiovascular health (where regular tea drinking may be beneficial), there is little evidence to demonstrate it has a role in cognition. There are some trials including one with matcha green powder, where 3 grams a day for 12 weeks had no benefit over placebo. Another trial on cognitive function in adults, also placebo-controlled, did not improve most measures of cognition.
Ginkgo leaf extract (60 mg) – Ginkgo has a long history of use in Chinese medicine. Interestingly, the ginkgo tree is the world’s oldest living tree species. Ginkgo is currently widely used, and the extract is considered safe and well tolerated. Ginkgo is believed to improve blood flow to the brain, and is claimed to treat memory loss and dementia. Clinical trials with ginkgo for the treatment of dementia are numerous and the results are mixed, with no consistent effect shown. Trials for prevention do not show a clear benefit.
French maritime pine bark extract (40mg) – This ingredient is commercially sold as a single ingredient in the supplement Pycnogenol. (Examine.com has a good summary of the trials and their limitations.) There are trials with that product that have examined cognition and reported positive effects on some measures. It isn’t known if trials with Pycnogenol are relevant to this or other supplements, as the method of preparation and actual chemical constituents may differ.
Walnut seed extract (25mg) – A search for evidence on this product finds that it is mainly used as a cosmetic. English walnuts are a tree nut which are a popular food. All the studies I could find were of whole nut consumption, mainly for cardiovascular conditions. I could find no trials with the extract and no trials examining effects on cognition.
Black pepper fruit extract (3mg) – This appears to be the same type of pepper you’re putting on your food. There is no evidence that this tiny amount has any effects on cognition, though there is research suggesting it may be helpful in mice models of dementia. Black pepper is claimed to promote the absorption of other chemicals, so that could also be the reason for inclusion in supplements.
Vitamins (Folate, Pantothenic acid, thiamine, niacin, riboflavin, B6, B12, etc.) – There is no evidence that vitamin supplements can improve cognition or reduce the risk of cognitive decline. The best way to obtain vitamins is via the diet, and supplementation is only suggested where dietary intake is low. Importantly, a nutrient-rich diet like the Mediterranean diet or the DASH diet is actually associated with a reduction in the risk of cognitive decline.
Does anything work to protect the brain from cognitive decline?
The World Health Organization has produced a detailed document on how to reduce the risk of dementia. Recommendations (with varying levels of evidence) include physical activity, tobacco cessation, Mediterranean-like diets, weight management, reducing alcohol consumption, managing hypertension, and preventing or treating diabetes. They noted no effects (and make no recommendations in favor of) multi-supplement complexes, vitamins B and E, and polyunsaturated fatty acids.
Strategies to support your cognition
No dietary supplements, either alone or in combination, have been proven to demonstrate any meaningful benefit to prevent or treat cognitive decline. There is no scientific justification for the sale of these supplements as the marketing claims are unsupported. Those interested in maintaining cognitive function as they age should strive to lead a healthy lifestyle that includes a balanced diet, regular exercise, managing health conditions like diabetes or hypertension, and moderating or minimizing alcohol consumption.

AARP report: Insufficient evidence that dietary supplements benefit brain health
Experts convened by the AARP say don’t waste your money on dietary supplements claiming they improve brain health. A healthy diet and lifestyle are the best medicine for your brain.
Jann Bellamy on January 2, 2020
Tweet

A 31-page report issued in 2019 by the Global Council on Brain Health (GCBH) concludes there is no convincing evidence to recommend dietary supplements for “brain health” in adults 50 and over who do not have identified nutrient deficiencies. (“The Real Deal on Brain Health Supplements: GCBH Recommendations on Vitamins, Minerals, and Other Dietary Supplements”)
Supplements have not been demonstrated to delay the onset of dementia, nor can they prevent, treat or reverse Alzheimer’s disease or other neurological diseases that cause dementia. For most people, the best way to get your nutrients for brain health is from a healthy diet. Unless your health care provider has identified that you have a specific nutrient deficiency, there is not sufficient data to justify taking any dietary supplement for brain health. . . Despite claims to the contrary, brain health supplements have not been established to maintain thinking skills or improve brain function.
The GCBH describes itself as an independent collaborative of scientists, health professionals, scholars, and policy experts convened and funded by the AARP, with support from the charity Age UK, “to offer the best possible advice about what older adults can do to maintain and improve their brain health.” Experts consulted for this report include the former Director of the NIH’s Office of Dietary Supplements, physicians and scientists from universities in several countries, and research foundations, as well as the president of an independent supplement testing lab.
“Brain health” is defined by the GCBH as
A state of having good underlying neural mechanisms to support high functioning mental processes of cognition that support well-being.
The GCBH notes that supplement marketers are making a plethora of unproven claims, such as:
A dietary supplement that has been clinically shown to help with mild memory problems associated with aging.
Clinically shown to be safe and support memory and brain function.
Clinically proven natural ingredients.
Helps your brain maintain healthy neurons to support learning and recall.
Designed to help improve memory while increasing focus and concentration.
Improve your ability to retain and recall various kinds of information.
The GCBH does not believe that there is sufficient evidence to support these claims and a number of others being made by marketers and listed in the report.
While supplement marketers are permitted to claim that their products “help maintain” or “support” brain health, labels and ads may also mislead or confuse consumers into believing the supplement safe and effective:
“Clinically studied” does not mean the same thing as proven safe and effective for the [intended] purpose by rigorous, well-designed scientific studies in humans. “Natural” does not always mean safe. “Statistically significant” doesn’t establish that it is likely to or actually will positively affect human health.
Countering these unproven claims is an uphill battle given the alarming statistics on widespread misinformation about dietary supplements. According to a 2019 AARP survey of American adults on dietary supplement use:
    • 81% of adults over 50 believe that supplements are “at least somewhat important for health”
    • 69% are currently taking a dietary supplement at least 3 times a week
    • 26% regularly take supplements for their brain health
Among adults specifically taking dietary supplements for brain health, 21% say they take them to maintain, and 20% to improve, brain health; 11% take them to delay the onset of dementia and 8% to “reverse” dementia.
These false beliefs are maintaining and improving the bottom lines of brain health supplement manufacturers, a growing segment of the supplement market. The Government Accountability Office recently found that “memory supplement” sales in the U.S. nearly doubled in value from 2006 to 2015, when sales were $643 million. One industry report found that brain health supplement sales totaled $3 billion worldwide in 2016, projected to reach $5.8 billion by 2023. In 2018, an estimated 85,000 types of dietary supplement products were sold in the U.S., amounting to more than $40 billion in retail sales. Worldwide the sales figure was $121 billion.
The report reviews a number of supplement ingredients often recommended for brain health, including apoaequorin, a protein isolated from the Aequorea victoria jellyfish and the active ingredient in the ubiquitous supplement Prevagen. After noting deficiencies in company-sponsored research, the review says that apoaequorin’s chemical structure is “likely broken down in the gut before reaching the brain, so it’s unlikely for it to have any brain benefits” and that the expert panel does not recommend taking it. Along with the state of New York and the FTC, AARP is one of the advocacy groups challenging Prevagen’s claims that it “improves memory and provides other cognitive benefits” as deceptive in federal court.
Other ingredients promoted for brain health garnering negative reviews include coenzyme Q10 (CoQ10), curcumin/turmeric, ginkgo biloba, coconut oil, and fish oil.
The report specifically warns about traditional Chinese herbal remedies, noting they are not required to undergo clinical trials prior to use. They may not contain the ingredients on the label and may be contaminated with toxins, heavy metals, or drugs. Some herbal remedies used in Chinese medicine can have serious side effects, interact with prescription drugs, or be unsafe for people with certain medical conditions.
The GCBH report includes Consensus Statements, Expert Recommendations, and practical tips for consumers. A brief summary:
    • Adopt healthy lifestyle habits and get your nutrients for brain health from a healthy diet, not dietary supplements. Well-designed studies of supplements for brain health found no benefit in people with normal nutrient levels. There is also insufficient evidence for “medical foods” being marketed to older adults for brain health.
    • Consult your health care provider before taking any supplement. Medications, surgery and having cancer can all be contraindications for using supplements.
    • Health conditions linked with aging, such as poor nutrient absorption and poor dental health, can increase the risk of nutrient deficiencies, and these can affect brain health. Your health care provider can determine whether you are deficient or at risk of becoming so. Even then, diet and other lifestyle recommendations may be better than supplementation. (E.G., eating fatty fish instead of taking fish-oil derived omega-3 supplements, for which there is insufficient evidence of benefit.)
    • Beware of vague or exaggerated claims about brain health made by supplement marketers. Dietary supplements, unlike drugs, do not require FDA review of their safety or effectiveness before going to market.
    • Ingredient quality in supplements can vary widely and there is generally no government review for purity or content. Some supplements contain harmful ingredients. Look for third-party verification of quality from ConsumerLab.com, NSF International, or U.S. Pharmacopeia.
    • More is not better: Some supplements can be toxic at high levels. For example, large doses of vitamins A,D, E and K, as well as excess iron and caffeine.
    • Dementia patients should avoid melatonin because of increased risk of falls and other adverse events.
I’ll interpose one caveat to this otherwise excellent advice: All “health care providers” are not created equal. Be very wary of the advice of naturopaths (including naturopathic “doctors” and naturopathic “physicians”), chiropractors, acupuncturists, and “integrative” physicians, especially if they sell dietary supplements to their patients (a huge conflict of interest), which many do. These practitioners may also use bogus tests to justify selling supplements. Just because your state licenses (or otherwise regulates) a particular type of health care provider, it doesn’t mean their practices are evidence-based or safe.
Unfortunately, the AARP does not seem to be aware of this problem: Its policies are based on the false assumptions that licensing “ensure[s] professional competence” and that “continuing education plays a critical role in maintaining a well-qualified workforce”. While this may be true for physicians, nurses, dentists, and other science-based health care professionals, it is dangerously naïve when applied to CAM practitioners, for whom licensing legalizes pseudoscience and continuing education spreads hazardous misinformation and quackery. Indeed, the AARP has, regrettably, supported legislation expanding the scope of practice for naturopaths in the past. The AARP’s policies also call for increasing clinical education in complementary, alternative, and traditional medicine, implying that physicians should actually learn these methods rather than simply being knowledgeable about them.
The report ends on a positive note and so will I. While brain health supplements do not maintain cognitive skills or improve brain function,
there are many other lifestyle habits such as getting enough sleep, exercising regularly, eating a healthy diet, staying mentally active and being socially engaged that are recommended by the council.
For more on these strategies, see the Global Council on Brain Health section of the AARP website.

Do dietary supplements improve heart health?
Dietary supplements are widely consumed to improve heart health. But what does the evidence say?
Scott Gavura on September 19, 2019
Link

The sale of dietary supplements is booming and continues to grow. Supplements are enormously popular with an estimated 75% of Americans using some form of supplement regularly. Supplements are widely believed (and advertised) to provide meaningful health benefits. As cardiovascular disease is the leading cause of death in the US, it is not surprising that supplements purported to treat, mitigate, or prevent cardiovascular disease would be popular. It has been noted in many posts on this blog that the supplement industry is very lightly regulated, meaning that claims of effectiveness may not be backed by credible evidence. Additionally, safety concerns have been raised with some supplements, with the suspicion that in some cases, they may harm more than help. 
With this question in mind, Safi Khan and colleagues from West Virginia University and other organizations undertook a massive umbrella review (a summary of systematic reviews) of dietary supplements and their effects on cardiovascular outcomes. The paper was published in the Annals of Internal Medicine in July 2019, and is entitled “Effects of Supplements and Dietary Interventions on Cardiovascular Outcomes“.
What did we know about supplements?
Before we get into the analysis, some background and context is helpful. There is a lot of interest in understanding if dietary supplements benefit cardiovascular health, and there have been several large trials designed to answer this question. The evidence overall is not compelling. A 2013 United States Preventive Services Task Force systematic review found little support for vitamin and mineral supplements. A meta-analysis of RCTs through 2017 found some stroke benefit from folate (folic acid) but no cardiovascular benefits from multivitamins, vitamin C, vitamin D, or calcium. Interestingly the analysis found evidence of harm for niacin and antioxidants. Other trials have looked at fish oils and vitamin D, with generally unimpressive results, with the exception of the REDUCE-IT trial which did find a clinical benefit with a prescription-only form of an omega-3 acid.
What did the authors do?
The methodology of the approach was as follows: The authors searched health databases for relevant English-language papers using appropriate key words. They included any meta-analyses or randomized controlled trials assessing efficacy of supplements or dietary interventions in adults that reported estimates of all-cause mortality and cardiovascular outcomes. These secondary outcomes were cardiovascular mortality, heart attacks, strokes, and coronary heart disease. Studies that looked at “surrogate” or other endpoints (surrogate endpoints are endpoints that patients don’t care about until their health professional tells them it’s important) were excluded. This review was narrowly focused just on these specific endpoints, so even measures like quality-of-life (which is highly relevant to patients) were excluded.
What did the authors find?
With these restrictive criteria the researchers found 942 citations but eventually extracted data on 24 interventions (16 types of supplements and 8 dietary interventions) which formed the data set for the analysis. This included 9 systematic reviews and 4 new RCTs, for a total of 105 meta-analyses, and 277 RCTs, encompassing 992,129 patients. The interventions studied included:
    • 16 different supplements: antioxidants, beta-carotene, vitamin B complex, multivitamins, selenium, vitamin A, vitamin B3 (niacin), vitamin B6, vitamin C, vitamin E, vitamin D, calcium plus vitamin D, folic acid, iron, omega-3 fatty acids.
    • 8 different dietary interventions: Mediterranean diet and intake of reduced saturated fat, modified dietary fat, reduced dietary fat, reduced salt diets, increased omega-3 alpha-linolenic acid, and increased omegas 6 fatty acids.
Here are some of the key findings, some of which are contrary to other published studies:
    • Reduced salt diets in people without high blood pressure (“normotensive”) was found to reduce all-cause mortality with moderate certainty. None of the other 23 supplement or dietary interventions were associated with any demonstrated risk reduction.
    • Reduced salt intake in hypertensive individuals was found to reduce cardiovascular mortality, again with moderate certainty. None of the other 20 evaluated dietary interventions or supplements were found to demonstrate any effect on cardiovascular mortality.
    • 21 interventions studied myocardial infarctions. Only the use of omega-3 fatty acids was associated with a modest but statistically significant reduced risk of heart attacks.
    • 20 interventions studied stroke. Folic acid was associated with lower risk of stroke, while calcium and vitamin D were associated with increased risk. Other interventions had no effect on risk.
    • 19 interventions studied coronary heard disease. Only omega-3 fatty acids were associated with a reduced risk of coronary heart disease.
The authors generated an “evidence map” which I will reproduce here summarizing the findings for all interventions. (The paper is open access and you can find it here.) Regrettably the colour choices are poor, but you can see how the authors attempted to map the certainty of the evidence (the circles) with the nature of the effect (the box shading). It is obvious from this representation, that the certainty of the evidence overall is not impressive. None of the interventions are backed by high-quality evidence.
Assessment
This analysis of 24 different dietary supplements and interventions found only modest evidence for a small number of products and approaches. The authors discuss the findings related to sodium and diet, an area of continued debate and controversy. A few observations: It seems implausible that a low sodium diet will decrease all-cause mortality in those without hypertension, but not in those with hypertension, while at the same time hypertensives have reduced cardiovascular mortality.
Findings related to omega-3 long chain polyunsaturated fatty acids are also puzzling, which is regrettable because fish oils are enormously popular. This study found evidence of some benefit with low quality evidence, yet some high quality randomized trials have shown no compelling evidence of effect. This isn’t to say that there may not be something to the ingredients in fish oils, as the REDUCE-IT trial showed a significant effect on cardiovascular outcomes in a specific population with a prescription-only, high-dose purified omega-3 fatty acid.
The authors note that folate’s benefit was driven by a single trial that evaluated its efficacy in China, where fortification is not done. Consequently the beneficial effects may not be relevant in countries like the US, where foods are routinely fortified.
Calcium and vitamin D, however, were associated with harm, including both stroke and heart attacks. This has been shown or hinted at in a few studies, suggesting that routine calcium supplementation in the absence of a medical need is probably not warranted and may in fact be harmful. Vitamin D on its own, however, at least hasn’t been shown to be harmful – but neither has it been shown to reduce the risk of cardiovascular disease.
For multivitamins, singly and overall, the authors restate the USPSTF 2014 statement that there is a lack of evidence to support the benefit of multivitamins to reduce cardiovascular disease or death.
The authors point out some important limitations that need to be considered when looking at the data:
    • There was a huge variation in the baseline characteristics of the different groups in the studies, including factors like age, sex, health and socioeconomic status.
    • There was a lack of dose-response analysis.
    • There was no stratification of these results by demographics or underlying medical disorders.
    • The certainty of evidence, overall, was very low.
Conclusion: No strong case for supplements
Reading studies of dietary interventions and supplements can be frustrating. The data is often poor, much of it is observational, and there are so many other variables that might possibly affect efficacy (e.g., product quality, baseline diets, accuracy of dietary recall) that identifying any signal in all this noise is inevitably going to be challenging. Reading this paper which focused on highly selected evidence, you may make one of the following assessments:
    • Dietary supplements don’t provide any meaningful benefits.
    • Dietary supplements haven’t been studied sufficiently or extensively enough to demonstrate the benefits that you believe exist, despite the lack of any convincing evidence.
    • The benefit of any dietary supplement, if it is real at all, is small in the context of all the factors that influence cardiovascular health.
In light of the overall evidence, I’m leaning towards the third assessment. If dietary supplements or specific dietary approaches had substantial effects on cardiovascular disease, we should have seen them consistently in the medical evidence. We do not. Consequently, it’s reasonable to assume that the overall benefit of individual dietary supplements or dietary interventions for cardiovascular disease has not been demonstrated, and that there is no solid evidence to support their use.

Fixing the supplement market for consumers
Scott Gavura on September 22, 2016
Link


When it comes to regulating and selling dietary supplements, should consumer interests be higher priority than those of manufacturers? While regulations are seemingly created to protect consumers, governments around the world have consistently given manufacturers the upper hand, prioritizing a company’s desire to sell a product over a consumer’s right to a marketplace with safe, effective products. Nowhere is this more the case than in Canada and the United States, where similar regulatory approaches have led to an industry boom and massive sales, but also a confusing marketplace for consumers and no persuasive evidence that all those supplements have any meaningful effects on our health. Drug store shelves in 2016 are packed with hundreds of products with unsubstantiated claims and untested products, and little credible information to guide selection. Since its beginnings, the contributors to this blog has been consistent in calling for more appropriate regulation: one that puts consumers first, not manufacturers, and evaluates all products (drugs, supplements or otherwise) with a consistent standard of science and evidence. Today, it looks like one regulator is preparing to move in that direction. Health Canada, Canada’s equivalent to the FDA, has proposed a new regulatory approach that is expected to block manufacturers from selling products with unsubstantiated and often misleading health claims. And they are asking for your input. Carly Weeks in The Globe and Mail writes:
Currently, natural health products are regulated in a manner similar to drugs – manufacturers must apply to Health Canada for a licence to sell and products are assigned a unique number that must appear on product labels to signal the department’s approval. But unlike drugs makers, natural health product manufacturers are not required to provide robust evidence that a product works before it’s allowed on the market.Under the proposed new system Health Canada would bring natural health products, over-the-counter drugs and cosmetics under one set of rules and regulate them based on the potential health risks they pose.The new regime would classify many vitamin, mineral and homeopathic products and cosmetics as “low risk,” meaning they would not be licensed by Health Canada. Manufacturers would still have to meet Health Canada’s quality standards, but they would be prohibited from making disease treatment or prevention claims on product labels. Any other claims on product labels would have to be accompanied by a disclaimer stating the information has not been verified by Health Canada.Products deemed “moderate” or “higher” risk – such as over-the-counter painkillers, allergy medications and products that contain new medicinal ingredients – would be reviewed by Health Canada and could only make health claims if enough scientific evidence is presented to prove the statements.
Treating products according to their risk, rather than their source, has the potential to be far more sensible from a scientific perspective than the status quo we see in Canada and around the world.
Why Canada lowered the evidence bar
Not too long ago, there was no such thing as a “natural health product” in Canada. Products were either drugs, and were registered as such, or they were food products, and drug regulatory requirements did not apply. A grey area existed and all kinds of supplements appeared – with no specific regulatory oversight, no defined quality or content standards, and no objective evaluation of the efficacy claims. In 2004, the Natural Health Product Regulations (NHPR) became a reality. They grouped together a disparate group of products: nutritional supplements, probiotics, traditional Chinese medicine, vitamins, herbal products, and homeopathy. Rather than fully regulating these products as drugs, or leaving them unregulated, the NHPR were a regulatory compromise. They introduced manufacturing quality, safety, labelling, importation, and distribution standards, while dramatically relaxing the standards for product efficacy claims. For example Health Canada’s Evidence for Homeopathic Medicines: Guidance Document (yes, it’s an actual document) states that applications for licenses for homeopathic products must include “evidence” to support the “safety, efficacy, and quality” of a homeopathic medication. Health Canada realized that given there’s no credible evidence to support homeopathy, it had to lower the evidence bar. So to Health Canada, anecdotes became evidence. Homeopathic manufacturers can use materia medica, which are essentially compilations of anecdotal information, to satisfy this requirement. Health Canada offers a list of 59 references it will accept, including texts that date back to 1834, which was three decades before germ theory was proposed. This is acceptable “evidence” today to earn Health Canada’s seal of approval.
Is there anything Health Canada won’t approve?
Health Canada’s absurdly low evidence standard was elegantly demonstrated by the television show CBC Marketplace in 2015. Having previously described how homeopathic remedies lack any medicine at all, they went one further, and decided to test Health Canada’s own licensing process. They applied for approval to market a homeopathic remedy they named “Nighton” (an anagram of “nothing”) to be used to treat fever and pain in infants and children. For evidence, they submitted a few pages photocopied from an old homeopathy textbook. No trials were conducted and no safety data was provided. Just some forms, a few photocopies and a fee. Without any questions, their product was approved and licensed as a “natural health product”, and for a time, was listed in the national database of health products Health Canada declared were “safe, effective, and of high quality.”
Industry wins, and consumers lose
After being embarrassed by the CBC, Health Canada finally acted. It announced new rules for homeopathic remedies marketed as cough, cold and influenza remedies (but ignoring the thousands of other homeopathic products had approved.) It prohibited any products for children 12 and under, unless those claims are supported by scientific evidence. That’s a significant change, and essentially created an impossible bar for homeopathy manufacturers.
Health Canada took action again when it was demonstrated (again by CBC Marketplace) that Canadian homeopaths were selling homeopathic “nosodes” as vaccine substitutes. A “nosode” is a remedy that starts with infectious material, like polio, measles or smallpox, and then it’s diluted sequentially until mathematically, there’s nothing left but water. Health Canada had approved 82 of these “nosodes” for sale over the years, and naturopaths and homeopaths were selling them as vaccine substitutes that were claimed to be “Health Canada approved”, which was technically true – but approval as a “natural health product” means completely different standards than actual medicine. It should be self-evident that fake vaccines are a public health problem. Canadian advocacy group Bad Science Watch launched a public campaign against nosodes, and succeeded in getting Health Canada’s agreement to force commercial manufacturers to place a label on their products stating “This product is not intended to be an alternative to vaccination.”
Putting warning labels on approved products to tell consumers that they really don’t actually work is a clumsy and possibly dangerous approach to regulation, and sidesteps the real issue: shaping a marketplace where consumers have good information to make their own self-care decisions. The picture below is from a retail pharmacy near me, where you can see homeopathic remedies shelved alongside real drug products for treating colds. All are approved for sale, but they are held to widely different regulatory standards – something that few consumers (and possibly even health professionals) understand:

Why the change?
In the explanatory document about the consultation, Health Canada explains the current problem frankly and accurately:
When shopping for a self-care product, you will often see various options grouped together on store shelves based on the condition for which they are intended to be used. For example, a wide variety of products for skin care may be grouped together or a number of different products for headache relief may sit next to each other on the shelf. Many of the products you see might make the same or similar claims about what they do and they may have packaging that all looks alike. These similarities may lead a consumer to believe that these products are equally effective and have had to follow the same rules and oversight to be allowed to be sold, but this may not be the case.
Based on definitions in legislation and regulations, Health Canada considers self-care products to be made up of three different product types:
    • Cosmetics, which are used for cleaning, improving or altering the complexion, skin, hair or teeth, such as moisturizing creams, deodorants, and shampoos;
    • Natural health products, which include vitamin and mineral supplements, probiotics, herbal preparations, homeopathic remedies, and traditional medicines (such as traditional Chinese medicines); and
    • Non-prescription drugs, also commonly referred to as “over-the-counter drugs” which include products for pain relief, cold and flu symptoms, and allergy relief.
Health Canada has different ways of overseeing the safety, efficacy, and quality of cosmetics, natural health products, and non-prescription drugs. By safety, we mean that the product will not be harmful or toxic when you use it according to the directions and warnings on the label. Efficacy refers to what the product is meant to do and is usually represented by a claim, e.g., “relieves headache”. A health claim is a description on the product about what it does in relation to someone’s health. Finally, quality means that the product is manufactured under controlled conditions and will be made properly.
And in this section, Health Canada finally acknowledges that homeopathy is magical thinking:
The level of evidence required for similar claims varies. Generally speaking, non-prescription drug claims require supporting scientific evidence. For natural health products, however, a wider range of supporting information is accepted for claims, ranging from scientific evidence to encyclopedias of health and wellness philosophies based on premises other than science. Health Canada’s practice of accepting other non-scientific information to support claims for natural health products is based on an attempt to recognize that these products are not the same as conventional drugs, and often have a basis in philosophies that support the general health benefits of some ingredients through means other than scientific standards. Some products, like traditional Chinese medicines, are based on thousands of years of use. Homeopathic products (also a type of natural health product) are grounded in homeopathy, a system that is not supported by science.
What this means for consumers is that a non-prescription drug and a homeopathic product could be making a similar claim (such as “relieves cough”) but only the claim on the non-prescription drug would be supported by scientific evidence. In our current system, this difference may not be clear to the consumer because there is no signal on the product label, so these products could appear to consumers as if they are equally effective.
This is exactly the situation we are in today. Products need proper labelling to ensure that consumers have the information they need to make evidence-informed health decisions. When consumers buy homeopathy thinking that they’re buying medicine, they’re wasting time and money, and may be putting their own health at risk.
What Health Canada wants to hear
There are three main proposals in this consultation:
Products of similar risk profiles would be treated in a similar manner: This ensure rules for bringing products to market are more consistent and easier to understand
The Department would review health claims based on a new definition. Companies would require scientific proof to support these health claims.
A risk-based approach to compliance and safety monitoring will continue. This allows Health Canada to take quick action to protect consumers
I really like the wording in this section of the consultation summary, and I wonder if someone’s been reading this blog in Ottawa:
Health Canada, as a science-based regulator, wants to make sure that Canadians can trust that a standard has been met when we authorize a claim. We want to support consumers in making informed choices in selecting and using self-care products by providing them with the necessary information to do so. This means a proposal that redefines what is currently considered a health claim and requiring scientific evidence to support these health claims. Under this proposal, only those claims that pertain to diagnosis, treatment, prevention, cure, or mitigation of a disease or serious health condition will be reviewed by Health Canada.
What this means is that non-medicine, like homeopathy, would no longer be reviewed and approved by Health Canada. And the manufacturer wouldn’t be permitted to make efficacy or treatment claims, as a result. Any claims would have to be supported by evidence, and held to the same standards as drug products. What Health Canada seems to prefer are more similar to the structure/function claims that you see in the United States. Examples of wording they would find acceptable would include:
    • Improves the look of acne scars
    • Moisturizes and nourishes the skin
    • Cleans teeth
    • Product A is 50% more effective than Product B
    • “Number one choice of dentists”
    • Source of omega-3
    • Generally supports health maintenance
    • Helps metabolize fat
    • Maintains healthy bones
    • Source of vitamin C
It’s this particular part of the proposal that I have the most problem with. Many of these statements are meaningless to consumers and health professionals alike. “Source of vitamin C” or “moisturizes the skin” is fair, but what does it mean that a product supports “health maintenance”? And how could a regulator approve a relative effectiveness claim, unless there’s actual evidence of efficacy to begin with? These types of claims need strict limits, otherwise Canada risks creating an American-style supplement market, where anything still goes.
The supplement industry hates the proposal: A good sign?
The supplement industry in Canada, represented by the Canadian Health Food Association, has launched a “NHPs are not drugs!” campaign. They’re ignoring the fact that this move is about labelling and information, not access, and they’re fighting to keep the lowered bar for efficacy claims. They’re intent on keeping the marketplace healthy – for manufacturers:
Our current pre-market approval system respects traditional values from many different cultures and allows Canadians freedom of choice and access to these important products. Changing the current NHP Regulations is trying to fix a system that is not broken. Natural health products shouldn’t be regulated like drugs. Natural health products are different in nature from drugs and must be treated differently.
They’re asking supporters to send the following letter to their Member of Parliament. Fill out your address and this letter will be auto-generated:
Dear XXXX:
As a constituent in your riding I was shocked to learn of a proposal from bureaucrats at Health Canada to take away consumer choice in natural health products. Our natural health products are just that – natural! They are not drugs and shouldn’t be regulated the same way as drugs.
Natural health products are safe and effective, and the current regulatory framework protects consumers and consumer choice. The proposal by bureaucrats throws out a world-class Canadian system brought in by Liberal Health Minister Allan Rock with all party support and a full year of parliamentary committee study.
As someone from your community, I am asking that you oppose this proposal and make my views known to the Minister of Health.
Add your own perspective to the consultation
Health Canada is accepting comments until October 24, 2016. You can complete a short survey here, and you don’t have to be Canadian. The supplement industry can be expected to lobby hard to keep the status quo. I’m encouraged by the direction Health Canada is signalling here. The proposed approach isn’t perfect, but will go a long way to clearing the confusion the current regulations have created for consumers. If you care about science-based medicine, take a few minutes and complete the survey today. 

A Call for Caution on Antioxidant Supplementation
Antioxidants have gotten a lot of press here on SBM; this post digs a little deeper into the basic science of antioxidants, and the importance of understanding more than just one part of a complex biological system before you interfere with it.
Justin Quiles on October 23, 2018
Link

[Editor’s note: A recent health issue has prevented Harriet from writing her usual Tuesday morning post; instead, here is an overview of some interesting basic science from PhD candidate Justin Quiles on the impacts and complexities of oxidative stress and its relation to health.]
Most of the health-conscious population can recognize the terms “antioxidant” and “free-radical”. In fact, you may have recently heard these buzzwords (in the absence of much science) when a Bai or Vitamin Water commercial interrupted your favorite television show. If not, maybe you know someone who has used this terminology to absolve themselves from the guilty pleasures of excessive red wine or dark chocolate. All jokes aside, while it is true that sufficient dietary intake of antioxidant vitamins and minerals is essential for optimal human health, emerging research indicates that too much of a good thing is in fact bad – a biochemical phenomenon known as reductive stress.
Redox reactions, oxidative stress and aging
The transfer of electrons between molecules is a fundamental aspect of cellular biochemistry. While oxidation describes a loss of electrons, reduction refers to a gain. Importantly, these complementary processes, collectively known as redox reactions, constantly occur in tandem to maintain life. Indeed, redox biochemistry explains how plants release the oxygen we breathe (photosynthesis), which in turn enables us to transform the food we eat into energy (oxidative phosphorylation).
Paradoxically, molecular oxygen (O2) is both essential and detrimental to human (and other) life. During oxidative phosphorylation, O2 is reduced to H2O as energy is produced in the form of adenosine triphosphate (ATP). However, during this very same process, O2 can accept electrons and become transformed into a variety of reactive oxygen and nitrogen species (ROS/RNS), toxic metabolic intermediates that damage DNA, degrade cell membranes, and impair protein function. Several key environmental and metabolic ROS/RNS byproducts are outlined below:
In the 1950s, these abstract chemical reactions reached the forefront of biomedical research as Denham Harman developed his Free Radical Theory of Aging, which suggested that an accumulation of oxygen-derived radicals (namely superoxide) causes or contributes to the cellular damage associated with progressive aging. Over time, this theory has been expanded to encompass additional reactive species that function as pro-oxidants, and has been supported by studies from a number of independent laboratories. While the intracellular sources, relative proportions, and biological targets of ROS/RNS remain an intense matter of debate, nearly six and half decades of research built upon Dr. Harman’s original hypothesis has led to a general consensus that oxidative stress contributes to aging and pathological conditions such as cancer, neurodegeneration, diabetes, and cardiovascular disease.
Exploiting antioxidants to combat oxidative stress
Fortunately, our cells possess an internal defense mechanism to nullify harmful oxidants. These molecules are aptly named the endogenous antioxidants. Encoded within our DNA, endogenous antioxidant proteins can be either enzymatic (i.e. requiring a cofactor for function) or non-enzymatic. In addition to these endogenous molecules, exogenous antioxidants, those not produced within the body, are regularly consumed through a well-balanced diet. A non-exhaustive list of critical endogenous and exogenous antioxidants can be found below (many of which you will likely recognize as vitamins):
Increasing evidence for oxidative stress in human disease and aging led researchers to develop experimental animal models in which endogenous antioxidant genes were manipulated to enhance their function (i.e. genetic overexpression). Despite promising results in lower organisms such as Caenorhabditis elegans (roundworms) and Drosophila melanogaster (fruit flies), overexpressing endogenous antioxidants in mice, our best non-human model for genetic studies, didn’t help them live longer. However, the overexpression of particular endogenous antioxidants was sufficient to improve health outcomes in mouse models of myocardial infarction (heart attack), diabetes, stroke, and Alzheimer’s disease (among others) suggesting that strategies designed to increase antioxidant abundance during these disease processes could potentially provide a level of protection in humans.
These observations in mice led to a battery of clinical trials in which varied combinations and proportions of exogenous antioxidants (most frequently vitamins) were administered to diverse patient populations in an effort to prevent or treat cancer, cardiovascular disease, and macular degeneration. Sadly, despite massive efforts involving thousands of patients and millions of dollars in grant money, the outcome of these trails was emphatically abysmal. As summarized by the National Institutes of Health (NIH), the primary funding agency for much of this work, antioxidant supplementation did not reduce risk of heart attack, stroke, cataracts, and age-dependent cognitive decline. In fact, in two separate studies, exogenous antioxidant supplementation actually increased the incidence of lung and prostate cancer.
So, why did antioxidant supplementation fail these patients? While there is no clear-cut answer to this question, the NIH has listed two key considerations raised by several research groups. First, “The effects of the large doses of antioxidants used in supplementation studies may be different from those of the smaller amounts of antioxidants consumed in foods”. Surely, anyone who has taken a multivitamin has noticed the absurd percent daily value (% DV) associated with just one serving. Next, “under some circumstances, free radicals actually may be beneficial rather than harmful, and removing them may be undesirable”. At first, this notion may seem contradictory to what you’ve been reading throughout this piece. However, despite the toxic effects of abnormally elevated ROS/RNS, basic science has shown us that within an appropriate physiological range, some of these molecules facilitate critical cellular functions. For example, the powerful oxidant hydrogen peroxide (H2/sub>O2, which you should not drink), has emerged as an important signaling molecule involved in cell division, growth, and inflammation. Interestingly, at low levels, H2O2 can stimulate the endogenous antioxidant system and actually help offset the harmful effects of stress. Thus, completely abolishing ROS/RNS through excessive antioxidant supplementation appears to be a poor strategy for improving health.
Reductive stress: An emerging phenomenon in human disease
Found on the opposite end of the redox spectrum, reductive stress is often characterized by a loss of physiological (healthy) ROS/RNS signaling and/or surplus of antioxidant molecules. Albeit far less studied than oxidative stress, reductive stress has recently been demonstrated in the development of neurological and cardiovascular disorders as well as cancer. Recently, those at risk for Alzheimer’s disease were shown to exhibit reductive stress, suggesting that antioxidant overabundance may serve as a useful diagnostic tool to help clinicians predict disease progression in these patients. In a heritable model of cardiomyopathy, high levels of antioxidant activity led to enlarged and dysfunctional hearts. In both the brain and heart, two highly oxidative tissues with minimal regenerative capacity, reductive stress is associated with the accumulation of toxic protein aggregates which presumably drives the eventual death of the cells in advanced stages of disease.
Unlike the non-dividing cells of the brain and heart, reductive stress apparently enhances the growth and survival of some particularly aggressive cancer cells. In response to chemotherapy, cells often reprogram their genes to enhance the expression of endogenous antioxidants in a feeble attempt to remove toxic byproducts of anticancer compounds. With successive drug administration, the goal is to eventually overwhelm and destroy these adaptive cells. While this works in some cases, several malignant cell types have developed ways to chronically boost their endogenous antioxidant defense system and become stubbornly resistant to chemotherapeutic agents. This can occur through the Keap1-Nrf2 signaling pathway.
Nrf2 is regarded as a master activator of endogenous antioxidant gene expression. In response to harmful ROS/RNS buildup, Nrf2 has the ability to promote the production of dozens of antioxidant proteins within the cell. However, in the absence of stress, the function of Nrf2 is inhibited by its binding partner Keap1. Cunningly, several tumor types have evolved to harbor DNA mutations in either Nrf2 or Keap1 such that endogenous antioxidant genes expression is always turned up to 11. Strikingly, in addition to appearing to accelerate cancer progression, four children suffering from undiagnosable disorders were recently found to possess Nrf2 mutations, in the genes controlling Nrf2, leading to its unrestricted activation. In these patients, sustained Nrf2 activity caused “an early onset multisystem disorder with failure to thrive, immunodeficiency and neurological symptoms”.
In spite of these reports, there are a number of laboratories persistently working to discover new pharmacological agents capable of enhancing Nrf2 activation. Sulforaphane, one such compound likely to be sold at your local supplements store, is currently being tested in clinical trials for prostate and lung cancer. While exogenous supplementation may be beneficial in some cases, the pathological evidence for oxidative and reductive stress suggest that additional research is needed to determine the optimal situation for antioxidant intervention. Indeed, careful consideration should be given when deciding on antioxidant regimens as these supplements are certainly not a guaranteed panacea for human health.
Take home message
By no means does this piece negate the decades of conclusive research illustrating the important protective role of antioxidants in cell biology. Rather, I hope this post helps convince you to be skeptical of the concept of antioxidants, and raise awareness of the under-appreciated reductive stress, in the field of biomedical research, and spread awareness to those regularly prescribing or consuming exogenous antioxidant supplements. Although many vitamins and minerals can be assessed by routine blood panels, I suspect that these values fluctuate considerably, and are not examined rigorously over time within most patients. Furthermore, the complex cross-talk among metabolic pathways makes it difficult to develop firm conclusions from any one single measurement. However, inferring redox status (e.g. oxidative vs reductive) from ratios of endogenous antioxidants such as glutathione may provide more useful diagnostic information. Hopefully, future research along these lines will look into stratifying patients according to their individual redox status, ideally leading to safer recommendations when it comes to antioxidant supplementation.

Increase In Supplement Poisonings
Current supplement regulations in the US (and many countries) are overtly anti-consumer and pro-industry, and are the direct result of aggressive industry lobbying and having powerful senators in their pocket. The rise in calls to poison control for supplements are just one manifestation of this situation.
Steven Novella on July 26, 2017
Link
One of the core points that we try to promote on SBM is that everything potentially is a toxin. Sola dosis facit venenum – the dose makes the poison – is an adage credited to Paracelcus about 500 years ago. This works both ways – in high enough dose, anything can be a poison, and in low enough dose, anything can be safe. Dosage is everything.
When we refer to things as being toxic or non-toxic, these are relative designations. Something is toxic if it potentially causes bad effects in doses that someone is likely to be exposed to. And something is non-toxic if it can be safely used without being exposed to toxic doses.
Pharmaceuticals are also mainly determined by dose. A drug is a substance that has a biological effect that can be exploited for useful purposes in a dose range that causes acceptable side effects. If the same dose that lowers your blood pressure also destroys your kidneys, that is not a useful drug that will make it to market. It takes on the order of magnitude of $100 million to determine if a substance has that useful dose range.
All drugs are toxins – it is their rational use in targeted patients at highly controlled doses that makes them medicine.
Supplements
What, then, are supplements? “Dietary supplement” is a regulatory term more than a scientific one. The FDA defines a dietary supplement as:
A dietary supplement is a product intended for ingestion that contains a “dietary ingredient” intended to add further nutritional value to (supplement) the diet.
However this is misleading. That is what the definition should be, including vitamins, minerals, and food concentrates or extracts. These are substances taken for their nutritional value. However, the Dietary Supplement Health and Education act of 1994 (brought to you in part by Orrin Hatch from the home state of the supplement industry) engaged in a stunning bit of legislative legerdemain. They snuck in “herbs and botanicals” onto the list of dietary supplements.
This is a brazen deception, because herbs and botanicals are not taken for their nutritional value, no matter what the FDA is legally forced to say. Herbs are taken for their pharmacological effects. Just look up any popular herbal product and see how they are described. I searched for the top ten herbal products, and Prevention.com listed turmeric at the top of their list, writing:
A heaping helping of curry could relieve your pain. That’s because turmeric, a spice used in curry, contains curcumin, a powerful anti-inflammatory that works similarly to Cox-2 inhibitors, drugs that reduce the Cox-2 enzyme that causes the pain and swelling of arthritis, says Lee.
It doesn’t get any clearer than that – they are describing a drug. Oral curcumin supplements are likely worthless by the way, (and IV curcumin possibly lethal) because of low bioavailability. Further, claims are based almost entirely on flawed bioassays, and not actual clinical evidence. If herbs and botanical are drugs, why are they regulated as if they are vitamins? That’s a good question.
Like all drugs, being a useful medicine means there is a dose range in which the substance has a beneficial or useful biological effect with acceptable side effects. Do the most common herbal products have such a dose range? No one knows, because they are not required to provide the kind of scientific evidence that would allow for such a determination. Instead, the public is assured that these substances are safe because they are “natural” and because of traditional use. Neither of these are a reasonable assurance, however.
The result is that the public is lulled into a false sense that herbs are safe. They falsely think they are properly regulated, and that they would not be sold (especially in pharmacies) if they weren’t generally safe. This disconnect between public perception and reality is a dangerous situation, and use of herbs has led to significant health harms.
Rise in supplement toxicity
A recent study published in the Journal of Medical Toxicology tabulates the “out-of-hospital dietary supplement exposures reported to the National Poison Data System from 2000 through 2012.” They found:
There were 274,998 dietary supplement exposures from 2000 through 2012. The annual rate of dietary supplement exposures per 100,000 population increased by 46.1% during 2000–2002, decreased 8.8% during 2002–2005, and then increased again by 49.3% from 2005 to 2012. These trends were influenced by the decrease in ma huang exposures starting in 2002.
The steady rise in toxic exposures to supplements was interrupted briefly when ma huang and other substances containing ephedra were banned by the FDA in 2003. This was based on 16,000 reports of adverse events, including 155 deaths. To my knowledge this is the only such banning of an herbal product by the FDA since the 1994 DSHEA legislation. This shows that proper regulation can have a beneficial effect, protecting the public from the harmful effects of these essentially unregulated drugs.
Energy products (such as drinks containing yohimbe and caffeine) still account for the majority of adverse events from toxic exposure to “supplements.” These products can cause cardiac arrhythmias, seizures, and even death.
In the study 60% of calls were for children under 6 (who, unsurprisingly, should not be consuming energy drinks) who had accidental exposures. However, 95% of the serious adverse outcomes occurred in those 6 years or older. In the older age groups more exposures are also intentional, 65% in teens and 40% in adults. So a large percentage of the serious adverse outcomes were due to intentional use of herbal products.
Poor quality control
The false assurance of safety based on the notion that these products are “natural” results in deeper problems as well. The supplement industry is generally poorly regulated. Supplements often contain contaminants, unlisted fillers, and even use fillers to substitute for the alleged active ingredients. You may think you are getting Gingko, but in fact you’re getting alfalfa and rice flour. Some of those substitutes may cause allergies. Supplements often have drug-drug interactions. Ingredient levels vary incredibly. Bioavailability is anyone’s guess. Supplements also often illegally and secretly contain real drugs.
So, even if an herbal product has some beneficial effect in highly controlled clinical trials, where barcoding is used to assure purity and dosage is carefully measured, you cannot apply these findings in the real world. When you buy an herbal product you essentially have no idea what you are getting.
There documented case of mislabeling and inappropriate use leading to serious toxicity. For example:
In Belgium in the early 1990s, the TCM herb Stephania tetrandra was used for weight loss. Aristolochia fangchi was mistakenly used instead, and this resulted in more than 100 cases of renal failure and more than 20 cases of urothelial dysplasia. Similar problems were later reported in the UK. The culprit is thought to be the aristolochic acid found in Aristolochia fangchi. In TCM practice, Stephania tetrandra and Aristolochia fangchi were never meant to be used for weight loss.
Herbs are drugs
None of this is to say that herbal products are more or even as potentially toxic as prescription drugs. I think in general herbs and botanicals are less toxic than prescription drugs because they have lower dosage and lower bioavailability. These features also lower the potential for a beneficial effect, however – they go hand-in-hand.
My real point is that herbs are drugs. Do not be deceived by the massive lobbying and propaganda campaign of the supplement industry. The notion that herbs are “natural” means literally nothing. Anecdotal evidence from traditional use is also a poor guide. Unless you track toxicity closely, you will notice only the most immediate and obvious toxic effects, and you will have no idea about any long-term or chronic effects.
The only facts that matter are those that relate to the pharmacological properties of herbs and botanicals. What is their therapeutic window, what are the active ingredients, their doses, bioavailability, half-life, routes of elimination, purity, consistency, and drug-drug interactions? This is the kind of information you discover when you do careful scientific research into the properties and biological effects of herbs and/as drugs. You can know these things when an industry is properly regulated for quality control and transparency.
Instead of knowledge, information, and transparency, the supplement industry offers deceptive marketing about being “natural.” They misinterpret basic science, ignore major concerns about their products, and half the time don’t even respond to FDA inquiries about their alleged deficiencies.
Current supplement regulations in the US (and many countries) are overtly anti-consumer and pro-industry, and are the direct result of aggressive industry lobbying and having powerful senators in their pockets. The rise in calls to poison control for supplements are just one manifestation of this situation. The fix is also pretty clear. We simply need to regulate the industry the way the public wants and thinks they already are being regulated.

Supplements and Herbs

A “Natural Cure” for Eczema Leaves a Young Child in Agony…..
Clay Jones on September 25, 2015
Link


A short post today, for me at least, but an important one to file away for the next time somebody asks “What’s the harm?” during a discussion on the use of irregular medicine in the care of pediatric (or any) patients.
The case
The September 2015 issue of Pediatrics in Review, the official American Academy of Pediatrics source for continuing medical education, contains a case report that should be of particular interest to readers of Science-Based Medicine. The authors, pediatricians at Children’s Hospital at Albany Medical Center, describe the ordeal of a six-year-old boy, previously healthy except for eczema, suffering with lower extremity pain to the point of crying with attempts to walk or to even bear weight. For those of you who don’t have experience with children of this age, it takes a considerable amount of discomfort or disability to interfere with their determination to remain in a near constant state of motion. Refusal to bear weight is a red flag that we take very seriously as the cause in a young child is often serious, ranging from traumatic injuries and severe infections of the bones or joints to diagnostic dilemmas such as leukemia and juvenile rheumatoid arthritis.
In addition to his pain, which had been steadily worsening over the twelve days prior to seeking care at the authors’ facility, his family was concerned about his malaise (extreme fatigue), nausea, poor appetite, and unusually dry lips that were cracked and bleeding. A preliminary evaluation by his primary care pediatrician at the onset of his symptoms was reasonable, ruling out the more common possible etiologies, yet was ultimately unfruitful.
The eventual finding of a significantly elevated serum calcium level, as well as the overall presentation of his symptoms, was concerning for cancer but labs and imaging, including bone marrow biopsy, CT of the brain, and MRI of the spine, were normal. A nuclear medicine study called a bone scan revealed abnormally elevated uptake of technetium-99m in his long bones, which was a clue for a endocrine abnormality. This led to additional but also unhelpful laboratory tests.
Meanwhile, initial attempts to treat the child’s increased blood level of calcium with hydration and a medication that inhibits the indirect bone resorbing activity of parathyroid hormone failed. His calcium level, and thankfully his symptoms, did respond once he was treated with a bisphosphonate and a strong diuretic. Bisphosphonates bypass parathyroid hormone and directly inhibit the activity of osteoclasts, cells vital to the healthy maintenance of our bones and in regulating levels of important minerals in our blood. It’s not a commonly prescribed medication in kids.
The reveal
Although the patient was recovering, it appears that the team was at a loss until the child’s parents revealed a game-changing piece of information later in the admission. Six months before his pain and other worrisome symptoms began, they had sought treatment for his eczema from a “natural health practitioner.” He had been prescribed a number of supplements containing vitamin A, one with a whopping 39,000 IU per pill. He had vitamin A toxicity.
Vitamin A toxicity in a healthy child living in the United States is rare as hen’s teeth. I doubt that the team would have figured it out without the (better late than never) disclosure by the family. Even checking vitamin A levels in the blood, which would normally result in a discussion of which member of the genus Equus is most likely to be the source of audible hoofbeats, might not have led to a lucky catch because they don’t correlate well with tissue levels.
The recovery
The patient responded to medical management, cessation of his dangerous supplement regimen, and a diet that limited his calcium and vitamin D intake. His recovery was not easy, however, as he needed physical therapy for persistent weakness that lasted for months. During his hospitalization, he underwent numerous blood draws and aspiration of his bone marrow for testing. He was also exposed to significant amounts of ionizing radiation and likely required sedation for either his bone marrow biopsy, his spine MRI (which can take over an hour), or both. He was treated with medications having significant, although unlikely, potential side effects. All of this because some irresponsible and poorly-educated quack thought it appropriate to prescribe supplements to a young child.
Vitamin A, what is it good for?
Vitamin A is an interesting chemical, and one traditionally associated with vision in the minds of the public and medical professionals. The ancient Egyptians first made the association between improved vision at night and eating animal liver but Swiss researchers first isolated and named vitamin A. We now recognize two primary forms of the compound: provitamin A carotenoids found in green leafy vegetables and carrots, beta-carotene being the only one metabolized by mammals, and the more active preformed vitamin A found in animal sources such as liver and egg yolk. Preformed vitamin A compounds, such as retinol and retinoic acid, are also typically used in drugs and supplements like the ones taken by the poor victim in the above case.
Provitamin A, even when ingested in large quantities, is generally felt to be incapable of causing toxicity. Our bodies must convert beta-carotene into active vitamin A, a process which is tightly regulated such that intake above a certain level causes a negative feedback inhibition. I once cared for a young infant who was being fed only 100% carrot juice because of religious beliefs pertaining to proper nutrition. The diffusely edematous and orange infant had a severe deficit in protein despite adequate calories, a condition known as kwashiorkor, but did not suffer any ill effects related to excessive vitamin A intake. Animal or synthetic sources of preformed vitamin A on the other hand are already highly active and can easily lead to toxic effects because there is no mechanism of feedback inhibition.
Vitamin A plays an important role in numerous biological functions, with vision being the most well known. Appropriate levels of vitamin A prevent pathologic dryness of the eye and surrounding tissues, a condition known as xerophthalmia, which is a leading cause of preventable blindness in developing countries. Vitamin A is also pivotal in the process of phototransduction, the conversion of light into electrical signals to the brain. Two photoreceptor cells, rods (motion and nightvision) and cones (light and color vision in bright light), require derivatives of vitamin A for proper function. Vitamin A is also important in cell health and growth, particularly in the skin and bone marrow, as well as immunity, bone metabolism, reproduction, and prenatal development.
Deficiency of vitamin A isn’t something we deal with much in the United States and other developed nations, although conditions that can result in poor absorption of fat, such as cystic fibrosis and Crohn’s disease, put some patients at risk. Sadly, deficiency is far from a rarity in the rest of the world where each year half a million infants and toddlers lose their vision because of a lack of dietary sources. Many of these children die. Efforts at providing supplementation to at-risk children are ongoing, but there are misinformed activists fighting against our most promising advances in the prevention of blindness and death in resource-poor regions.
Too much of a good thing
Excessive vitamin A intake leading to toxicity is also rare, and is likely even less common than deficiency in developed countries although data on prevalence is lacking. There are no disease states that predispose patients to toxicity. As stated earlier, we get vitamin A from our diet in the form of certain plants (provitamin A) and animal products (preformed vitamin A), but it is difficult to overdose through diet. It isn’t impossible though. Vitamin A is primarily stored in the liver, and consumption of that organ harvested from some animals, such as polar bears and seals, can cause severe acute illness and even death.
How much vitamin A we should get daily is a bit complicated because it depends on where it comes from. A much smaller amount of preformed vitamin A from animal organs or supplements is acceptable compared to a relatively large amount of plant-derived beta-carotene, which must be converted to an active form. Just giving an amount in international units (IU) can be confusing if you don’t know the source. Daily allowances are usually measured in micrograms of retinol activity equivalents (RAE) that take into account biologic activity. Since beta-carotene really never leads to toxicity, we only have to worry about preformed compounds that come in supplements and drugs.
Toxicity, when it occurs, usually results after the ingestion of vitamin supplements containing amounts well above the recommended intake for long periods of time. Although the amount that will consistently result in symptoms is variable from person to person, as expected it takes less to cause damage in children than in adults. Daily intake of 3,000 IU or 900 micrograms RAE is considered the upper limit for safe daily intake in a 6-year-old child. Intake of 1,500 IU/kg body weight of preformed vitamin A (recommended daily allowance would be around 1,000 IU total in kids if all they got was the preformed compound) would be very likely to lead to toxicity in our patient, who received almost 2,000 IU/kg every day for six months from his bogus eczema treatment.
Acute toxicity can cause nausea and vomiting, dizziness, and blurry vision. Severe cases can result in effects on the central nervous system with resulting excessive tiredness and headache. The skin is also often involved in acute toxicity, becoming dry, sometimes painfully so, with cracked lips that can bleed. Longer term excess intake tends to affect the liver, bone, brain, and muscle leading to a variety of impairments including the presentation seen in the above case.
Vitamin A for eczema?
Vitamin A does play a role in the health of our skin. A deficiency can cause overgrowth of the outer layer of the skin and loss of hair follicles. But it doesn’t cause eczema. And even if it did, deficiency is extremely rare here in the United States.
Extremely high oral doses of chemicals closely related to vitamin A called retinoids are frequently used to treat severe cystic acne and psoriasis. Although the mechanism of action isn’t fully understood, the hypothesis is that the retinoids induce the death of sebaceous glands and a reduction in the amount of sebum, an oily secretion believed to play a large role in the pathophysiology of acne. The side effect profile of these medications is rough and as expected includes extremely dry and fragile skin. It is, essentially, purposeful and controlled vitamin A toxicity.
The use of megadoses of vitamin A to treat eczema, an allergic condition infamous for its pathologically dry and irritated skin manifestations, is absurd and potentially very dangerous. High-dose topical formulations of vitamin A derivatives, such as Retin-A, are also used to treat acne and can also cause severe skin reactions that would mimic and certainly exacerbate existing eczema. And there is no good evidence to support even the use of lower dose vitamin A-containing moisturizers for eczema in children.
Yet there are multiple online “resources” recommending the use of vitamin A for eczema, such as this nonsense from a nutraceutical company informed by a “team of naturopathic physicians.” WebMD lists eczema as a condition treated with vitamin A as well. And Orthomolecular Hall of Fame member Patrick Holford BSc, DipION, FBANT, NTCRP (I kid you not) loves vitamin A for eczema. There are so many more but I’ll stop there.
Conclusion: Harmful nonsense is harmful
There is a reason why Science-Based Medicine comes down so hard on practitioners of alternative medicine. And naturally we are particularly concerned about those who feel that they have the expertise to care for pediatric patient. This case is a perfect example.
Young children don’t have the ability to understand the complex variables involved in healthcare decisions and are helpless when their caregivers make poor choices based on misinformation and unscientific world views. This child should not have had to go through such an ordeal because there should not have been a “natural health practitioner” allowed to take part in his care. Unfortunately, fixing that problem is an uphill if not unwinnable battle so we must focus instead on education of the public and the prevention or removal of legislation that places children at greater risk.
        ◦ s

   High dose vitamin C and cancer: Has Linus Pauling been vindicated?
David Gorski
Link
THE ZOMBIE RISES AGAIN
Vitamin C as a treatment for cancer is back in the news again.
I’m not surprised. This is one therapy favored by advocates of “alternative” medicine that keeps popping up periodically (seemingly every couple of years or so). This latest bit of news has turned up almost right on time after the last time there was a push for rehabilitating vitamin C as a cancer cure a couple of years ago. Back in the spring of 2006, there were two studies published (more on them later) which were touted by the “complementary and alternative medicine” (CAM) crowd as evidence that Linus Pauling was supposedly vindicated. A little less than two weeks ago, an animal study was published suggesting that high dose intravenous vitamin C had antitumor activity in mouse models. A couple of weeks prior, there had also been published a phase I clinical trial that showed that megadoses of IV ascorbate were safe and well-tolerated in cancer patients if they were appropriately screened for renal disease. Given the latest studies of this particular modality against cancer, it seemed like an opportune time for me to examine this new evidence and ask the question: Has Linus Pauling been vindicated?
I’ll cut to the chase. The short answer is: Not really, with the qualification that it depends on what you mean by “vindicated.” The long answer follows.
THE NOBEL DISEASE
It’s been noted that there appears to be a tendency among Nobel Prize recipients in science to become enamored of strange ideas or even outright pseudoscience in their later years. Indeed, it’s happened often enough that some wags have dubbed this tendency the “Nobel disease.” Be it Linus Pauling and his obsession with vitamin C, Nikolaas Tinbergen and his adoption of the “refrigerator mother” hypothesis as the cause of autism (which has led one blogger going by the ‘nym Prometheus to quip that Tinbergen’s Nobel acceptance speech represented a “nearly unbeatable record for shortest time between receiving the Nobel Prize and saying something really stupid about a field in which the recipient had little experience”), or Louis J. Ignarro going from a Nobel Prize in Medicine for his work in figuring out nitric oxide signaling pathways to pushing his book on arginine supplementation as a cure-all for heart disease and becoming a shill for Herbalife, there’s something about becoming a Nobel Laureate that has a tendency to lead people to becoming cranks. Either that, or maybe it’s because mavericks who make Nobel-worthy discoveries have a tendency not always to recognize that not all of their ideas are as brilliant as the ones that garnered the Nobel Prize for them, although certainly another possibility is that winning the Nobel Prize tends to give some scientists an inflated sense of their own expertise in fields of science not related to the ones for which they won their Nobel Prize in the first place. Maybe it’s a bit of all of these.
LINUS PAULING’S DESCENT INTO PSEUDOSCIENCE
Be that as it may, the concept that megadoses of vitamin C can cure cancer has been around for decades now, ever since two-time Nobel Laureate Linus Pauling first proposed it. It began in 1972, when Ewan Cameron hypothesized that ascorbate could have anti-cancer action by inhibiting hyaluronidase and thereby preventing cancer spread after two-time Nobel Laureate Linus Pauling had first proposed that taking 1,000 mg of vitamin C daily can reduce the incidence of colds by 45% for most people. It wasn’t long before the two teamed up, and in 1976 Pauling and Dr. Ewan Cameron reported that a majority of 100 terminal cancer patients treated with 10,000 mg of vitamin C per day survived three to four times longer than patients who were not so treated.
Unfortunately, as experimental clinical protocols go, this study was a complete mess. Linus Pauling was not a clinician and had no experience in clinical trial design, and it really showed. Even as a restrospective analysis, the paper was a total embarrassment. There was no standardization, no good matching of controls by age, stage of cancer, or performance status; given the terrible design, there was clearly serious selection bias going on at a minimum. The study’s flaws, which were too numerous to mention, rendered its results essentially meaningless. If you want a quote from his original paper that shows this better than anything, here it is: “We believe that the ascorbate-treated patients represent a random selection of all the terminal patients in the hospital, even though no formal randomization process was used.” Suffice it to say that, in a clinical trial, it is not sufficient to “believe” that your groups were properly randomized and matched. You have to show it. Indeed, Dr. William D. DeWys, Chief of the Clinical Investigations Branch of the National Cancer Institute’s Cancer Therapy Program, pointed out that Pauling and Cameron failed at even a rudimentary effort to control for these variables:
Cameron’s patients began getting vitamin C when Cameron judged them “untreatable” and their subsequent survival was compared to that of the control patients from the time they had been labeled “untreatable.”
DeWys reasoned that if the two groups were comparable, the average time from the initial diagnosis to “untreatable” status should be similar for both groups. But they were not. He concluded that many of Cameron’s patients had been labeled untreatable earlier in the course of their disease and would therefore be expected to live longer. DeWys also noted that more than 20% of the patients in the control group had died within a few days of being labeled untreatable, whereas none of Cameron’s patients had died. This, too, suggested that Cameron’s patients had had less advanced disease when they were labeled untreatable.
The bottom line was that, for the above reasons and others, Pauling and Cameron’s study was shockingly bad. Undeterred, they published a followup study in 1978 that purported to confirm the findings of their 1976 study. It was little better. Pauling and Cameron used many of the same patients and selected a different control group, but the patients were still not matched for stage of cancer, age, or performance or nutritional status. It, too, was a shockingly poorly designed study, even for a retrospective study.
Three decades later, I have to wonder how these studies saw print. It turns out that they were originally published in the Proceedings of the National Academy of Sciences, which is not a clinical journal. Not surprisingly, given his Nobel Prizes, Linus Pauling was a member of the National Academy of Sciences. What is not really known much outside the scientific community is that thirty years ago members of the NAS could contribute papers to PNAS as they see fit and in essence pick their reviewers. Indeed, until recently, the only way that non-members could have papers published in PNAS was if a member of the Academy agreed to submit their manuscript for them (known as “communicating” it), and, in fact, members were supposed to take the responsibility for having such papers reviewed before “communicating them” to PNAS. Thus, in essence a member of the Academy could get nearly anything he or she wished published in PNAS, whether written by him or herself or a friend. Normally, this ability has not been such a big problem for quality, because getting into the NAS is so incredibly difficult and only the most prestigious scientists are invited to join. Consequently, PNAS is still a highly prestigious journal with a high impact factor, and most of its papers are of high quality. Scientists know, however, that sometimes Academy members use it as a journal of last resort to publish some of their leftover findings. They also know that on occasion, when rare members fall for dubious science, as Pauling did, they can “communicate” their questionable findings and get them published in PNAS unless they’re so outrageously ridiculous that even the deferential editorial board can’t stomach publishing them. All they have to do is to find a couple of sympathetic colleagues to review their manuscripts and then submit them. What keeps the overall quality of most of the journal’s articles high is primarily the desire of members of the Academy not to sully their names by communicating papers that they consider to be poor quality science. These days, submission requirements for PNAS are more rigorous, whether that manuscript is submitted by the member or “communicated” to the journal for another investigator. Even so, getting a paper published in PNAS is quite easy for an Academy member and incredibly difficult for a non-member who does not have the connections that allow him to line up an Academy member willing to act as referee and thus is forced to submit his manuscript directly to the journal. These observations largely explain how Linus Pauling could submit such shoddy studies to PNAS and have them published. (Thus endeth my chance for ever getting a manuscript of mine published in PNAS. Probably.)
Eventually, three different randomized trials of high dose vitamin C used to treat cancer were carried out by the Mayo Clinic. The first study was published in the New England Journal of Medicine in 1979, and Pauling was not pleased. He wrote a letter to the editor complaining that most patients had had extensive prior chemotherapy, which in his view meant that they wereimmunologically compromised. Given that his concept was that high dose vitamin C somehow boosted the immune system, he thought it was an unfair trial, even though his first trial had pointed out that the patients undergoing vitamin C treatment had received standard therapy, including surgery, radiation, and chemotherapy as appropriate. This was followed by two other randomized clinical trials, which when coupled with the first trial, involved 367 patients and failed to find a benefit from high dose oral vitamin C in cancer. Meanwhile, some studies were pointing out that high dose ascorbate was not without adverse reactions, including diarrhea, and even renal failure after high dose IV administration. Since then, among conventional oncologists at least, vitamin C as a therapy for cancer has been viewed as having no value.
It is highly doubtful that the concept that vitamin C might cure cancer and other diseases would ever have been taken as seriously as it was for as long as it has been had it not been championed by a scientific figure as towering as Linus Pauling. Unfortunately, in his zeal, Pauling popularized his ideas not primarily by publishing in scientific journals, but mostly by writing books, giving talks, and forming his own insitute to do experiments designed to prove his ideas. Another sure sign of a zealot, Pauling couldn’t tolerate data that contradicted his belief in vitamin C. Indeed, when data from the experiments of a colleague at his institute, Arthur Robinson, suggested that vitamin C at the doses advocated by Pauling might actually increase the rate of tumor growth in an experimental model in mice:
Robinson, a former student and long-time associate of Pauling, helped found the institute and became its first president. According to an investigative report by James Lowell, Ph.D., in Nutrition Forum newsletter, Robinson’s own research led him to conclude in 1978 that the high doses (5-10 grams per day) of vitamin C being recommended by Pauling might actually promote some types of cancer in mice [18]. Robinson told Lowell, for example, that animals fed quantities equivalent to Pauling’s recommendations contracted skin cancer almost twice as frequently as the control group and that only doses of vitamin C that were nearly lethal had any protective effect. Shortly after reporting this to Pauling, Robinson was asked to resign from the institute, his experimental animals were killed, his scientific data were impounded, and some of the previous research results were destroyed. Pauling also declared publicly that Robinson’s research was “amateurish” and inadequate. Robinson responded by suing the Institute and its trustees. In 1983, the suit was settled out of court for $575,000. In an interview quoted in Nature, Pauling said that the settlement “represented no more than compensation for loss of office and the cost of Robinson’s legal fees.” However, the court-approved agreement states that $425,000 of the settlement was for slander and libel.
In 1994, Robinson and two colleagues summarized the results of four mouse studies he had carried out while working at the Pauling Institute. Nearly all of the mice developed skin cancers (squamous cell carcinomas) following exposure to ultraviolet radiation. Altogether, 1,846 hairless mice received a total of 38 different diets. The researchers found that (a) the rate of onset and severity of tumors could be varied as much as 20-fold by just modifying dietary balance; (b) diets with the worst balance of nutrients had the greatest inhibitory effect on cancer growth; and (c) no cures or remissions were observed (although the researchers were not looking for this). In 1999, Robinson commented:
The results of these experiments caused an argument between Linus and me, which ended our 16-year period of work together. He was not willing to accept the experimentally proved fact that vitamin C in ordinary doses accelerated the growth rate of squamous cell carcinoma in these mice.
At the time, Linus was promoting his claim that “75% of all cancer can be prevented and cured by vitamin C alone.” This claim proved to be without experimental foundation and not true. . . . Vitamin C increased the rate of growth of cancer at human equivalents of 1 to 5 grams per day, but suppressed the cancer growth rate at doses on the order of 100 grams per day (near the lethal dose), as do other measures of malnutrition [21].
Of course, this could just be sour grapes after a falling out among old friends, or it could be only one side of a more nuanced story. It could also be that the acceleration of growth reported by Robinson may not be the behavior of all tumors or even most tumors in response to high dose vitamin C. However, if Robinson’s results as he reported later were correct, in the case of at least one tumor vitamin C appeared not to inhibit growth but rather to accelerate it. Pauling’s apparent willingness to suppress data that did not fit with his vitamin C hypothesis and to fire the man whose experiments yielded such data must be acknowledged, particularly given the libel settlement that resulted from legal action by Robinson. The representation of Pauling as a scientist unfairly vilified for his ideas that were outside the mainstream may have an element of truth to it, but just an element. The whole story is not nearly so flattering to Pauling, and he deserved more than a little of the vilification heaped upon him for his vitamin C advocacy and for his role in the promotion of orthomolecular medicine, which consisted mostly of recommending megadoses of vitamins and nutrients to treat disease.
Of course, falling from grace as Pauling did led to wishes for that most American of stories: His triumph and vindication, even if posthumous. At least, so Pauling’s admirers have been hoping for at least 20 years.
THE 21st CENTURY “VINDICATION” OF LINUS PAULING? (Take 1)
One aspect of dubious “alternative” therapies is that virtually no amount of evidence can persuade their adherents that their favored therapy really and truly does not work. However, in the case of vitamin C as a cancer therapy, one loophole in the clinical studies that did not show efficacy is that in all of well-designed randomized clinical trials, it was oral vitamin C that was studied. The evidence regarding high dose intravenous dosing was not as copious, and this oversight was exploited by all manner of CAM practitioners, some of whom promised near miraculous results with intravenous vitamin C, sometimes combined with various other supplements and minerals, while even as early as 2000 some “conventional” physicians and scientists suggested that a reevaluation was in order or that intravenous vitamin C could improve the quality of life for cancer patients.
It turns out that emerging data showed that ascorbate was differentially toxic to some tumor cell lines at concentration in the millimolar to tens of millimolar range. That’s an incredibly high concentration to have to achieve in blood and tissues. Indeed, if you told most pharmacologists that you had a new experimental compound for the treatment of cancer (or any other disease, for that matter) but that it required blood and tissue concentrations of 10 mM to be effective, nearly all of them would suggest that you give up in a hurry because of how difficult it is to reach concentrations that high in humans without toxicity. Even so, two and a half years ago, there came a study published in PNAS by Mark Levine and colleagues at the National Institute of Diabetes and Digestive and Kidney Diseases at the the National Institutes of Health. The PNAS study was simply an in vitro study using five tumor cell lines that showed selective toxicity due to ascorbate in tumor cells compared to normal cells at concentrations that are achievable with intravenous doses of ascorbate. It turns out that ascorbate was four- to twenty-fold more toxic to the tumor cells tested than to normal cells, and that cell killing depended upon hydrogen peroxide generation, as it was abrogated when cells were pretreated with peroxide scavengers. It’s a pretty straightforward paper. My only quibbles with it were that the concentrations of ascorbate used were very high, in the 2 to 20 mM range (hence the need for very high intravenous doses of vitamin C to achieve such levels in the blood) and that Levine only used monocytes, lymphocytes, fibroblasts, and breast epithelial cells as the “normal” cells. Also, he only exposed the cells to the ascorbate for one hour, even though the paper itself states that it can take several hours for a large intravenous dose of vitamin C to be eliminated from the body. At the time I thought that the paper represented an interesting in vitro observation, but, as they say, you can kill tumor cells in vitro with just about anything if you crank the concentration high enough. In vitro experiments can generate hypotheses, but they are inherently highly artificial systems. As clinicians, we want to know if this works in vivo. Many are the chemotherapeutic agents that appear to kill cancer cells selectively in vitro but fail in animal experiments. All in all, this study was hardly a stunning vindication of Pauling.
At around the same time, another study was published in the Canadian Medical Association Journal (CMAJ), also by Mark Levine and colleagues in collaboration with a group at McGill University. Based on the concept that only intravenous dosing can produce high enough blood levels of ascorbate and that that is the reason previous trials failed to show a benefit from high dose vitamin C, three cancer cases were reported, all of whom received high dose vitamin C and all of whom, it was claimed, showed much longer than expected survival. The problem is, there was a lot less there than has been reported, especially given that this study was of a type that I particularly detest (but that CAM advocates particularly love), the so-called “best case” series.
The first patient of the three reported, for instance, had renal cell carcinoma with putative lung metastases and received 65 g vitamin C intravenously twice a week for 10 months. The lung metastases were never biopsy-proven to be renal cell carcinoma, leaving some doubt about them. However, let’s accept that they probably were real lung metastases, even though none of them were ever biopsied. (We don’t always biopsy metastases to prove that they are metastases, particularly if the biopsy would be unduly risky. However, in oncology generally it is always better to have a tissue diagnosis than not.) The problem is that renal cell carcinoma is a tumor type that is one of the more common tumor types to be reported to undergo unexplained spontaneous remissions. It’s uncommon, but it has definitely been documented. Also, the patient received a number of other “alternative therapies,” including thymus protein extract, N-acetylcysteine, niacinamide, and whole thyroid extract. This led me to ask: If the authors believed that alternative therapies like high dose vitamin C can cure certain cancers, why did they automatically assume that it had to be the vitamin C? Why couldn’t it have just as plausibly been one of the other treatments or some combination of them? The fate of this patient was ultimately not good: “Unfortunately, the woman — a long-time smoker — was diagnosed four years later with small-cell lung cancer. She again opted for vitamin C treatment, but the second cancer did not respond.” Was there vitamin C resistance in the second tumor as opposed to the first, or did the first tumor just go into spontaneous remission, or was it something else? It’s impossible to say much of anything from this case.
The second case presented was of a man who had a primary bladder tumor with multiple satellite tumors. These were all resected with apparently clear margins transurethrally using a cystoscope. Rather than additional conventional therapy, the man chose intravenous vitamin C and was reported alive and well nine years later. Normally, this would be a pretty poor prognosis tumor without more therapy, but, as the accompanying commentary points out, long term survival has been reported with surgical therapy alone. Indeed, this case reminds me a lot of breast cancer patients who undergo excision of their primary tumor, forgo adjuvant therapy for alternative therapy, and then attribute their survival not to the conventional therapy (surgery) but rather to the alternative therapy. In addition, this patient also took a variety of other alternative therapies, leading to the question again: Why did the authors assume that it was the vitamin C? They may be correct, but there are too many confounding factors. It could just as plausibly been the surgery.
Finally, the third patient had a large paraspinous mass that turned out to be diffuse B-cell lymphoma. She agreed to radiation therapy but refused chemotherapy, opting instead for intravenous vitamin C. She, too, used a variety of other alternative therapies, including beta-carotene, bioflavonoids, chondroitin sulfate, coenzyme Q10, dehydroepiandrosterone, a multiple vitamin supplement, N-acetylcysteine, a botanical supplement, and bismuth tablets. It’s utterly ridiculous to include this case as “evidence” for the efficacy of vitamin C. Besides the confounding factor of using multiple alternative therapies, the patient reported only had, as far as can be told from the case report, a Stage I diffuse B cell lymphoma. Radiation therapy alone used to be a common treatment for such tumors and is well known to be able to produce long term survival in such cases. To try to show that this was something other than Stage I disease, the authors made much of the observation that the patient subsequently developed enlarged lymph nodes in numerous other nodal basins over ten years. However, nowhere did they report that any of these enlarged lymph nodes were ever biopsied to prove conclusively that they were recurrent lymphoma, and the only pathology result reported was from the biopsy of the paraspinous mass. One thing oncologists that I’ve worked with damned near always insist upon before diagnosing a recurrence of lymphoma is proof by tissue diagnosis, and it is very puzzling why such a simple procedure was not done at some point over the ten year case history reported. It would have been very easy to do biopsies of any of the superficial lymph nodes that were reported to have become enlarged. Another point I noticed was that, looking at the authors’ descriptions, only one of these nodes would I have even considered particularly suspicious (a 3 cm supraclavicular node). The majority of the nodes reported were merely described as merely “palpable” or as measuring 1.0 or 1.5 cm, which is within the normal range for lymph nodes in those basins.
This study is one reason why I really, really detest “best case” series. CAM advocates love such series, though, because they allow them to cherry pick patients. The problem is this: Even if these three cases do represent legitimate tumor responses to vitamin C, we have no idea what the denominator is. These cases were collected over many years, and it’s impossible to know how many thousands of patients underwent similar vitamin C regimens with no response at all. In fact, I find it hard not to point out that these were the very best cases the authors could come up with over a span of many years, and yet they are only marginally more convincing than the anecdotes. The bottom line: as of 2006, the evidence supporting the use of vitamin C in cancer, either intravenous or oral, was not compelling. Considering that even in theory very high ascorbate concentrations would be needed, meaning very high doses, for an effect that in vitro was fairly weak, made the whole thing seem like a long run for a short slide.
THE 21st CENTURY “VINDICATION” OF LINUS PAULING? (Take 2)
Fast forward to July and August 2008.
Two and a half years have passed, and Levine et al are back, this time with another study published in PNAS entitled Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. This time, they’ve done animal studies. Once again, these studies show mildly positive results. Once again, the whole obsession with using vitamin C to treat cancer, even if Levine’s results hold up as reported, strikes me as a long run for a short slide. Once again, I remain puzzled as to why there is such intense interest in what, even if it “works,” strikes me as a cumbersome and only mildly effective anticancer therapy.
How good is the study? Answer: It’s OK but it’s nothing special. In fact, it’s not particularly “meaty,” with only four figures, one of which is essentially a rehash from Levine’s previous PNAS paper with some extra cell lines added. Indeed, if this paper were not about a controversial and questionable therapy that had been thought to have been found wanting and instead been about a new cancer chemotherapeutic, my guess is that this result would have been viewed as mildly promising but nothing earthshaking. However, it’s not about some new chemotherapy agent; it’s about vitamin C. Consequently, it got a fair amount of attention in the press when it came out a couple of weeks ago.
Basically, this study reports the results of in vivo experiments in mouse tumor models using high dose vitamin C to treat tumors. In the introduction, Levine argues that the reason previous studies using high dose vitamin C to treat cancer failed to show an antitumor effect was because the drug was administered orally. The human body, he points out, keeps a pretty tight control over the allowable blood concentration of vitamin C, and it’s not possible to pump that concentration up above a certain level through oral dosing alone. If the blood level of ascorbate could be boosted far beyond the limit that can be achieved with oral dosing, Levine hypothesized, it might reach concentrations in the 10 mM range, which is the concentration range in which he has shown that ascorbate can kill tumor cells in vitro.
One very important thing to emphasize here, though, is that at these doses ascorbate is not acting as a nutrient. It is not a “nutritional” treatment for cancer, as some CAM advocates claim. Rather, it is acting as a drug, more specifically a prodrug that generates peroxide and ascorbate radicals. (It is not an uncommon for antioxidants to become prooxidants when administered at high doses.) Indeed, these are doses that are many, many, many times greater than what is required for good nutrition; they are true “megadoses.” To illustrate the point, I note that the doses used in mice by Levine et al were on the order of up to 4 g/kg twice daily. Translating that dose to the proverbial 70 kg man would mean a dose of up to 560 g per day, or nearly a pound and a quarter, administered intravenously. Of course, mice are not humans, and, as it turns out, it doesn’t take doses that high to reach blood concentrations in humans as high as those achieved in the mice using 4 g/kg ascorbate; it takes up to 1.5 g/kg (more on that later). Even so, we’re still talking huge doses of ascorbate just to get its blood and tissue concentrations into a theoretical potentially therapeutic range. Given that a typical orange contains approximately 45 mg of vitamin C, 1.5 g/kg administered to a 68 kg adult would translate into over 2,000 oranges’ worth of vitamin C. It’s also a ten-fold higher dose than was used by Pauling and Cameron.
After in essence recapping results presented in Figure 1 of their previous study for this study again and adding more cell lines to the panel to show that high concentrations of ascorbate are selectively toxic to tumor cells compared to normal cells, Levine gets to the meat of his results by testing his vitamin C regimen in three different mouse models of cancer in athymic nude mice: Ovcar5, a human ovarian cancer cell line; Pan02, a mouse pancreatic cancer cell line; and 9L, a rat glioblastoma cell line. Why he chose these particular cell lines is not really explained clearly. Personally, if I were doing this experiment I would have made sure to use nothing but human tumor cell lines; in this study only one of the xenograft models used was human. Be that as it may, tumors were allowed to grow to a volume of 50 ± 10 mm3, at which point treatment with either intraperitoneal injections of ascorbate or saline placebo were commenced. The results are below:
As you can see, the growth of the tumors was delayed, but there doesn’t appear to be any tumor shrinkage. It turns out that this is actually not a particularly uncommon result for a potential cancer chemotherapeutic drug (and, make no mistake, in this study ascorbate is being used as a chemotherapeutic agent). That’s why I don’t hold it against this study. I agree, based on the data presented, that against these three cell lines, at least, ascorbate at these doses does appear to exhibit some in vivo antitumor activity. However, it’s modest and it requires massive doses producing high concentrations of ascorbate in the blood to achieve, but it’s clearly there. At the end of the study, treated tumors were anywhere from 40-53% smaller than the untreated controls, and in the 9L cell line there was reportedly a major decrease in the frequency of detectable metastases. That’s fairly convincing. The rest of the study involved mainly measuring the levels of H2O2 in the tissues of treated animals. Amazingly, peak levels of as high as 30 mM were measured, and high concentrations of the oxidant ascorbate radical and H2O2 were measured.
The observation that such high ascorbate concentrations in the mice’s blood could be achieved led the authors to reference a phase I clinical trial of high dose intravenous vitamin C in advanced malignancy that had been published two weeks earlier and reported that it is possible to approach such high concentrations of ascorbate in humans with doses of 1.5 g/kg. Even though that’s not 4 g/kg, that dose is still a lot and still problematic, as the infusion of high volumes of high osmolarity solution did cause problems in this trial. Nonetheless, according to this phase I study, with appropriate screening for conditions that might predispose to adverse events, especially renal failure, the results of the phase I clinical trial suggest that high dose intravenous vitamin C is fairly well tolerated even at the highest dose range.
Based on the animal studies and the safety data from the phase I trial, Levine concludes that high dose intravenous ascorbate represents a promising new therapy that should be further investigated. If his were the only evidence I saw being presented, I’d agree that it’s mildly to moderately promising as an anticancer therapy. However, I find Levine’s results much less compelling in light of the history of the use of vitamin C in cancer and in light of my knowledge of cancer chemotherapeutics. More importantly, I know that the phase I clinical trial described above did not identify even a single patient with an objective response to therapy. In other words, not one patient’s tumor shrank. True, the lack of a single objective response in a phase I trial does not necessarily mean that a new cancer chemotherapy drug doesn’t work, but it certainly does dampen considerably any optimism that that the drug will work as a single agent. Taking the animal studies and the phase I trial together, I view the results with mild optimism that high dose vitamin C might have efficacy in human cancer and be useful in combination with other chemotherapy. However, putting these results in context with what has been reported before over 30 years decreases even that mild enthusiasm, especially when coupled with my observation of just how modest the responses were in the mice and by just how much ascorbate was required to result in even a mild antitumor effect. Indeed, the authors of the phase I trial even admitted:
In summary, this study shows that 1.5 g/kg ascorbic acid infused >90-120 min three times weekly is essentially free of risk and important side-effects when simple precautions are taken. In people with normal renal function, this dose achieves a plasma ascorbic acid concentration >10 mmol/l for several hours. No patient experienced an objective anticancer response, although two patients at the 0.6-g/kg dose received greater than six cycles of ascorbic acid with stable disease. Even though only six patients received the recommended phase II dose, our results suggest that the likelihood of an objective anticancer response to i.v. ascorbic acid alone is slight in unselected patients with multiply treated advanced cancer.
I do note the qualifiers in this admission: unselected patients and multiply treated advanced cancer. The latter qualification is in essence meaningless, because no one is going to use an agent like vitamin C as a first line therapy for any cancer if there is not strong clinical trial evidence showing that it works at least as well as current chemotherapeutics. To do otherwise would be highly unethical. On more solid ground is the former qualifier, as there conceivably might be a subpopulation that will respond to high dose vitamin C. Even if that is true, however, based on the results of this phase I trial and the animal studies, clearly vitamin C is not any sort of “miracle cure.”
LINUS PAULING: VINDICATED OR NOT?
All of this brings us back to the title of this post, to the question that just can’t be avoided: Do these two studies released in the last month vindicate Linus Pauling and all the alternative practitioners of high dose vitamin C therapy for malignancy? Again, it depends on what you mean by “vindicate,” but my answer is nonetheless: Not really, except perhaps in the weakest of ways.
Here’s why. Linus Pauling didn’t claim that vitamin C in combination with other chemotherapeutic drugs might provide an additional incremental benefit to patients, which is the very best that can be claimed for high dose ascorbate based on all the in vitro, in vivo, and clinical evidence thus far. That’s far too modest a claim. No, actually Pauling said that “75% of all cancer can be prevented and cured by vitamin C alone.” Similarly, boosters of vitamin C as a cancer therapy don’t claim that it provides a small additional benefit when administered with chemotherapy, either, which again is the very best that can be possibly claimed based on the experimental results described. Rather, they claim that high dose vitamin C cures cancer a high percentage of the time. Even the most optimistic appraisal of Levine’s results of Levine’s mouses study or the phase I clinical trial do not support any such claims. That much is brutally clear.
The bottom line from my perspective: Yes, vitamin C probably has some antitumor activity for some tumors, but as I contemplate the evidence for this effect the word “underwhelming” comes to mind, as does one of my favorite metaphors, namely the long run for a short slide. Apparently there are a lot of people who like getting their butts dirty sliding into base after a long run, though, because the attraction to vitamin C still lives on despite unimpressive evidence. Naturally, the authors of the phase I trial suggest using vitamin C in combination with chemotherapy, which is a perfectly reasonable approach for drugs that don’t show any objective evidence of activity as a single agent. However, this will not be easy, given that the sheer mass and volume of ascorbate that must be administered and the very high concentrations that are required even in the best case scenario could easily interfere with other chemotherapeutic agents.
One thing is fairly clear from the data reported thus far, even Mark Levine’s data and his calls to “revisit” the question of vitamin C and cancer with an “open mind”: If high dose intravenous ascorbate has antitumor activity in humans, that activity is almost certainly quite modest at best, and to achieve even such modest antitumor activity definitely requires incredibly high doses of ascorbate. Once again, I point out that any other experimental drug requiring such high plasma concentrations and high doses to achieve such a modest antitumor effect would probably garner very little interest from anyone, even if it were a potentially patentable product of big pharma. It’s possible that high dose IV ascorbate might ultimately find its way into the armamentarium of science-based oncology, but it’s very unlikely ever to become a mainstay of treatment for any malignancy. It’s just too wimpy.
REFERENCES:
1. Chen, Q., Espey, M.G., Sun, A.Y., Pooput, C., Kirk, K.L., Krishna, M.C., Khosh, D.B., Drisko, J., Levine, M. (2008). From the Cover: Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proceedings of the National Academy of Sciences, 105(32), 11105-11109. DOI: 10.1073/pnas.0804226105
2. Hoffer, L.J., Levine, M., Assouline, S., Melnychuk, D., Padayatty, S.J., Rosadiuk, K., Rousseau, C., Robitaille, L., Miller, W.H. (2008). Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Annals of Oncology DOI: 10.1093/annonc/mdn377

   Vitamin C strikes (out) again
David Gorski
Link
I didn’t think I’d be revisiting this topic again so soon. After all, I wrote one of my characteristic magnum opuses (opi?) less than two months ago, when I asked whether a recent animal study had vindicated Linus Pauling’s belief that high dose vitamin C is a highly effective cancer treatment. After that tsunami of verbiage that can only be exceeded by my fellow blogger Dr. Atwood when he’s on a roll doing a multipart deconstruction of some woo or other, I thought it would be best to give it a rest for a while. I guess less than two months will have to be enough.
The reason struck me as I was perusing the very latest issue of Cancer Research, hot off the presses October 1. As I did so, it didn’t take me long to come across an article from the Memorial-Sloan Kettering Cancer Center and the Herbert Irving Comprehensive Cancer Center at Columbia entitled Vitamin C Antagonizes the Cytotoxic Effects of Antineoplastic Drugs, whose first author is Dr. Mark Heaney.
Once more into the fray!
You may recall that, when last I discussed the topic of vitamin C as a “cancer cure,” I discussed a recent study out of Mark Levine’s laboratory at the Molecular and Clinical Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, at the National Institutes of Health. At the time, Dr. Levine argued that the doses of vitamin C used in previous randomized, double-blind trials of vitamin C against cancer were oral and thus did not produce levels of ascorbate in the serum high enough to kill cancer cells because absorption of vitamin C is limited by the rate that the gastrointestinal tract can take it up. He argued that, to reach the very high doses found to be necessary in cell culture to kill lymphoma cells preferentially to normal cells,. We’re talking huge concentrations ranging from 2 to 20 mM, which are levels of active drug that are virtually unheard of for normal drugs. In mice, he showed that attaining such high blood concentrations was feasible in mice and that they demonstrated a mild antitumor effect in a three mouse models of cancer and differential toxicity to cancer cells over normal cells through, paradoxically, the induction of reactive oxidant species, as it turns out that this particular antioxidant can become a pro-oxidant at sufficiently high concentrations. Overall, I concluded that the available evidence suggests that, even if vitamin C does have an anti-tumor effect, it’s likely to be modest, making it a long run for a short slide; in other words, huge doses of vitamin C, such that they are difficult to get into the patient, for a pretty wimpy benefit.
Of course, as I pointed out before, every time there’s a study suggesting that “vitamin C might work after all,” the press go ga-ga all over it. Certainly that’s what happened for Dr. Levine’s cell culture study back in 2006 and his animal model study a couple of months ago. So, take a guess. What do you think the reaction to to the study I mentioned above published in the October 1 issue of Cancer Research?
Crickets chirping.
Yes, the silence was deafening. I wonder why? True, I did find articles in the Canadian press, in Medpage Today, and Medscape, but not much anywhere else. To find out why, let’s look at what the study found:
October 2, 2008 — Large supplemental doses of vitamin C could interfere with the therapeutic cytotoxic effects of a wide range of chemotherapy agents, suggests a new preclinical study. Although the finding comes from research conducted in cancer cell lines and mice, the authors say the conditions they created are similar to those found in the body, and speculate that the same mechanism might affect patient outcomes.
“It is possible that vitamin C supplementation may alter the effectiveness of commonly used chemotherapeutic agents and adversely influence treatment outcome,” the researchers write in the October 1 issue of Cancer Research.
So what did the researchers do? First, you have to understand that a common mechanism of action of many chemotherapeutic drugs is the generation of reactive oxygen species (some of which are known as oxygen free radicals), which the result in DNA damage. Consequently, one might reasonably hypothesize that vitamin C (ascorbate) might interfere with the action of some of these chemotherapeutic agents. On the other hand, if Dr. Levine is correct it could be argued that ascorbate might potentiate the activity of such chemotherapeutic agents.
Therefore, first, as scientists so often do, investigators tested combinations of different chemotherapeutic agents with increasing concentrations of vitamin C. One difference between this study and the previous two studies by Dr. Levine is that the range of ascorbate concentrations examined was from 0 to 0.5 mM, which is 10 to 20 times lower than the concentrations that Levine used. In any case, what he found was that treating two different leukemia and lymphoma cell lines with ascorbate at those concentrations before treating them with chemotherapeutic agents, including mechanistically dissimilar agents such as doxorubicin, which intercalates with DNA and causes DNA breaks; methotrexate, which inhibits folate metabolism; cisplatin, which crosslinks DNA; vincristine, which interferes with microtubule function; and imatinib mesylate (better known by its trade name of Gleevec), a selective inhibitor of the activity of a protein called bcr-abl, which is the oncogene that plays a central role in the development of chronic myelogenous leukemia (CML). The point is that these drugs all have very different mechanisms of action, and the finding was that vitamin C inhibited their effects. At the concentrations used, it didn’t inhibit or stimulate the growth of cells in and of itself. However, it did interfere with the actions of these drugs, decreasing their cytotoxicity to tumor cells by 30-70%.Next, they tested the effect of vitamin C and chemotherapy in mouse models of cancer using 250 mg/kg, again a much lower dose than what Dr. Levine used. Once again, vitamin C interfered with chemotherapy.
What was puzzling about these results is that not all of these drugs are thought to have as part of their mechanism of toxicity the generation of reaction oxygen species, and yet vitamin C interfered with them all. The question then became: Why? A series of additional experiments showed that it wasn’t because vitamin C made tumor cells better able to pump chemotherapeutic agents out. They then compared vitamin C to another chemical (N-acetylcysteine), which like vitamin C helps cells replenish their supply of free radical scavenging thiols such as glutathione, which neutralize reactive oxygen species. When cells were treated with N-acetylcysteine, it only protected them from one of the five chemotherapeutic agents, cisplatin, and vitamin C had minimal effects on intracellular reactive oxygen species. This result suggested that vitamin C works through a more general mechanism than simply an antioxidant mechanism. A further experiment showed that vitamin C was protective against mitochondrial damage caused by chemotherapeutic agents, a mechanism of action common to all five of the drugs. Dr. Heany speculates:
“Our study is a preclinical model that addresses only the situation when vitamin C is given in the setting of chemotherapy treatment,” Dr. Heaney emphasized. There have been no clinical studies of this topic so far, he said.
However, the finding could be of potential concern because “many people, cancer patients included, take supplemental vitamin C,” Dr. Heaney pointed out. Clinical studies of vitamin C supplementation in patients with advanced cancers have had mixed results. There are conflicting hypotheses, he explained. One theory is that vitamin C supplementation protects the cancer and is therefore detrimental to the patient. But there is also the opposite view, that vitamin C supplementation enhances the immune system or prevents indolent cancers from mutating more and becoming aggressive, which would be beneficial for the patient.
Asked to comment on this study, Len Lichtenfeld, MACP, deputy chief medical officer at the American Cancer Society said: “Vitamin C has a long history in cancer prevention and treatment. Although there is no evidence to demonstrate that vitamin C improves the outlook for patients with cancer, there are still reported observations that cancer patients continue to believe in the potential benefits of vitamin C. Although oncologists do not routinely recommend that patients with cancer take excessive doses of vitamin C, there are reports that cancer patients are being treated with vitamin C by alternative practitioners.”
Once again, it must be emphasized that this is a study in cell culture and a mouse model (in fact, much like the studies of Dr. Levine). It’s applicability to humans is not clear and requires testing. However, it does bring up an issue. Clinical trials are moving forward, spearheaded by Dr. Levine, of high dose intravenous vitamin C and cancer. Granted, the doses he is using are many times higher than what was used in the study showing vitamin C interference with chemotherapy. Also granted, Dr. Levine’s study implicates reactive oxygen species generated by vitamin C when it is present in very high concentrations, while Dr. Heaney’s study examined concentration ranges that are achievable with oral dosing. It’s not clear if the same results will apply. So what to do?
Dr. Heaney is cautious:
Lead author Mark Heaney, MD, PhD, from Memorial Sloan-Kettering Cancer Center, in New York, New York, told Medscape Oncology that he advises his cancer patients to avoid supplemental vitamin C during chemotherapy. “I recommend that my patients continue to eat a well-balanced diet that includes fruits and vegetables that contain vitamin C.”
“Such a diet could be expected to have moderate amounts of vitamin C as well as other important nutrients. There are no data to suggest that vitamin C obtained from fruits and vegetables is intrinsically different from vitamin C supplements. Given that our research was done in experimental model systems and was not a clinical trial, I am reluctant to predict a dose of supplemental vitamin C that could be extrapolated to our work. That said, oral vitamin C supplementation with doses as low as 250 mg over a 1-month period resulted in intracellular vitamin C concentrations in normal white blood cells that were close to those that we studied in white blood cell cancers,” Dr. Heaney said.
One thing that concerns me about this study is that any clinical trial that will be carried out with vitamin C and cancer will be chemotherapy plus vitamin C, not just vitamin C alone. After all, that’s the standard methodology for testing a putative chemotherapeutic agent: Add the experimental agent to standard of care chemotherapy. Based on Dr. Heaney’s result, a compelling case can be made that such a trial would be unethical, at least at the lower “megadoses” of vitamin C, because there is a plausible mechanism by which vitamin C might actually interfere with chemotherapy and thus do harm. At the the super high doses of vitamin C, such as the ones that Dr. Levine studied, we don’t know whether the vitamin C would interfere with chemotherapy based on a mechanism similar to that postulated in Dr. Heaney’s study or whether it might potentiate the activity of chemotherapy by generating reactive oxygen species, as the results of Dr. Levine’s studies might predict. However, I would argue that any study of super high dose vitamin C a la Dr. Levine plus chemotherapy would also be unethical, unless animal and cell culture data could be produced that would show that vitamin C as such high concentrations does not interfere with chemotherapy.
Another thing that bugs me about this study is that it’s another example of how the media reports anything having to do with Linus Pauling’s idea that megadoses of vitamin C can treat cancer. Whenever a study is reported that seems to be consistent with a use for vitamin C in treating cancer, almost inevitably it gets wide coverage. When a study is reported that suggests that high dose vitamin C has no use or–even worse–may be harmful, you hear nothing about it.
Same as it ever was.

The effectiveness of zinc and vitamin C on the duration of COVID-19 infections
Vitamin C and zinc have been heralded as treatments for colds for decades, but how well do they work against COVID-19? A new clinical trial provides the answer.
Scott Gavura on February 18, 2021
Link
In 1747, James Lind proved that scurvy could be prevented by a diet that included citrus fruit. It wasn’t until 1912 that the active ingredient, ascorbic acid (later called vitamin C), was discovered. Scurvy has been relatively rare since that time in populations with access to a varied diet. We likely wouldn’t have pharmacy shelves lined with bottles of vitamin C today if it were not for Linus Pauling, who spent the later parts of an otherwise brilliant scientific career touting megavitamin therapy, with, among other supplements, vitamin C. Since the 1970s, massive doses of vitamin C in those without deficiency have shown no meaningful medicinal effects, but the vitamin retains a health halo among alternative medicine proponents that is utterly resistant to research that shows it to be, on balance, useless.
COVID-19 emerged just over a year ago and has resulted in a pandemic the likes of which has not been seen in generations. While many patients only experience mild symptoms, some patients progress to severe illness, hospitalization, and death. Because most cases are mild and because the likelihood of progressing to severe disease isn’t perfectly predictable, it is perhaps not surprising that (1) many people, understandably fearing severe disease, will try any number of folk remedies, and (2) because most people recover, that their recovery may be attributed to whatever treatment approach they followed, no matter how unorthodox or implausible.
Vitamin C and zinc have been touted as effective treatments for the common cold for decades. While the evidence is poor for vitamin C and weak (but better) for zinc, the virus that causes COVID-19, SARS-CoV-2, is a coronavirus, and coronaviruses can also cause the common cold. Yes it’s a stretch, but anything that could potentially help reduce the morbidity and mortality of COVID-19 would be welcomed, and given the public’s embrace of zinc and vitamin C for colds, it was perhaps warranted to test these two products for their effectiveness against COVID-19 disease. The results will not surprise you.
The evidence to date
I blogged about zinc and COVID-19 last November. At that time there were no clinical trials that studied zinc for preventing or treating SARS-CoV-2 infections. The evidence for colds (which can be caused by coronaviruses) is promising, but weak overall, only possibly modestly reducing the duration of colds. In terms of COVID-19 trials with Vitamin C, I found 45 clinical trials in the COVID-19 / WHO clinical trials database. Searching PubMed for published clinical trials, I could only find this protocol studying intravenous high-dose vitamin C, and the results have not been published. Another open-label trial found no benefit from high-dose intravenous vitamin C. An open-label pilot trial in China also showed no benefit in terms of “invasive mechanical ventilation-free days”. Even outside of COVID-19 infections and looking at the critically ill more generally, there is no strong evidence for its use. So that brings us to the current trial.
COVID A to Z
This trial was published on February 12, 2021, and is from Thomas et al. from the Cleveland Clinic. The “COVID A to Z Clinical Trial” was a randomized controlled trial intended to study adults diagnosed with a SARS-CoV-2 infection who were expected to recover at home. The trial enrolled only adults and participants were randomized to one of four groups:
8,000 mg of ascorbic acid (to be divided over 2-3 times per day with meals) for 10 days,
50 mg of zinc gluconate at bedtime for 10 days,
both therapies for 10 days, or
usual care (no treatment)
Participants were asked to track their symptoms daily, and to complete a survey until day 28 to assess hospitalization and adverse effects. The primary end point was the number of days from the time of peak symptom score to a 50% resolution in those symptoms. They also measured the number of days to reach a symptom score of zero, as well as the incidence of hospitalizations, death, other medications, and adverse events.
The trial was intended to recruit 520 participants but an interim analysis was completed after 214 patients were enrolled. Based on pre-specified stopping rules, the trial was then terminated for futility, as there were no meaningful differences between the three treatment groups and the control group that received no treatment.
The average age of participants was 45 years old, 62% women and 38% were current or former smokers. At least one-quarter had used vitamins and minerals previously.
There was no significant difference in the time required to reach a 50% reduction in symptoms. In the usual care group, this was 6.7 days, while it was 5.5 days in the ascorbic acid group, 5.9 days in the zinc gluconate group, and 5.5 days in the group that received both products:

In terms of secondary endpoints, there were no significant differences in any parameter. Few reported any adverse effects, with slightly more in the vitamin C group.
Not promising but also not harmful
This was a prospective trial of two supplements intended to simulate what someone might do if told they had a COVID-19 infection – take large doses for the duration of the illness with the hope that it will support recovery and reduce the risk of severe disease. This trial showed that these products, in these doses, had no measurable effects on the severity of COVID-19 infections. This is perhaps not surprising given the evidence for vitamin C and zinc against colds is not impressive, so there was weak plausibility for a strong treatment effect. However, both of these supplements were generally well tolerated, and there were also no serious negative consequences from their use. So while there is no evidence, based on this trial, to support their use, those that choose to take these supplements in line with this trial can also be reassured that they are unlikely to cause themselves any harm.

   Vitamin E and Stroke
Steven Novella
Link
One of the recurrent themes of science-based medicine is that any medical intervention that can plausibly cause physiological benefit can also plausibly cause physiological harm. There is no such thing as “it can’t hurt.” Sometimes the risk may be minuscule – but we should never assume that it is zero. Being “natural” or “holistic” or being blessed with some other alleged marketable virtue does not affect the risk vs benefit calculation of an intervention.
Vitamins are an excellent example. There is widespread sentiment that vitamins are harmless, and that supplementing with vitamins is therefore a no risk-possible benefit scenario. It is certainly reasonable to conclude from the evidence that vitamins (at usual supplemental levels) are low risk, compared to many other types of medical interventions. High doses, or megadoses, of vitamins, however, risk toxicity and this risk increases with the dose.
But even at sub-toxic doses vitamins should not be assumed to be risk free. This is especially true when we take a public health perspective – what is the net effect of large scale supplementation on the population? A new meta-analysis looking at the net effects of Vitamin E supplementation on stroke risk reinforces this caution.
Vitamin E has received a lot of attention recently because of its antioxidant effects. Oxidative stress plays a role in tissue damage, aging, and various disease processes, and so supplementing with anti-oxidants seems like an obvious treatment to mitigate this damage. However, biology is complex, and oxygen free radicals also play a role in cell signaling, for example, so that exogenously suppressing them may have negative unintended consequences.
For example, the emerging research regarding Vitamin E and heart disease is mixed and complex. Vitamin E supplements actually seem to increase total mortality and heart failure. However, observational studies show a decreased risk of cardiac disease in those who take Vitamin E. The difference may be that foods rich in Vitamin E come with a health benefit (which may be from the foods that are not eaten with such a diet), but vitamin pills do not convey this benefit. There may also be a difference between primary prevention (in those without prior cardiac events) where there is a net benefit and secondary prevention (in those who have suffered a cardiac event) where there is net risk. There may be subpopulations, like diabetics, who benefit more.
The bottom line at this time is that eating a healthful diet rich in fruits and vegetables is consistently associated with decreased risk of various diseases, including heart disease. However taking vitamin E supplements may not have this same benefit, and in fact may come with a net risk of increased heart disease and mortality.
What about stroke risk? While there are differences, stroke is also a vascular disease, like myocardial infarction, and the risk factors tend to be similar. In the new meta-analysis the researchers found:
In this meta-analysis, vitamin E increased the risk for haemorrhagic stroke by 22% and reduced the risk of ischaemic stroke by 10%. This differential risk pattern is obscured when looking at total stroke. Given the relatively small risk reduction of ischaemic stroke and the generally more severe outcome of haemorrhagic stroke, indiscriminate widespread use of vitamin E should be cautioned against.
Again we see a bottom line caution against supplementing with vitamin E. It is important to note that even a small increase in net stroke incidence has a huge effect on the general population. Stroke is a debilitating disease, potentially fatal, and a huge financial burden on the health care system. Even small percentage increases therefore have a huge societal effect. A 22% increased in hemorrhagic stroke is a very large clinical effect.
Conclusion
The research on vitamins in general and vitamin E in particular is messy and complicated. My overall impression of this research is that there is no consistent signal of net benefit for routine supplementation. There are many specific conditions in which specific supplementation is of benefit, but not routine supplementation for general health.
At the same time there is a consistent signal of benefit to having a healthful diet, the primary feature of which is to have a diet rich in fruits and vegetables. So in the end, after decades of research, what your mother always told you turns out to be the best advice – eat your vegetables.

Vitamin E for Alzheimer’s
Harriet Hall on January 7, 2014
Link
Recently you may have seen headlines like “Vitamin E slows decline in patients with mild Alzheimer’s” or “There’s still no cure for Alzheimer’s disease, but the latest hope for slowing its progression is already on drugstore shelves.” They were referring to an article in the January 1, 2014 issue of the Journal of the American Medical Association (JAMA) announcing the results of the TEAM-AD VA Cooperative Randomized Trial of vitamin E and memantine (Namenda) for Alzheimer’s disease (AD).
The study attracted a lot of media attention. Most of the news reports I have seen were accurate and cautious, explaining the nuances of the study rather than suggesting that everyone should run out and buy vitamin E; but I wouldn’t be surprised to learn that a lot of readers ignored the fine print and did just that. It would be interesting to track sales of vitamin E and see if there was a bump following the publicity.
We know of no treatment that will delay, prevent or cure Alzheimer’s disease, or that affects the underlying disease process. It’s a tragic, frustrating disease that takes away the very things that make us who we are: memory and personality. It is affecting more and more people as the numbers of elderly increase. Available prescription medications are only modestly effective in slowing functional decline and delaying the need for institutionalization. They are expensive, they don’t help everyone, and when they do help, they only help for a limited time. It is very exciting to think an inexpensive vitamin could help patients with mild to moderate AD, but we must resist the temptation to read too much into this study.
Study design
The study was a large, rigorous, multicenter randomized placebo-controlled trial with 33 authors, carried out at 14 Veterans Affairs (VA) medical centers. It enrolled 613 patients age 53 to 96 with a diagnosis of possible or probable AD of mild to moderate severity who were already taking an acetylcholinesterase inhibitor (AChEI). 65% were on Donepezil, 32% on Galantamine, and 3% on Rivastigmine); 97% were male, 86% were white, 13% black, and 11% Hispanic. (Note: these were classified as possible or probable cases, since definitive diagnosis of AD is only possible at autopsy.)
Participants were randomized to one of four groups:
    • Alpha tocopherol (vitamin E) 1,000 IU twice a day + memantine-matching placebo
    • Memantine 10 mg twice a day + vitamin E-matching placebo
    • Both vitamin E and memantine
    • Two placebos
Primary outcome measure was the Alzheimer’s Disease Cooperative Study/Activities of Daily Living Inventory (ADCS-ADL), a validated questionnaire that assesses functional abilities to perform activities of daily living. A difference of 2 points on this scale is generally considered significant because it potentially represents, for example, a loss of dressing or bathing independently. Secondary outcome measures included tests of cognitive function and dementia severity, memory, language and praxis functions, assessment of psychological and behavioral problems, the time required for caregivers to assist patients in major areas of daily activities, and a measure of functional dependence.
Annual assessments included physical exams, review of concomitant medications, blood concentrations of the study drugs to assess adherence, and careful questioning about adverse experiences. 42% of subjects failed to complete the trial, most commonly due to death (50%), withdrawal of consent (30%) and adverse events possibly related to the study medication (1%). Mean follow-up time was 2.27 years.
Findings
All participants got worse over the period of the study. Subjects in the vitamin E group had a significantly slower decline than those in the placebo group (3.15 units less on the ADCS-ADL Inventory, annual rate of decline 19% less, delay in progression of 6.2 months). There was no significant difference between the placebo group and the memantine or memantine + vitamin E groups. The group taking both vitamin E and memantine did significantly worse than the group taking vitamin E alone.
Adherence was estimated at 65-68%, which isn’t all that bad considering the age of patients and the effects of Alzheimer’s.
Secondary outcomes showed no significant differences between the four groups except that caregiver hours increased less in the vitamin E group than in the memantine group.
Safety: there were no significant differences between groups for serious adverse events. The annual mortality rate was 7.3% for vitamin E, 11.3% for memantine, 9% for vitamin E + memantine, and 9.4% for placebo.
Discussion
They concluded that 2,000 IU of vitamin E significantly delayed clinical progression in activities of daily living in patients with mild to moderate AD who were also taking AChEI. Paradoxically, the combination of memantine and vitamin E had less effect than either drug alone; the authors could not think of a plausible mechanism for this finding. No significant changes were seen in cognition or memory, but the researchers considered the 6.2-month delay in progression of functional loss to be of more practical importance. Mortality rate was reduced with vitamin E, in contrast to a previous meta-analysis of vitamin E studies that had showed an increase in all-cause mortality with doses typically lower than the 2,000 IU used in this study. Interestingly, only one study in that meta-analysis involved Alzheimer’s patients, and that one also showed a decrease in mortality.
Editorial
An accompanying editorial praised the study as reflecting the best in trials of AD therapy, especially because of its size, duration, and separation from commercial motivation; but it characterized the therapeutic effect as “modest” and more relevant to functional disability than to any effect on the disease process itself. They pointed out that functional ability is non-specific (decreasing with age as well as with disease), that the primary outcome was not confirmed by any of the secondary outcomes, and that the mechanism of vitamin E in AD is uncertain. Memantine is only approved for moderate to severe AD, and this study confirms that it is not indicated for milder disease. The results for vitamin E are encouraging, but can’t be extrapolated to situations other than the specific ones in the study.
Another opinion
An ND quoted on one website said “This new study demonstrates that scientists seeking to slam the door on vitamins, and new vitamin research, is the antithesis of what science is all about.” He is responding to a straw man. Several recent studies and editorials have discouraged indiscriminate use of multivitamins in healthy populations, especially as a substitute for a nutritious diet. But no one has recommended we stop studying individual vitamins for new indications where there is preliminary evidence that they might be helpful in specific populations or diseases.
Conclusion
This study is encouraging, but it doesn’t mean everyone should start taking high doses of vitamin E to ward off Alzheimer’s. And it would be premature to incorporate vitamin E into routine treatment of Alzheimer’s patients on the basis of this one study. There are too many unanswered questions. Women and minority groups were underrepresented, the interaction with memantine is puzzling, the secondary outcomes didn’t support the primary outcome, the beneficial effect on mortality may not be generalizable to all AD patients, and interactions with other medications or illnesses have not been studied.
I agree with the Alzheimer’s Association’s call for caution:
No one should take vitamin E to treat Alzheimer’s disease except under the supervision of a physician. Vitamin E — especially at the high doses used in the ADCS study — can negatively interact with other medications, including those prescribed to keep blood from clotting or to lower cholesterol.

Vitamin D: To Screen or Not to Screen?
Harriet Hall on December 2, 2014
Link

Vitamin D, the so-called sunshine vitamin, has generated a lot of attention in recent years. It has been claimed to benefit a wide variety of diseases, everything from cancer to multiple sclerosis. It is widely used along with calcium for bone health. It is added to milk and prenatal vitamins and is prescribed for breastfed babies. Some doctors are recommending everyone take it for prevention. Some CAM advocates are recommending it as a more natural way to prevent the flu than getting a flu shot.
It has been touted as a panacea; Michael Holick even wrote a book titled The Vitamin D Solution: A 3-Step Strategy to Cure Our Most Common Health Problems. Christiane Northrup praised it, saying “This information can save your life. Really.” (Really? I’m skeptical, and her recommendation is not enough to make me want to read the book.) Then there’s Jeff Bowles’ book The Miraculous Results of Extremely High Doses of the Sunshine Hormone Vitamin D3 My Experiment With Huge Doses of D3 From 25,000 To 50,000 Iu A Day Over A 1 Year Period. That one’s not on my reading list either; the tolerable upper intake level is 4,000 IU a day.
It’s hard to avoid the hype and just examine the actual scientific evidence without any bias. The United States Preventive Services Task Force has tried to do just that. It recently evaluated screening for vitamin D deficiency and concluded that the current evidence is insufficient to recommend either for or against screening. Predictably, their announcement has already led to misunderstandings and protests.
What is the USPSTF?
It’s an independent, volunteer panel of national experts in prevention and evidence-based medicine. Its purpose is to improve the health of all Americans by making evidence-based recommendations about clinical preventive services. Its 16 members are appointed by the Director of the Agency for Healthcare Research and Quality (AHRQ) to serve 4-year terms. Candidates are screened to ensure that they have no substantial conflicts of interest, and they come from all areas of primary care, including behavioral health, family medicine, geriatrics, internal medicine, pediatrics, obstetrics and gynecology, and nursing. The biographies of the current members are listed here. In addition to providing recommendations to patients and providers, the Task Force makes an annual report to Congress recommending priority areas for research.
What do their recommendations mean?
Their recommendations are meant as public health measures for the asymptomatic general population; they do not apply to people who have symptoms or are at higher than average risk. They address the evidence-based health benefits and harms of each preventive measure without factoring in costs or economic factors. They are meant as guidelines, not mandates. They are not a one-size-fits all “cookbook.” They are only meant to serve as a starting point for clinicians to use in deciding how to approach prevention for each unique individual patient.
How do they evaluate the evidence?
They have explained their process in detail. They review all available evidence on a subject, try to evaluate all potential benefits and harms, and take into account the quality of the research studies. They then assign a “grade”:
    • Grade A: Recommended. High certainty of net benefit.
    • Grade B: Recommended. High certainty of moderate net benefit or moderate certainty of moderate to substantial net benefit.
    • Grade C: No recommendation. People can opt to use it, but any benefit is likely to be small.
    • Grade D: Recommendation not to use. Moderate or high certainty that there is no net benefit or that harms outweigh benefits.
    • “I” statement: current evidence insufficient to assess the balance of benefits and harms.
What evidence did they find on vitamin D?
Screening for vitamin D got the “I” statement: the USPSTF felt the evidence was insufficient for a variety of reasons. You can read their detailed reasoning and the research they based it on here, but here are the key points:
    • There is no consensus on the definition of vitamin D deficiency.
    • There is no consensus on optimal levels.
    • Testing methods are not standardized and results vary between laboratories.
    • There are no studies evaluating the direct benefit of screening.
    • There is adequate evidence that treatment of asymptomatic vitamin D deficiency has no benefit on cancer, diabetes, mortality, or even on fracture risk in persons not at high risk of fracture.
    • There is inadequate evidence on the benefit for other outcomes including psychosocial and physical functioning.
    • Although the evidence is adequate for a few limited outcomes, the overall evidence on the early treatment of asymptomatic, screen-detected vitamin D deficiency to improve health outcomes is inadequate.
    • There are no studies evaluating the direct harms of screening.
    • There is adequate evidence that the harms of treatment of vitamin D deficiency are small to none.
The “Discussion” section is illuminating. They cover the effects of vitamin D deficiency, from clear dangers like rickets to less conclusive risks of falls, functional limitations, depression, etc. They cite a study showing that 19% of the US population is at risk for vitamin D inadequacy. They cover risk factors for low vitamin D levels. They point out that dark-skinned people have lower vitamin D levels than whites but that it may be more bioavailable, and they are less likely to have adverse clinical outcomes. Obese people have lower levels, but we don’t know whether they have greater requirements or have greater sequestration into fat tissues. They mention studies showing adverse effects of supplementation, but state that methodological deficiencies in those studies make it difficult to determine actual harms. They plan future updates and may look into risk assessment tools.
Who agrees? Who disagrees?
    • No national primary care professional organizations currently recommend routine, population-wide screening for vitamin D deficiency.
    • The American Congress of Obstetricians and Gynecologists, the American Geriatric Society, and the National Osteoporosis Foundation recommend testing for vitamin D as part of osteoporosis management or falls prevention.
    • The Endocrine Society recommends screening only patients at risk.
    • The Institute of Medicine has no guidelines on screening, but recommends an intake of 600 IU a day up to age 70 and 800 IU a day for those over 70.
    • The American Academy of Family Physicians agrees with the USPSTF that the evidence is insufficient to assess the balance of benefits and harms of screening the general population, but emphasizes that there are many situations where testing may be indicated, for instance in patients with osteoporosis or malabsorption disorders.
    • Several doctors have spoken out against the USPSTF findings.
What’s the harm?
It could be argued that we could just skip the step of testing and have everyone take vitamin D supplements, since they would benefit those who are deficient and would be unlikely to harm those who are not. We add iodine to salt to benefit those who need it, and it doesn’t hurt the rest of us.
That is a reasonable suggestion, but as with everything else in medicine, we shouldn’t jump to conclusions before adequate testing. We might find out that it does more harm than good and/or that it wastes money. Some studies do suggest that there might be adverse consequences of supplementation to high vitamin D levels.
Conclusion
Should you be tested for vitamin D? It would be nice if there were a simple clear-cut answer to that question that would satisfy everyone, but there isn’t. The USPSTF has given us the evidence-based statement that the current evidence is insufficient to recommend either for or against screening. Science can inform us, but it can’t dictate how we should respond to the information. There is room for different responses. Some will choose to screen selected patients with risk factors for low levels of vitamin D. Some will choose to take vitamin D supplements on the precautionary principle, with or without screening tests. Some will decide to spend more time in the sun and risk skin cancer. Some will be content not to screen or supplement until there is better evidence to guide us.
Science-based medicine is complicated. In contrast, CAM frequently appears to be far less complicated. It tends to provide definitive answers that are simple and reassuring. Unfortunately those simple answers all too often turn out to be wrong. Sometimes “I don’t know” is the only reasonable answer.

Are guidelines for calcium and vitamin D rooted in evidence, or vested interests?
Scott Gavura on September 10, 2015
Link


Do osteoporosis guidelines overstate the benefits of calcium and vitamin D supplements? And is their continued presence due to vested interests and conflicts of interest? That’s the provocative argument made by Andrew Grey and Marc Bolland, two endocrinologists who recently detailed their analysis in The BMJ, in a paper entitled “Web of industry, advocacy, and academia in the management of osteoporosis” [PDF]. They introduce their case by noting:
For many years, recommendations for prevention and treatment of osteoporosis have included increasing calcium intake (by diet or supplements) and use of vitamin D supplements. Since the average dietary calcium intake in most countries is much less than that recommended by guidelines, many older people are advised to take calcium supplements to prevent osteoporosis. The recommendations have been implemented successfully: over half of older Americans take calcium and vitamin D supplements, either prescribed or over the counter, and bone health is the most common specific motivation for use of nutritional supplements. However, this behaviour does not reflect evidence that has emerged since 2002 that such supplements do not reduce the risk of fracture and may result in harm. Guideline bodies also continue to recommend calcium and vitamin D supplements. Here, we argue that change is made difficult by a complex web of interactions between industry, advocacy organisations, and academia.
Osteoporosis is a medical condition for which supplements have been considered an accepted part of conventional medicine for some time. Are conflicts of interest trumping good science? And are calcium and vitamin D supplements truly useless? Like many clinical questions, there is evidence to support a range of opinions, and it’s very difficult to state, with certainty, that one position is the correct one. Despite this, that’s the case that Grey and Bolland make in their analysis.
Osteoporosis can develop over a lifetime
Strong bones are less likely to break. Our bone density peaks when we’re young, and then starts declining. Osteoporosis describes a reduction in the strength and density of the bone, as well as changes in the architecture of the bone itself. We care about osteoporosis because hip fractures and other bone fractures are more likely when bones are weak. Fractures, particularly in the elderly or already debilitated, can lead to reduced mobility issues, disability, and even death. Consequently it’s a significant public health issue, with millions of fractures per year causing hundreds of thousands of hospitalizations. These events significantly impair or reduce quality of life, as well as costing health systems billions. Once osteoporosis is already present, treatments can slow the decline or reduce the risk of fracture, but can’t be expected to restore bones to pre-osteoporosis levels. Consequently there has been tremendous research and medical interest in trying to reduce the likelihood of osteoporosis, with the overall goal of reducing the incidence and consequently the harms that result from fractures. Your future fracture risk is based on your age, your measured bone mineral density, and other factors, some of which can be modified. Drug therapy is usually recommended when the risk of fractures is high, and I won’t discuss those treatments here. In those with low fracture risk, preventative strategies are usually recommended: regular exercise, moderate alcohol/caffeine, and ensuring the diet contains adequate calcium and vitamin D. Given not everyone consumes adequate calcium and vitamin D in their diet, supplementation has been evaluated in clinical trials. While the number of studies is large, these studies have been complicated by the acknowledged difficulties in measuring dietary habits within a clinical trial.
Calcium and vitamin D: The premise
Calcium and vitamin D support the production and maintenance of the skeleton. Calcium is the major mineral in bone. Dietary guidelines for all ages emphasize the importance of dietary calcium as an essential component (along with physical activity and lifestyle factors) of life-long behaviours to promote bone strength and density. While the evidence does not support increasing dietary calcium to reduce fracture burden, it’s also acknowledged that this evidence is confounded by the challenges in measuring daily intake based on self-reported data. In general, calcium supplements are considered unnecessary if adequate amounts are consumed in the diet, which is possible with most diets (even for those that do not consume dairy).
Vitamin D is also important for normal bone development. A deficiency of vitamin D causes the bone-softening disease rickets in children, by reducing the absorption of calcium in the diet (osteomalacia in adults). The elderly and the debilitated may have low levels of vitamin D owing to dietary deficiencies as well as a lack of exposure to sunlight. With vitamin D, the necessity of supplements is less clear, but is typically unnecessary except where there is inadequate intake. In some countries, food (e.g., milk) may be fortified with vitamin D. It has long been hypothesized that vitamin D supplementation may reduce the risk of osteoporotic fractures, and there’s been interest in the role of supplements, particularly in those that may not obtain adequate amounts through diet or through sun exposure.
What’s the level of evidence for calcium and vitamin D?
Grey and Bolland claim that starting around 2002, evidence began to emerge that calcium and vitamin D supplements may not reduce fracture risk:
By the end of 2010, 14 large (>1000 participants) randomised trials of calcium supplements, vitamin D supplements, or their combination had been published: three reported reduction in fracture risk, nine no effect, and two increased fracture risk (figure⇓). Among 24 small randomised trials, 21 found no effect. Meta-analyses of these trials, when analysed by intention to treat, report either no effect on fracture risk or marginal risk reduction of doubtful clinical importance. A trial sequential analysis reported last year that sufficient evidence is available to conclude that vitamin D with or without calcium does not reduce total fracture risk by >10% and that additional trials are unlikely to alter that finding. Randomised trials of the effect of food sources of calcium have not been conducted, but observational evidence does not suggest that increasing dietary calcium intake reduces fracture risk.
They summarize the evidence as follows:
We conclude that increased calcium and vitamin D intake should not have been recommended for older adults living independently after 2007, a view consistent with the conclusion of the 2009 Cochrane review.
And this is the conclusion from that 2009 Cochrane review:
Frail older people confined to institutions may sustain fewer hip fractures if given vitamin D with calcium. Vitamin D alone is unlikely to prevent fracture. Overall there is a small but significant increase in gastrointestinal symptoms and renal disease associated with vitamin D or its analogues. Calcitriol is associated with an increased incidence of hypercalcaemia.
A 2014 Cochrane review had a slightly different conclusion:
Vitamin D alone is unlikely to prevent fractures in the doses and formulations tested so far in older people. Supplements of vitamin D and calcium may prevent hip or any type of fracture. There was a small but significant increase in gastrointestinal symptoms and renal disease associated with vitamin D and calcium. This review found that there was no increased risk of death from taking calcium and vitamin D.
The Cochrane analysis looked at the role of vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men. In the results, the authors note:
There is high quality evidence that vitamin D alone, in the formats and doses tested, is unlikely to be effective in preventing hip fracture (11 trials, 27,693 participants; risk ratio (RR) 1.12, 95% confidence intervals (CI) 0.98 to 1.29) or any new fracture (15 trials, 28,271 participants; RR 1.03, 95% CI 0.96 to 1.11).
There is high quality evidence that vitamin D plus calcium results in a small reduction in hip fracture risk (nine trials, 49,853 participants; RR 0.84, 95% confidence interval (CI) 0.74 to 0.96; P value 0.01). In low-risk populations (residents in the community: with an estimated eight hip fractures per 1000 per year), this equates to one fewer hip fracture per 1000 older adults per year (95% CI 0 to 2). In high risk populations (residents in institutions: with an estimated 54 hip fractures per 1000 per year), this equates to nine fewer hip fractures per 1000 older adults per year (95% CI 2 to 14).
There is high quality evidence that vitamin D plus calcium is associated with a statistically significant reduction in incidence of new non-vertebral fractures. However, there is only moderate quality evidence of an absence of a statistically significant preventive effect on clinical vertebral fractures. There is high quality evidence that vitamin D plus calcium reduces the risk of any type of fracture (10 trials, 49,976 participants; RR 0.95, 95% CI 0.90 to 0.99).
While the review didn’t find evidence of overwhelming efficacy, the authors conclude that calcium and vitamin D does have an effect. They note that side effects are modest and manageable, which is reassuring given recent concerns raised about cardiovascular harms.
Differences of opinion, or conflict of interest?
Having concluded that calcium and vitamin D supplements are ineffective, Grey and Bolland question why they remain in treatment guidelines. The “possible explanation” they offer are vested interests. To evaluate whether vested interests could play an interest, they took the following approach:
We searched the websites of key commercial and advocacy organisations and specialist societies to determine the extent of these interests.
Too profitable to quit?
Grey and Bolland describe calcium and vitamin D supplements as “very profitable” and then cite sales figures – but not actual profits. I have to admit that I laughed out loud when I read this statement. In Canada, calcium and vitamin D are among the least expensive supplements you can buy. While global sales of calcium ($6 billion, 2013) and vitamin D ($748 million, USA, 2012) look impressively large, there’s no evidence that they are excessively profitable, especially compared to the drug products used to treat osteoporosis. It’s also notable that the major treatment guidelines recommend supplements only where calcium and vitamin D dietary requirements cannot be met through a normal diet. Supplementation, when it is recommended, is necessary only to achieve the recommended daily intake.
Grey and Bolland also cite the benefit of supplements to labs that test vitamin D levels. While there has been a surge of interest in vitamin D testing as interest in the therapeutic use of this vitamin has grown, Gray and Bolland offer nothing more that growth in utilization as suggestive of a conflict of interest. There’s nothing conclusive provided that links the two.
Is there evidence of a conflict of interest here?
Grey and Bolland examined the websites of the National Osteoporosis Foundation and the International Osteoporosis Foundation, and suggested that the objectivity of these organizations “may be compromised” by the range of commercial sponsors that support them, which they note include pro-supplement organizations like the Council for Responsible Nutrition as well as food companies like Nestle and Danone. They don’t discuss the numerous pharmaceutical company sponsors that these associations also attract. To be clear, conflicts of interest can be very real. But other than identifying the fact that sponsorship is occurring, Grey and Bolland offer no further argument to demonstrate that the objectivity of these associations are actually compromised. The evidence seems to be restricted to the fact that their treatment guidelines have made a different recommendation about the role of calcium and vitamin D supplementation.
Grey and Bolland note that the two major osteoporosis foundations have not changed their position despite the conclusions of the US Preventive Service Task Force panel, which in 2013 recommended that neither calcium nor vitamin D supplements are necessary in most older adults. Is this due to a conflict of interest? Or is it simply a differing view of the evidence regarding supplementation? Given the evidence remains strong enough for the Cochrane Collaboration to conclude that supplementation has modest effectiveness, it seems a stretch to say (as Grey and Bolland do), that “calcium and vitamin D do not safely reduce fracture risk”.
Grey and Bolland then turn their focus to the interrelationships between researchers and funders that may have vested interests in specific findings. Again, conflicts of this type can be real, and so can publication bias, where positive studies are more likely to be published. They list several examples which they believe provide evidence to support their assertion that industry relationships are poorly disclosed and may be influencing guidelines. But again they provide no actual evidence to demonstrate influence is real.
The authors conclude that the interrelationships between industry, academia, and advocacy organizations provide benefits to all parties at the price of overtreatment, wasted health resources, and ultimately, eroded trust. All of which can be real. But is this really the reason that vitamin D and calcium are in osteoporosis treatment guidelines?
So what can we conclude?
Grey and Bolland believe that there is a web of industry, advocacy and academia that keeps vitamin D and calcium in osteoporosis treatment guidelines. They do not believe these products have any value in the prevention and treatment and osteoporosis, and this, they conclude, must be the reason that they persist in the guidelines. Taking out Occam’s razor, I can describe a second scenario, which I think is more plausible. The role of calcium and vitamin D in the prevention and treatment is indeed controversial. However, there is adequate evidence of sufficient quality that even groups like the Cochrane Collaboration acknowledge that vitamin D with calcium offers a real (albeit modest) reduction in hip fractures and other fractures. And while there have been some worrying safety signals with calcium supplements, there have been no conclusive harms shown with a strategy of maximizing consumption via dietary sources. Given the modest benefits, low cost, and relative lack of side effects, vitamin D and calcium continue to remain a component of osteoporosis treatment guidelines. Are there inappropriate influences at work here? There may be, but little convincing evidence has been provided. Overall, I find the arguments from Grey and Bolland to be weak, and find myself in the rare situation where I continue to see a potential role for supplements as a part of science-based care.

Vitamin D shows no efficacy against moderate to severe COVID-19 infections
A new trial failed to find evidence that a massive dose of vitamin D improves outcomes in patients with moderate to severe COVID-19 infections.
Scott Gavura on March 4, 2021
Link


Vitamin D has long been thought to play a role in supporting immune function, in addition to effects on muscle and bone. Given many people live where there is inadequate sunlight to support vitamin D synthesis for parts of the year, there has been widespread interest in the possible role of vitamin D supplements to help raise vitamin D levels, and possibly prevent infection or minimize the severity of disease. Last September, Dr. Anthony Fauci noted that he was among the millions of Americans that take vitamin D supplements, elevating interest in this supplement. Now a new randomized controlled trial investigates the effects of a single massive dose of vitamin D in hospitalized COVID-19 patients.
What did we already know about COVID-19 and vitamin D?
Dozens of observational studies published since the pandemic began have examined the relationship between vitamin D and COVID-19 infections. Other publications have tried to make sense of all of these studies. The National Institute for Health and Care Excellence (NICE) published guidelines on vitamin D and COVID-19 in December 2020 which incorporated a comprehensive evidence review. It found little evidence for vitamin D to prevent COVID-19 infections:
The panel discussed the evidence for the association of vitamin D status with COVID‑19. They agreed that low vitamin D status was associated with more severe outcomes from COVID‑19. However, it is not possible to confirm causality because many of the risk factors for severe COVID‑19 outcomes are the same as the risk factors for low vitamin D status. Vitamin D is a negative acute phase reactant, meaning its serum concentration falls during a systemic inflammatory response, which may occur during severe COVID-19 illness. Therefore, it is difficult to know if low vitamin D status causes poorer outcomes or vice versa.
The panel discussed the significant limitations in the retrospective association studies. These included historic and inaccurate vitamin D status measurements, lack of generalisability to UK practice, the likelihood of confounding and general low quality of the evidence.
The panel reviewed only one controlled trial that used vitamin D to treat COVID-19, which used oral calcifediol (the circulating metabolite of vitamin D). While the stated outcome of the trial was positive (reduced need for ICU treatment), the panel noted several concerns with the design and approach, leading to the conclusion there remained insufficient evidence to support routine use. Notwithstanding the evidence for prevention and treatment, the panel noted that vitamin D deficiency is widespread in the United Kingdom, so it recommended the everyone should consider a supplement in the winter months, and some should continue supplementing year-round. It did not recommend vitamin D solely to prevent or treat COVID-19, except as part of a clinical trial.
Another comprehensive summary was published in January 2021 by Alberta Health Services which summarizes 12 studies, selected based on quality criteria. This review noted that most of these studies found a statistically significant difference with greater deficiency in those with COVID-19 or more severe disease. However, vitamin D deficiency may be an indicator of general nutritional deficiency, or overall health status. That is, it is possible that this is an association only, and not a causal relationship:
There is an overlap between groups at high risk of vitamin D deficiency and groups at high risk of severe COVID-19. Examples include people with chronic disease, older age, and people of Black and minority ethnic heritage, which makes assessment of observed associations between low vitamin D and COVID-19 infection challenging. Vitamin D levels may be indicative of co-morbidities that may themselves impact COVID-19 outcomes, so whether low vitamin D levels are a cause of disease or consequence of health disparity has remained a point of debate.
The report also identified three prospective randomized controlled trials assessing vitamin D in hospitalized patients with COVID-19, noting the largest trial showed no benefit.This report also noted that it is important to have adequate vitamin D levels, regardless of any potential effects on COVID-19. It recommended that health care providers and patients follow supplementation guidelines established by Health Canada.
So based on these two reviews from the United Kingdom and Alberta, there is sufficient evidence to support routine supplementation of vitamin D, but insufficient evidence to suggest that vitamin D supplementation can help prevent or treat COVID-19.
What did this new study find?
Recognizing that many people are vitamin D deficient and noting the correlation between low vitamin D status and outcomes of COVID-19, this study measured the effect of vitamin D (as vitamin D3, the version usually sold in stores) on hospital length of stay in patients hospitalized with moderate to severe COVID-19. The study is from Igor H. Murai and colleagues from the University of Sao Paulo in Brazil, and was published February 17, 2021 in The Journal of the American Medical Association.
This was a double-blind, multi-site, randomized, placebo-controlled trial that enrolled 240 patients from June through August, 2020. In order to be included participants had to be at least 18 years old, had a confirmed diagnosis of COVID-19, and clinical signs that suggested moderate to severe COVID-19. People were excluded if they were already taking vitamin D3 supplementation or had a number of other factors.
Participants were randomized to a single oral dose of 200,000 IU of vitamin D (that is 200 tablets if you take 1,000 IU tablets, a dose sold in many stores) or placebo. Rather than tablets, the study used vitamin D dissolved in peanut oil. The 200,000 IU dose was chosen as it is in the recommended range for treating individuals with vitamin D deficiency. The primary outcome measured was length of stay, but they also measured in-hospital mortality, the number of patients admitted to the intensive care unit, the number of patients requiring mechanical ventilation, and serum levels of vitamin D. After randomization the groups were fairly evenly matched, with an average age of 56 years and about 55% males.
Effects of Vitamin D supplementation
Before we look at the efficacy, let’s take a look at the effects of this massive supplement on serum vitamin D levels. In Figure 3 (below) vitamin D levels are shown on the day of randomization and also on the day of discharge. In all patients, as well as those who were admitted with a vitamin D deficiency, the vitamin D supplement significantly raised vitamin D levels:
Effects on hospitalization
There were no significant differences between the two groups with respect to the primary endpoint. This was consistent for all patients as well as those who had been admitted with a vitamin D deficiency:
There were no significant differences between the groups for any of the secondary outcomes. No significant adverse events were reported with the exception of one patient who vomited the vitamin D dose.
A companion editorial raises concerns about several limitations in the trial, which are worth noting:
First, the study was underpowered. The authors state that the number of participants was chosen on the basis of feasibility, and that with 208 participants they would have 80% power to detect a 50% difference in hospital length of stay, which is a highly improbable result. Second, the authors excluded patients who required invasive mechanical ventilation and those admitted to the intensive care unit, and less than 15% of patients required noninvasive ventilation. Accordingly, most of the patient population would be considered moderately ill and the results cannot be generalized to critically ill patients, who were excluded. This is important because the benefit of other anti-inflammatory therapies among patients with COVID-19 (e.g., dexamethasone, tocilizumab) is highly dependent on severity of illness, with moderately ill patients receiving little or no benefit and severely ill patients receiving a substantial benefit.13–15 Third, only 115 study participants (48.3%) had vitamin D deficiency (25[OH]D <20 ng/mL), and only about one-fourth of the patients had severe vitamin D deficiency (25[OH]D <12 ng/mL) (based on Figure 3 in the article12). Fourth, although the authors demonstrated that circulating levels of 25(OH)D increased in the patients who received vitamin D3, they did not measure circulating levels of 1,25-dihydroxyvitamin D, the active form of vitamin D. Accordingly, it is unclear whether patients were able to efficiently convert 25(OH)D to 1,25-dihydroxyvitamin D, because this conversion is inhibited by the osteocyte-derived hormone fibroblast growth factor 23, which is elevated in acutely ill patients.
Vitamin D doesn’t seem to help COVID-19, but supplements may still be advisable
In this randomized controlled trial, a single large dose of vitamin D had no effect on outcomes in hospitalized COVID-19 patients. This was despite the measurable effectiveness of the supplement at significantly raising serum vitamin D levels. Prospective trials with vitamin D in COVID have been relatively rare, and have suffered from poor quality and mixed results. The findings from this large trial gives more strength to the hypothesis that low vitamin D levels may correlate with poor COVID-19 outcomes, but may not be worsening them. Having said that, there is good evidence that many people have vitamin D deficiency, and supplementation may in fact be appropriate. But there is no strong evidence to suggest that supplementation will help protect you from severe COVID-19 infections.

Vitamin D supplements do not reduce the risk of depression
A newly-published randomized controlled trial finds vitamin D supplementation has no effect on depression. This adds to the long list of medical conditions for which vitamin D supplementation has turned out to be ineffective.
Scott Gavura on August 6, 2020
Link


Few vitamins continue to disappoint like vitamin D supplementation. But the same could be argued for vitamin research in general: Observational trials find correlations between low levels of, or consumption of, specific vitamins, and a long list of maladies. But when actually studied prospectively, in clinical trials, the evidence comes up short. Again and again and again. Supplementing your diet with vitamins remains popular not because of the evidence, but despite the evidence. Sales of vitamins continue to grow (and have been accelerated by COVID) despite evidence that they are neither necessary nor beneficial for the majority of people that take them.
It is important to note that vitamin supplementation is not pseudoscience. There are some circumstances where vitamin supplementation may be beneficial. While medically significant deficiencies of vitamins are generally rare in developed countries (you don’t see scurvy or rickets much anymore), dietary restrictions, pregnancy, and even socio-economic status may increase the possibility of a deficiency, and in those situations, supplementation may be evidence based. The million (billion) dollar question is whether supplementation in the absence of any clear medical need is advisable or necessary. As a pharmacist I have spent a lot of time “in front of the counter” discussing the merits of vitamin supplements and cautioning consumers that supplementation is not innocuous, despite aisles and aisles of products for self-selection. Many people take the view of vitamins as a reasonable “insurance policy” for their diet, and a net positive thing they can do to support healthy living. And for most of my career, I viewed vitamin supplementation without any clear medical need as producing “expensive urine” for the user, but unlikely to cause much harm. But as more evidence has emerged, my view has changed, and I’m far more skeptical of the net benefits of vitamin supplementation in the absence of a clear deficiency. That position is based on the results of studies that have shown that supplementation is not harmless and has been associated with conditions like heart failure, kidney stones, and overall mortality.
Some of the problems with vitamin supplementation, particularly vitamin D, have emerged when we have identified a correlation between therapeutic levels of a vitamin and a clinical condition. Such is the case for depression where observational research has suggested a potential relationship between vitamin D3 levels and depression. This led to a number of clinical trials that prospectively evaluated vitamin D supplementation using a variety of doses, patient populations, and durations. All but one trial has been negative. Now a new trial provides very persuasive evidence that there’s no there, there.
The trial
The VITAL-DEP trial (Vitamin D and Omega-3 Trial-Depression Endpoint Prevention) was a side trial to the VITAL study, and was published this week. It evaluated the effects of vitamin D3 supplementation on 18,353 adults without depression.
Let’s start with the investigators and the funders. This was a trial primarily funded by the National Institute of Mental Health, with additional grants from other National Institutes. The study supplements were donated by manufacturers. Neither the funders nor any manufacturer had any role in the design or conduct of the study. The lead author was Olivia I. Okereke, from Massachusetts General Hospital and Harvard Medical School. The other investigators are from other US-based healthcare institutions and schools.
The main trial was a double-blind placebo-controlled trial testing vitamin D3 and fish oil supplementation on the prevention of cancer and cardiovascular disease. Participants were randomized into one of four groups, and could receive the active substance, or an identical placebo. The vitamin D3 dose was 2000IU (of cholecalciferol) per day. You were excluded from the trial if you were already taking more than 800IU of vitamin D per day, had cardiovascular disease, and a number of other conditions.
For this side trial, additional exclusion criteria included the presence of clinically relevant depressive symptoms or had features of depression. Other mental health conditions also led to exclusion. After all exclusions there were 18,353 eligible patients.
Patients were followed annually via survey, for a median duration of 5.3 years. Pill adherence (considered to be taking at least 2/3 of the doses) was considered high. A subset of patients had vitamin D levels measured, and the changes were consistent with what was expected.
There were two pre-defined outcomes of interest:
    • Risk of depression or clinically relevant depressive symptoms, defined as a new self-report of depression diagnosed by an MD, new treatment for depression, or the presence of clinically relevant symptoms of depression on an annual questionnaire, using a validated survey tool.
    • Longitudinal mood scores, measured based on annual questionnaires.
This was a large trial, and the authors calculate it was powered to detect minimally clinically important differences between the groups, if any existed. All participants were followed until the occurrence of the end point, death, or the end of the trial. 90.5% of participants finished the trial, and the two groups were well balanced with no meaningful differences between them. Women made up 49% of the population, 17% were minorities, and 19% were Black.
The results
There were 609 cases of depression or depressive symptoms in the vitamin D3 group and 625 cases in the placebo group. The curves tell the story here: Yes there are two lines, but they are virtually superimposed in (A) below:
Across every group (age, ethnicity, baseline D3 use, geography, BMI), there was no effect observed with vitamin D supplements:
Should we stop doing trials with vitamin D?
The evidence for supplementation with vitamin D is unconvincing for the prevention of most medical conditions. However, given the low cost, and relative lack of side effects, vitamin D supplementation at modest doses is safe and has not been shown to be harmful. This large randomized controlled trial provides compelling evidence that vitamin D supplementation has no effect on the risk of depression (or depressive symptoms) or its recurrence in adults aged 50 or older. There is no longer an argument to be made that “more research is needed”. This study is probably enough.
The repeated failure of vitamin D in prospective trials raises the question as to whether or not these large trials can be justified financially with public dollars. On one hand, the compelling results could help patients and physicians make better treatment decisions about vitamin D, if those decisions are influenced by evidence. There is also continued public interest in vitamin D consumption, driven in large part by the supplement industry. Given the limited research dollars available and the number of public health issues that would benefit from research, it would seem that industry should be funding this research. But in the absence of requiring supplement manufacturers to provide persuasive evidence to justify marketing their products, it falls on governments and other researchers to do these types of studies. For that reason, we should be grateful for this study which provides conclusive evidence against the use of vitamin D for the prevention of depression.

Should You Take Vitamin D Supplements?
Recent research found that supplemental vitamin D doesn’t prevent fractures or have any effect on the diseases it has been claimed to help, and blood tests for vitamin D are useless.
Harriet Hall on December 27, 2022
Link

Half of all postmenopausal women will have an osteoporosis-related fracture in their lifetime. Hip fractures are common in the elderly and have serious consequences. More than 300,000 people are hospitalized every year in the US for hip fractures. When untreated, the one-year mortality is 70%; with surgery, the one-year mortality is 21%. Patients may never return to their pre-fracture level of activity and may not even regain the ability to walk. The US Preventive Services Task Force (USPSTF) recommends screening women age 50-64 and younger women at high risk, but their strategy has been tested and found to be little better than chance.
Vitamin D supplements are among the most popular supplements on the market.
A typical pro-vitamin D website, LifeExtension.com, tells us:
Most people can benefit from taking vitamin D. Since it’s unlikely that you’re getting enough vitamin D from the sun and from diet, vitamin D supplements are going to be a good idea for many individuals…Approximately 42% of Americans have vitamin D deficiency.
They acknowledge that experts disagree on what constitutes a normal vitamin D level. Commonly accepted categories are:
    • Deficiency: < 20 ng/mL
    • Insufficiency: 20-30 ng/mL
    • Sufficiency: > 30 ng/mL
But they warn that “normal” may not be optimal. Some authorities define optimal levels as 40-60 ng/mL. They go a step further and recommend aiming for 50-80 ng/mL. They suggest having your vitamin D level tested repeatedly along with your routine blood tests for total blood count and lipid profile.
The USPSTF used to recommend vitamin D and calcium supplements to prevent falls in community-dwelling adults aged 65 years or older who are at increased risk for falls.
Having read information like this, I was worried because I am seldom exposed to the sun and I don’t drink milk. For many years I took a calcium and vitamin D pill prescribed by my doctor. At one point I asked my doctor if I could stop taking it and she said it was probably best to continue.
I thought it was protecting me from hip fractures, but recent research says otherwise. There is a lot of research suggesting associations of low vitamin D levels with mortality, ADHD, depression, cognitive impairment, schizophrenia, diabetes, and some infectious diseases; but the evidence is mixed, often flawed, and low quality. Increasing low vitamin D levels with supplements may not be effective for reversing these conditions. The evidence is summarized in the Wikipedia article on vitamin D.
The VITAL trial was a large placebo-controlled study designed to address the cardiovascular and cancer benefits of omega-3 fatty acids and vitamin D for healthy adults. It found that vitamin D supplements don’t protect against developing cancer or cardiovascular disease, falls, cognitive decline, migraines, stroke, macular degeneration, or joint pain—nor do they reduce body weight or BMI. In an ancillary study published in The New England Journal of Medicine the authors found no difference in the incidence of fractures between those taking vitamin D and those taking placebo. An accompanying editorial by two MDs, Steven Cummings and Clifford Rosen, was titled “A Decisive Verdict on Vitamin D Supplementation”.
They found:
…no substantial between-group differences in fracture incidence among participants who were at high fracture risk (i.e., those taking osteoporosis medications [1240 participants] or with a history of fragility fractures [2578 participants].
And when the blood levels of vitamin D were stratified, even those with levels below 20 ng/mL did not benefit from supplements. There was also no benefit for levels below 12 ng/mL, but the number of people in this group was small, so doubt remains.
Complications: there were no substantial differences in the incidence of hypercalcemia and kidney stones between the vitamin D and placebo groups.
In the light of the VITAL study and other recent research, the editorialists concluded:
Providers should stop screening for 25-hydroxyvitamin D levels or recommending vitamin D supplements, and people should stop taking vitamin D supplements to prevent major diseases or extend life.
They said the terms “deficiency” and “insufficiency” should be reconsidered. And of course, the “sufficient” level of vitamin D has yet to be determined.
They did point out that some uncertainties remained. Blood tests might be useful for some patients who might have severe deficiency, such as people living in residential settings with no sun exposure, patients with malabsorption, or those receiving treatments for osteoporosis that might cause hypocalcemia and may benefit from vitamin D.
I decided to stop taking the calcium/vitamin D pills, and this new information confirms that it was a good decision.

The effects of vitamin D supplementation on major cardiac events
A large randomized controlled trial of vitamin D supplementation generates good data to show there is likely no benefit.
Scott Gavura on July 6, 2023
Link

Vitamin D has a long history of use as a medical treatment of osteoporosis. While observational studies have linked low vitamin D blood levels to a range of illnesses, prospective trials that have examined the medical benefits of vitamin D supplementation have not been impressive. While there have been some high-quality, large prospective trials using vitamin D as a therapy, there are also a huge number of smaller, poor-quality trials, many of which have produced positive results that haven’t been replicated in larger studies. The net effect has been lots of positive attention, but some persistent questions about whether supplementation is useful or beneficial. While testing is widespread, optimal serum concentrations for skeletal health and broader health benefits are controversial, and have not been clearly defined. Now a new randomized controlled trial examines the cardiovascular effects of monthly doses of vitamin D.
Why another trial of vitamin D?
Heart disease and stroke are leading (and growing) causes of death, especially in older individuals. Vitamin D acts on cells throughout the vascular system, reducing inflammation, regulating the renin-angiotensin-aldosterone system, and inhibiting vascular smooth muscle proliferation. Observational studies have shown an inverse relationship between vitamin D levels and cardiovascular disease risk. Prospective controlled trials, on the other hand, have produced mixed results. Some studies indicate an inverse association with cardiovascular disease risk at certain vitamin D levels, while others found no significant association. Consequently, there is ongoing interest in verifying if vitamin D can reduce the risk of disease.
A meta-analysis of randomized controlled trials concluded that vitamin D supplementation did not prevent cardiovascular events. However, that analysis was predominantly based on the Women’s Health Initiative Trial, which had limitations in terms of participant characteristics, dosage of vitamin D, and compliance. The Vitamin D Assessment (ViDA) study and the Vitamin D and Omega 3 trial (VITAL) also found no effect on cardiovascular disease outcomes, but they both had noted limitations.The D-Health Trial was a large study involving 21,315 older Australians. Previous analyses of the trial showed no reduction in all-cause mortality or cardiovascular mortality with vitamin D supplementation. However, the impact on major cardiovascular events specifically had not been analyzed. In this current study, we examined data from the D-Health Trial to determine if monthly vitamin D supplementation (60,000 IU) affected the incidence of major cardiovascular events in Australians aged 60 years and above.
The D-Health Trial
The D-Health Trial was a randomized controlled trial with two groups: vitamin D recipients (60,000 IU of vitamin D3 (cholecalciferol)), or placebo, taken as once monthly doses. The trial included adults aged 60-79 years from across Australia. Every year, participants were sent 12 tablets, and reminded to take them monthly by text, email or landline call. Participants were selected randomly from voter registration, which is mandatory in Australia. Additionally, individuals aged 60-84 years were also recruited through media coverage and existing participants’ contacts. Individuals with specified conditions, (hypercalcaemia, hyperparathyroidism, kidney stones, osteomalacia, sarcoidosis) or those who already consumed more than 500 IU of vitamin D per day were excluded from the trial. Participants in the study provided information about their demographics, lifestyle, health conditions, and vitamin D intake through a baseline questionnaire.
Participants were asked annually to report the number of study tablets they consumed, and if they took any other vitamin D supplements outside of the study. Adherence was assessed by comparing the number of tablets taken to the total number they should have taken if fully adherent ( 60, except for those who died during the trial). Participants were encouraged to limit their use of vitamin D supplements not provided by the study, but were allowed continue in the trial as long as that intake did not exceed 2000 IU per day. (This would keep intake below 4000 IU per day.)
Cardiovascular events were one of the planned outcomes in the D-Health Trial, along with 44 other outcomes. The main outcome was the occurrence of the first major cardiovascular event, (myocardial infarction, stroke, or coronary revascularization). Secondary outcomes included the first myocardial infarction, stroke (total, ischemic, and hemorrhagic), and coronary revascularization. Events were determined from linked hospital data, medicare benefits data, and mortality records, which was very comprehensive owing to Australia’s universal health insurance system. Australia’s Pharmaceutical Benefits Scheme has data on prescription drug use and was used to determine use of statins and other cardiovascular drugs.
The sample size was determined to ensure 80% power to detect a 9% difference in the mortality rate, with a type 1 error rate of 0.05. Based on the available sample size for this analysis (n=21,302), the authors estimated they would have 80% power to detect a 16% difference in the incidence of the first major cardiovascular event. Participants were followed from the time of randomization until the earliest occurrence of a major cardiovascular event, the last known date of being alive, five years and one month after randomization, or December 31, 2019 (the date which hospital data were available for all states).
Over 21,000 participants were recruited and participated. At the end of the five-year trial, the majority of participants (79%) were still taking the study tablets. The percentage was similar between the vitamin D group (80%) and the placebo group (78%). Before completing the intervention period, 866 individuals died. The average duration of treatment was five years, and over 80% of participants reported taking at least 80% of the study tablets. This adherence rate was consistent in both the vitamin D group (84%) and the placebo group (82%).
During the trial, the mean serum 25(OH)D concentration was 77 nmol/L (with a standard deviation of 25) in the placebo group, while it was 115 nmol/L (with a standard deviation of 30) in the vitamin D group. The incidence of adverse events was comparable between the two groups.
Overall, there were a total of 1,336 major cardiovascular events. Among these, 637 occurred in the vitamin D group (6.0%) and 699 in the placebo group (6.6%). The rate of major cardiovascular events was slightly lower in the vitamin D group compared to the placebo group, with a hazard ratio of 0.91 (confidence interval 0.81 to 1.01). Given the confidence interval crossed one, this means that there was no statistically significant effect. On average, 172 participants would need to be treated (NNT) with vitamin D supplementation to prevent one major cardiovascular event. The confidence interval for this estimate (not provided by the authors) is 82 to infinity. If 1,000 people aged 60-84 in this group of participants took a placebo, 66 will have a cardiovascular event. If the same group took, vitamin D, that might drop to 60. Or there may be no difference.

When you dig into the hazard ratios for the individual events, there are some statistically significant differences (e.g., heart attack, which is barely significant). At this point this feels a bit like dumpster diving for positive results, so I’ll leave a link to that data here if you want to peruse it.
Conclusion: Vitamin D likely offers no cardiovascular benefits
We already know from this same data set that vitamin D had no effect on all-cause mortality. This well done clinical trial offers modest evidence that supplementation may reduce the incidence of some cardiovascular events. However, in aggregate, no benefit was show on overall cardiovascular event occurrence. When considered in the context of accumulated research to date that has showed vitamin D has no measurable benefit, it is difficult to consider even these very weak findings to be very compelling. We do know that vitamin D is inexpensive, and that there is low risk of toxicity. But this trial adds to the body of evidence showing no cardiovascular benefits to supplementation.

Does Vitamin D Prevent Autoimmune Disease?
A new study published in The BMJ suggests vitamin D might prevent autoimmune disease, but there are reasons to be cautious.
Harriet Hall on September 13, 2022
Link
Up to 75% of American teens and adults are said to be deficient in vitamin D, but there is no agreement on what level constitutes deficiency. Claims for the health benefits of vitamin D supplements abound, from preventing dementia and cancer to reducing the risk of infections and heart disease.A study of vitamin D and fish oil in The BMJ has been getting a lot of press, with claims that autoimmune disease can be prevented with dietary supplements and even a prediction that doctors may soon recommend vitamin D supplements for all adults over the age of 50. When I read the study, I wasn’t expecting much; I’ve become jaded from the many news reports that take a simple correlation and try to hype it as evidence of causation. This study didn’t make that mistake, but neither did it provide convincing evidence that everyone should start taking supplements.
The study
The study was a large, randomized, placebo-controlled evaluation of two supplements, vitamin D (cholecalciferol; 2,000 IU/day) and marine omega 3 fatty acids (1 g/day as a fish oil capsule containing 460 mg of eicosapentaenoic acid and 380 mg of docosahexaenoic acid), to assess their benefits and risks for the prevention of autoimmune disease. Patients self-reported new diagnoses of autoimmune diseases during the study, and these diagnoses were reviewed for accuracy by physicians.
Findings
Vitamin D supplementation for five years, with or without omega 3 fatty acids, reduced autoimmune disease by 22%, while omega 3 fatty acid supplementation with or without vitamin D reduced the autoimmune disease rate by 15% (not statistically significant).
Some caveats
Most participants were not deficient in vitamin D.The dose of vitamin D was higher than the recommended daily level.No benefit was seen for any individual autoimmune disease.This study has not yet been confirmed by other independent research.The relative risk reduction was 22%, the absolute risk reduction was much less. If vitamin D were being used to reduce the risk of autoimmune diseases, the number needed to treat would be expected to be high.This was part of the VITAL study which involved 16 ancillary studies, most of which had negative results; since there was no statistical correction for multiple comparisons, one false positive result at the p=0.05 level could be expected.
Conclusion: still many unanswered questions
If vitamin D can help prevent autoimmune disease, we still don’t know who is most likely to benefit (only those with a deficiency of vitamin D?), or what dose they will need. More research will be needed to provide better guidance. Meanwhile, it seems obvious that the evidence doesn’t support giving it to everyone over a certain age. As is all too often the case, media enthusiasm outran the data.

Vitamin D for the prevention of COVID-19: A randomized controlled trial
A large clinical trial shows vitamin D supplementation had no effect on COVID-19.
Scott Gavura on March 31, 2022
Tweet

Depending on where you live, and the persistence of public health rules like masking and vaccination entry requirements, it feels like the beginning of the end of COVID-19, or maybe the end of the end. While some have made the decision to “move on” after more than two years, there’s still a lot of COVID-19 being spread around, along with the continued problem of getting populations vaccinated. Recognizing that disease control will continued to be challenged by new variants, waning immunity, possible vaccine escape, and continued vaccine hesitancy (where vaccines are widely available), we continue to need good measures for preventing or controlling disease.
A year into the pandemic I blogged about one of the earliest randomized controlled trials that studied vitamin D for the prevention of COVID-19. Vitamin D has long been thought to play a role in supporting immune function, in addition to effects on muscle and bone. Given many people live where there is inadequate sunlight to support vitamin D synthesis for parts of the year, deficiency, particularly in older adults, is common. There has been widespread interest in the possible role of vitamin D supplements to help raise vitamin D levels, and possibly prevent infection or minimize the severity of disease. This was the case prior to the arrival of COVID-19, and interest grew in the early period of the pandemic, particularly before the arrival of effective vaccines.
Trials studying the effectiveness of vitamin D for the prevention of upper respiratory infections have been either negative or weakly positive. No clear, consistent benefit has been established. A challenge with much of the observational data is that vitamin D blood levels may be a indicator of poor overall health status, but deficiency may not independently be causing more illness. This highlights the importance of prospective trials with randomization, where actual causality can be inferred. The study I blogged about a year ago was an interesting design of a single dose of 200,000 IU (which would be the equivalent of taking 200 tablets of the standard 1000 IU tablet strength). Compared to placebo, the massive dose did raise vitamin D levels in the blood but had no effect on any of the outcomes measured.
The trial
This new trial, which has been published as a preprint (meaning it has not undergone peer review), was recently discussed on Twitter by epidemiologist Gideon Meyerowitz-Katz. It is from David A. Jolliffe and colleagues from a number of centres across the United Kingdom. It’s titled “Vitamin D Supplements for Prevention of Covid-19 or other Acute Respiratory Infections: a Phase 3 Randomized Controlled Trial (CORONAVIT)”. CORONAVIT was a prospective trial conducted “within” the COVIDENCE cohort study, which was a trial established in May 2020 with the goal of identifying risk factors related to COVID-19 infections.
This was a three-arm, parallel, open label study. To be included, you had to be 16 years of age and participating in the COVIDENCE trial. You were excluded if you were already taking vitamin D, or had a small number of medical conditions. 6,200 patients were assessed as eligible, and randomized (1:1:2) as follows:
     1.  High Dose Group – Offered supply of 3,200 IU vitamin D per day if their blood 25(OH)D levels were less than 75 nmol/L
     2.  Low Dose Group – Offered supply of 800 IU vitamin D per day if their blood 25(OH)D levels were less than 75 nmol/L
     3.  No Dose Group – Not offered testing or any supply of vitamin D
Participants were asked to complete monthly follow-up survey which included questions about respiratory infections, exacerbations of asthma or chronic obstructive pulmonary disease, COVID-19 symptoms, and adverse effects. The final survey was sent in June 2021 which was the six-month follow-up. Vitamin D testing was offered to a subset of participants (800 in each treatment group and 400 who were randomized but received no treatment.)
The primary endpoint was the proportion of participants that developed at least one (swab- or physician-confirmed) acute respiratory illness of any kinds. Secondary endpoints included:
    • the proportion of participants developing (PCR-confirmed) COVID-19
    • the proportion of participants hospitalized for COVID-19
        ◦ the proportion of hospitalized patients requiring respiratory support (i.e., mechanical ventilation)
    • the proportion of all participants dying of COVID-19
    • the proportion of participants developing confirmed COVID-19 who reported symptoms lasting more than four weeks
        ◦ the proportion reporting ongoing symptoms at the end of the study
Harms that were measured included the incidence of death, serious adverse effects (and the % leading to discontinuation from the study), high calcium and high levels of vitamin D.
The results
Here is a snapshot from Table 1 showing baseline characteristics. The median age of participants was 60 with a fairly wide age range (16-88+), predominantly female, and overwhelmingly White (94%+).
Only a small percentage (2.5%) of participants had been vaccinated (1 or more doses) at the time of recruitment.
In those where baseline vitamin D was tested, the mean 25(OH)D was 39.7nmol/L. Per the UK National Health Service, adequate levels are defined as ≥75 nmol/L, and 97.4% were below this threshold. Almost all (95.4%) of participants randomized to the treatment groups consented to a 25(OH)D test (by mail).
Follow-up was for six months (December 2020 to June 2021). During this period almost 90% received one or more doses of a COVID-19 vaccine. 90.9% of participants randomized to treatment reported they took their vitamin D supplement at least 6 days per week. In the intention-to treat analysis, there were significant increases in vitamin D levels noted in those on the supplements:
    • High dose treatment 102.9 nmol/L
    • Lower dose treatment 79.4 nmol/L
    • No treatment 66.6 nmol/L
In a sensitivity analysis where non-adherent participants were excluded as well as those in the no-treatment group that actually took vitamin D supplements, the differences were greater:
    • High dose treatment 103.4 nmol/L
    • Lower dose treatment 79.5 nmol/L
    • No treatment 53.7 nmol/L
Primary and secondary endpoints
So did vitamin D prevent respiratory infections, including COVID-19? No. There were no statistically significant differences between the group in terms of the proportion who experienced at least one confirmed acute respiratory infection. With some of the measures like symptom persistence, the vitamin D groups look (non-significantly) worse. There were also no differences in the incidence or severity of COVID-19 infections, the duration of related symptoms, or in any other measure (I have trimmed out the P values here for readability, they’re on page 20 if you want to see them).
A subgroup analysis showed no evidence that vaccination modified the effects of the allocation. Moreover, the sensitivity analysis (described above) did not reveal any differences compared to the primary, intention-to-treat, analysis. That is, excluding patients in the control group who took vitamin D supplements didn’t change the results. Also, excluding patients in the treatment groups who were non-compliant with therapy didn’t change the results.
There were few adverse events. A few patients in the high-dose group developed hypercalcemia and symptoms resolved with the discontinuation of vitamin D.
Conclusion: Vitamin D strikes out again
There were multiple strengths to this study, including the baseline low levels of vitamin D, and the demonstrable effectiveness of the supplements. Compared to the study I blogged about a year ago, this was a more typical (daily) dose versus a single massive dose. There were few dropouts and a modest number of COVID-19 cases. The limited number of cases, particularly of hospitalizations, means we need to be cautious in making definitive conclusions. However, there was no suggestion of benefit.
In this randomized controlled trial, vitamin D had no effects on the incidence or consequences of COVID-19 or other acute respiratory infections. This was despite active treatment with vitamin D that did meaningfully raise serum vitamin D levels.
This is another prospective trial with vitamin D in COVID-19 to show no meaningful effect in the prevention of acute illness. Having said that, it’s clear that (at least in this population) vitamin D deficiency is widespread, and supplementation may be appropriate for individuals anyway. But there continues to be no persuasive evidence to suggest that vitamin D supplementation will help protect you from COVID-19 infections.vurv

Vitamin D and Diabetes: Another Case Where Supplementation Sounded Like a Good Idea But Wasn’t
A new study shows vitamin D supplements don’t prevent diabetes. But there are still unanswered questions.
Harriet Hall on August 13, 2019
Link

Low vitamin D levels appear to be a risk factor for diabetes. Observational studies have found a correlation between a low blood level of Vitamin D (25-hydroxyvitamin D) and the risk of developing type 2 diabetes. There is biological plausibility, and supplementation has been shown to improve pancreatic beta-cell function. But does vitamin D supplementation lower the risk of diabetes? A new study just published in The New England Journal of Medicine set out to answer that question. The answer was “No.” But questions remain.
The study
It was a gold-standard trial: a large, well-designed, rigorous, multiauthor, multicenter randomized double-blind placebo-controlled clinical trial sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases, independently monitored, with no input from manufacturers. The 2,423 participants were at high risk of developing diabetes: they met at least two out of three glycemic criteria for prediabetes. 44.8% were women, 33.3% were non-white, mean age was 60 years, and mean BMI was 32.1. They were randomized to get either a daily soft-gel pill of vitamin D3 (4000 IU of cholecalciferol) or a matching placebo. They were followed for an average of 2.5 years.
Optimal vitamin D levels are still controversial. Values from 20 to 50 ng/ml are generally considered adequate. In this study, 21.7% of participants had levels below 20ng/ml. Average baseline serum level of vitamin D was 28 ng/ml; this rose to 54.3 ng/ml in the vitamin D group but remained unchanged at 28.8 ng/ml in the placebo group. 293 people in the vitamin D group developed diabetes compared to 323 in the placebo group. The difference was not statistically significant.
The study’s results were consistent with the results of other studies. Giving everyone supplemental vitamin D is not likely to decrease the incidence of diabetes. But what if we targeted people with unusually low levels? This study did not ask or answer whether supplementation could prevent diabetes in people with very low serum levels of vitamin D. That would be nice to know.
Vitamin D deficiency and correlation vs. causation
Some people don’t get enough sun or a good enough diet to prevent vitamin D deficiency. The elderly, breastfed infants, and certain other high-risk groups are particularly susceptible. Deficiency may cause rickets or osteoporosis. In many cases, supplemental vitamin D is indicated. But in many other cases, supplemental vitamin D has been recommended without any real evidence that it does any good.
In addition to diabetes, low levels of vitamin D have also been linked to a long list of other health problems, including an increased risk of cardiovascular disease, cancer, pre-eclampsia, hypertension, multiple sclerosis, autism, Alzheimer’s disease, rheumatoid arthritis, inflammatory bowel disease, asthma severity, the flu, and even all-cause mortality. These links are only correlations. Correlation is not the same as causation. If A is correlated with B, that could mean that A causes B, that B causes A, that some other factor causes both A and B, or it could be a spurious correlation, like the correlation between civil engineering doctorates awarded and the per capita consumption of mozzarella cheese. We need to know whether the low level of vitamin D causes the increased health risk. If we determine that it is a cause, it’s only natural to assume that raising the vitamin D level with dietary supplements will reduce the risk. But assumptions can be wrong, and the only way to know is to test the assumptions.
Common sense can be wrong
This new study of diabetes is one of several studies that have recently shown that dietary supplementation is not the answer. Here are just a couple of examples:
    • A large randomized placebo-controlled double blind study published in The New England Journal of Medicine in January 2019 found that supplementation with vitamin D did not reduce the risk of cancer or cardiovascular disease.
    • A study of older African-American women found that vitamin D supplementation did not prevent cognitive decline.
This is part of a pattern. Whenever a low level of any nutrient is linked to a disease, people tend to assume that raising the level with supplements will prevent the disease. But testing often proves otherwise. For instance, a high level of homocysteine is a risk factor for heart disease, and it’s associated with low levels of vitamins B6, B12, and folate. Vitamin supplements effectively lower the level of homocysteine, but they do not reduce the risk of heart disease.
More is not always better
If vitamin D is a good thing, that doesn’t mean that more is necessarily better. In some cases, supplements are just a waste of money. What’s worse, too much vitamin D can be harmful. A Canadian man who was prescribed high doses by a naturopath developed kidney damage. And Gary Null sued the manufacturer of “Gary Null’s Ultimate Power Meal” when a bad batch of his eponymous dietary supplement nearly killed him. He thought he was getting 2000 IU of vitamin D per day (the recommended upper limit) but he was actually getting 2 million IU. Oops!
Bottom line: Test everything
We can’t rely on logic or common sense. Assumptions may seem very convincing, but they must be tested with controlled scientific studies. More research is needed to clarify what level of vitamin D is optimal and when raising low levels with supplements is beneficial. We’ll have to stay tuned.

Vitamin D supplements do not reduce the risk of cancer or cardiovascular disease
Vitamin D has been widely touted as beneficial for preventing cancer and cardiovascular disease. A large, well-conducted clinical trial now show that it has no effect.
Scott Gavura on January 10, 2019
Link

Vitamin supplements are a triumph of marketing over evidence, where sales continue to grow despite the evidence that they are neither necessary nor beneficial for the majority of people that take them. There are absolutely cases where vitamins are beneficial, however. While medically significant deficiencies of vitamins are generally rare in developed countries (you don’t see scurvy much anymore), dietary restrictions, pregnancy, and even socio-economic status may increase the possibility of a deficiency, and supplementation may be evidence based. It’s more of an open question if supplementation in the absence of any clear medical need is advisable or necessary. As a pharmacist I have spent a lot of time “in front of the counter” discussing the merits of vitamin supplements and trying to convince people that more is not necessarily better. Many patients take the view of vitamins as a reasonable “insurance policy” for their diet, and a net positive thing they can do to support healthy living. And for most of my career, I viewed vitamin supplementation without any clear medical need as producing “expensive urine” for the user, but unlikely to cause much harm. But over the past 25 years, my view has changed, and I’m far more skeptical of the net benefits of vitamin supplementation. That position is based on the results of multiple studies that have shown that vitamin supplementation is not always harmless – in some cases vitamins even appear to be harmful.
Many of the problems with vitamin supplementation have emerged when we have assumed that isolated vitamins are an appropriate or equivalent substitute for foods that contain those same vitamins. Compound this with the equally bad idea that more=better, and you have supplement doses much higher than would be consumed in diet alone. Antioxidants are the most representative example. The idea for antioxidants emerged from observations about oxidative stress and their contribution to illness and aging, and the hypothesis that antioxidant supplements could minimize these effects. Yet trials have failed to show that antioxidant supplements have the same effects as antioxidant-rich foods. Over time it became clear that beta-carotene supplements could raise your risk of cancer. Vitamin E supplements also appears to raise, rather than lower, prostate cancer risk.
Vitamin D deficiency results in the bone disease rickets and supplementation (in combination with calcium supplements) has established effectiveness in the prevention of fractures in those with osteoporosis. But there has been widespread interest for some time about the purported ability of vitamin D to prevent or treat almost any condition, driven by observational studies have linked low vitamin D levels to a range of illnesses. This has in turn driven widespread interest in supplementation, as well as the interest in testing vitamin D levels in the blood, in the hopes that apparent “deficiencies” can be identified and treated. Back in 2016 I summarized a narrative review that looked at vitamin D use for multiple health outcomes. It concluded that the evidence for supplementation was unconvincing for most uses. In that post, I noted that there was little evidence to show supplementation had any meaningful effect in cancer, but better quality evidence was needed. In mid-2018, I summarized a paper that examined the relationship between vitamin D levels and colorectal cancer risk, and found, again, the evidence for supplementation was unconvincing. Now a new, large randomized trial provides good evidence that vitamin D supplementation to prevent cancer (and cardiovascular disease) is ineffective.
VITAL answers
This was the VITamin D and OmegA-3 TriaL (VITAL) (NIH funded, thank you residents of America) that looked at vitamin D (as D3, cholecalciferol) 2,000 IU per day and marine n-3 (omega-3) fatty acids at a dose of 1,000 mg per day. For this blog post I will focus only on the vitamin D results and leave the omega fatty acids for a future post. 25,871 participants (including 5,106 black participants) were recruited from across the United States, and balanced with respect to sex. Participants had to have no history of cancer or cardiovascular disease. They were randomized to one of: vitamin D + omega-3, vitamin D + placebo, placebo + omega-3, or dual placebos. Men had to be at least 50 years of age, and women, 55 years of age. The primary endpoints of interest were (1) cancer of any type and (2) a major cardiovascular event (heart attack, stroke, or death from cardiovascular disease.) There were a number of secondary endpoints.
Participants received periodic surveys to assess adherence, use of additional vitamin D supplements, development of major illnesses, and potential side effects of trial agents.
Results
There was an increase in average vitamin D levels from 31 ng/mL to 42 ng/mL in vitamin D recipients and no change in the group that received placebo. There were no significant differences with respect to adverse (side) effects reported either group. Over a median of 5.3 years, there was no significant difference found between vitamin D recipients and placebo recipients in terms of the major endpoints: cancer or major cardiovascular events. Additional, there were zero difference in all-cause mortality. No impressive graphs to show with this study – all the lines can be superimposed, as there are no differences between the groups. In terms of secondary endpoints, there was a reduction in deaths from cancer. The authors note that vitamin D was associated with a 25% decrease in cancer deaths that started one to two years after participants began treatment (which they argue is relevant for slowly developing diseases, like cancer). However it’s important to note that overall, there were no mortality differences.
Discussion
This new trial answers important questions that had been raised in previous reviews. The US Preventive Services Task Force has previous concluded that there was insufficient evidence to evaluate vitamin D for the prevention of cancer or cardiovascular disease. The Institute of Medicine reached a similar conclusion. This new trial used a larger dose of vitamin D, and also included a substantial number of black participants, for whom the self-synthesis of vitamin D is lower than other ethnic groups. From this study we can conclude that for healthy adults, supplementing with 2,000 IU/day of vitamin D is not effective for the prevention of cardiovascular disease or cancer. If you’re taking vitamin D with the hope of preventing cardiovascular disease or cancer, this study doesn’t suggest that you need to stop supplementing. But neither does it suggest that your supplementing is doing anything beneficial. Given the totality of evidence for vitamin D, supplementation may be appropriate in some circumstances, such as the prevention or treatment of osteoporosis. But there is now convincing evidence that supplementing to prevent against cancer or cardiovascular disease is not warranted.
.

Vitamin D and the relationship to colon cancer
Colorectal cancer is common. A new study examines the relationship with vitamin D levels.
Scott Gavura on June 28, 2018
Tweet

Almost every week there a new story about vitamin D and its relationship with some health outcome. There is a long list of observational studies have linked low vitamin D levels to a range of illnesses. This has driven widespread interest in supplementation, as well as the interest in testing vitamin D levels in the blood, in the hopes that apparent “deficiencies” can be identified and treated. Back in 2016 I summarized a narrative review that looked at vitamin D use for multiple health outcomes. It concluded that the evidence for supplementation was unconvincing for most uses. In that post, I noted that there was little evidence to show supplementation had any meaningful effect in cancer, but better quality evidence was needed. Recently a new paper was published that examined the relationship between vitamin D levels and colorectal cancer risk. Colorectal cancer is a very common cancer (your lifetime risk is about 4.2%) and any intervention to reduce the overall incidence of cancer would offer significant public health benefits. I took a closer look at the new paper to determine if my 2016 assessment required revision. Key questions include (1) the relationship between blood levels of vitamin D and colon cancer incidence, and (2) whether or not vitamin D supplementation has any relationship with colon cancer. As you’ll see these are two very different questions.
The evidence thus far
Vitamin D has for some time been associated with colorectal cancer, in the belief that it can lower colorectal cancer risk via antiproliferative, pro-apoptotic, and anti-angiogenic properties
Back in 2016 I referenced a meta-analysis of existing randomized controlled trials of vitamin D supplements, with or without calcium, which looked at an range of outcomes, including cancer. It looked at seven trials for cancer, involving over 48,000 patients and noted that supplementation “lay within the futility boundary, indicating that vitamin D supplementation does not alter the relative risk of any of these endpoints by 15% or more.” The authors’ conclusion was that “Future trials with similar designs are unlikely to alter these conclusions.” I had also noted that the Cochrane Review had also concluded that there was a lack of evidence to support vitamin D supplementation:
There is currently no firm evidence that vitamin D supplementation decreases or increases cancer occurrence in predominantly elderly community-dwelling women. Vitamin D₃ supplementation decreased cancer mortality and vitamin D supplementation decreased all-cause mortality, but these estimates are at risk of type I errors due to the fact that too few participants were examined, and to risks of attrition bias originating from substantial dropout of participants. Combined vitamin D₃ and calcium supplements increased nephrolithiasis, whereas it remains unclear from the included trials whether vitamin D₃, calcium, or both were responsible for this effect. We need more trials on vitamin D supplementation, assessing the benefits and harms among younger participants, men, and people with low vitamin D status, and assessing longer duration of treatments as well as higher dosages of vitamin D. Follow-up of all participants is necessary to reduce attrition bias.
The new study
This new study, entitled “Circulating Vitamin D and Colorectal Cancer Risk: An International Pooling Project of 17 Cohorts ” is an analysis of 17 studies that looked at the relationship between circulating vitamin D levels in the blood, and the relationship with colorectal cancer. It was funded by the National Heart, Blood, and Lung Institute and the National Cancer Institute. This was not a study that looked at supplementation. The authors combined data sets to give a final count of 5,706 patients that had developed colorectal cancer, and 7,107 patients that had not. All of the studies had collected blood samples pre-diagnosis, and all tested for 25(OH)D or 25-hydroxyvitamin D in a consistent manner (which allowed pooling) as all were part of the international Circulating Biomarkers and Breast and Colorectal Cancer Consortium. (25(OH)D is the commonly-accepted measure for vitamin D levels in the body.) Those with cancer were matched according to main characteristics (gender, age, etc.) The authors then estimated the risk of cancer by the absolute (pre-cancer) blood concentration of 25(OH)D.
There was voluminous statistical analysis done, and I will leave it to methodologists to appraise. The population studied was mainly white (83.9%), fairly evenly split male/female, and the median age at blood draw was 60 years. The median time from blood draw to cancer diagnosis was 5.5 years. The authors created quintiles of 25(OH)D measurements, using the 3rd quintile as the reference. In a logistical regression model, participants in the lowest quintile had a 23% greater risk of colorectal cancer, and those in the highest quintile had a 21% lower risk of colorectal cancer. This trend was observed even after adjusting for exercise, body mass index (BMI), recognized non-dietary colorectal cancer risk factors, and alcohol consumption. They also adjusted for seasonal variation in vitamin D levels. Figure 1 shows the key observation well, showing risk decreasing as levels are higher. You can also see that the association was stronger in women than in men.

The authors found that colorectal cancer risk decreased steadily and significantly with increasing pre-diagnosis 25(OH)D levels, up to 100 nmol/L. Circulating 25(OH)D at levels below 30 nmol/L (considered “deficient” by the IOM) was associated with a 31% greater risk of colorectal cancer compared with 50 to <62.5 nmol/L, the lower range of 25(OH)D considered sufficient for bone health. Interestingly, colorectal cancer risk was lower at 25(OH)D concentrations that are higher than those currently considered sufficient for bone health. What this study doesn’t answer, and can’t answer, is whether or not people with higher vitamin D levels (and lower rates of colorectal cancer) differed in some unobserved way from those with lower levels. This could mean that vitamin D isn’t the causative factor at all.
The bottom line
        ◦ The evidence for supplementation with vitamin D is not that convincing. However, given the modest benefit, low cost, and relative lack of side effects, vitamin D supplementation at modest doses is safe and is not likely to cause harm. This newest study does not show that there is a benefit to supplementation, however it does show a positive association with higher levels. How those levels may have become higher (diet vs. supplementation vs. sun exposure) was not explored in this study. While this new study shows what appears to be a relationship between vitamin D levels and colorectal cancer, it doesn’t tell us anything about supplementation itself. At this time, there is little support in treatment guidelines for vitamin D supplementation to prevent colon cancer. However, it adds to the body of evidence about vitamin D and cancer. It would seem the safest things to do to avoid colorectal cancer would be to ensure that you’re getting adequate vitamin D in your diet, and, perhaps more importantly, you’re addressing the biggest factors for colorectal cancer prevention. Until better evidence emerges, continuing to take a cautious approach to vitamin D supplementation seems the most reasonable approach.

The rise and inevitable fall of Vitamin D
Scott Gavura on June 23, 2016
Link


It’s been difficult to avoid the buzz about vitamin D over the past few years. While it has a long history of use in the medical treatment of osteoporosis, a large number of observational studies have linked low vitamin D levels to a range of illnesses. The hypothesis that there is widespread deficiency in the population has led to interest in measuring vitamin D blood levels. Demand for testing has jumped as many physicians have incorporated testing into routine care. This is not just due to alternative medicine purveyors that promote vitamin D as a panacea. Much of this demand and interest has been driven by health professionals like physicians and pharmacists who have looked at what is often weak, preliminary and sometimes inconclusive data, and concluded that the benefits of vitamin D outweigh the risks. After all, it’s a vitamin, right? How much harm can vitamin D cause?
There’s no lack of research on vitamin D. Unfortunately, much of that research has been observational, which can find interesting correlations, but can’t demonstrate cause and effect. While there have been some high-quality, large prospective trials using vitamin D as a therapy, there are also a huge number of smaller, poor-quality trials, many of which have produced positive results that haven’t been replicated in larger studies. The net effect has been lots of positive press, but some persistent questions that may not be as widely understood. A new paper from Michael Allan and colleagues set out to summarize the evidence base for vitamin D across multiple uses. It was published in the Journal of General and Internal Medicine, and is entitled “Vitamin D: A Narrative Review Examining the Evidence for Ten Beliefs.” And scanning the list, most of the common claims and beliefs are there: osteoporosis, falls, colds and the flu, cancer, etc. As a narrative review, it is important to note that this type of paper has a high risk of bias. The authors do state that they preferentially sought out systematic reviews and meta-analyses (which, when well conducted, can produce very objective information) but when wrapped in a narrative commentary, the risk of bias increases. This doesn’t mean the findings are incorrect, but that the conclusions emerging from a narrative review (compared to a well-conducted systematic review) will be less robust and quantifiable. While the paper is behind a paywall, I will touch on each of the myths and the evidence they cite, because the paper neatly summarizes the overall evidence base for many of the claims made for vitamin D that I and other contributors have discussed in past posts.
#1: Vitamin D supplementation may modestly reduce falls in the elderly
A few small observational trials found an association between low levels of vitamin D and falls in the elderly. Falls are a source of considerable morbidity in this group, so a cheap vitamin that has even a modest effect at reducing falls would be welcomed and likely quickly put into use. There have been eight meta-analyses conducted, with overall inconsistent results. The effect of vitamin D may be real, but if real, it is modestly effective at reducing both the number of falls and the number of people that fall. The effect estimate may fall into the “futility boundary”, implying borderline clinical significance.
#2: Vitamin D supplementation may reduce fractures, when given with calcium
I blogged about vitamin D, calcium and fractures several months ago in response to a paper that claimed that treatment guidelines that included these products were not evidence-based, and were more likely due to a confluence of conflicts-of-interest. I disagreed.
Calcium and vitamin D support the production and maintenance of the skeleton. Calcium is the major mineral in bone. Dietary guidelines for all ages emphasize the importance of dietary calcium as an essential component (along with physical activity and lifestyle factors) of life-long behaviours to promote bone strength and density. Vitamin D is also important for normal bone development. A deficiency of vitamin D causes the bone-softening disease rickets in children, by reducing the absorption of calcium in the diet (osteomalacia in adults). Given observational studies link low levels of vitamin D with fractures, it has long been hypothesized that vitamin D supplementation may reduce the risk of fractures. There’s long been interest in the role of supplements, particularly in people who may not obtain adequate amounts of the vitamin through diet or sun exposure.
This review looks at systematic reviews published in the past five years and noted that vitamin D, when given at doses of 800IU per day or more, and combined with calcium, significantly reduces hip fractures and fractures overall. The relative reductions are about 10-15%. About 45-67 people need to take calcium and vitamin D for 10 years to prevent one fracture. Again, while the result is modest, it does appear to be real.
#3: Vitamin D supplementation doesn’t reduce respiratory tract infections
Based on a cohort study that linked low vitamin D levels with upper respiratory tract infections, the idea that vitamin D supplements could reduce colds and the flu was born. Three systematic reviews or meta analyses have been done. Criticisms of these papers have included the fact that the populations studied have been quite different, ranging from children in Afghanistan to healthy adults from Long Island. The authors conclude the most robust analysis was likely Mao 2013, which found that vitamin D had no effect. The authors refer to their own separately published summary of the evidence which also concluded that vitamin D has no effect in western populations, but might have an effect in children in developing countries with more profound vitamin D deficiencies. Notably, the single randomised, controlled trial that’s both high quality and most relevant to an otherwise healthy population (Murdoch 2012) found no meaningful effects.
#4: Vitamin D supplementation has little effect on mental well-being
Multiple studies, summarized in a systematic review and meta-analysis, have found that lower vitamin D levels are associated with an increased risk of depression. Trials that have studied supplementation have been difficult to interpret owing to multiple sources of bias. Systematic reviews are conflicting. At best, vitamin D may have a small effect on patients with clear depression, but the evidence is still unclear. Vitamin D has no effect on well-being in the general population who do not have clear depression, even when vitamin D levels are low.
#5: Vitamin D supplementation hasn’t been shown to meaningfully improve the treatment of rheumatoid arthritis
In following a population of women that developed rheumatoid arthritis (RA) over the course of an observational study, a correlation was found between low consumption of vitamin D and a higher likelihood of rheumatoid arthritis. However, another, larger study failed to show the same correlation. In clinical trials, the Women’s Health Initiative study failed to show any relationship between calcium + vitamin D (vs. placebo) and the prevention RA over 5 years. In those that have RA already, there’s only poor quality data, none of which is conclusive. Overall, there’s no convincing evidence to suggest a role for vitamin D supplements to prevent or treat RA.
#6: Vitamin D supplementation doesn’t appear to benefit the treatment of multiple sclerosis
Given what appears to be a correlation between increasing latitude and the prevalence of multiple sclerosis (MS) in the population, the link with vitamin D levels has been suggested. This has been supported by observational trials that have shown that MS patients with more active disease may have lower levels of vitamin D. This important question can’t be answered with confidence because the trials have been small with methodological quality issues. The three published systematic reviews have shown null-to-mixed effects across multiple outcomes. There’s currently no compelling evidence to suggest supplementation is worthwhile.
#7: Vitamin D supplementation may have a modest effect on mortality
This is the granddaddy of all endpoints – all cause mortality. Recognizing how difficult this would be to assess hasn’t preventing this question from being studied. Populations studied have included older adults who were sometimes institutionalized. All six systematic reviews have shown effects that cluster at or around zero, and the mortality effect could range from an relative increase of 2% to a reduction of 13%. The authors estimate that a relative reduction of 5% is probably more likely, but that there could be no effect at all. There is some ongoing research which may clarify this question in time.
#8: Vitamin D supplementation has little effect in cancer
While there’s consistent evidence showing lower vitamin D levels and the risk of cancer, prospective data is lacking. Two newer meta-analyses have been conducted and both reported no effects of vitamin D supplementation on the incidence of cancer. If there’s any effect at all, it’s indistinguishable from zero effect. The Cochrane analysis looked at cancer mortality and did find a modest benefit. The overall evidence base, however, was of low quality. The authors concluded (and I agree) that we need better quality data to truly answer this question.
#9: More supplementation isn’t better
Given the ubiquity of supplementation in the absence of deficiency, there’s been research into the harms of vitamin D, driven by the belief that more=better. Ironically, high doses of vitamin D seem to increase the risk of falls and fractures, causing the consequences that we are trying to prevent. There’s also weak evidence that high doses are associated with higher mortality rates.
#10: No role for routine vitamin D testing
There’s a lack of evidence to demonstrate that routine vitamin D testing is necessary. The Choosing Wisely campaign recommended against routine testing as the results of the test are not likely to change the medical advice you’ll receive, which includes basic lifestyle advice (stop smoking, control your weight, be active, and to focus on getting your vitamin D from food and the sun). Despite the recommendations against testing, it has become widespread: In 2011, US Medicare spent $224 million on vitamin D tests for seniors.
Conclusion: More hype than hope
Despite the correlation of low vitamin D levels with an array of medical conditions, the evidence for supplementation remains unconvincing for most uses. Given the modest benefit, low cost, and relative lack of side effects, vitamin D, when used with calcium, retains a role in the prevention of fractures, along with the possibility it may modestly reduce falls and mortality. As for testing, you might need one if you have osteoporosis, or have any medical condition that affects your ability to obtain or use vitamin D. In the broader population, there’s no clear need for testing at all. This area, like a lot of nutritional research, is plagued with lots of low-quality evidence that is more than likely to steer us in the wrong direction. Until better evidence emerges, taking a cautious approach to vitamin D seems sound. Supplementation at modest doses is safe. If you do decide to supplement, remember that more isn’t better, and keep your dose low enough to avoid potential harms.

Should You Take Vitamin K With Your Vitamin D?
Vitamin K is increasingly marketed with Vitamin D. But is this combination evidence-based?
Scott Gavura on June 5, 2025
Link
Vitamin D3 supplements have been popular for decades for its purported benefits in supporting bone health, immune function, and other conditions and there have been multiple posts sorting out the hype from the science on this blog. Over the past several years, vitamin K2 has emerged as a new supplement, touted as an essential companion that makes vitamin D3 supplementation safer and more effective. This has led to the marketing of combined D3 and K2 supplements. Do these safety and efficacy claims hold up under scientific scrutiny? And if you take vitamin D3 supplements, should you combine it with vitamin K2 supplements?
Theoretical Rationale for Combined Supplementation
Vitamin D3 (cholecalciferol) plays a central role in calcium regulation and bone metabolism. It promotes calcium absorption in the gastrointestinal tract and helps maintain adequate serum calcium and phosphate concentrations in the blood, which is essential for normal bone mineralization. A deficiency of vitamin D causes the bone-softening disease rickets in children, by reducing the absorption of calcium in the diet (osteomalacia in adults). Vitamin K2 (menaquinone), a lesser-known but increasingly marketed supplement, is involved in the activation of vitamin K-dependent proteins. These proteins help regulate calcium deposition—osteocalcin supports its incorporation into bone, while matrix Gla protein (MGP) inhibits its accumulation in blood vessels and soft tissues. Vitamin K administration to infants is well-established and evidence-based. The hypothesis that underpins adult supplementation is that while vitamin D3 increases calcium absorption, concurrent vitamin K2 supplementation is claimed to help ensure that this calcium is directed to bones (good) rather than accumulating in blood vessels (bad).
The proposed synergy sounds reasonable, but is it really that simple? Supplement marketers often invoke this mechanism to claim that taking vitamin D3 alone could, paradoxically, increase the risk of arterial calcification if vitamin K2 is not also taken. Marketers use terms like “calcium mismanagement” or “nutrient harmony,” reinforcing the idea that supplementation is synergistic (a common alternative medicine trope) and even necessary to avoid harm. While the biochemistry supports a potential complementary role, it is a large leap to justify supplementation. So let’s take a closer look at the evidence.
The Evidence Check
Bone Health
There is RCT evidence and meta-analyses that demonstrate that that combined vitamin D3 and K2 supplementation modestly improve bone mineral density (BMD) and bone turnover markers, particularly in postmenopausal women and older adults. A 2020 meta analysis concluded that the combination can increase total BMD. The effect seems more pronounced with vitamin K2, which appears to be better absorbed than vitamin K1 and seems to last longer in the bloodstream, making it more active in the body. Overall, findings are not consistent, and the the clinical impact of combining therapy is less clear when it comes to reductions in fractures. Most trials are short in duration, small in size, and use surrogate endpoints. Benefits seem limited to postmenopausal women with osteoporosis or low bone mass. To date, no large, high-quality RCTs have shown that vitamin D3 and K2 co-supplementation significantly reduces fracture incidence in the general population.
Given the mixed evidence, clinical practice guidelines for osteoporosis prevention or treatment including those from the United States and Canada do not recommend routine combined vitamin D3 and K2 supplementation. The United States Preventive Services Task Force (USPSTF) recommends against routine supplementation with vitamin D, with or without calcium, for the primary prevention of fractures in community-dwelling postmenopausal women and men 60 years or older, and does not address vitamin K2. Overall, current first-line management for osteoporosis focuses on adequate calcium and vitamin D intake, lifestyle modification, and pharmacologic therapy when indicated.
Heart Health
There is evidence to suggest that combined low vitamin D and K levels is associated with increased risk of adverse cardiovascular outcomes, including higher all-cause mortality, when compared to having adequate levels of both vitamins. This is perhaps not surprising considering the role they play in calcium regulation.
However, to date, no high-quality RCT has demonstrated that combined supplementation with vitamins D3 and K2 improves cardiovascular outcomes. Few prospective trials have assessed cardiovascular endpoints, and existing studies have not shown consistent or clinically meaningful benefits. Consequently, supplementation for cardiovascular prevention is not supported by current evidence and is not recommended by major guidelines.
Safety Considerations
At typical supplement doses, vitamin K is generally safe. Toxicity from overdose is rare. Vitamin K supplements should be used with caution in those that take medications such as vitamin K antagonists (“blood thinners”, like warfarin), as supplementation will interfere with their effectiveness, increasing the risk of blood clots. In these cases, it is important to maintain a consistent intake of vitamin K from both diet (and supplements, if taken) to avoid fluctuations in the drug’s effectiveness.
Is there a role for Vitamin K supplements?
Vitamin K deficiency in an otherwise healthy adult or child is rare. This is largely due to the availability of vitamin K1 in plants (particularly green leafy vegetables) and vitamin K2 production by gut micro-flora.
Vitamin K supplements are evidence based when used for the prevention and treatment of vitamin K deficiency. Signs of vitamin K deficiency include easy bruising, mucosal bleeding, petechiae, splinter hemorrhages, blood in the stool and blood in the urine. Vitamin K deficiency may be observed with inadequate dietary intake, fat malabsorption syndromes (e.g., cystic fibrosis, celiac disease, chronic liver disease, post-bariatric surgery), chronic kidney disease, and in patients receiving long-term intravenous nutrition or prolonged courses of broad-spectrum antibiotics.
Vitamin K deficiency is typically diagnosed by blood tests showing an elevated prothrombin time (PT) or international normalized ratio (INR), which reflect impaired blood clotting due to reduced activation of vitamin K–dependent clotting factors.
No Clear Case for Co-Supplementation
While the combination of vitamin D3 and K2 is widely promoted in health circles and by manufacturers of these products, current evidence does not support routine co-supplementation in the general population. While there is some evidence suggesting modest effects on bone markers in specific groups like postmenopausal women, meaningful clinical benefits, such as fracture or cardiovascular risk reduction have not been demonstrated in high-quality trials. Vitamin K supplements have an evidence-based role in treating or preventing deficiency, but for most individuals, adequate intake is achieved with a balanced diet. Until better evidence emerges to clarify the benefits and risks of combined supplementation, clinical guidance remains appropriately cautious. As with many supplements, the marketing and hype outpaces the evidence.


If you don’t buy this supplement for your child, you’re a terrible parent
Scott Gavura on September 25, 2014
Link
The supplement industry wants you to buy their products, and they’re not above using a little parental guilt to make you into a customer. In the photo above, the promoter is my local pharmacy, where the large window display caught my eye:
Give your Child The Tools to SUCCEED in School!
Who doesn’t want their child to succeed? And if you knew a supplement could give you or your child a learning edge, would you consider it? I’d imagine many do. Supplements have a remarkable health halo. As a pharmacist myself, I’ve noticed this when speaking with patients – few consumers identify any potential risk or downsides to supplement use. Some don’t even think of them as medicine at all. The marketing has resonated: Supplements are perceived as “safe”, “natural” and “effective”. But whether you’re giving your child a prescription medicine to treat attention deficit hyperactivity disorder, or you’re giving a supplement to “improve focus and brain function”, you’re still administering a chemical substance to a child with the intent of changing brain function. We’d probably think twice before pouring an unknown substance in our car’s gas tank, especially one claimed to boost performance. We’d probably ask for some evidence that it works, and some assurance it wouldn’t harm our vehicle. A decision to use a drug or supplement in a child deserves just as much consideration of benefits and risks.
Kids DHA
The product on the left is advertised for use in primary and secondary school children. It’s called “Kids DHA”, and is marketed by Renew Life, a company which seems to think we are all contaminated with heavy metal toxins, and believes even migraines are caused by toxins. Kids DHA is claimed to “improve focus and brain function” and “promotes healthy eye and bone development.” The website’s claims are even more elaborate, including promises of “softer and healthier skin” and the ubiquitous “boost” to the immune system that every supplement seems to promise. Amazingly, they even make therapeutic claims about serious childhood illnesses, including “helpful for mental health, including childhood depression”.
Each capsule of KIDS DHA contains vitamin D and omega-3-fatty acids (docosahexaenoic acid (DHA) 100mg & eicosapentaenoic acid (EPA) 25mg), with a recommendation to give two doses per day. So what do we know about DHA and EPA? They are omega-3 fatty acids, which cannot be synthesized by the body. When eaten, DHA and EPA are incorporated into cell membranes, particularly the heart and brain. This is particularly important in pregnancy, so guidelines recommend pregnant women consume foods containing omega-3 fatty acids. In adults, there’s good evidence that fish oils (good sources of omega 3) have cardiovascular benefits. All the dietary guidelines I could find seem to be near unanimous in recommending that children and adults get sufficient omega-3 containing foods in our diet. It’s also a major component of the Mediterranean Diet, which has one of the better track records for cardiovascular and general health benefits.
Do DHA and EPA, when given as a supplement, improve focus and brain function, or promote eye and bone development? There’s no published evidence to demonstrate that this product has any meaningful effects. Nor is there any good evidence to show that DHA and EPA can improve focus in otherwise-normal children. If it had an effect, we might expect it to be most beneficial in children who couldn’t focus, or who suffered from learning disabilities. And that’s where it’s actually been studied. A Cochrane review of polyunsaturated fatty acids (PUFA) (which include omega-3 fatty acids like DHA and EPA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents found 13 high-quality trials, and concluded there is little evidence that PUFA supplementation provides any benefit. Another Cochrane review looked at PUFA for children with learning disorders, and could not find any high-quality studies that have adequately examined its effectiveness.
With respect to the depression claim, the hard evidence is also lacking. There’s only a small study with methodologic issues (no intention-to-treat analysis). In adults, however, the evidence is promising, albeit based on limited data. Certainly there’s nothing persuasive to substantiate the claims made about the supplement being “helpful” for depression in children at all.
Are DHA and EPA harmful? There’s no evidence to suggest it’s harmful when consumed in the diet. In terms of guidelines, there are recommendations from the Canadian Pediatric Society to ensure adequate DHA and EPA, and consider supplements, in vegan children. The American Academy of Pediatrics recommends eating fish, and does not mention supplements. The Institute of Medicine doesn’t recommend a dose, citing a lack of evidence. However, most guidelines and advocates for omega-3 supplementation tend to recommend dietary supplements in those that don’t already have sufficient amounts in their diets. There’s also no evidence to suggest that taking DHA and EPA is inherently risky or harmful. So as a supplement for children, there’s not likely to be any observable beneficial effects, but we also don’t expect any harms.
Cerebrum
The second product advertised is called Cerebrum, also from RenewLife, and the advertising makes a very specific claim on the poster:
    • Boosts cognitive ability by 10% for 6 hours after use.
    • Improves memory and focus.
The advertising on the website is even more specific:
Imagine for a moment being able to increase your cognitive ability and the positive impact that would have on your life. With Cerebrum™ you can! Cerebrum™ will increase your cognitive performance by 10% for a 6 hour period after taking it. Cerebrum™ contains Cereboost, a specific and unique extract of American Ginseng that has been clinically proven to increase cognitive performance by 10%!
Cerebrum is another fish oil supplement, but with American ginseng added. Each capsule contains 540mg of DHA, 27mg of EPA, 200mg of American ginseng (Panax quinquefolius), 5mg of lipase and 0.18 mg of rosemary extract. Here’s their “evidence” cited by the manufacturer:

The data appear to come from a trial that evaluated ginseng alone: “Effects of American ginseng (Panax quinquefolius) on neurocognitive function: an acute, randomised, double-blind, placebo-controlled, crossover study.” The full study is online and frankly, the findings are not impressive. To the researchers’ credit, it’s randomized, double-blinded and placebo controlled. But the design and methodology are heavily biased towards finding positive results. The study looked at 3 different single doses of ginseng versus placebo, and participants went through a large battery of tests after 1, 3, and 6 hours after doses of 100mg, 200mg, or 400mg, with one-week periods between tests. The researchers found improvements in three measures, but not the rest. And even the positive effects are inconsistent. There was a statistically significant and consistent change in “choice reaction time” for the 100mg strength only. “Working memory speed” only improved consistently and significantly with the 200mg dose, but not the 100mg or the 400mg dose. “Alphabetic working memory speed” only improved with the 100mg and 400mg doses, and not the 200mg dose. Only “Corsi block performance” significantly improved across all doses and all durations. There were no consistent positive findings in all of the other tests. While the authors tout this as evidence of cognition and mood enhancement, the evidence is much less clear. There is no obvious relationship between dose and response, something we should expect if the ginseng is having a beneficial effect. It’s quite possible this is just random noise we’re seeing in the testing, and not a true effect. That conclusion is even more likely given the authors did not control for multiple comparisons. It’s exactly like the classic XKCD comic: test enough times, you’re bound to get something statistically significant. But statistically significant doesn’t mean it’s a real and meaningful effect. And that’s what we can conclude from the evidence for Cerebrum, and more generally, the evidence base for American ginseng. There’s a lack of evidence it has any meaningful effects.
Conclusion
The idea of a “natural” product that boosts cognition and learning, without downsides, is appealing to students and to parents alike. Despite the marketing, there’s no good evidence to suggest that either Kids DHA or Cerebrum will have any meaningful effects on learning or cognition. This is yet another example of spinning weak data to make it look like convincing. We’ve seen this movie before. We all want quick fixes, and reaching for a bottle in the pharmacy is about as quick and easy as you can get. But when it comes to learning, there’s no evidence that supplements need to play a role. Eat a decent diet, and feed one to your child. The “Tools to Succeed” that you or your child need won’t be found in the supplement aisle of your local pharmacy.

Vitamin K Refusal – The New Anti-Vax
Steven NovellaonAugust 20, 2014
Link

A small but increasing number of parents are refusing vitamin K injections for their newborns, an intervention recommended since 1961. This is yet another example of the difference between a science-based and philosophy-based approach to medicine. Science has given us the tool of knowledge, and in medicine that knowledge can have very practical applications.
The term “vitamin” was coined in 1912 by the Polish biochemist Kazimierz Funk. A vitamin is an organic nutrient that an organism requires in small amounts but cannot synthesize in adequate amounts and therefore must obtain from the diet. Knowledge of specific vitamins, their food source, and their biochemical activity in the body, has allowed medical scientists to cure many serious nutritional diseases, such as scurvy, rickets, and blindness.
The Vitamin K family are derivatives of 2-methyl-1,4-naphthoquinone, a fat-soluble molecule. It is a cofactor necessary for the formation of factors that function in blood clotting and in bone formation. The primary effect of vitamin K deficiency is therefore bleeding. Infants are at risk for vitamin K deficiency because this molecule does not cross the placenta well. Infants are therefore born relatively deficient in vitamin K. Further, breast milk contains little vitamin K (regardless of the mother’s diet) so infants are at risk for vitamin K deficiency until they start eating solid food at around 6 months (see Clay Jones’ post on the topic here).
The standard of care for many decades has been to give all newborns a vitamin K intramuscular injection. This contains enough of the vitamin to cover them for 6 months until they start getting enough vitamin K in their diet.
Without supplementation, there is an incidence of vitamin K deficiency bleeding (VKDB) in the first week of life of 0.25-1.7%. There is also a late VKDB that is more severe but has a lower incidence of 4.4-7.2 per 100,000 live births. Bleeding most commonly occurs in the brain, and when severe it can be devastating and even fatal.
A single injection of vitamin K at birth significantly reduces the risk of VKDB. In fact, it virtually eliminates the risk. Recent studies looking at infants who have VKDB show that most or all of them did not receive vitamin K prophylaxis. This is a simple, safe, and effective preventive measure, essentially just giving a vitamin to newborns, that prevents a common and potentially devastating outcome. Why would anyone refuse such a clear homerun intervention?
As you might suspect – ideology can trump science and reason. A study published this week in Pediatrics by Sahni et. al. found that 0.3% of those in the study refused neonatal vitamin K. Those who did refuse were 14.6 times more likely to also have refused all recommended vaccines up to age 15 months. They were also 4.9 times more likely to have a planned home birth, and 3.6 times more likely to have delivered at a birth center. A New Zealand survey also published this year found that 100% of medical staff, but only 55% of midwives, agreed that all newborns should receive vitamin K.
One way to interpret this data is that there is a pattern of distrust of the medical establishment or distrust of science in general, and reliance upon so-called “alternative” approaches to birth and childcare. In other words, this is a result of ideology trumping science. As a result, there is an increasing incidence of early and late bleeding in infants.
The numbers of refusals are still low, but are rising fast, clustering in certain centers and hospitals. A recent Tennessee abstract found that in one hospital the refusal rate was as high as 3.7%. They also found that:
Of 102 vitamin K refusers surveyed, 47 (46%) responded; 31/47 (66%) identified bleeding as a risk of refusing prophylaxis. The leading reasons for refusal were desire for a natural birthing process (43%) and believing prophylaxis was unnecessary (43%). Hepatitis B vaccine and erythromycin eye ointment were also refused by 65% of respondents.
In other words, an irrational adherence to the naturalistic fallacy was largely to blame. This was possible combined with misinformation, but I have to wonder if the bleeding risk excuse was simply a post-hoc justification and not the true reason for refusal. Further, we see that those who refuse vitamin K also refuse other recommended interventions, including erythromycin eye ointment used to prevent blindness.
Conclusion
In my opinion, what we are seeing here are the downstream effects of the “alternative medicine” philosophy and world-view. Promoters of CAM often instill a general distrust in science and the institution of medicine. They promote dubious treatments with the notion that “natural” (even though poorly defined) is somehow inherently superior, and therefore interventions that seem technological are to be feared.
They have been unfortunately successful in marketing their philosophy. As a result there are parents who refuse for their newborn children safe and effective interventions supported by solid scientific evidence.

Update on Vitamin K Refusal
Vitamin K shots at birth are a safe and effective method for preventing bleeding, but that doesn’t stop some parents from refusing.
Steven Novella on February 26, 2020
Link

It has been six years since I’ve posted anything on Vitamin K refusal – in 2014 I described it as the new anti-vax (though Clay provided a repost last November). Unfortunately it continues to be a problem for newborns, despite efforts at public education.
Why vitamin K?
Newborns lack sufficient vitamin K, largely because the vitamin does not easily cross the placenta. It also exists in low quantities in breast milk, and so babies may be deficient until around six months of age when they start to include other food in their diet. Vitamin K is necessary to form clotting factors, and so the primary risk of being deficient it an increased risk of bleeding, including spontaneous bleeding (i.e. not provoked by trauma or any external event), known as vitamin K deficient bleeding (VKDB). Bleeding can occur early, within the first week of life, or late, after the first week but within the first six months. According to a recent review:
Without prophylaxis, estimates of the incidence per 100 000 births of VKDB range from 250 to 1700 for early VKDB and from 10.5 to 80 for late VKDB.
The absolute risk is therefore low but still significant. The most common locations for VKDB in newborns is either the brain or the bowels. Bleeding in the brain can impair neurological development and even cause death. Intestinal bleeding can also be life-threatening. But worry not – one shot of intramuscular vitamin K at birth significantly reduces that risk (relative risk in that study was 0.19, with a number needed to treat of 74). The shot immediately increases vitamin K levels, with most of the vitamin being stored in the liver where it is slowly released over the next six months.
Medical interventions are all about risk vs benefit, so what are the potential risks of one IM shot of vitamin K at birth? The risks are actually minimal, and specific risks are rarely cited as reasons for refusal. There was one preliminary study showing a potential correlation between vitamin K shots and childhood cancer, but this correlation was later completely refuted by larger and more rigorous studies. I have only seen mention of it in resources, like this one, citing the evidence to refute a correlation. So unlike the myth that vaccines cause autism, this debunked correlation does not seem to be driving vitamin K refusal.
Right now the recommendation of the American Academy of Pediatrics and other medical organizations is for every newborn to receive one IM dose of vitamin K at birth. This ensures universal coverage for the first six months of life, it reduces the risk of VKDB and all the morbidity and mortality that results, and it is extremely safe. However, some still find reasons to refuse this safe and effective medical intervention.
Why people refuse vitamin K
In my original 2014 article I discussed a review of Nashville area hospitals conducted in 2013 which found that:
At hospitals, 3.0% of infants did not receive injectable vitamin K due to parental refusal in 2013, a frequency higher than in 2011 and 2012. This percentage was much higher at birthing centers, where 31% of infants did not receive injectable vitamin K. The most common responses for refusal were a belief that the injection was unnecessary (53%) and a desire for a natural birthing process (36%). Refusal of other preventive services was common, with 66% of families refusing vitamin K, newborn eye care with erythromycin, and the neonatal dose of hepatitis B vaccine.
Three percent is low, but that still represents a lot of potentially avoidable VKDB. The more concerning figure is the 31% in birthing centers who refuse. This may be due to self-selection of the type of parents who choose birthing centers, but there is concern that it also reflects the philosophy of the midwives and other practitioners at these centers. In a good 2019 article on the topic, pediatrician Rachel Pearson relates stories of patients told by their midwives not to get the vitamin K shot. We need good data on this practice, but the 31% figure is alarming in any case.
A 2020 review found essentially the same results:
The frequency of refusal of intramuscular vitamin K by parents ranged from 0% to 3.2% in US hospitals, up to 14.5% in home births, and up to 31.0% in birthing centers. Reported reasons for refusal were concern of harm from the injection, a desire to be natural, and a belief in alternative methods of prophylaxis. Parents who refused intramuscular vitamin K were more likely to refuse immunizations.
So essentially nothing has changed. The main reason for objection to vitamin K is not based in evidence or any solid logic, but is rather philosophical – the desire to be “natural”. This is a downstream effect of the appeal to nature fallacy that is ubiquitous in the marketing of alternative medicine. It also strikes me as interestingly selective. When CAM providers give high dose intravenous vitamins for their treatments, the vitamins are considered “natural” remedies, and the high doses justified. When doctors give an evidence-based dose of a needed vitamin with clear benefits, that is not “natural”.
The notion that the shot is “unnecessary” is a claim that is subject to facts. It is based in a misconception, that a healthy newborn without trauma does not need the vitamin K. On one “mommy” blog, the author explains their reasons for refusing vitamin K:
Yes, I believe there may be instances where a newborn may need it if there are bleeding issues, but my daughter was completely healthy and normal with no visible signs of trauma after coming out of the birth canal unassisted.
This is a myth. Otherwise-completely-healthy newborns without signs of trauma can still have VKDB. Also, by the time you notice the signs of a bleed, it’s too late, the (potentially catastrophic) damage is done. Yet again, there is selective use of logic here – CAM proponents market themselves (falsely) as being more focused on prevention. Well here is an evidence-based preventive measure, criticized for being preventive rather than reactive.
I point out these inconsistencies because what is at work here is not evidence and reason, but marketing and world-view. The important factor here is a lack of trust in the medical and scientific establishments, a lack of trust resulting from the CAM culture that is constantly beating the drum of paranoia and conspiracy theories. This is the result.
The alternative methods usually refers to oral vitamin K. So far there is no evidence-based oral regimen shown to work. There is evidence that single dose oral vitamin K is less effective than the IM shot. It is still an open question if multiple oral doses can be as effective as IM, but even if this does work the problem is compliance. You have to keep up with the regimen of oral doses. A single IM dose at birth, however, is all you need. So the real-world effectiveness of the single shot will always be better.
The evidence is crystal clear in this case – single dose IM vitamin K at birth is a very safe and effective method for preventive VKDB in newborns and infants. Objection to this effective intervention is based on misconceptions rooted in the alternative medicine marketing and philosophy, and spread mostly by non-physicians. We have to stay ahead of this phenomenon, and perhaps a dose of science-based information may be preventive.

K2: The Vitamin, Not the Mountain
Harriet Hall on September 30, 2014
Link


Science is complicated. Simple concepts that appear at first to be obviously true or untrue usually turn out to be more nuanced than we thought. Newtonian physics was taken as “the truth” until we learned in the 20th century that it didn’t apply on cosmological or subatomic scales. Medicine and human physiology are more complicated than most people realize or want to believe. A case in point is the recent realization that vitamin K is not a single chemical compound, but a whole family of them, and that vitamin K2 has unique properties that vitamin K1 lacks.
Recently, there has been some interesting preclinical research on K2 that warrants further study to tease out its implications for human health, diet, and supplementation. There has also been a lot of hype that warrants taking its claims not with a grain but with a large bolus of salt. According to Canadian naturopath Kate Rhéaume-Bleue, author of Vitamin K2 and the Calcium Paradox:
    • It could save your life
    • It is missing from the modern diet
    • It is the most important anti-aging nutrient for fighting wrinkles, Alzheimer’s, heart disease, osteoporosis and more
    • It promotes straight, cavity-free teeth
    • It is needed to get the benefits from calcium and vitamin D supplements; without it, those nutrients will increase the risk of heart attack and stroke
    • It is the only vitamin known to prevent and reverse atherosclerosis
The old adage is still true: if something sounds too good to be true, it probably is. There is only weak evidence behind these strong claims.
A brief review of vitamins
The first vitamin was discovered in 1912 when Dr. Kasimierz Funk found that the disease beriberi occurred in people who ate polished, processed white rice but not in those who ate brown rice. He isolated the responsible factor, thiamine, and called it a “vital amine.” A growing alphabet of vitamin discoveries followed, from A through K. Later, some of them had to be re-classified. The former vitamin F is now known as essential fatty acids, G and H are the B vitamins riboflavin and biotin, and J is choline, no longer considered to be a vitamin. The B vitamins are numbered 1 to 12; B4, 8, 10 and 11 are missing because they were found not to be essential nutrients.
Vitamin supplementation for deficient patients and vulnerable populations is one of the triumphs of scientific medicine, but supplements for healthy people have a poor track record. A parade of studies over the last decade has shown an absence of benefit or even harm in ingesting extra vitamins in pill form, as discussed in many posts on SBM (for example, see Should I Take a Multivitamin?, Vitamins and Mortality, and More evidence that routine multivitamin use should be avoided).
Vitamin K is a group of fat-soluble compounds essential for blood coagulation and calcium binding in bone and other tissues. Vitamin K1, phylloquinone, is important for coagulation and vitamin K2 (menaquinone) is more important for calcium metabolism. We get most of our vitamin K from diet; K1 is abundant in leafy vegetables. We get K2 from animal sources, and the bacteria in our intestines synthesize a small amount. There are several types of menaquinone, including MK-4 from animals and MK-7 from bacteria, with somewhat different properties. Available supplements may contain MK-4 or MK-7, and the smelly, slimy, fermented soybean Japanese breakfast food natto contains large amounts of MK-7 but is seldom acceptable to the American palate. One supplement, menadione or K3, is known to be toxic to the liver and is no longer used.
In a recent SBM article, Clay Jones explained the need for routine vitamin K injections in newborns. Vitamin K is present in many foods, and deficiency is thought to be uncommon in adults. Patients taking the anticoagulant warfarin are advised to limit the vitamin K in their diet, and vitamin K is used as an antidote to reverse the anticoagulant effect in patients with an overdose.
Evidence for the benefits of K2
Does K2 deficiency cause heart disease? The population-based Rotterdam study found an inverse correlation between dietary K2 intake and atherosclerosis, coronary heart disease, and all-cause mortality. A cross-sectional study of post-menopausal women found a reduced risk of coronary calcification (not actual cardiac events) in those with higher dietary intakes of K2.
Rhéaume-Bleue reports on a lot of K2 studies, but they are mostly in vitro and animal studies, with a few epidemiologic studies in humans that found correlations (which we know don’t necessarily imply causation). She marshals a lot of preclinical evidence, but makes claims based on speculation and reasoning that go beyond the actual evidence. No reliable clinical studies have been done to test whether supplementation of K2 would have any meaningful effects on disease progression or health outcomes in humans.
The reliable source The Natural Medicines Comprehensive Database, disagrees with Rhéaume-Bleue. They found there was “insufficient evidence to rate” the use of vitamin K for coronary heart disease. They made this determination after reviewing all the available published evidence. They noted that it was likely safe, with few adverse effects, but that it could interact with various drugs and supplements, and with lab tests, and could lead to complications in patients with liver disease or on hemodialysis. They found little evidence to support increasing the currently recommended vitamin K intake for the population.
The calcium paradox
Rhéaume-Bleue explains the calcium paradox: we take calcium supplements to prevent osteoporosis, but that doesn’t actually do much to prevent fractures, and it increases the risk of coronary heart disease. She envisions calcium supplements as killing us by causing calcium deposition in our arteries, and K2 as effectively preventing that deposition and of removing existing calcifications. She tells us that if 1,000 women take calcium supplements for 5 years, it will prevent 3 fractures but will cause 6 heart attacks or strokes. There are indeed studies indicating cardiovascular risk from calcium supplements, but the risk is not dose-dependent and does not occur with dietary calcium. This 2013 review showed that the evidence for cardiac risk is varied and the benefits of supplementation exceed the risks. And this 2014 meta-analysis of randomized controlled trials concluded that:
current evidence does not support the hypothesis that calcium supplementation with or without vitamin D increase coronary heart disease or all-cause mortality risk in elderly women.
She seems to think that it is a buildup of calcium that causes artery-clogging atherosclerotic plaques, but calcium deposition is really only a secondary phenomenon occurring mainly in advanced lesions. Coronary heart disease is not a feature of hypercalcemia, and although CT heart scans are done to measure coronary calcium scores, they are not recommended for general screening. Not all plaques contain calcium; the larger ones are more likely to contain it, but smaller plaques with no calcium are the ones that are more likely to rupture.
Vitamin D is taken along with calcium supplements to improve the body’s ability to use the calcium, but K2 is essential for vitamin D to work. She highlights the importance of interactions between nutrients in the case of D, K2, and calcium, but doesn’t seem to consider the possibility that K2 supplementation might cause unforeseen harmful interactions between nutrients. There are many examples of vitamin supplements having adverse effects on heart disease and other conditions. Vitamin K and K2 appear to be safe, but the safety of K2 supplementation needs to be better tested before supplementation can be widely recommended.
She says if you have osteoporosis or heart disease, vitamin K2 deficiency is “a given,” and you are probably deficient if you have any of a whole list of other conditions, including diabetes, cancer, wrinkles, varicose veins, dental cavities, kidney disease, or a narrow, crowded dental arch. She says adolescence and menopause are times when vitamin K2 deficiency is even more likely. She says that bone density and arterial calcification vary cyclically with the seasons, showing “humans’ delicate interconnectedness to the sun and earth.” Essentially, she thinks everyone is deficient in K2, mainly because our cows and chickens are no longer grass-fed. Most of these claims are just speculation on her part. They may or may not be true; they need to be tested.
She makes a good point that older studies may have produced misleading results because they looked at vitamin K rather than at K2. Now that we are aware of K2, we need to re-assess the evidence with new eyes.
She marshals an impressive array of references in the endnotes for much of what she says, but then she makes statements like this without any citations:
Research now confirms that vitamin K2 is the single most important nutritional factor in preventing and even reversing arterial blockages. Indeed, ensuring adequate vitamin K2 intake might be the most important thing you can do to extend your life.
I must remain skeptical of those claims until I see some supporting evidence.
The references she provides for other claims don’t really support the claims. For instance, she says “vitamin K2 also helps restore arterial flexibility once the calcium has been removed.” She cites a study titled “Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats.” That’s nice to know if you are a warfarin-treated rat that has developed elastocalcinosis; but it tested vitamin K rather than K2, and it doesn’t necessarily translate to a benefit in humans. Anyway, elastocalcinosis is not the same as atherosclerosis.
She says things that are demonstrably not true, for instance that high doses of the statin drug Crestor “carry crippling side effects for most people.” (They do cause side effects, but only in a minority of users, and the side effects are not always crippling.) She idolizes Weston Price, a man who has been called “the patron saint of crank dentistry” and who is criticized on Quackwatch. Price travelled around the world making uncontrolled observations of native peoples and drawing unwarranted conclusions about nutrition. He saw physical perfection in those who ate a traditional diet, and thought that after women switched to a Western diet, their children had poor jaw development, needed orthodontia, and had pointy teeth, an atavism harking back to the canines of our primate ancestors. She claims that he figured out the health consequences of K2 deficiency without being able to identify the cause, which he called factor X. Among other things, he blamed increasing C-section rates on nutritional deficiencies. She describes how Price stopped drilling and filling cavities, and healed them with a combination of vitamins. But she isn’t willing to follow Price that far; she doesn’t advocate giving up dental care.
Conclusion
We are just starting to learn about vitamin K2, and I intend to watch developments with great interest. But I subscribe to what Druin Burch called “Medicine’s Beautiful Idea,” the idea that even the most reasonable-sounding theories must be properly tested. Rhéaume-Bleue’s claims have not been properly tested, and promoting them in a popular book is jumping the gun. I’m willing to believe that K2 deficiency might be widespread and harmful, but I’m not willing to believe for sure that it is until I see better evidence. And I don’t think telling everyone to take K2 supplements is justified at this point.

Vitamins are not for vaping
Vaping vitamins is a bad idea.
Scott Gavura on February 3, 2022
Link


Vaping products and e-cigarettes are fairly new technologies for drug delivery: the first commercially successful product is attributed to a Chinese pharmacist back in 2003. Introduced in Europe and the United States in 2006, they have been widely available worldwide for just over a decade. In many countries, e-cigarettes are a technology that occupy a “grey zone” where they are regulated differently than cigarettes. The main components (a battery, a heating element, and a vaporizing liquid), are most commonly used to deliver nicotine, so the products can be used as cigarette substitutes. The evidence that these products are effective smoking cessation products is modest but seems real. But the devices can be used to deliver almost any substance into the lungs. The biggest growth area for e-cigarette use over the past several years has been youth and young adults, in part through the sale of novelty- and candy-flavoured vape liquids that can also deliver concentrated nicotine doses.
Perhaps not surprisingly, some enterprising businesses have begun incorporating vitamins into vape liquids, trying to build on the novelty of vaping along with the possible health halo from those that see vaping as a healthier alternative to smoking. There are many reasons why this is a terrible idea.
The claims
VitaStick sells a cigarette-shaped “essential oil aromatherapy dispenser” with products containing four vitamins (C, B2, B6, and B12) along with herbs (e.g., valerian) and hormones (e.g., melatonin). They claim “inhaling=ingesting” and that their products are food-grade. They also claim that you can safely vaporize their products, including the vitamins.
Breathe sells B12 “diffuser kits” that deliver 5,000% of your daily needs with one dose. Their product is very similar to VitaminVape which also sells B12 vapes (they even show the same picture of a factory as Breathe). VitaCig apparently contains fruit juices along with vitamins A, B2, B6 and B12. Some versions contain stimulants like caffeine and herbs like ginseng and gingko biloba. They claim their products are “safe to use” but no evidence of safety testing is presented.
The evidence
While all of the products I examined above go to great lengths to position their products as “healthy”, none provided any information or actual data that showed their products had been tested and been found to be safe or effective. Some contain other chemicals (e.g., propylene glycol, glycerine) in addition to essential oils and vitamins. There is no published evidence showing that any of these ingredients can be safely vaped – or that the vaporization process doesn’t degrade the vitamins completely.
It also goes without saying that we did not evolve to get our vitamins by inhalation, but via our gastrointestinal tract. The best sources of vitamins are food and a balanced diet obviates the need for vitamin supplements in most cases – for most people, vitamin supplementation is unnecessary. When supplements are advisable, they are almost always supplied orally. In rare circumstances, injectable vitamins may be necessary. There is no medical case for inhaled vitamins.
What is EVALI?
E-cigarette or vaping product use associated lung injury (EVALI) was first described a few years ago as a respiratory illness that can be life-threatening. It is a form of acute lung injury where the key risk factor in the thousands of cases reported is an e-cigarette. Tetrahydrocannabinol (THC) and vitamin E acetate have been linked to most of the reported cases, but nicotine, cannabinoid (CBD) oil, and other substances have also been attributed to EVALI. Most cases require hospitalization and some even case, mechanical ventilation. Given how little is known about EVALI, and the severity of the illness, the Centers for Disease Control has recommended avoidance of e-cigarettes and vaping.
The FDA responds
The FDA is warning consumer and cracking down on manufacturers who sell vitamin vapes. They note,
Some vaping products are being illegally offered for sale with unproven health or wellness claims, including improving mental clarity or treating tumors or asthma. Some examples of these companies’ fraudulent product claims are:
    • “Fight off tumors and alleviate symptoms of chemotherapy!”
    • “It’s been used as a [sic] organic asthma remedy, ADHD remedy, and dementia treatment.”
    • “Helps prevent a type of anemia called megaloblastic anemia that makes people tired and weak.”
    • “Neroli oil… has long been used as a treatment against anxiety and depression, to calm the mind and soothe away tension.”
These claims are unproven, and the products may be ineffective, a waste of money, unsafe, and may prevent or delay you from seeking an appropriate diagnosis and treatment from a health care professional.
Risks from inhaled productsIn addition to unproven health claims, these vaping products may present other risks. Inhaled products can be dangerous and even may trigger severe coughing, cause airway tightening, and make speaking and breathing difficult. Also, there’s no way to know if these “wellness” vaping products contain ingredients or impurities that may cause or make these symptoms worse, or cause permanent damage, such as bronchiolitis obliterans (also called popcorn lung).
The FDA sent a number of warning letters to manufacturers of these products in December 2021. They are describing these products as unapproved drugs:
Your Caffeine Pen products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). FDA approves a new drug on the basis of scientific data submitted by a drug sponsor to demonstrate that the drug is safe and effective. No approved applications are in effect for your products.
For the love of all things that are holy, don’t vape your vitamins
        ◦ There is zero biochemical logic to inhaling vaporized vitamins. We all evolved an unbelievably efficient gastrointestinal tract that effectively extracts what we need from the foods that we eat. Eat a balanced diet and you probably won’t ever need to take a vitamin. If you do need to take vitamins, oral supplements are cheap, efficient, effective, and generally safe. None of that can be said for vaping vitamins.

   The benefits and risks of folic acid supplementation
Scott Gavura 
Link
Could a vitamin with proven benefits in one group cause harm to another? That’s the growing concern with folic acid, the vitamin that dramatically reduces the risk of neural tube birth defects such a spina bifida. Studies designed to explore the possible benefits of folic acid for heart disease, stroke and cancer are giving out some worrying signs: At best, folic acid is ineffective, and at worst it may be increasing the risks of some cancers. So what does this say about routine supplementation for the typical healthy individual, and its overall risk and benefit?
Folate (vitamin B9) is an essential nutrient found green, leafy vegetables, broccoli, peas, corn, oranges, grains, cereals, and meats. Folate has important roles in the synthesis of DNA, and consequently cell division. Significant folate deficiency can lead to macrocytic anemia. Folic acid, a synthetic form of folate, is used in multivitamins supplements because it is better absorbed.
Folic acid’s benefits in pregnancy are well documented. Supplementation before conception, and in the first few weeks of pregnancy, significantly and substantially lower the risk of several different birth defects, including neural tube defects (NTDs). The neural tube is the embryonic precursor to the brain and spinal column. NTDs include very serious defects like spinal bifida and anencephaly, birth without part of the brain.
The stakes are high, and because the neural tube forms so early in pregnancy (day 26 to 28), deficiencies must be corrected before a woman knows she is pregnant. This has led to public health strategies that mandate supplementation in food products: In both the United States and Canada, folic acid has been added to white flour since the late 1990’s, where it finds its way into baked goods like bread. Following food fortification, neural tube defects have subsequently dropped.
In addition to food fortification, women that could become pregnant are generally advised to take a multivitamin containing at least 0.4mg of folic acid daily. Women at high risk of NTDs may be advised to take higher doses. But as higher doses of folic acid can mask the symptoms of Vitamin B12 deficiency, higher doses warrant medical advice and supervision.
Even with fortification, it’s clear there are still opportunities to improve folic acid consumption in pregnancy. A Canadian population study showed that 20% of women of childbearing age failed to have appropriate folic acid levels in their blood. And while virtually no-one was dangerously deficient, over 40% had levels that would be considered high.
Beyond pregnancy
Observational trials have correlated a diet rich in fruits and vegetables with a lower risk of diseases like colorectal cancer. Based on this epidemiologic evidence, several randomized controlled trials were initiated investigating the effect of the B vitamins (including folic acid) on cancer risk. Folic acid held particular promise because of its proven effects preventing neural tube birth defects.
But the effects were not as expected.
The Warning Signals
That folic acid may interfere with cancer has been known since the 1940’s. The chemotherapy drug methotrexate is an antifolate agent that blocks the metabolism of folic acid, developed after it was noted that a diet deficient in folic acid helped patients with leukemia.
Studies of folic acid supplementation are raising flags about the potential risks of therapy, possibly as a result of excessive consumption. One of the most startling was a study that looked at folic acid supplementation in patients with colorectal adenomas, which are cancer precursors. Participants were randomized to folic acid 1mg or placebo for up to six years. While it was hypothesized that folic acid would provide a protective effect, the results were disappointing. Not only did folic acid have no effect on adenoma incidence (even in those with low folate status), there was a significant increase in the risk of non-colorectal cancers (10.5% vs. 6.3%), due mainly to an excess of prostate cancers.
Futher worrying evidence emerged in 2009, when a Norwegian study of heart failure patients was published. Researchers randomized almost 7000 patients to folic acid and vitamin B12 versus other vitamins or placebo. The vitamins significantly raised the risks of both cancer and all-cause mortality, driven mainly by more cases of lung cancer. On balance, looking at heart disease, folic acid supplementation don’t seem to have any persuasive effects, either. In combination with other B-vitamins to lower homocysteine levels it hasn’t been shown to have meaningful effects on cardiovascular disease prevention, either.
The same worrying cancer signal has appeared with breast cancer in postmenopausal women, even while dietary folate seems to be beneficial. And in studies looking at prostate cancer, when folic acid is combined with other vitamins, the data are unclear.
So could fortification be causing harm? While correlations have been drawn between food fortification and population studies of colorectal cancer, causality hasn’t been established. Screening rates or other factors could be contributing. Still, the idea is troubling, even though the harms (if real) are slight compared to the demonstrable and significant benefits fortification has played in reducing NTDs.
Conclusion
In women of childbearing age, folic acid supplementation has a demonstrable and meaningful benefit, reducing the incidence of NTDs. Its use in this population is evidence-based and demonstrably effective. And for treatments for conditions like end-stage kidney disease, folic acid may be of benefit. But when we look at the use of folic acid for primary prevention, the data are less clear. In children, men, and women beyond their childbearing years, supplementation in the absence of deficiency has no demonstrated health benefits, and there are worrying signals that it may raise cancer risks, possibly by “feeding” existing cancers.
Is fortification of our food supply harming and hurting? The benefits on NTD incidence have been demonstrated, while the harms haven’t been proven yet. Still, folic acid’s evolving story may become a cautionary tale about the consequences of fortification and supplementation with the hope of improved health outcomes. If we’re not in our childbearing years, we may be better off relying only on food sources for folate. So pass the spinach, and hold the multivitamins with folic acid.

Faith and Supplements – B17
Amygdalin is a toxic snake oil dating back to 1830, but it is still sold today with a combination of supplement industry deception, faith, and conspiracy theories.
Steven Novella on September 13, 2017
Link

Why would someone intentionally poison themselves with cyanide thinking it is good for their health? That is the question raised by a recent article in the medical journal BMJ. They report the case of an otherwise-healthy 67-year old man who was found to be hypoxic (low blood oxygen) while being monitored during anesthesia for a routine procedure. They report:
Postoperatively, the patient admitted to daily self-prescription of apricot kernel extract for a period of 5 years. Apricot kernel is a commonly taken extract used for a range of ailments, and is associated with cyanide toxicity, which was confirmed through blood analysis.
It’s easy to simply blame this gentleman for his own cyanide toxicity, and he does shoulder personal responsibility, but at the same time he is a victim in important ways. He is a victim of the government, which inadequately regulates “supplements” allowing for what are essentially poisons to be sold with the promise of health benefits. He is a victim of the supplement industry which essentially lies to the public and distorts science in order to create a market for their mostly fraudulent products. He is a victim of the medical establishment and academia who have not taken this issue seriously enough. And he is a victim of the culture that has bought into an irrational fetish with all things “natural.”
His decision to slowly poison himself with cyanide, in other words, was not made in a vacuum. 
The story of amygdalin
The history of belief in cyanide compounds derived from apricot pits goes back a long way, to 1830. Here is a good summary from Dr. Benjamin Wilson, writing for Quackwatch:
Laetrile is the trade name for laevo-mandelonitrile-beta-glucuronoside, a substance allegedly synthesized by Ernst T. Krebs, Jr., and registered with the U.S. Patent Office for the treatment of “disorders of intestinal fermentation.” This compound is chemically related to amygdalin, a substance found naturally in the pits of apricots and various other fruits. Most proponents of Laetrile for the treatment of cancer use the terms “Laetrile” and amygdalin interchangeably.
Amygdalin was originally isolated in 1830 by two French chemists. In the presence of certain enzymes, amygdalin breaks down into glucose, benzaldehyde, and hydrogen cyanide (which is poisonous). It was tried as an anticancer agent in Germany in 1892, but was discarded as ineffective and too toxic for that purpose. During the early 1950s, Ernst T. Krebs, Sr., M.D., and his son Ernst, Jr., began using a “purified” form of amygdalin to treat cancer patients. Since that time scientists have tested substances called “Laetrile” in more than 20 animal tumor models as well as in humans and found no benefit either alone or together with other substances. Along the way its proponents have varied their claims about Laetrile’s origin, chemical structure, mechanism of action, and therapeutic effects. Its place in history is assured, however, as a focus of political activities intended to abolish the laws protecting Americans from quackery.
A 2015 Cochrane systematic review of clinical studies of amygdalin/Laetrile for cancer concluded:
The claims that laetrile or amygdalin have beneficial effects for cancer patients are not currently supported by sound clinical data. There is a considerable risk of serious adverse effects from cyanide poisoning after laetrile or amygdalin, especially after oral ingestion. The risk-benefit balance of laetrile or amygdalin as a treatment for cancer is therefore unambiguously negative.
It’s good to see a Cochrane review that is unafraid to use words like “unambiguously” or fall victim to the gratuitous, “more research is needed,” when it clearly isn’t.
What this story indicates is that once a suggestion is made within the popular culture that a substance may be a useful treatment, it rarely goes away completely. Further, the modern alternative medicine/supplement industry is adept at recycling old snake oil claims. Sometimes they repackage them with more modern marketing lingo, but it is amazing how old most of the marketing strategy really is. It still mostly revolves around a reverence for anything “natural” and a distrust of establishment medicine.
It was also interesting to learn that promotion of laetrile as a fake cancer cure may have significantly contributed to the modern alternative medicine movement itself. Obviously we can’t know how things would have gone if laetrile were not in the picture, but its role is pretty clear. Organizations mobilized to promote health freedom focusing on laetrile, but then expanding to health freedom and alternative medicine in general.
Eric Hovind gets involved
Another interesting aspect of the amygdalin story is that it has become a great example of the intermingling of faith and alternative medicine. CAM, we have long argued, is a faith-based system. It is ultimately about promoting spirituality and mysticism as medicine. At times it tries to disguise itself as scientific, but that is always a ruse.
CAM largely promotes Eastern mysticism, because it is exotic and does not immediately seem like a religion to Westerners, but it is. Reiki, for example, is basically faith healing. But Western fundamentalist religions don’t want to be left out – they already have promotion of pseudoscience and conspiracy theories in their skill set. Eric Hovind has now made himself an excellent example of this.
Hovind’s God Quest, Inc, doing business as Creation Today, until recently was selling laetrile as a cancer cure. Laetrile was given the fake name, “vitamin B17” to make it seem more natural, when of course it is not a vitamin at all. Hovind was selling B17 amygdalin, raw bitter apricot seeds (which contain amygdalin) and the quack book, World Without Cancer, which promotes both laetrile and the conspiracy theory that the medical establishment is hiding a cure for cancer.
His website selling this poison deceptively proclaims:
Learn and experience first hand from these important and popular resources, the results that could occur if the solution should be found in a simple vitamin!
And:
These kernels are fresh, high quality, California grown apricot kernels which have not been steamed or cooked and, thus, retain their full complement of natural nutrients. God has blessed us with B17 in abundance!
This is a complete intermingling of a reverence for all things natural and fundamentalist religious faith. God created natural supplements for our benefit.
I said that Hovind was selling this snake oil until recently because he had to stop due to FDA action. They sent him a letter, which itself is very revealing, citing him for selling laetrile with illegal health claims. In the US the claims make the drug – in other words, part of what defines a substance as a drug under FDA control is that it is claimed to treat an actual disease. Hovind was careful not to make any explicit disease claims on his website, as you can see above. He implies claims, but never says that laetrile treats cancer.
However, he made the mistake of packaging laetrile with the book, which does clearly make disease claims. The FDA letter states:
In addition, along with offering your B17 Amygdalin and Bitter Raw Apricot Seeds by Apricot Power for sale through your website at www.creationtoday.org, your website offers for sale the book, World Without Cancer: The Story of Vitamin B17,which includes claims relating to Vitamin B17, an ingredient in your products B17 Amygdalin and Bitter Raw Apricot Seeds by Apricot Power.
For now Hovind has simply stopped selling laetrile on his Creation Today website, citing the FDA warning. I suspect, however, that he is looking into just selling the laetrile without the book. This should not work, but it might. He has already established a market for his snake oil by linking it to explicit claims that it is a cancer cure. Even before him, this link has been made clear.
No one would take amygdalin and risk poisoning themselves with cyanide unless they had been convinced by such claims. You cannot separate the two. However, current regulations allow for this fiction. You can sell herbal drugs and even toxins as if they are dietary supplements as long as you are coy about your health claims. More explicit health claims can be made elsewhere, but you have to be careful not to clearly link the two in your marketing.
It’s all a game, one rigged in favor of the supplement industry and against the consumer. The lack of outrage by consumer protection organizations and the medical establishment is by itself a scandal. I doubt the BMJ article will move the needle significantly.

Vitamin B12 – The Energy Panacea?
Scott GavuraonDecember 8, 2011
Link
Having spent many hours working in close proximity to a wall of vitamins, I’ve answered a lot of vitamin questions, and given a lot of recommendations. Before I can make a recommendation, I need to ask some questions of my own. My first is almost always, “Why do you want to take a vitamin?” The most common response I’m given is “insurance” – which usually means supplementation in the absence of any symptom or medical need. Running a close second is “I need more energy.” With some digging, the situation usually boils down to a perceived lack of energy compared to some prior period: last week, last year, or a decade ago. While I may identify possible medical issues as a result of these interviews (these are referred to a physician), I’m often faced with a patient with mild and non-specific descriptions of fatigue. And more often than not, they’ve already decided that they’re going to buy a multivitamin supplement. When it comes to boosting the energy levels, they’re often interested in a specific one: Vitamin B12 (cobalamin). So why does vitamin B12, among all the vitamins, have a halo of benefit for fatigue and energy levels? The answer is part science and a whole lot of marketing.
As has been described repeatedly SBM, multivitamins have an impressive aura of benefit and safety that, by and large, hasn’t been substantiated. Beyond the multivitamins, there are dozens of single-ingredient vitamins that contain doses that greatly exceed anything you can pack into a multivitamin, and usually significantly exceed the Reference Daily Intake. While these products may be appropriate for those that actually need a specific supplement (e.g., high dose folic acid, or calcium) they also increase the potential for unanticipated effects, giving a much higher dose than the typical diet can provide.
How the single-agent vitamins are consumed when self-selected by consumers seems to be influenced more by perceptions of efficacy, rather than the underlying scientific evidence. Vitamin C is associated with preventing colds and influenza (though it doesn’t work) and may be shelved alongside the other cold remedies. The B Vitamins are considered to be the “stress” vitamins, based on the perceptions that these vitamins are more rapidly depleted in people who are more “stressed”. Multivitamins like Stresstabs trade on this image. Among the B vitamins, B12 is often held out as as an almost miraculous energy booster. It’s often marketed as a sublingual product – you place it under your tongue, presumably for rapid, extensive absorption. It’s a claim hyped by supplement purveyors like Mercola, with his not-so-subtly-named “B12 Energy Booster” (warning, the video starts immediately):
If you often feel tired, run-down, and lacking in energy, you’re not alone. Low energy is one of our country’s biggest health complaints.
Some of the top reasons for this are:
    • Refined foods sold in grocery stores are depleted of vital nutrients…
    • Refined foods are loaded with sugar…
    • Refined foods are full of chemicals…
    • Refined foods are overloaded with food colorings; and…
    • Refined foods are loaded with preservatives…
…but it doesn’t stop there, either.
Add the harmful effects of caffeine, pollution, conventional therapies, and the stress most of us experience everyday… and you’ve got yourself a recipe for energy drain.
Well, I’m here to tell you there’s a new way to give yourself extra energy.* Actually, a cutting edge way to feel more energized — without the jitteriness of caffeine.* More on this in a moment.
Now, of course, powering up with extra energy is just one of B12’s many health benefits*
(The asterix in the ad copy points to Mercola’s Quack Miranda warning)
It goes on and on, espousing the wonders of “microscopic nanodroplets™” and how it’s conveniently packaged “pre-metered, non-aerosol container that easily fits in your purse or pocket.”
Mercola’s is just one example. Searching “B12” and “energy” brings me 117 million results. If web hits were evidence, this is Cochrane-level persuasive. But let’s take a closer look at the rationale for B12 and the effect of supplementation – will B12 supplements give “extra energy” as Mercola promises?
The Chemical

The history of vitamin discovery is fascinating and the identification of vitamin B12 is no exception. The result of a search for a treatment of pernicious anemia, vitamin B12 was initially thought to be the active ingredient in liver that supported recovery from blood loss. While the true active ingredient was iron, not B12, raw liver or liver “juice” (ugh) was a source of B12 and was the standard treatment for years. The vitamin was eventually isolated, and its molecular structure identified, by the 1950s. It was also identified that B12 is actually a group of very closely related chemicals, the cobalamins. Cyanocobalamin is the form that’s found in supplements and replacements; other forms include hydroxocobalamin and methylcobalamin.
While pernicious anemia is the classic sign of B12 deficiency, the vitamin plays an essential role in multiple pathways and systems, including the nervous system, where severe deficiency can lead to permanent damage. Where there are unexplained neurologic symptoms, such as paresthesias, numbness, or cognitive changes, particularly in the elderly, we might suspect deficiency.
We depend on our diets to provide B12. It’s naturally present in foods of animal origin: liver, clams, beef, and fish are excellent sources. Among manufactured foods, B12 is also fortified into products like cereals. Deficiency is due to one of three causes: malabsorption, insufficient intake, and other medical conditions:
Pernicious anemia is a consequence of an immune reaction that destroys the stomach’s ability to secrete intrinsic factor, which is essential for most of our B12 absoption. No intrinsic factor = little B12 absorption = pernicious anemia. Pernicious anemia can develop slowly, over decades – it’s most common in the elderly, and rare in those under 30.
Diet is the next common cause: Vegetarians and vegans that do not consume animal products must take a supplementary source of B12 – as supplements are yeast-derived, vegetarians are generally pretty responsive to advice and the justification for supplementation, which is particularly important in pregnancy. Outside of these groups, dietary deficiency is rare.
Other medical conditions can cause deficiency through a reduction in absorption, all of which may be more prevalent in older adults:
    • gastritis and H. pylori infection
    • intestinal effects and consequences of from gastrointestinal disease, cancer, or HIV
    • reduced gastric acid secretion secondary to drug therapy like proton pump inhibitors
    • other drugs, like the diabetes drug metformin, which can have gastrointestinal effects
Diagnosing deficiency in symptomatic patients includes measurement of serum vitamin B12. Unfortunately the test is somewhat limited in its usefulness, as it measures total, not active B12. Levels don’t correlate well with symptoms. There’s also overlap between what’s considered “normal” and “abnormal”, so deficiency can exist even when levels look “normal”. Different nomograms have been developed to support evaluation and treatment decisions. Where B12 deficiency is obvious, supplementation may be started without extensive investigations.
The Need for Supplementation
Deficiency is never the result of any short-term issue. The usual (non-vegetarian) “Western” diet provides 5-7 mcg of B12 per day, which is more than adequate to maintain appropriate levels: the RDA is 2mcg/day (2.6mcg/day in pregnancy). The total body stores are 2-5 milligrams, meaning that deficiency is the result of years of reduced intake – missing a day, a week or a month or more of any B12 consumption would not be expected to result in any clinically meaningful effects in someone with previously normal body stores.
Beyond preventing and treating B12 deficiency, supplements are consumed for a huge array of conditions: From the non-specific protection against “toxins” to infertility, depression, cancer, weight loss, kidney disease, Lyme disease and more. When it comes to demonstrated efficacy, B12 has only been conclusively established to be effective for preventing or treating B12 deficiency. There is preliminary evidence suggesting that B12 supplementation, in combination with folic acid, and pyridoxine reduces homocysteine levels. However it’s not as clear if lowering homocysteine levels reduces morbidity and mortality, as it may be a marker, rather than a cause, of disease. The evidence continues to evolve, and it’s not yet well established that treating elevated homocysteine levels with supplements is justified. There’s also some evidence to support B12 for reducing the risk of macular degeneration.
What about fatigue? In the deficient, yes, fatigue may be symptom of a B12 deficiency. But in those with normal B12 levels, the limited data on supplementation is not persuasive. The few investigations that have been conducted suggest that supplementing in the absence of a deficiency has no effect on fatigue.
Replacing B12
Beyond your basic tablets, there are sublingual sprays and wafers, and even intranasal administration. An injectable form of B12 is sometimes used, though oral supplementation is the general recommendation, except in cases of serious deficiency with obvious neurologic symptoms. Oral administration fof cases of malabsorption may sound counterintuitive. While oral absorption is limited, particularly in those with pernicious anemia, oral supplements do correct deficiencies – about 1% is absorbed even in the absence of intrinsic factor and stomach acid. (Oral supplements are typically 1000mcg, meaning at least 10mcg will be absorbed, adequate to meet daily requirements and replace body levels gradually. And despite Mercola’s hype, sublingual versions of B12 are no better than oral forms of the vitamin.
Most typical multivitamins contain 6mcg. This alone provide more than necessary for anyone that can absorb B12. Large doses, particularly oral forms, don’t appear to be harmful, and are well-tolerated. So supplementation as part of multivitamin “insurance”, or as a specific supplement, isn’t likely to harm.
Conclusion
While there is an important role for supplementing with vitamin B12 in some groups, high dose supplements to treat fatigue should be guided by a medical evaluation. For the energy seekers, supplementation in the absence of deficiency offers no benefits. Even in the deficient, B12 supplements won’t offer any sudden “boost” of energy: replacement and recovery takes time. Anyone concerned about their B12 intake should ensure they’re looking to dietary sources first. And for vegetarians and other at-risk groups, supplementing with B12 may be appropriate and science-based.

New Cautions About Vitamin B6 and Peripheral Neuropathy
Two countries are putting warning and limits on Vitamin B6 supplements
Scott Gavura on August 13, 2026
Link

Vitamin B6 is probably in your multivitamin. You’ll also find it on pharmacy shelves, promoted for energy, metabolism, and general health maintenance. But a Health Canada safety bulletin published in June 2026 highlighted a real but less well-known risk: even relatively small doses of vitamin B6 in natural health products may be associated with peripheral neuropathy, a nerve condition marked by numbness, tingling, and pain in the extremities. Health Canada’s action isn’t isolated. Australia’s Therapeutic Goods Administration has reached a similar conclusion, rescheduling higher-dose B6 products to require pharmacist involvement, after finding that peripheral neuropathy couldn’t be ruled out at doses well below what was previously assumed safe.
A very old problem
Concerns about vitamin B6 and nerve damage are not new: they go back decades. In 1983, Schaumburg et al. reported seven patients with disabling sensory neuropathy linked to high-dose pyridoxine supplementation, publishing their findings in the New England Journal of Medicine. Those patients were taking huge (gram-level) doses, far above anything found in a typical multivitamin. The paper established pyridoxine neurotoxicity as real, but it also shaped thinking that the risk was confined to massive doses. So why are regulators now flagging products containing as little as 10 mg? Part of the answer is that newer reviews have identified a possible, though far less certain, signal at doses well below the gram-level range that first drew attention to the problem. Whether some individuals are more susceptible than others remains unclear.
The 1983 report generated a surprising response. In a letter to the New England Journal of Medicine, a proponent of orthomolecular medicine commented on the findings. Orthomolecular medicine proponents believe that vitamins can be beneficial when given at doses that dramatically exceed what is necessary to prevent or treat a deficiency. Whether this is the first appearance of “if a little is good, more must be better” I can’t say, but the letter may have been written by Linus Pauling himself: He was one who invented the term ‘orthomolecular’ fifteen years earlier, right on schedule with this letter’s own timeline. Either way, it’s a familiar argument, then and now. (I could only access the excerpt, if anyone has fulltext access to confirm the author, please let me know.)
What the evidence shows
It’s worth describing what is established and what is less clear with respect to vitamin B6 toxicity. The potential for high doses of vitamin B6 to cause neurotoxicity is well established: typically at doses of 250 mg/day and higher. What is newer, and considerably less clear, is the suggestion that neuropathy may occur at much lower doses, including around 10 mg/day. A 2023 systematic review concluded that the evidence supports the relationship between excessive vitamin B6 exposure and peripheral neuropathy, but noted that the potential risk associated with lower-dose supplementation remains incompletely understood and warrants further investigation. Health Canada’s own review reflects this: Of 17 cases identified (15 Canadian, 2 international), only two, both involving natural health products, were considered suitable for further assessment, and even those were complicated by potential confounders. Consequently, the recent label changes could be thought of precautionary, rather than definitive proof that taking 10 mg/day of supplemental vitamin B6 causes peripheral neuropathy. It appears to be a plausible safety signal, but not definitive proof.
Two countries, two different approaches
An interesting aspect of Health Canada’s decision is the distinction it drew between supplements and prescription drugs. Despite reviewing prescription products containing similar amounts of vitamin B6, Health Canada found insufficient evidence to justify additional warnings for those products, citing established prescribing practices. Yet it did require new warnings for non-prescription natural health products. This looks inconsistent, but reflects the fact that prescription vitamin B6 products in Canada are specifically approved for pregnancy (nausea/vomiting and prenatal support). These patients would already be monitored as part of routine prenatal care. Unclear risks may warrant more caution (and warning) when consumers are managing all decisions on their own.
Australia has taken a much stricter approach to manage this toxicity risk. The TGA (Australia’s FDA equivalent) has decided that higher-dose non-prescription (50mg – 200mg) oral vitamin B6 products should no longer be treated as ordinary self-selection items. Purchasing will require pharmacist involvement, beginning in 2027. This inserts a healthcare professional into the decision-making process. The policy reflects the reality that a warning label itself may be insufficient.
Risk-free insurance?
The growing shelf space devoted to vitamin supplements speaks to their appeal. For many people, they’re viewed as a form of risk-free health insurance: They can only be beneficial, and if your body doesn’t use them, they’ll be expelled. With that framing, supplementing seems like an easy choice. But this also ignores the possibility of harm. It means that vitamins escape the scrutiny that we might apply to other health interventions and decisions. The vitamin B6 evidence challenges this assumption. Vitamins are biologically active chemicals and not a panacea that can only do good. Even when the risks are low, or uncertain, they are still risks, and they need to be considered alongside any hoped-for benefits.
Conclusion
For most pharmacists, and I’m counting myself here, vitamin B6 is not a product that has traditionally attracted much attention. It sits on a shelf for self-selection, alongside an entire category of products that most consumers view as inherently safe and exempt from the “benefit vs. risk” thinking that accompanies a prescription medicine decision.
These newer concerns about peripheral neuropathy remind us that even products marketed as “natural” involve decisions, trade-offs, and uncertainty. And no product is free of risk, even a vitamin that has been marketed in huge doses for decades. Regulation changes can improve labels, restrict access, or mandate additional oversight by a health professional, but they do not change the underlying mindset that more supplementation is automatically better. The lesson of vitamin B6 is not that supplements are inherently dangerous. It is that the absence of perceived risk should never be mistaken for the absence of actual risk.

Macular Degeneration and AREDS 2 Supplements
Harriet Hall on June 10, 2014
Link

Four years ago I wrote about the premature marketing of a diet supplement for macular degeneration before the results of a trial to test it were available. Now that we know the results of that trial, a follow-up post is in order.
Age-related macular degeneration (AMD) is a leading cause of blindness. The incidence increases with age; it affects 10% of people by age 66-74 and 30% of people by age 75-85. There are known risk factors including genetics and smoking, but there is no effective prevention. There are multiple diet supplement products on the market that are advertised as “supporting eye health.” Some are based on evidence from randomized, controlled studies; but the advertising hype goes beyond the evidence and tends to mislead consumers. There is evidence that supplementation may slow the progression of moderate to severe AMD, but there is no evidence that supplements are effective in milder disease or for preventing AMD from developing in the first place. 
The AREDS trial
The original AREDS (Age-Related Eye Disease Study), was a large, multicenter trial of patients with established AMD to evaluate the effect of a combination of 3 antioxidants (vitamin C, 500 mg; vitamin E, 400 IU; and vitamin A in the form of beta carotene, 25,000 IU), with zinc and copper. Over 5 years, patients taking the antioxidant and zinc supplement had a 23% chance of developing vision loss from advanced AMD compared to a 29% chance of developing vision loss from advanced AMD for patients taking a placebo pill. This effect was statistically significant, but modest. Concerns were raised about the high dose of vitamin A, since beta carotene was known to cause harm at those levels, so another study was designed to evaluate a different combination that omitted the vitamin A and added other possibly beneficial components.
The AREDS 2 trial
In the new trial, there were four groups: (1) a control group got the original AREDS formula, and the other 3 got a formula that omitted the vitamin A and added (2) lutein and zeaxanthin, (3) the omega 3s DHA and EPA, and (4) both lutein/zeaxanthin and DHA/EPA. There was no control group of patients not taking any supplement.
They concluded:
Addition of lutein + zeaxanthin, DHA + EPA, or both to the AREDS formulation in primary analyses did not further reduce risk of progression to advanced AMD. However, because of potential increased incidence of lung cancer in former smokers, lutein + zeaxanthin could be an appropriate carotenoid substitute in the AREDS formulation.
AREDS 2 had a number of strengths. It was large (4,203 subjects), it lasted 5 years during which 1940 eyes progressed to advanced AMD, the drop-out rate was low, it assessed adherence, and it measured blood levels of the study nutrients.
It also had some weaknesses. They didn’t use a no-supplement control group because they assumed that the original AREDS had proved the benefit of supplementation. This is a bit worrisome, since we know it is risky to rely on a single study. The AREDS trial has not been replicated, and a Cochrane systematic review concluded:
People with AMD may experience delay in progression of the disease with antioxidant vitamin and mineral supplementation. This finding is drawn from one large trial conducted in a relatively well-nourished American population. The generalisability of these findings to other populations is not known. Although generally regarded as safe, vitamin supplements may have harmful effects. A systematic review of the evidence on harms of vitamin supplements is needed.
A personal note
I have macular degeneration that is due to myopia, not AMD. It has not yet caused any loss of visual acuity, but I am being monitored by a retinal specialist. A couple of years ago, she suggested I take a supplement based on AREDS 2, but with the addition of bilberry and omega 3’s, available directly from the manufacturer as a mail-order subscription service. She offered it more as an option than a recommendation, and she didn’t push it. I declined, because that particular formulation has not been studied, and because the AREDS evidence is only for AMD, not for myopic macular degeneration. I can understand her wanting to “do something,” and the rationale that it might help and couldn’t hurt, but that wasn’t enough to convince me.
Conclusion
The AREDS trial provided evidence that a mixture of diet supplements slowed the progression of moderate-to-advanced macular degeneration, and the AREDS 2 trial found that a safer formulation was equally effective. The evidence would be more convincing if there were confirmatory studies with no-supplement control groups. There is no evidence of benefit for patients with mild AMD, and no evidence that supplements can prevent AMD. Advertising that products “support eye health” is misleading.
I found it interesting that 50% of the AMD patients were smokers or former smokers, a much higher rate than in the general population. This suggests that smoking cessation might be as important or more important than any supplement (at least in well-nourished people), and it is an intervention that has many other health benefits.

VacciShield: Pixie dust for an imaginary threat
John Snyder on June 6, 2014
Link

I know by now I shouldn’t be, but I am still amazed by how readily so many people buy into the seemingly endless array of bogus sCAM nostrums. Many are marketed and hawked for the treatment or prevention of diseases that are poorly managed by science-based medicine. There are countless examples of dietary supplements that are purported to effectively treat back and joint pains, depression, anxiety, autism, chronic pain, and chronic fatigue; the list goes on and on. The lure for these treatments is at least understandable and, although frustrated that scientific literacy and rational thought loses out, I empathize with the desire to believe in them. On the other end of the spectrum is the even more ethically corrupt substitution of safe and effective treatments with products that are not. I encountered what I find to be possibly the most frightening and dangerous example of this recently at my practice. A family new to the area called to schedule a routine health-maintenance visit for their 5-year-old daughter. When our nurse reviewed the medical records the mother had faxed over, she noted that the child was unimmunized and explained to her that she would need to begin catch-up vaccinations. The mother matter-of-factly stated that her daughter was actually fully vaccinated with a vaccine alternative. She had received a series of homeopathic vaccines from a naturopath. I am not going to discuss this egregious example of sCAM here, though it was addressed in previous SBM posts.1,2 Instead I’d like to focus on another part of the sCAM spectrum. Here lies a form of sCAM that, in some ways, is even more difficult for me to comprehend. These are products invented, marketed, and sold solely for the treatment or prevention of fictitious diseases or problems that exist only in the realm of fantasy.
Vaccishield: yes, you clearly CAN make this sh** up.
A mother-naturopath by the name of Catherine Clinton has identified a little known condition that has launched her career as a producer and seller of one of the newest health-maintaining elixirs. At $27.99 USD for 1.36 ounces, she’s probably doing all right. It’s not a condition, exactly, that her elixir is aimed at. It’s more of a, well, I guess you can call it a state of unsupported peri-vaccination health, or something. In her own words, VacciShield was designed to “fill a gap that we saw in the vaccination process”. To be a little more specific, ND Clinton explains on her company’s website:
I became concerned about vaccinating my son and wanted another option to support him during vaccinations. I looked to the research to see if there was something I could do nutritionally to support health during this vulnerable time. So we created VacciShield to fill a gap that we saw in the vaccination process. VacciShield is designed for infants and kids to help support healthy brain, immune, gastrointestinal and detoxification function during vaccination.
The gap in the vaccination process she refers to is clearly something she found missing from her child’s routine pediatric care. A gap she has identified that, if not filled, places children at risk. At risk from what is not made clear anywhere on the company’s website. But since VacciShield is intended to support healthy brain, immune, gastrointestinal, and detoxifying function, I’m assuming she believes these body systems are at some sort of risk from vaccinations. Actually, it’s pretty clear what she’s referring to by her albeit vague terminology. And the name VacciShield is certainly not ambiguous. It is meant to shield children from the potentially damaging effects of vaccines, while still presumably allowing the benefits of the vaccines to slip through.
To be fair, ND Clinton’s vagueness about what, exactly, this product is supposed to shield against and how is not entirely her fault. The Dietary Safety, Health, and Education Act (DSHEA) of 1999 (under which all dietary supplements fall) prohibits her from making any specific health claims (such as “VacciShield protects your baby from vaccine-toxin-induced autism”). That would place VacciShield in the drug category, and would require the support of real scientific evidence and FDA oversight. As a dietary supplement, so-called “structure-function” claims (such as “supports healthy brain, immune, gastrointestinal, and detoxifying function”) are permitted providing they are truthful and non-misleading, and require only that the FDA be notified within 30 days of the supplement going on the market.
Now, these claims are truthful and non-misleading by only the most legal, non-scientific interpretation. The “active” ingredients in VacciShield include vitamins C, D3 (really a hormone), and E, zinc and selenium, the amino acid L-glutamine, and the nutrients choline and inositol, which are all involved in well-described biochemical or bio-synthetic processes in the body. As such, in the strictest, most uninformative way, these ingredients do “support” body function. In addition to the “active ingredients” mentioned above, VacciShield contains the probiotics Lactobacillus casei and Bifidobacterium lactis.
Based on the ingredients she has chosen to include in this product, and the references she cites in support of them, it seems that ND Clinton’s concerns about vaccinating her son are fueled by just about every vaccine myth out there, including Wakefield’s MMR-induced leaky gut-autism myth, the too-many too-soon gambit, the glutathione-deficiency vaccine-induced autism hypothesis, the thimerosal-induced neurotoxicity myth, the intestinal flora dysregulation and autism hypothesis, and probably others all thrown into the mix.
But to play devil’s advocate, let’s look into the evidence in support of VacciShield’s claims (Note: at the end of this post I present a brief synopsis of each of the references cited on the VacciShield website.)
The probiotics
Without delving into the topic of probiotics and the microbiome, suffice it to say that there is, in fact, a growing but still murky body of evidence supporting a host of either protective or treatment effects of probiotics, including possibly enhancing the immune response to the live oral polio and rotavirus vaccines. The VacciShield website cites several references to support their inclusion of Lactobacillus casei and Bifidobacterium lactis in this product. None of these references, however, provide any evidence that can be construed as supporting the use of these probiotics when vaccinating, and some refer to studies that include probiotics not contained in VacciShield.
The vitamins
VacciShield contains small amounts of vitamins C, D3, and E. The VacciShield website cites several references to support their inclusion in this product. While some of these references document real immune-modulating and antioxidant effects, none provide any evidence suggesting benefits of supplementation during vaccination. The website states the following rationale for including these vitamins:
Vitmain C
Vitamin C has been shown in clinical research to support brain, immune, detoxification and gastrointestinal function in a growing child. Vitamin C is a powerful antioxidant that helps protect the body from free radical damage. Vitamin C is also necessary to hundreds of metabolic processes. Research out of Australia suggests Vitamin C’s ability to decrease the side effects of vaccination.
Glutathione, in its reduced state, plays an important role in the body as a free radical-scavenging anti-oxidant. The unsupported hypothesis that glutathione deficiency exists in children predisposed to autism has led some anti-vax pseudoscientists to believe that antioxidants (vitamin C is one) may protect against purported vaccine-induced autism. Other equally unsupported theories claim that thimerosal (now only in some influenza vaccines) lowers glutathione levels to cause neurotoxicity. It seems that this is the likely flawed rationale for the inclusion of vitamin C in this product.
Vitmain D3
Vitamin D3 has hormone like actions by binding to DNA receptors and promoting cell growth. Research highlights the vital role Vitamin D3 plays in maintaining healthy immune, brain, gastrointestinal and detoxification function. Recent research shows how vitamin D3 assists in the immune response to vaccination.
Vitamin D3, which is really a steroid hormone, has many important functions in the body, and there is evidence supporting its role in modulating immune responses. Though they are interesting examples of the important role that vitamin D3 plays in immune modulation, none of the references cited on the VacciShield website support its use as a dietary supplement around the time of vaccination. To claim that they do is an absolute over-reading or misrepresentation of the existing science.
L-glutamine
L-Glutamine is an amino acid found in breast milk and plays an important role in several metabolic processes. L-Glutamine is an important precursor to the major detoxification enzyme, glutathione. L-Glutamine fuels the cells that line the gastrointestinal tract, helping to maintain a healthy digestive tract. Recent studies in 2005 and 2007 showed that L-Glutamine improved intestinal barrier function in children ages 2 months to 6 years old.
These statements sound okay, but they do not give us even a clue as to why we would want to provide a child with extra L-glutamine around the time of vaccination. Unless, of course, you subscribe to some vague, pseudoscientific theory of vaccine toxin-induced, leaky gut, neurotoxicity. The use of these citations is truly beyond belief (make sure you see the summaries below…).
Zinc
Zinc has been shown in research to support brain, immune, detoxification and gastrointestinal function in a growing child. Zinc is an essential mineral that is necessary in hundreds of metabolic processes. Zinc helps maintain a healthy immune system as well as healthy growth and development. Research in 2009 highlighted zinc’s ability to enhance infants immune response to vaccination as measured through immune titers.
Again, these statements are (mostly) true. But replacing the word zinc with almost any biochemically active molecule would be equally true. The last bit about zinc’s ability to augment the immune response to vaccines is another huge stretch, or it simply indicates ND Clinton’s inability to grasp the science. The study cited refers to the finding that zinc supplementation of young Bangladeshi children enhanced their antibody response to the cholera vaccine. Zinc deficiency is extremely common in Bangladesh, but not so in the developed world. Supplementing well-nourished (and zinc-replete) children prior to vaccination is pointless.
Selenium
Selenium has been shown to be a necessary component of detoxification pathways as well as immune function. Selenium is an important precursor to the major detox enzyme glutathione peroxidase. Research with selenium and the polio vaccine shows how important selenium is to the handling of vaccines and immune function.
Yes. And thankfully children have more than enough selenium in their little bodies for all of their little body functions. There is not one stitch of evidence (including the ridiculous choice of references on the VacciShield website) suggesting that supplementation with additional selenium does anything to support a child through their vaccinations.
Choline and inositol
Choline and Inositol work together as primary sources of a healthy cell membrane. They help enhance brain development in infants and children.
Yes, again. And again, this has no relevance to the recommendation for supplementation.
None of the references cited to support supplementation provide any such evidence. Her references for choline are laughably irrelevant, and there is not a single reference for inositol.
In summary, there is no evidence that any of these ingredients improve the efficacy of any vaccine. Nor is there any evidence or reason to believe that an infant or child’s immune system requires “support” to either adequately respond to or be able to handle routinely administered vaccines. Much of the evidence referenced on the VacciShield website is related to the immune modulating and enhancing effects of the substances in question. Putting aside the fact that the evidence is badly misrepresented, it seems from the research cited that the primary benefit of VacciShield must be to augment the response to vaccines rather than to shield or protect against their damaging effects. Reading between the DSHEA-restricted lines on the product website, it is implied that vaccines somehow tax or overload a child’s immune system, thus making “immune support” beneficial. We have heard this canard many times, and it has been mercilessly dealt with ad nauseam elsewhere. Simply put, an infant’s immune system is more than adequately equipped to handle the antigen load of our current vaccine schedule. In fact, compared to the immune challenge faced by the act of simply going outdoors, not to mention fighting the common cold, a child’s vaccine visit is like a drop in the bucket. And though I won’t rehash this topic here, the “toxic threat” of vaccines is no threat at all. Those who claim otherwise are either ignorant of the science or are willful fear-mongers. In the end, VacciShield can be seen only as an expensive and useless solution to a non-existent problem. Not surprisingly, the website testimonials are over-the-top, and rather hilarious. My favorites are those crediting VacciShield for a trouble-free vaccination experience,
I have been using VacciShield since my children first starting immunizations and thanks to this great product, the side effects have been minimal. No fevers, swollen arms or legs and the best part, no panic from mom! I feel at ease taking them in now. I recommend this to all my friends who have children. It really works, and it’s great for all ages!!– Ditton in Oregon
On the other hand, maybe this is the trick for getting all of my vaccine-hesitant parents to get their children vaccinated…

Probiotic references:
“Daily probiotic’s (Lactobacillus casei Shirota) reduction of infection incidence in athletes.” Int J Sport Nutr Exerc Metab. 2011 Feb;21(1):55-64.
    • A double-blind, placebo-controlled RCT demonstrating a reduction in the frequency of upper respiratory tract infections in athletes taking Lactobacillus casei during 4 months of winter training. It also demonstrated a significant increase in salivary IgA, which was hypothesized to play a role in the lowered incidence of infections.
    • There is no reason to conclude from these results that Lactobacillus casei can enhance the immune response to vaccines, particularly if increased secretory IgA is the responsible factor, as suggested by the authors.
“Effect of probiotic supplementation in the first 6 months of life on specific antibody responses to infant Hepatitis B vaccination.” Vaccine 2010 Mar 19;28(14):2577-9.
    • This was an underpowered RCT that produced confusing results suggesting an increase in IgG antibody response in infants receiving a very specific schedule of hepatitis B vaccination, but not another schedule.
    • The authors state that the study was designed to evaluate the effect of probiotic supplementation in the first 6 months of life on eczema in at-risk infants, however eczema is mentioned nowhere in the paper, making me wonder whether the study endpoint may have been changed during the study, or that there were multiple-endpoints.
    • The probiotics used in this study (Bifidobacterium longum and Lactobacillus rhamnosus) were not the same as those in VacciShield, making this study no use as supporting evidence, though I don’t see how it would support the use of these probiotic even if they were.
“Probiotic bacteria stimulate virus-specific neutralizing antibodies following a booster polio vaccination.” Eur J Nutr. 2005 Oct;44(7):406-13.
    • A double blinded RCT demonstrating a greater increase in poliovirus-specific serum IgA and IgG levels following vaccination with oral polio vaccine in patients receiving Lactobacillus rhamnosus or acidophilus compared with placebo.
    • Again, The probiotics used in this study were not the same as those in VacciShield, making this study inappropriate to use as supporting evidence.
“Ability of probiotic Lactobacillus casei DN 114001 to bind or/and metabolise heterocyclic aromatic amines in vitro.” Eur J Nutr. 2009 Oct;48(7):419-27.
    • An in vitro study exploring the ability of Lactobacillus casei to absorb and/or metabolize several heterocyclic aromatic amines, which may be potentially carcinogenic dietary compounds.
    • This study has no relevance as a piece of supporting evidence for the use of this or any other probiotic during vaccination.
(Two additional studies cited as supporting evidence were not included here because they were simply topic overviews.)
Vitamin references:
“Selected vitamins and trace elements support immune function by strengthening epithelial barriers and cellular and humoral immune responses.” Br J Nutr. 2007 Oct;98 Suppl 1:S29-35.
    • This is a journal supplement that summarizes the roles of selected vitamins and trace elements in immune function, discusses how deficiencies in these micronutrients may lead to immune disregulation, and then hypothesizes that supplementation may support the body’s natural defense system.
    • No evidence here.
“Combined ascorbate and glutathione deficiency leads to decreased cytochrome b5 expression and impaired reduction of sulfamethoxazole hydroxylamine.” Arch Toxicol. 2010 Aug;84(8):597-607.
    • A study suggesting that guinea pigs fed a vitamin C and glutathione-restricted diet may be less able to metabolize reactive metabolites of the antibiotic sulfamethoxazole (SMX). The authors hypothesize that this mechanism could contribute to the higher risk of SMX hypersensitivity in patients with AIDS and antioxidant depletion.
    • To cite this as evidence for the use of vitamin C around the time of vaccination indicates either profound scientific illiteracy or outright fraud. That said, there are anti-vaccination pseudoscientists who believe subtle glutathione deficiency predisposes some children to autism following vaccination, or that thimerosal lowers glutathione levels to produce vaccine-induced neurotoxicity. There is no sound science to support these beliefs. Even if there was, the paper cited here still provides no evidence for the use of vitamin C with vaccination.
“Ascorbic acid promotes detoxification and elimination of 4-hydroxy-2(E)-nonenal in human monocytic THP-1 cells.” Chem Res Toxicol. 2009 May;22(5):863-74.
    • This in vitro study demonstrated that pre-treating a human leukemia cell line with vitamin C decreased HNE-induced formation of reactive oxygen species and formation of protein carbonyls. HNE (4-Hydroxy-2(E)-nonenal) is a reactive aldehyde derived from oxidized lipids, and has been implicated in the pathogenesis of cardiovascular and neurological diseases. According to the authors, the study results suggest that the protective effects of vitamin C are related to its ability to reduce glutathione.
    • This is an in vitro study that has nothing to do with vaccines. Unless, again, you believe in the glutathione theory of vaccine-induced autism.
    • If you are looking for evidence to support the use of vitamin C with vaccinations, you will not find any here.
“TLR-induced local metabolism of vitamin D3 plays an important role in the diversification of adaptive immune responses.” J Immunol. 2009 Apr 1;182(7):4296-305.
    • Discusses the role that naturally occurring vitamin D3 and calcitriol have on the adaptive immune response to injected antigens and actual infection.
    • Does not discuss the role or potential effect of vitamin D supplementation during vaccination.
“TLR ligands that stimulate the metabolism of vitamin D3 in activated murine dendritic cells can function as effective mucosal adjuvants to subcutaneously administered vaccines.” Vaccine. 2008 Jan 30;26(5):601-13.
    • This study demonstrated in a mouse model that active metabolites of vitamin D3 produced locally are able to affect various aspects of innate and acquired immune responses. This may be useful in developing new forms of adjuvants (substances added to vaccines to “jump start” the immune response).
    • It in no way supports the notion of supplementing the diet with vitamin D3 when vaccinating.
“Developmental vitamin D deficiency causes abnormal brain development.” Psychoneuroendocrinology. 2009 Dec;34 Suppl 1:S247-57.
    • The authors developed an animal model to test the biological plausibility of the hypothesis that developmental vitamin D deficiency may play a role in schizophrenia. They report structural brain changes in the developmentally deprived animals, and some subtle behavioral changes.
    • Really? Evidence for giving vitamin D to children prior to vaccinations?
    • This is getting ridiculous.
“1,25-Dihydroxyvitamin D3 regulates genes responsible for detoxification in intestine.” Toxicol Appl Pharmacol. 2007 Jan 1;218(1):37-44.
    • Using microarray technology, the authors studied the effect of a single dose of vitamin D3 on gene expression in the intestine of vitamin D-deficient rats. They found increased expression of several phase I and phase II biotransformation genes, and an increased expression of antioxidant genes. They suggest that the results support the idea that vitamin D is a significant factor in detoxification and protection against environmental toxins.
    • Ok, so if you believe these results, and you believe that vaccines contain dangerous toxins that need to be eliminated, and you believe that administering vitamin D3 to children around the time of vaccination will stimulate the relevant enzymes to do the relevant detoxifying, then maybe you’ve hit on something here. Another enormous stretch.
“Vitamin D receptor negatively regulates bacterial-stimulated NF-kappaB activity in intestine.” Am J Pathol. 2010 Aug;177(2):686-97.
    • By ablating the vitamin D receptor (VDR) in mice, the authors demonstrated that the VDR negatively regulates bacterial-induced intestinal NF-kappaB activation and attenuates response to infection. They conclude that VDR is an important contributor to intestinal homeostasis and host protection from bacterial invasion and infection.
    • And how does this support “protecting” children through vaccination with supplements of vitamin D3? It doesn’t.
L-glutamine references:
“Intestinal barrier function and weight gain in malnourished children taking glutamine supplemented enteral formula.” J Pediatr Gastroenterol Nutr. 2005 Jan;40(1):28-35.
    • Malnourished infants/young children fed a formula supplemented with glutamine had a lower Lactulose/mannitol excretion ratio (used as a surrogate marker for intestinal permeability) than those receiving standard formula, indicating improved intestinal barrier function.
    • So? Again, if you believe that vaccines damage your intestinal barrier (there is NO evidence for this anywhere in the literature. ANYWHERE.), and your child is malnourished, then go at it.
“Wasting and intestinal barrier function in children taking alanyl-glutamine-supplemented enteral formula.” J Pediatr Gastroenterol Nutr. 2007 Mar;44(3):365-74.
    • Same authors and basically the same as the above.
“Zinc and glutamine improve brain development in suckling mice subjected to early postnatal malnutrition.” Nutrition. 2010 Jun;26(6):662-70.
    • Malnourished Swiss mice that received subcutaneous injections of glutamine showed increased hippocampal gamma-aminobutyric acid and synaptophysin levels, and increased CA1 brain layer volume vs. controls.
    • Ok then, clearly we need to give our kids glutamine when they get their shots.
    • Are you laughing or crying? If neither, you need serious help. Or you need to buy some VacciShield…
Zinc references:
“The influence of marginal zinc deficient diet on post-vaccination immune response against hepatitis B in rats.” Hepatol Res. 2006 May;35(1):26-30.
    • In vitro cell-mediated immune response and in vivo specific antibody response to hepatitis B vaccine was decreased in rats fed a diet with marginal zinc content. The authors suggest that marginal Zn deficiency might influence the efficacy of hepatitis B vaccination in humans.
    • See above.
“Micronutrient deficiencies are associated with impaired immune response and higher burden of respiratory infections in elderly Ecuadorians.” J Nutr. 2009 Jan;139(1):113-9.
    • This was a cross-sectional study of elderly Ecuadorians in a low-income community in Quito, Ecuador. It demonstrated that the burden of infectious diseases, micronutrient deficiencies, and anemia was substantial in this elderly Ecuadorian population, and that deficiencies of essential vitamins and minerals place these elderly adults at risk for infections through their negative impact on immune function.
    • If you’re an elderly Ecuadorian with micronutrient deficiencies, it might be a good idea to take some zinc supplements. If your children live in a well-developed nation and are fortunate to be well-fed, stop wasting your money on products like VacciShield, and donate it to UNICEF instead.
“Therapeutic potential of N-acetyl cysteine with antioxidants (Zn and Se) supplementation against dimethylmercury toxicity in male albino rats.” Exp Toxicol Pathol. 2012 Jan;64(1-2):103-8.
    • Combined treatment of zinc and selenium with N-acetyl cysteine (replenishes reduced glutathione stores) to dimethylmercury-exposed rats showed a substantial reduction in the levels of DMM-induced oxidative damage and comet tail length (a measure of DNA damage).
    • In the US there are no more thimerosal-containing vaccines (except for multi-dose vials of influenza vaccine).
    • Thimerosal contains ethyl mercury, not methyl mercury. There is a huge difference.
    • Thimerosal was never a risk to children and has been shown to have no linkage to autism (nor does industrial methyl mercury by the way…).
    • This can in no way be construed as evidence supporting the use of zinc supplementation for children receiving vaccines.
Selenium references:
“High selenium status in individuals exposed to arsenic through coal-burning in Shaanxi (PR of China) modulates antioxidant enzymes, heme oxygenase-1 and DNA damage“. Clin Chim Acta. 2010 Sep 6;411(17-18):1312-8.
    • The authors conclude that inorganic arsenic exposure from coal-burning power plants in China is associated with oxidative stress, which may be prevented by high levels of selenium.
    • Do I really need to address this? No, because if you believe this is good evidence to support supplementing children with selenium prior to vaccination, then the cause is lost.
“Influence of selenium on innate immune response in kids.” Folia Microbiol (Praha). 2009 Nov;54(6):545-8.
    • Supplementation of baby goats with inorganic selenium was found to up-regulate some in vitro immune responses but not others.
    • We’re scraping the bottom here. And why are we trying to upregulate immune response again?
“Selenium-dependent and -independent transport of arsenic by the human multidrug resistance protein 2 (MRP2/ABCC2): implications for the mutual detoxification of arsenic and selenium.” Carcinogenesis. 2010 Aug;31(8):1450-5.
    • Explores the role played by selenium in the transport and detoxification of arsenic in human embryonic kidney cells.
    • No relevance to the use of selenium in vaccinating children.
“An increase in selenium intake improves immune function and poliovirus handling in adults with marginal selenium status.” Am J Clin Nutr. 2004 Jul;80(1):154-62.
    • Selenium-deficient adults who received selenium supplements showed increases in some but not all measured immune responses to oral polio vaccine compared to controls.
    • These were adults who were selenium deficient, and the vaccine was the oral polio vaccine, which is no longer given in the US.
    • Children respond just fine to vaccines and do not need their immune response augmented.
Choline and inositol references:
“Pre- and postnatal health: evidence of increased choline needs.” J Am Diet Assoc. 2010 Aug;110(8):1198-206.
    • Reviews the importance of choline in fetal development and suggests that pregnant woman may not consume adequate choline during pregnancy. Once again, this is not relevant to the discussion of supplementing children who receive vaccines.
“Dietary choline reverses some, but not all, effects of folate deficiency on neurogenesis and apoptosis in fetal mouse brain.” J Nutr. 2010 Jun;140(6):1162-6.
    • This study demonstrated that choline supplementation could reverse some, but not all, of the damaging effects of folate deficiency in fetal mouse brains.
    • This is another evidentiary non sequitur. It is meaningless to the issue of peri-vaccination supplementation.
“Early reduction of total N-acetyl-aspartate-compounds in patients with classical vanishing white matter disease. A long-term follow-up MRS study.” Pediatr Res. 2008 Apr;63(4):444-9.
    • Leukoencephalopathy with vanishing white matter is an autosomal recessive degenerative disease of the brain and spinal cord that can present in children or adults. It is not linked in any way to vaccines.
    • I can only guess that ND Clinton cited any references containing the terms choline and brain disease that came up in her PubMed search, because while the word choline does appear twice in this paper, it has no relevance to a deficiency state or anything else I can imagine her wanting to reference. Oops.

   Short Attention Span SBM
Mark Crislip
Link
The bar on this blog is set high. The entries are often complete, with no turn left unstoned. Yet, not every topic needs the full monty with every post. The blog has extensive evaluations on many topics, and new medical literature doesn’t require another complete analysis. Many new articles add incrementally to the literature and their conclusions need to be inserted into the conversation of this blog, like a car sliding into heavy traffic. My eldest son just received his driver’s license, and car metaphors are on my mind. As are crash metaphors and insurance metaphors.
So in response to this need, a need only recognized by me, I give you Short Attention Span SCAM. Occasionally I will summarize a few recent studies and their key points as they relate to prior posts at SBM.
Influenza
…any man’s death diminishes me, because I am involved in mankind, and therefore never send to know for whom the bells tolls; it tolls for thee. — John Donne
Influenza season will be starting soon. There are multiple misstatements made about influenza and its treatment in the SCAMosphere. The first concerns death. Flu does not kill, or so it is asserted, or it only kills a thousand people a year. During last year’s H1N1 season I took care of a pair of patients who died of acute influenza, not its complications. Direct deaths from influenza are always a fraction of the deaths from indirect causes: worsening of heart failure or lung disease or a secondary infections. I try to never use the word ‘only’ when discussing direct flu deaths; perhaps I take it too personally. Not patient of mine was ever an ‘only’ and it annoys me no end when the deaths of others are diminished.
How influenza deaths are calculated was discussed in the past, but the CDC released new information on influenza deaths from 1976 to 2007. Calculating flu deaths is not easy. The number lies somewhere between direct deaths from flu, and the deaths from other acute, but related causes:
Deaths from pneumonia and influenza causes are highly correlated with the circulation of influenza and can be considered a lower bound for deaths associated with influenza. However, a diagnosis of influenza virus infection often is not confirmed with sensitive and specific laboratory diagnostics, particularly among older persons, and even when identified is rarely recorded on death certificates (5). Many deaths associated with influenza infections occur from secondary infections such as bacterial pneumonia or complications of chronic conditions such as congestive heart failure and chronic obstructive pulmonary disease. Therefore, estimates using underlying respiratory and circulatory mortality data (which include pneumonia and influenza causes) can provide an upper bound for influenza- associated deaths.
The striking result is that, on average, there is no average flu season. Deaths vary from year to year and depends on the circulating strain of influenza.
Over 31 consecutive flu seasons, on average there were about 23,600 deaths a year linked to the flu varying from a low of 3,349 deaths in 1986-1987 to a high of 48,614 in 2003-2004.
When H3N2 predominated, deaths were 2.7 times higher than compared to other strains. As a comparison, 8,330 to 17,160 are estimated to have died from H1N1.
The ‘classic‘ number given is about 36,000 deaths a year, but the number is an average and, like so much in medicine, it depends. As the CDC says,
A single estimate should not be used to summarize influenza-associated deaths; a range of estimates should be described in the context of circulating virus strains and underlying causes of death among age groups.
Death is often a bad outcome and it is better to not die of the flu or its complications. A recent case controlled study compared flu vaccinated vs unvaccinated and found that the receipt of the flu vaccine decreased the risk of heart attack.
We included 78 706 patients, of whom 16 012 were cases and 62 694 were matched controls. Influenza vaccination had been received in the previous year by 8472 cases (52.9%) and 32 081 controls (51.2%) and was associated with a 19% reduction in the rate of acute myocardial infarction (adjusted odds ratio [OR] 0.81, 95% confidence interval [CI] 0.77-0.85). Early seasonal influenza vaccination was associated with a lower rate of acute myocardial infarction (adjusted OR 0.79, 95% CI 0.75-0.83) than vaccination after mid-November (adjusted OR 0.88, 95% CI 0.79-0.97).
The authors do not speculate on the mechanism of the protection, but that will not stop me. Infections are pro-inflammatory and pro-thrombotic. Myocardial infarctions, strokes and pulmonary embolisms are increased during and after acute infections, perhaps in part due to increased stress on the heart, but also, perhaps due to the pro-thrombotic state. It is reasonable to suggest that flu leads to increased inflammation and thrombosis which leads to MI. No flu, no pro-thrombotic state, no MI. If one could “boost the immune system“, and you can’t, what you would get is a inflammatory/thrombotic state that should lead to more vascular events: strokes, MI and pulmonary embolism.
Vitamin D
Dont get the vaccine, many a site will say, all you need is vitamin D to prevent and treat flu. I am not going to deny the importance of having sufficient vitamin D to keep immune function optimal.
Having higher vitamin D serum levels does decrease the risk of a viral infection, although the effect is modest.
During 114 days of the fall and winter in a temperate zone a serum concentration of 25-hydroxyvitamin D of 38 ng/ml or higher was associated with a two-fold decrease (p<0.0001) in the risk of developing acute viral infections of the respiratory tract.
A modest decrease in risk, and enough to keep me drinking milk shakes all winter to keep my vitamin D levels elevated.
The question is, if you supplement vitamin D in patients, can you treat or prevent influenza? There is zero data for influenza. But there is data for viral upper respiratory tract infections. In Finland they they did a placebo-controlled double-blinded study in 164 young Finnish men (1828 years of age) who were randomly assigned to 400 IU (10 mg;) vitamin D3 daily or placebo.
The treatment and placebo group had the same initial levels of Vitamin D and a difference in levels at the end of the trial.
Intervention (78.7+- 14.9nmol/L) and placebo (74.4+- 20.8 nmol/L groups (P p .35)…after daily supplementation with 400 IU vitamin D or placebo for 6 months, the mean serum 25(OH)D concentrations were 71.6 +- 22.9 nmol/L in the intervention group and 51.3 +- 15.5 nmol/L in the placebo group.
Let’s see: moles to molecular weight to Avogadro’s number to … it’s late and I am tired and do not have there intellectual wherewithal to convert nmol/l to mg/ml. I must have a homeopaths understanding of concentrations. I will leave that as an exercise for the comments (yes, it is also fun to whitewash a fence) to see if they started at the 38 ng/ml that was effective to decreasing risk. Hey. I can’t be expected to do everything can I?
The results were, again, modest.
The main outcome variable, which was the number of days absent from duty due to respiratory tract infection, did not differ between groups. Mean number of days absent was 2.2 +-3.2 days in the intervention group and 3.0+-4.0 days in the placebo group . There was an effect during the first 6 weeks of the study, with a mean of 0.7+-2.1 days of absence in the intervention group and 1.4 +- 2.6 days absent in the placebo group. After the first 6 weeks, there tended to be no difference between groups. Nevertheless, the proportion of men remaining healthy throughout the 6-month study period was greater in the intervention group (41 [51.3%] of 80) than in the placebo group (30 [35.7%] of 80).
Not impressive, but something, and when it comes to avoiding illness, something is better than nothing. Better still, being replete in vitamin D will increase the response to the flu vaccine, so taking vitamin D, especially if you are deficient, may increase the antibody levels after the flu vaccine, still the best way to avoid the disease.
So would I suggest vitamin D? Yes, as part of a healthy breakfast and if you are deficient. It is one of a number of interventions you can use to prevent getting ill in the viral season. But is vitamin D the be-all and end-all of flu prevention and treatment. No. Not even close.
Acupuncture
Man is the only animal that blushes. Or needs to. — Mark Twain
Acupuncture is all placebo effect, what ever that is. This was re-confirmed in “A randomized controlled trial of acupuncture for osteoarthritis of the knee: Effects of patient-provider communication“.
In this trial, patients had real acupuncture or sham acupuncture (as if there is a difference) and they had neutral or enthusiastic acupuncturists. Those that had an enthusiastic acupuncturist had a better decrease in reported pain, whether the acupuncture was real or sham.
TCA was not superior to sham acupuncture. However, acupuncturists styles had significant effects on pain reduction and satisfaction, suggesting that the analgesic benefits of acupuncture can be partially mediated through placebo effects related to the acupuncturists behavior.
This result is of no surprise. Expectations will often color people’s perceptions. More expensive wine is rated higher than the same vintage labeled as cheaper. An expensive placebo is more effective than an cheap placebo.
But does perception of reality mean reality was altered?
I play golf with my kids almost every night in the summer and towards the end of the season I get right elbow tendinitis. As I make my downswing the pain fibers fire and can mess up my swing if I am not focused on hitting through the pain. If I take 400 milligrams of ibuprofen before I play, I have less pain and my swing is unchanged. Not enough to beat my son, but that is another matter.
Decreasing pain leads to improved function when pain limits function. If you have a musculoskeletal problem, you usually have a reproducible limit to your function due to the pain. If the pain is decreased, the function should improve.
As I have discussed at length, I do not think there is really a placebo effect. Certainly for objective endpoints, there is no placebo effect. Buried in the acupuncture paper were two objective end points: range of motion and the Timed Up and Go Test. For objective endpoints there were no changes in any of the groups. So it makes me wonder just what improvement these patients ‘really’ had. Subjectively better, objectively no change.
Is the placebo effect no more than a patient convincing themselves they are better when in fact nothing has changed? That is my interpretation. If function is not improved, if they are still limited by pain, is the pain really gone? Is this response a milder example of the same cognitive processes that can lead to hysterical blindness or not seeing tumors the size of a large mushroom? Man is the only animal with the ability to convince themselves that the tangible is unreal or that the unreal is tangible.
“Always keep your words soft & sweet in case you have to eat them!”
I have said numerous times that I was envious of SCAM practitioners as they live an essentially never-changing world. Once the ideas of homeopathy, reiki, acupuncture were codified, there is no change. Learn once … use forever.
Not so, it turns out, thanks to a report in Medscape (COI warning: I am a paid Medscape blogger).
New acupuncture points have been discovered! Acupuncture advances.
We generally modify acupoints to make them effective and more appropriate for cancer patients…For example, the acupoints which are predetermined places on the body where needles are inserted for therapeutic effect for hot flashes for normal menopause are “not necessarily the same ones for early menopause due to chemotherapy”.
Unfortunately, this breakthrough in acupuncture has yet to be published, although this pioneering work was done at Memorial Sloan-Kettering Cancer Center. Evidently, the only way you can learn this incredible clinical breakthrough is by paying $495 dollars and taking the online acupuncture class offered by Sloan-Kettering. I guess there are some medical cures they really dont want you to know about unless you pay first. It worked for Kevin Trudeau, it works for Sloan-Kettering.
When this phenomenal pioneering work is finally published, I suppose in the NEJM, I will have a second helping of words.

   Echinacea for Cold and Flu
Steven Novella 
Link
Echinacea continues to be a popular herbal product, used primarily for treating and preventing colds and flus. Sales were estimated at $132 million in the US alone in 2009, an increase of 7% over the previous year. Reports of major negative clinical trials have had only a modest and temporary effect on the popularity and sale of this herb, contradicting claims that the utility of such research is to inform consumers.
In the current issue of the Annals of Internal Medicine there is a new study of Echinacea for the treatment of cold symptoms: Echinacea for Treating the Common Cold, A Randomized Trial. I won’t hold out the punchline – the study was completely negative. But let’s put the results of this study into the context of the history of echinacea and the clinical evidence.
History of Echinacea
Modern proponents of echinacea frequently cite as support the claim that this plant has been used for centuries by many Native American cultures. This much is well-documented, but what is not clear is what echinacea was used for. For this there is no clear answer, except that echinacea was used for 15-20 different and unrelated conditions, from fatigue to snake bites. Let us consider the value of the claim for traditional use of any treatment.
Native American cultures did not have a written language, nor a tradition of science, rigorous observation, or objective confirmation. This is not a criticism – the latter points are true of every human pre-scientific culture. This is perhaps exacerbated by the dependence upon oral tradition. Further, the concept of illness and of specific ailments was very different in ancient cultures than modern concepts of disease. Add to that the challenge of proper translation, and it is extremely difficult to correlate what echinacea was actually used for with any modern application. In addition, there is no clear record that echinacea was used to treat upper respiratory viral infections.
So the claim for traditional use is dubious, but even if it were demonstrably true that is still a very weak justification for any specific treatment. The traditional use claim is based upon the demonstrably false assumption that centuries of use of a treatment (without rigorous testing) is compelling evidence for its efficacy. This assumption is contradicted by history, one dramatic example of which is the use of blood-letting and purging as part of Galenic medicine (the balancing of the four humors) for not just centuries but over two millennia in Western culture. Antiquity is no guarantee of efficacy. Human nature can apparently perpetuate worthless treatments indefinitely.
The journey of echinacea from traditional use in the New World to its modern popularity as a cold remedy is a tortuous one. It was first popularized by a dubious physician and snake-oil salesman called H.C.F. Meyer. In the late 1800s he sold echinacea as a panacea, claiming it cured everything, including cancer. He also heavily marketed the Native American connection, which was popular at the time. Meyer was unable to convince mainstream doctors of the time of his product’s value, but he was able to convince an eclectic physician by the name of Dr. King. (Eclectic physicians followed a tradition that included heavy use of herbal remedies.) King was instrumental in the popularity of echinacea at this time and until about the 1930s.
The story of echinacea then resurfaces in Germany in the 1930s. A German doctor by the name of Gerhard Madaus became interested in echinacea. He was a proponent of unconventional medical treatments and a promoter of herbal medicine in Germany. He visited the US with the intention of bringing back seeds for Echinacea augustifolia (the variety used, apparently, by Native Americans) but instead brought back seeds for Echinacea purpurea – and for that reason the latter variety of echinacea became popular in Europe.
While there were and continue to be many studies of the basic science of echinacea, there were no rigorous clinical trials of its safety or efficacy. Modern claims that it “boosts” the immune system, or is useful for infections, are not based upon any solid clinical evidence. Given the history, there is also no particular reason to believe that echinacea might be useful for colds, versus any other medical ailment.
Clinical Evidence
This latest study add to the prior clinical research for echinacea and cold symptoms, which is basically negative. Like any such clinical research, there are lots of small and poorly controlled studies, with mixed results. Even the larger and somewhat controlled studies have mixed results, but the largest and best controlled studies are all negative.
A 2006 Cochrane review found:
Main results
Sixteen trials including a total of 22 comparisons of Echinacea preparations and a control group (19 placebo, 2 no treatment, 1 another herbal preparation) met the inclusion criteria. All trials except one were double-blinded. The majority had reasonable to good methodological quality. Three comparisons investigated prevention; 19 comparisons investigated treatment of colds. A variety of different Echinacea preparations were used. None of the prevention trials showed an effect over placebo. Comparing an Echinacea preparation with placebo as treatment, a significant effect was reported in nine comparisons, a trend in one, and no difference in six. Evidence from more than one trial was available only for preparations based on the aerial parts of Echinacea purpurea (E. purpurea).
Authors’ conclusions
Echinacea preparations tested in clinical trials differ greatly. There is some evidence that preparations based on the aerial parts of E. purpurea might be effective for the early treatment of colds in adults but the results are not fully consistent. Beneficial effects of other Echinacea preparations, and Echinacea used for preventative purposes might exist but have not been shown in independently replicated, rigorous RCTs.
Basically – this is the random scatter of evidence that we typically find for an ineffective treatment. But I also think the reviewers are being too generous. There does seem to be a relationship between the quality of the study and the likelihood of negative results. In addition, there are further well-controlled clinical trials since this review that are also negative.
A 2008 study added to the evidence that echinacea is not useful for prevention of colds or flus. They found no difference in incidence of cold symptoms in 90 volunteers taking echinacea vs placebo.
Echinacea studies for colds are divided into prevention and symptomatic treatment. Treatment trials generally fall into two categories – testing a cold virus challenge (giving subjects the cold), and treating colds acquired out in the world. Well-designed studies for cold prevention are all negative, including the additional 2008 study. Now we have another study of echinacea for the treatment of symptoms. Patients were enrolled in the study within 24 hours of getting cold symptoms. They were treated either with echinacea blinded, placebo blinded, echinacea open-label, or nothing. Here are the results:
Of the 719 patients enrolled, 713 completed the protocol. Mean age was 33.7 years, 64% were female, and 88% were white. Mean global severity was 236 and 258 for the blinded and unblinded echinacea groups, respectively; 264 for the blinded placebo group; and 286 for the no-pill group. A comparison of the 2 blinded groups showed a 28-point trend (95% CI, −69 to 13 points) toward benefit for echinacea (P = 0.089). Mean illness duration in the blinded and unblinded echinacea groups was 6.34 and 6.76 days, respectively, compared with 6.87 days in the blinded placebo group and 7.03 days in the no-pill group. A comparison of the blinded groups showed a nonsignificant 0.53-day (CI, −1.25 to 0.19 days) benefit (P = 0.075). Median change in interleukin-8 levels and neutrophil counts were also not statistically significant (30 ng/L and 1 cell/high-power field [hpf] in the no-pill group, 39 ng/L and 1 cell/hpf in the blinded placebo group, 58 ng/L and 2 cells/hpf in the blinded echinacea group, and 70 ng/L and 1 cell/hpf in the open-label echinacea group).
Bottom line – no benefit from echinacea. In the discussion the authors desperately try to put a positive spin on the data, essentially making two points. One is that there was a non-statistical trend in the data towards a positive effect. Non-statistical trends are useless, however. There already is a fairly low bar for statistical significance in clinical trials, biasing them toward false positives. Lowering the bar further to talk up “trends” is disingenuous spin, in my opinion. Further, a close look at the randomization in this trial shows that 6 of the 10 pre-study conditions also deviated by an amount equal to or greater than the deviation in outcome. In other words, there was a random scatter in the randomization just as in the outcomes – but all of which fell below statistical significant and is therefore just noise.
Their second point is that the data do not rule out a clinically significant benefit. Again – this is just spin. Studies never rule out a benefit too small to be measured by the study. So you can say this about any negative study. This study was reasonably powered, but it was not a huge study with thousands of subjects, so if you take the entire range of possible statistical results, it’s within the realm of possibility that this study missed a clinically relevant effect. But that is not the same thing as there being evidence for such an effect, and it in no way changes the fact that this study is nothing but negative.
The lead author, Bruce Barrett, is quoted as saying:
“Adults who have found echinacea to be beneficial should not discontinue use based on the results of this trial, as there are no proven effective treatments and no side-effects were seen,” Barrett added in a release.
This seems like an attempt to downplay negative results. In the discussion the authors argue that this one study, given the positive results in the past, should not change our thinking on echinacea. But I disagree with their assessment of prior research. They reference mainly two meta-analyses, which I found to be very low quality. They also cite the 2006 Cochrane review, making it seem as if this review is positive, when in fact it in generally negative. Further there is an implied endorsement of anecdotal experience in that statement – a naive position for a researcher to take.
Conclusion
The prior plausibility for echinacea as a cold remedy is very low, but not zero. As an herbal product it can feasibly have biological activity. The claim that it “boosts the immune system” is not credible, as such a phenomenon is not generally accepted. Basic science research essentially finds that the immune system is activated by echinacea, but this has not been distinguished from a non-specific immune response to a foreign substance. In other words, stimulating the immune system non-specifically (I can do this by punching you in the arm) and “boosting” the immune system so that it functions more effectively against an infection, are not the same thing. Leaping to the latter conclusion is not justified by the evidence.
From an historical perspective, there is no particular reason to conclude that echinacea might be effective for the cold. Its traditional use by Native Americans was for many indications, possibly including cough, but not specifically the cold or flu. The great number of conditions for which it was used indicates that echinacea was treated as a panacea, which further indicates there was no particular evidence for its effectiveness as a cold remedy. And further, such evidence would only amount to anecdotal evidence – the fact that belief in echinacea became culturally embedded is not a reliable indicator of efficacy.
While herbs are drugs, and drugs can have biological effects, it is unlikely that any random drug would work for any particular clinical indication.
It is therefore no surprise that the clinical evidence shows that echinacea is not effective for the prevention or treatment of colds or cold symptoms. This latest study adds to the evidence for lack of efficacy.
The market for echinacea, however, endures, largely on a sea of anecdotes and marketing spin that is incongruous with the evidence.
Note: This post was written partly from material and analysis provided by Wallace Sampson.

   Belief in Echinacea
Harriet Hall 
Link
Is Echinacea effective for preventing and treating the common cold or is it just a placebo? My interpretation of the evidence is that Echinacea does little or nothing for the common cold. Initial reports were favorable, but were followed by four highly credible negative trials in major medical journals. A Cochrane systematic review was typically wishy-washy The Natural Medicines Comprehensive Database rates it as only “possibly effective” commenting that
Clinical studies and meta-analyses show that taking some Echinacea preparations can modestly reduce cold symptom severity and duration, possibly by about 10% to 30%; however, this level of symptom reduction might not be clinically meaningful for some patients. Several other clinical studies found no benefit from Echinacea preparations for reducing cold symptoms in adults or children…
A review on the common cold in American Family Physician stated that Echinacea is not recommended as a treatment.
I have a friend who believes in Echinacea. She says for the last several years she has taken Echinacea at the first hint of a cold, and she hasn’t developed a single cold in all that time. I told her that if that was valid evidence that it worked, I had just as valid evidence that it didn’t. For the last several years I have been careful not to take Echinacea at the first hint of a cold, and I haven’t had a single cold in all that time either. So I could claim that not taking Echinacea is an effective cold preventive! I thought my “evidence” cancelled out hers; she said we would just have to agree to disagree.
A recent study looked at the effect of belief on response to Echinacea and dummy pills. “Placebo Effects and the Common Cold: A Randomized Controlled Trial” was published by Barrett et al. in the Annals of Family Medicine. 
A news report about the study said “the placebo effect reduced the duration of common colds.” And that the study “reflected the power of mind over body.” But that is not what the study showed.
Methods
719 subjects with colds were randomized into 4 groups:
     1.  No pills
     2.  Placebo, blinded (didn’t know whether they were getting placebo or Echinacea)
     3.  Echinacea, blinded (didn’t know whether they were getting placebo or Echinacea)
     4.  Echinacea open label (knew they were getting Echinacea)
How do we know the subjects had colds? We don’t, really.
    • They answered yes to either “Do you think you have a cold?” or “Do you think you are coming down with a cold?”
    • They scored at least two points on the Jackson scale (8 self-reported symptoms rated from 0 to 3 for severity).
How was improvement measured? Were they really improved? We don’t know.
    • Twice a day they answered “Do you think you still have a cold?”
    • They answered a questionnaire rating 19 cold symptoms and functional impairment.
    • Biomarkers of immune response and inflammation were measured from nasal wash on day 1 and day 3: interleukin 8 and neutrophil counts. Are these biomarkers a reliable way to measure objective improvement in colds? I don’t know. It doesn’t matter anyway, since they didn’t change significantly.
Belief in Echinacea was assessed by asking if they had ever taken Echinacea before and how effective they thought it was on a 100 point scale.
Blinding was adequate: on an exit interview, patients in groups 2 and 3 couldn’t tell which group they were in.
Results
Compared to those receiving no pill, those receiving any pill reported modest improvement regardless of the content of the pill. They reported that their illness was 0.16 to 0.69 days shorter and 8% to 17% less severe. But these results were not statistically significant! Rather than showing that placebos reduced the duration of common colds, it showed that they didn’t have any statistically significant effect.
Contrary to expectations, open label was not superior to blinded Echinacea. (“I know I’m getting it” was no better than “I might be getting it.”) I found that intriguing.
Changes in biomarkers were not statistically significant.
Interestingly, four of the 6 assessed side effects were reported most frequently in the no-pill group. Headache was reported by 62% of those without pills compared with less than 50% in the other 3 groups. Statistical analysis showed that this was not due to chance. Does this mean that not taking pills causes headaches? Or that Echinacea and dummy pills are effective headache remedies? 62% seems like an unusually high incidence of headaches; does that mean that people who enroll in studies are unusually susceptible to headaches? Even if it was “greater than chance,” I suspect that it just represents noise in the data.
The most interesting finding was that those who believed in Echinacea did better regardless of which pill group they were in. Among the 120 participants who had rated Echinacea’s effectiveness as greater than 50 on a 100-pointscale, illness duration was 2.58 days shorter in those given Echinacea or placebo than in those who got no pill, and mean global severity score was 26% lower but not significantly different.
A Further Question
In his book Snake Oil Science, R. Barker Bausell analyzed research showing that those who believed they got real acupuncture reported more relief than those who believed they got sham acupuncture, regardless of which they actually got. I wondered if this would be true for the Echinacea study as well, if those who believed they got Echinacea reported more improvement than those who believed they didn’t, regardless of whether they actually did or didn’t. I wrote the lead author to ask that question, and he replied
that data hasn’t [sic] been properly analyzed or presented. Given small subsample sizes, confidant [sic] conclusions would likely be impossible.
I asked if it would be possible for someone to go back and look at the data and he answered:
It would take many dozens of hours to adequately address the question, and I’m afraid that the sample size is too small. And resources too limited. I am advising several post-docs and leading several papers and this one just doesn’t merit the attention. If you want to come to Madison for a month and can write up the background and methods section for the paper beforehand, I could probably get someone to do the data analysis and join you as a co-author.
I’m still curious, but I don’t want to know that badly!
Conclusion
The significant new finding of this study was that belief in Echinacea was more important than the content of the pill, regardless of whether subjects received Echinacea or placebo. To be more precise, it showed that subjects who thought they had a cold and who thought Echinacea was effective and who got either Echinacea or a placebo and who either knew they were getting Echinacea or thought they might be getting Echinacea were more likely to think their cold was gone sooner than if they got no pills.
Otherwise, the study only confirms some things we already knew. Patients report more subjective improvement with any pill than with no pill, and with any intervention compared to no intervention. Administering a placebo elicits self-reports of improvement. Echinacea is no more effective than placebo. The placebo phenomenon in colds is subjective and of such small magnitude that it can be considered not clinically important.
The authors said
Overall, this trial could be interpreted either as an appropriately powered trial that failed to conclusively show placebo effects, or as a trial suggesting small but perhaps meaningful effects related to expectation and pill-allocation.
Then they misrepresented their findings in the abstract when they said
Participants randomized to the no-pill group tended to have longer and more severe illnesses than those who received pills.
Yes, they “tended” to have (more correctly, to “report”) longer and more severe illnesses, but the tendency was not statistically significant. Why didn’t they follow the usual convention for scientific articles and say there was no significant difference between the groups?
No matter how you look at it, the news report was wrong: the study is interesting, but it didn’t show that the placebo effect reduced the duration of common colds and it didn’t show the power of mind over body. It did show the power of mind to put a spin on study findings.

Aloe Vera
Many claims are made for the health benefits of aloe vera, used both topically and orally. The scientific evidence is lacking.
Harriet Hall on July 10, 2018
Link


I had heard of aloe vera. I’ve seen it grown in flowerpots in the home and broken open to apply its juices to irritated or injured skin. I’ve encountered it many times in crossword puzzles. I know a woman who has taken it orally. But recently it seems to have developed miraculous new properties. I’ve been seeing ads for aloe vera products claiming that it is a leading acid reflux pill and is now being recognized as an Anti-Aging Phenomenon. In fact, this is being called “the greatest accidental discovery in decades”.
Who knew? I decided it was time to look into the many health claims for aloe vera and see which ones were supported by scientific evidence.
What the National Center for Complementary and Integrative Health (NCCIH) says
Aloe vera is featured on the NCCIH website. They say aloe vera’s use can be traced back 6,000 years to early Egypt, where the plant was depicted on stone carvings. Known as the “plant of immortality”, aloe was presented as a funeral gift to pharaohs.
They say its uses have historically included treatment of wounds, hair loss, and hemorrhoids; it has also been used as a laxative.
They say it is used in health products today both topically, for burns, frostbite, psoriasis, and cold sores; and orally, for osteoarthritis, bowel diseases, fever, and constipation.
They don’t mention acid reflux or anti-aging. They do say “There’s not enough evidence to show whether aloe vera is helpful for most of the purposes for which people use it.”
What the Natural Medicines Comprehensive Database says
The NMCD is a reliable source of information about natural remedies, rating them for safety and effectiveness and providing links to the scientific studies that its ratings are based on. It doesn’t give aloe vera any ratings of “effective” or “likely effective” for any condition. It rates it as “possibly effective” for a long list of conditions: acne, burns, constipation, diabetes, herpes simplex, lichen planus, oral submucous fibrosis, psoriasis, and weight loss. It rates it as “possibly ineffective” for burning mouth syndrome, HIV/AIDS, and radiation-induced skin toxicity. It says there is some preliminary evidence but “Insufficient Reliable Evidence to Rate” it for other uses including alveolar osteitis, anal fissures, cancer, canker sores, chronic radiation proctitis, dental plaque, diaper rash, dry skin, frostbite, gingivitis, hepatitis, hyperlipidemia, insect repellent, oral mucositis, pressure ulcers, scabies, seborrheic dermatitis, ulcerative colitis, and wound healing. Nowhere does it mention using it for acid reflux or anti-aging.
Aloe contains both a gel and a latex. The NMCD considers it “likely safe” when used topically, “possibly safe” when the gel is used orally and short-term, “possibly unsafe” when aloe latex is used orally, and “likely unsafe” when used orally in doses of 1 gram or more daily. There have been reports of renal failure and death. They recommend against oral use in pregnancy or lactation.
It covers interactions with drugs. It warns that using it with Digoxin can cause toxicity, and it advises caution with anticoagulant and platelet drugs, anti-diabetes drugs, diuretics, sevoflurane (a surgical anesthetic), stimulant laxatives, and warfarin.
It says aloe vera should be discontinued at least two weeks before elective surgery, and it is contraindicated in hemorrhoids and gastrointestinal conditions such as intestinal obstruction, inflammation (Crohn’s disease, ulcerative colitis, appendicitis), ulcers, nausea and vomiting, and undiagnosed abdominal pain.
What the FDA said
In 2002, the FDA removed over-the-counter aloe vera laxatives from the shelves, saying they had not been proven safe or effective, and there was inadequate data on toxicity.
What the ads for AloeCure say
My local newspaper has repeatedly published half-page ads for AloeCure, thinly disguised as a news story from a health correspondent. The claims:
    • AloeCure is a leading acid reflux pill. [I couldn’t find it on any list of acid reflux pills]
    • Backed by clinical data documenting its ability to provide all day and night relief from heartburn, acid reflux, constipation, irritable bowel, gas, bloating, and more. [I couldn’t find any such clinical data]
    • Improves the pH balance of your stomach; “scientists now believe that this acid imbalance is what contributes to painful inflammation throughout the rest of the body.” [Not any scientists I know of; sounds like they’ve bought into the nonsensical acid/alkaline theory of disease]
    • A healthy gut is the key to reducing swelling and inflammation that can wreak havoc on the human body. [No evidence. Sounds like they’ve bought into the “leaky gut syndrome”]
    • In clinical studies, participants taking the active ingredient in AloeCure saw a stunning 100% improvement in digestive symptoms. [I couldn’t find any such studies, and I question whether anything could be 100%]
    • No known side effects. [Demonstrably untrue]
    • Helps users feel decades younger. [Just as any placebo might]
    • Suppresses the inflammation that contributes to premature aging. [No evidence from human studies; there is evidence that it ameliorates cardiac inflammation in rats with autoimmune myocarditis]
    • Soothes stiff and aching joints. [I couldn’t find any evidence]
    • Reduces appearance of wrinkles and increases elasticity. [I couldn’t find any evidence]
    • Manages cholesterol. [Some preliminary suggestive evidence of a small effect, but other studies reported no effect; no credible evidence of a clinically significant benefit]
    • Supports healthy immune system. [A typical claim from alternative medicine sources; meaningless, since a healthy immune system doesn’t need any extra support from dietary supplements]
    • Improves sleep and brain function. [Again, no evidence]
    • “Readers can now reclaim their energy, vitality, and youth regardless of age or current level of health.” [Evidence?]
    • The ad includes the usual meaningless anecdotes and testimonials, the usual special deal if you act now, and the usual warning that phone lines will be busy.
Conclusion: “Aloe” those claims not “vera”-fied
    • I was able to confirm that the NCCIH got it right when they said, “There’s not enough evidence to show whether aloe vera is helpful for most of the purposes for which people use it”.

Zinc and COVID
Should you take a zinc supplement to prevent a COVID-19 infection?
Scott Gavura on November 26, 2020
Link

It’s been a few months since I blogged about hydroxychloroquine and COVID-19, and I’m still getting emails defending its use, even as more and more evidence has emerged to show that it is not effective to prevent or treat the disease, regardless of setting. It seems, according to some disgruntled readers, that I didn’t properly account for the magical healing powers of zinc in my analysis. I regularly receive apparent statements of fact like “The hydroxychloroquine helps zinc to enter cells and stop the virus,” backed not by references, but by ALL CAPS telling me just how ignorant I am to even write about the topic. So today’s post is a closer look at zinc.
Zinc as an antiviral is nothing new. It’s one of the first “alternative” medicines I remember researching way back in the 1990s, when claims circulated that zinc lozenges could shorten the duration of a cold. And the studies into zinc lozenges go way back into the 1980s. Working often in community pharmacy settings, there were regular requests for zinc lozenges during cold and flu seasons, usually followed by complaints from consumers about their (lack of) palatability. It’s been a topic of this blog over the years, most notably when a “homeopathic” zinc spray was identified that (1) actually contained zinc and (2) caused a loss of the ability to smell.
Do we need zinc at all?
In short, yes. Zinc is a trace mineral with functions throughout the body. Zinc deficiency is a significant issue worldwide where access to a healthy diet and adequate calories is a problem. In diets where foods that contain zinc (e.g., meat, shellfish, chicken, nuts, lentils) are consumed regularly, zinc deficiency is less common, but still possible. Depending on where you live, some foods may be fortified with zinc, such as breakfast cereals. Severe deficiencies when food access is not a problem are more common where there are chronic diseases that cause reduced absorption (e.g., inflammatory bowel diseases) or as a consequence of gastrointestinal tract surgery. Some medications can increase the body’s loss of zinc as well (e.g., diuretics).
A severe zinc deficiency is most commonly associated with impaired growth, but the effects include immune system dysfunction. So being deficient in zinc could conceivably affect your susceptibility or response to a COVID-19 infection, but there is no evidence to suggest that supplementing with zinc has any meaningful effects. Absence of evidence is not evidence of absence, and the signals of benefit that have appeared in research studying zinc supplementation and the common cold (which can be caused by coronaviruses, among other viruses) has led to questions about whether or not zinc is a reasonable preventative option to try, considering overall risks and benefits.
The evidence for zinc to prevent or treat the common cold
There is no evidence to suggest that zinc-containing nasal sprays are safe or effective and they should be avoided. The same can be said for anything labelled as “homeopathic”. The preparations that have been the most studied are lozenges and tablets. One systematic review, published in 2011, identified 13 placebo-controlled trials with wide variation in doses. Low doses (<75mg/day) were found to be ineffective and trials with higher doses were founds to reduce the duration of colds (by 42%), but not their incidence. Another systematic review included 17 trials that compared zinc to placebo or no treatment. This analysis found that zinc reduced the duration of cold symptoms (by an average of 1.65 days) but the results varied widely across the trials. This review noted that adverse events (taste, nausea) were more common in the zinc group. Finally a Cochrane review from 2013 was withdrawn in 2015, citing concerns with the data analysis. It remains withdrawn as of the last update in 2016.
So should you take zinc to prevent or treat COVID-19?
Malnutrition in general is associated with reduced immunity, so situations where zinc deficiency is known, or highly likely, should be addressed, just as they should be for other vitamin deficiencies. There is some evidence that lower zinc levels may be associated with poorer outcomes from COVID-19 infections. Whether it’s the zinc, or zinc is just a surrogate for another factor, is not established.
Supplementing with zinc, in the absence of a known deficiency, is trickier. One approach for those interested in minimizing any risk, even theoretical, could include looking at your diet and then evaluating whether it is providing you with adequate zinc. For most of you without major medical conditions or restrictive diets, it probably is. Regular supplementation in the absence of a deficiency has some risks, however, as long-term high doses can interfere with copper absorption. Moreover, zinc is not easy to take as a supplement, especially in lozenge form, and can cause nausea and stomach upset. If you are feeling sick and decide to start supplementing with zinc lozenges, there is no persuasive evidence to suggest that it will be harmful, but neither is there good evidence to suggest it will offer you much benefit. And if in spite of the lack of evidence, you want to take a zinc supplement routinely, it will likely be safe as long as you keep the daily dose low (stay under 40mg/day, if you’re an adult). Just keep distancing, masking, and avoiding crowded indoor spaces.

Zinc for the prevention or treatment of respiratory tract infections: A new systematic review
A new systematic review examines the evidence for zinc to prevent or treat respiratory tract infections.
Scott Gavura on August 18, 2022
Link

It was back in the early 1990s when I first reviewed the evidence for zinc for respiratory tract infections. That particular journal club during my residency is somehow still occupying space in my mind – I even remember prepping my presentation with overhead projector slides (That should give you an idea of how long ago this was). At the time, the buzz was that zinc tablets or lozenges could shorten the duration of a cold. Even then, there were studies that dated back into the 1980s. Unlike a lot of dietary supplements, enthusiasm has never completely disappeared over the following decades, as there has been a slow trickle of weakly positive, poorly controlled studies.
In 2020 with the appearance of COVID-19, there was renewed interest in zinc to prevent infections or potentially lessen their severity. Given colds can be caused by coronaviruses and there was somewhat positive (if conflicting) evidence for zinc in colds, this was perhaps not unreasonable – especially before the availability of vaccines.
Since the 1990s the evidence for zinc has remained weak and not particularly convincing. Now there is a newer study published in The BMJ from the NICM Health Research Institute at Western Sydney University. This institute is “Australia’s leader in integrative and complementary medicine research and policy” with funding from different levels of the Australian government and also individuals and industry. The authors include a general practitioner, naturopaths, and academics with backgrounds in natural and “integrative” medicine. Some of the authors report payments related to complementary and alternative medicines. However, this particular paper was not commissioned, sponsored or funded by any one organization.
Why zinc?
Zinc is a trace mineral with functions throughout the body. Zinc deficiency is a significant issue worldwide, where access to a healthy diet and adequate calories is a problem. In some countries, foods may be fortified with zinc, such as breakfast cereals. Where regular diets include zinc-containing foods (e.g., meat, shellfish, chicken, nuts, lentils) like many in the USA, zinc deficiency is less common, but still possible. Severe deficiencies in these countries are more common where there are chronic diseases that cause reduced absorption (e.g., inflammatory bowel diseases) or as a consequence of gastrointestinal tract surgery. Some medications can increase the body’s loss of zinc as well (e.g., diuretics).
A severe zinc deficiency is most commonly associated with impaired growth, but the effects also include immune system dysfunction. Being deficient in zinc could conceivably affect your susceptibility or response to colds viruses including coronaviruses. Zinc could also have direct anti-viral effects. The signals of benefit that have appeared in research studying zinc supplementation and the common cold has led to continued questions about whether or not zinc can meaningfully affect your susceptibility to, or response to, a viral respiratory infection.
The evidence for zinc to prevent or treat the common cold
There is evidence to demonstrate that zinc-containing nasal sprays may be harmful as they can cause temporary and in rare cases permanent loss of smell. Other formulations that have been well studied are lozenges and tablets. One systematic review, published in 2011, identified 13 placebo-controlled trials with wide variation in doses. Low doses (<75mg/day) were found to be ineffective and trials with higher doses were founds to reduce the duration of colds (by 42%), but not their incidence. Another systematic review included 17 trials that compared zinc to placebo or no treatment. This analysis found that zinc reduced the duration of cold symptoms (by an average of 1.65 days) but the results varied widely across the trials. This review noted that adverse events (taste, nausea) were more common in the zinc group. Finally a Cochrane review from 2013 was withdrawn in 2015, citing concerns with the data analysis. It remains withdrawn as of the last update in 2016.
The new systematic review
This is not a new trial. It is an analysis of previously-published randomized controlled trials. The authors stated that their review conforms with Cochrane guidance on how systematic reviews should be conducted. I admit that I am not an expert in systematic review methodology, so I have taken their approach at face value. Some of our experts in the comments may have additional observations about the methods.
The authors started with a comprehensive database search to identify any relevant trials. Eligible for inclusion were any randomized or quasi-randomized clinical trials. Trials needed to be specific to adults. Any type of zinc product or route of administration could be included. Any type of control group was acceptable. English and Chinese databases were searched through August 2020, including searches for RCTs that studied zinc’s effects against SARS-CoV-2. These searches included preprint databases. The search and extraction method followed standard rapid review extraction methods, where data on each trial was verified by a second reviewer. Risks of bias of each trial were also assessed with a Cochrane tool.
From 1,360 articles and trials screened, 28 RCTs with 5,446 participants met the inclusion criteria. Three trials were published in Chinese only. 95 RCTs evaluating zinc in pediatric populations were excluded, as were seven RCTs studying zinc in COVID-19, as those results were still pending.
Participants in the trial were generally healthy, with symptoms consistent with mild to moderate respiratory tract infections. The average age was 37. The median sample size for prevention studies was 53 and for treatment studies, 78. Most of the trials (19) were conducted in the USA with 5 in Europe, 3 in China, and 1 in Australia.
The most common zinc formulations studied were lozenges (45-300mg) , but nasal spray and nasal gels (0.9-2.6mg) were also studied. For prevention, the daily dose was 15mg or 45mg daily for 7 or 12 months, respectively.
The authors note that most of the outcomes reported had at last some concerns about the overall risk of bias. There were substantial differences in the trial in terms of design, drug formulation, population etc., which challenged overall observations. Here are the results for prevention of respiratory tract infection:
If we ignore the nasal spray studies (which showed efficacy, but use a route of administration that can cause significant adverse effects) there is a single trial showing efficacy at 45mg per day, and one that does not at 15mg per day. For prevention of infection from direct inoculation of the cold virus, zinc does not appear to be effective.
Here are the results for treatment, where symptoms of colds were studied:
Even ignoring the topical trials, here the results for treatment (Day 3 symptom severity score) look slightly more impressive and consistent, recognizing there are substantial bias concerns in these trials. And here are the duration of infection results:
Again, modest but suggestive evidence in favour of zinc. Finally, here are the adverse effects:
It’s clear that zinc has side effects, with most trials reporting more side effects in the treatment group compared to placebo.
Overall the results were summarized by the authors as follows (bolding is mine):
    • Compared with placebo, oral or intranasal zinc prevented 5 RTIs per 100 person-months (95% CI 1 to 8, numbers needed to treat (NNT)=20, moderate-certainty/quality).
    • Sublingual zinc did not prevent clinical colds following human rhinovirus inoculations (relative risk, RR 0.96, 95% CI 0.77 to 1.21, moderate-certainty/quality).
    • On average, symptoms resolved 2 days earlier with sublingual or intranasal zinc compared with placebo (95% CI 0.61 to 3.50, very low-certainty/quality) and 19 more adults per 100 were likely to remain symptomatic on day 7 without zinc (95% CI 2 to 38, NNT=5, low-certainty/quality).
    • There were clinically significant reductions in day 3 symptom severity scores (mean difference, MD −1.20 points, 95% CI −0.66 to −1.74, low-certainty/quality), but not average daily symptom severity scores (standardised MD −0.15, 95% CI −0.43 to 0.13, low-certainty/quality).
    • Non-serious adverse events (AEs) (eg, nausea, mouth/nasal irritation) were higher (RR 1.41, 95% CI 1.17 to 1.69, NNHarm=7, moderate-certainty/quality). Compared with active controls, there were no differences in illness duration or AEs (low-certainty/quality). No serious AEs were reported in the 25 RCTs that monitored them (low-certainty/quality).
Zinc is no panacea
Despite multiple trials over the past 40 years, there remains limited evidence to demonstrate that zinc offer meaningful benefits to prevent or treat respiratory tract infections. While there is some evidence it may prevent infections and shorten their duration, the effects are modest. The authors describe zinc as “a viable ‘natural’ alternative”, but “viable” is doing some heavy lifting in that sentence. Zinc products do have side effects that may be noticeable, and the topical nasal spray formulation is associated with rare but sometimes permanent disturbances in the ability to smell, which seems like a poor trade-off for a product that, at best, may provide a slight benefit.

Calcium supplements and heart attacks: More data, more questions
Scott Gavura on February 28, 2013
Link
Why take a drug, herb or any other supplement? It’s usually because we believe the substance will do something desirable, and that we’re doing more good than harm. To be truly rational we’d carefully evaluate the expected risks and benefits, estimate the overall odds of a good outcome, and then make a decision that would weigh these factors against any costs (if relevant) to make a conclusion about value for money. But having the best available information at the time we make a decision can still mean decisions turn out to be bad ones: It can be that all relevant data isn’t made available, or it can be that new, unexpected information emerges later to change our evaluation. (Donald Rumsfeld might call them “known unknowns.”)
As unknowns become knowns, risk and benefit perspectives change. Clinical trials give a hint, but don’t tell the full safety and efficacy story. Over time, and with wider use, the true risk-benefit perspective becomes more clear, especially when large databases can be used to study effects in large populations. Epidemiology can be a powerful tool for finding unexpected consequences of treatments. But epidemiologic studies can also frustrate because they rarely determine causal relationships. That’s why I’ve been following the evolving evidence about calcium supplements with interest. Calcium supplements are taken by almost 1 in 5 women, second only to multivitamins as the most popular supplement. When you look at all supplements that contain calcium, a remarkable 43% of the (U.S.) population consumes a supplement with calcium as an ingredient. As a single-ingredient supplement, calcium is almost always taken for bone health, based on continued public health messages that our dietary intake is likely insufficient, putting women (rarely men) at risk of osteoporosis and subsequent fractures. This messaging is backed by a number of studies that have concluded that calcium supplements can reduce bone loss and the risk of fractures. Calcium has an impressive health halo, and supplement marketers and pharmaceutical companies have responded. There are pills, liquids, and even tasty chewy caramel squares embedded with calcium. It’s also fortified in foods like orange juice. Supplements are often taken as “insurance” against perceived or real dietary shortfalls, and it’s easy and convenient to take a calcium supplement daily, often driven by the perception that more is better. Few may think that there is any risk to calcium supplements. But there are now multiple safety signals that these products do have risks. And that’s cause for concern.
Calcium is a critically important mineral for body function. It’s not only the major building block in bones, it’s required for muscle contraction, blood clotting, and multiple hormone and neurotransmitter actions. Vitamin D function is closely linked with dietary calcium absorption and its activity in the body, and also facilitates the exchange of calcium to and from bone “stores”. The dietary importance of both vitamin D and calcium have been acknowledged and recommended daily intakes have been established for both agents.
Calcium and vitamin D have been studied extensively because the burden of illness from osteoporosis is so great. Almost 50% of all women over the age of 50 will have an osteoporosis-related fracture. And fracture can mean significant, sometimes permanent decreases in quality of life, increasing the odds of ending up in a long-term care facility, and raising mortality risks dramatically.
About two years ago I asked if calcium supplements were causing heart attacks. New studies were raising questions about efficacy and safety, which was worrying. Some older data had pointed to the potential relationship. In 2010 Bolland et al. published a meta-analysis of all randomized controlled trials of calcium supplements (≥500 mg/day), excluding trials that also gave vitamin D concurrently. Two sets of data were analyzed: those with patient-level data, and those with trial-level data. Both data sets, when analyzed, showed an association of calcium supplement consumption with increased rates of heart attacks — the relative risk increase was about 30%. There was some fair criticism of the analysis after it was published — the studies were never designed or intended to assess cardiovascular events as primary endpoints; a composite endpoint was not significant; and the exclusion of studies of calcium given with vitamin D made the value questionable, given treatment is now typically with both products. Bolland subsequently addressed the vitamin D question with the (161,000 patient) Women’s Health Initiative dataset, and added in two other trials that studied calcium and vitamin D. Once again, he observed a significant increase in heart attacks. Finally he combined all the data into one overall risk estimate: calcium alone, and calcium with vitamin D. The association was still present and statistically significant: A 24% relative risk increase for heart attacks in those that take calcium supplements.
In light of the warning signals, I suggested two years ago that caution be exercised with calcium supplements, and that routine supplementation in the absence of a dietary deficiency was inadvisable. Furthermore, given no harms had been shown with dietary intake, that all possible efforts should be made to maximize intake by that route. Finally, I suggested that in the case of dietary deficiency, that the potential risks of therapy be considered, along with the expected benefits. Given the modest benefit of calcium supplementation on real outcomes, like fracture risks, the cardiovascular warning signals were concerning enough that they should factor into treatment decision-making.
That was 2011. There’s new data and new guidance on calcium supplements. And the risk and benefit perspectives have shifted again.
In 2012 Li and colleagues examined a group of Heidelberg, Germany residents enrolled in the publicly-funded European Prospective Investigation into Cancer and Nutrition study. Like Bolland, the goal was to evaluate the relationship between dietary calcium, calcium supplements, and cardiovascular events like heart attacks and strokes. Participants were asked if they took vitamins and supplements regularly — dosages were not recorded. Over 23,000 patients were examined for an average duration of 11 years, and 354 heart attacks, 254 strokes, and 267 cardiovascular-related deaths were reported by participants and confirmed by examining medical records. A long list of potential confounders were adjusted for, including total dietary calcium intake, consumption of anti-inflammatory drugs, and reported high cholesterol levels, in order to isolate the potential association of supplements with any cardiovascular benefits.
There were significant differences between the groups, which complicates the interpretation. Consuming higher levels of dietary calcium was associated with a number of other factors including younger age, more education, more physical activity, less smoking and less alcohol consumption. Supplement users were more likely to be women, more active, and less likely to be overweight. However there was more smoking and less education in this group. Controlling for these factors, the authors observed the following:
    • Dietary calcium intake did not appear to affect the risk of cardiovascular disease. When consumption was divided into four groups by total intake, the third quartile had fewer cardiovascular events than the lowest quartile. The risk for stroke was increased in the second quartile for two years, then disappeared. Overall, there was no clear pattern observed.
    • Calcium supplement consumptionwas associated with more heart attacks, but not strokes or overall cardiovascular death. The observed rise in heart attack risk was substantial and statistically significant (hazard ratio of 1.86, confidence interval of 1.17-2.96). This elevated risk was even higher in calcium-only supplementers, where a 2.39x elevated risk was observed (confidence intervals 1.12-5.12).
There were a number of important limitations to the conclusions, a notable one being that calcium supplement doses were not collected. However, the large population, long duration of study, and confirmation of all outcomes, like heart attacks and deaths, supports the credibility of the analysis. The lack of association between dietary calcium (dairy and non-dairy) and cardiovascular death is reassuring. On the other hand, the relationship between calcium supplements and heart attack risk is consistent with the Bolland meta-analyses, and troubling. We now have different authors studying a different dataset and identifying the same signal,which strengthen the hypothesis that this association is real.
Next we have an analysis by Xiao and associates. The study, Dietary and Supplemental Calcium Intake and Cardiovascular Disease Mortality was published in JAMA Internal Medicine in February 2013. It also used a massive cohort of patients, pulling data on almost 400,000 adults enrolled in the NIH-AARP Diet and Health Study. This study started in the mid-1990’s and assessed dietary and supplemental calcium intake over 12 years of follow-up. Calcium supplements were taken by about a quarter of all men and over half of all women. Again, there were differences between calcium supplement users from non-users: They were more likely to be non-Hispanic whites, to have more education, to be active, to rate their health as “excellent”, and to eat more fruits, vegetables and whole grains. Supplement users were less likely to smoke and consumed less alcohol.
They found the following:
    • Calcium intake as supplements (>1000mg/day) by men was associated with a 20% elevated risk of cardiovascular death, due to an increased incidence of heart disease (confidence intervals 1.05-1.36). There was no effect on rates of stroke.
    • Supplemental calcium intake by women was not associated with cardiovascular death. There was a slight but non-significant increase in supplement users compared with nonusers.
    • There was no relationship of dietary calcium intake to cardiovascular death in men or women.
Once again, the lack of any association between dietary calcium intake and cardiovascular disease adds strength to the findings in other studies. Some reassurance, but more questions. The association with cardiovascular death in men only, but not women, is puzzling. Is the association real? My personal sense is that the association identified by Bolland looks more real than it did two years ago, despite the Xiao findings. So while we don’t have consistent evidence of harm, we do see an association that probably should not be ignored.
So what’s the role of calcium supplements? If it comes down to an evaluation of risk and benefit, where does calcium supplementation fit?
Two days ago the Vitamin D and Calcium Supplementation to Prevent Fractures in Adults: U.S. Preventive Services Task Force Recommendation Statement was published. As should be clear from the name, the USPSTF makes recommendations about prevention — not treatment. It does not consider cost, but only benefit and harms. This was an analysis that looked at primary prevention — the supplementation for adults (community dwelling, not hospitalized) for bone health in the absence of confirmed osteoporosis or a vitamin D deficiency. It did not look at the appropriate dietary intake levels, or the effects of calcium supplements alone. It also did not consider outcomes unrelated to bone health such as prevention of falls, cardiovascular disease, or overall mortality. Consequently, the data set studied by the USPSTF excluded the studies discussed above. With respect to cardiovascular outcomes, it remarks that the association of harms is “not consistently demonstrated”.
The new statement reflects the findings of two systematic reviews and a meta-analysis which sough to understand the relationship between vitamin D, calcium, bone outcomes like fractures, and adverse effects of taking supplements.
With respect to the net benefits of supplements, it made the following observation:
Except for postmenopausal women, there is inadequate evidence to estimate the benefits of vitamin D or calcium supplementation to prevent fractures in noninstitutionalized adults. Due to the lack of effect on fracture incidence and the increased incidence of nephrolithiasis in the intervention group of the WHI trial, the USPSTF concludes with moderate certainty that daily supplementation with 400 IU of vitamin D3 and 1000 mg of calcium has no net benefit for the primary prevention of fractures in noninstitutionalized, postmenopausal women. Although women enrolled in WHI were predominately white, the lower risk for fractures in nonwhite women makes it very unlikely that a benefit would exist in this population.
The final recommendations summarized as follows:
    • insufficient evidence to determine benefit of calcium & vitamin D supplements in premenopausal women or in men to prevent fractures
    • insufficient evidence to determine benefit of calcium (>1000 mg/day) and vitamin D (>400 IU/day) in postmenopausal women
    • sufficient evidence to recommend against supplementation with calcium (<1000mg/day) and vitamin D (1000mg of calcium and >400IU of vitamin D) in postmenopausal women and older men.
It’s also nicely summarized in this handy table:
It also calls for prospective trials to study the benefits of vitamin D and calcium supplementation in early adulthood on fracture incidence later in life. Quite frankly, we’ll be waiting decades for this — if it ever appears.
Conclusion
Assuming benefit from a drug or supplement, in the absence of confirming evidence, can lead to bad health care decision-making. Yet we do this all the time, particularly with supplements that are generally believed to be safe and effective. These studies show that supplements can indeed be rigorously studied, and that surprising findings can emerge. Not only have calcium supplements been closely scrutinized for therapeutic use in dozens of prospective clinical trials, the evidence suggests that use in the absence of deficiency is at best, probably useless, and at worst, substantially elevating the risk of heart attacks and cardiovascular death. Without any clearly established benefits for most people, but exhibiting worrying signs of harms, it’s time to take the health halo off calcium supplements.
References
Li K., Kaaks R., Linseisen J. & Rohrmann S. (2012). Associations of dietary calcium intake and calcium supplementation with myocardial infarction and stroke risk and overall cardiovascular mortality in the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition study (EPIC-Heidelberg), Heart, 98 (12) 920-925. DOI: 10.1136/heartjnl-2011-301345
Xiao Q. Dietary and Supplemental Calcium Intake and Cardiovascular Disease Mortality: The National Institutes of Health–AARP Diet and Health StudyCalcium Intake and CVD Mortality, JAMA Internal Medicine, 1. DOI: 10.1001/jamainternmed.2013.3283
Moyer V. (2013). Vitamin D and Calcium Supplementation to Prevent Fractures in Adults: U.S. Preventive Services Task Force Recommendation Statement, Ann Intern Med, DOI: 10.7326/0003-4819-158-9-201305070-00603

Magnesium: The cure to all disease?
Scott Gavura on September 13, 2012
Link
Having spent many evenings and weekends working in a retail pharmacy with a thriving vitamin and supplement aisle, I’m no longer surprised at the purchasing habits of consumers. The setting gave me not only the opportunity to learn about the latest supplement fads, but also to speak with consumers that place great faith in these products. A recent paper suggests 25% of CAM users account for 75% of all expenditures on CAM. And that’s consistent with what I saw in the pharmacy. Some consumers spend hundreds per month on supplements, so the belief that these products are beneficial must be very strong. So I like to ask about reasons for use. Many attribute their current health status to supplements, and usually tell me that their supplements are for preventing disease, optimizing health, or “boosting” the immune system. And while I’m encouraged to see these consumers take an active interest in maximizing their own health, I’m often puzzled by the decision-making that’s occurring. In some cases, beliefs about health, medicine, or the effectiveness of their supplements are misguided, or flat-out wrong. They’re getting expensive urine and positive feelings, but there’s little evidence to suggest the supplementing is having any objective benefits. More surprisingly, some consumers take products for which there is no medical indication at all – it’s intended as “primary prevention” of a medical condition they believe they can avoid through supplement use. Afraid of macular degeneration? Take lutein. Or worried about Alzheimer’s? Grab some ginkgo biloba. No matter your anxiety, there’s a supplement marketed for your. One supplement with enduring popularity is magnesium. It cures cancer. And depression. Throw away your inhalers, because it cures asthma too. Read enough online, and you’ll conclude that magnesium is quite possibly the prevention and the cure to all disease. 
Magnesium really is everywhere in the body – it’s the 4th most abundant mineral. It’s involved in hundreds of different biochemical reactions and enzyme systems, supporting processes like protein synthesis, cell growth, and energy production. It has roles in nerve function, muscle control, and blood pressure. Even blood sugar regulation depends on magnesium. The body has several mechanisms to stabilize levels. We’re carrying about 25 grams in total, much of which of which is locked in the skeleton. Some magnesium sits on the surface of bone and helps (slowly) regulate levels in the rest of the body: Only a tiny fraction of the total body’s magnesium (1%) is actually in the blood.
We obtain magnesium in our diet, with an “average intake” of 360mg per day. Most foods contain magnesium, though some have more than others. After ingestion, magnesium enters the blood stream through a combination of diffusion and also active absorption at sites throughout the bowel. Some of this effect appears to be influenced by vitamin D. Kidneys manage most of the excretion of magnesium and actively control the amount that is eliminated to maintain steady levels. Interestingly, almost all magnesium filtered out initially, and then about 95% of it reabsorbed. Drugs which inhibit the regular function of the kidney, like diuretics (“water pills”) can affect magnesium levels. Some diuretics promote excretion of magnesium, while others promote retention – it depends on their mechanism of action. There are a long list of other drugs that can influence magnesium levels, most by affecting the kidney’s filtration process. Proton pump inhibitors (e.g., Nexium) are among the offenders, and can cause hypomagnesemia in some. Given its multiple actions, low magnesium levels are associated with conditions like hypertension, cardiovascular disease, and diabetes. Other medical conditions can affect magnesium levels, either through action on absorption or elimination. Alcoholism, kidney or liver disease, and various gastrointestinal malabsorbtion conditions (e.g., Crohn’s disease) can all reduce magnesium levels.
Does magnesium have medicinal effects when consumed? In medical and pharmacy practice, it has several demonstrated uses – the most well known are probably as an antacid or laxative. Good old milk of magnesia (MOM) works because magnesium is partially absorbed – enough stays in the bowel, drawing water into the colon and softening and dislodging anything below. Injectable magnesium, sold as a prescription drug, allows large doses to be given quickly, and is ued for the treatment of preeclampsia (pregnancy-induced hypertension) and eclampsia (the resulting seizures) – it’s well tolerated and better than other drugs. Magnesium also seems to be effective for treating some forms of arrhythmia, as well as asthma exacerbations. Some types of migrane and cluster headaches also seem to respond to magnesium supplements.
In other medical conditions, magnesium’s role is less clear. Magnesium levels may be related to osteoporosis, but the role of supplements is still being established. Diets high in magnesium seem to reduce the risk of stroke, but supplementation doesn’t seem to offer the same benefit. The same can be said for managing high blood pressure – effects with supplements are inconsistent and unimpressive. For treatments of conditions like anxiety, ADHD, muscle cramps, and restless leg, more data is required before we can determine if supplements are beneficial.
In cases where drugs or diseases have reduced blood magnesium levels, supplementation is appropriate. Magnesium supplements effectively treat and prevent low magnesium. There’s debate over which type of oral supplement is “best”, fueled by a lack of studies that have actually examined how much magnesium is actually absorbed. Magnesium gluconate and magnesium chloride seem to be preferred over magnesium oxide and magnesium sulfate, which are associated with more diarrhea. Some pharmacies manufacture magnesium glycinate, which is claimed to be superior. There is little credible information to guide selection, unless you are a rat. Given the influence of food and other factors, the specific version used may depend more on individual preferences and side effects. Magnesium is often combined with calcium in tablets, sometime in specific ratios (e.g., (3:1). There’s no scientific basis for these proportions.
Supplements or Diet?
Having established magnesium’s bona fides as a drug, with medicinal uses, what does this suggest about supplementation in the absence of a confirmed deficiency? Given the number of systems and processes that are controlled by magnesium, supplementation could plausibly have biological effects. However, for it to do so, it would need to act against all of our regulatory systems that work to keep our levels fairly constant. Magnesium supplements are generally well tolerated and toxicity is rare. But here’s where we run into questions about correlation and causation. Without prospective data from randomized controlled trials, we cannot infer that supplements have the same effects as dietary changes. Benefits in studies seem to be related consuming foods rich in magnesium, not necessarily magnesium supplements.
Magnesium is abundant on earth and so it’s also abundant in food. In general, the absorption of magnesium from the diet is estimated at about 50%. Despite the prevalence in food there is information to suggest that dietary magnesium consumption can still be insufficient. Plants, and particularly grains, have more magnesium than meat or dairy. A simple rule of thumb is that magnesium usually accompanies fiber. The water supply can also contribute to magnesium intake, particularly in areas with “hard” water. There’s epidemiological evidence that connects water hardness with cardiovascular disease. While the data are interesting, few studies have measured consumption and correlated it with magnesium levels. Given that most of our magnesium consumption is from food, the current consensus does not support minimum hardness levels being established in the water supply.
Risk and Benefit
No harms or adverse effects have been observed when magnesium is consumed as a food ingredient. Supplements, however can cause adverse effects – diarrhea being the most common when daily doses exceed 350mg. High levels, hypermagnesemia, is uncommon but has been reported, particularly with regular consumption of magnesium supplements in people with decreased kidney function. In the absence of risk factors, particularly undiagnosed kidney disease, magnesium supplementation is generally considered safe.
Conclusion
Magnesium supplementation has an established role for some diseases and medical conditions, and looks promising for others. Whether supplementation is required in the absence of a relevant disease or documented deficiency is unclear. While it is tempting to extrapolate the relationship between low magnesium and various diseases into an argument for supplements, the issue of confounding in dietary studies cannot be ignored. As we have seen with other vitamin studies, the long-term benefits of supplementation should not be assumed until they have demonstrated. Given the complexity of magnesium’s role in the body, the best way to answer questions about the benefit of supplements is with randomized trials. But there’s another approach that has an attractive risk/benefit perspective: Boosting magnesium intake through dietary changes. Helpfully, foods rich in magnesium are already recommended in diets associated with positive health outcomes: Green vegetables, beans, whole grains, nuts and seeds are all good sources of magnesium. Supplementation may not turn out to be harmful, but it may be unnecessary. And it may distract people from making positive changes to their diet. Without a confirmed deficiency, or specific medical need, magnesium supplementation seems unnecessary.

Is Magnesium the Underlying Cause and Treatment for Everything?
Carolyn Dean believes magnesium deficiency is the cause of a great many diseases and recommends that everyone take magnesium supplements, preferably the one she sells, ReMag. I remain skeptical.
Harriet Hall on May 26, 2020
Link

I was recently asked about the book The Magnesium Miracle, by Carolyn Dean. The word “miracle” in the title put me off, but I wanted to read it and try to understand what it was claiming. I wanted to, but I couldn’t. I’m good at reading. I have slogged my way through some really atrocious books, and I have learned from them, if only to gain insight into the authors’ thinking processes. I can’t remember ever trying to read a book and failing, but this time I met my Waterloo. I hate to admit defeat, but I simply could not read this book. Not my fault. In my opinion, the book is unreadable.
The author is an MD but also a naturopath (ND). The book is not a scientific treatise; it is a poorly organized, biased screed and an infomercial for the author’s products. It claims that most people are deficient in magnesium, that magnesium deficiency is the cause of a huge number of symptoms and diseases (“one cause of all disease“?), that magnesium is the cure, and that everyone should take a magnesium supplement. But not just any magnesium supplement, only the one that she developed and sells. She claims her product ReMag is better absorbed and won’t cause the diarrhea that other magnesium supplements do (except that it will if you take more than you need!). Her other products include ReMyte, ReCalcia, Detox: ReAlign, ReStructure protein powder, RnA ReSet Drops, vitamins, probiotics, and more.
Instead of laying out her arguments in an orderly fashion and building a solid case based on evidence, she takes a scattershot approach, jumping from topic to topic. The Introduction sets the pattern. In it, she starts by bragging that her previous book was a best seller and bragging about an award she received. Then she attacks mainstream doctors, saying they got it all wrong and they haven’t understood the evidence about magnesium. She says testing for magnesium deficiency is misleading, because the best test for magnesium levels is not available. Within the first few pages, she is already hyping her own supplement, ReMag. She briefly touches on arrhythmias, kidney disease, and other conditions. She claims our soil is depleted. She provides emails and testimonials from patients that don’t prove anything and don’t ring true. Then she wards off complaints by listing 14 reasons that you might feel worse while taking magnesium, even though it is benefitting you.
Every time I started to think she was sustaining a train of thought and getting into some meat that I could investigate by checking her references and looking for other confirming or disconfirming evidence, she was off on a new tangent, often saying something that made me cringe. For instance, it seems Dr. Russell Blaylock told her that 20-55% of drugs are fluorinated, and “she knows” that fluoridation of tap water is a disaster afflicting the population with an epidemic of chronic disease, including arthritis and cancer. The American Cancer Society disagrees; and of course, she offers no evidence in support of her alarming claim. She claims statins are potentially toxic fluoride compounds that may release fluoride ions that can irreversibly bind to magnesium, contributing to muscle pain. That idea is easily refuted by anyone with an elementary knowledge of chemistry. Surely the author has studied chemistry and should know better. Statin compounds contain fluoride atoms, but they are not released as ions. That’s as silly as saying hemoglobin is toxic because it contains iron atoms and elemental iron is toxic.
Gleanings
Although I found the book unreadable, I was able to learn a great deal by skimming. I quickly realized there would be no profit in delving more deeply. Here are a few of the things that popped out at me. Much of this misinformation and some of the “experts” she cites have been covered previously on SBM, and not in a good way.
She says 70-80% of people are deficient in magnesium, and she claims magnesium deficiency is the cause of many diseases. Doesn’t that mean 20-30% are not deficient? And yet she recommends that everyone take magnesium supplements. That doesn’t compute.
She asserts that our soils are depleted and lacking in nutrients: “some of our foods are not worth eating”. There is much evidence to the contrary showing that vegetables are still an excellent source of nutrients and supplementation with vitamins and minerals is not needed.
“You may need a particular kind of magnesium to achieve therapeutic levels.” What kind? Her ReMag, of course. Her evidence? Lacking.
Some of the questionable diagnoses she accepts are yeast overgrowth syndrome, detox reactions, multiple chemical sensitivity, and electromagnetic sensitivity. She’s a chemophobe, saying, “Toxic chemicals are being found in all foods, all bodies of water, and all humans in every study performed.” (Sure, our modern instruments can identify trace contaminants, but that doesn’t mean they are harmful to our health. The poison is in the dose.)
She says the most accurate test for magnesium is the ionized magnesium blood test, a non-standard test that costs $390 and is not readily available; but she tells you how you can order it for yourself. Then she says it’s not always accurate either, so she recommends not testing but just taking her supplement and seeing if you feel better.
She quotes “detox expert” Sherry Rogers, who believes everyone should use far infrared saunas (FIR) to eliminate stored environmental toxins. (What toxins are eliminated? Where is the evidence?). An article in The Atlantic criticizes FIR as devoid of evidence, and comments, “they lie to people about their health while stealing their money”.
She says you need to “drink half your body weight in ounces of water daily.” That’s a myth.
She cites a study that showed 80% reduction in migraines with 200 mg magnesium daily. Her source was the book What Your Doctor May Not Tell You. Since the study had no control group, its results are meaningless. I couldn’t find that study in PubMed, but I did find a 2014 systematic review that reached this very different conclusion:
The strength of evidence supporting oral magnesium supplementation is limited at this time. With such limited evidence, a more advantageous alternative to magnesium supplementation, in patients willing to make lifestyle changes, may be to focus on increasing dietary magnesium intake.
She tells us Dr. Fereydoon Batmanghelidj, in his book Your Body’s Many Cries for Water, says dehydration is the cause of high blood pressure. Batmanghelidj is not a trustworthy source of information. He has been characterized as a crank and has been criticized on several grounds; the references can be found here. Other more reputable sources tell us that dehydration has been linked (correlation, not evidence of causation) to high blood pressure but that research into this topic is limited.
To treat edema, she says you need to drink more than 4 cups of water a day and you need to spike the water with sea salt, ReMag, and ReMyte. To each quart of water, add 1/4 tsp unrefined sea salt, pink Himalayan Salt, or Celtic sea salt. That advice contradicts mainstream medical advice to limit sodium intake.
While pushing ReMag, she also recommends homeopathic magnesium. Yes, she advocates homeopathy! She thinks it has been scientifically tested and proven to work, that its effects can’t be attributed to placebo because it is effective for children and animals, and she brings up the old canard about homeopathic hospitals getting better results in the 1919 influenza epidemic.
Her approach amounts to throwing everything into a blender. She mixes cherry-picked science (every published study and book that passed the filter of her confirmation bias), with pseudoscience, the opinions of unqualified people, misinformation, demonstrably false statements, speculations, correlations with no evidence of causation, gullible acceptance of fake diseases, unquestioning approval of bogus treatments like homeopathy, lifestyle advice, recipes, shameless commercials advertising her products, and much more. All mixed together and blended into an incoherent mush. If there are any useful facts in this blenderized mishmash, it would be impossible to pick the fragments out of the mush and make sense of them.
A typical testimonial: she told a patient to start taking her brand of magnesium supplement for symptom X and the patient told her that not only had symptom X resolved, but that symptoms A, B, C, D, and E had also improved. No systematic evaluation, no control group, no attempt to rule out other reasons for improvement…in short, no science. Just hearsay, unverified stories, testimonials, anecdotes, and the praise of appreciative customers – the sort of thing every snake oil salesman and charlatan can provide in abundance.
Conclusion: Advertising and persuasion, not science
        ◦ I can’t recommend this book. The sad thing is, I do think there are things to be learned about magnesium; but we can’t hope to learn them here. We’ll have to wait for a reliable evaluation of the evidence by a trustworthy, science-based expert.

Magnesium oil: Not so magical
Despite the hype, there is no evidence to show magnesium oil is effective for any purpose.
Scott Gavura on July 18, 2024
Link

I’ve been contributing to this blog since 2010, and fourteen years later, I’m hitting my 345th post and still seem to have have an endless supply of topics. I can thank Facebook for many of them. Pseudoscience springs eternal. Today’s topic was forwarded to me, and I have to admit, I had never heard of magnesium oil until I saw this:
Facebook won’t let me embed the reel itself, but it’s just a guy massaging his foot. There is a lot to unpack here – even ignoring the antiperspirant/aluminum angle. The main claims seem to be:
    • Body odour is a sign of magnesium deficiency
    • 3/4 of the waste in your lymph expels through your left armpit
    • rubbing magnesium oil will eliminate body odour
    • magnesium oil will help your body “detox properly”
    • magnesium oil will restore your magnesium levels
A quick search of the internet and a browse of TikTok suggests that magnesium oil is marketed as a sort of panacea. Not only does it apparently help with sleeping, it also apparently helps muscle cramp, skin conditions, and yes, detoxification.
The Role of Magnesium
Magnesium is an abundant mineral in the body and critical to hundreds of cellular actions, including DNA and RNA synthesis, muscular contraction, blood pressure, insulin metabolism, and more. We obtain magnesium from our diet. Normal absorption is about 24%–76% of what’s ingested, which varies based on whether the body is deficient. Major sources of magnesium in the diet are water (particularly if you have “hard” water), chlorophyll from leafy greens, and then nuts, whole grains, and legumes. In general, foods high in fibre tend to be good sources of magnesium. Dietary surveys suggest that many “Western” diets provide lower than recommended intakes of magnesium.
Our bodies contain about 24-25g of magnesium, roughly divided equally between the skeleton and tissue. Magnesium on the surface of bone can be released quickly to maintain magnesium levels in the rest of the body. Elimination of magnesium is via the kidneys.
Magnesium supplements, conversely, tend to be poorly absorbed. Because these products tend to cause diarrhea, magnesium products like magnesium citrate are used primarily for this reason. It’s use as a laxative is one of the medical conditions for which magnesium supplements are demonstrably effective. That and treating low magnesium levels. Even conditions for which magnesium supplements are taken widely, like muscle cramps or insomnia, are not backed by convincing evidence. Consequently, there is little role for supplementation in the absence of a documented deficiency, or in circumstances where a medical condition (e.g., celiac disease) or a medication (e.g., a proton pump inhibitor) may be interfering with dietary magnesium absorption.
Topical Magnesium’s Achilles’s Heel: Absorption
While there may be some health benefits from taking magnesium supplements orally, there is a lack of evidence to show that magnesium is absorbed to any meaningful extent when it is applied to the skin. This makes sense, because the skin is an excellent barrier against radiation, chemicals and allergens, while conserving against the loss of water and electrolytes. In order for magnesium to be absorbed, it would have to penetrate the stratum coneum – 15-20 layers of cells that are water repellent. Drug absorption is only possible for fat-soluble drugs – not ionized chemicals like magnesium chloride solution (the typical form found in topical products). The only way magnesium could potentially be absorbed would be through sweat glands or hair follicles. But it isn’t. Extensive evidence show that magnesium is not absorbed through the skin. The one study that seems to be quoted widely to “demonstrate” that topical magnesium is effective for fibromyalgia didn’t have a control group and didn’t measure magnesium levels, and so can be discounted as evidence. Another study that looked at neuropathy also lacked a placebo control – so it is also not persuasive.
Another popular source of topical magnesium are epsom salts or magnesium sulfate heptahydrate. The effectiveness of epsom salts has been extensively analyzed by friend-of-the-blog Paul Ingraham, and I encourage you to read his very long article about them. In short, everything you think you know about epsom salts is probably wrong.
Facebook Fact Check
With the knowledge above, it’s fairly easy to break down this video. In reality, body odour is caused by bacteria on the surface of the skin breaking down the protein molecules in sweat. Low magnesium is associated with muscular tremor, cramping, seizures, cardiac arrhythmia, and conditions like low calcium and low potassium. It is not associated with body odour. The lymphatic system is a network in the body that collects plasma and liquid that has leaked out of capillaries and returns it to the bloodstream. This liquid, called lymph, moves through tubes to one of two major ducts where it returns to the bloodstream: the lymphatic duct, and the thoracic duct. While there are lymph nodes in both armpits, there is no expulsion of lymph from the left armpit, an observation that should be apparent to anyone with armpits. Given magnesium oil isn’t absorbed to any meaningful extent, massaging it into your feet will have zero effects on the physiology of your body or its ability to “detox”. If you have kidneys and a liver that are functioning normally, then you have a detox system that’s working fine.
Conclusion: No evidence of effectiveness
All the anecdotes and videos about topical magnesium can’t refute physics – magnesium isn’t absorbed through the skin, so any effects attributed to magnesium oil are placebo. Striving to eat a diet rich in magnesium is a good idea, however, and there are some circumstances where magnesium supplements are medically appropriate.

Maternal Fluoride and IQ – The Scientific Community Pushes Back
A follow-up on a questionable study of the impact on water fluoridation and IQ. Science marches on, and we’re helping it out!
Grant Ritchey on November 1, 2019
Link

This past August (2019), a prospective cohort study by Green et al. was published in JAMA Pediatrics, a well-respected, high impact medical journal, entitled “Association Between Maternal Fluoride Exposure During Pregnancy and IQ Scores in Offspring in Canada“. Steve Novella covered it on SBM previously (I encourage you to read through it before finishing this post); in a nutshell, the study claimed that maternal exposure to fluoride while pregnant results in a small but significant decrease in a child’s IQ at 3-4 years of age. Dr. Novella addressed the study, some of the flaws therein, and how the scientific community immediately criticized the paper.
As a dentist, I took a special interest in the study. I have written about fluoride and fluoridation before in SBM (here, also here, and also also here), so anytime new research comes out, I am keen on seeing what it has to say. It’s no secret that I am pro-fluoride; the evidence for benefit in conjunction with its low risk and cost is overwhelming. That said, I am also open minded enough to objectively evaluate new claims. I am not beholden to fluoride and fluoridation as an ideology, nor do I receive huge checks from the Fluoride Lobby that critics seem to think is lurking in dark alleyways. Fluoride is simply one tool among many we employ to fight the most prevalent disease in children and adolescents. If solid evidence overturned current thinking – either challenging the efficacy of caries (tooth decay) prevention or the safety of fluoride at proper doses – I would be on the forefront to not only change my stance but to educate my patients, community, and the public. That is why I wanted to ensure that the scientific community’s response to the JAMA Peds paper was sound, thorough, and based upon data, not merely a knee-jerk emotional reaction to the questioning of established doctrine.
The first wave of response by experts was swift and concise, pointing out many of the concerns that scientists and health care professionals had about the study’s methodology and statistical analysis. Some of the findings (e.g. why was there an IQ drop only in one sex?) seemed to be incongruous and defied plausibility, while some aspects of the methodology (e.g. the accuracy of self-reporting of fluoride intake is questionable, as well as possible “p-hacking“) seemed suspect. Of course, it must be stated that just because some aspects of a study are questioned or challenged doesn’t automatically make it invalid or wrong. That is the purpose of peer review and transparency in research. Put the findings under the microscope, see if they hold up to scrutiny, and replicate them if possible. That is what was done in this case, and after the initial response, a more in-depth follow-up challenge was launched – but more on that later.
Of course, the anti-fluoridationists are screaming foul. They are accusing those of us who are challenging the study of summarily rejecting the findings simply because it goes against our pre-established dogmatic stance on the subject. They believe that we are either willfully ignorant or are in some way part of a conspiracy. Unfortunately, the feeling is for the most part mutual, which makes it difficult if not impossible to engage in any sort of respectful, meaningful dialogue with critics.
Checks and balances
One of the main tenets of the scientific process is that no hypothesis or theory should shy away from interrogation and critique. If it can stand up to rigid scrutiny, then it becomes part of the scientific canon and be used to advance the boundaries of human knowledge and utility. If it withers under the light of inquisition, that too is a good thing, because not only will we not base future endeavors upon shaky foundations, but our valuable and finite resources (time, talent, and money) can be directed in more fruitful and promising directions. These “checks and balances” keep the arc of scientific progress moving forward, sometimes by leaps and bounds but more commonly in fits and starts, progress gained and lost, false starts and false hopes, serendipitous discoveries, followed by incremental victories.
Recognizing the importance and impact the Green et al. paper could have in policy as well as personal decisions, on October 23rd 2019, a group of thirty concerned health care professionals and scientists drafted a letter to Rick Woychik, PhD, Acting Director, National Institute of Environmental Health Sciences (NIEHS) and Gwen W. Collman, Ph.D. Acting Deputy Director of the same institute. The NIEHS provided funding for the Green et al. study, and we felt it was imperative to express our concerns to this body, not because the conclusions did not meet with our approval, but because there was a lack of transparency in the data they used as well as fundamental statistical errors in analyzing the data. Our letter to the NIEHS:
…[requested] that NIEHS formally ask the Green authors to release the HIPAA-compliant, Research Identifiable File (RIF) data sets from their study, as well as a complete explanation of their methods and the computer program/codes used in their data management and analysis.
As of this post no release of data has been forthcoming, but we hope that will change in the upcoming days and weeks. If the data can be independently analyzed (and I’m confused as to why the authors would want to withhold the data), it could shed light on the validity and applicability of the research. As a dentist, a parent, soon-to-be grandparent, and all-around science guy, I want to see what the data really show. If the findings of the Green paper are confirmed and maternal fluoride intake is indeed harmful to cognitive development in young children, what should be done about it? I would certainly follow the evidence wherever it leads and adjust my thinking and practice accordingly. However, if the re-analysis refutes the initial findings, parents (and prospective parents) can breathe easier, knowing that their li’l nuggets aren’t having their precious bodily fluids sapped and impurified. And if the erstwhile flawed study winds up being used by municipalities to support discontinuation of community water fluoridation (or to prevent fluoride from being added to the water in the first place), it could have significant public health implications, as we have already seen in Calgary.
Updates
Since our letter was sent to the NIEHS last week, there have been a few developments, with more rolling in daily. Here are some of the more significant ones as of publication, but I encourage you to stay abreast on future developments by following us on social media (especially Twitter):
     1.  We received an initial response from the NIEHS, which read in part:
Thanks very much for your letter to Drs. Woychik and Collman, and the detailed information you provided regarding the Green et al. MIREC study. Your letter was carefully reviewed and then was forwarded to the NIEHS Office of Communications and Public Liaison for response.
Please know that the NIEHS does encourage the sharing of data when we have supported its collection. We are currently working to understand the challenges and barriers to sharing data from this study.
This is promising and shows a willingness by the NIEHS to be scientifically rigorous in their funding processes and review.
     2.  A leading Canadian health agency has completed an evaluation of the article written by Green et al. Last week, the Canadian Agency for Drugs and Technologies in Health (CADTH) published a report evaluating the Green study. CADTH’s evaluation reached this conclusion:
The evidence is weak due to multiple limitations (e.g., non-homogeneous distribution of data, potential errors and biases in the estimation of maternal fluoride exposure and in IQ measurement, uncontrolled potential important confounding factors); therefore, the findings of this study should be interpreted with caution.
If you would like to read the CADTH evaluation, it is accessible at http://bit.ly/CADTHGreen
     3.  The National Post (one of Canada’s largest newspapers) wrote an article about the NIEHS letter. The link is below. The story includes this quote from Dr. Joe Schwarcz a chemistry professor at Montreal’s McGill University: “What are you hiding? Whoever owns the data should be willing to release it.” If you would like to read the Post article, the link is: https://nationalpost.com/health/so-much-is-at-stake-academics-call-for-release-of-data-behind-controversial-canadian-fluoride-study
Conclusion
Blog posts like this one serve two overarching purposes. The first is to report the news, as it were, so that the readers of SBM can stay current on developments that could impact them and the public at large. The second is to show the important role the science-based community plays in fact checking published research, pushing back against dubious claims and flawed methodologies, and flat out fighting against pseudoscience. Often it feels as though we are losing the battle and it’s easy to get discouraged, but through coordinated efforts such as the one I’ve described, involving people from scientific disciplines across the spectrum in a short period of time, we can mobilize in a common and unified effort that suggests that there is hope for science and critical thinking after all.

Fluoride and IQ
The evidence continues to support that low levels of fluoride in drinking water are safe.
Steven Novella on November 1, 2023
Link

The anti-fluoride movement continues to make dubious claims about the safety of fluoride in public drinking water. They are also expanding into new social media platforms, like TikTok, where everything old is new again. These platforms give a second (or more) life to old debunked claims, which means we have to constantly be whacking these moles down again.
Recent anti-fluoride activism has been focusing on studies showing that high enough fluoride levels can be a neurotoxin. This tactic took off with the Harvard study back in 2012. The Harvard study still gets prominent mention in anti-fluoride posts, as if it’s still news, or somehow is being suppressed. The study was a meta-analysis of studies, mostly occurring in China. These were ecological studies comparing measures of IQ in children to see if there is a statistical correlation with fluoride exposure from drinking water. The study found a positive correlation, making it a permanent member of the anti-fluoride rhetoric.
However, details matter. The studies involved naturally-occurring fluoride in drinking water, not communities where the levels of fluoride were controlled (which is why they took place in China, that largely does not control fluoride levels). They found that communities with high levels of fluoride in the drinking water had lower IQs on average than communities with low levels of fluoride. But here is the critical point missed in a lot of reporting and in anti-fluoride propaganda – the low level communities had fluoride levels in their drinking water in the same range as fluoridated water in the US and other Western nations. Fluoridated water was the low-level control group that had the higher IQs.
Meanwhile, it should be pointed out that the association with lower IQs and very high levels of fluoride have not been definitely established. There are lots of confounding variables in the observational studies, and it takes some fancy statistics to tease out a small statistical effect. A New Zealand study, for example, found no association between IQ and fluoride once confounding variables were adequately taken into account.
A 2023 systematic review did find a correlation between fluoride levels and IQ, but generally found the quality of the evidence to be low.
The inverse association between fluoride exposure and IQ was particularly strong in the studies at high risk of bias, while no adverse effect emerged in the only study judged at low risk of bias.
So the one study deemed high quality showed no association, and meanwhile there seems to be a correlation between low quality (high risk of bias) and a positive effect. This pattern of evidence does not lead to high confidence. The one thing that all studies appear to agree with is that better studies are needed to settle the question.
But it is plausible that at high doses there may be a neurotoxic effect from fluoride. As always – toxicity is all about dose. What we need are studies that look carefully at the range of fluoride levels that are contained in managed municipal water. Instead we appear to be getting more of the same. The latest study to make the rounds in being presented with headlines such as: “Water Worry: Excess Fluoride Linked to Cognitive Impairment in Children.”
This study is similar to the China studies in that it takes place in a rural community, this one in Ethiopia, in which there is high levels of naturally occurring fluoride. This is also a pilot study, which the researchers hope will “spur further research”. The researchers broke the subjects into three categories based on fluoride levels, <3 mg/L, 3-8 mg/L, and 8-15.5 mg/L. The recommended level of fluoride in drinking water in the US is 0.7 mg/L. The WHO recommends level below 1.4 mg/L.
So once again the low fluoride level control group was in the range of fluoridated water, while the high level groups were very high. Even if we take these results at face value, they show us, if anything, managed fluoride levels are safe. But in reality they don’t tell us anything either way, because the data is not looking at a range of fluoride that covers deliberately fluoridated water.
The results are also not that compelling, even for a risk of high fluoride exposure. The researchers used three measures of cognitive function, a picture drawing test, a memory test, and a paired association learning test. The findings were inconsistent but there was an overall statistically significant trend toward lower performance at the higher fluoride exposure levels. But as you can see from this graph of some of the data, the noise level appears to be far greater than the signal. Just looking at the data (if the trend lines were not present) it would not be possible to discern a trend.
The effect, in other words, if it is real, does not appear to be clinically dramatic.
Of course, all potential neurotoxicity to the developing brain should be taken very seriously. Every IQ point is a precious human resource. For this reason we should err on the side of caution when it comes to potential toxicity. What the current data shows is that there is a potential of neurotoxicity from fluoride at high levels, significantly higher than in the drinking water. But the same data shows, if anything, the managed drinking water levels are safe. Further, the best quality evidence does not show any clinical effect.
What I think all this means is that current drinking water fluoridation levels (below 1.4 mg/L) are safe, and provide a significant benefit for dental health. But also, we need to conduct higher quality studies to show if there even is a real neurotoxic effect, and to zoom in on the levels in managed drinking water (rather than just using that range as the low-level control).
And, as always, the media needs to do a better job of reporting this data and putting it into proper perspective.

Maternal Fluoride and IQ
New study purporting to show correlation between fluoride and IQ comes under heavy criticism.
Steven Novella on August 21, 2019
Link

A recent study published in JAMA Pediatrics claims: “Association Between Maternal Fluoride Exposure During Pregnancy and IQ Scores in Offspring in Canada“. This is getting a lot of press, but also a lot of pushback. The study is at odds with a large body of evidence showing no association with normal fluoride exposure and IQ. There is still an open question about high levels of exposure – higher than is added to some public water systems – but there is no association at <2ppm (fluoridated water typically has 1ppm ).
The new study is a prospective study correlating IQ scores in children with the fluoride exposure of their mothers. Exposure was estimated based on the fluoride levels in the community and self-report of water intake, but was backed up by urine fluoride levels. The authors also measured lead and other heavy metals, which is an important control.
They found that:
A 1-mg/L increase in MUFSG was associated with a 4.49-point lower IQ score (95% CI, −8.38 to −0.60) in boys, but there was no statistically significant association with IQ scores in girls (B = 2.40; 95% CI, −2.53 to 7.33). A 1-mg higher daily intake of fluoride among pregnant women was associated with a 3.66 lower IQ score (95% CI, −7.16 to −0.14) in boys and girls.
While many aspects of the methods used by the researchers were reasonable, the results are curiously at odds with prior research, and have come under significant criticism, at least in their interpretation. Perhaps the most significant curious aspect of the results is the stark difference between boys and girls in the study. It’s hard to believe that a drop of 4.49 IQ points in boys was missed by prior research, and why is that effect so large while there is no effect in girls (just a non-statistical trend toward increased IQ).
When combined the statistical significance almost disappears. There was also a significant disconnect between performance IQ (-13.79* (-18.82, -7.28)) and verbal IQ (3.37 (-1.50, 8.24)). Why would verbal IQ increase while performance IQ decrease? Also, look at the wide variance in results.
I am also concerned that the unadjusted IQ differences were not significant. There was only a significant difference when they adjusted the scores, which they describe:
adjusted for HOME score, maternal education, race, child sex, and prenatal second-hand smoke exposure; because city was strongly multi-collinear with water fluoride concentration (VIF >20), it was excluded from the model
It is perfectly legitimate to make adjustments for these kinds of variables, but the need to do so exacerbates the major limitation of this study – it was entirely observational. At best the authors can conclude there is a correlation (but only for boys). They can try to control for known confounders, but doing so is difficult, and they cannot control for unknown confounders.
Further, when you have to do subgroup analysis in order to find significant results that is a red flag for noisy data. There are other red flags as well, like the huge variance in results, and the disconnect between performance and verbal IQ. So we have noisy correlational data at odds with prior research. Perhaps even more damning is that the negative results were driven largely by a small number of boys who had extreme levels of exposure. Take out the outliers, and the overall effect becomes non-significant.
There are also some specific technical criticisms. Alastair Hay, Professor (Emeritus) of Environmental Toxicology, University of Leeds, said:
Firstly, as the authors acknowledge maternal intake of fluoride has not been validated. I see this as a crucial failure. For a substance with a short half-life, such as fluoride, urine concentrations vary hugely and are really only representative of the last drink. Validation of intake is something you must do before looking at associations.
He also points out that while the authors controlled for maternal lead exposure, they did not control for post-natal lead exposure. Lead is known to have a profound effect on IQ, so this was a critical failure.
Rick Cooper, Professor of Cognitive Science, Birkbeck, University of London, pointed out:
The male sample includes a couple of extremely low IQ scores (below 70 would be special needs, but they have two boys with IQ in the 50s). The results would be more convincing if it were shown that they did not depend on these children.
And:
There is no consideration of whether an effect, if present, might be non-linear. For example, it appears that there is no effect at low concentrations, with the effect only arising at extreme levels. The chosen statistical approach does not allow consideration of this possibility.
There are other criticisms along these same themes. There are a lot of anomalies in the statistics, meaning that you could choose to look at the data in different ways and get different results.
There was complete agreement among those experts commenting that these results at best amount to an interesting hypothesis that needs further study. We cannot, however, generalize from these findings or make any public recommendations. Overall the results are unconvincing and are most consistent with noisy data with the effects largely due to a few outliers.
The results remind me of the last study to allegedly find a correlation between lower IQ and fluoride exposure – the Harvard review in 2012. There it was very clear that there was only an effect when the highest levels of exposure were considered – much higher than water fluoridation. So again the best current conclusion is that there may be neurotoxicity from fluoride at toxic levels of exposure, many times what is considered safe, but no evidence upon which to conclude that the levels of exposure from fluoridated water have any neurotoxicity.

Chromium and Fluoride – What an ‘Interesting’ Combination
Craig D Pearcey on October 28, 2016
Link 

It is fairly apparent that the chief editor of Natural News (Mr Mike Adams – The Health Ranger) and his associated writers appear to be thoroughly determined to “prove” that there is a conspiracy to deliberately poison the US public – en mass – using contaminated public and state drinking water. Quite recently, within the space of a week, Natural News published three separate articles on this general topic, with a fourth article discussing an apparent related Big Pharma pharmaceutical conspiracy. The first of these was authored by Mr Adams and is entitled ” Hexavalent chromium (chromium-6) was just found in 75% of drinking water… the mass chemical suicide of America is under way.” In this article Mr Adams states:
An Environmental Working Group review of government water analysis data reveals that 75% of drinking water in America is contaminated with cancer-causing hexavalent chromium (also known as chromium-6).
The key source for Mr Adams is an article entitled “‘Erin Brockovich’ carcinogen in tap water of more than 200 million Americans” by David Andrews and Bill Walker. The article focuses on hexavalent chromium (i.e. Cr6+) and its level in the public drinking water system. As before, Mr Adams proceeds to link these new claims of chromium VI with his prior work from his ISO 17025 Accredited CWC Laboratory on the supposed heavy metal contamination of US public drinking water with a claimed conspiracy to poison the US public on a large scale. This is clearly illustrated in his statement:
This is on top of our own efforts at EPAwatch.org where my lab tested hundreds of municipal water samples from across the country and found high levels of lead and other heavy metals in 6.7% of samples.
In addition, Mr Adams makes reference to the debunked claims of fluoridation of drinking water being a serious health hazard as illustrated by his statements:
This doesn’t even cover the deliberate poisoning of public water systems with fluoride, a neurotoxic chemical purchased in bulk from Chinese chemical plants (or sometimes acquired as a waste product from fertilizer manufacturing factories). Fluoride is dumped into public water supplies under the quack science claim that every person in the nation is deficient in fluoride — a blatantly false and highly irresponsible claim. In reality, many children suffer from fluorosis, a dark mottling and discoloration of the teeth caused by too much exposure to toxic fluoride.
In the second article by Natural News entitled “Study confirms that fluoride causes weight gain and depression,” the writer states:
A study published in the Journal of Epidemiology and Community Health found that certain areas of England with fluoridated community water had increased rates of hypothyroidism. It was one of the largest studies to examine the adverse effects of elevated fluoride exposure.
The scientists discovered that areas with fluoridated water– such as the West Midlands and the North East of England – were 30 percent more likely to develop hypothyroidism than communities with low, natural levels of fluoride in their water. The scientists from the University of Kent warned that around 15,000 people in the U.K. could be suffering from preventable depression, fatigue, memory loss or weight gain.
Additionally, the third article by Natural News entitled “Water fluoridation linked to ADHD, obesity and depression states:
(NaturalNews) Water fluoridation has been linked with attention deficit hyperactivity disorder (ADHD) in a new study conducted by researchers from York University in Toronto, and published in the journal Environmental Health.
Although prior studies have suggested that there might be a connection between fluoride and hyperactivity, the new study is the first to look at the relationship between ADHD and water fluoridation in particular.
“Given the number of children in the U.S. exposed to fluoridation, it is important to follow this up,” said Thomas Zoeller of UMass-Amherst, who was not involved in the study.
The study used fluoridation data from 1992. Since then, the proportion of the U.S. population drinking fluoridated water has increased from 56 to 67 percent. During that same time, the proportion of children diagnosed with ADHD has increased from 7 to 11 percent.
Furthermore, the fourth article by Natural News entitled “Prescription nightmare! Fluorinated drugs used for anxiety and depression cross the blood-brain barrier, cause permanent nerve damage” makes a number of claims around the apparent risks of state and municipal water supplies in an article on the dangers of fluoroquinolone:
Fluoride accumulates in the human body, so people who drink unfiltered tap water regularly are more susceptible to poisoning from fluorinated drugs, which include – but are not limited to – general anesthesias, chemotherapy, antidepressants and anti-anxiety drugs. Once the human body reaches the saturation threshold, symptoms become unbearable and unmanageable by doctors, including severe nervous system disorders, nerve pain, tendon ruptures, gastrointestinal issues, sensory impairments, autoimmune diseases, blood sugar problems and even emotional disorders. Due to the catapulting of drug toxicity by fluorination, the human threshold for toleration can be crossed after just a few prescription pills. Imagine how many people wash down such medications with tap water or drinks made with fluoridated water.
Once a person becomes poisoned by the bioaccumulation of fluoride, they can become hypersensitive to even extremely small amounts. Think now of how many dentists push fluoride as “healthy” and good for building or maintaining “strong teeth.” Most medical doctors in America prescribe fluorinated drugs for even the mildest health conditions. Some doctors prescribe these toxic antibiotics for viral infections, where the drugs are not only useless, but extremely toxic and harmful. One good example is fluoroquinolone, an antibiotic with an added fluoride atom. The fluoride in drugs is boosted far beyond the limits allowed in drinking water, and is also commonly mass-prescribed in anti-inflammatory steroids and even anesthetic drugs used to put patients under for surgical procedures.
Drug companies and their evil scientists love using fluorine in medications because it serves as a solvent for penetrating human tissue, decreasing the amount of the expensive drug needed to be delivered to its “end goal.” Not only do fluorinated drugs penetrate the blood-brain barrier, but they also hinder the thyroid gland’s activity by replacing iodine.
And yes, fluoride causes cancer too. It also easily seeps into the pineal gland of the brain, calcifying it slowly over time. Fluorinated antibiotics are often completely synthetic and kill the good bacteria in the human gut that is responsible for the majority of immunity. This is also why free radicals are able to take over many human bodies and another reason cancer attacks one in every three Americans, killing about half in the process. Now you see why prescription medications are often the “beginning of the end” for so many people.
A look at the hexavalent chromium claims
A review of the article by Andrews and Walker, cited by Mr Adams in regards hexavalent chromium, indicates that their case is not as conclusive as they imply. In brief, Andrews and Walker commence by discussing the public health goal of 0.02 parts per billion (ppb) Cr (VI) in drinking water for life taken by the California Office of Environmental Health Hazard Assessment (OEHHA). The concept behind the OEHHA decision appears to ensure that exposure levels to Cr (VI) are low enough over the individual’s entire life-span to give absolutely nil chance of developing cancer due to hexavalent chromium. In other words it is an extremely overcautious approach that was proposed by the OEHHA. It is at this point that Andrews and Walker argument becomes somewhat “opaque”. They proceed to claim that due to strong lobbying by large chemical industrial interests within California as well as an apparent conspiracy between Big-Chem, the state of California, and the EPA, that dangerously high limits for chromium (hexavalent and otherwise) were adopted by both the EPA and the state of California. It is this argument, and the fact that EPA data generally shows chromium levels above the public health goal of 0.02ppb, that Mr Adams cites as proof of deliberate poisoning of the US public via state and public drinking water (including a reference to his earlier claim based on analyses by his CWC laboratory).
Given Andrews and Walker claims, a review of the standards/limits set by the other regulatory bodies allows for an adequate evaluation of both the OEHHA public health goal and the EPA limits. The limits set by both the European Union (EU) and the World Health Organisation (WHO) – ie. the UN – for total chromium in drinking water is 50 ppb. Also, neither make any distinction in testing for the different forms or cations of chromium (ie. Cr3+ and Cr6+) in drinking water. The limits set by the US EPA are 100 ppb for total chromium, and 10 ppb for hexavalent chromium as well as 50 ppb for total chromium respectively for the Californian state EPA. These limits are notably different from the EU and WHO limits, but within the same order of magnitude, suggesting that the EPA and Californian limits are adequate. In addition, a review of data provided by Andrews and Walker indicates that chromium levels in US state and public water are below the limits set by the EPA, EU, WHO and Californian state in all cases with most giving chromium levels below 1.0 ppb. Thus, even by the most stringent standards (ie. California’s EPA), US municipal water supplies are perfect safe to consume when considering chromium. This indicates that Andrews and Walkers claims, and by extension Adams, are completely unfounded.
Interestingly though, the OEHHA public health goal is 2,500, 5,000 and 500 times lower than the EU/WHO, EPA and Californian EPA limits. This raises the question of where such low public health goal values originated from. As stated, the 0.02 ppb public health goal set by the OEHHA is apparently to ensure no chances of an individual ever catching cancer from Cr (VI) through daily exposure during their lifetime. Also as stated, this would result in an extremely low value by definition. This article’s author conjectures that this is more likely due the lowest detection limits available presently for the standard analytical methods employed for such analysis or the lowest levels that can be achieved by one of the most robust water purification method available today – namely reverse osmosis. In essence, the unstated aim of the OEHHA appears to be: “nil exposure to Cr (VI) equate to nil possibility by Cr (VI- induced cancer”. Although admirable, in real world applications, this is overkill in dealing with a given threat.
But we’ve been here before …
Returning to Mr Adams claims around heavy metals and fluoride in US public drinking water, we can clearly state that we have been here before. Both sets of claims have been adequately reviewed and debunked. One of my prior articles has shown that the results from Mr Adams’ own CWC lab do not support his claim that the US public is being deliberately poisoned en mass by elevated levels of heavy metals in the public drinking water. In fact, his own results show the complete opposite (among other things). Furthermore, a review of the data presented by Mr Adams to support his claims around hexavalent chromium itself also now shows that chromium levels in state and public water supplies are well within the safety limits specified by the EPA as well as the EU and UN (ie. most of the rest of the world). In regards perfluoro and polyfluoro-alkanes, as stated in my other article, the EPA (and other relevant governmental agencies) are aware of the problem presented by these and are taking actions around the issue. In the same article, water fluoridation within the acceptable levels of 0.7-1.3 ppm has been shown to beneficial to dental hygiene, with dental fluorosis and skeletal fluorosis only occurring at much higher levels (4.5-10 ppm for dental, and approximately 10 times higher than that for skeletal).
A look at the new Natural News anti-fluoride claims
In regards the second Natural News article and its claim around hypothyroidism (underactive thyroid) due to fluoride in US municipal water (based on the article published in the Journal of Epidemiology and Community Health originally written by Stephen Peckham), a more than adequate counter has be provided by the Open Parachute website in an article entitled “Paper claiming water fluoridation linked to hypothyroidism slammed by experts.” A summary of the contents of this counter article are:
     1.  Correlation is not causation: As discussed in Open Parachute, the Peckham study referenced by Natural News used data from two sets which were collected in complete isolation from each other in two unrelated studies. The authors of these original two studies and Prof. Peckham made no attempt to directly link the occurrence of hypothyroidism to elevated fluoride uptake so no direct causation was demonstrated. Thus, Prof. Peckham has done no more than make a comparison between two broad (all-inclusive) trends without addressing the critical issue of causation between the two key parameters. A large number of such correlations exit, but they do not necessitate causation, an aspect that is particularly true for a comparison of broad all-inclusive generalized trends. A perfect example of this questionable approach, as proposed by the present author, is to draw an all-inclusive correlation between increases in inflation and increased autism reporting – two trends that move together but have no reasonable link between them.
     2.  Critical role of iodine: Prof. Peckham also ignores the impact of the confounder iodine as the lack thereof is a major cause of hypothyroidism. Not adequately considering iodine as confounder, particularly as the study was implying that fluoride is an iodine inhibitor, invalidates the conclusions of the study.
     3.  The size of the effect: The size of the observed effect was very small (3.2% with 1.1% standard deviation). This raises the question as to whether, assuming this is a true effect, the benefits of avoiding a small level of hypothyroidism in the general populous would justified the large and broad loss of benefits in dental hygiene that would result if water and other fluoridation efforts ceased. (This argument, though, maybe morally questionable in the opinion of some.)
     4.  Stephen Peckham is a well-known anti-fluoride activist: As indicated in Open Parachute, Prof. Peckham is a well-known anti-fluoride activist and has been so for some time. This raises questions around his objectivity – particularly in the light of a distinct lack of direct evidence for his assertions. Peckham is also not an epidemiologist, so the research is outside of his field of expertise.
A counter of the third Natural News article, based on a paper published by Ashley Malin and Christine Till and claiming of a link between fluoride and ADHD, is also provided by Open Parachute, and is entitled “More poor-quality research promoted by anti-fluoride activists.” Many of the counter points here are a repeat of the first and an overall summary thereof are:
     1.  Exploratory investigation – correlation not causation: Once again, correlation does not necessitate causation. The authors of this study also used two unrelated data sets that were collect in complete isolation from each other, and also conflated two broad trends without critically addressing the issue of causation. Furthermore, one of the data sets used (ADHD prevalence reporting) was of questionable quality because of the subjectivity by which ADHD prevalence was assessed by the observing reporter. This data set was collected via a randomized telephone survey, from selected locations, in which parents were asked to indicate the ADHD status of their children based their own opinions and observations. In other words, no standardized assessment or expert diagnosis was used, just the parent’s personnel view regardless of their socio-economic, ideological, and educational status. The survey also did not account for how well informed and educated the parents were of their children’s ADHD status. Furthermore, the authors made no attempt to directly inquire about the fluoride intake for those children in the data from this survey.
     2.  The starting hypothesis: Although there was a literature survey, it was limited and brief, focusing on two articles (Grandjean & Landrigan (2014), and Choi et al. (2012)) which claim a detrimental impact of fluoride on health. However, they failed to cite Broadbent et al., (2014) whose work showed contrary evidence. In addition, not all of their sources appear to be relevant to the topic. As Open parachute states, Broadbent is relevant to the topic, Choi is not.
     3.  ’Natural’” vs ‘artificial’ fluoride: It is interesting to note that although a correlation between fluorosilicate (“artificial”) and ADHD was observed, the opposite was observed with regards to “natural” fluoride (ie. no correlation). In addition, their claim that fluorosilic acid could cause elevated lead levels due to corrosion (the main mechanism proposed for a correlation between “artificial” fluoride and parent-reported ADHD) is also not strongly supported by the literature. Fluorosilicate is known to decompose into fluoride anions and silica once dissolved in water, having very little impact of the pH of the water.
     4.  The thyroid story again: Little needs to be said here given the debunking of the Peckham paper by Open Parachute.
Another point of interest is that Malin and Till did not include in their analyses the well-documented fact that genetics is the most important cited driver of ADHD (75%) and that environmental contributions are typically very small (as noted here, here and here).
In short, the claims of both the second and third Natural News articles are just as unfounded as Mr Adams’ prior claims in the first. They ultimately prove nothing.
Fluorinated drugs
The fourth Natural News article discusses the views of its author on fluorinated pharmaceuticals which also contains a number of claims in regards the fluoridation of water. At least one or two of these claims have raised a number of times in the past by a variety of writers and these have already be thoroughly debunked. However, Wells has made new claims around fluoride (which this author has not reviewed), which involve the hypothesis that fluoride “bio-accumulates” in the human body and its subsequent health impacts. In Wells’ view, fluoride accumulates over time in the soft tissues of the body to near-toxic levels, from the fluoride present in drinking water. Then, upon the uptake of prescription medications containing fluorine as fluoride or as fluorinate pharmaceuticals, the toxic limit of the body is quickly exceeded, resulting in severe adverse effects. However, there is one key problem with the proposed mechanism, namely that fluoride does not accumulate within soft tissues. It is readily removed by normal renal functions to levels equivalent to that in the drinking water consumed. In regards its content in bone and the teeth, these levels are also dictated by the concentration within the drinking water as fluoride does not additively accumulate with time in the bone and teeth due to the dynamic process of fluoride dissolution and re-absorption by dental hydroxyapatite/fluoro-hydroxyapatite. At the stipulated EPA limits, the fluoride present within the bone and teeth of a human is far below the hypothetical limits suggested for a toxic response. Thus, without the possibility of “bio-accumulation”, the assertions becomes completely unfounded. Claim around “bio-accumulation” are, hence, completed debunked. In addition, the article appears mix the chemical properties of “free” fluoride with those of pharmaceuticals when one of the functional groups is replaced by a fluoride atom (eg. fluoro-quinolone). In other words, the article mixes and equates the chemistry and kinetics of two completely different chemical species, which is poor chemistry as the chemical properties of each are determined by the whole composition of the molecule and not solely by a single atom in the structure, a point I discussed in the prior article.
It is also noteworthy that the article refers to an entry on fluoride from Truthwiki (a website maintained by Mike Adams):
Mustard gas from World War I was modified and used to kill the Jews in gas chambers (Zyklon-B). In fact, Zyklon-B would later be used by Americans for chemical warfare in a country named Vietnam (aka Agent Orange).
These claims are completely incorrect. First, mustard gas (both that used in World War I and today) is known as a blistering agent. It attacks and damages any moist epidermal layer like the lining of the eyes, nose, throat and lungs, resulting in blindness and preventing the adequate uptake of oxygen through the now damaged air-sacks of the lungs. In the worst cases, the victim then dies of slow asphyxiation, usually in considerable pain. Zyklon-B is actually hydrogen cyanide stored in sealed cans and stabilized by a filler material – typically wood pulp (ie. same material as highly fluffed brown cardboard container boxes or brown paper bags) or clay filler. It kills by shutting down the “energy factory” in all living cells by binding to the cytochrome c oxidase protein subunit on the surface of the inner membrane of the mitochondria via a non-competitive inhibitor process. This disables the cellular respiration pathway and stops the energy production in all cells affected. This results in death within seconds. Agent Orange, on the other hand, is an equal combination of two well-known herbicides: 2,4,5-trichlorophenoxyacetic acid and 2,4-dichlorophenoxyacetic acid, that are generally not used today due to their environment persistence (ie. they tend not to break down in the environment and, thus, are susceptible to building up in the food-chain). These three materials are most definitely not the same chemical. If Truthwiki (ie. Mike Adams) and his contributing authors cannot get this simple chemistry correct, how can we give any credence to what they have to say in regards the chemistry and biochemistry of any other topic they broach? It would be advisable to view much of what they state, particularly when it runs contrary to the general accepted consensus of academia, with great suspicion and caution. As the old mariner seamen used to say: “Beware! Here be dragons!”
Where one invests the most is where one will stand…
In general, the fact that the Natural News website has an entire separate section on water “feature articles” replete with numerous entries on the topic of the supposedly toxic US municipal and state water sources, is clear evidence that the writers of Natural News and Adams in particular appear to be heavily invested in this narrative. Review of the Natural News website also indicates that these views have been held for years prior to Mr Adams CWC lab being started and accredited, as well as before testing of these accretions could have even commenced. Hence, this appears to be another case of a core-belief and narrative being held, and subsequent attempts to make the scientific evidence fit the claim, rather than doing the analyses first and allowing the results dictate the direction of their conclusions. In other words, a typical case of pseudoscience rather than real science.
Conclusion: The water is safe, drink it
Despite a lively campaign by Natural News and its chief editor to “prove” the dangers inherent to drinking water (municipal and state) in the US, using a numerous and varied range of sources, the facts behind the science proves what has been known for a considerable length of time. Most of the US municipal and state drinking water (approximately 90%) is perfectly safe for human consumption due to the actions taken by and controls in place in most US municipalities, and no amount of assertion by Mr Adams and his supporters to the contrary will make it any different. Properly executed and undertaken science never lies.

The Fluoride Dragon Cometh! Or does he?
Craig D Pearcey on September 18, 2016
Link


[Editor’s note: With no further ado, and with no introduction necessary, here is a second post from Craig Pearcey; Witness his science and despair, quacks of the world!]
First for the basic chemistry
There is one particular word that tends to get many CAM supporters very vocal and the conspiracists thinking about running for their home-made bunkers in a basement somewhere. It is the word “fluorine” or any of its analogues. However, before getting into their anti-fluorine claims, we need to briefly review it properties as both an element and in various molecular forms. Without this background it may be possible to make certain assumptions about fluorine that are baseless for a given molecular structure and application. It is this very type of error that the antivaxxers and many in the CAM field make in regards thimerosal – i.e. Ethyl(2-mercaptobenzoato-(2-)-O,S) mercurate(1-) sodium, methyl-mercury, and elemental mercury. All three have significantly differing chemical properties based on their molecular structure, but some individuals/groups continue to attribute the toxicity and chemical properties for elemental mercury to thimerosal (Ethyl(2-mercaptobenzoato-(2-)-O,S) mercurate(1-) sodium). Similarly, drawing conclusions on thimerosal toxicity from methyl mercury is equally flawed. In addition, in their instance in equating the three they refuse to provide any viable mechanism how thimerosal is converted into either elemental mercury or methyl mercury, or how they can be attributed the same chemical properties.
And now for fluorine chemistry
Fluorine is one of the halides (i.e. halogen), and is located in Period 2 (the second row of the periodic table), Group 17 / Group VIIa (the column second most from the right of the table). It has the highest electronegativity of any of the elements (i.e. a “love” for accumulating extra electrons) in the periodic table, and consequently is one of the strongest oxidants in nature. This strong oxidizing potential tends to make it dangerous to any living organism that comes into contact with it in it elemental form (typically as molecular fluorine – F2) due to its tendency to cause severe oxidative damage. Fluoride on the other hand, the anion of fluorine, is supplied in various forms for the prevention of cavities. These forms include sodium fluoride, fluorosilicic acid, and sodium fluorosilicate. As an anion, i.e. F–, its potential for oxidation is spent and it tends to form salts like sodium fluoride (NaF) with any cation in its immediate environmental. However, sodium fluoride is still toxic in small to moderate amounts (the lethal dose for a 70kg/154lb individual is 5-10 grams) and has a health warning of three on the NFPA 704 scale. In addition, sodium fluoride is also highly soluble in water. Lithium fluoride on the other hand, is far less water soluble and is typically associated with molten salts, and is used for (among other things) solar energy conduction in solar plants. Fluorosilicic acid (H2SiF6) and sodium fluorosilicate (Na2SiF6) are the acid and conjugate base of the same fluoridated silicon chemical species. Both are highly toxic (given by the NFPA 704 scale numbers of 3 and 2 respectively) and fluorosilicic acid is corrosive, including corrosive to glass. When elemental fluorine is chemically bonded to organics, its high electronegativity allows it to form strongly bonded associations with the organic backbone. This allows multi-fluoro-alkyls to have considerable thermodynamic stability, which lends them to multiple commercial and industrial uses (eg. high performance fire-retardants), particularly when multiple or complete hydrogen-fluorine substitution has been effected such as the various perfluor-alkyls and polyfluoror–alkyls (PFAS).
Turning Flint waters into a merry-go-round…
Given the prior discussion on heavy metals, it is appropriate at this point to move onto another issue Natural News writers often frequent – even though it does not include the topic of fluoride. Most recently, the writers of Natural News have published the an article entitled:- “City governments across America are poisoning children with lead and nothing is being done about it” in which they reference what is now known as the Flint Water Crisis. It is one of a number of articles in the similar vane in which they attempt to link the Flint Water crisis and the hazardously high lead levels in in Flint’s (Michigan) public water system to their unfounded claim of deliberate poisoning of the general US public with elevated levels of heavy metals in all US public and water drinking water. The whole story of the Flint Water crisis is known by most of the US public (though little known outside of the US) and has been extensively covered in the US press. In essence, the metropolitan of Flint changed over its water supply from the Detroit Water and Sewerage Department to the Flint River, but did not add the necessary corrosion inhibiters to the Flint river water supply. This resulting in hazardously elevated levels of lead in the public water supplied to Flint due corrosion / leaching of lead out from the old lead-pipe based public water system into the public water. The effects on the citizens of Flint, particularly the poorer, were severe with as many as 6000-12000 children experiencing health related problems. In addition to, that when the problem became openly known, there were attempts by certain individuals to hide evidence of negligence. At present, extensive efforts have been undertaken to address the problem, include the changing back to the Detroit Water and Sewerage Department water supply, replacing the old lead pipe-lines with something more modern and infrastructure upgrades. Legal action is also being presumed against certain individuals. In addition, the story of the Flint Water Crisis is still developing as these efforts are ongoing. In general, Natural News’ coverage thereof is within acceptable bounds until they move beyond the basic facts of the case. Once, the writers of Natural News attempt to link the events of the Flint Water Crisis to their broader conspiratorial claims of heavy-metal poisoning of the general US public, they move from a factual position to one of unsupported supposition. The general mountainous preponderance of Water Quality testing data/evidence in the US, by the EPA and others, does not support they preposition. In fact the avalanche of evidence actually supports the counter claim. This cannot be more clearly demonstrated than by the fact that Mr Adams’ own CWC laboratory results (a review of which was undertaken earlier) strongly suggests no heavy metal poisoning of the general US public , but overall; adequate to good quality drinking water instead.
RED-ALERT! PFAS invasion on the way …
With this background, it is appropriate at this juncture to mention three recent articles on the Natural News website as they illustrate the approach in regards the general topic of anything to do with fluorine by many CAM supporters and conspiratists. The first of these was written by Mr. Mike Adams (Health Ranger) and is entitled “Millions of Americans exposed to deadly, toxic chemicals in public water supplies… massive scientific investigation backs up Health Ranger findings“. In his article, Mr. Adams states:
The study comes on the heels of the Natural News nationwide water quality assessment effort which analyzed hundreds of water samples via ICP-MS instrumentation to determine that 6.7% of the U.S. water supply is contaminated with toxic heavy metals that exceed allowable EPA limits. Click here to read the results of my own study in the Natural Science Journal, the journal I launched to publish real science in the public interest (without corporate or government influence). My article explaining the illegal heavy metals contamination found in the U.S. water supply is detailed at this link.
This article was subsequently followed reasonably quickly by two further articles on Natural News regarding the same topic and are entitled “Millions of Americans at risk for cancer and other harmful diseases due to toxic tap water” and “California tap water most toxic in nation; Harvard study finds deadly industrial chemicals used to fight fires, insulate pipes and more“. All three articles refer to the same recent joint study undertaken by the Harvard T.H. Chan School of Public Health and the Harvard John A. Paulson School of Engineering and Applied Sciences in which the lead author, Xindi Hu, discussed the progressive emergent threat of PFAS in US public drinking water as part of her doctoral thesis. The author of the Harvard study used data supplied by the EPA’s Third Unregulated Contaminant Monitoring Rule (UCMR3) program and a brief review of part of the contents thereof indicates that the Harvard study itself was well designed and executed. However, it is clear from both the title and the quoted contents of Adams’ article that he is trying to ram through his claims of heavy metals poisoning of the US public via its drinking water on the coattails of Hu’s completely unrelated study. A prior debunking of Mr. Mike Adams’ prior claims around heavy-metal poisoning of US public and state water is available on Science-Based Medicine. The impression that all three articles attempt to produce is that the EPA is either neglectfully ignorant of the risks associated with PFAS contamination of the national water supply, or criminally inactive about it. However, neither impression is true as, firstly, the EPA has been aware of the risks associated with PFAS for some time as given by the EPA’s UCMR3 testing program used in the Harvard study and, secondly, they have instituted activities to deal with the threat. In other words, the EPA has not been caught suddenly by surprise, and they are already at work tracking and attempting to address the problem. Furthermore, the issue of PFAS is not just a US problem, as the three Natural News articles appear to imply, but a global problem. This is clearly evident in the considerable amount of work and investigation being undertaken by the UNEF under the UN Global Monitoring Plan on POPs. Data from these and many other sources show similar levels of PFAS’s in the ground water, fauna and populous of all EU countries as compared to the USA. A similar trend is also observed around the rest of the globe. Lastly, given Mr. Adams related claim, a final comparison of the maps provide for heavy-metal results and the EPA on PFAS clearly suggests that there is no significant correlation between Adams’ heavy-metal data and the EPA PFAS data. In the end, these three Natural News articles are nothing more than an attempt to appeal to authority to justify their unfounded claims of US public water heavy-metal poisoning using a good-quality study that is not at all related to their claims – a “guilty by association” approach.
Beware the dental hygiene!
In addition to these three articles on the Natural News website on PFAS, a pair of articles on fluoride and dental hygiene were also been published during the same period. As with the three on PFAS, the central theme has been the issue of the apparent toxicity of US state and national drinking water, but this time in regards the addition of various sources of fluoride with a view to improving dental hygiene. These articles include “Whiten your teeth naturally, without chemicals” and “How New Zealand is systematically poisoning its citizens with fluoride… while crushing local control over water safety” and if you are really curious about what Mr Mike Adams’ is actually think on the subject, you can find a whole category of articles on fluoride. Overall, the general tone given by Natural News is that the writers believe that the use of fluoride at any dosage level (even the smallest) is extremely toxic and harmful to any individual regardless of the method of delivery or the frequency of the dose. There are a few references on Natural News to dental fluorosis and skeletal fluorosis as well as frequent references to avoiding fluoride or filtering it out as given by the titles: “Water purification breakthrough revealed: AquaTru countertop water purifier removes 128 toxic chemicals, fluoride, heavy metals and more” and “Big Berkey beats ProPur gravity water filter for removal of heavy metals and toxic elements“. It is almost as though they are talking about high intensity radioactive contaminants like Cobalt-60 or Iodine-131. Most recently, the writers of Natural News have also published the an article entitled:- “How to prevent fluoride from destroying your brain” which refers to a study undertaken by Dr. Philippe Grandjean (Harvard School of Public Health) and Dr. Philip Landrigan (Icahn School of Medicine published) in the medical journal The Lancet (Neurology)- see abstract and full article. In their article, Natural News asserts:-
In 2014, the journal Lancet Neurology declared that fluoride is a developmental neurotoxin. A meta-analysis of 27 cross-sectional studies was lead by Dr. Philippe Grandjean of the Harvard School of Public Health, and Dr. Philip Landrigan of the Icahn School of Medicine. The study analyzed the effects fluoridation had on children across the world, though most were from China. What the researchers found was shocking. Exposure to elevated levels of fluoridation led to a decrease in IQ of about seven points, on average. Most of the water supplies in the studies had fluoride levels that would be permissible by current EPA standards, of less than 4mg per liter.
However, these views by the writers of Natural News are unsupported scientifically and have no basis in reality. The science behind the application of fluoride to teeth for good dental health has been extensively studied and is well established. Among the aspects covered by these studies is the chemical mechanics behind the conversion of hydroxyapatite to fluoro-hydroxyapatite in tooth enamel with fluoride application, as well as chemical/solubility equilibrium studies (Le Châtelier’s principle) and reaction kinetic studies associated hydroxyapatite deposition/re-deposition – including some more recent studies. The impact of dosage levels has also been well studied and from these studies, the appropriate and safe levels for fluoride application have been determined (0.7 – 1.2 ppm in drinking water). These studies have also shown that dental fluorosis and skeletal fluorosis only occur at high and extremely high levels respectively, typically at consumption levels one or more orders of magnitude above those proposed (i.e. 10 or even 100 ppm), at which point community water supplies would begin removing fluoride from the water. Thus, the claim by the Natural News writers that fluoride application at any dosage is dangerous is without any basis. In regards the Lancet study, the writers of Natural News appear to have quoted the Lancet study completely out of context. The language and structure of Natural News article suggests that its writers are attempting to create the impression that the Lancet article was sole about fluoride and its dangers, specifically in regards that added to US drinking water. However, the original Lancet article is actually a study that focuses on a large variety of known neurotoxicants (not just fluoride) and how they impact on cognitive development, with a specific emphasis on children. Some of the neurotoxins referenced in the article are Lead , polychlorinated biphenyls (PCB) , arsenic, toluene, manganese, chlorpyrifos, dichlorodiphenyltrichloroethane, tetrachloroethylene, and polybrominated diphenyl ethers. Fluoride is only mention twice in the article, once in table 2 and once in the abstract, however, it is not discussed at all in the article, including in the abstract. Thus, it is difficult to know the context of the fluoride (ie. the dosage level) that the article is referring to. A study of the sources sighted by Dr Gandjean and Dr Landrigan in the original article is more revealing. One of the sources referenced is an article published in the journal of Environmental Health Perspectives that deals with developmental delay in respect to fluoride dosage levels that are abnormally high as given by an article entitled:- “Developmental Fluoride Neurotoxicity: A Systematic Review and Meta-Analysis” . An extract from the articles abstract states:-
Conclusions: The results support the possibility of an adverse effect of high fluoride exposure on children’s neurodevelopment. Future research should include detailed individual-level information on prenatal exposure, neurobehavioral performance, and covariates for adjustment.
Lastly, the mention of 4.0 ppm (4.0mg/L) as the current EPA standard by the Natural News writers appears to be a break-down in understanding and general confusion around the NCR 2006 study (which was into the adverse impact of fluoride at the 2-4 ppm level) and the stipulated EPA specifications for fluoride in drinking water (0.7 – 1.2 ppm).
Further afield …
Two other claims that have been made by those in the anti-fluoridation camp are:
     1.  That the rest of the world is against the use of fluoride to dental hygiene entirely, and
     2.  That fluoride aids the uptake/release of heavy metals in the human body – thus aiding heavy metal poisoning.
In regards the rest of the world being against fluoridation, this is completely untrue as both the UN World Health Organization and EU European Food Safety Authority are strongly in favour thereof. This, then, raises the question as to why considerably more countries do not add fluoride to their drinking water than do. The answer is that the majority of the countries whom do not add fluoride to their public water use other methods to provide fluoride to their general public, such as fluoride in toothpaste, oral medications, and dental fluoride treatments typically involving pastes/gels. The reasons behind this are based more political and legal issues, not scientific or health ones. In regards higher heavy-metal uptakes/release by fluoride, the proponents hereof have not provided any viable scientific evidence for these claims, nor have they ever proposed a viable chemical mechanism for this. The single article they reference mentions only increased lead levels in the water supply to certain areas of Flint due to the increased corrosion of lead pipes via fluorosilicate.
Final words on PFAS and fluoride
So, in summary:
     1.  PFAS are a clear point of concern in the US, the EU and globally. Presently, the EPA and UN are carefully monitoring PFAS levels and working to address these concerns. However, for the Natural News writer to try link their unfounded claims of heavy-metal poisoning of the general US public via their drinking water with the PFAS study is completely without merit and inherently false.
     2.  The use of fluoride for dental health is well documented and thoroughly scientifically proven, provided the dosage of fluoride is maintain within the appropriate range. For the writers of Natural News to claim the use of fluoride at any dosage level, by any mechanism, and at any frequency, to be dangerous and damaging to public health, is totally unfounded and pure misinformation.
     3.  Although most of the world does not use fluoridation of water as a means of supplying fluoride to the general populous, they generally are in favour of fluoride application for oral hygiene and supply it in other forms.
     4.  The CAM and conspiracy camps have not provided a viable chemical mechanism to explain how fluoride worsens the uptake/release of heavy-metals by the human body to facilitate poisoning thereby.
An unrelated bit of fun chemistry
And now for something completely off topic and of interest in regards Period 2 chemistry. Being in Period 2, each fluorine atom processes only s and p-orbitals (i.e. electron shells), but no d or f-orbitals which gives fluorine some unique properties. Consequently, this is why (together with the number of protons in its nucleus against its size) fluorine has the highest electronegativity of all known elements. This lack of d and f-orbitals also tend to confer unique properties to all the other Period 2 elements such as boron, carbon, nitrogen and oxygen, ect. This unique s/p-only orbital property for carbon as well as its four-valence bonding capacity makes it the only element in the universe that can readily and easily form polymers and chains of endless length that are thermodynamically stable. Silicon, the next four-valence bonding element in the Periodic Table (Period 3), does not readily form long polymers due to it having d-orbitals which favour silicon-oxygen linkages. Consequently, silicon tends to form silanes and silicones polymers, but only to a given size due to steric hindrance of the polymer structure. It is for this reason that any possible extra-terrestrial life (if it exists) on any exoplanets (include those recently discovery by either radial-velocity or transit methods – see the Kepler satellite) will always be carbon based rather than silicon based (despite science fiction’s general enthusiasm for silicon based life-forms).

Iron supplements for fatigue
Scott Gavura on September 27, 2012
Link
How are you feeling today? Tired? Is it your active lifestyle wearing you down? Or is it a sign of something more serious? Complaints about fatigue seem ubiquitous. Perhaps it’s a product of a culture with little downtime. Yet from a medical perspective, fatigue can’t be dismissed with a simple instruction to “get more sleep”. When approached in the pharmacy, I take the perspective that anyone actively seeking advice on treatment probably needs a medical assessment. That’s not something I can offer, but I try to impress upon patients the importance of finding the cause, rather than reaching for any quick fix that may be for sale. (5-hour Energy, anyone?) And I can use the opportunity to discuss the appropriate role of supplements for treating fatigue.
I’ve elaborated in other posts why I’m not a fan of routine vitamin or mineral supplementation in the absence of any established need – the risks with some supplements are concerning, and the benefits haven’t been clearly established. Recently I’ve had a my position on supplements questioned by people interested in taking iron supplements to treat fatigue. They’re correct, to a degree: fatigue and iron are usually linked. Iron deficiency is the most common nutritional deficiency in the world. And iron deficiency is the major cause of anemia. The statistics are remarkable – in developing countries, 50% of pregnant women and 40% of children are anemic, a result of iron deficiency as well as other illnesses. In contrast with other vitamin deficiencies, anemia is also present to a significant extent in developed countries: 19% of the population in the Americas and 10% in Europe. The incidence is highest in women, particularly pregnant, and youth.
So why not a trial of iron supplements? “Iron loss explains why you’re tired all the time,” suggested a recent Atlantic article. That statement was based on a recent paper that does suggest that iron supplements may reduce fatigue – even in those without anemia. But is supplementation warranted on this basis? In some cases, it could be the wrong approach. Fatigue is a non-specific symptom, so serious causes should be ruled out before thinking about a treatment plan. Medical or psychiatric issues can cause fatigue – depression among the most common. Medications are also a significant (and frequently overlooked) direct cause of fatigue. The long list include antihistamines, opioid narcotics, muscle relaxants, and some antidepressants. Chronic fatigue syndrome is a rare but disabling cause of fatigue that may also be a consideration.
A medical workup will usually include a physical examination and laboratory investigations to rule out specific causes like thyroid dysfunction, cancer, heart failure and other conditions. Laboratory tests will always include hemoglobin and ferritin, two measure to evaluate the iron stores in the blood. The body holds about 4 grams of iron. Two grams is within the hemoglobin of red blood cells, and most of the remainder is stored in ferritin. Low iron can be spotted here.
If there is a confirmation of anemia present, there’s further considerations. Anemia is usually due to increased iron losses, or decreased intake. Fixing the deficiency, without identifying the cause, is foolish. Iron loss can be a signal of diseases like cancer. Or it may be something more straightforward. Pregnancy and menstruation are common causes. Celiac disease is also possible. Reduced absorption is a less common cause of anemia, but several drugs can make matters worse.
When causes of loss have been investigated, treatment considerations are more straightforward. For most people, oral iron supplements are effective, inexpensive, and (generally) well tolerated. When iron supplements are necessary, here are a few considerations:
    • The degree to which the different types of supplements cause side effects seems to be directly related to the amount of elemental iron per pill. Slow release and other forms of iron are more expensive and may be better tolerated, but may also contain less iron.
    • Iron should be taken on a empty stomach to maximize absorption – but few people seem to tolerate this. It’s a trade off, and you need to determine what works. Better to find a dosing schedule that you’ll stick to, rather than making yourself miserable with supplements, or quitting prematurely.
    • For maximal tolerance and absorption, spread doses out throughout the day.
    • Vitamin C may help iron supplement absorption. Taking a tablet with each dose can be considered. Some prefer orange juice instead.
    • Liquid iron supplements are popular, but they’re an inconvenient and expensive way to replace iron stores. I usually suggest generic iron tablets to start, with liquids only where all other dosage forms have failed.
    • Your stools will turn black. Don’t be frightened. Iron isn’t fully absorbed.
    • To replace low iron levels, you should aim for 150-200 mg of elemental iron per day. 300mg per day is about the maximum that people can tolerate.
There is some data suggesting linkages between iron levels and cancer, and others that draw associations between high iron intake and cardiovascular disease. While the relationships are unclear, it suggests that supplementation in the absence of deficiency may not be risk free. Iron is toxic and even fatal at high doses. In children, excessive iron is much more toxic than many prescription drugs, and is a leading cause of poisoning death. (Ten adult-strength ferrous sulfate tablets can kill a small child.) With respect to daily supplementation in the absence of a deficiency, adults taking up to 45 mg of elemental iron per day is generally considered safe. Multivitamins for pregnant women will usually a small amount of iron, to offset pregnancy-related losses.
Iron stores can be depleted before any anemia is present. It’s traditionally thought the fatigue related to iron deficiency is due to anemia. That hypothesis was tested in a study published in the CMAJ earlier this year which randomized 198 premenopausal women complaining of fatigue, with low ferritin, but not anemia, to iron supplements or placebo. By Vaucher and associates, it’s entitled, Effect of iron supplementation on fatigue in nonanemic menstruating women with low ferritin: a randomized controlled trial. All other causes of anemia had to have been ruled out in order to participate. The two treatment groups were comparable with the notable exception that the “iron” group had more women with significantly lowered hemoglobin or ferritin. However, mean values were similar. Also notably the study was sponsored by the manufacturer of the iron supplement studied.
The treatment consisted of 80mg/day of elemental iron (packaged as a slow-release tablet combined with Vitamin C) for 12 weeks. Both groups improved with treatment, as evaluated by a validated scale that measures fatigue with a score of 0-40. Given fatigue can wax and wane, it’s possible that they entered the study at a more fatigued point, and simply improved with time. There was a modest improvement over placebo in the iron group: Women taking iron reported a net improvement of 3.5 points over placebo, which was barely statistically significant. And given the subtle differences between the groups, however, I’m not convinced it’s relevant. So while this is being heralded by purveyors as a 50% improvement, whether it’s a real and meaningful improvement is difficult to say. In a post-hoc analysis , the authors estimate a number needed to treat of 10, suggesting that 10 women reporting significant fatigue need to be treated for 12 weeks in order for one woman to experience less fatigue after 12 weeks. Not that impressive. In contrast to the subjective reports of fatigue, objective measures all improved as expected, including ferritin, hemoglobin, and other. Blinding seems to have been maintained – both groups had equal amounts of gastrointestinal discomfort. But given iron stains the stool black, it’s not clear why they didn’t ask participants to guess their allocation. And overall, the treatment was well tolerated. The bottom line from this study seems to be that iron supplements in the absence of anemia restore biochemical measures, but their effect on fatigue is modest.
One group that asks me about iron frequently are marathon runners – because I’m a runner too. Running has been associated with iron loss for decades, so I’m often questioned about supplements to prevent any possible anemia. The data suggests that iron deficiency in male runners is rare, so supplementation in the absence of a known deficiency is not advisable. For female athletes, deficiency and anemia is more common. Whether this justifies routine screening is unclear, but my advice to athletes and non-athletes who are concerned about iron is the same: Maximize the consumption of iron in the diet by ensuring a regular intake of iron-rich foods. Meat products provide “heme iron” which is well absorbed, and “non-heme-iron”, which is not. Plants only contain non-heme-iron. Vegetarians, particularly females, and especially vegetarian female athletes, must carefully monitor their diets to ensure they’re consuming enough iron.
Conclusion
Fatigue can be caused by an array of conditions. Iron deficiency is a common cause, though whether iron supplements offer benefit in the absence of anemia remains to be established. Children and women, particularly pregnant women, need adequate iron in their diet. While low-dose supplements are considered safe and may be helpful in meeting daily requirements, specific supplementation isn’t necessary or advisable in the absence of a clear deficiency. And just because it’s a supplement doesn’t mean it can’t be harmful. Iron supplements can be toxic in children, and should be stored like any other potential poison.
ReferenceVaucher, P., Druais, P.L., Waldvogel, S. & Favrat, B. (2012). Effect of iron supplementation on fatigue in nonanemic menstruating women with low ferritin: a randomized controlled trial, Canadian Medical Association Journal, 184 (11) 1254. DOI: 10.1503/cmaj.110950

Pink Himalayan Sea Salt: An Update
The claims of health benefits from pink Himalayan sea salt are not supported by a shred of evidence. In fact, its vaunted “84 trace minerals and elements” include several poisons and many radioactive elements.
Harriet Hall on January 31, 2017
Link

In 2014 I wrote an article about salt in which I disparaged Himalayan pink salt. Perhaps I didn’t disparage it enough. It is still wildly popular, and egregious lies are still being told about it. Its proponents now claim that a double-blind placebo-controlled study has proved that it has health benefits. They are wrong: that study doesn’t prove any such thing!
What? Sea salt in the Himalayas?
Yes, the salt beds were deposited from ancient oceans 250 million years ago and the ocean layers were uplifted when the Himalayas formed. They were covered by lava and were enveloped in ice and snow for millennia. The salt was protected from modern day pollution and preserved in an untouched, pristine environment. So buzz words like natural, unpolluted, pure, and ancient come to mind and appeal to the gullible.
Why pink?
The color is due to impurities. Pure sodium chloride is white. It is ironic that pink Himalayan sea salt is advertised as “The purest salt available today.” Its very color belies that claim.
What health benefits are claimed?
It is alleged to store vibrational energy and to provide many specific health benefits. Here’s a typical list of claims:
    • Aids in vascular health
    • Supports healthy lungs and respiratory function
    • Promotes a stable pH balance within the cells
    • Reduces the signs of aging
    • Promotes healthy sleep patterns
    • Increases libido
    • Prevents muscle cramps
    • Increases hydration
    • Strengthen bones
    • Lowers blood pressure
    • Improves circulation
    • Detoxifies the body of heavy metals
There is no evidence for these claims. They are speculations based on findings about larger amounts of minerals that are present only in minute amounts in pink Himalayan salt.
Mercola makes similar health claims and sells his own brand in which the:
array of elements forms a compound in which each molecule is interconnected. The connectedness allows the vibrational component of the 84 trace elements present in their natural mineral form in the salt to be in harmony with each other and adds to the ability to promote a healthy balance.
That’s pure pseudoscientific piffle.
It is also recommended for bathing and for use in a salt lamp to improve air quality and release negative ions, providing various health benefits such as taming allergies and asthma, boosting energy levels, and treating depression. There is no evidence that these lamps produce negative ions or improve your health. Even Snopes has pronounced the claims false.
84 trace minerals: so what?
Pink Himalayan sea salt is advertised to contain “the 84 trace minerals valuable to the body.” Naïve customers assume that more is better, and that we need more trace nutrients, so those 84 minerals ought to make pink Himalayan salt healthier than regular salt. That assumption is completely misguided.
Most sources list far fewer trace minerals and elements in the human body, from 41 to 60, some in barely detectable amounts. And many of those 60 are toxic and radioactive, not only useless to human physiology but harmful. Radioactive elements like uranium can be detected in trace amounts in the human body, but they should be considered contaminants, not useful nutrients.
I went back and looked at the spectral analysis. It is readily available online and reading it is illuminating. Only 15 minerals are known to play important roles in biological processes, and seven others are considered ““possibly essential but not confirmed.” By my count, only about a quarter of the minerals in Himalayan pink salt are nutrients that the human body can or might be able to use. The other three quarters are not recognized nutrients and would be better classified as contaminants. They have no known health benefits, and many of them are known to be harmful. The list includes many poisons like mercury, arsenic, lead, and thallium. It includes radioactive elements: radium, uranium, polonium, plutonium, and many others. Radiation causes cancer, and even tiny amounts are potentially harmful. The amounts of most of them are listed as less than a certain amount, from <1 ppm to <0.001 ppm, which could mean anything. It could mean there is none present, but bragging about the 84 minerals contained in pink Himalayan sea salt means the company is claiming all 84 are present.
Ironically, two minerals on the list, technetium and promethium, are listed as unstable artificial isotopes! No amount is given, presumably because they decay to something else before they can be measured. How do you suppose these manmade elements found their way into that pure, natural, pristine, ancient Himalayan sea salt? The entire analysis is a tribute to how good our labs have gotten at detecting minuscule levels of contaminants that can be found everywhere in our environment. Some of the amounts measured are less than one part per billion.
Even for the acknowledged nutrients, the amounts in sea salt are not enough to correct a nutritional deficiency if a deficiency exists; and if you are not deficient and already have obtained (for instance) all the magnesium atoms your body can use from trace amounts in your diet, adding a few extra magnesium atoms from sea salt wouldn’t be expected to improve your health in any way.
The study
The study they cite is described on the Himalayan Crystal Salt website. It was a 30 day double-blind placebo-controlled trial with 70 participants. 50 subjects were given a Himalayan Crystal Salt solution and told to take one teaspoon mixed into 8 oz of purified water upon rising. 20 subjects served as a control group and were given a placebo solution of a generic sea salt.
This does not appear to be a study published in a peer-reviewed journal. It is not listed on PubMed. They don’t provide a citation, title, or authors’ names. And their findings have not been replicated elsewhere; most published studies turn out to be wrong, so we should never believe a single study in isolation. They mention one corroborating reference: the book Water and Salt: The Essence of Life, which apparently offers only anecdotal patient reports. Neither the book nor the study constitute scientific evidence of health benefits.
The study used an “Optimal Wellness Test” that is computer-based and relies on a combination of 39 tests run on non-fasting urine and non-fasting saliva. The “Optimal Wellness Test” has not been validated and is not used anywhere except at Fenestra Labs, a questionable organization. RationalWiki characterizes Fenestra as a company that specializes in clinical trials for alternative medicine practitioners “in the cause of woo-laundering.” And the study allegedly found improvements only in the test’s measures of “mineralization, oxidative stress, and hydration.” Improvements in lab numbers on a questionable test are not indications of meaningful improvements in human health. Do people who use sea salt live longer, have fewer heart attacks, have fewer colds? Do their wounds heal faster? Are they less likely to develop cancer? How could we possibly know they are “healthier”? They measured blood pressures 3 times during the study, and since they didn’t comment on the results, we can assume that they were not even able to show that blood pressures went down, one of the benefits claimed for the product.
What about taste?
Even the claims that it tastes better are open to question. You can’t really know if it tastes better until you do a blind taste test. Humans are notoriously good at fooling themselves when they think they know what they are getting. For instance, there was a study where they put the same wine in two bottles, identical except for the price tag, and subjects consistently said they preferred the taste of the wine in the bottle with the higher price tag. I would be very surprised if the average person could distinguish between food prepared with Himalayan salt and regular salt.
Even if it tasted better, would it taste enough better to justify the much higher price and the possible risks of exposure to radiation and poisons?
Conclusion: silliness, not science
There is no evidence that pink Himalayan sea salt is healthier than regular table salt; if anything, there is reason to suspect it might be less healthy. It’s not “pure;” it’s full of contaminants. Its popularity is a triumph of marketing over science and common sense.

Zapping a Cold with Copper
Will an overpriced piece of copper prevent or treat the common cold? The science is not there.
Steven Novella on November 13, 2019
Link

Can you prevent or stop a common cold just with copper? Usually when an article asks an upfront question like that the answer is no. In this case the answer is – maybe, well, it’s complicated. The seller of CopperZap would like you to think that it does, however. On their website they proclaim, “New research indicates you can stop a cold naturally before it starts.” The site is also loaded with anecdotes, such as, “Seven years without a cold. – Inventor Dr. Doug Cornell, PhD.
What did Dr. Doug invent? A chunk of copper. It is shaped into a convenient wand that can nicely fit up your nose, which is the intended function. For this convenience he charges $69.95, for what looks like less than $1 worth of copper (currently $2.65 per pound). Can simple copper prevent a cold? It certainly sounds like a classic crank medical device, like copper bracelets and magnetic wraps. But there is some actual science behind these claims, just insufficient to justify the specific claims being made.
There are various kinds of medical pseudoscience we encounter. Sometimes the alleged intervention is spiritual in nature, or it is basically some kind of magic (or might as well be). Homeopathy, for example, is essentially witchcraft, with magic potions that have zero basis in reality. But a lot of modern snake oil is based on some science. This is extremely useful for marketing, because you can cite the relevant science and pretend to be all legitimate. What makes such products snake oil is that they are making claims that go well beyond the existing science. Typically this amounts to taking basic science or pre-clinical evidence and then skipping over decades of clinical research to make specific unsupported clinical claims.
This can superficially seem reasonable, especially to those without medical expertise, but even many experts who should know better fall for this fallacy. If, for example, a certain substance increases a marker of immune activity in a petri dish, it seems reasonable to extrapolate to the hypothesis that it may increase immune activity in an organism and help fight infections or cancer.
However, such simplistic (if compelling) extrapolations have a very poor track record. In one review, only 1% of such basic science mechanisms led to a treatment even decades later. The problem is – there is a lot that can go wrong when leaping from the petri dish to the clinic. First, markers are just that – markers. They are something we can measure that we think indicates an underlying process, which is what we are really interested in. But markers may not indicate what we think. They may be a byproduct, and not the process itself.
But even if we are measuring something useful more directly, like killing cancer cells or viruses, a petri dish is not a full biological organism. Creatures are complex dynamic homeostatic systems. These systems are not easily manipulated in a positive way, and it is horrifically complex to predict the net effect of any intervention in a living system. You have to study the effect itself to really know.
There are also some practical limitations, one being bioavailability. If you are dripping a substance directly onto cells in culture that does not predict what will happen when you eat the same substance. Will it get absorbed, will it go to the part of the body where it is needed, in what concentration, and will it be inactivated in some way along the way? There are all points of potential failure.
Also, are there any unintended negative effects? What is the balance of benefit to side effects? What is the dose-response curve of benefit vs toxicity? What about long-term effects, or interactions with other interventions or disease states?
This is where clinical research comes in. Ideally we should have some reason to think that an intervention will have a specific positive effect, either from basic science or clinical observation. Then we conduct carefully designed rigorous clinical trials to evaluate all the questions above. Again – only a tiny portion of good ideas make it all the way through this clinical gauntlet to become a useful medical treatment.
Or – you can take a basic science or anecdotal observation, skip over the clinical research that would be necessary to know if it actually works, and go straight to marketing. That is apparently what Dr. Doug did (by the way, that PhD is in social psychology).
So what does the science at this point actually say? The basic claim that metallic copper kills viruses (and bacteria) on contact is actually true. There are now several studies indicating that copper is a “contact killer” of many microorganisms and potential pathogens. It seems that copper ions released from the surface create powerful oxygen free radicals will destroy cell membranes and DNA. Copper can bind proteins and inactivate them, and interfere with nutrients.
Alloys of copper are also effective, but it appears that the more pure the copper the more quickly it kills. Zinc has similar but less robust activity. This means that brass, which is a copper zinc alloy, has good antimicrobial activity, which is probably good news for the brass section of the orchestra.
Based on current evidence, in fact, it is reasonable to recommend copper surfaces for high germ areas, like hospitals. It might even be reasonable to have copper covered counters and sinks in your bathroom. But even this more direct extrapolation should be studied – because the final piece to the puzzle when going from basic science to clinical claims is this – is the observed effect clinically relevant? Does it actually help people?
In fact, when studied, having copper surfaces in the hospital does significantly reduce the rate of hospital acquired infections. This evidence is still preliminary, but is sufficient to take it further. As more extensive use of copper in hospitals is used, it should be tracked to measure the real effect size and also monitor for any unintended effects.
What about copper in the home? I could find no data on this. This is not a no-brainer, because copper surfaces may simply be unnecessary in a home setting. It may even have a net negative effect by causing complacency – people may not clean their surfaces as well because they are relying on the copper.
There are also no published studies looking at placing copper in your nose to abort or prevent a cold. This is a huge stretch for a few reasons. One is that the virus may already be too deep in the tissue for copper to work. The studies show that bacteria and viruses sitting right on top of the copper are killed, but this may not apply to viruses in tissue. This is a bioavailability problem.
Also, is the contact area sufficient? How much of the nose membrane do you have to touch, and how deep? What are the dangers of having people put a copper wand deep into their nasal passages? Finally – what duration is sufficient? The evidence does show that germs can die within minutes, but how long will it take in the nose, and how much of the virus or bacteria do you need to kill to make a clinical difference? Will it take five minutes, 10, an hour? Do you have to do each nostril for this time, with how many applications? These are the exact questions a clinical trial could answer.
I always like to hit the “science” tab on websites selling dubious products. In this case, as I would predict, there is a lot of discussion of the basic science (which is not the part that is in doubt). Clinically, there are no published peer-reviewed studies. All they have are in-house studies which are unblinded and therefore anecdotal.In other words – there is no real clinical evidence. I could not find any in several searches, and it is safe to assume that if such studies existed and were positive they would be prominently featured on the website.
My final assessment is that the copper zapper is another “snake oil” type product with unsupported clinical claims. The basic science is real, however, and the idea is not entirely unreasonable, but we would need to do clinical trials to answer all the practical questions I listed above.Also – the $69.95 price tag, in my subjective opinion, is a rip-off. It’s a piece of copper. If you want to put copper up your nose in the hopes it will save you from a cold, then go onto Amazon or Etsy and buy a small copper rod for 2-3 dollars.
In one picture on the website they show someone holding the wand against a cold sore. This is even less plausible, as killing any virus on the surface is unlikely to have much effect. But I couldn’t help thinking that you could literally just be holding a penny against the cold sore. There, I just saved you $69.94.

GLUCOSAMINE

Knee Osteoarthritis: Thumbs Down for Acupuncture and Glucosamine
One more time: acupuncture and glucosamine are useless for osteoarthritis.
Harriet Hall on June 11, 2013
Link
Osteoarthritis is the “wear and tear” kind of arthritis that many of us develop as we get older. Cartilage becomes less resilient with age, collagen can degenerate, and inflammation and new bone outgrowths (osteophytes) can occur. This leads to pain, crepitus (Rice Krispie type crackling noises with movement), swelling and fluid accumulation in the joints (effusion), and can severely limit activity for some patients. Patellofemoral pain is one of the most common of the repetitive strain injuries and is like an early onset of arthritis.
Since knee osteoarthritis is such a ubiquitous annoyance, home remedies and CAM offerings abound. Previously we have covered a number of CAM options on this blog, including glucosamine, acupuncture, and several others. The American Academy of Orthopaedic Surgeons (AAOS) has just issued a 1200 page report evaluating the evidence for various treatments for knee osteoarthritis short of total knee replacement surgery. A 13 page summary is available online. They have done the heavy lifting for us, reviewing all the available scientific studies for evidence of effectiveness. Here’s what the science says: (I’ve highlighted the ones where the evidence is strong.) 
     1.  Exercise – strong evidence for effectiveness
     2.  Weight loss – moderate evidence for
     3.  Acupuncture – strong evidence against
     4.  Physical agents (TENS, ultrasound, etc.) – inconclusive
     5.  Manual therapy (chiropractic, massage) – inconclusive
     6.  Valgus-directing force brace – inconclusive
     7.  Lateral wedge insoles – moderate evidence against
     8.  Glucosamine and chondroitin – strong evidence against
     9.  NSAIDs – strong evidence for
     10.  Acetaminophen, opioids, pain patches – inconclusive (this is particularly interesting since acetaminophen is the standard first-choice drug)
     11.  Intraarticular corticosteroid injections – inconclusive
     12.  Hyaluronic acid injections – strong evidence against (and if injections are ineffective, those oral diet supplements certainly don’t have a chance)
     13.  Growth factor injections and/or platelet-rich plasma – inconclusive
     14.  Needle lavage – moderate evidence against
     15.  Arthroscopy with lavage and debridement – strong evidence against
     16.  Partial meniscectomy in osteoarthritis patients with torn meniscus – inconclusive
     17.  Valgus-producing proximal tibial osteotomy – limited evidence
     18.  Free-floating interpositional device – no evidence; consensus against
They apparently didn’t think it was worthwhile even mentioning such things as copper bracelets, magnets, prayer, or supplements like boswellia. Or homeopathy!
Naturopaths and other critics of mainstream medicine claim that MDs don’t recommend lifestyle measures like exercise and weight loss, but here is a mainstream medical organization that clearly does, and even puts them first on its list. Critics who claim doctors are just out to make money, take note: if they were the evil money-grubbers some make them out to be, wouldn’t these surgeons want to promote income-generating arthroscopic lavage and debridement? Wouldn’t they want to suppress information about conservative treatments and keep patients in pain until they were desperate enough to consent to expensive joint replacement surgery? Gee, do you suppose maybe they really are just trying to do what’s best for their patients?
I was glad to see that the AAOS reached the same conclusions we did on SBM regarding acupuncture and glucosamine, but I wasn’t surprised. After all, we are looking at the same published evidence. Unbiased scientific minds think alike. Recommendations on other websites like WebMD and the Mayo Clinic still favor acupuncture and glucosamine. It will be interesting to see if they modify their websites in response to the AAOS report. I’m not holding my breath.
I was curious: if AAOS is an American Academy, why do they spell Orthopaedic the British way? I looked it up: Orthopaedic is the correct medical spelling! So thanks to the AAOS, I learned something about spelling as well as about knees.

Glucosamine Update
Harriet Hall on February 17, 2015
Link


Osteoarthritis, the “wear-and-tear” type of arthritis, affects a great many of us as we grow older. Knee pain is a common symptom. The diet supplements glucosamine and chondroitin have been proposed as a more “natural” treatment than pharmaceuticals, and they are components of a number of proprietary “joint health” formulations like Osteo Bi-Flex. The GAIT study (Glucosamine/Chondroitin Arthritis Intervention Trial), compared glucosamine, chondroitin, a combination of the two, and a pharmaceutical (celecoxib) to a placebo in patients with knee pain from osteoarthritis. The only one that worked better than placebo was celecoxib. I wrote about the GAIT trial in 2008. The study was reported in the media as both negative and positive. The positive reports emphasized the subgroup analysis: in one of ten subgroups, patients with moderate to severe pain, the combination of glucosamine and chondroitin outperformed placebo. But in the subgroup of patients with mild to moderate pain, it did not. The authors themselves commented that their study was not powered to draw any conclusions from subgroups and that further studies would be required. (The “power” of a study is a measure of its ability to show an association or relationship between two variables if such a relationship exists.) Now a further study with sufficient power claims to have confirmed the subgroup findings. This may encourage some people to try glucosamine/chondroitin, but I remain skeptical.
Contradictory evidence
Following the GAIT trial, there were several other studies showing that glucosamine was ineffective for osteoarthritis. There are other studies showing it is effective. There are a lot of studies out there, with varying quality. I think it’s fair to say the evidence is mixed and still questionable even when the new study is added into the mix. I was particularly impressed by a 2004 discontinuation study that followed-up on a group of patients who had had a positive response to glucosamine. It compared continuance of glucosamine with one half of the group to substitution with a placebo in the other; it found no difference in disease flares or any of the secondary outcomes they looked at. Pain is particularly susceptible to placebo responses, and studies of pain must be interpreted with more caution than studies with more objective outcomes. The American Academy of Orthopaedic Surgeons reviewed the evidence and recommended against the use of glucosamine, chondroitin, and the combination. They said:
Glucosamine and chondroitin sulfate have been extensively studied. Despite the availability of the literature, there is essentially no evidence that minimum clinically important outcomes have been achieved compared to placebo, whether evaluated alone or in combination.
The new study
The new study, “Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis“, was published in the Annals of the Rheumatic Diseases on Jan 14, 2015. The full text is available online. It was a randomized double-blind study of patients with moderate to severe knee pain from osteoarthritis. 264 patients were given a prescription drug sold in Europe that contains 400 mg chondroitin sulfate plus 500 mg glucosamine (taken 3 times daily) and 258 were given celecoxib, a non-steroidal anti-inflammatory drug (NSAID), in a dose of 200mg once daily, plus placebo capsules to provide the same number of pills. Celecoxib outperformed glucosamine/chondroitin for the first four months of treatment, but by 6 months there was no difference. They concluded that glucosamine/chondroitin was equivalent to celecoxib. The authors recognize that current evidence-based guidelines advise against glucosamine/chondroitin, but think their study supports its use in patients with cardiovascular or gastrointestinal conditions where NSAIDs are inadvisable.
Why I remain skeptical
A Medscape reporter contacted me about the new study because I had written a letter to the editor that was published in American Family Physician where I identified misconceptions about the GAIT trial. She asked me several questions, and in the resulting article she devoted two paragraphs to my answers. I expressed my reservations and said I would withhold judgment until the weight of evidence falls more clearly on one side or the other. In the comments to the Medscape article, a pathologist said:
I doubt that dietary glucosamine or chondroitin sulfate are absorbed from the gut as such. Further, human cartilage contains N-acetyl galactosamine, not glucosamine. Depending on source, the dietary CS may have a different structure than human CS. Finally, the cartilaginous glycosaminoglycan matrix is synthesized by the chondrocytes, and it is naive to assume that dietary supplements will “home” to that avascular tissue. It is all placebo effect, making lots of money for manufacturers.
I don’t know enough about that to comment on it, but I remain skeptical for several reasons of my own:
    • Neither drug alone has been shown effective, only the combination. A synergistic effect can’t be ruled out, but such an effect would be unusual.
    • Glucosamine and chondroitin are produced in the body in far greater amounts than the pills contain. Wallace Sampson, one of the founders of SBM, wrote: “Glucosamine is not an essential nutrient like a vitamin or an essential amino acid, for which small amounts make a large difference. How much difference could that small additional amount make? If glucosamine or chondroitin worked, this would be a medical first and worthy of a Nobel. It probably cannot work.”
    • Patients who responded continued to respond when their glucosamine was replaced by placebo.
    • I don’t know of any other medication for pain that is effective only for more severe pain and ineffective for less severe pain.
    • The study was done with a prescription formulation that is not available in the US; patients who buy it over the counter may not be getting the equivalent of the study drug.
    • Celecoxib was more effective in the first 4 months and was equally safe; I’d think most patients would want the faster-acting option.
Conclusion
Glucosamine/chondroitin might work for osteoarthritis, and might be worth trying in patients who can’t take NSAIDs, but the evidence is still far from clear. Based on the currently available evidence, I wouldn’t feel comfortable prescribing it or telling patients “it works;” but if a patient wanted to try it, I wouldn’t have any objections to a therapeutic trial. There don’t appear to be any worrisome side effects, and even if patients only had a placebo response, they might feel better.

   Does Glucosamine Really Work?
Harriet Hall
Link
Glucosamine and chondroitin, used separately or together, are among the more popular diet supplements. They are used widely for osteoarthritis, especially of the knee, and have been better studied than most other diet supplements. But do they really work?
The journal of my medical specialty, American Family Physician, recently published an article about the use of dietary supplements in osteoarthritis. They gave a “B” evidence rating to both glucosamine and chondroitin. This means there is inconsistent or limited-quality patient-oriented evidence. They recommended the use of glucosamine sulfate, saying, “Overall, the evidence supports the use of glucosamine sulfate for modestly reducing osteoarthritis symptoms and possibly slowing disease progression.” They did not exactly recommend chondroitin, although they said it “may provide modest benefit for some patients.”
I remain skeptical. And so does R. Barker Bausell, who devoted several pages of his book Snake Oil Science to an analysis of the research on glucosamine and chondroitin.
The American Family Physician recommendations were based largely on the results of meta-analyses. Meta-analyses are only as good as the studies they evaluate. Ioannidis has shown that published research findings are more likely to be false than true. It has been suggested that the Dona brand of glucosamine sulfate produced by the Rotta company showed positive results and that negative studies were done on other brands. But Bausell points out that trials involving the Dona brand were primarily older trials in non-English speaking countries where the percentage of positive studies tends to be higher. Those trials were superseded by better quality trials in the US, Canada, and the UK that were all negative.
An intriguing 2005 study looked at patients who were already taking glucosamine for knee osteoarthritis and who had experienced at least moderate relief of pain. They left half of the patients on the glucosamine and switched half to placebo. There was no difference in outcome.
The NEJM study in 2006 was the best-designed study yet. It deserves particular attention because it was reported in the press as both positive and negative! They originally hoped to look for an objective endpoint, joint-space narrowing, but they ended up measuring subjective pain relief instead. They tested 5 groups of patients on glucosamine, chondroitin, glucosamine and chondroitin together, a nonsteroidal anti-inflammatory drug (NSAID) or a placebo. The NSAID worked fastest and best, but not significantly so. None of the drugs worked significantly better than placebo. The placebo response rate was very high, which has been used to question the results, but which might also mean that there is a naturally high placebo response rate for this condition, which is known to involve fluctuations in severity over time.
The study was clearly negative, but when they broke the data from each of the 5 groups into 2 subgroups of patients with mild-to-moderate vs moderate-to-severe pain, they found one subgroup that showed significance: the group with moderate-to-severe pain that took both glucosamine and chondroitin. You might expect one out of ten subgroups to be falsely positive just by chance. Besides that, the results don’t make sense. I don’t know of any other treatment that is effective for more severe pain but not for lesser pain. And in previous studies, the combination of glucosamine and chondroitin had been no more effective than either supplement by itself. The authors themselves pointed out that their study was not designed to differentiate between those subgroups. so no clinical recommendations could be made on the basis of this finding.
Wallace Sampson, one of the other authors of this blog, has pointed out that the amount of glucosamine in the typical supplement dose is on the order of 1/1000th or 1/10,000th of the available glucosamine in the body, most of which is produced by the body itself. He says, “Glucosamine is not an essential nutrient like a vitamin or an essential amino acid, for which small amounts make a large difference. How much difference could that small additional amount make? If glucosamine or chondroitin worked, this would be a medical first and worthy of a Nobel. It probably cannot work.”
The existing evidence is compatible with the hypothesis that glucosamine and chondroitin work no better than placebo, and that the trials that seem to show otherwise are flawed for various reasons.
Critics will say that the evidence for glucosamine and chondroitin is as good as the evidence for many pharmaceuticals. That may be. Some pharmaceuticals may actually be no better than placebo. Rather than an argument for using glucosamine and chondroitin, this is an indication that we need to look as carefully at the evidence for pharmaceuticals as Bausell has looked at the evidence for glucosamine and chondroitin. When we look at any research, we should remember all the possible sources of bias in published results, and we should remember that meta-analyses are only as good as the studies they are analyzing.

   Glucosamine Update: A New Study and a New Product
Harriet Hall 
Link
When I recently wrote about glucosamine, I discussed the evidence up through the New England Journal of Medicine study of 2006, which I thought was a pretty definitive study showing that neither glucosamine, chondroitin or a combination of the two was more effective than placebo. Subsequent studies have continued to fuel the controversy. One 2007 study showed that glucosamine sulfate was better than placebo for knee osteoarthritis. Another 2007 study showed that glucosamine HCl and chondroitin, with or without exercise, were no better than placebo for knee osteoarthritis. Sources like the Natural Medicines Comprehensive Database believe the evidence favors glucosamine sulfate but not glucosamine hydrochloride.
A new study was published 19 February 2008 in the prestigious Annals of Internal Medicine. It is arguably the best study to date, and may shed some light on the controversy. Carried out in the Netherlands in a primary care setting, it studied 222 patients with hip osteoarthritis over a 2 year period. Half the patients took glucosamine sulfate 1500 mg a day; half took a placebo. They concluded that glucosamine sulfate was no better than placebo in reducing symptoms and progression of hip osteoarthritis.
Some of the highlights:
     1.  It was done with glucosamine sulfate, the form preferred by advocates.
     2.  It was independently funded, without pharmaceutical company or supplement manufacturer support.
     3.  It had adequate numbers of subjects (111 per group).
     4.  It had a low dropout rate.
     5.  It was carefully double-blinded.
     6.  At the end of the study they confirmed that patients had not been able to guess which group they were in.
     7.  The study lasted for 2 years, much longer than previous studies.
     8.  In addition to subjective (pain) endpoints, they measured an objective endpoint: joint space narrowing on x-ray. They tried to improve on the methods used for this measurement in previous studies, which had been questioned. They achieved excellent inter-observer agreement.
     9.  They did quality control checks to insure accurate dosage.
     10.  They followed the published guidelines for clinical trials in osteoarthritis as formulated by a task force of the Osteoarthritis Research Society over 16 months of deliberations.
     11.  It was published in one of the most prestigious peer-reviewed medical journals.
It seems to me that this study should put an end to the controversy. Previous research can be characterized as inconclusive, with 8 out of 15 trials showing no effect, and with higher quality trials less likely to show an effect. This study did its level best to avoid the pitfalls of previous studies and provide as definitive an answer as possible.
Of course, it won’t put an end to the controversy, because there are too many people who are invested (emotionally, financially or otherwise) in the idea that glucosamine works. They can always complain that maybe it works for knees but not for hips, or that a different dosage might have worked better, or that it works for some small sub-set of patients. There will always be “one more study” to do.
Rozendaal, R.M., et al, . (2008). Effect of Glucosamine Sulfate on Hip Osteoarthritis. Annals of Internal Medicine, 148(4), 268-277.
Part 2 – JointFlex Cream.
In another bizarre development, a cream containing glucosamine and chondroitin is now on the market - you simply rub it on wherever the pain is. The trademarked Fusome proprietary delivery system allows it to penetrate into the joint and work its magic. It offers instant relief and a money-back guarantee. I saw an ad for JointFlex in the newspaper and looked into the science behind its claims. There is one published study from Australia that supposedly supports its use.
The study, published in The Journal of Rheumatology in 2003, compared a topical preparation to placebo in 63 patients over an 8-week period. They concluded that it was effective in relieving pain in osteoarthritis of the knee, and improvement was evident within 4 weeks. The test cream contained glucosamine sulfate, chondroitin sulfate, shark cartilage, camphor and peppermint oil. The rationale for this mixture is not explained, but they claim chondroitin acts as a transfer agent for dermal drugs. The test cream also contained high efficiency emulsifiers, skin emollients, and micro-encapsulation of the active ingredients. The placebo cream used conventional skin emollients, petrolatum and mineral oil, conventional emulsifiers, and stearic acid and glycerol stearate rather than the proprietary technology. It also contained a lesser amount of peppermint oil. They comment that “there may have been some slight differences in the texture of the placebo and active creams” but they made no effort to ask patients which they thought they were getting, or to verify that the lesser amount of peppermint could not be used to identify the placebo. The endpoints were subjective. They made no effort to determine whether the active ingredients had actually penetrated into the joint. The study has not been replicated elsewhere.
In the first place, the quality of this research was inferior in almost every way to the study described above in Part 1. In the second place, the study appears to show that glucosamine and chondroitin are effective topically, but the marketer completely disregards that, even while using the study to validate its product!
The real surprise for me was the list of ingredients in JointFlex on the Natural Medicines Comprehensive Database website. Only one active ingredient is listed, and that is camphor 3.1%!! There is a long list of inactive ingredients: Acetylated lanolin, acrylates/C10-30, alkyl acrylate, crosspolymer, Aloe Vera, C12-15 alkyl benzoate, Chondroitin Sulfate, purified water, diazolidnyl urea, dimethicone, dimethiconol stearate, disodium EDTA, dl panthenol, Glucosamine Sulfate, glycerin, Glycerol stearate, glycosaminoglycans, hydroxylated lanolin, hydroxypropylene methylcellulose, lodopropynyl, butylcarbomate, methyl gluceth-20, methyl glucose, sesquistearate, Peppermint oil, polysorbate 20, Potassium carbomer, tocopheryl acetate.
I went back to the JointFlex website and noticed a strange disclaimer: “These nutrients have been added as part of the skin conditioning base. We believe that the healthier and moister the skin, the better we can deliver the active pain relieving ingredients [sic - the NMCD lists only one active ingredient] to the spot where they are needed most making JointFlex® effective at relieving pain. We do not make any other claims at this time regarding these nutrients.”
This is really weird. I don’t know what’s going on here, and I’m not sure I want to know. I can’t see my way to recommending glucosamine in any form until I see more credible evidence that it works.
Is doing more glucosamine studies a good use of our research dollars, or is it time to turn to more promising avenues of research?
REFERENCE:
Rozendaal, R.M., Koes, B.W., van Osch, G.V., Uitterlinden, E.J., Garling, E.H., Willemsen, S.P., Ginai, A.Z., Verhaar, J.A., Weinans, H., Bierma-Zeinstra, S.M. (2008). Effect of Glucosamine Sulfate on Hip Osteoarthritis. Annals of Internal Medicine, 148(4), 268-277.

   Glucosamine: The Unsinkable Rubber Duck
Harriet Hall
Link
Glucosamine is widely used for osteoarthritis pain. It is not as impossible as homeopathy, but its rationale is improbable. As I explained in a previous post,
Wallace Sampson, one of the other authors of this blog, has pointed out that the amount of glucosamine in the typical supplement dose is on the order of 1/1000th to 1/10,000th of the available glucosamine in the body, most of which is produced by the body itself. He says, “Glucosamine is not an essential nutrient like a vitamin or an essential amino acid, for which small amounts make a large difference. How much difference could that small additional amount make? If glucosamine or chondroitin worked, this would be a medical first and worthy of a Nobel. It probably cannot work.”
Nevertheless, glucosamine (alone or with chondroitin) is widely used, and there are some supporting studies. But they are trumped by a number of well-designed studies that show it works no better than placebo, as well as a study showing that patients who had allegedly responded to glucosamine couldn’t tell the difference when their pills were replaced with placebos. The GAIT trial was a large, well-designed, multicenter study published in The New England Journal of Medicine that showed no effect in knee osteoarthritis. A subsequent study of hip osteoarthritis also showed it worked no better than placebo.
A new study shows that glucosamine works no better than placebo for osteoarthritis pain in the low back. It was published in the JAMA: Effect of Glucosamine on Pain-Related Disability in Patients with Chronic Low Back Pain and Degenerative Lumbar Osteoarthritis: A Randomized Controlled Trial, by Wilkens et al.
It is well-designed, randomized and double blind, with 250 subjects, a low drop-out rate, a 6 month duration with a one year follow-up, appropriate clinical criteria for improvement (disability, pain, quality of life, use of rescue medications), intention-to-treat analysis, and even an “exit poll” to insure that blinding had been effective, that patients couldn’t guess which group they were in. It used the doses of glucosamine sulfate that had been called for by critics of previous studies. It was done in Norway, where glucosamine is a prescription drug (in the US it is marketed as a diet supplement under DSHEA regulations so there is a greater possibility of dosage variations and impurities); it was independently funded, with no involvement of industry.
Although no one study can be definitive, this one is pretty convincing when viewed in the context of all the other published data. The authors rightly conclude that glucosamine doesn’t work any better than placebo, but they go on to say some rather strange things. They say it should not be recommended for “all” patients with osteoarthritic low back pain, implying that it might still be recommended for “some” patients. But if so, which patients and according to what criteria? They seem strangely defensive. They stress that glucosamine caused no side effects and could be used safely. They suggest that glucosamine might work for a subset of patients or for joints other than the spine. For instance, the knee. But another new study has confirmed that it is ineffective for the knee.
I don’t understand this. If they had found that a new antibiotic worked no better than a placebo for pneumococcal pneumonia, would they say it should not be recommended for “all” patients with pneumococcal pneumonia or would they simply say it should not be used for pneumococcal pneumonia? Would they speculate that it might work for a small subset of pneumonia patients or for infections in other parts of the body? Probably not. They thought glucosamine worked; they tested it; it didn’t. Why not just say so? Are they letting a prior belief in glucosamine influence their thinking? Unbiased science-based researchers are not usually so hesitant to give up on a treatment that repeatedly fails to pass tests.
I must be psychic, because I had predicted this in a post I wrote two and a half years ago (about the study showing that glucosamine didn’t work for hip pain). I said:
They can always complain that maybe it works for knees but not for hips, or that a different dosage might have worked better, or that it works for some small sub-set of patients. There will always be “one more study” to do.
This new study confirms my opinion that we shouldn’t spend any more research dollars doing “one more study” on glucosamine.

Hyaluronic Acid Adulteration
There may be undisclosed ingredients in your hyaluronic acid supplement.
Scott Gavura on May 7, 2026
Link

Some supplements marketed as “hyaluronic acid” don’t just contain hyaluronic acid. According to a recent release from the U.S. Food and Drug Administration, several have been found to contain undisclosed prescription drugs—ingredients that consumers were never informed about, and that could pose serious health risks.
Hyaluronic acid itself isn’t controversial. It’s a naturally occurring molecule found throughout the body, particularly in the skin, joints, and eyes, where it helps retain water and maintain tissue lubrication. It also has legitimate medical uses: formulations regulated by the FDA are used in joint injections for osteoarthritis, as dermal fillers, and in ophthalmic procedures. But those evidence-based use with prescription brands are a long way from the over-the-counter supplements now being sold for skin health, joint pain, and general wellness and marketed as “hyaluronic acid”.
Over-the-counter, oral hyaluronic acid has much less evidence to support its use. While claimed to reduce wrinkles or relieve joint pain, the evidence supporting these claims is limited. Most studies are small, often poorly designed and report modest effects on subjective outcomes that may not translate into meaningful clinical benefit.
There’s also a basic biological question: oral hyaluronic acid may not be particularly bioavailable, meaning available in the body after ingestion. It is a large molecule that appears to be broken down during digestion, and there is limited evidence showing meaningful absorption into the bloodstream after oral consumption. Even when present in circulation, hyaluronic acid is cleared rapidly, making it uncertain how much, if any, could reach tissues or joints in an active form and meaningful amount.
Taken together, the clinical evidence does not instill much confidence. Even when studies report benefits, it remains unclear whether oral hyaluronic acid itself is responsible for the observed effects, or the result is a function of a trial of weak methodological quality. And if a supplement with questionable systemic activity appears to produce noticeable, even dramatic results, but inconsistently, it raises the possibility that something else in the product may be contributing.
The FDA release notes that some products marketed as hyaluronic acid supplements contained active pharmaceutical ingredients that were not disclosed on the label. As I have noted in past posts, supplements cannot be used safely or with evidence-based intent, or alongside other medications, if the label is inaccurate. And including products like non-steroidal anti inflammatory drugs, or corticosteroids is probably not an accident – it’s more likely there design, to make users feel better. And these ingredients have significant potential toxicities. Consumers could inadvertently put themselves at risk of side effects, drug interactions, allergic reactions, or even negatively affect existing medical conditions. Incredibly, if you look at the warnings for Umary, it appears the manufacturer keeps marketing an adulterated product and the FDA keeps warning about it, again and again.
By (legislative) design, dietary supplements marketed in the United States can be sold without meaningful evidence (or an evaluation) demonstrating safety, effectiveness, or even accurate labeling. In a competitive market where consumers expect noticeable effects, there is an obvious incentive to add substances that make products appear to “work,” even if that’s by other means.
Marketing and social media typically position supplements as gentle, natural, and inherently safe alternatives to medicines. But products sold with minimal evidence and limited regulatory oversight deserve our skepticism, particularly when they make dramatic claims or seem to work surprisingly well. (That statement arguably applies to all dietary supplements, not just hyaluronic acid products).
Unfortunately, when you buy a dietary supplement in the USA, you are not just accepting uncertainty about whether it works. You are also accepting some risk about what’s actually in the bottle.

Collagen: An implausible supplement for joint pain
Scott Gavura on November 10, 2011
Link
I’m one of those odd people that enjoys distance running. I end up spending a lot of time in the company of other runners. And when we’re not running, we’re usually griping about our running injuries. As the cohort that I run with ages, the injuries are getting more prevalent. Besides the acute conditions, the chronic problems are starting to appear. Our osteoarthritis years are here.
As the available pharmacist, I get a lot of questions about joint pain. What’s reassuring, I tell them, is that they shouldn’t blame running. Osteoarthritis is common — the most frequent cause of joint pain. For some, it starts in our twenties, and by our seventies, osteoarthritis is virtually certain. Regardless of your level of exercise, the passage of time means the classic osteoarthritis symptoms — joint pain and morning stiffness, that worsens over time.
Osteoarthritis progresses gradually. Blame biomechanics and biochemistry. It starts with a breakdown of the cartilage matrix. Stage 2 progresses to erosion of the cartilage and a release of collagen fragments. Stage 3 is a chronic inflammatory response. The goals of treatment are to reduce inflammation and pain, and stop progressive disease. There’s no drug therapy that’s been show to actually improve joint function. Reduce pain, or slow inflammation, yes. Analgesics, like Tylenol, and anti-inflammatories are mainstays. But repair damage? Sorry: you lose it, it’s gone. Chondrocytes don’t seem to be able to repair the overall matrix — which is made mainly of collagen.
I don’t advise people with joint pain and morning stiffness to stop running. (It’s futile to suggest this to a runner, anyway.) The idea you can “wear out” your joints is is a popular image, but it’s inaccurate. In most cases exercise can continue — exercise doesn’t seem to accelerate the rate of osteoarthritis development. When the pain is persistent, I’ll suggest a physician evaluation, and describe some non-drug and non-prescription approaches to symptom management that might be appropriate.
I’m prepared now, for the inevitable question that follows: “But what about supplements? What do you think of X?” Glucosamine is a common inquiry (discussed at length here) as is chondroitin (which it is often co-packaged with). As with most supplements, their popularity is not related to good clinical evidence. Rather it seems to be secondary to perceptions of efficacy, driven by lots of anecdotes and general awareness. But the message that it’s ineffective may be getting out — I’m getting fewer inquiries about it these days. The market has shifted, and there are new products on the shelves for those with sore joints.
The latest supplement trend for joint pain may be collagen. Collagen supplements have been around for years, and their traditional popularity has been its purported effects on skin and nails. There are regional trends, with collagen-rich foods and even restaurants gaining popularity in Japan. (Anyone want a meal of pig’s feet?) The enthusiasm for collagen is now being more actively tapped for the arthritis market – perhaps it’s a way to drive demand among all ages.
Genacol, a collagen supplement, is currently being actively marketed here in Toronto, and seemingly distributed worldwide. This particular brand caught my attention not just because I see the giant image of Indy care driver and spokesperson Alex Tagliani) everywhere, but because of an explicit efficacy claim made in the advertisements and on the website: “Scientifically proven to reduce joint pain.” There’s no other supplement with convincing evidence for any type joint pain. So I went looking for the proof.
Why collagen, and what does it have to do with our joints? Collagen is the major component of connective tissue in the body — it’s about a quarter of our body mass, and is found in skin, muscle, tendons, etc. Hence the pig’s feet. All animals are mainly collagen: it’s the most abundant protein in the animal kingdom. Your leather coat? Think of it as a collagen coat. In fact, that’s where your Genacol is coming from: the collagen source for this particular supplement is European bovine skin collagen.
If we don’t have enough collagen, we’re in big trouble. There’s several different types in the body, each with their own role. Remember that M. Night Shyamalan movie Unbreakable with Bruce Willis and Samuel L. Jackson? Jackson’s character had Lobstein syndrome (osteogenesis imperfecta), a congenital disease that results in the failure to produce type 1 collagen, which results in exceptionally brittle bones.
Or think of scurvy — now rare, but once the worst thing about extended sea voyages. Vitamin C is a necessary cofactor for collagen synthesis. Without it, multiple systems are affected, and biological disaster ensues, starting with your teeth falling out. History’s first clinical trial was performed by James Lind, a British Royal Navy physician, to compare a variety of scurvy cures, including the one that worked: fresh lemons.
Both scurvy and Lobstein’s are basically collagen shortage diseases. But, interestingly, guess what doesn’t work for either scurvy or Lobstein’s? Eating collagen. That’s because collagen is a protein: a triple-helix, long chain protein. It’s the product of an elaborate synthesis process that occurs throughout the body. When we consume collagen, usually in the form of food, the long chain proteins are broken down during digestion to their original amino acids. Only then can they be absorbed. Once absorbed, these amino acids are available as building blocks to support collagen synthesis throughout the body. So from a dietary perspective, your body doesn’t care (and can’t tell) if you ate a collagen supplement, cheese, quinoa, beef, or chick peas — they’re all sources of protein, and indistinguishable by the time they hit the bloodstream. The body doesn’t treat amino acids derived from collagen any differently than any other protein source. For this reason, the idea that collagen supplementation can be an effective treatment for joint pain, osteoarthritis, or any other condition, is highly implausible, if not impossible in principle.
But about that proof …
The company links to a press release with its scientific evidence for Genacol. Two clinical trials are described. A search of PubMed reveals neither have been published. That doesn’t prevent the efficacy claims:
With Genacol, a “statistically significant” beneficial effect with relation to pain was observed in the subjects: the best result that can be obtained during a clinical trial. “These two new trials demonstrate without a doubt that millions of people suffer less with Genacol, proving the impeccable quality of the products under this brand,” says Guy Michaud, President of Groupe Genacol.
Not quite. Setting aside the grandiose claims, statistical significance isn’t enough — we want clinical significance. A tiny change in pain may be enough to be statistically significant — but is it relevant in the real world? We only have the abstracts, so the information is incomplete. However, as a general rule, if study authors don’t mention effect size in the abstract, it’s probably because they are not worth mentioning.
The first trial, A 6-month randomised, double-blind, placebo controlled study to assess the clinical benefit of a food supplement made of a proprietary collagen hydrolysate in subjects with joint pain at the lower or upper limbs or at the lumbar spine randomized 200 patients to 1200mg of collagen daily, or placebo. The results don’t sound promising:
At 6 months, the proportion of clinical responders to the treatment, according to VAS scores, was significantly higher in the collagen hydrolysate (CH) group 51.6%, compared to the placebo group 36.5% (p<0.05) , .[sic] However, even if there was no significant difference in the number of clinical responders at 3 months (44.1% vs 39.6%, p=0.53), there was still a higher proportion of responder in the group using collagen hydrolysate demonstrating a certain evolution. Using other pain and function assessment tools (i.e. questionnaires Lequesne, DASH or EIFEL) no significant effect of collagen hydrolysate was observed compared to placebo.
The second trial is also lacking in information. A randomized controlled trial on the efficacy of oral collagen treatment on the medial knee joint space and functional outcome among veterans memorial medical center patients diagnosed with osteoarthritis of the knee: open label and single blind (the blinding is not described) this trial randomized 150 patients, with 113 completing the trial. Right away, that many patient dropouts is a massive red flag, as patients that drop out usually are not responding to treatment. Patients were randomized to collagen, 1200mg per day, or the anti-inflammatory aclofenac (which I’ve never heard of) 100mg daily for five days, then as required. Both groups could use ketoprofen gel as desired. The results?
Patients in Group A significantly scored lower in the average WOMAC score from baseline to the sixth month follow up. On the other hand, patients in Group B had no significant change in their average WOMAC score after six months. There was no significant difference in the medial knee joint space measured at baseline and after six months in both groups.
There’s no additional data, so there’s no way to determine if the groups were properly matched, or if the effect observed was both real and clinically meaningful. Given the trial was single-blind, the risk of bias is large. Perhaps not surprisingly, when objective measurements (joint spaces) were taken, there were no differences between the groups.
It could be that collagen supplements provide a meaningful clinical benefit to arthritis and joint pain, but there’s certainly no persuasive evidence to suggest that’s the case. Based on what collagen is, how it’s absorbed, and how we know collagen is actually synthesized in the body, it’s highly implausible that 1200mg of additional protein consumed daily will have any meaningful therapeutic effects. Genacol, like other collagen supplements, appears to be little more than an expensive protein supplement. If you want to supplement with collagen, my suggestion is to skip the supplements, and go for a well-marbled steak. Enjoy it, but don’t expect the steak, or any collagen supplement, to relieve your joint pain.

Collagen Supplementation: Hype and Hope
Collagen is an expensive protein supplement – nothing more.
Scott Gavura on June 6, 2024
Link

Way back in 2011 I blogged about collagen, a supplement that was growing in popularity for osteoarthritis. I wasn’t impressed at the time, and since that time I still receive the occasional email telling I’m an idiot in the thrall of Big Pharma, and if I would only look at their YouTube video, I’d see the errors of my ways.
Thirteen years later and despite my post, collagen has only grown in popularity, and is promoted for skin, hair and general longevity. Let’s take a look at the evidence behind what is said to be billion-dollar market.
What is Collagen?
Collagen is the major component of connective tissue in the body and the most abundant protein — it’s about a quarter of our body mass, and is found in skin, muscle, tendons, etc. . Your leather coat? Think of it as a collagen coat. There are dozens of types of collagen, with types I, II, and III being the most prevalent in the human body. Type I, the majority of our collagen, is made of densely packed fibers, in teeth, bones, ligaments, skin, and connective tissue. Type II collagen is located in the elastic cartilage of joints. Type III collagen is found in the structure of muscles, arteries, and organs.
Collagen is a triple helix of fibrils which are formed from amino acids. It is not static, and breaks down due to oxidative damage and normal metabolism by collagenase. Serious collagen issues in the body can mean severe illness. Lobstein syndrome (osteogenesis imperfecta), is a congenital disease that results in the failure to produce type I collagen, which results in exceptionally brittle bones. Or think of scurvy — now rare, but once the worst thing about extended sea voyages. Vitamin C is a necessary cofactor for collagen synthesis. Without it, multiple systems are affected, and biological disaster ensues, starting with your teeth falling out. History’s first clinical trial was performed by James Lind, a British Royal Navy physician, to compare a variety of scurvy cures, including the one that worked: fresh lemons.
Both scurvy and Lobstein’s are basically collagen shortage diseases. But, interestingly, do you know what doesn’t work for either scurvy or Lobstein’s? Eating collagen.
Why supplement with collagen?
As we age, our bodies naturally start reducing collagen production. You may see it first as wrinkles on your skin. Our body creates collagen from amino acids, not collagen itself. Collagen can be an excellent source of protein, however. Collagen-rich foods, once eaten, are broken down into oligopeptides and amino acids, which can then be absorbed into the bloodstream and used to build various proteins, including collagen in any connective tissue.
Collagen peptides are a popular supplement and may be called hydrolyzed collagen or collagen hydrolysate. It is small chains of amino acids. A common method used to produce collagen peptides is by preparing gelatin from fish, chicken or another animal, and then breaking down the gelatin further.
There is some evidence that oral collagen peptides may improve skin elasticity and hydration. However, it’s not clear if the improvements are really meaningful – or if you could get the same results from just eating more protein of any kind. There is no good evidence that applying topical collagen peptides to the skin does anything – this would be like thinking rubbing a steak on your body will help build muscle. There is no reason or evidence to suggest that we can absorb meaningful amounts of protein through the skin itself.
Finally, I was unable to find any convincing evidence that collagen supplements benefit or affect hair growth/shine/thickness or volume. Supplementing for nail health and strength, one of the original uses of collagen, is supported by only weak unblinded non-randomized evidence.
Conclusion: An expensive protein supplement?
Based on what collagen is, how it’s absorbed, and how we know collagen is actually synthesized in the body, it’s highly implausible that the tiny amounts of additional protein consumed in most collagen peptide supplements consumed daily will have any meaningful therapeutic effects. Moreover, there is no evidence that if you take a collagen supplement, it will definitively end up in your skin, hair, or joints. Collagen peptides and other forms of collagen are sources of protein that are absorbed and used by the body. But there is no compelling evidence to demonstrate that they provide any meaningful benefits over other less expensive protein supplements – or more simply, just eating a diet with adequate amounts of protein.

New Evidence for Chondroitin
Several previous studies showed chondroitin was ineffective for knee osteoarthritis, but a new study says it is as effective as celecoxib. There are reasons to be skeptical.
Harriet Hall on May 30, 2017
Link

The dietary supplements chondroitin and glucosamine, separately or in combination, have been widely used to treat the pain of osteoarthritis of the knee. But do they work? When I wrote about glucosamine and chondroitin in 2008 and in 2015 the evidence was mostly negative. Some studies supported the combination of glucosamine and chondroitin, but many others didn’t; and there was little evidence that chondroitin alone had any effect. After reviewing all the published studies, the American Academy of Orthopaedic Surgeons recommended against the use of glucosamine and/or chondroitin.
A new study (the CONCEPT trial) published in the BMJ Annals of the Rheumatic Diseases contradicts several previous studies: it found that chondroitin was effective, as effective as celecoxib, a non-steroidal anti-inflammatory drug (NSAID). A common objection when a dietary supplement fails testing is that they didn’t use the right dose or the right formulation. This reasoning might be valid, but it could easily lead to an unending and unproductive proliferation of studies each using slightly different regimens. This new study avoided that objection by using the dose and the specific formulation that had been shown effective in the most positive studies.
Previous studies of chondroitin had suffered from idiosyncratic trial design. This new study followed the guidelines of the European Medicines Agency:
    • a minimum 6-month study
    • a three-arm design including a placebo and an active comparator (i.e. an oral NSAID)
    • two primary endpoints evaluating pain and function
Is chondroitin really as effective as NSAIDs? If it is, it might be the best choice for osteoarthritis pain, since it doesn’t have the side effects that are problematic for other osteoarthritis medications. Should we discount the previous negative studies? Should we rely on this new study to guide clinical treatment? I’m skeptical.
The new study
604 patients with pain from knee osteoarthritis were recruited from 5 European countries. It was a prospective 6-month, double-blind, double-dummy trial of chondroitin sulfate (CS) vs. placebo vs. celecoxib. Subjects were randomly assigned to one of three groups:
     1.  Real CS and placebo celecoxib
     2.  Placebo CS and real celecoxib
     3.  Placebo CS and placebo celecoxib
Meds were taken once daily for 6 months. CS tablets contained 800 mg of highly purified chondroitin 4 & 6 sulfate in a concentration not less than 95% (European patents E 1582214 and EP 1705192) Condrosulf (other brand name: Chondrosulf, Condral); IBSA Institut Biochimique SA; Pambio-Noranco, Switzerland.
The study was sponsored by the manufacturer of Condrosulf.
Results:
A 800 mg/day pharmaceutical-grade CS is superior to placebo and similar to celecoxib in reducing pain and improving function over 6 months in symptomatic knee osteoarthritis (OA) patients. This formulation of CS should be considered a first-line treatment in the medical management of knee OA.
Previous double blind studies of chondroitin for knee osteoarthritis had mixed results
A 1998 pilot study found that Condrosulf 800 mg was an effective and safe slow-acting drug that reduced pain, increased mobility, and “might” be able to influence the natural course of osteoarthritis.
A 2005 study compared Condrosulf 800 mg to placebo. It had no effect on symptoms, but appeared to slow joint space narrowing on x-ray.
A 2009 study found that 800 mg of Condrosulf slowed joint space narrowing and improved pain faster than placebo.
A 2013 study used an Australian formulation of CS, 800 mg. along with glucosamine 1,500 mg. The combination didn’t relieve pain better than placebo, but it reduced joint space narrowing.
The GAIT trial was a multicenter double-blind placebo-controlled study of 1,583 patients with knee osteoarthritis published in the highly respected New England Journal of Medicine (NEJM) in 2006. It used 1,500 mg glucosamine hydrochloride and 1,200 mg sodium chondroitin sulfate. It found that “glucosamine and chondroitin sulfate alone or in combination did not reduce pain effectively in the overall group of patients with osteoarthritis of the knee. Exploratory analyses suggest that the combination of glucosamine and chondroitin sulfate may be effective in the subgroup of patients with moderate-to-severe knee pain.”
The MOVES trial (January 2016) was a large double blind trial using a combination of 400 mg chondroitin sulfate plus 500 mg glucosamine hydrochloride (Droglican, Bioiberica, S.A., Barcelona, Spain) three times a day or 200 mg celecoxib (Celebrex, Pfizer) every day for 6 months found comparable efficacy to celecoxib in reducing pain, stiffness, functional limitation and joint swelling/effusion after 6 months in patients with painful knee osteoarthritis, with a good safety profile.
A Cochrane meta-analysis in 2007 found that trial quality was generally low, but “Large-scale, methodologically sound trials indicate that the symptomatic benefit of chondroitin is minimal or nonexistent. Use of chondroitin in routine clinical practice should therefore be discouraged.”
A Cochrane review in 2016 again found that many of the studies were low quality and heterogeneity was a problem. It found that after 6 months, chondroitin reduces pain by eight points on a 100-point scale compared to placebo. These differences persisted in some sensitivity analyses and not others.
Reasons for caution
If a medication is truly effective, that should become more and more obvious over time as more and better studies are done. And that hasn’t happened with chondroitin. The most recent Cochrane review said:
Studies published before 2000 showed that participants treated with chondroitin had significantly better pain scores than those in the placebo group while studies published after 2000 reported no statistically significant difference between chondroitin and placebo.
Studies of pharmaceuticals are frequently accused of bias because they are funded by the manufacturer. The Cochrane review said:
Studies funded by chondroitin sulfate manufacturers showed that participants in the chondroitin group had statistically significantly better pain scores than those in the placebo group, and the effect size was -0.52. Studies that did not specify their source of funding or with no pharmaceutical sponsorship did not report a statistically significant difference between participants in the chondroitin group and those in the placebo group.
Studies that found a positive effect tended to be low-quality, and outcomes other than pain were generally negative. The Cochrane review said:
among studies that found a statistically significantly positive effect with chondroitin for these various outcomes, heterogeneity was moderate, and factors that affect the study’s quality, such as size and independence of funding, were generally low quality.In nearly all other outcomes, including physical function, stiffness, grip strength, morning stiffness, global assessment on VAS (mm), change in bone marrow lesion scores of several different compartments, OMERACT-OARSI, HAQ Disability, HAQ continuous, HAQ MCID scores, and both mental and physical components of SF-36, no statistically significant difference between chondroitin and placebo was noted.
Questioning the rationale
Proposed mechanisms of action include restoring the extracellular matrix of cartilage, preventing further cartilage degradation, and overcoming a dietary deficiency of sulfur-containing amino acids, which are essential building blocks for cartilage extracellular matrix molecules. This rationale is questionable.
In response to a Medscape article, a pathologist commented:
I doubt that dietary glucosamine or chondroitin sulfate are absorbed from the gut as such. Further, human cartilage contains N-acetyl galactosamine, not glucosamine. Depending on source, the dietary CS may have a different structure than human CS. Finally, the cartilaginous glycosaminoglycan matrix is synthesized by the chondrocytes, and it is naive to assume that dietary supplements will “home” to that avascular tissue. It is all placebo effect, making lots of money for manufacturers.
And our own editor emeritus Wallace Sampson wrote:
Glucosamine [and chondroitin] is not an essential nutrient like a vitamin or an essential amino acid, for which small amounts make a large difference. How much difference could that small additional amount make? If glucosamine or chondroitin worked, this would be a medical first and worthy of a Nobel. It probably cannot work.
What do you get when you buy “pharmaceutical grade” chondroitin sulfate?
Sources of chondroitin used in nutritional supplements include bovine trachea, pork byproducts, shark cartilage, and whale septum.
A 2015 study analyzed 16 preparations of pharmaceutical grade chondroitin sulfate and found that 11 of them contained less than 15% CS; five samples contained more than 90% CS, but their structures varied as to size and sulfation. Nine of the samples were from the US, one from Brazil, four from China, and two from Germany. The European brands used in the BMJ study are not available in the United States.
Conclusion: Maybe, but I’m not convinced
How do you know if a treatment works? Simple: you do a randomized, placebo-controlled, double-blind study. Only it’s not that simple. Ineffective or marginally effective treatments will yield a mixture of positive and negative findings, muddying the waters. Meta-analyses are no better than the studies they review: if the individual studies are poor quality it’s just GIGO (garbage in, garbage out). Studies comparing a treatment to usual care are almost guaranteed to give false positive results. The pragmatic “real world” studies favored by alternative medicine are unreliable and were never meant to evaluate the efficacy of a treatment. The new chondroitin study appears to be well-designed, but even the best-designed studies can yield false positive results.
The new study’s findings are encouraging. If chondroitin really works as well as NSAIDS and has practically no side effects, it would be the obvious drug of choice for osteoarthritis pain. And there is even a possibility that it might slow the progression of joint-space narrowing. But I’m not convinced. The new study must be considered along with previous research. Some of the previous studies used the same or even a higher dose of the same CS formulation and found no improvement of pain. The positive studies were funded by CS manufacturers, raising the issue of possible bias. The mechanism of action is questionable. My biggest concern is that the formulation that appears to be the most promising, Condrosulf, is not available in the US. If we just tell patients to buy pharmaceutical-grade chondroitin, they are likely to get an inferior product. For all these reasons, I wouldn’t feel justified in recommending chondroitin based on the current state of the evidence.
That said, I couldn’t argue with doctors choosing to recommend a trial of chondroitin before prescribing a drug with troublesome side effects. They can honestly tell patients there is some scientific evidence to support it, (although it would be more honest to explain that there was also reason to be skeptical). If it doesn’t work, patients can stop taking it. If their pain improves, we won’t know whether it is a placebo response or a true effect, but they will be better off than if they had taken an NSAID and risked serious side effects.

Liver damage associate with turmeric ingestion
Reports of serious liver damage from turmeric supplementation are becoming more common
Scott Gavura on November 24, 2022
Link

Turmeric has a long history of use as a traditional medicine and as a food ingredient. The turmeric you buy is the spice made by drying and grinding up the root of the Curcuma longa plant. Curcumin is one of the natural chemical constituents in turmeric, and is thought to be one of the ingredients that has medicinal benefits and effects. Sales of turmeric have been growing over the past several years and it is now among the top selling natural products in the USA. It has also been receiving increased scrutiny by researchers and regulators, as serious reports of liver injury associated with consumption are becoming more frequent.
Clinical trials with turmeric have not been impressive from an efficacy perspective. There is some suggestion of benefit for conditions like knee osteoarthritis, mucositis, high triglycerides, or allergic rhinitis, but no persuasive evidence for routine medical use has been established. The main challenge with using curcumin as a medicine seems to be that the chemical is poorly absorbed. Manufacturers have come up with several different formulations (e.g., nanoparticles, liposomes) which complicates the interpretation of any trial. Doses vary widely from 100mg to several grams per day, and formulations include tablets, liquids, and root extracts. The poor absorption may also be responsible for its safety profile, which is generally considered safe orally even at daily doses measured in grams when consumed for several weeks. However, some turmeric supplements are now marketed as being combined with black pepper which substantially improve its absorption. (If you haven’t already seen the Marc Maron bit on turmeric and black pepper, it’s pretty funny.) Piperine, a component of black pepper, appears to inhibit glucuronidation (a metabolic process) in both the intestines and liver. Through inhibition, the amount of curcumin available to the body is greater. Consequently, the potential risk of unwanted or harmful effects is also increased. Other means to increase the absorption, such as nanoparticles, have also been developed.
Through better absorption, higher (effective) doses seem to be resulting in more cases of liver damage. Cases have occurred in weeks to months after routine ingestion begins – it is reported to start with fatigue, nausea, and poor appetite, followed by dark urine and jaundice. Recovery is usually rapid when the turmeric consumption is discontinued.
A recent paper published in the American Journal of Medicine describes ten cases of liver injury associated with turmeric. The Drug-Induced Liver Injury Network (DILIN) was established in 2003 as a cooperative agreement across academic centres and studies liver-related injuries associated with medications bout also herbal products and other dietary supplements. In this paper, all cases between 2004 and 2022 in which turmeric was implicated as a cause were reviewed. Causality was assessed, and available product was analyzed for the presence of turmeric. Ten cases of turmeric injury were reported, all since 2011, with six since 2017. Five of the ten were hospitalized, and 1 patient died of acute liver failure. Chemical analysis confirmed turmeric in all seven of the available products tested. Three products also contained piperine.
Genetics may also play a factor in putting some individuals at higher risk of liver damage from turmeric. Seven cases were found to carry the HLA-B*35:01 allele that has already been implicated as a potential biomarker that predicts liver damage from other products like green tea and Polygonum multiflorum, a Chinese herbal medicine. It is also associated with the risk of injury from regular medications as well. This allele is carried by 5-15% of the US population.
Based on concerns about health claims associated with turmeric and the potential but rare risk of serious harms, Italy recently prohibited health claims linked to turmeric and put a warning on products derived from Curcuma longa root. This followed reports of about 20 cases of liver damage in the country attributed to use:
IMPORTANT WARNING In case of liver, biliary or calculosis abnormalities in the biliary tract, the use of the product is not recommended. Do not use during pregnancy and lactation. Do not use for prolonged periods without consulting your doctor. If you are taking medications, it is it is advisable to hear the opinion of the doctor.
Conclusion: Turmeric has rare but serious risks
Turmeric supplements have medicinal promise but their role is not well established. Combining turmeric with black pepper demonstrably increases the absorption of the drug. Liver damage is a rare but seemingly-real risk of consumption. If consumption as a supplement is considered, use with or without piperine should be held consistent. Research into genetic risk factors for liver damage from supplements like turmeric are still preliminary but have the potential to identify those at greater risk of harm. Until then, whether it’s turmeric or any other dietary supplement, carefully monitoring for signs and symptoms of liver damage or other harms is important.

Herbal Medicine and Aristolochic Acid Nephropathy
Herbs are little more than dirty drugs, with uncertain dosing, potency, and often-unrecognized side effects. Aristolochic acid, which is present in the Aristolochia genus of plants often used in Traditional Chinese Medicine for many uses. Used in the West as a weight loss aid, Aristolochia is a case study in the unrecognized dangers of herbal medicine; it is a powerful nephrotoxin, and has led to many consumers developing urinary tract and kidney cancers, requiring surgery and transplants.
Natural doesn’t mean effective, and more importantly doesn’t mean safe.
Steven Novella on April 11, 2012
Link
It has been a stunning triumph of marketing and propaganda that many people believe that treatments that are “natural” are somehow magically safe and effective (an error in logic known as the naturalistic fallacy). There is now widespread belief that herbal remedies are not drugs or chemicals because they are natural. The allies in Congress of those who sell such products have even passed laws that embody this fallacy – taking herbal remedies away from FDA oversight and regulating them more like food than drugs.
The other major fallacy spread by the “natural remedy” industry is that if a product has been used for a long time (hundreds or thousands of years), then it must also be safe and effective because it has stood the test of time (this fallacy is referred to as the argument from antiquity). This fallacy even has a specific regulatory term to invoke it – GRAS or “generally recognized as safe.” With food and food ingredients the FDA does not require evidence of safety if the ingredient is generally recognized as safe. This might make sense when referring to foods that have be eaten by humans for a long time. Although the logic is still dubious, it’s just practical – the FDA could not take upon itself the task of proving that every food eaten by humans has no significant negative health consequences. It is more a recognition of practicality than reality.
The GRAS principle, however, is misplaced when referring to herbal remedies, as is the naturalistic fallacy. Herbal remedies are drugs, plain and simple. They contain chemicals that are ingested on a regular basis for their pharmacological effects. The fact that they derive from plants is irrelevant. The fact that individual chemicals are not purified and given in precise amounts does not mean they are not pharmacologically active chemicals – it just means that when taking an herbal remedy you are getting a mixture of many chemicals in unknown doses.
Every now and then the public needs to be reminded of this fact. Recent studies of the effects of aristolochic acid on the renal system are a good opportunity to do so. Aristolochia is an herb that has been used for thousands of years in many cultures for many indications, such as child birth, weight loss, and joint pain. It is both “natural” and ancient. It is also a powerful nephrotoxin – it causes kidney damage.
This first came to world-wide attention in the 1990s when a group of Belgian women who were taking Chinese herbs as part of a weight loss regimen developed end-stage kidney failure. The syndrome became known as Chinese Herbs Nephropathy, and it was soon discovered that aristolochic acid was likely the culprit. It was later discovered that Endemic Balkan Nephropathy was also likely due to aristolochic acid – aristolochia seeds were being baked into bread and therefore consumed on a regular basis. Now some researchers are recommending that these two entities be combined into one – aristolochic acid nephropathy.
This latest research just published finds that use of aristolochia is linked to the high incidence of urinary tract cancer in Taiwan. The rate of urinary tract and renal cancer in Taiwan is about four times higher than in Western countries. This led the study authors to suspect there was an environmental cause, and they quickly suspected that aristolochia might be the culprit. Although use of aristolochia was banned in Taiwan in 2003, its use is still widespread. The study found that 60% of the 151 subjects with renal cancer studied had specific mutations that previous research has linked to aristolochia.
There is now extensive research demonstrating that aristolochic acid causes kidney damage and increases the risk for urinary tract cancers. This latest study adds to that growing evidence. And yet this connection was entirely unknown prior to the 1990s, despite thousands of years of use of aristolochia. This example just highlights the fact that widespread use of an herbal product, or any treatment, is not sufficient to ensure that it is safe, or even that it is effective. Common use may be enough to detect immediate or obvious effects, but not increased risk of developing disease over time. That requires careful epidemiology or specific clinical studies. We know about the risks of prescription drugs only because they are studied, and then tracked once they are on the market. Without similar study and tracking there is simply no way to know about the risks of herbal products. Relying upon “generally recognized as safe” is folly.
It is also interesting to consider how aristolochia came to be used to aid in the birthing process – one of its most popular uses and the source of its name, which means “noble birth” in Greek. As with the traditional use of many herbs, it appears to be based entirely on sympathetic magic – the belief that a plant will be useful for an indication based upon what the plant looks like. In this case the flower of many aristolochia species looks like a birthing womb. The rest is anecdote, placebo effect, and confirmation bias – but no science.
We cannot know how many people over the centuries have been harmed by the use of aristolochia, for indications for which there is no evidence or good reason to believe that the herb is effective. In short, aristolochia is both unsafe and ineffective. This has not stopped it from being a popular herbal remedy for thousands of years. So much for the naturalistic fallacy and the argument from antiquity.

Bad advertising for UPGRAID
UPGRAID combines a new formulation of turmeric (curcumin) with 3 other ingredients. It is said to be more bioavailable and to offer unique advantages. The advertising is bad, and can’t compensate for a lack of evidence.
Harriet Hall on June 16, 2020
Link


I got an email with the subject line “95% of people deal with annoying everyday aches and soreness and UPGRAID is here to help.” I have annoying everyday aches and pains, so I was intrigued. I would like to believe I could take a dietary supplement and get relief. When I opened the email and read it, I was disappointed over and over.
It started off, “95% of 35-55 year olds experience some type of ache or pain throughout their day – everyday”. So the subject line was deceptive: this is not about 95% of people, but only about people age 35-55. What about people younger than 35 and over 55? Do they not get the same aches and pains? Would UPGRAID not help them?
In the first place, is the statement even true? I suspect not. 95%? Throughout the day? Every day? It certainly wasn’t true for me when I was in that age range, and this Healthline article provides a much lower estimate (but maybe for a different kind of pain?): “nearly 1 in 6 working Americans are in pain every day”. But what do they mean by pain? How do they define it? Where did they get the figure of 95%? Self-reports on a questionnaire? If so, how was the question worded? Sure, everyday aches and pains are not uncommon, especially as we get older; but I can’t accept the 95% figure without evidence.
The next sentence says “UPGRAID is a sustainable, science-first and fully organic daily supplement to tackle pain and inflammation made by a former Pfizer and GlaxoSmithKline scientist. Its focus is to battle inflammation and chronic health issues.”
    • Sustainable sounds good, but what exactly does that mean and are other supplements not sustainable?
    • “Science-first”? It quickly becomes obvious that science doesn’t come first for them.
    • Fully organic? Organic is a marketing term with no scientific basis; there are inorganic supplements like iodine and iron, and there is no evidence that foods labelled “organic” are better for health.
    • “To tackle pain and inflammation”? So they are not just claiming it helps with pain, but also with inflammation. How does it compare to drugs like nonsteroidal anti-inflammatory drugs (NSAIDS) that have been proven to have anti-inflammatory effects?
    • “Made by a former Pfizer and GlaxoSmithKline scientist.” That tells me nothing. Logical fallacy: appeal to authority? It shouldn’t make any difference whether it was invented by a reputable scientist or by your brother-in-law’s plumber; the only relevant questions are whether the rationale is plausible and whether it has been tested and proven to work.
    • “Its focus is to battle inflammation and chronic health issues.” Now another new claim: to battle chronic health issues.
They go on to explain that inflammation is a regular culprit linked to diseases such as heart disease or stroke, COVID-19, and may also lead to autoimmune disorders.
    • “Linked to diseases”? “Links” may indicate correlation, but correlation is not causation. Does inflammation cause those diseases, or do the diseases cause inflammation? Or does something else cause both the disease and the signs of inflammation?
    • “May lead to auto-immune disorders”? May? Maybe. Or maybe auto-immune disorders cause inflammation.
    • Did you notice how they sneaked in the reference to COVID-19? They say inflammation is a regular culprit linked to COVID-19. A culprit? Or maybe just one of the signs of COVID-19 infection? They don’t claim their product is effective against COVID-19; they can’t, because that would be illegal. But they sure would like you to start thinking about it.
It continues: “UPGRAID uses only four, all-organic ingredients”. Is there some advantage to having only four ingredients? As opposed to what? And if it is “all-organic”, are other products only “part” organic? And as I already mentioned, “organic” means nothing to science. They don’t tell us what the four ingredients are, but that was easy enough to learn from their website; more about that later.
Then come the expected celebrity endorsements. They say “supporters already include basketball legend Dikembe Mutombo, soccer great (MLS Rookie of the Year) Julian Gressel, as well as Obama’s chef and Senior Policy Advisor on Nutrition Sam Kass.” Are you impressed? I’m not. Every snake oil salesman and charlatan has supporters and testimonials.
Finally, the email asks, “Would you be interested in talking to UPGRAID co-founder Helene Rutledge about the survey and solution?” What survey? That’s the first mention of a survey. Helene Rutledge has no medical background; her experience is in marketing and management. She has an MBA and a BE in chemical engineering, and for 3 years she worked for GlaxoSmithKline to lead global commercialization for their smoking and weight control products. No, I have no interest in talking to her: I wouldn’t expect to learn what I want to know about her product.
The website
The UPGRAID website identifies the four ingredients as turmeric, ashwagandha, tart cherries, and ginger root. It proudly proclaims that there are “Real Clinical Studies”, (as opposed to “Fake Clinical Studies”?) that the ingredients are combined to work better, and that the product will “promote a healthy response to inflammation, help you recover faster, and feel better every day.” The ingredients are vegan and organic, non-GMO, natural, transparent, clean, dairy-free and gluten-free, and contain no CBD and no allergens. Lots of buzzwords, but not much science, not even in the “See Our Science” section.
Turmeric (curcumin)
OK, here’s the essence of their science: “Curcuminoids are clinically proven to be effective in more than 100 studies to support healthy joint function and a healthy inflammatory response”. No, turmeric has not been clinically proven to be effective. I reviewed the evidence for turmeric in 2014 and found it lacking. In 2017, Steven Novella wrote about Curcumin Hype vs Reality on his Neurologica blog, citing a systematic review that concluded “No double-blinded, placebo controlled clinical trial of curcumin has been successful.”
Advocates of curcumin claim that that’s only because of its poor bioavailability, and there have been numerous efforts to improve bioavailability. UPGRAID claims to have developed a uniquely bioavailable formulation, TurmiPure GOLD. They claim “300mg TurmiPure GOLD® is found to deliver more curcuminoids in human blood than 1900mg of standard turmeric.” The TurmiPure GOLD website describes a study done in France on 30 subjects to test 5 products. They describe it as “the strongest comparative human pharmacokinetic study to date”. They do not provide a link to a published trial, and no such study is listed in PubMed or Google Scholar.
A review article published in 2020 compared highly bioavailable forms of curcumin. It did not mention TurmiPure GOLD, and it said “the curcumin formulation comprised of liquid droplet nano-micelles containing Gelucire® and polysorbate 20 (BioCurc®) has been shown to have the highest bioavailability with an absorption >400-fold as compared to unformulated curcumin.” There are no studies comparing UPGRAID to those products.
Ashwagandha
They say the Ayurvedic herb ashwagandha has a long history of use and “has been reported” to have several health-promoting effects including “healthy energy, metabolism, stress response, physical performance and joint heath.” They supply it as Sensoril, a trademarked ingredient that they say “showed results in as little as 2 weeks”. But they don’t say what results, and they don’t supply links to any published study.
Tart cherry fruit and ginger root
They added these ingredients because they “have both been used traditionally for generations.” They have been “used” but have they been “effective”? They don’t provide any evidence or links to studies. And they don’t explain why they chose them to add to UPGRAID. Is this mixture of four ingredients superior to TurmiPure GOLD alone? There’s no way to know, since they haven’t been compared in clinical studies.
Irrelevant videos and more
They provide a video showing that UPGRAID instantly dissolves in water, comparing it to an unnamed competitor, a standard “bio-available” turmeric power. Quick solubility in water does not prove it is bioavailable or superior to the other product.
They have a documentary showcasing young healthy individuals who caught Covid-19 in New York and survived. The documentary has nothing to do with UPGRAID; it seems to me to be gratuitous scaremongering to make potential customers worry about their health. They have a blog, with subjects that are not directly relevant to their product.
Conclusion: Vague claims, deceptive marketing, scant science
        ◦ UPGRAID’s new formulation of turmeric may be effective for…something. But they never specify what clinically significant health benefits to expect, and they don’t provide any evidence that it is superior to other turmeric products or that it is actually effective for anything. I don’t think I’ll be trying it for my annoying everyday aches and pains. I can stand minor discomforts. I can’t stand being fooled by bad advertising.

The Hormone Myth
“Mary is really bitchy today; she must be on the rag.” Comments like this are all too common, and are misguided. In her new book, Robyn Stein DeLuca dispels the myths about how hormones affect women’s moods and mental health, myths that have contributed to unequal treatment of women. Junk science supported the myths; good science debunks them.
Harriet Hall on August 15, 2017
Link

Women have historically been considered inferior to men, and those attitudes have only recently begun to change. Women have physiological experiences that men don’t have. Menstruation, pregnancy, and menopause are all accompanied by changing hormone levels. It is commonly believed that these changing hormones can make women moody, irrational, emotional, depressed, angry, and sometimes even crazy. That belief has been used as an excuse to put women down and discriminate against them. That belief is wrong. Robyn Stein DeLuca explains why in her new book The Hormone Myth: How Junk Science, Gender Politics and Lies About PMS Keep Women Down. She reviews some of the junk science that seemed to support the belief and the good science that has revealed it to be a myth:
The evidence is clear: for the great majority of women, changes in hormones caused by reproductive events don’t cause mental disorders.
I can remember reading, a while back, that a woman should never be president because her judgment couldn’t be trusted during her periods. And just recently, a conservative commentator questioned the wisdom of appointing Sonia Sotomayor to the Supreme Court, saying:
Let’s hope that the key conferences aren’t when she’s menstruating or something, or just before she’s going to menstruate. That would really be bad. Lord knows what we would get then.
That concern was doubly ridiculous, since she was at an age where she was not likely to still be menstruating.
Today women are treated more equally than ever before, but the idea that hormones cause mental instability is still pervasive. As I was reading this book, I happened to read something in another book, American Fire, by Monica Hesse, that reinforced it. She reports that German scientists studying arson in the late 1700s believed (based on anecdotal evidence and prurient wishful thinking) that most fires were set by young peasant women; they attributed it to puberty and the trauma of menstruation. “Fire starting was an illness of tragic, hysterical, impoverished women who lacked coping skills and were victims of the unpredictability of female biology.” And in a novel I was reading, when a pregnant woman is accused of forgetting something, she calls herself a “pregnant airhead.”
Menstruation
Numerous studies have evaluated the impact of the menstrual cycle on skills like spelling, writing, memory, academic performance, arithmetic, spatial tasks, factory performance, judgment, and social skill such as detecting others’ mood from facial expressions. They have shown that menstruation had no impact on any of these skills, and some studies even showed improved performance during menstruation.
PMS
Dr. Oz says 85% of women have at least one symptom of premenstrual syndrome (PMS). DeLuca points out that having only one symptom of lung cancer (a cough?) doesn’t mean you have lung cancer. One website claims that 30-40% of women have PMS symptoms severe enough to impair their daily functioning. Some sources say PMS symptoms can last as long as 14 days every month: half of a woman’s life! Women accused of homicide have been acquitted with a PMS defense.
But no strong consensus exists on the definition, the cause, the treatment, or even the existence of PMS. The research on PMS suffers from fatal flaws. More than 150 different symptoms have been included in the definition, so that pretty much anyone would qualify. DeLuca lists five reasons PMS research was wrong: retrospective reporting, no standardization, homogeneity of researchers and subjects, problems with timing, and not using control groups. Today it is more properly called “premenstrual dysphoric disorder,” and only 3-8% of women qualify. For most women, other variables like stressful events, happy occasions, or even the day of the week are more predictive of mood than hormone levels.
DeLuca explores the many reasons for the persistence of the PMS myth, including the profit motive. Medications are widely used, including Sarafem and herbal medicines; Midol is marketed to teens and is a $48 million dollar business. And women gain social benefits from attributing anger or irritability to their PMS. Blaming hormones is easy; taking responsibility is hard.
Pregnancy
Pregnant women report that they feel like their abilities to remember and stay focused are impaired, but there is no consistent evidence for a decline in cognitive abilities. Some women report mood swings, crying spells, etc.; but most women experience a stable emotional state, and there are many other reasons for pregnant women to be upset that have nothing to do with hormones. “When a pregnant woman becomes angry or forgetful, calling it baby brain also delegitimizes the actual cause” and avoids dealing with the real problems. If she is feeling overwhelmed and stressed, her hormones are not to blame. Jobs are affected by employers’ misconceptions about performance during pregnancy and by the belief that women won’t return to work after childbirth (75% do). The myths contribute to income inequality based on the belief that women can’t do the same work because of their ability to reproduce.
Postpartum depression
Three different postpartum conditions are often lumped together in the public mind: postpartum blues, postpartum depression, and postpartum psychosis. Hormones play a role in the fleeting postpartum blues that only last a week, but their role in serious postpartum depression and psychosis is negligible. Four percent of women with postpartum psychosis attempt to hurt or kill their children. Irresponsible media reports falsely blame hormones, and even attribute depression four years after childbirth to hormonal changes that are no longer present. Recognizing that it’s not the hormones will help women get proper treatment for depression and hospitalization for psychosis. As for the baby blues, women with newborn babies would benefit from sympathy, support, and concrete help, the kinds of things that were provided by extended families in the past.
Menopause
Menopause is a modern illness, a normal life change that has been demonized and medicalized. Attitudes about menopause are largely culturally determined: women in Greece, Mexico, and India view it positively, especially where older women are valued. The myth is that menopause makes women sick, ugly, and unpleasant. One influential book called it “the horror of this living decay.” The disease model says that it is a hormone deficiency disease that needs to be treated with medication. There are physical symptoms like hot flashes, but for most women it is a time of happy thriving. The upsides: no more periods, no worries about pregnancy, a time to evaluate and reprioritize, freedom to focus on self, permission to be wise and assertive. Many menopausal women do report depression, but rather than blaming hormones, we should consider the bigger picture: midlife challenges and situational factors.
Hormone replacement therapy (HRT) is big business. Hormones were once prescribed indiscriminately to “keep women young,” but recognition of the risks has limited HRT to brief periods and minimal doses. Bioidentical hormones are big business too. Advocates like Suzanne Somers make exaggerated claims for their benefits, but the FDA doesn’t recognize the designation “bioidentical,” and there is no evidence that they are safer or more effective than conventional hormone replacements. They are prepared in compounding pharmacies, many of which have had serious quality control problems.
Why do hormone myths persist?
If women believe the myth but don’t experience the symptoms, they think they are the exception to the rule. We are flooded with a tsunami of information about the myth. The hormone myths are a form of gender policing. The myths provide an excuse for poor behavior. They give women permission to be angry or emotionally unavailable. They justify special treatment by others. Social inequalities are justified by assuming that men and women are fundamentally different psychologically and behaviorally because of their different reproductive systems; we are trapped by biology. Gender stereotypes hurt men, too.
How can we defend against the myths?
DeLuca offers a series of tools to combat the myths as well as an appendix showing how to recognize junk science. She concludes:
By embracing and promoting the truth, that reproductive hormones are not related to women’s mental health in any significant way, we can hail the reality that is clear to see: in all ways, most of us function at very high levels throughout our lives. This is the powerful truth about women.

Lipogen for Premenstrual Syndrome (PMS)
Lipogen PMS-Free is a dietary phospholipid supplement marketed as a remedy for PMS. The evidence for its effectiveness is less than convincing.
Harriet Hall on March 17, 2020
Link


A cure for PMS that is safe, natural, and proven effective by randomized, placebo-controlled, double-blind scientific trials? If only that were true!
Lipogen PMS-Free is a dietary phospholipid supplement containing PAS, a complex of 400 mg phosphatidylserine and 400 mg phosphatidic acid. It is described as “a nutritional supplement designed and clinically proven to alleviate the diverse symptoms of premenstrual syndrome (PMS).” Health News Review gave the press release a rating of only one out of five stars and described it as “all hat, no cattle.”
There’s a study!
The claim that Lipogen PMS-Free will reduce PMS symptoms has been tested in a randomized, placebo-controlled, double-blind clinical trial. The full text of that trial is freely available on the internet, but instead of linking to it, the Lipogen website asks readers to request a downloadable copy. They require customers to provide their contact information, which they then use to flood inboxes with emails that make several claims for the product and include a “Buy now” button.
The emails claim that the product:
    • Reduces emotional symptoms
        ◦ Reduces depression
        ◦ Boosts mood
        ◦ Levels out mood swings
    • Improves quality of life
        ◦ Reduces appetite problems
        ◦ Relieves sleep disturbances
        ◦ Lessens relationship interference
    • Boosts cognitive performance
        ◦ Lowers impact on productivity
        ◦ Heightens concentration
        ◦ Improves functioning
But the study doesn’t support those claims.
What did the study actually show?
The rationale for doing the study was a word-of-mouth advertising campaign by the manufacturer in which 23 out of 220 women reported improvement in PMS. And they relied on findings of preclinical hormone studies suggesting there might be a role for PAS in improving memory, learning, mood, and stress management. Those studies had inconsistent results, and most were not really pertinent. A couple of examples: one study showed a lack of consistent evidence for cortisol dysregulation in premenstrual syndrome/premenstrual dysphoric disorder, and another tested the stress reactivity of chronically stressed male subjects.
The subjects were 40 women in Germany who had been diagnosed with PMS by a gynecologist. They did not take the actual product Lipogen PMS-Free, but took four doses a day of a pill containing 100 mg PS and 100 mg PA. They were followed through one baseline menstrual cycle and 3 treatment cycles. Various hormone tests were done (they called them biomarkers, but I don’t think that is accurate), and the subjects filled out a subjective daily record of symptoms.
Statistical analysis showed a significantly greater overall improvement in PMS symptoms compared to placebo (p = 0.001). That may seem impressive, but the graph is less convincing:
And the devil is in the details. The effects were small in magnitude. Many subscale results were negative and others only reached “a marginal level” of statistical significance, varying from p = 0.052 to p = 0.838. And there was no good evidence of actual clinical significance. For instance, the reduction of reported depressive symptoms was greater for the PAS group, but only at the level of p = 0.068. In other words, other than the overall score, the results of this study were negative, but the authors tried to cast them in a positive light. They concluded, “the positive results of this clinical study merits consideration of developing the PAS complex as a botanical drug for treatment of PMDD.” I don’t think that conclusion is justified by the data.
For what it’s worth, the study was financed by Lipogen Ltd, and one of the authors disclosed that he had “a commercial interest” in the product. In fact, he is the CEO of the Lipogen company. Not a reason to reject the study, but a reason for careful scrutiny.
Lipogen PS Plus
That same author (D.R.) was co-author of another study that can be downloaded from the company website for a related product, Lipogen PS Plus. “Positive Effects of Soy Lecithin-Derived Phosphatidylserine plus Phosphatidic Acid on Memory, Cognition, Daily Functioning, and Mood in Elderly Patients with Alzheimer’s Disease and Dementia.” As before, there is no reason to require a download and solicit identifying information, since the full text of the article is freely available on the web.
That article reports previously unpublished, early pilot studies, not of the product currently being sold, but of three daily doses of a pill containing 100 mg PS and 80 mg PA. They mention another study using six daily doses that failed to show any cognitive improvement. One study reported “positive” results that were actually not statistically significant (p = 0.84). Overall, this review of unpublished studies covered what were only pilot studies, with encouraging trends but requiring further study.
Another Lipogen product, Lipogen PSPA is advertised to help you stay calm and focused under stress. It was tested in 50 healthy male volunteers subjected to a stress test. It was apparently successful in normalizing salivary hormone levels. I didn’t bother to download that study; I could see where this was going and I didn’t want to waste any more time.
A pattern emerges
Lipogen would like you to believe that doctors have specifically designed an effective “natural” treatment for PMS. In fact, they already had a phospholipid supplement that they were marketing as a nootropic, and they merely repurposed it to fill another niche in the market. What Steven Novella wrote about nootropics was not encouraging. None of them have been proven effective. The idea is to find an aspect of brain function like memory, identify a metabolic precursor, and offer a nutritional supplement to supply that precursor. They tend to extrapolate from preclinical and pilot studies and make hyped-up speculative claims about presumed effectiveness that are not supported by good science. The studies cited often use a different dosage of the active ingredient, and do not represent typical use of the marketed product by a typical consumer. Positive results are often marginal. The researchers spin negative findings as positive findings that just didn’t quite reach statistical significance. They usually conclude that more study is needed, and this is certainly true.
Better studies needed
At least they understand the importance of randomized, placebo-controlled, double-blind studies, while so many CAM proponents don’t. That’s a step in the right direction. But here’s what I would like to see:
    • Large, well-designed placebo-controlled studies of the actual products they are selling, with subjects typical of prospective customers
    • Objective data to confirm subjective reports
    • Independent replications of positive studies
    • Reporting of confidence intervals
    • Exit polls to check whether subjects could tell which group they were in
    • Comparisons with other treatments that have been proven effective
    • Discussion of contraindications and reported adverse effects
Bottom line
Phospholipid supplements may be effective as PMS remedies and/or as nootropics, but so far the evidence is far from compelling.

   Bioidentical Hormones
Harriet Hall
Link
The Medical Letter recently evaluated “bioidentical” hormones and concluded
There is no acceptable evidence that “bioidentical” hormones are safe or effective. Patients should be discouraged from taking them.
“Bioidenticals” include progesterone, estrogens (estriol, estradiol, and estrone), and testosterone. They have mainly been promoted as a safer, more natural alternative to menopausal hormone replacement therapy (HRT), but they are also claimed to increase energy, well-being, and quality of life, and to have an anti-aging effect. Suzanne Somers recommends them for all age groups and both sexes. There is no evidence to support any of those claims.
The whole “bioidentical” thing is a pseudoscientific concept: it is a marketing term rather than a scientifically meaningful one. Bioidenticals are promoted by celebrities like Suzanne Somers, a few maverick medical doctors like Kent Holtorf, proponents of “natural” medicine, patients who were frightened by the Women’s Health Initiative study of hormone replacement therapy, and critics of Big Pharma. The mainstream scientific community is in consensus: a number of medical organizations, from the American Cancer Society to the Mayo Clinic, have issued statements similar to that of The Medical Letter.
The terminology is confusing. Bioidenticals are plant extracts modified to have the same molecular structure as endogenous hormones. But there are FDA-approved Big Pharma hormones that are just as “bioidentical”: they are also plant extracts modified to have the same molecular structure as hormones produced by the ovary. Only one bioidentical hormone, estriol, has no corresponding FDA-approved version. It is only present in large amounts during pregnancy: its safety and efficacy as a supplement have not been tested. Proponents of “bioidenticals” make much of the difference between “artificial” Big Pharma progestins and “natural” progesterone, but that same progesterone molecule is also sold as a prescription drug. (Progestins were originally developed because progesterone is poorly absorbed, but now Big Pharma has developed a micronized version of progesterone that is absorbed adequately.)
One of the biggest concerns is that “bioidenticals” are prepared in compounding pharmacies that are not regulated. The FDA has long been concerned about these pharmacies. In a 2006 survey, the potency ranged from 67.5% to 268.4% of the amount specified on the label, and there were variations within the same samples. Contaminants have also been found, including bacteria. Package inserts describing risks are required for FDA approved products but not for compounding pharmacy products.
From 1990 to 2005, FDA learned of at least 240 serious illnesses and deaths associated with improperly compounded products. Because pharmacists are not required to report adverse events to FDA, there may be additional deaths and injuries of which the agency is unaware.
Another big concern is that dosage is usually guided by salivary hormone levels, which are unreliable. Suzanne Somers even advocates that the patient adjust her own dosage from day to day just depending on how she feels.
Advocates claim that bioidenticals are safer than pharmaceuticals, but since they are essentially the same compounds, there is every reason to think they would have the same side effects. At least 3 cases of endometrial cancer have been reported in women taking bioidentical hormone replacement therapy.
Critics complain that Big Pharma is profit-motivated. Interestingly, bioidenticals are more expensive than the Big Pharma versions of the same hormones and they are not covered by insurance.
Proponents speak of individualizing dosage to “balance” the hormones, but I can’t understand how they could ever hope to do that. The body produces several different hormones and the amount of each varies according to the stage of the menstrual cycle. With each constantly going up or down, how could you define balance or hope to mimic the natural state?
“Bioidentical” hormones may satisfy some of the psychological needs of people like Suzanne Somers, but they don’t satisfy the requirements of science-based medicine or even of common sense.

   Hormone Replacement Therapy
Harriet Hall
Link
For years postmenopausal women were told that estrogen was safe. Now they’re being told that estrogen is dangerous. Women are confused. The media haven’t helped; they’ve only increased the confusion and created some myths. Alternative medicine offers the option of herbal remedies they say are safer than estrogen. Suzanne Somers says all of us (even men!) should be taking bioidentical hormones and adjusting our own doses according to how we feel. What’s a woman to do? What does the science really say?
Before the Women’s Health Initiative (WHI) of 2002, there were two main reasons for prescribing hormone replacement therapy (HRT): it relieved perimenopausal symptoms like hot flashes, and it helped prevent osteoporosis and fractures. There was good reason to believe that estrogen might also reduce the risk of heart attacks, but very few doctors (if any) ever prescribed it for the sole purpose of reducing heart risks. And doctors were always aware that estrogen and progestins were powerful drugs and were not risk-free.
There was a time in the mid-20th century when estrogen was thought to be a fountain of youth and women were encouraged to start taking it at menopause and continue for the rest of their lives. That attitude quickly changed as we realized these hormones were associated with blood clots, strokes, and increased rates of some cancers. We also learned that unopposed estrogen caused uterine cancer, and women who still had their uterus had to take progestins along with their estrogen.
I remember prescribing HRT in the 80s. I would discuss the pros and cons with the patient. We would consider how bad her menopausal symptoms were and what her risk factors were. We would discuss the potential side effects of HRT. And we would decide together on an individual basis. The published evidence available at that time showed that HRT improved cardiac risk factors, but I never prescribed it for that purpose. I prescribed it for what I thought were other good reasons, and I considered the reduction of cardiac risk just an extra added bonus. I think my approach was typical of what most doctors were doing at that time.
The WHI was a wake-up call. A very large randomized trial of estrogen/progestin vs placebo in women aged 50-79, it was stopped early because the women on HRT were developing more cardiovascular disease than those on placebo. The message that some people got from the media was that HRT was killing women, but that wasn’t true. Over 10,000 person-years, women on estrogen plus progestin had 7 more coronary events, 8 more strokes, 8 more pulmonary emboli, and 8 more invasive breast cancers than women who didn’t take hormones; but they also had 6 fewer colorectal cancers and 5 fewer hip fractures, and the same number of deaths overall.
Instead of reporting the absolute risks, the media reported relative risks which sounded much worse. A 29 percent increase in risk of heart attack sounds pretty bad, but it translates to 37 heart attacks on HRT therapy versus 30 heart attacks on placebo per 10,000 women-years of treatment. These statistics are for all women including those who smoke, have strong family histories of heart disease, are overweight, etc.; those with no other cardiac risk factors would be less likely to have heart attacks.
I’ve seen alarmist claims that “doctors have killed millions of women by prescribing HRT.” That’s clearly not true. Women weren’t dying from HRT. They were more likely to develop some diseases and less likely to develop others, and overall the risk was greater than the benefit, but the risk of death did not increase. Current recommendations are to use HRT for a limited time only to control perimenopausal symptoms, and not to use it for disease prevention.
To help women make an informed decision, there is a good overview of the WHI, PEPI and HERS study results, of the pros and cons of HRT, and of other treatment options at this link.
The WHI is not the last word. It had flaws that have been extensively critiqued. Some of its findings were consistent with other studies, but some were not; the discrepancies need to be explained. There was a high dropout rate, and a preponderance of older women: only 1 in 6 were within 5 years of menopause. Current thinking is that HRT may have cardioprotective effects or at least be more benign if started in the perimenopausal period. More studies are needed in that age group.
Heart disease is multifactorial, and it is overly simplistic to look at the effects of HRT in isolation. HRT might conceivably benefit women with one risk factor profile but not with another. And just going by the data of the WHI, you might think that if a woman has a low risk of heart disease and breast cancer and a high risk of colon cancer and osteoporosis, HRT might just offer her more benefit than risk. Hip fracture can be devastating to elderly women: a substantial percentage never walk again, and older women are at greater risk for death after hip fracture than after breast cancer,
One thing seems clear. Estrogen is the most effective treatment we have for perimenopausal symptoms like hot flashes. Because of the WHI scare, thousands of women stopped their HRT. Many of those ended up going back to it in desperation when nothing else controlled their symptoms.
Of several proposed herbal alternatives, black cohosh was the most promising, but several recent studies (here, here, and here) have shown that it is no better than placebo, and there are concerns about possible liver toxicity.
Anything that has enough estrogenic effects to relieve hot flashes is likely to have all the risks and side effects that go along with estrogens themselves. We can’t assume other remedies are safer until they have been tested as rigorously as conventional HRT has been tested. The fad of so-called “bioidentical” hormone replacement a la Suzanne Somers is not based on science; the less said about it the better. The compounding pharmacies that make up the “bioidenticals” produce inconsistent products and the FDA is concerned about the need for better regulation.
Sales of Premarin plummeted when the news from the WHI first came out: from $2 billion to $880 million. Sales are now rising again. As we learn more about the risks and benefits of hormone replacement for different subsets of the population, our current recommendations will change. Individual advice may be based on the individual genome in the near distant future. We may learn that progesterone is better than progestins; we may learn that some forms of estrogen or some routes of administration are safer (so far there are lots of speculations and plenty of strong opinions but not much data). One thing is certain: estrogen and progestins will be a source of controversy for a long time to come.

Expert review warns against compounded bioidentical hormone therapies
A National Academies report finds widely-marketed compounded hormone replacement therapies lack evidence of safety and effectiveness, and recommends restriction of their use.
Jann Bellamy on July 16, 2020
Link
A committee of the National Academies of Sciences, Engineering and Medicine (National Academies) recently concluded that there is insufficient evidence to support the clinical utility* of compounded bioidentical hormone therapy (cBHT) to treat symptoms of menopause and male hypogonadism (testosterone deficiency), as well as a number of other conditions for which these products are marketed. (Free download of prepublication report available here; Highlights here [PDF].)
While the FDA has approved dozens of hormone therapy products for men and women, such as estrogen, progesterone, and testosterone, many health care providers and patients have turned to compounded hormone preparations as an alternative. These products, often marketed as “bioidentical” or “natural”, account for an estimated 26 to 33 million prescriptions and cost upwards of $2 billion annually. While FDA-approved hormone therapies must undergo extensive safety and efficacy testing before they can legally be marketed, cBHT products are exempt from these requirements.
The report finds that there are likely tens of thousands of different cBHT products available to patients, including a wide array of different dosage forms, single active ingredient and multiple active ingredient preparations, and “an extensive range of different active ingredient doses and dose combinations.”
Because the popularity of cBHT products presents a “substantial public health concern”, the FDA asked the National Academies to examine the clinical utility of treating patients with these preparations. In response, an ad hoc committee of experts appointed by the National Academies undertook a review to understand why providers and patients are using cBHT preparations in lieu of FDA-approved therapies and whether there is evidence to support marketers’ claims of their safety and efficacy. Their report, some 350 pages long, details the committee’s findings and makes recommendations, including restricting the use of cBHT preparations.
The committee defines “bioidentical hormones” as
hormones that are chemically and structurally identical to those produced by the human body, with the implication that an identical structure translates to an identical physiologic response as endogenous hormones. Bioidentical hormones may be synthesized from plant or animal sources or completely synthesized chemically, and they are offered both as products approved by the U.S. Food and Drug Administration (FDA) and as preparations that have not undergone FDA approval. [Emphasis added.]
The vast majority of FDA-approved BHT products are indicated for treating symptoms of menopause and male hypogonadism, and the report focuses on cBHT use for these indications as well. However, as the committee notes, marketed claims for cBHT also include the treatment of conditions related to “antiaging” (longer, fuller hair; smoother skin), sexual health, joint pain, general chronic pain, insomnia, cardiovascular disease, and mental health disorders.
As the report points out, current evidence-based clinical practice guidelines recommend the use of FDA-approved products for treatment of menopausal symptoms and male hypogonadism. Why, then, are cBHT preparations so popular with health care providers and patients? Unfortunately, there is a paucity of evidence addressing this question. Based on the available research, the report concludes that drivers of patient interest in, and use of, cBHT, may include unsubstantiated marketing claims of superior safety and effectiveness from compounding pharmacies, medical clinics, and “wellness clinics”, amplified by social media and celebrity endorsements; “boutique patient experience”; mistrust in the healthcare and pharmaceutical industries; and the appeal of “natural” hormones and/or dosage forms.
Interestingly, the committee found that, despite healthcare provider claims of “customized” and “personalized” cBHT formulations,
compounders often offer preprinted prescription pads for cBHT with a checklist of popular ingredient combinations, concentrations, and dosage forms. These are often used as a marketing tool to increase the requests for and sale of cBHT, and they may appeal to certain clinicians by making the compounding prescription process “quick and easy.” However, there is no available evidence to suggest the sample menus of formulations, and associated doses and dosage forms, are supported by empirical data related to their safety and efficacy. [Citations omitted.]
The committee also accepted public testimony and written comments. Disturbingly, the report concluded,
It is clear from these communications that many clinicians, compounding pharmacists, and patients using cBHT hold minimum, if any, concerns regarding the medications’ safety and effectiveness.
Compounding the problem
As the report discusses extensively, the compounding process itself introduces its own issues due to “inadequate regulation and oversight”.
Compounding – defined as “the process of combining, mixing or altering ingredients to create a medication tailored to the needs of a patient” – can take place in community pharmacies, physicians’ offices, hospitals, or in large outsourcing facilities. (We’ve discussed problems with compounded drugs several times here on SBM.) Issues identified by the report include:
    • Pharmacists’ lack of adequate training in compounding.
    • Lack of standardization in drug formulae and production methods, as well as formulation difficulties (e.g., the poor water solubility of steroid hormones).
    • Significant variations in pharmacy oversight from state to state and lack of coordination between state and federal regulators.
    • Minimal labelling requirements for compounded drugs. For example, an FDA-approved drug may have a black-box warning, but a compounded drug with the same active ingredient is not required to carry the same warning.
    • Inadequate safety inspections, particularly of community pharmacies.
    • Undisclosed financial conflicts of interest between health care providers and compounding pharmacies as well as the inherent conflict arising when the health care provider and the compounder are the same person. (The disclosure requirements for physicians and pharmaceutical companies do not apply.)
In sum, under the current regulatory scheme, there is no assurance that
the compounded preparation contains the purported amount of active ingredient or can deliver the active ingredient to the patient and the site of action. Because of these limitations, different compounders may use different processes to compound an identical prescription, and as a result, cBHT preparations ordered with identical prescriptions and labeled with the same name will likely vary between compounders. Indeed, FDA has received adverse event reports that reveal harmful variations in compounding.
Marketing versus evidence
In addition to problems associated with compounding itself, the report finds the evidence does not support the cBHT marketing hype. For starters:
Many patients believe that bioidentical means that plants are the source of the hormones, however, it is the chemical structure and not the source that determines whether a hormone is bioidentical. Furthermore, bioidentical hormone medications that have plant sources and are called “natural” are, in fact, chemically modified in the laboratory before they are provided to a patient.
In fact, the source isn’t the important thing anyway:
Regardless of whether the bioidentical steroid hormone is produced endogenously or exogenously, it is the structure of the hormone and the way in which it is metabolized that determines its biological action. This point is critical to understanding the effects of steroid hormones.
[Not just that, it is critical to the understanding of any drug, dietary supplement, homeopathic remedy, or TCM herb. Scott Gavura crafted an excellent tutorial on why this is so.]
As for the widely touted “personalization” of cBHT, while the committee says, diplomatically, that it “appreciates the potential of personalized medicine and what it can offer patients”, personalization must be balanced against safety and effectiveness. When “personalization” means an
immense number of potential combinations of different hormones, excipients, dosage forms and strengths, as well as the lack of uniformity of . . . cBHT preparations . . . determining definitive bioavailability of those preparations [is] difficult. Without reliable bioavailability data, an accurate characterization of the safety and effectiveness of cBHT preparations is not possible.
And if this personalization is based on blood, serum, or saliva tests, “there is insufficient evidence to support claims that these tests can be used to individualize hormone therapy”.
Nor do marketing claims about the superior safety and effectiveness of cBHT products hold up to an exhaustive evidence review:
The majority of marketing claims about the safety and effectiveness of compounded bioidentical hormone therapy preparations, whether in absolute terms or in comparison to FDA-approved bioidentical hormone therapy, are not supported by evidence from well-designed, properly controlled studies.
As well, adverse event reporting for compounded preparations in general is “voluntary and incomplete” and “limits assessment of the frequency, type, and severity of adverse events” related to cBHT use.
Based on its review, the committee makes several recommendations, the first of which is to “restrict the use of cBHT preparations”. The committee also says that prescribers and compounders should “clearly explain the limited evidenced-based information” and that cBHT preparations are not FDA-approved. Unfortunately, the recommendation is addressed to providers, not regulators, and will likely be ignored by physicians, naturopaths, and other healthcare providers who prescribe cBHT, except for perhaps the few who were genuinely unaware of the lack of evidence and care about such things. The same observation goes for recommendations to “improve education for prescribers and pharmacists who market, prescribe, compound, and dispense cBHT preparations” and disclosure of financial conflicts of interest, although the latter does come with the suggestion that states collect this information and make it publicly available.
Improvements in the compounding process are also recommended, among them the inclusion of a standardized insert for dispensed cBHT preparations, analogous to the inserts required for FDA-approved drugs, as well as boxed warnings for prescriptions including estrogens and androgens. The committee also wants the FDA to review some BHT therapies as candidates for the FDA Difficult to Compound List, which prohibits listed substances from being used in compounding.
Unfortunately, but perhaps understandably in light of the pandemic, I cannot find that the National Academies report has been picked up by the mainstream media, despite its importance to the thousands of patients who are prescribed cBHT, unaware of the lack of evidence and health risks. Absent action by the FDA and state regulators, none of them will be the wiser.

* “Clinical utility” is defined as “A multidimensional construct that reflects evidence about safety, effectiveness, and therapeutic need. Patient preference is also a component of clinical utility, reflecting patients’ variable acceptance of benefits and risks.”

Herbal Products and Pregnancy
A recent review shows that herbal products do present a potential risk during pregnancy, and should not be considered automatically safe.
Steven Novella on May 27, 2020
Link

While pregnancy is a healthy condition, not a pathological one, it does require special consideration for medical treatment. The same is true to some extent for breastfeeding mothers. The obvious reason is that medications and other interventions might have negative effects on the developing child or newborn. It is therefore standard of care that any woman of childbearing age is asked about the possibility that they might be pregnant, and essentially treated as if they are pregnant unless we know they are not (using effective prophylaxis is adequate reassurance). Any medication that is not known to be safe in pregnancy is also treated with caution, and not used if it can be avoided.
Some pregnant women have medical conditions that need to be treated, however, and themselves might pose a risk to their child. Therefore a risk vs benefit approach is taken for any possible treatment, and when multiple options are available, greatest priority is given to the interventions that are safest for the pregnancy.
But then, in many cases, all this caution and calculus are thrown out the window when it comes to use of herbal products and dietary interventions. Most patients do not even disclose their use of herbal products to their doctors unless specifically asked. Literally centuries of marketing have created an unearned health halo around any product arbitrarily labeled as “natural” (the appeal to nature fallacy). In the US and elsewhere the herbal product industry has largely been deregulated, leaving few consumer protections in place. The lines between food and medicine have also been deliberate blurred, with so-called “nutraceuticals” and alleged “superfoods”.
There are good reasons for concern, however, that “natural” products, and even some foods, do present a potential risk to an unborn child. A recent review of the relevant literature finds that there is evidence substances derived from foods and herbal products can cross the placental barrier. Somethings this only occurs after they have been metabolized by intestinal flora. This means that we need to study not only the products themselves, but all downstream metabolites (which is common practice in pharmacology).
This is yet more evidence that the double standard between herbs and drugs is a false one, based upon the flawed premise of the appeal-to-nature fallacy. Co-author Andrew Machpherson summarizes the implications of their research:
Although plants products are ‘natural’ substances, they are always so-called xenobiotic substances that are foreign to the body and should be handled very carefully, especially when pregnant women take plant-based products in large quantities.
The use of herbal products during pregnancy is difficult to estimate because of low levels of reporting. Estimates vary from 4 to 69%. A 2010 study form the US estimated the use at 5.8%, but this is likely an underestimate. Even at the low end of the estimate range, this still represent a significant use for the pregnant population.
This is also not just a theoretical concern. A 2015 literature review found extensive evidence of harm from herbal product use during pregnancy. The authors warn:
While definitive data emerge, all herbal products should be viewed with caution, although there are no explicit warnings that herbals should not be used during pregnancy and lactation.
They key in on the problems. First, we don’t really know what the risk is. We have evidence for potential harm, and we have essentially case reports of actual harm. But we lack the kind of systematic safety research that is required for medications. This highlights the second problem they identify – lack of explicit warnings. This in turn is due to the double standard, both in popular belief and reflected in regulations. Herbal products are largely thought of as “natural” which somehow makes them magically safe. It is worth pointing out that many things found in nature – such as botulinum toxin and the death’s cap mushroom – are extremely toxic.
As I have been pointing out since the beginning of this blog, herbs are drugs. When an herbal product is taken in concentrated form for alleged pharmaceutical (as opposed to nutritional) effects, that is a drug. Herbs have drug-drug interactions, they have to be metabolized, they can cause toxicity, and they can cross the placental barrier or be excreted in breast milk.
However, we allow the supplement industry to falsely tell consumers not to worry about their herbal products, because they are natural, or because they are “nutraceuticals”. We allow them to self-regulate when it comes to product purity and fidelity. There is no standardization of dosage. We largely lack the kind of specific information we demand for pharmaceuticals, such as pharmacodynamics and pharmacokinetics.
Herbs need to be thought of for what they are – unregulated, poorly studied drugs with largely unknown properties. Further, they are marketed with health claims that are not substantiated by research. In fact, they are often marketed with claims that have already been shows not to be true. As I have pointed out before:
One by one rigorous clinical trials have shown that the most popular herbal remedies do not work as advertised: ginkgo biloba for memory and dementia, echinacea for cold and flu, glucosamine and chondroitin for arthritis, black cohosh for hot flashes, and saw palmetto for the prostate and urinary tract.
Further, the popular antioxidants are also largely useless, and may even be harmful in some cases. We are essentially allowing an entire industry to gaslight the public, to make false claims, and to be free of any burden of having to prove safety or efficacy. The results are predictable.
        ◦ Pregnancy does present a special case, and woman who are pregnant, trying to become pregnant, or may be pregnant, should exercise extreme caution when it comes to any herb, supplement, extreme diet, or alleged “superfood”. Taking large amounts of anything should be avoided. The risk vs benefit analysis is pretty clear – there is potential risk, and no proven benefit.

Lactation cookies feed on breastfeeding anxieties
There’s little good evidence to say “lactation cookies” do anything at all. If you want cookies, eat cookies. Lactation cookies are an expensive scam.
Scott Gavura on June 13, 2019
Link
Breastfeeding is entirely natural, yet can be exceptionally difficult for many new mothers. There is tremendous (unfounded) societal pressure to breastfeed, and many women feel guilty for struggling with the process, or not producing sufficient milk. Consequently, there is an entire industry dedicated to supporting and promoting breastfeeding. Today I want to focus on a single product, shown above, that represents much that is wrong in the way in which we support breastfeeding. The image is of what’s called a “breastfeeding supplement” which looks an awful lot like chocolate chip cookie, priced at whopping $21.99 for 20 cookies. The idea that a cookie can promote breast milk led me down a rabbit hole of research into supplement use in lactation, and the mercenary world where alternative medicine is routinely promoted without solid evidence of effectiveness or safety.
What is a galactagogue?
Galactagogue are substances that promote breast milk production (lactation). While no prescription drugs are approved solely to promote lactation, some drugs do have limited evidence to support galactagogue properties, and they are occasionally considered when women are not producing sufficient milk. However, clinical practice guidelines tend to support the use of galactagogues only after all other factors that may compromise breast milk production (e.g., latching difficulties, frequency of feeding) have been addressed. Diet is routinely thought to affect breast milk production, and every culture has its own food products that it believes support milk production. As per La Leche League, they include:
    • Whole grains, especially oatmeal
    • Dark, leafy greens (alfalfa, kale, spinach, broccoli)
    • Fennel
    • Garlic
    • Chickpeas
    • Nuts and seeds, especially almonds
    • Ginger
    • Papaya
    • Spices like cumin seeds, anise seeds, fennel seeds, turmeric
Herbs as galactogogues
Herbal products have long histories of use across cultures, with lots of anecdotes, like foods, to support their use as galactagogues. Despite widespread use, research is lacking on these products, both in terms of their effectiveness, but also in terms of their safety to the mother and the infant. Given the possibility that any herbal supplement consumed will be passed through the breast milk to the baby, dual evaluations are necessary. Consequently, safety is a critical concern when considering herbs and supplements in women that are breastfeeding. As has been documented and discussed at this blog repeatedly, there is a lack of standardization and quality control in the dietary supplement industry and there is little enforcement (and no routine testing) to assure consumers that what is on the label is actually in the bottle. It is a buyer beware market, and one that requires cautious decision-making by breast-feeding women.
There are several reputable references on drug and supplement use in breastfeeding. While not all are online and freely accessible, I’ll summarize the evaluation from several sources as we look at the expected efficacy of these lactation cookies.
Cookies for lactation?
For some reason cookies to promote lactation have grown in popularity over the past several years. There are plenty of recipes online, and most seem to rely on household baking staples with some of the ingredients from the list above, like brewer’s yeast, flax, chickpeas, and oats. You can also find lactation brownies, lactation lemonade, and lactation lattes for sale online.
Digging into the product above, Upspring Milkflow, I found the following main ingredients:
    • Enriched wheat flour
    • butter
    • sugar and brown sugar
    • chocolate chips
    • eggs
    • 230 mg of a “Proprietary blend” of fenugreek seed extract (10:1) and blessed thistle extract (4:1)
Two cookies is 190 calories providing 6 grams of saturated fat, 25 grams of carbohydrate, and 2 grams of protein. Most of the ingredients are conventional cookie ingredients, with the exception of the two herbs. Let’s look closer at the effectiveness and safety of these products.
The evidence for fenugreek
The LactMed database is freely available online and probably the best open-access reference for information on drug and supplement use in lactation. Here is what it notes about fenugreek (Trigonella foenum-graecum):
Fenugreek (Trigonella foenum-graecum) seeds contain mucilage, trigonelline, 4-hydroxyisoleucine, sotolon, diosgenin, luteolin, phenolic acids, and protodioscin. Fenugreek has been used in a number of geographical regions worldwide as a galactogogue to increase milk supply and is included in numerous proprietary mixtures promoted to increase milk supply.[1][2][3][4][5][6][7][8] [9]The galactogogue effect of fenugreek may be primarily psychological.[10] Evidence for a galactogogue effect is mostly anecdotal. A limited number of published studies of low to moderate quality have found mixed results for a galactogogue effect for fenugreek.[11][12][13][14] A meta-analysis of controlled studies found fenugreek to have a mild galactogogue effect and unknown safety profile.[13] Some evidence indicates that fenugreek might be more effective in the first few days pospartum than after 2 weeks postpartum.[15] Some of these studies used a multi-ingredient combination products in which fenugreek was only one component, so the results might be different from studies in which fenugreek was used alone. Galactogogues should never replace evaluation and counseling on modifiable factors that affect milk production.[16]
Emphasis added.
Up-to-Date, which is a proprietary reference, notes the following on fenugreek:
Fenugreek is the most widely used herbal agent, but data are insufficient to determine its efficacy and safety [38-41]. Reported side effects include diarrhea, flatulence, allergic reactions, and hypokalemia. In addition, it is not known whether components of the herb are transferred to the infant via breast milk. As with all herbal supplements, manufacturers are not required to demonstrate efficacy, and the contents of individual products vary.
The Natural Medicines Database, another proprietary references, notes that fenugreek is “possibly safe” when used to stimulate lactation and that there is “Insufficient Evidence to Rate” in terms of its effectiveness when promoting lactation. It notes that while there is some evidence of effectiveness over placebo, some conflicting results have also been published.
The American Academy of Pediatrics, in a paper entitled, “Complementary, Holistic, and Integrative Medicine: Advice for Clinicians on Herbs and Breastfeeding“, notes the following on fenugreek:
Fenugreek (Trigonella foenum-graecum), a popular cooking spice in India and the Middle East, is traditionally used as a galactagogue to aid digestion. (14) Fenugreek is included in the Food and Drug Administration’s list of herbs generally regarded as safe. (15) Despite its wide popularity, there is little research on fenugreek and breastfeeding women.
And also:
Although fenugreek appears to have a good safety profile, particularly at doses typically used (3-6 g of powdered seed), its effectiveness as a galactagogue, optimal dose, and adverse effect profile in infants have not been established in clinical trials.
On balance, there is little evidence to establish the efficacy of fenugreek to support lactation. There is a long history of safe use of the product, but the safety profile has also not been closely evaluated.
The evidence for blessed thistle
This will be a much shorter summary, as there is very little published evidence on blessed thistle (Cardui benedicti) . The LactMed database entry is short and notes “no scientifically valid clinical trials support this use.” Up-to-Date has no information at all. The Natural Medicines Database notes “Insufficient reliable information available; avoid using” with respect to safety, and in terms of effectiveness for any clinical condition, simply “insufficient reliable information available”.
Cookies can be delicious, but probably won’t help with milk production
Women are understandably concerned when they have difficulty breastfeeding. Health professionals including lactation experts are the best resource for women experiencing challenges and can point to reputable resources online. While many foods and supplements are promoted to encourage breast milk production, there is very little evidence to suggest that these products are effective. Considering that breastfeeding is so widespread, this is frustrating to mothers and health professionals alike. It is important to note that, seeing a business opportunity, a large industry has developed that targets women at this vulnerable time. Products that are promoted to assist with lactation may not be supported by robust evidence of effectiveness or safety for either the mother or the infant.

“Low T”: The triumph of marketing over science
David Gorski on November 25, 2013
Link

A man on TV is selling me a miracle cure that will keep me young forever. It’s called Androgel…for treating something called Low T, a pharmaceutical company–recognized condition affecting millions of men with low testosterone, previously known as getting older.
—The Colbert Report, December 2012
And now for something completely different…sort of.
After writing so much about the latest developments in the ongoing saga of the cancer doctor who is not an oncologist and not a legitimate cancer researcher, plus a rumination on what’s up with President Obama’s nominee for Surgeon General and our favorite form of unscientific medicine, so-called complementary and alternative medicine (CAM), also known as “integrative medicine,” I thought it was time for a change of pace. I wasn’t sure what I was going to write about as Sunday rolled around, but fortunately, as sometimes happens, the New York Times dropped a topic right in my lap, so to speak, both figuratively and literally. It comes in the form of a long article on something that directly concerns men of a certain age, which unfortunately happens to mean men of my age and older. I’m referring to what pharmaceutical company advertising campaigns have dubbed “low T,” short for low testosterone. It’s not clear how the term “low T” originated but Dr. Abraham Morgentaler, founder of Men’s Health Boston, claims to have coined the term when his patients were embarrassed by their difficulty pronouncing the word “testosterone.” Other sources report that it was Solvay Pharmaceuticals that coined the phrase. It doesn’t really matter where the term “low T” came from. The term has stuck, even though the more “correct” medical term would be hypogonadism, as in a man’s testes not working.
The NYT article appears, very appropriately, not in the Health section of the paper, but rather in the Business section. Indeed, if you believe the hucksters and manufacturers of testosterone replacement therapy, pretty much every man over the age of 40 or 50 is prone to a devastating lack of testosterone that must be replaced, preferably by products provided by big pharma like AndroGel. Indeed, the NYT article, written by Natasha Singer, is entitled ‘Selling That New-Man Feeling,’ and she makes a very good case that selling is what it’s really all about, more so than science-based medicine. Since we haven’t addressed the issue of “low T” in over three years, this NYT article seemed to me like the perfect excuse to revisit the topic, looking at how pharmaceutical companies and doctors sell the concept and whether or not there has been any new evidence to guide us in the last three years.
Apparently, 70 year old men should be as virile as 20 year olds
Three years ago, both Peter Lipson and Harriet Hall wrote about the phenomenon that’s been sweeping the men’s health world over the last five years or so of diagnosing and treating “low T.” Peter acknowledged that “low T” can be a real phenomenon but pointed out that it generally only affects small numbers of men. Harriet quite rightly pointed out that testosterone, contrary to the way it’s being marketed, is not an anti-aging panacea. None of this is to say that legitimate diagnoses of low testosterone shouldn’t be treated, but questions proliferate. How low is really “too low”? What are the goals of treatment? Do low or low-normal testosterone levels actually cause the symptoms being attributed to them? For instance, if you wander over to the AndroGel site and look at the sorts of symptoms being attributed to “low T,” you’ll find:
Signs and symptoms of Low Testosterone may include:
    • Fatigue or decreased energy
    • Reduced sex drive (libido)
    • Sexual dysfunction (weak erections, fewer erections)
    • Depressed mood
    • Increased body fat
    • Reduced muscle mass and strength
    • Decreased bone strength
    • Loss of body hair (less frequent shaving)
    • Hot flashes, sweats
There’s then a test, which takes the form of a series of questions:
     1.  Do you have a decrease in libido (sex drive)?
     2.  Do you have a lack of energy?
     3.  Do you have a decrease in strength and/or endurance?
     4.  Have you lost height?
     5.  Have you noticed a decrease in your enjoyment of life?
     6.  Are you sad and/or grumpy?
     7.  Are your erections less strong?
     8.  Have you noticed a recent deterioration in your ability to play sports?
     9.  Are you falling asleep after dinner?
     10.  Has there been a recent deterioration in your work performance?
Just for yucks, I took the quiz, and this is what I got back:
Yes, it turns out that AbbVie, the drug maker behind AndroGel, is very concerned that I might have “low T” and really thinks that I should get myself checked out. I think I’ll probably pass, given the origin of this questionnaire, which is known by the acronym ADAM, which stands for the Androgen Deficiency in Aging Males test:
More than a decade ago, a Dutch pharmaceutical company, Organon BioSciences, asked Dr. Morley to devise a screening questionnaire covering symptoms common to older men with low testosterone. The way Dr. Morley recalls the drugmaker’s instructions, “they said, ‘Don’t make it too long and make it somewhat sexy.’ ”
In return, he says, Organon gave $40,000 to his university for research into the effects of testosterone on muscle. Along the way, Dr. Morley’s quiz acquired an official name that emphasized its intended audience was older men: the Androgen Deficiency in Aging Males, or ADAM, test.
That test has become standard fare on brand-name drug sites like androgel.com and on informational sites like AbbVie’s IsItLowT.com — where the ADAM test has been re-branded as the “ ‘Is It Low T?’ Quiz.” If the questions drive many men to identify themselves as low-T sufferers and visit their doctors seeking remedies, well, that is their purpose.
Indeed, it is, which is why I failed it. Particularly amusing is the section where it asks if you’re falling asleep after dinner. A particularly pithy quote was included from Dr. Adriane J. Fugh-Berman, an associate professor at Georgetown University Medical Center in Washington and director of Pharmed Out, who quipped, “Depends how long after dinner. We all do eventually. It’s called sleep.” Also, I would add, if it’s a particularly carb-rich dinner, I might indeed doze off not long after. Clearly many of us who will be partaking in a mere few days of our yearly Thanksgiving feasts suffer from low T!
It turns out that these “low T” advertisements take advantage of a loophole in the law. The FDA and Federal Trade Commission carefully monitor pharmaceutical company advertising. In particular, the FDA looks out for drug companies that advertise “off-label” uses for their drugs; i.e., uses for which the drug is not FDA-approved. As we’ve discussed from time to time here at SBM, off-label prescribing is a common and often accepted practice that is not necessarily outside the purview of science-based medicine, given that FDA approval can lag behind the evidence for a new indication for a drug. However, pharmaceutical companies are not permitted to promote such uses. After all, if they could market drugs for off-label uses, then why bother going to the trouble of doing all those expensive and pesky clinical trials to gain approval for new indications?
There is one sort of advertising campaign, however, that the FDA doesn’t really regulate. You can look at it as a similar end run around FDA regulations used by supplement manufacturers when they make vague “structure-function” claims. In this case, the end-run is known as “unbranded” promotions or “disease-awareness” campaigns. These are promotions that do not advocate the use of a specific brand of a drug and/or promote “awareness” of a condition:
The Food and Drug Administration closely regulates advertisements for brand-name prescription drugs, but does not generally regulate unbranded campaigns. That two-track system, says John Mack, an analyst who runs a blog called Pharma Marketing, has enabled companies to position low T as a malady with such amorphous symptoms — listlessness, increased body fat and moodiness — that it can be seen to afflict nearly all men, at least once in a while. Drug makers also promote low-T screening quizzes directly to consumers, Mr. Mack says, in an effort to prompt men to seek testosterone prescriptions from their doctors.
For this sort of campaign:
Earlier this year, Medical Marketing & Media, a trade magazine, named two AbbVie executives as “the all-star large pharma marketing team of the year” for promotions of AndroGel and unbranded efforts to advance low T.
“It didn’t hurt that baby boomers have proven less than shy about availing themselves of any product that they believe will increase their quality of life,” an article in the magazine said. The article lauded AbbVie’s DriveForFive.com, an unbranded site that encourages men to have regular checkups and to ask their doctors about five tests, among them tests for cholesterol and blood pressure — and testosterone.
Mr. Freundel of AbbVie described the effort as “a national disease-awareness initiative aimed at encouraging men to take a more proactive approach to their health.” The F.D.A., he added, encourages companies to develop such initiatives “because they serve an important role by enhancing awareness of health conditions.”
Described in Medical Marketing & Media thusly:
AbbVie took a taboo topic and, via a cagey media-and-marketing presence, rendered it less wince-inducing among its target audience. It did so at a time when a number of critics voiced their concerns that the marketing and use of testosterone-boosting products had gotten ahead of the science.
Notice how blatant MMM is in trumpeting this as a triumph of advertising over science. AbbVie overcame all those nasty doctors trying to tell people that there’s no good science to indicate that all these millions of men need testosterone replacement therapy. I guess AbbVie showed them! Indeed, this marketing campaign, coupled with other, similar campaigns by other testosterone manufacturers and physicians specializing in men’s health, testosterone prescribing is way, way up. Indeed, a recent study in the Medical Journal of Australia concluded:
In the absence of any new indications, off-label testosterone prescribing has increased in most countries in 2000–2011, especially over the last half of the period. The increased testosterone prescribing appears to be primarily for older men and driven by clinical guidelines that endorse testosterone prescribing for age-related functional androgen deficiency (andropause). By eliminating the fundamental distinction between pathological and functional androgen deficiency, these guidelines tacitly promote increased testosterone prescribing, bypassing the requirement for high-quality clinical evidence of safety and efficacy and creating dramatic increases in prescription of testosterone products.
In the U.S., monthly use per 1,000 population increased nearly ten-fold between 2000 and 2011; in Canada, the increase in usage was nearly 40-fold, even though it started at about the same rate in 2000. It is truly astounding how much the use of testosterone supplementation has increased in developed countries. It’s almost impossible to escape the advertising. It’s in newspapers, on television, and all over the Internet. As I’ve seen it quipped, ads for “low T” seem to be directly competing with the ads, ubiquitous since the late 1990s, for erectile dysfunction drugs. One wonders when “awareness” of “low T” will surpass awareness that, seemingly, older couples must sit side-by-side in separate bathtubs before getting it on, as anyone who’s seen a Cialis ad knows.
But I digress. Let’s take a look at “low T” and what the scientific evidence, rather than the marketing hype, says about it.
Low T, high T, fitting testosterone to a T
The Is It Low T? website claims that “millions” of men in the US suffer from “low T.” Perusing the various ads and promotional materials, one will soon see an estimate of 13 million men in the US over the age of 45 suffering from “low T.” This estimate is sometimes attributed to the American Diabetes Association, but if you look at the link to a page about low testosterone on the ADA website it says nothing about the prevalence of this condition, other than that it is “common.” As Jim Laidler pointed out in the comments of Harriet’s post on the topic, according to the US Census Bureau, there are over 53 million men over age 45 in the US as of 2010. This would mean that nearly a quarter of men over 45 have “low T.” It’s a figure that seems rather high and difficult to believe.
Part of the problem is that as is the case with estrogen levels in women, testosterone levels in men begin decreasing after the age of 30. The topic was reviewed well in the New England Journal of Medicine nine years ago, so this is not new information. Contrary to the abrupt and rapid decrease in sex hormone levels that occurs in women when they enter menopause, in men testosterone levels decrease more slowly, with the serum total testosterone concentration decreasing from a mean of about 600 ng/dL (20.8 nmol/L) at 30 years of age to a mean of about 400 ng/dL (13.9 nmol/L) at 80 years, although, the review noted, the range is wide at all ages. However, the “normal” range for serum testosterone levels varies with age, decreasing as a man ages. In younger men, the low end of the normal range is generally considered to be around 300 ng/dL, and that is often the level recommended as the cut-off by the “low T” websites.
Testosterone levels also vary considerably in that they can be affected by illness and medications such as opiates and glucocorticoids. They also can vary significantly due to circadian and circannual variations, episodic secretion, and measurement variations. In the circadian variation, peak levels are noted in the morning, although this variation is less in older men. Indeed, even with this blunting of the circadian variation of testosterone levels, a significant proportion of men over 65 with low testosterone levels in an afternoon blood draw will have normal levels in a morning blood draw. Depending on the specific male sex hormone, the various standard deviations imply that a clinician can expect to see a difference exceeding 18% to 28% about half the time when two measurements are made on the same man and a difference exceeding 27% to 54% a quarter of the time. Also, 15% of healthy young men will have a testosterone level below the normal range in any 24 hour period. That is why the Endocrine Society, in its clinical practice guideline for Testosterone Therapy in Adult Men with Androgen Deficiency Syndromes, emphasizes that “day-to-day variations in serum testosterone concentrations were found to be sufficiently large that single testosterone measurements were inadequate to characterize an individual’s levels, and at least two testosterone measurements were needed to diagnose androgen deficiency with greater confidence.”
Funny, then, that a recent study (the same study that found skyrocketing rates of androgen replacement prescribing) also found that among all new androgen users from 2001 to 2011, only 74.72% had had their testosterone level measured in the year prior to starting to take androgen replacement. That means slightly over one quarter of men started on testosterone had never been shown to have low testosterone levels! Given this result, one wonders how careful a workup was done before prescribing testosterone replacement. After all, there are multiple forms of hypogonadism, primary and secondary. Primary hypogonadism is due to failure of the testes to make adequate testosterone, while secondary hypogonadism is due to a problem in the hypothalamus or pituitary gland, the parts of the brain that signal the testes to produce testosterone. The hypothalamus produces gonadotropin releasing hormone, which signals the pituitary gland to make the follicle-stimulating hormone (FSH) and luteinizing hormone. Luteinizing hormone then signals the testes to produce testosterone. Either type of hypogonadism may be caused by an inherited (congenital) trait or something that happens later in life (acquired), such as an injury or an infection, and there are specific workups and tests that need to be done to differentiate between the two, as detailed in the Endocrine Society’s guidelines.
For these men, most likely, testosterone was prescribed for some of those vague symptoms that the “Low T” websites promote as being due to low testosterone levels or to make a man “feel younger.” These are the sorts of symptoms that are relieved by testosterone in testimonials, like this one by former pro football player Daryl “Moose” Johnston, whose complaints were mainly:
I was feeling more tired than usual and I noticed that I was having trouble keeping up with my regular activities. These signs were pretty subtle at first, but it didn’t take long until they started to get in the way of things I loved to do, like exercising. As an athlete and someone who has been active my entire life, I knew something wasn’t right. That’s when I decided to see my doctor.
There’s a term for symptoms like that: Getting old. Yes, it sucks, particularly if you used to be a professional athlete and your identity is heavily invested in being physically fit and active. It often hits athletes hard when they realize that they can’t keep up with young men anymore. But how does one distinguish symptoms that are really due to “low T” from the normal changes that men (and women) experience as they get older? I’m experiencing these sorts of things, even though I was never an athlete and never particularly physically active. I highly doubt it’s due to “low T.” It’s probably because I’m getting older and, frankly, because my lifestyle and diet aren’t the greatest.
All of this brings me to asking whether there is anything to the claims that replenishing low or borderline-low testosterone levels will correct many of the symptoms for which testosterone replacement therapy is prescribed. In considering this question, it is useful to frame it as a series of four questions asked by Peter Lipson three years ago:
     1.  Is there a plausible connection between testosterone levels and certain symptoms?
     2.  What is a normal testosterone level?
     3.  Are there specific symptoms that correlate with lower levels?
     4.  Does replacement therapy correct these symptoms?
I’ve already discussed #2 in detail. Question #1 would suggest that, at the very minimum, symptoms of sexual dysfunction, such as decreased libido, infertility, and erectile dysfunction, could be plausible consequences of low testosterone levels. After all, testosterone is the primary male sex hormone. Besides libido, fertility, and sexual function, testosterone also influences energy and stamina, mood, cognitive functioning, bone density, red blood cell production, and maintenance of secondary sexual characteristics.
However, such symptoms can be caused by many things. Depression and medication side effects, for instance, can result in decreased libido. Atherosclerotic vascular disease can result in erectile dysfunction due to decreased blood flow, as can damage to the nerves controlling erection. A number of studies have looked at the symptoms attributed to low testosterone with mixed results, such that it is not unreasonable to characterize the clinical importance of age-related decreases in testosterone as controversial. For example, a recent study of middle-aged and elderly men found that only poor morning erection, low sexual desire and erectile dysfunction were associated with low testosterone levels. Other symptoms, such as decreased vigorous activity, difficulty walking more than one kilometer, fatigue, and loss of energy, all symptoms frequently attributed to “low T,” correlated poorly with testosterone levels. So the answer to #3 really only includes primarily symptoms of decreased libido and erectile dysfunction.
There are other clinical problems that have been attributed to low testosterone, but it is hard to determine whether they are causative or a consequence of the conditions associated with low testosterone. For example, metabolic syndrome has been associated with low testosterone levels. Although testosterone levels were associated with metabolic syndrome, this relationship appeared to be associated with lipid categories, hs-CRP, BMI, and insulin resistance levels and did not appear to be an independent marker for metabolic syndrome. Similarly, a recent review of the literature concluded that low testosterone is associated with depressive disorders but that “there is insufficient evidence to conclude that low testosterone level routinely leads to major depressive disorder in men,” while another recent review concluded that “men with COPD [chronic obstructive pulmonary disease] have clinically relevant lower than normal TT levels” but that “insufficient evidence from short-term studies in predominately male COPD patients suggests that testosterone therapy improves exercise capacity outcomes, namely peak muscle strength and peak workload.”
One of the strongest claims made by advocates of treating “low T” is that low testosterone levels are associated with cardiovascular diseases, such as atherosclerosis, hypertension, and myocardial infarction. A “hot off the presses” review from Belgian researchers based on the literature from 1970 to 2013 concluded:
On the one hand, a modest association is suggested between low endogenous T and incident cardiovascular disease or cardiovascular mortality, implying unrecognized beneficial T effects, residual confounding, or a relationship with health status. On the other hand, treatments with T to restore “normal concentrations” have so far not been proven to be beneficial with respect to cardiovascular disease; neither have they definitely shown specific adverse cardiovascular effects. The cardiovascular risk-benefit profile of T therapy remains largely evasive in view of a lack of well-designed and adequately powered randomized clinical trials.
Also hot off the press, however, is a cohort study published JAMA from the University of Texas Southwestern involving 8,709 men with low testosterone undergoing coronary angiography in the VA medical system, of whom 1,223 started testosterone therapy after a median of 531 days post-angiography. The investigators found that testosterone replacement therapy was associated increased risk of mortality, MI, or ischemic stroke. The effect sizes weren’t huge, but the results were consistent with an earlier small randomized, placebo-controlled trial of testosterone replacement therapy in men 65 or older with limitations of mobility had to be stopped because of a higher number of adverse events in the testosterone group.
There’s no doubt that for men with true hypogonadism, testosterone replacement therapy can have definite therapeutic effects, as both Peter Lipson and Harriet Hall have described, but that’s not what we’re talking about here. Moreover, testosterone replacement has known adverse effects, including sleep apnea, elevated red blood cell count, heart disease, acne, benign prostatic hypertrophy, breast enlargement, reduced sperm production, and shrinkage of testicles. It might also have unknown adverse effects over the long term, as some of the studies cited above show. At the very least, it is not the panacea that it’s advertised as.
Low T: When science meets marketing, marketing wins
The best summary of the controversy over “low T” that I’ve seen appeared in JAMA in August. It was written by Lisa M. Schwartz and Steven Woloshin and entitled Low “T” as in “Template” How to Sell Disease. Schwartz describes that template in terms of three strategies:
    • Lower the bar. By this, Schwartz means to broaden the criteria for a “disease” beyond what was previously accepted, evidence or no evidence. In other words, “lower the bar” for diagnosing that disease, so that more people need “treatment.”
    • Raise the stakes. This involves increasing the claims for the harm that comes from not treating the new condition and the benefits of treating the condition. Schwartz writes: “It is one thing to tell men that Low T can make them grumpy; it is another to say that it can kill them. Messages raising the stakes about Low T have appeared regularly in scientific meeting reports and journal articles7 and often make their way into the news (“Low testosterone could kill you,” according to ABC News).”
    • Spin the evidence. This one is self-explanatory. As Schwartz puts it: “Testosterone therapy results in only small improvements in lean body mass and body fat, libido, and sexual satisfaction, and has inconsistent (or no) effect on weight, depression, and lower extremity strength. Whether these effects are big enough to matter to patients is unknown. Nor is it known whether they are big enough to outweigh the harms of testosterone therapy, i.e., polycythemia that may increase thromboembolic events, edema, serious hepatotoxic effects, gynecomastia, worsening of sleep apnea, prostate enlargement, and rise in prostate-specific antigen level (and potential increased risk of prostate cancer).”
All of these things are going on with respect to testosterone replacement therapy. There is a paucity of evidence that “low T” is the problem that it is advertised to be and even less evidence that testosterone replacement therapy corrects the problems attributed to “low T.” Before pharmaceutical companies launch big money campaigns to make millions of men “aware” of low T, they should be required to do what they have to do before introducing a new drug for a new indication: the appropriate large-scale randomized trials to demonstrate that testosterone therapy for otherwise-healthy aging men whose testosterone levels are below the normal range for young men does more good than harm. Right now, we don’t have that evidence, and we’re not likely to get it from pharmaceutical companies.

Testing Testosterone Treatments
Harriet Hall on March 22, 2016
Link


Ponce de Leon is said to have been looking for the Fountain of Youth when he explored Florida. That’s only a myth. Now there’s a new myth, that testosterone supplements are a Fountain of Youth for aging men. Men are urged to get their testosterone levels checked if they have any of a long laundry list of vague symptoms. Anti-aging clinics promote testosterone supplementation in many forms: prescription, bioidenticals from compounding pharmacies, natural remedies, testosterone boosters, and precursors. There are highly inflated estimates of the number of men who need supplementation, often relying on broadened criteria for diagnosis or non-standard lab tests. Testimonials abound: “My depression symptoms disappeared in 20 minutes when I started using Androgel.” (That one’s particularly hard to believe. Suggestion can be powerful.)
Until recently, evidence for the benefits of testosterone supplements was scanty, and there was concern about increased cardiovascular and prostate risks and other side effects. A 2013 study found that while testosterone was clearly indicated for younger men with classic hypogonadism caused by known diseases, a general policy of testosterone replacement in all older men with age-related decline in testosterone levels was not justified. In 2003 an Institute of Medicine panel called for a set of coordinated clinical trials to determine whether testosterone would benefit older men who had low testosterone levels for no known reason other than age and who had clinical conditions to which low testosterone might contribute. The results of those trials are starting to come in. The findings to date were covered in an article in the New England Journal of Medicine in February 2016. The full text is available online.
A background on testosterone
Testosterone levels rise at puberty and peak in the late teens and early twenties. Then they decline by about 1% a year. Declining levels are a natural consequence of aging. With age, men have decreases in strength, mobility, sexual function, and energy. Are those decreases due to lower testosterone levels or due to the aging process itself? Wouldn’t it be great if we could prevent many of the consequences of aging by simply keeping testosterone at the levels found in young men? That’s a nice dream, but the reality is otherwise.
Early studies showed that testosterone increases muscle mass. That’s why some athletes, even young men with normal testosterone levels, have used it, sometimes in massive doses. It is on the list of drugs banned from the Olympics. There were inconsistent results from studies of the effects of testosterone on other measures like increased physical performance, sexual function, and energy.
The Testosterone Trials
The Testosterone Trials set out to resolve the inconsistencies in the evidence. They are a coordinated set of double-blind, placebo-controlled trials being carried out at 12 sites. They were designed to address seven outcomes: sexual function, vitality, physical function, cognitive function, anemia, bone density, and cardiovascular status. The first three of those have been completed.
The trials were large and well designed. Selection of subjects was stringent. They had to be 65 or older, to have testosterone levels below the normal range for men 19-40 years of age, to have symptoms related to predetermined outcomes, and to have none of a long list of contraindications (like high risk of prostate cancer or cardiovascular disease or severe depression). Only 1.5% of those screened were eligible and enrolled. Inclusion in the Sexual Function Trials had several more requirements including self-reported decreased libido. Inclusion in the Physical Function Trial required self-reported difficulty walking or climbing stairs and a gait speed of less than 1.2 m per second on the 6-minute walk test. The Vitality Trial required self-reported low vitality and a score of less than 40 on the Functional Assessment of Chronic Illness Therapy-Fatigue (FACT) scale. They were randomized into two groups and treated with either testosterone gel (Androgel) or a placebo gel with an identical appearance. The Androgel dose was adjusted to keep the serum testosterone levels in the normal range for men aged 19-40. The dose of placebo gel was changed simultaneously to maintain blinding.
The results
There were modest improvements in sexual function but they tended to wane after several months and were not as robust as with Viagra-type drugs. There were small gains in physical performance and in indexes of mood and depression; overall vitality was no better than with placebo. No major toxic effects were observed, although hemoglobin and prostate-specific antigen (PSA) levels were affected. The study was too short and too small to rule out negative outcomes for prostate or cardiovascular health.
As summarized in the accompanying editorial:
The results show that testosterone therapy did yield certain benefits, but at this point their clinical importance is uncertain. Therapy was not a panacea, and the findings alone might be insufficient to support a decision to initiate testosterone therapy in symptomatic older men.
These findings may be used to support treatment of elderly men with very low testosterone levels, but they may not apply to younger men, those with not-so-low testosterone levels, those with risk factors for prostate and cardiovascular disease, those without symptoms, or those with symptoms not studied in the trials.
The oversell by manufacturers
Solvay Pharmaceuticals mounted an aggressive campaign to sell its Androgel, claiming that 13 million men suffered from low testosterone, 90% of them undiagnosed. In reality, only 0.1% of men in their forties, 0.6% in their fifties, 3.2% in their sixties, and 5.1% of men in their seventies would meet the criteria for the diagnosis of androgen deficiency. But never mind the facts. At a chain of Low-T centers, a man can walk in, have his blood drawn, and get his first testosterone injection 30 minutes later. They promise to boost energy, decrease body fat, irritability and depression, and even claim that research has found testosterone can solve long-term health issues like Alzheimer’s and heart disease. One man was offered a free workup; when he protested that he felt fine, they told him he only “thought” he felt fine.
There are testosterone doctors like Paul Campion, who was first treated and then recruited by Cenegenics. He and his patients plan to take testosterone for life. He charges $5,000 for an initial visit and then $1,000 a month, with lab tests every 3 months. His aim is to promote well-being, not to treat disease. He says “Testosterone is ridiculously powerful…I can tell you from experience, the feeling of well-being, of focus, and of masculine energy are massively increased. It’s like you’re back to being 35.”
A Harvard urologist named Abraham Morgentaler wrote the book Testosterone for Life. He says:
Men have symptoms that are related or possibly related to a deficiency of a hormone and if the symptoms are bothersome, then the men will undergo a trial of treatment and it is often but not always successful…This is what we do in medicine. There is nothing that’s different.
No, that’s not what we do in scientific medicine. What we do is compare the success of treatment to the success of placebo, because we know that a simple trial of treatment may deceive doctors and patients when it is followed by improvement that is not due to the treatment itself.
An FDA investigation found that fully half of men taking testosterone hadn’t been diagnosed with the disease hypogonadism, and a quarter of them were given hormones without a previous blood test.
Natural remedies
Naturopaths use saliva and other non-standard tests to diagnose androgen deficiency, and they treat it with lifestyle and dietary modification, nutrient supplementation, and herbal remedies like Korean ginseng, tribulus, saw palmetto, damiana, oat seed, and liquorice. The evidence for this approach is lacking.
Joseph Mercola of mercola.com also advocates raising testosterone levels by natural means. He recommends zinc, vitamin D, limiting sugar, consuming organic dairy products, high intensity interval training, and controlling stress with Emotional Freedom Technique (rhythmically tapping designated spots on the body with the fingertips). There is some evidence that low zinc levels are associated with low testosterone levels, but zinc deficiency is rare and the other recommendations are not likely to be helpful.
Conclusion: Modest benefits to testosterone supplementation, at best
The other four studies in the Testosterone Trials (on cognitive function, anemia, bone density, and cardiovascular status) are still in progress, and we can look forward to learning more from them. At present, all we can conclude is that for men over 65 who have the specific symptoms studied, who are at low risk of prostate and heart disease, and who have testosterone levels below 275 ng per deciliter, raising testosterone levels to the normal range for men aged 19-40 has modest benefits. There is no good evidence to support treatment for men younger than 65, men with higher levels of testosterone, men at higher risk of prostate and heart disease, and men with other symptoms or no symptoms. The risks remain uncertain. The side effects are not limited to the patient himself: if women or children come into contact with testosterone gel or to a man’s unwashed hands after he has applied it, it can cause hair growth, menstrual irregularity, and premature puberty. It has even been reported to cause aggressive behavior in pets.
There is no evidence to support using bioidentical hormones, particularly from compounding pharmacies, natural remedies, testosterone boosters, or precursors like DHEA.
Clearly, a lot of men are taking these products for indications that are not evidence-based. An article in The Atlantic likened it to a “mad T party”. Let’s guard against turning a natural phenomenon of aging into a disease. Testosterone may be useful when prescribed appropriately for symptomatic androgen deficiency, but it is clearly no Fountain of Youth; the hype has far exceeded the reality.

Update on Testosterone Supplementation
Testosterone supplementation is a legitimate treatment for properly-diagnosed androgen deficiency, but it is being overprescribed by doctors who make exaggerated claims for it. New evidence clarifies its modest benefits and worrisome risks.
Harriet Hall on March 14, 2017
Link


Lots of men are taking testosterone supplements, some of them for good reasons and some for not-so-good reasons. There are Low-T clinics that treat most if not all comers and make exaggerated promises for health benefits, presenting testosterone supplementation as something like a Fountain of Youth for men. They have testimonials galore from patients who claim to feel younger and more vigorous. Please see my 2010 article on testosterone supplementation for more details, as well as these posts by Peter Lipson and David Gorski.
Symptoms of low testosterone
A July 2010 article in the NEJM by Wu et al. found that the only symptoms that clearly correlate to low testosterone levels are poor morning erection, low sexual desire, and erectile dysfunction. But the websites promoting testosterone treatment provide a whole laundry list of symptoms that they say could be caused by low testosterone levels, including fatigue, weakness, depression, mood problems, irritability, infertility, reduction of pubic hair, sweating, memory loss, sleep disturbances, low self-confidence, lack of motivation, aches and pains, diminished mental aggressiveness, decreased stamina, and many more. They imply that if you have any of these symptoms, you should be at least tested and probably treated.
Normal testosterone values vary from 270-1070 ng/dl; the definition of “normal” varies slightly according to different experts. Levels decrease with age, but that is a normal physiologic process, not a disease requiring treatment. There is no reason to think a 70-year-old man should have the testosterone level of a 20-year-old. Low-T doctors say if your level is normal but in the lower end of the normal range, you may have symptoms and benefit from replacement. That claim is not supported by scientific evidence. They suggest a trial of treatment for anyone with suspicious symptoms, to see if they improve. That is not a good idea. It amounts to an uncontrolled experiment; it would be confounded by placebo responses, misattribution of spontaneous improvements and regression to the mean, and would provide the doctor with an excuse to keep prescribing testosterone long-term for patients who may not need it. They also claim that low testosterone causes a higher risk of diabetes, osteoporosis, and cardiovascular disease. That’s a misleading claim apparently based on the risk of those diseases in infertile men and the fact that men with low sperm counts are more likely to be diagnosed with hypogonadism.
The TTrials, part 1
I wrote about testosterone again in 2016 when the first results from the TTrials were released. The TTrials were a coordinated set of double-blind, placebo-controlled trials lasting one year, carried out at 12 sites on men over the age of 65 whose testosterone levels were below the normal range for men 19-40 years of age. Low testosterone was not very prevalent; they had to screen 51,085 men to find 790 who had sufficiently low testosterone levels and met the other criteria for enrollment. There were seven separate trials. For each trial, patients were randomized and treated with either Androgel or a placebo gel. Results for three of the seven trials were released in 2016.
Sexual Function Trial required self-reported decreased libido. Results: modest improvements in sexual function that tended to wane after several months and were not as robust as the effects of Viagra.
Physical Function Trial required self-reported difficulty walking or climbing stairs and a gait speed of less than 1.2 m per second on the 6-minute walk test. Results: small gains in physical performance.
Vitality Trial required self-reported low vitality and a score of less than 40 on the Functional Assessment of Chronic Illness scale (FACT). Results: overall vitality was no better with Androgel than with placebo.
In short, some modest benefits with questionable clinical significance.
The TTrials, part 2
In February 2017, the results of the other four trials were released.
Bone Trial, on 189 men, found that testosterone improved bone density and estimated bone strength.
Anemia Trial found that testosterone significantly improved hemoglobin concentrations in 54% of 62 patients with unexplained anemia and 52% of 64 patients with anemia of known cause.
Cardiovascular Trial found that testosterone increased coronary artery noncalcified plaque volume and narrowed coronary arteries in 73 men using Androgel compared to 65 in the placebo group.
Cognition Trial found no effect on memory or cognitive function in 493 patients with age-associated memory impairment.
What do these findings really tell us?
The clinical significance of the positive findings is not clear. No major cardiovascular events occurred during the study and there was no reduction in the incidence of fractures, but the trials only lasted a year. The number of subjects in some of the trials was small. Longer, larger trials will be needed to confirm findings. Other studies have reached different conclusions: for instance, a retrospective cohort study found an association of testosterone prescriptions with a reduced risk of cardiovascular events in men over the age of 40 with testosterone levels lower than 300ng/dL.
Side effects of testosterone treatment
Testosterone is not harmless. It can contribute to sleep apnea, cause acne, stimulate benign prostatic growth and prostate cancer, enlarge breasts, cause male pattern baldness, reduce sperm production, shrink testicles, and increase the risk of a blood clot. A long list of other side effects can be found here. And some studies have found that it increases the rate of cardiovascular events.
The dangers are not limited to the patient. The gel can be transferred from the patient’s body to others by simple contact, affecting children, women, and pets. There have been reports of early puberty and aggressiveness in children, increases in acne and body hair and menstrual irregularity in women, and severe hormonal effects in pets.
Conclusion: Still no easy answers
The new studies don’t really change the overall equation, although they add to the information doctors can give patients. Testosterone supplementation has both benefits and risks, and the decision to prescribe it should be carefully considered for each individual. The Endocrine Society has published clinical practice guidelines for the treatment of androgen deficiency, stressing caution in making the diagnosis, but these guidelines have not been updated since 2010. As with so much in medicine, it’s complicated. But one thing is clear: testosterone supplementation is not an anti-aging panacea.

   Testosterone: Not an Anti-Aging Panacea
Harriet Hall
Link
On the car radio, I have several times happened upon “infomercial” programs touting the benefits of testosterone replacement therapy for men, broadcast by doctors who specialize in prescribing the drugs. They have lots of wonderful stories about men who feel younger, happier, and more vigorous because of their macho remedies. It’s a tribute to the power of the placebo.
I have been reviewing John Brinkley’s goat gland scam for a presentation on medical frauds. In an era before the isolation of the hormone testosterone, Brinkley transplanted goat testes into human scrotums in an attempt to treat impotence and aging. We are more sophisticated today … but not much. Longevity clinics and individual practitioners are offering testosterone to men as a general pick-me-up and anti-aging treatment. Their practice is not supported by the scientific evidence.
Men’s testosterone levels drop as they age. According to a review article in the New England Journal of Medicine
the decrease in testosterone in men occurs moderately and gradually over a period of several decades. The serum total testosterone concentration decreases from a mean of about 600 ng per deciliter (20.8 nmol per liter) at 30 years of age to a mean of about 400 ng per deciliter (13.9 nmol per liter) at 80 years, although the range is wide at all ages. In one study, approximately 20 percent of men older than 60 years of age had total serum testosterone concentrations that were below the normal range for young men.
An essential but still unanswered question is whether this decrease in the testosterone concentration is physiologic, perhaps conveying a benefit, or pathologic, causing harm.
Other things happen as men age, and a simplistic, hopeful approach is to blame many of the consequences of aging on decreased testosterone levels and to use replacement therapy to bring the levels back to those of healthy youth. That approach is not science-based. Science only supports raising testosterone levels in patients who have specific problems attributable to abnormally low levels.
A recent article in JournalWatch reviewed the subject with reference to three new studies.
A July 2010 article in the NEJM by Wu et al. found that the only symptoms that correlate to low testosterone levels are poor morning erection, low sexual desire, and erectile dysfunction. Other psychological and physical symptoms correlated poorly with low testosterone levels. Total testosterone levels were sufficient for diagnosis; free testosterone levels did not add to diagnostic accuracy.
An article in the Journal of Clinical Endocrinology and Metabolism by Krasnoff et al. found that total testosterone was not associated with mobility limitation, subjective health, or any physical performance measures, whereas free testosterone was associated with subjective health and some (but not all) physical performance measures. Low baseline free testosterone levels were associated with subsequent decline in mobility but not in subjective health. JournalWatch editor Dr. Alan Brett comments that this study
shows correlations between free testosterone and some measures of physical performance; however, findings were mixed, and significant associations in observational studies do not necessarily indicate cause-and-effect.
A third study by Basaria et al. published in the New England Journal of Medicine studied older men with limitations of mobility to see if testosterone supplementation would improve mobility by increasing muscle mass and strength. This trial was stopped early because of a higher rate of cardiovascular events in the testosterone group compared to the placebo group.
The JournalWatch editor comments:
These studies — considered alongside other recent studies in which testosterone supplementation did not yield impressive results in frail older men or in healthy older men — argue against indiscriminate use of testosterone as an “anti-aging” drug. This conclusion is supported by a new practice guideline from the Endocrine Society.
Testosterone is not harmless. The Mayo Clinic website lists several adverse effects of testosterone: sleep apnea, elevated red blood cell count, heart disease, acne, benign prostatic hypertrophy, breast enlargement, reduced sperm production, and shrinkage of testicles. Mentioning a risk of testicular shrinkage in the infomercials would put quite a dent in sales, I imagine.
Meanwhile, Suzanne Somers recommends testosterone for everyone: both men and women. On the Oprah website, readers provide testimonials:
Just ask my husband who take [sic] testosterone daily thanks to Suzanne’s books.
The unsupported opinions of celebrities and longevity opportunists versus the evidence of science-based medicine: take your pick.

   James Ray and testosterone replacement therapy (TRT). 
David J Kroll
Link
For the last four years I have served in a volunteer capacity among a panel of pharmacotherapy experts queried regularly by the ABC News Medical Unit about breaking or upcoming news involving the efficacy and safety of drugs and supplements. Where appropriate, I provide background information that informs the story. My incentive is largely to put my time where my mouth is when I say that scientists need to take a more active role in making sure medical stories are reported accurately. An additional dividend is paid to my students who then benefit from my presentation of the science behind timely medical developments.
On occasion, perhaps once or twice a year, I’ll be asked for an on-camera interview. Even when this occurs, the resulting story will contain no more than 15 seconds of the interview and some summary by the reporter of other issues we discussed. I take this responsibility very seriously and prepare as much as I can given the deadlines of the press and my daily education and research schedule. But given airtime constraints, much of what I prepare would normally end up in the abyss of my files and come out in the classroom when I lecture about that particular topic. However, blogging now allows us to expand further on stories where we are consulted, giving us an opportunity to air, albeit to a smaller audience, the information we found important from our perspective. Authoring a blog, therefore, takes away the excuse some scientists and physicians have in not wanting to talk to the press: “There’s never enough airtime to tell the whole story the way I would tell it.”
This post was informed by one of those brief appearances, this time on ABC World News Sunday with Dan Harris. The interview was solicited last weekend following the release of information obtained during the execution of a search warrant in lodging occupied by the self-help guru, James Arthur Ray, who led an Arizona sweat lodge ceremony last October where three people ultimately died and almost two dozen were hospitalized. The segment was not archived to the World News website but some ABC affiliates subsequently aired truncated versions of the story.
———————————–
On October 8, 2009, paramedics responded to a 911 call at a mystical retreat being held at Angel Valley Spiritual Retreat Center in West Sedona, Arizona, a stunningly beautiful area known widely as a mecca for New Age enthusiasts. Eyewitness accounts compiled in this October 21 New York Times article describes what medics encountered upon arriving at a 415-square-foot “sweat lodge” on the center’s grounds:
Midway through a two-hour sweat lodge ceremony intended to be a rebirthing experience, participants say, some people began to fall desperately ill from the heat, even as their leader, James Arthur Ray, a nationally known New Age guru, urged them to press on.
“There were people throwing up everywhere,” said Dr. Beverley Bunn, 43, an orthodontist from Texas, who said she struggled to remain conscious in the sweat lodge, a makeshift structure covered with blankets and plastic and heated with fiery rocks.
Dr. Bunn said Mr. Ray told the more than 50 people jammed into the small structure — people who had just completed a 36-hour “vision quest” in which they fasted alone in the desert — that vomiting “was good for you, that you are purging what your body doesn’t want, what it doesn’t need.” But by the end of the ordeal on Oct. 8, emergency crews had taken 21 people to hospitals. Three have since died.
Participants paid $9,695 each to attend a “Spiritual Warrior” retreat led by Mr. Ray, an event whose next offering continues to be advertised on the website for James Ray International, Inc.
Yes, the 2010 event is still scheduled for September 18-23, 2010 and registration remains open.
But I wouldn’t put up my ten grand just yet because an investigation of Mr. Ray is ongoing and the Yavapati County Sheriff’s Office has recently released the affidavit from a search warrant executed shortly after this tragedy.
This December 30 New York Times article displays the 33-page search affidavit and this January 3 Prescott News article has several photographs and an excellent distillation of the affidavit.
Many other news sources will provide you with details on the circumstances of the tragedy with eyewitness reports and you can read elsewhere of Mr. Ray’s appearances on The Oprah Winfrey Show associated with the book, The Secret by Rhonda Byrne.
But here we would like to discuss some of the pharmacology associated with the Sedona tragedy. Lynne LaMaster in the Prescott News notes that according to the search warrant documents, investigators were originally looking for:
“A saleable/useable quantity of unlawful drugs including but not limited to marijuana, methamphetamine and peyote, paraphernalia for packaging, manicuring, weighing, distributing, including but not limited to scales, baggies, grinders, bindles, envelopes, seals paraphernalia used to administer the drug, i.e., syringes, cotton swabs, alcohol swabs, spoons, razor blades, tubes.”
While investigators did not appear to find any overtly psychoactive substances, they did find a veritable cornucopia of prescription drugs, dietary supplements, and syringes, with prescriptions in the name of Mr. Ray. But it wasn’t the supplements that caught my eye. It was this letter from a Michigan doctor of osteopathy:
Dr. Crisler operates the website, allthingsmale.com, and offers in-clinic and online consultations. The frontpage of his site argues strongly that he is in the business of anti-aging therapies as shown lecturing to the American Academy of Anti-Aging Medicine and offering subscriptions to Life Extension Magazine. Further exploration of his website reveals that he specializes further in assessment of low testosterone levels, or hypogonadism.
Testosterone cypionate, hGH, hCG, Arimidex (anastrozole) and finasteride (sold previously as Propecia or Proscar, but now available generically). OK, that’s starting to make sense. Testosterone and human growth hormone (hGH) are anabolic agents. That is, they enhance the development of lean, skeletal muscle mass. But you might have some questions at first glance.
(For pharmacology students and professors, dissecting the endocrine pharmacology of this combination would make a great comprehensive qualifying examination question for graduate candidacy.)
Arimidex/anastrozole? Isn’t that used to treat estrogen-dependent breast cancer?
Finasteride? Isn’t that used to treat prostate cancer?
Let’s take a closer look at some of these drugs.
Testosterone cypionate is known as a “depot” form of testosterone that has a half-life of 5-8 days, sold as DEPO®-Testosterone in the US. Testosterone, the steroid hormone primarily responsible for secondary sex characteristics in men, is not active when taken orally because it is rapidly metabolized by the liver. Therefore, if one wishes to boost testosterone, it is commonly formulated into a gel or patch that slowly releases the hormone across the skin. But it is more effectively delivered by injection, usually into muscle. When combined with a fat-soluble compound like cypionic acid, the testosterone is slowly released from the injection site. According to a PowerPoint presentation available at Dr. Crisler’s website (here, 4.5MB), his regimen employs weekly injections of 100 mg testosterone cypionate, about double the manufacturer’s recommendation for treating clinical hypogonadism.
When I was interviewed by Dan Harris for ABC World News Sunday last weekend, we discussed in footage that did not appear whether testosterone qualified as an “anabolic steroid.” The public normally thinks of ultrapotent, clandestine compounds as being the anabolic steroids used by athletes. But in purely pharmacological terms, testosterone is a steroid based on its chemical structure and it has anabolic, or tissue-building, activity. However, testosterone is an anabolic steroid that we make naturally, men and women.
Hence, testosterone is an endogenous anabolic steroid. When injected as testosterone cypionate, this would be called the exogenous supplementation of an endogenous steroid. But true bodybuilders wouldn’t bother with something like testosterone when more potent and effective synthetic anabolic steroids are available on the clandestine market.
Arimidex (anastrozole) is classified as an “aromatase inhibitor.” You may not know that testosterone is the starting material for estradiol, the steroid hormone primarily responsible for secondary sex characteristics in women. Testosterone, which we all make from cholesterol as the starting material, is converted to estrogen by aromatase or CYP19, an enzyme that is highly abundant in the ovaries. When a woman is diagnosed with a form of breast cancer that required estrogen to grow, aromatase inhibitors are given to prevent the ovaries from making more estrogen from testosterone (Older drugs such as tamoxifen can also be given as they directly block the effects of estrogen on breast cancer cells themselves.)
We do not know if Mr. Ray was among the approximately 1% of breast cancers that occur in men. Former drummer of the rock band KISS, Peter Criss, is the most recently public of male breast cancer patients in the US.
However, it does not appear that Dr. Crisler is a board-certified oncologist, so there must be some other reason that he prescribed Arimidex to Mr. Ray. Men have some testosterone that gets converted to estrogen but usually it’s not enough to cause estrogenic side effects such as gynecomastia and testicular shrinkage. But when taking supplemental, supraphysiological doses of testosterone, the small amount of aromatase that men have will convert enough of it to estradiol such that they may experience some feminizing effects.
Interestingly, Dr. Crisler notes on slide #66 of his aforementioned PowerPoint presentation that anastrozole’s #1 use worldwide is in testosterone replacement therapy regimens. Unfortunately, a citation is not available to support that statement.
Finasteride prevents conversion by 5-alpha-reductase of testosterone to dihydrotestosterone or DHT, a form of the hormone that can cause benign prostatic hypertrophy, can promote prostate cancer, and is also partly responsible for hair loss. Hence, finasteride combats several side effects of testosterone supplementation. So, these testosterone injections can be combined with anastrozole and finasteride to maximize testosterone’s anabolic effect while minimizing “unsightly” side effects.
Human growth hormone (hGH) is a peptide normally produced in the pituitary gland that is also anabolic on its own and augments the muscle-building effects of testosterone.
Human chorionic gonadotropin or hCG is normally the hormone produced by the placenta during pregnancy and is the hormone detected in the urine by home and clinical pregnancy tests. Yes, men taking this hormone would give a positive pregnancy test.
Understanding why hCG might be given in this cocktail requires that we revisit the hypothalamic-pituitary-gonadal axis (HPGA). Gonadotropin-releasing hormone, or GnRH, is produced in the hypothalamus of the brain and signals that pituitary gland to synthesize and release several peptide hormones that each share a common subunit: LH, FSH, TSH, and hCG. LH, or luteinizing hormone, when released from the pituitary gland and causes the testes to create mature spermatozoa and release testosterone. However, when too much testosterone is produced, or too much is available from external injection, a negative feedback loop suppresses LH secretion. Suppression of LH over time will cause testicular atrophy. It is thought that providing hCG will provide more of the subunit shared with LH, restoring LH levels. I am not convinced that this actually occurs. Restoring LH also is purported to increase the conversion of cholesterol to pregnenolone, a precursor or building block of testosterone. Believe it or not, this is an oversimplification of the pathway but I hope that gives you an idea of the rationale behind hCG use.
There were also some other drugs found in Ray’s room at the lodge prescribed by other physicians that included Diovan (valsartan), an antihypertensive of that competitively binds receptors for an endogenous vasocontrictor, angiotensin II, and an injectable relative of vitamin B12 called methylcobalamin. Although we don’t know for certain if Ray was taking the drugs prescribed by Dr. Crisler, investigators did at least find anastrozole and Genotropin brand of hGH, Propecia brand of finasteride, together with pregnenolone, the testosterone precursor. Also found were bags, suitcases, and pill boxes of energy supplements and amino acids. The complete litany of objects confiscated from his possession are detailed at the Prescott News website.
As mentioned at the outset, one of the biggest reasons investigators were interested in any drugs that might have been in Ray’s possession was that there may have been psychoactive substances that could have impaired his judgment or that of followers/clients in the sweat lodge at the retreat. Ray was reported by several eyewitnesses as being aggressive and aloof, and even unhelpful when medics arrived at the sweat lodge. Dan Harris at ABC News asked me if I thought that Ray’s pharmacopeia might have contributed to his state of mind.
This is very difficult to do for a plethora of reasons, not the least of which because I am not a physician nor am I privy to what drugs he was actually taking or his basal personality characteristics. However, I am a pharmacologist and did train in endocrinology during my postdoctoral fellowship and can make some general comments.
A person taking an anabolic steroid regimen (recall that testosterone is a natural anabolic steroid) is prone to mood swings, anxiety, and aggressive behavior. In “TRT: A Recipe For Success,” a Word document available at All Things Male, Dr. Crisler apparently makes note that the intent is not to create an anabolic steroid cycle but rather testosterone replacement therapy, where testosterone levels are targeted to the upper-level of a normal range. Unfortunately, we cannot be sure if Mr. Ray was taking the drugs as directed or at doses greater than those recommended.
A physician colleague also reminded me that some of the drugs on the search warrant could alone cause electrolyte disturbances that could be exacerbated by being in an enclosed area with hot stones where other people were vomiting and begging to get out after fasting for 36 hours. Specifically, testosterone can cause sodium retention and Diovan/valsartan can cause potassium retention. These ionic imbalances can certainly influence one’s state of mind and one can speculate that these imbalances would be made worse by fasting and dehydration.
Off-label drug prescribing
This case also raises some questions as to how these drugs were prescribed in the first place. Sources close to Ray told ABC News that the “practical mystic” was being treated for a hormonal imbalance.
It is peculiar why a man of Ray’s means living in Carlsbad, CA, would be prescribed drugs by a physician in Michigan rather than seeing a board-certified endocrinologist or urologist at one of the outstanding medical centers in southern California.
Nevertheless, there are no laws that would have prevented Dr. Crisler from prescribing this regimen to Mr. Ray. To the contrary, physicians in the United States, whether they are MDs or DOs, are granted the latitude to prescribe any FDA-approved medicine for any indication they see fit. While it is illegal for drug companies themselves to promote “off-label” uses of drugs (i.e., indications for which the company has not received explicit FDA approval), a physician can legally prescribe a breast cancer drug to a man wishing to build lean muscle mass. I will leave it to my physician colleagues to comment on whether this falls under the standards of medical practice. In fact, the ethics of off-label prescribing would be an excellent separate issue to discuss in another post.
But let us not forget that this is a very sad case where three people lost their lives and nearly two dozen people were hospitalized. Press accounts of the sweat lodge incident and subsequent investigation suggest that blame and potential criminal penalties will fall where they may. The Camp Verde Journal noted in its 2009 roundup that:
Lawsuits have been filed by survivors, victims’ families and the Black Hills Sioux Nation, alleging Ray “committed fraud by impersonating an Indian,” thus violating the 1868 Treaty of Fort Laramie.
What we have offered here is a perspective on the pharmacology and toxicology of prescription hormone products and considerations of issues raised in publicly available documents and questions posed of us by the press. It is likely that several factors conspired to end up with this loss of life. As always, tragic events are what drive changes in laws and regulations.

What do mRNA vaccines, Synthroid, and pharmaceuticals have in common (according to MAHA)?
If you want to understand why Secretary of Health and Human Services Robert F. Kennedy Jr. has halted $500 million in funding for mRNA vaccine development, look no further than Synthroid and herbal medicines.
David Gorski on August 18, 2025
Link
A lot of digital ink has been spilled regarding Secretary of Health and Human Services Robert F. Kennedy Jr.’s decision earlier this month to put the kibosh on $500 million dedicated to research intended to develop the next generation of mRNA vaccines. This decision was, of course, not unexpected given RFK Jr.’s history of unrelenting hostility to vaccines in general and mRNA-based COVID-19 vaccines in particular. That is why so many doctors and scientists whom I consider allies (e.g., Dr. Paul Offit, who sarcastically referred to RFK Jr.’s “scientific explanation” for the decision as “Scienze“) were quick to emphasize the outright lies about the science supporting COVID-19 vaccines used by RFK Jr. to justify his decision. Examples included false claims that the vaccines don’t protect against upper respiratory infections, promote more mutations and “antigenic shift,” and cause more harm than good. Personally, I took a particular interest in this part of RFK Jr.’s proclamation:
The move signals a broader shift in federal vaccine development priorities. Going forward, BARDA will focus on platforms with stronger safety records and transparent clinical and manufacturing data practices. Technologies that were funded during the emergency phase but failed to meet current scientific standards will be phased out in favor of evidence-based, ethically grounded solutions – like whole-virus vaccines and novel platforms.
Note the emphasis on “whole-virus” vaccines, which are basically vaccines produced by growing up huge batches of virus and then inactivating them with heat or chemicals, thus using the whole virus as the antigens that provoke an immune response. The same can be done for bacteria causing disease. Dr. Offit and others did, of course, point out quite correctly and obviously that there is absolutely nothing new about whole-virus killed vaccines. Dr. Offit even emphasized that whole-virus vaccines have been around since the rabies vaccine was developed in the late 1800s. On another occasion in May, I myself pointed out that the “updated” aspect of this technology recently by RFK Jr. dates back 80 years when I characterized this puzzling shift away from cutting edge mRNA vaccine technology to last century’s vaccine technology. Specifically, I was referring to chemically inactivated whole-organism vaccines, which were being promoted a few months ago under the “Generation Gold Standard” moniker, which I lumped under a more general phenomenon in public health since RFK Jr. was named HHS Secretary, namely Lysenkoism 2.0.
The idea is that single antigens, like what mRNA vaccines induce cells in our body to produce, are bad, while the whole organism, with its dozens or even hundreds of antigens, is good. Why does RFK Jr., who has long been rabidly (if you’ll excuse the term) antivax think that whole-organism vaccines are the way to “safer” vaccines? I was looking for a good way to explain how It has nothing to do with science, immunology, or infectious disease and everything to do with the overall ethos behind his “Make America Healthy Again” (MAHA) movement. Then I came across an article by a friend and ally of RFK Jr. Sayer Ji posted to his Substack over the weekend and entitled The FDA’s War on Natural Thyroid: A Medical Tyranny That Threatens Millions, in which he rants about how the FDA favors Synthroid (a synthetic form of thyroxine, or T4, taken by millions of people with hypothyroidism as thyroid hormone replacement) over desiccated thyroid extract, which he characterizes as a “safe” and “natural” treatment that “patients overwhelmingly prefer.” Moreover, I discovered Ji’s post via Dr. Robert “inventor of mRNA vaccines” Malone, a COVID-era antivaxxer who, thanks to RFK Jr., is now on the CDC Advisory Committee on Immunization Practices (ACIP).
You can likely see where I’m going with this. If you remember that RFK Jr.’s MAHA is basically an extension of “alternative medicine” and its “integration” into medicine in the form of “integrative medicine,” the reason why RFK Jr. fetishizes “whole organism” vaccines over those nasty mRNA vaccines will become obvious (that is, if you ignore his 20+ year history of demonizing the MMR vaccine, which consists of three whole attenuated live viruses in one package, as The One True Cause of Autism). See if you can see the parallels between Ji’s attack on T4 and RFK Jr.’s attack on mRNA technology.
The appeal to “natural” and “holistic” in…thyroid hormone!
The first thing one notices reading Sayer Ji’s post is how much he channels universal and common alternative medicine tropes, even going so far as to incorporate the deceptive “food is medicine” trope into his railing against the FDA for supposedly “suppressing” natural treatments. I’m going to include a link to Ji’s post on X about this, because the art and images included from the post are…something:
1⃣The Bioidentical Truth

Natural thyroid isn't just "another option"—it's the COMPLETE hormone your body recognizes:

✓ T4, T3, T2, T1 + Calcitonin 
✓ Bioidentical molecular structure
✓ Natural conformational folding 
✓ 130 years proven safe

Synthetic? Just T4. Made in a… pic.twitter.com/k2oCOxVFeP
— Sayer Ji (@sayerjigmi) August 16, 2025
I love the obvious AI slop showing people with hypothyroidism breaking
their chains to grasp for the glowing giant thyroid gland being held
just out of their reach by the evil FDA. Never mind that dessicated
thyroid is freeze-dried and powdered.
It is notable, predictable, even, that Sayer Ji doesn’t actually link to the FDA letter or press release announcing the letter. As an aside, given that much of the letter emphasizes that these products are considered “biological” products, I have to wonder if boy wonder and Director of the Center for Biologics Evaluation and Research (CEBR) Dr. Vinay Prasad had anything to do with this letter before he was forced to resign, even though he hadn’t yet been reinstated. These letters generally take a fair amount of time and investigation. Be that as it may, one notes that the only direct answer Ji has to the FDA besides ranting about “overreach” and the “naturalness” of desiccated thyroid extract comes from an anonymous antivax source, OpenVAERS, claiming that there are way more reports of adverse events related to T4 than to desicated thyroid extract to the FDA Adverse Events Reporting System (FAERS), which is very much like the Vaccine Adverse Events Reporting System (VAERS) in that it is a database to which anyone can contribute a report. Both have similar shortcomings.
In any event, Ji combines common tropes in alternative medicine (and therefore in MAHA) that “natural” is better and “food is medicine”:
This is the systematic dismantling of a treatment that has worked successfully for 130 years—since 1891 when Dr. George Redmayne Murray first used desiccated thyroid extract to save a woman dying from myxedema, an extreme form of hypothyroidism.[2] The FDA’s August 6, 2025 enforcement letters threatening to ban all natural desiccated thyroid (DTE) products—including Armour Thyroid, NP Thyroid, and Nature-Throid—represent medical tyranny designed to funnel billions into synthetic drug manufacturers while condemning millions to unnecessary suffering.
But here’s what makes this particularly egregious: natural thyroid is essentially ancestral food—organ meat that humans have consumed for millennia. The FDA is attempting to ban what is fundamentally a concentrated form of dietary thyroid gland, the same substance our ancestors prized as sacred medicine and nutrient-dense food.
In case you don’t get the point, this is an image included in Ji’s post:
The AI slop is not subtle about this. I also like how the people eating the desiccated thyroid contrast to the bureaucratic FDA guy.
Does all of this sound familiar? It should. This is the same argument often made for herbal medicines. To make this argument, Ji includes some images that take the fallacy of an appeal to nature to incredible levels, for example:
Note the difference between this image and the one included in Ji’s X posting. The one in the X posting doesn’t have religious connotations, whereas this one portrays thyroglobulin as a “cathedral,” with T4 being mere “pebbles,” presumably only making up part of the “cathedral.”
Later in the post, Ji asserts:
The image above exposes the breathtaking gulf between natural and synthetic thyroid hormone. Natural desiccated thyroid contains T4, T3, T2, T1, and calcitonin bound to the massive thyroglobulin protein—a 660,000 dalton molecular complex representing millions of years of evolutionary optimization. Each hormone exists in specific conformational states, held in precise spatial relationships, creating an information-rich matrix the body recognizes holistically.
In contrast, synthetic hormone consists of isolated T4 molecules floating in pharmaceutical void, stripped of biological context, devoid of the intricate molecular choreography that defines natural thyroid function.
In fairness, he’s referring to the image not mentioning a “cathedral,” but it’s all still nonsense. Remember, you have to swallow the desiccated thyroid, just as one swallows Synthroid. That “cathedral” of a massive thyroglobulin protein is therefore digested in the gastrointestinal tract before any T4 or T3 can be released. One also notes that calcitonin is a 32 amino acid peptide that will also be digested. None of that stops Ji from waxing poetic about the wonders of thyroglobulin and “information” in a truly woo-tastic manner:
To understand the true magnitude of this difference, we must invoke Levinthal’s Paradox. For thyroglobulin to fold from a linear chain into its precise three-dimensional structure requires navigation through near-infinite conformational possibilities—a journey that would take longer than the universe’s age if done randomly. Yet it folds perfectly in milliseconds.
What Levinthal’s Paradox teaches us is that biological specificity contains inconceivable amounts of information—but not information as mere data. This is information as that which in-forms—that which puts form into biological matter, guiding the transformation of potential into actuality.
When thyroglobulin folds into its native state, it demonstrates information as a formative force. Each T4 molecule bound to thyroglobulin is literally in-formed by this protein matrix. The scaffold puts form into:
    • How the hormone is held in three-dimensional space
    • What microenvironmental conditions it experiences
    • How it relates to neighboring hormone molecules
    • When and how it will be released
    • What conformational memory it carries forward
This formative information—accumulated over millions of years of evolution—cannot be replicated in a reaction flask.
“Conformational memory”? Sounds like homeopathy, doesn’t it? You know what I’m referring to, namely how homeopaths claim that water retains the “memory” of the substances that were in it but diluted to nothingness in the production of the homeopathic remedy. Apparently, even if the thyroglobulin protein is actually digested in the GI tract, the T3 and T4 retain the “memory” of being in the thyroglobulin protein, you know, all that “information.” Nowhere does Ji explain how that mystical “information” is transmitted to the receptors to which T4 and T3 bind.
If that’s not enough:
Consider a dimension rarely discussed: every biological molecule exists within a hydration shell—a structured water envelope. Research into water’s fourth phase reveals it as an exquisite carrier of information and memory, capable of structuring itself in ways that drive molecular actions and cellular communication. The water surrounding naturally-produced hormones has been structured by living processes, carrying biophysical information that influences hormone behavior.
But, wait! Desiccated thyroid extract is…dessicated thyroid gland. It’s basically freeze-dried, ground up, and packaged in pills or capsules. So how can hydration even be an issue? Fear not, SBM readers, Ji has an explanation, because of course he does:
Remarkably, even when natural thyroid is desiccated, this information is not entirely lost. The freeze-drying process preserves molecular architecture, and upon rehydration in the body, water restructures itself according to the biological template, partially restoring the information field. It’s like a compressed file expanding back to its original form—not perfectly, but with far more fidelity than starting from scratch.
The synthetic hormone’s hydration shell, formed in industrial conditions, lacks this biological structuring entirely. The qualitative difference between natural and synthetic forms is ontologically vast—an insurmountable chasm that the false equivalence model cannot bridge.
I love the reference to lossy compression of computer files. Ji even illustrates it with these bonkers images:
Aw. How sad. The synthetic T4 is lonely, while the “natural” T4 enjoys the embrace of thyroglobulin.
If that’s not enough, there’s this:
Hydration. Toujours hydration.
None of this, of course, is science-based. It’s all very much homeopathy-adjacent, with ill-defined appeals to “biological information” and influences of water on the “natural” hormones that are never demonstrated that might be better boiled down to being magic. This is then compared to the cold “industrial” production of T4 through chemistry, concluding with this howler:
The critical epistemological issue is this: absence of evidence is not evidence of absence. Just because current assays cannot detect functional differences between synthetic and natural T4 doesn’t mean such differences don’t exist. Biological systems are nonlinear and exquisitely sensitive to subtle variations that cascade into significant physiological effects.
That’s right. Just because no scientist has demonstrated a difference in physiological and biological effects due to synthetic T4 compared to the effects of “natural T4” doesn’t mean they don’t exist. Just trust Sayer Ji. My retort would be: Even if they exist, if differences in such effects haven’t been detected, they are certainly too tiny to be significant.
In fairness, Ji does make one point made that might mean something other than woo:
The dirty secret of synthetic thyroid treatment: up to 15% of patients cannot efficiently convert T4 to T3 due to genetic polymorphisms affecting deiodinase enzymes.[8] For these millions, synthetic levothyroxine is metabolic poison. Their bodies flood with inactive storage hormone while being starved of active T3.
Yes, it’s true. T4 is a precursor to the active hormone, T3. Unsurprisingly, that bit about T4 “poisoning” the body is utter bullshit. Moreover, it is not true, as Ji claims, that T4 is completely inactive, as this article describes:
Thyroid receptors are transcription factors that can bind to both T3 and T4. However, they have a much higher affinity for T3. As a result, T4 is relatively inactive. Deiodinases convert T4 to active T3 or inactive reverse T3 (rT3).
See what I mean? Knowing this, however, you might ask: Why is T4 the preferred form of thyroid hormone for thyroid replacement therapy? It’s nothing nefarious, contrary to what Ji implies. The main advantage is that T4 has a longer half-life, which allows for once-daily dosing. Given that the enzymes that convert T4 to T3 are present in a number of tissues in the body, that advantage alone is very important, as the American Thyroid Association explains:
The thyroid gland makes T4 predominantly, along with a small amount of T3. T3 is the active form of thyroid hormone, and is mainly formed when T4 is converted to T3 on an as-needed basis in the cells of the body. This conversion of T4 to T3 occurs normally even if your thyroid gland is sick or absent. T3 has a very short life span in the body, while the life span of T4 is much longer, ensuring a steady supply. A preparation of synthetic T3 (Cytomel®) is available. After taking a tablet of Cytomel® there are very high levels of T3 for a short time, and then the levels decrease very rapidly in the bloodstream. This means that T3 has to be taken several times each day, but even this does not smooth out the T3 levels entirely. In addition, it is impossible to avoid having too much thyroid hormone in the system soon after each dose of T3 is taken. High T3 levels can lead to unpleasant symptoms such as rapid heartbeat, insomnia and anxiety. High T3 levels also can possibly harm the heart and the bones. Another concern with using T3 treatment is that the body is deprived of the ability to adjust the conversion of T4 to T3 to regulate the supply of T3 according to the body’s own needs. Thus, there is no indication for the use of T3 alone for the treatment of hypothyroidism.
The American Thyroid Association also explains why desiccated thyroid is no longer recommended:
Desiccated (dried and powdered) thyroid extract obtained from pigs or cows, was a common and inexpensive form of thyroid therapy before the individual active thyroid hormones were discovered. It is currently available for purchase as a supplement, or by prescription as a medication (Armour®, NatureThyroid®, NP Thyroid®). Since pills made from animal thyroid are not purified, they contain hormones and proteins that do not exist in the body outside of the thyroid gland. Desiccated thyroid contains both T4 and T3, however the balance of T4 and T3 in animals is different from the human thyroid. The amounts of both T4 and T3 can vary in every batch of desiccated thyroid, making it harder to keep blood levels stable throughout the day. Desiccated thyroid pills contain chemicals (binders) to hold the pill together, so they are not completely “natural”. Animal thyroid extract should not be used in pregnancy, as the T3 portion does not reach the developing baby. For these reasons, desiccated thyroid extract is less frequently prescribed today.
In other words, there is nothing nefarious about why synthetic T4 is the preferred form of thyroid hormone replacement for patients who have hypothyroidism, either as a result of thyroid disease of having had their thyroid glands removed. This is the way medicine advances. Just as effective herbal medicines led scientists to search for the specific chemicals in the herbs that produced the desired therapeutic effect in order to isolate and purify the specific active chemicals, thus producing pharmaceutical drugs in which the amount of active ingredient is constant from lot to lot, the discovery 130 years ago that thyroid extract could reverse the symptoms of hypothyroidism led scientists to look for and isolate the hormone(s) responsible in order to be able to manufacture them in a form that provides reliable and predictable amounts of active hormone to the body.
The worship of the “natural form” of thyroid hormone is very much the same as the worship of herbal medicine, in which old methods that found biological activity in crude biological preparations, be they thyroid glands taken from animals or from plants or plant extracts, by alternative medicine practitioners is held up against the supposed evil (or at least inferiority) of highly purified active ingredients from natural sources either isolated from plant or animal sources or purified in the lab. It’s not a coincidence that Ji peppers his post with references to “bioidentical” hormones for women, nor is it a coincidence that Robert Malone wonders on Twitter, “You might think that the FDA wanted older women to be disabled with brittle bones, cognitive decline, metabolic disease, obesity, and poor health.” It’s the very same mindset that elevates “natural” estrogen for estrogen replacement therapy over the various synthetic estrogens that have been used for decades, claiming without good evidence superior efficacy and safety.
Indeed, the FDA in its letter mentions concerns about desiccated thyroid extract products, noting that tablets “made from the same manufacturing batches may not always provide the same thyroid hormone levels,” that inconsistent doses “can have serious consequences for patients,” and that too much “medication can cause unwanted effects, and too little could not be effective.” The letter also notes that “medications derived from animal thyroid glands have an increased risk of certain impurities due to the source – animal thyroid tissue – or the way it is manufactured” and that these “issues can lead to infections and other health concerns.” And, yes, the FDA states that it has received adverse event reports related to desiccated thyroid products.
Before I move on to vaccines, remember how I noted that I was surprised that the FDA had issued such letters and wondered whether Dr. Prasad had anything to do with it? It turns out that FDA Commissioner Dr. Marty Makary is feeling the heat, as he posted to X:
FDA is committed to pursuing the first-ever approval of desiccated thyroid extract, pending results of the ongoing clinical trials. In the mean time, we will ensure access for all Americans.
— Dr. Marty Makary (@DrMakaryFDA) August 14, 2025
Dr. Makary’s capitulation was entirely predictable. Although I don’t have a source to tell me this, I can’t help but strongly suspect that RFK Jr. probably read Makary the riot act after having felt the heat from a number of influential owners of compounding pharmacies who manufacture desiccated thyroid products and wellness influencers who sell and recommend them. Many of these people are aligned with RFK Jr. and MAHA, and some of them RFK Jr.’s friends. My only question is: Who will run these clinical trials, and will they bother to compare the efficacy and safety of desiccated thyroid to that of T4? Inquiring minds want to know.
Unsurprisingly, RFK Jr. was quick to praise Dr. Makary for his decision:
Love your approach of using gold standard science and common sense, @DrMakaryFDA. https://t.co/a8rhiEKiBc
— Secretary Kennedy (@SecKennedy) August 14, 2025
As some of us used to say in the 1980s, gag me with a spoon.
The MAHA take on vaccines
Let’s circle back again to the press release in which RFK Jr. announced that the NIH would be winding down its $500 million program to fund the development of new mRNA vaccines, including this video that he posted to X, the hellsite formerly known as Twitter:
We reviewed the science, listened to the experts, and acted. BARDA is terminating 22 mRNA vaccine development investments because the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu. We’re shifting that funding toward… pic.twitter.com/GPKbuU7ywN
— Secretary Kennedy (@SecKennedy) August 5, 2025
One wonders which “experts” RFK Jr. listened to, given that the reaction to this decision among real vaccine experts has been uniformly negative. The reasons are obvious. First, as Dr. Offit discussed, RFK Jr. is very wrong about the science, where he says:
Most of these shots are for flu or COVID, but as the pandemic showed us mRNA vaccines don’t perform well against viruses that infect the upper respiratory tract.
Wrong. The vaccines performed quite creditably against COVID-19. One wonders what he means by “do not perform well.” Remember, the primary function of a vaccine against a disease like COVID is not necessarily to completely prevent infection (although it’s fantastic when a vaccine can accomplish that). It’s to prevent serious infections that land people in the hospital, infections that necessitate mechanical ventilation in an ICU, infections that kill. We know from a number of studies (e.g., a CDC study in 2022) that the vaccines were highly effective in decreasing ICU admissions requiring mechanical ventilation. Even a study by someone whom we might call a COVID contrarian, Dr. John Ioannidis, that was recently published found that the vaccines saved more than 2.5 million lives. I don’t have space to go into detail, but let’s just say that, given Ioannidis’ reputation and pessimism regarding the efficacy of vaccines, I would say that this is a far low end of the number of lives saved.
It’s when we get into the reasons why (according to RFK Jr.) that the similarity in “reasoning” (if you can call it that) between Sayer Ji’s take on synthetic T4 versus desiccated thyroid extract becomes apparent:
Here’s the problem. mRNA only codes for a small part of the viral proteins, usually a single antigen. One mutation, and the vaccine becomes ineffective. This dynamic drives a phenomenon called antigenic shift, meaning that the vaccine paradoxically encourages new mutations and can actually prolong pandemics as the virus constantly mutates to escape the protective effects of the vaccine.
This is just plain bullshit. For one thing, the mRNA vaccines encoded for a whole subunit of the COVID spike protein, specifically the S1 subunit, which is responsible for interacting with ACE2 receptor proteins on the surface of the host cell in the first step of viral entry. The mRNAs used for Pfizer and Moderna vaccines are both over 4,000 nucleotides long. In brief, it takes cumulative mutations, not just a single mutation, to render antibody binding to this protein ineffective.
As Dr. Offit explains:
The SARS-CoV-2 virus strain that first appeared in late 2019 in Wuhan, China was called the Wuhan-1 or ancestral strain. That’s not the strain that left China. The strain that left China was the first variant; called the D614G strain, it was far more contagious, sweeping through Asia and Europe. The D614G variant was replaced by the alpha variant which was replaced by the delta variant. All these changes occurred before the mRNA COVID vaccines were available. Also, we have remained in the omicron variant era since November 2021.
RFK Jr.’s claim that the vaccine “encourages” new mutations is, at its core, the same nonsense that Andrew Wakefield was peddling in 2019 about the measles vaccine in which he claimed that the measles vaccine would drive new mutations that would produce, in essence, a “super-measles” that would endanger humanity and potentially even cause a “mass extinction.” I kid you not. It’s also highly related to the nonsense that Geert Vanden Bossche started peddling in early 2021 about COVID-19 vaccines (and still peddles). You know what encourages new mutations? Very widespread infection with a virus. You know what discourages new mutations? Keeping the overall number of infections as low as possible.
RFK Jr. also gets the term “antigenic shift” completely wrong. Hint: It’s not the same thing as just the accumulation of mutations that produce new strains that allow the virus to evade vaccine-induced immunity and, as much as fans of “natural immunity” like go gloss over it, immunity after infection with a prior strain as well. That is known as “antigenic drift,” not antigenic shift. Let’s listen to a real expert, Dr. Paul Offit, again:
The term “antigenic shift” is typically reserved for influenza virus, which has a segmented genome that allows for entire gene segments to be transferred from one strain to another. SARS-CoV-2 doesn’t have a segmented genome. When antigenic shifts occurred in 1957 (“Asian flu”), 1968 (“Hong Kong flu”) and 2009 (“Swine flu”), influenza pandemics ensued. If SARS-CoV-2 underwent an “antigenic shift”, the entire world would once again be completely susceptible to this virus, and we would be right back to where we were in late 2019. Sounds scary. Complete nonsense.
The “tell” here is that RFK Jr. lumped SARS-CoV-2, the virus that causes COVID-19, in together with the influenza virus. They are two different viruses, and COVID-19 does not have the genomic characteristics that would even allow it to undergo antigenic shifts, although, like many viruses, it can undergo antigenic drift. Also, you know what are good ways to mitigate the possibility of antigenic shift? One is global surveillance, in order to spot such shifts fast and react to them, but the Trump administration has pulled the US out of the World Health Organization beginning in January 2026, which means that we will not sharing surveillance data with the WHO any more. The other is the rapid production of new vaccines, something that, as the pandemic showed us, the mRNA platform allows us to do faster than ever before.
RFK Jr. then goes on to say that the reason so many people were infected with Omicron despite having been vaccinated was “because a single mutation can make mRNA vaccines ineffective.” No, Omicron had accumulated 37 mutations in its spike protein compared to its predecessors. While it is true that some investigators argued that so many mutations in the spike protein did represent an “antigenic shift,” it’s really the classical antigenic shift that comes from a segmented genome like that of influenza. Not that RFK Jr. is interested in such nuances; rather, he’s interested in implying that vaccine-induced immunity against COVID-19 is so fragile that a single mutation can eliminate it. That’s just utter piffle, or, as Dr. Peter Hotez put it, “That’s flat out wrong,” adding that in no case has a single mutation rendered the mRNA COVID-19 vaccines ineffective. Vaccine-induced immunity against Omicron variants declined, but did not disappear, and, contrary to RFK Jr.’s apparent belief, even partial protection is better than no protection.
To show you just how bad RFK Jr.’s arguments are, even Dr. Jay Bhattacharya, the useful idiot picked by the administration to be the face of the dismantling of NIH, couldn’t agree. He published an op-ed in the Washington Post last week entitled Why the NIH is Pivoting Away From mRNA Vaccines:
The mRNA platform is promising technology. I do not dispute its potential. In the future, it may yet deliver breakthroughs in treating diseases such as cancer, and HHS is continuing to invest in ongoing research on applications in oncology and other complex diseases. But as a vaccine intended for broad public use, especially during a public health emergency, the platform has failed a crucial test: earning public trust. No matter how elegant the science, a platform that lacks credibility among the people it seeks to protect cannot fulfill its public health mission.
See what I mean? Even Dr. Bhattacharya can’t seem to swallow the codswallop that his boss laid down as the rational for pivoting away from the mRNA technology for vaccines. Instead, he makes quite the amazing argument that the technology can’t work because the public doesn’t trust it. Of course, who were the people who stoked that distrust more than anyone else? Dr. Bhattacharya’s boss RFK Jr., Dr. Bhattacharya himself, and a number of the rogues’ gallery of antivax-adjacent COVID contrarians now holding leadership positions in HHS, including Dr. Makary. There is only one meme for this, and I sometimes feel bad that I keep using it so often:
Quoth Dr. Bhattacharya: “We’re all trying to find the guy who did this.”
I’m not going to dwell on the massive exercise in sheer self-delusion that is Dr. Bhattacharya’s editorial given that our very own Dr. Jonathan Howard has already done so capably, as has Dr. Angela Rasmussen. I will, however, mention that RFK Jr. spent two decades before he became HHS Secretary undermining trust and confidence in all vaccines, including whole virus vaccines, and so did the antivaccine movement before him. Bhattacharya is delusional if he thinks that using old vaccine technology while claiming it’s new will result in vaccines that the people who have been sucked into the MAHA movement will trust any more than they trust mRNA vaccines. Doubt is the product. Doubt has always been the point. Is Bhattacharya being naive or cynical? I don’t know. I do know that very likely RFK Jr. is just speaking MAHA language to justify canceling mRNA vaccine grants and will, when the time comes, find a reason to falsely claim that his shiny new-old vaccine technology is inadequate, ineffective, and unsafe, because, of course, he is antivax to the core—and has been at least since 2005, if not longer.
Instead, let’s move on. Why, you might ask, is the preferred method of developing new vaccines based on using single proteins, or even fragments of proteins containing the most relevant antigens for an immune reaction? As I pointed out, inactivated whole-virus vaccines have a long and storied history going back over a century, but they also have a number of problems. In this context, I like to think of this in terms similar to what I just discussed regarding herbal medicines versus active ingredients from natural products purified to make pharmaceutical drugs and desiccated thyroid extract versus T4, or even “bioidentical” estrogen compared to synthetic estrogen. It’s yet another example of MAHA’s misguided belief that more “natural” must be better, and, I guess, to MAHA stans growing up viruses in eggs (influenza) or in cell cultures to produce large quantities of them and then inactivating them with chemicals like formaldehyde is more “natural” than producing single proteins (or fragments) of proteins using genetic engineering or inducing the body to produce them with mRNA vaccines.
One can look at the development of vaccines from using whole-organism to the cutting edge mRNA platform this way. Beginning in the 1980s recombinant DNA technology allowed scientists to produce individual proteins or peptides. Given that for some diseases only a single antigen (e.g. surface glycoprotein like influenza hemagglutinin or hepatitis B surface antigen) is required for protective immunity, it makes sense to use the minimum antigen that can elicit a protective immune response. Also remember that, as mentioned above, whole virus vaccines require large-scale propagation of the virus, which then must be completely inactivated. Need I remind you what can happen if inactivation is not complete. Yes, I’m talking about the Cutter incident in 1955, when lots of Salk polio vaccine manufactured by Cutter Laboratories contained some live virus; in other words, the virus was not completely inactivated. The error resulted in 120,000 doses of polio vaccine containing live polio virus and produced one of the worst public health catastrophes in history. Of the children who received the vaccine, 40,000 developed abortive poliomyelitis (a form of the disease that does not involve the central nervous system), 56 developed paralytic poliomyelitis, and of these, five children died from polio. These cases were transmitted to the families and communities of the affected children, resulting in a further 113 people paralyzed and 5 deaths.
Something like this can’t happen with single-antigen vaccines or, for that matter, mRNA vaccines. Indeed, one of the drawbacks of attenuated live virus vaccines (vaccines in which the virus is weakened so that it can’t cause disease but is still functional) is reversion to its wild-type, disease-causing strain. This, also, can’t happen with single-antigen vaccines or mRNA vaccines. Add to that the observation over the decades that whole virus vaccines contain lots of proteins that include non-protective or even potentially harmful antigens, and, as was the case with desiccated thyroid extract and herbal medicines, there was an impetus to isolate the minimum active ingredient—or, in the case of a vaccine, antigen—that causes the desired effect. Then there’s the issue of manufacturing again. In propagation of large amounts of virus is slow, making vaccine development using these “traditional techniques” much slower than with the new technique of mRNA vaccines.
Hostility towards “reductionist science” now dominates our federal health infrastructure
Just like the case of desiccated thyroid extract, herbal medicines, and bioidentical hormones, RFK Jr. and MAHA fetishize what they perceive as more “natural,” which in the case of vaccines is basically 20th century technology that uses whole organisms as the source of antigens in much the same way that MAHA stans like Sayer Ji demand “whole” organ in the form of desiccated powdered thyroid in favor of proven safe and effective single hormone T4 and naturopaths and “alternative medicine” practitioners demand herbal medicines in favor of pharmaceutical products containing highly purified active ingredients coming from the same plants. This view is not based on science, but rather an ideology in which the “natural” form of whatever remedy or preventative being considered is deemed superior regardless of whether it actually is and ignoring the reasons that science moved from the “natural” form to the more purified, targeted, or—dare I say?—reductionistic form. It also completely ignores the history of science and medicine that provide the obvious reasons why science has moved on from natural products to pharmaceuticals, from desiccated animal organs like thyroid to purified hormones, and from whole organisms in vaccines to just the proteins in the organism necessary to provoke an effective protective immune response. Everything in MAHA flows from the idea that messy and crude “natural” extracts are always superior to purified active components or antigens.
When science is based more on ideology than actual experimentation and data, I call it Lysenkoism 2.0. That’s exactly what’s driving RFK Jr. Once you see the similarities between the MAHA view on thyroid replacement hormones and on vaccines, you will see why I invoke Trofim Lysenko so often these days, as I conclude that MAHA is Lysenkoism 2.0 and that the dismantling of the NIH is motivated largely by Lysenko-like ideological “science.” Worse, why damage is being done to US federal medicine, public health, and biomedical research that will take a generation, if not more, to repair. In the meantime, I hope we all enjoy falling further an further behind China and the rest of the world in science, because that is the trajectory that President Trump and RFK Jr. has put our country on.


Viotren and Other Dietary Supplements for Erectile Dysfunction: Buyer Beware
Viotren and other dietary supplements are being illegally marketed to treat erectile dysfunction. Some of them work, but only because they are adulterated with prescription drugs like Viagra (at up to 31 times the prescription dose). Using them can be risky.
Harriet Hall on August 22, 2017
Link


The headline reads “New $2 Sex Pill Used in China for 63 Years Finally Receives U.S. Patent.” It’s called Viotren. All the usual red flags are there. It’s a half-page ad made to look like a news story. It says a discount will be available for a short time only, so buy now. It even offers a double your money back guarantee. It makes claims not supported by evidence. They claim it restores testosterone levels in 72 hours and improves blood circulation throughout the body. In the first 30 days, “many users note an increased sense of well-being, vitality, and sexual performance.” Of course, it is “all natural” and has no side effects. You can read the ad here.
Being awarded a patent does not mean the product has been proven to work. The patent is for a method of preparing the active ingredient in Viotren, tongkat ali (Eurycoma longifolia). A recent systematic review found “convincing evidence” that Eurycoma longifolia is effective for treating male sexual disorders, but 4 out of the 11 studies they reviewed found no effect. The manufacturer, The American Institute of Longevity, claims to have developed an improved formulation that is more potent and absorbed faster.The Natural Medicines Comprehensive Database rates Eurycoma longifolia as only “possibly effective for male infertility” but says there is insufficient reliable evidence to rate its effectiveness for hypogonadism. It did not consider its use for erectile dysfunction per se. They comment “Preliminary clinical research shows that taking a water-based extract of Eurycoma longifolia 200 mg daily for one month might significantly increase testosterone levels in men with low testosterone levels.” And they warn about concerns of potential contamination with lead and mercury.
Tongkat ali is the active ingredient, but there are other ingredients. I tried to find out what they were, but the only mention I could find was on a Q&A website where they said it contained Piper nigrum extract (black pepper), piperine (also black pepper), Rhodiola rosea, DIM, and tongkat ali. The Natural Medicines Comprehensive Database had no information on the use of any of these ingredients for erectile dysfunction.
The scamadviser website says the Viotren website viotren.com might be unsafe. It appears to be based in the US but there are other countries involved. The site is using an anonymous service which prevents identification of the site owner. The website had been newly registered with a short life expectancy, following the pattern used by many fraudulent and fake selling websites. I searched for viotren.com, couldn’t find it, and assumed it no longer existed. But today I checked again, and viotren.com had miraculously reappeared. It includes a list of ingredients for Viotren and Viotren Plus. It also features a single scientific study on one ingredient. Pretty slim pickings. Not even testimonials.
I tried to look up the manufacturer, The American Institute of Longevity, and found nothing but a site that said, “we do not have current ad for you today.” The American Institute of Longevity is not listed with the Better Business Bureau. I couldn’t find any information as to whether dissatisfied customers actually get twice their money back. If they do, that would be an easy way to earn some money!
This is all very strange. In all my years of researching products like this on the Internet, I have never found so little information. It makes me suspicious. What do you suppose is going on here?
The treatment of erectile dysfunction
Erectile dysfunction is caused by low blood flow to the penis, usually as a result of conditions like arteriosclerosis, high blood pressure, and high cholesterol. Viagra (sildenafil) is a prescription drug that increases blood flow to the penis. It works. The natural remedies are alleged to work by increasing testosterone levels; but increasing testosterone is useless for men with normal testosterone levels or men with low levels whose only symptom is erectile dysfunction. Viagra has a lot of side effects, warnings, and precautions. And it is expensive ($60.10 per tablet at CVS, $58.70 per tablet at Walmart pharmacy).
There are other options. Sildenafil has a number of relatives: tadalafil (Cialis), vardenafil (Levitra), and avanafil (Stendra). There is also alprostadil self-injection into the penis, alprostadil urethral suppositories, penis pumps, and penile implants. These have been tested. They work. Supplements have not been tested and shown to work.
According to a website that rated the top male-enhancing formulas, Viril-X was the best. It contains 21 powerful all-natural ingredients: Korean Ginseng, Tribulus terrestris, L-Arginine, Avena sativa (oats), Muira Puama, Maca, Orchic, Niacin, Nettles, American Ginseng, Zinc, Eleuthero, Catuaba, Kola Nut, Boron, Pumpkin seed, Ginger, Sarsaparilla, Barrenwort, L-Citrulline, and Cayenne. There is no rationale for those ingredients, and no studies to evaluate whether the mixture is effective. And interestingly, there is no overlap of ingredients with Viotren.
And then there’s low intensity extracorporeal shock wave therapy. How does it work?
The gently pulsating waves of the GAINSWave™ promote increased blood flow to the penis by opening existing blood vessels and stimulating the growth of new blood vessels. The improvement in blood flow results in stronger, harder, and more sustainable erections.
The pulsating waves also trigger a healing response that “wakes-up” dormant stem cells and growth factors in the penis. The release of these “growth factors” also leads to the creation of new blood vessels, as well as the overall rejuvenation of erectile tissue.
Maybe. I’m skeptical. It traumatizes tissue and I question whether it really activates stem cells; how could they know that? Did they measure stem cells in the penile tissue after treatment and determine that they had been activated? The systematic review concludes “Owing to the limited number and quality of the studies, more large-scale, well-designed and long-term follow-up time studies are needed to confirm our analysis.” I’ll withhold judgment for now.
FDA warning
Some of the natural products for erectile dysfunction do really work, but that’s because they are adulterated with prescription drugs. The FDA provides a long list of nearly 300 “sexual enhancement” products that have been found to contain sildenafil, tadalafil, vardenafil, and other analogs. And it says the list only includes a small fraction of the potentially hazardous products with hidden ingredients. They warn consumers about undeclared ingredients, unknown contaminants, risky interactions with other medications, and uncontrolled doses. One tainted product contained a whopping 31 times the prescription dose of tadalafil in combination with an antidepressant that is not approved by the FDA. That amount could potentially be fatal.
CBS News published a list of 10 products the FDA issued health warnings about this year or told manufacturers to get them off the shelves: Man Up Now, Stiff Nights, Rock Hard Weekend, Mr. Magic Male Enhancer from Don Wands, Magic Power Coffee, Duro Extend Capsules for Men, Vigor-25, Time Out Capsules, Vitalex, and Xiadafil VIP. They all contain versions of the same pharmaceutical that is in Viagra. Federal Marshals seized almost $75,000 worth of Xiadafil VIP after the manufacturer refused an FDA request to recall it. The founder of Vitalex is in a federal prison in Texas for Medicare fraud. These products all have the usual disclaimer that they are not intended to diagnose, treat, cure, or prevent any disease. But the marketing makes it clear that they are intended to treat erectile dysfunction and to replace prescription drugs. To my mind, they are in clear violation of DSHEA rules and should all be removed from the market. I can’t really blame the FDA for not stopping all these crooks: they try, but they simply don’t have the manpower or budget to pursue all of them, and they try to concentrate their efforts on the things they think are most likely to harm the public.
Conclusion: Buyer beware
There are legitimate treatments for erectile dysfunction that have been tested and shown to work. The dietary supplement products are irrational mixtures of natural medicines that have not been tested and are not likely to help (unless they have been adulterated with unknown quantities of prescription drugs). Buying those products is risky. You never know what you’re getting, and you might get something harmful. Caveat emptor.

   Black Cohosh and Hot Flashes
Steven Novella 
Link
Black Cohosh, an herbal “supplement” (i.e. unregulated drug) remains popular for the treatment of hot flashes and other autonomic symptoms resulting from menopause. This product is yet another good example of the double standard that the supplement industry and ideological promoters are allowed to employ.
The NCCAM website gives this summary:
Black cohosh, a member of the buttercup family, is a plant native to North America. It has a history of use for rheumatism (arthritis and muscle pain) but has been used more recently to treat hot flashes, night sweats, vaginal dryness, and other symptoms that can occur during menopause.
While the information is available if you look through the links below, their summary makes no mention of the fact that their own studies show black cohosh is ineffective. In their “at a glance” summary they characterize the scientific evidence as “mixed.”
The Natural Standard website is far worse. Although touted as a reliable source of scientific information on herbal supplements, they reveal a very biased editorial agenda. Here is their “bottom line” summary of Black Cohosh:
Black cohosh is one of the highest selling herbs in the United States and is popular as an alternative to hormonal therapy in the treatment of menopausal (climacteric) symptoms such as hot flashes, mood disturbances, diaphoresis, palpitations, and vaginal dryness (1;​2). Several controlled trials and case series have reported black cohosh to improve menopausal symptoms for up to six months. Although these initial studies are suggestive, they have been few in number and have universally suffered from methodological weaknesses.
They also state:
Since the Women’s Health Initiative Trial was halted early due to an excess risk of stroke and other adverse outcomes, millions fewer women are using prescription hormone replacement therapy. However, a 2005 survey has shown there has been no appreciable increase in alternative therapies, including black cohosh (13).
Why are they so concerned that women are not using black cohosh or other “alternative” therapies when the evidence does not support their efficacy?
Let’s take a look at the actual evidence. The best study to date is the 2006 double-blind placebo-controlled trial funded by the NCCAM. They compared Black Cohosh alone, plus with other herbs, plus with other herbs and soy, to standard hormone replacement therapy and placebo. The three herbal groups showed no significant difference from placebo, while the hormone replacement group did show significant improvement. The only exception was the soy group, which showed greater symptom intensity at 12 months. This is the best evidence to date and it was dead negative.
The authors of the study listed as a limitation:
The trial did not simulate the whole-person approach used by naturopathic physicians.
How is this a limitation? Where is the evidence that the “whole-person” approach of naturopaths has any basis in reality or provides any improvement in outcome? This is nothing but special pleading, an attempt to water down the significance of these negative results.
A 2008 systematic review of black cohosh and hot flashes concluded:
The evidence from these RCTs does not consistently demonstrate an effect of black cohosh on menopausal symptoms; a beneficial effect of black cohosh on peri-menopausal women cannot be excluded. The efficacy of black cohosh as a treatment for menopausal symptoms is uncertain and further rigorous trials seem warranted.
In other words — the evidence is negative, but we don’t want to give up yet because black cohosh is still popular. Of course, its popularity was manufactured by unfounded claims for efficacy, which have not held up under rigorous study.
It must also be noted that in the controlled trial all groups, placebo included, did show a decrease in the number of hot flashes over the year of the study. This likely reflects the natural course of symptoms (hot flashes do tend to resolve over time) and also the placebo effect in terms of noticing and reporting symptoms. The lesson from this is that any unblinded study of any treatment for menopausal hot flashes is likely to show a significant decrease in symptoms over time. This study emphasizes the virtual uselessness of unblinded studies in evaluating subjective symptoms, like hot flashes.
And yet, it is precisely these unblinded studies that proponents are using to argue that the evidence is “mixed” and that black cohosh deserves further study.
However, a more rational science-based evaluation would take into consideration the relationship between the rigor of the studies and the effect size. The most rigorous studies are negative — that is consistent with the null hypothesis — with the conclusion that black cohosh simply does not work for hot flashes.
Conclusion
If black cohosh were a pharmaceutical and not a supplement, I don’t think there would be much debate about its effectiveness. The data is essentially negative, which means that the only reasonable science-based recommendation is not to recommend black cohosh for hot flashes. Further study is not unreasonable, but neither it is needed.
However, the NCCAM and Natural Standard shy away from this recommendation. Natural Standard doesn’t even mention the negative evidence in their bottom line summary, but rather decry the fact that more women are not using black cohosh or other supplements. NCCAM resorts to their typical weasel statement that black cohosh “has a history of use” or “has been used for.”
For proponents, when it comes to supplements (or any so-called “alternative” modality), no evidence for lack of efficacy ever seems to be adequate.

Black Salve Still Thriving Online
Black salve is still dangerous quackery, but it thrives online.
Steven Novella on November 6, 2019
Link

Here the short version – black salve is a fake cancer cure that is dangerous pseudoscience. It is one of those treatments that is so bad it pushes the limits of credulity, and in this case it is directly harmful in the extreme.
As I have discussed before, black salve is sold as a “natural” herbal-based cancer treatment. It is an escharotic topical treatment, which means that it is corrosive to skin and other tissue, resulting in the formation of a thick scab, or “eschar”. The main ingredient is Sanguinaria canadensis, which contains a number of phytochemicals and the alkaloid poison, sanguinarine.
Sanguinarine [13-methyl (1,3) benzodioxolo(5,6-c)-1,3-dioxolo (4,5) phenanthridinium] is a toxin that kills animal cells through its action on the Na+-K+-ATPase transmembrane protein.
You will notice that it kills “animal cells”. The fact that it can be derived from a plant is irrelevant. It is a powerful caustic substance that eats through all tissue. But of course, there are always layers of complexity that can be cherry picked through motivated reasoning to pain an alternate reality. There are studies that show that sanguinairine, in specific concentrations, may have more toxicity to some type of cancer cells than to healthy cells. This is often the case, because cancer cells are highly metabolic. At the same time, some forms of cancer are relative resistant to its effect. None of this means you can safely slather it on your skin and it will leave healthy tissue untouched while eating away all cancer cells. As one review notes:
However, in vitro studies of sanguinarine suggest it causes indiscriminate destruction of healthy and cancerous tissue at doses higher than 5 µM, limiting its practical utility.
“Indiscriminate destruction” is not a feature rational people value in medicine.
Still those selling and promoting black salve claim the opposite of what the evidence shows. It is a dangerous distortion of reality. Black salves containing sanguinairine eat through any tissue, leaving behind horrific wounds and scars. There are many case reports of morbidity and even mortality from using black salve. Also, ironically, sanguinairine is potentially carcinogenic – which means it may produce cancerous cells.
Reviews of cases and research seem to employ ironic understatement when summarizing the clinical effects of using caustic paste to self-treat lesions and cancer. For example:
…case study reports of excessive scarring, deformity, and treatment failure.
Or:
…suboptimal therapeutic and cosmetic outcomes associated with its use.
Yes, I consider causing a massive wound that later becomes infected, a disfiguring scar, and failing to actually remove the cancer, to be “suboptimal”.
It is also important to understand the psychology at work, especially from the perspective of someone trying to promote science-based medicine. People who consider using black salve for known cancer or a suspicious lesion are faced with two broad choices. On the one hand, you can have an expert evaluate your disease, and if necessary precisely excise the lesion, examining the borders microscopically to make sure they are clean, and therefore any potential cancer is removed. The treatment is evidence-based and designed to produce the optimal chance of a cure with the minimum scarring necessary.
Or – you can treat yourself with a black paste you purchased online, applying it to your skin until you leave a nasty hole in your body. You may have no idea if the lesion was cancer to begin with, you have no idea if you removed it all, and the scarring is far more than was necessary to remove the lesion. But, this treatment is “natural.” You were also empowered to treat yourself, so you can take comfort from that every time you look in the mirror.
Black salve persists despite the obvious facts because a compelling narrative can be more powerful than reality. When people are plied on a regular basis with conspiracy theories and false narratives, even otherwise intelligent and well-meaning people can get to a place where incredibly bad decisions seem reasonable.
Psychologically, people want the magic salve. Medicine always involves some trade-offs, and practitioners should be transparent about what those trade-offs are. They may be minor, like you have to take medicine or change your lifestyle, or it may be significant, like undergoing a major procedure or getting the equivalent of chemotherapy. Alternative medicine often promises magical treatments without trade-offs – no risk, no side-effects, etc. The lure of such false promises is just too great for some people, especially if it is packaged inside a comforting narrative.
The marketing of unrealistic promises with compelling narratives has been given a huge boost by social media, which is increasingly a battleground between the forces of quackery and consumer protection. A recent investigative report shows how the promotion of black salve is still thriving online, despite promises from major outlets to crack down. Youtube, for example, says it is against its policy to promote health misinformation on its platform, and it will remove videos if reported. However, it is still easy to find videos promoting black salve on Youtube, so whatever process it is using is not adequate.
Facebook is much worse, and will not categorically ban pages promoting black salve (like “SW Florida Black Salve”, which is directly selling it). They will, instead, change their algorithm to not promote such pages. But of course they are easy to find if you search.
It is illegal to sell black salve in the US, but you can still buy it online from international sellers. I would think that promoting or selling an illegal health product is a pretty bright line for banning content. I understand the complexity of banning something as vague and sometimes subjective as “misinformation”, but illegal products banned by the FDA are not ambiguous or subjective.
I did submit a report to the FDA concerning SW Florida Black Salve, so we will see what kind of response we get. Reporting often does work, as does complaining to Youtube and to a lesser extent Facebook. Vigilance on the part of consumer protection outlets will always be necessary, but it is a game of whack-a-mole. Systemic protections are necessary. Black salve is clearly dangerous quackery, so it is low hanging fruit, and therefore a good indicator of how the system it working. At present – not good enough.

Does marshmallow root tea have medicinal benefits?
Many medicinal benefits are attributed to marshmallow root. What does the evidence actually say?
Scott Gavura on April 14, 2022
Tweet

A reader of the blog asked me for my opinion about marshmallow tea, and if it presented any health benefits or risks. I was intrigued, as my marshmallow knowledge is limited to bonfire roasting. They sent me a link to “7 Unbelievable Things Marshmallow Root Can Do To Your Body” which is a YouTube video that is long on excitement and the use of the word “may”. The video describes the common benefits that are attributed to marshmallow root including digestion/gastrointestinal benefits, pain relief, use for coughs and colds, wound healing/skin benefits, and general use as an antioxidant. Like most posts it’s short on references, so I took a closer look.
What is marshmallow root?
I quickly learned that the marshmallows you buy in bags have little to do with the perennial herb Althea officinalis. The plant is indigenous to Europe and Asia, and naturalized throughout North America. The edible leaves, flowers and roots of A. officinalis have been used in traditional herbal medicine for over 2,000 years. Primary uses have been based around mucilage, which is produced by the roots and leaves and forms a gummy substance when mixed with water. Usage for throat irritation and colds, based on its ability to coat the throat, is well documented historically.
The candy marshmallow has roots in an Egyptian candy made from marshmallow root and honey. Later French pharmacists made a meringue of marshmallow root, egg white and sugar. Eventually the marshmallow root was dropped and today’s candy contains no actual marshmallow root.
Does marshmallow root have medicinal uses?
The most common usage of marshmallow root is for oral/mucosal use. When you purchase the root, it is usually as an unpeeled, dried root. These roots contain polysaccharides, carbohydrates, other forms of sugars, and other components. However, it is the mucilage properties that are thought to provide the medicinal effects.
There is limited (in-vitro and animal) research into potential anti-inflammatory effects of marshmallow root. Laboratory studies have found that marshmallow root may stimulate cytokine release, interleukin-6, and tumor necrosis factor, but how that translates into actual medicinal effects is unclear. Animal studies suggest anti-inflammatory properties, but again, whether or not this can be translated into benefits in humans is unclear. There are no in-human trials that show any effects.
There is also limited evidence to suggest that marshmallow root has antimicrobial effects. Yes there is laboratory research and some animal research showing antimicrobial activity. Animal wound models seem to show beneficial effects, but how or if that is relevant to humans is unclear. Again, there are no human studies from which we could draw some conclusions about possible benefit.
Marshmallow root has also been studied in children with eczema. In this population, we want to avoid (or minimize) the use of drugs with side effects, like corticosteroids. A small trial showed a 1% ointment had some benefit compared to a hydrocortisone ointment. However, most of the patients that dropped out of the study were in the marshmallow group, making it difficult to draw conclusions. Unfortunately there have been no further trials.
The best researched use of marshmallow root is for its effects on cough. The European Medicines Agency has published an evidence review, noting that marshmallow root preparations can be used to treat irritation of the mouth or throat and associated cough, as well as mild discomfort of the stomach. It made this conclusion not on the basis of clinical trials but based on “traditional use” of the product combined with plausibility. The agency noted that it actually did identify two poor-quality trials: one was a clinical trials in 900 children with mouth/throat irritation and cough. While the product reduce coughing, there was no comparison group. The second trial in 63 adults concluded that marshmallow root drops reduced cough vs. placebo, but the active treatment product was insufficiently described. Neither trial factored into its evaluation. I also identified a small trial in patients with cough due to ACE inhibitors, drugs commonly used to treat high blood pressure. Cough is a common side-effect of ACE inhibitor treatment, and marshmallow root drops were found to be helpful, but the lack of a placebo control group makes any conclusions difficult.
While there have been no formal evaluations of safety, marshmallow root is thought to be safe when used orally and topically. Because of its mucilage effects it could conceivably affect the absorption of other drugs, so it may be advisable to separate consumption of medication from consumption of marshmallow root by an hour or so.
Conclusion: A tea alternative, but don’t expect miracles
Based on its chemical components, marshmallow root has some interesting, though not unique, pharmacological properties. From an evidence-based perspective, there is little to suggest that the product is harmful when consumed, and it may have some effects that are felt to be helpful. Marshmallow root is reported to have an “earthy” taste that some websites describe as “bland” and others warn it may take some time to get use to. Consuming the root (e.g. as a tea) is a reasonable option for those that want to self-medicate, particularly for those interested in a product for a sore throat or upset stomach. However, beyond that there’s little to suggest that the product has other medicinal benefits.

   Scientific evidence for synergy in a botanical product
David J Kroll
Link
So, you’re curious about herbal medicine. Is there any truth to this stuff?
Uncle Howie tells you that he read in the National Enquirer about an herb that has better antibacterial effects on cuts and scrapes than Neosporin ointment — never mind that Neosporin is composed of three different antibiotics that come originally from bacteria themselves.
So you set out on a quest to purchase some of this herb, known colloquially as goldenseal. When you go to your local Whole Hippie Dump-a-Load-of-Cash Emporium you find goldenseal allright, in about twenty different forms. On one side of the aisle are containers with loose, crushed up leaves and roots that look like medical marijuana. On a shelf, you find see-through capsules that seem to contain a powdered version of the herb. Down the aisle a bit you find boxes of blister-packs containing a proprietary extract of free-range goldenseal from the Appalachians harvested under moonlight by bare-breasted virgins. The same company also makes an ointment, allegedly procured the same way.
A scraggly young man with a rainbow-colored Whole Hippie tam comes by and says, “Dude, can I help you?” As you wave away the cloud of patchouli oil and three days of body odor, you ask him, “So, this goldenseal — which one should I buy?”
Hippie Boy looks both ways down the aisle and motions with his finger to come close.
“Dude, all this expensive stuff is just a ploy by The Man trying to make a buck with their fancy scientific words and processes. What you want is the whole herb, man — the stuff given to us by the sprites and spirits. Those capsules miss the point. Part of the magic is missing. You pay extra to get less.”
“But, dude,” you say. “I want to try the ointment, you know, for cuts and scrapes. How do I use this herb?”
The fine young man then explains how to make a poultice, an old-fashioned decoction of plant material that one wraps on a cut — sort of like collard greens.
This really seems like more trouble than it’s worth. You’re about a millisecond away from just heading down to the Done-Rite Drugs, Liquor, and Tobacco to buy a simple tube of Neosporin. But hey, it’s an experiment and you’re curious.
While you’re checking out from the health food store, a local scientist friend is in line at the next register, checking out your stash of goldenseal.
“You know, you should really go read Science-Based Medicine to get the straight dope on that stuff.”
And so, here you are. And I’m here for you.
[Note to readers: Apologies to my hippie friends. I love you all. No hippies were harmed in the drafting of this blogpost.]
Is there any scientific evidence to support a common herbalist claim that whole plant materials are “better” than semi-purified extracts or pure, individual chemicals made by the plant?
And I can tell you this — it depends.
But as long as the National Center for Complementary and Alternative Medicine (NCCAM) is in existence, this is the exactly the kind of work that should be supported by this arm of the US National Institutes of Health. In a recent paper to appear in the Journal of Natural Products, Dr. Nadja Cech and colleagues from the University of North Carolina at Greensboro, Dept. of Chemistry & Biochemistry, used traditional separation chemistry and cutting-edge analytical chemistry techniques to address this very question.
[Update: I neglected to note at the time of posting that Catherine M. Cooney wrote a nice article on this work at the online site for Chemical & Engineering News.]
The medicinal use of goldenseal (Hydrastis canadensis L. (Ranunculaceae)) dates back to Native Americans of the Cherokee and Iroquois tribes. Goldenseal was used externally for skin and eye infections and internally for relief from gastrointestinal symptoms. Today, goldenseal ranks among the 20 top-selling herbal products in the US.
In her group’s paper, Cech demonstrates the cooperative action in goldenseal between berberine, a weak, naturally-occurring antibacterial compound in the plant, and other chemicals that make the berberine more active. Even more fascinating is that these berberine-enhancing chemicals have no antibacterial activity on their own. In other words, these other chemicals potentiate the bacteria-killing effects of berberine. This potentiation is a form of synergy, a process where the combined action of two or more chemicals is greater than the sum of the parts.
(Disclosure: I have a NIH-funded collaboration with co-authors on Dr. Cech’s paper but not with her laboratory).
Cech and her co-workers had already known that berberine killed Staphylococcus aureus bacteria at relatively high concentrations. Microbiologists use a term called, “minimum inhibitory concentration,” or MIC, to describe the minimum concentration of a drug required to kill a population of bacteria. But Cech had also observed that some parts of the goldenseal plant could increase the action of berberine.
To find out what these chemicals were, Cech’s lab purchased whole goldenseal plants, crushed them up in a series of alcohols and solvents, and separated out the constituents using a process called flash chromatography. Picture a tube filled with a specialized type of sand, silica gel. When you pour a gimmish on top of this column of separation material, some chemicals stick to it and flow through the bottom of the tube rather slowly while others wash past the silica quickly. Other chemicals bind somewhere in between, allowing this complex plant extract to be separated into smaller groups of chemicals.
Each fraction of these chemicals were then tested in multiple combinations alone and together with pure berberine. The research team observed that some of these fractions could increase the antibacterial action of berberine by a factor of 16. This synergistic action was not due to berberine in the plant extract of other related antibacterial alkaloid compounds.
After repeating the separation and antibacterial assay several times, Cech used a molecular sizing technique called mass spectrometry to identify two compounds whose size had not been previously known to occur in goldenseal. The group then used nuclear magnetic resonance spectroscopy to determine the strengths of bonds between individual atoms in the chemicals.
This combination of techniques led to the identification of three flavonoid compounds responsible for this synergy. One of the goldenseal chemicals is called sideroxylin. The other compound turned out to be two isomers that share the same molecular size, 8-desmethyl-sideroxylin and 6-desmethyl-sideroxylin. But how do these chemicals work?
Staphylococcus aureus has a protein that pumps toxic compounds out of the cell. This pump called NorA considers the plant chemical berberine to be toxic to its survival. The siderloxylin compounds block the action of the NorA pump and allow berberine to accumulate in the S. aureus cells to cytotoxic levels. Cech demonstrated that in S. aureus cells lacking the NorA pump, these chemicals could no longer potentiate berberine’s antibacterial action.
Cech’s team then went back to the original plant material to investigate where these synergistic compounds were present. Interestingly, the sideroxylin compounds were up to 50-fold more concentrated in the leaves relative to the root and rhizomes. In contrast, berberine was 5-fold more prevalent in the roots. Cech writes,
The finding that goldenseal leaf extracts have higher levels of synergists while root extracts contain higher levels of alkaloids suggests the potential benefit of using a mixture of root and leaf material in the production of dietary supplements from goldenseal. Further studies would, however, be needed to evaluate the safety and efficacy of goldenseal leaf extracts in vivo.
Indeed, goldenseal still needs to be studied in living models of bacterial infections rather than on laboratory dishes containing an optimal growth medium. Nevertheless, the traditional use of goldenseal alone has caused the plant to be endangered due to overharvesting in the wild. The plants used for this study were instead cultivated in their native environment of hardwood forest understory. Cech’s work provides a strong argument for herbalists and herbal compounds to be more responsible in sourcing their products and use cultivated plants.
But the primary significance of this work is that substantiation of common claims for combined or synergistic action in herbal products requires intensive chemical and biological investigation by a multidisciplinary research team. In this one case of goldenseal, synergy does indeed exist. This synergy-directed fractionation research strategy should be applied to other natural products where similar cooperative activity is suspected.
Reference
Junio HA, Sy-Cordero AA, Ettefagh KA, Burns JT, Micko KT, Graf TN, Richter SJ, Cannon RE, Oberlies NH, & Cech NB (2011). Synergy-Directed Fractionation of Botanical Medicines: A Case Study with Goldenseal (Hydrastis canadensis). Journal of Natural Products PMID: 21661731

Nugenix Total T
Nugenix Total T is one of many so-called testosterone boosters on the market. Vague claims, insufficient evidence.
Harriet Hall on April 5, 2022
Link

The commercials insult my intelligence. They show men on a golf course commiserating with each other about how their performance had gone downhill since the good old days of their youthful manhood, and some telling others how Nugenix Total T had restored them. It’s all suggestion and innuendo (“your wife will like it too”), with no specific testable claims and no science.
The claims
This product is a so-called “testosterone booster,” one of many on the market. Most of them claim to boost T or free T, build body lean mass or muscle mass, or increase sex drive or libido. Some products make many other claims such as better sleep, improved erections, increased energy, better mood, decreased cortisol, promotes healthy aging, and much more. Many of these are subjective and typical of placebo responses.
The data
A study published in 2020 identified 50 “testosterone booster” products containing a total of 109 ingredients, with a median of 8.3 ingredients per product. They found that only 24.8% of these products had any data to support their claims, and for some of those the data were conflicting. 10.1% had data showing a decrease in T, and 18.3% had data showing no change in T. No data were found on 61.5% of supplements on their effect on T. Several ingredients were present in higher than recommended doses, (a median of 1,291% of the RDA for vitamin B12, and 13 products contained doses of zinc, magnesium, or vitamin B3 that exceeded the FDA’s upper limit).
A free offer
They offer a free sample so you can try it risk-free. But there’s a catch, actually two catches. The free sample is only enough for two weeks, while they say it may take 30 days to see results. And you will be automatically signed up for regular shipments. Customers have reported great difficulty trying to cancel those subscriptions.
Conclusion: Insufficient evidence
Some men need testosterone replacement, but “Low-T” is a controversial fad diagnosis.Some symptom lists virtually guarantee that any middle-aged man will self-diagnose low T. If a patient really needs testosterone, he should take testosterone itself, not products that are claimed (without evidence) to boost testosterone.

Stupid Videos Meet Penis Growth Scams
There is a pattern of stupid, misleading videos promoting dietary supplements. This video discloses a secret African ritual for penis enlargement; the “ritual” consists of taking a pill with 14 natural ingredients. The claims are too silly to take seriously.
Harriet Hall on February 23, 2021
Link

Earlier this month I wrote about a pattern I had noticed in advertising for dietary supplements: deceptive video presentations that promise to reveal a secret but make you watch the entire video to find out what the secret is. They are full of emotional language, misinformation, and sales gimmicks, and offer little or nothing in the way of scientific evidence. The secret is eventually revealed to be a dietary supplement that they just happen to be selling, at a special price only available if you order now.
I thought I had already said everything I wanted to say about such presentations, but then an email from SavageGrowPlus appeared in my inbox with a link to yet another video, this one selling a product derived from an ancient sacred African penis elongation ritual. At least this one doesn’t force you to watch the whole video; it offers a convenient transcript you can read. I recommend you check it out. It is not scientifically credible, but it has great entertainment value. It won’t inform you, but it will make you laugh. The whole thing is so monumentally silly I just had to share it. It’s hard for me to believe anyone would be persuaded to buy the product, but I guess P.T. Barnum was right about a sucker being born every minute.
It starts “Those dicks are insane!” my wife yelled at me…They were looking at 18 black men with penises 12, 13, and even 18 inches long. “Penises so huge, it would have made God himself envious.” They were visiting an island to observe the African tribe renowned for the largest penises in the world, allegedly due to a secret ritual that “can increase any man’s penis by 48%.” They were told rich Chinese billionaires had been visiting the island and paying big bucks to get longer penises. They don’t identify the island, but they do identify the tribe: the Somba. The website 101 Lost Tribes describes the ritual as an initiation ritual and shows a picture of a man with a very long penis. It is not a secure website, so I won’t link to it. It says the Somba live in Togo and Benin, not on an island. It gives its sources: two blogs and Wikipedia. Wikipedia says the Somba are known for their traditional body scarring rituals and their distinctive house construction style; it does not mention a penis elongation ritual. So right off the bat, the information in the video is highly questionable.
It gets worse. It says you can replicate the secret Somba ritual at home by simply taking a pill that contains all the (no longer secret) ingredients used by the Somba tribesmen. Your penis will grow at least 4 inches in a few weeks. They claim it is clinically proven to work for all men. They say:
This secret ritual comes with a whole bunch of other advantages. It will help you get stronger, longer lasting erections, It will give you firmer, more pronounced body muscles…Will significantly increase your energy levels, turbo boost your sexual confidence and even help you lose those nasty pounds off your belly.
The speaker is Mike Nolan, whose lifelong goal has been to research and find a solution for “the terrible small penis syndrome”. He admits to having a small penis himself and says, “I know how it feels to have your gut frozen every time you take your pants off and she sees your little guy.” And he knows how completely humiliating it can be when other guys accidentally see your penis and react with pity and disgust. He will reveal how a “dangerous blockage” is preventing the penis from growing and he will tell you how to fix it. He will show that having a small penis is not a life sentence.
He says he even contemplated sharing his wife with a tribesman, thinking that once she had been satisfied by a big penis, she would love him more.
He claims that more than 50% of women cheat on their partner because he’s less endowed. (But according to an article in Psychology Today, penis size is not even on the list of reasons for female infidelity.) He claims that women prefer a penis at least 8 inches long, with a circumference of over 5 inches.
The tribe wouldn’t divulge their secrets, but he followed them around and observed what plants they used to prepare a cocktail that was only ready to drink after being buried two feet underground for 24 hours. Back at home, he replicated the cocktail (presumably sans burying) and tested it on 120 volunteers. He discovered that those with penises under four inches had two things in common:
     1.  Their urine was the same color in the morning.
     2.  Their penile tissue had the same skin tone
He discovered the reason: their bodies were unable to assimilate the critical nutrients needed for penile growth. Confusingly, he refers to this as “a blockage” and also as an allergy. A lifetime of nutrient deficiency resulted in a tiny, unnatural penis with a 78% increased chance of developing deadly reproductive system problems. He says you can tell if you are affected if your urine is yellow in the morning. (What color is it supposed to be?)
100% of his study participants reported an increase in penis length of over 3 inches, and also reported that they could sustain an erection for over 30 minutes. In addition, they lost pounds of nasty belly fat and noticed firmer muscles, improved sex drive, increased stamina, and skyrocketing energy levels.
He considered sharing his discovery with Big Pharma, but realized they would only bury it or would take 10 years to study it and would then replace all the natural ingredients with chemical-filled compounds, full of side effects. And the final product would cost an arm and a leg and be at least 10-15 times less effective than the original formula. So he found a company that was FDA approved and GMP (Good Manufacturing Practices) certified. They called their product SavageGrowPlus. They say it is a mixture of 14 (elsewhere it says 12) superfoods that will make your penis grow. It is GMO-free and has no side effects. In addition to growing your penis, it will eliminate bad cholesterol, improve sleep, improve digestion, treat type II diabetes, reduce stress and anxiety, make you happier, give you greater mental focus, and boost your memory and brain power.
He is not out to make money (of course he isn’t!), so he offers a special low price with a discount and a money-back guarantee. But don’t wait, because they will soon run out of their current supply and it will take a long time to make more.
Another reason not to wait:
Eventually, Big Pharma will see this. And when this happens, the secret will be fully blown and we’ll be forced to take this website down. I simply don’t have the resources to go head-to-head against the multi-billion-dollar giants and their high-dollar legal teams.
He claims to have made many enemies by posting this video, including vicious male enhancement gurus, snake oil drug manufacturers, and angry porn stars.
The rest of the video is a typical marketing spiel. I don’t think I need to point out all the red flags. This video has all the hallmarks of the deceptive videos I wrote about, including buzzwords like toxins.
Does a small penis mean a higher risk of infidelity? That doesn’t really make sense, since most people choose their sex partners before seeing them naked. And a study in Kenya found that infidelity in wives was more common if their husbands had longer penises.
Are women less likely to orgasm with smaller penises? An old joke gives these instructions for sex: “in, out, repeat if necessary”. But of course, it’s more complicated than that. The depth of the average vagina is around 3-7 inches. If the penis measures 18 inches, most of it will not be able to enter the vagina. And it doesn’t need to. Size doesn’t matter; technique is far more important. Women seldom have orgasms with vaginal penetration alone; some kind of direct or indirect clitoral stimulation is usually required. A penis is not required for a satisfying sex life. The feminist slogan comes to mind: “a woman needs a man like a fish needs a bicycle”. Lesbians don’t have penises but can enjoy a satisfying sex life without them. Women can achieve orgasm through manual or oral stimulation of the clitoris, stimulation of other erogenous zones, sex toys, or even through fantasy and thought alone.
The average penis measures 3.61 inches when flaccid, and 5.17 inches when erect. Penises over 6 inches long are rare. This video claims that anything less than 8 inches is abnormal. A study found that 85% of women were satisfied with the size of their partner’s penis, but only 55% of men were satisfied with their penis size.
Conclusion: the video for SavageGrowPlus is just too silly to take seriously
In my opinion, the idea of a “small penis syndrome” is a typical alternative medicine tactic: invent a nonexistent disease, then offer to cure it. This misleading video is full of misinformation designed to give normal men an inferiority complex and make them feel insecure. I think that’s despicable.
I couldn’t help but wonder why they sent the email to me. Maybe they thought Harriet was a man’s name. Or maybe they thought that as a woman I would want my partner to have a larger penis. They were wrong on both counts. Internet marketing algorithms work in mysterious ways…

The Prostrate Placebo
Mark Crislip on October 7, 2011
Link

I seem to be writing a lot about the urinary tract this month. Just coincidence, I assure you. As I slide into old age, medical issues that were once only of cursory interest for a young whippersnapper have increasing potential to be directly applicable to grumpy old geezers. Like benign prostatic hypertrophy (BPH). I am heading into an age where I may have to start paying attention to my prostate (not prostrate, as it is so often pronounced, although an infection of the former certainly can make you the latter), so articles that in former days I would have ignored, I read. JAMA this month has what should be the nail in the coffin of saw palmetto, demonstrating that the herb has no efficacy in the treatment of symptoms of BPH: Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial.
It demonstrated that compared to placebo, saw palmetto did nothing. There have been multiple studies in the past with the more or less the usual arc of clinical studies of CAM products: better designed trials showing decreasing efficacy, until excellent studies show no effect. There is the usual meta analysis or two, where all the suboptimal studies are lumped together, the authors bemoan the quality of the data, and proceed to draw conclusions from the garbage anyway. GIGO.
The NEJM study from 2006 demonstrated that saw palmetto was no better than placebo but it was suggested that perhaps the dose of saw palmetto was not high enough or that the patients were not treated long enough to demonstrate an effect, and the JAMA study hoped to remedy that defect.
There is, as is often the case, no good reason to suspect that saw palmetto would benefit or harm the prostate. Like many herbal preparations, it had widespread uses back in the day, when I had an onion tied to my belt, which was the style at the time. You couldn’t get white onions, because of the war. The only thing you could get was those big yellow ones.., but I digress:
“It is also an expectorant, and controls irritation of mucous tissues. It has proved useful in irritative cough, chronic bronchial coughs, whooping-cough, laryngitis, acute and chronic, acute catarrh, asthma, tubercular laryngitis, and in the cough of phthisis pulmonalis. Upon the digestive organs it acts kindly, improving the appetite, digestion, and assimilation. However, its most pronounced effects appear to be those exerted upon the urino-genital tracts of both male and female, and upon all the organs concerned in reproduction. It is said to enlarge wasted organs, as the breasts, ovaries, and testicles, while the paradoxical claim is also made that it reduces hypertrophy of the prostate. Possibly this may be explained by claiming that it tends toward the production of a normal condition, reducing parts when unhealthily enlarged, and increasing them when atrophied.”
At the turn of century Edwin M Hale, MD and homeopath, wrote a treatise on the topic, extolling its benefits on the prostate and other organs. You will be happy to know that if you have testicular atrophy from being an old masturbator, saw palmetto will help. For no good reason I can find, it became popular only for BPH. As best I can determine from the internet, there was a natural medicine fad in the early 1900’s, and saw palmetto became part of the fad. No clinical trials were responsible for the use. And, like acupuncture and homeopathy, there are many explanations for an efficacy that does not exist.
The JAMA study followed 369 men for 72 weeks. They received placebo or saw palmetto twice a day, and at weeks 24 and 48 the dose of each was increased.
They were followed for subjective complaints with the AUASI score, which is a 7 question self administered questionnaire:
Well validated as a tool for BPH symptoms, it relies overmuch on memory and is subject to wishful thinking on the part of the test taker. I doubt I could ever accurately remember my urinary patterns over the prior month without writing it down.
There were also objective endpoints like peak urine flow, PSA levels, and post void residual. Makes me wonder again what they want done when the radio advertisement says ‘Void were prohibited by law.’ Would saw palmetto make that easier? When it came to the subjective measurements, there was a slight, and similar, improvements in both groups. Objective, anatomic and physiologic endpoints were not affected. No surprise. So much for the powerful placebo.
Adverse effects were the same in both groups, with the only significant difference that the saw palmetto group had more physical injury and trauma. Was this the dreaded nocebo effect, or the random badness that occurs as a result of life? Probably the latter.
Based on the JAMA and NEJM trials, it is reasonable to conclude that saw palmetto has no efficacy in the treatment of symptoms due to BPH.
More interesting is what this article says about the so called placebo effect. This is yet another article that demonstrates that for hard endpoints, altering abnormal physiology or anatomy, placebo does nothing. I bet if we did brain scans of these patients they would show changes when the patient took the medications, and to that I would yawn. Do anything to anyone, give a placebo, tickle their feet, there will be changes in the brain. And while in some studies, increasing placebo amounts and frequency leads to increasing effects, in this study an increase in placebo dose led to no improvement in subjective outcomes.
More real world data to suggest that there are no real placebo effects.
Of course, I have bias. I have spent 30 years in acute care hospitals. My patients have derangements of anatomy and physiology that, if not corrected or at least ameliorated, lead to death or permanent morbidity. Placebo isn’t going to cure endocarditis, stop a gastric ulcer bleed, or reverse a stroke. And even if the patient feels better from the therapeutic relationship, if the anatomic/pathophysiologic abnormalities continue unabated, the patient is toast.
I am not even certain it can be said that placebos cure gastric ulcers. There is little on the natural history of ulcers in the flexible endoscopy age. The only reference I could find suggests that patients who have ulcers found with x-ray screening (not a reliable way to diagnose ulcers and probably under-represented the incidence) and who are not treated had a 24% cure rate at 6 months and a 29% relapse rate at 24 months. Most of the placebo trials followed patients around 4 weeks and had a higher cure rate in the placebo wing than seen in the natural history report, but the two are not directly comparable. Given the propensity of untreated ulcers to come and go and the unreliability of symptoms for diagnosis, unless there was a study that had a treatment, a placebo, and a no intervention arm, I do not think it is reasonable to conclude that placebos ‘cure’ ulcers. Especially given the NEJM review that suggested that placebo is usually no more effective than a no treatment/waiting arm.
Perhaps it is me. I do have some intellectual blind spots, like the anthropic principal. Every time I come across it in a cosmology book, I think that it is inane. I lack the imagination, or perhaps I am not stoned enough, to recognize its significance. So too with the placebo effect.
Placebo effects are probably more like quantum mechanics. The single slit experiment gives key insights into the fundamental nature of reality, but in the macroscopic world of day to day life my electrons move about just fine to heat my house and run my computer. No need to worry about probability functions, I can throw potatoes at a slit all day and never see a interference pattern. So too with the placebo effect. Most of the practical effect is lost in the noise of the complexity of illness, especially in the acute care hospital where I spend most of my time.
As Harriet quotes Dr. Benedetti
the take-home message for clinicians, for physicians, for all health professionals is that their words, behaviors, attitudes are very important, and move a lot of molecules in the patient’s brain. So, what they say, what they do in routine clinical practice is very, very important, because the brain of the patient changes sometimes… there is a reduction in anxiety; but we know that there is a real change…in the patient’s brain which is due to… the ‘ritual of the therapeutic act.’
I do not disagree with that. I consciously try to accentuate just those interactions with every patient, because I know my job as a physician is more than ‘Me find bug, Me kill bug. Me go home’. But I do not think it is important for modifying any disease process I am involved with. Grooming each other has salubrious effects in monkeys, and as best I can tell, the placebo is no more than evolutionarily advanced nit picking.
Large swaths of the world rely on native healers and the only tool in their armamentarium is the “ritual of the therapeutic act.” And across the world and throughout time, people have suffered and died in droves. You may argue that is not a fair comparison, people suffered from poor hygiene, no vaccines, malnutrition and no health infrastructure. But the US has a group whose health care is only placebo, relying entirely on the ritual of the therapeutic act, and despite being surrounded by the benefits of western societal infrastructure, they die faster and younger: Christian Scientists.
At the end of the day, the practice of medicine is practical endeavor. I am a builder, not an architect. I have to try to make my patients better objectively and subjectively, and the placebo is a tool that has little utility in my toolbox. When my prostate grows to the size of a tennis ball, I am going to go looking for a therapy that will shrink it, not fool me into thinking I can write my name in the snow a little better.

SARMs Harms
Selective androgen receptor (SARMs) are sports supplements marketed to teens via social media influencers.
Scott Gavura on April 11, 2024
Link

Selective androgen receptor modulators (SARMs) are a class of drugs thought to have effects similar to anabolic steroids. Marketed via social media to youths and young adults via social media as a simple way to boost testosterone and muscle, these drugs can cause serious harms. The FDA has issued a caution about these products, noting SARMs are not dietary supplements, but actually unapproved drugs. Meanwhile, documented harms are accumulating in the medical literature. SARMs are yet another consequence of a weakly-regulated marketplace and unscrupulous vendors who see a business opportunity.

SARMs were developed as alternatives to anabolic steroids
SARMs are a group of compounds that influence the androgen receptors within the body. Androgens, such as testosterone and dihydrotestosterone (DHT), are hormones causing effects such as muscle development, bone density, and sexual desire and performance. Androgens require binding to specific receptors in the body to exert their effects. SARMs modify the responsiveness of androgen receptors in muscles and bones, increasing the action of testosterone and DHT. This may lead to accelerated muscle growth, reducing (but not eliminating) the work associated with bodybuilding and muscle building.
SARMs were developed with the idea of triggering anabolic steroid benefits, without expected negative side effects. Marketed as “legal” alternatives to steroids, SARMs have gained popularity despite lacking approval from regulatory bodies like the FDA. While many products have been synthesized and are called SARMs, none have been brought forward to market or been approved by the FDA, so far. While marketed as dietary supplements, they are actually unapproved drugs. The FDA has been vigorously pursuing those that sell these products, with recently-announced jail terms for vendors. There’s also been high profile suspensions from sport, such as Cleveland Cavaliers forward Tristan Thomas who violated NBA rules by taking a SARM named LGD-4033.
SARMs are not safe
While marketed at being safer, allowing one to avoid the well known harms of anabolic steroids, the FDA reports a list of possible side effects with SARMs:
    • Increased risk of heart attack or stroke
    • Psychosis/hallucinations
    • Sleep disturbances
    • Sexual dysfunction
    • Liver injury and acute liver failure
    • Infertility
    • Pregnancy miscarriage
    • Testicular shrinkage
Importantly, there is a lack of any long-term safety data with SARMs, so there is no information confirming the safety of SARMs, particularly in young adults, who have a lifetime ahead of them. A 2023 systematic review noted that SARMs have been associated with serious health risks such as drug-induced liver injury, rhabdomyolysis, tendon rupture, and adverse cardiovascular outcomes.
SARMs are being promoted on social media
In late 2023, the Center for Countering Digital Hate produced a report that identified that TikTok videos that promoted SARMS (sometimes directing users to sites where they could purchase the products) had been seen at least 587 million times in the US over three years – including 420 million views from users aged 18-24 years. Today, if you search for SARMS on TikTok, you won’t find anything – searches are not permitted. The same can’t be said for Instagram, where I found hundreds and hundreds of posts and video. Thanks Zuck!
Like other supplements, you cannot trust the label
I and others have discussed supplement quality at length in past posts. When it comes to SARMs, because they are not approved and therefore regulated, little can be inferred from the label. A 2017 paper looked at 44 products marketed via the internet. It found that only 52% of products actually contained SARMs, while 39% contained another unapproved drug. Only 41% had a quantity of SARM that matched the labelled amount. 25% of products contained undisclosed drugs. 9% did not contain an active substance.
Conclusion
I’ve written extensively about the dietary supplement industry. Among these products, sports supplements are perhaps the most likely products to be adulterated. Because there is no justification to market SARMs as dietary supplements, regulators like the FDA have been more aggressive in trying to limit their illegal sale. With the help of the social media giants, and despite their documented harms, SARMs continues to find a market.

MELATONIN

Melatonin for sleep disorders – Safe and effective?
Scott Gavura on July 4, 2013
Link
It’s summertime, and the living is easy. Forget the solstice. For most of North America, this week is the real start of summer – July 1 in Canada, and July 4 in the USA. Vacation time means breaking out of that those usual routines of work and school. I’m amazed after a few weeks of vacation how much sleep my body will accept if given the opportunity, where it will climb from six to nine hours a night within a week. I try not to change my kids’ habits too much, and one area I’m fairly disciplined with is maintaining a predictable sleep/wake cycle, even when they’re on vacation. I’ve learned, mainly through trial and error, that I suffer the consequences when my own kids don’t get enough sleep, or when their sleep cycle is thrown off. It wasn’t always like this. I remember a period of what felt like years when I had to crawl out of my child’s bedroom on my hands and knees so as to not disturb a child who simply would not fall asleep. And when it finally, mercifully, occurred, it would be a brief respite before the cycle began again. The sleepless nights left us all cranky and exhausted. Admittedly I was fortunate, either due to my successful parenting (but more likely mean reversion) and my kids are pretty good sleepers now. I’m reminded of my good fortune when I speak with exhausted and frustrated parents who have children that cannot sleep and are worried about the causes and consequences of persistent insomnia. As a pharmacist I’m regularly asked about insomnia for both kids and adults as there are a number of over-the-counter products available, and many consumers are understandably apprehensive about seeking out prescription products. Tell someone there’s “natural supplement” for sleep and there’s usually a lot of interest. That’s what I’ve seen with melatonin, a hormone that is sold without a prescription in Canada, the United States, and other countries. It is widely perceived as safe and alternative health purveyors like naturopaths, and even some health professionals, may recommend it for treating sleeping problems in both adults and children. Beyond sleeping, some believe melatonin is a wonder drug with efficacy for diseases ranging from chronic fatigue to cancer to irritable bowel. 
I never take sleep questions lightly. While in many cases there may be no identifiable causes, insomnia and sleep disturbances can be symptoms of more serious medical conditions. I try to identify the main complaint (difficulty falling asleep, waking up during the night, waking up early, and daytime exhaustion) and identify any possible contributing factors, such as those with breathing disorders (e.g., asthma), on medication (e.g., ADHD drugs, anti-histamines, antidepressants, and some supplements), or developmental disorders (e.g., autism). (I could probably add blogging to that list.) Contributing factors require a detailed evaluation, and I generally advise against any self-medication in all but the most urgent or transient situations. Insomnia may not be the reason for a physician’s visit, but it should be, especially for children with persistent problems. One of the most foolish things health professionals can do is endorse drug treatment (natural or otherwise) before looking for underlying contributors, first.
I never recommend over-the-counter products to treat insomnia in children. Without a physician’s evaluation and recommendation, I strongly discourage parents from administering these products to children. It can be a difficult pitch because products like melatonin are just sitting on the shelf, and are backed by lots of advertising touting efficacy and safety. After all, if melatonin were unsafe, it wouldn’t be sold without a prescription, right?
My concern was partially reflected in a recent column in the Wall Street Journal, entitled “Melatonin: A ‘Magic’ Sleeping Pill for Children?”
Sales of melatonin have risen dramatically over the past five years, according to Nutrition Business Journal. Estimates for 2012 put sales at $260 million; in 2007, the market was just $90 million. Melatonin is available over the counter in the U.S., but in the U.K. and several European countries, the hormone supplement requires a doctor’s prescription.
A handful of companies market melatonin directly for children’s use, offering flavored, low-dose versions of the supplement. One melatonin manufacturer’s website even urges parents to “prepare your child for academic success” by getting him or her to sleep. It cites one study that found “students with C’s, D’s and F’s got about 25 fewer minutes of sleep and went to bed an average of 40 minutes later than A and B students.”
The column takes a fairly critical eye to the pediatric use of melatonin, citing a lack of data as well as what may be unwarranted parental enthusiasm for the product:
“I’ve never seen such widespread abuse of any drug or therapy in all my years of practice,” said Stuart Ditchek, clinical assistant professor of pediatrics at New York University School of Medicine. One mother told him that “she lines up her six healthy children nightly to give them their melatonin pill.” Dr. Ditchek believes the supplement should only be used for the most serious sleep and neurological disorders. The concern, he said, is the lack of long-term clinical studies to see how the hormone supplement interacts with other hormones in the body, potentially affecting fertility or sexual development.
Still, the natural=safe idea is hard to shake, especially for a product that is perceived as being safe enough to be sold in health food stores, without restrictions of any kind. Could melatonin be a supplement that actually works? It’s a hormone with an interesting but brief history – its function wasn’t understood until fairly recently and the gland that produces it (the pineal gland) was originally thought to be an evolutionary vestige without function. In the early 1900’s it was observed that the pineal gland did secrete a substance with physiologic effects, and the hormone itself was named in 1958. By the seventies, melatonin’s role in the circadian rhythm was beginning to be understood. Receptors for the hormone have been identified in the hypothalamus, the pituitary, and in other organs in the body. In humans and other mammals, melatonin secretion by the pineal gland follows the light cycle, being low during daylight hours, surging in the evening and peaking in the middle of the night. This secretion starts in infancy and continues through adulthood, followed by a decline as we age.
The supplement
When consumed orally, melatonin is not consistently or extensively absorbed, so individual responses to doses can vary, which complicates dosing. Supplement doses can push blood levels much higher than any levels that can ever been reached naturally. Receptors are highly sensitive to high doses, and their activity decreases as a result, suggesting that long-term supplementation may have unanticipated consequences. It appears to have a good short term safety profile, however, and toxicity reports are rare. Supplement doses range from 0.1 – 10mg with most doses at the lower end of this scale.
How did a hormone come to be deemed a supplement? This is difficult to answer based on scientific principles, given melatonin is primarily synthesized in the pineal grand from the amino acid tryptophan, with serotonin produced in an intermediary step. There is no good evidence to suggest that dietary or supplementary tryptophan affects melatonin levels. Diet seems to have no effect on melatonin levels at all. Hormone pills don’t “supplement” any dietary source at all. Another challenge to the “supplement” and “natural” label is the fact that melatonin sold as a supplement is synthesized in a laboratory – there are no reliable natural sources. The consequence of being treated as a supplement, as has been described repeatedly at this blog, is a lowered regulatory bar for safety and efficacy. There is no evidence to show that the different forms of melatonin (e.g., extended-release) are well-absorbed or comparable to products studied in clinical trials. There is also no information to suggest that different brands are equivalent to each other. Given melatonin is inconsistently absorbed, switching brands may affect absorption, and ultimately, effect.
The evidence
Melatonin supplementation does appear to have effects on sedation, fatigue, time to fall asleep and the total sleep duration. Studies are hard to synthesize, given they include big range of doses, a variety of dosing schedules, and a wide number of underlying conditions. The best evidence seems to be for circadian sleep disorders, where melatonin has FDA orphan drug status for this use. Based on the physiologic effects of melatonin, this makes some sense.
For general sleep disorders, the evidence is mixed. There is some tentative support for use in children, however the evidence base used to make this claim is based on an analysis of six small clinical trials, only one of which was in children with sleep disorders without other contributing cause or underlying medical issue (e.g., behavioral disturbances). This study, only four weeks in duration, noted a significant improvement in sleep onset (57 minutes) with 5mg of melatonin, but no change in total sleep time. Studies in children with secondary sleep disorders showed some improvements in sleep indicators as well, but whether these effects are meaningful isn’t clear. In all studies melatonin was well tolerated, though none of the studies looked at extended use of the drug. There is also some evidence to suggest that melatonin is effective at helping calibrate the sleep-wake cycle in children with developmental disabilities. But again, it had no effect on total sleep time. Overall the data are inconsistent and often unimpressive.
In adults, a 2005 meta-analysis suggested that melatonin would reduce the time to fall asleep by four minutes, while increasing total sleep duration by 13 minutes. Another 2005 meta-analysis drew a similar conclusion: melatonin was well tolerated but not very effective, improving the time to fall asleep by 12 minutes. A 2006 meta-analysis looked at secondary sleep disorders, like jet lag and shift work, and concluded that melatonin offered no meaningful benefits beyond placebo. It could be the short half-life of of the supplement that’s a factor. Show release versions or drug-based variants of melatonin (i.e., ramelteon) could plausibly have more meaningful effects.
Despite the array of doses used, melatonin is well tolerated. The most common side effects reported include daytime sleepiness, dizziness and headaches.
There are concerns about long-term use in children. Melatonin’s long-term effectiveness and safety are unclear. Given melatonin is a hormone, and receptors for this hormone are distributed throughout the body (including the sex organs), the safety, particularly during puberty, has not been estabilished. For this reason there’s good cause for caution in children.
There are few comparisons between melatonin and other drugs like the infamous benzodiazepines, or newer agents like zolpidem. Reassuringly, there is no evidence of withdrawal effects caused by stopping melatonin, though there is admittedly a lack of long-term studies that have examined this potential risk thoroughly.
Conclusion
Melatonin is a hormone that is sold as a dietary supplement in some countries and as a prescription drug in others. Regardless of its regulatory status, evidence suggests that melatonin is only modestly effective, and many who use it will not show substantive improvements in their sleep quality. What is clear is while there’s nothing “natural” about taking huge doses of this hormone, it is well tolerated when used for short-term trials. Its safety in children, or with long-term use in adults, is less clear. Like other supplements, it’s a victim of a weak regulatory structure. In Canada and the United States, there’s little conclusive evidence to guide product selection and dosing. Buyer beware.

Melatonin: What’s on the label isn’t in the bottle
Melatonin is taken by millions each year. But does it work? Is it safe? And can you trust the label?
Scott Gavura on March 9, 2017
Link

Multiple cases of medicines killing and harming people have led, over decades, to progressive increases in the regulation and oversight of prescription and non-prescription drugs. It was the thalidomide disaster that’s primarily responsible for the current regulatory framework that is in place today, and has been successfully emulated around the world. This system ensures that products are tested before they are approved, and that products are manufactured to a consistent quality standard. With all the discussion about how the FDA’s regulatory approach for drugs might be changing, it’s worth asking how producers of products might react if regulatory standards were relaxed. History isn’t the only example we can look to. As a case study, we can look to the shelves of pharmacies and health food stores, where you’ll find hundreds of “dietary supplements” and remedies. They may look like drugs, and they may be packaged in tablets and capsules, just like medicines. But the United States, among several other countries, has enacted completely different regulations for dietary supplements. In general, they are not expected to meet the safety, quality, and effectiveness standards that are in place for medicines. In the USA, the framework is DSHEA, which removed the onus of demonstrating safety and efficacy from the manufacturer and put the requirement to demonstrate harm on the FDA – exactly the same scenario that drugs faced in the early 1900s. In Canada, the Natural Health Product regulations had a similar effect, and implemented a lowered bar for non-drug supplements.
Is there any rationale to exempt natural health products from stronger regulatory oversight? Both can have medicinal effects. Herbal remedies, if they have biological activity, are effectively unpurified, unstandardized drug products. Supporters of the industry point to the lack of harms that have been proven with dietary supplements as an argument for weaker regulation. And from one perspective, that is true. Despite their widespread use, surveillance of supplements (the limited amount that occurs) reveals generally few adverse events. It could be that many products lack meaningful pharmacologic activity — either positive or negative. An adverse event is probably less likely in placebos that have no beneficial effects. Beyond possible ineffectiveness, there are other reasons, unique to supplement use, that may contribute to the perception (and under-reporting) of harms from supplements, such as:
Consumers believing natural products are safe may be less likely to associate adverse events with supplement use.
    • The side effect profile may not be well understood, as few products are studied rigorously in clinical trials. Known side effects may not be disclosed to consumers.
    • Supplements don’t require a prescription. No health professional may be involved in measuring the response to therapy, who might be able to identify adverse events.
    • Side effects and harms may not be reported, as some are reluctant to share concerns with health professionals.
    • Consumers may not know how to manage an adverse event, and to whom they should report an adverse event. They may be unwilling to describe health consequences to the vendor of a product, or report in a setting like a natural foods store.
    • Users may have a distrust of “conventional” medicine which drove their initial use of the product. When adverse events were identified, they may be reluctant to consult “conventional” health care providers for assistance.
    • Some fear of losing access to supplements, which may drive a reluctance to report adverse events.
    • Supplements are commonly used for short intervals for self-limiting conditions, and long-term harms may not appear (or be detectable easily.)
With weak regulations, we really have little insight into the safety, quality, and effectiveness of many of these products.
Melatonin: Drug or supplement?
The regulation of melatonin varies around the world. In some countries, it’s regulated like a drug, and manufacturing is held to the same quality standards. In countries like Canada and the United States, it’s considered a supplement or natural health product. Melatonin is the fourth most popular natural product taken in the United States (after fish oils, glucosamine/chondroitin, and probiotics). In children, it’s second only to fish oil in terms of popularity. Sales are robust and keep growing, from $62 million in 2003 to $378 million in 2014. In the early 1900s it was observed that the pineal gland secreted a substance with physiologic effects, and the hormone itself was named in 1958. Receptors for the hormone have been identified in the hypothalamus, the pituitary, and in other organs in the body. And it’s definitely a natural substance: Melatonin is found in vertebrates, invertebrates, animals, bacteria, fungi, algae and plants. In humans and other mammals, melatonin secretion by the pineal gland follows the light cycle, being low during daylight hours, surging in the evening and peaking in the middle of the night. This secretion starts in infancy and continues through adulthood, followed by a decline as we age. It has been explored in clinical trials mainly for the prevention and treatment of sleep disorders like insomnia and jet lag.
Disappointingly and despite the fact that it is considered a drug product in some countries, the clinical evidence to support the use of melatonin is really not all that impressive. A 2014 summary of the evidence on melatonin identified six systematic reviews with seven meta-analyses, which included 9-19 randomized controlled trials with 279-1,683 patients. Studies tend to be small, of short duration, and poorly designed. Overall the data is inconsistent and relies on subjective data. When looking at all of the trials, the evidence suggests that melatonin may:
    • Promote falling asleep faster by 4-11.7 minutes sooner (23 minutes faster in those with “sleep onset disorder”)
    • Increase total sleep time by 8.2-18.2 minutes (four of six meta-analyses showed statistically significant increases)
    • Modestly improve perceived sleep quality and efficiency (time asleep while in bed)
    • In those with jet lag and shift workers, melatonin improved sleep time by 18.2 minutes but didn’t improve sleep onset or quality
In terms of short-term side effects, melatonin is well tolerated. Long-term, there’s no evidence available to determine if melatonin is safe. There’s little evidence to demonstrate that melatonin is safe in children. Moreover, it’s not even clear that when you purchase melatonin, that you’re actually getting what’s on the label.
Poor quality, contaminated supplements
A new paper from Lauren Erland and Praveen Saxena raises concerns about the safety and quality of melatonin supplements. There was a variety of products purchased including tablets and liquids. Different lots of the same product were purchased, in order to examine variation in content lot-to-lot. The authors quantified the amount of melatonin, and also looked for the presence of serotonin. Their findings suggest that there’s little quality control in the products that were studied:
Melatonin content was found to be highly variable between samples and lots, with no pattern observed between brand, form of supplement, labelled value, or presence of other herbal extracts. The most variable sample, chewable tablet E1, showed a 478% increase from label claim containing almost 9 mg of melatonin, compared to the 1.5-mg label claim, though this was also highly variable between lots (465% difference). The supplement that showed the greatest decrease in melatonin content as compared to labelled values was the capsule G5 which contained lavender, chamomile, and lemon balm, with a decrease of 83%.
What’s on the label isn’t what’s in the bottle:
    • 71% of products failed to meet label claims (per-dose content was expected to be +/- 10%).
    • Actual content ranged from 83% below labelled claim to 478% above labelled claim.
    • Lot-to-lot, product content varied by as much as 465%
    • Undeclared serotonin was found in 8 of the products. Serotonin is a precursor of melatonin and isn’t sold as a supplement. Serotonin syndrome is a well-documented reaction with some prescription medications. The presence of undeclared serotonin could potentially lead to serious adverse reactions.
Here’s Table 1, illustrating that manufacturers of melatonin do not appear to be producing consistent, high-quality products:
Buyer beware
These finding add to other studies that have found that dietary supplements may be manufactured to poor quality standards, with little assurance that what’s on the label is actually in the bottle. Not only does it appear difficult for consumers to identify a product of high quality, there’s no assurance that product content is even consistent, lot-to-lot. What would be really interesting would be to conduct the same analysis using product purchased in countries where melatonin is regulated as a drug. In doing so, we might obtain even more insight into manufacturing quality standards for drugs versus supplements. Given the drug approval standards in place in Canada, the United States, and around the world, I’d wager that those products would be found to be far more consistent in content and quality.
Until consumers and health professionals alike have confidence that dietary supplements are of uniform and consistent quality, and are free of undeclared contaminants, it’s not possible to use them safely, or to expect that they will deliver any predictable effects.The supplement marketplace continues to serve as a case study to those that think that looser regulation actually benefits consumers, or helps ensure better health care.

Melatonin
Melatonin supplements are increasingly popular, but the evidence is weak and mixed.
Harriet Hall on December 15, 2020
Link

I don’t understand how Facebook’s algorithms work; but I wonder if they have gotten the false impression that I suffer from insomnia, since I have recently been bombarded with information about a multitude of natural sleep remedies. Most of them contain melatonin, sometimes combined with other natural ingredients. One product that is billed as “the No. 1 sleep supplement, with 1000s of happy customers” contains magnesium, valerian root, chamomile, L-theanine, and 5-HTP. They say it is clinically proven, but the product they sell has not been tested. I had heard that melatonin was useful for treating jet lag, but there are claims for its effectiveness in many other situations, and it has been studied for everything from cancer to heartburn. Its use is skyrocketing, with over 3 million Americans currently using it. I thought it would be useful to review the evidence.
Melatonin is indeed natural. It is a hormone produced in our pineal glands; more is produced at night than during daylight, and it plays an essential role in regulating our circadian rhythms.
Melatonin works in our bodies, but do melatonin supplements work?
A systematic review of published studies examined 35 randomized controlled trials; 83% were rated as high quality. They concluded:
The use of melatonin by healthy adults shows promise to prevent phase shifts from jet lag and improvements in insomnia, but to a limited extent. For the initiation of sleep and sleep efficacy, the data cannot yet confirm a positive benefit. No recommendation can be proposed for the use of melatonin in shift workers.
An information page from the National Center for Complementary and Integrative Health (NCCIH) recommends melatonin for jet lag, delayed sleep-wake phase disorder, some sleep disorders in children, and anxiety before and after surgery. But it doesn’t recommend it for cancer symptoms, shift workers, or insomnia. It reports side effects and safety concerns in children.
Clinical guidelines from the Journal of Clinical Sleep Medicine found “weak evidence against clinically significant efficacy in the treatment of sleep onset insomnia, with little systematic evidence regarding harms. However, mixed evidence suggests possible improvement in SL in an elderly population. Therefore, benefits were deemed to be approximately equal to harms.” The Sleep Foundation has published recommendations for good sleep hygiene and many experts recommend sleep hygiene over pills.
Side effects
Daytime drowsiness, headaches and dizziness are reported by a small percentage of users. Agitation and bedwetting have been reported in children. There is concern that it might delay puberty in children, but the research is inconclusive. There has not been enough research to evaluate its long-term safety or its use during pregnancy and breast-feeding. A number of drug interactions and interactions with medical conditions have been reported.
Choosing a supplement
The optimum dosage has not been established. In studies, the doses have ranged from 1 to 12 mg. Supplements typically contain 1-3 mg. Dosages between 1 and 10 mg can raise melatonin levels to 3-60 times the levels normally found in the body.
Caution is advisable, since quality control is a documented problem. 71% of products did not contain within 10% of the labelled amount of melatonin, with variations ranging from -83% to +478%, lot-to-lot variability was as high as 465%, and the discrepancies were not correlated to any manufacturer or product type. To make matters worse, 8 out of 31 products were contaminated with the neurotransmitter serotonin.
Conclusion: Strong claims, weak evidence
The evidence is mixed and weak. There is some positive evidence for melatonin, and side effects are mild. I wouldn’t discourage anyone who wants to give it a try, but I think good sleep hygiene measures would be a better first step for treating insomnia.

Melatonin quality varies widely
A new study shows most melatonin products are inaccurately labelled.
Scott Gavura on April 27, 2023
Tweet
If there is one aspect of the dietary supplement industry that both critics and fans should agree on, it’s that what’s on the label should accurately describe what’s in the bottle. Whether it’s a supplement, or an over-the-counter drug, consumers deserve health products manufactured to high standards. When it comes to ensuring the products we buy are of high quality, we’re largely reliant on regulation to protect us. Yes, there are independent organizations that test some products. But only a regulator can enforce production to consistent and strict quality standards. A weak regulatory framework, which doesn’t hold manufacturers to account, would be expected to result in a product of lower quality. And that’s exactly what you see when you look at supplements on the market today. A recent research letter in the Journal of the American Medical Association adds more evidence to established concerns about supplement quality in the United States.
Insomnia can be a persistent issue for both children and adults. Melatonin is a hormone that is sold without a prescription in many countries. It is widely perceived as safe and effective and many health professionals recommend it (despite mixed evidence) for treating sleeping problems in both adults and children. In the United States, sales of melatonin increased from $285 million in 2016 to $821 million in 2020 and continue to grow at 10% annually. With this growing popularity the number of pediatric poisonings reported to poison control centres has also increased. In 2020, melatonin also became the most frequently-reported pediatric poisoning reported. 
What is melatonin?
In the early 1900s it was observed that the pineal gland secreted a substance with physiologic effects, and the hormone itself was named in 1958. Receptors for the hormone have been identified in the hypothalamus, the pituitary, and in other organs in the body. And it’s definitely a natural substance: melatonin is found in vertebrates, invertebrates, animals, bacteria, fungi, algae and plants. In humans and other mammals, melatonin secretion by the pineal gland follows the light cycle, being low during daylight hours, surging in the evening and peaking in the middle of the night. This secretion starts in infancy and continues through adulthood, followed by a decline as we age. It has been explored in clinical trials mainly for the prevention and treatment of sleep disorders like insomnia and jet lag. The evidence suggests melatonin is modestly effective. It seems to be most effective for sleep-onset insomnia, and may give a slight increase in total sleep time. In children melatonin may be recommended for long-term use in autism spectrum disorder and attention deficit hyperactivity disorder.
New quality concerns
Melatonin supplements in the United States are not subject to prescription drug manufacturing standards in the United States. The Dietary Supplement Health and Education Act of 1994 (DSHEA) established the regulatory framework for dietary supplements. It effectively excludes manufacturers of these products from virtually all regulations that are in place for prescription and over-the-counter drugs. Under DSHEA, the FDA may not approve dietary supplements for safety and effectiveness before they are marketed. The FDA can only intervene to pull products off the market, after they are marketed, and only if they are adulterated or misbranded.
In the absence of FDA oversight, a group of researchers undertook their own analysis of products available for sale:
In September 2022, products formulated as gummies with “melatonin” on the label were identified in the National Institutes of Health’s Dietary Supplement Label Database, the most comprehensive database of dietary supplements sold in the US.4 The 30 unique brands entered into the database in 2021 were purchased online. Products’ labels were examined after purchase and excluded if “melatonin” did not appear on the actual label.
The gummies were dissolved and then analyzed for the presence of melatonin, cannabidiol (a chemical isolated from cannabis) and serotonin, which has previously been found as a contaminant in melatonin products.
The results
Of the 30 products identified, four were unavailable for purchase and one product didn’t list “melatonin” on the label, leaving 25 products for analysis. One product contained no melatonin at all but contained 31.3mg of CBD. Among the remaining products, the actual quantity of melatonin ranged from 74% to 347% of the labelled content. For example, on product labelled to contain 3mg actually contained 10.4mg. Another labelled to contain 5mg contained only 3.7mg. Overall, 88% of the products where inaccurately labelled. Only 3 products contained melatonin that was +/- 10% of the labelled content.
Five products listed CBD as an ingredient. The quantity of CBD ranged from 104% to 118% of the labelled content – much better than the melatonin. Serotonin was not detected in any products.
Shopping in a market tilted again consumers
This analysis joins many others in pointing out serious quality concerns with dietary supplements. Based on this small sample of melatonin gummies, these products are not being manufactured to prescription-quality standards. The fact that these products are being used in children is concerning, given the potential for overdoses with poor quality products and unlabelled ingredients (i.e., CBD). Lax regulation has undoubtedly been a boon to manufacturers, leading to many products being marketed – but also making it harder for consumers to find products that are safe, effective and have high quality standards.

Melatonin poisonings in children are increasing
Melatonin use is increasing, and accelerated during the pandemic. Overdoses are also increasing in children, and in rare cases are linked to serious harms.
Scott Gavura on July 7, 2022
Link

Insomnia can be a persistent issue for both children and adults. While there are a few over-the-counter and multiple prescription drugs used for insomnia, many people are understandably apprehensive about using them. Tell someone there’s “natural supplement” for sleep, and there’s usually a lot of interest. That’s what I’ve seen with melatonin, a hormone that is sold without a prescription in many countries. It is widely perceived as safe and effective and many health professionals recommend it for treating sleeping problems in both adults and children. In the United States, sales of melatonin have increase from $285 million in 2016 to $821 million in 2020. With this growing popularity the number of pediatric poisonings reported to poison control centres has also increased. In 2020, melatonin also became the most frequently-reported pediatric poisoning reported. A new report from the Centers for Disease Control and Prevention documents how these poisonings are causing an increase in serious adverse effects.
In the early 1900s it was observed that the pineal gland secreted a substance with physiologic effects, and the hormone itself was named in 1958. Receptors for the hormone have been identified in the hypothalamus, the pituitary, and in other organs in the body. And it’s definitely a natural substance: melatonin is found in vertebrates, invertebrates, animals, bacteria, fungi, algae and plants. In humans and other mammals, melatonin secretion by the pineal gland follows the light cycle, being low during daylight hours, surging in the evening and peaking in the middle of the night. This secretion starts in infancy and continues through adulthood, followed by a decline as we age. It has been explored in clinical trials mainly for the prevention and treatment of sleep disorders like insomnia and jet lag. The evidence suggests melatonin is modestly effective. It seems to be most effective for sleep-onset insomnia, and may give a slight increase in total sleep time. In children melatonin may be recommended for long-term use in autism spectrum disorder and attention deficit hyperactivity disorder.
Melatonin is generally very well tolerated. The most common side effects reported include daytime sleepiness, dizziness and headaches. Melatonin’s long-term effectiveness and safety are not clear. Given melatonin is a hormone, and receptors for this hormone are distributed throughout the body (including the sex organs), the safety, particularly during puberty, has not been established. So the advice is to use with caution and when necessary. Moreover, given the problems with quality of dietary supplements in many countries, there are legitimate concerns about product consistency and safety.
Poison control center reports
This new paper, published by the CDC in Morbidity and Mortality Weekly Report, is a study of all pediatric and young adult (<19 years old) melatonin ingestions reported to poison control centers in the United States between 2012 and 2021. During that period, 260,435 ingestions were reported, representing 2.25% of all reports. Ingestions were primarily in those <5 years old (84%), were unintentional 94% of the time, and occurred in the home 99% of the time. Reassuringly, most ingestions were without any symptoms (84.4%). When side effects were reported, the most common effects were central nervous system, gastrointestinal, and cardiovascular.
Of the 260,435 ingestions, 27,795 were treated at a health care facility. 71.6% were discharged, 14.7% were hospitalized, and 1% (287 cases) required intensive care unit support. Five children required mechanical ventilation, and two children died. Both of those children were under the age of two.
Interestingly, the largest increase in ingestions occurred between 2019 and 2020. (The authors speculate that this could conceivably have been driven in part by stay-at-home orders, school closures, and pandemic-related sleep disturbances.) By 2021, melatonin was accountable for almost 5% of all poisonings reported to poison control centers, compared with 0.6% in 2012. It’s a linear trend:
FIGURE 1. Rate* of pediatric† melatonin ingestions reported to poison control centers, by year§ — United States, 2012–2021
* Ingestions per 100,000 population, based on U.S. Census Bureau Annual Estimate.
† Aged ≤19 years.
§ Linear trend, p<0.001.
The authors noted the following limitations with their analysis: (1) data is collected based on self-reports that may underestimate actual exposures (2) poison control centers are not able to verify the accuracy of all case reports, and (3) poison control data does not allow one to confirm if deaths are due to the toxic effects of melatonin or because of other factors.
In the discussion, the authors discuss the quality control issues that have been identified with supplements, including melatonin, where products may not match the labelled claim. Given melatonin is treated as a dietary supplement in the United States, it continues to be marketed without manufacturing being held to “drug-like” standards for quality, consistency, and even packaging.
Treat melatonin like a drug
Melatonin is considered innocuous, safe, and effective, and its use has exploded over the last decade. There is widespread use and marketing of melatonin for children and it is even available in “gummy” form for that population. Likely due to growing popularity and use, accidental ingestions are increasing in frequency. While these products may not be packaged in child-resistant containers or considered to be potentially harmful, health professionals and consumers alike should be aware of the risks of melatonin toxicity and take steps to avoid accidental poisonings.

Despite safety and quality questions, melatonin use growing in children
A new survey shows use of melatonin in children is widespread despite modest efficacy and an unknown long-term safety profile.
Scott Gavura on November 23, 2023
Link

When my son was very young, like many children, he had a terrible time sleeping at night. Some nights I had to crawl out of his bedroom on my hands and knees so he wouldn’t sense me leaving and wake up. If I was lucky there was an hour of two of respite, before the cycle began again. Sleepless nights left us all cranky and exhausted. It got better, but it seemed to take years. Parents who deal with sleeplessness in children understandably worried about the causes and consequences of what they feel is persistent or atypical insomnia. While there are lots of folk remedies and tips, many are understandably apprehensive about “medicating” their child to help them sleep. Tell someone there’s a “natural product” for sleep, and you can expect a lot of interest. That’s what’s happened with melatonin, a hormone that is sold without a prescription in the United States, and other countries. Stores have shelves of melatonin, many in dosage forms designed for just for children, like gummies. 
Natural, but not really
In the early 1900s it was observed that the pineal gland secreted a substance with physiologic effects, and the hormone itself was named in 1958. Receptors for the hormone have been identified in the hypothalamus, the pituitary, and in other organs in the body. And it’s definitely a natural substance: melatonin is found in vertebrates, invertebrates, animals, bacteria, fungi, algae and plants. In humans and other mammals, melatonin secretion by the pineal gland follows the light cycle, being low during daylight hours, surging in the evening and peaking in the middle of the night. This secretion starts in infancy and continues through adulthood, followed by a decline as we age. As a therapeutic drug, melatonin has been explored in clinical trials mainly for the prevention and treatment of sleep disorders like insomnia and jet lag. The evidence overall suggests melatonin is modestly effective. It seems to be most effective for sleep-onset insomnia, and may give a slight increase in total sleep time. In children, melatonin may be recommended for long-term use in autism spectrum disorder and attention deficit hyperactivity disorder.
The regulation of melatonin varies around the world. In some countries, it’s regulated like a drug, and manufacturing is held to the same quality standards. Melatonin supplements in the United States are not subject to prescription drug manufacturing standards. This is despite the fact that most commercial melatonin supplements contain a laboratory-synthesized active ingredient. The Dietary Supplement Health and Education Act of 1994 (DSHEA) established the regulatory framework for dietary supplements. It effectively excludes manufacturers of these products from virtually all regulations that are in place for prescription and over-the-counter drugs. Under DSHEA, the FDA may not approve dietary supplements for safety and effectiveness before they are marketed. The FDA can only intervene to pull products off the market, after they are marketed, and only if they are adulterated or misbranded.
Earlier this year, I described one of the apparent effects of this regulation: A variety of melatonin “gummies” were analyzed. In a sample of 25 different brands, one product contained no melatonin at all but contained 31.3mg of CBD. Among the remaining products, the actual quantity of melatonin ranged from 74% to 347% of the labelled content. Overall, 88% of the products where inaccurately labelled. Only 3 products contained melatonin that was +/- 10% of the labelled content. Inconsistent product quality means it isn’t possible for parents to know what dose of melatonin they’re actually giving to their children.
The unreliable manufacturing standards along with growing usage may be contributing factors in the observation that poisonings in children are increasing. In 2020, melatonin also became the most frequently-reported pediatric poisoning reported. Between 2012–2021, the annual number of pediatric ingestions of melatonin increased by 530%. While most poisonings had few or no harms, some did have very serious outcomes, including hospitalization and death.
Use in children and adolescents
A new paper by Lauren Hartstein and colleagues at the University of Colorado Boulder was published last week in JAMA Pediatrics. It describes the results of a survey of parents of children aged 1-14 which queried sleep practices and melatonin use in the past 30 days. Data was collected over three months in early 2023. Data was collected for 933 children and adolescents, 53% femail with a mean age of 6. The main results were as follows:
Almost one in five children aged 5-9 had been given melatonin in the past 30 days. What’s also interesting is that children in all age groups are receiving melatonin, some continuously (7 days per week). The melatonin dosage increased across age groups, ranging from a median of 0.5mg in preschool children to 2 mg in preteens. Among preschool children who had taken melatonin in the past 30 days, the median duration of usage was 12 months. This duration extended to 18 months for school-aged children and 21 months for preteens. In terms of the preferred form of melatonin, across all age groups, the majority used gummies (64.3%), followed by chewable tablets (27.0%), pills (6.3%), and liquid (2.4%).
The survey results suggest widespread use of melatonin among children and adolescents in the United States, with some parents using it in very young children. The popularity of child-friendly melatonin forms, such as gummies, may be contributing to the increased usage. Moreover, parents may administer melatonin for an extended duration, often exceeding 12 months.
What do we know about the safety of melatonin in children and adolescents?
According to the Natural Medicines Database, melatonin in children is considered possibly safe when taken orally in low doses for a short duration. It has been studied in clinical studies with doses up to 12 mg per day. Concerns have been raised regarding the potential impact of melatonin on gonadal development in children, although evidence supporting this is limited and primarily based on three small observational studies with inadequate follow-up and imprecise measures of pubertal timing. Pediatric overdoses are rare but possible, emphasizing the need for careful use. Overall, melatonin is recommended to be reserved for children with a specific medical indication and not employed to induce sleep in otherwise healthy children. There is a lack of information on the long-term safety of melatonin use in children.
Conclusion
Melatonin is widely considered innocuous, safe, and effective, and its use has exploded. This survey provides more information on the use of melatonin in children. Some of that usage appears prolonged. Considering the manufacturing and quality issues with melatonin supplements, and the lack of long-term safety information, this paper raises additional concerns about the popularity of melatonin. More information is needed, especially in children.

   An Herbal Cure for Peanut Allergy?
Harriet Hall
Link
Peanut allergy is uncommon but devastating. Even a tiny trace of peanut can cause an anaphylactic reaction and death. That’s why labels specify “produced on shared equipment with nuts or peanuts” or “produced in a facility that also processes nuts.” There is no effective treatment: patients have to rely on avoiding peanuts and carrying emergency epinephrine injectors. Parents of peanut-allergic children live in fear that their child will be inadvertently exposed at school or at a friend’s house. Wouldn’t it be great if we could fix it so they could eat peanuts with impunity?
There is a ray of hope. Studies are underway on a Chinese herbal medicine (FAHF-2) that shows promise. I generally shy away from Chinese herbal remedies, because they are marketed without adequate testing and the products are not quality controlled. The typical course of events is (1) a preliminary study or a history of use in China, (2) marketing in the U.S. with overblown claims.
This is different.
FAHF-2 has been tested in a mouse model in well-designed studies at reputable U.S. institutions (Mount Sinai and Johns Hopkins). Research was funded by private foundations and government grants (not by manufacturers or business interests) and published in a reputable peer-reviewed journal, The Journal of Allergy and Clinical Immunology. As far as I can find, it’s not being marketed in the U.S. No claims are being made for it. It hasn’t been tested in humans. The NCCAM has funded the first clinical trial with an estimated completion date of December 2009.
The researchers had been studying a mouse model of allergic asthma and had had some success with another herbal formula. This prompted them to look into peanut allergy. Food allergy is not described in the traditional Chinese medicine (TCM) literature, but there was an herbal formula called Food Allergy Herbal Formula -1 (FAHF-1) that had been used in Asia for prevention of allergies and asthma. It contained ling zhi, an herb that had anti-inflammatory and anti-allergy properties, and wu mei wan, which had been used to treat gastrointestinal symptoms. It also contained 9 other herbs.
They tested FAHF-1 on a mouse model of peanut allergy. They found that it completely blocked the anaphylactic reaction when the allergic mice were challenged with peanuts. It not only blocked clinical symptoms, but it reduced mast cell degranulation, histamine release, peanut-specific serum IgE levels, and Th2 cytokine secretion. They checked the mice for possible toxic effects on liver and kidney and for possible immune suppression, and found no abnormalities.
Two of the ingredients were worrisome. Xi xin is wild ginger, which can contain aristolochic acid. Fu zi contains aconite. Both are toxic to humans. Aristolochic acid was implicated in an epidemic of kidney damage in Belgium from a contaminated herbal weight loss product. They simplified the mixture by removing these two ingredients, and called the new formula FAHF-2. They tested this new formula and found it worked just as well. The effects persisted for several weeks after treatment was discontinued.
They wondered if using just wu mei or ling zhi alone would work. In preliminary studies it appeared that neither was as effective as the whole formula. They postulated that some kind of synergism was at work. I wondered why they didn’t try eliminating herbs one by one, starting with the ones they thought were least likely to contribute. I find it difficult to imagine that all 9 herbs are necessary for the synergism, especially since they already removed 2 herbs without making any difference. It’s always possible that one herb might be acting antagonistically and that removing it might improve the effect.
Lo and behold, in 2008 they did almost what I thought they should. They tested individual components and found only partial activity in them. They concluded that the whole shebang was the best thing to use in continued testing.
The formula they are now working with contains:
• ling zhi (ganoderma lucidum), 28.17%
• wu mei (fructus pruni mume), 28.17%
• huang lian (rhizoma coptidis), 8.46%
• ren shen (radix ginseng), 8.45%
• huang bai (cortex phellodendri), 5.63%
• gan jiang (rhizoma zingiberis officinalis), 8.45%
• dang gui (radix angelicae sinensis), 8.45%
• gui zhi (ramulus cinnamomi cassiae), 2.81%
• chuan jiao (pericarpium zanthoxyli bungeanum), 1.41%
They have experimented with different extraction methods and have tried to minimize the bitter taste.
A clinical trial was approved by the NCCAM and is in progress. It is only a small preliminary study with 18 subjects. If this trial is successful, they will go on to larger trials.
Most drugs that enter initial clinical testing never make it to market. I don’t have high hopes for this one. It may not have the same effect in humans. It may turn out to have harmful side effects. The mouse model may be flawed. One or more ingredients may be superfluous.
There doesn’t seem to be any rhyme or reason to the particular combination of nine ingredients. That doesn’t mean it can’t work, but it makes me wonder. How many evidence-based remedies can you think of that contain multiple herbal ingredients? I can’t think of any offhand. They thought for a while that PC-SPES was one. It was a mixture of 8 herbs that appeared to slow the progression of prostate cancer, but it turned out to be a real fiasco. Double-blind testing showed it was significantly better than placebo – but only because the manufacturer had been spiking the mixture with 3 pharmaceutical drugs! Independent lab analysis of early batches showed significant amounts of diethylstilbestrol (DES), which is a synthetic estrogen, and indomethacin, a potent anti-inflammatory drug. Later batches showed that warfarin, a powerful anticoagulant (blood thinner), had been added to counteract the tendency of DES to cause blood clots. The researchers were sincere, but their suppliers were engaged in deliberate and dangerous hanky-panky.
Whether FAHF-2 pans out or not, I have to applaud the researchers. They didn’t patent it as a diet supplement and try to sell it to the public. They are doing good science. This is the way all herbal medicine claims should be handled, with stepwise investigation including attempts to isolate effective components.
If it does turn out to work, they’ll have to come up with a snappier name.

   Ginkgo biloba – No Effect
Steven Novella
Link
Another one bites the dust.
The National Center for Complementary and Alternative Medicine (NCCAM) is generally a waste of taxpayer money, but they have sponsored several well-designed large trials of popular herbal supplements. And one by one these studies have shown these popular products, such as echinacea for the common cold, to be ineffective.
To add to the list, published in JAMA this week are the results of the largest and longest trial to date of Gingko biloba for the improvement of cognitive function and to treat, prevent, or reduce the effects of Alzheimers disease or other dementia. The results of the study are completely negative.
The study was very rigorous – a consensus trial designed to address all the criticisms of prior smaller studies. It was a direct comparison of Gingko biloba at 120mg twice a day, double blind, randomized, multi-center trial involving 3019 subjects aged 72-96 for a median of 6.1 years. Subjects were followed with standardized tests of cognitive function.
The results are easy to report – every measure showed no difference between G biloba and placebo. There was no difference in cognitive function, risk of developing dementia, rate of progression of dementia or normal cognitive decline with aging. Usually such studies involve some random noise in the results, especially when several outcomes are measured. But with such a large study, random fluctuations should average out, and that is exactly what happened.
Gingko biloba has been used for centuries as a medical herb, and the most popular claim made for its use was to enhance cognitive function. The justification for this claim was always thin – G biloba has a mild blood thinning effect. It was therefore claimed that the herbal drug would enhance blood flow to the brain and improve brain function.
However, this is not a plausible mechanism. The brain exquisitely regulates its own bloodflow, and suboptimal perfusion results in a widening of the blood vessels to increase flow. This autoregulation would not be enhanced by mild blood thinning in a healthy individual.
In someone with severe atherosclerosis or narrowing of the arteries, to the point where autoregulation of blood flow is not able to optimize perfusion of brain tissue, the result is typically stroke-like symptoms. In this situation a blood thinner may improve perfusion, and generally drugs like aspirin are prescribed.
This, of course, implies that if simple blood thinning could improve cognitive function, then aspirin would be more effective at this than G biloba. In any case, this putative mechanism was never very plausible.
More recent studies have found that G biloba has some anti-oxidant effects. However, anti-oxidants as a class have not been found to be effective for cognitive function or any other clinical outcome. So this too lacks plausibility.
It was also found that G biloba can reduce amyloid aggregation. Amyloid plaques build up in the neurons of patients with Alzheimers disease, so this is a plausible mechanism for slowing the progression of some forms of dementia. However, as we now know this does not translate into a measurable clinical effect.
The lessons from this study and the lack of effect for Ginkgo biloba should learned and generalized.
Historical use of an herbal drug is not sufficient evidence for its effectiveness.
Preliminary, small, or poorly designed studies are unreliable, and often result in false positives. Only large definitive trials are reliable.
Finding a potential mechanism for a drug, herbal or otherwise, is not a sufficient basis for a clinical claim – you need clinical trials with actual people to support such claims. Further, if researchers go looking for potential mechanisms to explain a putative action of a drug or supplement, it is not surprising that they will find some. Drugs typically have many biochemical actions in the body, and finding an effect is not surprising. There is also likely confirmation bias and the file-drawer effect at work – favoring the publishing of interesting and positive studies.
In the end – all the ancient wisdom, small studies, and putative mechanisms meant nothing. They were all trumped by a large and impeccably designed study that shows Gingko biloba is of no measurable benefit for cognitive function.
These results call into question the practice in many countries of allowing pharmacological agents like G biloba to be marketed as supplements with health claims prior to being adequately studied. The European and US markets for G biloba are in the hundreds of millions of dollars per year. It will be interesting to see what happens following this study.
The study did find that G biloba was generally safe. However, it should be noted that G biloba, although sold in the US as a supplement, should be considered a drug. It does have an anti-platelet blood-thinning effect and should not be taken prior to surgery. However, because many people think of herbs as supplements and not drugs, patients rarely disclose their supplements to their doctors, and doctors fail to take a supplement history. Safety is therefore still an issue.
Herbs and botanicals have been and can be a valuable source for useful pharmacological agents. However, regulating and using them as supplements has many flaws – as the history of Gingko biloba once again highlights.

St. John’s Wort for depression – A herbal remedy that works?
St. John’s wort is a herbal remedy that appears to be effective for the treatment of depression. But how does it compare to antidepressants?
Scott Gavura on April 5, 2018
Link

Depression in our society is very prevalent, yet it can be invisible to others. Many struggle alone, and may even be reluctant to seek the advice of health professionals. Some may choose to self-medication. This may explain the persistent popularity of St. John’s wort (SJW) a herbal remedy that can be purchased over-the-counter in pharmacies and in most supplement stores. The effectiveness of SJW for the treatment of depression, and the relative merits of SJW versus prescription drug alternatives, has been the subject of debate for some time.
There is no a priori reason why herbal remedies shouldn’t have medicinal properties. After all, herbs are just unstandardized, unpurified drugs. And a huge number of commercially-produced drug products have botanical sources as their roots. But there are important differences between raw herbal remedies, like SJW, and prescription drugs that need to be considered when considering the merits of either. The key questions are: Does SJW effectively treat depression? And how does SJW compare to other treatment approaches, including prescription antidepressants?
Does St. John’s Wort effectively treat depression?
St. John’s wort (Hypericum perforatum), pictured above, is a flower that has been used as medicine for many hundreds of years for different “nervous” conditions. There are a number of compounds with biological effects that have been identified in SJW. Earlier research suggested that the active ingredient might be hypericin, and many products you’ll find in stores state the standardized amount of hypericin per capsule. However, more recent research suggests the chemical hyperforin may have a larger role in giving SJW its neurological and psychiatric effects. This ingredient may not be reported on the label. Like antidepressant drugs, hyperforin may affect neurotransmitter levels in the brain of compounds like serotonin, norepinephrine, and dopamine. Ultimately, however, the mechanism of action, and the active ingredient(s) of SJW, when used to treat depression, are not known with certainty.
Before looking at the evidence, it’s important to note how the multitude of chemicals in SJW complicate clinical trials. If there was a clinical trial conducted of a particular brand (and lot) of a SJW product, there is no simple way to verify that other lots even of the same brand contain the same combination of ingredients. While standardizing one or more ingredients may be helpful, even this isn’t an assurance of quality, unless it’s absolutely clear that it’s the standardized ingredient(s) that are producing the effect. This puts herbal products at a disadvantage in clinical trials. If we are not certain of the active ingredient, and the product isn’t standardized with verified ingredients, we can’t be certain that a negative trial is negative because it really doesn’t work – or if it didn’t contain the precise combination of chemicals to be effective.
The data on St. John’s Wort is of mixed quality, with the research methods often poorly described. Studies are generally of a short duration and usually funded by manufacturers (which is also the case for many pharmaceutical antidepressants). A recent review identified seven systematic reviews of randomized controlled trials examining effectiveness in moderate depression. It found:
    • A response rate (more than 50% decrease in symptoms) of 56% vs. 35% with placebo, over a median follow-up of six weeks.
    • No difference in remission rates from placebo.
    • No difference in adverse effects from placebo.
    • A clinically detectable and statistically significant improvement, when measured on a depression scale.
There was an interesting observation made in data made by the Cochrane review:
Overall, the St. John’s wort extracts tested in the trials were superior to placebo, similarly effective as standard antidepressants, and had fewer side effects than standard antidepressants. However, findings were more favourable to St. John’s wort extracts in studies from German-speaking countries where these products have a long tradition and are often prescribed by physicians, while in studies from other countries St. John’s wort extracts seemed less effective. This differences could be due to the inclusion of patients with slightly different types of depression, but it cannot be ruled out that some smaller studies from German-speaking countries were flawed and reported overoptimistic results.
Given the inconsistent and regional effects, there is some skepticism about the overall effectiveness of SJW.
SJW appears to be well tolerated when taken alone. The most common side effects are gastrointestinal effects, CNS effects (dizziness/confusion), tiredness/sedation, dry mouth and photosensitivity, albeit at rates similar to placebo in some trials. There is a lack of evidence to suggest that it is safe to use while pregnant or breastfeeding, however.
How does St. John’s wort compare to antidepressants?
Harriet Hall discussed the effectiveness of antidepressants a few weeks ago, and I will not go into that issue in depth today. While antidepressants have little effect on mild depression, they have been shown to be effective for moderate to major depression. There have been comparisons to prescription antidepressants, over about 27 trials, which were noted to be of poor to fair quality. While the quality of the trial data raises questions about the overall validity of the evidence, it appears that, for moderate depression:
    • depression scores, remission rates, and response rates are similar between SJW and antidepressants
    • SJW appears to be better tolerated than antidepressants
The supplement quality con
Supplements like SJW, and ongoing questions of its effectiveness, illustrate how weak and ineffective supplement regulation harms consumers. While regulations will differ between countries, supplements like SJW get a light touch, from a regulatory perspective, from most governments. This means that SJW isn’t subject to the licensing requirements (and evidence standards) that applies to conventional drug products. It will vary somewhat depending on what country you live in, but in countries like the USA and Canada, this is what you’ll find:
    • There are few limits on what can be legally sold as a supplement or natural health product.
    • There are few limits on the health claims that can be made about these products.
    • There are few, if any, requirements to directly test supplements for safety.
    • There are often no requirements to test supplements for actual effectiveness.
The result is a marketplace that is a boon to supplement makers, but puts consumers at a considerable disadvantage. What’s on the label should accurately describe what’s in the bottle. Product quality standards are essential. And when it comes to ensuring the products we buy are of high quality, drugs, supplements, or otherwise, we’re all effectively reliant on others to verify this. While the product manufacturer may be reputable, it’s only a regulator, or possibly independent testing, that can realistically verify and enforce production of complex and sophisticated molecules like pharmaceuticals to strict quality standards. The same cannot be said for products like supplements and herbs which are regulated differently than drugs, and held to different, and in some cases, weaker standards. A weak regulatory framework, which doesn’t hold manufacturers to account, would be expected to result in a product of lower quality. And that’s exactly what we see in the supplement market today. And that could be contributing to the mix evidence we have on SJW.
Interactions with everything
Once we swallow a substance, be it a herb or a drug, our body can’t distinguish the difference in source – whether that source is a steel vat or a plant. Chemicals are absorbed into the bloodstream, circulate in the body, and presumably reach the site of action and then have some sort of biological effect. Like prescription drugs, herbal remedies can interact with other drug products. And SJW is one of the worst offenders, seemingly causing drug interactions with almost every drug product on the market. SJW has an effect on several different metabolic pathways, increasing their effect. This has led to a decreased effectiveness of other drugs, and treatment failures have been noted from concurrent use of SJW with contraceptives, organ transplant drugs, narcotics, treatments for HIV, blood thinners and other therapies. The safest approach is to assume that SJW shouldn’t be taken concurrently with any other medication, without verifying a lack of problem with a pharmacist.
Conclusion
While it may be tempting to consider a “natural” alternative for depression, there are several reasons why few health professionals or mental health organizations recommend St. John’s wort. Given the weak regulation of herbal products like SJW and the potential for multiple drug interactions, prescription antidepressants give more certainty about the drug, the dosing, and the relative safety of the product purchased. And while there is some data that shows that SJW has an antidepressant effect, the evidence is not consistent across different studies, and may reflect the underlying variety in manufacturing processes and products available on the market. But perhaps most importantly, depression is a condition that seems to most effectively respond to a combination of drug therapy and psychotherapy. Working with a health professional who can give an accurate diagnosis and help assess the relative appropriateness of any medical treatment – be it St. John’s wort, or pharmacotherapy, is likely to yield a better approach than self-medication.

Cranberry, the alt-med zombie
Scott Gavura on April 11, 2013
Link
If there’s a characteristic that’s common among proponents of alternative medicine, it’s tenacity. The willingness to stick with an idea, no matter the evidence, must give one a certain clarity. The naturalistic fallacy is often the foundation. Natural is good, synthetic is bad, no matter the evidence. In some cases, in spite of the evidence. How one deals with contradictory evidence is an effective tool to differentiate between medicine and alternative medicine – given sufficient convincing evidence, medicine changes its practices. The same can’t be said for alternative medicine, where few treatments are ever discarded. Otherwise practices like homeopathy, acupuncture, reiki, and chiropractic would have disappeared long ago. It’s also why disproven products continue to have occasional resurgences in interest. Cranberry is one. It has been touted as a treatment and a preventative for urinary tract infections for years.  And it doesn’t seem to work – not well, and not reliably, if you look at all the trials. And that’s being generous, considering the poor quality of the evidence with its inherent biases. I know a dead parrot when I see one. Yet its advocates, mainly manufacturers (is there a Big Cran?) keep insisting it’s alive, supported by the occasional positive report that appears. With a new systematic review and meta-analysis that declares it’s effective, it’s time to update our review.
Mark Crislip did a nice overview of cranberry juice back in 2011. It’s most commonly used as a supplement (as juice, extract, or capsules) to prevent and treat urinary tract infections (“acute cystitis”). These infections are generally very responsive to antibiotic treatment. If untreated, it can worsen and move up into the kidneys and beyond. Some women (UTIs are uncommon in men) have repeated UTIs, and there are a number of non-drug strategies that can be used to reduce them. Cranberry juice has been a popular folk treatment for years. A decent reason why cranberry might prevent or treat urinary tract infections is still lacking despite five decades of study. An ingredient in cranberry, proanthocyanidins, is thought to block some variants of E. coli bacteria from adhering to bladder cells, which might reduce the risk of infection. But these “fimbriated” bacteria are uncommon in species isolated from urinary tract infections. So even if the theoretical mechanism of action is correct (which remains unproven), the real-world effect, based on this assumption, should be minimal. And that’s largely what the evidence shows, when you account for the poor research quality. But we don’t need to know how it works, if it works. And there is no good evidence that cranberry is an effective treatment for UTIs. The data are less clear with prevention. There are lots of trials and the results are mixed. The best reviews of clinical evidence are systematic in nature, and happily Cochrane has a perspective. A 2012 review noted the following:
Cranberries (usually as cranberry juice) have been used to prevent urinary tract infections (UTIs). Cranberries contain a substance that can prevent bacteria from sticking on the walls of the bladder. This may help prevent bladder and other UTIs. This review identified 24 studies (4473 participants) comparing cranberry products with control or alternative treatments. There was a small trend towards fewer UTIs in people taking cranberry product compared to placebo or no treatment but this was not a significant finding. Many people in the studies stopped drinking the juice, suggesting it may not be a acceptable intervention. Cranberry juice does not appear to have a significant benefit in preventing UTIs and may be unacceptable to consume in the long term. Cranberry products (such as tablets or capsules) were also ineffective (although had the same effect as taking antibiotics), possibly due to lack of potency of the ‘active ingredient’.
The Cochrane review included both juice and capsules of cranberry. Most trials were about 6 months in duration, which is probably the minimum time period in which a difference could be identified. Of the 24 trials Cochrane identified, 13 could be combined in a meta-analysis. The meta-analysis found no significant difference in the rates of recurrent urinary tract infections. There was a suggestion of benefit, with a relative risk of 0.86 but a confidence interval of 0.71 to 1.04. Trials that could not be included in the meta-analysis were also studied, with the majority finding no benefit. Is there any reason to be optimistic? Probably not, given the overall quality of the research. There was little follow-up and lots of patient dropouts, likely a result of the difficulty in taking the juice daily. Perhaps not surprisingly, cranberry manufacturers and their affiliated scientists insist cranberry is effective, despite the evidence, and blamed poor quality products and poor quality trials for hiding what they felt was a benefit. One researcher, Amy Howell, even dismissed the idea that cranberry could be evaluated in a Cochrane review:
“At Cochrane they typically review pharmaceutical drug studies and their prevention of disease. They do not have anyone on their staff that specializes in supplements and functional food products. This is not their strong point,” Howell said. A European commentary in 2005 had already cited problems with Cochrane review of nutrition studies. That review, Howell said, found that, “you really cannot really use drug criteria to review these types of foods. It just doesn’t work. You can’t look at just one thing.” Howell quoted the European review as saying: “It’s hard to even imagine a human clinical trial in which one half of a large group of middle age people agreed to avoid vegetables for five years and then agreed to be followed up to see how many developed of them developed cancer.”
Handwaving and a straw man argument. Studies required the consumption of a specific supplement for about 6 months – not unlike any other clinical trial of an intervention. If cranberry works, we should be able to measure its effects when we test it. Now I’m in agreement with the other contributors to this blog that Cochrane can get CAM wrong. But it’s because they don’t consider prior plausibility – not because the the technique of a systematic review isn’t applicable. If anything, Cochrane’s methodology is somewhat biased towards accepting implausible treatments, not against them. (Consider this evaluation of a homeopathic remedy, for example.)
Now there’s another systematic review of cranberry with a different conclusion. This one is by Wang and colleagues, and it’s entitled, Cranberry-containing products for prevention of urinary tract infections in susceptible populations. It, like Cochrane, is also systematic review and a meta-analysis. This study also identified 13 trials (mainly juice, some capsules) and included 1616 subjects in its dataset. The authors looked at the risk of bias in each trial, and all but two were rated “High Risk” in at least one category.
Their conclusion: a relative risk of 0.62 (with a confidence interval of 0.49-0.80). Just better enough to achieve statistical significance. How did this occur? Some statistical sleight-of-hand. The authors put all the trials into a Galbraith plot, a test to measure statistical heterogeneity (non-uniformity). One is strongly positive (A) and one is strongly negative (B). The authors declare that the negative trial by Babosa-Cesnick is too heterogeneous to be included, so the exclude it. Yet the positive trial by Ferrara, which is also heterogeneous, is included. Guess what happens to the result?
Dropping the negative trial makes the overall benefit from cranberry look positive. So the authors announce that cranberry “seemed to be effective in prevention of UTIs”. The authors then go on to illustrate how questionable the cranberry data set really is. They look at the statistical significance of the combined by removing other trials, one by one. You can see how excluding the negative Babosa-Cesnik data slides the risk ratio to the left (see the bottom line), making the result look much more compelling:
Perhaps not surprisingly, the cranberry producers and their scientists like this study a lot more. The same researcher, Amy Howell, who dismissed the Cochrane methodology seems to find this one a lot better:
Commenting independently on the review’s conclusions, Amy Howell, PhD, from the Marucci Center for Blueberry Cranberry Research at Rutgers University told NutraIngredients-USA: “The results of this latest meta-analysis of clinical trials in a highly regarded journal provide further convincing support for the use of cranberry in the prevention of recurrent UTI in susceptible populations. Results indicate that despite the challenges of utilizing cranberry in different formulations, dosages, and target populations, overall positive outcomes were obtained in many cases.”
In other words, this meta-analysis supports my confirmation bias, so it’s a good paper.
My personal take is that if there is an effect from consuming cranberries, it’s so slight that the clinical trials so far haven’t been large enough to pick it up. Whether it’s an attractive approach, despite the evidence, depends on a a consideration of consequences, alternatives, and costs. The excellent Therapeutics Education podcast did a clinical review of the evidence and included a brief dietary and economic analysis. They estimated that even if we accept the positive data, we need to consider the following:
    • You need to consume about 500mL of cranberry cocktail to obtain the studied amount of the pure juice. This costs $0.45-$0.66 per day and could provide 120-150 calories.
    • Over 6 months, in order for a 1 in 12 chance of avoiding a UTI (that’s the efficacy), you’d spend about $180 and consume about 45,000 calories which (holding everything else equal) could cause a weight gain of several pounds.
I calculated 61 grams of sugar per day in two cups of Ocean Spray cocktail, which means 24 lbs of sugar consumption over 6 months. So while it’s “natural”, and may not have many acute side effects, it’s not without the potential for unwanted effects.
Finally, let’s look at the alternatives to the alternative. Antibiotics taken for the prevention of UTIs are very effective, reducing the risk of an infection by up to 95%. You only need to treat two people for one year to prevent 1 recurrence. An NNT of 2 is pretty impressive, anywhere you see it in medicine. It’s not a panacea, though. There are justifiable concerns about the risk of antibiotic resistance developing, and there are drug-related side effects, including more yeast infections. However, long-term antibiotics appear to be far more useful as a strategy for those experiencing many infections per year. Some choose just to take antibiotics when infections recur – managing the infection effectively while minimizing overall exposure to these drugs.
Conclusion
Medicine isn’t unlike any other aspect of our lives. We see what we want to see. These two systematic reviews, and their interpretation, illustrate this nicely. Methods matter if we want to minimize bias. Cochrane has the most rigorous approach to data collection, synthesis and analysis. Their conclusion is a reasonable analysis of the evidence base. There is no persuasive evidence that cranberry can prevent or treat urinary tract infections. In comparison, the Wang paper looks more like an exercise in data-dredging, where the analysis was manipulated until a positive result could be identified. This post-study rationalization is akin to throwing darts at the wall, drawing the target around the darts afterwards, and then declaring victory – or in this case, clinical effectiveness. Even taking the analysis at face value, cranberry is only modestly effective, expensive, and may come at a high dietary cost. And, it’s substantially less effective than conventional treatments. So is this the final word on cranberry? It probably should be, but that’s unlikely. It’s a zombie, and it will be back.
References
Jepson R.G., Williams G. & Craig J.C. (2012). Cranberries for preventing urinary tract infections., Cochrane database of systematic reviews (Online), PMID: 23076891
Wang C.H. (2012). Cranberry-Containing Products for Prevention of Urinary Tract Infections in Susceptible PopulationsA Systematic Review and Meta-analysis of Randomized Controlled Trials, Archives of Internal Medicine, 172 (13) 988. DOI: 10.1001/archinternmed.2012.3004

Cranberry Juice, Revisited
A new review suggests that cranberries may in fact be effective at preventing urinary tract infections.
Scott Gavura on March 27, 2025
Link
Cranberry juice has long been touted as a natural remedy for preventing and treating urinary tract infections (UTIs). I and other contributors to this blog have written several posts about it over the past decade. I called it an alt-med zombie in 2013 and again in 2016, and here it is, back again in 2025. Over the years, research has showed mixed results, with some studies suggesting a potential benefit while others finding little to no effect. Compared to many other alternative medicine treatments, new evidence in the form of randomized controlled trials continue to emerge, so I wanted to use this post to look at the current state of the evidence to see if this popular natural product can help reduce the risk of UTIs.
Any folk remedy guide from the past 40 years will likely mention the use of cranberries and cranberry juice to prevent or treat urinary tract infections. It may be used as a supplement (as juice, extract, or capsules) to prevent or treat urinary tract infections (“acute cystitis”). A scientific reason why cranberry might prevent or treat urinary tract infections is still lacking despite over five decades of study. Is it because the berries are so bitter, that they must be medicinal? An early hypothesis may have been the ability of cranberry to lower urinary pH, which was thought to help treat UTI. Later, an ingredient in cranberry, proanthocyanidins, was thought to block some variants of E. coli bacteria from adhering to bladder cells, which has been proposed as the mechanism by which it reduce the risk of infection.
There’s another significant issue with cranberry juice as a medicine: The calorie load. Unsweetened cranberry juice is unpalatable, so it’s usually sweetened. You’d need to consume about 500mL of cranberry cocktail to obtain the typical amount studied in clinical trials. Two cups of cocktail supplies 52 grams of added sugars per day. Over a year, that’s 41 pounds of added sugar you’re putting in your diet to prevent a urinary tract infection, unless you’re taking a low-calorie version, or capsules. Capsules have been studied (although there is less evidence than with the juice) and it’s not clear that they are comparable, though one RCT found no difference. So even if cranberry juice was show to be an effective treatment, the benefits and harms need to be considered carefully.
I will skip a review of evidence to treat UTIs. In short there is no convincing evidence that cranberry juice is useful once an infection is present. The evidence is more interesting for the prevention of UTIs. There have been several systematic reviews over the past few years which I haven’t blogged about previously.
An updated Cochrane Review
The largest systematic review is a Cochrane review (updated 2023) that included 50 randomized controlled trials with 8857 patients. And it’s a positive review – with a bunch of caveats. Forty‐five studies compared cranberry products with placebo, water or no specific treatment in six different groups of participants. Twenty‐six of these 45 studies could be combined into a meta-analysis. The proanthocyanidin content varied significantly per dose, from 2.8mg to 118 mg. With moderate certainty, cranberry products were estimated to reduce the risk of UTIs by about 30%. When groups were analyzed, the following was observed:
    • In women with recurrent UTIs (8 studies), the infection rate was 18% vs. 24% for placebo, meaning you’d need to treat 17 women for one to benefit (NNT=17).
    • The was larger effect in children with past UTIs (5 studies), the infection rate was 16% vs. 34% for placebo, giving an NNT of 6.
    • In adults following pelvic radiation and surgery, infections rates were 11% versus 23%, giving NNT of 9.
    • No benefit was found in institutionalized adults, pregnant women, or those with intramuscular dysfunction.
There were no meaningful differences in adverse effects between the cranberry and the placebo groups.
There are some cautions to consider when interpreting these results. There appears to be the presence of publication bias in cranberry data, which suggests the efficacy may be overestimated. In addition, larger RCTs showed a smaller effect compared to smaller RCTs.
So are cranberries a reasonable alternative to antibiotics, which are the usual treatment to prevent UTIs in those that experience recurrent infections? Antibiotics are very effective, reducing the risk of recurrent UTIs from 66% to about 12% when taken over 6-12 months. However, they can cause side effects (15% vs. 8% with placebo) and the effects on long-term bacterial resistance are not well studied.
The Berry Bottom Line
One of the most interesting parts of medicine is seeing it progress and seeing practice change as evidence emerges. Cranberries are not a groundbreaking panacea as a medicinal product, but there appears to be something there. Recognizing the limitations of the data, cranberries may be effective at preventing UTIs. They have not been shown to be effective in everyone, which increases my skepticism about whether these efficacy findings are real. Having said that, if a patient with recurrent UTIs (not pregnant, institutionalized or with neuromuscular dysfunction) wanted to try cranberries instead of antibiotics, I would be cautiously supportive, noting that cranberries are not a slam dunk and may not be effective. But if an individual was adamant about avoiding daily antibiotics, then cranberries may be a reasonable option to try.

Cinnamon for diabetes? The consequences of “natural alternatives”
Scott Gavura on August 16, 2012
Link
A customer strolled up to the counter one night when I was working in a retail pharmacy:
“My doctor says I have prediabetes. I don’t want to take any drugs. Do you have something natural I can use to cut my blood sugar?”
I looked at him in the eye, and pointed at his sizeable midsection. “Sir, if you’re at risk for diabetes, and you don’t want to take medication, the single best thing you can do for yourself is lose some weight.”
He grinned and asked, “Great – what supplement can I take to help me?”
This type of discussion occurs all the time. A patient has been assessed by their physician, and informed that they have a medical problem of some sort. The patient, reluctant to accept the physician’s evaluation, heads to the pharmacy for a second opinion. In some cases, the patient may question the physician’s advice: “All my physician wants to do is prescribe drugs.” Yet there’s a disconnect when it comes to strategies for management. More often than not, non-drug approaches are rejected out-of-hand (probably because the sample I speak with have already made the decision to buy something). And in those that are leery of medical management, there’s often a willingness to consider anything that’s available without a prescription – particularly if it’s perceived as “natural.” Natural products are gentle, safe, and effective, while medicine is thought of as unnatural, harsh, and potentially dangerous. This is the appeal to nature fallacy, nothing more. Purveyors of supplements leverage the appeal to nature fallacy into the marketing strategy of choice for almost all supplements and “alternative” medicines. And it leads to bad health care decisions.
Alternative medicine for diabetes is big business, because the public health burden of diabetes is massive, and growing. In 1985, the worldwide prevalence was 30 million people. In 2000, it was 150 million. By 2030, it could be 250 million. Why are more people being diagnosed with diabetes? Obesity, sedentary lifestyles, and an aging population. At its core, diabetes is a disease of sugar (glucose) management. Insulin, secreted by the pancreas, allows cells to use glucose. When the pancreas doesn’t produce insulin, it’s called Type 1 diabetes. This is an autoimmune disease that strikes early in life, and was a death sentence until insulin was discovered. When the pancreas can produce insulin, but the amount is insufficient, or when there’s a problem with the uptake of insulin into cells, it’s termed type 2 diabetes. 90% of all diabetes is type 2. Typically a disease of older adults, type 2 diabetes can potentially be treated without drugs of any kind, but success rates are low and medication is eventually advisable. There’s also gestational diabetes, a disease of pregnancy, and prediabetes, where blood sugars are elevated, and diabetes is an expected future diagnosis.
Given the prevalence of diabetes and the chronic nature of the disease, it’s no surprise that CAM is a popular treatment option. I don’t see a lot of CAM use in Type 1 diabetics. Insulin is the primary treatment, it works well, and patients can objectively measure their own blood sugar. Type 1 diabetics don’t seem to experiment with supplements that might alter their blood sugars. Those patients end up hospitalized or dead.
It’s the patients with type 2 diabetes that lean towards supplements. While lifestyle modifications (exercise, weight loss, and smoking cessation) are the foundation for managing diabetes, drug treatment is usually also required. There are an array of prescription drugs like metformin and glyburide with a long history of use and demonstrated efficacy. Some drugs even decrease mortality – the primary outcome we’re after. But proper treatment has also been shown to the reduce the risk of an array of other consequences: Diabetes is the biggest cause of blindness, kidney failure and non-traumatic amputation. Diabetes is associated with an elevated risk of cardiovascular disease, too. Yet despite the irreversible consequences of diabetes, and the availability of effective medications, type 2 diabetes remains poorly-controlled in many, often because of poor self-management.
The diagnosis of diabetes, and the effectiveness of treatments can be objectively measured. Fasting plasma glucose (FPG) measurements and then the oral glucose tolerance test accurately measure insulin function, and guide diagnosis. While routine blood sugar monitoring (with test strips) is generally unnecessary in Type 2 diabetes, measurement gives a point estimate of blood sugar levels. Glyclated hemoglobin (A1C) levels reflect overall blood sugar trends, with higher levels associated with more complications of the disease. Interestingly, super-intensive blood glucose lowering isn’t associated with additional risk reduction, and it increases the risk of side effects due to too-low blood sugar. Treatment goals are individualized (hey, it’s “holistic”), balancing a number of factors including risks as well as a patient’s ability to manage complex treatment plans.
The evidence for cinnamon
Given the consequences of diabetes, self-management is something I want to encourage, not discourage. Without a commitment from the patient to take an active role in managing their diabetes, any treatment plan is doomed to fail. So is self-treatment with supplements a wise idea? There’s an array available, and patients regularly ask about the latest treatment “Big Pharma doesn’t want you to know about”. That treatment used to be chromium. Ginseng was popular for a time, too. Fenugreek and bitter melon are used as well. The treatment that seems most popular now is cinnamon. Like any other herbal remedy, most sources will tell you that it’s been used for “thousands of years” as a medicinal herb. As a treatment for diabetes, I have my doubts. While reports of diabetes go back to 1552 BCE, the ability to effectively measure any diabetes treatment only goes back a few decades. Interest in cinnamon as a treatment seems to have started with in vitro tests but gained some plausibility in 2003, when a study from Alam Khan suggested several grams of cassia cinnamon per day could lower fasting blood glucose. Khan randomized Type 2 diabetes to 1g, 3g, or 6g of cinnamon for 40 days. All three groups improved their fasting blood glucose, and blood lipid levels, but there was no effect on A1C.
Like trials with any other supplement or herbal product, the primary question we must answer is “What exactly was studied?”. The cinnamon you have in your kitchen may be a single species of plant or a mix of different cultivars. Ceylon cinnamon (Cinnamommum verum) is more commonly found in the West. Cassia cinnamon (Cinnamomum aromaticum) is the version of cinnamon that’s been studied in trials. The chemical hydroxychalcone has been identified as a potential active ingredient, which is believed to modify the sensitivity of cells to insulin, enhancing their uptake. If that’s the true mechanism of action, then it would work in a manner similar to that of the drugs Avandia, Actos, and metformin (Glucophage). Given the active ingredient (or ingredients) have not yet been definitively isolated, the issue of studying cinnamon is problematic. There’s no way to assess the potency of any batch, which complicates any evaluation. And that may be a reason why the research with cinnamon is inconsistent and largely disappointing.
While the Khan study looked promising, supplementary studies have failed to consistently show beneficial effects. Vanschoonbeek gave 1.5g of cinnamon or placebo to postmenopausal women over 6 weeks. There was no effect reported on blood sugar or blood lipid levels. Baker’s 2008 meta-analysis identified 5 trials including the Khan and Vanschoonbeek studies and concluded the following:
In this meta-analysis of five randomized placebo-controlled trials, patients with type 1 or type 2 diabetes receiving cinnamon did not demonstrate statistically or clinically significant changes in A1C, FBG, or lipid parameters in comparison with subjects receiving placebo.
In that analysis, the Khan study looks like an outlier. More studies have emerged since then: Crawford in 2009 found 1g of cinnamon per day reduced A1C levels compared to placebo. Suppapitiporn found no effect on any measure with 1.5g per day. Akilen, in 2010, found an effect with 2g per day. Another meta-analysis, published in 2012 and included 6 studies, concluded the opposite of Baker, and made positive conclusions:
A total of 6 clinical trials met the strict inclusion criteria and considered a total of 435 patients; follow up between 40 days–4 months, doses ranging from 1 g to 6 g per day. Meta-analysis of RCTs showed a significant decrease in mean HbA1c [0.09%; 95% CI was 0.04–0.14] and mean FPG [0.84 mmol/l; 95% CI was 0.66–1.02].
But look closer. The results may be statistically significant, but they’re not that impressive compared to medication. Cinnamon lowered A1C by 0.09%, versus the usual 1% with medication. Give A1c reflects overall glucose trends, cinnamon doesn’t look that impressive. Even at the extreme of the confidence interval, cinnamon has, at best, 10% of the efficacy of drug treatments. At worst, it’s completely ineffective.
Until the findings are reproduced consistently, and cinnamon has been show to provide a meaningful improvement in relevant measures, there is no persuasive evidence to suggest that cinnamon has potential as a useful treatment option. Drugs that work, work consistently and provide meaningful improvements in measures of the disease. Why doesn’t cinnamon work? There may be an active ingredient, but it’s present in low concentrations, and varies in content between the different batches of cinnamon used in the different trials. In that case, the active ingredient needs to be standardized and possibly isolated, which would make it a drug treatment. Or this could be yet another example of a supplement that looks promising in early studies, only to see the effect disappear as the trials get larger and control for bias more effectively.
The risks
If a drug treatment’s efficacy is questionable, the adverse event and safety profile is even more important. As a popular food additive, cinnamon seems safe when consumed at doses of a few grams per day. (1 teaspoon of the powder is about 4.75 grams). While the trials have been small and short in duration, no significant adverse events have been reported. It is Generally Recognised as Safe (GRAS), as a seasoning and flavoring. However, reversible liver damage has been reported with therapeutic use, due to coumarin, a chemical also present in Cassia cinnamon. Those with liver impairment or dysfunction may be at greater risk of harm. There are no published long-term studies with cinnamon that inform us whether chronic consumption of high doses is safe.
Conclusion: Not a substitute for real treatment
    • Cinnamon’s effectiveness as a treatment for diabetes has not been established. A prescription drug as ineffective as cinnamon likely wouldn’t pass FDA muster. Existing drug treatments for diabetes, on the other hand, are cheap, effective, and generally well tolerated. Compared to drug therapy, we don’t know if cinnamon can reduce the risk of mortality due to diabetes, or the progression to any of the other serious outcomes of diabetes. For my patients that insist on trying cinnamon, I’d caution them of the risks, and reinforce that cinnamon is no alternative for lifestyle changes and medication if necessary. It may be natural, sure, but that doesn’t mean it’s either safe or effective.Search

Pycnogenol – Does maritime pine bark extract live up to the hype?
Scott Gavura on December 5, 2024
Link
Prescribed medicines are somewhat resistant to fads. Marketing can certainly drive demand and use, but long-term use tends to be driven by effectiveness. Some medicines used routinely today are decades old (e.g., penicillin for strep throat), because nothing better has been identified. Other drugs may be used for decades, only to largely disappear as newer, more effective treatments are introduced (I’m thinking of drugs like theophylline for airway disease, largely replaced by safer and more effective treatments).
The opposite is often the case with dietary supplements. With some exceptions, supplements tend not to be supported by convincing scientific evidence. Their use is driven by marketing, word-of-mouth, and hype. In the pharmacy we used to call it the Oprah effect or the Dr. Oz effect – remember green coffee bean? Or red palm oil? These supplements surged in popularity only to disappear – because they were ineffective. Effective products have the best sales pitch of all – they work.
My usual first response to a request about the effectiveness of a new supplement is to look at the evidence base. I may go to PubMed and search directly, but I’ll more commonly look at a trustworthy tertiary reference like UpToDate, NatMed, or Examine.com for their take on the product and the evidence. In a lot of cases, there’s little to no evidence worth reviewing, which makes for a boring blog post. I was asked about a product recently that was actually assessed in multiple randomized controlled trials – which makes for better blog fodder, as there’s some science to actually consider.
Maritime Pine Bark
Maritime Pine Bark is a extract from the Pinus pinaster tree, often marketed with the trade name Pycnogenol. The maritime pine is a tree native to Mediterranean countries like Spain, France, Portugal, Italy, Croatia, and Morocco. Its bark is used in supplements for various conditions. Pycnogenol, a patented extract from French maritime pine (pictured above), comes from trees grown only in Landes de Gascogne, in southwest France.
One of the biggest challenges with evaluating clinical trials related to herbal remedies is that products will differ in terms of their chemical constituents. If you think of a herbal remedy as essentially an unrefined drug, the individual compounds in it will vary based on the variety of the plant, when it was harvested, what part of the plant was harvested, and how the supplements was actually prepared. Standardization address this by ensuring (usually through manufacturing and testing) that there are consistent amounts of one or more specified chemicals that are thought to be the “active” ingredients. Standardization, when it’s in place, gives the user more confidence that the results of clinical trials with that product will be relevant to the product that you’re taking and the effects you’re expecting.
The Pycnogenol brand of maritime pine bark is rich in potentially biologically active compounds like flavonoids and phenolic acids, including procyanidins, catechin, epicatechin, taxifolin, caffeic acid, and ferulic acid. Most clinical studies have been conducted with the Pycnogenol-branded extract, so I will refer to this product in the review of the evidence.
One of the general rules of drugs (and supplements) is that the more diverse the effects a product is claimed to have, the less likely that any of those claims are probably true. And there are a lot of claims for Pycnogenol: Coronary artery disease, osteoarthritis, chronic venous insufficiency, asthma, high blood pressure, diabetes, irritable bowel and male sexual dysfunction are all claimed to benefit from this supplement. While it’s not impossible for one product to have beneficial effects (and no harms) in so many conditions, it’s definitely unlikely.
Pycnogenol’s health benefits are attributed to its mix of polyphenols. After consumption, some of these compounds are broken down by gut bacteria into biologically active ingredients which are absorbed. Experimental evidence suggests that it could reduce pain and inflammation by blocking pathways that produce inflammatory compounds. As an antioxidant, Pycnogenol could be neutralizing free radicals, and boosting the effectiveness of other antioxidants like vitamins C and E. It may support blood flow and vascular health by promoting nitric oxide production and strengthening blood vessels. All of these are possible based on the chemistry, but the proof is when the effects are demonstrated in actual humans.
Evidence base
The trials themselves are generally small and prone to bias. Having said that, there are some positive findings that look interesting. Pycnogenol is felt to be possibly effective for asthma (it may reduce rescue inhaler use) when added to regular asthma medications. It may also improve leg pain and reduce feelings of heaviness in patients with chronic venous insufficiency. When taken for oseteoarthritis, Pycnogenol use reduced the need for anti-inflammatory medications, compared to a placebo.
For other conditions, the evidence is less compelling. There may be some positive effects on cardiovascular conditions, but bias in trials makes the conclusions less interesting. The same can be said for effects on cognition or ADHD, skin health, and allergies. A 2012 Cochrane review of Pycnogenol for chronic disorders looked at evidence for asthma, ADHD, chronic venous insufficiency, diabetes mellitus, erectile dysfunction, hypertension and osteoarthritis. it concluded,
Due to small sample size, limited numbers of trials per condition, variation in outcomes evaluated and outcome measures used, as well as the risk of bias in the included studies, no definitive conclusions regarding the efficacy or safety of Pycnogenol are possible.
It’s worth giving credit to a supplement manufacturer for sponsoring clinical trials with their product, which is a step often skipped, when you can sell a product without any research. Certainly the product looks to have biological and potentially positive medicinal effects. It is generally well-tolerated and has been studied in trials of up to a year in adults. Rare side effects include stomach issues like nausea, headache, dizziness, drowsiness and vertigo.
“More research is required” is a common statement, but it’s applicable here. While there are some promising hints of medicinal effects, there’s no compelling research to suggest that Pycnogenol can replace medicine or delay its need. For those that are really interested in using the product, maritime pine barks supplements that contain Pycnogenol are the most studied and have the benefit of being standardized, so you can be more confident in what you’re buying.
So when it comes to Pycnogenol, I wouldn’t recommend it as a daily or routine supplement, but I wouldn’t dismiss it if someone wanted to use it for one of the more evidence-backed reasons for use. Hopefully more trials will be conducted to better establish its place in therapy.


Biotin: Haircuts Plus Health Advice?
Harriet Hall on October 8, 2013
Link
A friend asked me, “What do you know about biotin?”
I said, “Not much. Why do you ask?”
She explained that the woman who cuts her hair at the hair salon recommended she take biotin to strengthen her nails and improve hair growth. She tried it, and within a couple of months, her nails looked better than they ever had in her whole life: the ridging was gone and they were no longer splitting or bending. And her hair, which had begun to thin, was noticeably thicker again.
I know what you’re going to say: this is nothing but a testimonial, and she could have been mistaken: post hoc ergo propter hoc and all that. Hair salons are not reliable sources of health advice, and perhaps not even a very reliable source of hair advice. I am leery of their recommendations for expensive shampoos and gimmicky conditioners. They offer things I don’t want, like hair coloring (I consider my gray hairs hard-earned badges of honor), waxing, eyebrow arch threading, scalp massage, and facials. Some of them have tanning beds in a back room. Incredibly, several of them in my area even offer ear candling!
I’m frequently asked to look into the evidence for various diet supplement products, and I’m almost always disappointed. The company websites offer little but claims and testimonials. There may not be a tab for “scientific studies” and if there is, the studies gathered there are often a farce, and may not even pertain to the product in question.
This time I was pleasantly surprised. The trustworthy Natural Medicines Comprehensive Database rated biotin “likely effective” for biotin deficiency and described preliminary evidence that biotin might increase the thickness of fingernails and toenails in people with brittle nails, although it considered that the evidence was insufficient to rate.
What is biotin?
Biotin is one of the B complex vitamins, sometimes known as vitamin B7 or vitamin H. The B complex vitamins are needed for healthy skin and hair. Biotin is produced in the intestines by bacteria and is also found in the diet. The mechanism of action and metabolism have been studied. Biotin is water soluble and its elimination half-life is slightly less than 2 hours, so you can’t build up a store of it. Biotin deficiency in humans is rare, but it can cause thinning of the hair, frequently with loss of hair color, and red scaly rash around the eyes, nose, and mouth. It can even lead to depression, lethargy, hallucinations, and paresthesias of the extremities. Deficiency is most likely in congenital biotinidase enzyme deficiency, malabsorption syndromes, and in long term parenteral nutrition. Other things that can deplete biotin are eating two or more raw egg whites daily over long periods, excess alcohol consumption, certain anti-seizure medications, and possibly diabetes and cigarette smoking.
The NMCD rates it as “likely safe.” It is well tolerated in doses of 10 mg per day. Only one severe reaction has been reported, and it has not been definitely linked to biotin. A dermatologist writing in the Huffington Post argues that the role of biotin is not totally clear, and users should avoid overdosing. He recommends 2.5 mg (2500 mcg) a day, but that isn’t based on hard evidence. Some supplements contain as much as 5000 or 10,000 mcg.
The evidence
On to PubMed…where I actually found 3 positive human clinical studies of subjects with brittle nails and no negative ones. A study of 35 patients who took daily biotin found that 22 showed clinical improvement and 13 reported no change in their condition. A small study in Switzerland used scanning electron microscopy to study whether favorable clinical results could be corroborated. Indeed, they were able to measure a 25% increase in the thickness of nails with biotin supplementation. In another study 45 patients were evaluated: 91% showed definite improvement and none of the patients considered the treatment altogether ineffective. At least one website calls the evidence “very weak.” Others consider it to be stronger.
There is good evidence from animal studies: biotin has been shown to improve hoof health, prevent lameness, and improve milk production in dairy cows. It has also been shown effective in Lipizzaner horses, ponies, and swine.
Is it worth trying?
If you have brittle nails, it might be worth a try. The evidence is consistently positive, albeit only from three small preliminary trials that have not been replicated. I don’t usually recommend using a medication until the evidence is much stronger than that. However, in this case I think there are good arguments for trying it:
    • There is a plausible mechanism.
    • There is supporting evidence from animal studies.
    • The human studies are not just based on subjective reports of improvement: one of them used objective measurements with electron microscopy and demonstrated a 25% increase in nail thickness.
    • It is safe.
    • There are no other good evidence-based treatment options. Horsetail, moisturizers, nail protection, gelatin and other remedies have been tried, but they haven’t been proven effective. So with the existing evidence, biotin is probably the treatment of choice.
    • I think the existing evidence justifies a therapeutic trial of biotin for brittle nails. If you haven’t improved after 6 months, you can stop taking it. A 3 month supply can cost as little as $4.19, so there is little to lose.
Conclusion
Brittle nails are a relatively minor item in the general scheme of things; but I’m glad I looked into biotin, and I think my experience offered a lesson applicable to other questions. The fact that Dr. Oz recommends biotin for hair loss made me very suspicious (what is the opposite of the “appeal to authority” fallacy?), and I was prejudiced against using a hair salon as a source of information. I was predisposed to reject biotin. But I was aware of that and I made an effort not to let my bias interfere with my judgment about the evidence. Even if a source is untrustworthy, it would be foolish to reject a claim before examining the evidence just as carefully as we would for any other claim. I certainly don’t recommend going to a hair salon for your medical advice, any more than I would recommend going to a doctor for a haircut; but it would be a mistake to assume that everything you hear there is wrong. In this case, the beautician got it right; you might say she nailed it. (pun intended)

Coenzyme Q10 for heart failure: The hype and the science
Scott Gavura on June 20, 2013
Link
Could a product sold as a dietary supplement really be delivering the benefits that advocates have claimed for decades? That’s what you might be wondering about coenzyme Q10, following recent stories like:
    • The energy-boosting supplement that could HALVE the number of deaths from heart failure screamed The Daily Mail.
    • It’s Official: Coenzyme Q10 Improves Heart Failure Survival from the “orthomolecular” advocates AOR.
    • Could Antioxidant Supplement Cut Heart Failure Risk? asked eMaxHealth.
    • First Drug to Significantly Improve Heart Failure Mortality in Over a Decade from Live Science.
    • Could supplements be the key to boosting survival from heart failure? asked WebMD.
What’s caused all the excitement about CoQ10 is the Q-SYMBIO trial, more properly called “The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure”, presented at the European Society of Cardiology conference last month. I’d normally wait for the full article to come out, and will review it if possible at that time, but the results are too interesting to ignore so I’ll dive into the study and the reaction – which is equally as interesting for advocates of science-based medicine. 
Coenzyme Q10 (CoQ10) has a long and mixed history filled with both promise and disappointment. Also known as vitamin Q10, ubiquinone, or ubidecarenone, CoQ10 isn’t actually vitamin, as the body produces its own supply. CoQ10 is found in most cells of the body, with high concentrations in the heart, liver, kidney, and pancreas. Its function seems to include antioxidant effects as well as acting as a cofactor in multiple metabolic pathways. Supplementation can push blood levels much higher than anything the body can produce on its own. While trials with supplements have been small and somewhat equivocal, CoQ10 seems to effectively treat rare cases of coenzyme Q-10 deficiency, as well as conditions resulting in mitochondrial deficiencies. At least one formulation of CoQ10 has been FDA-approved as an orphan drug for the treatment of these rare disorders. The majority of the CoQ10 research (and it’s considerable) has focused on cardiovascular disease such as congestive heart failure and angina, but there is also some limited study of its use in diabetes, hypertension, chronic fatigue, and a long list of other conditions. Finally there’s the question of whether it’s useful for preventing “statin”-drug-induced muscle pain, where the bottom line seems to be “maybe”. In general, most of the studies have been poorly designed and had small sample sizes, giving lots of results which are promising but little that is unambiguously positive. This hasn’t stopped advocates, particularly supplement vendors, from recommending it as a panacea for just about anything, and even adding it to products like cosmetics. Given what appears to be a reasonably good safety profile, CoQ10 is a supplement advocate’s dream: a “natural” product that seems safe and may actually work.
But is CoQ10 actually a supplement at all? The line between supplements and therapeutic drugs isn’t an easy one to define. Vitamins can be treated like drugs (e.g., niacin) and some drugs are rebranded as supplements if they can’t pass the evidence standards to be approved drug products. Natural substances can be marketed as both supplements and drugs (e.g., magnesium) or as drugs alone (e.g., epinephrine). There is not always a clear line, and the variations between countries can be striking. It generally seems to be based more on evaluations of safety than that of efficacy. This may in part explain the varying use of CoQ10 around the world. It’s probably most widely used in Japan, which coincidentally is also the world’s biggest supplier. There it’s apparently used as a routine treatment for congestive heart failure, where it was approved for this purpose almost 40 years ago. It’s also used Europe and Russia, though the U.S. and Japanese markets make up 85% of the world’s consumption. Supplement or drug, what matters is whether it works when it’s evaluated using objective standards. So describing a supplement like CoQ10 as an “alternative” or “complementary” treatment for heart failure is using misleading terminology. As has been said before, there is no such thing as alternative medicine: There is medicine, which are treatments shown to work, and treatments which are unproven to work, or proven not to work. Medicine does not fail to work in a conventional sense and yet work in some “alternative” sense.
The study
It has not been established that CoQ10 helps in heart failure, but smaller studies have shown improvements in exercise tolerance and other measures, though not consistently. Observed benefits may be due to the prevention of oxidative damage (antioxidant) or to some other mechanism that has not yet been determined. The evidence to date suggests that at best, CoQ10 may offer some benefit to patients already taking other drugs for heart failure but still experiencing significant disease effects. The current study was quite simple by design, with what appears to be a meaningful and unambiguous endpoint: major adverse cardiac event (MACE) including hospitalization due to worsening CHF, cardiovascular death, and cardiac transplantation. The Q-SYMBIO trial included 17 centres across 8 countries, and randomized 420 people with moderate-to-severe heart failure into two groups: One which took 100mg of CoQ10 three times daily, the other a placebo. All continued their regular medications. Patients had an average ejection fraction of 31% (that’s not good) and they were, on average, 62 years of age. After two years:
    • 14% on CoQ10 experienced a major adverse cardiac event, versus 25% in the placebo group (p=0.003).
    • 9% of patients on CoQ10 died, versus 17% in the placebo group (p=0.01).
These are remarkable results for any treatment, and are particularly impressive if patients were already optimized on medical treatments (which isn’t clear). And if they are validated, then CoQ10 offers a dramatic benefit to patients with heart failure. But is the effect real? Notwithstanding the fact that we don’t actually have the full paper to critique, criticisms and concerns have been raised:
    • The trial took over 10 years to complete, which is long for a trial with a two year endpoint, suggesting difficulty recruiting patients. The trial was first described over a decade ago.
    • We don’t know the medications the participants were taking, and if they would still be considered appropriate and optimal, based on today’s evidence.
    • The mortality rate of about 9% per year seemed low for a population this ill.
    • Reporting and documentation of harms is not well described.
    • The benefit seems implausibly good, and similar benefits haven’t been observed in other endpoints, consistently, in other trials of CoQ10.
    • What we know about how CoQ10 might work is inconsistent with what’s been seen with statin trials in patients with heart failure. Statins lower CoQ10 levels, but don’t worsen CHF.
    • As cardiology studies go, this is a small trial. It’s not clear if it was powered to detect mortality differences. The small numbers of deaths leads to imprecise estimates of risk reductions.

Interestingly (supplement proponents and conspiracy theorists, please note) this trial has Big Pharma’s fingers all over it. Sponsors included the International Coenzyme Q10 Association (the advocacy organization), Kaneka Corporation of Osaka (the manufacturer) and Pharma Nord (the marketer) which sells products containing coenzyme Q10. So much for the old trope that that pharma’s trying to suppress dietary supplements, or that pharma won’t study it because it’s not patentable. With the global market for the chemical estimated at $835 billion (in 2009), it’s not surprising that there’s a lot of interest in expanding the use of this compound. The sponsorship doesn’t invalidate the study, but it does make me more cautious about drawing any conclusion until the full publication is available and has been subjected to peer review.
Investigator spin
The study still hasn’t been subjected to peer review, but the lead investigator is already calling for widespread use:
Professor Mortensen said: “CoQ10 is the first new medication to improve survival in chronic heart failure and it should be added to standard therapy.”
and he went on, describing a mechanism of action:
“Other heart failure medications block rather than enhance cellular processes and may have side effects. Supplementation with CoQ10, which is a natural and safe substance, corrects a deficiency in the body and blocks the vicious metabolic cycle in chronic heart failure called the energy starved heart.”
Natural. Safe. Mortensen has clearly drunk deeply from the CoQ10 Kool-Aid. And I can understand (in part) his enthusiasm, given the results he’s reporting. But has he really found a holy grail for CHF patients? It’s rare that a single trial results in a major change in medical practice. If you’re a regular reader of this blog you’ll know that many of us are fans of the research of John Ioannidis, particularly his work showing that new and often exciting scientific results rarely hold up to scrutiny, and more importantly, replication. More simply, most published research findings are false. In particular, follow-up studies can invalidate highly-cited initial studies. So a strong, unexpected effect in a single trial should be a red flag for skepticism. Replication is absolutely essential, and cardiologists are unlikely to endorse CoQ10 as a validated treatment until that occurs. This isn’t a bias against supplements, it’s good science at work. In the case of cardiology and antioxidants, there is very good reason for caution. When hype outpaces the evidence, unanticipated harms can result. Millions took antioxidant vitamins for years thinking that they were heart healthy, when evidence eventually showed they are at best, useless, and at worst, harmful.
Risks and harms
Coenzyme appears to be a safe product with few harms documented. Trials consistently report no significant adverse effects. The most common manageable side effect is stomach upset, which can be reduced by dividing the dose throughout the day (as was done in this study). The other downside to the product is the cost, which can be considerable, although CoQ10 prices seem to vary dramatically between brands and there’s a lack of information to help sort out the products which provide the best value-for-money.
Conclusion
Whether CoQ10 becomes an routine treatment for heart failure remains to be seen. The Q-SYMBIO results are surprisingly good, and for that reason, there is good reason to be skeptical. The history of medicine is replete with stories of breakthrough studies that subsequently fail to be replicated. Yet despite knowing this, we continue to make the same mistake again and again. When something appears to be too good to be true, it almost always is. Until the Q-SYMBIO study is published and replicated, I’ll remain skeptical of CoQ10’s role in heart failure.

   Is Kava Safe?
Harriet Hall
Link
Kava is a plant that grows in the western Pacific. It was traditionally prepared as a drink and used for its psychoactive properties, including sedation, relaxation, and relief of anxiety. It is intoxicating but not addictive.
It has become a popular supplement in the US, used to treat anxiety, depression, insomnia, stress, and menopausal symptoms. It has also been suspected of killing quite a few people.
The AAFP Recommends Kava
In August 2007 American Family Physician, the journal of the American Academy of Family Physicians, published an article on “Herbal and Dietary Supplements for Treatment of Anxiety Disorders.”
They concluded that
St. John’s wort, valerian, and omega-3 fatty acids have little therapeutic value for anxiety disorders, and their use should be discouraged.
But they recommended kava. Not only that, they gave it the highest quality-of-evidence rating: A. They said,
Short-term use of kava is recommended for patients with mild to moderate anxiety disorders who are not using alcohol or taking other medicines metabolized by the liver, but who wish to use “natural” remedies.
In an accompanying table, they admitted that “Cases of liver toxicity have been reported, some requiring organ transplants; kava preparations withdrawn from the market in many countries; the FDA issued an advisory” – but they more or less dismissed these warnings by adding “later, research SUGGESTED [my emphasis] that nonstandard inclusion of the kava plant’s bark in kava preparations increased toxicity level.” And they went on to say, “Researchers concluded that liver toxicity is rare and idiosyncratic, with the majority of reported cases resulting from the combination of kava with other hepato-active agents; the benefits of kava seem to outweigh its risks.”
Not everyone reads the details in tables. In the body of the article, the text only said, “side effects reported with long-term use include a reversible skin rash or lesion and a yellow tint to the skin, but these reports have not been routine. Despite the absence of long-term data on safety and effectiveness, the evidence shows that short-term use (i.e., up to 24 weeks) can lead to small improvements in generalized anxiety, and that short-term risks do not outweigh the benefits.”
Other Sources Disagree
The Natural Medicines Comprehensive Database doesn’t give kava an “A” rating. It doesn’t rate it as effective or even probably effective. It only gives it a “possibly effective” rating. While the majority of evidence shows it is superior to placebo, there is contradictory evidence showing it is not superior to placebo. And the clinical studies used an extract that was more than twice as concentrated as most commercially available products.
It also rates kava as “possibly unsafe:”
There are at least 68 reported cases of liver toxicity following kava use. The use of kava for as little as one to three months has resulted in the need for liver transplants, and even death. Kava has been banned from the market in Switzerland, Germany, Canada, and several other countries are considering similar action. Some patients may be more at risk than others. Patients who are “poor metabolizers” might be at greatest risk, but this has not been verified. Until more is known, tell patients to avoid kava. Recommend routine liver function tests for patients who continue to use kava.
It particularly warns against use in pregnancy or lactation.
It also gives a long list of side effects, from minor gastrointestinal symptoms to serious reactions and kava dermopathy. Kava has been associated with severe, rapidly progressive Parkinson’s disease. It has caused erratic driving resulting in DUI citations. It may cause extrapyramidal side effects (involuntary movements). Liver toxicity may occur in kava users after a single occasion of alcohol consumption.
It lists numerous drug interactions. Kava significantly inhibits several cytochromes. It points out that Up to 10% of people of European descent have a genetic deficiency of CYP2D6, a deficiency that has not been found in Pacific Islanders.
In The Desktop Guide to Complementary and Alternative Medicine: An Evidence-Based Approach, Edzard Ernst and his co-authors cite serious safety concerns and recommend that if kava is taken it should be short term and under close medical observation.
The AAFP Ignores Me
Immediately after the article was published, I wrote a letter to the editor. I expressed the concerns above and said the article unfairly minimized the potential dangers of kava and should at least have reminded physicians that under the Diet Supplement Health and Education Act of 1994 these products are not regulated to insure consistency and purity.
They didn’t publish my letter.
The AAFP Has Second Thoughts
In August 2008 (a year later), the journal published a letter to the editor from the authors of the original article. It said in part,
The FDA warnings in 2002 are still in effect and are echoed widely by respected sources such as the Natural Medicines Comprehensive Database, the National Center for Complementary and Alternative Medicine, and the NSRC research collaboration. Given the lack of regulation for supplements and the absence of clear indicators of who is at risk for toxic reactions, cautionary statements continue to be justified. Physicians who supervise patients taking kava for the treatment of GAD should take care to avoid the following: (1) high dosages (more than 300 mg per day); (2) combining kava with hepatoactive agents; (3) using non-root preparations; and (4) exposure for longer than 24 weeks. Use of WS1490 standardized kava extract is also recommended. If these safety precautions are followed, kava can be appropriate therapy for selected patients diagnosed with GAD
Is There a Double Standard?
A friend told me that most of the recent liver transplant cases he’s been involved in were on patients who had been using kava. I wonder if all the cases of liver toxicity associated with kava are being reported in the medical literature. I wonder if some patients with liver toxicity neglect to tell their doctors they have used kava. I wonder: if 68 cases of liver toxicity, transplants and death were reported in association with a prescription drug, would it still be on the market?

Kava and Liver Damage
Steven Novella on May 1, 2024
Tweet
Kava is an herbal supplement used mainly for its calming psychoactive effects. It is a traditional drink in Oceania that has been used for centuries. It has also been linked to liver toxicity and cases of liver failure and even death. However, the liver toxicity of kava is extremely controversial – this controversy, however, reflects the various narratives that we see surrounding “natural” products and can be very instructive.
A recent Tik Tok video warns of the liver toxicity of kava, and the comments are filled with these dueling narratives. The pro-kava camp is well reflected by this article: “Kava Liver Damage Myth Debunked by New WHO Study.” Yet many medical outlets still warn of the potential for liver damage. The truth is somewhat complex, and is not reflected either in the “debunked myth” narrative or the “never take kava” narrative. Rather, let me (unsurprisingly) frame the controversy as a science-based medicine narrative.
Background
Kava is the common name for the plant Piper methysticum in the pepper family. Extracts from this plant, referred to as either kava or kava kava, have been used for at least centuries, possibly thousands of year, in Oceania. More recently kava extracts have been marketed as herbal supplements in pill, powder, or drink (herbal tea) form.
Starting in the 1990s there were reports of liver failure, starting in Europe, in people taking kava products. Initial case reports, case series, and reviews found that such cases are uncommon but usually extremely serious, with fulminant liver failure leading to the needs for transplant or death in some cases. This lead to many national bans on kava products and general warning away from its use.
However, this only lead to controversy, as many traditional users and kava promoters cast doubt on the evidence. A 2007 WHO review (not a study), the one referenced above, came to some interesting conclusions (none of which amount to debunking a myth). They reference a single 2004 epidemiological study that found no association between regular kava use in Oceania with liver disease, even in daily users. However they also cite the extensive evidence of individual cases of liver failure associated with the use of kava products.
There are two primary issues here. One is the difference in preparation of kava. Traditional preparations use a water extract, and there are many reasons to hypothesize that the water extract version of kava is safer. It contains lower doses of active ingredients, may contain some protective chemicals (like glutathione), and does not contain ingredients that may cause drug-drug interactions with kava or exacerbate its liver toxicity. If we look at the case reports of liver damage, most (but not all) are in people who used kava products extracted with alcohol, not water, although there are a few cases that used water extracts.
The second issue is that the data is all muddy with lots of confounding factors. As the WHO reports says: “There are several possible reasons why hepatotoxicity may occur with kava, such as dose, variety of kava, plant parts used, or type of extract. It is likely that the main problem is related to the chemical composition of the kava product taken.” Also we have poor control in terms of the total dose of various active ingredients, contaminants, adulterants, and drug-drug (including herbal products) interactions.
At present it is fair to say that there is potential liver toxicity from kava products. However, the traditionally prepared water extracts are probably safe as used, although it is difficult to make a firm conclusion from one study. There is still a strong case to be made for rare liver toxicity from kava products prepared for the western market, mainly in pills and tablets.
However, all the reasons given by kava proponents to doubt that kava itself is causing liver damage is in reality an indictment of the supplement industry itself. First, if you get liver failure, it probably doesn’t matter much to you if it was from the product itself, a contaminant, substitution, or interaction.
These are also not defenses of herbal products in general or kava in particular. They indicate the real risk of herbal products – they are poorly regulated, examined, and understood. They are rife with contaminants and substitutions and have poorly regulated and measured dosages. It is not rational to use these limitations and risks of herbal products to fend off evidence of toxicity because they introduce uncertainty. The uncertainty is the problem.
Further, as we see in the Tik Tok comments and in kava defenders, the point is often made that the toxicity of western brands of kava says nothing about the risks of traditional use. But also – the safety of traditional use says nothing about the safety of western kava products where preparations are different and doses tend to be more concentrated. It cuts both ways.
In the end there is still reason to be cautious about using kava products (outside traditional use). Herbal products are poorly researched and regulated drugs. They have real drug risks and side effects. Kava is a great example of why herbal products should not be considered generally safe.

Black Cumin – Be Skeptical
The claims made for black cumin follow a familiar pattern – implausible and a lack of evidence.
Steven Novella on January 22, 2020
Link

There are countless dietary supplements and herbs out there with countless clinical claims, but often little in the way of plausibility or supporting clinical evidence. The latest “mole” to pops its head up in this endless game to whack them is black cumin (also referred to as black seed, black caraway, black sesame, and other common names). These are the seeds of the Nigella sativa plant, a traditional medicinal herb common in the Middle East and parts of Asia. According to one review:
It is very popular in various traditional systems of medicine like Unani and Tibb, Ayurveda and Siddha…In Islamic literature, it is considered as one of the greatest forms of healing medicine.
The same reference indicates:
…a wide spectrum of its pharmacological actions have been explored which may include antidiabetic, anticancer, immunomodulator, analgesic, antimicrobial, anti-inflammatory, spasmolytic, bronchodilator, hepato-protective, renal protective, gastro-protective, antioxidant properties, etc.
The claims made for black cumin follow many of the themes and tropes common to popular herbal products. Most significantly, black cumin is alleged to treat or cure an implausibly wide range of unrelated conditions. It’s almost as if it works for everything, which is a very good reason to suspect that it more likely works for nothing. Many of the conditions have completely different mechanisms – why would one product treat asthma and diabetes, cancer and liver disease?
Further, many of the conditions listed are contradictory. It does not make sense that one substance would simultaneously be antimicrobial and anti-inflammatory. The anti-inflammatory treatments that work have as a potential side effect reducing immune activity against infections. It is theoretically possible to have direct anti-microbial effects and be anti-inflammatory, but this gets back to ascribing numerous pharmacological properties to one product. Further, proponents claim that black cumin is effective against bacteria, viruses, fungi, and parasites – which would make it the only substance in the world with such broad spectrum activity. We can’t even engineer a drug to be effective against all bacteria, let alone also viruses and fungus, which are very different forms of life with different vulnerabilities.
The other blaring contradiction is that black cumin is alleged to be both antioxidant, and anti-cancer. This gets back to the inherent problem with antioxidant hype – the immune system actually uses oxygen free radicals to fight invaders and cancer cells. Further, cancer cells have high metabolism, and so are under increased oxidative stress. It turns out, if anything, antioxidants may be protective of cancer cells, and therefore counterproductive in cancer.
Another problem that plagues herbal products is pharmacokinetics, such as bioavailability – how much of the active ingredient actually gets absorbed and distributed to the target tissue? This is the fatal problem for turmeric, for example. I could not find any studies looking at pharmacokinetics in humans, only studies calling for such research to be done (a good indication that so far it hasn’t been). I did find a study looking at the pharmacokinetics of thymoquinone (thought to be the primary active ingredient in black cumin) in chickens. They found an 85% bioavailability with oral use, which is good, but they also found that the half-life was 1 hour, which is bad.
In order for pharmaceuticals to be medically useful, they need to have a host of properties all at the same time. They need reasonable bioavailability for the route of administration, they need to be chemically stable, both on the shelf and after introduction into the body, they need to get to the target tissue in the body, they need a useful half-life (the time it takes for the body to eliminate half of the blood level), and, of course, useful therapeutic effect at a dose with tolerable side effects and toxicity. It’s also good to know about drug-drug interactions. A really short half-life is one of the deal-killers for useful pharmaceuticals.
This is exactly why active ingredients are identified and studied. Almost always the chemical structure needs to be tweaked in order to achieve all of the desirable characteristics at the same time, with no deal-killers.
Another feature of the claims made for black cumin that is very common is that they are closely tied to a cultural belief. (Sometimes a cultural connection is false, manufactured for marketing purposes, but in this case it appears to be true.) My concern here is that a strong cultural belief is a powerful thumb on the scale of scientific research. This is not a hypothetical concern. It has been established, for example, that 100% of acupuncture studies coming out of China are favorable, a statistically unlikely outcome that is a blaring signal of researcher and publication bias.
Similarly, while I have not done a statistical analysis, in my review of published studies of black cumin or thymoquinone, nearly 100% of studies are both published by Middle Eastern authors and favorable. This would certainly explain why black cumin seems to work for everything. This is also a good rule of thumb – if your process results in 100% positivity, don’t assume you have discovered a miracle, assume your process is flawed.
The aforementioned review says of black cumin, “Due to its miraculous power of healing, N. sativa has got the place among the top ranked evidence based herbal medicines”. That hardly sounds like a sober scientific review, rather more of a point of cultural pride.
Despite all of these concerns, what does the research actually say about the clinical effects of black cumin (or thymoquinone)? Most of the research is pre-clinical, and the claims made are based on unreasonable extrapolation from the petri dish to the living organism. As we have pointed out here multiple times, this is not appropriate. Basic science findings rarely translate directly to clinical outcomes, partly because of all the pharmacokinetic issues I discussed above, but also because whole organisms are complex dynamic homeostatic entities.
The clinical research is mostly preliminary, and again focusing on dozens of unrelated claims. Every single study I found was favorable, but was also not convincing due to methodological limitations. This is also a common feature of fringe treatments that have not garnered mainstream acceptance (for a reason) – weak research methodology with positive findings but generally small effect sizes. One review, for example, notes that there is evidence for some metabolic and anti-inflammatory effects, but “the amount of benefit it confers is too small for it to be considered a good intervention.”
This is a familiar pattern, because even a little bit of researcher bias can manufacture apparent small positive effects. When we combine the low plausibility (especially given the number of claims), the apparent isolation to one culture, the weak methodology with small effect sizes, we see an overall picture consistent with herbal medicine hype, not scientific reality. It is certainly possible that thymoquinone or some other active ingredient may ultimately have useful medical purposes, when properly studied and developed. That remains to be seen. But honestly, by existing in the fringe of alternative/herbal/cultural medicine, it is less likely to actually be developed as effective medicine.
For now, there is no evidence to support black cumin as an herbal product for any indication, and there are good reasons to be skeptical.

How effectively does cinnamon treat diabetes?
Cinnamon is often touted as a “natural” supplement that’s effective for treating diabetes. The evidence (still) isn’t convincing.
Scott Gavura on June 27, 2019
Link

A customer strolled up to the counter one night when I was working in a retail pharmacy:
“My doctor says I have prediabetes. I don’t want to take any drugs. Do you have something natural I can use to cut my blood sugar?”
I looked at him in the eye, and pointed at his sizeable midsection. “Sir, if you’re at risk for diabetes, and you don’t want to take medication, the single best thing you can do for yourself is lose some weight.”
He grinned and asked, “Great – what supplement can I take to help me?”
I’ve had variations of this scenario through my career as a pharmacist. A patient has been assessed by their physician, and informed that they have a medical problem of some sort. The patient, reluctant to accept the physician’s evaluation, heads to the pharmacy for a second opinion. In some cases, patients have directly questioned their physician’s advice: “All my physician wants to do is prescribe drugs.” Yet there’s sometimes a disconnect when it comes to strategies for management. Sometimes, non-drug approaches are rejected out-of-hand (probably because the people I speak with have already made the decision that they want to buy something). And in those that are leery of medicine, there’s often a willingness to consider anything that’s available without a prescription – particularly if it’s perceived as “natural”. Natural products are often thought to be gentle, safe, and effective, while medicine may be considered unnatural, harsh, and potentially dangerous. This is the appeal to nature fallacy, nothing more. Purveyors of supplements leverage the appeal to nature fallacy into the marketing strategy of choice for almost all supplements and “alternative” medicines. And it can easily lead to unwise health care decisions.
Alternative medicine for diabetes is big business, because the public health burden of diabetes is massive, and growing. In 1985, the worldwide prevalence was 30 million people. In 2000, it was 150 million. By 2030, it could be 250 million. Why are more people being diagnosed with diabetes? Obesity, sedentary lifestyles, and an aging population. At its core, diabetes is a disease of sugar (glucose) management. Insulin, secreted by the pancreas, allows cells to use glucose. When the pancreas doesn’t produce insulin, it’s called Type 1 diabetes. This is an autoimmune disease that strikes early in life, and was a death sentence until insulin was discovered. When the pancreas can produce insulin, but the amount is insufficient, or when there’s a problem with the uptake of insulin into cells, it’s termed type 2 diabetes. 90% of all diabetes is type 2. Typically a disease of older adults, type 2 diabetes can potentially be treated without drugs of any kind, but success rates are low and medication is eventually advisable. There’s also gestational diabetes, a disease of pregnancy, and prediabetes, where blood sugars are elevated, and diabetes is an expected future diagnosis.
Given the prevalence of diabetes and the chronic nature of the disease, it’s no surprise that complementary and alternative medicine (CAM) is a popular treatment option. I don’t personally see a lot of CAM use in Type 1 diabetics. Insulin is the primary treatment, it works well, and patients can objectively measure their own blood sugar. Type 1 diabetics don’t seem to experiment with supplements that might alter their blood sugars. Those patients end up hospitalized or dead.
It’s the patients with type 2 diabetes that seem to be interested in supplements. While lifestyle modifications (exercise, weight loss, and smoking cessation) are the foundation for managing diabetes, drug treatment is usually also required. There are an array of prescription drugs like metformin and glyburide with a long history of use and demonstrated efficacy. Some drugs even decrease mortality – the primary outcome we’re after. But proper treatment has also been shown to reduce the risk of an array of other consequences: Diabetes is the biggest cause of blindness, kidney failure, and non-traumatic amputation. Diabetes is associated with an elevated risk of cardiovascular disease, too. Yet despite the irreversible consequences of diabetes, and the availability of effective medications, type 2 diabetes remains poorly-controlled in many, often because of poor self-management.
The diagnosis of diabetes and the effectiveness of treatments can be objectively measured. Fasting plasma glucose (FPG) measurements and then the oral glucose tolerance test accurately measure insulin function, and guide diagnosis. While routine blood sugar monitoring (with test strips) is generally unnecessary in Type 2 diabetes, measurement gives a point estimate of blood sugar levels. Glyclated hemoglobin (A1C) levels reflect overall blood sugar trends, with higher levels associated with more complications of the disease. Interestingly, super-intensive blood glucose lowering isn’t associated with additional risk reduction, and it increases the risk of side effects due to too-low blood sugar. Treatment goals are individualized (hey, it’s “holistic”), balancing a number of factors including risks as well as a patient’s ability to manage complex treatment plans.
The evidence for cinnamon
Given the consequences of diabetes, self-management is something I want to encourage, not discourage. Without a commitment from the patient to take an active role in managing their diabetes, any treatment plan is doomed to fail. So is self-treatment with dietary supplements a wise idea? There’s an array available, and patients regularly ask about the latest treatment “Big Pharma doesn’t want you to know about”. That treatment used to be chromium. Ginseng was popular for a time, too. Fenugreek and bitter melon are used as well. One of the most persistently popular treatments is cinnamon. Like any other herbal remedy, most sources will tell you that it’s been used for “thousands of years” as a medicinal herb. As a treatment for diabetes, I have my doubts. While reports of diabetes go back to 1552 BCE, the ability to measure the effectiveness of any diabetes treatment only goes back a few decades. Interest in cinnamon as a treatment seems to have started with in vitro tests but gained some plausibility in 2003, when a study from Alam Khan suggested several grams of cassia cinnamon per day could lower fasting blood glucose. Khan randomized Type 2 diabetes to 1g, 3g, or 6g of cinnamon for 40 days. All three groups improved their fasting blood glucose, and blood lipid levels, but there was no effect on A1C.
Like trials with any other supplement or herbal product, the primary question we must answer is “What exactly was studied?” The cinnamon you have in your kitchen may be a single species of plant or a mix of different cultivars. Ceylon cinnamon (Cinnamommum verum) is more commonly found in the West. Cassia cinnamon (Cinnamomum aromaticum) is the version of cinnamon that’s been studied in trials. The chemical hydroxychalcone has been identified as a potential active ingredient, which is believed to modify the sensitivity of cells to insulin, enhancing their uptake. If that’s the true mechanism of action, then it would work in a manner similar to that of the drugs Avandia, Actos, and metformin (Glucophage). Given the active ingredient (or ingredients) have not yet been definitively isolated, the issue of studying cinnamon is problematic. There’s no way to assess the potency of any batch, which complicates any evaluation. And that may be a reason why the research with cinnamon is inconsistent, and on balance, not impressive.
While the Khan study looked promising, supplementary studies have failed to consistently show beneficial effects. Vanschoonbeek gave 1.5g of cinnamon or placebo to postmenopausal women over 6 weeks. There was no effect reported on blood sugar or blood lipid levels. Baker’s 2008 meta-analysis identified 5 trials including the Khan and Vanschoonbeek studies and concluded the following:
In this meta-analysis of five randomized placebo-controlled trials, patients with type 1 or type 2 diabetes receiving cinnamon did not demonstrate statistically or clinically significant changes in A1C, FBG, or lipid parameters in comparison with subjects receiving placebo.
In that analysis, the Khan study looks like an outlier. More studies have emerged since then: Crawford in 2009 found 1g of cinnamon per day reduced A1C levels compared to placebo. Suppapitiporn found no effect on any measure with 1.5g per day. Akilen, in 2010, found an effect with 2g per day. Another meta-analysis, published in 2012 and including 6 studies, concluded the opposite of Baker:
A total of 6 clinical trials met the strict inclusion criteria and considered a total of 435 patients; follow up between 40 days–4 months, doses ranging from 1 g to 6 g per day. Meta-analysis of RCTs showed a significant decrease in mean HbA1c [0.09%; 95% CI was 0.04–0.14] and mean FPG [0.84 mmol/l; 95% CI was 0.66–1.02].
But look closer. The results may be statistically significant, but they’re not that impressive compared to medication. Cinnamon lowered A1C by 0.09%, versus the usual 1% with medication. Given A1c reflects overall glucose trends, cinnamon doesn’t look that impressive. Even at the extreme of the confidence interval, cinnamon has, at best, 10% of the efficacy of drug treatments.
Finally, a 2012 Cochrane review from Leach and Kumar included 10 RCTs that compared cinnamon to placebo in patients with type 1 or 2 diabetes. The underlying risk of bias in most of the trials was rated as high. Doses were an average of 2g per day for 4-16 weeks. They noted:
No statistically significant difference in glycosylated haemoglobin A1c (HbA1c), serum insulin or postprandial glucose was found between cinnamon and control groups. There were insufficient data to pool results for insulin sensitivity. No trials reported health-related quality of life, morbidity, mortality or costs. Adverse reactions to oral cinnamon were infrequent and generally mild in nature.
Until the findings are reproduced consistently, and cinnamon has been show to provide a meaningful improvement in relevant measures, there is no consistent evidence to suggest that cinnamon should be recommended as a treatment option for diabetes. Drugs that work, work consistently and provide meaningful improvements in measures of the disease. Why doesn’t cinnamon work? There may be an active ingredient, but it’s present in low concentrations, and varies in content between the different batches of cinnamon used in the different trials. In that case, the active ingredient needs to be standardized and possibly isolated, which would make it a drug, not a supplement.
The risks
If a drug treatment’s efficacy is questionable, the adverse event and safety profile is even more important. As a popular food additive, cinnamon seems safe when consumed at doses of a few grams per day. (1 teaspoon of the powder is about 4.75 grams). While the trials have been small and short in duration, no significant adverse events have been reported. It is Generally Recognised as Safe (GRAS), as a seasoning and flavoring. However, reversible liver damage has been reported with therapeutic use, due to coumarin, a chemical also present in Cassia cinnamon. Those with liver impairment or dysfunction may be at greater risk of harm. There are no published long-term studies with cinnamon that inform us whether chronic consumption of high doses is safe.
Cinnamon is delicious, but it’s not medicine
Cinnamon’s effectiveness as a treatment for diabetes has not been established. A prescription drug as ineffective as cinnamon likely wouldn’t pass FDA muster. Existing drug treatments for diabetes, on the other hand, are cheap, effective, and generally well tolerated. Compared to drug therapy, we don’t know if cinnamon can reduce the risk of mortality due to diabetes, or the progression to any of the other serious outcomes of diabetes. I wouldn’t encourage anyone take cinnamon routinely for diabetes. For my patients that are determined to try cinnamon, I’d caution them of the risks, and reinforce that cinnamon is no alternative for lifestyle changes and that medication may still be required. Cinnamon is indeed natural, but that doesn’t mean it’s either safe or effective.


Elderberry Elixir for the Common Cold
There is evidence from blinded, placebo-controlled studies that elderberry can modestly shorten the duration of colds and flu. Since there is no cure for the common cold, elderberry might be worth a try; but more research is needed.
Harriet Hall on December 31, 2019
Link

The common cold is usually a minor illness that is self-limiting. It resolves in a week or so with or without treatment. Unless you are chronically ill or debilitated, it is unlikely to have serious consequences; but it can cause plenty of misery and days lost from work. Science has made great progress in other areas, but it has found no cure for the common cold. Antibiotics are useless. For prevention, the best science can offer is handwashing. There are medications that can provide some temporary relief from symptoms like fever, congestion, runny nose, and cough, but they do nothing to shorten the duration of the illness.
In desperation, many people have resorted to herbal remedies, folk remedies, and supplements like zinc, Vitamin C, and Echinacea. These supplements have all been studied, with inconsistent results that have not verified their effectiveness. Zinc may shorten the duration of a cold by a day, but it can cause permanent loss of smell and the appropriate dosage and schedule have not been established. Linus Pauling advocated large doses of Vitamin C, but the results of controlled studies have been disappointing. Studies of Echinacea have shown little or no benefit. But there’s another dietary supplement that is supported by more convincing evidence: preparations of flowers and berries from the black elder tree. Elderberry remedies have been used for centuries and are popular in Europe. Various formulations of black elderberry extract are marketed under the brand name Sambucol. They include syrups, gummies, pills, chewable pills, pediatric, and homeopathic (!) versions. They advertise that it provides strong immune system support and is safe to take every day.
Black elderberry is a nutritious fruit with high concentrations of anthocyanins; it has twice as much antioxidant capacity as blueberries and significantly more than cranberries. A multitude of beneficial health effects have been claimed for it since the time of Hippocrates, who reportedly called it a medicine chest. Sambucol carries the usual FDA disclaimer that it is not intended to diagnose, treat, cure, or prevent any disease; but it is commonly used for prevention and treatment of colds and flu. There is speculation about why it might work, but the mechanism of action is not actually known.
Placebo-controlled studies
In contrast to many supplements on the market, there are studies that used the same brand, Sambucol; and randomized, placebo-controlled, double blind studies have been done.
Sambucol was tested in a placebo-controlled double blind study during an outbreak of influenza in a kibbutz in Israel. Hemagglutination inhibition titers to influenza B were higher in the treatment group, and there was significantly more symptom improvement in the treatment group than in the controls (93.3% significantly improved in 2 days compared to 91.7% in 6 days).
In a randomized, double-blind, placebo-controlled study in Norway, 60 patients with influenza-like symptoms were given an elderberry extract or a placebo; self-rating of symptoms indicated that symptoms were relieved 4 days earlier in those taking elderberry.
In 2016 in Australia, a randomized, double blind placebo-controlled study found that elderberry reduced cold duration and symptoms in air travelers. They recruited 325 volunteers who were planning an overseas trip with a minimum 7-hour flight. Subjects were randomized to receive either a standardized elderberry extract (Iprona, a brand from Italy) or a placebo. They were instructed to take the pills from 10 days before flying to 5 days after arriving at their destination. Symptoms were self-reported in a diary, with subjects recording each day whether they believed they had a cold or were experiencing rhinorrhea. An exit poll asked participants to guess whether they were in the elderberry or the placebo group; it confirmed the success of blinding. Elderberry did nothing to prevent colds, but those in the elderberry group reported a 2-day shorter duration of the cold (4.75 days vs. 6.88 days) and lower symptom severity (21 vs 34).
Other studies and reviews
A standardized elderberry extract (Rubini) inhibited bacteria and influenza virus in an in vitro study.
A 2014 review found “no animal- or human studies of safety of elderberry in pregnancy” and advised pregnant women not to use it.
A 2019 article in The Medical Letter concluded, “There is no acceptable evidence to date that elderberry is effective for prevention or treatment of influenza and its safety is unclear”.
A 2017 review evaluated the state of current research. They found evidence that elderberry extract has antiviral and antimicrobial properties but said that a lack of studies made clinical recommendations impractical.
Adverse effects
While standardized elderberry extracts are generally recognized as safe (GRAS) by the FDA, homemade preparations may be poisonous. The commercial preparations have not been tested in long-term studies or in pregnancy, and precautions are advised. Prolonged use (more than 12 weeks) or use during pregnancy and breastfeeding are not advised; and patients with autoimmune diseases are advised to avoid elderberry because stimulating the immune system might be expected to make symptoms worse.
Prospective customers may be discouraged by a recent report of acute pancreatitis attributed to Sambucol. The report didn’t mention whether he still had cold symptoms. It seems to me a cold would be preferable to pancreatitis.
What is missing?
We still lack a really good study. I’d like to see one that not only uses the same product and is large, randomized, double-blind, and placebo-controlled; but that relies on objective diagnosis rather than self-reporting of symptoms, and one that recruits the typical purchasers of Sambucol and tests the product as actually used in practice.
Conclusion: Promising, but questions remain
The research on elderberry for colds and flu is promising, but better evidence is needed. Surely there are compounds in elderberry extract that are not needed and could even be harmful. We need to know more about the mechanism of action and the possibility of pancreatitis. We need to know more about safety in pregnancy and breastfeeding and with long-term use. We need to know which products are the best standardized, with accurate labeling and absence of contaminants. The best-case scenario would be isolation of the active ingredient or ingredients and scientific development of a specific drug with good enough evidence to gain FDA approval. Meanwhile, since there is no cure for the common cold, elderberry might be worth trying…if you’re not worried about the possibility of pancreatitis.

Phenibut Is Neither Proven Nor Safe As A Prosocial Wonder Drug
Abby Campbell on November 25, 2016
Link

Editor’s note: With Mark Crislip away on yet another vacation, we present an inaugural guest post from Abby Campbell, a practicing MD, Ph.D and contributor at HealthyButSmart.com. Welcome Abby!

On average for the past year, phenibut has been typed into google 49,500 times a month. Phenibut is a supposed wonder drug that claims to promote sociability and lessen anxiety.
When people run that search in Google, they find stores that sell phenibut, as well as blogs and forums where people discuss and make recommendations for the use of phenibut. The main qualification of these people is that they themselves have taken the drug.
What a searcher doesn’t find is any reference to any credible research. Yet another supplement market has been born driven by anecdotal social marketing, and no one seems to care about the evidence.
What is phenibut?
Phenibut is a designer drug which was synthesized by a group of Russian scientists in the 1960s. Perekalin and his colleagues in St. Petersburg added a phenyl ring to butyric acid to make what we now call phenibut. The addition of the phenyl group to the butyric acid enables the compound to cross the blood-brain barrier and enter the brain.
This basic chemical structure of the compound explains the origins of the name ‘phenibut’. Phenibut is also known as fenibut and is sold under the brand names of Noofen and Citrocard.
Phenibut is structurally similar to the neurotransmitter GABA (gamma amino butyric acid). GABA occurs naturally in the human nervous system and has a calming effect on the brain.
GABA itself does not cross the blood brain barrier and so is not viable as a drug or supplement to reduce anxiety. The addition of the phenyl ring by the Russian scientists overcame the problem of penetration into the brain. However this means that phenibut is not totally identical to human GABA which means that we can’t just extrapolate information on GABA to phenibut, as some websites have done.
What is phenibut used for?
Phenibut is a licensed medication in Russia and is used for a variety of conditions including anxiety, insomnia, post- traumatic stress disorders, depression, stuttering, tics, attention deficit disorders, and vestibular disorders.
Unlike most other anxiolytic drugs, phenibut is also promoted as a nootropic drug, which implies that it can improve motivation, attention, and concentration.
Phenibut is not licensed as a prescription medication by the FDA in the USA but is available as a nutritional supplement.
It is interesting to look at the process behind the licensing of nutritional supplements to understand why phenibut is positioned as a nutritional supplement and not a drug.
Individual countries review the data on any agent and make a decision as to whether or not to allow the sale of that substance. As an example, St John’s Wort and gingko are approved for sale in the USA but it is illegal to sell them in Ireland.
Substances which are approved for sale can then be licensed as either a medicinal product or as a dietary supplement. The Dietary Supplement Health and Education Act of 1994 (DSHEA) defines and oversees dietary supplements in the USA. Phenibut fits under the remit of the DHSEA as a synthetic amino acid derivative. The FDA has guidelines on the regulations for labelling any dietary supplement – specifically if any dietary supplement such as phenibut claim to affect well-being or the structure or function of the body then there must be a disclaimer stating that the claim has not been evaluated by the FDA and that the product is not intended to treat to prevent any disease.
However there is a technical loophole in the labelling guidelines for dietary supplements. The FDA tries to make a distinction between ‘disease’ claims and ‘health maintenance’ claims when it comes to dietary supplements. The FDA tightly regulates ‘disease claims’ but there is much less regulation when it comes to ‘health maintenance’ claims. As an example, it is perfectly acceptable to say that calcium helps build strong bones but not OK to say it cures osteoporosis. So technically this means that a manufacturer of phenibut can decide to say that their product ‘helps keep you calm’ which is a ‘health maintenance’ claim. However they cannot say that phenibut ‘reduces anxiety’ (a disease claim) without getting FDA approval.
Another advantage of fitting under the ‘health maintenance’ umbrella is that the FDA does not require the manufacturer to obtain pre-marketing authorisation, as is the case with supplements making disease claims.
So phenibut has dodged that hurdle for the time being, but the real question is, “Do their claims have any scientific validity?”
Let’s take a look.
So Russian cosmonauts used it…
There is an “interesting” story about the use of phenibut in the Russian space program. In 1975, a US-Russian joint space mission known as Apollo-Soyuz ran into technical problems on the Russian side. No solution could be found to fix the docking mechanism of the Soviet Soyuz spacecraft.
When all seemed lost, the Russian astronauts were instructed to take phenibut and rest. According to the story, the restorative powers of the rest and phenibut helped the astronauts stay calm find a really creative solution to the problem which saved the day.
This popular story speaks to the combined anxiolytic and nootropic effects of phenibut which is sometimes called ‘the Russian wonder drug’.
Story telling has been described as ‘data with a soul’ and this is, to some, a great story. Sometimes it is easy to be carried away with a story which romanticizes a difficult situation.
It is great that things worked out for the Russian team but it is worth noting that phenibut was used as a last ditch effort when all else had failed and there was nothing to lose. The Russians certainly did not use phenibut as an early performance enhancer, as some websites have claimed.
What is the actual evidence for phenibut in the medical literature?
There are over 300 published papers on phenibut. This is actually relatively little information on a drug that has been around for over fifty years.
Many of these publications are in the Russian language and/or are based on studies in cats, rats or mice. Straight away this raises issues. Our four legged friends are great but can hardly tell us much about a prosocial wonder drug (and may fail to reveal problems in humans).
One online medical platform summarized things simply by saying “phenibut has not been studied in people and so no-one can say if it might work as a medicine.”
But if someone was trying to be overly fair to phenibut, they could say that the lack of information on it can be explained by the fact that it is not a licensed medication in the USA.
So let’s look in more detail at the available research to see what support there is for the many claims about it.
Does phenibut relieve anxiety?
I was able to find just 37 studies relating ‘phenibut’ and ‘anxiety’. The majority of these studies are in the Russian language which makes it difficult to assess the quality of the information. From just looking at the title of the Russian studies we can tell that quite a few of these studies are based on rat, mice or cat models.
The human studies are largely confined to observational studies in children and all come from one research group in Russia.
The same group did a study in adults and gave phenibut at a dose of 1,000mg/day to 62 adults with protracted anxiety-phobic disorders and concluded that the findings “may lead to the conclusion that phenibut is highly effective in the treatment of patients with protracted anxiety phobic disorders.”
For one, this is a tiny sample, it’s only ever been looked at by one group of researchers, and in a study not subject to peer review.
For two, this study used phenibut in people with protracted anxiety, not like the people you read about on internet forums trying phenibut for a “little social worry”.
Oh, and the risks?
Two studies described phenibut-related dependence and withdrawal symptoms. One of the case reports in The BMJ described a patient who self-medicated with phenibut for anxiety. The patient reported that the phenibut was beneficial at the beginning but that he subsequently developed tolerance and withdrawal symptoms. The withdrawal symptoms were severe and the patient needed a nine-week detoxification program under medical supervision to come off phenibut. It would be pretty hard to justify any initial anxiety relief given the fact that the patient needed a nine week detox.
Bottom Line: There is no solid evidence to support the efficacy of phenibut in anxiety and there are reports of significant side effects.
Does phenibut help with sleep?
I found five published papers relating to sleep and phenibut. Only one of these studies related to humans, and it looked at phenibut in patients with alcoholic abstinence syndrome. Again this is nothing that would be of any use to someone who was just looking for a nutritional supplement that promotes a good night’s sleep.
Bottom Line: There is no convincing direct evidence that phenibut helps with sleep.
Does phenibut help in body building and weight training?
Again there are no great studies on phenibut for body building or weight training. There are some studies on the use of other GABA-like drugs on growth hormone which have been extrapolated to mean that phenibut may benefit be of benefit in body building. However there is no direct evidence that phenibut itself helps with body building and we cannot just extrapolate from GABA-based drugs to phenibut.
Bottom Line: We can’t say either way if phenibut helps in body building and weight training.
Does phenibut enhance sexual performance?
There are no published studies or case reports on the role of phenibut in enhancing sexual performance. Even the original studies which looked at the relationship between the structure of phenibut and its activity makes no mention of a role for phenibut relating to sex.
Bottom Line: We can’t say either way if phenibut enhances sexual performance.
What are the side effects of phenibut?
Side effects of phenibut include headache and depression. An overdose of phenibut can result in lowered body temperature, muscle relaxation and sleepiness.
There is an editorial which describes phenibut as a potentially dangerous product. There is also a case report of two patients who purchased phenibut online and who presented to urgent care with serious phenibut related toxicity. Both patients had measurable levels of phenibut in their blood.
One of these patients used phenibut with THC and alcohol and had to be admitted to the intensive care unit for airway protection. He needed airway protection because of his ‘behavioural state’. This is really worrying and should be the end of the line for anyone doing their best to be “open minded” about phenibut.
Even the original research on phenibut says that its effects depended on the emotional state of the animal. Anxious but passive cats had reduced anxiety but developed aggression (and phenibut did not affect the aggression of already-aggressive cats)!
But this of course is beside the point.
Bottom line: To put it mildly, Phenibut does not have a good safety profile.
Conclusion: Clever marketing, little evidence
Phenibut is a cleverly-designed drug with an even cleverer marketing campaign. There is no legitimate evidence to support the fact that it works for any of the stated purposes, but there are worrying reports of significant toxicity. Efforts should be made to balance the informational scales, and lessen enthusiasm for yet another untested marketing-driven supplement.

Turmeric: Tasty in Curry, Questionable as Medicine
Harriet Hall on June 17, 2014
Link
A correspondent asked me to look into the science behind the health claims for turmeric. He had encountered medical professionals “trying to pass turmeric as some sort of magical herb to cure us from the ‘post-industrial chemical apocalypse.’” It is recommended by the usual promoters of CAM: Oz, Weil, Mercola, and the Health Ranger (who conveniently sells his own superior product, Turmeric Gold liquid extract for $17 an ounce).
Turmeric (Cucurma longa) is a plant in the ginger family that is native to southeast India. It is also known as curcumin. The rhizomes are ground into an orange-yellow powder that is used as a spice in Indian cuisine. It has traditionally been used in folk medicine for various indications; and it has now become popular in alternative medicine circles, where it is claimed to be effective in treating a broad spectrum of diseases including cancer, Alzheimer’s, arthritis, and diabetes. One website claims science has proven it to be as effective as 14 drugs, including statins like Lipitor, corticosteroids, antidepressants like Prozac, anti-inflammatories like aspirin and ibuprofen, the chemotherapy drug oxaliplatin, and the diabetes drug metformin. I wish those claims were true, because turmeric is far less expensive and probably much safer than prescription drugs. It clearly has some interesting properties, but the claims go far beyond the actual evidence.
The Natural Medicines Comprehensive Database has reviewed all the available scientific studies and has concluded that it is “Likely Safe,” “Possibly Effective” for dyspepsia and osteoarthritis, and “Insufficient Reliable Evidence” to rate effectiveness for other indications, such as Alzheimer’s, anterior uveitis, colorectal cancer, rheumatoid arthritis, and skin cancer.
Mechanism of action
The “14 drugs” website says turmeric is one of the most thoroughly researched plants ever, with 5,600 peer-reviewed studies, 175 distinct beneficial physiological effects, and 600 potential preventive and therapeutic applications. They provide a database of 1,585 hyperlinks to turmeric abstracts. Naturally I can’t read all of them, but a sampling indicates that they are almost entirely animal and in vitro studies. The NMCD has conveniently provided a list of the most pertinent studies.
The pertinent preclinical studies, in animal models and in vitro, indicate that curcumin has anti-inflammatory properties; can induce apoptosis in cancer cells and may inhibit angiogenesis; has antithrombotic effects; can decrease the amyloid plaque associated with Alzheimer’s; has some activity against bacteria, Leishmania, HIV; etc. These effects sound promising, but animal studies and in vitro studies may not be applicable to humans. As Rose Shapiro pointed out in her book Suckers, you can kill cancer cells in a Petri dish with a flame thrower or bleach. Preclinical studies must always be followed by clinical studies in humans before we can make any recommendations to patients.
Preliminary clinical research
There are preliminary pilot studies in humans suggesting that:
    • it does not change mental state examination scores in Alzheimer’s
    • it might improve symptoms in anterior uveitis
    • it might stabilize some markers of colorectal cancer in some patients with treatment refractory colorectal cancer
    • high doses may decrease the number of aberrant crypt foci in smokers with abnormalities detected on colonoscopy
    • it might reduce some symptoms of rheumatoid arthritis and might be more effective than diclofenac
    • it might relieve odor and itching associated with skin cancers
Clinical research on turmeric is being funded by the National Center for Complementary and Alternative Medicine (NCCAM), but the NCCAM website is not very encouraging. Under the section What the Science Says, it reads:
    • There is little reliable evidence to support the use of turmeric for any health condition because few clinical trials have been conducted.
    • Preliminary findings from animal and other laboratory studies suggest that a chemical found in turmeric—called curcumin—may have anti-inflammatory, anticancer, and antioxidant properties, but these findings have not been confirmed in people.
    • NCCAM-funded investigators have studied the active chemicals in turmeric and their effects—particularly anti-inflammatory effects—in human cells to better understand how turmeric might be used for health purposes. NCCAM is also funding basic research studies on the potential role of turmeric in preventing acute respiratory distress syndrome, liver cancer, and post-menopausal osteoporosis.
Side effects
Turmeric is generally considered safe, but high doses have caused indigestion, nausea, vomiting, reflux, diarrhea, liver problems, and worsening of gallbladder disease. The NMCD warns that it may interact with anticoagulants and antiplatelet drugs to increase the risk of bleeding, that it should be used with caution in patients with gallstones or gallbladder disease and in patients with gastroesophageal reflux disease, and that it should be discontinued at least 2 weeks before elective surgery. Purchasers of supplements are not given that information.
Conclusion
The “14 drugs” website recommends that everyone:
use certified organic (non-irradiated) turmeric in lower culinary doses on a daily basis so that heroic doses won’t be necessary later in life after a serious disease sets in.
There is no evidence to support any part of that recommendation. And the scientific evidence for turmeric is insufficient to incorporate it into medical practice. As with so many supplements, the hype has gone way beyond the actual evidence. There are some promising hints that it may be useful, but there are plenty of promising hints that lots of other things “may” be useful too. Since I have no rational basis for choosing one over another, I see no reason to jump on the turmeric bandwagon. On the other hand, I see no compelling reason to advise people not to use it, as long as they understand the state of the evidence well enough to provide informed consent and know that they are essentially guinea pigs in an uncontrolled experiment that makes no attempt to collect data. I will keep an open mind and stay tuned for further evidence in the form of well-designed clinical studies in humans.

Bee Stings for Arthritis
Bee sting therapy may be somewhat effective for arthritis, but it can’t be recommended.
Harriet Hall on July 16, 2019
Link

Are bee strings [correction: stings, not strings!] an effective treatment for arthritis? Many patients with arthritis have reported that their symptoms went away after they were stung by bees. There are testimonials galore from beekeepers whose arthritis resolved after they were stung and from patients who dramatically proclaim that bee venom injections cured their arthritis or even saved their life. But testimonials are notoriously unreliable and anecdotal evidence must be confirmed by controlled clinical studies. Should rheumatologists be encouraged to keep beehives on their roof as a convenient source of bees to apply to patients’ skin for sting therapy? What does the scientific evidence say?
The subject of apitherapy is confusing, since it can involve stings by live bees or injection of bee venom, even injections at acupoints (bee venom acupuncture or BVA). Since acupoints have never been shown to exist, and acupuncture is basically a theatrical placebo, I’m very skeptical of BVA.
There are some positive studies in animals, but animal research doesn’t necessarily translate to human benefits. For example, a study reported in The Journal of Ethnopharmacology found that bee venom can help prevent one type of arthritis in rabbits. Humans are not rabbits.
For what it’s worth, bee venom does have anti-inflammatory properties. So it is plausible that it might have an effect on inflammatory arthritis like rheumatoid arthritis (RA) but somewhat less plausible that it would work for osteoarthritis (the wear-and-tear type). There are many pharmaceutical treatments for arthritis that have anti-inflammatory effects that may be stronger than bee venom and are probably a better choice. We don’t know, because there have been no comparison studies. And there is one big cause for concern: for rheumatoid arthritis we have effective disease-modifying anti-rheumatic drugs (DMARDs) that can help prevent the development of deformities and loss of joint function, especially when started early in the course of the disease. If patients rely on bee stings, they might be missing out on the chance to really improve their outcomes with a well-established, evidence-based treatment.
There has been only one randomized clinical study of bee-sting therapy for rheumatoid arthritis. It found significant improvement, but I don’t trust its results because (1) it is a Chinese study, and only positive results get published in China; other studies may exist that were negative but were relegated to the file drawer and not published, (2) it applied bee stings to Ashi-points, which exist only in the minds of acupuncturists, and they inconsistently added other points for some patients, and (3) it was an A vs A+B study, which will almost always generate a positive result. Both the treatment and the control groups got the same oral anti-arthritis medicines (A), and bee stings were added for the treatment group (B). This type of study is beloved of alternative medicine researchers but is useless because it will always indicate better results for the A + B group. And patients knew when they got bee stings, which was bound to cause placebo responses and bias in their reporting.
A Korean study published in an acupuncture journal found bee venom injections more effective than normal saline injections for rheumatoid arthritis. It claimed to be double blind, but I find it hard to believe that patients couldn’t tell the difference.
What about side effects?
WebMD calls bee venom therapy “possibly ineffective for arthritis” – not supported by research results. It lists multiple side effects, including itching, anxiety, trouble breathing, chest tightness, heart palpitations, dizziness, nausea, vomiting, diarrhea, sleepiness, confusion, fainting, and low blood pressure. The page also says it may decrease the effectiveness of many immunosuppressive drugs.
1-5% of the population is allergic to bee venom; they can develop anaphylaxis and die. Several deaths from apitherapy have been reported. Previous tolerance to bee stings doesn’t guarantee safety. A Spanish woman had been getting live bee acupuncture for two years when she developed a severe reaction and died of multiple organ failure.
Gwyneth Paltrow recommends it, which is not a good sign. She says it’s pretty incredible, “but, man, it’s painful”. Gwyneth Paltrow is not a reliable source of health information; her recommendations are usually pretty incredible themselves (jade eggs in the vagina?). Some patients less stoic than Gwyneth have found bee venom injections too painful to continue therapy.
The evidence is far from impressive
Despite some positive studies, “BVT is still very low on the list of safe and effective treatments. The risks and discomfort associated with these therapeutic methods greatly outweigh the potential benefits”
A systematic review in The BMJ concluded:
There is low-quality evidence, based on one trial, that BVA can significantly reduce pain, morning stiffness, tender joint counts, swollen joint counts and improve the quality of life of patients with RA compared with placebo (normal saline injection) control. However, the number of trials, their quality and the total sample size were too low to draw firm conclusions.
A Korean review found “there is limited evidence demonstrating the efficacy of BVA in arthritis”.
Various dosages and protocols have been used, but they have not been tested so there is no way to know which to choose.
Conclusion: Getting stung by bees is not recommended
Despite the many testimonials, scientific studies have not provided any acceptable evidence that bee stings are effective in arthritis. They hurt. They cause side effects. They can kill. They cannot be recommended.

   Bee Venom Therapy – Grassroots Medicine
Steven Novella 
Link
Pat Wagner (or “The Bee Lady,” as she likes to be called) treats herself for multiple sclerosis (MS) by allowing bees to sting her. She calls this bee-venom therapy (BVT) and believes it has saved her from MS.
There are now thousands of people who administer BVT to themselves or others, mostly in private homes by unlicensed practitioners. BVT is not prescribed by a doctor, yet it is used like any other drug, given in regular doses at regular intervals. There is no scientific evidence to support its use, and yet thousands of multiple sclerosis sufferers and others tout its effectiveness.
BVT, which is one modality within Apitherapy, or the use of various bee products as a medical treatment, is still a relatively small phenomenon. It is largely an unrecognized grassroots or folk medicine treatment – but like all such phenomena has been given a huge boost recently by the easy spread of information via the internet. It has also been adopted by many so-called alternative medicine (CAM) practitioners, and has been increasingly wrapped in the typical marketing jargon of CAM. So, in a way, this grassroots treatment has been corporatized by the CAM industry.
And yet, there if no convincing evidence that it is an effective treatment for any of the conditions for which it is used. Apitherapy.com claims it can be used to treat over 500 conditions (always a red flag for quackery), but I will focus on one – multiple sclerosis.
Multiple Sclerosis
In order to fully understand how apitherapy arose, one needs to understand the disease at which it is primarily targeted: multiple sclerosis. MS is a disease of the central nervous system, resulting in a variety of neurological symptoms. The cause of MS is still unclear, but what is known is that in patients with the disease the immune system attacks the brain and spinal cord, which are normally isolated from the immune system. The resulting inflammation causes areas of demyelination (myelin is the insulation around nerve fibers) which results in a plaque, an area where normal conduction is slowed or blocked. The location of the plaque determines the neurological deficit which results.
The important feature of MS, however, is its unpredictability. New plaques arise at random times and locations, and 90% of plaques are silent (without noticeable symptoms). Plaques can also vary in size and severity, and also in their potential to heal. Most new lesions will resolve spontaneously, either partially or even completely. Also, even in a person with stable MS, with no new lesions forming, symptoms can vary significantly and rapidly based on other factors, such as body temperature.
The end result is that nobody, not the patient nor the physician, can predict the course of MS in any individual. The MS sufferer must live with the uncertainty of what the future will bring, as they are buffeted by unpredictable exacerbations and remissions. It is for this reason that MS patients are especially susceptible to the claims of new miracle cures, and why anecdotal information regarding such therapies are all but worthless in terms of forming reliable scientific conclusions. In this way, MS is typical of diseases which are favorite targets of folk medicine: it is unpredictable, susceptible to spontaneous remissions, and cannot be cured by mainstream medicine.
Anecdotes and Human Nature
How, then, does the existence of MS result in the American Apitherapy Society, which claims to be tracking over 6,000 patients receiving regular bee-sting therapy (for MS and arthritis). Often times such a phenomenon begins with a single observation, one patient who, for example, receives bee sting for another ailment, or even accidentally, and then experiences a remission of their symptoms. Human psychology does the rest.
It is human nature to associate two events which are temporally related and assume cause and effect. Eat a roast beef sandwich and then get sick, and most people will assume that the roast beef was bad, even though they may be sick from a virus they were exposed to a day earlier. It is important to realize that coincidences are much more common than one would naively believe, and that the assumption of cause and effect is perhaps the most common logical mistake that people make.
So, once the story that a person was cured, or even helped, by bee venom gets around, many MS patients will seek out this new therapy out of desperation and hope. This is a reasonable and, one might even argue, rational response. Out of this self-selected (not random) assortment of MS sufferers who will try apitherapy, many are destined to have spontaneous remissions. Those that do are likely to spread the praises of this new therapy at MS support group meeting and other public venues and will give stunning testimonials at apitherapy meetings. The rare patient with a dramatic remission is likely to become a crusader for their miracle savior. Those without a response are likely to abandon therapy and not be heard from. They will probably move onto the next potential cure, and will not spend their time spreading the word that apitherapy did not work for them.
In fact this is exactly what I see in my practice. Patients with chronic neurological diseases with often try many therapies, even unconventional ones. If these treatments did not work, they do not talk about them much, and often will only report them if I directly ask about specific prior treatments. If, however, they feel they were helped by a treatment, they will shout it from the roof tops.
This process described above is the essence of anecdotal evidence, and is the reason why it is unreliable – because it is not controlled. The waxing and waning potential of MS symptoms makes it especially difficult to draw conclusions from uncontrolled observations.
It is also possible, although unlikely, that apitherapy is effective in the treatment of MS. Bee venom contains many biologically active chemicals. One or more may have anti-inflammatory or immune modulating effects. We will never learn this from anecdotal clinical evidence alone, however.
BVT Research
Until well designed and reliable clinical trials are completed which demonstrate honey bee venom’s safety and effectiveness, there is no rational basis for using it to treat MS. Many will argue, however, that those patients with severe progressive MS have nothing to lose and therefore they should not be denied any hope of a treatment. The use of unproved therapy in otherwise untreatable illnesses is a complex ethical issue, beyond the scope of this article. There are a few points I would like to discuss, however.
First, MS patients do have something to lose. Apitherapy certainly has its risks. All drugs have side effects and toxicity, which need to be weighed against their therapeutic effect. Bee stings commonly cause allergic reactions, which may result in anaphylaxis and death. Also, patients who put their hopes in an unproved treatment may be kept from mainstream treatment.
In the last decade several effective drugs for the treatment of relapsing remitting MS have emerged: Avonex (interferon beta-1a), Betaseron (interferon beta-1b), Copaxone (copolymer I), and Rebif (interferon beta-1b). More recently Tysabri has come on the market. This is an extremely effective drug and reduces MS exacerbations dramatically.
These are all powerful drugs, and not without their side effects, but they are useful in the treatment of MS and there is a large and growing body of data to support their use and to inform doctors and patients about their risks and benefits.
No such information exists for BVT. It is also impossible to regulated the dose of BVT with the precision that pharmaceuticals can.
In addition to risk of side effects, and potentially distracting patients from mainstream therapy, there is also the more subtle psychological harm of being given false hope in a treatment that may not work.
Second, compassionate use of experimental drugs is already built into the system. Drug trials are conducted in multiple phases. Before human testing can occur, potential new drugs are tested in animals to see if they are safe, and then to see if they have any potential benefit on the disease in question (or a close animal model of the disease). A phase I human trial may then be performed simply to test for safety in humans, and learn about the pharmacology of the drug – how it affects the body and how the body metabolizes it. A phase II trial is a placebo controlled human trial conducted in a small number of patients (dozens to a few hundred), tracking side effects and dosage response, but now also therapeutic effect. These trials involve too few patients to achieve reliable results, and are used to screen drugs for safety and possible benefit before they are given to a large number of patients. A phase III trial is a large, usually multicenter placebo controlled trial involving many patients (hundreds to thousands) over a longer period of time. This trial is designed to answer definitively the question of whether or not a drug is safe and effective, two of which are required for FDA approval. A phase IV trial is uncontrolled and simply tracks the side effects of a new drug once it is in wide-spread use (post FDA approval and marketing).
After a successful phase II trial, drugs can be given to patients as part of an open label trial on a compassionate basis. Also – treatments that are considered unproved or experimental can and should be given in the context of a clinical trial. One could argue that every patient getting BVT should be part of a trial until such time that we can confidently conclude that it either works or does not work.
Proponents of apitherapy will often point to basic science research which indicates that honey bee venom contains several compounds with powerful anti-inflammatory properties. There is a rationale to believe that anti-inflammatory drugs, like those currently used to treat MS, may have some benefit. There is also interest in a wide variety of venom therapies (snake venom, and anemones, for example) as potential sources of pharmaceuticals, including as anti-inflammatories.
This sort of basic science information, however, is pre-phase I, meaning that it is useful for picking a drug to study as a possible treatment for a particular disease, but it is a long way from concluding that the drug should be used to treat that disease. A very small percentage of drugs which enter phase I trials ultimately achieve FDA approval, most because the balance of risks and side effects to potential benefit is unfavorable.
Current Research
The National Multiple Sclerosis Society (NMSS) sponsored a study and published the following reports: Preliminary Test Results Of Bee Venom In Mice With Ms-Like Disease May 8, 1998. They studied the effect of bee venom on mice with experimental allergic encephalitis (EAE), the standard animal model of MS. They conclude:
In their initial series of small experiments, honey bee venom had no beneficial effect against the course of EAE, and some of the mice treated with bee venom experienced a worse course than those that received inactive placebo.
Honey bee venom contains a mixture of toxins and other biologically active compounds. Additional studies are underway to determine whether any of these individual components may have potential benefit for treating symptoms of MS.
The investigators caution that their finding that some mice experienced a worse course of disease after receiving honey bee venom raises possible safety concerns for the use of honey bee venom therapy in humans.(3)
A recent randomized cross-over (unblinded) study published in Neurology in 2005 found absolutely no effect by any measure for relapsing-remitting MS (the most treatable form) from BVT. Another small Phase I study showed no effect.
At this time the animal data and the preliminary (phase I and II) clinical data for BVT in MS is negative. Of course, this is not definitive, but strongly argues against an effect, and at the very least rules out a large clinical effect.
Conclusion
Unfortunately, as we often see with grassroots or folk medicine in general – practice and belief are completely disconnected from scientific research. Apitherapy has evolved into another CAM belief system – one with an almost spiritual belief in the power of the honey bee to “heal”. Evidence is irrelevant.

Bee Venom Therapy Update
Steven Novella on June 20, 2012
Link
I wrote previously about bee venom therapy (BVT), also called apitherapy or bee sting therapy, as an emerging “alternative” therapy. Both use and research into BVT continue, providing an excellent example of the many things that are wrong with the CAM movement.
A recent Reuters article on the topic is also an excellent example of the frequent complete failure of the mainstream media in dealing with such topics. The articles discusses a Filipino bee keeper who decided to practice medicine based upon his personal anecdotal experience. Joel Magsaysay suffered a stroke and right-sided weakness. He attributes his recovery from the stroke partly to bee stings.
He admits he is not a physician and has no medical or scientific background. He has concluded that BVT works based upon anecdote along. He seems to be unaware of the unreliability of individual anecdotes in stroke recovery. Most patients will improve following a stroke. There are also two kinds of recovery, including neurological recovery from brain plasticity.
But there is also functional recovery separate from repairing some of the brain damage itself. After being hospitalized with a stroke and then having a prolonged recovery, there is likely going to be a degree of debility from the loss of normal activity. Depression is also common following a stroke. Patients deciding they are going to do something to improve their function, no matter they decide to do, is likely going to be accompanied by greater physical activity and perhaps elevated mood. Stroke researchers are careful to control for this so-called “cheerleader effect” (a type of placebo effect) when trying to determine if a specific intervention is having a physiological effect.
Magsaysay, in other words, has no idea what the effect of bee stings was on his recovery. He likely would have recovered to the same degree without the stings. But now he feels qualified to treat a range of conditions with his bees. The Reuters report, for example, shows him treating a woman with an enlarged thyroid. She was hopeful that it would help because “people are saying it helps” and because it’s “natural.”
Bee venom is an interesting compound because it is a mixture of powerful chemicals. Venoms as a category are usually highly biological active – they evolved to be highly active, either inducing pain, paralysis, or death. So it is no surprise that they are a resource of potentially powerful drugs. The question, of course, is if they can be exploited for therapeutic effect. The best way to approach this is to isolate and purify specific components of a venom and then go through the normal process of drug testing to find a safe and effective therapeutic dose for a specific indication. This has not happened, but there is some interesting basic science and animal research being done.
Ultimately, whether purified, diluted, or simply given as bee stings, we need rigorous clinical trials to assess ultimate safety and efficacy. My previous article focused mainly on BVT for multiple sclerosis. In the last four years there has been no new published research on this question – it seems to be a dead end. BVT is not effective for MS.
There are no published clinical studies of BVT and stroke recovery (however I did find a case report of a stroke following bee stings). There is also no legitimate scientific reason to suspect that BVT would be effective in stroke recover. Magsaysay gives his own explanation for how he thinks it works. His description is pure pseudoscience, just made up science-sounding nonsense. He claims that the pain induced by BVT causes neurons to synapse and reconnect to the brain. This does not even make basic anatomical sense. The problem with stroke is not with the peripheral nerves connecting to the brain, but to neurons in the brain itself that have been damaged.
The area of BVT research that seems the most promising is with neuropathic pain. Bee venom induces pain and inflammation acutely. A number of studies show that it also decreases markers of pain and inflammation following the exposure. This can simply be the effect of compensatory mechanisms kicking in. We see this as a general phenomenon – after any stimulus that causes pain and inflammation the body mobilizes mechanisms to counteract the pain and inflammation and reestablish the normal baseline. This effect is also temporary. Perhaps, however, the duration of the decrease in pain and inflammation is longer than that induced acutely by the sting.
This is still a matter of investigation, and it is not clear if any useful therapy will emerge from this. There are some interesting animal studies working with injecting diluted bee venom into a rat model of neuropathic pain. This is a long way from a specific clinical application, however.
Conclusion
After years of research there is still no proven application for bee venom therapy. The most encouraging preliminary data is with pain, and I would not be surprised if a component of bee venom is isolated that is useful for neuropathic (nerve induced) or nociceptive (tissue) pain. There is still a focus on rheumatoid arthritis, because of the alleged anti-inflammatory effects of BVT, but the data so far may just be reflecting the pain effects of BVT.
There are no neurological uses of BVT that are backed by any reasonable evidence. At this point I think we can say that it is not effective for multiple sclerosis. For other neurological conditions there is no clinical data, only the most preliminary basic science (looking at specific biochemical effects of bee venom).
While it is still unclear if any legitimate treatment will emerge from the study of bee venom, it is a mixture of powerfully biological active chemicals and is a potentially fruitful target of research. This does not justify, however, the exploitation of bee venom by the CAM community, who are making claims that go beyond the basic science evidence and are not supported by clinical evidence.
In fact we can see, side by side, the legitimate scientific approach to bee venom and the CAM approach. The scientific approach is reductionist, methodical, and rigorous and actually has the potential to develop something useful. The CAM approach is to make appeals to nature and antiquity, to make nonsensical hand-waving pseudoscientific justifications, to call it “therapy” before any proven therapeutic effect, and to use it carelessly for a wide range of different conditions.

Bee Pollen Supplements – Not Safe or Effective
Steven Novella on May 23, 2012
Link
Among the myriad of supplements being offered to the public are various bee products, including bee pollen. The claims made for bee pollen supplements are typically over-hyped and evidence-free, as is typical of this poorly regulated industry. The claims from bee-pollen-supplements.com are representative:
The benefits are enormous and the substance has been proven by many health experts. This particular substance is known as an effective immune booster and one of the best ways to achieve a sound nutritional regime.
The pollen from the bee has been proven to increase sexual functions in both men and women. It stimulates our organs, as well as our glands and is known to improve the natural increase on a person’s lifespan.
What you never find on such websites are references to published peer-reviewed studies that substantiate the specific claims being made. There are also concerns about safety which have not been adequately studied.
Safety
A recent case report highlights one safety concern regarding bee pollen products – allergic and even anaphylactic reactions. The Canadian Medical Association Journal reports:
A 30-year-old woman with seasonal allergies but no history of allergies to food, drugs, insects or latex had an anaphylactic reaction after taking bee pollen. She had swelling of the eyelids, lips and throat, difficulty swallowing, hives and other life-threatening symptoms. After emergency treatment and discontinuation of the bee pollen supplements, there were no further reactions.
This is also not the first report. There is another case report of anaphylaxis from bee pollen in 2001, and another in 2010. Those with a history of airborne allergies to pollen show positive reactivity to bee pollen supplements, but a reaction can occur even without a history of allergies.
Allergic reaction is also not the only reported risk from bee pollen products. There is a published case report of a photosensitive skin reaction to a supplement containing bee pollen in one patient. Another report details a case of renal failure from bee pollen. Yet another study found substances known to cause liver damage (hepatotoxic pyrrolizidine alkaloids) in bee pollen.
These studies highlight the potential health risks of bee pollen supplements, but do not document the magnitude of the risk – and that is precisely the problem. In many countries, such as the US, there is no need for specific safety studies of supplements prior to marketing. This regulation, and popular belief in the safety of such products, is largely the result of the naturalistic fallacy – the notion that because bee pollen is “natural” (a vague term without a specific definition) it must be safe. Of course nature is full of deadly toxins, so this reasoning does not follow.
Efficacy
In medicine it is not adequate to assess risk alone. Rather, we consider the risk vs benefit of any intervention. It is clear that injesting bee pollen products is not risk free, and the risks may be substantial. Only controlled clinical trials will establish exactly what the magnitude of potential risks from bee pollen is. We also need controlled clinical trials to assess any potential health benefit from these products. Unfortunately, such studies are completely lacking.
Many of the claims for bee pollen are supported by the notion that it is a “superfood” – a dubious category that is used to claim miraculous health benefits from “perfectly balanced” foods. Such claims are based on the fallacy of more is always better, and an exaggerated role of nutrition in overall health. Not all alleged superfoods are even good sources of nutrition (perhaps the most notorious being wheat grass juice), but even for those that are, the claims made for superfoods are not justified by an evidence or even plausibility. There is no theoretical benefit to deriving all required nutrition from one food source (even assuming that is possible) vs just having a well rounded diet.
There are some older studies of bee pollen as an “ergogenic” – an alleged category of food that enhances athletic performance. The consensus of research is that bee pollen has no ergogenic benefit. That is the extent of research into bee pollen as a super food – negative.
Everything else is hype and anecdote. Unfortunately, online information about bee pollen is overwhelmed by hype from companies and individual selling bee pollen products. One site claims you will live to 125 from eating bee pollen, and is complete with the typical anecdotes about some village in the Caucasus mountains of Russia who eat bee pollen and live to be 125. These are the same people that were used to sell the health benefits of eating yogurt (and still are). This claim linking their longevity to bee pollen is repeated endlessly on bee pollen sites, and all refers back to the work of Dr. Nicolai Tsitsin, a Russian botanist from the first half of the 20th century. I could find nothing substantiated about these reports – it seems to be bee pollen legend.
Other bee pollen health claims are completely unsubstantiated by controlled clinical trials. Some are based upon preclinical studies looking at the constituents and biological properties of bee pollen. There is no doubt that bee pollen contains many biologically active chemicals, and it is not implausible that one or more of these chemicals might have a medically useful property. It’s just as plausible, and a-priori more likely, that they will have properties that have negative health effects, as indicated above.
One study did find anti-inflammatory effects of some extracts from bee pollen. The anti-inflammatory effect came from inhibition of NO production and inhibition of COX-2 (but not COX-1). Incidentally, the inhibition of COX-2 but not COX-1 is the same effect as Vioxx, that was found to increase the risk of heart attacks in susceptible individuals. The point is that it is difficult to extrapolate from such effects to their net clinical outcome. Not all chemicals with an anti-inflammatory effect are overall beneficial. Further, even if they can be clinically useful that would require purification and standardization of active ingredients.
Interestingly, the claim that bee pollen “boosts the immune system” is common on promotional sites. This is not a meaningful term scientifically, and is used simply because it is the type of claim that can be made without the burden of any evidence. Also, anti-inflammatory effects, if they are significant from consumed bee pollen, is the opposite of “boosting” the immune system, as by definition anti-inflammatory effects result from suppressing or inhibiting one or more aspects of the immune system.
Conclusion
Bee pollen products are a classic example of the current fallacies of the supplement industry. The claims made for such products are full of hype but are completely unsubstantiated by rigorous scientific evidence. What little evidence we do have shows that it is ineffective. What passes for “scientific” evidence on promotional websites are ancient tales and anecdotes. Further, there are increasing safety concerns about bee pollen products, mainly from the potential for allergic reactions but also including organ toxicity.
There is no current basis on which to recommend the use of bee pollen products. There is a basis for caution, however.

The Beekeeper: Sentinel Chicken?
Bee venom. Will it help Andy’s rheumatism? Doubtful
Mark Crislip on November 17, 2022
Link

My Bees. My Bees.– Rita Farr aka the Beekeeper
A while back I saw a hospitalized patient with cellulitis of the arm. An odd place to get a cellulitis. It looked like a typical group A Streptococcal infection. But why? One of the three questions I try and answer with every consult: What is the infection, how best to treat it and, of the most interest, why do they have it?
Why, why why? Sometimes it is Luck! Blind, stupid, simple, doo-dah, clueless luck! But I want an answer that is more satisfying than bad luck. The rule in infectious diseases is people usually get what they are exposed to. So I start asking questions and discover that the patient is a beekeeper and deliberately stings themselves on the arms and legs. Two bees (or not two bees. Is that questionable?) to each arm and leg each day.
It helps their joint and muscle pain from some undiagnosed arthritic condition. They combine the bee stings with bee milk. Just how does one milk a bee? I would be an udder failure.
Two bee-related treatments I had not heard of. I have discussed honey twice on this blog, in 2013 and 2011. But bee sting therapy? What rat holes would that take me down?
My first thought was, poor bees. The sting is the delivery vehicle for the therapeutic agent, bee venom. Stinging is fatal for bees, so that treatment causes almost 3,000 dead bees a year. My wife is a big-time gardener and in the summer I sat in the yard and watched the bees come and go while she slowly dug a hole 3 feet wide, 6 feet long and 6 feet deep. It is almost finished. I still can’t discover what she hopes to plant in there. But the bees were interesting to watch and it is sad to think of their little deaths. Mosquitoes? They deserve death. But not bees.
The trauma of a bee sting is certainly enough to result in a secondary infection. But what, if anything, is known about the microbiology of the bee stinger and venom? Bedbugs, for example, have been credited with methicillin resistant S. aureus and vancomycin-resistant Enterococcus transmission.
Bees have:
A distinctive microbial community of approximately nine bacterial species clusters [that] inhabits the bee gut.
As is likely for all creatures with a gut.
The stinger and venom? Sterile, or mostly so. Products in the venom have reasonably potent antimicrobial actions and:
Given the environmental conditions and the nature of the bee venom, a high microbial load might be expected. However, the microbial load was almost non-existent for most samples. This shows that bee venom produces its own antimicrobial protection system.
So I could not blame bacteria from the bee venom or stinger, just the bee trauma. So it was half the bees.
What about bee venom? Many a biologically active molecule was first discovered in nature and then refined to optimize it effects in humans, he says while sipping a combination of various processed yeast derivatives. Mmmmm. Processed yeast derivatives. I mean, if we can stave off dementia with products derived from jellyfish, and if there is any creature with a better memory than a jellyfish I can’t remember it, why not therapeutic bee venom?
Bee venom has 7,043 hits on the PubMeds dating back to 1926. Wow, that is a lot of papers on bee venom and more than I can review in this little blog entry. So let’s wander through a few.
First off, the venom volume is small. A drop of venom is mostly water and “one drop of BV consists of 88% of water and only 0.1 µg of dry venom”.
0.1 µg isn’t a lot of material although not quite homeopathy levels of nothingness. It takes one million sting deposits on a collector board to make 1 gram of dry venom.
That 0.1 µg of bee venom is:
…an extremely complex blend of peptides including melittin, adolapin, apamin, and MCD-peptide. It also contains enzymes, most importantly PLA2, and compounds of low molecular weight like bioactive amines (e.g., histamine and epinephrine) and minerals.
Still, that drop of bee venom is potent stuff, remembering back to the time I was swarmed by ground (nest in the earth, not chopped up) bees. Bee stings hurt, at least to the unexposed.
To treat patients you can either apply the poor bee directly or bee venom can be harvested. Venom can be gathered without killing bees by passing an electric current through the hive:
When the current is turned on, bees that are on the sheet automatically stick out their stingers, and the action of the muscles pushing the stinger also pumps a small amount of venom out the end of the sting.
I am going to avoid NSFW comments here. I know. Grow up, Crislip.
Uses of bee venom? Many purported. Rheumatologic diseases especially arthritis, cancer, Parkinson’s, Alzheimer’s, Amyotrophic Lateral Sclerosis and more. Much more. Dr. Novella has written about venom therapy from a neurologist’s perspective. There is apparently no disease process for which bee venom cannot help. Color me skeptical, but when an NRLM therapy purports to treat everything, it likely treats nothing.
Arthritis is the most popular use of bee venom, supposedly because beekeepers do not get arthritis. Is that true? I can’t find any epidemiologic studies to confirm or deny the idea. Perhaps my Google-fu is lacking. But. There is a specific beekeeper arthropathy.
Beekeepers have joint disease apparently related to bee stings. Etiopathogenesis is unknown. Mechanical trauma, venom compounds, infection, and foreign body synovitis are factors that are thought to influence the pathogenesis of this syndrome.
Some references suggest therapeutic bee venom has been used for 5,000 years for arthritis and the treatment is mentioned in the Bible, always a good source for science-based medicine. None of the footnotes actually point to the section of the Bible where bee venom is used, and when I search the Bible for bee or sting treatment, nothing.
This drives me nuts. The medical literature has references that point to articles that do not support the text or do not even exist. You will find this frequently if you spend a lot of time going back to the original literature, as I have in infectious diseases.
So what about bee venom to treat arthritis?
… it is known to be effective for musculoskeletal diseases, including arthritis, arthralgia and immune-related diseases, because bee venom has anti-inflammatory and analgesic effects
That has always been one of the primary characteristics of a bee sting: the marked lack of inflammation and pain. It does make me wonder why anyone would try bee stings as a therapy for an inflammatory condition, the alleged lack of disease in beekeepers not withstanding.
This is not to say that at pharmacologic doses, milligrams or grams, of bee venom products could not have wide-ranging effects. Mice and rats have been injected with a variety of bee venom products (phospholipase A2 and melittin as examples) at high dose with a variety of effects on the physiology of those animals. I am skeptical that these models have much to do with the treatment of human disease by the laying on of bees.
Are there human studies? Actually, no. All the clinical trials I found use bee venom on acupoints or with acupuncture, so there is already a huge overlay of the NRLM. And that is true of most of the bee venom studies for other diseases; it is used as a form of acupuncture. So even where bee venom was compared to placebo, it was as part of acupuncture. Odd, really, and what conclusions can be made from a placebo controlled intervention added to bogus medical theater? Nothing.
I cannot find a clean, i.e., a non-TCPM based, randomized, placebo-controlled study of bee venom in humans for the treatment arthritis. And there are the nonspecific effects of pain and anxiety: both can lead to an increase in cortisol, and, perhaps, need to be taken into consideration in study design.
Not everyone uses bee venom as an acupuncture adjunct. Some use the bees directly, with:
…seven to 10 live bees are used to sting the aching joint and it is done at least three times a week.
I mentioned this to my wife, who did not believe me at first. Are they nuts? she asked me. I just shrugged. I could find no studies evaluating bees directly and it would be difficult to come up with a placebo bee. “Placebo bee” has no hits on Google scholar, but I do not doubt someone clever could come up with a placebo bee.
Do bee stings affect rheumatologic processes? I can’t say from the literature. But I doubt it, if no other reason than the dose of venom is too small to cause any systemic effect besides an allergic reaction.
And, no surprise, bee venom therapy has frequent side effects:
The median frequency of patients who experienced adverse events related to venom immunotherapy was 28.87% (interquartile range, 14.57-39.74) in the audit studies. Compared with normal saline injection, bee venom acupuncture showed a 261% increased relative risk for the occurrence of adverse events (relative risk, 3.61; 95% confidence interval, 2.10 to 6.20) in the randomized controlled trials
The solution? Just how does one ensure “…the practitioner’s education and qualifications regarding the use of bee venom therapy…” is appropriate? I wonder what the tuition of NRLM U is.
And bee venom should give around half the population pause:
The findings of this study showed that repeated bee venom treatment by sting or injection to adult male mice resulted in a significant decline in testosterone levels, sperm count, sperm motility, and a very significant increase in the percentage of abnormal sperm morphology; also, there were harmful testicular histological changes in the structural organization of seminiferous tubules and degenerative changes in the germinal epithelium compared to control group.
Not the best approach to male infertility. I will admit to being skeptical about this study as well, but I have asked our exterminator to give it a go for our mice infestation.
Beekeepers are the origin of other bee investigations. It was suggested in China that beekeepers were also resistant to COVID 45, perhaps because of the recurrent bee stings. Not that beekeepers work alone, outside, in protective gear. Nope. Has to be the bee stings. It wasn’t. In further studies, bee venom therapy is not protective against COVID 45.
Is being a beekeeper protective for cancer and other medical problems for which bee venom has efficacy? I can’t find it. I doubt it. Leave those bees alone. They have some serious pollinating to do.

Honey Boo Boo
Mark Crislip on February 8, 2013
Link
My son has been coughing for several weeks, and the cough will probably persist for another 2 or 3 weeks. Coughs last a long time. Patients think a cough will go away in less than a week but in reality they are likely to last several weeks.
Coughs are a pain for the patient and an annoyance for the people around them. You never really know if the cougher in the row behind you has asthma, a post infectious cough or is actively spewing TB or influenza all over the airplane. I learned from Clinton the importance of not inhaling, especially on airplanes.
I tend to leave most symptoms alone if the they are not life threatening or otherwise unbearable for the patient. Codeine is the only really good cough suppressant and none of the over the counter cough medications are effective. I assume that coughing with infection, like diarrhea, is beneficial. Key to treating all infections is to physically remove it. Undrained pus doesn’t heal, and a good cough is the most efficient way I know to remove potential pathogens from the lungs.
If there are benefits to suppressing the cough associated with acute respiratory infections I can’t find any and we have all seen people who, because of inability to cough secondary to rib fractures, develop severe pneumonia. As a resident I had an elderly male die of just such a series of unfortunate events.
I suffer from a mild form the the naturalistic fallacy. I tend to let normal physiologic processes run their course unimpeded as long as they pose no harm to the patient. So I do not treat infectious coughs, in part because medications are not effective, in part there is no benefit and in part because the medications that are effective, and those that are not, have side effects. 
Not only has my son been coughing, but, thanks to flu-like illness season, almost everyone around me is coughing as well and someone asked me about honey as a cough treatment, pointing to a recent article in Pediatrics.
I like honey. Of the roughly 40,000 PB&J sandwiches I estimate I have consumed in my life, I bet half have been made with honey. For a variety of reasons I occasionally recommend honey for wounds. But as a cough therapy? Why would honey have an effect on cough? Whatever the active ingredient, it would have to survive gastric acid and pancreatic enzymes, be absorbed and have sufficient half life to have an effect.
Given that honey is >95% water and sugar there is little room for any ‘active’ ingredients. I went looking for a coherent, plausible mechanism for how honey might suppress cough but failed. Much was written about the complexity of honey, its antioxidant and antibacterial effects:
Honey is a remarkably complex natural liquid that is reported to contain at least 181 substances. It has well-established antioxidant and antimicrobial effects.
True and interesting, but it has little to with suppressing cough. The link between antioxidants and cough is tenuous at best, most of my Google-fu found references to asthma. It was also suggested that the sweetness of the honey is key:
Because of the close anatomic relationship between the sensory nerve fibers that initiate cough and the gustatory nerve fibers that taste sweetness, an interaction between these fibers may produce an antitussive effect of sweet substances via a central nervous system mechanism.
Neither seem particularly likely to me as a mechanism for cough suppressant.
There is a strong placebo effect when treating cough:
Placebo treatment has been reported to improve subjective and objective measures of disease in up to 30-40% of patients with a wide range of clinical conditions. A review of 8 clinical trials on the effects of antitussive medicines on cough associated with acute upper respiratory tract infection shows that 85% of the reduction in cough is related to treatment with placebo, and only 15% attributable to the active ingredient.
Although any author who routinly uses the word ‘powerful’ in conjunction with placebo, as Dr. Eccles does, probably has a stronger bias in favor of placebo effects than I. Coughs improve with time. Because of the favorable natural history of cough, a “positive” response in medication trials should not be assumed to be due to the medication.
The ever questionable Cochrane Reviews had evaluated honey as an anti-cough therapy and concluded
We included two RCTs of high risk of bias involving 265 children. The studies compared the effect of honey with dextromethorphan, diphenhydramine and ‘no treatment’ on symptomatic relief of cough using the 7-point Likert scale. Honey was better than ‘no treatment’ in reducing frequency of cough (mean difference (MD) -1.07; 95% confidence interval (CI) -1.53 to -0.60; two studies; 154 participants). Moderate quality evidence suggests honey did not differ significantly from dextromethorphan in reducing cough frequency (MD -0.07; 95% CI -1.07 to 0.94; two studies; 149 participants). Low quality evidence suggests honey may be slightly better than diphenhydramine in reducing cough frequency (MD -0.57; 95% CI -0.90 to -0.24; one study; 80 participants). Adverse events included mild reactions (nervousness, insomnia and hyperactivity) experienced by seven children (9.3%) from the honey group and two (2.7%) from the dextromethorphan group; the difference was not significant (risk ratio (RR) 2.94; 95% Cl 0.74 to 11.71; two studies; 149 participants). Three children (7.5%) in the diphenhydramine group experienced somnolence (RR 0.14; 95% Cl 0.01 to 2.68; one study; 80 participants) but there was no significant difference between honey versus dextromethorphan or honey versus diphenhydramine.
Since all over the counter medications for cough are essentially worthless, if honey is equal to dextromethorphan and dextromethorphan does nothing, then honey does nothing. Or does it?
Enter Effect of Honey on Nocturnal Cough and Sleep Quality: A Double-blind, Randomized, Placebo-Controlled Study, which received a lot of press, most of it favorable.
The study was simple and really, really flawed. Really.
First, it was partially funded by Big Honey (sounds like a New Orleans madame), and we know the Honey Board of Israel has their hooks into every aspect of honey-related therapies and has corrupted medicine in pursuit of good outcomes in clinical trials. I am sure they are suppressing the negative studies and side effects, information they do not want you to know.
They enrolled children 1-5 years old with uncomplicated upper respiratory infection. Children with asthma, pneumonia, sinusitis, or allergic rhinitis were excluded. There were pre- and post intervention questionnaires with 5 items that evaluated the child’s cough and degree of sleep difficulty the night before and the night of the intervention.
Three types of honey were used: eucalyptus honey, labiatae honey, and citrus honey. The placebo was Silan, a syrup made from dates, because it was brown and sweet like honey. The children received 10 g (10 ml) of the honey or placebo 30 minutes before going to sleep. The next day the parents were called and completed the post intervention questionnaire. Parents were asked the following:
So parents were asked about cough before enrollment, given the therapy, then quizzed the next day. Like veterinary medicine the researchers relied on second hand information as to efficacy and there is ample opportunity for bias. I would say, and this is without data, people tend to play up the symptoms at the beginning and play down their symptoms after the intervention.
But the data was impressive, despite the fact it seems like a minor intervention. Cough was better in all four groups and the honey outperformed the placebo:
There were big flaws in the study. First, of course, is they relied on the parents’ impression of efficacy. Not a reliable technique. There has been some interesting work with cough recognition software that, for example, can determine if the cough is likely due to pertussis. It would have been nice to have an objective measure of the cough severity before and after. Just a recorder in the child’s room would have been sufficient. It is also possible that they were seeing the natural history of cough, but I doubt it was a significant component of the response. Coughs do not get better that fast on their own.
And think about the parents. Your kid is ill. Is it serious? You are hyper-alert to your kids every cough and wheeze and are up all night. When my kids had fevers I would check them every 10 minutes for purpura, Meningococcal infection was always my worst infectious fear. Being up all night with the kid you are tired. The next day you find out the child has a trivial, self limited disease, nothing to worry about. Reassured, the next night you are not going to pay as much attention to the child’s cough and you need, and get, a better night’s sleep as a result. You will be paying less attention. It would have been so much better to get a baseline after the assessment, preferably with cough recognition software as back up, then the next night do the intervention.
But the big question they did not ask, and should have, is what did you think your child received? Could the parents tell if the kids were getting honey or Silan date extract? I expect they could.
The article says “The parents, the physicians, and the study coordinator did not know the content of the preparation that was dispensed.”
I like to cook and honey is a royal pain. It is thick and sticks to the measuring cup and spoon. I always end up some honey on my finger from trying to scrape it off the cup or the spoon or the spatula and that finger goes in the mouth. The honey was
packed in small plastic containers of 10 g each and marked with the letters A, B, C, or D. The study preparations were distributed to the pediatric community clinics in blocks of 4. Parents were instructed to administer 10 g of their child’s treatment product within 30 minutes of the child going to sleep. The parents were instructed that the preparation could be given undiluted or together with a noncaffeinated beverage.
You are going to squirt something in your ill fussy kids mouth, and being honey it almost certainly would have to be milked out of the container and in the process get it on the fingers. What parent would not smell it, taste it or otherwise check it out? No one. There is no way almost every parent, unless blind and anosmiac, would not know if their child received honey. The question is whether they would know if they had the date extract.
It wasn’t an o-ring in ice water moment, but I went hunting and found 2 different date extracts. It wasn’t easy. Only one store in Portland sold the product and I had to get the other from Amazon. The date syrup I could find is darker than honey, looks more like molasses, is not as viscous as honey and tastes good but nothing like honey. It tasted like sweet dates. No way did the products I found resemble honey. Too much datey goodness. To say the date syrup was a reasonable placebo for honey because it was sweet and brown is like saying my bicycle could be a mistaken for my car because it has wheels and is red.
As I read the paper, there is no way for the parents to have not known what their kids were receiving, honey or date extract, especially as the study was done in Israel where use of date syrup is common. There is the caveat that I do not know for sure if the products I sampled were equivalent to the ones in the study, but I strongly suspect it would be simple enough to know if you child received honey or date.
As they note in the final paragraph
The dropout rate was higher for children receiving citrus and eucalyptus honey. The exact reason for the higher dropout rate in these groups is not known. Because these types of honey are more aromatic, it is possible that some children disliked the honey taste.
For placebo to be a valid control it has to be indistinguishable from the active therapy, and, after tasting some date syrup, I call horsefeathers. The parents were almost certainly aware of whether their children were getting honey or date extract and that would render the conclusions of the paper fatally flawed. The key characteristic in most studies of implausible or impossible therapies that demonstrate benefit is there is no placebo. People know what they are getting and respond accordingly. Bias central. As in this study. Calling something a placebo does not make it so. Placebo. You keep using that word, I do not think it means what you think it means.
So did the paper demonstrate honey is better than placebo? I suspect not. I suspect the parents knew very well what their children were taking and bias flooded in. Someone, and I can’t find the quote, suggested I thought the placebo effect was the patient lying to themselves and/or to their doctors. Not quite. People will convince themselves that they are better when they are not and report the imagined improvement to their doctors. Humans are most expert at convincing themselves that what is not real is real. I always think the archetype is the Penn and Teller show with the the gutter downspout bent and painted to look like a giant magnet and the person telling the man in the white coat her arthritis was better (13:30 in). The same effect is probably occurring in this study.
Does the study demonstrate that honey is better than date extract? Yes. But in a study to compare honey and placebo where the patients almost certainly know what they are getting. Like acupuncture, it is effective only when the patient knows they are getting needles.
Does it demonstrate when you do not have an adequate placebo and make it simple for someone to break the blinding that it renders a study nearly worthless? Yes.
Does it suggest that neither the editors and reviewers of Pediatrics nor those reporting the study took the time to think about the validity of the study? Yes. It is the new peer review. Peer: to appear partially or dimly.

   Honey
Mark Crislip 
Link
I cram for TAM, and, combined with other commitments, not the least of which is that it is finally sunny and warm in Portland, after a year that has resembled All the Summer in a Day, which leads to a relatively short post. There are just so many hours in a day and if possible those days need to be spent in the sun.
In my first year in practice I was sitting on a nursing station writing a note when a patient started howling in pain. Further investigation revealed that the patient had a chronic, open surgical wound and the (old) surgeon had ordered sugar poured into the wound as part of wound care. The cafeteria mistakenly sent up salt, and a metaphor became reality. It did pique my interest in both sugar and honey for wound care, an area where you have to be careful not to fall prey to all the errors in CAM thinking: a reliance on anecdotes, using suboptimal studies as evidence, mistaking a gobbet of basic science as a meaningful clinical application, and not realizing the warping effect of confirmation bias.
That being said, I have suggested honey and sugar for years for patients, and many patients with prior refractory wounds had healing. And what are the three most dangerous words in medicine? In my experience. I have recommended honey less in the era of the wound vac, but there are not an insignificant number of people with insufficient financial resources who cannot afford even simple wound care supplies. Many of the ointments, creams and special bandages for wound care costs too much. Patients also like honey as it is natural (people do love to fall for the naturalistic fallacy) and inexpensive, and I always tell patients that the data is iffy, but not stupid.
Wound itself is mostly a combination of tradition and hype. One doc learned from his attending who learned from their attending, in a line that stretches back to the first barber-surgeon. I was told as a medical student, never put in a wound what you wouldn’t put in your eye, which seemed to be a good guiding principle, although it is expensive to pack a wound with soft contact lenses. New products, often combinations of old treatments, come out monthly with flashy brochures and little good data.
“There is a lack of large, high-quality published RCTs evaluating debridement per se, or comparing different methods of debridement for surgical wounds, to guide clinical decision-making. 
So I rely on basic principals. Keep the wound clean, keep the new tissue from drying out, remove the dead meat, and keep the bacteria at bay, and do not let your pet lick it are more or less guiding rules in wound care. That, and no matter what you do, most people will heal. My rule remains: take credit for success, blame nursing when things go wrong. That’s ‘humor’ for the sarcasm impaired.
What is the rationale for sugar and honey for wounds and burns?
Basic Biologic Plausibility
The first is mechanism of action is primarily mechanical. The high osmolality of sugar and honey prevents bacterial overgrowth. Food can be preserved in sugar (jam is a good example) so the honey and sugar can prevent or decrease bacterial colonization of wounds. Honey has a low pH and contains hydrogen peroxide, both of which are antibacterial, but I doubt clinical relevance of the latter. And there may be bee and flower constituents that aid in antibacterial properties, although again I wonder about clinical relevance. Also, sugar and honey do not damage new tissues and when the honey is washed off, it painlessly removes the dead tissues with it, so it is good for debridement.
Honey, and to make sure you can charge a premium amount call it medical grade honey, can kill bacteria and decrease skin colonization. Avoid raw honey, as it can contain C. botulinum and has been the source of botulism in children. I don’t expect it would be of much use on facial wrinkles
At least from a basic science perspective, honey and sugar have mechanical, perhaps biochemical, and certainly financial, reasons it could be beneficial in wound care.
Clinical trials
So how are the clinical trials? There are lots of poor quality studies. Almost 400 references if you are in the mood for cherry picking. The preponderance of the poor quality studies points to benefit.
For burns?
“Available evidence indicates markedly greater efficacy of honey compared with alternative dressing treatments for superficial or partial thickness burns, although the limitations of the studies included in the meta-analysis restrict the clinical application of these findings.
and
Honey may improve healing times in mild to moderate superficial and partial thickness burns compared with some conventional dressings.
For Wounds?
From the ever helpful and potentially flawed Cochrane reviews:
Honey dressings as an adjuvant to compression do not significantly increase leg ulcer healing at 12 weeks. There is insufficient evidence to guide clinical practice in other areas.
and as they note
The poor quality of most of the trial reports means the results should be interpreted with caution.
So be it. I have read many of the 400 references over the years, and the sense is that honey is of some value in wound care.
There is even less information of granulated sugar, where it looks encouraging and has been used to treat mediastinitis , diabetic foot ulcers and sloughing wounds.
Of course, honey is not the end all and bee all of treating soft tissue infections. Depending on the process, surgery and antibiotics will do far more to resolve the infection and promote healing, especially for acute and/or acutely infected wounds. Relying on only natural products has lead to one death in a complimentary practitioner who treated himself with honey:
“a minor injury became infected with gangrene, the judge was told. He died, aged 52, in April 2007. Instead (of standard care) he used honey and magnesium sulphate.
The doctor who treats themselves has a fool for a patient and an idiot for a doctor.
So in the end, do I recommend honey and sugar? Yes. The literature is interesting and I give patients a long list of caveats. It is maybe sort of probably useful in patients with chronic wounds who cannot afford other interventions. In my experience it always works. Back to TAM.

Are Berries the New Snake Oil?
Are berries a superfood? No, they’re just good for you, like all fruit.
Steven Novella on August 8, 2012
Link
I have nothing against berries. I, in fact, enjoy many kinds of berries in my diet. My favorite fruit, the banana, is actually a berry (botanically speaking). I am disturbed, however, at the extent to which various kinds of berries are being sold as the latest superfood cure-all.
Dr. Oz, for example, has been pushing the lingonberry (a relative of the cranberry and blueberry) as “a new superfruit for longevity.” An attached article on his site states:
“Today, scientists are showing its value in both human and animal studies that are proving to have positive results.”
Curiously, there are no links or references to these studies.
Polyphenols and antioxidants
We are still in the midst of the “antioxidant craze” – if you read the justification for just about any so-called “superfood” or longevity supplement you are sure to read about antioxidants. I have already covered antioxidants, but briefly: Cell metabolism in part creates oxygen free radicals which are molecules that steal electrons from other molecules, causing a cascade of reactions that can damage proteins and other chemicals in the body. Anti-oxidants are chemicals that can stop free radicals and limit the damage. They therefore decrease “oxidative stress” on cells. So far it sounds like anti-oxidants are therefore a good thing and we should be gobbling up as much as we can. However – free radicals and anti-oxidants exist in cells in a homeostasis. Free radicals are used by the immune system, for example, to fight invading organisms. They are also important signaling molecules, triggering other cell-protective mechanisms.
Therefore, taking large amounts of anti-oxidants and disrupting this normal balance may not necessarily be a good thing. I’m not saying it’s necessarily a bad thing, we just don’t know. You cannot extrapolate from pre-clinical data – essentially looking at what happens to various molecules and cell functions – to clinical claims. The role of free radicals and anti-oxidants in the body is too complex for us to extrapolate to net clinical effects. At best the existing data might suggest the potential for a clinical effect, but in order to know we would have to do properly designed clinical studies.
A researcher observed in a recent article:
“Antioxidant therapies have been evaluated in placebo-controlled trials involving tens of thousands of patients. Despite pathophysiologic, epidemiologic, and mechanistic data suggesting otherwise, these clinical trial results have been, to date, mostly negative in the setting of chronic preventative therapy.”
He goes on to speculate that perhaps we have not used the right antioxidants, in high enough dose, for long enough a period of time (the usual special pleading heard after negative trials.) Or – perhaps they just don’t work. Perhaps pathophysiologic, epidemiologic, and mechanistic data can be misleading. At best they can provide plausibility and prior probability, but in the end we need rigorous clinical trials.
This is because one tiny fact of metabolism that we might be missing can undo all the pathophysiological plausibility of hundreds of studies. The history of modern scientific medicine is festooned with a massive trash heap of therapies that were highly plausible in animal and in-vitro studies, but failed in rigorous clinical trials. This history should be humbling. It should motivate the intellectually honest doctor or scientist to avoid making grandiose claims such as increased longevity or disease prevention because of interesting preclinical data.
Polyphenols seem poised to be the next anti-oxidants. Berries have polyphenols (which themselves are antioxidants) and other antioxidants, which is partly why there is a stream of superberries hitting the health food market. Oz, for example, touts the health benefits of berries and cites cranberries for urinary tract infections as an example. It is true that cranberries likely have some benefit in preventing UTI, but the clinical studies have been problematic. A recent review concludes:
Meta-analyses have established that recurrence rates over 1 year are reduced approximately 35% in young to middle-aged women. The efficacy of cranberry in other groups (i.e. elderly, paediatric patients, those with neurogenic bladder, those with chronic indwelling urinary catheters) is questionable. Withdrawal rates have been quite high (up to 55%), suggesting that these products may not be acceptable over long periods. Adverse events include gastrointestinal intolerance, weight gain (due to the excessive calorie load) and drug-cranberry interactions (due to the inhibitory effect of flavonoids on cytochrome P450-mediated drug metabolism). The findings of the Cochrane Collaboration support the potential use of cranberry products in the prophylaxis of recurrent UTIs in young and middle-aged women. However, in light of the heterogeneity of clinical study designs and the lack of consensus regarding the dosage regimen and formulation to use, cranberry products cannot be recommended for the prophylaxis of recurrent UTIs at this time.
So perhaps there is some benefit in young to middle-aged women, but not other groups. But there is a suggestion that most people cannot maintain the diet for long. Further, taking regular high doses may cause interactions with prescription drugs (I didn’t see that on Oz’s website). In the end, the utility of cranberries for UTI prevention is questionable and problematic. Even if there is an effect, there are problems with compliance, side effects, and dosage.
This, of course, brings up a generic point about so-called nutriceuticals – foods as drugs. It’s difficult to regulate bioavailability, dose, and other factors when food is the drug delivery system. Further, there may be unintended consequences of altering the diet in order to maximize certain nutrients. Berries, for example, are high in calories and sugar.
The flavonoids mentioned in the review above, that can cause interactions with drugs, are a class of polyphenols. They have other potentially negative effects, such as impairment of glucose metabolism. The combination of high calorie, high sugar, and impaired glucose metabolism is not a good one, especially for diabetics. The net clinical effect of this has also not been studied adequately, but it’s just as plausible as any alleged beneficial effect.
Conclusion: Berries are fruit, not miracles
Metabolism and biology are complex. That may seem like an obvious statement, but it bears repeating. In the US and many other countries there is little to no regulation of food and supplement health claims. In the US we have DSHEA, which allows for companies to make health claims without any burden of proof as long as they don’t claim to treat or cure specific diseases. We therefore have a health food and supplement industry that aggressively markets a never-ending sequence of new products with amazing health claims (either direct or implied). Some of this is simply made up, but much of it is extrapolated from basic science – which gives it the marketing appeal of sounding as if it is supported by scientific evidence. The problem is magnified when celebrity doctors, like Oz, promote these products without providing the background information to put them into the proper perspective.
Chances are most of these products are simply useless, but some may even be harmful. In most cases we lack rigorous clinical trials to understand what the net clinical effects of specific products, foods, and diets in specific populations actually are. In the last couple of decades we have seen the rise of noni-juice, acai berry, pomegranate products, blueberries, now lingonberries, and others – all with amazing claims and a simplistic and over-hyped narrative that is not supported by the science. That is the very definition of snake oil.

A Popular Home Remedy Causes Severe Burns in Pediatric Patients
Garlic has been used medicinally for thousands of years, but the evidence for benefit isn’t great. And topical use, particularly in young children, can cause severe burns. Stick to using garlic as a recipe ingredient rather than as a remedy.
Clay Jones on October 28, 2022
Link

I often write about the potential direct and indirect harm that can come from the various forms of so-called complementary/alternative/integrative medicine. I have even discussed several cases where children have suffered serious injury or even death, but I can count on one hand how many times I have encountered such a patient myself. Sadly, my streak was recently broken by a case of severe chemical burns caused by the well-meaning application of garlic paste to the skin of a child with a presumed fungal infection.
This won’t be the first time that a discussion of garlic has graced the pages of Science-Based Medicine. It’s a popular remedy that is frequently recommended by naturopaths and well-meaning friends and families for a vast array of complaints, after all. The evidence in support of any true medical benefit, as discussed by our own Scott Gavura back in June, is lacking. I will say, however, that the evidence in favor of culinary efficacy is definitely trending positive, though this is an entirely subjective assessment.
Scott’s post focused on systemic garlic taken in the form of supplements for medical concerns such as heart disease, diabetes, infections, and even allergies. And while there is some potential benefit when it comes to the first two on that list, the evidence so far is flimsy and don’t justify recommendations for that purpose. Topical applications are another common way that garlic is used for medicinal purposes, and one in which the risk to benefit assessment is vastly more problematic.
Topical garlic is typically recommended for a variety of skin ailments because of it’s antimicrobial and anti-inflammatory properties, which are real…in a petri dish. They just haven’t been proven to equate to clinical benefit in humans. The internet is full of articles recommending topical garlic preparations based on those properties, however. This one from Perfect Image is fairly representative and claims that topical garlic can help with alopecia, warts, fungal infections, psoriasis, keloids, corns, and leishmaniasis.
The above article at least does mention the possibility of allergic and irritant dermatitis, though it leaves out the possibility of 2nd degree burns in children. Thankfully the specific recommendations for how to apply the garlic they discuss, with short exposure times and absent occlusive wrappings, are unlikely to cause any severe injuries even if used on a child. Not all online resources are as careful about recommending topical garlic. This one from Medical News Today recommends a lengthy exposure and gauze wraps, and also doesn’t mention the possibility of severe injury.
Walnut Creek Naturopathic, among others, recommends intravaginal garlic for yeast infections:
A garlic clove can also be inserted into the vagina to kill the yeast off locally. Peel the garlic clove carefully, so as not to nick it, and insert it vaginally at bedtime for 6-8 hours. You can also thread the garlic like a necklace for easy removal. Otherwise, the garlic may occasionally be harder to remove. Relax. It is in there somewhere! In all seriousness, it can sometimes tuck itself behind your cervix. Bearing down as if you are having a bowel movement while searching for it usually does the trick.
I’m not a gynecologist, but Dr. Jen Gunter is and she isn’t a fan of garlic for yeast infections:
“My advice,” Dr. Gunter tweeted, “do not take medical advice from anyone recommending vaginal garlic for yeast or anything else.” There’s a big difference, she explains, between garlic demonstrating antifungal properties in a petri dish in a lab and garlic clearing up a pesky yeast infection. “Your vagina is not a dish of cells,” she wrote.
To be fair, many of the websites, naturopathic practices, and comment sections on parenting blogs don’t specifically recommend topical garlic use in a way that is likely to cause harm. They shouldn’t be recommending it at all, of course, but the other big problem is that most don’t specifically recommend against the harmful ways of doing it either. So parents and caregivers are left up to their own devices to figure it out, and unfortunately some end up figuring that if a little is good, a lot must be even better. It isn’t.
Garlic contains many chemicals that can cause physical reactions in the human body, some potentially beneficial and others decidedly not. It is widely known, for example, that some people can develop a topical allergy to garlic, which is not uncommonly seen on the hands of chefs and home cooks working with raw garlic. Diallyl disulfide, allyl propyl disulfide, and allicin are the chemicals in garlic considered to the be the likely culprits when it comes to these allergic reactions.
Diallyl disulfide, particularly when the skin is exposed for several hours or longer and held tight by some kind of occlusive wrap, can cause an irritant dermatitis as well. This can evolve into blisters and severe chemical burns, with young children being at the highest risk because of a thinner outermost protective layer of skin called the stratum corneum. So the younger the child, the shorter the exposure time needed to cause a chemical burn.
In the case of my patient, I can’t go into any specific details. But their presentation was consistent with the handful of case reports of severe garlic burns that have been published, the first being in 1987. When the area of involved skin is large, patients with severe burns regardless of the cause require care in a specialized burn unit where expert attention can be paid to maintaining hemodynamic stability, preventing secondary infections, treating pain, and improving long-term cosmetic outcomes.
The bottom line here is that there is not compelling evidence to support the use of garlic for any medicinal purpose. When taken systemically in the form of a pill, or even applied topically for a few minutes here and there, garlic is pretty safe. Still, a rational assessment of the benefits and the potential risks isn’t favorable. I recommend sticking to culinary use.

   The Annals of Internal Medicine Qualifies for Fail Blog.
Mark Crislip
Link
As most readers of the blog know, I am mostly an Infectious Disease doc. I spend my day diagnosing and treating infections and infectious complications. It is, as I have said before, a simple job. Me find bug, me kill bug, me go home. Kill bug. It is the key part of what I do everyday, and if there is karmic payback for the billions of microbial lives I have erased from the earth these past 25 years, my next life is not going to be so pleasant. I will probably come back as a rabbit in a syphilis lab.
It is always fun when my hobby, writing for SBM, crosses paths with my job. This month the Annals of Internal Medicine published “Oseltamivir Compared With the Chinese Traditional Therapy Maxingshigan–Yinqiaosan in the Treatment of H1N1 Influenza. A Randomized Trial.”
I though big pharma was good at coming up with names I do not know how to pronounce. If someone could provide a pronunciation guide in the comments, it would be ever so helpful, so I will not have to embarrass myself when this entry becomes a Quackcast. Dr. Hall wrote about this article on Tuesday, and I have avoided reading her post until this one is up, so there may be overlap in what is discussed.
What is Maxingshigan–Yinqiaosan (MY)? Twelve herbs, one better than the Colonel (and speaking of pronunciation, why is it pronounced “kernel”?) but lacking the spices. It contains
zhimahuang (honey-fried Herba Ephedrae), 6 g; zhimu (Rhizoma Anemarrhenae), 10 g; qinghao (Herba Artemisiae Annuae), 15 g; shigao (Gypsum Fibrosum), 30 g; yin- hua (Flos Lonicerae Japonicae), 15 g; huangqin (Radix Scutellariae), 15 g; chaoxingren (stir-baked Semen Armeniacae Amarum), 15 g; lianqiao (Fructus Forsythiae), 15 g; bohe (Fructus Forsythiae), 6 g; zhebeimu (Bulbus Fritillariae Thunbergii), 10 g; niubangzi (Fructus Arctii Tosum), 15 g; and gancao (Radix Et Rhizoma Glycyrrhizae), 10 g.
Quite the melange of products. Could there be antiviral or immunomodulating molecules in such a hodgepodge? Certainly. There is no a priori reason that Maxingshigan–Yinqiaosan would, or would not, have efficacy against influenza or its complications.
The reasons to test MY are partly appeals to antiquity, “Traditional Chinese medicine has been used to treat seasonal influenza for thousands of years,” plus a reference that, upon searching, does not contain the word influenza. Or pneumonia. Or respiratory tract infection.
You have to wonder, when you are in the second paragraph of the introduction and looking up the primary sources and they do not match the text, just how careful the researchers and the editors of the journal are. It’s the Annals. Not very. Which is why my subscription lapsed. And, to demonstrate just how infantile I can truly be, when I discuss the journal with residents, I pronounce it as if it had one ‘n’. But do not accidentally type in the url at work with Annals spelled with one ‘n’; I discovered our firewall filter has an Anals.org weakness.
In Europe, pandemic influenza has been recognized for perhaps 500 years: “Then suddenly, in July and August 1510, a ‘gasping oppression’ with cough, fever, and a sensation of constriction of the heart and lungs began to rage, seemingly everywhere at once.” And local flu has been known for maybe 650 years. Given those numbers, “thousands of years” seems a wee bit of hyperbole, especially when the reference doesn’t support the assertion. And as best I can tell from the Googles, no influenza was reported in China until the 1800s, and given traditional diagnostic testing modalities, I doubt they were looking at patterns of disease that would be identified today as influenza.
Then they say
In a recent meta-analysis of 31 randomized clinical trials including 5514 cases of influenza, the authors concluded that TCM had significantly increased clinical efficacy compared with placebo or no intervention.
And that analysis was? A systematic review of chuanhuning for acute respiratory tract infections. Chinese Archives of Traditional Chinese Medicine. 2007;25:2200-3.
The abstract said “There were 31 RCTs with 5514 cases were involved.” 5514 cases of acute respiratory tract infections, not 5514 cases of influenza. Although I may be slapped down for this, as the original is in Chinese and there is nothing on the Pubmeds relating to chuanhuning.
Looking for the primary references of the systematic review as best as I could given the language issues, the Googles find “etiological diagnosis by clinical experiments and tissue civilization experiments show namely the product of inactivated influenza virus A type Ⅰ, Ⅲ type A, pneumonia, adenovirus (Adv) Ⅲ type, Ⅳ type, intestinal syncytial virus and respiratory syncytial virus (Rsv) have inactivation” and the few trials I could locate were for a hodgepodge of viral and other upper and lower respiratory infections.
Chuanhuning is not in the current regimen to be tested, and the authors of the systemic review mention “the evidence is not strong due to the general poor methodological quality.”
The argument, not supported by the references, for testing MY is: product A may work for influenza, so let’s try an entirely different product for influenza. Could the editors of the Annals be doing a worse job at reading the papers in their journals?
They then mention “Modern pharmacologic studies demonstrated that some TCM formulas had antiviral and immunomodulating effects (13, 14).” Reference 13 is Chen N, Ren L. [Modern pharmacology research and clinical use of max- ingshigan]. Academic Journal of Guang Dong College of Pharmacy. 2004;545-6. and reference 14 is Huang JM, Chen DP, Yang LP. [The immunomodulating effects of maxingshigan on asthma mice models]. Journal of Fujian Traditional Chinese Med- icine. 2003;34:38-9. At least both references have maxingshigan in the title, but whether the content matches the assertions, well, let’s say their credibility has not been demonstrated.
Of course, no study of “Eastern” medicine would be complete without the appeal to popularity:
During the early days of the 2009 H1N1 influenza A pandemic, the popular herbal formula maxingshigan–yinqiaosan was used widely by TCM practitioners to reduce symptoms.
Years ago, at conference, one of my attendings was being detailed about a new antibiotic, and the rep finished up with “and it is popular in Europe.” To which my attending replied “So was Hitler for a while.” A pre-Interweb version of Godwin’s Law.
Searching for Maxingshigan–Yinqiaosan in the Pubmeds yields little but the intriguing, yet unavailable, Two hundred and thirty-five cases of high fever caused by exopathogen treated with yinqiao maxing shigan tang.
I went through the tedium of searching each component of MY in the Pubmeds and its relationship to influenza and found nothing of note.
So the reason for the study, really, is that people were using it. Let’s see if it really works.
They randomized people with mild PCR proven influenza to
Oseltamivir, 75 mg twice daily; maxingshigan– yinqiaosan decoction (composed of 12 Chinese herbal medicines, including honey-fried Herba Ephedrae), 200 mL 4 times daily; oseltamivir plus maxingshigan–yinqiaosan; or no intervention (control). Interventions and control were given for 5 days.
Primary outcome was time to fever resolution. Secondary outcomes included symptom scores and viral shedding determined by using real-time reverse transcriptase polymerase chain reaction.
It was not blinded, only a small flaw given the endpoint, and most patients did not receive an intervention until relatively late in the disease, when the impact would be lessened
In our study, the median time from onset of illness to randomization was 34.5 hours; 23.2% of patients presented 48 to 72 hours after the onset of symptoms.
Sooner is better with the treatment of all acute infections, and given the delay in therapy, they are approaching a natural history of disease study more than a therapeutic intervention study.
They found
Significant reductions in the estimated median time to fever resolution compared with the control group (26.0 hours [95% CI, 24.0 to 33.0 hours]) were seen with oseltamivir (34% [95% CI, 20% to 46%]; P < 0.001), maxingshigan–yinqiaosan (37% [CI, 23% to 49%]; P < 0.001), and oseltamivir plus maxingshigan– yinqiaosan (47% [CI, 35% to 56%]; P < 0.001). Time to fever resolution was reduced by 19% (CI, 0.3% to 34%; P < 0.05) with oseltamivir plus maxingshigan–yinqiaosan compared with oseltamivir. The interventions and control did not differ in terms of decrease in symptom scores (P < 0.38).
The actual numbers: control had fever for 26 hours, oseltamivir for 20, the MY 16 and the oseltamivir plus MY was 15, in real numbers the results are almost clinically irrelevant. And the treatment groups were randomized later than the no treatment group, and temperatures measurement started at randomization. So if the treatment groups have a head start in temperature measurement, that wipes out at mostly of the therapeutic advantage doesn’t it? Most of the difference due to when they started counting.
If you measure from symptom onset to resolution of fevers, you get
Control: 56 hours
MY: 51 hours
Oseltamivir: 55 hours
MY plus oseltamivir: 47 hours
It is the duration of illness that is clinically the important feature, so even if the effects are statistically significant, the difference is not clinically significant. And besides fever, there was no improvement in other symptoms: “No difference in any individual symptom, including cough, sore throat, headache, or fatigue, was observed after treatment.” Fever often remits before other symptoms of influenza, and given the duration of illness, from a clinical perspective, none of the interventions did much of anything.
As to viral shedding
the median viral titer in throat swabs at enrollment was similar, and a rapid decrease in virus shedding was observed in all 4 groups (P < 0.001) Changes in virus shedding from baseline to day 5 did not differ by treatment group (P < 0.69 for time-by-treatment interaction).
Both baseline swab specimens and specimens collected on days 1 to 5 for evaluation of virus shedding were available for 148 participants. Compared with the 262 patients without viral shedding measurements, these 148 patients had lower symptom scores; a lower proportion of cough, headache, and fatigue; lower leukocyte counts; and longer time from onset of illness to randomization. Therefore, the virus shedding results from these 148 patients were not representative of the entire study population
But when you look at the actual curves,
Link
there is separation between the oseltamivir containing regimens and those without, with the MY closer to the control. It suggests that the effect of MY is anti pyretic/immunomodulatory rather than antiviral. And given that the control group started the PCR measurements earlier as well, yo would expect slighly higher viral levels. If there is an effect from MY, it is a small one, and it appears to be less antiviral and more antipyretic, although the authors state
The study could not determine whether the observed effects of maxingshigan–yinqiaosan were due to anti- pyretic or antiviral effects.
I bet the former.
Given that the patients were all healthy, had mild illness and were treated relatively late in the disease, I would expect to any intervention to have a modest effect, and theirs was modest indeed.
Non sequitur central continues in the discussion where they discuss potential mechanisms of action and note
During the outbreak of the severe acute respiratory syndrome in Hong Kong, Poon and associates (24) showed that 2 herbal formulas had immunomodulating effects. In their study of healthy volunteers, they found that the CD4 –CD8 ratio of T lymphocytes was significantly increased after participants received Chinese herbal medicine for 14 days (24).
The reference, Immunomodulatory Effects of a Traditional Chinese Medicine with Potential Antiviral Activity: A Self-Control Study, states
We investigated the immunomodulating effects of an innovative TCM regimen derived from two herbal formulas (Sang Ju Yin and Yu Ping Feng San) for treating febrile diseases.
I am limited by language, variability in TCM medications and lousy editors at the Annals, but apparently Sang Ju Yin is Mulberry & Chrysanthemum Pills and Yu Ping Feng San, or Jade Screen Teapills, and neither have any ingredients in common with MY.
Sang Ju Yin and Yu Ping Feng San has to do with the mechanism of MY how? That is the kind of discussion the Annals has for its readers: randomness. Linear, logical thought appears passé these days. The authors seem to think all TCM are the same, and there is no reason to differentiate one TCM over another for mechanism of action: “More studies are needed to clarify the mechanisms of TCM.”
Me and my reductionist Western approach, thinking that different products, with different constituents, are actually different, with perhaps different, unrelated mechanisms of action, if they have a mechanism of action at all.
There were articles, again not available in English, that demonstrate in vitro effects of shigan on influenza A. That the references indeed demonstrate what the authors purport, well, I will have to trust the researchers and the editors of the Annals. They have done a fine job to date.
It would appear from one abstract, that 31.25 mg/ml of maxing shigan had multiple effects on viral replication in the test tube and that 31.25 mg/ml was the optimal concentration of the product.
In the study patients received 200 mL of MY orally 4 times daily. So for fun, assume 100% bioavailabilty. Lets assume 31.25 mg/ml in the preparation the patients received. Who knows. 200 x 31.25 is 6250 mg. A human volume is about 70,000 mls. Assuming a uniform volume of distribution, that gives the concentration of MY at 0.089 mg/ml. Seems a wee bit below the needed MIC. Of course, a lot of assumptions in the calculation, mostly around the concentration of the medication, its absorption and the volume of distribution. The first and third were guesses, the second was probably a large overestimation (medications are rarely 100% absorbed). The real concentrations of MY are probably much less that 0.089 mg /ml.
50% alcohol will also inactivate influenza in vitro. Outside of a frat party, those levels are not achievable in vivo. Always the issue of going from in vitro to in vivo studies
The authors finish up with
In conclusion, in previously healthy young adults and adolescents who presented with uncomplicated 2009 H1N1 influenza A virus infection, therapy with oseltamivir and maxingshigan–yinqiaosan (alone and in combination) was associated with faster resolution of fever. Maxingshigan– yinqiaosan can be used as an alternative treatment of H1N1 influenza A virus infection when oseltamivir is not available.
and the abstract, which is all most people will read, ends with
These data suggest that maxingshigan– yinqiaosan may be used as an alternative treatment of H1N1 influenza virus infection
So here is where I am going to get picky.
My take, looking at the PCR data, is that MY does not treat influenza. There is no real change in the PCR viral concentrations. When you treat an infection, you kill it, or at least prevent it from reproducing. They did not treat influenza, they treated an epiphenomena of influenza, the fever. Treating fever is not the same as treating infection. And of course, it looks like the effect is an artifact of when they started counting, and given the lack of response of other symptoms, this is a mostly a natural history of influenza study.
And should you treat fever? Well, no. There is an interesting literature, with many a methodological issue, that suggests treating a fever is not a good idea.
In animal models and human studies, treating a fever is associated with prolonged illness and, depending on the study, increased mortality. There is no definitive study, but an hour of perusing the literature will show an interesting pattern. Fevers are usually good. Treating fevers is usually bad.
Fevers are an important and ancient response to infection. Most parts of the immune system function better at higher temperatures. Sometimes the patient lacks the physiologic reserve to cope with the metabolic demands of fever (poor cardiac or lung function) and strokes and heart attacks may be larger if the patient has a fever. So sometimes you need to treat fevers. But for most acute infectious diseases that have been evaluated, patients and animals that have their fever suppressed are have a more prolonged illness, more complications, or increased mortality.
I never treat my kids fevers. They make less noise when they are 102 and will probably resolve their infection faster if I let the fever go, and that will get them to school and me to work that much sooner. Of course, when my wife takes over, she gives them Tylenol. No man is a hero to his valet. Not that my wife is my valet. It is a saying.
I could find no specific data regarding outcomes in treating influenza associated fevers, but I expect like most other infections, it would be a bad idea. And there is always that point in the inflammatory response where the beneficial effects are overwhelmed by the adverse effects of too brisk a response: SIRS, sepsis, TSS and the ever popular cytokine storm, although the fever per se is not issue in those processes.
What annoys, and concerns me at the end, is the confusion between treating influenza and treating the symptoms of influenza. The first was not demonstrated, the second perhaps was and is usually a bad idea.
Conclusion
The effects of MY on fever are probably not real, and if real are mostly clinically irrelevant and probably counterproductive for the treatment of influenza.
As to the mechanics of the paper (proper use of references, critical thinking), if it were from a college student, I would give it a ‘C’. If it were from a resident on service? Flunk.
And the Annals? In my professional lifetime they have gone from a first tier journal to second tier to now? Now, I shed a tear. Almost as funny as Fail Blog.

   Testing a Chinese Herbal Flu Remedy
Harriet Hall 
Link
During the early days of the 2009 H1N1 influenza A pandemic, the popular herbal formula maxingshigan–yinqiaosan was used widely by TCM practitioners to reduce symptoms. (It’s hard to pronounce and spell, so I’ll refer to it as M-Y.) A new study was done to test whether M-Y worked and to compare it to the prescription drug oseltamivir. It showed that M-Y did not work for the purpose it was being used for: it did not reduce symptoms, although it did reduce the duration of one sign, fever, allowing researchers to claim they had proved that it works as well as oseltamivir.
“Oseltamivir Compared With the Chinese Traditional Therapy: Maxingshigan–Yinqiaosan in the Treatment of H1N1 Influenza” by Wang et al. was published in the Annals of Internal Medicine earlier this month. The study was done in China, which is notorious for only publishing positive studies. Even if it were an impeccable study, we would have to wonder if other studies with unfavorable results had been “file-drawered.” It’s not impeccable; it’s seriously peccable.
It was randomized, prospective, and controlled; but not placebo controlled, because they couldn’t figure out how to prepare an adequate placebo control. They considered that including a no treatment group compensated for not using a placebo control, and that objective temperature measurement could be expected to get around any bias. It might not: the nurses who took the temperatures were blinded to the study, but the patients were not. It’s possible that those who knew they were getting M-Y might have believed in it and their bias might have somehow subtly influenced data gathering so that M-Y appeared more equivalent to oseltamivir than it actually was.
There are other problems besides the lack of blinding.
Background
It’s always fun to read the introduction section of a CAM paper. It gives insight into the researchers’ beliefs and frequently includes footnote references to studies that don’t say what they seem to think they say. In their introduction, Wang et al. say
Traditional Chinese medicine has been used to treat seasonal influenza for thousands of years.
The article they reference to support that claim doesn’t support it. It is an opinion piece about “Chinese medicinal materials and their interface with Western medical concepts.” It’s not a historical study, and it doesn’t directly address influenza . Anyway, thousands of years ago TCM did not recognize influenza as a unique disease entity or have any way of diagnosing it accurately. And TCM does not equate to M-Y.
Next they cite a meta-analysis that they say showed the effectiveness and safety of TCM, but it was not about flu or about M-Y. It was about studies of common cold patients with wind-cold syndrome. It concluded
TCM new drugs developed in recent years for preventing and treating common cold have better therapeutic effects than the old ones. They can accelerate the onset time of lowering body temperature and improve the symptoms of common cold without any significant adverse reactions. Because of lacking of placebo-controlled and blank-controlled studies, further high-quality trials are still needed.
The abstract is too garbled to understand, but it indicates that if there was any significant effect of “TCM” it was very small in magnitude. Saying that a study of TCM for colds shows that M-Y works for influenza is like saying that a study of Western medicine for pneumonia proves that penicillin works for bronchitis.
Design
the decision about whether to initiate antiviral therapy is individualized on the basis of the clinician’s judgment and on what is known about the benefits of therapy. Therefore, it was ethically possible for us to include a control group that received no intervention.
If individual decisions are ethically acceptable, how can it be ethical to decide that a whole random group of patients will be consigned to treatment or no-treatment groups?
The new study had over 400 subjects and few dropouts. Patients were admitted to the hospital and followed closely. Viral studies confirmed H1N1 influenza. There were 4 arms: M-Y, oseltamivir, M-Y plus oseltamivir, and a no treatment group. Endpoints were both objective (temperature and viral shedding) and subjective (reported symptoms).
Results
Time to resolution of fever was significantly shorter in all treatment groups than in no-treatment control group, and was comparable in the different treatment groups. There were no differences between groups on symptoms or viral shedding. There was no difference in acetaminophen use between groups. Patients in the control group were more likely to be prescribed antibiotics, even though they acknowledge that physicians often respond inappropriately to persistent temperature elevations by administering antibiotics that are not called for in that situation. If they knew that, why did they allow it to happen?
Complications like pneumonia were rare and not significantly different between groups.
Side effects were incomprehensibly rare: Two patients reported nausea and vomiting while taking M-Y and there were no side effects in the other groups. This is puzzling, since studies of oseltamivir have shown a 9-10% incidence of nausea and vomiting with the drug and 3-6% with placebo.
They interpreted their findings as showing that maxingshigan–yinqiaosan does not act as an antiviral, whereas the benefit of oseltamivir derives entirely from its antiviral activity. Their data do not justify that interpretation.
The Mixture
When herbs are mixed, I always wonder how they decided which ones to use. In this case, maxingshigan studies have shown immunomodulatory effects, but what about the other 11 ingredients?
M-Y is a mixture of 12 herbs. In this study the herbs were tested to rule out contamination with heavy metals, insecticides, and microbes. The need for such testing brings up a concern: when patients buy M-Y on the market, what are they getting?
The 12 ingredients, as far as I could determine from the information in the paper, correspond to ephedra, anemarrhena rhizome, artemisia (wormwood), gypsum, honeysuckle, skullcap, bitter apricot kernel, forsythia fruit, peppermint, fritillaria bulb, burdock, and licorice. Only about half of these are listed in the Natural Medicines Comprehensive Database. For most of these, flu is not listed as an indication (although allergies and respiratory infections are sometimes mentioned), and most say there is insufficient evidence to rate safety or to rate effectiveness for any indication. Some include warnings: ephedra is unsafe and is illegal in the US; apricot kernels are a source of cyanide. It is hard to imagine a rationale for combining these particular 12 ingredients for any purpose, much less for flu. Maybe I lack imagination.
An appendix that lists Chinese and English names for the ingredients includes this helpful explanation:
Chinese herbs are usually prescribed in formulas that contain “king” medicines, which provide the strongest therapeutic action; “minister” medicines, which assist the “king” medicine in its therapeutic actions; “assistant” medicines, which aid the “minister” medicine in treating a lesser aspect of the disease; and “ambassador” medicines that are intended to reduce the toxicity of the other medicines in the formula or guide the formula to the targeted organ or region of the body.
They offer no justification for which ingredient has which of these purposes or how they knew whether they actually work for those purposes. These terms are not scientifically meaningful and are unexpected in a journal like the Annals of Internal Medicine.
Conclusion
Most patients with influenza recover with no specific treatment; but oseltamivir is often used with the goals of faster recovery, reduced symptoms and fewer complications. It is also used to prevent influenza. But it is far from perfect. Studies have shown that it reduced the risk of pneumonia and of pneumonia, fever, and viral shedding. Its symptom-reducing effects are not very robust, and it can have some side effects. It would be nice if we had a safer, more effective remedy.
They concluded:
Maxingshigan–yinqiaosan can be used as an alternative treatment of H1N1 influenza A virus infection when oseltamivir is not available.
I can’t really argue with that, but why not try to make oseltamivir available? Why not try to insure the purity and safety of available preparations of M-Y? More importantly, why not try to figure out what each of those 12 herbs does, whether all 12 are essential for its effectiveness, and whether worrisome ingredients like ephedra and cyanide could be eliminated?
It is admirable that TCM practitioners are trying to study their remedies scientifically; but this study doesn’t convince me that M-Y offers any advantage over oseltamivir, or even that it is a reasonable substitute.

How To Listen to Chi
Harriet Hall on July 14, 2015
Link


You will need flat shoes and a bottle of vitamins, herbal formula, or prescription medicine.
Step 1: Hold the bottle with both hands, touching your chest
Step 2: Stand up straight and get your balance
Step 3: Close your eyes and feel what is happening to your body.
Results:
If your body moves forward or stays neutral – going side to side – then whatever you are holding near your chest is okay for you. Your Chi matches.
If your body moves backwards – whatever you are holding is not good for you. Your body is repelling it. Chi is saying it doesn’t want that.
You can do this test on just about anything – a bottle of wine, foods, clothing. It’s easy to test and see if these things bring positive or negative energy to your body.
Oh dear, my Chi says it doesn’t match my new shoes. Guess I’ll have to take them back to the store. My body moved forwards when I held a bottle of rat poison; does that mean my Chi wants me to die?! My body swayed backwards when I held my new puppy against my chest; I guess my Chi wants me to take it back to the pound. I won’t do it! Fuck you, Chi! Pardon my language, but I love my puppy and that really made me angry.
No, seriously, how can anyone fall for such nonsense? Even if you thought it might be true, anyone who’s ever watched Mythbusters ought to know enough to set up a simple blinded test and bust that ridiculous myth all to smithereens.
Why does Restful Sleep™ hate puppies?
But apparently people are falling for it. The company that sells Restful Sleep™ is making enough money to pay for a half-page ad in USA Today, which is where I read those instructions. That can’t be cheap. No, it’s not cheap; I looked it up and a half-page black-and-white ad goes for $73,200. Apparently plenty of gullible consumers are spending their hard-earned money on a 2,000-year-old sleep remedy that Dr. Yan Ping Xu says produces healthy sleep by balancing the spleen Chi, which is the central train station for your entire body. Every organ is affected by spleen Chi. When it is not functioning properly, you may experience fatigue, anxiety, worry, restlessness, and poor concentration.
Testimonials. Exclusive low introductory price. Free shipping. 30-day, satisfaction-guaranteed, risk-free trial period. Not sold in stores! Déjà vu, anyone?
What are the ingredients?
Restful Sleep™ contains:
King herbs to nourish the Chi:
    • Asian ginseng
    • Atractylodes (which of the eight species?)
    • Astragalus (which of the 3,000 species?)
Queen herbs to support the King herbs and nourish the blood:
    • Longan
    • Dong quai
    • Jujube seed
    • Poria (a fungal genus that is no longer used)
    • Jujube fruit
Assistant herbs to calm the spirit:
    • Costus (which of the more than 100 species?)
    • Polygala (which of the many hundreds of species?)
Harmonizer herbs to bring balance to the formula and help moderate any harsh effects associated with other herbs:
    • Licorice
    • Ginger
Modern minerals (the Western approach [sic]):
    • Calcium
    • Magnesium
    • Potassium
And we can be sure this will help you sleep because…
It has the same exact ingredients in Yi-Fang that have been used for over 2,000 years! A Chinese healer says it supports the spleen! Customers say it works! There is even a “Science” tab (albeit with nothing even remotely resembling science). Doesn’t that inspire confidence that the claims are true?
Conclusion: Get a puppy instead
I won’t waste any more time on this. I just thought SBM readers would enjoy a laugh. I printed out what I had written, put it in a bottle, held it to my chest and closed my eyes. My body stayed neutral. So I know my Chi wants me to share it with you. You, too, can listen to your Chi. Have fun!

   Do calcium supplements cause heart attacks?
Scott Gavura
Link
Calcium is good for us, right? Milk products are great sources of calcium, and we’re told to emphasize milk products in our diets. Don’t (or can’t) eat enough dairy? Calcium supplements are very popular, especially among women seeking to minimize their risk of osteoporosis. Osteoporosis prevention and treatment guidelines recommend calcium and vitamin D as an important measure in preserving bone density and reducing the risk of fractures. For those who don’t like dairy products, even products like orange juice and Vitamin Water are fortified with calcium. The general perception seemed to be that calcium consumption was a good thing – the more, the better. Until recently.
In a pattern similar to that I described with folic acid, there’s new safety signals from trials with calcium supplements that are raising concerns. Two studies published in the past two years suggest that calcium supplements are associated with an significantly increased risk of heart attacks. Could the risks of calcium supplements outweigh any benefits they offer?
Why Calcium? Osteoporosis
Osteoporosis is a progressive bone condition of reduced bone mass and deterioration of bone tissue, and a correlating increase in fracture risk. 80% of those diagnosed are women. Hips and spines are the most common fracture locations, but they can appear in any bone, and osteoporosis makes fractures more likely. In postmenopausal women over the age of 50, the lifetime risk of a vertebral fracture is about one in three, and one in five for a hip fracture. Because they are so common, hip and vertebral fractures cause considerable aggregate and individual morbidity and mortality. So prevention and treatment are major health issues.
The initial strategy to preventing and managing osteoporosis is ensuring adequate calcium and vitamin D dietary intake, as both influence bone density. Calcium intake influences overall calcium balance: adequate vitamin D and calcium ensure calcium balance is positive. This occurs at about 1000mg per day in premenopausal women, and 1500mg per day in postmenopausal women not taking estrogen. The North American Menopause Society’s (NAMS) 2006 osteoporosis guidelines recommends [PDF] adequate calcium and vitamin D for all postmenopausal women, regardless of osteoporosis risk factors. The guidelines note that requirements increase with age owing to reduced absorption, and recommending adequate intake (preferably via diet) as the preferred sources. The 2010 Canadian guidelines [PDF] are similar, recommending 1200mg of calcium (diet and supplements) and vitamin D for all individuals over the age of 50. The Institute of Medicine recently updated its calcium and vitamin D guidelines (pdf) as well. It concluded with the caution that the consumption of levels beyond those recommended have not been shown to offer additional health benefits, and may in fact be linked to other health problems.
The effectiveness of calcium and vitamin D for the prevention and treatment of osteoporosis has been studied in both observational and prospective clinical trials. Wile there are data to demonstrate that calcium and vitamin D can prevent bone loss, the data on fracture prevention are much less convincing, with some trials showing no effect. Beyond density effects, calcium is also associated with generally positive effects on muscle strength, balance, and the risk of falls. So for most men and women with (or at risk of) osteoporosis, calcium and vitamin D are standard treatments. Given dietary intake in those at greater risk of osteoporosis may be below recommended levels, supplements are often used to meet recommended amounts.
The Safety Signals
Prior studies of calcium supplements have pointed to a possible relationship between calcium supplementation and cardiovascular events. Bolland et al specifically examined the relationship of calcium with the risk of heart attacks and cardiovascular events in a 2010 BMJ meta-analysis. It included all RCTs of calcium supplements (≥500 mg/day), with a study size of 100 or more participants, an average age over 40, and a duration of more than one year. Trials that included vitamin D as an intervention were excluded. 15 trials were identified: some with patient-level data, and some with trial level data. Analyses of both sets of data identified a significant increase in heart attacks in those randomized to calcium supplements. The trial-level analysis show a hazard ratio (pdf) of 1.27 with a 95% confidence interval of 1.01 to 1.59 (p=0.038). The patient level analysis revealed a similar hazard ratio for myocardial infarction of 1.31 (95% confidence interval 1.02 to 1.67, p=0.035). Overall, the analysis suggests that calcium supplements increase the relative risk of myocardial infarction by about 30%. Reassuringly, there were no statistically significant increases in the risk of stroke, death, or the composite endpoint of MI+stroke+death in either analysis. Based on the patient-level data, the authors estimated that treating 69 people with calcium for five years will cause one additional heart attack. The authors suggested that in light of calcium’s unimpressive efficacy against fractures, that calcium’s role in osteoporosis prevention and treatment should be reevaluated.
Time to stop the calcium? As noted above, the data to support the use of calcium supplements alone to prevent fractures are, on balance, unimpressive. And there are possible models for how calcium could be causing these harms: vascular calcification is a potential (though not proven) consequence that might be more likely in the elderly patients. However, given calcification can take years, and harms appear shortly after dosing starts, it could be a due to effects on carotid plaque thickness, leading to aortic calcificiation, and subsequent cardiovascular events. (Reid describes potential mechanisms for these harms in a2010 paper in Clinical Endocrinology.)
What happened after this paper was released? There were criticisms of the endpoints, and the fact the composite endpoint was not significant. Concerns were also raised that the trials included were not designed with cardiovascular endpoints – a valid criticism. And many pointed to the fact the studies excluded vitamin D, contrary to treatment guidelines and common use. Now the same group has done a new analysis, incorporating vitamin D. Bolland and associates followed up their calcium-only therapy with a study of calcium + vitamin D. They used the Women’s Health Initiative (WHI) dataset to answer the vitamin D question, added in some other studies, and redid their meta-analysis.
The WHI was a massive 15-year trial of over 161,000 women that sought to answer a number of questions about women’s health. The most well known components were the hormone therapy trials which changed our understanding of the risks and benefits of hormone treatments. The calcium and vitamin D study was a component of the WHI which randomized 36,282 postmenopausal women aged 50-79 into two groups. One group received 1,000 mg of calcium carbonate and 400 UI of vitamin D once daily, the other, placebos. Interesting in the design was that 54% of women were already taking calcium, and 47% were already taking vitamin D, and they were allowed to continue with their therapy, even after randomization. This meant that actual calcium and vitamin D doses women consumed varied from zero to substantially more than the intervention dose. The clinical question the study sought to answer was to understand the effects on fracture risk and the prevention of colorectal cancer — and the results were disappointing: no effects on colorectal cancer, and insignificant effects on fractures (though in a subgroup analysis of compliant patients, significant reductions in hip fractures were noted.)
Bolland sought to analyze the WHI data for cardiovascular effects, and then add these data into the previous meta-analysis. In the over 16,000 women not taking their own calcium and vitamin D, there was a significant increase (hazard ratio 1.22) in myocardial infarction noted in the group randomized to calcium and vitamin D (p=0.04, 95% CI 1.00 to 1.50). Similarly, significant effects were also noted in other composite endpoints. In contrast, women taking their own calcium and vitamin D didn’t show any changes in their cardiovascular risk when randomized to calcium and vitamin D. In addition, no relationship was found between calcium dose and risk of cardiovascular events.
The authors then pooled their own WHI analysis with two other studies of calcium and vitamin D where trial-level data for cardiovascular events were available: In total, over 20,000 participants could be studied. In this pooled analysis, calcium and vitamin D were associated with a significant increases in myocardial infarction (relative risk 1.21), stroke (RR 1.20) and a composite endpoint of both (RR 1.16).
Finally the authors combined the trial level data from their calcium-only meta-analysis with their trial level calcium plus vitamin D data:, resulting in a pool of over 28,000 patients across nine trials. In this analysis, there was risk increase of 1.24 (95% confidence interval 1.07-1.45, P=0.004) for myocardial infarction and 1.15 for the combined endpoint (1.03-1.27, P=0.009).
Difficult to interpret? Yep. The lack of effect of “personal” use of calcium on endpoints, and the lack of dose response, means this isn’t case closed for the clinical question. But the persistent and significant correlation between randomization to calcium, with or without vitamin D, and myocardial infarction, does concern me. There are a number of additional criticisms outlined in the editorial that accompanied the Bolland WHI analysis, and the keen reader is referred there for more.
Evaluation
Is it possible that calcium supplements can be causing harms that could outweigh their benefits? Yes, but the evidence isn’t clear enough to give an definitive answer. These data need to be factored into individual evaluations of diet as well as risk factors for cardiovascular disease and osteoporosis. I’d like to see these findings validated by other groups, as both meta-analyses came from the same group of researchers. The meta-analysis can be a very useful tool, but it’s not without its own limitations, as is often pointed out by the contributors to this blog. Interestingly, a 2010 meta-analysis, from a different group of authors, and using a different methodology, has come to a different evaluation of calcium. So the question remains an open one. More data may help refine our estimates of number needed to treat, and number needed to harm, to inform treatment decisions. And it should help guide advice for younger, premenopausal women, as well as men. So until more data emerges, my tentative recommendations to consumers are as follows:
    • Calcium supplementation has been associated with increased risks of cardiovascular events like heart attacks. Until there is more evidence to confirm or refute this association, it’s prudent to be cautious when taking calcium supplements.
    • No harms have been shown from calcium consumption via dietary sources. Efforts should be made to first meet dietary requirements through food products, before considering supplements.
    • Routine supplementation, in the absence of a dietary deficiency, is not necessary or advisable.
    • Calcium supplements may still be advisable for those with low dietary intakes, or those at risk of or being treated for osteoporosis. The risk-benefit assessment for calcium supplements needs to consider risk factors for both osteoporosis and for cardiovascular disease.
    • Vitamin D supplements are advisable for most people, and are recommended for the prevention and treatment of osteoporosis. The suggested doses of calcium and vitamin D may vary based on diet, medical conditions, and other considerations. Sources for target doses could include the IOM or recent osteoporosis guidelines (Canada) (USA).
Conclusion
The emerging safety data on calcium may yet become another cautionary tale about the unexpected and undesirable outcomes of targeted supplements. Until more evidence emerges, the safety of calcium supplements will continue to be questioned and debated. But that’s science-based practice: Data can be conflicting, messy, and difficult to interpret. There is always the possibility of unintended consequences when we make therapeutic decisions, and only by rigorously evaluating what we’re doing can we continue to improve the way we prevent and treat disease.
References
Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, & Reid IR (2010). Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ (Clinical research ed.), 341 PMID: 20671013
Bolland, M., Grey, A., Avenell, A., Gamble, G., & Reid, I. (2011). Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women’s Health Initiative limited access dataset and meta-analysis BMJ, 342 (apr19 1) DOI: 10.1136/bmj.d2040

   The latest chapter in the seemingly never-ending saga of dichloroacetate as a cancer treatment
David Gorski
Link
The road from an idea to a useful drug is a long one, and in cancer it is often particularly long. One reason is that to be able to tell whether a given treatment is effective against cancer often takes several years at a minimum, in order to determine if patients receiving the new treatment are surviving their disease longer than those who are not. Surrogate endpoints are usually not enough. Tumor shrinkage in response to a drug often does not correlate with prolongation of survival, although the converse (i.e., lack of tumor shrinkage in response to a new drug) does strongly correlate with failure of a treatment to prolong survival. In other words, effects observed on surrogate endpoints are not enough to judge whether a cancer therapy is working or not.
Three years ago, predating the existence of this blog by nearly a year, I became aware of a story that involved many of the issues in bringing a compound from the laboratory to the clinic. The case was unusual in that is is very rare to see the scientific process by which new drugs progress through the stages of cancer research, from concept to testing in cell culture to testing in animals to testing in humans challenged so strongly by patients themselves. The reason that this normally doesn’t occur is that new cancer treatments are almost always the product of either university-conducted research, pharmaceutical company-conducted research, or partnerships between the two. This case was markedly different in that it involved a chemical that was not only easy to synthesize, but cheap and long out of patent. Even more intriguing, it targeted a metabolic abnormality found in many cancer cells, an abnormality first described nearly 80 years before by Otto Warburg in 1928. This latter aspect of the drug gave it every appearance of a “rediscovery” of old wisdom that big pharma had ignored for 80 years, and that only added to its mystique.
The chemical was dichloroacetate (DCA), and three years ago it created a world-wide sensation. Last week, it created a sensation again, as breathless news reports once again overhyped its promise. Since I’ve been following the story since early 2007, I appear to be in as good a position as anyone to tell the story thus far and put the new findings into context. To begin that process, let’s head back to January 2007.
“The cure for cancer big pharma doesn’t want you to know about”
The DCA saga began in January 2007, when I started noticing a bunch of posts by various bloggers as well as news stories that all had similar titles, such as Cheap, safe drug kills most cancers, Objectively pro-cancer, Gotta pay, When promising cures are ignored, and, my personal favorite, Potential cheap, safe cure for cancer: Will Big Pharma Allow It? These stories described some intriguing work by University of Alberta researcher Evangelos Michelakis regarding this old/new drug that showed great promise in cell culture and rodent models of cancer (more on that shortly) that was published in Cancer Cell. Typical quotes I saved at the time:
    • “Big Pharma won’t put up the dough to fund human research and enable this drug to come to market, there’s no money in it. In fact, it wouldn’t surprise me to discover that they had an interest in actively preventing the research so as to maintain demand for more expensive less effective drugs. This drug looks to be extremely promising, and I can’t imagine that it won’t get government funding for human trials, but that said, it doesn’t pay to underestimate the power of Big Pharma…” (unfortunately the original link is gone, but the text lives on)
    • “And here I thought the pharmaceutical companies had to charge such high prices because of all the research they were doing. Seems without the possibility of future revenue they can’t be bothered. Of course, a cheap cure for cancer would cut into profits in so many ways, wouldn’t it?” (From Digby, who really, really should have known better, but didn’t.)
    • “It seems to good to be true. A cheap, effective cancer cure that BigPharma doesn’t own. If further research proves effective in humans, it could be the answer to many peoples prayers. I’ve always thought something simple, rather than the current convoluted regimen of surgery, radiation and chemicals would be the cure for cancer. Again, if proven effective, will we ever see it in use in this country? Will patients have to take ‘DCA tours’ to Canada for treatment?” (Source: Randular’s diary.)
    • “Here’s the big catch. Pharmaceutical companies probably won’t invest in research into DCA because they won’t profit from it. It’s easy to make, unpatented and could be added to drinking water. Imagine, Gatorade with cancer control.” (Source; this particular editorial was truly overwrought.)
    • “My bet is that the dichloroacetate news will fade into the background very quickly. Because neither the US government, nor any major university, nor any private company (pharma or otherwise) will have the least bit of interest in funding further studies. There will be a small handful of tiny, underfunded studies, and that will be that. Indeed, already those with vested financial and personal prestige issues will be doing their best to put the brakes on anyone who takes this development seriously. Not because the megacomplex of big government and big business wants to kill people–it doesn’t, there are few if any mustache-twirling villains–but because of the age old factors of bureaucracy, personal pettiness, ego, and conflicts of interest.” (Source: Dean Esmay, scroll down for post.)
Note that there were two assumptions here three years ago. First, these bloggers and pundits assumed that the cell culture and animal work were definitive evidence that DCA might be a “cure” for cancer. Second, the assumption was that, because the drug was out of patent and very cheap to make, neither the government nor pharmaceutical companies would be interested in funding it, thus condemning thousands, maybe millions, of people to die of cancer unnecessarily. Unfortunately, the New Scientist article and articles in the Edmonton Sun featured headlines to that effect and quotes by the investigator Evangelos Michelakis lamenting how he had had difficulties finding funding to do the next step, clinical trials in cancer. As a result of these sensationalistic stories, unscrupulous “businessmen” sought to bring DCA to the masses.
DCA and the Warburg effect
DCA is a very simple molecule, deceptively simple. Basically, it is an analog of acetic acid in which two of the three hydrogen atoms of the methyl group have been replaced by chlorine atoms. Interestingly, it is only one chlorine atom off from trichloroacetic acid (TCA), a chemical we routinely use in the laboratory to precipitate nucleic acids and proteins from solution. The structure of DCA is depicted below.
DCA has been around for a long time (which is why is it no longer under patent) and has primarily been used for inherited diseases of mitochondrial metabolism. Mitochondria are often (and correctly) referred to as the “powerhouses” or the “batteries” of the cell, because it is in the mitochondria that the main energy-containing molecule, ATP, is produced using byproducts of glycolysis and the Krebs citric acid cycle to generate a proton gradient across the mitochondrial membrane, which supplies the energy for the enzyme ATP synthase, which, true to its name, synthesizes ATP for use in the cell as a chemical source of energy. The key thing to remember about oxidative phophorylation is that it requires oxygen, whereas glycolysis does not. When there is insufficient oxygen, the end products of glycolysis end up being turned into lactic acid, which is one of the things that make muscles feel tired after a rapid workout that exceeds the capacity of the body to deliver oxygen to the tissues. The primary activity of DCA in cells is to inhibit the enzyme pyruvate dehydrogenase kinase. The result, to boil it down (and not to have to stress my knowledge of the basic biochemistry of glycolosis, the Krebs cycle, and oxidative phosphorylation too much) is to shift the metabolism of pyruvate from glycolysis towards oxidation in the mitochondria. To boil it down even further, DCA shifts the cell’s metabolism from anaerobic to aerobic metabolism.
The three components of glucose metabolism are shown below in simplified illustrations:
Why, then, would such an activity be useful as an anticancer therapy?
It all boils down to something known as the Warburg effect, which Otto Warburg first described way back in 1928 and reported in Science back in 1956. Over the last five years or so, cancer researchers have been increasingly coming to appreciate the role of abnormalities in metabolism, in particular the mitochondria, in cancer. To put it briefly, many cancers (approximately 60-90%) favor glycolysis, even in the presence of adequate oxygen for oxidative phosphorylation, leading to a voracious appetite for glucose. Indeed, it is this very avidity of cancer cells for glucose that is the basis of the PET scan, which detects the high uptake of a radiolabeled form of glucose by cancer cells relative to the surrounding normal cells.
Over the last few years, there has been a sort of “chicken or the egg” argument about what is more important and what is the first abnormality leading to cancer. The traditional view has long been that mutations in DNA lead to the activation of protooncogenes into cancer-initiating and causing oncogenes and to the shutdown of tumor suppressor genes. Under this model, mutations leading to cancer also lead to the observations of abnormalities in metabolism. In the wake of the DCA furor, there have been data reported suggesting that the metabolic derangements may actually occur first or simultaneously with the mutations. p53, for instance, the granddaddy of tumor suppressor genes, can trigger the Warburg effect when mutated. Whatever the case, it is now fairly clear that abnormalities in cancer cell metabolism are very important in driving cancer growth and could well represent targets for cancer therapy. AS a result of these new data, studying the metabolism of cancer cells has become a much hotter topic of research than it has been in the past. Everything old is new again, it seems. Why cancer cells might have an advantage due to the Warburg effect is a matter of debate, although, given how tumors frequently outgrow their blood supply, being able to maintain themselves in low oxygen situations would be advantageous.
This fascinating basic science met the public in January 2007, when Michelakis and his colleagues at the University of Alberta in Edmonton published a seminal paper in Cancer Cell. In the study, DCA was tested in multiple cell culture and rodent models of cancer. In rats, tumor weights in animals treated with DCA were approximately 60% lower than the tumors in the untreated control groups. The drug increased apoptosis, decreased proliferation, and inhibits tumor growth by acting on a critical enzyme that controls the switch between aerobic and anaerobic metabolism without harming non-cancerous cells. Even better, DCA had already been FDA-approved for mitochondrial disorders, meaning that using it in humans would be an “off-label” use of an already existing drug to test it in humans. Thus, the regulatory requirements were considerably easier to meet for early drug trials in cancer.
The “Pet DCA” phenomenon
The media coverage of the Michelakis study unleashed the proverbial perfect storm of conspiracy mongering about big pharma. Never before (at least that I can recall) had a chemical that was so cheap and so easy to synthesize, not to mention already used in patients for another indication, been reported as being a “cure” for cancer. This hype, of course, neglected what those of us who do cancer research as part of our living, namely that many are the candidate drugs that show a great deal of promise in animals but fail in humans and that at present there is no such thing as a “cure for cancer.” I like to think of the example of angiogenesis inhibitors, which I’ve been studying for 13 years now. Part of what attracted me to the study of these compounds were the amazing results of the late Dr. Judah Folkman in mice, which I’ve described on this blog before. However, the amazing results in mice did not translate to humans. That’s not to say that angiogenesis inhibitors don’t work, but in humans they did not produce anywhere near as dramatic results as they did in Dr. Folkman’s mouse experiments. That’s why, rather than being a “magic bullet” for cancer, angiogenesis inhibitors entered our armamentarium of anti-cancer drugs as a useful, but not miraculous, new addition. Avastin, for instance, has increased the five year survival rates in colorectal cancer metatastic to the liver and several other cancers, when added to the current standard of care, but it has not resulted in the cure of any metastatic cancer.
That being said, I can understand how cancer patients incurable with standard therapy would leap at this drug as their last hope. Unfortunately, there were unethical “entrepreneurs” who were more than eager to supply DCA to them. The most famous of these who appeared in the months following the publicity surrounding Michelakis’ study was a pesticide dealer named Jim Tassano, who leapt to create a website known as TheDCASite.com and BuyDCA.com (the latter of which appears to be unreachable at the moment). His way of getting around the FDA? To market his DCA as “Pet DCA,” to be sold for pets dying of cancer. It was as disingenuous an approach as could be imagined, because not only did Tassano openly admit that he knew that people were buying the drug for themselves but he blithely dismissed the possibility of serious side effects in adults. Although children could take the drug with few side effects, adults who took the drug often developed serious severe peripheral neuropathy. Since peripheral neuropathy is a side effect of some commonly used cancer chemotherapeutics, taking DCA with these cancer chemotherapies has the potential to do serious harm. Moreover, when asked about the source of DCA, the webmaster Heather Nordstrom replied:
In my opinion, it is not that difficult to get, but that may be because my step father has connections with manufacturers since we invent and sell tools for our family business. We know of a chemical company in China that makes DCA. It is pharmaceutical grade. More information on the quality and source will be posted on the website that sells it.
Naturally, I was…skeptical. Worse, scammers were hyping DCA as not being “chemotherapy,” when, if it works for cancer, that’s exactly what it is.
Meanwhile, cancer patients and their families flooded the discussion boards of TheDCASite.com to write about their self-experimentation. Here are a couple of posts that I saved (the DCASite.com purged many of its forums when it started to get into legal trouble):
My husband has been using DCA since early February. He has Glioblastoma, an aggressive brain cancer that DCA is proposed to target. The naDCA he is using was made in a private lab. We turned away from our medical community, realizing that we would not receive blessings from them, since they considered him a “dead man walking”. From what I have read here, my husband seems to be the earliest “labrat”. We obtained the DCA in early February, started at a 5% dose,(to test toxicity or side effects, I suppose) and after 4 days , he insisted on taking 25mg per kg. He takes a liquid dose twice a day( totaling 25mg per kg). He has been taking DCA since Feb 7, 2007, with full dose as of Feb 11. No side effects to report as yet. Though side effects of DCA(numbness in fingers and appendages) are also symptoms of his disease, there are none to report at this time. He is also taking 100mg per day of thiamine. He is also on CCNU, Heparin, and 16 mg steroid. So far, so good. I am taking weekly urine samples to check his billyrubin, ph , etc. He still sees an oncologist, and takes chemo( CCNU). His doctors do not know that he is taking DCA. I do not trust them, they have not been terribly compassionate through this, and I do not feel that they would be as knowledgable as those of us that are in these desparate situations. I pray for all of us that I can report great news in the weeks to come. I still can’t decide at this point if he should take THiamine or not? Any thoughts?
My thought at the time was that this woman’s husband was endangering his life by taking DCA along with his chemotherapy and not telling his doctors about it. Meanwhile, as time went on, someone on the DCASite actually questioned the anecdotes in May 2007:
Maybe I am crazy but it seems like every time I ask this question the admin removes it – if not then where is the question I asked last time?
I am asking this Question -
Do we want to know or not? is this a site for lies or truth? I have DCA and I also sent money in for the clinical trials as well as having my wife dealing with stage four lung cancer currently stable with antioxident regimens. Today we go in with DCA to see if her oncologist will support her using it.
Some news here would sure be great but NO ONE who has been CT scanned after using DCA for a couple months is talking or coming back except for squareb who gave us bad news. What is going on here? are we participating in a venting session where these folks are linked with those folks selling us DCA? what exactly is going on – our lives and our loved ones lives are on the line and not ONE CT SCAN in 4 months!!!! or the TRUTH is being removed from the site and people who had scans did post bad results so it was also removed like my questions are.
I am not happy about this admin – gee sorry I lost everything sorry – what? didn’t this happen last month on another persons testimony who DIED!! while using DCA. Something is definitely missing here and I am starting to think its THE TRUTH.
I believe in DCA but I am starting to think these admins are manipulating the information to suit them which is pretty typical for us trying to survive to run into. Sorry but these admins need to either post it ALL or explain why they are not allowing CT scan results to be listed on this site. Folks just think about it – Jan, Feb, March, April and now May – 4 months and nothing – come on folks lets get real here – do you really think its a coincidence?.
It is too bad that more people didn’t ask questions like this. squareb, by the way, was an early adopter of DCA whose tumor progressed on the drug.
Unfortunately, Jim Tassano wasn’t alone. For example, a family physician in Toronto named Dr. Humaira Khan, even though agreeing with the warnings not to use DCA outside the auspices of a clinical trial, decided to start selling DCA for $150 a week, using arguments of “health freedom” and wanting to “supervise” patients who would take the drug anyway. Dr. Khan’s webpage on DCA appears not to have been updated since 2008 but is claiming a high response rate. Odd, though, I haven’t seen this published anywhere in the peer-reviewed scientific literature, and a PubMed search turns up…nothing, at least nothing by Dr. Khan or anyone associated with her. Jim Tassano himself also tried to do a “clinical trial” of DCA that was basically nothing more than a questionnaire that–I kid you not–included questions like:
    • Do you think DCA is working for you? Why or why not? Scans? Examinations? Blood level testing? Here, I encourage you to freeform answer.
    • How do you rate your health compared to when you started DCA? 1. Much better; 2. Somewhat better; 3. About the same; 4. Somewhat worse; 5. Much worse
I trust that SBM readers will immediately recognize why such questions are worse than useless. Basically, they are doing nothing more than soliciting testimonials, and testimonials in cancer are often highly misleading, and that’s all TheDCASite has now. This is just as true for something like DCA as it is for any alternative medicine cancer therapies. Fortunately, in July 2007 the FDA finally acted to shut down TheDCASite.com, at least as far as selling DCA went. In response, Tassano shut down BuyDCA.com and morphed TheDCASite.com into an “informational” website. Much of what was on the forums there disappeared. Meanwhile, conspiracy theorists had a field day denouncing the FDA’s action.
Back to the future
Over the last couple of years, my biggest fear was that the activities of “entrepreneurs” like Jim Tassano would taint what is a scientifically fascinating and potentially very useful new cancer therapy with the indelible stain of quackery. DCA is most definitely not quackery. It is, however, unproven in humans and thus may not be effective, which is why self-treatment and treatment by doctors who have no clue what they are doing are not advisable. Fortunately, while ignorant businessmen like Tassano and opportunistic doctors were selling DCA to desperate cancer patients, a clinical trial was beginning by Michelakis and his team, and last week the results were reported in Science Translational Medicine entitled Metabolic Modulation of Glioblastoma with Dichloroacetate.
The first part of the study was something quite fascinating that I don’t recall ever having seen before in a clinical trial. Michelakis and colleagues studied 49 consecutive surgically excised glioblastomas. Glioblastoma is an aggressive form of brain cancer known to exhibit the Warburg effect and thus a good candidate for the first attempts at testing DCA in humans. These tumors were then tested in vitro with DCA. The excised tumors did demonstrate evidence of the Warburg effect, and treatment with DCA resulted in significant reversal of some of these features in the excised tumors, particularly mitochondrial hyperpolarization, while not having any effect on normal tissues excised with the cancers. The second part of the study is what most media and blog reports focused on. Michelakis treated five patients with neuroblastoma with oral DCA. However–and this needs to be emphasized–patients were also treated with temozolomide and radiation, with DCA added to the mix. The DCA dose started at 12.5 mg/kg orally twice a day for 1 month, and then the dose was increased to 25mg/kg orally twice a day. Michelakis then followed a dose de-escalation protocol, decreasing the dose by 50% when dose-limiting toxicity occurred. The patients were followed clinically for up to 15 months. In other words, this appeared to be a combined phase 0/phase I clinical trial.
For those not familiar with the various types of clinical trials, phase I clinical trials are not trials of efficacy. They are designed to determine two things: dose and dose-limiting side effects. They generally use a few patients (although five patients represent a rather small number, even for a phase I trial, which usually requires around 10 or 20), and it is not uncommon to perform a dose escalation. Researchers don’t expect necessarily to see tumor response in a phase I trial, as that is not the purpose of the trial, but it is heartening when tumor shrinkage is observed, for obvious reasons. Phase 0 trials similarly are not therapeutic trials but rather seek to determine if the drug is doing biochemically what it is expected to do based on preclinical studies. The usual design is to take a biopsy of the tumor, test it for biochemical markers in the laboratory, treat the patient with experimental drug, and then resect the tumor. The biochemical markers in the resected tumor are then compared with those measured in the pre-treatment biopsy. The idea is to see whether the drug can recapitulate biochemical changes in actual living tumors in human patients, the idea being that, if it can, then the drug is “hitting the target” (i.e., its molecular target) and therefore “working.” Whether its “working” actually shrinks tumors or results in prolonged patient survival is then the next question that has to be tested.
Michelakis went one further in that he isolated tumor cells from the pretreatment biopsies and produced glioblastoma cell lines. He could do this in three of the patients because he had tissue from their first debulking surgery, and these patients had recurrent glioblastoma that had failed additional chemotherapy (patients 1 through 3). All of them had had multiple rounds of different chemotherapy. Patients #1 and #2 showed signs of improvement or were at least stable for the full 15 months of the study, while patient #3 died three months after starting DCA therapy. Two other patients (patients #4 and #5) had new diagnoses, allowing initial tumor tissue from debulking surgery to be examined. Their treatment was somewhat different. After his first surgery, patient #4 underwent DCA therapy for three months followed by DCA and standard therapy. However, by the end of the third month, the patient showed evidence of progression requiring a second operation. Patient #5 underwent surgery followed by DCA and radiation with temozolomide for six months and then stayed on DCA for nine more months and is doing well.
The reason I mention this is because not only were there only five patients, but they were not all even treated the same way. They were treated with varying regimens of surgery, with drug therapies combining DCA and chemotherapy (mostly temozolomide), some with and some without radiation. Even so, the tissue from these tumors showed signs of metabolic reversion to an oxidative phosphorylation phenotype. The problem is, as both our very own David Kroll pointed out, we don’t know for sure if the DCA was responsible for this effect. As a cancer researcher, I can’t say whether the regressions observed were due to DCA, although the regression of paraventricular masses in patient #1 and the regression observed in patient #5 are certainly fairly suggestive (at least to me) of an anti-tumor effect due to DCA alone. The only side effect Michelakis reported was a reversible change in peripheral nerve function.
So what does this all mean?
I’m frequently asked why we shouldn’t just use DCA now–or even let people use it the way that they were using Jim Tassano’s homemade DCA? What’s the harm? That’s a rather difficult question, because there is always a conflict between wanting to do something now for suffering patients, damn the consequences, and following the scientific method to demonstrate efficacy and safety. Our nation has been at both extremes. Indeed, until 1906, pharmaceutical companies could make essentially any claims and sell essentially anything to the public as a drug without regulation. We all know how well that worked out. Early in the history of the FDA, as Dr Jerome Groopman points out, companies often tested new drugs by sending them to doctors to offer to their patients, asked for little information regarding side effects and complications, and had no standard criteria for efficacy. There was a reason we moved away from such a system.
I think Dr. J. Leonard Lichtenfeld, Deputy Chief Medical Officer for the national office of the American Cancer Society, put it well in writing about this latest DCA study on his blog, Dr. Len’s Cancer Blog:
This research still needs lots of work before we know whether it works or doesn’t work, and whether it is really safe or not when given to patients with cancer under a variety of circumstances.
If that sounds overly cautious, so be it. I have seen too many dashed hopes in my medical career which make me a bit cautious about reports like this. That’s not to say I don’t think it could work—it could, as I mentioned above—but I want to see evidence in well done trials that prove the point that DCA is effective in the treatment of which cancers under what circumstances.
Early in my cancer training there was a substance isolated by a researcher that was supposedly non-toxic and would cure leukemia. The research center where I was working was inundated from people around the globe who wanted this treatment, especially after the lead researcher injected himself on a nationwide morning show to demonstrate its apparent lack of toxicity.
Only grams of this medicine existed. Fortunes were offered in return for getting this miracle drug.
But the miracle drug—after reasonable clinical trials were done—didn’t work after all.
Many are the lists of new “miracle cures” that have met this same fate. The difference today is that the Internet has allowed news of these drugs to be disseminated to more people than ever before–and faster than every before. Moreover, it has linked patients and activists into mutually supportive disease-specific communities, who can inform and educate each other, as well as publicizing research about their disease and lobbying legislators. The dark side of this power, however, is that it can facilitate the spread of false hope and the demand for a drug after only cell culture and animal work, before it even makes it to human trials. Add unscrupulous “entrepreneurs” into the mix, and the potential for harm is great.
One has to remember that cancer is not just one disease. Not only that, but even a single type cancer is often not just one disease. As I have written extensively about before, cancer is incredibly complex. Because of that complexity, it’s incredibly unlikely that any one drug will be any sort of “magic bullet” to cure cancer. Worse, simply using a drug like DCA outside the auspices of well-designed clinical trials will virtually guarantee that we will never know for sure whether the drug actually works. Because of that, as frustrating as it is, as slow as it is, letting science take its course to determine if DCA works, how it works, and for what cancers it works, is the best method to make sure that the most patients are helped and the fewest are harmed. I don’t say this because I want DCA to fail; I say it because I would very much like to see DCA succeed.

Dr. Seeds’ Chill Pills
Dr. Seeds sells a Chill Pill to treat stress and anxiety. There’s no scientific evidence.
Harriet Hall on June 23, 2020
Link

Dr. Seeds’ Chill Pills are said to be “meditation in a bottle”. They allegedly relieve stress and anxiety. Is meditation a cure for anxiety? If so, it requires a lot of time and effort. Wouldn’t it be great if you could get all the benefits of meditation by simply swallowing a pill? What does the scientific evidence say?
Scientific studies lacking
The active ingredient in Chill Pills is dihydrohonokiol-B (DHH-B), a derivative of magnolia bark. Magnolia bark has been long used in traditional medicine for a large variety of conditions, from asthma to anxiety. There have been a few human clinical studies of various magnolia formulations, but they were only small pilot studies. A search of PubMed for dihydrohonokiol-B yielded only three in vitro studies in cultured mouse hippocampal cells. There is also a study of a related compound, honokiol, measuring its behavioral effects on rats in an elevated plus-maze test. Prolonged time spent in the open arms of the maze “suggested” an anxiolytic effect. (But rats can’t tell us if they feel anxious; there might have been another explanation for their behavior.) There are no clinical studies of DHH-B in humans.
What is it supposed to do?
Amazon sells it for what amounts to $2.50 per pill. They say,
    • LIVE WITH A CALM SENSE OF SELF – Let go of feelings of stress and anxiety and float into a new calm sense of self. With Dr. Seeds Chill Pill envelope your body in the positive mood you deserve to be in.
    • BACKED BY SCIENCE – The team at Dr.Seeds established the Chill Pill as the go to mood support to boost feelings of calm support and let go of stress and anxiety
    • SAFE & EFFECTIVE SUPPLEMENTATION – Dr. Seed’s Chill Pill is made right here in the USA, within a GMP-certified facility. High absorption and potency makes this formula an essential in letting go of stress and anxiety
    • STRESS RELIEF SUPPORT PILLS – With our 30 day supply of stress relief capsules. Dr. Seeds Chill Pill will alleviate anxiety, boost positive mood, and enable you to chill.
    • SEEDS SATISFACTION GAURANTEE – Experience a calm, happy boost with our mood support supplement. We are so confident in our product and research that if you don’t like it simply reach out and we will provide you with our 100% money back guarantee.
From the customer reviews, it is apparent that people are using it for anxiety, panic attacks, and insomnia. Some customers claim it is effective; others say it didn’t work. That’s just what we would expect from an ineffective product that elicits only subjective placebo responses.
On Dr. Seeds’ website, there is a link to “read more about dhh-b’s study”. The link is to this 20-year-old study that compared the “anxiolytic-like” activities of honokiol, diazepam, and various honokiol derivatives in mice. Both diazepam and DHH-B were more effective than the other derivatives in prolonging time in the open arms of the maze. That’s good to know if your intent is to improve maze performance in mice, but it says nothing about the efficacy of DHH-B in humans.
That study did have some interesting information about the pharmacokinetics:
The label for Dr. Seeds’ product says it contains 7.5 mg per serving, and the various ads claim it provides relief in less than 20 minutes or provides “instant relief.”
It does not say how long the effect lasts or how soon the dose can be repeated. The advertising for Chill Pills is inconsistent with the pharmacokinetics demonstrated in the mouse study.
Is this product safe?
There is no information about DHH-B, but magnolia bark has been reported to cause side effects. It may cause bleeding and should not be used prior to surgery or when taking anticoagulants. Due to lack of information, it should be avoided during pregnancy and breast-feeding.
Who is Dr. Seeds?
He is an MD, a board-certified orthopedic surgeon who specializes in sports medicine and total joint treatments. He claims to be the world’s leading authority on peptide therapies. On his “about” page he claims to have “consulted, trained, or operated on” athletes from the NFL, NBA, Dancing with the Stars, and other groups. Under “board certifications”, the items he lists are not board certifications at all. He says supplements are essential, and he sells a variety of his own supplement formulations, for instance “Thyroid Support” for all-day energy and “Body Protective Complex” for recovery from aches and pains. On his blog, he advocates all kinds of questionable treatments, including essential oils, IV vitamin C for Covid-19, inhaled hydrogen, nasal ozone (held in the sinuses, not inhaled), boosting the immune system, “optoceutics,” anti-aging remedies, and more. He believes water fluoridation decreases the IQ of children, and he lists 50 benefits of CBD. He has published no studies on dietary supplements. In my opinion, he is not a trustworthy source of health information.
Other chill pills
In addition to Dr. Seeds’ Chill Pills, Amazon sells a number of other products they call chill pills. Some of them are essential oils, others are mixtures of vitamins, minerals, and herbs. Elsewhere, magnesium, holy basil, taurine, and L-theanine are promoted for stress and anxiety. And then there’s Happy Saffron Plus. And Ayurveda offers daily oil massages and herbal remedies.
Then there are the real chill pills that have been scientifically tested and proven to work: benzodiazepines and antidepressants. And of course, cognitive behavioral psychotherapy can help.
Conclusion: probably just a placebo
        ◦ Chill Pills are not supported by scientific evidence. If you are suffering from stress and anxiety, they might produce placebo effects, but you would probably be better off consulting a science-based health care professional.

Product B: Here We Go Again
Harriet Hall on November 25, 2014
Link


New health products are constantly appearing on the market in such numbers that I can’t hope to keep up. Product B was new to me. I was introduced to it by a doctor who said a family member was “quite enthusiastic” about its potential to “lengthen telomeres and thereby address a myriad of health issues.” Of course, I immediately asked “What exactly are they claiming Product B does?” and “Do they have evidence that it actually does what they claim?” Their website didn’t provide satisfactory answers.
Product B is described as “a powerful blend of complex botanicals and vitamins uniquely designed to offer superior telomere support for youthful aging.” It is sold as part of a multilevel marketing (MLM) scheme. Because it is classified as a dietary supplement, FDA regulations only allow them to make “structure and function” claims, so the claims are deliberately nebulous. Basically, they seem to be saying that short telomeres are bad (they cause aging and disease), telomerase is good because it makes telomeres longer, and Product B is an effective way to increase telomerase; therefore Product B prevents disease and retards aging. But these assertions are questionable, and the website doesn’t offer any credible evidence of clinical efficacy for any single health issue, much less a myriad of them. Or any evidence of safety, for that matter.
Oh, good grief! It’s sold by the Isagenix company. Talk about déjà vu! Isagenix keeps coming back to haunt me; it even generated my favorite insult ever: “Dr. Harriet Hall is a refrigerator with a head.” You can read the three articles I wrote about Isagenix here, here, and here.
If I am a refrigerator, at least I try to be a fair one. I wasn’t going to reject the claims out of hand just because Isagenix made them. I spent quite a bit of time searching the Internet for information, and I even wrote the company to ask directly for their evidence. They didn’t bother to reply.
One thing puzzled me right off the bat. Was there a Product A that I had somehow missed? Why did they name this “Product B”? That doesn’t impress me as a savvy marketing choice. Couldn’t they have thought up something catchier like “Telomiracle”? I couldn’t help wondering what the B might stand for and my mind quickly associated the words bogus, blarney, business, baloney, bunk, bullshit, blunder, basura (Spanish for garbage), barbaridad (Spanish for stupid thing), and blague (French for joke). It made me think of second choice, as in “plan B.” What does it make you think of?
Pardon the digression. It makes no difference what they call it. “A rose by any other name…” All that matters is what it is and whether it works.
What’s a telomere?
Every chromosome has a telomere, a repeated sequence of nucleotides at the end of the DNA strand. It is a disposable section that carries no genetic information. For vertebrates, the nucleotide sequence is TTAGGG; this repeats from 300 to several thousand times according to the species of animal. Telomeres are sort of like the aglet, that little hard piece on the end of a shoelace that keeps it from unraveling. They protect the end of the chromosome and keep it from losing important genes or sticking to other chromosomes.
When cells divide, each strand of DNA is copied. The enzymes that carry out that job don’t actually make a perfectly identical copy: when they get to the end of the DNA strand, they are unable to copy all the way to the very last nucleotide, so every time a cell divides, the DNA is shortened. Some of those TTAGGG’s are lost. When enough of them are lost, the cell is kaput. The Hayflick limit is the number of times a cell can divide before it becomes incapable of dividing further, typically 40-60 times for human cells in cell culture in the lab. If your cells stop dividing, you die.
Telomerase is a reverse transcriptase enzyme that has its own RNA. It serves as a template to make more TTAGGG sequences and add them to the telomere, reversing the usual shortening process. Telomerase is active in cells that can’t afford to stop dividing: embryonic cells, the testicular cells that produce sperm, and stem cells; but it is not found in most adult body cells. So the hypothesis is that if you could make the telomerase gene express itself in somatic cells, the telomeres might not shorten with age, the Hayflick limit might be over-ridden, the aging process might be stopped in its tracks, and we might overcome natural death and become immortal. So far, this hypothesis is only a dream.
Telomerase is not always a good thing
There’s a downside: encouraging telomerase might be dangerous. Cancer is characterized by unregulated growth, and telomerase is active in 90% of human malignancies. We don’t want cancer cells to live forever. Drugs that reduce telomerase activity are being investigated as cancer treatments. So if Product B really increases telomerase activity, that might not be such a good thing. We might fall from the frying pan of the aging process into the fire of more cancers.
The role of telomerase in aging is still controversial. Short telomeres could be just a sign of cellular age rather than a cause. In at least one species of seabird, they are neither: telomeres become longer with age.
The Product B website says “Almost every known disease can be attributed to the shortening of telomeres.” That is demonstrably false. Well, maybe they “can be attributed” by someone who is willing to make false attributions; but there is no evidence that short telomeres actually “do” cause almost every known disease. In fact, it has not been conclusively established that they cause any disease. There are correlations, but science is still trying to tease out causation.
Questionable information
The website doesn’t provide much in the way of scientific evidence, but it provides the usual testimonials and a couple of slick video presentations. Aging is a complex subject not well understood by science, and the science of telomeres is still in its infancy. They grossly oversimplify and misrepresent the science with sound bites like “We age because our cells age, and our telomeres get shorter.” They say we are born with 10,000 telomere bases, and when we get down to 5,000 bases we begin to die of old age. No, it’s not that simple.
The videos feature William H. Andrews, “a world-leading researcher on telomeres.” They call him “the principal discoverer of RNA and protein components of telomerase.” I was unable to verify that. He is not listed as one of the authors of this study that identified the protein composition of human telomerase.
Elsewhere on the web I learned that Andrews started out trying to develop a pharmaceutical drug that would activate the telomerase gene. He tested thousands of compounds in vitro; some of them worked but were toxic. After his research funding dried up, he met John Anderson, a “nutritionist” with decades of experience in formulating nutritional products. Anderson persuaded him to stop trying to develop a pharmaceutical drug, to just bypass the FDA and market a diet supplement instead. Together, they formulated a diet supplement product and accumulated lots of testimonials about more energy, sounder sleep, feeling younger, etc. Andrews says:
I have never seen so many anecdotal testimonies for any product ever. [He has obviously led a sheltered life!] I am a pharmaceutical scientist by training. I believe in double blind placebo controlled studies. I believe that placebo effects occur but I have just never seen this many testimonials before. I strongly believe something is happening but I am not going to make any claims until the clinical studies are done.
Sound familiar? Maybe he’s not making any claims, but the Isagenix company is certainly managing to get the Product B message across to its customers despite the required FDA disclaimer. I’d bet that most of their customers believe they are buying a product that will lengthen their telomeres, retard aging, give them lots of energy, and make them feel and look younger.
What’s in Product B?
You can read the list of ingredients here. Basically, it’s a mixture of four vitamins with a proprietary blend of some 30 herbal products such as thistle, horny goat weed, ginseng, and green tea. Most of these have never been shown to have any effect on telomerase.
This 2012 review article covered “Pharmaceutical Regulation of Telomerase and Its Clinical Potential.” They report that a commercially developed telomerase activator molecule, TAT2, derived from the root of Astragalus membranaceous has been found to transiently activate telomerase in the lab in T lymphocytes that were not proliferating. They say it “could” prove useful, but “more work needs to be done to determine mechanism of action and safety.” Neither TAT2 nor Astragalus are ingredients of Product B.
In Table 1 of that review, they list all the phytochemicals that are known to regulate telomerase. There are only 2 known telomerase activators and 7 known inhibitors. Several of the inhibitors are among the ingredients of Product B, which is being sold to activate telomerase. Something doesn’t add up. I can’t see any rationale for the particular kitchen sink of ingredients in Product B. It seems like they just threw in a little of everything anyone had ever suggested might be good for you.
The review concludes:
Pharmaceutically inhibiting telomerase may prove an important option in cancer therapy in conjunction with traditional chemotherapeutics. Conversely, the activation of telomerase could be useful to treat age related diseases and HIV/AIDS patients where lymphocytes have stopped proliferating. However, the long-term effects of regulating telomerase either positively or negatively are unclear.
William Andrews was one of the authors of this study that tested the Astragalus derivative TAT2 as part of a complex dietary supplement protocol. It activated telomerase in vitro, and in vivo it produced a decline in senescent toxic T cells and killer cells, mainly in subjects who were seropositive for cytomegalovirus (CMV). Mean telomere length did not increase, but they interpreted the results as positive because there was a reduction in the percentage of short telomeres. This was an uncontrolled pilot study by researchers who had a declared financial interest in the product, and it gives us no useful information about clinical benefits. William Andrews was one of the authors and he also served as a subject. The financial disclosure statement reports that he is founder and president of a company that develops therapeutics for inducing telomerase expression and that the study was partly financed by his company.
A single study of Product B
But TAT2 is not in Product B. I found only one study that actually tested Product B. It was a randomized, placebo-controlled double blind study but was small (only 43 subjects) and was presented at a conference but has not yet been accepted for publication in a peer-reviewed journal. It found that Product B increased catalase activity by 30% in red blood cells. That doesn’t tell us much. Why did they measure catalase instead of telomerase levels or telomere length? One of the authors explained, “There is yet to be a direct measure of telomeres that is reliable enough for an accurate measurement of telomere length for obtaining statistical significance in a clinical trial.”
That sounds to me like a poor excuse. It can’t be that difficult to measure telomere length, since so many studies have done it; after all, that’s how we learned that telomeres shorten with age. And I know there is an accurate method to measure telomerase: the TRAP method (Telomeric Repeat Amplification Protocol) that most researchers accept and that has been used in many other studies.
Isagenix is not the only company selling products targeted at telomeres. “America’s number one anti-aging pioneer,” Dr. Al Sears sells UltraEssence, described as a “reliable telomere support supplement.” And the Geron company sells Imetelstat to inhibit telomerase and treat cancer.
Conclusion
There are lots of proposed anti-aging remedies, and there are even Longevity Clinics, but as far as I know, no treatment has yet been proven to slow the aging process or extend the human lifespan. There are only preventive measures to reduce the risk of premature death and to improve the likelihood of staying healthy while you age (exercise, weight control, smoking cessation, vaccines, screening tests, seatbelts, treating high blood pressure, etc.).
I wouldn’t go so far as to call Product B a scam, but it certainly is not supported by good scientific evidence. It is based on bold extrapolations from basic research along with speculation, unwarranted assumptions, and wishful thinking. There are lots of products out there with similarly unproven claims, for instance Protandim, which I wrote about here, here, and here.
My Plan A: remain skeptical of Product B and wait for Evidence E.

Brief Update: Protandim
Harriet Hall on March 13, 2012
Link
I’ve already devoted more time to Protandim than it deserves. I’ve written about it twice on SBM: here and here . But I can’t resist covering a new Protandim study that not only serves as a bad example but that made me laugh.
Protandim is a mixture of 5 herbal supplements intended to upregulate the body’s own production of antioxidants. Its patent application claimed that it was useful to treat or prevent an astounding 126 diseases and medical conditions, from tinnitus to aging, from hemorrhoids to cancer. At the time of my last article, only one human study had been done. It found increases in blood test markers and interpreted them as a surrogate for increased antioxidant activity in the body, but did not even attempt to assess whether those increases corresponded to any measurable clinical benefit, for cancer or for anything else. I begged Protandim supporters not to ask me about it again until there were human clinical studies with meaningful outcomes. 
Now there is finally a second human study, although still not one that qualifies as a clinical trial. Curiously, it is not listed on the company’s website. I wonder why? Perhaps because it showed Protandim didn’t work. Oops. 
Rationale
Most customers seem to be taking Protandim because of its alleged ability to prolong life, improve diabetes, prevent cancer, make them feel better, etc. Instead of studying any of those things, the researchers chose to study alveolar epithelial permeability.
In the introductory section of their paper, they explain that alcohol use disorders (AUDs) have been linked to the development of acute lung injury. They admit that the underlying factors are elusive and probably multifactorial. One potential contributor is the patients’ propensity for severe pulmonary infections mediated through abnormal pulmonary innate immunity. Additionally, they say that prior research had “suggested” an association between AUDs and abnormal alveolar epithelial permeability which “might” be mediated through pulmonary oxidative stress. So they did a double blind study, not to test whether Protandim would improve lung disease or reduce the rate of infections in alcoholics, but to see if Protandim would reduce markers of oxidative stress and normalize abnormal alveolar epithelial permeability. 
To recap their chain of reasoning: alcoholics might develop lung disease, that lung disease might be correlated with abnormal epithelial permeability, protein levels measured by bronchoalveolar lavage (BAL) might be a valid measure of permeability, permeability might be affected by underlying oxidative stress, and Protandim might reduce oxidative stress by stimulating the body to produce its own antioxidants. Do they perhaps think that lots of “mights” add up to a “mighty” argument?
Why would they want to study this particular mixture of 5 herbs? The second listed author, Joe McCord, has a vested interest: he is an officer of the LifeVantage company, the manufacturer of Protandim. They explain that Protandim is “a nutraceutical with a lengthy history of use in homeopathic, Ayurvedic, and traditional Chinese medicine.” An interesting statement, since Protandim was invented only a few years ago by a person with no medical background and it was patented in 2007. Doubly interesting since it belies the common myth that natural medicines are not profitable because they can’t be patented.
How many Protandim customers are alcoholics taking it for lung injury due to alcohol abuse? I would guess not many. Why on earth would they pick an esoteric detail like this to study and why would they look at Protandim’s influence on lab tests instead of looking for a useful clinical benefit?
Bronchoalveolar Lavage (BAL)
They randomized 30 alcoholics and gave 16 of them placebo and 14 of them a double dose of Protandim. There are some methodological problems: randomization was imperfect, with unequal numbers and some significant differences between the groups; some possible confounders were not eliminated (for instance, some of the subjects got intermittent benzodiazepines for alcohol withdrawal symptoms); and some of the blood tests were only done on smaller subsamples of the group. A separate small control group of 11 normal subjects also got a single BAL and their BAL protein levels were not significantly different from the AUD subjects, which sheds doubt on the whole rationale for the study by failing to confirm that alveolar permeability correlates with AUD. They did BAL twice on the AUD subjects, before and after a week’s treatment with Protandim or placebo. The utility of BAL is limited, since there is a large range of normal values for the substances measured and a number of confounding factors. Of more concern, this procedure is invasive, unpleasant, and far from benign. It requires the use of drugs for topical anesthesia and conscious sedation and can result in serious complications. It involves passing a bronchoscope deep into the lungs, wedging it into a lung segment, squirting in a small amount of saline, and then sucking out the liquid for analysis. In other words, putting water into the airways: sort of a partial drowning. With known risks and no possible benefit to patients, why did the Institutional Review Board approve it? I hope their consent forms were adequate, and I hope they paid their subjects well.
Results
They assessed alveolar epithelial permeability by measuring the total protein in bronchoalveolar washings. Total protein levels did not change in either experimental group. They also found no change in oxidative stress indices, epithelial growth factor, fibroblast growth factor, interleukin-1β, interleukin-10, liver function tests, or other blood chemistry tests. The one finding that was statistically significant was a significant decrease in plasma thiobarbituric acid reactive substances (TBARS), a marker of lipid peroxidation — but that was only in the placebo group!
In short, Protandim was significantly (p<0.01) worse than placebo. No wonder they’re not bragging about this study!
Why?
I really don’t get it. Why did they do this study? Why did they use twice the recommended dose? What was the IRB thinking? Why didn’t they study something with a useful clinical endpoint? As an e-mail correspondent said, “They make claims about diabetics being able to go off of insulin or reduce insulin…why not do a trial on that?” That’s an excellent point: a diabetes trial would not involve invasive procedures and would be far easier to carry out and far more meaningful. When advocates do esoteric, convoluted laboratory studies instead of straightforward simple clinical trials, it raises the suspicion that they believe at some level that such clinical trials wouldn’t help their case.
No, on second thought, I think I do get it: they want to prove, by any means possible, no matter how circuitous or far-fetched, that Protandim does something, anything, antioxidantish (not a word? Well it is now!). Then they can dredge the literature for every condition where a possible correlation with oxidative stress has been mentioned. Then they can try to convince customers they should take Protandim for all those conditions.
Big Pharma gets a lot of criticism, but aren’t Big Supplement and Big Multi-Level Marketing every bit as guilty of self-interest, distortions, and profit motives? At least Big Pharma can’t make its big bucks without first demonstrating effectiveness and safety to the FDA with clinical trials.
Does Protandim provide any real benefit to its customers? I don’t know, and they can’t hope to know unless they do proper clinical studies.

Systemic Enzyme Therapy
Scott GavuraonApril 12, 2012
Link
One of the recurrent themes in alternative medicine is the practice of simplifying complex medical conditions, and then offering up equally simple solutions which are positioned as still being within the realm of science. This approach allows the practitioner to ignore all of the complexity and difficulty of practicing real medicine, yet offer nostrums that, on first glance, can sound legitimate. Science-y, even.
I’ve discussed this before in non-science-based approaches to food intolerances, whether it’s using clinically useless IgG blood tests, or declaring the universal dietary enemy to be gluten. David Gorski elaborated on the same theme just a few days ago in the context of cancer treatment, contrasting the simplistic views of alternative medicine purveyors with the facts of cancer research. Cancer is stunningly complex – each of the hundreds of different variants of the disease. I’m always amazed when I speak with oncologists about how treatment regimens have been established. They describe how the results of dozens of clinical trials, led by different trial groups around the world have each contributed to establishing the current “best” regimens for each cancer: the appropriate drugs, doses, intervals and treatment intensities. Good evidence speaks all languages, and as new data emerges, practices change quickly to build upon whatever new evidence has emerged. The complexity of treatments continue to increase. Overlay the genetic and genomic complexity David described, and you get a sense of the challenges (and opportunities) cancer researchers face in order for science continue to improve outcomes for patients with cancer.
So it’s a bit of a shock when you shift your attention to the alternative medicine “literature”, where simple solutions abound. One that’s popular among patients I speak with, particularly those with European backgrounds, is the use of what are called systemic enzymes – enzymes, consumed orally, with the intent of whole-body effects. These products are not used as part of “conventional” medicine but are popular supplements recommended by alternative practitioners. I was recently asked about a product called Wobenzym N, a product with German roots which is advertised with the following claims [PDF]:
Taking Wobenzym®N as directed will assist several of your body’s key systems. This product supports the musculoskeletal system by promoting health and mobility in joints and muscles, and has been used for many decades. Wobenzym®N supports the circulatory system by promoting vein health. This product also supports the respiratory system and sinus health. Wobenzym®N is used by many people in the support of a balanced immune system and assists in promoting healthy aging. Wobenzym® is safe and effective and has been used by over 100 million people for over 40 years all around the world.
Vague and non-specific claims, and there’s the Quack Miranda warning there, too. But what does Wobenzym N actually do? Other sites promoting its use go much further in their treatment statements, describing use for conditions ranging from Alzheimer’s and angina to multiple sclerosis, prostatitis, respiratory infections and right through the alphabet to uveitis. Some mention utility in treating cancer. What ties all of these disparate conditions together? There is, as David Gorski terms it, One True Cause. When you’re using systemic enzymes, your “OTC” of all illness is inflammation.
Rubor, calor, dolor, tumor
Inflammation is our body’s response to infection and injury and is part of the healing process. Diseases with an inflammatory component are common, and have a huge health impact – think of asthma, arthritis, and inflammatory bowel disease, all common, chronic illnesses affecting millions. Low grade inflammation associated with obesity may be the trigger of a number of obesity-related complications. But “inflammation” doesn’t come in one form. There are multiple mediators, such as cytokines and ecosanoids. There’s a wide variety of cellular responses. As Peter Lipson has explained before:
Inflammation is a medical term that refers to a host of complex physiologic processes mediated by the immune system. Inflammation gets its ancient name from the obvious physical signs of inflammation: rubor, calor, dolor, tumor, or redness, heat, pain, and swelling. As the vitalistic ancient medical beliefs bowed to modern science, inflammation was recognized to be far more complex than just these four external characteristics. In addition to being a response to injury and disease, the cellular and chemical responses of inflammation can cause disease. For example, in asthma and food allergies, a type of immune reaction called type I hypersensitivity elicits a harmful type of inflammation. Coronary heart disease, the biggest killer of Americans, is believed to have a significant inflammatory component.
While there can be inflammatory components to many different diseases, it is a gross oversimplification to think that we can treat all forms in the same way, until there’s evidence to show that’s the case. Asthma and arthritis both have inflammatory elements, but they are different diseases with different treatments. But simplify the conditions to just be “inflammation” and you can introduce an equally simple solution. That solution? Systemic enzyme therapy:
Wobenzym®N works by providing “systemic enzyme support,” which describes a process that uses enzymes to assist the body’s various regulatory and communication systems, specifically the immune system.† A balanced immune system is necessary for maintaining overall health. Active enzyme molecules must be readily available in the small intestine to make sure that the systemic effect of the enzymes is achieved.
Enzymes play a critical role in the body and are involved in an astounding number of metabolic processes. Scientists suspect there may be as many as 15,000 enzymes at work in our bodies on a daily basis. Enzymes are involved in a variety of bodily processes including: breathing, growing, digesting, producing energy, conducting nerve impulses, clotting blood, recovering after exercise, or balancing the complex processes of the immune system.
Enzyme supplementation can be science-based. Its use in pancreatic disease is common, as well as diseases like cystic fibrosis. But those are not uses where the enzymes need to be absorbed from the gastrointestinal tract. Systemic enzyme replacement is something different.
I first encountered the idea of massive enzyme superdoses when I learned about the Gonzalez regimen, an alternative cancer treatment regimen discussed at length in prior posts by Kimball Atwood. The treatment includes coffee enemas and hundreds of tablets of pancreatic digestive enzymes daily. The regimen itself was based around the speculation of cancer causes which have now been definitively disproved. A clinical trial of the Gonzalez regimen was funded by the National Centre for Complementary and Alternative Medicine (NCCAM), which included a large number of pancreatic enzymes. The results of the trial were remarkable, but not in a positive way for the “alternative” approach: Conventional chemotherapy treatment for pancreatic cancer was three times better than the Gonzalez regimen.
Our pancreas secretes enzymes to help in digesting food. Should we expect that consumed enzymes will be absorbed into the body? Enzymes are large proteins that act as catalysts for biochemical reactions throughout the body – many chemical transformations are catalyzed by an enzyme. Many parameters can affect enzyme activity, including pH and temperature, and the presence of activators and inhibitors. Given the importance of enzymes in the body, genetic disorders that affect enzyme production and function can have catastrophic consequences. We’d also expect that the production and distribution of enzymes in the body would be fairly tightly controlled, given the potential effects, and given the food we eat will have its own share of naturally-occurring enzymes in it, too.
The use of proteins as therapeutic agents to influence disease is one of significant research interest. The challenge in introducing proteins into the body is that most are quickly eliminated from circulation, whether it’s by biotransformation by enzymes or renal filtration. Very large doses may be required, increasing the potential for non-specific toxicity and even allergic reactions. The most common therapeutic uses of proteins is by injection, because large chemical molecules are generally either destroyed by our endogenous digestive enzymes or, if they survive, cannot cross membranes into the bloodstream.
So the concept of giving enzymes orally, and achieve meaningful therapeutic effects in the body, is one with a considerable number of drug design hurdles. Is that occuring? Looking at Wobenzym N, each enteric coated tablet contains:
    • Bromelain 45mg
    • Chymotrypsin 1 mg
    • Pancreatin 100 mg
    • Papain 60 mg
    • Rutin 50mg
    • Trypsin 24mg
The recommended dosage is 3 tablets, twice daily, 45 minutes before meals. Before digging into the clinical data, I wanted to better understand the formulation and the dosing, keeping the design and administration issues in mind.
ADME
Every summary of a drug’s characteristics (the “monograph”) will have the same section. It’s abbreviated ADME which stands for Absorption, Distribution, Metabolism and Elimination. This is the section where behaviour of the the chemical in the body is summarized. This isn’t the clinical section, describing the therapeutic effects. It’s simply characterizing how extensively and how quickly the drug is absorbed from the gastrointestinal tract, where it distributes in the body (the “volume of distribution”) how and if it is broken down or “biotransformed” to make it easier to eliminate, and how quickly it is eliminated from the body. (I described this process in more detail in a previous post on generic drugs.) I want to see this graph, or be presented with enough data to understand what it looks like.

It’s the basic pharmacology work that’s done on a drug that gives us the information to understand its characteristics in the body. There is no point in doing clinical trials of a chemical packaged as a tablet, if we cannot confirm that the active ingredient is actually absorbed when it’s consumed. Clinical trials follow the basic pharmacology work. If the drug is treating different conditions, we may need to study different doses to establish the MEC for each condition. (For example, you need to take a lot more of an anti-inflammatory drug to treat rheumatoid arthritis than you need to treat a headache).
This is the study of pharmacokinetics, and it allows us to determine how the drug should be dosed and delivered in the body. Is it slowly eliminated, so the dosing can be infrequent – daily or even weekly? Is it rapidly eliminated from the body, meaning we need to dose multiple times a day to stay in the sweet spot of the therapeutic range? How is it eliminated from the body? Is it transformed by the liver? What impact does changing the dose have on the elimination of the product? What dose ranging studies have been done on the product that have established the appropriate dose? And how does that dose change, depending on the condition being treated?
My reason for belaboring this points is that understanding the ADME is essential to using drugs, supplements, or chemicals of any kind in a rational way. With herbs, it’s the difference between herbalism and pharmacognosy. Without it, dosing of any product is empirical – a shot in the dark. Coming back to Wobenzym N, we have a combination product with six different ingredients. The dosing instructions are very specific: 3 enteric coated tablets, twice daily, 45 minutes before meals. It’s the same for all of the different reasons for use described. But why this dose? Why 3 tablets? Why twice daily? What happens if you take more, or less? Different ingredients typically have their own physicochemical characteristics. What effects does each have? I looked at each ingredient first in the Natural Medicines Comprehensive Database (NMCD), and then in the primary literature itself. Here’s what I could find:
    • Bromelain is a term used for a collection of enzymes isolated from pineapple. While it’s rated by NMCD as “possibly effective” for osteoarthritis, the data are contradictory with some studies suggesting it has no effect on osteoarthritis. It has not been well demonstrated that bromelain reaches any clincially meaningful concentration in the blood. These are large protein molecules and it’s not clear how effectively they are absorbed – doses of 3000mg/day seem to result in tiny, albeit measurable, blood levels. Blood plasma components may inactivate any bromelain that is absorbed, though a half-life has been described [PDF]. On balance, the data are not impressive.
    • Chymotrypsin is a protein-digesting enzyme that is synthesized and secreted by the pancreas. I could locate no published efficacy of supplemental single ingredient chymotrypsin for any condition. It’s not clear what a supplemental dose of a few milligrams would have. I couldn’t locate any information that characterizes its ADME.Pancreatin is a mix of digestive enzymes including lipase, protease, and amylase, is used as prescription drug to treat pancreatic insufficiency, in conditions like cystic fibrosis. High doses have been linked to increases in blood/urine uric acid levels. There is no well-established use of oral pancreatin for anything other than pancreatic inefficiency. Again, little information exists to describe the ADME.Papain is a papaya-derived combination of enzymes. I could find a single study (in German) which compared oral supplements favourably to acyclovir for herpes zoster pain. Given the limited info in the abstract, it’s not possible to evaluate the data more fully. Little data exists to characterize the ADME.Rutin is a flavenoid rated as “possibly effective” for osteoarthritis on the basis of a single double-blind trial of an enzyme product (bromelain, trypsin, and rutin) versus diclofenac. Rutin does not seem to be absorbed intact, through it appears to elevate plasma levels of quercetin, and seems to have an effect on the absorption of other drugs. Again, little information exists to understand the pharmacokinetics.
    • Trypsin is another enzyme produced in the pancrease for digestion of proteins. Beyond the trial with rutin, I could locate no published trials evaluating efficacy for any other condition. Limited information exists to describe the ADME.
As I noted, getting large proteins like enzymes to be absorbed is a drug design challenge. Even if absorbed, how large molecules would escape rapid metabolism and elimination isn’t clear, either. With the ingredients in Wobenzym N, there appears to be some data to suggest that some components do reach the bloodstream. And there are some studies with the individual ingredients – but nothing that unequivocally establishes a meaningful effect. With that in mind, I looked for studies using the Wobenzym combination of ingredients.
The studies
I stared a review with the Natural Medicines Comprehensive Database (NMCD). Regarding Wobenzym N, it says, in part:
Wobenzym N is promoted for reducing inflammation and edema, and speeding recovery from certain injuries. Often it is used by individuals with arthritis and by athletes, including some professional and Olympic athletes. Enzymes in this product are thought to activate macrophages that attack inflammation-causing circulating immune complexes. Rutoside, an additional ingredient, acts as an antioxidant. To date there is no convincing clinical evidence that Wobenzym is effective for these uses. Because these enzymes do not affect prostaglandin synthesis, Wobenzym N is also promoted to be free of many of the side effects associated with non-steroidal anti-inflammatory drugs (NSAIDS). Adverse reactions reported after oral administration include loose stools, increased gas, and skin reactions.
NMCD cautions that there is also potential for the product to affect blood coagulation.
Are there clinical trials with Wobenzym? Yes, but few are in English, which complicates the review. I could locate no evaluable trials in PubMed, but other websites list trials in conditions such as pelvic inflammatory disease, cancer, and multiple sclerosis (URL Removed – Malware site! -webmaster). Some therapeutic improvements have been attributed to the consumption of Wobenzym (e.g., diabetes, post-heart attack) but the studies are preliminary, sometimes unblinded, and don’t appear to be duplicated. One of the few English papers appeared in Medical Hypotheses, not a good sign for someone seeking science-based medicine. There’s an uncontrolled trial in bronchitis in children, in a study published in Russian. Other studies are published in Czech, Ukranian, Latvian, and Russian. One German systematic review declared “oral proteolytic enzyme treatment does not offer a justified alternative in comparison with NSAID in the anti-inflammatory treatment of rheumatic disease.” Overall, no large clinical trials with relevant clinical outcomes, and no persuasive evidence to demonstrate clinically meaningful effects for any single condition it is used to treat. On balance, the safety profile of the product seems acceptable, but it’s not clear how extensively safety data was captured in these small trials.
There are several trials with a similar product, Phlogenzym (rutoside, bromelain and trypsin). One didn’t suggest impressive results for ankle strains. A trial studying the same combination for hip osteoarthritis suggests non-inferiority with diclofenac, and an open-label trial for osteoarthritis of the knee found non-inferiority as well. I even found a small trial declaring it effective for treating pediatric sepsis, which left me curious if there are research ethics boards in India.
There is also the interesting case of the enzyme serrapeptase, also sold as an anti-inflammatory. Sold by the pharmaceutical company Takeda since 1968 for asthma, bronchitis, and touted as an enzyme anti-inflammatory for a large number of other uses, it was withdrawn from the Japanese market in 2011, after double-blind trials concluded that it had no therapeutic effects.
On balance, looking at the data for systematic enzymes, I wasn’t impressed. Despite the generalized claims of effectiveness, there are so many limitations in the data itself it’s not clear we can infer that the treatment effects are real. And given the lack of data on the absorption, distribution, metabolism and elimination of Wobenzym, it’s not clear that this product is even absorbed to a meaningful extent and available in the body to havse systemic effects. Without any objective measure to evaluate efficacy, it’s not clear that supplementation will have any meaningful therapeutic effects for any condition, chronic or otherwise. You may feel better when you take it, but there’s no persuasive evidence yet that it’s having a meaningful effect.
This rock keeps tigers away
It would be an amazing discovery – Nobel worthy – if there were an oral therapy with demonstrably beneficial effects on a variety of chronic diseases without evidence of toxicity. Even demonstrating that large protein molecules can be consumed orally and be delivered in significant amounts to the bloodstream would be notable. Unfortunately, neither have been convincingly demonstrated with Wobenzym or other “systemic” enzyme treatments. Science is complicated, and simple solutions may be attractive, but they’re also quite possibly wrong. Given the weak clinical and pharmacokinetic data for this product, I expect that, should more research be done, it will follow the same evidence trajectory of many other supplements with an implausible premise: As the research studies improve in size and methodologic rigor, the treatment effects will disappear. Until better evidence appears to demonstrate the efficacy and safety of systemic enzyme therapy, their use can’t be considered science-based.

MARIJUANA AND CBD

Medical Marijuana: Where is the evidence?
Marijuana is widely touted as an effective medicine for an array of conditions. But what does the evidence actually tell us?
Scott Gavura on January 11, 2018
Link

This year will bring a Canada Day for the history books. Only July 1, 2018, recreational marijuana (also called cannabis) will be legalized and regulated in Canada. The federal Cannabis Act creates a legal framework for producing, possessing and selling marijuana across Canada, meaning that each Canadian province will set its own rules to oversee its distribution, subject to federal government conditions. Provincial and federal governments will share in the responsibility for the oversight of this new system, and will also share in the tax revenue. Different provinces are taking different approaches, similar to how alcohol purchases vary between jurisdictions. This trend follows what we’re seeing at the state level in the United States, with different states moving to decriminalize recreational use.
Marijuana has been legal to some extent in Canada (and in many US states) for some time, in the form of “medical” marijuana. The Canadian government authorized the sale of marijuana for that purpose, while it simultaneously emphasizes that cannabis is not an approved therapeutic product. The medical market, for many, appears to simply be a means to access products for recreational, or non-medical use, and has generated wildly unsubstantiated claims about the medical merits of marijuana for conditions like autism and the treatment of cancer. Dispensaries have appeared across Canada and the US, usually with very easy referrals for prescriptions. Some dispensaries ignore any prescription requirement entirely and will sell marijuana directly to the public without any medical assessment or advice. With the introduction of government-overseen (and in some Canadian provinces, government-delivered) retail sales in Canada later this year, it’s reasonable to assume that unregulated dispensaries will eventually disappear.
With recreational sales imminent in Canada (and already here, in states like California), there are questions about the future market for “medical” marijuana. Should use for medical purposes be treated like recreational use, where consumers make their own selections, and purchases are taxed like other consumer products? Or should some forms or uses of marijuana be treated like prescription drugs, where a health professional remains involved, and products may be even be covered by insurance plans? Given the major changes we are seeing in how we can access marijuana, it’s worth summarizing the current state of evidence for marijuana when used for specific medical purposes. With marijuana becoming much more accessible, physicians, other health professionals, and their patients need high-quality information about its value for different medical conditions. David Gorski reviewed much of the evidence in a series of posts over the past three years. Now, three new documents prepared for Canadian physicians and health professionals concisely summarize the current evidence base for medical marijuana.
The pharmacy profession seemingly sees a bright future in medical marijuana, with big chains striking deals with producers and even hiring “brand managers” in anticipation of the shuttering of unregulated dispensaries and a continued demand for “medical” uses. The argument being made by the pharmacy profession seems to be that (1) marijuana is a legitimate drug for medical purposes, and should be treated as such, which includes (2) a pharmacy and pharmacist being involved in the provision. The latter we can set aside for now, and focus first on whether or not marijuana is indeed a drug that should be treated like other prescription drugs.
Before I continue, I should state my personal position on marijuana. I am fully supportive of the legalization of marijuana for recreational use and support regulation and taxation, treating it along the lines of alcohol or tobacco. I should also state that I have no “skin in the game” when it comes to marijuana in pharmacies, or medical marijuana more generally – I don’t work in retail pharmacy, and while pharmacy professional associations seem enamored with the idea of medical marijuana in pharmacies, I have no personal opinion on it, other that wanting pharmacies to be places that offer and promote science-based and medically useful products, not pseudoscience or harmful/ineffective products (see my post on the commercial and professional ethical obligations of pharmacists for more).
It’s worth mentioning as an aside that there’s a somewhat similar set of circumstances in US history, when alcohol was available only by prescription during Prohibition. This prescription (via the Smithsonian Institute) could be used by physicians to prescribe alcohol for an array of ailments:
Naturally, the prescription market for alcohol disappeared once Prohibition ended. But marijuana is not alcohol. It contains an array of potentially medically useful chemical substances, several of which have been clinically investigated for the treatment of different medical conditions.
The pharmacology of marijuana
As David Gorski has pointed out in previous posts, there are a number of biologically active chemicals in marijuana. The main psychoactive ingredients are called cannabinoids, and the primary cannabinoid produced is delta-9-tetrahydrocannabinol (Δ9-THC, or simply THC.). Cannabinoids are produced in the stalk, leaves, flowers, seeds and resin of marijuana plants. Marijuana can be smoked, vaporized, or eaten, among other forms of ingestion. THC is rapidly absorbed, and when inhaled, reaches the brain within minutes. (Oral absorption is lower owing to a significant reduction in available drug after passing though the liver.) These chemicals bond to cannabinoid receptors on cells throughout the body, triggering or modulating different effects. Marijuana immediately affects and impairs attention, concentration, memory, learning and motor coordination, proportional to the dose. You might wonder why our cells have receptors for THC and other cannabinoids. That’s because we (and other mammals) have an endocannabinoid system, and we naturally produce endocannabinoids. It is absolutely plausible that drugs that target endocannbinoid receptors, like THC (or derivatives), have the potential to produce beneficial medicinal effects, given the presence of receptors on nearly every organ system. With the growing understanding of the endocannabinoid system, and the identification of different types of receptors, there’s the potential for targeting specific effects on specific organs. That could mean products that produce beneficial effects and minimize any adverse effects (e.g., fewer psychoactive effects).
Cannabinoids are highly fat soluble and so are difficult for the body to eliminate – the complete elimination of a single dose may take up to one month. With repeated doses, levels can rapidly accumulate. While the liver eliminated cannabinoids, even the metabolites of THC can persist in the body, and there is little relationship between the levels of THC found in the blood and the degree of THC-induced effects. Owing to metabolism in the liver, THC has the potential to interact with other drugs. The overall impact has not been well studied. As a drug, there is lot we do not know about marijuana. However, we can be confident in observing that there is little acute toxicity of marijuana, unlike many other drugs and substances. While not addictive, there are also cases of cannabis use disorder, which while infrequent, can occur. It should be acknowledged that cannabis use disorder is a minor public health issue compared to the widespread harms and mortality caused by substances like alcohol and opioids.
The evidence check
Let’s now look at a trio of documents prepared by the Alberta College of Family Physicians. They routinely produce “Tools for Practice” which are concise, actionable answers to clinical questions. All the documents are available online, and are fully referenced, but I will summarize each document here:
Are medical cannabinoids (MC) effective for the treatment of pain?
Bottom Line: Evidence for inhaled marijuana for pain is too sparse and poor to provide good evidence-based guidance. Synthetic MC-derived products may modestly improve neuropathic pain for one in 11-14 users but perhaps not for other pain types. Additionally, longer and larger studies (better evidence) show no effect. Adverse events are plentiful.
The full document is available here.
    • Chronic pain: 39% experience pain reduction of >30% versus 30% with placebo, resulting in a number needed to treat (NNT)=11. Larger and longer RCT show no effects. The mean pain improvement is 0.5 on a 0-10 scale, which isn’t clinically meaningful.
    • Neuropathic pain: With inhaled MC, the NNT=6. With any MC, the NNT=14.
    • Cancer pain: In six randomized controlled trials, the pain reduction was not statistically significant.
    • HIV neuropathy: with smoked MC: NNT=4.
    • Pain from multiple sclerosis: Mean pain improvement over placebo was 0.8 on a 1-10 scale which was borderline insignificant.
    • Acute pain: One positive trial, one negative trial, and five trials showing MC is equivalent to placebo.
    • When compared to medication, MC was no better than amitriptyline (with more adverse events), or worse than dihydrocodeine with similar adverse events.
    • No overall differences shown in quality of life.
    • Little evidence for back pain, fibromyalgia, or osteoarthritis.
What are the harms associated with medical cannabinoid therapy?
Bottom Line: Compared to placebo, medical cannabinoids cause multiple different adverse events in patients, from visual disturbance or hypotension (1 in 3-10) to hallucination or paranoia (1 in 20). Stopping due to adverse effects occurs in 1 in every 8-20 patients. Regardless of the type of medical cannabinoid used, adverse events are common and likely underestimated. Given the extensive harms, potential benefits must be impressive to warrant a trial of therapy.
The full document is available here.
    • Eleven systematic review with meta-analyses of harm were identified.
    • 79-92% of patients using MC experienced any adverse event versus 56-78% with placebo, giving a number needed to harm (NNH)=5-8.
    • Serious adverse events measured in 3 meta-analyses, with two studies reporting no significant differences versus placebo. The third reported an odds ratio of 1.41.
    • Seven meta-analyses reporting stopping MC due to adverse events, with a range of 7-14% for MC versus 1-5% for placebo, giving an estimated NNH of 8-22. One of the seven analyses showed no significant difference versus placebo.
    • Side effects, overall, are very frequent: Sedation (NNH=5), feeling high (NNH=2-4) and euphoria (NNH=9). Other adverse events include visual blurring/hallucinations (NNH=3), dizziness (NNH=5), speech disorders (NNH=5), ataxia/muscle twitching (NNH=6), disconnected thought (NNH=7), dysphoria (NNH=8), hypotension (NNH=8), impaired memory (NNH=12), and disorientation (NNH=15).
    • MC increased adverse effects compared to drugs like prochlorperazine, causing more sedation and dizziness.
    • Adverse event rates varied little between different MC products, including synthetic cannabinoids and inhaled marijuana (NNH=4-7).
Besides pain, are medical cannabinoids effective for other conditions?
Bottom Line: For most conditions (example anxiety), cannabinoid evidence is sparse (at best), low quality and non-convincing. Dronabinol/nabilone improve control of nausea/vomiting post chemotherapy for 1 in 3 users over placebo. Nabiximols likely improve multiple sclerosis spasticity ≥30% for ~1 in 10 users over placebo. Patients’ preference for cannabinoids exceeds cannabinoids effectiveness.
The full document is available here.
    • Two comprehensive systematic review suggest reasonable evidence for nausea and vomiting due to chemotherapy (NNT=3) and for spasticity (NNT=7).
    • Evidence is sparse but suggestive for potential for children with Dravet epilepsy.
    • Evaluations show that patient preference exceeds effectiveness measures.
    • In other conditions, high level evidence is sparse, low quality, or negative, for conditions such as glaucoma, anxiety, or other causes of nausea and vomiting.
    • Blinding in trials was noted to be difficult, with 85-95% of patients and clinicians identifying who receiving MC.
Developing an evidence base for marijuana
Studying marijuana under rigorous circumstances has been difficult until fairly recently. The plant itself isn’t patented, so even ignoring the legal access issues, there may be a lack of industry enthusiasm in conducting clinical trials. The other issue is the challenge of a proper placebo control, particularly for non-oral forms of use. Given the psychoactive effects and the widely heralded effects on conditions that can only be assessed subjectively, like nausea, fatigue or appetite, a proper placebo is essential to separate out actual from placebo effects. While some commercial products have been developed and marketed with standardized ingredients and quality control (e.g., nabilone), these products are exceptions. However, these purified and standardized products have allowed for proper placebo controls and more rigorous assessments of effectiveness. Regrettably, these products haven’t been shown to be that effective which may suggest that the perceived beneficial effects may be largely placebo effects. Hopefully, clinical trials will become more common and more marijuana-based drugs can be more rigorously evaluated.
Conclusion: Evidence is lacking
The use of psychoactive drugs like marijuana is a health issue, particularly when used for medical purposes. Regrettably, there is a lack of high-quality data that shows marijuana for most medical purposes is both safe and effective. What little evidence exists is of poor quality and may not even be representative of the purposes for which medical marijuana is sought. There are significant gaps in information necessary to treat marijuana like other forms of medicine: Dosage standardization and overall quality control may not be in place. Overall effectiveness, contraindications, drug interactions, adverse events and long-terms risks when marijuana is used as medicine are not well understood. The best evidence suggests that marijuana may be a reasonable treatment option only when safer, more effective, and better tolerated treatment options have been tried first. If marijuana is to be treated as medicine, then it needs to meet the same standards of quality, effectiveness, and safety we would expect of any other prescription drug. That standard has not yet been met.

Medical marijuana as the new herbalism, part 1: Science versus the politics of weed in New York and beyond
Medical marijuana. It’s promoted as a seeming panacea that can cure whatever ails you. While there are potentially useful medicinal compounds in marijuana, in general the medical marijuana movement vastly oversells the promise. The truth is far more prosaic and nuanced.
David Gorski on July 7, 2014
Link
A while ago, I wrote about how the Cleveland Clinic had recently opened a clinic that dispensed herbal medicine according to traditional Chinese medicine (TCM) practice. As regular readers of the SBM blog might expect, I was not particularly impressed or approving of this particular bit of infiltration of quackademic medicine into a major academic medical center, particularly given some of the amazingly pseudoscientific treatments espoused by the naturopath who was running the clinic. I also pointed out that, although herbalism is the most plausible (or perhaps I should say the least implausible) of modalities commonly associated with “complementary and alternative medicine” (CAM) or “integrative medicine”, it still exhibits a number of problems, the biggest of which is what I like to call either the delivery problem or the bioavailability problem. In brief, herbs, when they work, are adulterated drugs. The active ingredient is usually a minor constituent, embedded in thousands of other constituents that make up herbs, and it’s almost impossible to control lot-to-lot consistency with respect to content or active ingredients given how location, weather, soil conditions, rainfall, and many other factors can affect how the plants from which the medicines are extracted grow and therefore their chemical composition. To demonstrate the concept, I pointed out that it’s much safer and more predictable to administer digoxin to a patient who needs its activity on the heart than it would be for the patient to chew on some foxglove leaves, given that the therapeutic window (the difference between the doses needed to produce therapeutic effects and the lowest dose that will cause significant toxicity) is narrow.
Which brings me to medical marijuana, a.k.a. medical cannabis.
Before I continue, let me just state my position on marijuana, which is different than it was, say, 20 years ago. Today, I believe there’s no reason why marijuana shouldn’t be legalized and treated by states the same way as tobacco products and alcoholic beverages are; they should be heavily regulated and taxed. Among physicians, this appears to be a common view, at least if you can believe a poll I saw a while back (for which I can’t find the link, alas). It’s also, these days, more and more of a mainstream view. In any case, medical marijuana has been a topic I’ve been meaning to write about for a while, now, but my “Dug the Dog” tendencies have kept popping up over squirrels topics like the Food Babe, Facebook, ketogenic diets for cancer, and a variety of other topics.
Medical marijuana arrived in my state in 2008, when the voters approved a measure permitting it. After some time for the state to draft regulations, the law was implemented, and I had the strange (to me at the time) experience of receiving notices about state regulations, requirements, and documentation should I wish to prescribe medical marijuana. Indeed, more than twenty states, plus the District of Columbia, have legalized medical marijuana. They’ve done so on the basis of a political movement among patients that make pot sound like a miracle drug that can help when no other intervention can. And it’s more than that. Medical cannabis has been touted as a near-panacea for everything from pain to chemotherapy-induced nausea to HIV- and cancer-induced cachexia to even curing cancer itself. Yes, there’s a lot of hype out there, and there are a lot of claims that sometimes go viral on various social media, even though the evidence to support the claims is often, to put it mildly, less than rigorous.
Indeed, the acceptance of medical marijuana appears to be far more driven by politics than it is by science, as was pointed out in a recent New York Times article about the impending legalization of medical cannabis in New York State:
New York moved last week to join 22 states in legalizing medical marijuana for patients with a diverse array of debilitating ailments, encompassing epilepsy and cancer, Crohn’s disease and Parkinson’s. Yet there is no rigorous scientific evidence that marijuana effectively treats the symptoms of many of the illnesses for which states have authorized its use.
Instead, experts say, lawmakers and the authors of public referendums have acted largely on the basis of animal studies and heart-wrenching anecdotes. The results have sometimes confounded doctors and researchers.
[Ed. Note: This post was written yesterday, which, as it turns out, was one day before New York State became the 23rd state to legalize medical marijuana.]
The article then goes on to give several examples, such as Alzheimer’s disease, lupus, Sjogren’s syndrome, Tourette’s syndrome, Arnold-Chiari malformation and nail-patella syndrome, and in particular rheumatoid arthritis:
Yet there are no published trials of smoked marijuana in rheumatoid arthritis patients, said Dr. Mary-Ann Fitzcharles, a rheumatologist at McGill University who reviewed the evidence of the drug’s efficacy in treating rheumatic diseases. “When we look at herbal cannabis, we have zero evidence for efficacy,” she said. “Unfortunately this is being driven by regulatory authorities, not by sound clinical judgment.”
As is the case with so much herbalism—and, make no mistake, medical marijuana is the new, popular herbalism of the moment—claims have far outstripped the evidence. Also, as pointed out in the NYT article, even advocates of medical marijuana admit that “the state laws legalizing it did not result from careful reviews of the medical literature.”
That’s the understatement of the year, and even famous doctors like Sanjay Gupta are getting in on the act with a report, “Cannabis Madness,” full of a lot of anecdotes and rhetoric about “policy against patients.” Again, I believe that marijuana should be legalized, regulated, and taxed, just like alcohol and tobacco. If marijuana is going to be approved for use as medicine rather than for recreational use, however, the standards of evidence it must meet should be no different than any other drug, and for the vast majority of indications for which it’s touted medical cannabis doesn’t even come close to meeting that standard.
The evidence
There are definitely compounds with potential medicinal use in the marijuana. No one, even the most die-hard drug warrior, denies that. These compounds are called cannabinoids, which is a term that describes a family of complex molecules that bind to cannabinoid receptors, which are proteins on the surface of cells. There are two types of cannabinoid receptors, type 1 (CB1) and type 2 (CB2). These receptors are seven transmembrane G-protein coupled receptors (so named for the seven protein domains that span the membrane), a class of receptor I’m pretty familiar with, because one of the receptors I study is of the same class, which looks like this:
“Cb1 cb2 structure” by Esculapio at it.wikipedia – Own work (Original caption: “Immagine creata da —Esculapio”). Licensed under CC BY-SA 3.0 via Wikimedia Commons.
The details of how this happens aren’t essential for this post, but when these receptors are stimulated by the binding of cannabinoid molecules, including endocannabinoids (produced by mammals), plant cannabinoids (such as (−)-trans-Δ9-tetrahydrocannabinol, more commonly referred to by its abbreviation THC, produced by the cannabis plant) and synthetic cannabinoids (such as HU-210), downstream chemical signaling pathways are initiated from the receptor to the inside of the cell, thus producing the effects on the cell and organism. There is mounting evidence that there are more than two types of cannabinoid receptors. In any case, CB1 receptors are found widely in the central nervous system, where they modulate a variety of responses, and are also found in other parts of the body, for instance, the pituitary gland, thyroid gland, lungs, and kidney, as well as fat cells, muscle cells, liver cells, and in the digestive tract. CB2 receptors, on the other hand, are expressed primarily in the immune system, the gastrointestinal tract, and, to a much lesser extent than CB1 receptors, in the brain and have been implicated in modulation of immune responses. In particular, stimulating CB2 receptors cannabinoids could be potentially useful as anti-inflammatory drugs. Over the last couple of decades, endocannabinoids and cannabinoid receptors have been implicated a large variety of functions, including memory, pain, energy metabolism, and more. It is thus plausible that manipulation of cannabinoid signaling could have therapeutic effects in a variety of areas.
Unfortunately, one of the problems with medical marijuana, as noted in the NYT article is that enthusiasm for weed as a cure-all has far outstripped existing medical evidence. This disconnect between the existing evidence base ranges from thin to nonexistent, depending on the condition. One of the most frequent claims I see is that cannabis can be used to treat cancer. I’m not going to address that claim specifically in this post, except very briefly, because I think it’s a large enough topic to warrant its own post. Suffice to say that interesting preclinical studies have been exaggerated beyond all evidence, but nonetheless certain cannabinoids could have potential in the treatment of certain cancers. I might also review the evidence base for cannabinoids and autism, given how I’ve been seeing discussions of its use starting to pop up lately on the usual sites. In other words, stay tuned for parts two and three spread out over the next several weeks, whenever no squirrels distract Dug the Dog.
In all fairness, in this country, at least, studying the medicinal properties of marijuana and its constituents is not easy, given that it is currently an illegal drug, as was discussed in the NYT article. It’s not for lack of interest, but mainly because the law (and therefore the Drug Enforcement Agency) classifies it as a schedule 1 drug with “no currently accepted medical use.” Scientists who want to do research on marijuana and its constituents—particularly clinical trials—must register with the DEA and submit an investigational new drug (IND) application to the Food and Drug Administration for human trials. Moreover, the National Institute on Drug Abuse is the only supplier of legal, research-grade marijuana. On the other hand, while doing research on marijuana is difficult in this country, researchers in other countries that have long had much more lax laws and regulations should have an easier time of it.
Another issue is how to do a proper placebo control. Given that many of the conditions for which medical marijuana is touted are conditions with a large subjective symptomatic component, such as pain, nausea, fatigue, or lack of appetite, clinical studies of medical marijuana are going to require really good placebo controls. Given that at least one of the active components causes a high, it’s arguably even more difficult than in the case of, for instance, acupuncture, to design studies with adequate controls. That’s why most of the more rigorous studies have used specific purified cannabinoids. For example, in this study, a titanium pipe loaded with doses of THC varying potencies is used rather than plant, while this study of cannabis for neuropathic pain used high-dose cannabis, low-dose cannabis, and placebo cigarettes.
Be that as it may, let’s look at the evidence base for conditions for which medical marijuana might provide a benefit. Remember, again: I’m leaving out cancer and autism for another day. Leaving these aside, here are the potential medical uses for marijuana for which evidence exists that ranges from reasonably good to suggestive.
Chronic pain. It’s been known for a long time that cannabinoids modulate pain responses; so it’s plausible that either smoked marijuana or cannabinoids isolated from marijuana (or synthetic cannabinoids) could be useful for chronic pain. Fortunately, this is one of the more widely-studied uses for medical cannabis. For example, a recent review of uses of cannabinoids for the treatment of non-cancer pain concluded that there was evidence that cannabinoids are safe and modestly effective in neuropathic pain, citing preliminary evidence of efficacy in fibromyalgia and rheumatoid arthritis. As is the case with most reviews, more study was recommended. This particular review included smoked cannabis, oromucosal extracts of cannabis based medicine, nabilone (a synthetic cannabinoid), dronabinol (a synthetic delta-9-THC), and a novel THC analogue. Most studies have only been short term, and adverse events have tended not to be serious. The current general recommendation is that cannaboids should probably not be used as first line agents “for conditions for which there are more supported and better-tolerated agents,” and adverse effects are not well studied.
Appetite stimulation. I’ve never smoked marijuana, but those who have, have told me about the “munchies,” something that anyone who’s ever seen a comedy in which characters smoke post has likely seen used as fodder for jokes. Given its ability to stimulate appetite, it is therefore plausible that medical cannabis might be useful for appetite stimulation in patients with cachexia due to cancer or HIV/AIDS. (Cachexia is the “wasting” that can occur in advanced cases of malignancy and AIDS, among other diseases.) Unfortunately, a recent Cochrane review noted variable outcomes and concluded that the “efficacy and safety of cannabis and cannabinoids in this setting is lacking” and noting no good evidence of long-term effects on AIDS-related mortality and morbidity. Regarding cancer cachexia, Peter Lipson noted several years ago a study that failed to find any benefit from cannabis extract for cancer-related cachexia, speculating that maybe the mechanisms that cause appetite suppression in cancer are different than the mechanisms by which cannabinoids modulate appetite.
Currently, there are few controlled trials cited at the NCI website, which, taken together, find that oral THC has variable effects on appetite stimulation and weight loss in patients with advanced malignancies and human immunodeficiency virus (HIV) infection. A PubMed review by yours truly also found the evidence rather sparse. For instance, this randomized trial testing cannabis extract (CE), THC, and placebo (PL) reported that “no differences in patients’ appetite or quality of life were found either between CE, THC, and PL or between CE and THC at the dosages investigated.” Another randomized trial comparing megestrol acetate (Megase) and dronabinol found that “megestrol acetate provided superior anorexia palliation among advanced cancer patients compared with dronabinol alone” and that “combination therapy did not appear to confer additional benefit.” A more recent small randomized trial tested THC versus placebo and found that “THC may be useful in the palliation of chemosensory alterations and to improve food enjoyment for cancer patients.” To be honest, I was shocked at how sparse the literature is covering this particular indication. Indeed, as the NCI notes, there are no randomized controlled trials of smoked cannabis for this indication in cancer patients.
Nausea/antiemetic. Despite many advances in anti-emetics (anti-nausea and vomiting) agents, cancer-induced nausea and vomiting (CINV) is still among the most troubling symptoms cancer patients face. There are two FDA-approved cannabis products for this indication, dronabinol and the synthetic cannabinoid nabilone. The NCI cites several clinical trials and meta-analyses finding that these two drugs are efficacious against CINV, and the National Comprehensive Cancer Network guidelines recommend these drugs as treatment for breakthrough nausea and vomiting due to chemotherapy. One systematic review from 2001 found that cannabinoids were slightly more effective antiemetics than prochlorperazine, metoclopramide, chlorpromazine, thiethylperazine, haloperidol, domperidone, or alizapride, but were not more effective in patients already using large doses of antiemetic drugs. A more recent systematic review and meta-analysis found that cannabinoids were superior to conventional drugs but that “adverse effects were more intense and occurred more often among patients who used cannabinoids.” In children with cancer undergoing chemotherapy, a Cochrane systematic review concluded that “cannabinoids are probably effective but produce frequent side effects” and that the review “suggests that 5-HT(3) [seratonin] antagonists with dexamethasone added are effective in patients who are to receive highly emetogenic chemotherapy although the risk-benefit profile of additional steroid remains uncertain.”
Inflammatory bowel disease (IBD). Last fall, the first clinical trial of cannabis in IBD was reported by a group of Israeli researchers. It was a small trial (21 patients), in which subjects were assigned randomly to groups given cannabis, twice daily, in the form of cigarettes containing 115 mg of Δ9-tetrahydrocannabinol (THC) or placebo containing cannabis flowers from which the THC had been extracted. A clinical response was achieved in 10 of 11 patients receiving cannabis with THC and 4 of 10 in the placebo group. Overall, this was a small study, but intriguing. No difference in complete remissions between the groups was observed, but that could easily be because of the small numbers. As with many conditions, all one can conclude is that more research is needed.
There is, of course, a laundry list of other conditions. Cannabinoids have been shown to lower intraocular pressure, making them potentially useful for treating glaucoma, although using cannabis to treat glaucoma is impractical in the vast majority of patients (see below), and there exist better treatments. After that, other conditions for which medical cannabis is frequently recommended include schizophrenia, for which a Cochrane Review concludes that there is no good evidence for or against the use of cannabis for schizophrenia. For epilepsy, data from double-blind randomized controlled clinical trials is lacking, although clinical trials are finally being done.
Overall, the evidence base, from my interpretation, ranges from nonexistent (most indications) to suggestive (anti-inflammatory), to fairly good (ant-emetic). However, most of the good clinical trials didn’t use marijuana cigarettes as most patients get them, but rather either purified cannabinoids (or synthetic analogues) or cannabis cigarettes spiked with varying amounts of THC. Indeed, all of these studies tend to suggest that purified drugs from cannabis or synthetic drugs based on compounds designed to mimic either endocannabinoids or cannabinoids from marijuana will be the future. I realize that that’s not what medical marijuana activists want to hear. I also realize that it is likely I will be lambasted as a “pharma shill” or as so conventional that I can’t think outside the box, but I’ve endured those attacks before when I’ve criticized other forms of herbalism. In any case, mine, I believe, is a reasonable interpretation of the currently existing medical literature.
Moreover, contrary to what advocates will claim, cannabis, particularly smoked cannabis, is not without adverse health effects, as was recently reviewed in the New England Journal of Medicine. Potential medical effects reported in long time users include motor vehicle collisions (not unreasonable to expect because driving while high is not a good idea), chronic bronchitis (not surprising as a result of smoke inhalation), schizophrenia (one wonders whether correlation really suggests causation here), depression, and addiction to other drugs, although the risk for cancer due to marijuana smoke appears to be much lower than with tobacco cigarettes. True, drug warriors and moralists will frequently exaggerate the risks in order to promote their agendas, but that doesn’t mean that cannabis is perfectly safe and doesn’t produce significant side effects or complications.
Then there’s the delivery problem.
Delivery, purity, highs
Let’s consider, for a moment, a generic herb that has medicinal properties. I began this post by briefly discussing the problems with herbs as medicine, but I didn’t discuss delivery. If one were to come up with a delivery method for an effective herb, one would be hard pressed to come up with a worse method than burning it and inhaling it. Consider the case of tobacco. The combustion of dried tobacco leaves produces a toxic stew of gases with carcinogenic effects. Of course, the main reason tobacco is so addictive is because it does have an active drug in it, specifically nicotine, which rapidly reaches the circulation through the alveolar sacs in the lungs. However, that nicotine is mixed with numerous combustion products that can cause cancer and contribute to the numerous other diseases to which smoking tobacco has been linked.
This brings us back to delivery. People have been using marijuana for the high and for medicinal purposes for a very long time, but cannabinoids were only first isolated from the plant in the 1940s, and the main active ingredient, (−)-trans-Δ9-tetrahydrocannabinol (THC), wasn’t discovered until the 1960s. Now, like the case with cigarette smoke and its delivery of nicotine to the bloodstream, the THC and other active cannabinoids delivered to the bloodstream through smoking marijuana are mixed in a similarly toxic stew of combustion products. While it is probably true that marijuana smoke is less carcinogenic than tobacco smoke, it has the same potential for respiratory irritation and deposits four times as much tar into the lungs as a typical cigarette, mainly because marijuana is usually smoked unfiltered. However, occasional marijuana use appears not to have a significant effect on lung function up to seven joint-years of lifetime exposure. (I chuckled when I read that term; it means one joint a day for seven years or one joint a week for 49 years). Of course, this hardly compares to a typical tobacco smoker, who smokes anywhere from a half pack to two packs a day (10-40 cigarettes), and those using medicinal marijuana can be expected to be smoking at least a couple of times a day. Medical cannabis advocates even basically admit that this is true.
In any case, if one were going to decide on a drug delivery device for cannabinoids, one could hardly design a worse device than burning the leaf and inhaling the gases, where the active drug is just one of hundreds of products of combustion, all loaded with particulate matter and tar. Sure, toking one joint a day probably doesn’t do appreciable lung damage in the intermediate term, but smoking one cigarette a day probably doesn’t either. In the case of glaucoma patients, a condition for which there is some evidence of efficacy, it’s been noted that patients would have to be toking up several times a day:
Since at least 2009, for instance, the American Glaucoma Society has said publicly that marijuana is an impractical way to treat glaucoma. While it does lower intraocular eye pressure, it works only for up to four hours, so patients would need to take it even in the middle of the night to achieve consistent reductions in pressure. Once-a-day eye drops work more predictably.
Yet glaucoma qualifies for treatment with medical marijuana in more than a dozen states, and is included in pending legislation in Ohio and Pennsylvania. At one point, it appeared in New York’s legislation, too.
And:
What’s more, for some of the ailments, such as glaucoma, patients would have to toke up every three to four hours day and night to maintain therapeutic levels in the bloodstream or tissues. Routinely consuming that much weed would be incapacitating.
Clearly, even if marijuana is efficacious for some conditions, there are serious drawbacks to burning the plant and inhaling the smoke as a drug delivery system. Other problems exist, not the least of which are the psychoactive effects of THC, which cause much of the “high” that pot smoking produces. To paraphrase one of the ophthalmologists in the NYT, his 60-year-old patients with glaucoma don’t want to be stoned all the time to get the beneficial effect of medical marijuana. The high is a particular problem for children, but none of this has prevented parents with autistic children from claiming that pot can treat autism, complete with seemingly-heartwarming anecdotes. One can imagine the temptation to simply keep the child toking until he becomes mellow and more “manageable.”Of course, medical marijuana being in essence herbalism, with the same claims for efficacy of the “whole plant” due to synergy of its ingredients and the same attitude that “natural is better,” it’s not surprising that the same problems exist that are routinely observed for any herb sold for medicinal purposes. These problems include as inconsistent potency and purity, adulteration with contaminants—or even questions of whether the plant being sold is actually what is being claimed. Indeed, a fascinating story that sounds very familiar to those of us who have been paying attention to adulterated herbs and supplements was published a month ago in The Seattle Times:
Tonani, 38, decided several years ago to try pot. And it has worked for her, she said, especially strains low in the psychedelic chemical THC and high in the non-psychoactive ingredient cannabidiol, known as CBD.
As a medical-marijuana patient, Tonani knows it can be hard to find the rare strains that don’t make you high — and it can be even harder to get the same kind of pot consistently.
Testing shows that some marijuana strains are not what they purport to be in name, chemical content and genetics. This is particularly concerning for patients seeking pot low in intoxicants and high in pain-relief or other therapeutic qualities.
One strain widely known for its high-CBD and popular among medical-marijuana patients is called Harlequin. But when Tonani and a leading Seattle pot-testing lab analyzed 22 samples of Harlequin from various growers and dispensaries, five of them were high in THC and had virtually no CBD, which means people trying to take medicine were just getting high instead.
Again, this is a very common problem with herbal medicines, and cannabis, when smoked or ingested as the plant, is an herbal medicine.
Medical cannabis: Politics versus science
There’s no doubt that what is driving the legalization of medical marijuana in so many states has far more to do with politics than with science. Right now, for all but a handful of conditions, the evidence is slim to nonexistent that cannabis has any use as a medicine, and those conditions, such as CINV and chronic pain, can often be treated more reliably with purified or synthesized active components. Moreover, for one condition for which there is reasonably good evidence for the efficacy of cannabis and/or cannabinoids, namely chronic pain, politicians are reluctant to approve medical marijuana, as described in the recent NYT article:
Often state legislators have been motivated not just by constituents in distress, but also by the desire to restrict access to limited patient populations so that legal marijuana does not become widely available as a recreational drug in their states.
For example, while there is research suggesting that marijuana alleviates certain kinds of chronic pain, Mr. Lang noted, legislators in Illinois were reluctant to legalize its use in such a broad patient population. The state’s list of qualifying conditions is lengthy partly because lawmakers tried instead to specify a number of diagnoses that result in pain, some quite rare.
“I’ll bet there are hundreds of conditions that cause pain, and now 30 are listed,” Karen O’Keefe, director of state policies at the Marijuana Policy Project, said of Illinois’s legislation.
So, for one indication for which there is reasonably good evidence for the use of cannabis, legislators in Illinois were reluctant to approve its use, while approving its use for a lot of indications for which there is no evidence to support them. Clearly, this is a policy area that cries out for better science, given how legislators are being swayed by anecdotes that do not demonstrate that cannabis is effective and stories of “persecution” for growing medical marijuana, rather than by well-designed randomized clinical trials. Add to that the conflict with currently existing federal law, which outlaws cannabis as a schedule I drug, and the political situation is a mess, making doing research to find out for what indications cannabinoids have efficacy much more difficult. Antidrug zealots hugely exaggerate the danger of pot smoking, while pro-medical marijuana zealots claim that “cannabis cures cancer.” (It doesn’t, as I will discuss in the next installment.)
Moreover, THC can have biphasic activity:
THC has what doctors and researchers know as biphasic activity. “At low doses it has certain effects, and at high doses it has opposite effects,” Dr. ElSohly explains. “Somebody using to get high at the right dose will be calm, happy, getting the munchies, and all of that,” Dr. ElSohly says. Someone using at the right dose could see medicinal benefits, too. But take in too much THC, and you can become irritable, even psychotic. “There are more emergency room admissions today than ever because of marijuana use,” Dr. ElSohly says. “That’s simply because of the psychoactive side effects of the high THC content that the public uses.”
This makes standardization and getting the dose right more important for medical cannabis than for most other drugs, which is why I’m not enamored of smoking pot as a THC/CBD delivery system. At the risk of being too personal and “anecdotal,” I couldn’t smoke pot if I wanted to, for recreational or medicinal uses, whatever my feelings about its legalization. I can’t smoke cigarettes, either, and have never tried either pot or cigarettes. The reason is simple. Inhaling just secondhand smoke sends me into fits of coughing—and has since I was a child. Inhaling smoke directly into my lungs has been and still is more or less unthinkable. And I’d bet I’m not alone, either.
My personal sensitivities aside (which are obviously not shared by most people), I see two critical unaddressed questions with respect to cannabis. The first issue is standardization. I’m sorry, herbalists and pot smokers, but smoking a dried plant just isn’t it, particularly given the relatively low doses of active compound needed for optimal effects. That means pharmaceutical-grade material. If cannabis is a therapeutic drug, it should be treated like every other therapeutic drug and be subject to clinical trials. The second issue is comparative effectiveness research. It’s not enough just to say cannabis (or whatever cannabinoid drug or derivative you might wish to use) is “efficacious” against this disease or this condition. We need to know how efficacious it is compared to the existing standard of care. In most cases, even for indications for which there is evidence of efficacy, the existing evidence base suggests that cannabis is less effective than existing treatments, with the possible exception of its use as an antiemetic. Yet none of this sways the zealots, just as similar evidence with respect to other herbs doesn’t sway believers in herbalism. Meanwhile, medical cannabis is rapidly becoming big business.
That’s because cannabis is the new herbalism. A more balanced, science-based approach is desperately needed.

Medical marijuana as the new herbalism, part 2: Cannabis does not cure cancer
Medical marijuana. It’s promoted as a seeming panacea that can cure whatever ails you. In particular, it’s touted, primarily in the form of cannabis oil extract, as a cure for cancer that “they” don’t want you to know about. While there are potentially useful medicinal compounds in marijuana, in general the medical marijuana movement vastly oversells the promise. While some cannabinoids do have modest antitumor activity in vitro, there is no compelling evidence that cannabis can cure cancer.
David Gorski on August 11, 2014
Link
About a month ago, I finally wrote the post I had been promising to write for months before about medical marijuana. At the time, I also promised that there would be follow-up posts. Like Dug the Dog seeing a squirrel, I kept running into other topics that kept me from revisiting the topic. However, over the past couple of weeks, the New York Times gave me just the little nudge I needed to come back and revisit the topic, first by openly advocating the legalization of marijuana, then by vastly overstating the potential medical benefits of pot (compare the NYT coverage with my post from a month ago), and finally this weekend by running a story lamenting the federal law that makes research into medical marijuana difficult in this country.
I stated my position on marijuana last time, which is that marijuana should be at least decriminalized or, preferably, legalized, taxed, and regulated, just like tobacco and alcohol. I also likened the cult of medical marijuana to the “new herbalism,” because it (1) vastly inflates the potential of medicinal uses of marijuana and (2) ascribes near-mystical powers to smoking or making extracts out of marijuana, rather than identifying and isolating constituents of the plant that might have medicinal value. All of this is very much like herbalism in alternative medicine. Indeed, promoting laws legalizing medicinal marijuana is such an obvious ploy to open the door to full legalization that some advocates don’t even bother to disingenuously deny it any more. Given that I tend to support legalization, as a physician this sort of deception irritates me. It also has consequences, particularly when overblown claims are made for what cannabis can do. Perhaps the best example of this is the claim that cannabis cures cancer, which pops up all over the Internet in memes such as the one in the image above.
Don’t believe me? Just Google “cannabis cures cancer” or “marijuana cures cancer.” To my relief, you’ll find the National Cancer Institute’s page on cannabis and cannabinoids, which, as I discussed last time, dwells more on whether cannabinoids are useful for pain relief, nausea, and cancer cachexia than on whether they can be used to treat cancer directly. However, you’ll also find pages like 20 Medical Studies That Prove Cannabis Can Cure Cancer, a Facebook page Cannabis Cures Cancers!, and articles like Rick Simpson’s Hemp Oil Medicine, which resembles a lot of articles for various alternative medicine and quackery in terms of providing lots of testimonials of cures for skin cancer, diabetic ulcers, and other skin diseases and conspiracy mongering but no hard evidence. Indeed, a commenter by the ‘nym of “Danman” showed up at another blog many of you are familiar with and proceeded to make hilariously bad arguments for the healing power of cannabis and how a post at that blog was a “prohibitionist hit piece,” even though it expressed the opinion that marijuana should be legalized over the course of over 150 comments. Meanwhile, others are recommending hash oil for gliomas with a near-religious fervor, touting the same sort of evidence that Stanislaw Burzynski uses to claim he can cure gliomas with antineoplastons.
So what is the story, really?
Cannabinoids versus cancer: Hype versus science
The first problem one encounters when examining the evidence concerning the effect of cannabinoids on cancer is that the vast majority of studies touted by advocates claiming that “cannabis cures cancer” are either in vitro or animal studies. In vitro and animal studies are what we in the biz call “preclinical data,” meaning data obtained before trying a treatment in the clinic. As the American Cancer Society put it:
More recently, scientists reported that THC and other cannabinoids such as CBD (cannabidiol) slow growth and/or cause death in certain types of cancer cells growing in laboratory dishes. Some animal studies also suggest certain cannabinoids may slow growth and reduce spread of some forms of cancer. However, these substances have not been tested in humans to find out if they can lower cancer risk. There is no available scientific evidence from controlled studies in humans that cannabinoids can cure or treat cancer.
This basically says it all, and it’s tempting to wind up this post right there, but, as Han Solo said after being urged to be quiet while taking out some storm troopers, “Hey, it’s me.” Besides, you, our SBM readers, expect science in addition to my self-absorbed blather, as amusing as it might sometimes be. So you shall have it. As good a place as any to start is, as you might imagine, 20 Medical Studies That Prove Cannabis Can Cure Cancer. After all, I assume that Arjun Walia, the person who put this list together, wanted to provide the very best evidence that could be found, particularly given the emphasis that “this is a short list.” I perused the papers in the list and was—shall we say?—underwhelmed. I’ll divide my discussion into tumor types, the way the list does. First, you have to understand that CBD, one of the cannabinoids found in marijuana, is viewed as particularly promising because it does not produce the same psychotropic effects as Δ9-tetrahydrocannabinol (THC), making it a particularly attractive for developing treatments whose side effects don’t involve being stoned all the time.
Glioma. The first thing that jumped out at me is that one of these papers has nothing to do with cancer, specifically this study that suggested that cannabinoids could protect the brain against neurodegeneration in neonatal rats caused by the toxin ouabain (an Na+/K+-ATPase inhibitor). The vast majority of the other studies were in human cell lines, such as this one studying the effect of cannabidiol, a nonpsychoactive cannabinoid, on glioma cell lines. As a cancer researcher, I noted that the IC50 (the concentration that produces 50% of maximal inhibition of the parameter being measured), was 25 μM, which is a bit higher than we like for an anticancer compound. I was thus not particularly impressed, although in fairness subcutaneous injection of CBD was able to inhibit the growth of glioma xenografts implanted subcutaneously in athymic nude mice, although no dose-response was demonstrated, and a dose of 0.5 mg per mouse is a pretty generous dose (25 mg/kg for a typical 20 g mouse). So while there does appear to be antitumor effect against the glioma cell lines tested, it was, at best, modest. Certainly it wasn’t the sort that would knock my socks off as a cancer researcher. A different study, which combined THC and temozolomide, produced more impressive results, not for the THC, which produced at best modest antitumor effect, but for the combination, which looked a bit more promising. Of course, one also must note that this is not hash oil or smoked pot, but the purified THC component. That THC might be useful against glioma does not tell us that hemp oil or smoking the weed will be useful against glioma any more than the fact that digoxin works in congestive heart failure tells us that it would be a good idea to ingest foxglove leaves.
Skeptical Raptor puts it in perspective:
In one study, the researchers determined that it would take a concentration of cannabinoids of approximately 10 µmol/L to cause the death breast cancer cells in cell culture. This converts to around 3.14mg/L of THC. So, you’d have to assume that to kill any breast cancer cells, you’d need at least a blood level of 3.14 mg/L to achieve breast cancer cell death. So how close to that 3.14 mg/L can we get by just smoking a joint or two? According to research, smoking one joint will give you a blood level of THC of around 1.3-6.4 ng/mL serum, or about .00013-.00064 mg/L. In other words, to get an anti-cancer effect, you need to light up around 1000 joints per day.
The IC50 values in these studies were higher than 10 μM.
Finally, there was one human study in the list of glioma papers. Basically, this was a phase I trial testing a method of administering THC. This was also some strange science in that nine patients with recurrent glioma had their tumors resected, but a catheter was left in the cavity left behind after surgery, and then:
Each day an aliquot of the THC solution (100 mg ml−1 in ethanol) was dissolved in 30 ml of physiological saline solution supplemented with 0.5% (w v−1) human serum albumin, and the resulting solution was filtered and transferred to an opaque syringe. This process was performed at the Department of Pharmacy of the Hospital Universitario de Canarias. Owing to the high hydrophobicity of THC, we controlled by gas chromatography/mass spectrometry (see below) the actual concentration of THC in the final solution. The THC solution was administered to the patients for different times starting at days 3–6 after surgery at a rate of 0.3 ml min−1 with a syringe pump connected to the subcutaneous reservoir. In the case of Patients 1 and 2, who received THC for 30 and 26 days, respectively, biopsies were also taken after the THC-treatment period and various tumour-cell parameters were evaluated.
As you can see, this is very different from smoking marijuana or ingesting hash oil. It involves directly infusing THC solution at a high concentration directly into the brain cavity where the tumor had been, in the hope of killing off any remaining tumor cells surrounding the cavity. Let’s just put it this way. There’s a reason why direct intratumoral injection of any drug is generally frowned upon, and that’s because it’s invasive and rarely works. Moreover, no one generally bothers with intratumoral infusion of a drug unless it requires a very high concentration to work. Mean survival was 24 weeks, and two patients survived approximately a year. The authors try (rather like Stanislaw Burzynski, actually) to argue that this is better than would be expected based on other studies and controls, and to claim that some patients responded. I find no convincing evidence of this in the paper, and in a cohort of nine patients though, it’s pretty darned hard to conclude this. I agree with Harriet. There is nothing “earth shattering” about these results. They could be consistent with an antitumor effect, but they could just as easily be consistent with no effect. Worse, this was not simply ingesting, smoking, or being injected with cannabinoids. The study involved having catheters sticking out of the subjects’s heads and having THC infused directly into the brain.
Breast cancer. I’m a breast cancer surgeon; so I’m going to go out of order here. There are four breast cancer studies listed. The first study examines CBD activity against a mouse breast cancer cell line 4T1 (another cell line I’m quite familiar with, having used it in my lab and because it was a cell line developed by a now retired investigator whom I know), and the breast cancer cell line MDA-MB-231 (which I’m more familiar with than I’d like to be). Basically, the study showed a modest effect against these two cell lines in vitro and in mouse models using 1 mg/kg and 5 mg/kg CBD. The second study looked at five different cannabinoids and found that CBD was the most potent inhibitor of breast cancer cell growth in vitro (IC50 between 6.0 and 10.5 μM) and that CBD and “CBD-rich oil” could inhibit the growth of MDA-MB-231 tumor xenografts. In this study, the effects of THC on cancer cell growth were weak (IC50 between 14.2 and over 25 μM, depending on the cell line). The third study showed similar results for HER2/neu(+) tumor cell lines using THC and specific synthetic agonists (activators) of cannabinoid receptors CB1 and CB2 (Win55,212-2 and JWH-015, which activate CB1 and CB, respectively) except that THC was not as weak. The fourth study didn’t look at marijuana cannabinoids at all, but rather the endogenous cannabinoid anandamine, with similar results.
Lung cancer. The next set of three studies look at lung cancer. The first study used a cell line with which I’m quite familiar, A549 lung cancer cells, using both cell culture and mouse xenograft models. I must say that I was singularly unimpressed with the effect sizes, at least in the in vitro studies, which also required fairly high concentrations (15 μM) of THC. In a mouse tail vein injection model of lung metastases, 5 mg/kg of THC decreased metastases by 50%, which is not bad, and in a straightforward xenograft model resulted in a 50% growth delay of the tumors, which is also not bad. The next study found similar results testing CBD against lung cancer cell lines and tumor cells from a patient in cell culture and mouse models. The third study showed that stimulation of cannabinoid receptors (CB1 and CB2) with synthetic agonists, Win55,212-2 and JWH-015, which activate CB1 and CB2, respectively, inhibited the growth and invasion of A549 lung cancer cells in vitro and their growth and metastases in mouse models.
And so it goes. Nearly all of these studies look at purified cannabinoids, usually either THC or CBD, but sometimes the endogenous cannabinoid anandamine (which isn’t even in marijuana), as with the breast cancer study above and this prostate cancer study. Some use synthetic agonists, such as the breast cancer and lung cancer studies above, or this study of mantle cell lymphoma that tested R(+)-methanandamide in addition to Win55,212-2, or this study of non-Hodgkin’s lymphoma, which also used R(+)-methanandamide. With the exception of the glioma study, all were preclinical studies looking at cell culture models and mouse models. One was a review article. One, as I pointed out above, had nothing to do with cancer, and I suspect the author included it to round up his list of studies to 20.
Unfortunately, it’s a highly intellectually dishonest list of studies if your goal is to provide evidence that “cannabis” (as in the plant or extracts from the plant) can cure cancer. Unfortunately, this is not the first time Arjun Walia has constructed such a list. Last year, Liz Ditz nailed him for constructing a similarly intellectually dishonest list of studies that “show vaccines cause autism.” Let’s just put it this way. In 2013, Walia was still citing some highly discredited studies, such as studies by Mark and David Geier.
The intellectual dishonest of representing this list of studies as evidence that cannabis cures cancer aside, it is a group of moderately interesting papers that suggest that purified cannabinoid receptor agonists can produce reasonable, albeit by no means spectacular, antitumor effects in preclinical models. As a whole, they suggest that some of these purified cannabinoid agonists, whether naturally occurring, such as THC, CBD, or synthetic, such as R(+)-methanandamide, or specific to CB1 or CB2, such as Win55,212-2 and JWH-015, might be worth investigating further. Again, we’re talking about pharmacology, isolating active substances and purifying or chemically modifying them to improve their activity and safety profile, not smoking weed or using hash oil. Cancer Research UK concludes:
But claims that this body of preclinical research is solid “proof” that cannabis or cannabinoids can cure cancer is highly misleading to patients and their families, and builds a false picture of the state of progress in this area.
It’s also noted that the best results in the lab have come from using a combination of highly purified THC and CBD, but that there have also been positive results with synthetic cannabinoids, such as a molecule called JWH-133, just as I’ve described, through mechanisms that include:
    • Triggering cell death, through a mechanism called apoptosis
    • Stopping cells from dividing
    • Preventing new blood vessels from growing into tumors
    • Reducing the chances of cancer cells spreading through the body, by stopping cells from moving or invading neighbouring tissue
    • Speeding up the cell’s internal ‘waste disposal machine’ – a process known as autophagy – which can lead to cell death
Unfortunately, as good as that sounds, it’s not all good. There is also evidence that cannabinoids, under some circumstances, can stimulate cancer cell growth and possibly contribute to tumor progression. They can also have different effects depending on dose and the level of cannabinoid receptors on the tumor cells being treated. For instance, this study suggests that cannabinoids only induce apoptosis in cells that express low levels of receptors that couple to a signaling pathway called ERK1/2 but don’t induce apoptosis in cells that have high levels of receptors because they then couple through a survival pathway known as AKT. Interestingly, cannabinoids also seem able to induce cell death through pathways that don’t involve cannabinoid receptors. In other words, it’s complicated, because cancer is complicated, and cancer drugs tend to work only against certain cancers. If cannabinoids do have anticancer effects in humans, it will likely only be against certain cancers, most likely combined with existing chemotherapy and targeted drugs. We also know from the preclinical work that has been done that it will take purified THC and/or CBD and/or synthetic cannabinoid receptor agonists to produce even the modest effects observed thus far, effects that are too modest to expect cannabinoids to be any sort of cure for cancer on their own. Smoking weed or using hash oil just isn’t going to cut it.
But what about the anecdotes?
On that other blog that you all hopefully know and love, one of the commenters, Justin Kander, cited a case report that’s been going around social media as “proof” that cannabis cures cancer. This case report describes a 14-year-old girl, PK, who presented with symptoms of “weakness, shortness of breath and bruising when she was taken to the Hospital for Sick Children, Toronto, Canada, on the 10th March 2006.” She was diagnosed with acute lymphoblastic leukemia (ALL) and underwent standard chemotherapy for ALL for six months. Upon analysis, she was found to be positive for a mutation in the Philadelphia chromosome, which is found in 2-10% of pediatric ALL cases. Philadelphia chromosome-positive ALL tends to have a poorer prognosis than other ALL. PK underwent a bone marrow transplant but was noted to have blast cells six months after treatment and therefore underwent aggressive chemotherapy along with a tyrosine kinase inhibitor. After more recurrences and more treatment (such as radiation therapy to the brain for a presumed, but never completely documented, infiltration of the brain by leukemia, it was stated in the case report:
On the 4th February 2009, blood was noted in the patient’s stools and a blood cell count revealed the presence of blast cells. As a result, all treatment including the disatinib was suspended and the patient’s medical staff acknowledged failure in treating her cancer. It was charted by the patient’s hematologist/oncologist that the patient ‘suffers from terminal malignant disease. She has been treated to the limits of available therapy… no further active intervention will be undertaken’. She was placed in palliative home care and told to prepare for her disease to overwhelm her body and from which she would suffer a stroke within the next 2 months.
The family found articles on how cannabis supposedly cures cancer, and found their way to Rick Simpson, who has been featured in utterly credulous articles in High Times and SF Weekly (the latter of whose editors really should have known better) as the man who can cure cancer with hemp oil, who provided her with hemp oil mixed with honey (because of the bitter taste and viscous nature of hemp oil). This was administered in daily doses. It is claimed in this case report that there was a strong correlation between increasing dose of the hemp oil and decreases in PK’s blast count (a measure of leukemia cells in the blood), but looking at Figures 1, 2, 3, and 4, I have a hard time seeing it. Figure 1 shows increasing doses of hemp oil from what was called the “chronic” strain. That’s the closest we see to decreasing blast counts correlating with hemp oil dose. By day 15, the chronic strain was gone, and PK started taking Hemp Oil #2 from an outside source. In actuality in Figure 2, we see the blast count increasing with increasing dose until day 27, when it starts falling. Figure #3 shows Hemp Oil #3 (Afghan/Thai strain) from days 44 to 49. Given that the blast count stayed the same one can’t say much about this. Then Hemp Oil #4 was tried from day 50 to day 67, and her blast counts started rising. Finally, Hemp Oil #5 was tried and PK’s blast count fell between days 69 and 78. During that time, PK suffered the psychotropic effects of the hemp oil, including euphoria, disoriented memory, and the like.
Unfortunately, PK developed gastrointestinal bleeding and bowel perforation with peritonitis on day 78 and passed away. So, basically, she lived two and a half months after being placed on hospice. The authors assert that a dose-response curve was achieved, but to my eye I really don’t see it, except perhaps at the beginning, nor do I really buy the claim that the bumps in blast counts correlate with using “lower potency” strains. They also assert because PK was treated for tumor lysis syndrome (a syndrome in which the waste products of tumor breakdown, often seen after intense chemotherapy in hematopoietic malignancies, injure organs such as the kidneys), it must mean that the hemp oil was effective.
Unfortunately, even if a mild dose-response effect was observed that would not rule out spontaneous remission. Spontaneous remission is known to occur in ALL, although it is usually temporary, and spontaneous tumor lysis syndrome has been reported, although it is rare. In any case, one has to wonder whether the patient’s bone marrow was petering out near the end, something that is hard to determine because almost no laboratory values other than blast counts are presented, except at the end, when she had a very low platelet count (8K; normal 150K to 450K), a low white blood cell count (1.4, normal 4.5-13.0), and severe anemia (hemoglobin 8.2; normal: 13 to 16). It wasn’t established how the diagnosis of tumor lysis syndrome was made other than that the patient had elevated urate levels. Indeed, the entire case report seemed to have been written with the belief that it was the hemp oil that accounted for the decrease in blasts. A lot of information has been left out about the patient’s clinical course. All we know is that, after being placed in hospice, she was fortunate to have her blast count fall, developed a central line infection, and was treated for tumor lysis syndrome. We can also infer that she was still having considerable issues with her gut because she was on total parenteral nutrition (being fed by vein) and had trouble when they started to try to feed her orally again.
It should also be remembered that, whether or not hemp oil was responsible for the decline in blasts (which is possible but not convincingly demonstrated by this case study) or whether it was “burnout” of the bone marrow in the terminal phase of the disease or even spontaneous remission, the patient still died. She still developed GI bleeding and a GI perforation with peritonitis and died of it only 78 days after going on hospice. There’s no way of knowing whether hemp oil prolonged her life. Probably it did not, as a two to three month survival after going into hospice after being declared terminal for leukemia is well within what is expected. In other words, this case report is mighty thin gruel indeed.
Of course, the sad story of PK and the treatment of her terminal relapsed ALL with hemp oil is probably the highest quality cancer cure testimonial out there, and unfortunately its quality is not that high at all. The rest of the anecdotes I ran into tended to be about as convincing to someone familiar with cancer as nearly all the other alternative cancer cure testimonials I’ve found; i.e., not very. If you don’t believe me, take a look at this article, in which Rick Simpson claims his success rate for patients with terminal cancer is around 70% and says:
“The ones that can’t be saved are usually the ones who’ve had the most chemotherapy and radiation, or wait too long to start the treatment,” he says. “They have to be able to stay alive long enough for the oil to start to work.” In fact, most patients who undergo chemotherapy die from the treatment, not the disease.
No, it is not a “fact” that most patients who undergo chemotherapy die from the treatment, not the disease. It’s a lie. In any case, Rick Simpson is just like cancer quacks the world over, who have no firm evidence to back up their miraculous-sounding cure rates and excuse their failures by claiming that the treatment patients had before prevented the quackery from working. Quacks like Rick Simpson do those who think that cannabinoids have promise in treating cancer no favors.
Conclusions
There’s a lot of interesting research about the role of cannabinoid receptors in cancer and whether targeting them with cannabinoid agonists from marijuana or other natural sources, synthetic agonists, or endocannibinoids will be a useful tool to add to the armamentarium of anticancer therapies. From what we know now, it is quite clear that cannabis does not cure cancer, at least not by itself and certainly not ingested or smoked as marijuana or ingested or applied topically as hemp oil. Even in purified form, naturally-derived or synthetic cannabinoid agonists show relatively modest antitumor activity in preclinical models, which means that they will have to be combined with existing chemotherapeutic regimens. If they do find their way into the routine clinical treatment of cancer, it will be through rigorous pharmacological studies and rigorous clinical trials, the latter of which, in particular, are painfully lacking. Indeed, if you search ClinicalTrials.gov, you’ll quickly find lots of trials of cannabinoids to treat cancer-related symptoms and side effects, but precious few to treat cancer itself. There’s this phase I trial of Dexanabinol in Patients With Advanced Solid Tumors, which has been open two years and is still accruing patients, as well as this one of Dexanabinol against brain cancers. It’s not a lot, and suggests that there is not much interest in even synthetic cannabinoids as a treatment for cancer. After all, there are so many other promising avenues that a class of drugs that show the modest effects that the cannabinoids I’ve discussed do just don’t excite researchers that much.
In any event, the claims of advocates that “cannabis cures cancer” are nothing more than herbalism infused with the magical thinking of the naturalistic fallacy. Just because it’s “natural” does not make it better. In the case of cannabis for cancer, the only potentially promising way forward is to isolate the active components and figure out which of the hundreds of different cancers in which these components have activity against.
Finally, I have no objection to lobbying for the legalization of marijuana for recreational use. I would support such measures myself. However, trying to use hugely exaggerated claims of medicinal benefit as a back door path to legalization gets my skeptical antennae all a’twitchin’ about all the other claims made by advocates and provides ammunition for critics whose real goal is prohibition.

Medical marijuana as the new herbalism, part 3: A “cannabis cures cancer” testimonial
Medical marijuana is often touted, primarily in the form of cannabis oil extract, as a cure for cancer that “they” don’t want you to know about. While some cannabinoids do have modest antitumor activity in vitro, there is no compelling evidence that cannabis can cure cancer. Yet that doesn’t stop a proliferation of testimonials claiming that cannabis cured cancer. They are no more valid evidence than alternative medicine cancer cure testimonials.
David Gorski on March 16, 2015
Link

It’s been a while since I discussed medical marijuana, even though it’s a topic I’ve been meaning to come back to since I first dubbed medical marijuana to be the equivalent of herbalism and discussed how the potential of cannabinoids to treat cancer has been, thus far, unimpressive, with relatively modest antitumor effects. The reason I refer to medical marijuana as the “new herbalism” is because the arguments made in favor of medical marijuana are very much like arguments for herbalism, including arguments that using the natural plant is superior to using specific purified cannabinoids, appeals to how “natural” marijuana is, and claims of incredible effectiveness against all manner of diseases, including deadly diseases like cancer, based on anecdotes and testimonials. Now, as I pointed out before, not only am I not opposed to the legalization and regulation of marijuana for recreational use, even though I’ve never tried it myself, but I support it. What I do not support are claims for medical effects that are not backed up with good scientific evidence, and for medical marijuana most claims fall into that category. That’s why I tend to view medical marijuana as a backdoor way to get marijuana legalized. Personally I’d rather advocates of marijuana legalization drop the charade, argue for legalization, and stop with the medical nonsense.
The last time around, I discussed the evidence supporting claims that “cannabis cures cancer” and found them to be wanting based on science. I didn’t however, discuss the “cannabis cures cancer” testimonial machine that drives the claim that marijuana is useful for treating cancer; at least, I only touched on it by discussing briefly Rick Simpson, who claims that his hash oil cures approximately 70% of patients with terminal cancer and a published anecdote in which it was claimed that hemp oil was effective in treating acute lymphoblastic leukemia. (It wasn’t. At least, the evidence presented was not convincing.) Since then, I’ve wanted to revisit the topic of “cannabis cures cancer” testimonials, and, for whatever reason, now seems like a good time to do it.
Stephanie LaRue
Last week, I discovered the “cannabis cures cancer” testimonial of a young woman named Stephanie LaRue. Hers is a sad story in that she was diagnosed at a young age (30 years old) after her boyfriend found a lump in her breast and misdiagnoses by three different doctors. In many ways, her story is an inspiring one based on her will to fight and her activism, which have led her to have served on the Board of Directors for the Los Angeles Susan G. Komen for the Cure, Southern California’s Breast Cancer Network of Strength, and the USC Norris Cancer Center’s Cancer Survivorship Advisory Council. Near and dear to my heart, she also is very much into rescuing and fostering many wounded, mistreated and special needs dogs. Indeed, I approach this particular testimonial with more than a little trepidation because there’s an incredible amount to admire about LaRue and, more importantly, her involvement with Komen and other breast cancer charities means that people I respect and admire (who might read this) very well might know her—or even be friends with her. Still, given the direction her story has taken, I feel obligated to discuss it.
Here’s a video of her from 2007 when she was still undergoing chemotherapy:
Notice the themes we see so often in cancer patients, particularly young cancer patients: Why me? There must be a reason. It can’t have “just happened”. Breast cancer is a disease of older women. (Indeed, the mean age at diagnosis is around 61.) There must have been something in the environment. Possibly. As I’ve pointed out before, for breast cancer, environment- and lifestyle-attributable causes account for a much smaller fraction of cancer diagnoses than most people believe, and 1.8% of cases of breast cancer occur in women 34 and under. Given that there are approximately 233,000 new cases of breast cancer diagnosed every year in the U.S., that means that close to 4,200 women under 34 are diagnosed each year with breast cancer. Still, being diagnosed with breast cancer at age 30 is unusual; so it’s understandable that LaRue would wonder why it happened to her.
Worse, LaRue was diagnosed with Stage IV disease, as described in an article by Sonja Renea published on the Medical Jane website entitled “Meet Stefanie LaRue: Cancer Survivor and Medical Marijuana Advocate“:
Stefanie was sent home several times with several rounds of antibiotics, which is quite telling of younger folks being misdiagnosed. By the time she could be tested thoroughly, the cancer had spread to her bones. Doctors diagnosed her with Stage 4 Metastatic Breast Cancer, which is cancer that has spread beyond the breast to other organs in the body. The prognosis was grim: she was given a year to live, at most.
Three weeks later, Stefanie began her first round of chemotherapy. To make matters worse, she had to to [sic] cope with her employer, who showed little sympathy for her situation. Despite her job in commercial real estate being very stressful, she was expected to work through her cancer treatment.
This is a big problem with health care in the U.S. besides the difficulty many people have affording health insurance, a problem only partially alleviated by the Affordable Care Act (a.k.a. Obamacare), which didn’t exist in 2005. You can be diagnosed with metastatic breast cancer and still be screwed as far as work goes. It happens far too often in this country.
So LaRue ended up quitting her job and filing for disability. She underwent six rounds of chemotherapy and then a mastectomy. At this point reading her story I had a question. If LaRue had bone metastases, it’s not clear to me why her surgeon and oncologist would recommend that she undergo a mastectomy. Three possible reasons suggest themselves to me as a breast surgeon. One is that it was done to prevent the primary tumor from growing through the skin and turning into en cuirasse disease, although usually such surgery is not done right after chemotherapy but when the tumor has started to grow again. Another is that she had a complete radiologic response to the chemotherapy, meaning that all her breast and bone disease disappeared. When that happens and the patient has been rendered “no evaluable disease” (NED), we will often treat her as though she were not stage IV and undertake surgery with curative intent. The final possibility is that surgery was done with the intent of prolonging survival even though metastases were still present. It’s been an ongoing controversy in breast cancer over whether removing the primary tumor prolongs survival in stage IV disease or whether the apparent improvement in survival due to surgery is due to selection bias; that is, bias towards healthier patients with less aggressive disease who are chosen to undergo surgery preferentially. More recent evidence suggests that removing the primary probably doesn’t improve survival, but that was not at all clear back in 2005. (To be honest, it still isn’t quite clear.)
On her website, LaRue reports that her tumor was 8 cm in diameter (which is big). Apparently her tumor didn’t shrink enough to be removed in a lumpectomy; so she needed a mastectomy:
After chemo she had surgery to remove the cancer. But her margins were not clear, so another surgery followed. She was left with only skin and a nipple on the right side of her chest. Her breast surgeon had scraped all the way down to the chest wall removing all the breast tissue possible but sparing the skin. Despite the advanced stage of her cancer, she got to keep the outside of her breast because she had a skin-sparing mastectomy. A plastic surgeon was later able to reconstruct her breast, restoring her shape, her femininity and her sexuality.
At this point in my reading, I was unclear as to why a surgeon would do a skin-sparing mastectomy in a patient with stage IV disease. Most plastic surgeons are reluctant to do reconstruction in such a patient because reconstruction can be a big operation, and if the patient isn’t expected to live more than a year it just doesn’t make a lot of sense to have the patient spend a significant chunk of her remaining time recovering from surgery, having additional surgeries to “touch up” the reconstruction. The willingness of her surgeon and plastic surgeon to undertake a skin sparing mastectomy and reconstruction suggests to me that she had a very good response to the chemotherapy and/or that her prognosis as a stage IV patient was viewed as being considerably more favorable than usual.
Whatever the case, during the chemotherapy that she underwent before her surgery, LaRue looked to alternative medicine to ease her symptoms:
She found help with an integrative oncologist at UCLA, where she learned how to make changes to her diet, use natural supplements, get acupuncture, and work on personal fitness; all of which are integrative, complementary, and alternative treatments to go along with chemotherapy.
Now here’s the thing. As a patient with stage IV disease, LaRue did really well for eight years. It’s hard to find a good detailed description of what happened between November 2005 (when she was diagnosed with breast cancer) and 2013, but she didn’t start using cannabis oil until 2013, which means that conventional oncology is what got her through nearly eight out of the nine and a half years she’s survived with her stage IV cancer. It’s important to remember that when looking at a lot of the articles about LaRue, because before 2013, although she had gone all in for “integrative oncology,” she hadn’t yet discovered cannabis and was still being treated with mostly conventional medicine. So, between 2006, when she finished her initial treatment, and at least September 2013, when she posted a series of images to Instagram of her hospitalization for thoracoscopic surgery, conventional medicine is what kept LaRue alive. So when Sonja Renea of the Medical Jane website writes that “Stefanie LaRue was 30 years old when she was diagnosed with Stage 4 Metastatic Breast Cancer and given the dismal prognosis of less than a year to live” and follows it up with, “That was nine years ago,” she is being deceptive.
This is how it’s described in the Medical Jane:
In 2013 Stefanie had a Video-Assisted Thoracoscopic Surgery (VATS) and the results were not good. This was now her third reoccurrence of cancer. The chemo sensitivity testing concluded there were five lines of chemo treatments that would work on the tumors.
Stefanie declined the treatment. “I did my homework. I researched as much as I could. I watched. I listened. I read. I contacted. I prayed. Most of all, I believed. I weighed my options, which were essentially chemotherapy or cannabis oil, and I decided to take the natural route this time…” she says.
Stefanie followed the Rick Simpson Oil (RSO) protocol until she was cancer-free. “Cannabis oil killed all of the tumors in my body. My monthly lab and quarterly scan results are proof that the cannabis oil treatment worked,” she says. Her doctor, who had previously been skeptical, now credits these “alternative” treatments as the reason for her speedy recovery.
On Instagram, LaRue described it thusly in a posting dated October 2, 2013:
Dear cancer, as we both know, yesterday was a big day of news. And sadly for you, you lost. You lost your “upper hand” you tried to claim in that you were potentially showing up again (unwelcomed in my body) not as a metastatic reoccurrence, but as a possible new primary cancer. Which would have been a much more challenging ass kickin match between you and I. None the less, I would have enjoyed. But since you are now known as the same initial metastatic breast cancer reoccurring, I hope you are preparing for what is coming to you. Because now I have the upper hand. When the chemo sensitivity tests are complete on my biopsy tissue at Caris Labs we will know exactly what to come after you and all your little friends with! Poor you. I know your still cowardly hiding in my body but you have pissed off some pretty important people that care a lot about me and guess what… Now they too are coming in to whip your ass!!!
We’ve encountered Caris Labs before in the context of discussing Stanislaw Burzynski’s incompetent “personalized gene-targeted cancer therapy.” Basically, Caris is a company that will do various genomic tests and immunohistochemistry on a tumor sample to try to identify which targeted agents it might be sensitive to. I’ve basically discussed how the routine use of such a test is premature, given that there isn’t any good evidence that using a test like the one from Caris or other competing tests results in better response rates or prolonged survival, but such tests have still proliferated and their use is not uncommon, even in academic medical centers.
In any case, at this point in the fall of 2013, LaRue was facing her third recurrence of cancer. Unfortunately, this is a story very much like the many alternative cancer cure testimonials I’ve deconstructed over the years in that we lack a lot of key information, which means that I can only speculate. First, we don’t know how extensive a cancer recurrence LaRue had. Given that she underwent thoracoscopic lung surgery (a thoracoscope is like a laparoscope, except that instead of letting a surgeon operate in the abdomen it allows the thoracic surgeon to operate in the chest with minimal incisions), presumably she had a lung nodule. In a patient with stage IV disease, most such lesions would be biopsied using a core needle under CT scan guidance, rather than excised surgically through a laparoscope. Why did the surgeon choose this course?
A couple of possible reasons suggest themselves from the story. First, perhaps she did undergo a CT-guided core needle biopsy and the diagnosis was uncertain. Certainly LaRue’s Instagram posting, in which she gloats over her tumor for not being a new primary tumor but just the same as the other recurrences of her original tumor, suggests that this could be the case. After all, a new suspicious lung nodule in a breast cancer patient is usually considered a new metastasis until proven otherwise. In any case, in patients with metastatic disease, a tissue diagnosis is always imperative before beginning treatment if at all feasible. Another possibility is that this tumor, whatever doctors thought it was before surgery, was the only site of disease detectable. In such a case, particularly in a young patient who had been doing well for nearly eight years even if she did have stage IV disease, strong consideration would be given for excising the cancer and eliminating the only known site of disease even though the evidence that metastasectomy (removing the metastasis) will prolong survival in breast cancer is mostly without controls and thus prone to selection bias. (Metastasectomy of liver and lung metastases can definitely prolong survival in colorectal cancer.) Still, there is evidence that in select patients removing pulmonary metastases can result in significant survival benefit. Whether LaRue is one of those select patients is unclear.
So here’s what I think probably happened. After surgery LaRue (understandably) did not want to undergo further chemotherapy. For whatever reason, she latched on to Rick Simpson’s hemp oil as the treatment that would control her cancer. How she found out about it and why she became convinced it would cure her, it’s hard to say from publicly available information. In the Medical Jane story, LaRue proclaims that “cannabis oil killed all the tumors in my body” and that her “monthly lab and quarterly scan results are proof that the cannabis oil treatment worked.” It is, of course, impossible to confirm or dispute this assessment without knowing what all her scans showed.
There is, however, a photo on Instagram of LaRue receiving a shot, which she identifies as Xgeva, which LaRue described as “bone mets maintenance.” And so it is. It’s a monoclonal antibody against the RANK ligand, a protein that acts as the primary signal for bone removal, and it prevents fractures in patients with bone metastases. So this implies that LaRue still has bone metastases. It also makes one wonder what other non-chemotherapy conventional therapy she might be taking. There’s also a post by her on Twitter asking about Afinitor (everolimus):
New treatment protocol side effects (third reoccurrence) should I take or seek other alt options? #cancersucks pic.twitter.com/hlAbCaa462
— Stefanie LaRue (@stefanielarue) October 28, 2013
Afinitor is a drug that inhibits an enzyme called mTOR and is used in cancer that is positive for the estrogen receptor after it develops resistance to anti-estrogen therapy. Apparently she did not take Afinitor, because on March 14, 2014 LaRue posted a photo on Twitter:
This is about the time when getting #treatment really sucks! #zoladex #injections #stomach #fuckcancerpic.twitter.com/MwNIqvwm0k
— Stefanie LaRue (@stefanielarue) March 8, 2014
In the photo, LaRue is receiving an injection of Zoladex (goserelin), a drug used to suppress production of sex hormones. In other words, six months after her thoracoscopy, LaRue was receiving conventional medical therapy, specifically a treatment to shut down her ovaries’ production of estrogen. Thus, LaRue appears to be the case of a cancer patient who chose unproven alternative medicine but at the same time continued to receive conventional medical therapy for her cancer and did very well. As is the case with most such patients, she attributes her excellent outcome, at least after her most recent relapse, far more to the alternative treatments (in this case, Rick Simpson’s hemp oil) than she does to the conventional therapy she is also taking, even after her discovery of hemp oil. I also can’t help but point out that the very fact that LaRue survived nearly eight years with stage IV cancer before discovering hemp oil is a pretty strong argument that from a biological standpoint her tumor is pretty indolent, as some tumors positive for the estrogen receptor are; so it’s not surprising that she would still be alive a year and a half after her thoracoscopy on Zoladex and Xgeva alone (plus whatever other conventional medical therapy she is receiving). Only LaRue and her oncologist know for sure, though, and her oncologist can’t tell anyone without her permission.
Cannabis versus breast cancer
As much as I admire the grace and determination with which Stefanie LaRue has endured over 9 years after her cancer diagnosis, as a cancer doctor it bothers me profoundly that she has allowed herself to fall under the spell of the “cannabis cures cancer” alternative medicine crowd, in particular Rick Simpson. I discussed Simpson the last time I wrote about cannabis and cancer. As I said at the time, Rick Simpson is just like cancer quacks the world over, who have no firm evidence to back up their miraculous-sounding cure rates and excuse their failures by blaming the treatment patients had before they started the quackery. Quacks like Rick Simpson do those who think that cannabinoids have promise in treating cancer no favors.
I also discussed how the vast majority of studies touted by the “cannabis cures cancer” advocates tend to be preclinical studies in cell culture or animal models that show relatively modest antitumor effects due to various cannabinoids. Indeed, this article on Medical Jane, “Studies Show Cannabinoids May Help Fight Triple-Negative Breast Cancer“, fails to provide particularly convincing evidence that they do. Before I look at the studies, I can’t help but note that triple negative breast cancer is breast cancer that makes neither the estrogen receptor (ER), the progesterone receptor (PR), nor overexpressed HER2. Yet the article invokes Stefanie LaRue, who clearly has ER(+) breast cancer.
Another thing that needs to be pointed out. Every single one of the studies invoked by Medical Jane has nothing to do with hemp oil, be it Rick Simpson’s hemp oil or some other type. Each of the studies examines either purified cannabinoids or, in the case of this study, a chemically modified cannabinoid. This study cited in Molecular Cancer, for instance, looks Δ9-tetrahydrocannabinol, the most abundant and potent cannabinoid in marijuana, and JWH-133, a non-psychotropic CB2 receptor-selective agonist. Both inhibit the growth of HER2(+) breast cancer cells in cell culture and in mice, but the concentrations needed are pretty high, with an IC50 (concentration that is 50% of maximum inhibition) in the range of 5 to 10 μM, concentrations achievable with injection of purified compound but certainly not by smoking pot
You are also unlikely to achieve these levels by drinking hemp oil, which, by the way, usually contains so little THC that it is below the limit of detection for common assays and manufacturers brag that it’s impossible to fail a drug test if you’re consuming hemp seed oil because “THC levels in our products are barely measurable.” Of course, I do realize that Rick Simpson calls his oil hemp oil even though it’s really cannabis oil derived from the buds rather than the seeds, but even he brags that “following the dosage previously described, many people can take the full treatment and never get high,” which implies that his oil achieves nowhere near the concentration of THC in the blood necessary to be active against cancer. Moreover, oral bioavailability of THC from such oils is notoriously low, between 4-20%, making it unlikely that concentrations well above the 10 μM necessary to inhibit or kill more than 50% of the cancer cells are achievable with oral dosing.
Thus, the various studies cited, such as this one, which shows inhibition of the epidermal growth factor pathway by purified cannabidiol (CBD), a non-psychotropic cannabinoid; this one, the aforementioned study that examines purified Δ9-THC and JWH-133 against HER2(+) breast cancer; and this one, which also examines CBD in breast cancer, are interesting and very preliminary. Moreover, they all examine cannabinoids purified from cannabis, and one even examines a chemically modified cannabinoid. In other words, even if cannabinoids make the jump from preclinical models to humans, these studies do not support the use of medical marijuana, either smoked as the plant or ingested as an oil, to treat breast cancer. They also do not suggest sufficient activity to produce miracle cures of stage IV cancer as described by Rick Simpson. Indeed, a recent review concludes that “current preclinical data does not yet provide robust evidence that systemically administered Δ9-THC will be useful for the curative treatment of cancer,” although CBD might have a role based on preclinical data.
Neither cannabinoid, however, is likely to be curative for advanced cancer. It’s possible that specific cannabinoids might have a role to play in the multimodality treatment of cancer, but, given what we know about them from preclinical studies, it’s highly unlikely that cannabinoids, medical marijuana, or Rick Simpson’s hemp oil can cure stage IV cancer of any kind.
Hope versus hype
I have no doubt that Stefanie LaRue honestly believes that Rick Simpson’s hemp oil is the reason why she’s still alive today and doing so well. I can’t help but point out that Stanislaw Burzynski’s patients, for example, also honestly believe that his antineoplastons are what saved their lives, even though even Burzynski can’t produce good evidence that they have antitumor activity. Depressingly, it just goes to show how even such an accomplished woman can fall prey to the same human cognitive shortcomings that we all share and confuse correlation with causation. If it were just her, I wouldn’t have felt obligated to write this post, but LaRue makes it very clear that not only does she believe that Rick Simpson’s hemp oil allowed her to heal herself of her longstanding metastatic cancer:
Did you know that the Rick Simpson hemp oil is being used to treat cancer patients? I’m one of them. And it’s working pic.twitter.com/XGX9tzJHTo
— Stefanie LaRue (@stefanielarue) July 4, 2014
But she plans on becoming an evangelist for Rick Simpson’s hemp oil and medical marijuana:
In this video she notes that she’s had multiple recurrences and they’re all gone, after which she challenges the viewer to “explain that.” Believe it or not, personally, I’d be overjoyed if something as simple as hemp oil could treat stage IV cancer so effectively. I really would, as it would mean that I’d rarely have to see a breast cancer patient die. However, although I can’t be sure without a lot more information (which is highly unlikely to be forthcoming) and I do have to concede the possibility, albeit remote, that Rick Simpson’s hemp oil is the reason why LaRue has survived a year and a half since her last new metastasis, I nonetheless suspect that it is far more likely than not that it is the Zoladex and the Xgeva (not to mention whatever other conventional treatments that LaRue may be taking that she hasn’t mentioned on social media) that are keeping her going now, combined with her disease’s already-demonstrated indolent biology.
And long may they continue to do so!
For nearly eight years, Stefanie LaRue fought a battle with courage, inspiring intelligence, and grace. Her story was (and still is) a story of hope for women with stage IV cancer that they can live a long time with the disease with good quality of life. Unfortunately, a year and a half ago her story took a turn into pseudoscience, becoming a cautionary tale of how even the most intelligent, ambitious, and determined person can be subject to magical thinking. This would not be an issue with me were it not that, inadvertently, and with the best of intentions, LaRue has declared her determination to promote Rick Simpson’s hemp oil as a cancer cure, using her own story as an example of what it can do. Given her proven history of advocacy and her numerous accomplishments with organizations like the Komen Los Angeles County Affiliate from 2008 to 2010 (before she discovered hemp oil), I can’t help but be worried that she will in her quest to save women from stage IV breast cancer end up doing exactly the opposite for some women.
I still hold out hope that, given her history, LaRue will eventually realize that her true story is a cause for hope for women with stage IV disease. Thanks to advances in breast cancer care, more and more women with stage IV disease are living a lot longer than expected, even ten years, all with no need to resort to unproven treatments promoted with testimonials, like Rick Simpson’s hemp oil.
That’s the real reason for hope.

Medical marijuana as the new herbalism, part 4: Cannabis for autism
Medical marijuana. It’s promoted as a seeming panacea that can cure whatever ails you. While there are potentially useful medicinal compounds in marijuana, in general the medical marijuana movement vastly oversells the promise. Nowhere is this more true than for cancer and autism, where there is no compelling evidence that cannabis cures cancer. Worse, parents are subjecting autistic children to cannabis with no evidence and even persuading state governments to list autism as a condition for which medical marijuana is appropriate.
David Gorski on August 3, 2015
Tweet

When I first started writing about the claims made for medical marijuana and the cannabis oil derived from it, it didn’t take long for me to characterize medical claims for cannabis as the “new herbalism,” as opposed to pharmacognosy, the branch of pharmacology devoted to the study of natural products. The reason is simple. Although I support legalization of marijuana for recreational use, when I look at how medical marijuana has been promoted as a “foot-in-the-door” prelude to legalization, I see testimonials and flimsy evidence ruling over all. I see all the hallmarks of alternative medicine herbalism and none of the hallmarks of pharmacology. Here’s what I mean. Pharmacognosy examines an herb, plant, or other natural product and seeks to identify the chemicals within it that have pharmacological activity against a condition or a disease, the better to purify and isolate those chemicals and turn them into drugs. Herbalism, on the other hand, emphasizes the use of whole plants or extracts from plants, rather than the isolation of the most active compounds. Thus, herbal remedies often contain hundreds, or even thousands, of different compounds, of which only one or a few are active. Even extracts, such as cannabis oil, contain many compounds.
In contrast to pharmacognosy, herbalists make the claim that whole herbs and plant components possess a synergy that is missing from the purified active constituents and/or that the mixture is safer than the pure components because one compound can reduce the side effects of another without reducing therapeutic efficacy. When looked at closely neither claim stands up to scrutiny. Synergism between plant constituents is rare and very difficult to demonstrate, for example. In essence, herbalism turns back the clock 200 years to a time before scientists had developed the techniques and abilities to isolate active ingredients with pharmaceutical activity. Moreover, herbalism, in contrast to pharmacognosy, emphasizes anecdotes over scientific evidence.
Indeed, in my previous posts in this series on medical marijuana, one theme has emerged, which is that cannabis—specifically, a class of active chemicals in marijuana known as cannabinoids—has potential for some diseases but is not the panacea claimed by its proponents. It does not cure cancer, for instance, contrary to glowing testimonials promoted by people like Rick Simpson. For other conditions, the evidence is either not particularly compelling or only mildly promising.
So I reacted with considerable dismay on Friday night when I saw this news report on the 11 o’clock news, “Michigan panel recommends allowing marijuana for autism“:
video platformvideo managementvideo solutionsvideo player
And, indeed, there have been stories all over the local news in Michigan like the one above and this one:
Note all the hearty cheering from the audience when the vote tally was read.
Here’s what happened:
Michigan would become the first state to allow medical marijuana for children with severe autism if a senior official follows the recommendation made Friday by an advisory panel.
The state’s Medical Marijuana Review Panel voted 4-2 to recommend autism as a condition that qualifies for the drug.
Supporters say oil extracted from marijuana has been effective in controlling extreme physical behavior by kids with severe autism. Pot wouldn’t be smoked.
The panel was influenced by comments received earlier from some Detroit-area doctors, especially the head of pediatric neurology at Children’s Hospital of Michigan, and parents desperate for relief. Many of the three dozen spectators cheered and applauded after the vote.
This is an utterly horrible idea, but it looks as though our state is nonetheless about to take the plunge into the Brave New World of treating autism with cannabis oil. Indeed, Michael Komorn, the President of the Michigan Medical Marijuana Association and the attorney who brought the petition before the board, basically admitted in the first news clip above that there was no science behind the board’s recommendations when he said: “It’s a no-brainer. And you heard the testimony of these people. They just want a little hope. That’s all they’re asking for.” Notice the distinct lack of any mention of strong science as a rationale for adding autism to the list of qualifying conditions. Komorn even went so far as to tout how the parents “are responsible for growing the plants or acquiring the cannabis, and they are in charge of dosing, frequency of use, and method of ingestion.”
Think about this for a moment. Is there another regulated drug for which this is the case? The board didn’t even provide, along with its recommendation for approving autism as a qualifying condition for treatment with cannabis oil, anything resembling recommendations for dosing, method of ingestion, and frequency of use, something very basic that is required by the FDA for even over-the-counter medications. Yet, here, in the fantasy world of medical marijuana, apparently parents are as knowledgeable as physicians and no guidelines for use are needed. The lack of dosing recommendations is another powerful indication that there is no science behind this recommendation, because if there was science behind it we’d know the optimal dose and method of administration to use cannabis oil to treat autism. Clearly, emotion, not science, ruled the day on Friday. Indeed, how Dr. Harry T. Chugani, the head of pediatric neurology at an institution as respected as Children’s Hospital could testify in favor of this is beyond me, but apparently he did:
“It seems to work. … Wouldn’t that be better than giving them all these psychiatric drugs?” Chugani said. “Not every autistic kid would take this, but if your behavior is wild and you have to be institutionalized, I as a physician would prefer to try medical marijuana. I have at least 50 patients on multiple drugs and still their behaviors are not controlled.”
Notice that Dr. Chugani, too, didn’t cite anything other than anecdotal evidence. How, for instance, did he know that the child isn’t calmer because he’s high on cannabis? And if we’re going to drug autistic children to make them behave, why not use opioids or other sedatives as well?
In any event, if you want evidence that medical marijuana is far more akin to herbalism than pharmacology, we need look no further than my state’s dubious position of becoming a “pioneer” in something that no state should be a pioneer in. That’s why I’ll first examine how the Medical Marijuana Review Panel got to where it is now, then the general claim that cannabis is a useful treatment for autism. Finally, I’ll evaluate the existing scientific evidence, which is pretty thin.
Autism biomed quackery embraces medical marijuana
As has been the case with virtually all uses of medical marijuana sanctioned by states, the road to the Michigan Medical Marijuana Review Panel recommending approval of cannabis for autism began not with doctors and scientists clamoring for it based on evidence, but with parents becoming politically active to lobby for it based on emotional anecdotes. Such was the case in Michigan, and, if you’ve been paying attention to the “autism biomed” movement, this quote will sound very familiar:
The review panel voted 4-2 in favor of a petition submitted by Lisa Smith, a Michigan mother who has said cannabis oil has helped improve her severely autistic 6-year-old son’s behavior, sleep patterns and eating schedule.
“The parents I’ve talked to are passionate and adamant that this represents a dramatic improvement in the quality of life for them and their affected children,” said David Crocker, a medical marijuana doctor and member of the panel.
What other treatments for autism have we heard the same claims for? Let me think… Oh, yes. We’ve heard them for quite a few “autism biomed” treatments, with parents being just as passionate. Unfortunately, the vast majority of “autism biomed” is rank quackery. Examples include “Miracle Mineral Solution” (MMS, a.k.a a form of bleach fed to autistic children and administered as enemas for which miraculous results are claimed), chemical castration with Lupron, chelation therapy, GcMAF, and many, many other pseudoscientific “treatments” featured at quackfests like Autism One. I’ve even seen glowing testimonials touting homeopathy for autism and the IonCleanse® “foot detox” bath. As regular readers know, homeopathy is, as I like to say, The One Quackery To Rule Them All, and “foot detox” baths are a scam.
Not surprisingly, segments of the autism biomed movement have embraced medical marijuana. For example, one prominent website advocating autism biomed quackery, the “Thinking Moms’ Revolution” (TMR), has numerous posts on its blog extolling the alleged virtues of medical marijuana for treating autism and advocating “freedom of choice.” If you doubt the increasing embrace of medical marijuana by the autism biomed quackery movement, look no further than this ad for an Medical Marijuana for Children with Autism eConference, sponsored in part by TMR. Indeed, Jeff Bradstreet, the longtime antivaccine autism biomed “practitioner” who committed suicide a month and a half ago after the FDA raided his clinic, was a speaker! So was a key supporter of medical marijuana for autism in Michigan, Lester Grinspoon.
Does this striking resemblance between autism biomed rhetoric and medical marijuana rhetoric mean that cannabis is useless for autism? Not necessarily, but it raises red flags. In any event, it would be more accurate to say that we don’t really know whether cannabis oil is efficacious for treating autism. I mention this similarity between the autism biomed movement and medical marijuana movement to emphasize how anecdotal evidence is incredibly unreliable, particularly for a complex condition like autism spectrum disorder (ASD). If you don’t believe me, consider this. Equally glowing testimonials for the rank quackery that is homeopathy to treat autism are not difficult to come by, which is one reason why testimonials are insufficient evidence upon which to base public policy; yet, that’s just what is happening in Michigan—and has been since medical marijuana was first approved. Remember, autism is a condition of developmental delay, not stasis, and autistic children frequently improve as they get older. Some even improve sufficiently to lose the ASD diagnosis.
Misguided activism advances cannabis for autism in Michigan
I understand (at least as much as someone who hasn’t actually experienced having a child with special needs can) how parents would be desperate to do everything they can for their children, but personal experience and anecdotes, contrary to what is claimed, can be extremely misleading, as we’ve described here many times before. That’s why anecdotes are not enough, and carefully controlled randomized clinical trials are needed, which, contrary to the claims of advocates, don’t really exist. Indeed, the science cited in the petition, as we will see in the final section of this post, is inadequate to make such a major policy change, consisting as it does of mainly preclinical evidence and case reports.
With that in mind, it’s useful to note that the road to this “victory” began years ago and actually represents a rebound from a defeat two years ago. In 2013, the Michigan Medical Marihuana Review Panel voted against adding autism to the list of indications for medical marijuana by a 7-2 vote:
Jenny Allen, whose 6-year-old son was diagnosed with autism several years ago, has tried giving him “mind-bending” medications, signed him up for behavior therapy and changed his diet. But his problems, including self-destructive behavior and biting, continue.
Now the 32-year-old Lansing mom wants to try giving him part of a brownie — a pot brownie — but was brought to tears Tuesday when the Michigan Medical Marihuana Review Panel rejected a petition that would have given her the legal means to do so.
The panel, in a 7-2 vote, gave a final recommendation against adding autism to a list of debilitating conditions suitable for treatment under Michigan’s voter-approved medical marijuana law.
“I’m incredibly disappointed,” Allen told MLive after the hearing, going on to question whether all panelists had thoroughly researched the topic. “I’m pretty shocked, actually, that nobody even brought up what the base condition is. It’s rather appalling.”
The panel made this decision in 2013 based on a correct assessment of the state of the evidence, which is that there is “not much quality, peer-reviewed research exploring marijuana as a treatment for autism,” that the case for adding autism to the list of approved conditions for which medical marijuana can be prescribed consists almost entirely of anecdotes and testimonials, and that not enough is known about the effects of long term use of cannabis on the developing brain. This assessment was correct in 2013, and nothing has happened in terms of the existing science during the intervening two years to change that assessment. So what really happened to reopen the case?
Not surprisingly, it was litigation that forced the Department of Licensing and Regulatory Affairs to submit a new petition for autism to the Medical Marihuana Review Panel. It was submitted on behalf of a woman named Lisa Smith for her son Noah, who has severe autism:
Lisa Smith says her son’s behavior was dangerous: hair pulling, kicks, punches, all related to a severe form of autism. But it began to change more than a year ago when he was given daily oral doses of oil extracted from marijuana.
“That’s all stopped. He’s more focused, he’s calmer,” Smith said of 6-year-old Noah. “He sleeps better through the night. He has a better appetite. You can tell he’s growing, gaining weight.”
Another parent who features in several of the news stories about this issue is Dwight Zahringer:
Dwight and Ixchel Zahringer’s son Brunello is going on 4 but has yet to speak. Last fall, his parents heard the chilling diagnosis — autism.
“We’ve had a hard, fast education in this for the last nine months,” Dwight Zahringer said. “Think of it like always being at a rock concert — everything really loud — and then you’re trying to have conversations or focus on things but you can’t because everything is overwhelming,” he said.
The dealings with health professionals form a familiar tale — advice to use powerful prescription drugs that are costly and may have worrisome side effects, the failure to see that those drugs are helping and the decision to stop them.
The Zahringers have thus far been disappointed with the progress their son Brunello has made with conventional therapy, such as Applied Behavioral Analysis. Seeking faster progress, they found medical marijuana and latched on to it for hope:
“We’ve been watching a lot of videos, a lot of documentaries, and we’ve seen proof that it can help,” said Ixchel Zahringer.
“One family had a kid who was very severe” with autism symptoms, “and they started giving him some of that (cannabis) oil, and they saw the child calming down.”
Dwight Zahringer came to his belief that he needs medical marijuana for his Brunello the same way that many in the autism biomed movement come to the conclusion that their child needs, for example, MMS. He pored over Internet sites and marijuana-themed literature, which convinced him that he needed to try cannabis on his son ASAP. He started using hemp oil, which apparently gets around the state’s current ban on treating autism with marijuana, but really wants the real thing. Parents like the Zahringers and Lisa Smith are clearly loving parents who want the best for their children, just as most parents who fall for “autism biomed” quackery love their children and want the best for them. Unfortunately, as we have seen and will see, the pro-cannabis literature and websites that tout cannabis as a treatment for autism provide a very biased and cherry-picked view of the medical literature.
Cannabis for autism: The evidence (or, more correctly, the lack thereof)
Perusing the news reports on the vote of the Michigan Medical Marijuana Review Panel, one point I’ve seen is that the reason why this vote came down in favor of adding severe autism to the list of qualifying conditions and the vote in 2013 did not is because the science was so much better described in the petition this time around. Indeed, advocates tout having bolstered the petition with “over 75 peer reviewed articles with over 800 pages of research on the issue of cannabis as a viable option for the treatment of autism” in addition to the “nineteen families, as well as physicians from MI and around the country.” Apparently, two advocates had a major hand in picking these articles:
The individuals who navigated the deepest into the science behind Autism’s riddling labyrinth of theories are without doubt Joe Stone and Dr. Christian Bogner. They were able to provide peer reviewed evidence that cannabis not only has the potential to provide palliative relief of symptoms related to autism, but may also have the potential to target the underlying causes of autism itself.
Note that nowhere in this report is mentioned evidence from well-designed clinical trials. In any event, I could not find the exact petition text, but there is a MoveOn.org petition to add autism to the list of qualifying conditions for medical marijuana in Michigan posted by Joe Stone and signed by Dr. Christian Bogner, Chad Carr, Dr. Harry Chugani, M.D., Dr. Lester Grinspoon, Michael A. Komorn, and Joe Stone. At the end, it lists links to research, specifically a paper written by Stone and Bogner that, one notes, was published online on the Cannabis for Autism blog rather than in a peer-reviewed medical journal, entitled “The Endocannabinoid System as it Relates to Autism“. This paper is also available on Scribd, with a complete list of references. It is clear to me that this discussion, along with its references, was the basis of the science presented to the panel.
Before I address this paper, which appears to be the best evidence advocates can put forward, let me just refer you to a good solid analysis of the state of the evidence for cannabis for neurological disorders by Skeptical Raptor. You can read the whole thing if interested, but the point I want to emphasize is that there is weak evidence that cannabis could be useful for epilepsy, as I discussed in my first post on this topic, but that a Cochrane review concluded that high quality evidence was insufficient to recommend it. There is also some evidence for the use of medical marijuana for spasticity and pain. The reason that this is relevant is because advocates for using medical marijuana for autism frequently point to cases where cannabis is used to control seizures, which many autistic children suffer from. This is a separate issue than whether cannabis is specifically therapeutic in autism, but the two issues are often conflated.
Sadly, Stone and Bogner’s “paper” is one of the most blatant examples of cherry-picked research I’ve seen in a long time, and that’s saying something. Indeed, plowing through the list and looking up key papers was a tediously predictable endeavor. Basically, Stone and Bogner take papers that look at some aspect of cannabinoid function, whether it’s about autism or not, and extrapolate to autism. Let’s take a look at their most convincing piece of evidence first (to me, at least). In this case, by “most convincing,” I mean least unconvincing:
“Rare mutations in neuroligins and nerexins predispose to autism” (Földy 2013). Neuroligin-3 is the only known protein required for tonic secretion of endocannabinoids that include AEA and 2-AG (Földy 2013). Neuroligin-3 mutations have been shown to inhibit tonic endocannabinoid secretion (Földy 2013). These alterations in endocannabinoid signaling may contribute to autism pathophysiology (Földy 2013, Krueger 2013, Onaivi 2011, Siniscalco 2013). These finding have in part prompted researchers to apply to conduct research with nonhuman primates in order to further elucidate this link (Malcher-Lopes 2013).
Endocannabinoid system deficiencies are suggested to be involved in the pathophysiology of a growing number of diseases (Marco 2012, Russo 2003). Pacher and Pertwee both cover the endocannabinoid system in detail (Pacher 2006, Pertwee 2010). The number of functions that endocannabinoid signaling regulate in the human body is extensive and beyond the scope of this paper (Pertwee 2010). For sake of brevity only a few potentially relevant aspects will be listed:
So what are these elements? Basically, Stone and Bogner cite a whole bunch of papers supporting the conclusions that endocannabinoids:
    • Modulate synaptic function
    • Regulate GI functions
    • Suppress proliferation and cytokine release in the central nervous system (CNS)
    • Regulate stress responses
    • Increase cerebral blood flow
    • Modulate neural and glial cell function
…you get the idea. So, yes, cannabinoids are important molecules in the CNS and elsewhere. No one argues against that. It’s also true that it was recently shown that mutations in neuroligins and nerexins appear to predispose children to autism and that neuroligin-3 mutations inhibit endocannabinoid secretion, suggesting that bolstering endocannabinoid secretion might antagonize or reverse the abnormalities associated with such mutations. (A decent overview of this research suitable for a lay person can be found here, and the original paper is here.) Let’s just put it this way. This is a rodent model, and right there it’s a question of how relevant it is to real, human ASDs. This is very preclinical evidence, meaning that it might or might not turn out to be relevant to human ASDs. At best, it justifies further study. Moreover, the primate model referenced in Stone and Bogner’s paper appears to be merely a proposal presented to a conference in Qatar. This is thin gruel indeed, as a recent review article on medical marijuana published in the Journal of Developmental & Behavioral Pediatrics by Hadland et al. points out:
Many advocates cite scientific literature regarding benefits of cannabis for the treatment of pediatric behavioral conditions, but often, data cited are from animal model-based research that does not yet have translation to human subjects. For example, a 2013 study 80 from Stanford University showed that mice with a specific and rare gene mutation linked to autism showed altered endocannabinoid signaling in the central nervous system. These data were then cited by online and print media supporters of medical marijuana (e.g., the High Times 81) as evidence that cannabis could be used as a treatment for autism. As another example, when another recent study 72 based on a mouse model of Fragile X syndrome (described earlier in this review) showed alterations in endocannabinoid signaling pathways, these data were referenced (in this case, by more mainstream media outlets, such as the Huffington Post 8 and Fox News 82) as evidence for a promising role for cannabis as treatment. Although these and other high-impact studies share important insights into the pathogenesis of autism spectrum disorders (ASD) and Fragile X syndrome, based on their results alone, it is erroneous and potentially harmful to conclude that cannabis should be used as treatment for either of these disorders at this time.
Indeed. Not surprisingly, Stone and Bogner’s article references that very same study on Fragile X syndrome as well. Much of the rest of their article boils down to the list I enumerated above plus other correlations, their arguments reduced to, in essence, this:
     1.  The endocannabinoid system is important in [insert important CNS function or signaling pathway here] in preclinical cell culture and animal models.
     2.  Autism and ASDs involve abnormalities of this important CNS function or signaling pathway.
     3.  Ergo, cannabinoids can be used to treat autism and ASDs.
     4.  Q.E.D.
In other words, there’s a whole lot of confusing correlation with causation and assuming pathogenesis when what is being observed might just be an epiphenomenon. There might be a direct role for these correlations in causing autism, and some of the signaling pathways might even represent promising targets, including the endocannabinoid pathway or a subset of it. Stone and Bogner go wrong by assuming all of these studies indicate a critical role for endocannabinoids in autism, such as elevated cytokine levels. For instance, take a look at this list of effects of cannabidiol (CBD):
    • CB1/CB2 agonist blocker (can inhibit overstimulation of CB1 by THC)
    • FAAH inhibition increases endocannabinoid levels (including AEA, 2-AG)
    • AEA reuptake inhibitor
    • 5-HT1a agonist
    • Suppressor of tryptophan degradation
    • PPAR alpha and gamma agonist Positive allosteric modulator at glycine receptors
    • TRPV1 and TRPV2 agonist
    • Adenosine uptake competitive inhibitor
    • Antagonist at abnormal-CBD receptor
    • Regulator of intracellular Ca 2+ T-type Ca 2+ channel inhibitor (Izzo 2009)
This is a wide range of effects, some of which could be relevant to autism/ASD. The problem, of course, is that we don’t know which ones are the most relevant and which ones actually involve promising therapeutic targets for intervention.
Extrapolate, extrapolate, extrapolate!
Whenever writing a research paper that is basic science that could potentially be translated into a treatment for a disease, it is generally considered mandatory to speculate at the end just how this could come about. For instance, when scientists write about cannabinoids in the context of models of neurodevelopmental disorders, after all the basic science, cell culture, and animal model work, naturally they try to describe how their results could be pursued so that they translate into a clinical treatment. It’s known as showing clinical relevance to your findings, no matter how basic science they are. Stone and Bogner quote several of these sorts of speculative statements in the discussion or introduction of papers as though they were Gospel truth, then conclude:
Given the known role of the endocannabinoid system in ASD it seems entirely possible, if not likely, that cannabinoid rich botanical extracts from cannabis can be utilized as useful agents targeting the pathophysiology of ASD, as well as the many debilitating symptoms and conditions associated with it. The wealth of options that cannabis has to offer those that suffer from ASD in MI is not currently legally permitted. We believe that needs to change.
As I said before, Q.E.D. (Yes, that’s sarcasm.)
Where’s the beef (i.e., the clinical evidence)?
What all these 75 references really mean is that there is some correlative evidence that the endocannabinoid system is abnormal in autism. However, it’s not at all clear whether these abnormalities are causative or downstream effects from the true cause or causes, whatever they might be. What this evidence means is that it’s probably worthwhile to study the endocannibinoid system in autism and whether modulating its activity can have an effect on autistic symptoms. What it most definitely isn’t is compelling evidence to authorize any doctor in the state who wants to do so to use cannabis oil to treat autism. Yes, because the law states two doctors have to sign off for use of medical marijuana in children, parents will have to find two doctors, but, really, does anyone think that will be very difficult?
To recommend a treatment for general use, we need high quality clinical evidence. Is there any such evidence for cannabis oil for autism? The answer is a resounding and unequivocal no. Indeed, an excellent indication of the paucity of evidence regarding cannabis oil and autism is the way Stone and Bogner dance around the issue by citing anecdotal reports about the use of cannabis oil and cannabinoids to treat epilepsy:
How can combinations of cannabinoids be put into practical use by individual families? For our purposes let’s review the anecdotal reports of cannabinoid based treatments currently being utilized in MI (and around the world) for pediatric epilepsy. I think this is a good comparison due to the range and complexity of both conditions. CBD continues to prove its effectiveness in treating many types of epilepsy, but not all (Porter 2013). Anecdotal reports provided in online groups with families that share dosing and other related information to cannabinoid based pediatric epilepsy treatments reveal that in many cases parents (and physicians) find that an increased ratio of THC is required to increase the efficacy of treatment. The range seems to vary significantly from 24:1 to 1:1 (CBD:THC). Some partial explanations for this might include the ability of THC to increase GABAergic transmissions via CB1 activation, its modulation of ion channels, and that it’s a PPAR gamma agonist which is neuroprotective in epilepsy (Stone 2014).
Due to the range of ASD it seems possible that, similar to cannabinoid based epilepsy treatments, varying ratios of cannabinoids (specifically CBD:THC) will prove to have a greater efficacy overall when compared to individual cannabinoid based treatments (like Dronobinal). This concept has been further supported by the research and clinical use of Sativex, a 1:1 (CBD:THC) botanical extract marketed for use in a range of treatments throughout the world (Hazekamp 2013, Russo 2006). The ability to specifically tailor cannabinoid ratios in botanical extracts from cannabis in a case specific manner may prove an even greater efficacy.
This is nothing more than handwaving, comparing two different conditions and assuming that what is observed in one condition will apply to another condition. Worse, as Skeptical Raptor reminds us, despite these anecdotal reports of benefit due to cannabinoids or cannabis oil in epilepsy, a recent Cochrane Review concludes that “no reliable conclusions can be drawn at present regarding the efficacy of cannabinoids as a treatment for epilepsy.” In other words, there’s no high quality evidence that cannabinoids are efficacious in treating epilepsy. There’s even less evidence that cannabinoids can be used to treat autism. Indeed, as the aforementioned review by Hadland et al. notes:
Regarding human data on use of cannabis for developmental and behavioral conditions, to the best of our knowledge, the only available data are from small case series or single studies. For example, one 6-year-old boy with autism was treated with daily dronabinol for 6 months and was noted to have improvement in hyperactivity, irritability, lethargy, stereotyped behaviors, and speech, as measured by the Aberrant Behavior Checklist.83 This single case study was uncontrolled and unblinded. In another single case study 84 of a cannabis-using adult male with attention-deficit hyperactivity disorder (ADHD) off stimulants, the subject’s driving skills in a simulated test during a time of abstinence improved after smoking marijuana (What is unclear is whether this subject may have actually been experiencing cannabis withdrawal from his abstinence, with alleviation of his symptoms through subsequent use of marijuana.85). Another small case series 86 showed an improvement in self-injurious behaviors among adolescents after dronabinol therapy, but to date, the study has not been published, leaving protocol details scarce. In sum, none of these studies provides sufficient, high-quality data to suggest that cannabis should be recommended for treatment of ASD or ADHD at this time.
And neither does Stone and Bogner’s analysis, which was the basis of the evidence submitted with the petition to the Michigan Medical Marijuana Review Board to add autism as a qualifying condition for medical marijuana treatment. Their analysis is the very definition of cherry picking studies and extrapolating wildly from preclinical cell culture and animal studies and studies that address other conditions to conclude that cannabinoids are efficacious treating autism, while ignoring the dearth of evidence that counts: Actual clinical trial evidence. As the Cochrane review I cited pointed out, there were four randomized trials including a total of 48 patients using cannabinoids to treat autism. One report was just an abstract; another a letter to the editor. None of the trials provided randomization details, and there was no description of whether the control and treatment groups were equivalent. The studies were thus of incredibly low quality. All there are, are a handful of uninformative single patient case reports like this one.
Yet, when this this incredibly thin gruel was combined with emotional testimonials of distraught parents of severely autistic children, it was the emotional testimonials of distraught parents that won out. There isn’t another drug for which the FDA or a state would give doctors the go-ahead to use to treat humans for conditions like autism or cancer based on such slim to nonexistent evidence.
Approving the use of cannabis oil for autism: “Premature” doesn’t even begin to describe it
There is no doubt that the approval of medical marijuana for various medical conditions is driven far more by politics than science or clinical observations. For no condition is that more true than autism, for which even the anecdotal evidence is weaker than it is for other qualifying conditions such as chemotherapy-induced nausea, chronic pain, and epilepsy. Moreover, in this case, the Michigan Medical Marijuana Review Panel abdicated its responsibility to interpret existing science with respect to medical marijuana and autism. It is a travesty that the panel could take the cherry picked list of studies annotated with unjustified extrapolation of preclinical studies and conclude that there was a compelling case for adding autism to the list of qualifying conditions. The panel failed even to require that only relevant specialists, such as pediatric neurologists, be allowed to prescribe cannabis oil for autism and instead let any licensed physician (OK, two licensed physicians) do it. Worse, these physicians don’t even have to monitor how often or how much is given to an autistic child for whom they prescribe medical marijuana. They can leave it all up to the parents, the vast majority of whom have no medical training.
This lack of oversight is a big deal because, contrary to what medical marijuana advocates claim, science still doesn’t have a good understanding of what the long term effects of chronic daily cannabis use are on the developing brain. We do know that teenagers who were found to be dependent on marijuana before age 18 and continued using it into adulthood lose IQ points. One can argue that IQ is a poor surrogate for intelligence, but nonetheless such findings are worrisome. We do know that marijuana use is associated with abnormalities in the brain in young users in an exposure-dependent manner. There are other potential adverse health effects as well. In any decision to use a drug, there is a risk-benefit analysis, and thus far in autism there’s almost no evidence for benefit and troubling evidence of risk when cannabis is used long term in children.
Fortunately, the recommendation of the Michigan Medical Marijuana Review Board is not binding. That recommendation will now go to Mike Zimmer, director of the Michigan Department of Licensing and Regulatory Affairs. He will have the final say over whether autism is added to the list of qualifying conditions. We in Michigan can only hope he realizes what a massive mistake the review board made and overrules their recommendation. Although new evidence might change this in the future, at present, medical marijuana for autism is unscientific herbalism, not pharmacognosy, and has no place in science-based medicine or state policy.

Medical marijuana as the new herbalism, part 5: Turning herbalism into science-based medicine
There’s a new clinical trial published in the New England Journal of Medicine showing a beneficial effect due to cannabidiol, a chemical isolated from marijuana, on drug-resistant seizures due to Dravet syndrome. Although there are a fair number of caveats, this is how you begin to turn the herbalism that characterizes medical marijuana advocacy into science-based medicine.
David Gorski on May 29, 2017
Link

It’s a holiday here in the US, and I have a grant deadline later this week; so I thought I’d (sort of) take the day off. I say “sort of,” because, as editor here I’m always loathe to leave a weekday without a post, even if it is a Memorial Day here in the US and the Spring Bank Holiday in the UK, the two countries from which most of our traffic arises. (I do so love how the UK calls some of its holidays bank holidays.) Fortunately, this blog isn’t my only outlet for writing about medicine, so I almost always have material to revise, reuse, and repurpose. So, if some of you have seen my discussion of this study before, fear not. I did add a bit to it and elaborate on some aspects I had disregarded before. If you haven’t, then it’s new to you! I think it’s interesting and important enough that it should be on SBM for the record.
And it’s about cannabis, too!

When I first started to take an interest in medical marijuana, I was struck by how much it reminded me of herbalism, so much so that I have a series on medical marijuana in which it is explicitly referred to as the “new herbalism” that’s up to four parts now. Although herbalism is scientifically the most plausible of modalities commonly associated with “complementary and alternative medicine” (CAM) or “integrative medicine” (or whatever you want to call combining quackery with medicine these days), the use of herbal medicines still involve a number of problems, the biggest of which is what I like to call either the delivery problem or the bioavailability problem. In brief, herbs, when they work, are, in essence, the equivalent of adulterated drugs. True, the contaminating compounds were not (unless you’re referring to heavy metals or real pharmaceutical drugs often found in Chinese herbs) from external sources. They’re inherent to the plant. Whatever you want to call the contaminating compounds, in herbal medicines, the herb’s content of active ingredient is usually relatively small, with the active ingredient combined with thousands of other constituents that make up the herb. It’s also very difficult to control lot-to-lot consistency with respect to content of active ingredient(s) given how location, weather, soil conditions, rainfall, and many other factors can affect how the plants from which the medicines are extracted grow and therefore their chemical composition. To demonstrate the concept, I frequently point out that it’s much safer and more predictable to administer digoxin to a patient who needs its activity on the heart than it would be for the patient to chew on some foxglove leaves, given how narrow the therapeutic window (the difference between the doses needed to produce therapeutic effects and the lowest dose that will cause significant toxicity) is for digoxin.
Indeed, to overcome these problems using plants as medicines is the very reason the specialty in pharmacology known as pharmacognosy, in essence natural products pharmacology, exists. Active chemicals in plants need to be identified, isolated, and purified in order to provide safe, reliable dosing.
A clinical trial of cannabidiol against severe seizures
I have nothing against recreational marijuana use and have come around to the view that it should be legalized, taxed, and regulated, just like alcohol and tobacco. Unfortunately, medical marijuana has been co-opted as a “foot in the door” to try to legalize marijuana. The problem with this approach is that it necessitated massively overblown claims for marijuana’s health benefits, up to and including claims that it is a great treatment for autism and that it can cure cancer. It isn’t and can’t. Nor does it stop exaggerated miraculous claims. Basically, the bottom line in terms of scientific evidence for medical marijuana is that it mostly doesn’t do what it’s claimed to be able to do.
None of this is to say that it might not have some value in some conditions. One condition for which cannabinoids isolated from marijuana have shown some promise is seizure disorders. That’s why I learned with interest of a study published in the New England Journal of Medicine (NEJM). This study is a randomized, placebo-controlled clinical trial of a candidate drug isolated from marijuana on severe drug-resistant seizures in children that made the national news last week. To be honest, over the last few days, the study’s gotten less press coverage than I would have predicted, particularly given that it was published in the NEJM, but it is an interesting study nonetheless. Medical marijuana proponents frequently misrepresent the skeptical position as being unalterably opposed to the idea that marijuana might have value as a medication. I can’t speak for anyone else, but what I’ve always objected to are the exaggerated, evidence-free claims so many advocates make, and the veritable cult that has sprung up around it. I actually like evidence, which is why this study caught my attention.
So let’s look at the study by Dr. Orrin Devinsky, a neurologist at New York University Langone Medical Center, and colleagues, “Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.” The first thing I can’t help but note is that this is not really medical marijuana, but rather an oral solution of cannabidiol (CBD), known for purposes of the study as Investigational Medicinal Product GWP42003-P. It’s manufactured by GW Pharmaceuticals under the trade name Epidiolex®. GWP42003-P is formulated from extracts prepared from Cannabis sativa L. plants that contain consistent levels of CBD as the principal phytocannabinoid. Extracts from these plants are processed to yield pure (>95%) CBD that contains less than 0.5% (w/w) THC. This highly purified CBD is subsequently dissolved in excipients with added sweetener and flavoring. So basically, it’s a drug isolated from a plant, as many drugs are isolated from plants (and sometimes chemically modified). It has the advantage of having low THC, which is the constituent of marijuana most responsible for its psychoactive effects.
Another thing that’s important to note is that this trial was to test whether CBD was useful against drug-resistant seizures due to a specific genetic disorder, Dravet syndrome, also known as severe myoclonic epilepsy in infancy (SMEI). Dravet syndrome is due to a mutation in the voltage-gated sodium channel α1 subunit gene SCN1A, which encodes the pore-forming subunit of the NaV-1.1 voltage-gated sodium channel. There are currently more than 700 known SCN1A mutations, and 90% of them occur in DS patients. Two-thirds of these mutations give rise to truncations in the protein while the remaining third are missense mutations that are predicted to severely impair channel function. In patients with Dravet syndrome, the severity of the epilepsy can vary, but myoclonic seizures are the defining feature of Dravet syndrome, and can be massive, contributing to a mortality rate as high as 20% by age 20. The syndrome is also associated with developmental delay. The most devastating aspect of Dravet syndrome is that the epilepsy associated with it is among the most drug resistant forms, and most anti-epilepsy drugs provide inadequate relief.
This trial was pretty straightforward. Basically, it was a multi-institution phase II study carried out in the US and Europe with the following protocol, summarized by this flow sheet (click to embiggen):
The baseline characteristics of the two groups were well matched, ranging in age from 2 to 18, and patients had previously tried a median of 4 antiepileptic drugs, with a range from 0 to 26(!). Subjects were randomized to receive either placebo or CBD, and the primary end point measured was frequency of convulsive seizures. The CBD solution contained 100 mg/ml, and the placebo solution was identical except for the absence of CBD. Before the intervention began, there was a four week baseline period in which investigators trained caregivers to record daily seizure information. Then CBD or placebo was added to the subjects’ regular anti-seizure regimen.
This is actually a very important point that most reporting of the trial I’ve seen misses. This trial does not show that CBD has anti-seizure activity as a single agent administered alone, only that, when added to existing anti-seizure multi-drug regimens, CBD can decrease seizure frequency. We can’t conclude from this trial that CBD alone would be a useful treatment for Dravet syndrome seizures. You might ask why this trial was designed this way, and the answer is simple. Given the severity of the seizure disorder associated with Dravet syndrome, comparing any investigational drug against placebo would be highly unethical, because it would mean leaving severe seizures untreated for half the children enrolled in the study. This is the same reason why many new anticancer drugs are not tested alone versus placebo, but in addition to existing systemic therapy regimens. One difference, though, is that anticancer drugs have to have robust preclinical evidence for efficacy as a single agent.
Back to the trial design. The dose was escalated up to 20 mg/kg per day with the use of a 14-day dosing regimen of twice daily administration. At the end of the treatment period, the cannabidiol and placebo solutions were tapered (10% each day) over a period of 10 days. After trial completion, all patients could enter a long-term open-label study. Each day, patients or caregivers recorded the number and type of seizures (tonic, clonic, tonic–clonic, or atonic) for the primary end point. Laboratory assessments were carried out at baseline and after 2, 4, 8, and 14 weeks of the trial regimen, as well as at the end of the taper period for those patients who did not enter the open-label extension study or who withdrew early and tapered the trial agent.
The results were encouraging. In the CBD group, the median frequency of seizures decreased from 12.4 to 5.9 per month, compared with a decrease from 14.9 to 14.1 in the placebo group. The percentage of patients with at least a 50% reduction on convulsive seizure frequency was 43% with CBD and 27% with placebo. The percentage of patients who became seizure-free was 5% in the CBD group, and 0% in the placebo group, but neither of these results achieved statistical significance (p=0.08 for both). I must admit that the way NBC reported Devinsky saying, “Quite remarkably, 5 percent of the children in the active treatment group with CBD were completely seizure free during the 14 weeks of the trial” but neglecting to point out that the result didn’t achieve statistical significance did irk me. I understand that there were some children who had dramatic remissions, but such observations do have to be put into context.
There were some adverse events due to the CBD, including diarrhea, vomiting, fatigue, fever, somnolence, and abnormal liver-function tests. There were more withdrawals from the trial in the cannabidiol group. Indeed, nine out of the 61 subjects in the CBD group withdrew from the study, compared to only three from the placebo group. Overall, serious adverse events were more common in the cannabidiol group than in the placebo group (16% vs. 5%).
One interesting aspect of this trial is that the mechanism of CBD against seizures in patients with Dravet syndrome is not known. The clinical manifestations of Dravet syndrome are due to a single gene, SCN1A. In an accompanying editorial, Dr. Samuel Berkovic notes:
A major aim in the field of the Dravet syndrome and other genetic encephalopathies is to develop precision therapies — treatments directed at the specific genetic defect. Because the Dravet syndrome has a single-gene basis, it is an attractive target for precision medicine. However, cannabidiol is not a precision treatment for the syndrome, because there is no established link of the cannabinoid receptors with the inhibitory interneuron pathology of the Dravet syndrome, and the response across the cohort of the current study was not uniform.
He also notes:
Devinsky et al. found a significantly greater reduction in seizure frequency among patients who received cannabidiol than among those who received placebo, and the seizure-free rate was 5% with the active drug as compared with 0% with placebo. Thus, anecdote has been confirmed by data, and one might ask whether a controlled trial was really necessary. The answer is absolutely yes. Perhaps counterintuitively, the rate of response to placebo in clinical trials is higher among children than among adults. Moreover, parents who go to enormous efforts to get cannabis for their children report a higher response rate than those who can easily obtain it. Cannabidiol is not without side effects. The dropout rate in the active-treatment group was appreciable, and common side effects included vomiting, loss of appetite, and diarrhea. With additional experience, perhaps these effects can be modified with dose adjustment and other strategies.
I would quibble again here. If you look at Table 3, you’ll see that the difference between placebo and control didn’t achieve statistical significance for reaching 100%, 75%, and 50% decreases in seizure frequency. Now, I’m not so dogmatic that I won’t accept that this difference is probably real, failure to achieve a p-value less than 0.05 notwithstanding, but if you state beforehand that you are going to use frequentist statistics and define a statistically significant difference between placebo and experimental group as a p-value under 0.05, then you should at least be consistent. That quibble aside, I do agree with Dr. Berkovic that absolutely a clinical trial was indicated. I would also add a further quibble that “anecdote has been confirmed by data” is overstating it a bit, given the tiny percentage of patients who were seizure free. However, some patients do apparently have fairly dramatic responses.
Another interesting aspect is that, counterintuitively, seizure frequency did decrease in the placebo group by 13.3%, compared to the CBD group, where seizure frequency decreased by 38.9%. This should be a lesson as to why placebo controls are necessary, even for seemingly objective measures. Of course, given that these were either self-reported or caregiver-reported measures, they are not completely objective; so it is not surprising that there was a slight decrease in seizure frequency, even in the placebo control group.
What’s good for the goose…
Finally, I can’t help but note that medical marijuana advocates, the ones who will be flogging this study as vindication that marijuana is a miracle drug (even though what this study shows is much more modest) tend also to be very much anti-pharma and pro-alternative medicine. That’s why I want to draw attention to this part of the methods section:
The funding source, GW Pharmaceuticals, was responsible for the trial design (with input from investigators and other experts), trial management, site monitoring, trial pharmacovigilance, data analysis, and statistical analysis. GW Pharmaceuticals prepared and provided the active treatment and placebo. Trial procedures were reviewed at multisite investigator meetings. Services were used for clinical laboratory testing; bioanalytical laboratory testing; design of the case-report form; data management; trial-agent distribution, returns, and destruction; the interactive voice-response system; diagnosis of the Dravet syndrome and seizure classification; and translation of documents. The authors vouch for the accuracy and completeness of the reported data and analyses and for the adherence of the trial to the protocol (available with the full text of this article at NEJM.org). The authors affirm that they approved the final draft of the manuscript.
This is, of course, a not uncommon practice for a drug company doing a clinical trial upon which it wants to base an application for FDA approval for its drug, and that’s exactly what GW Pharmaceuticals is doing. Nothing wrong with that. As is the case with most clinical trials of new experimental drugs (and, make no mistake, Epidiolex® is an experimental drug) whose manufacturer is seeking FDA approval for an indication, this study was heavily influenced by the company as well as funded by it. It’s what a drug company needs to do, and GW Pharmaceuticals is a drug company. It is, however, a good idea to be a little more skeptical about the results of this study than most medical marijuana advocates I’ve seen gloating over it as total vindication are doing. This is a positive study, but not as strongly positive as it’s being spun, and there are issues with CBD and adverse events. As Dr. Berkovic puts it:
This trial represents the beginning of solid evidence for the use of cannabinoids in epilepsy. It requires replication. Future trials may answer further questions about the applicability of cannabinoids to the many other syndromes of childhood epilepsy and to treatment in adults. After an era dominated by anecdote and obfuscated by medicolegal issues and emotionally infused debate, more scientific studies are under way. Much more research is needed to understand the basic science, benefits, and risks of cannabinoids in epilepsy.
Correct. This is a study that demonstrates that one chemical that can be isolated from marijuana has promise as a treatment for the epilepsy associated with Dravet syndrome. The mechanism by which it appears to work is not clear, as the relationship between cannabinoid receptor and SCN1A is not clear. It’s thus not clear whether this result is generalizable to other forms of seizure disorders, but it’s worth investigating. In other words, CBD is just like any other drug. It appears to have reasonable activity against the epilepsy due to Dravet syndrome, but it also has significant side effects, just like a lot of other antiepileptic drugs. It’s no miracle, but it could be a step forward, particularly if its study leads to a greater understanding of the role of cannabinoid receptors in seizure disorders.
As is the case with all first phase II clinical trials of new experimental drugs, this trial is a start, not a finish. Does it definitively demonstrate that CBD has antiseizure activity? Not quite, but it is promising. Also, one has to remember that this is a very specific and uncommon form of epilepsy for which the genetic and biochemical basis is known to result in defective function of a single sodium channel. It’s not clear whether the results of this trial are generalizable to other seizure disorders due to other causes, but it will be worth investigating whether it is. It would also be worth investigating whether chemically modifying CBD could increase its efficacy while decreasing side effects, although preclinical mechanistic studies would be necessary to figure out how CBD works in the first place so that scientists can use a science-based strategy to chemically modifying the drug. This is how you turn herbalism into science.

Cannabis use and cardiovascular disease
New research suggests that cannabis use may be harmful and could be causing cardiovascular disease.
Scott Gavura on September 12, 2024
Link

Cannabis use is increasingly common as a consequence of decriminalization and even legalization. With legalization in Canada, I swear that there is now seemingly no place in Toronto free of the scent of cannabis smoke. (A few weeks ago I was paddleboarding in Lake Ontario hundreds of feet from shore, and I caught a whiff of that characteristic smell – it was another paddleboarder, smoking, even further out from shore.)
The health effects of cannabis use, particularly the cardiovascular risk, are not well understood. A recent study published in the Journal of the American Heart Association examined the association of cannabis use with myocardial infarction (heart attacks) stroke and coronary heard disease. The findings suggest that there may be some distinct risks with use that users should be aware of.
Cannabis use in the U.S. has significantly increased, with daily or near-daily use tripling between 2002 and 2019. At the same time, the public’s perception of the drug’s risks has declined, with fewer people viewing cannabis use as highly dangerous. Little is known about the specific health risks of use, particularly for cardiovascular disease, which remains the leading cause of death. Research into cannabis use and cardiovascular disease has historically been complicated by simultaneous cigarette smoking, which is known to be be harmful. Cannabis may be linked to heart disease because its active component, delta-9-tetrahydrocannabinol (THC), can affect the cardiovascular system, with cannabinoid receptors throughout the cardiovascular system. Smoking cannabis poses additional risks due to inhaled particles. Evidence is lacking related to the distinct cardiovascular impact of cannabis, especially among non-tobacco users.
The Study
This paper was entitled Association of Cannabis Use With Cardiovascular Outcomes Among US Adults, with lead author Abra M. Jeffers and senior author Salomeh Keyhani, and funding for the study from the National Cancer Institute. The authors used data from the Behavioral Risk Factor Surveillance Survey (BRFSS) between 2016 and 2020, collected from adults aged 18 to 74 across 27 U.S. states and two territories. Participants were asked how many days they used cannabis in the last month, with usage categorized on a scale from 0 to 1 daily. This meant daily use was rated as 1, and anything less was a fraction of 1. Demographic, socioeconomic, and cardiovascular risk factors were also recorded, including tobacco use (never, former, current), alcohol, and e-cigarette use.
The study analyzed the relationship between cannabis use and cardiovascular diseases like coronary heart disease, myocardial infarction, and stroke. This was entirely self-reported:
Outcomes were assessed when respondents were asked, “Has a doctor, nurse, or other health professional ever told you that you had any of the following….?”. Coronary heart disease (CHD) was assessed by: “(Ever told) you had angina or coronary heart disease?” The lifetime occurrence of myocardial infarction (MI): “(Ever told) you had a heart attack, also called a myocardial infarction?” Stroke: “(Ever told) you had a stroke?”
Statistical methods accounted for variables like age, tobacco use, and lifestyle factors. The study also explored how cannabis use affects those who never smoked tobacco and younger adults at risk for early cardiovascular disease. Sensitivity analyses compared daily users to non-users. Statistical methods were also used to adjust for the complex survey design and factors such as age, gender, and socioeconomic status.
The Results
Among 434,104 respondents aged 18 to 74, 4% reported daily cannabis use, while 7.1% used it less than daily. Nonuse was 88.9%. Most cannabis users smoked the products, with 73.8% reporting smoking as their method of consumption. The average respondent was 45 years old, and about half were women. The majority were White (60.2%), followed by Hispanic (19.3%) and Black (11.6%). Around 61.1% had never smoked tobacco, and 7.4% experienced coronary heart disease, myocardial infarction, or stroke, the cardiovascular conditions of interest in this study.
There were significant differences between cannabis users and non-users. Adults who used cannabis daily or occasionally were more likely to also use tobacco and alcohol compared to non-users. Cannabis users showed higher rates of CHD, MI, and stroke, with the lowest rates seen in occasional users. Interestingly, cannabis users tended to have fewer other cardiovascular risk factors, such as obesity and diabetes, and were generally younger and more educated.
The analysis found no significant link between daily cannabis use and CHD – risk was slightly elevated but not statistically significant. However, there was a 25% higher risk of MI (95% confidence interval, 1.07–1.46) among daily cannabis users compared to non-users, and a similar increased risk for stroke. as well as the composite of CHD, MI and stroke. The study also found that the more frequently cannabis was used, the higher the likelihood of these cardiovascular issues. Importantly, this relationship remained even after adjusting for tobacco use, suggesting cannabis has its own distinct impact on heart health, separate from smoking.
In a supplemental analysis of younger adults at risk for premature cardiovascular disease (men under 55 and women under 65), cannabis use was linked to higher risks of CHD, MI and stroke, and the combined outcome of all three conditions. These associations held even when accounting for tobacco use. Among those who had never smoked tobacco or used e-cigarettes, the risk of stroke and the combined triple outcome was notably higher, suggesting a relationship between cannabis use and cardiovascular problems even in this younger population.
Implications and Limitations
Overall, this study found that cannabis use correlates with an increased risk of heart attack, stroke, and a combination of cardiovascular events in adults aged 18 to 74, even after controlling for factors like tobacco use, age, and lifestyle. The more frequent the cannabis use, the higher the risk observed. This association was independent of tobacco use, with similar results for people who have never smoked tobacco or used e-cigarettes.
There are a number of important limitations, primarily a consequence of the design and methodology. Importantly, these findings do not establish cause and effect. While prospective studies would be needed to confirm the link between cannabis use and heart problems, that is not realistic or even ethical. Also notably, cardiovascular conditions and cannabis use were entirely self-reported, which could introduce some bias because of recall and a lack of objective measurements. The study also lacked hard data on key risk factors like blood pressure and lipid profiles. Finally, most cannabis users in the study were young, potentially underestimating the long-term cardiovascular impact.
Conclusion: Cannabis use associated with adverse heart outcomes
In this study, cannabis use was associated with higher risk of heart problems, even when accounting for factors like age, tobacco use, and health conditions. This risk is seen both in the general population, younger adults, and non-smokers or users of e-cigarettes. Smoking cannabis was the most common means of consumption, so the impact of other forms of consumption is less clear. However, given the cardiovascular effects of cannabinoids, risks from edibles and other dosages forms of cannabis may be real. Given the growing popularity of cannabis, as well as the decreasing perception of risk with the drug, more information is needed about how cannabis use is affecting health outcomes.

Did cannabis oil save Deryn Blackwell, the “boy in seven billion,” when his bone marrow transplant for two cancers was failing?
In a forthcoming book The Boy in 7 Billion, Callie Blackwell claims that cannabis oil, which she had started giving her son Deryn to relieve his symptoms during a bone marrow transplant for two cancers, actually saved his life when the bone marrow transplant appeared to be failing. Unfortunately, her story appears to be another testimonial that confuses correlation with causation.
David Gorski on March 27, 2017
Link

[Note: Callie Blackwell has commented after the post. Although I can’t agree with her conclusion that Deryn’s story is strong evidence that cannabis played a vital role in his recovery from bone marrow failure, she did make one good point, specifically that she never claimed that cannabis cured Deryn’s two cancers and that I shouldn’t have represented the excerpt to her book that way. She has a point. Although she clearly portrays cannabis as having been vital to her son’s seemingly miraculous recovery, to her it was because it somehow helped rescue the failing bone marrow transplant, not because it cured his cancer. Because I strive for accuracy in what I write and don’t even want to give the wrong impression stating facts, I have edited this post to remove any passage that said (or sounded as though it were saying) that Ms. Blackwell ever claimed that cannabis cured her son’s cancers. Mea culpa. Unfortunately, I doubt that the UK media will be so quick to stop representing Deryn’s story as proof that cannabis can cure cancer.]

It’s been a while since I’ve written about the burgeoning business of selling marijuana as a cure for whatever ails you. As I’ve written before, there exists a mystical faith that is very much like herbalism that marijuana is a magical plant that can cure, well, almost anything, including cancer, glaucoma, autism, ADHD, and many other conditions, when in fact the evidence is rather shaky for most, if not all, of these claims. Regarding cancer, the usual claim is not that smoking marijuana cures the disease, but rather that cannabis oil isolated from marijuana cures cancer, a claim that Rick Simpson has profited from after claiming to have cured his skin cancer with cannabis oil in 2003.
Over the years, I’ve examined a number of “cannabis cures cancer” (or, truth be told, “cannabis cures” this or that condition) testimonials (e.g., Stephanie LaRue’s story). Like most alternative cancer cure testimonials, when you take a closer look, inevitably the case being made that it was the cannabis oil (or whatever derivative from marijuana was used) cured the cancer (or saved the patient’s life after complications of therapy) is nowhere near as convincing as the advocates making the testimonial claim. Usually, there is another explanation for how well the patient is doing and/or the link between starting cannabis oil and clinical improvement is not nearly as convincing as it seems on the surface. As with the case of the belief that vaccines cause autism, human beings mistakenly attribute correlation to causation. Add to that a dash of confirmation bias, something we human beings all suffer from, and it’s very easy to come to develop an unshakable belief in a post hoc ergo propter hoc fallacy in which something they observed or did before something else happened must have caused that something else to happen, be it vaccines “causing” autism or cannabis “curing” cancer.
I bring this up because there is a new “cannabis cures” testimonial going around the UK that was brought to my attention yesterday. It was about a boy named Deryn Blackwell, who beat leukemia and the very rare Langerhans sarcoma through multiple bone marrow transplants (BMT). The cannabis comes in during his last BMT, when his mother gave him cannabis oil to relieve his symptoms as his transplant appeared to be failing and was overjoyed when her son recovered after having been in hospice for over a month. Her story portrays cannabis oil as being responsible for bringing Deryn back from the brink of death. Predictably, the British tabloid media is portraying his story as a “cannabis cures cancer” story, even though, even taken at face value, it is not. I had already started a post on another topic when I saw this, and it grabbed my attention to the point where I abandoned what I was writing before to take a look at this testimonial. On the surface, it is a very convincing testimonial, which is why I decided, as Seth Myers would put it, to take a closer look.
The story of Deryn Blackwell, as told in the media
Deryn Blackwell is a 17-year-old boy whose story appeared in The Daily Mail over the weekend in an article entitled “I gave my little boy CANNABIS to help cure his cancer: Mother reveals how her teenage son who was given days to live made a miracle recovery when she gave him the drug behind his doctors’ backs.” (As an aside, besides its being a tabloid rag, it’s always irritated me how The Daily Mail loves ridiculously long headlines.) Other papers featured basically the same story with long similarly long headlines like “‘I GAVE MY BOY CANNABIS’ Mum reveals she gave her cancer-stricken son CANNABIS in bid to ease his pain… and now he’s made a miracle recovery.” Basically, Deryn’s story was all over the UK press over the weekend. The Daily Mail story is an excerpt from a forthcoming book (of course) chronicling Deryn’s battle with cancer entitled The Boy In 7 Billion, by Callie Blackwell with Karen Hockney, to be released on April 6. The description of the book reads:
The powerful and moving true story of a remarkable relationship and a tenacious fight for survival. Callie reveals her son’s struggle through the physical and mental torment of battling cancer against impossible odds, and the truth behind her son’s ‘miraculous recovery’ that she has held secret for years.
And it’s true. Deryn’s story is indeed remarkable, as you will see. The “secret” that Callie Blackwell has never revealed—until now!—is that it was cannabis that saved her boy when he was on the brink of death due to a failing bone marrow transplant. But was it? Let’s take a look at that excerpt. It starts out with this heart-rending description of Deryn as he got sicker:
The pain was getting worse. The tips of my son Deryn’s fingers were hard and black from a superbug infection. His nails were peeling away and any remaining live flesh was covered in weeping sores.
Every day, he begged me: ‘Please tell them to cut my hand off, Mum. I can’t take this any more.’
Deryn was nauseous and, worse, had become addicted to his anti-sickness drugs. He was allowed a dose every seven to eight hours but within an hour of being given some, he would press the buzzer to call the nurses back in.
What mother wouldn’t be utterly distraught watching her son suffer like this? What mother wouldn’t start to consider things that she normally wouldn’t, if only she could ease her son’s suffering. So Callie Blackwell did this:
Deryn had suffered enough. In 2010, when he was just ten years old, he had been diagnosed with leukaemia.
Eighteen months later, he was told he had a secondary cancer, the extremely rare Langerhans cell sarcoma. Only 50 cases have ever been recorded and only five people in the world currently have it. But no one had ever been found to have the two cancers combined, making Deryn unique. One boy in seven billion people.
By 2013, after nearly four years of hospital treatment, it seemed that the only thing left for him were opiate drugs to ease the pain as he reached the end of his life.
Like any mother would be, I was desperate to find something to alleviate his suffering.
I spent hour after hour researching on the internet, and that’s where I came across reports of a substance called Bedrocan, a cannabis-based painkiller that wasn’t available in the UK. Surely Bedrocan had to be a better option than mind-numbing morphine?
But the doctor told me that while it was effective, it had not been tested on children and she couldn’t prescribe it.
So Simon and Callie Blackwell, in an effort to ease their son’s suffering, sought out cannabis. Simon nobly took responsibility for obtaining some marijuana, using the rationale that if anyone were to go to jail for this he wanted it to be him and didn’t want Callie to be away from their son. The two of them did what most people who’ve decided to use alternative treatments do and read extensively on the Internet, where they learned to make cannabis extract suitable for a vaporizer pen using a rice cooker and vegetable glycerin, noting that in 2013, when they first decided to use cannabis:
Back at the hospital, meanwhile, our son’s latest bone marrow transplant had failed. Staff were giving up on him. It seemed Deryn’s death was a done deal and now all we could do was wait until he drew his final breath. If there was no improvement in two weeks, he would be placed in palliative care.
So what happened? Callie Blackwell went through with her plan. She brought her son the vapor pen:
Deryn sucked on the pen, breathed in and blew out a massive cloud of vapour – and we frantically waved our hands around trying to disperse it, although there wasn’t the smell of cannabis. It smelt more like popcorn. After ten minutes, Deryn said that the pain had decreased a little and he felt more relaxed – the words we had been longing to hear.
Alas, his condition continued to worsen. By December 2013, Deryn had moved out of hospital and into a hospice, where he planned his own funeral. His bravery attracted national attention and some of his favourite celebrities, including Paul Hollywood, Pauline Quirk and Linda Robson came to meet him.
I note that, here, despite Ms. Blackwell having started to sneak a cannabis vapor pen to her son for an unclear number of times, her son continued to deteriorate, and the vapor pen was only providing him with modest relief from the pain. He went to hospice, as far as I can reconstruct, two weeks after his mother started to sneak him puffs of cannabis. This is hardly the sort of “cannabis saved my child” story that sounds promising, at least not to this point.
Further deterioration…and then a “miracle”
What happened next is that, as Deryn’s condition continued to deteriorate during the two weeks after Callie Blackwell started to give him cannabis oil. Because he complained that he didn’t want any more morphine because it made him “feel like I’m not here,” she wanted to provide better relief and started wondering whether she could achieve a higher dose of cannabis by giving it to him orally. In actuality, she was almost certainly providing him a higher dose through the vapor pen, but she nonetheless decided to try. So on New Year’s Eve in 2013, roughly five weeks by my reckoning after she started sneaking her son cannabis oil by vapor, she tried it:
I was sitting next to him, a nightly vigil, and held his hand. Once again, the situation seemed quite desperate. What would happen, I wondered, if I gave Deryn a small amount of golden cannabis tincture directly in his mouth? The vaporiser had brought him some relief but could a higher dose have better results?
I took a small, empty syringe from the medicine cupboard in the hospice and quickly checked that there was no one outside. It was New Year’s Eve so staff levels were minimal. I drew up 5ml of the honey-like substance, which had a sweet, floral flavour.
Still sobbing uncontrollably, Deryn opened his mouth and I popped the syringe underneath his tongue. Deryn held it for a minute before swallowing. Half an hour passed. He was no longer having a panic attack. He looked peaceful. I asked him how he was feeling.
‘I feel relaxed,’ he told me. ‘I’m aware of everything. I just feel at peace, Mum. It’s beautiful.’
It’s a powerful story. No wonder it’s so compelling. Indeed, it’s an archetypical story, that of the parents who will go to any length to save their child from a deadly disease and succeed in doing so. Ms. Blackwell further relates that, after he swallowed the 5 ml of cannabis oil, he refused a dose of cyclizine, the antinausea drug upon which he had become dependent and that he virtually never refused. If there’s one part of this anecdote that puzzled me, it was the part about the cyclizine. Basically, cyclizine is painted as this powerful, addictive antinausea medicine when in reality it’s a histamine blocker and anticholinergic that is pretty well tolerated, with the usual adverse events of anticholinergic drugs, like dry mouth, and, less commonly, constipation, urinary retention, and double vision. Yet in this excerpt, the drug is painted as if it were a powerful, addictive opioid.
Be that as it may, the story certainly makes it sound as though 5 ml of cannabis oil beat cyclizine for nausea, although certainly there could be significant placebo effect here given his mother’s care and her giving him something new. Convinced it was working, Ms. Blackwell continued to give her son cannabis oil whenever he “felt a twinge somewhere.” Then, one evening:
One evening, I heard Deryn yell: ‘Mum – look!’ The bandage on his middle finger had worked its way loose and completely come off, showing his third finger – which had been blackened and dead – had now healed. How on earth had a child with no immune system and no way of fighting infection managed to heal himself after being off medication for more than three weeks?
I called Deryn’s team to tell them what had happened. Not one of them could give me any answers.
We knew his bone marrow wasn’t functioning and it was not scientifically possible for his wounds to heal. Deryn had spent months in isolation because a common cold could be fatal – yet, somehow, he had overcome three catastrophic infections.
Hundreds of people had been praying for Deryn, blessing him in their own ways. Was this a miracle?
Later that evening, the hospice doctor arrived. ‘We’re no longer sure Deryn is dying,’ she admitted.
The doctors were not sure whether or not the hospice was now the best place for us.
The story sure makes it seem like a miracle. One can only imagine the delight and relief, mingled with confusion and fear, that the Blackwells experienced, as their son, to whom they were preparing to say goodbye forever, made a sudden and unexpected recovery. Human nature being what it is, not surprisingly, Ms. Blackwell started looking for a cause for her son’s good fortune, and, human nature being what it is (and confirmation bias being what it is in all of us), she soon found one:
When we’d arrived four weeks earlier, he’d been given three days to live. Now here he was a month later, in far better health than when he’d left his hospital room. They had no idea how this was possible.
Then it dawned on me. Only one thing had changed since Deryn started to recover: the cannabis tincture. I couldn’t tell the doctors what we’d done.
Now, three years later, she’s revealing to the world what she did, and presenting it as a case of cannabis saving her son’s life. But did it? There is considerable reason to doubt. Those of you who are regular readers can probably identify the issues in this testimonial that make it less than convincing as evidence that cannabis salvaged Deryn’s failing bone marrow transplant. See if you can identify them before reading the next section.
The forthcoming book based on Deryn’s story aside, I’m very happy to report, Deryn returned to school and appears to be doing quite well now. Until now, his story popped up every so often as a human interest story in the UK press of a boy who beat what seemed like insurmountable odds to beat two different forms of cancer after “four failed bone marrow transplants,” while religious groups present him as a miracle. He even wants to study biochemistry, although he still suffers from sequelae of his disease:
“Deryn still struggles with mobility a bit and he gets very tired.
“But the main reason for going back was so he can develop emotionally and socially in that way teenagers, particularly boys, need to at that age.
“He has spent two years in a room by himself with just a nurse or me around, so it is good for him to just be normal for a while.”
Even after defeating cancer Deryn has had to confront other serious threats such as aplastic anaemia.
The family has also set up a charity, Do Everything, although currently the website is listed as Under Construction.
Did cannabis save Deryn’s life? It’s doubtful.
Remember how Ms. Blackwell discussed visits by celebrities to see Deryn around December 2013, as things looked very grim and doctors thought that Deryn’s final days were upon him? The beauty of his brief celebrity back then was that there are contemporaneous accounts of what was happening then that we can compare to Ms. Blackwell’s account today. It also turns out that Deryn and his family had a fairly robust social media presence (for 2013 back then, with a Twitter feed, Facebook page (which appears to be no longer there), and website. Although the website turns up as “Under Construction,” fortunately the almighty Wayback Machine lets us see what was on it as recently as 2015, which will be helpful in my discussion. Deryn’s Twitter feed has no Tweets since this one:
Please everybody go and follow my mums page about me 🙂 @_DoEveRYthiNg
— Deryn Blackwell (@DerynChemoKid) March 25, 2014
Perusing this Twitter feed and Ms. Blackwell’s recently set up author Twitter feed, I didn’t see any mention of cannabis until this flurry of weekend stories. For instance, the announcement of the book didn’t mention cannabis:
Some incredibly exciting news for @DerynsMum – You can now pre-order Callie’s book ‘The Boy in 7 Billion’ https://t.co/5mlL9e24fV Exciting! pic.twitter.com/hDz62pm2D8
— 1in7billion! (@_DoEveRYthiNg) February 20, 2017
I found all this very curious, how Ms. Blackwell said absolutely nothing about cannabis until this weekend, even when her book release was announced and as she provided updates on her progress on her personal Twitter feed. Maybe the publisher made her keep it a secret. [Note: This is confirmed in the comments below.] Be that as it may, I found it instructive to fire up the almighty Wayback Machine and look at what the Do Everything Foundation website said. Helpfully, it provided a timeline, which was not nearly as clear in the book excerpt published by The Daily Mail. I think it’s worth posting the entire timeline from his last bone marrow transplant, which encompasses the time when Deryn went into hospice:
On 17th October 2013, his own cells failed because of extremely rare complications.
Thankfully Deryn had one more chance left, he had one more bag of his own cells.
The Dr’s gave Deryn more chemotherapy and on the 29th of October 2013, Deryn has his own and final bag of cells transplanted into his body.
Three days after the transplant, Deryn trapped his fingers and suffered TWO catastrophic infections in his hand.
He had Cellulitis and Herpes whitlow in his hand and he also had Klebsiella in his mouth, another catastrophic infection.
40 days after a bone marrow transplant, the Dr’s told us that it is highly unlikely that someone will graft if they haven’t already – after 50 days there is no way someone can graft.
In their experience, no one has ever grafted after 50 days.
On December 11th 2013, at day 46, we were moved to a hospice where it was expected that Deryn would die within a few days.
We were told that Deryn’s fourth and final transplant had in fact failed and there was nothing more they could do, it was believed that once they took away the life supporting drugs that Deryn would leave us very quickly.
Deryn had NO immune system and NO way to fight off even a simple cold.
After two Christmases, one New Year’s Eve and quite a few worrying moments, on day 78 Deryn’s bandages accidentally came off his fingers and he was – infection free!
Deryn continued to improve and he started to produce his own blood products.
On day 104 – Deryn officially engrafted!
Not one Dr can explain how Deryn fought off THREE catastrophic infections with NO immune system and then went on to engraft with what recent tests said was empty bone marrow!
On February 25th 2014, Deryn had his line removed from his chest and was officially ‘Off treatment.”
After coming to terms and accepting that he was going to die, Deryn was finding it harder to accept that maybe he wasn’t.
It all happened so quickly.
His future is still very uncertain and he is still poorly.
BUT
We are for the first time, starting to plan for a future with Deryn.
Thank you so much for visiting Deryn’s page and for reading his wonderful story.
** Miracles do happen and dreams can come true **
It’s not entirely clear exactly when Ms. Blackwell started giving Deryn cannabis oil, but it was clearly some time before he went into hospice on December 11, 2013. In the excerpt above, in the context of giving Deryn his first dose of cannabis, that the doctors would give him two weeks to improve and then, if he didn’t, move him to hospice, which suggests that she started dosing him in late November 2013. Then, by her own account, she didn’t start giving Deryn oral cannabis until New Year’s Eve 2013. Day 78 after his transplant would have made it January 15, 2014 when the bandages came off his fingers and revealed that he had healed much of his ulcers, and Day 104 would have been February 10, 2014.
One can see how this timeline might have led Ms. Blackwell to think that what had saved her son was the cannabis oil. She started giving him oral cannabis oil about two weeks before the ulcers on his hands unexpectedly healed. However, there are a number of reasons to doubt that it was the cannabis. For one thing, from this account we have no idea what strain of cannabis was used, making it difficult to estimate the cannabinoid content of the oil and therefore how much and what types of cannabinoids were in the actual oil Ms. Blackwell used. We don’t know the cannabis to oil ratio. We don’t even know the regularity of the dosing except that she gave it to her son “whenever he had a twinge.” Given the experimental data I’ve discussed before that shows that the various cannabinoids only have a modest anti-cancer effect, it’s hard to conclude that the doses Ms. Blackwell was giving her son were high enough to have had such a dramatic effect. For another thing, what Ms. Blackwell is claiming is not so much that “cannabis cured her son’s cancer,” but rather that cannabis somehow fired up his immune system so that it could fight off the infection and his cells could actually engraft after three times the length of time it normally takes. In reality, the evidence regarding cannabinoids and the immune system is mixed, with at least one study showing that they can suppress immune function. Indeed, cannabinoids are being studied more as a potential treatment for autoimmune diseases rather than as any sort of means of increasing immune cell engraftment. Basically, it’s not very plausible at all based on what we know about cannabis that Ms. Blackwell’s secret treatment of her son resulted in such a dramatic turnaround.
So what happened? Did cannabis really rescue Deryn Blackwell’s bone marrow transplant?
What probably happened is that Deryn Blackwell was a highly unusual case in which his last stem cell infusion took a far longer amount of time to engraft than the doctors at the hospital treating him had observed before. It just so happened that, as Deryn was deteriorating, his mother, anguished at watching him suffer and desperate to do anything possible to alleviate his suffering, decided to give vaporized cannabis oil a try to help his symptoms. Unfortunately, her son continued to deteriorate and entered hospice. She decided to give him the cannabis oil by mouth three weeks after he entered hospice, and it seemed to relieve his symptoms somewhat more effectively. Two weeks later, the “miracle” occurred, and the bandages fell off. Deryn’s rare and unexpected recovery, happily, manifested itself. The rest, as they say, is history.
Deryn’s recovery was unexpected, but unexpected and rare recoveries do occur in medicine. Given what we know about cannabis oil, its rather modest effect on cancer, and the tendencies of cannabinoids to be, if anything, immunosuppressive, it strains credulity on a strictly scientific basis to attribute Deryn’s turnaround on homemade cannabis oil. That’s not to say it’s impossible that cannabis oil was responsible for Deryn’s recovery, only that it’s incredibly improbable. Remember, we know a fair amount about cannabinoid activity against cancer and its activity in the immune system, and what we know doesn’t support the plausibility of Ms. Blackwell’s testimonial. However, as is the case with a lot of other alternative cancer cure testimonials, the all-too-human tendency to want to attribute cause, combined with the form of selective memory known as confirmation bias, which leads all of us to tend to remember what confirms our beliefs and to forget what does not, has led to a conclusion that is almost certainly not correct. Remember again, Ms. Blackwell seems not to remember the several weeks she was giving her son cannabis oil via vapor stick and he was continuing to deteriorate to the point of entering hospice. I repeat that again because it is important. This testimonial is almost certainly a case of confusing correlation with causation.
But what about this claim:
Yet there was a direct correlation between Deryn having the cannabis tincture and his improved blood counts. Whenever he didn’t have it, they dropped. It was enough hard evidence to suggest that cannabis tincture was playing a vital role in his recovery. I hadn’t imagined in my wildest dreams that it could have saved Deryn’s life.
Without very detailed record keeping in which Deryn’s counts were listed by date and then correlated contemporaneously with whether or not he was taking cannabis oil and at what dose, it’s impossible to support or refute this claim. It’s probably more confirmation bias.
Be happy for Deryn Blackwell, but be skeptical
Although I highly doubt that cannabis oil had anything to do with Deryn Blackwell’s “miraculous” recovery, I am very happy that he did recover. Nothing pains me more than seeing children die of diseases like cancer. I can also understand why Callie Blackwell and her husband Simon have come to believe that cannabis cured their son. They are human. They have all the cognitive quirks that lead humans to incorrect conclusions that we all have, and those tendencies are only magnified when it is someone they love deeply that is the object of their hopes and prayers. Confirmation bias is a very powerful thing indeed under these circumstances. Unfortunately, the timeline that I have been able to reconstruct is thin gruel indeed to support Ms. Blackwell’s belief that cannabis oil saved her son by somehow helping his immune cells engraft in his bone marrow.
Unfortunately, what I fear is that a combination of love for Deryn, confusing correlation with causation, and confirmation bias have led the Blackwells to become true believers on the order of Rick Simpson, but with an even more dramatic story in which cannabis is portrayed as having literally pulled their son back from the brink of death. Consider this. Deryn’s story is quite inspirational without the cannabis angle. Yet what excerpt did the publisher decide to release first as part of the book’s publicity campaign? Yes, it released the part describing how Callie Blackwell surreptitiously dosed her son with cannabis oil, and the Daily Mail and the rest of the UK tabloid media responded predictably with stories portraying Deryn Blackwell as proof that cannabis can cure cancer, even when his story shows nothing of the sort. Unfortunately, the narrative that is being spun has the potential to influence patients with cancer and parents to try unproven and quack treatments, like cannabis for cancer and who knows what else. In seeking to do good, I fear that the Blackwells could actually make it less likely that future Deryns actually survive their cancers. It saddens me to say it, but it has to be said.

   Hash Oil for Gliomas? What Would You Do?
Published by Harriet Hall
Link
A friend asked me to look at the evidence for hash oil as a treatment for glioma. His teenage daughter was recently diagnosed with brain cancer: a grade 3 anaplastic ependymoma. It recurred very rapidly after surgery and radiotherapy and the latest tissue diagnosis shows an aggressive grade IV glioma. Her prognosis is not good. No further attempts at curative therapy are indicated; the oncologist prescribed only palliative therapy with temozolomide. Her father, who had recently lost his wife to cancer (breast cancer metastatic to lungs and brain), was understandably devastated. As he puts it, he remains “focused on the belief that just maybe a cure can be found.” He stumbled on what he calls “earth-shattering news” regarding hash oil. He and his friends established a private wiki website which they are constantly updating with information about THC (tetrahydrocannabinol, the active ingredient in marijuana and hash) and other possible cancer cures: everything from curcumin to diet. He asked me to look at the information he has accumulated. He said
I hope to convince you in the same way I have done with my daughter’s GPs and her neuro-oncologist at BC Children’s Hospital.
The oncologist was not exactly convinced. He didn’t say he thought hash oil was likely to work; he only said it would be reasonable to try it as a complementary therapy. He said
the data published so far appears very preliminary, most of its potential effectiveness in vivo so far appears in colonic disease, having said that there doesn’t appear to be any obvious down side as a complementary therapy and may have synergistic effect, so may be reasonable as add on to temodal if she tolerates it
I wasn’t convinced either.
I will discuss two issues here:
     1.  What does the evidence say about gliomas and hash oil?
     2.  When is it reasonable to try an unproven treatment as a last resort?
What Does the Evidence Show?
Several plausible mechanisms have been demonstrated, suggesting that it might work; but the evidence consists almost entirely of in vitro (test tube) and animal studies, with only a couple of small pilot studies in humans and a lot of speculation.
The Guzman study was a pilot study of 9 patients who got THC injected directly into their tumors.
The Salazar study concluded
we identify what we believe is a new route that links the ER stress response to the activation of autophagy and promotes the apoptotic death of tumor cells. The identification of this pathway will help to understand the molecular events that lead to activation of autophagy-mediated cell death by anticancer drugs and may contribute to the design of new therapeutic strategies for inhibiting tumor growth.
The Kogan study elucidates cellular anti-cancer mechanisms of THC but warns “sometimes they can act also as pro-cancer agents, especially in low concentrations, acting mostly through growth factors and their receptors activation/induction.” It concludes
In summary, cannabinoids possess some anticancer activity. Possibly they may represent a new class of anticancer drugs that retard cancer growth, inhibit angiogenesis and the metastatic spreading of cancer cells.
None of these studies concluded that we should be treating glioma patients with any form of THC.
A study by Foroughi reports spontaneous regression in 2 glioma patients. One happened to have smoked pot almost every day, the other used it twice a week. They speculate that the THC might have had something to do with the regression. But it might just as well have been coincidental. Spontaneous regression is known to occur in gliomas. A 2004 German study showed spontaneous regression in a mouse model. A study in the Archives of Ophthalmology documented 13 cases of spontaneous regression in humans with large optic gliomas.
The literature is confusing because it addresses different doses, different compounds, and different routes of administration: THC, smoking pot, hash oil, injecting it directly into tumors, applying it topically to skin tumors, inhaling, taking it by mouth, etc. Positive pilot studies are an encouragement to further studies; they are not proof that the treatment works.
The information on the Internet includes glowing testimonials but is contaminated with obvious bias. Advocates come mostly from the ranks of notorious “legalize marijuana” activists. Emotions run high. Many arguments in favor are full of the kind of fallacies we often discuss here, including “they didn’t listen to Semmelweis.” Protestations that THC research is being unfairly suppressed are not credible. Cancer researchers want to find cures, and even Big Pharma stands to reap huge benefits if active molecules can be separated out, modified, and turned into prescription drugs.
I didn’t find anything I would call “earth-shattering” or even anything that could be considered credible evidence that hash oil can cure advanced gliomas. The most I can conclude from my research is that hash oil has promise and is worth studying.
Last Resort?
When a patient is out of options, it is natural to grasp at any straw. Even though the evidence for hash oil is inadequate, there are some preliminary indications that it might help, and some plausible mechanisms have been elucidated. Isn’t it better to try something that possibly might work than to just give up?
How do you know what to try? The private website addresses all kinds of other possible cancer treatments, including curcumin, garlic, diet, etc. Incidentally, it cites a lot of very untrustworthy sources, such as a book by a doctor who repeats the old myth about cancer and sugar and a company that is selling curcumin pills. Should you try all of these treatments at once? If you try hash oil, how do you decide how much and how often?
We read articles in the popular press, for instance in Reader’s Digest, about the child with the rare disease whose heroic parents refused to give up and kept searching until they found the one doctor in the world who was able to cure their child with a new treatment. We hear about these success stories because they are unusual.
We don’t hear about the vast majority of cases where parents wasted time and money in a futile search.
It disturbed me to read through the private wiki, because it was “déjà vu all over again.” I’ve seen this so many times. Someone desperately wants to find a cure, latches onto something that he thinks might work, locates a mass of evidence to confirm his bias, but fails to appreciate the limitations of that evidence and fails to seek out information that argues against his bias (like the possibility that cannabinoids might have pro-cancer effects, mentioned above). In the course of my long career I’ve seen so many promising treatments bite the dust that I have become not only skeptical but probably cynical about it.
Yes, hash oil might be an effective treatment for gliomas and for other cancers. But we can’t possibly know until we test it properly. A patient with glioma today can’t wait for the results of future tests. Forgoing the treatment might mean dying sooner than necessary, but it is far more likely that using the treatment will be useless. It’s a gamble. Where is that crystal ball when we need it?
When you try a treatment on your own, you are essentially acting as a guinea pig in an uncontrolled experiment. Ideally, you could enroll in a randomized controlled trial that would result in some useful knowledge for future patients. But such trials are not always available, and you might not get the treatment; you run the risk of being assigned to the placebo group.
Is aggressively pursuing a cure really the best goal? Success is possible but very unlikely; and the search can become obsessive; dominate the searcher’s life; and consume time, funds, and energy that might be best employed otherwise. How about pursuing other goals that have a much higher chance of success: spending quality time with the loved one, trying to make the most of whatever time she has left, helping her cope, trying to make her remaining life as worthwhile as possible, saying goodbye, creating good memories for the survivors?
I’m going to be mean and ask some difficult questions. Is this father really doing this for his child or for himself? He wants to be able to say he did everything possible and left no stone unturned, so he will have no guilt feelings afterwards. Is the daughter really on board with all this, or is she cooperating mainly to please her father, knowing that it gives him comfort? Is she giving up the foods she loves to follow a restricted diet that has no proven benefit? Would it be better for all concerned to accept the terrible prognosis and confront its reality in more constructive ways? Do false hopes do more harm than good? There are always real hopes: that palliative therapy might extend life, that a spontaneous regression might occur, that life might still be rich with meaningful experiences?
Conclusion
Hash oil has enough promise to warrant further research but not enough evidence to warrant prescribing it as a cancer cure. Is it worth trying anyway? I don’t know. I am asking questions, not condemning. I can’t imagine what it is like to learn that your beloved child has a fatal illness. I don’t know how I would react, or whether I would want to try something like hash oil. It’s possible that I might feel desperate enough that all my judgment, skepticism, and common sense would fly out the window and I might be persuaded to try even the most wildly irrational things. I do know that refusing to accept reality often has unfortunate consequences. It distresses me when families aggressively pursue a will-o’-the-wisp that ends in failure and uses up precious time they might have spent otherwise to make the patient’s last days more meaningful and to create lasting memories.
What would you do? I welcome readers’ input in the comments.

The Parasympathetic State
The claims for an essential oil mixture, Vibrant Blue Parasympathetic, are devoid of science. They are a mixture of pseudoscience, misrepresentation, lies, and imagination.
Harriet Hall on January 7, 2020
Link

Starting a new year. For the past 12 years, I have written an article for the Science-Based Medicine blog every Tuesday. I have often thought that the best way to illustrate the value of science-based medicine is to examine medicine that is not science-based. A bad example can be memorable and instructive. I thought I would start 2020 by writing about a particularly bad example, Vibrant Blue Oils Parasympathetic. I won’t call it the worst ever, because every time I say that, something worse is sure to come along. But it’s a good example of the worst. Vibrant Blue Oils Parasympathetic is about as far from science-based medicine as you can get: a mixture of pseudoscience, misrepresentation, lies, and imagination.
The autonomic nervous system
The Vibrant Blue Oils website explains “How Parasympathetic is Critical to Your Health“. It claims that “digestion, detoxification, and immune functions are only turned on when your body is in a parasympathetic state” and you should optimally be in a parasympathetic state 80% of the time. And “almost all disease and dysfunction result from you not being able to drop into the Parasympathetic state.” What follows is a confused, simplistic discussion of the autonomic nervous system with its two components: the sympathetic branch governs the fight or flight response, and the parasympathetic branch is known as the “Rest, Digest, and Heal” state.
The term “the parasympathetic state” is not recognized by science. The sympathetic and parasympathetic systems work together and neither is ever “turned off.” There is no “parasympathetic state”, but there are ways to increase parasympathetic activity. An article from the Canyon Vista Recovery Center lists ways to activate the parasympathetic nervous system to decrease stress and anxiety. The list includes exercise, meditation, massage, prayer, play, deep breathing, spending time in nature, and doing things you enjoy. It even suggests gently touching the lips to activate the parasympathetic fibers there. Another website lists “12 ways to rest and digest“, repeating many items from the other list and adding acupuncture, yawning, gum chewing, and immersing the face in cold water. One thing these lists do not mention is essential oils.
Essential oils
Vibrant Blue Oils claims that essential oils are a natural way to achieve the parasympathetic state. Their Parasympathetic blend is “a proprietary synergistic combination of two essential oils: clove oil (which is highly stimulatory) and lime oil (which “has super small molecules”). These oils allegedly carry other healing properties, and are said to dull pain, heal infections, purify blood, and balance blood pressure. They claim that lime oil was found to be more effective than antidepressants, but I couldn’t locate any such study. Systematic reviews have concluded that “the evidence is not sufficiently convincing that aromatherapy is an effective therapy for any condition”.
I found one reference to the potential of essential oils for treating irritable bowel syndrome (IBS). Clove oil is one of several essential oils that contain eugenol. The study referred to was in mice that developed gastrointestinal dysfunction when stressed by being restrained. The eugenol was instilled directly into the stomach by gavage. Not aromatherapy, not IBS, and humans are not mice: not relevant.
They recommend applying the Parasympathetic blend to the vagus nerve three times daily, ideally before meals (why?). They incorrectly state that the vagus nerve wraps through almost every organ in the body. The way to apply the oil to the vagus nerve is to apply it to the mastoid bone behind the ear. The vagus nerve does indeed have an auricular branch, but I question whether applying essential oils to skin over the bone of the mastoid process would produce any measurable effect on the vagus nerve or on the parasympathetic nervous system, and they offer no evidence or rationale.
There is a lot of nonsense about vagus nerve toxicity (not a recognized medical condition) and how to recover from it. They offer other essential oil products to support the gallbladder, kidneys, lymph, and liver. “To support the flow of bile and, with it, toxins out of the body, apply Gallbladder™ on the right side of the body under the bra under-wire or along and slightly under the right rib cage two to three times daily”.
You can buy a 5cc (1 teaspoon) bottle of Parasympathetic for $36.95. They also offer essential oil products for circadian rhythm, hypothalamus, sleep, frankincense, and more.
Conclusion: No science here
Vibrant Blue Oils Parasympathetic is a very bad example that mixes pseudoscience, misrepresentation, lies, and imagination. Fantasy-based, not tested, not supported by any scientific evidence.
And yet people will buy it. A typical testimonial:
First time I used your oil, I literally felt my heart lifting. Ever since then, I don’t go anywhere without your parasympathetic oil. Now I’m trying your fertility blend and I’m feeling positive that I will get pregnant. Thank you so much. I really love what you do.
Hope springs eternal, customers have placebo responses, and people who disregard science make money.

CBD Oil: The new miracle cure
Cannabidiol (CBD) oil is hyped as a miracle product to treat virtually everything. What is the evidence to support this?
Scott Gavura on July 11, 2019
Link

Cannabidiol (CBD) oil is everywhere and seemingly in everything these days. It’s touted as a panacea for a massive range of illnesses and conditions, and even recommended as a daily supplement to help one smooth out the rough edges of life. CBD is one of the many chemical compounds called cannabinoids that is isolated from cannabis (marijuana). Cannabis contains over 400 chemicals including at least 120 cannabinoids, which are chemicals that stimulate cannabinoid receptors in the body. Yes, your body has cannabinoid receptors and you actually produce your own cannabinoids. The most well-studied cannabinoids that are isolated from cannabis are delta-9-tetrahydrocannabinol (THC) and CBD. CBD is not psychoactive like THC, and there are hundreds if not thousands of producers and products now on the market, sold everywhere from country markets to pet stores to pharmacies. Like most panaceas, the hype outpaces the evidence.
CBD and cannabinoids
CBD is an extract from cannabis leaves or flowers, typically dissolved in an edible oil. The extraction process and solvents used can dramatically affect the final product – from characteristics like taste and colour but also the CBD:THC ratio as well as other cannabinoid ingredients. Edible oils are a popular delivery form, especially for people seeking something more discreet than smoking or vaping. Edible oils can contain large amounts of CBD, and if the manufacturing is consistent and of high quality, doses should be predictable and reproducible from drop-to-drop and from bottle-to-bottle.
Regulation? It depends
Much of what I want to touch on in an examination of efficacy is grounded in an issue that I’ve repeatedly discussed on this blog in terms of natural products and supplements – the poor quality and consistency of products. Depending on where you live, CBD oil might only be available on the black or “grey” market which means there’s little consumers can rely on with respect to product quality and consistency. Without being assured that you’re purchasing a high quality product, it’s impossible for consumers to base expectations on published evidence. If you can’t trust what’s on the label of your CBD oil, then any published evidence, even if it’s of the highest quality, is largely irrelevant.
Studies in countries like the Netherlands have shown wide variations between label claims and actual ingredients, and the CBD:THC ratio is often if not invariably incorrect. However, in some countries like Canada, where cannabis has been legalized, licensed cannabis products sold by licensed producers and vendors must have independent validation of CBD and THC content, as well as verification of overall product quality. (If you’re interested you can see the label claims for products at the Ontario Cannabis Store.) Depending on where you live in the United States, your access to CBD and cannabis-based products varies at the state level, and it would be a blog post in itself to break this down. Even where it is technically illegal, CBD products may be widely accessible owing to lack of enforcement issues. Legality does not mean products are subject to any specific quality control specifications and regulations, and consumers interested in CBD oil will need to do their own homework, or consult a trusted health care provider. As with dietary supplements and herbal remedies, independent and verified testing by external organization is the gold standard for consumers seeking CBD oil.
Medical (prescription) products based on cannabis or that contain cannabinoids are available in many countries. Epidolex is an FDA-approved CBD extract that is approved for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome. There is also Marinol, which is a synthetic THC approved for nausea and vomiting associated with chemotherapy, and for the treatment of AIDS-related anorexia. There is also medical cannabis available based on medical authorization in many countries. While many expected the medical cannabis market to disappear with the legalization of cannabis, it continues to exists in countries like Canada.
The coexistence of CBD both in supplement form as well as in prescription form raises the question about whether or not CBD oil should be treated as a drug or as a supplement. As has been discussed on this blog repeatedly, drugs are typically considered unsafe and unproven until evidence shows otherwise. Regulators tend to take a different approach with supplements and “natural” products, generally assuming these products have long histories of use and are safe until evidence emerges to show otherwise. In countries like Canada where there are cannabis-based products available based on medical authorization and simultaneously via retail channels, sellers may be obtaining the same products from the same producers – they are just branded differently. Fortunately, for the sake of this post, whether it’s sold as a “drug” or as a “supplement” doesn’t matter – what is relevant is the evidence base.
Does CBD oil “work”?
I’ll cut to the chase and tell you that overall, the evidence for CBD oil isn’t impressive at all. There is something “there” for sure – CBD oil has pharmacological and drug-like effects. But the enormous enthusiasm is backed by very weak evidence, and the efficacy is well-established only for a few circumstances. Dravet syndrome and Lennox-Gastaut syndrome have been established as responsive to CBD. There are studies but a lack of convincing evidence for Parkinson’s disease and other movement disorders, schizophrenia, insomnia and anxiety disorders. Whether or not CBD is useful for treating chronic pain is unclear. When you have a licensed, regulated and quality controlled product, it’s probably safer than opiates, but there’s a lack of evidence to substantiate the grandiose claims made about the ability of CBD to be an effective pain control medication.
There is zero credible and convincing evidence to suggest that CBD is effective for serious conditions like treating cancer, or that routine use while well can prevent disease.
The risks
Substances that have pharmacological effects will also have side effects, and cannabinoids and CBD oil are no exception. Importantly, CBD oil can interfere with the effects of numerous prescription drugs owing to its effects on specific liver enzymes. Depending on the drug, levels can be raised or lowered, so anyone that takes prescription drugs must carefully verify the risk of drug interactions when CBD oil is consumed.
CBD oil seems to have a better side effect profile than THC-containing products, including cannabis, but the lack of robust study makes any itemization of side effects a challenge. Aggression/anger, irritability/agitation, and sleepiness have been reported with CBD products like Epidolex so they should be expected with CBD oil.
Conclusion: CBD isn’t a panacea
Every era has its preferred panacea, and CBD is what’s hot today. Indiscriminate and uncontrolled use may be what some consumers want, but it won’t answer questions about efficacy, long-term effects, or safety. Importantly, while it’s sold as a retail product, many consumers may be using it for medicinal purposes that are not supported by good evidence. While there are hundreds of clinical trials underway, the uncontrolled clinical trial in the consumer marketplace has also begun, and it won’t give us the answers we need anytime soon. At minimum, it’s important for consumers to be able to trust what’s on the label, and some jurisdictions have taken steps to ensure that consumers can at least have some confidence in what they’re buying. Time will tell if their confidence and enthusiasm in CBD is justified.

Where Are We With CBD
The science is not yet in on cannabinoids for most indications. We should wait until it is.
Steven Novella on September 30, 2020
Link

In July Scott Gavura wrote a review of cannabidiol (CBD, one of the active ingredients in cannabis) as an herbal drug and correctly pointed out that the hype is greatly outpacing the science. His main points were that, generally, the quality control of CBD products is poor (as with many herbal products) and this makes it difficult to extrapolate from scientific studies to actual use. Further, the evidence for efficacy for many of the claimed uses, such as pain, movement disorders, and psychiatric disorders, is actually quite poor and unconvincing (the exceptions being the very narrow uses in Dravet syndrome and Lennox-Gastaut syndrome). Some claims, like treating cancer, are pure pseudoscience. And finally there are side effects and drug-drug interactions with CBD, and so safety cannot be assumed.
A recent study emphasized Scott’s concerns. This is an observational study looking at older adults with COPD (chronic obstructive pulmonary disease) and their use of cannabinoids. The study included 4,000 individuals, and they found:
Researchers observed particularly worse health outcomes among patients with COPD who were using higher doses of cannabinoids. Compared to non-users, new higher-dose cannabinoid users had a 178 per cent relative increase in hospitalizations for COPD or pneumonia, and a 231 per cent relative increase in all-cause death.
That is a significant effect size, especially for mortality as an outcome. This is the kind of data that could kill a new drug in development. The study also found that those using cannabinoids were no better off than patients using opioids for chronic pain. The usual caveats to an observational study apply – this is not randomized, which means that people may have chosen to use cannabinoids because they were sicker, rather than the use making them sicker. Or there may be some other confounding variable. This will need to be sorted out with randomized controlled trials.
And that is the point. I am not saying (and Scott was not saying) that CBD specifically or cannabinoids in general do not work or are unsafe. Right now we mostly have preliminary data. What we are saying is essentially two things. First, the preliminary data is not that impressive. It certainly isn’t a home run, especially for the most common uses of these agents. This does not rule out that eventually we will find a formulation that has a benefit for specific indications. It means we don’t know.
Second, and the point that I most want to emphasize here, is that we really do need high quality research in order to know what the net health effects are of any new proposed treatment. Long-term anecdotal use means very little. People were extolling the virtues of radioactive tonics while they were killing themselves. Native Americans used tobacco as a medicinal. Bloodletting was all the rage for two millennia. Uncontrolled observations are misleading for many reasons, such as our poor grasp of statistics (such as regression to the mean) and the vagaries of perception and memory that lead to confirmation bias and subjective validation.
There is another factor when it comes to products like CBD or other cannabinoids – the public has been programmed by literally centuries of marketing to accept the health halo around things that are deemed “natural“. This is a meaningless distinction, however. CBD is a drug, nothing more and nothing less.
In the end what matters is good clinical decision-making backed by solid scientific evidence. Clinical decision-making generally revolves around considerations of risk vs. benefit, personalized to the individual patient’s priorities and values. In order to make a risk vs. benefit determination, you need objective data (not vague reassurances). We need to know the quality and consistency of the product, so that we can determine exactly what the patient is getting and in what dose. We need to know, as much as possible, what the body does to the drug and what the drug does to the body, how the drug is eliminated, the half life, and any drug-drug interactions. We then also need to know the effect of the drug, both beneficial and negative, in different populations and conditions.
Yes – you really do need to know all of that before you can make any reasonable risk-benefit decision. One piece of missing information can make a dramatic difference in outcome. CBD is no different. The existing evidence is showing that there are serious drug-drug interaction (mostly because of changes to liver enzymes), and there are potentially serious side effects in certain populations. In addition, beneficial effects are mostly small and/or dubious.
I am not saying this to fearmonger about CBD – all of this is also true of most new drugs. The point is that we should not give CBD special treatment, because of its mystique, or because of the appeal to nature fallacy. We need to complete the normal process of studying CBD as the drug that it is. There is no justification for short-circuiting this process. If we do, then we risk causing far more harm than any realized benefit, as the new study of increased death in older COPD patients suggests. We are currently at the point analogous to when radioactive tonics were in their heyday – all hype, little science, and marketed more with feelings than with facts.
Although it’s probably too late, we should hit the pause button on cannabinoids until proper research has a chance to play itself out. A “what’s the harm” approach here is not appropriate. Appeal to anecdote is more likely to cause harm than good. Let the science happen.

How Safe is CBD?
CBD is a drug, but sold as both a drug and herbal supplement. What does the current evidence say about its safety?
Steven Novella on June 15, 2022
Link

There has definitely been a rapid cultural change over the last decade. Cannabis products have become more generally accepted, first for medicinal use and increasingly for recreational use. Cannabidiol (CBD) use in particular has taken off – CBD is a component of cannabis that does not contain the psychoactive properties of THC. It has become popular as an “herbal supplement”. On most city streets you will see signs advertising CBD products. But the rapid popularity of CBD may be premature.
As I have written before, “herbal supplements” are not supplements, and the fact that they are herbal is entirely inconsequential. They are, in fact, drugs, by any reasonable definition. In essence we have two parallel systems for selling drugs in the US (and many other countries). In one system drugs go through a highly regulated research protocol where they are purified and tested for safety and efficacy. Their pharmacokinetics and pharmacodynamics are characterized, proper dosing is established, drug-drug interactions are studied, and side effects are carefully tracked. Most drugs do not make it through this process, and those that do come with a detailed description of their pharmacological profile. Drugs are also classified based on their potential for harm, with many requiring a doctor’s prescription. This does not mean they are risk free, but at least there is a transparent process for minimizing harm and maximizing the benefit to risk ratio.
In the parallel drug market, however, drugs can be sold direct to the consumer with literally zero requirement for any prior study. They can be sold in combination with other ingredients, at unknown and highly variable doses, without any information about their pharmacology or safety, and with claims that have not been adequately scientifically demonstrated. Unsurprisingly, they have demonstrably high levels of ingredient substitution, contamination, and adulteration. But even when pure, there is simply no way to know the risks and benefits and therefore make rational decisions regarding their use. Fortunately (from one perspective) most products in this category have low bioavailability and overall dosing, which reduces both the potential for direct harm and benefit.
This second category of essentially unregulated drugs are called herbal supplements. They are regulated more like food than drugs, with general use being considered as adequate evidence of safety, and no mind paid to claims of efficacy. The one stipulation is that sellers cannot make disease claims regarding their products, but this is easily side-stepped and often ignored.
CBD is simply another pharmacologically interesting chemical. It may turn out to be, in one form or another, a useful drug. There is preliminary evidence that it may be useful in treating anxiety and other mood disorders, and have antiemetic properties. Actually, one form of CBD has been purified, studied, and FDA approved as a prescription drug for certain kinds of epilepsy, Epidiolex. It is a bit strange that a drug is available simultaneously in a prescription and “herbal” form.
This dual life of CBD shows how thin the justification for the current lack of regulations for herbal drugs is. The primary justification is that herbs are “natural”, but this is a meaningless term. It is not clearly defined, and there is no reason to think that being “natural” in any way conveys safety. The most deadly poisons on the planet are all natural, by any definition.
Another justification is that herbal supplements have “traditional use” which gives us a long history of safety. This is flawed reasoning on multiple levels. First, anecdotal evidence, no matter how extensive, will only tell you about obvious immediate side effects. It will not provide information about statistical risks, complex interactions, rare but deadly side effects, and subtle effects such as organ toxicity (see, for example, Aristolochia and kidney damage). Further, many herbal products do not have a long history of traditional use, even when claimed. This is more of a marketing tool than reality. In short, traditional use is no substitute for scientific evidence.
But as I said, there is an FDA approved form of CBD, which we cannot assume has identity risks of every herbal version out there, but does give us some information on safety. As is almost always the case, any drug that is pharmacologically active enough to have a demonstrable benefit likely also has potential risks and interactions. CBD, it turns out, has a safety profile that is fairly typical for a prescription drug, and in fact is worse than many drugs on the market.
A 2019 review found:
Nearly one-half of CBD users experienced [adverse drug events, ADEs], which displayed a general dose-response relationship. Common ADEs include transaminase elevations, sedation, sleep disturbances, infection, and anemia.
“Transaminase elevations” means effects on the liver while anemia could mean bone marrow suppression. These are concerning side effects because they can indicate organ toxicity. Also, just as with any drug, controlled trials are limited in their ability to detect rarer side effects. These tend to come out only when the drug is in wide use, which is why drugs are monitored after they are on the market. As an example, there is a recent case report of a patient who had a severe cardiac reaction to herbal CBD. She had prolonged QT intervals, which indicates an adverse effect on electrical conduction in the heart. This led to a life-threatening cardiac arrhythmia. No other cause was found, and the abnormal rhythm resolved when she stopped the CBD supplement.
In this case the patient was taking high doses of CBD, but that is part of the point – she was taking it without a prescription, without any physician advice or supervision, and was lulled into a false sense of safety because CBD is a “natural herb”.
CBD also has a relatively high potential for drug-drug interactions (DDI). What this means is that one drug alters the pharmacology of another, but increasing or decreasing its effective blood level, for example. The same 2019 review above found:
Given CBD effects on common biological targets implicated in drug metabolism (e.g., CYP3A4/2C19) and excretion (e.g., P-glycoprotein), the potential for DDIs with commonly used medication is high.
In other words, relative to other prescription drugs, the DDI potential of CBD is high. Taking CBD without supervision, therefore, results in a potential that it can affect other medications, resulting in a host of possible other risks.
CBD, in short, is a drug, and it behaves like a drug, and not a particularly clean one. The reviewers above concluded:
General clinical recommendations of reducing substrate doses, monitoring for ADEs, and finding alternative therapy should be considered, especially in medically complex patients. CBD is implicated as both a victim and perpetrator of DDIs and has its own ADE profile. These effects should be considered in the risk-benefit assessment of CBD therapy and patients and consumers made aware of potential safety issues with CBD use.
Of course, none of this can happen if consumers are taking CBD products over the counter without any supervision, and under the false impression that CBD is natural and therefore perfectly safe. To be clear, I am not against CBD itself. My criticism is of the current regulatory framework that creates a false dichotomy between drugs and supplements. CBD should be studied and regulated like any other drug, because that’s what it is.

Cannabinoids for Acute Pain
A systematic review of cannabinoids for acute pain shows the evidence is preliminary, and not very encouraging.
Steven Novella on March 25, 2020
Link

Cannabinoids are a medically interesting group of molecules, and a great example of the potential benefits of pharmacognosy – the development of drugs from plants and other natural sources. Nature is a great laboratory, with millions of experiments over hundreds of millions of years. Plants mostly evolved substances as defense mechanisms, to be toxic to the creatures that might eat them. However toxins in measured low doses and in the right clinical context can be medicines. A toxin that causes diarrhea, for example, can be a treatment for constipation.
But of course just consuming plants is not a good idea. Most of the plants we eat for food were cultivated to have dramatically reduced protective chemicals. Animals evolved a taste for bitterness, which is a way of detecting these potentially harmful chemicals. So if our ancestors selected plants that were less bitter, they were also less toxic. I think most people know they shouldn’t walk into the woods or a field and eat a random plant. Chances are it will taste awful an they will get sick.
But through collective experience most cultures detected plants in their environment that can have potentially medicinal effects. Without modern scientific methods, however, only the most obvious effects were reliably detected. One such effect may be a reduction in pain, although pain is also highly susceptible to placebo effects. We are now in the middle of extreme hype over one plant’s potential medical benefits, including pain – cannabis. Two main constituents are phytocannabinoid tetrahydrocannabinol (THC) which is the primary psychoactive compound in cannabis, and cannabidiol (CBD).
SBM has already published several articles detailing the fact (going back to 2014) that the hype surrounding CBD and other cannabinoids as medicinals is outstripping the evidence. Historically putting hype before evidence usually doesn’t end well. We are seeing the creation of an industry and a market for CBD products before there is published scientific evidence confirming safety and efficacy. This was bound to happen in our loose regulatory environment. Experts were calling for lifting of restrictions on research, so we could find out if CBD and other products were useful. Promoters immediately took this to mean that it worked and started making money.
Preliminary evidence is now coming in so we can start to answer the many questions about efficacy. A recent systematic review and meta-analysis looks specifically at cannabinoids and acute pain. Here are the results:
Six trials (678 participants) were included examining oral (5 trials) and intramuscular (1 trial) cannabinoids. Overall, there was a small but statistically significant treatment effect favoring the use of cannabinoids over placebo (−0.90, 95% confidence interval [CI] −1.69 to −0.1, i2=65%, p=0.03). When stratified by route of administration, intramuscular cannabinoids were found to have a significant reduction in pain relative to placebo (−2.98, 95% CI −4.09 to −1.87, i2=0%, p<0.0001). No difference in effect was observed between oral cannabinoids and placebo (−0.21, 95% CI −0.64 to 0.22, i2=3%, p=0.34). Serious AEs were rare, and similar across the cannabinoid (14/374, 3.7%) and placebo groups (8/304, 2.6%).
For some reason, in their conclusions, the authors combine the evidence from oral and IM cannabinoids to say there is a small but statistically significant effect. I don’t think this makes sense, however, and is ultimately misleading. Rather, the most reliable outcome of this review is that oral cannabinoids have no effect beyond placebo for acute pain, with data from 5 trials. This is still a preliminary conclusion and we could argue for more research being necessary. But it is not encouraging that after 5 studies there is no effect from oral cannabinoids for acute pain. Effect sizes tend to decrease over research time, not increase, as protocols tighten.
While this is 5 studies of oral cannabinoids, they were all with different substances or doses. Two were with Nabilone at different doses, one with THC, one with AZD1940, and one with GW842166. Even combing this data is questionable (which is why I am not sure the meta-analysis was of any use). But reviewing the individual studies is useful.
None of the oral studies produced convincing evidence of efficacy, and together they are negative. One might argue that the studies were not powerful enough (total subjects 622) to detect a signal (pain reduction). But with pain reduction, if the signal is too small then that means the pain reduction is clinically insignificant (which is not functionally different from no pain reduction).
It’s possible that the cannabinoids do have a potentially useful effect but the bioavailability of the oral route is simply too low. The authors note this:
Specifically, oral absorption of cannabinoids is slow and variable with maximal plasma concentrations occurring 60–120 min postingestion but can be delayed upward of 6 h. Cannabinoids are subjective to significant first-pass liver metabolism, which further reduces the bioavailability.
Low oral bioavailability is what dooms most herbals from having a significant clinical effect. This is precisely why they are developed into pharmaceuticals in the first place – the active ingredients are identified, purified, and then tweaked chemically to reduce toxicity and increase bioavailability.
This may also be why the only study to show a significant effect was the intramuscular study, which used a form of artificial THC called levonantradol. When we take a closer look at this study, however, it is not impressive. First, it is small, with 56 subjects. Further, of the six studies reviewed it was found to have the highest risk of bias. This is especially important with pain studies because of the high potential for placebo effects. Further still, needle injections have a known greater placebo effect than taking pills. So basically we have one small preliminary study showing potential benefit for IM levonantrodol. This is the very definition of – too early to hype and requires further research.
So at present the data on cannabinoids in general for acute pain is not impressive. No oral agent shows positive preliminary data, and while further research is necessary this data does not predict a positive outcome. That leaves open the window, however, for developing pharmaceuticals based on these cannabinoids that have greater bioavailability and efficacy.
The IM route for levonantrodol has one preliminary study showing a significant effect, but such preliminary data usually does not survive later research (if we are playing the odds). But this is still encouraging preliminary results and deserves further research.
Research into cannabinoids is critical at this stage. First, we can use more options for the treatment of acute and chronic pain, especially in the face of an opioid epidemic. But we need to know that they actually work. If they don’t work, that is critical to know also, and hopefully that evidence would be used to blunt and reverse the exploding preliminary hype into this new class of drugs.

Avemar: Wheat Germ for Cancer
Avemar is fermented wheat germ. It is claimed to be an effective addition to conventional cancer treatment. The evidence is lacking.
Harriet Hall on August 31, 2021
Link

The initials of the Australian organization Friends of Science in Medicine (FSM) happen to be the same as the Flying Spaghetti Monster but the two are diametrically opposed. The latter began as a satire on creationism and developed into a religion that makes unsupported and untestable claims; the former was established in 2011 to emphasize the importance of rigorous science in health care and to question unsubstantiated health claims. It focuses on Australia but has many members around the world, including most of the writers for Science-Based Medicine. Friends of Science in Medicine is currently challenging Australian regulations regarding “food as medicine”. They have found a marked discrepancy in consumer protection between the standards for therapeutic claims for medicines and therapeutic claims for foods. FSM’s current president, Ken Harvey, has written about Avemar, classified as a “Food for Special Medical Purposes for Cancer”, here. He mentions that the price of a month’s supply is $220 AUD.
Outrageous claims
Avemar is being promoted in the US with these outrageous claims:
Researchers have proved that Avemar is an effective cancer treatment that unlike other alternative cancer treatments does not treat a single type of cancer but works effectively in treatment of all types of cancer. It can therefore be used effectively in fighting breast cancer, cervical cancer as well as other cancers that have victimized our women for centuries.
Avemar also helps the immune system in identifying and killing the cancer cells. It strengthens the natural killer cells to spot and destroy the cancer cells as well as any other foreign body that may enhance the growth of the cancerous cells and cause more harm to the cancer patient. The cancer cell unfortunately may escape the natural killer cell by masking themselves in a special membrane that the natural killer cells cannot identify as foreign, Avemar helps in this situation as it inhibits the release of this special membrane thereby making it possible for the natural killer cells to spot the cancer cells and kill them.
What is it?
Avemar is a fermented wheat germ extract marketed as a medical food to supplement the diet of cancer patients undergoing standard cancer treatments including surgery, immunotherapy, chemotherapy, and radiation. It is said to improve quality of life.
What does the science say?
A 2018 systematic review found 16 studies suitable for analysis. All were on human cell lines cultivated in a lab; none of the studies evaluated clinical outcomes. They found some promising results, but concluded, “further in vitro and in vivo studies are necessary to prove its effectiveness and safety in humans.” An earlier systematic review in Australia had concluded “While the early evidence, particularly at the cellular level are promising, and of interest, the broader questions regarding Avemar as an adjunctive therapy in cancer treatment, and its clinical effectiveness have not been established to date”. So the claim that Avemar is an effective treatment for all types of cancer is not supported by the evidence.
I found a lot of studies of Avemar listed in PubMed, but they were mostly in vitro and animal studies. One clinical study of patients with rheumatoid arthritis found Avemar beneficial; but it was a small, uncontrolled open-label pilot study with only 15 patients. Another pilot study found that adding Avemar to a regimen of chemotherapy for high risk melanoma patients significantly improved survival. I found no rigorous research that compared clinically significant outcomes with Avemar to outcomes with placebo.
More questionable claims
On Amazon.com, Avemar is claimed to be an all-natural, holistic supplement that:
    • Supports the Immune System, Quality of Life, Mental Clarity, Physiological Cellular and Hormonal Immune Balance.
    • AVEMAR Supports Blood Sugar Levels and Glucose Metabolism. Supports White Blood Cells for Peak Performance.
These claims clearly go beyond the evidence. I couldn’t figure out what they were talking about when they said that cancer cells mask themselves in a special membrane that the natural killer cells can’t identify as foreign and that Avemar inhibits the release of that membrane.
Conclusion: Inadequate evidence
        ◦ The published evidence didn’t convince me that it doesn’t work, but I didn’t find convincing evidence that it does work. More and better research is needed. Wheat germ is food, but is Avemar a “food for special medical purposes” that warrants promoting this expensive product to vulnerable cancer patients? I’m skeptical.

   Can it get any worse?: industrial bleach as cancer and HIV cure
David J Kroll
Link
On the heels of Scott Gavura’s superb post yesterday on dietary supplement regulation in the US and Canada, I bring you one of the most egregious and obscene product cases I have seen in 15 years of teaching on botanical and non-botanical products: Miracle Mineral Solution. Please accept my apologies in advance for not having a scholarly post for you today – this is just too unbelievable not to share with Science-Based Medicine readers.
On July 30, the FDA released this warning:
FDA NEWS RELEASE
For Immediate Release: July 30, 2010
Media Inquiries: Elaine Gansz Bobo, 301-796-7567, elaine.bobo@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA
FDA Warns Consumers of Serious Harm from Drinking Miracle Mineral Solution (MMS)
Product contains industrial strength bleach
The U.S. Food and Drug Administration is warning consumers not to take Miracle Mineral Solution, an oral liquid also known as “Miracle Mineral Supplement” or “MMS.” The product, when used as directed, produces an industrial bleach that can cause serious harm to health.
The FDA has received several reports of health injuries from consumers using this product, including severe nausea, vomiting, and life-threatening low blood pressure from dehydration.
Consumers who have MMS should stop using it immediately and throw it away.
MMS is distributed on Internet sites and online auctions by multiple independent distributors. Although the products share the MMS name, the look of the labeling may vary.
The product instructs consumers to mix the 28 percent sodium chlorite solution with an acid such as citrus juice. This mixture produces chlorine dioxide, a potent bleach used for stripping textiles and industrial water treatment. High oral doses of this bleach, such as those recommended in the labeling, can cause nausea, vomiting, diarrhea, and symptoms of severe dehydration.
MMS claims to treat multiple unrelated diseases, including HIV, hepatitis, the H1N1 flu virus, common colds, acne, cancer, and other conditions. The FDA is not aware of any research that MMS is effective in treating any of these conditions. MMS also poses a significant health risk to consumers who may choose to use this product for self-treatment instead of seeking FDA-approved treatments for these conditions.
The FDA continues to investigate and may pursue civil or criminal enforcement actions as appropriate to protect the public from this potentially dangerous product.
The FDA advises consumers who have experienced any negative side effects from MMS to consult a health care professional as soon as possible and to discard the product. Consumers and health care professionals should report adverse events to the FDA’s MedWatch program at 800-FDA-1088 or online at www.fda.gov/medwatch/report.htm.
Even with this forceful warning, the product website is still live and it is full of the most unreal claims I’ve seen in any online marketing scheme:
This Breakthrough can save your life, or the life of a loved one.
Please read.
The answer to AIDS, hepatitis A,B and C, malaria, herpes, TB, most cancer and many more of mankind’s worse diseases has been found. Many diseases are now easily controlled. More that 75,000 disease victims have been included in the field tests in Africa. Scientific clinical trials have been conducted in a prison in the country of Malawi, East Africa.
Separate tests conducted by the Malawi government produced identical 99% cure results. Over 60% of the AIDS victims that were treated in Uganda were well in 3 days, with 98% well within one month. More than 90% of the malaria victims were well in 4 to 8 hours. Dozens of other diseases were successfully treated and can be controlled with this new mineral supplement. It also works with colds, flu, pneumonia, sore throats, warts, mouth sores, and even abscessed teeth (it’s the only thing that controls and cures abscessed teeth).
The inventor believes that this information is too important to the world that any one person or any group should have control. The free e-book download on this site gives complete details of this discovery. Please help make sure that it gets to the world free. There are many medical facts that have been suppressed and this invention must not be added to that list. The name of the e-book is The Miracle Mineral Supplement of the 21st Century. This book tells the story of the discovery, and how to make and use it. This book can save your life. Give it a try.
No. No. Don’t give it a try.
Instead, please follow this advice from FDA if you are a consumer who has stumbled upon this post in a search term query:
The FDA advises consumers who have experienced any negative side effects from MMS to consult a health care professional as soon as possible and to discard the product. Consumers and health care professionals should report adverse events to the FDA’s MedWatch program at 800-FDA-1088 or online at www.fda.gov/medwatch/report.htm.
Blogging colleague, Liz Ditz, brought me this information from the “inventor’s” Q&A blog:
Is taking MMS IV much more efficient than drinking it? Should I stop taking my medication for HIV?
Posted by: admin in AIDS, HIV, Intravenously (IV), MMS General, tags: AIDS, HIV virus, Intravenous treatment, iv, medications, vomit
Please treat me as your son and tell me what best should I do to get rid of this HIV virus. Would you tell me to stop my three drugs medication and when? Is it ok to overlap MMS with current medication? Should I take MMS IV if it’s much more efficient than drinking it? Stopping medication is a big decision for me to make as I always felt to rely on them in order to live. Please help me with your experience and testimonials.
=====
MMS IV is much more effective than taking by mouth. Stop the drugs immediately. HIV is not dangerous. It does not cause AIDS. What causes AIDS is the drugs that you are taking, each one is extremely poisonous. That causes AIDS. The vomiting was a good sign. It means you body is getting rid of bad stuff. It takes a certain amount of courage to stop the drugs, but you really know that they are bad, and that they will not help you live longer. Just depend on the MMS as it is a thousand times better. Read the MMS data a few times. See the logic. Ask yourself that is not more logical that taking poisons. Visit http://www.miraclemineral.org for the MMS book and DVD and http://www.jimhumble.com for more info.
Keywords: Intravenous treatment, HIV virus, AIDS, medications, vomit, iv
In cases such as these, the US Federal Trade Commission has more power to intervene than even the FDA. False advertising to the point of directing the consumer to harm themselves is much more their purview. In fact, some readers will recall that in 2001 the FTC ran “Operation Cure All,” a multi-agency initiative to target internet health fraud in cooperation with Health Canada.
But I’m wondering where the FTC is in the case of Miracle Mineral Solution. A site search conducted at the time of this post revealed no FTC action against the marketers or manufacturers of this bleach product. I am simply stunned that this product website and associated promotional materials remain online.
This is not a case of a supplement adulterated with a prescription drug or containing trace amounts of heavy metals. This is an active scheme directed not only to driving the consumer to use a harmful product (and even inject it IV), but also encourages the discontinuation of beneficial prescription drugs.
I will be filing a complaint today with the FTC – I encourage those of you so inclined to do so here.

Lorenzo’s Oil: Hollywood versus science
Lorenzo Odone, son of Italian economist Augusto Odone, was diagnosed at age 5 with a horrific genetic disease, X-linked adrenoleukodystrophy (X-ALD), which is usually a death sentence by age 10 or so. As portrayed in the movie Lorenzo’s Oil, the story of the Odones is a typical Hollywood cliche of a plucky family badgering scientists, finding a “brave maverick scientist” to synthesize the oil that Augusto believed would help Lorenzo, and then testing it on their son, in essence portraying the oil as a miracle cure. As is often the case with Hollywood adaptations of real life stories, real story is much more complex.
Steven Novella on October 30, 2013
Link
Augusto Odone is an Italian economist best known for his son, Lorenzo, after which Odone named the oil that he helped develop to treat his son’s neurological disease. Lorenzo’s oil was the subject of a 1992 movie starring Nick Nolte and Susan Sarandon, and of course what most people think they know about the story they learned from the Hollywood version.
This past week Augusto Odone died at the age of 80, prompting another round of media reporting about Lorenzo’s oil.
Probably because of the Hollywood movie, this story more than any other is an iconic example of the disconnect between the simple narratives the media love to tell (and we love to tell ourselves) and the more complex reality.
The basic facts of the story are not in dispute. Lorenzo Odone, son of Augusto and his wife, had a neurological disease known as X-linked adrenoleukodystrophy (X-ALD). This is a devastating genetic disease in males, with two basic forms. Childhood onset tends to progress rapidly and typically death occurs by age 10, although lifespan can be increased if an early bone marrow transplant is given. In adult onset, symptoms may not appear until adulthood, and then tends to progress more slowly, over decades. Some boys with the X-ALD gene do not develop clinical findings. Women are carriers, with partial protection from their second X chromosome. About half of female carriers become symptomatic, with the slower adult form of the disease.
The disease is a metabolic disorder that results in the buildup of very-long-chain fatty acids (VLCFA) in nervous tissue and the adrenal glands. This leads to disruption of the myelin, the insulation around nerve cells that helps them conduct signals efficiently. Buildup of VLCFA in the adrenal glands causes adrenal dysfunction, which needs to be treated with hormone replacement.
Lorenzo Odone started to develop neurological symptoms at the age of 5. He was diagnosed with X-ALD, and given a prognosis of surviving for a few years. His parents, however, were not content to accept this prognosis and began their attempt to find a cure, or at least a treatment. Augusto, who apparently had significant financial resources, organized an international meeting of X-ALD specialists to discuss possible strategies. The idea for Lorenzo’s oil was inspired by insights that came out of this conference.
The oil itself is a 4:1 mixture of oleic and erucic acids – found in common cooking oils. Consuming the oil reduces the serum level of VLCFAs. When the oil was first given to Lorenzo, his VLCFA levels reduced rapidly from very high to normal. Lorenzo survived until age 30, far longer than his original prognosis. The oil did not seem to reverse any of his neurological deficits, but did seem to slow progression.
The Hollywood version of this story annoyed and dismayed scientists and families with X-ALD for various reasons. By the time the movie came out many children with X-ALD were taking Lorenzo’s oil, as it was rapidly adopted by the medical community and routinely prescribed. Most of these children, however, did not seem to benefit from the oil and were progressing despite treatment. Many doctors, in fact, had stopped prescribing the oil. The movie, therefore, seemed to promote false hope in a miracle cure that did not work for most children.
The Hollywood narrative also followed the fairly standard plotline of plucky parents who would not give up on their child and had to struggle against an uncaring medical system. However, the facts don’t seem to support that narrative. I’m sure the Odones encountered some resistance or doubt along the way, but the facts support a narrative in which the medical community was largely cooperative with the Odones’ quest.
In fact, the real story of Lorenzo’s oil represents a fruitful collaboration of a disease advocate and the professional community. Augusto Odone started the process by convening the world experts on the disease, and then listening to them. He collaborated with scientists to develop and purify the oil, and of course the oil was prescribed by physicians, and ultimately scientifically studied by physicians and scientists.
This is an excellent model identifying a disease, getting or providing funding, and then using those resources to do science targeted at understanding and curing the disease. Hollywood, however, decided to portray this relationship as antagonistic in order to play up the Odones as maverick crusaders succeeding despite (rather than with) the medical community.
The story of Lorenzo’s oil also carries another lesson – science and medicine often turn out to be more complex than it may seem at first. It is likely that there was cautious skepticism regarding Lorenzo’s oil when first proposed. Initial cautious skepticism is appropriate. It is unfair and misleading, for those new ideas that turn out to be true, to look back at previous skepticism as nihilistic or obstructionist. This is the scientific version of Monday morning quarterbacking.
It also turns out that the caution of scientists was vindicated in part, as was the hope of the parents. The longest study we have of Lorenzo’s oil found that it was of no benefit at all to people with symptomatic X-ALD.
However the same study, and others, show that if Lorenzo’s oil is given to asymptomatic boys with the X-ALD gene then their chance of going on to become symptomatic is significantly reduced, by about half. Lorenzo’s oil is therefore currently recommended for preventive therapy in asymptomatic boys with X-ALD.
Why the oil works for prevention but not treatment is unclear. It is interesting that even though the oil reduces VLCFA in symptomatic people with X-ALD, that does not affect the disease itself. There therefore must be more going on than just increased VLCFA. Perhaps VLCFA are just a marker for some other metabolic process that is truly pathological, or it’s a trigger, but once that process has started (and sufferers are symptomatic) it is no longer dependent on VLCFA levels.
It is exactly these kinds of complexities, frequently encountered in science and medicine, that result in cautious skepticism when new treatments and ideas are proposed. This is also why, no matter how good the story sounds, we still have to do the detailed science, ask all the hard questions, and show that a new treatment actually works.
Contrast this to the way CAM operates – which would have adopted the oil as a miracle cure and not questioned it further, or continued to use and promote the oil after it was shown not to work for symptomatic individuals.
Conclusion
The story of Lorenzo’s oil is a fascinating but complex one. It does show how collaboration between families and disease advocates on one side, and scientists and physicians on the other, can be fruitful in advancing our medical knowledge toward a goal of treatment.
There are important caveats, of course. Such stories are like catnip to journalists and Hollywood; they cannot resist them, or resist shoehorning them into their preferred narratives. This has the tendency to promote false hope or premature hope, and can reduce confidence in the medical community even while they are working to advance medical knowledge.
Second, as I have pointed out before, and was also pointed out in this Lancet commentary regarding Lorenzo’s oil itself, grassroots effort to fund medical research sometimes has the unintended effect of directing research in a counterproductive way. In short – there needs to be a proper balance between basic research to understand mechanisms of disease, and clinical research to develop treatments. Grassroots funding tends to favor clinical research. People want a cure. But this can shift the balance prematurely from basic to clinical research and actually slow scientific progress and even delay an ultimate cure.
There is also one enduring mystery in this story. We now know from extensive research that Lorenzo’s oil does not seem to work in symptomatic individuals. Why, then, did Lorenzo himself survive to age 30? Every account of his case I can find credits the oil, but this is likely not the situation. His neurological condition continued to progress despite use of the oil.
This, of course, is the problem with anecdotal evidence. There are too many unknowns. He may have simply had an unusual case. It is also likely that he received excellent supportive care (given his family’s resources and the special attention his case drew), and this supportive care may have resulted in his long survival despite the illness.
Lorenzo’s oil continues to be a focus of scientific research. Clearly, there is something here of benefit. Perhaps tweaking the formula will provide symptomatic benefit, or perhaps it is just part of the puzzle, with the other pieces remaining to be discovered.
The real story of Lorenzo’s oil is inspiring and hopeful, but complicated by scientific reality, and containing many lessons and nuances. If only Hollywood could see the power in such real stories, rather than their simplistic fairy tales.

COFFEE AND CAFFEINE

This stimulant can kill, yet you can legally buy it online. Why?
Scott Gavura on July 2, 2015
Link


If there’s one thing that unites all countries and cultures, it’s our love of caffeine. Whether it’s coffee, tea or other foods, caffeine is the most widely consumed drug in the world — more than alcohol, and more than tobacco: 90% of adults worldwide consume caffeine daily. At doses found in food and beverages, the effects are predictable and the side effects are slight. But natural or not, caffeine is a drug; isolate the pure substance, and the risks change. It would be difficult for most people to drink 16 cups of coffee in a row, but that’s the equivalent of just one teaspoon of caffeine powder. If that doesn’t hospitalize you, a tablespoon of the powder will probably kill you. Yet despite the risks, there are no restrictions on the sale of caffeine powder. You can buy a 1kg bag for $35, which provides the caffeine of about 5,000 cups of coffee. Caffeine powder is freely available to buy because regulators treat it differently – not because of its inherent properties, but because it’s “natural” and sold as a dietary supplement rather than a drug. This is a regulatory double-standard that harms consumers. It’s leaving a body count. And it needs to change:
A year ago, Logan Stiner of LaGrange, Ohio, was an honors student and prom king looking forward to his high school graduation. “He was burning the candle at both ends, because he had a couple of projects that he had to finish for finals,” said his mother, Kate Stiner. On May 27, his brother found him unresponsive on their living room floor. In an effort to increase his energy, Mr. Stiner had used caffeine powder a friend had purchased on Amazon, but miscalculated the dosage, overdosed and died. The medical examiner said the cause of death was “cardiac arrhythmia and seizure, due to acute caffeine toxicity due to excessive caffeine ingestion.”A few weeks later, 24-year-old James Wade Sweatt, a newly married, recent college graduate living in Georgia, blended a drink with powdered caffeine, also purchased online. Health conscious, he reasoned that pure caffeine and water would be a healthier way to get a lift than the Diet Mountain Dew that he usually drank. He overdosed, fell into a coma and died.
Caffeine is a natural substance produced by over 60 plants. Chemically, caffeine is 1,3,7-trimethylxanthine. Why so many plants produce this chemical is not well understood, as it’s not essential for a plant’s survival. Whether caffeine is a pesticide (repelling invaders) or a herbicide (fallen leaves inhibiting plant growth) isn’t clear. When consumed, caffeine is a central nervous system stimulant, increasing your heart rate and respiration. It also relaxes smooth muscle (producing another known effect) and is a mild diuretic. When used at modest (food-like) doses, caffeine is considered safe to consume. At usual daily doses of 100-200mg per day, caffeine reduces feelings of fatigue and raises perceptions of alertness. As a drug, caffeine has some medicinal uses. Caffeine is chemically very similar to theophylline, an old drug used to treat asthma and other lung diseases. It is combined with some painkillers for headaches and migraine. There’s some evidence it can improve athletic performance. Then there’s a long list of unproven but promising attributes, such as reducing the risk of type 2 diabetes or Parkinson’s disease. I’ve written before about how it is used for conditions like ADHD without good evidence it actually works.
Given its frequency of use, caffeine overdoses are rare, because the amount in foods and drinks are modest enough to make overdose difficult. Abuse can occur, and at high doses (the equivalent of 80+ cups of coffee), caffeine can be fatal. When abused, caffeine can produce feeling of euphoria. In an overdose situation, caffeine causes delusions, hallucinations, and heart conduction abnormalities, leading to death.
Despite its roots as a natural product, powdered caffeine is similar to the caffeine in soda in that it is synthetic, and not actually derived from natural sources at all. Apparently Americans are importing 17 million pounds of it, with much of it going to soda. Recently it has started to appear in other products, like gum, marshmallows, gummi bears and even sunflower seeds.
A lack of meaningful regulation
Caffeine that’s packaged as a dietary supplement is sold virtually unregulated in the United States, not because of a loophole in regulations but because of the explicit intent to remove regulatory barriers and limit any action from the FDA. The Dietary Supplement Health and Education Act of 1994 (DSHEA) is an amendment to the U.S. Federal Food, Drug and Cosmetic Act that establishes a regulatory framework for dietary supplements. It effectively excludes manufacturers of these products from virtually all regulations that are in place for prescription and over-the-counter drugs. The FDA notes:
Generally, manufacturers do not need to register their products with FDA nor get FDA approval before producing or selling dietary supplements. Manufacturers must make sure that product label information is truthful and not misleading. FDA’s post-marketing responsibilities include monitoring safety, e.g. voluntary dietary supplement adverse event reporting, and product information, such as labeling, claims, package inserts, and accompanying literature. The Federal Trade Commission regulates dietary supplement advertising.
The FDA recognizes the problem with powdered caffeine, but in its warning to consumers, it is clear that the agency is powerless to do anything meaningful about it:
The FDA is warning about powdered pure caffeine being marketed directly to consumers, and recommends avoiding these products. In particular, FDA is concerned about powdered pure caffeine sold in bulk bags over the internet. The FDA is aware of at least two deaths of young men who used these products. These products are essentially 100 percent caffeine. A single teaspoon of pure caffeine is roughly equivalent to the amount in 25 cups of coffee. Pure caffeine is a powerful stimulant and very small amounts may cause accidental overdose. Parents should be aware that these products may be attractive to young people.
No recalls, or “stop sales” orders. Just a warning to consumers. The FDA notes that manufacturers can add caffeine to foods as long as they include it on the ingredient list. When it approved adding caffeine to cola back in the 1950s it could not have contemplated how many foods and products like energy drinks would be supplemented with caffeine today. The only recent action was in 2010 to prohibit caffeinated alcoholic beverages – for obvious reasons.
While some supplement industry groups are supportive of restrictions on the sale of bulk powder, others disagree. The Natural Products Association does not support regulation. After all, salt and water can kill you, just like caffeine:
Take water [or] salt for example — if you use too much, it creates problems. I think that’s really the issue here. People safely use caffeine every day.
But this argument ignores fundamental facts. It’s true that the dose makes the poison, but the recommended dose of caffeine is tiny. You can’t accurately measure or weigh 200mg of caffeine powder using home measures and scales. And no-one is likely to seek an energy boost from consuming sodium or water.
Short of any federal regulation (the FDA remains noncommittal beyond a warning), other legislation is pending. Some senators have asked the FDA to act. While caffeine sales bans have been proposed at the state level, it’s not likely to have any meaningful effect when you can buy this product over the internet. There’s also the litigation approach:
Amazon.com and caffeine powder distributors didn’t provide proper warnings about the supplement’s dangers, resulting in the death of an Ohio high school student last year, the teen’s father said in a lawsuit filed Friday.
Eighteen-year-old Logan Stiner was just days from graduating high school in northeast Ohio when, on May 27, his brother found him unresponsive in the family’s home in LaGrange, southwest of Cleveland. A coroner ruled that Stiner died of cardiac arrhythmia and seizure due to acute caffeine toxicity. The amount of caffeine in his system was about 23 times greater than the level in a typical soda or coffee drinker. Stiner was a popular student who was voted prom king, wrestled and planned to study chemical engineering at the University of Toledo.
The lawsuit names as defendants a classmate who gave Stiner the caffeine powder; Amazon, which shipped it to the woman last March; and six Arizona-based companies that the father’s attorney said packaged and sold the pharmaceutical-grade powder under the name Hard Rhino. The lawyer, Brian Balser, said Friday that the Arizona companies appear to be related.
As long as we maintain a regulatory double-standard for supplements and “natural” products, there is not likely to be much change, and we can probably expect more people to die from caffeine powder overdoses.
“It’s natural, therefore it’s safe” is an appealing yet baseless health myth. Yet this is the primary argument that has been used to give supplements and natural health products completely different regulatory structures than what exist for drug products. Weaker regulation of supplements and natural health products has been a boon to manufacturers, but the same can’t be said for consumer safety. Natural or not, we need to assess the risk and benefits of products on their own merits, not simply because some chemicals happen to be produced by plants. We need meaningful regulation that acknowledges this.

Caffeine Overdose Death Raises Question of Weak Regulations Across the Pond
A personal trainer in England died from a massive overdose caused by a deadly miscalculation aided by weak regulations of the sale of pure caffeine powder.
Clay Jones on April 1, 2022
Link

Last month, news of the tragic death of a British personal trainer in January of 2021 made the rounds. 29-year-old Tom Mansfield, a father of two young children who also worked as a security guard, miscalculated the amount of legally purchased pure caffeine powder that he would add to a beverage by a significant, and ultimately deadly, amount. Soon after drinking the concoction, he began clutching his chest and complaining of an unusually rapid heart rate. Within minutes of developing symptoms, he went into cardiac arrest and was not able to be saved despite what sounds like a valiant effort by medical professionals on the scene.
Mansfield had purchased a 100-gram container of pure caffeine powder and likely planned to add between 60 and 300 milligrams to his drink, though the amount appears to be an assumption based on typical pre-workout doses. According to several news reports, no scoop was provided by the company, Blackburn Distributions, to aid in measuring a safe amount of the powder. This was a fact focused heavily on by Coroner John Gittins during an inquest last month:
Mr Gittins added that he has since been “massively reassured” that action has been taken to help prevent similar cases from occurring in the future with this brand of caffeine powder due to the provision of a scoop and an A4 instruction sheet in all new packets. Had these scoops been provided at the time, Mr Mansfield would likely still be alive today, the coroner said in his conclusion.
Coroner Gittins probably shouldn’t feel that confident in that assertion, but the provision of a measuring scoop and additional warnings along with these products might reduce the chance of accidental fatal overdose. There is, of course, a much better option. I’ll get into the nuance of this shortly. But first, a brief primer on caffeine and caffeine toxicity.
The most popular psychoactive drug in the world
Though I have never been a fan of coffee or tea, like roughly 90% of the world’s adult population I do consume caffeine daily, mostly in the form of chocolate and Diet Coke. When I wrote about the dangers of energy drinks in the pediatric population back in 2014, I discussed my strategic use of caffeine pills, which typically contain 200 milligrams of caffeine, when I needed a boost in alertness or athletic vigor. I generally avoided caffeine on other days in order to stave off the development of tolerance.
Over the next several years I found myself taking a caffeine pill almost daily, largely because I became more dedicated to running and was logging 5-6 miles most days. I also began having more frequent headaches. After finally making the connection between my headaches and caffeine withdrawal in early 2020, I stopped taking the pills prior to workouts and now only get caffeine in my diet as described above. I sometimes miss the boost in endurance I enjoyed while taking a caffeine pill prior to going for a run, but I now very rarely have a migraine, which is a trade off that I’m very happy to make.
Mr. Mansfield, the unfortunate British personal trainer, also used caffeine for a boost in athletic performance. As I mentioned above, his goal was likely to make a drink with about the same amount of caffeine as in my caffeine pills. To do this using pure caffeine powder, at least according to the reports, he used a digital scale. And though it is not outright stated that this was the first time he had worked with pure caffeine powder, or this particular digital scale, it certainly sounds like this was the case.
First off, he used a standard kitchen scale with a minimum weight capacity of 2 grams, meaning the endeavor was doomed from the start because his goal was around 3% to 15% of 2 grams. Kitchen scales with that minimum weight capacity typically round to the nearest gram. Some small pocket scales measure in increments of .1 grams (100 milligrams), but that’s not the kind of scale he owned. So a combination of using an inappropriate scale, if he actually used it, and seriously botching the conversion from grams to milligrams could have easily resulted in Mansfield putting much more caffeine powder into his drink than he realized.
The news articles, which were primarily based on information from the government inquest, claimed that he was shooting for 60-300 milligrams, but again that’s just an assumption. Many online resources of questionable legitimacy recommend amounts up to 500 milligrams as a pre-workout supplement. Ultimately, nobody witnessed him preparing the drink so we will never know what really happened. There is not a small chance that he just dumped some of the powder in his drink without any thought at all.
This is your brain on caffeine
Most people who consume caffeine every day, which again is close to all adults and even most older kids, take in at least a couple hundred milligrams in the form of coffee, tea, energy drinks, food, or supplements. Most experts would agree that intake of 2.5 milligrams per kilogram of body weight over a day is unlikely to cause any concerning symptoms in older kids and adults, although some people are more sensitive than others or have underlying conditions that put them at risk of adverse effects. There is more nuance to this issue, particularly when it comes to withdrawal symptoms like my headaches, or sleep deprivation in adolescents, but I’m going to focus on severe toxicity in this post.
Regardless of the source, caffeine is fairly quickly absorbed in the gastrointestinal tract (< 1 hour) and acts as a potent antagonist of adenosine receptors in both the peripheral and central nervous system. Caffeine is a non-selective adenosine receptor antagonist, and there are different receptors in different parts of the body that lead to different physiologic effects when stimulated, so caffeine alters physiology in a variety of interesting ways, some of which are clinically meaningful. The one we tend to care about most though is its role as a central nervous system stimulant.
The longer we go without sleep, the more adenosine builds up in our neuronal synapses and the more a specific type of adenosine receptor in the ventrolateral preoptic area of the brain is stimulated, which results in us feeling sleepy. If these receptors are plugged up with caffeine molecules, preventing adenosine from binding to them, you feel more alert until eventually the sheer amount of adenosine overwhelms the blockade or the caffeine in the adenosine receptor is degraded, which usually takes 2-4 hours depending on individual genetics.
There is not compelling evidence to support claims that caffeine use leads to dependence or abuse, but tolerance does develop and many people, though not everyone, will experience withdrawal symptoms upon abstinence if they have been consuming at least 100 milligrams every day for at least a few consecutive days. Headache is the most common symptom, but withdrawal can also involve fatigue, decreased alertness, drowsiness, depressed mood, and irritability. Withdrawal can occur within 12-24 hours of consuming caffeine, last more than a week, and in people who are consuming large daily doses of caffeine it might feel like the flu, complete with nausea and muscle aches.
Caffeine toxicity and the role of weak regulations
When someone consumes large amounts of caffeine, the definition of which varies a bit based on things like size, tolerance, and genetics, they can experience a number of potential adverse effects ranging from annoying to deadly. As experienced by Mr. Mansfield, heart palpitations from an abnormally rapid pulse, tremors, and agitation are common complaints, as is an upset stomach. More severe toxicity can present with dangerous alterations in the hearts rhythm, which can result in cardiac arrest, hallucinations, and seizures. Death, though uncommon, can occur.
According to the FDA, more serious toxic effects, such as seizures, are more likely to be seen once someone has consumed around 1.2 grams in a short period of time. According to a 2018 review of caffeine toxicology in Toxicology Reports, cases of fatal overdoses tend to involve much larger amounts:
In cases of overdose, often intentional but sometimes undetermined and unintentional, at least 5 g or more (i.e., often around 10 g but up to 50 g) have been ingested leading to fatalities particularly if the individuals are not treated in time or at all. However, doses up to 50 g have also been treated successfully otherwise. Some have indicated that after a dose of around 1 g, toxic symptoms begin to manifest, a dose of 2 g requires hospitalization, while higher doses (e.g., typically 5 g or more) could be lethal. However, some have determined that as little as 3 g could be lethal under certain circumstances.
We don’t know if Mansfield had any underlying health problems that put him at higher risk of cardiac arrest from a caffeine overdose, or if he was taking additional medications or supplements that raised the chance of an adverse reaction. We don’t know if his metabolism of caffeine was impacted by genetic factors that increased (or decreased) the effect of caffeine on his physiology. Regardless, it was estimated that he ingested so much caffeine in a matter of only a few minutes that none of that really mattered.
This conclusion is based on the finding of a caffeine level of 392 milligrams per liter of blood during a post-mortem analysis. A regular 8-ounce cup of filtered coffee drunk in a short period of time would raise a typical adult’s blood level of caffeine by about 2 to 4 milligrams per liter. This means that Mansfield consumed the equivalent of anywhere from 98 to 196 cups of coffee in one go. 8 ounces of regular coffee contains anywhere from 70 to 140 milligrams of caffeine. Using the lower figure, he ingested a minimum of almost 7 grams of caffeine, which could easily have killed him. But, using the upper limit of cups and caffeine per cup, Mansfield potentially drank nearly 27.5 grams of caffeine.
One thing made clear in the many articles on this tragic case, and in my review of British food and drug regulations, is that there are no laws that prevent the sale of pure caffeine, either powder or liquid, in bulk quantities. There are no laws that stipulate what kind of measuring aids or even what if any warnings must be included along with these products. As I mentioned earlier, the manufacturer has announced that it now voluntarily provides a measuring scoop and more detailed information on both how to measure a safe dose and the risk of overdose. This isn’t enough.
There are no standard measuring scoops or spoons that are going to be found in most kitchens that could accurately measure amounts as small as 60 or even 300 milligrams accurately. So the claim that providing a small scoop with pure caffeine powder sales sounds like a reasonable safety measure. To give you an idea of how tiny these scoops are, below is a 100 milligram scoop placed next to a dime for scale.
If accompanied by clear warning labels, use of a scoop such as this might significantly reduce the risk of extreme overdose. Mansfield likely would have realized something was off if he found himself putting tens or even hundreds of scoops on to his kitchen scale, which would be necessary to reach 7 to almost 28 grams of powder. But there could be a bit of a false sense of security when it comes to less severe overdoses depending on if a consumer uses a heaping scoop or packs the powder into each scoop, which could inadvertently add hundreds of extra milligrams of caffeine depending on the desired amount. And a scoop wouldn’t protect against conversion errors when using a scale that can’t accommodate such small amounts.
Better measures are needed to prevent inaccurate measurements
The solution to this issue is to prevent the sale of pure caffeine powder or liquid. It’s far too risky, even with scoops and warnings, to rely on measuring out such small amounts at home. This problem could easily be solved by selling reasonable servings of caffeine powder or liquid in individual containers for adding to drinks, or by producing caffeine tablets, like my old migraine-inducing nemesis, that dissolve in liquid. But honestly is there really a need to ever add caffeine to a homemade drink?
This post serves as a bit of an update to a 2015 post by Scott Gavura, where he discusses two fatal cases of caffeine overdose and rightfully blames weak regulations in the United States. At the time, the FDA had recognized the danger of pure caffeine powder being sold in bulk for consumer use but had only issued toothless warnings. Scott predicted that more deaths would occur:
No recalls, or “stop sales” orders. Just a warning to consumers…As long as we maintain a regulatory double-standard for supplements and “natural” products, there is not likely to be much change, and we can probably expect more people to die from caffeine powder overdoses.
I have some good news to report as I finish up this post. Since 2015, the FDA has done more than simply warn the public about the risk of caffeine overdose. For example, in 2018 they publicly went after companies selling pure caffeine products, giving them 15 days to stop or face consequences such as seizure and/or injunction. This change in approach is based on the decision to consider these products to be adulterated under section 402(f)(1)(A) of the Federal Food, Drug, and Cosmetic Act:
(f)Dietary supplement or ingredient: safety
(1) If it is a dietary supplement or contains a dietary ingredient that –
(A) presents a significant or unreasonable risk of illness or injury under-
(i)conditions of use recommended or suggested in labeling, or
(ii)if no conditions of use are suggested or recommended in the labeling, under ordinary conditions of use;
Manufacturers of pure caffeine powder in the United States now will not sell to individual consumers and their websites contain warnings such as this:
Warning: Owing to the risk of personal HARM, INJURY, or DEATH with the use or misuse of Pure Caffeine Powder sales are limited to qualified commercial, scientific and business buyers only. Sales to the general public are not allowed. To be considered for approval submit the form below with documents, or if previously approved log into your account to purchase.
This doesn’t mean that the risk of overdose in the United States has been completely removed. I wouldn’t trust the guy behind the counter making me a caffeinated smoothie with this stuff any more than I would trust myself, though a business would at least be more likely to use appropriate scales and scoops. And we all know how it tends to go in the supplement industry. There will likely always be unscrupulous companies willing to take a chance for profit, and there are still plenty of products that, while not as risky as a homemade drink made with added pure caffeine powder, contain absurd amounts of the drug and can result in overdose. But we have at least moved in the right direction.

Go ahead, have that coffee
Coffee drinkers, rejoice. A new paper shows positive associations between consumption and an array of health outcomes.
Scott Gavura on November 30, 2017
Link

Would it be ethical to conduct a clinical trial where you could be randomly assigned to drink coffee, or to abstain from it? Notwithstanding any of your personal feelings about the beverage, it would be ethically appropriate to verify that, at minimum, coffee consumption wasn’t harmful. Given coffee’s massive, world-wide popularity, its safety may seem self-evident. Yet it’s not impossible that coffee could be causing subtle health effects (say, very slight increases or decreases in the risk of common diseases, like cancer or cardiovascular disease) that would be undetectable without some sort of population-level study. Observational studies have shown mixed effects of coffee consumption on a range of health conditions, including pregnancy outcomes. But what are the overall effects? That’s what a new study set out to understand.
What are the chemicals in coffee?
Coffee was possibly the original “functional food”, in that it was routinely consumed for specific effects. Coffee starts as the unroasted green been (of Dr. Oz infamy) and through roasting, undergoes chemical changes to produce over 1,000 biologically active compounds. The ingredient that most people associate with coffee is caffeine, thought to be produced by the plant as an insecticide. But there are many other ingredients that have potential medicinal effects, including chemicals identified to have anti-oxidant, anti-inflammatory, anti-fibrotic, and even anti-cancer properties. The extent of roasting, and the brewing method will influence what ends up in your cup. Interestingly, genetic differences and even the microbiome in your digestive tract will ultimately affect which components are ultimately absorbed into the bloodstream. Recognizing all of these potential variations, only population-level studies can be expected to give us meaningful data.
What was the objective of this study?
Given the popularity of coffee there has been considerable research between consumption and different health outcomes, including mortality, cancer, cardiovascular disease, as well as effects in pregnancy. Almost all research has been observational in nature, in that there was no randomization – meaning causality couldn’t be inferred. One of the more interesting areas of study has been the relationship between coffee consumption and liver disease, including liver cancer, where there appears to be signals of a substantial benefit. Before randomizing patients to drink (or not drink) coffee, a comprehensive analysis of health effects was felt to be warranted. If there were signs of possible harm, randomizing people to drink coffee would not ethical. So this study sought to summarize all of the available evidence of coffee consumption and health outcomes.
This new study by Robin Poole and colleagues is entitled “Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes.” It was published in the BMJ earlier this month. This was an umbrella review, which is a summary of existing systematic reviews and meta-analyses. The authors sought to evaluate all evidence for associations between coffee consumption and multiple health outcomes. This was specifically a study of coffee, not of caffeine alone, recognizing that the health effects of coffee could be based on any of (or a combination of) the chemical constituents. A comprehensive search of the medical literature found 201 meta-analyses in 135 articles studying 67 different endpoints. There were also 17 meta-analyses found of randomized controlled trials in six articles with 9 outcomes. Here are the compiled results for (a) High versus low coffee consumption (b) Any versus no coffee consumption and (c) Consumption of “one extra cup per day”. Each figure shows relative risk estimates for the ten most harmful associations, and the ten most beneficial associations.



As you can see, the associations for liver disease, including liver cancer, appear the most beneficial. It’s worth reiterating that given the associations are from observational studies, they cannot prove cause and effect. It’s also worth noting that the effects are reported as relative risks, not absolute. And overall, those relative effects are small.
In terms of all-cause mortality, the authors noted a recent meta-analysis by Grosso concluded that the largest benefit was observed in those drinking 3 cups of coffee per day, giving a relative risk of 0.83 compared with no coffee consumption. The same study found that this effect held for cardiovascular disease (including heart attack and stroke) as well. Compared with non-drinkers, risk were reduced by 19%. More coffee was not harmful, but the benefit was less pronounced, and became insignificant at the highest intakes. This is despite what have been observed to be unfavourable effects on blood lipid levels themselves. Interestingly, coffee consumption had marginally beneficial effects on blood pressure.
In terms of cancer, a lower overall incidence of cancer was found in high versus low consumption of coffee, but the effects were modest. There was a harmful association found between coffee and lung cancer (high versus low consumption) but the effect was reduced when smoking was adjusted for, with no association found in never smokers.
In addition to the beneficial effects observed in liver cancer, coffee consumption was observed to reduce risk of a number of liver diseases, including non-alcoholic fatty liver disease (29% lower risk, any versus no consumption), liver fibrosis (27% lower risk), and liver cirrhosis (39% lower risk).
In terms of effects in pregnancy, there are consistent signals that coffee may be harmful. High versus low consumption is associated with a greater risk of low birth weight, pregnancy loss, and first and second preterm birth. No effects were observed in third trimester preterm birth, neural tube defects, and congenital malformations. Interestingly there’s also consistency in the associations between coffee consumption in pregnancy and childhood leukemia, which is illustrated in the two tables above.
Coffee for everyone?
There are countless reasons why coffee drinkers could differ from non-drinkers. What we can conclude from this umbrella review is that coffee consumption is usually safe, and that there is the suggestion that regular consumption may actually be beneficial. With the exception of consumption during pregnancy, there is also reassuring evidence that coffee intake is unlikely to cause harm. So if you don’t drink coffee, should you start? If you don’t like the taste of coffee, the beneficial effects are modest enough that you’re likely not giving up a remarkable benefit. But if you do enjoy your coffee, and want to maximize the possibility of health benefits, keep you consumption moderate (around 3 cups per day). And feel satisfied that you’re possibly doing something that’s good for you.

Full disclosure: I drink coffee, usually 2 cups per day.

Healthy Habits Global: Spreading False Information about an MLM Coffee with Herbal Additives
Harriet Hall on April 7, 2015
Link


When my husband was helping a friend with a project at the house of someone he didn’t know, the lady of the house gave him an earful about the health benefits of the coffee sold by Healthy Habits Global (HHG), a multilevel marketing (MLM) enterprise for which she is a distributor. She sent him home with samples and a brochure with a long list of health claims. She told him she could provide lots of testimonials, and there was a wealth of evidence for her products on PubMed.
Before believing any health claims, especially from an unknown source, it is only prudent to examine the evidence. I consulted the company website, PubMed, and other sources; and I learned that the company’s advertising was full of false information and the whole rationale of the products was questionable. I am not persuaded that HHG coffee has any health benefits. It appears to be just another in a long line of gimmicks used by MLM businesses to sell untested, usually ineffective “health” products to gullible consumers who have little knowledge of science.
What is it?
It’s a whole line of beverages provided as single-serving packets of powder to be mixed with water: coffee, tea, hot chocolate, and energy drinks. The products contain TAGG, a combination of tongkat ali (Eurycoma longifolia, a flowering plant found in East Asia), Panax ginseng, and reishi mushroom (Ganoderma lucidum). How much of each? The amount is not disclosed on the website, and the distributor didn’t know, but she was able to get the information for me from her corporate office:
Energy drink
    • Ganoderma 30 mg
Coffee, tea, and cocoa
    • Ganoderma 24 mg
    • Tongkat ali 12 mg
    • Ginseng 12 mg
The rationale
The idea is to change everyday unhealthy habits such as drinking coffee, hot cocoa, tea, and energy drinks into healthy habits by enriching those beverages with beneficial nutrients. The underlying assumption is wrongheaded: drinking coffee in moderation is not an unhealthy habit. In fact, there are numerous documented health benefits of plain old coffee. Can those health benefits be augmented by the diet supplements added by HHG?
The claims
A video on the website starts by comparing HHG coffee to orange juice. They say HHG coffee contains 154 anti-oxidants and 200 phytonutrients vs. 8 and 4 in orange juice. (With 354 components, we can assume there must not be clinically effective amounts of all of them, perhaps not of any of them; and orange juice contains other important nutrients like vitamin C, so it’s not a fair comparison.)
Because the coffee is enriched with TAGG (tongkat ali, ginseng and ganoderma extracts), it “promotes the body’s ability to function in an optimal state in a single serving.” Here are the specific benefits they claim for the three components:
Ganoderma (reishi mushroom)
    • Used in China and Japan for 4,000 years
    • Provides more energy and vigor
    • Boosts immune system
    • Reduces cholesterol
    • Reduces blood pressure
    • Promotes sexual stamina
    • Helps regulate blood sugar
    • 5 amazing components:
        ◦ Polysaccharide
        ◦ Triterponeoid
        ◦ Adenosine
        ◦ Ganoderic essence
        ◦ Organic germanium, which they say is “known for its ability to balance the body’s electrical system by regulating electrical charges around cells.” (As far as I could determine that is only “known” by sellers of energy bracelets.) It is also known for being toxic, but they don’t mention that.
    • Helps prevent degenerative diseases
    • Regulates digestive health
    • Helps prevent antigen-related allergies (aren’t all true allergies antigen-related?)
    • Helps regulate your whole body’s electrical system.
    • Contains 154 antioxidants, 200+ phytonutrients, is anti-bacterial, anti-viral, and anti-candida.
They say it is “The most studied herb on the face of the planet.” They invite you to see for yourself on PubMed, and they provide this handy link to a PubMed search that produced 634 hits, many of which are irrelevant, preclinical, uncontrolled, or poor-quality studies. Some of those hits are actually evidence for harm, not benefit, such as a recent case report of reishi ingestion being mistaken for a persistent parasitic infection. In fact, the very first study listed is a Cochrane systematic review that directly refutes some of the company’s claims. It found no evidence that ganoderma improves blood pressure, blood sugar, or cholesterol levels. And the typical doses used in the studies were between 1.4 and 3 grams daily. That’s 1,400 and 3,000 mg, compared to the 24-30 mg in HHG products.
Panax ginsengThey provide a long list of alleged effects including benefits for chronic fatigue syndrome and erectile [sic] dysfunction. Ginseng studies supporting those claims are largely in vitro or animal studies with only a few small, poor-quality studies in humans. For erectile dysfunction there have been a total of six randomized controlled studies (RCTs) in humans; four showed benefit and two didn’t. In the ones that showed benefit, the dosage ranged from 600 mg to 1,000 mg taken three times a day. Compare that to the 12 mg of ginseng in HHG products.
Tongkat aliThey say this triggers the body’s ability to produce testosterone, combating “the negative health risk revolved around Low Testosterone in both men and women.” The same webpage lists 10 benefits including “burns fat” and increases libido. They don’t provide any links to studies, and most of the claims seem to be for therapeutic doses of testosterone rather than for tongkat ali. They don’t say how much more testosterone is produced by the body with the amount of tongkat ali in their coffee, so any claims based on the benefits of testosterone are irrelevant. And the RCTs of tongkat ali that showed positive results in humans used doses on the order of 200-300 mg compared to the 12 mg in HHG products.
Arguments for the superiority of their products
They supply endorsements from the media and cite their high-quality production standards. (Neither of these can be taken as evidence that the products are effective).
They claim that regular coffee:
    • Is acidic. (Actually, coffee is relatively low in acid, lower than any fruit juice and no higher than carbonated water.)
    • Dehydrates you. (No it doesn’t; this is only a popular myth.)
    • Raises blood pressure. (Not in regular coffee drinkers).
    • Can give you caffeine jitters and coffee crash. (Only if you overdo it).
    • It takes 17 cups of water to neutralize the negative effects of one cup of coffee. (This is apparently taken from pseudoscientific websites that say coffee lowers body pH and it takes 17 cups of alkaline or ionized water to restore normal pH. This is completely false. Coffee doesn’t lower pH, and the body’s homeostatic mechanisms maintain the same narrow range of pH regardless of your intake of acidic or alkalinized liquids.)
In contrast, they claim that their coffee:
    • Hydrates. (Of course it does, because you prepare it with water!)
    • Balances your body’s pH levels. (Nonsense! See above.)
    • Naturally detoxifies. (Detoxification is a pseudoscientific alternative medicine buzzword).
    • Strengthens and boosts your immune system. (“boosting the immune system” is a common CAM claim that is meaningless, and anyway stimulating the immune system would be a big mistake for patients whose immune systems are already over-active enough to have caused immune-mediated diseases like arthritis and allergies.)
    • Improves energy and stamina with no jitters or caffeine crash. (Really? Where’s the evidence?)
    • Oxygenates the body. (Really? How? How do they know this?)
    • Improves blood circulation. (Really?)
    • Improves sleep quality. (Maybe if you have been drinking too much caffeine and switch to a product lower in caffeine, you will sleep better…)
They say their (unspecified) competitor’s coffee has mediocre taste and aroma (but how does the taste and aroma compare to brewed coffee?). And they say the competitor’s coffee is more expensive. HHG is as low as 80 cents per cup (cheap if it offers real health benefits, but expensive if all it offers is false hopes and the chance of a placebo response).
Aluminum?
Compared to the competitor’s coffee, HHG says its products contain four times the ganoderma, but they don’t tell you that still isn’t enough to produce any health effects. And they say there is no aluminum in the non-dairy creamer HHG puts in some of its products. They say, “Aluminum may cause Alzheimer’s or other diseases.” They cite a CDC website to support that claim, but that website actually says pretty much the exact opposite, even for large occupational exposures:
Three studies have examined the possible association between occupational exposure to aluminum and the risk of Alzheimer’s disease. Two case-control studies did not find a significant association between occupational exposure to aluminum dust or fumes and the risk of Alzheimer’s disease (Graves et al. 1998; Salib and Hillier 1996). Another study of former aluminum dust-exposed workers (retired for at least 10 years) found some impairment in some tests of cognitive function; the investigators raised the possibility that cognitive impairment may be a pre-clinical indicator of Alzheimer’s disease (Polizzi et al. 2002)…The possible association between aluminum and Alzheimer’s disease was proposed over 40 years ago; however, the evidence that aluminum may or may not be a risk factor is inconsistent and inconclusive…In conclusion, the available data suggest that aluminum is not likely the causative agent in the development of Alzheimer’s disease [emphasis added].
Incidentally, that same source says that aluminum levels in tea are 10-50 times higher than the typical levels found in drinking water, so if they are so concerned about aluminum, why are they selling tea?
Do you want antioxidants?
Coffee is the number one source of antioxidants in the American diet. Green coffee beans contain 1,000 antioxidants and brewing adds another 300. So the additional 154 antioxidants in ganoderma represent only a 12% increase over the number antioxidants already in coffee. Would you expect 1,454 antioxidants (in trace amounts) to be significantly better than 1,300 antioxidants?
Anyway, there is growing evidence that more antioxidants may not mean better health and in some cases may actually be harmful.
Beyond PubMed
I consider the Natural Medicines Comprehensive Database (NMCD) to be the most reliable source of information about natural medicines. It is compiled by an unbiased group of experts in various fields who have combed PubMed, herbal medicine texts, and other sources and have summarized all available evidence about the remedies. They rate natural remedies for safety and effectiveness. They rate all three of the TAGG ingredients as only “possibly” safe, below their ratings of “safe” and “likely safe.” Here’s what they have to say about their effectiveness, side effects, interactions, and precautions:
Tongkat ali
    • Possibly effective for male infertility. Insufficient evidence to rate it for other uses.
    • Avoid in pregnancy and lactation.
    • Drug interaction with propranolol (a prescription drug that is widely used for heart disease, blood pressure, migraine prevention, and other indications): reduces propranolol levels by 29%.
    • There are concerns about contamination with heavy metals.
    • The plant is a protected species
Ganoderma
    • Insufficient evidence to rate effectiveness for any use.
    • Adverse reactions have included stomach upset, nosebleeds, and bloody stools.
    • Numerous interactions with herbs, supplements, and drugs.
    • May increase risk of bleeding in some patients, should be discontinued two weeks before surgery.
Panax ginseng
    • Possibly safe when used for up to 6 months, possibly unsafe with longer use. Likely unsafe in infants, possibly unsafe in pregnancy: has teratogenic effects in animal models.
    • “Possibly effective” (less than their rating of “probably effective”) in Alzheimer’s disease, COPD, cognitive function, erectile dysfunction, HBP, premature ejaculation, sexual arousal.
    • Most common side effect is insomnia; many other reported side effects including vaginal bleeding, HBP, diarrhea, fever, vertigo, euphoria, and mania.
    • Multiple interactions with herbs, supplements, alcohol, and a long list of drugs including caffeine, insulin, anticoagulants, immune suppressants, estrogens, antidepressants, heart drugs, and many others.
    • Might exacerbate autoimmune diseases.
    • Decreases blood coagulation.
    • Contraindicated for women with hormone sensitive conditions including uterine fibroids, endometriosis, and breast cancer.
    • Might increase the risk of hypoglycemia in diabetics.
    • Should be used with caution in patients with cardiovascular disease.
    • Typical dosage for erectile dysfunction: 900mg taken 3 times daily.
Conclusion
The rationale for adding these supplements to coffee is far from clear. This specific combination and dosage of ingredients has not been shown clinically effective; in fact, it has never been tested. If you are convinced by some of the favorable studies in PubMed and decide to take ginseng, ganoderma, or tongkat ali to get a possible health benefit, it would make a lot more sense to take the amount that had been shown in those studies to provide that benefit, not a minuscule amount that is entire orders of magnitude smaller. These substances have potential harms, and it is doubtful whether distributors know about them. Do they warn their customers to stop using HHG beverages if they might be pregnant or if they have uterine fibroids? Do they warn customers to stop using the products two weeks before surgery? I doubt it.
There is no good evidence that adding TAGG to coffee will make it any healthier. You could arguably make coffee healthier by adding red rice yeast containing therapeutic amounts of natural statin drugs known to be effective, but I can’t imagine anyone would want to do that. Admittedly, the TAGG additives have fewer adverse effects than statins, but they are not entirely innocuous. Although in this case they are present in such small amounts that we needn’t worry.
The claims for HHG products range from the unsubstantiated through the misleading to the demonstrably false. Both the customers and the lower-level distributors are being duped by those at the top of the MLM pyramid who are the only ones likely to make money. They hype the income opportunities and even offer a luxury car club bonus, but the sad fact is that 99% of MLM distributors end up not only not making a profit but losing money. The mission statement of the company is all about creating income opportunities, not about improving the health of their customers. Caveat emptor.

   Caffeine for ADHD
Scott Gavura 
Link
“I don’t want to give my child any drugs or chemicals for their ADHD,” says a parent. “Instead, I’m thinking about using caffeine. Sound strategy?”
It may be dispensed by a barista and not a pharmacist, and the unit sizes may be small, medium and large, but caffeine is a chemical and also a drug, just as much as methylphenidate (Ritalin) is. Caffeine is even sold as a drug — alone and in combination with other products. But I regularly speak with consumers who are instinctively resistant to what they perceive as drug therapy — they want “natural” options. Caffeinehas been touted as a viable alternative to prescription drugs for ADHD. But is caffeine a science-based treatment option? This question is a good one to illustrate the process of applying science-based thinking to an individual patient question.
I’ve already described my personal fondness of caffeine, particularly when it’s in the form of freshly-roasted coffee. I’m not alone in my love. Caffeine is the most widely consumed drug in the world — more than alcohol, and more than tobacco: 90% of adults worldwide consume it daily. The average American consumption is 280mg per day — about two cups of coffee. The main source is coffee, but tea consumption is growing. And caffeinated soft drinks and energy drinks are a growing source of caffeine for children. Why do we love it so much?
Caffeine is quickly absorbed once consumed — and it immediately gets to work stimulating neurotransmitter release. Besides psychiatric effects, it has effects on alertness (positive), headache (also effective, except in withdrawal situations), athletic performance (another win), the cardiovascular system (my fingers are crossed), and the endocrine system, where it may improve diabetic control. It’s also being studied for effects on the gastrointestinal system, as well as its impact on cancer risk. In adults, caffeine consumption is associated with a negative relationship with all-cause mortality, largely due to a reduction of cardiovascular effects. Causation hasn’t been established though. Most of you are very familiar with the side effects of caffeine: agitation, tremors, insomnia, headache. Overall, despite documented cases of dependence and withdrawal, caffeine consumption has a generally attractive safety profile with a wide therapeutic range.
The symptoms of Attention Deficit Hyperactivity Disorder (inattention, impulsiveness and hyperactivity) have been identified for at least 100 years. But once the diagnosis appeared in the DSM-IV, its standardized criteria became commonly used, and the prevalence is now estimated at about 3-7% of children. The term Attention Deficit Hyperactivity Disorder is somewhat of a misnomer, as the dysfunction appears related to an inability to regulate attention — not a deficit. Magnetic resonance studies suggest ADHD may manifest as a weakening of inhibitory signalling in the frontal cortex.The cause appears most likely to be genetic, with environmental influences.
The two main interventions for ADHD are behavioural treatments and drug therapies. The traditional therapies are the stimulant drugs, including amphetamine (Adderall), methylphenidate (Ritalin), and dextroamphetaime (Dexedrine). Some have been in use since the 1960’s. Over time, a wide array of dosage forms including controlled-release versions have emerged, driven by the desire to stabilize blood levels. The basic drugs themselves are short-acting, leading to a fluctuation of effects and the need for mid-day treatments — not ideal for school-age children. Non-stimulant drug therapies (e.g., antidepressants) have more recently emerged as treatment options and may be combined with stimulants, as additional therapies where symptom control isn’t reached with stimulants.
The treatment goals with ADHD are symptom based, so dosing is dependent on the effects observed. Treatment goals usually include reductions in disruptive behaviours, improvements in relationships (with peers, siblings, teachers, and parents), or specific academic parameters. Ideally, treatment goals should be objective and measurable, and agreed-up by parents, teachers, physicians, and children.
The stimulant medications have an impressive safety record and are generally well tolerated. There’s a long history of use. Are they effective? There’s reasonably good data to suggest they are, although comparative data are lacking. [PDF] Response rates to ADHD treatments appears high — 60-80%, and side effects are generally mild and manageable.
So that brings us back to the original question — I developed a focused clinical question using the PICO framework:
    • Patient: Who are what are we treating? In this case, children.
    • Intervention: What are we treating with? Caffeine
    • Comparison: Compared to what? Let’s assume stimulants.
    • Outcome: The effect we want to measure. In this case, symptomatic control.
So the question may be summarized as: In children, how does caffeine compare to stimulants for symptomatic control of ADHD?
It’s helpful to start with pharmacology to consider plausibility before we look at clinical trials. Caffeine, or more properly, 1,3,7-trimethylxanthine, has central nervous system effects, mainly thought to be due to blocking adenosine receptors in the brain. Given we don’t know the specific mechanism of action of the ADHD drugs, I’ll accept caffeine as a plausible treatment: it crosses into the brain, and it has CNS stimulant effects.
So let’s look at the data. I started with a tertiary reference: the Natural Medicines Comprehensive Database rates caffeine as “possibly ineffective”. Then I went to PubMed, and ran my own search. Are there placebo-controlled, or head-to-head trials? Yes, and they’re disappointing:
The data are limited by small trials, mostly conducted in the 1970s. There doesn’t appear to be many trials exploring the dose-response relationship, and trials don’t seem to titrate doses — so it’s not clear if we’re evaluating comparable doses. While there don’t appear to be any systematic reviews, there are trials comparing caffeine to other drugs. In one comparison, 20mg of methylphenidate was found to be superior to 160mg of caffeine. In another trial, seventeen children who had positively responded to stimulant drugs were trialed on placebo, or two different doses of caffeine. Caffeine didn’t have any statistically significant effects on behavioural measures. In a trial comparing amphetamines to 600mg caffeine daily, plus amphetamines, caffeine was reported to provide incremental benefit, but side effects were noted. That’s not surprising: 600mg is the caffeine in two Starbucks Grande-sized coffees. A double-blind crossover examination of caffeine, methylphenidate, and dextroamphetamine in 29 children concluded that while the two stimulants had meaningful effects, caffeine was indistinguishable from placebo. Overall — no strong signals of efficacy in the evidence.
Conclusion
Caffeine is a questionable treatment option for ADHD. There is mixed to negative efficacy data, and no long-term safety information in children. Depending on the form given, there’s challenge of ensuring standard doses (especially when using coffee) and maintaining stable blood levels. In comparison, prescription stimulant medications offer a variety of drug choices that have more convincing efficacy data, and are accompanied by a long history of use. There’s also a wide array of product types, making it easier to customize a treatment regimen. So while I can understand the hesitation to medicate and to “go natural” instead, it’s not a trade off that’s attractive. “Go science” instead — look to the data, and make treatment decisions based on the best evidence.

The Decaf Wars
Steven Novella on June 19, 2024
Link

We can add decaffeinated (decaf) products to the list of things you probably shouldn’t worry about but someone wants to make you worry anyway. You may have read recently that some decaf coffee and tea brands have “chemicals” in them that may be a health risk. The real story, as you might imagine, is more complicated.
The cause of the recent headlines is that several activist groups have petitioned the FDA to ban the most common chemical used in the decaffeination process, methylene chloride. Once again this is essentially a debate about hazard vs risk. But let’s start with some background on the decaffeination process.
There are several common methods for decaffeination, the most common being the so-called European method, or the indirect solvent method. This method first boils green coffee beans to soften them up and remove some flavor components from the beans. It then exposes the beans to methylene chloride or ethyl acetate to bind and remove the caffeine. The beans are then washed to remove the solvent and caffeine. The beans are then heated again to further evaporate off the volatile chemicals and then recombined with the water to return the flavor chemicals. The beans are then dried and roasted.
The advantage of this method is that it is the fastest and cheapest method of decaffeination. It is therefore the most popular. Using this method with ethyl acetate is often marketed as a “natural” alternative, or a “sugar” method because ethyl acetate can be sourced as a byproduct of sugar processing. However, it can also just be manufactured.
Alternatives include various water methods that allow the beans to soak for a longer period of time, leaching out the caffeine and many other chemicals. Caffeine is the largest chemical, however, so it can be removed with charcoal filters, and the other flavor chemicals then returned to the beans. There is also a carbon dioxide method where CO2 is bubbled through the beans, binding to caffeine, and then removed.
Is there any difference among these methods in terms of the health safety of the resulting tea or coffee? The answer here is pretty clearly no. The FDA has set the safety limit of methylene chloride in food products at 10 parts per million. This is based on safety data, usually with an order of magnitude buffer built in. Many news outlets, including WebMD, mention that a 2020 test by an activist group, the Clean Label Project, did a study of different decaf brands and found methylene chloride in many of them. But most outlets fail to mention that in every single case the levels were below the FDA limits, often far below. There is no evidence that exposure at these trace levels poses any health risk.
Which brings us back to the hazard vs risk debate. The FDA uses a risk-based model in determining whether or not to allow use of chemicals in products and sets safety limits. However, some advocacy groups and regulatory agencies rely on a hazard approach (whether or not they explicitly acknowledge this). If a chemical can potentially be harmful, it should be banned, even if it is now demonstrated to be harmful at the doses consumers will be exposed to.
There isn’t necessarily one correct approach – it depends on what tradeoffs we are willing to make. Do we want to err on the side of the precautionary principle (the hazard approach), or see everything as a risk vs benefit calculation? I do think the risk vs benefit approach is more rational. The hazard approach casts too wide a net, and leads to unintended consequences that may actually increase net risk for consumers. In order to avoid imagined risks people may change their behavior in a way that increases their risk (such as drinking more caffeine).
Economics should not be ignored either. Often consumers make economic choices, especially those at the lower SES levels. Mandating more expensive products or methods in order to avoid a potential hazard with no proven risk may have a net negative impact on overall food quality. Even just scaring people into more expensive options, like organic produce (which has no proven health advantage over traditionally-farmed produce) may result in lower consumption of fresh fruits and vegetables, which is likely to have a negative health impact.
Often groups like the Clean Label Project explicitly argue for consumers to make informed choices, and I agree. But this works both ways – you can’t advocate for informed choices and then fearmonger about hazards without putting them into context of actual risk. Trace chemicals from solvent-based decaf methods are below safety limits and pose no known health risk.
There are, however, other issues that complicate the choice of decaf method. You can find lots of taste tests comparing different methods. They do remove and then replace lots of chemicals that influence the flavor of the coffee, so there is a plausible mechanism here. I would just take them with a grain of salt, unless they are well-blinded tests (unblinded taste tests are notoriously subject to bias and expectation). Also, the only taste test that matters is you.
There is one very legitimate issue, and that is industrial and environmental exposure to chemicals like methylene chloride. Again, the chemical is a carcinogen, and can be a risk to workers who are exposed. This is less of an issue for the FDA and more one for OSHA and the EPA. Work standards should protect workers and keep exposures below safe limits, and we should definitely regulate which chemicals find their way into the environment and in what amounts. For these reasons the use of methylene chloride has been limited over the years, and that’s reasonable.
        ◦ But there is no reason for consumers to worry about the decaf method from a personal health perspective. This is essentially another round of hazard-based fearmongering from activist groups, not spawned by any new science or evidence of risk.

Caffeine Withdrawal Headaches
Caffeine is not addictive. Regular users of caffeine can develop tolerance and mild physical dependence, and sudden withdrawal can cause headaches and other symptoms (but only in half the population). This is does not qualify as addiction.
Harriet Hall on February 5, 2019
Link


In the Feb/March 2019 issue of Free Inquiry magazine, there was an article by John Frantz, MD, titled “The Biology of Addiction”. The title is a misnomer. Rather than covering the biology of addiction, he speculated about one possible explanation for why addiction might have evolved, and then told a series of anecdotes about headache as a withdrawal symptom of caffeine addiction. The article was unfortunate. He’s entitled to his own opinions, but not to his own facts. In the first place, there’s no such thing as caffeine addiction.
Evolutionary explanations of addiction
He speculates that addiction might have been a survival advantage because addicts can develop a tolerance to high doses of the substances they are addicted to. He says,
Imagine vegetarian animals surviving a drought because they become tolerant of toxic chemicals in a plant that is also surviving the drought.
He points out that opium plants have edible components. But are they drought-resistant? Are they likely to be the only available food source? Could an animal get enough nutrition from them without dying of an overdose of opioids?
That’s pretty far-fetched speculation. It doesn’t make sense to me. And evolutionary biologists have explored the evolutionary origins and significance of addiction in the light of biological, psychological and social factors. Psychotropic plants and human brains may have influenced each other’s evolution. The plants may indeed be used as food sources, but withdrawal is inevitable. Speculating about emotion, fitness, reward systems, and social factors, Tammy Saah said, “Regardless of the possible co-evolution of drugs and mammalian brains, abuse of drugs inevitably causes long-term disadvantages.”
Another commenter said, “I think that addiction is a byproduct (a nasty one, quite often) of having a brain designed to maximize goal-pursuit in an uncertain world.”
In yet another evolutionary model, acting on pleasurable desires was once adaptive, but now we have pleasurable substances that will kill us, and we have not had time to adapt to the availability of addictive substances.
Dr. Frantz offers one, and only one, speculation about the evolutionary advantages of addiction. He seems to assume that evolution only proceeds by adaptive selection, for survival advantage; but sometimes evolution produces accidental byproducts or spandrels, as Stephen Jay Gould called them, characteristics that were not selected for but just came along for the ride. And pure chance can create characteristics that are neither beneficial nor harmful; and they can persist because they are irrelevant.
However you look at it, the evolution of addiction is complicated, and has been looked at in depth by experts. It is not a question likely to be solved by one newcomer who invents his own idea and doesn’t even acknowledge the work of others.
Caffeine is not addictive
Dr. Frantz starts by saying we are prone to becoming addicted to substances. He mentions alcohol and cocaine, but says “Caffeine is our primary example.” That’s a mistake; caffeine is not addictive in the strict sense of the word.
People can be addicted to opioids, cocaine, amphetamines, nicotine, and alcohol; but can they be addicted to caffeine? Lots of people think so. There are plenty of testimonials, for instance “How one cup of tea per day turned me into a caffeine addict.” The main reason they believe it is addictive is that they experience withdrawal symptoms, especially headaches. They confuse dependence with addiction. Regular coffee drinking results in mild physical dependence but addiction is a pathological and compulsive form of use. Some sources say caffeine addiction is real, but they define addiction as excessive use and relying on it to cope with life in spite of negative effects. The word “addiction” is used even more loosely in common conversation (“I’m addicted to cooking shows.”) True caffeine addiction has never been documented in humans. A review of the literature found that caffeine does not meet either the common-sense or the scientific definition of an addictive substance. Caffeine use disorder and caffeine withdrawal are listed in the DSM 5, but caffeine addiction is not.
Regular coffee drinking leads to tolerance. Tolerance is a pharmacological concept where patients have a reduced response to a drug following repeated use, and have to increase the dose. It is common with addictive drugs but can occur with non-addictive drugs too.
According to the National Institute on Drug Abuse,
Addiction is defined as a chronic, relapsing disorder characterized by compulsive drug seeking and use despite adverse consequences. It is considered a brain disorder, because it involves functional changes to brain circuits involved in reward, stress, and self-control, and those changes may last a long time after a person has stopped taking drugs.
Withdrawal from coffee can cause symptoms like headache, fatigue, anxiety, irritability, depressed mood, and difficulty concentrating. Caffeine withdrawal has been recognized as a disorder. Withdrawal symptoms begin 12-24 hours after cessation, peak in 20-48 hours and have been reported to last as long as 7-12 days. Many sources report severe, intense caffeine withdrawal headaches. But 50% of habitual coffee drinkers will not experience any withdrawal symptoms. I am one of that lucky half. I have abruptly stopped my usual 5 cups a day and had no withdrawal symptoms whatsoever. I found that I was not craving coffee, but I missed the comfort of having that cup of hot liquid to sip on. I found that other hot beverages were just as satisfying (hot lemonade, bouillon, etc.).
Alternative medicine has chimed in. Predictably, dietary supplements and essential oils have been recommended to treat withdrawal symptoms; their effectiveness has not been scientifically tested. But it makes more sense to prevent withdrawal symptoms than to treat them: gradually reducing consumption is proven to work. When avoiding caffeine, it’s important to remember that it’s not just in coffee. There is caffeine in tea, cocoa, chocolate, soft drinks, energy drinks, pain medications, diet pills, and there is even a small amount in decaffeinated coffee.
Coffee is good for you
Frantz’s article is very one-sided. It provides many anecdotes of caffeine withdrawal headaches, makes them sound terrible, and makes it sound like everyone will get them. He says if he drinks one cup of coffee a day for lunch and then skips a day, he will develop a headache at 4 pm that day. He calls it tachyphylaxis. I wonder if it might just be suggestion. He fails to mention that half of caffeine users will never have any withdrawal symptoms.
Coffee has many health benefits. It has been linked to reduced risks of diabetes, cirrhosis, colorectal cancer, heart disease and stroke, Alzheimer’s and Parkinson’s disease, and even a longer lifespan. Numerous studies have shown that coffee is the biggest dietary source of antioxidants. Coffee has a mild diuretic effect, but the water in coffee replaces what is lost in the urine, so it doesn’t cause dehydration. There are no significant health risks unless you drink excessive amounts.
Conclusion: Caffeine is not addictive
Coffee drinking is a pleasant habit with health benefits and only a 50/50 chance of withdrawal symptoms – and that’s only if you stop abruptly rather than tapering. Dr. Frantz’s article was very misleading.

Ask the (Science-Based) Pharmacist: What are the benefits of coffee enemas?
Scott Gavura on July 11, 2013
Link

It might not occur to you, sipping your morning coffee, that you could derive tremendous health benefits by simply shooting that coffee directly into your rectum. Yet many people believe this. Suzy Cohen, who calls herself, “America’s Pharmacist™” and also “America’s Most Trusted Pharmacist®” is a proponent. Her syndicated column Ask the Pharmacist recently contained this question and response:
Question: I see a naturopathic doctor for chronic fatigue and fibromyalgia. She recommended coffee enemas. Suzy, I’m a faithful reader, do you think this is safe? V.A., Seattle, Washington
Answer: Yes. Coffee enemas are used by holistic physicians for all sorts of conditions including cancer. Lots of people find help with constipation, fatigue and liver detoxification concerns. I know this sounds bizarre because you prefer to taste your coffee, not insert it rectally! Agreed. You may be hearing about coffee enemas today, but they are nothing new and complications from coffee enemas are highly unusual. Hey, I just thought of a new franchise concept called Starbutts … entrance in the rear.
Seriously, coffee enemas may help relieve constipation, insomnia and cognitive problems; they may eliminate (or control) parasites, candida and other pathogens (without disrupting intestinal flora). Coffee enemas are frequently used in natural cancer protocols such as the Gerson Therapy (www.gerson.org). Coffee enemas were outlined as a treatment in the revered “Merck Manual,” a thick book that physicians used as their primary reference for decades, until the mid 1970s.
It’s not the enema as much as it is the coffee that helps. You are exposed to a barrage of toxic compounds in your life, you can easily become overloaded. Some of you cannot detoxify properly. Coffee enemas help you make glutathione, an antioxidant and that sends poisons packing. More on that momentarily.
Coffee enemas can be done at home inexpensively. You just need a comfortable spot on the floor of your bathroom, or bathtub. As the coffee is retained in your bowel, the fluid goes through your intestinal wall, through the portal vein to your liver. The stimulating effects and healing compounds of coffee jumpstart your liver and gallbladder. Bile flows. There are compounds in coffee like kahweol and cafestol which spark production of glutathione, and that is a strong cleansing compound in your body, one that consumers pay good money for when they buy glutathione as a dietary supplement, or get IV injections of it. To make more glutathione naturally (by using a coffee enema) is awesome.
These enemas may allow for relaxation, a better mood, more energy, refreshing sleep and greater mental clarity. If you do too many enemas per week, you may experience electrolyte imbalances. Restoring your electrolytes is crucial, as coffee is a potent drug mugger of minerals. While the controversial cancer specialist Dr. Max Gerson suggested up to six per day, I think that is way too much for the average person. Doing a coffee enema weekly (even daily for awhile) is probably okay for most, but always follow your doctor’s recommendation. The recipe for a coffee enema is different than the beverage.
I was pretty stunned to see this response, particularly from a health professional. Here’s how I’d answer the same question:
The Science-Based Response
Question: I see a naturopathic doctor for chronic fatigue and fibromyalgia. She recommended coffee enemas. Scott, I’m a faithful reader of Science-Based Medicine, do you think this is safe?
Answer: No. Coffee enemas are considered unsafe and should be avoided. Rare but serious adverse events like septicemia (bacteria in the bloodstream), rectal perforation, and electrolyte abnormalities have been caused by coffee enemas. Deaths from the administration of coffee enemas have been reported.
Coffee enemas are based on a pre-scientific idea called “autointoxication”, the belief we are being poisoned by toxins because we are not digesting and eliminating waste products from our colons. This concept is not new, and has roots as far back as our records of medicine. Autointoxication as a concept was discarded over time, as the scientific basis for disease was discovered. It’s perhaps not surprising that your naturopath recommends coffee enemas, as naturopathy is an alternative medicine practice that is based on prescientific and unscientific concepts of health and disease, such as autointoxication. “Humoral medicine” emerged from ancient Egyptian and Roman ideas that the body was composed of four liquids: black bile, yellow bile, phlegm, and blood. “Balance’ in the humors was the goal, and an accumulation of waste in the colon was though to lead to humoral imbalances. The remedy was flushing colon through enemas and purgatives. This philosophy, now discarded from science-based medicine, is still embedded in naturopathy practice.
There is no credible evidence to suggest that coffee enemas can help with insomnia and cognitive problems. In fact, caffeine is absorbed by the colon when coffee is administered as an enema, so it is a poor option for insomnia. The idea that you are are contaminated with parasites or candida are just that – ideas.  While alternative practitioners believe these conditions are widespread in the population, there is no scientific evidence to suggest this. There is no reason to treat conditions which do not exist.
Coffee enemas have their roots as part of the “Gerson Treatment” for cancer, developed by physician Max Gerson in the 1940’s. His regimen included coffee enemas, supplements, juice, and injections of calves’ liver. The approach has been investigated and been shown to be useless for the treatment of cancer.
Some proponents of coffee enemas believe that the chemical components of coffee stimulate liver and gall bladder function. There is no credible evidence to suggest this occurs, or that it is necessary. Your liver and gallblader don’t need an enema in order to work effectively. There is no evidence to suggest that you need to boost your liver’s production of glutathione with enemas. You may in fact be boosting your glutathione already, if you’re a coffee drinker.
I’m very sorry to hear about your chronic fatigue and fibromyalgia. Science-based medicine lacks a good understanding of this illness, and there is a lack of effective treatments. Unfortunately, that can make patients with these illnesses targets to those that profess certainty and offer dubious and unproven treatments, like coffee enemas. A decision to undergo any treatment needs to consider the risk and benefits. And treatments need to be investigated to determine if the benefits outweigh the risks. With coffee enemas, the evidence is clear. Given the lack of benefit and potential harms, there is no plausible justification to undergo these treatments. You should ignore any medical advice from anyone that recommends coffee enemas to you.
Discussion
Autointoxication is a belief that has persisted for hundreds of years, and survives today as the rationale for an array of alternative medicine practices, including coffee enemas, ear candles, “detox” diets, and “cleansing” kits. (For some, the idea that we are being poisoned internally can become downright pathological. A Florida couple admitted to administering coffee enemas four to ten times per day.) These ideas seem almost a part of human nature: Purification rituals are common features of different cultures worldwide. In modern society, and with today’s alternative medicine providers, detoxification is wrapped with a scientific banner, in an attempt to give the treatments (and their purveyors) a veneer of credibility. Autointoxication beliefs are not only wrong, but they are demonstrably dangerous. Practices like coffee enemas have no plausible benefit and a real risk of harm. More broadly, and perhaps most importantly, the continued promotion of these practices distracts from science-based advice that can support better health decision-making.

How do you like your coffee? Rectally?
Fill it to the rim? Please don’t.
Scott Gavura on May 2, 2019
Link
Owing to a busy schedule, today’s post is a “best of” from way back in 2013. Nothing has changed, and coffee enemas are still hot. Err…still popular.
It might not occur to you, sipping your morning coffee, that you could derive tremendous health benefits by simply shooting that coffee directly into your rectum. Yet many people believe this. Suzy Cohen, who calls herself, “America’s Pharmacist™” and also “America’s Most Trusted Pharmacist®” is a proponent. Her syndicated column Ask the Pharmacist contained this question and response:
Question: I see a naturopathic doctor for chronic fatigue and fibromyalgia. She recommended coffee enemas. Suzy, I’m a faithful reader, do you think this is safe? V.A., Seattle, Washington
Answer: Yes. Coffee enemas are used by holistic physicians for all sorts of conditions including cancer. Lots of people find help with constipation, fatigue and liver detoxification concerns. I know this sounds bizarre because you prefer to taste your coffee, not insert it rectally! Agreed. You may be hearing about coffee enemas today, but they are nothing new and complications from coffee enemas are highly unusual. Hey, I just thought of a new franchise concept called Starbutts … entrance in the rear.
Seriously, coffee enemas may help relieve constipation, insomnia and cognitive problems; they may eliminate (or control) parasites, candida and other pathogens (without disrupting intestinal flora). Coffee enemas are frequently used in natural cancer protocols such as the Gerson Therapy (www.gerson.org). Coffee enemas were outlined as a treatment in the revered “Merck Manual,” a thick book that physicians used as their primary reference for decades, until the mid 1970s.
It’s not the enema as much as it is the coffee that helps. You are exposed to a barrage of toxic compounds in your life, you can easily become overloaded. Some of you cannot detoxify properly. Coffee enemas help you make glutathione, an antioxidant and that sends poisons packing. More on that momentarily.
Coffee enemas can be done at home inexpensively. You just need a comfortable spot on the floor of your bathroom, or bathtub. As the coffee is retained in your bowel, the fluid goes through your intestinal wall, through the portal vein to your liver. The stimulating effects and healing compounds of coffee jumpstart your liver and gallbladder. Bile flows. There are compounds in coffee like kahweol and cafestol which spark production of glutathione, and that is a strong cleansing compound in your body, one that consumers pay good money for when they buy glutathione as a dietary supplement, or get IV injections of it. To make more glutathione naturally (by using a coffee enema) is awesome.
These enemas may allow for relaxation, a better mood, more energy, refreshing sleep and greater mental clarity. If you do too many enemas per week, you may experience electrolyte imbalances. Restoring your electrolytes is crucial, as coffee is a potent drug mugger of minerals. While the controversial cancer specialist Dr. Max Gerson suggested up to six per day, I think that is way too much for the average person. Doing a coffee enema weekly (even daily for awhile) is probably okay for most, but always follow your doctor’s recommendation. The recipe for a coffee enema is different than the beverage.
I was pretty stunned to see this response, particularly from a health professional. Here’s how I’d answer the same question:
The Science-Based Response
Question: I see a naturopathic doctor for chronic fatigue and fibromyalgia. She recommended coffee enemas. Scott, I’m a faithful reader of Science-Based Medicine, do you think this is safe?
Answer: No. Coffee enemas are considered unsafe and should be avoided. Rare but serious adverse events like septicemia (bacteria in the bloodstream), rectal perforation, and electrolyte abnormalities have been caused by coffee enemas. Deaths from the administration of coffee enemas have been reported.
Coffee enemas are based on a pre-scientific idea called “autointoxication”, the belief we are being poisoned by toxins because we are not digesting and eliminating waste products from our colons. This concept is not new, and has roots as far back as our records of medicine. Autointoxication as a concept was discarded over time, as the scientific basis for disease was discovered. It’s perhaps not surprising that your naturopath recommends coffee enemas, as naturopathy is an alternative medicine practice that is based on prescientific and unscientific concepts of health and disease, such as autointoxication. “Humoral medicine” emerged from ancient Egyptian and Roman ideas that the body was composed of four liquids: black bile, yellow bile, phlegm, and blood. “Balance’ in the humors was the goal, and an accumulation of waste in the colon was though to lead to humoral imbalances. The remedy was flushing colon through enemas and purgatives. This philosophy, now discarded from science-based medicine, is still embedded in naturopathy practice.
There is no credible evidence to suggest that coffee enemas can help with insomnia and cognitive problems. In fact, caffeine is absorbed by the colon when coffee is administered as an enema, so it is a poor option for insomnia. The idea that you are contaminated with parasites or candida are just that – ideas. While alternative practitioners believe these conditions are widespread in the population, there is no scientific evidence to suggest this. There is no reason to treat conditions which do not exist.
Coffee enemas have their roots as part of the “Gerson Treatment” for cancer, developed by physician Max Gerson in the 1940s. His regimen included coffee enemas, supplements, juice, and injections of calves’ liver. The approach has been investigated and been shown to be useless for the treatment of cancer.
Some proponents of coffee enemas believe that the chemical components of coffee stimulate liver and gall bladder function. There is no credible evidence to suggest this occurs, or that it is necessary. Your liver and gallbladder don’t need an enema in order to work effectively. There is no evidence to suggest that you need to boost your liver’s production of glutathione with enemas. You may in fact be boosting your glutathione already, if you’re a coffee drinker.
I’m very sorry to hear about your chronic fatigue and fibromyalgia. Science-based medicine lacks a good understanding of this illness, and there is a lack of effective treatments. Unfortunately, that can make patients with these illnesses targets to those that profess certainty and offer dubious and unproven treatments, like coffee enemas. A decision to undergo any treatment needs to consider the risk and benefits, and treatments need to be investigated to determine if the benefits outweigh the risks. With coffee enemas, the evidence is clear. Given the lack of benefit and potential harms, there is no plausible justification to undergo these treatments. You should ignore any medical advice from anyone that recommends coffee enemas to you.
Discussion
Autointoxication is a belief that has persisted for hundreds of years, and survives today as the rationale for an array of alternative medicine practices, including coffee enemas, ear candles, “detox” diets, and “cleansing” kits. (For some, the idea that we are being poisoned internally can become downright pathological. A Florida couple admitted to administering coffee enemas four to ten times per day.) These ideas seem almost a part of human nature: Purification rituals are common features of different cultures worldwide. In modern society, and with today’s alternative medicine providers, detoxification is wrapped with a scientific banner, in an attempt to give the treatments (and their purveyors) a veneer of credibility. Autointoxication beliefs are not only wrong, but they are demonstrably dangerous. Practices like coffee enemas have no plausible benefit and a real risk of harm. More broadly, and perhaps most importantly, the continued promotion of these practices distracts from science-based advice that can support better health decision-making.
Enema bag photo from flickr user serraboten used under a CC licence.

Lessons from the dubious rise and inevitable fall of green coffee beans
Scott Gavura on October 23, 2014
Link

News this week that a randomized controlled trial of green coffee bean (GCB) has been officially retracted from the medical literature signals what is hopefully the end to one of the most questionable diet products to appear on the market in years. Plucked from obscurity and then subjected to bogus research, it’s now clear that the only people that actually benefited from GCB were those that profited from its sale. GCB had some powerful boosters, too. Once it became one of Dr. Oz’s “miracle” weight loss cures, sales exploded following two hype-filled episodes. Oz even did a made-for TV clinical trial with GCB, ignoring the requirements for researchers to obtain ethical approvals before conducting human subject research. Oz’s promotion of GCB was so breathless and detached from the actual evidence that his actions were subsequently eviscerated by Senator Clair McCaskill during televised hearings on weight loss scams. It’s a long, sordid, ugly and yet entirely predictable story.
Green coffee bean wasn’t the first miracle weight loss treatment, and I’m certain it won’t be the last. As long as there is an obesity problem, there will those that promote quick fixes and snake oil to treat it. These treatments exist because reality is hard to accept: permanent weight loss is difficult. We all know obesity is a Bad Thing, yet its prevalence continues to grow. As obesity rates rise, so do cases of diabetes, heart disease, and even cancer. Short of quitting smoking, there are few things you can do for your health with as much benefit as maintaining a healthy weight. Given how widespread obesity is, and how difficult it is to fix permanently, it’s not surprising that weight loss cures are fodder to those that want to sell magical cures. And when it comes to promoting quick fixes, there is no platform better than one you can get from being profiled on The Dr. Oz Show.
The story of GCB can’t be told without describing the pivotal role played by Dr. Mehmet Oz. If you’re trying to sell a product, yet you don’t have actual scientific evidence to back up your claims, The Dr. Oz Show is the best platform on television. There is no other show that can top The Dr. Oz Show for the sheer magnitude of bad health advice it consistently offers, all while giving everything a veneer of credibility. That’s because Dr. Oz is a real physician – he just doesn’t play one on television. That might surprise you given his show’s content. He’s promoted homeopathy and faith healing. He’s hosted supplement marketer Joe Mercola to promote unproven supplements, and the notorious “Health Ranger”, antivaccinationist and conspiracy theorist Mike Adams. Oz has promoted ridiculous diet plans, and he gives bad advice to diabetics. Then add the long list of “miracle” foods like red palm oil, or manufactured public health scares like cell phones causing breast cancer. “The Dr. Oz Effect” was coined to describe how Oz drives product sales, but it more accurately describes how Oz’s advice wastes the time and finances of consumers that actually follow the advice he offers.
The dubious trial that convinced Dr. Oz
Dr. Oz’s first episode on GCB looked at the Vinson trial. Even taking the paper at face value (before there was any evidence of fraud), the results were questionable, as I noted when I actually read the study:
    • The study was published in an obscure journal that accepted the paper after 12 days, a period which apparently included peer review
    • The trial was never registered at clinicaltrials.gov, which is an expectation for credible clinical trials
    • The authors had no particular history of research in this area. The lead author was a chemist in Pennsylvania
    • The trial was funded by a supplement manufacturer
    • The trial was made up of just 16 patients and lasted 12 weeks only
    • There was no detail in the paper on how patients were recruited, or if inclusion and exclusion criteria were applied
    • How body mass index (BMI) was measured wasn’t disclosed
    • There was no evidence of research ethics board (institutional review board) approval of the trial
    • The randomization process wasn’t described
    • How the doses were calculated wasn’t described
    • While the trial was called “blinded”, it actually wasn’t, as the design made it easy for patients to figure out if they were receiving GCB or placebo
    • Some patients lost as much weight while taking placebo as they did taking GCB. There was no clear GCB effect
    • There was no tabulation or reporting of side effects
All we could conclude from the Vinson trial was that it was poorly conducted, sloppily written and provided unimpressive and clinically-useless results. There was no convincing evidence to suggest that GCB offered any meaningful benefit. As I noted in my conclusion at the time, GCB had all the features of a bogus weight loss product. It was implausible, and backed by flimsy evidence with some serious methodological issues. Even before we knew it was fraudulent, it was clear this trial should not be used to guide treatment decisions. None of this was an obstacle to Oz, who declared it to be the newest panacea for weight loss, using words like “magic”, “staggering”, “unprecedented”, “cure” and “miracle pill”. He concluded his episode with an absurd “trial” in two audience members who took the supplement for five days. One reported a two pound loss, the other, a six pound loss. In doing so he illustrated one of the worst ways to evaluate a weight loss supplement: short duration of use and informed by anecdotes. It served as nothing more than an extended advertisement for the product.
Part 2: Dr. Oz doubles down on green coffee bean with his own bogus trial
In a hamfisted attempt to address the criticism of Oz’s first episode on GCB, Dr. Oz revisited the topic in a follow-up episode, which he called The Green Coffee Bean Project (Oz has scrubbed the episode’s notes from his website now, but the internet never forgets.) It’s not surprising. Based on the Vinson study, Oz designed and conducted a clinical trial of green coffee bean on his studio audience. He gave what appeared to be about 100 women either GCB or placebo for two weeks. Oz noted that the group taking the green coffee bean extract group lost 81.5 pounds collectively, while the placebo group lost 42 pounds. Assuming 50 participants per group, that’s 1.6lbs in the green coffee bean group, and 0.84 pounds in the placebo group. You can review the whole list of problems with this trial in my prior post, but what’s more concerning to me was that Oz didn’t obtain ethical approval to conduct the trial. (Oz subsequently admitted this in later Senate testimony.) How this could be acceptable to Columbia University, where he still practices as a surgeon, is incredible, yet perhaps reflects another aspect of The Dr. Oz Effect: Daytime TV trumps research ethics.
If Oz’s first episode was a mockery of looking at the evidence, the second episode was a mockery of how we generate evidence. Oz is a published research scientist. He knows how to do proper research. This wasn’t even close. His made-for-TV trial delivered only one thing: more accolades and praise from Oz about a product that still lacked any convincing evidence of benefit.
Dr. Oz and the Terrible, Horrible, No Good, Very Bad Day
When Dr. Oz arrived to speak at Senate hearing into weight loss scams in hearings led by Senator Clair McCaskill, he probably wasn’t expecting to be verbally disemboweled on television. McCaskill called him out for his breathless hyperbole, drawing attention (among all of Oz’s “miracles”) to green coffee bean:
Dr. Oz: Well, if I could disagree about whether they work or not, and I’ll move on to the issue of the words that I used. And just with regards to whether they work or not, take green coffee bean extract as an example. Uh, I’m not gonna argue that it would pass FDA muster if it was a pharmaceutical drug seeking approval, but among the natural products that are out there, this is a product that has several clinical trials. There was one large one, a very good quality one, that was done the year that we talked about this, in 2012. Listen, I’ve…
Sen. McCaskill: wh..wha..I wanna know about that clinical trial. Because the only one I know was sixteen people in India that was paid for by the company that, that was in fact, at the point in time when you initially talked about this being a miracle, the only study that was out there was the one with sixteen people in India that was written up by somebody that was being paid by the company that was producing it.
McCaskill got the evidence exactly right. There was still only a single trial (Vinson) with sixteen people studied. Yet the Oz Effect had driven a massive demand for GCB. And yet Oz was hardly apologetic, and described himself as a victim, rather than the cause of the problem. What was clear from his testimony is that when it comes to facts versus infotainment, television wins, every time:
Dr. Oz: I actually do personally believe in the items I talk about in the show. I passionately study them. I recognize that often times they don’t have the scientific muster to present as fact, but nevertheless, I would give my audience the advice I give my family all the time, and I have given my family these products.
Emphasis added. If you haven’t watched the hearings yet, the best and smartest summary on Oz and supplements in general came from John Oliver.
The Federal Trade Commission gets involved
In May of this year, the FTC announced it was suing a Florida-based company (Applied Food Sciences) for its promotion of green coffee bean. The vendor established web sites that made unsubstantiated claims about green coffee bean, while linking to clips and images of The Dr. Oz Show. In September, the FTC announced it had a deal and settlement from Applied Food Sciences (AFS) and it was a bombshell. Not only was the advertising misleading, but the trial itself was fraudulent:
The FTC charges that the study’s lead investigator repeatedly altered the weights and other key measurements of the subjects, changed the length of the trial, and misstated which subjects were taking the placebo or GCA during the trial. When the lead investigator was unable to get the study published, the FTC says that AFS hired researchers Joe Vinson and Bryan Burnham at the University of Scranton to rewrite it. Despite receiving conflicting data, Vinson, Burnham, and AFS never verified the authenticity of the information used in the study, according to the complaint.
Despite the study’s flaws, AFS used it to falsely claim that GCA caused consumers to lose 17.7 pounds, 10.5 percent of body weight, and 16 percent of body fat with or without diet and exercise, in 22 weeks, the complaint alleges.
Although AFS played no part in featuring its study on The Dr. Oz Show, it took advantage of the publicity afterwards by issuing a press release highlighting the show. The release claimed that study subjects lost weight “without diet or exercise,” even though subjects in the study were instructed to restrict their diet and increase their exercise, the FTC contends.
The FTC complaint really needs to be read to be believed. During the “revisions” to the manuscript, the following appears to have been changed:
    • The trial went from being described as open label to double-blind, placebo controlled
    • The duration of the study grew from 20 weeks, to 24 weeks, and then to 28 weeks
    • Six of the sixteen final weights were restated
Vinson and Burnham, the two authors hired by AFS to be the “authors” of the paper, never actually reviewed the raw data for the trial. Despite the repeated restatements of data, they subsequently finalized and signed off on a manuscript and found a journal willing to publish the results. Add the Dr. Oz effect, and AFS subsequently sold 500,000 bottles, apparently at $50 each. And that’s how a chemist and psychologist in Pennsylvania came to be the authors of a bogus clinical trial of green coffee bean, driving millions of dollars in sales for AFS.
The retraction
In light of the FTC’s findings, it was just a matter of time before there would be pressure to retract the study. And it happened this week. In a terse one-sentence retraction highlighted by Retraction Watch, Vinson and Burnham have now retracted the paper:
The sponsors of the study cannot assure the validity of the data so we, Joe Vinson and Bryan Burnham, are retracting the paper.
In an amazing display of handwaving and fingerpointing, the two hired “authors” are now blaming the sponsor for the validity of the data. No apologies for the serious ethical lapse of pasting their names on research they didn’t even conduct. And yet they blame the sponsor, who was the manufacturer, who should be last group with any involvement in the data collection and analysis.
What have we learned
The retraction of the Vinson trial has been cited by some as damaging Oz’s credibility. I frankly don’t think Oz had any credibility to lose. Even at face value, the evidence was never there and should never have been promoted by Oz as a treatment. Yes, admittedly that’s the case for almost everything Oz seems to promote on his show. Yes, the green coffee bean paper was fraudulent – but the fraud was so incompetent, they couldn’t even make the fake results look impressive, or make the study look credible. Even the fake data wasn’t impressive enough to justify the hype and hyperbole. Yet there seems to be no stopping Dr. Oz. The miracles continue, even after his Senate smackdown. I’m heartened by medical students like Benjamin Mazer, who is determined to go after Dr. Oz by asking his medical regulator to take action against him. Is the Dr. Oz strong enough to deflect a regulator? Time will tell.
Avoiding the next green coffee bean
One of the most frustrating aspects of the green coffee bean is the underlying fact that there simply are no magical pills or panaceas for weight loss. None. So how does one avoid the next miracle cure? It’s what Dr. Oz actually admitted to under Senate questioning: There are no miracle pills that replace a proper diet that includes calorie restriction. The facts of weight loss aren’t catchy, but they are based in reality, not hype. I covered many of them in my review of Yoni Freedhoff’s The Diet Fix:
The laws of thermodynamics hold. To lose weight you must expend more calories than you consume. For practical purposes, you must focus on the consumption side because…
You can’t outrun a bad diet. Calories are simply too easy to come by, and food is too calorie dense, to not restrict your diet. The most effective way to do so is to…
Track your calories consumed. Calorie tracking and journaling is highly correlated with more successful, permanent weight loss. This strategy works because…
The best diet is one you can sustain permanently. You don’t need to demonize any food groups. Temporary changes give temporary results. Permanent weight loss must be accompanied by permanent change. Quick fixes in the form of pills and potions are unnecessary, because…
Supplements, by and large, are useless. Even the most effective weight loss products (that are prescription drugs) provide only modest incremental benefit. In most cases, the benefit from supplements (or prescription drugs) is questionable.
Conclusion
Green coffee bean would probably be a fringe supplement if it wasn’t for a supplement company that decided to buy its own “evidence”. Once the Vinson trial was published, the Dr. Oz Effect pushed green coffee bean from nothing into a supplement blockbuster. Yet the entire trajectory was entirely predictable. Green coffee bean wasn’t the first useless weight loss supplement, and it definitely won’t be the last. While you won’t hear it from Dr. Oz (unless he’s speaking in the Senate) there simply are no quick fixes and no weight loss “miracles”. Let’s hope everyone’s a little more skeptical when the next “miracle” appears.

Dr. Oz and Green Coffee Beans – More Weight Loss Pseudoscience
Scott Gavura on July 5, 2012
Link
I can’t keep up with Dr. Oz. Just when I thought the latest weight loss miracle was raspberry ketone, along comes another weight loss panacea. This time, it’s green coffee beans.
Eveyone knows Dr. Oz, now. Formerly a guest on Oprah, he’s got his own show which he’s built into what’s probably the biggest platform for health pseudoscience and medical quackery on daytime television. In addition to promoting homeopathy, he’s hosted supplement marketer Joe Mercola several times to promote unproven supplements. He has been called out before for promoting ridiculous diet plans, and giving bad advice to diabetics. And don’t forget his failed attempt to actually demonstrate some science on his show, when he tested apple juice for arsenic which prompted a letter from the FDA about his methodology. His extensive track record of terrible health advice is your caution not to accept anything he suggests at face value. So when the sign in front of my local pharmacy started advertising “Green coffee beans – as seen on Dr. Oz”, I tracked down the clip in question. The last time I saw Dr. Oz in action when when he had SBM’s own Steven Novella as a guest, where there was actually a exchange (albeit brief) about the scientific evidence for alternative medicine. Replace Dr. Novella with a naturopath, and you get this: 
https://www.youtube.com/watch?v=Fslw-u7o-qI
Yes, Oz did use the terms “magic”, “staggering”, “unprecedented”, “cure” and “miracle pill”. And clearly the naturopath, Lindsay Duncan, is enamored with this product. But Dr. Oz is a health professional – he’s the Vice-Chair of the Department of Surgery at Columbia University. He’d be a bit skeptical, right? This exchange at the end, made me shake my head – Dr. Oz really has crossed the woobicon:
Now I always pride myself at having the smartest TV audience out there. So I’m hoping that some of you are skeptical about this. I was certainly skeptical about it. Am I speaking for a couple of you, anyway? It does seem a little too good to be true.
So what did Dr. Oz do – issue cautions about obesity panaceas? No. He created some anecdotes:
So I gave the supplements to two viewers 5 days ago. I gave all the information I could find on this product to our medical unit, they did diligent work, but we still wanted to see what would happen in real life.
One viewer dropped 2 pounds in 5 days. The other viewer lost 6 pounds in 5 days. Convincing weight loss? It was persuasive to Dr. Oz.
So now I’m going to do what Dr. Oz, the producers of the show, and the naturopath Lindsay Duncan didn’t do — actually review the evidence.
The Evidence Check
There is some suggestion, but no convincing evidence, that coffee consumption or caffeine consumption may have a modest, effect on weight. This study examined unroasted or “green” coffee beans, and was published in the online journal Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. The journal says it’s a peer-reviewed publication, but with an average of 12 days from submission to editorial decision, which apparently includes peer review, it’s obvious the review is cursory at best. The study is entitled Randomized, double-blind, placebo-controlled, linear dose, crossover study to evaluate the efficacy and safety of a green coffee bean extract in overweight subjects. The lead author, Joe A Vinson, is a chemist at the University of Scranton, Pennsylvania. None of the three authors appear to be clinicians or medical professionals, and none appear to have published obesity-related research before, according to PubMed. The study was funded by a supplement manufacturer, Applied Food Sciences.
To start — this is a very tiny trial — just 16 patients (8 males, 8 females) with an average age of 33 years. The research location was a hospital in Bangalore, India. How these patients were recruited was not disclosed. Normally a trial would list detailed inclusion and exclusion criteria, and then describe how many patients were considered and the reasons for exclusion. This paper just reports the final number, and there is no information provided on why 16 was felt to be the desireable number. The average weight was 76.6kg (168 lbs) and the average body mass index (BMI) was 28.22. While the BMI on an individual basis may not be informative, when looking at a population, a score between 25 and 30 is usually accepted to mean overweight, but not obese. The details on how these measurements were taken were not well described — which is surprising, given this is a this is a pretty important part of the study.
One of the tricks that researchers (both pharma and supplement) can play when conducting clinical trials is to change parameters of the trial, after the trial is started. Because of the risk of conflicts of interest, there has been a growing commitment to publish the trial parameters in advance of the trial at the website clinicaltrials.gov. Many medical journals will now refuse to publish a trial if it was not initially entered into a public registry. Not only does a registry ensure that negative results don’t disappear, it gives valuable information about the study, including its design, entry criteria, and who gave formal ethics approval for the study. This study was never registered at clinicaltrials.gov. And there’s no evidence provided that a research ethics board ever reviewed the protocol. I find it hard to believe that any investigator would undertake a clinical trial of an unproven supplement without obtaining prior ethics approval – but that seems to be the case.
Green coffee extract (the brand “GCA”) was used in the study. The authors note that GCA has a standardized content of 45.9% chlorogenic acid, which is purported to be the active ingredient. Now contrary to what was said on the Dr. Oz show, chlorogenic acid is also in roasted coffee in significant amounts, so you don’t need to take green coffee extract to get a good dose. Patients were “randomly” divided (method was not disclosed) into three groups: high dose, low dose, and placebo (which was described only as an “inactive substance”). No clear justification for how the dose was determined was provided. Each group stayed in one group for six weeks, had a washout of two weeks, then moved to the next group. Here’s where we run into more problems.
Double-blind in name only
Groups served as their own controls, and rotated betwen a “high dose”, a “low dose” and the placebo.
    • Group 1 (6 patients): High dose (x 6 weeks) — washout (x 2 weeks) — low dose (x 6 weeks)- washout (x 2 weeks) — placebo (x 6 weeks)
    • Group 2 (4 patients): Low dose — washout — placebo — washout — high dose
    • Group 3 (6 patients): Placebo — washout — high dose — washout — low dose
This doesn’t look that unreasonable. But the investigators noted the following:
The high-dose condition was 350 mg of GCA taken orally three times daily. The low-dose condition was 350 mg of GCA taken orally twice daily. The placebo condition consisted of a 350 mg inert capsule of an inactive substance taken orally three times daily.
Wait, what? The low dose arm was twice daily, while the placebo and the high dose arm were three times per day? That means that participants and investigators could determine which period was the “low dose” treatment. Knowing this, the other two treatment periods can be determined. So much for blinding and placebo control – we can’t credibly consider this to a blinded trial.
Based on the protocol, participants were evaluated at weeks 0, 6, 8, 14, 16, and 22. Diet was assessed by interviews and recall — a notoriously unreliable means of measuring actual calorie consumption. Weight, height, body fat, and blood pressure were calculated each visit. So here are the results for the three groups:
The table above is where Dr. Oz got his statistics of “17 lbs” of weight loss and 10% weight loss over 22 weeks. Oz also points out that there is no reported difference in dietary intake at the beginning and end of the trial – which is correct, but this is based only on patient recall. So is the weight loss due to the intervention? The group-by-group results are baffling.
Spot anything odd? Check out the HD/LD/PL group. This group lost about 4kg during the 6-week treatment period, but then lost an additional 4kg during the washout. There was relatively no change thereafter on the low dose. The PL/HD/LD group is even odder. In the first eight weeks of no active treatment (placebo & washout), the group lost about 8kg, but then didn’t budge on the high dose, and lost about 1kg on the low dose. Finally the LD/PL/HD group lost about 3kg on the low dose, was flat on the placebo, and then lost a smaller amount of weight on the high dose, which continued during the washout.
The results don’t add up. If the green coffee is having an actual effect, it should be occuring when the dose is given, not during the washout, or when a placebo is taken. Bias? Random noise? In a tiny, poorly-controlled trial, it’s not possible to say. The breakdown of the results by arm are interesting:
Here it’s a bit more revealing. The changes in each period are modest. Given the small sample size, the repeated measurements, and lack of proper blinding, the risk of bias is high.
Safe and Effective?
Both Oz and the authors state that the supplement was safe and free of side effects. But the trial doesn’t report any side effect information at all, other than stating “no side effects of using GCA”. Given no information seems to have been systematically collected, it’s not clear we can accept this statement. At a minimum, the authors should have reported side effects between the three treatment periods. Surprisingly, there was a non-significant increase in systolic and diastolic blood pressure, which the authors note appeared restricted to the placebo treatment component.
Did the weight loss last? The authors claim that 14 of 16 participants maintained their lowered weight after completing the study – this is doubtful, as no supplement or medication for obesity continues to work after you stop taking it.
The Red Flag Bogus Weight Loss Test
Diet products that promise rapid weigh loss with no exercise or calorie restriction are nothing new. The Federal Trade Commission routinely takes on on diet supplement scams, and has a list of claims it calls “red flags” in advertisements for worthless products. Let’s put green coffee beans to that test:
    • Cause weight loss of two pounds or more a week for a month or more without dieting or exercise? Weight loss claim is just under 1lb/week with no dieting or exercise.
    • Cause substantial weight loss no matter what or how much the consumer eats? Investigators claim there was no difference in calorie type or intake, yet weight loss occurred.
    • Cause permanent weight loss (even when the consumer stops using product)? Investigators claimed weight loss sustained after trial ended.
    • Block the absorption of fat or calories to enable consumers to lose substantial weight? Actual mechanism (if any) is not clear. On the show it’s called a “fat blocker”.
    • Safely enable consumers to lose more than three pounds per week for more than four weeks? Claims 10% over 22 weeks.
    • Cause substantial weight loss for all users? Study claims all participants lost weight, lost fat, and reduced their BMI.
    • Cause substantial weight loss by wearing it on the body or rubbing it into the skin? — not applicable
The Dr. Oz segment raises several of the FTC’s red flags – if it was a paid commercial message, you could report it to the FTC.
Conclusion
Green coffee bean supplements have the characteristics of a bogus weight loss product. The supplement lacks plausibility, the only published clinical trial is tiny, and it appears to have have some serious methodological problems. Ignoring all of this, Dr. Oz has instead embraced it as the newest panacea for weight loss. Obesity is a real health issue, yet Dr. Oz seems quite content touting unproven products instead of providing credible, science-based information. In the real world, permanent weight loss is difficult, and there are no quick fixes. But not in the Land of Oz.
Reference
Vinson, Joe A, Burnham, Bryan R, & Nagendran, Mysore V (2012). Randomized, double-blind, placebo-controlled, linear dose, crossover study to evaluate the efficacy and safety of a green coffee bean extract in overweight subjects Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy (5), 21-27 DOI: 10.2147/DMSO.S27665

Dr. Oz Doubles Down on Green Coffee Bean with a Made-for-TV Clinical Trial
Scott Gavura on January 3, 2013
Link
“One of the most important discoveries I believe we’ve made that will help you burn fat – green coffee bean extract” – Dr. Oz, September 10, 2012, Episode “The Fat Burner that Works”
Dr. Mehmet Oz may be biggest purveyor of health pseudoscience on television today. How he came to earn this title is a bit baffling, if you look at his history. Oz is a bona fide heart surgeon, (still operating 100 times per year), an academic, and a research scientist, with 300+ or 400+ (depending on the source) publications to his name. It’s an impressive CV, even before the television fame. He gained widespread recognition as the resident “health expert” on Oprah, and went on to launch his own show in 2009. Today “The Dr. Oz Show” is a worldwide hit, with distribution in 118 countries, a massive pulpit from which he offers daily health advice to over 3 million viewers in the USA alone. For proof of his power to motivate, just look at the “Transformation Nation Million Dollar You” program he launched in 2011, enrolling an amazing 1.25 million participants. Regrettably, what Oz chooses to do with this platform is often disappointing. While he can offer some sensible, pragmatic health advice, his show’s content seems more focused on TV ratings than medical accuracy, and it’s a regular venue for questionable health advice (his own, or provided by guests) and poorly substantiated “quick fixes” for health issues. (And I won’t even touch Oz’s guests like psychic mediums.) One need only look at the number of times the term “miracle” is used on the show as a marker of the undeserved hyperbole. Just this week, Julia Belluz and Stephen J Hoffman, writing in Slate, itemized some of the dubious advice that Oz has offered on his show, with a reality check against what the scientific evidence says. It’s not pretty.
I know I’m not alone in my dismay with the Dr. Oz show – As a health professional, Oz should know better than this. He has the education and training that should allow him see through the pseudoscience that he now embraces on a regular basis. I took a close look at Dr. Oz’s show on green coffee beans a few months ago as a case study in pseudoscience, after being inundated with questions about it. In short, green coffee bean extract is derived from unroasted coffee beans and is touted as a source of chlorogenic acid, purported to be the active ingredient in what Dr. Oz called a “miracle” and a “fat burner”. All the clinical trials done on green coffee beans have been small and inconclusive, and a recent meta-analysis noted these limitations, and called for better conducted studies. On his show, Dr. Oz introduced a naturopath touting the product (who also happens to sell his own line of green coffee bean extract, but never disclosed his conflict of interest.) The naturopath and Dr. Oz discussed a small clinical trial by Joe A. Vinson that studied just 16 patients in India. Even from a cursory review of the study, the trial design and reporting was so poor that there was no way to make any definitive conclusions about its efficacy.
Instead of describing the problems with the trial, and cautioning the audience not to get suckered in by cures that look too good to be true, Oz did the exact opposite. He did a case study. He asked two members of his audience to take the supplement for five days. One reported a 2 pound loss, the other, a six pound loss. A five day, unblinded evaluation of a supplement in women who are about to be profiled on television is quite possibly the worst possible way to evaluate a treatment for obesity. But it was good enough for Dr. Oz.
“It’s important for everyone to understand what green coffee bean is, and why I think it’s so important for weight loss.” – Dr. Oz, September, 2012
Perhaps stinging from the well-deserved criticism he endured with his first show and his laughable case study, Dr. Oz recently dedicated another show to green coffee bean. He called it The Green Coffee Bean Project:
To test the effects of the green coffee bean extract for The Dr. Oz Show, the show’s Medical Unit conducted a project under the guidance of experts including Dr. Caroline Apovian and registered dietician Kristin Kirkpatrick. It is the largest project the show has ever done.
So what was the “project”? The website describes the undertaking:
The show’s Medical Unit enlisted 100 women between the ages of 35 and 49 who were overweight with BMIs between 25 and 45. The women were not pregnant or breastfeeding and didn’t have any major medical problems including diabetes, or history of heart attack or stroke. These women received either the green coffee bean extract or a placebo, and were instructed to take 400mg capsules, three times a day – 30 minutes before each meal. No participant knew which pill they were given. Furthermore, the participants were instructed to not change their diet, and to keep a food journal that would help The Dr. Oz Show learn what these women were eating. After two weeks, the study participants were weighed.
In two weeks, the group of women who took the green coffee bean extract lost, on average, two pounds. However, the group of women who took the placebo lost an average of one pound – possibly because they were more aware of their diet for that two weeks because of the required food journal.
There is a bit more detail in the episode clips. All women started with an examination with extensive measurements, including blood pressure, weight, heart rate, and waist size. The bottles are shown on screen for a moment, and the label says “Green Coffee Bean Project”, “For investigational use only” and what looks like “There are no known side effects.” Dr. Oz mentions that the placebo is “almost identical” in appearance. The study product (green coffee bean or placebo) was mailed to participants. All participants were also asked to complete a daily food diary, which appeared to be completed online. The study lasted two weeks.
Oz then moves to discuss the evaluation with the studio audience, which is made up entirely of the participants in the study. Overall, everyone (approximately 100 women, it’s not clear) is reported to have lost 123 lbs over the 2 weeks. Oz then notes that the group taking the green coffee bean extract group lost 81.5 pounds collectively, while the placebo group lost 42 pounds. Assuming 50 participants per group, that’s 1.6lbs in the green coffee bean group, and 0.84 pounds in the placebo group. No final numbers of participants are provided, so it’s not clear what the average weight loss really was.
Does 1.6 lbs versus 0.84 pounds sound convincing enough? There’s not a lot of detail here, but what is reported raises some serious questions about the approach and methodology.
Oz calls this a “project” but we should be clear on what this really was: a randomized clinical trial. He recruited participants, randomized them, gave them a treatment, and measured an outcome. Oz is presumably the principal investigator here, so my first question is if he obtained clearance to conduct this trial from an Institutional Review Board (IRB), either from Columbia University, or elsewhere. As staff at Columbia University, their requirements would presumably apply. Ensuring clinical trials are conducted in ethically sound ways is no trivial matter. Institutional review boards emerged in part as consequence of the horrific medical abuses of the second world war, to protect the right of research subjects. While IRB approval doesn’t guarantee a trial is credible and safe for participants, it does provide an external validity check of its overall approach and ethics. Now it could be the case that the show did obtain IRB approval from some organization who reviewed the protocol, consent forms, and overall methodology. I sincerely hope so, from a research ethics and patient protection perspective.
Another quality indicator is trial registration, a critical issue in research and a means of holding investigators more accountable for reporting their results in a transparent and unbiased manner. Public registration serves as international resource that catalogs human experiments, and allows for more systematic evaluations of treatments. Disappointingly, there are no clinical trials registered at clinicaltrials.gov that refer to green coffee bean. There are trials that are studying chlorogenic acids – but in coffee. Yes, despite what Dr. Oz said on his show, brewed coffee is also a source of chlorogenic acids.
Taking a closer look at the results that Oz reported, there’s even more missing data. No information is provided on how women were recruited, how they were randomized, and how comparable the two group were. The only condition for enrollment seems to have been BMI, which is not a good measure of obesity on an individual basis. There is no discussion of informed consent. Then we come to the blinding and the group allocation (placebo or active treatment). It’s noted that participants didn’t know which group they were in. Was this a”single-blind” trial where the staff collecting data knew of the allocation, raising the risk of bias? Again, it’s not clear. (One need only look at acupuncture trials to see how single-blinded studies generate misleading results.)
Now let’s look at the treatment itself. Two weeks is insufficient for a clinical trial of a drug for weight loss. Real obesity studies last months – not days. And multiple measures are collected before, during, and after the trial, including changes in figures like BMI, waist size, lipid levels, and weight. Reporting only overall weight loss per group, as Oz has done, is both uninterpretable and suspicious. What about all of the other measurements collected? Even looking only at weight loss, we need both the average and the standard deviation. We then need a statistical analysis of the results, to see if the results differ from random chance. None are reported, or even mentioned.
Finally let’s look at the safety. There’s little mention of side effects other than a question that Oz asks the audience. Were participants asked to report on side effects? Were there any differences at all? Again, it’s not reported. Two weeks is insufficient to evaluate safety, in any case. And if the bottle really says, “There are no known side effects,” should we really expect participants to report any negative effects? What still hasn’t been answered with green coffee bean is the long-term safety. Concerns have been raised about the potential for chlorogenic acid to raise levels of homocysteine. While the relationship between elevated homocysteine and cardiovascular disease isn’t clear, it does suggest that the safety profile should be confirmed, and not assumed.
“This stuff really seems to work” – Dr. Oz
This clinical trial makes a mockery of good research methodology. As a clinician scientist, Dr. Oz knows the evidence bar for good research. This made-for-TV trial doesn’t even come close. The idea of doing a clinical trial on green coffee bean extract is a good one. And the Dr. Oz show certainly has the resources to fund a proper evaluation. So why design it in a way that will guarantee meaningless results? If he truly believes that this was a fair and ethical test of green coffee bean extract, I invite the Dr. Oz show to prove it: Show us the IRB approval, show the consent forms, give us the pre- and post-test comparison of the two groups, describe the randomization, show all the collected data, and show us the statistical analysis that let to the conclusion that green coffee bean actually works as a weight loss product. And I’ll happily write up a follow-up post heralding the first non-prescription product ever to generate meaningful weight loss despite no changes in dietary consumption and exercise. I’m not going to hold my breath.
Despite the impression given by Oz, the laws of thermodynamics hold, even on daytime television. There is no magical product that allows you to eat whatever you want, hold your calorie expenditure constant, and still lose weight. Weight changes are driven by by overall calorie intake and expenditure, so weight loss is always a consequence of a negative balance. In the case of the Dr. Oz study, weight loss in both groups was almost certainly due to food journaling of calories, and a heightened awareness of calorie intake simply from being in a clinical trial. In fact, Oz goes on to recommend the food diary as an acceptable alternative to those that don’t want to purchase green coffee bean extract, which may be the most sensible statement he makes in the entire episode.
Conclusion
A year ago green coffee been was a little known product showing some promising but unverified results in small clinical trials. Then came the Dr. Oz effect. Lots of publicity, lots of use of the term “miracle”, and then a made-for-TV clinical trial. Despite all this hype, the evidence base is no better today than it was one year ago. Yet sales have skyrocketed, will millions likely trying green coffee bean, in the absence of good efficacy or safety data. Thanks to Dr. Oz, many consumers have the impression that green coffee bean has been evaluated, it’s safe, and it offers a meaningful benefit for weight loss. In short, it’s a panacea. Unfortunately, there are no panaceas for weight loss, and there are no short cuts when it comes to science. Of course, these uncomfortable realities don’t lend themselves well to daytime television.

The Great and Powerful Oz versus science and research ethics
Dr. Mehmet Oz conducted a (poor-quality) clinical trial of green coffee beans for weight loss. Somehow between taping his show and being a doctor, he forgot to get institutional review board approval for ethics. Oops!
David Gorski on January 4, 2013
Link

That Dr. Mehmet Oz uses his show to promote quackery of the vilest sort is no longer in any doubt. I was reminded yet again of this last week when I caught a rerun of one of his shows from earlier this season, when he gazed in wonder at the tired old cold reading schtick used by all “psychic mediums” from time immemorial, long before the current crop of celebrity psychic mediums, such as John Edward, Sylvia Browne, and the “Long Island Medium” Theresa Caputo, discovered how much fame and fortune they could accrue by scamming the current generation of the credulous. Speaking of Theresa Caputo, that’s exactly who was on The Dr. Oz Show last week (in reruns), and, instead of being presented as the scammer that she is, never was heard even a hint of a skeptical word from our erstwhile “America’s doctor,” who cheerily suggested that seeing a psychic medium scammer is a perfectly fine way to treat crippling anxiety because, well, Caputo claims that it is. Even worse, apparently it wasn’t even the first time that Dr. Oz had Caputo on his show, and Caputo wasn’t even the first psychic whose schtick he represented as somehow being a useful therapeutic modality for various psychological issues. “Crossing Over” psychic John Edward was there first in a segment Oz entitled Are Psychics the New Therapists? I could have saved him the embarrassment and simply told him no, but apparently Oz is too easily impressed. As I said before, if he’s impressed by clumsy cold readers like Browne, Caputo, and Edward, it doesn’t take much to impress him. Also, apparently his producers aren’t above editing science-based voices beyond recognition to support their quackery.
I was further reminded how Dr. Oz promotes quackery by an article in Slate yesterday entitled Dr. Oz’s Miraculous Medical Advice: Pay no attention to that man behind the curtain. I suppose it would be mildly hypocritical of me to snark at the rather obvious “Wizard of Oz” jokes aimed at Dr. Oz. After all, I’ve used the same joke myself at one time or another and, in light of the Slate.com article, couldn’t resist using it in the title of my post. However, I wasn’t about to let that distract me from the article itself, which is very good. The reason is that there are two aspects to Dr. Oz’s offenses against medical science. There is the pure quackery that he features and promotes, such as psychic scammers like John Edward and Theresa Caputo, faith healing scammers like Dr. Issam Nemeh, and “alternative health” scammers like reiki masters, practitioners of ayruveda, Dr. Joe Mercola, who was promoted as a “pioneer” that your doctor doesn’t want you to know about. Never was it mentioned that there are very good reasons why a competent science-based physician would prefer that his patients have nothing to do with Dr. Mercola, who runs what is arguably the most popular and lucrative alternative medicine website currently in existence and manages to present himself as reasonable simply because he is not as utterly loony as his main competition, Mike Adams if NaturalNews.com (who has of late let his New World Order, anti-government, “Obama’s coming to take away your guns” conspiracy theory freak flag fly) and Gary Null.
The second aspect is that Dr. Oz also does give some sensible medical advice. The problem, as I’ve pointed out before, is that he “integrates” all manner of quackery into his science-based advice. Now, that pure nonsense is being “integrated”is pretty obvious when we’re talking about faith healing and psychic mediums, but Dr. Oz’s “integration” is actually seamless in that he integrates all manner of dubious and scientifically questionable claims with the more standard, stodgy, boring science-based advice (e.g., lose weight, exercise more, eat more vegetables and less red meat, treat your high blood pressure, and the like). For example, it is not surprising that Oz features a lot of dubious diet supplements on his show, given that losing weight is one of the single most important health issues many people face and the fact that effective weight loss strategies are rarely easy. They involve diet and exercise, neither of which is fun or easy for many people. So what we hear from Oz are stories like this:
As people were getting ready for the holiday season and its accompanying waist expansion late last year, Dr. Mehmet Oz let viewers of his TV show in on a timely little secret. “Everybody wants to know what’s the newest, fastest fat buster,” said the board-certified cardiothoracic surgeon and one of People magazine’s sexiest men alive. “How can I burn fat without spending every waking moment exercising and dieting?”
He then told his audience about a “breakthrough,” “magic,” “holy grail,” even “revolutionary” new fat buster. “I want you to write it down,” America’s doctor urged his audience with a serious and trustworthy stare. After carefully wrapping his lips around the exotic words “Garcinia cambogia,” he added, sternly: “It may be the simple solution you’ve been looking for to bust your body fat for good.”
In Dr. Oz’s New York City studio, garcinia extract—or hydroxycitric acid found in fruits like purple mangosteen—sounded fantastic, a promising new tool for the battle against flab. Outside the Oprah-ordained doctor’s sensational world of amazing new diets, there’s no real debate about whether garcinia works: The best evidence is unequivocally against it.
As Julia Belluz and Steven J. Hoffman, the authors of the article, point out, garcinia extract has been tested, and in a randomized trial in 1998 it was no better than placebo for weight loss. A more recent systematic review of the literature concluded that the evidence was at best equivocal and that the effects, even if real, were so small as make it unlikely they were clinically relevant. Belluz and Hoffman also point out that Dr. Oz takes full advantage of the scientific respectability that his current position affords him:
Oz may be the most credentialed of celebrity health promoters. He’s a professor and vice-chair of surgery at Columbia University College of Physicians and Surgeons. He earned his degrees at Ivy League universities, namely Harvard and the University of Pennsylvania. He’s won a slew of medical awards (in addition to his Emmys) and co-authored hundreds of academic articles. He’s clearly a smart guy with qualifications, status, and experience. It’s reasonable to assume he is well-versed in the scientific method and the principles of evidence-based medicine. “Because he’s a physician, that lends a certain authority and credibility to his opinions,” said Steven Novella, a clinical neurologist and assistant professor at Yale University School of Medicine who has taken Oz to task for his science. “But it lends credibility to anything he says.”
Indeed it does. I often wonder about this. First of all, I wonder how Dr. Oz can manage to do a daily hour-long talk show and still see patients and hold all the academic positions that he holds. I realize that it’s Oz’s producers and writers who do most of the grunt work for his show, but it’s still hard to believe that during the nine months or so a year when his show is in production Oz doesn’t spend at least 20 hours a week working on it. Just the taping of five episodes a week alone must surely, when added up, take up at least a full (and long) day, given all the filing of audiences in and out, changes in the set, and the like. Then there’s oversight, consultations with the producers and writers, story approval, not to mention travel and promotion. It’s a huge time commitment. Or, if it’s not a huge time commitment and Oz really doesn’t do that much, then we’d have to conclude that Dr. Oz is nothing more than a figurehead, a Ted Baxter– or Ron Burgundy-like character, who comes in one day a week, reads his cue cards, and has little or nothing to do with the creative process behind the show. Somehow, given how driven he’s always been, I think Oz has more involvement in putting his show together than that. Sheer ego alone, at the very minimum, makes me think that, too, as I doubt Oz would want his brand and message to be completely controlled by others. Assuming he does have significant involvement in putting his show together, it’s hard to figure out how from September to June Dr. Oz has enough time to take care of patients, handle his administrative duties, and do anything resembling academic work. Besides the difficulty of maintaining one’s technical operative skills and knowledge base in a surgical specialty as complex as cardiac surgery, Dr. Oz must have the most understanding surgical partners in the world, given how often and for how long they must have to cover his patients, and he must have the most understanding department chair in the world given how little time he probably has left after his show to do any real administrative work. (Remember, he’s not just the vice chair of the department of surgery; he’s also the director of the Cardiovascular Institue and the Complementary Medicine Program at New York Presbyterian Hospital.) On the other hand, no doubt Columbia derives considerable rewards from Dr. Oz in terms of publicity for its medical school, programs, and hospitals, not to mention probably a not insignificant amount of cold, hard cash. So it’s probably not that surprising that Oz’s administration and partners put up with him and bend over backwards to enable him.
The sad thing is that Dr. Oz, for all his fascination with reiki even as far back in the 1990s, used to be a halfway decent surgical scientist. The vast majority of his publications from that period are pretty mainstream and unremarkable. They were competently done, although I didn’t find any major breakthroughs or any new really interesting findings, admittedly Oz did produce a lot of publications.
Of course, all of this makes it even sadder to see what Dr. Oz has become. He’s already proven that he knows how to do decent science; the evidence is in dozens of publications from years past. Yet when he’s on TV all of that flies out the window, and Oz apparently either forgets (or rejects) everything his pre-Oprah scientific career. For example:
Take a breaking-news segment about green coffee-bean supplements that “can burn fat fast for anyone who wants to lose weight.” Oz cited a new study that showed people lost 17 pounds in 22 weeks by doing absolutely nothing but taking this “miracle pill.”
A closer look at the coffee-bean research revealed that it was a tiny trial of only 16 people, with overwhelming methodological limitations. It was supported by the Texas-based company Applied Food Sciences Inc., a manufacturer of green coffee-bean products. Oz didn’t mention the potential conflict of interest, but he did say he was skeptical. To ease his mind, he conducted his own experiment: It involved giving the pills to two audience members for five days and seeing what would happen. Unsurprisingly, both women reported being less hungry, more energetic, and losing two and six pounds, respectively.
Dr. Oz knows as well as any regular reader of this blog who has imbibed of its content and message how worthy of ridicule such a TV “study” of two is: no blinding, no control group, far too short a time period of observation, and a number so small as to be meaningless; yet somehow Dr. Oz thinks that something like this “eases his skepticism” about the tiny study (which only had either four or six subjects in each experimental group). Particularly informative is Figure 2 of the study, in which all three groups basically decreased their BMI at the same rate in the initial period regardless of whether they were in the group to receive placebo, low dose, or high dose green coffee bean supplement. One also notes that there were no error bars on any of the graphs to provide an idea of the scatter in the data. All in all, it’s a pretty worthless and unconvincing study, not even taking into account the conflict of interest. Come to think of it, one wonders whether Dr. Oz (or any promoter of alternative therapies and supplements) would accept a study like this from a pharmaceutical company as convincing evidence that the company’s product worked. Somehow I doubt it.
Oz then went beyond this, as Scott Gavura described yesterday, setting up what he called the Green Coffee Bean Project. Scott quite accurately described it as a “made for TV clinical trial,” and that’s exactly what it was: a randomized clinical trial set up for Dr. Oz’s television show. True, it was a shoddily designed and useless clinical trial, but it was clearly a clinical trial nonetheless. Unfortunately, there was no statistical analysis and no approval by an institutional review board (IRB), even though this was clearly human subjects research. Quite frankly, doing a research project like this involving human subjects is profoundly unethical without IRB approval. In fact, arguably, Dr. Oz was in direct violation of Columbia University’s Human Research Protection Program, which states:
The IRB has the responsibility to oversee the conduct of research that it approves. Consistent with this responsibility, the IRB may audit research studies conducted at Columbia University or Columbia University Medical Center as well as research in which faculty and/or staff of Columbia University are engaged outside the institution. The Compliance Oversight Manager is responsible conducting audits at both campuses and reports to the Executive Director of the IRB.
If that’s not clear enough, the executive summary states:
The Columbia HRPP covers all entities, offices, and individuals engaged in and/or responsible for the review and conduct of human research at Columbia and New York Presbyterian Hospital (NYPH). CU has two Federalwide Assurances (FWAs): one for Columbia University Medical Center (CUMC) and one for the main campus at Morningside Heights (CU-MS). NYPH has its own FWA and is a separate legal entity from CU. Although there are three FWAs, the Columbia HRPP is responsible for all human research conducted at CUMC, CU-MS, and NYPH, or by any affiliated faculty, employees, or staff of CU and NYPH regardless of location.
Let me emphasize: This policy applies to research carried out by all Columbia and NYP-affiliated faculty regardless of the location where the research is done. Quack researchers like Mark and David Geier seem to be able to manage to skirt these laws because they aren’t faculty at an institution that receives federal funding and because they fly under the radar. In contrast, Dr. Oz is Columbia faculty. Even though he conducted human subjects research outside of Columbia university and clearly his research is not federally funded, it’s hard not to wonder whether he violated Columbia’s HRPP policy. Federal law is very clear on this. Institutions receiving federal funding must abide by the Common Rule, which states that all human subjects research that’s federally funded carried out at such institutions or by the faculty of such institutions must be overseen by a duly constituted IRB. All such institutions that I’ve ever worked at or had dealings with also agree to apply the Common Rule to all human subjects research conducted at their facilities and/or by their faculty, regardless of whether the research is federally funded or not. Also, it doesn’t matter if the research in question is being carried out at a location outside of the university. If the Office for Human Research Protections ever had a mind to investigate and concluded that Oz did perform human subjects research without proper oversight by Columbia’s IRB, Columbia University could potentially be in for a world of hurt, up to and including the possibility of having its federal research funding withheld. At the very least, a federal investigation would be very intrusive and painful, even if it ultimately exonerated Oz and Columbia. At the very least we have to wonder whether Oz violated Columbia policy on human research subjects protection, which is why the university should investigate, in my opinion. It likely won’t, however. This is the Great and Powerful Oz, and the university gets too many rewards in terms of publicity and probably cash.
I can speculate endlessly why Dr. Oz has devolved from a respected cardiothoracic surgeon and surgical investigator into, let’s face it, a huckster selling whatever he thinks his audience will buy. Well, that’s not exactly true. As Dr. Oz so often and so piously reminds us, he doesn’t make any money from endorsements, and he claims to aggressively go after companies that falsely advertise his endorsement to sell products. The product that Dr. Oz is selling to America is, above all else, Dr. Oz. There’s also the relentless pressure to come up with material to fill five hour-long episodes a week for nine months a year. TV is a bottomless sink for material, and it demands material that will attract, engage, and, above all, entertain its audience. Telling people to lose weight and exercise isn’t that entertaining or interesting. Telling people there are supplements that will let you lose weight without dieting or exercise is. Strategies to deal with anxiety based on research are difficult to present in an entertaining fashion. Presenting psychics like John Edward or Theresa Caputo as being therapeutic is easy and potentially entertaining even to skeptics, and it can be done with Dr. Oz’s “aw, shucks” disclaimer that fools no one in which he opines over and over again that “science doesn’t know everything” and that “medicine can’t explain everything.” So, as Dara O’Briain puts it, Oz fills in the blanks with whatever fairy story appeals to him—or, more accurately, appeals to his audience.
As 2013 begins, I’ve been thinking a lot. We skeptics and supporters of science-based medicine are massively outgunned, and Dr. Oz is simply the most telling example of this. Quacks have Dr. Oz to sell their products. We have a loosely-knit, unorganized bunch of bloggers trying to refute the torrents of nonsense that promoters of quackery like Dr. Oz spew forth, and a few academics like Dr. Edzard Ernst trying to counter the flood of quackademic medicine filling academic journals. Dr. Oz has an audience of millions every day. Bloggers like Steve Novella, Steve Salzberg, and I have an audience of a few thousand each every day, and our audiences have considerable overlap. Moreover, even in the skeptic movement itself, countering quackery and medical pseudoscience is all too often the neglected stepchild that gets far less time, attention, and love than creationism, Bigfoot, the paranormal, and religion. Even within the skeptical movement itself, I’ve personally all too often seen a shocking level of tolerance or even acceptance of antivaccine views and alternative medicine.
That’s why one of my aims this year is to come up with ideas about how we can work to change this, because this matters, or should matter, to everyone. All of us will get sick at some point in our lives. Many of us will become seriously ill at some point in our lives, and all of us have known or will know someone who becomes seriously ill. All of us will require medical care, and many of us require chronic treatment for some condition or other. Blogging is important. Exposing quackery and medical pseudoscience is important. However, it isn’t enough.

5-hour Energy
Harriet Hall on June 26, 2012
Link
What should you do if you feel tired? Taking a nap isn’t always possible. The ever-inventive capitalist marketplace has come up with another option.
5-hour Energy is a flavored energy drink sold as 2 oz “shots.” It was invented by Innovation Ventures in 2004. It is intended to counteract the afternoon slump, to increase alertness and energy, to help you stay sharp, improve attention, leave grogginess behind and sail through your day.
Ingredients
According to the label, its ingredients are:
    • Niacin 30 mg — 150% of the RDA
    • Vitamin B6 40 mg — 2000% of the RDA
    • Folic acid 400 mg — 100% of the RDA
    • Vitamin B12 500 mcg — 8333% of the RDA
    • Energy blend: taurine, glucuronic acid, malic acid, N-acetyl L tyrosine, L-phenylalanine, caffeine, and citicoline. Total amount of blend: 1870 mg. The caffeine content is not specified on the label, but it is supposedly comparable to a cup of the leading premium coffee.
It contains only 4 calories, with no sugar.
A profitable business
Its taste has been compared to “chalky cough syrup,” but astute marketing has cornered 90% of the market and made millions if not billions for the company and its CEO, Manoj Bhargava, a mysterious entrepreneur who avoids the limelight. His paper trail consists primarily of 90 lawsuits.
Possible harms
The company warns that users may experience an uncomfortable niacin flush, that it should be avoided by people with phenylketonuria (PKU), by women who are pregnant or nursing, and by children under 12; and that large amounts of caffeine can be problematic for some people. The 8,333% of RDA of vitamin B12 might seem alarming but is probably safe, since there is little or no toxicity from high doses of B12; but one wonders why they chose to put so much in the product.
There has already been one lawsuit alleging that the product triggered a heart attack and that without the deceptive label the victim would not have used it. The case was voluntarily dismissed. There is a case report of an adolescent experiencing his first-ever seizure after consuming 5-hour Energy. There’s another report of a woman who damaged her liver and ended up in the hospital because she exceeded the dose recommended on the label.
Does it work better than caffeine alone?
Consumer Reports reported on 5-hour Energy. They had access to an unpublished double-blind study furnished by the company. I couldn’t find that study, but I did find a study where they compared 5-hour Energy to the vehicle alone, and not surprisingly the mixture containing caffeine was superior to the version with no active ingredients. Of course caffeine works better than no caffeine; the question is whether 5-hour Energy works better than caffeine alone. As far as I could determine, that has never been tested. Consumer Reports concluded that:
5-Hour Energy will probably chase away grogginess at least as well as a cup of coffee.
I think they got it just about right.
What do the other ingredients do?
    • Their claims for B vitamins amount to vague support claims, like “niacin is important for energy production.” There is no evidence that B vitamins would increase energy levels unless the user was suffering from a clinically-significant B vitamin deficiency.
    • They claim that citicholine plays a role in neurotransmission and can help support brain function. Citicholine has been used for Alzheimer’s disease, dementia, head trauma, and thinking problems related to circulation problems in the brain, but there’s no evidence that it benefits healthy people who are tired.
    • They claim that tyrosine transmits nerve impulses to the brain. Yeah, so what?
    • They claim that phenylalanine enhances alertness, but I couldn’t find any studies in PubMed to support that claim.
    • They say that taurine plays a role in digestion and maintains the integrity of cell membranes. Yeah, so what?
    • For malic acid, they only say the body synthesizes it in the process of converting carbohydrates into energy. Yeah, so what?
    • They claim that glucuronolactone has been shown to reduce sleepiness, but the only study I could find tested it in an energy drink that also contained caffeine.
The majority of these claims had an asterisk to a footnote with the usual disclaimer: “* This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.”
How did they choose this mixture of ingredients?
I asked the company that question and did not get a response. There doesn’t seem to be any rationale for anything but the caffeine, and certainly no rationale for the specific amounts of each ingredient.
There is a small study suggesting that L-ornithine supplements might benefit people with physical fatigue, but that’s not in the 5-hour Energy formulation. Why not?
I can only guess that the formula was not created by rational design, but was brainstormed by non-scientists looking for anything they could add to caffeine that might impress the naïve consumer and help sell their product.
Why I’m not going to buy it
    • If you are getting tired during the day, instead of counteracting the fatigue with drugs it would be more useful to look for underlying causes: for instance, it might mean you are not getting enough sleep at night.
    • A nap or exercise might be a better choice than caffeine.
    • Coffee tastes good and the warmth is satisfying: I wouldn’t want to give up my pleasure. Sitting down with a cuppa to rest and change gears appeals far more to me than chugging a quick shot of an energy drink.
    • Coffee contains a lot of antioxidants and is thought to have health benefits that caffeine alone doesn’t. /li>
    • Just on general principles, it seems prudent to avoid high doses of unnecessary ingredients, especially when the particular mix of ingredients has never been properly tested for safety.
Why others might rationally choose to buy it
It’s a source of caffeine that is convenient to carry and to use and does not involve large amounts of liquid or calories. The other ingredients are unnecessary but probably not harmful. It costs less than a cup of Starbucks coffee.
“Try it for yourself”
I was urged to try it, but I’m going to pass. Trying something to see if it works for you sounds intuitively reasonable, but the history of science has taught us otherwise. Personal experience is often misleading and it contaminates our ability to judge something objectively.

Lies, fraud, conflicts of interest, and bogus science: The real Dr. Oz effect
Scott Gavura on January 29, 2015
Tweet

I thought I’d written my final post on the Dr. Oz-fueled green coffee bean extract (GCBE) diet supplement fad. But now there’s another appalling chapter, one that documents just how much contempt The Dr. Oz Show seems to show for its audience, and how little Dr. Oz seems to care about providing advice based on good science. This week it was revealed that the “naturopath” that Dr. Oz originally featured in his GCBE segment, Lindsey Duncan, didn’t disclose a direct conflict of interest when he spoke. After inaccurately describing the supplement’s effectiveness, he directed consumers, using keywords, to web sites that he owned or operated. The infamous “Dr. Oz Effect” worked, with Duncan selling $50 million in GCBE supplements in the following months and years. This week it was announced that Duncan and his companies have been fined $9 million by the Federal Trade Commission. The documentation released by the FTC [PDF] gives remarkable insight into how a scam to make millions was launched, and how the Dr. Oz Show is a platform for the routine promotion of dubious “experts” and worthless supplements.
The story of GCBE is really the story of Dr. Mehmet Oz, and his eponymous daytime television show. If you’re trying to sell a supplement, yet you don’t have actual scientific evidence to back up your claims, The Dr. Oz Show is your ticket to recognition and sales. No other show on television can top The Dr. Oz Show for the sheer magnitude of bad health advice it consistently offers, all while giving everything a veneer of credibility. Yet, this is a symbiotic relationship. Oz needs products that excite his audience. After all, everything is a “miracle” to Oz (He’s found 16 so far). The story of green coffee bean extract actually began in April, 2012, in a revealing email from the show to Duncan [PDF]:
“We are working on a segment about the weight loss benefits of green coffee bean and I was hoping that Lindsey Duncan might be available to be our expert. Has he studied green coffee bean at all? Would he be able to talk about how it works?” At that time, Duncan had no familiarity with the purported weight-loss benefits of GCBE, nor did Defendants sell GCBE. Nevertheless, within a few hours, a senior member of the Defendants’ public relations team replied: “Awesome! Thanks for reaching out, Dr. Lindsey does have knowledge of the Green Coffee Bean. He loves it!” Later that day, Defendants contacted a manufacturer of GCBE and, on or about the same day, submitted a wholesale order for GCBE raw material.
Note that the topic had already been decided upon before hand-picking the “expert” to profile it. Duncan was known to the producers, having promoted another supplement on the show before. Why Duncan? While he called himself “Dr. Lindsey Duncan”, Duncan has a naturopathy degree from the Clayton College of Natural Health, a school that the State of Texas considers a “fraudulent or substandard degree”, as it’s on a list that Texas maintains called “Institutions Whose Degrees Are Illegal To Use in Texas“. Not only is Duncan’s naturopathic degree shoddy, Texas doesn’t recognize the degree of Naturopathic Doctor at all. Despite this, Duncan lives in Texas and presented himself as “Dr. Lindsay” in the media repeatedly. Aside from the FTC prosecution, Duncan has also been prosecuted by the State of Texas [PDF] for Violations of Texas Education Code and for False, Misleading and Deceptive acts:
In addition to the use of the honorific “Dr.,” Mr. Duncan presents the appearance of a health practitioner, which he has done in television show appearances, media interviews, speaking engagements, and video promotions, by donning lab coats and making references to clinical experience and practice. Mr. Duncan’s acts and practices mislead the public into believing that he is disseminating health advice or knowledge, but such advice or knowledge is based on educational background and training which he does not have and when his underlying motivation is to sell products in which he has a financial interest.
Duncan and his companies have been selling supplements since at least 2010, and the FTC documents note how his marketing strategy has been directed at securing television appearances on programs like The Dr. Oz Show and The View. Duncan and his companies appeared to use a consistent approach:
Find a supplement to sell.
Get Duncan on television, pretending to be a health professional.
Have Duncan promote products in which he has a direct financial interest.
Do not disclose the conflict of interest.
Have Duncan describe how to find product on the internet, suggesting search terms he knows will direct traffic to his own website (e.g., “pure”).
Used pre-arranged search engine optimization (SEO) to drive internet searches to his own website.
Buy Google AdWords advertisements to capture even more traffic.
Profit.
The FTC documentation gives a “behind the scenes” perspective of The Dr. Oz Show. When the show’s producers contacted Duncan about GCBE, they did no work to independently verify he had any credible expertise or education that might suggest he would be an appropriate guest to provide medical advice. They did not appear to ask if he had any conflicts of interest. It seems they simply decided he would be their “expert”. The producers and Duncan then actively collaborated on the segment’s script. Duncan edited the script to ensure he could subtly verbally promote the brands in which he had direct financial interest. To do so, he emphasized that viewers should look for “pure” GCBE online which was a keyword he’d linked with his own brand. He emphasized that consumers should buy 400mg capsules, the type his company sold. Subsequent to the taping, the producers went one further, asking Duncan which web sites he recommended. He recommended his own, without disclosing his relationship with those companies. He then set up several fake websites that all linked to his own sites, with the intention of boosting his Google ranking to the top.
Duncan went even further. He contacted Walmart with “extremely confidential” information, offering to sell them GCBE based on the expected Dr. Oz effect. He also tried to buy up a large supply of the raw GCBE material, apparently with the intention of reselling it after the expected surge in interest.
Normally, I don’t recommend weight loss supplements, especially weight loss supplements that claim “easy weight loss” or “fast weight loss,” but the Green Coffee Bean has truly amazed me.
– Not-a-Doctor Lindsey Duncan on The Dr. Oz Show, broadcast April 26, 2012.
Duncan’s strategy worked. The episode was first broadcast on April 26, 2012. It’s worth watching again. Sales surged.
The real shame of the entire GCBE saga is that the signs it was bogus were always available. After Duncan’s first appearance on Dr. Oz, I reviewed the study itself, and concluded it looked questionable. The trial was small, not properly blinded, poorly written and didn’t pass the sniff test for credible research. The findings were suspicious, with participants losing as much weight on the placebo as the drug. There was no information presented to confirm it was a safe product. Anyone on Oz’s staff that spent an hour actually reading and understanding the paper should have seen there were serious problems with its credibility. The claims and statements made by both Duncan and Oz were outlandish, with the entire episode triggering most of the Federal Trade Commission’s “red flags” in advertisements for worthless products. And all of this was well before the investigation that subsequently determined that the entire study was fraudulent, prosecuted by the FTC, and subsequently, retracted. These investigators were so incompetent, they couldn’t even fake data convincingly. The FTC has now concluded that Duncan ought to have known the trial and its conclusions were questionable:
The defendants’ representations that GCBE would cause rapid and substantial weight loss without diet or exercise had no scientific support. The study the defendants continually referenced in their advertising, even absent Duncan’s mischaracterizations of it, suffered from serious facial flaws that should have been evident to the defendants. Accordingly, our complaint alleges that the defendants’ efficacy claims were false or unsubstantiated, and that their clinical proof claim was false. The proposed order approved by the Commission includes appropriately strong injunctive relief and requires the defendants to pay $9 million in equitable monetary relief.
– FTC statement
It’s worth noting the extent of the hoax that Duncan perpetuated after the show was broadcast. The other spokepeople for Duncan’s products that appeared on television and radio? They were paid, often without disclosing a conflict of interest. The online reviews from “ordinary consumers” on Amazon.com? Also paid for by Duncan and his companies. The video testimonials on his websites? Those were his employees. It was all a carefully-orchestrated facade to drive sales of his own products.
I actually do personally believe in the items I talk about on the show. I passionately study them. I recognize that oftentimes they don’t have the scientific muster to present as fact. Nevertheless, I would give my audience the same advice I give my family, and I have given my family these products.
– Dr. Mehmet Oz Senate subcommittee testimony, June 17, 2014 (Emphasis added)
The green coffee bean extract saga didn’t end there. Each time Dr. Oz revisited the topic, even without Duncan on the show, Duncan’s sales spiked. In 2013, Oz discussed GCBE on his show again. This time, the bad science was all on Oz’s hands. Oz conducted a clinical trial on his audience, without obtaining IRB (research ethics) approval. 50 women were randomized to the supplement or placebo for two weeks. Not surprisingly, there were no substantive effects found: The GCB group lost about 2 pounds, and the control group lost about 1 pound. Without any detailed statistics being presented, it was impossible for anyone to evaluate the Oz “research”.
The next nail in the GCBE coffin came in 2014. Dr. Oz appeared at Senate subcommittee hearing where he was verbally eviscerated for his promotion of GCBE and other weight loss products, in the face of no credible evidence. That same year, the FTC announced it was suing a Florida-based company (Applied Food Sciences) for its promotion of Green Coffee Antioxidant (GCA), a supplement containing GCBE. In September, the FTC announced it had a deal and settlement from Applied Food Sciences (AFS) and it was a bombshell. Not only was the advertising misleading, but the trial itself was fraudulent:
The FTC charges that the study’s lead investigator repeatedly altered the weights and other key measurements of the subjects, changed the length of the trial, and misstated which subjects were taking the placebo or GCA during the trial. When the lead investigator was unable to get the study published, the FTC says that AFS hired researchers Joe Vinson and Bryan Burnham at the University of Scranton to rewrite it. Despite receiving conflicting data, Vinson, Burnham, and AFS never verified the authenticity of the information used in the study, according to the complaint.
Despite the study’s flaws, AFS used it to falsely claim that GCA caused consumers to lose 17.7 pounds, 10.5 percent of body weight, and 16 percent of body fat with or without diet and exercise, in 22 weeks, the complaint alleges.
Although AFS played no part in featuring its study on The Dr. Oz Show, it took advantage of the publicity afterwards by issuing a press release highlighting the show. The release claimed that study subjects lost weight “without diet or exercise,” even though subjects in the study were instructed to restrict their diet and increase their exercise, the FTC contends.
Now, with the Duncan settlement, the GCBE saga seems to be complete.
Conclusion
Green coffee bean extract would be a fringe supplement today if it weren’t for the “Dr. Oz Effect” and a supplement seller that knew exactly how to exploit it. We’ve seen this story before. Shoddy science, a bogus product, a conflicted seller and unrealistic claims of efficacy. Oz and his show were either oblivious to the facts, or indifferent to them. At no time did Oz appear take his responsibility as a medical doctor seriously. While Duncan and his companies have been fined, it’s clear that the Dr. Oz show played a big part in this enormous, yet avoidable, weight loss scam.

Kombucha: A symbiotic mix of yeast, bacteria and the naturalistic fallacy
Scott Gavura on June 6, 2013
Link
If you grew up in the seventies, you may remember the same food fads as I do. There was the oat bran buzz that was replaced by the wheat germ movement, the family fondue set and the homemade yogurt maker. And for a while I remember my father making what I called “aquarium water” – a foul-looking jug sitting on the kitchen counter with a gelatinous white mass floating on top. Despite the assurances it was good for me, I declined the taste tests. They didn’t push it and I never volunteered to drink this “cure all”. I thought kombucha had gone the way of gelatin-based salads and entrees, until a friend told me she was drinking it. Not only is it still a home-brew darling, kombucha isn’t just for hippies: There’s probably some for sale at your local organic grocery. Yet after a bit of digging, kombucha culture still seems mired in the 1970s. It’s still touted as a panacea, and it’s still one of the more questionable folk remedies out there.
I understand the intrinsic appeal of the folk remedy. In an era where we can buy everything we possibly need, there’s something meaningful and satisfying about making your own food from scratch. I prefer bread, particularly sourdough – but I’m not making any health claims. Like food recipes, some home remedies are handed down from generation to generation, or passed on by word-of mouth. The attractiveness is both an appeal to antiquity combined with pattern-seeking and anecdotes. We remember the “hits” of those home remedies but not the misses. And we never test causality. Is it possible that kombucha could have medicinal effects? Sure. Beer and wine didn’t come out of a medicinal chemistry laboratory either – and look how helpful those fermented products are. As a fan of beer, cheese, sauerkraut, and yogurt, I’m strongly pro-fermentation. So while we can’t make Tylenol in our bathtub, or grow our own antibiotics, how about an odd-flavoured tea-based beverage filled with the magical healing properties of yeast and bacteria? I’m told it’s all about the microbiome, so perhaps they were on to something in the 1970s. Authentic and artisanal is where it’s at today, and what could be more artisanal than home fermentation of a remedy?
What is kombucha?
As with most folk remedies there are multiple claims for kombucha’s ancestry, from the Ukraine to Asia, from “millennia ago” to a few hundred years ago. However or whenever it occurred, the recipe is similar. Kombucha is sweetened black tea fermented by a mixture of yeasts and bacteria that form what looks like a “mat” on the surface. Sometimes called a symbiotic colony of bacteria and yeast (SCOBY), the “mushroom” or simply the “mother”, this “zoogleal mat” ferments the sugar, producing alcohol, vinegar, and other by-products. To get started, you need to obtain a starter mat – you can order them online, or ask someone that already grows their own. The result of fermenting on your counter is exactly what I remember growing in our kitchen, though it actually looks more brackish than I remember. After fermentation it’s lightly carbonated. Taste reports of kombucha vary from “refreshing apple cider” to “vomit”.
Like other folk remedies, kombucha’s efficacy is apparently legion. HIV, aging, hair growth, gout, diabetes, hemorrhoids, memory loss, PMS, cancer, hypertension, and the perennial “boosting” the immune system are no match for the healing and restorative power of kombucha.
What is that growing on and in my drink?
Several researchers have examined the bacteria and yeast in the kombucha mat. Content can vary considerably, based on the geography, climate, and local bacteria and yeasts. Bacteria include Bacterium xylinum, Bacterium gluconium, Acetobacter hetogenum, Pichia fermentons. Sometimes antibiotic-producing bacteria like Penicillium species can be detected. And then there’s the toxic bacteria that has been detected, such as Bacillus anthracis – anthrax. Yeasts include Schizosaccharomyces pombe, Torulaspora delbrueckii and Zygosaccharomyces bailii. Contamination with Aspergillus fungus has also been reported, as well as Candida. Yes, that fungus that’s poisoning us all (according to alternative medicine proponents). Various Candida species including C. albicans, C. kefyr, and C. krusei are also found in kombucha.

The final ingredients vary with the bacteria and yeast in the mat, as well as the extent to which fermentation has taken place. Analyses have identified small amounts of alcohol (usually under 0.5%), substantial acetic acid (vinegar), ethyl acetate, glucoronic acid, and lactic acid. There’s some residual sugar, depending on how long it’s been fermenting. Caffeine is still present and may be responsible for some of the energy claims. It’s claimed to contain B vitamins, though I could locate no reliable source to confirm this.
The evidence
Despite the hundreds of thousands of posts on kombucha praising its medicinal and health effects, I was unable to identify a single clinical trial for any specific use. There’s a systematic review by Edzard Ernst dating to 2003 that also failed to find any clinical trials or even case series that suggest kombucha has medically beneficial uses. So there is no evidence to demonstrate or even hint at efficacy. Based on what’s known about the active ingredients, there’s no reason to expect it would offer any medicinal effects other than the consequence of low levels of alcohol or caffeine.
The toxicity
Given this is usually a home-brew concoction, there is the significant risk of contamination. In contrast to the lack of benefit, there is good documentation of the potential for harms associated with kombucha:
    • an alcoholic developed jaundice after two weeks, which resolved after discontinuation
    • dizziness, nausea and vomiting that resolved with discontinuation and restarted with rechallenge
    • toxic hepatitis that resolved with discontinuation
    • metabolic acidosis and disseminated intravascular coagulopathy, resulting in subsequent cardiac arrest and death
    • metabolic acidosis, cardiac arrest (with recovery)
    • anthrax infections of the skin through topical application of kombucha
    • lactic acidosis and acute renal failure
    • lead poisoning secondary to making it in a ceramic pot
Given the potential for kombucha to grow potentially dangerous pathogens, it’s particularly important for those with compromised immune systems to avoid the product. Given the risks, pregnant or lactating women should avoid kombucha as well.
Kombucha sells out
Kombucha isn’t limited to the home brewer anymore, there are several commercial suppliers such as Synergy (touted by Dr. Oz, of course) and the requisite story of the breast cancer survivor who credits kombucha for her health (but not the chemo and radiation she also accepted). The claims come fast and furious: the fermented liquid heals all and cures all – digestion, immune system “boosting”, amino acids that “detoxify”. You can now find it combined with different juices and flavors, for those that don’t like the taste of the original. The recipes are the same, and the final products are not pasteurized, a situation that caused products to be pulled in the United States until producers found ways to stop the alcohol from exceeding 0.5%.
The bottom line
    • The best that can be said about kombucha is that it probably won’t kill you. There are no documented health benefits, so unless you really like the taste, there’s no clear reason to consume it. As I have written before, health decisions should be based on an evaluation of the risks and benefits. In the case of kombucha, the benefits, other than the subjective, are unsubstantiated. The risks are real, but also rare. So if that bet still looks attractive, kombucha may be for you. To each his own fermentation. As for me, I’ll stick with my own favourite fermentations: IPA and wheat beer, and pass on the moonshine panacea.

Kratom – An Emerging Herbal Drug
Kratom is an emerging herbal drug used for pain and fatigue but also has abuse potential. What is the current state of the science?
Steven Novella on August 29, 2018
Link

You may never have heard about kratom (though if you’re a regular reader, you probably have), but there is already a thriving market for this Southeast Asian herb, and groups dedicated to the business of selling kratom. Kratom has also come onto the radar of the FDA and DEA, who would like to regulate it (it currently is essentially unregulated, except as a supplement). This has sparked a controversy over whether and how kratom should be regulated, fueled partly by a lack of clear scientific studies.
So let’s take a close look at what we currently know about kratom.
Mitragyna speciose is a tropical evergreen tree in the coffee family native to Southeast Asia. It produces alkaloid chemicals, mitragynine and 7-hydroxymitragynine (7-HMG), among other compounds. The leaves are traditionally consumed either raw or as a tea, but they can also be smoked, or concentrated into capsules or liquid. The local name for the leaves is kratom or biak. Kratom is used for fatigue, as a pain reliever, and a mood enhancer.
It has been known since 1996 that kratom has opioid effects – mitragynine binds at opioid receptors, which means it has at least some of the effects of opioid drugs like morphine. This is part of the controversy, as the FDA is using this fact as justification for tighter regulation. It is true, however, that mitragynine likely binds only weakly to the opioid receptors, and perhaps to only a subset of receptors. 
Mitragynine had > 2- or ~ 16-fold greater affinity for the mu opioid receptor than, respectively, for kappa or delta opioid receptors. Its affinity for the mu receptor was ~ 200-fold less than that for morphine.
This suggests that mitragynine might have less addictive potential than other opiates such as morphine, and may have fewer side effects. However, it may also have less potent benefits as well, which could mean a higher dose is necessary to achieve desired analgesia, which would also increase risks and side effects. This needs to be sorted out in human trials, but that data is limited. A 2017 review of published studies found:
Data analysis suggested that kratom possesses some benefits such as stimulant and sedative effects as wells as antinociceptive effects. It seems to inhibit pro-inflammatory mediator release and vascular permeability and can enhance immunity. In addition, it may be an antidepressant and anorectic. However, kratom can cause intrahepatic cholestasis, seizure, arrhythmia, impair [sic] memory function, coma, and death. Psychological manifestations described are euphoria and feeling relaxed to severe symptoms such as aggression, hostility, and psychosis. Medical manifestations described are polyuria, dry mouth, vomiting, and jerky movements.
There are also case reports of addiction and withdrawl from kratom use.
Of particular concern is the potential for liver toxicity from chronic use. This is often a toxicity that kills drugs in the development stage. Since kratom is being touted specifically for chronic pain, and as an opiate substitute for this, we need to look carefully at chronic toxicity. This may not be easily apparent to users, and the absolute risk might be low, but as kratom use increases cases of liver toxicity will increase proportionally. This is exactly why we conduct toxicity studies before allowing a drug to be sold to thousands or millions of users.
Proponents of kratom often cite its safe traditional use as an argument against regulation (and it is not a good one), but because it is a psychoactive drug it has the potential to be used, and is being used by some, to get a legal high. It produces opiate-like effects of euphoria at high doses, and can also cause similar psychological side effects, like hallucinations. Essentially, traditional use raw or as a tea generally involves low doses, and this does not mean kratom is safe at the higher doses that are likely if it is used as a recreational drug. Traditional use outside of scientific studies is also very poor at detecting statistical risks or long term toxicity, like liver toxicity.
What about the potential for fatal overdose? The FDA’s statements on kratom have emphasized and updated their reports of acute overdose leading to death. These are essentially any death where mitragynine was found in the toxicology. It is not clear in most cases what role the mitragynine played in the death, however in some of the cases mitragynine was the only substance found. The most recent count is 40 deaths associated with kratom (again, not necessarily caused by kratom use).
It is the FDA’s job to protect the public from harmful drugs, so their concerns are understandable. At the other end of the spectrum the Kratom Association denies any overdose or death potential, and that does not make sense or square with the evidence either. At the current time the evidence supports the conclusion that there is overdose potential from kratom, but further study is necessary to evaluate what that potential is. There may be important drug-drug interactions, for example, or susceptible populations due to concurrent illness that need to be discovered.
Animal studies have found that mitragynine at high doses can cause respiratory suppression, but this potential seems to be much less than for morphine or other opiates. Respiratory depression has not been reported clinically in humans, however. One recent review of this and overall kratom safety concluded that there simply is not enough data to reach any firm conclusions.
So where do we stand?
Kratom and its constituents, mitragynine, 7-hydroxymitragynine, and others, should be considered a serious drug. The fact that it is derived from a plant and has a long history of traditional use is irrelevant. The exact same thing can be said of opium. Mitragynine is a drug that acts in the brain with a wide range of effects, related to opioid receptors and other receptors as well, such as monoamine receptors. Kratom components are also Cox-2 inhibitors, which means it has aspirin-like effects.
Drugs have different effects at different doses, some of which are potentially exploitable for benefit, while others are negative side effects. Drugs also have the potential for toxicity, drug-drug interactions, and in this case for addiction, abuse, and withdrawal. There is no reason not to go through the normal process of drug development, identifying active ingredients, studying them, and making a full assessment of their risks and benefits. Often naturally derived chemicals are tweaked to improve their pharmacological profile.
It seems that kratom has a great deal of potential as a source of new drugs. However, so far it seems that the constituents of kratom work through known receptors and pathways. Still, it may have an opiate receptor activity profile that is potentially superior to other opiates in terms of the balance of beneficial effects to harmful side effects.
I do not think that kratom should be classified as schedule 1, which the FDA and DEA did try to do two years ago, but had to back off due to public and political backlash. Schedule 1 is for substances with abuse potential but no legitimate medical use. The problem with this categorization is that it will frustrate scientific investigation, and that is exactly what we need right now.
It may be too late because it is already widely available as an herbal supplement, but kratom should be considered an investigational new drug, and properly scientifically studied. We desperately need more options in treating pain, especially chronic pain, and any addition to our toolkit is extremely welcome.
It would be extremely unfortunate if, rather, kratom continues to develop as an unregulated supplement. That will also impede scientific study, and likely result in unnecessary harm. As the market increases, so will more concentrated and potent forms of the drug, and along with it the abuse potential, toxicity, risk of overdose, and side effects. These markets also promote themselves through anti-establishment conspiracy mongering that harms the entire system.
I understand that there are people currently using reasonable doses of kratom to manage their own chronic pain, and I would not take that away from them. But perhaps they can continue to access a regulated form of kratom, under proper medical supervision, while studies are ongoing. This is not an appropriate drug for the street, however.
In the end the only long term solution is to do the science. We need quality clinical trials to flesh out the risks and benefits.

POM: Not So Wonderful
Jann Bellamy on May 31, 2012
Link
“POM Wonderful” is a brand of pomegranate juice. It is manufactured by a company owned by Linda and Stewart Resnick, California billionaires who pretty much single-handedly created a multi-million dollar market for pomegranate juice where none existed before. Or, as LA Times columnist Michael Hilzik wrote,
It has long been clear that the most wonderful thing about Pom Wonderful pomegranate juice is the spectacular marketing skill that persuades consumers to fork over their hard-earned cash for a liquid that sells for five to six times the price of, oh, cranberry juice.
He’s right about the expense: a daily 8 oz. dose of POM Wonderful juice costs about $780 annually according to a recent Federal Trade Commission case, which we’ll get to soon.
The Resnicks parlayed their success selling pomegranate juice into two additional products, both dietary supplements, in the form of POMx pills and POMx liquid. The Resnicks and their companies have shelled out $35 million in sponsored research to determine what health benefits might arise from ingesting pomegranate juice or its components, research they have not been shy about using in touting their products. The couple apparently has a flair for taking the mundane and making it appear, well, wonderful to the consumer – they also own Fiji Water and the Franklin Mint, among other business interests.
In 2010, the Federal Trade Commission (FTC) filed a complaint against Resnicks, one of their business partners, and two of their companies (which I’ll refer to collectively as “POM”), alleging unfair and deceptive trade practices. POM, according to the FTC complaint, made false and misleading claims that its POM products treat, prevent, and reduce the risk of heart disease, prostate cancer and erectile dysfunction.
An Administrative Law Judge (ALJ) agreed with the FTC and on May 17, 2012, issued a 335-page decision and cease and desist order, ruling POM lacked competent and reliable scientific evidence that drinking 8 ounces of POM Wonderful Juice daily, or taking one POMx pill, or one teaspoon of POMx liquid, treats, prevents or reduces the risk of heart disease, prostate cancer, or erectile dysfunction. In the Matter of POM Wonderful, LLC, et al., F.T.C. No. 9344 (May 17, 2012).

Battle of the Experts No. 1: What Consumers Think
POM denies it ever made such claims, but the FTC argued otherwise and the ALJ agreed with the FTC. In fact, it is undisputed that none of the ads under scrutiny expressly makes the contested claims. But the only legally relevant question is whether “consumers, acting reasonably under the circumstances, would interpret the advertisement to contain that message.”
Because a finding of deceptive trade practices necessarily looks at whether the advertisements are likely to affect consumers’ conduct or decision to purchase, consumer surveys, with accompanying expert testimony, were presented by both sides. These surveys show just how impressed consumers were by POM Wonderful’s claims. In a survey of POM juice drinkers, 91% said it “contains naturally occurring antioxidants,” 57% said it “promotes heart health,” 47% of men said it “helps protect against prostate cancer,” 45% said it “provides immunity from colds and flu,” and 43% said it “helps protect against other cancers (besides prostate).” These supposed benefits are important to consumers. In another survey of pomegranate juice drinkers, consumers ranked cardiovascular health as the first or second most important health benefit. The number two choice for men was “prostate.”
As noted, POM’s ads did not come out and flatly state that POM could prevent, treat or reduce the risk of disease. Rather POM implied this by giving the consumer information which would lead at least some consumers to come to that conclusion on their own. For example, the ALJ found that POM made claims about the effectiveness of POM products in treating, preventing or reducing the risk of heart disease
indirectly and obliquely, typically by presenting, through words and images, a logical syllogism that: free radicals cause or contribute to heart disease; the POM Products contain antioxidants that neutralize free radicals; and, therefore, the POM Products are effective for heart disease.
The ALJ found POM used a similar approach in its prostate cancer claims:
These advertisements typically communicate the claim by juxtaposing statements and representations that prostate cancer is a leading cause of death in men; antioxidants, such as those provided by the POM Products, may help prevent cancer; that PSA is an indicator of prostate cancer; that PSA doubling time is an indicator of prostate cancer progression; and that the POM Products have been shown in clinical testing to slow PSA doubling time.
In the erectile dysfunction ads, the claims are more direct. For example, POM ads claimed
    • Powerful antioxidants in the POM products enhance the actions of nitric oxide in vascular endothelial cells, showing potential for management of erectile dysfunction.
    • A preliminary study of “erectile function” showed that men who consumed POM Juice reported “a 50% greater likelihood of improved erections,” as compared to a placebo.
    • A pilot study involving 61 male subjects showed that men drinking 8 ounces of POM Juice daily for 4 weeks were “50% more likely to experience improved erections.”
In the dry language which often accompanies legal reasoning, the ALJ notes that as “Dr. Butters [one of POM’s expert witnesses on ad interpretation] acknowledged, contemporary speakers of American English could interpret the phrase ‘erectile function’ to relate to the ability of men to achieve and maintain erections. Erectile function and the absence of erectile dysfunction are closely related.” I suppose that in the field of expert witnesses, as in so much of modern life, areas of expertise are becoming more and more specialized. But I digress.
Battle of the Experts No. 2: Level of Substantiation Required
In determining whether POM’s ads were misleading or deceptive, a key issue was the level of substantiation required for a particular health claim, a decision controlled by five factors: the product involved, the type of claim, the benefits of a truthful claim, the ease of developing substantiation for the claim and – a big issue in this case – the amount of substantiation experts in the field would agree is reasonable. Needless to say, the experts in this case did not agree except in the most general sense: that “competent and reliable scientific evidence” was the appropriate standard for substantiation. Exactly what constituted “competent and reliable scientific evidence” was hotly disputed.
The ALJ decided that double-blind, placebo controlled randomized clinical trials were not required in this particular instance to substantiate POM’s claims that its products treated, prevented, or reduced the risk of serious diseases like heart disease and prostate cancer. In this, the ALJ accepted the testimony of POM’s experts, including Dr. Dean Ornish, that RCTs were not required. However, for each of the three diseases in question in this case – heart disease, prostate cancer and erectile dysfunction – the ALJ determined that clinical trials, even if not RCTs, were required for each of POM’s claims.
Battle of the Experts No. 3: Evidence (vel non) of Effectiveness
The case then boiled down to another battle of the experts over whether POM’s disease claims indeed met the competent and reliable scientific evidence test. This included conflicting testimony over underpowered trials, endpoints chosen, valid surrogates for improvement in condition, and other matters which I am incompetent to evaluate and discuss. ( You should feel free, however.) In each case, POM fell short of the mark. Even Dr. Dean Ornish himself couldn’t overcome the lack of “competent and reliable scientific evidence” for ability of fruit juice to treat, prevent or reduce the risk of cardiovascular disease.
On the other hand, the ALJ ruled claims that POM Wonderful can “support prostate health” and “support erectile health” (whatever the heck those terms mean) were supported by competent, reliable scientific evidence.
“Cease and Desist” Order
Because of the seriousness and deliberateness of POM’s violations, the ALJ’s cease and desist order, based on his findings of fact and conclusions of law, covers not only the three pomegranate juice products, but “any food, drug, or dietary supplement” made by the manufacturer of POM products and several related companies for the next twenty years.
In the future, POM and the related companies must have competent and reliable scientific evidence to support both treatment, prevention or risk reduction claims, as well as general claims about the health benefits, performance, and efficacy of their products. This evidence must meet generally accepted standards in the relevant scientific field AND must be viewed in light of the entire body of relevant and reliable scientific evidence. (In other words, no cherry-picking allowed.) POM and related companies, as well as the Resnicks and a business partner [“Respondents”],
shall not make any representation in any manner, expressly or by implication, . . . that such product is effective in the diagnosis ,cure, mitigation, treatment, or prevention of any disease; . . . unless, at the time it is made, the representation is non-misleading and Respondents possessed and relied upon competent and reliable scientific evidence that is sufficient in quality and quantity based on standards generally accepted in the relevant scientific fields, when considered in light of the entire body of relevant and reliable scientific evidence, to substantiate that the representation is true.
“Competent and reliable scientific evidence” means
tests, analyses, research, or studies, conducted and evaluated in an objective manner by persons qualified to do so, using procedures generally accepted in the profession to yield accurate and reliable results.
The same prohibition applies to representations regarding the health benefits, performance or efficacy of any product covered by the order. The Respondents are further prohibited from misrepresenting, “in any manner, expressly or by implication, . . . the existence, contents , validity, results, conclusions, or interpretations of any test, study, or research.”
Response to the Order
The supplement industry put a positive spin on the decision. It found comfort in the fact that the ALJ did not require randomized double blind placebo controlled clinical trials in order to make claims for health benefits as well as refusing to require FDA approval of all future health claims, both of which the FTC sought to impose.
Several aspects of the ALJ’s ruling might cause the supplement industry to temper its enthusiasm for this decision. First, the ALJ did not say that double blind, placebo controlled RCTs would never be required for a supplement or food product making a health claim, and, in fact, case law cited in the decision makes it clear that this possibility remains open. What the ALJ did say is that where, as was true of the POM products, there was scientific evidence that these products were very safe and where there was no claim that they were a substitute for medical care, a lesser standard would suffice. In a future case, where safety is not as clear or a suggestion that the product is a substitute for medical care is made, the possibility of requiring a more stringent level of evidence remains.
Second, not requiring an RCT does not mean anything flies. The ALJ decided that claims for treatment, prevention and risk reduction of disease require “a heightened level of substantiation,” which the ALJ determined would be “competent and substantial evidence” based the standards generally accepted in the relevant scientific community. In other words, whether “competent and substantial evidence” supports a claim must be determined case by case and based on what experts in the particular field would regard as such. Again, this leaves open the possibility that in another case expert testimony could support a finding that one or more RTCs would be required to make a particular claim.
And POM’s response?
A random quote from the decision plucked out of context and run in ads like this:
And this:
According to the New York Times, a POM spokesman said “the company would run the new ads ‘as long as necessary to inform the public of the truth,’” but “declined to disclose the budget for them.” I know you are as relieved as I am that we consumers will be informed of “the truth.” Interestingly, in 2009 the UK Advertising Standards Authority ruled that a POM Wonderful ad displaying a cut hangman’s noose and the phrase “Cheat Death” was misleading and could not be used again.
Even a column in the usually business-friendly Forbes magazine found POM’s response “disturbing,” and went on to excoriate DSHEA as anti-consumer. That opinion was not universally shared.
Even if POM didn’t literally ‘win’ the case, consumer psychologist Kit Yarrlow calls its ad campaign ‘a sophisticated move.’ ‘Consumers are ready to battle, love to champion underdogs and consider the government to be a big ugly Goliath,’ says Yarrow, a Golden Gate University marketing professor.
We’ll wait and see.
Any of the parties can appeal the decision to the full Federal Trade Commission or the Commission can choose to review the decision on its own. According to the Canadian newspaper, The Star, a POM spokesperson said POM would appeal. No matter what the full Federal Trade Commission decides, that decision may not, and likely won’t, be the end of things. Any party can appeal the full Commission’s decision to a federal appellate court. Because of the stakes, I imagine this case will be around for a few more years.
Conclusion
The complaint in this case was filed in 2010. The administrative hearing began on May 24, 2011 and concluded on November 4, 2011. Twenty four witnesses, including 14 expert witnesses, testified. There were nearly 2000 exhibits and the transcript ran almost 3300 pages. All in all, I imagine this case cost hundreds of thousands of dollars to prosecute and defend. In fact, I wouldn’t be surprised if the total price tag is over $1 million. And it’s still not over.
This cat and mouse game between the food and supplement industry on the one hand, and government regulators on the other, is not in the best interest of anyone, least of all the consumer. Congress could fairly easily enact a law that would provide clear guidelines on the level of evidence which should be required to make a health claim for a product in a manner that is understood by consumers and backed by good science. While regulatory agencies such as the FDA and FTC can issue regulations and guidelines governing health claims, these are subject to challenges as well, ending in more litigation. Unfortunately, Congress is in the thrall of industry, as is evidenced by DSHEA. This means that litigation will continue to define the parameters of permissible claims, case by case. The cat and mouse will continue to play, and the lawyers and experts will continue to profit.

Teenager? Anxious? Yes, there’s a supplement for that, too.
Health Canada has criticized the marketing of an “anxiety supplement” for teens, without recognizing the larger problem involved; the poor regulations and lack of safety and efficacy data for this, and many other supplements sold.
Scott Gavura on October 3, 2019
Link

While health regulations are seemingly created to protect consumers, governments may prioritize a company’s desire to sell a product, over a consumer’s right to a marketplace with safe, effective products. Nowhere is this more the case than in Canada and the United States, where similar regulatory approaches have led to enormous boom in the supplement industry, but also a confusing marketplace for consumers where there is often little evidence to suggest that a given supplement might work.
While the FDA is forced to take a largely “hands off” approach to supplement regulation, as has been described in past posts, Canada took the opposite approach and licenses and approves dietary supplements. While this might be expected to improve the safety and quality of supplements, the opposite has been the case. Owing to a different, and much lower evidence standard, Health Canada has approved hundreds of “natural health products” including placebos like homeopathy which are deemed “safe and effective”. Health Canada will even allow references to homeopathy textbooks written in the 1800s as “evidence” of a product’s efficacy. Unlike drug products, there is no requirement for licensed supplements, termed “natural health products” to be actually tested in clinical trials.
Health Canada’s regulatory scheme has come into criticism again because it recently approved a supplement for teenagers, called Veeva Teen, which is being marketed as a treatment for anxiety. The CBC notes:
A new natural health product aimed at teens may be marketing itself as a treatment for anxiety, counter to Health Canada guidelines.
The federal department is investigating the advertising for Veeva Teen, an herbal supplement it approved for sale in April to treat “nervousness and/or restlessness.” Under Health Canada rules the product cannot be marketed as a treatment for anxiety.
Veeva Teen’s promotional materials claim it is the first product of its kind for teens that’s licensed by Health Canada “for the relief of nervousness and agitation due to mental stress … all without any scary side-effects.”
The product’s website had said, “Veeva Teen has been professionally formulated as a powerful blend of botanicals, minerals and vitamins to help teens suffering from anxiety.” The word “anxiety” was removed some time after 6 ET on Friday, and one day after CBC News spoke with Veeva’s founder.
The product is approved for nervousness/stress but not for anxiety. Confused? It’s a consequence of Health Canada’s regulatory scheme and the confusing way they try to apply standards to these products.
Is there anything Health Canada won’t approve?
Health Canada’s absurdly low evidence standard was elegantly demonstrated by the television show CBC Marketplace back in 2015. They decided to test Health Canada’s own licensing process. They applied for approval to market a homeopathic remedy they named “Nighton” (an anagram of “nothing”) to be used to treat fever and pain in infants and children. For evidence, they submitted a few pages photocopied from an old homeopathy textbook. No trials were conducted and no safety data was provided. Just some forms, a few photocopies and a fee. Without any questions, their product was approved and licensed as a “natural health product”, and for a time, was listed in the national database of health products Health Canada declared were “safe, effective, and of high quality.”
In the case of Veeva Teen, Health Canada is defending its approval, but stating that problem is the marketing – not the fact that they have approved a supplement for teenagers:
In an email to CBC News, Health Canada said it “approved specific claims for this product, including ‘to help relieve nervousness and/or restlessness’ but not to help relieve anxiety.”
It said it is looking into Veeva Teen and will ask the company to take corrective action if it finds any non-compliance.
So let’s take a closer look at Veeva Teen, the ingredients, and the evidence.
What’s in Veeva Teen?
The manufacturer makes specific statements about each ingredient which I’ve quoted below from this table. To check the evidence, I consulted the Natural Medicines Database, a widely-used reference on natural products.
Linden 750mg – “Nervousness”
There is no published evidence establishing the efficacy of linden for any use.
Passionflower 200mg – “Agitation/restlessness”
Considered “possibly safe” when used orally and short-term. For anxiety it is considered “possibly effective” at a dose of passionflower extract 400mg twice daily, based on this trial which I couldn’t track down. There is no information in the abstract to suggest it has been studied in teenagers.
Lemon balm 200mg – “Mental stress”
Considered “possibly safe” when used orally. For anxiety it is considered “possibly effective’ based mainly on this trial, which was a 15-day, open-label evaluation on “stressed volunteers”.
Magnesium 50mg – Physical relaxation, (muscles), fatigue
Magnesium is safe when used orally at low doses. There is no published information to suggest that magnesium supplements can help with fatigue or physical relaxation, especially in the absence of any deficiency.
Zinc 5mg – “Hair, skin, nails, immunity”
Zinc is safe to take at this low dose. There is no evidence that zinc supplementation will help with hair, skin, nails or immunity as a supplement or in the absence of any deficiency.
Vitamin D3 500IU – “Mood, bones, teeth”
Vitamin D is safe for teenagers at this dose. It is effective for treating vitamin D deficiency. There is some evidence of vitamin D deficiency in the pediatric age range. Vitamin D deficiency may manifest in mood disorders.
Vitamin B6 25mg – “Energy, fatigue”
Vitamin B6 supplements effectively treat B6 deficiency, which is rare. There is no proven benefit in the absence of deficiency. The recommended dietary allowance (RDA) for teenagers is 1mg-1.3mg, so why such a large dose is in this supplement is unclear.
Vitamin B12 500mcg – “Tiredness, immunity”
Deficiency of B12 is rare in those that eat a varied diet. Strict vegans/vegetarians, for example, need supplemental B12. Routine supplementation is otherwise unnecessary.
The bottom line here is neatly summarized by 16-year-old teenager and mental health advocate Erin Kendall whose criticisms are quoted by the CBC:
Kendal has been on prescription medication since she was 13 and says she worries that there haven’t been any clinical trials to support Veeva Teen’s claims — something Health Canada does not require for natural health products.
Kendal is also concerned there isn’t enough information about the scientific basis for the product’s claims, or about how it may interact with other medications.
And:
Kendal thinks most teens won’t be able to distinguish between anxiety and the symptoms Veeva Teen says it can help.
“What I don’t love is that it does seem to be promoted as almost like a magic drug fix,” Kendal said.
Kendall seems to have more sense than Health Canada in recognizing that marketing an untested, unproven product to address mental health issues to teenagers is a problem. Casually marketing a supplement as a treatment for mental health may not only send the wrong message about the use of supplements and medicines, it could also lead to delays for teenagers who genuinely need real, effective mental health support. There is no question that being a teenager can be stressful, but is encouraging a supplement really the right approach? Especially when that supplement hasn’t even been shown to be effective?
Conclusion: Approved doesn’t mean effective
There is a lack of evidence to show that Veeva Teen is effective for the treatment or prevention of anxiety, nervousness, stress, or any other mental condition. While some of the ingredients may be possibly effective based on very limited trials, this particular combination of ingredients has not been subject to any clinical trials that show it has any meaningful effects. While Health Canada sees the issue of Veeva Teen as a manufacturer marketing issue, it ignores the broader issue of a confusing and consumer-unfriendly regulatory scheme that approved Veeva Teen in the first place. Teenagers, and consumers more generally, deserve regulations that prioritize access to quality health products over a manufacturer’s desire to sell a supplement for every circumstance – evidence be damned.

   Fake Treatments for Fake Illnesses
Steven Novella
Link
I wrote previously on NeuroLogica blog about Morgellons disease. Both Peter Lipson and Wallace Sampson have also covered this interesting syndrome here on SBM. Briefly, sufferers of this dubious syndrome believe they have foreign material exuding from their skin, causing chronic itching and sores. The evidence suggests that in truth they suffer from something akin to delusional parasitosis – the false belief of foreign parasites in their skin, leading to chronic itching which causes the sores and also works clothing fibers into the skin, which are later exuded.
Morgellons, in short, is a fake disease, a false and somewhat far-fetched explanation for symptoms that have a much more prosaic, if undesired, explanation.
Those who believe they have Morgellons, however, are legitimately ill and are an extremely vulnerable population. They feel they have a serious and mysterious illness, and worse the medical profession does not understand their illness and so denies that it exists. This is a perfect setup for snake oil-peddling con-artists.
Colloidal Silver
Colloidal silver is a suspension of metallic silver in a colloidal base. It has been around for a long time, and was used in limited indications for infections prior to the development of antibiotics. Use was phased out of scientific medicine decades ago because of lack of efficacy, because better options were available, but primarily because colloidal silver products have the potential to cause a serious side effect called argyria – deposition of silver salts in the skin and organs. This causes the skin to turn gray or bluish. In short, colloidal silver failed as a drug because it is toxic and ineffective.
However, colloidal silver is enjoying a second life as a “supplement.” Thanks to the Dietary Supplement Health and Education Act of 1994 (DSHEA) the FDA was able to only shut down sale of colloidal silver as a drug – meaning with claims that it cured or altered a specific disease, but could not prevent its sale as a supplement. Over the years the FDA has fined or sent strongly-worded letters to various companies selling colloidal silver as a supplement, but stepping over the line and making disease claims.
As a result of DSHEA, the public is no longer protected from this worthless and dangerous compound, rather the misguided or uncaring companies selling it are slightly inconvenienced in their marketing.
Two Cons in One
What if, however, a “supplement” (as legally defined by DSHEA) were marketed toward a fake disease? Would that violate FDA regulations? It seems that some colloidal silver marketers hope the answer is no. NutraSilver is a company that is selling colloidal silver as a nutritional supplement, but specifically claiming that it treats Morgellons disease. Their website says:
Thousands of Morgellons victims have used NutraSilver to eliminate their brain fog, fatigue, depression and lesions in about 3 weeks.
NutraSilver, a scientifically engineered natural mineral,when taken as a nutritional supplement, kills the most severe pathogens known to mankind very quickly.
The product is also marketed through Morgellons-specific websites, like morgellonhope.com. There also seems to be a viral campaign underway, with individuals pushing NutraSilver on Morgellons message boards and blogs. One even infiltrated my own blog on Morgellons and left a comment that was obviously a sales pitch, complete with a link back to the NutraSilver website (which I deleted).
This may represent a new strategy – evading FDA regulations by marketing supplements towards fake diseases. We will see if it works. I have a complaint in to the FDA on NutraSilver and I will give follow up on what response, if any, I get.
NutraSilver is also being marketed toward Lyme disease and arthritis. In fact their website has a section called “disease applications.” So perhaps they are not savvy enough to evade the FDA. This would mean they are targeting Morgellons because they believe they have found a vulnerable population. The most cynical interpretation is that the marketers of NutraSilver believe that those who label themselves as having Morgellons are delusional and therefore easily manipulated with false hope.
Wilson’s Syndrome
There are many other examples of dubious therapies being aimed at equally dubious diseases. Years ago I heard a radio ad for “Wilson’s Syndrome”, which was nothing more than a list of non-specific symptoms. Dr. Wilson seems to have just made up the syndrome, which he named after himself, so that he could lure the unsuspecting to his clinic. Over the years the “syndrome” has evolved into a mysterious hypothyroid syndrome, with the same list of non-specific symptoms (from fatigue to carpal tunnel syndrome), but also including occasional body temperature measured below 98.6. Dr. Wilson has published no research establishing his fake illness, which is, of course, not recognized by the medical establishment as having any legitimacy. The temperature claim is actually absurd – there is a normal range for body temperature – 98.6 being exactly normal is a fiction. But Wilson can convince the unsuspecting that they have a real syndrome by having them obsessively take their own temperature until they get a reading below the magic number.
Not surprisingly, clinics treating Wilson’s Syndrome also treat candida, chronic fatigue, and multiple environmental/chemical sensitivity – all dubious or highly overdiagnosed entities based upon non-specific symptoms.
Conclusion
Establishing that a set of signs and symptoms is a specific syndrome or disease is an extremely important function of scientific medicine. Recognizing that different people can suffer from the same pathophysiological disease in fact was the key insight that lead to modern scientific medicine. This is now also critical to medical research, and clinical trials often use very strict criteria for diagnosis the entity under study.
A further utility of having objective diseases, however, is regulation – especially when that regulation (like the current laws in the US) is based upon whether or not a claim can be made for a disease. The existence of fake or dubious diseases and syndromes has the potential (in addition to exploiting patients) to further frustrate efforts at objective and effective regulation in the health product marketplace.

   Help – My Doctor is a Crank!
Steven Novella
Link
I often receive e-mail from SBM readers (or SGU listeners) who have had the experience of their doctor, nurse, dentist, physical therapist, or other health care provider recommending to them a treatment option that seems dubious, if not outright pseudoscientific. They want advice on what to do. There are common themes to the e-mails – the writer often feels very uncomfortable in the situation. They do not feel comfortable confronting their provider directly, yet they do not want to acquiesce to the advice either. They are also often asking my opinion about the advice – is it really as wacky as it seems. This uncertainty saps them of their resolve, leaving them feeling a bit helpless.
Here is one such e-mail:
Ten days ago, my wife and I welcomed our first child into the world. She was born a couple weeks early, which left her mouth a bit too small and week to breastfeed effectively. To prevent her from losing too much weight, we were referred to a lactation consultant (who works out of the pediatrics department at the hospital where our daughter was born). This consultant (who is also an RN) suggested a regimen of supplementing nursing with pumped breast milk.
This was working great until my wife’s milk production dropped the day before our follow-up appointment. When we asked what to do about this, the nurse recommended that my wife take fenugreek, an herbal supplement. I was a bit skeptical of this advice, so I asked what it was about fenugreek that helped with milk production. The lactation nurse’s answer was vague — she said things like, Herbs can be helpful for lots of health issues, and, a lot of women I see seem to think it helps (oh, the logical fallacies). When we pushed her on this a little more, she handed us a flyer, printed by the hospital about fenugreek. The flyer seemed to support the use of the supplement, but mentioned that there was no scientific research demonstrating that fenugreek increases milk supply. When we asked why it hadn’t been researched, the nurse responded that there wasn’t a lot of money in lactation and that scientists generally aren’t interested in the kind of things she does (basically, that she was doing the good work that cold-hearted scientists refused to do).
She also mentioned that there was a prescription drug that boosts milk supply, but it carries with it the risk of a pretty serious side effect (depression), so she prefers her patients to try the supplement first. I asked how we could be sure the supplement didn’t also carry the risk of negative side effects if it hadn’t been studied, she simply said that it worked out fine for the patients she’s seen.
My wife and I decided to let it go for the time being and decide later whether or not to go the supplement route (it’s hard to argue with a nurse when you’re under-slept, one of you is topless, and the baby is screaming for food). Fortunately, her milk supply picked up a bit on its own, so we didn’t have to resort to using an untested therapy (yet).
First, let’s address the recommendation – fenugreek to increase breast milk production. Substances that increase milk production are called galactogogues. There are a number of drugs that have been shown to increase milk production, although the levels of evidence varies. For many there are only case series. Oxytocin is supported by double-blind placebo controlled trials, and is both safe and effective. Other commonly used drugs, like metoclopramide, are supported by unblinded case series only.
Fenugreek is a common spice and medicinal herb used in India. Among its putative effects is increased lactation, however, there are no clinical trials to support its use. Recommendations are based upon anecdotes only. This 2010 review article reports:
The side effects most commonly reported are a maple-like smell of the urine, breast milk, and perspiration, diarrhea, as well as the worsening of symptoms in individuals with asthma or hypoglycemia. The potential for transfer to milk or side effects in the infant are unknown. As is the case for most herbal products, the dose necessary to obtain a galactogogic effect has not been defined. Only one study on the effect of fenugreek on lactation has been reported. Swafford asked 10 mothers to maintain a diary of the quantity of milk produced with a pump for a period of two weeks. In the first week, baseline milk production was evaluated; in the second week, mothers took fenugreek, 3 cups, three times daily. In the first week average quantities were 207 ml/day, whereas, milk production in the second week averaged 464 ml/day (p = 0.004). Unfortunately, the report excluded any information regarding the characteristics of the mothers enrolled in the study or the postpartum period during which the study was done. Nevertheless, the daily milk quantities reported during treatment do not seem to be particularly high (reference: Swafford S, Berens P. Effect of fenugreek on breast milk production. Abstract 5th International Meeting of the Academy of Breastfeeding Medicine September 11-13, 2000, Tucson, Ariz Academy of Breastfeeding Medicine News and Views 2000;6(3).)
So – there are side effects, even potentially serious side effects like exacerbating asthma and hypoglycemia. The dosing is unknown, and the one small efficacy study that was done was unimpressive.
There is nothing implausible about the claim that an herb can be an effective galactogogue – herbs can be drugs with pharmacological activity. What is disturbing about the nurse’s recommendation is the double standard. She seems to believe that herbs are inherently safer than drugs, which is a false dichotomy based on the naturalistic fallacy, but not logic or evidence. She essentially recommended an untested drug with uncertain dosing, side effect, or efficacy over drugs with better evidence for both safety and efficacy.
It should also be noted that the e-mailer’s mild production spontaneously increased after the consultation. If she had taken fenugreek, that would have been one more anecdotal report apparently supporting its efficacy.
But onto the real question of the e-mail – how to respond in this situation. My advice is to first not be intimidated. Feel free to express your concerns or uncertainty about the recommendations being made. I commend this e-mailer for asking for published evidence, but don’t take an evasive answer as adequate. Ask for published evidence or authoritative reviews. If they do not have any handy, they can certainly prepare this material for the next visit or simply e-mail it to you.
If you feel up to the task, you can research the question yourself and then ask your health care provider to comment on the material you find (but don’t overwhelm them with mounds of material).
Depending on how egregious the pseudoscientific advice was, you should also consider simply leaving that provider for someone with whom you feel more comfortable and confident. I do recommend, whether or not you stay with the provider, to give them feedback. Express your exact concerns about their advice. How they respond will also tell you a great deal about their approach and dedication to evidence-based practice.
In short, I think patients should feel empowered to push back against practitioners who stray from science and reason as a basis for health care recommendations and practice. Those pushing for anti-science in medicine are certainly vocal, and their agenda will advance if others simply do nothing. In fact – if a practitioner recommended an outright anti-scientific treatment (like homeopathy, say) I would go beyond giving them individual feedback. I would write to the head of their clinic, hospital, or department and express your concerns. You are a consumer as well as a patient, and administrators listen to their consumers.
The above situation is becoming distressingly common, and it is not easy to deal with. It is one more type of harm that is caused by the infiltration of anti-science into medicine. I had a similar experience myself. My wife and I were referred to a practitioner to address a problem with one of our children (I am being deliberately vague on details). At the first visit the practitioner made a comment (as an aside, not directly related to the visit) about vaccines and autism. I, of course, politely challenged her on that statement, and she backpeddled – I think just to end the confrontation. My wife thought that I was inappropriate to challenge her – she was concerned about my accepting the role as patient rather than physician.
At the next visit, however – the visit when the practitioner was giving us her actual recommendations, my wife had a change of heart. The practitioner’s recommendations were entirely limited to “natural” interventions like diet and herbs, and she shied away from any medications. Her recommendations were ideology-based, not evidence-based, and in the end the consultation was entirely useless. My concerns at the first visit – that perhaps this practitioner does not have a firm grasp on the concepts of science-based medicine, were entirely vindicated.
This is an important point – if a practitioner recommends something that is blatantly against the science and evidence, how can you have confidence in any of their recommendations? I am not talking about not being up on one bit of latest evidence – no one can know everything. A serious lapse, however, can reveal a systematic bias in a practitioner’s approach to evidence and practice.
Unfortunately, patients cannot take for granted that a licensed professional is necessarily science-based.

   The Great Sunscreen Cover Up
Scott Gavura
Link
If there’s one thing the media love, it’s a “bungling bureaucrats” story. Yep, the FDA, wrapped up with their science dogma, enslaved to Big Pharma, pushing toxic, unnatural chemicals and ignoring safety data. And that’s the story being told about sunscreens:
“Study: Many Sunscreens May Be Accelerating Cancer”
“Did The FDA Ignore Proof That Sunscreens May Speed Up Cancer?”
“FDA Coverup Of Sunscreen Cancer Risk”
What’s a consumer to do? If you only read the headlines, you may get the impression that sunscreens do more harm than good. The impetus was the release of the Environmental Working Group’s (EWG) 2010 Sunscreen Guide. EWG is an environmental advocacy organization that focuses on consumer products, and has been conducting annual reviews of sunscreens since 2007. Of the 500 products it reviewed, it only recommends 8%, or 39 products in total. Why were so many products deemed “not recommended”? Reasons for negative ratings included the following:
any product containing retinyl palmitate (vitamin A), which is described as a photocarcinogen
any product containing oxybenzone, called a “potential hormone disrupter”
any sunscreen packaged as a spray or powder, due to inhalation concerns
EWG also raised concerns about nano-sized particles in sunscreens. But before we dive into the report, let’s consider what we’re trying to do with sunscreen.
Effects of UV Radiation
Ultraviolet radiation that reaches the earth may be divided into UVA (320–400 nm) and UVB (290–320 nm). UVA is further subdivided into UVA I, II and III. A simplified way to differentiate between the two types is to think of UVA as the aging radiation, and UVB as the burning radiation. Your exposure to UV radiation depends on factors such as latitude, altitude, time of year/day, and atmospheric conditions such as clouds and pollution. For example, if you’re on the Mediterranean coast at noon in the summer, the radiation mix is about 95% UVA, and 5% UVB.
UVB has been the traditional focus — stop the sunburn. UVA wasn’t scrutinized. But not only can UVA pass through glass, its rays can penetrate deeper into the skin and are responsible for skin breakdown and thickening. Both UVA and UVB are now implicated as cancer-causing, and UV radiation is considered a carcinogen.
Acutely, we see the effects of UVB. Sunburns can range from mild redness to life-threatening situations. Long term, the skin will show signs of both UVA and UVB damage. Degenerative changes including skin thickening as well as fibrous tissue and circulatory changes follow chronic exposure. And then there’s the big worry: cancer.
Why use Sunscreen?
Sunscreens reduce UV damage by reflecting or absorbing UV radiation:
Physical (inorganic) barriers (i.e., zinc oxide and titanium dioxide) physically block the skin from sunlight with particulate matter, reflecting and scattering UV rays. Physical barriers are near-perfect sunscreens: they protect against UVA and UVB, they start working immediately, they’re stable and don’t break down in the sun, and they are safe. Their use has traditionally been limited by aesthetic qualities, with formulas that are greasy, white, and opaque.
Chemical (organic) barriers filter and absorb UV radiation. Their chemical structure converts UV radiation to heat. They vary in their chemical properties, as well as their ability to absorb UVA, UVB, or both.
The Sun Protection Factor (SPF) is a estimate of how effectively a sunscreen will reduce the time to a sunburn. For example, a sunscreen that extends burning time from 10 minutes to 150 minutes has an SPF of 15. Because sunburn is the endpoint measured, SPF is a measure of UVB protection, not UVA protection. While UVA is implicated as a carcinogen, along with UVB, there are currently no well-established short-term endpoints for measuring UVA protection. But this is changing, with the FDA proposing a new set of rules for labeling UVA protection.
There is little difference in sunscreens beyond SPF 15. Consider the following:
SPF 15 will allow 7% of UVB radiation through to the skin
SPF 30 will allow 4% of UVB radiation through to the skin
SPF 60 will allow 2% of UVB radiation through to the skin
SPF values are calculated based on a dose of about 1oz (30mL, or 2 tablespoons) for the entire body — much more than is typically used. In general, insufficient amounts of sunscreen are applied to achieve the labeled UV protection. In real-world observations of use, actual protection is limited far more by the amount applied, and how often it is reapplied, than by the SPF. The EWG report illustrates the consequences of inadequate use of sunscreens, based on applying one-quarter of the recommended amount:
When used properly, SPF 15 provides more than adequate UVB protection for most individuals. EWG recommends that higher SPF products should be avoided if they contain higher concentrations of ingredients they deem potentially hazardous. While it’s unclear how much risk these ingredients truly represent, it’s a fair statement that higher SPF products are more about marketing, rather than meaningful differences in potential sun protection. You get better protection using a sunscreen properly.
Sunscreens and Cancer
There are three major types of skin cancer. Basal cell carcinoma and squamous cell carcinoma are common, but rarely fatal. They often appear on sun-exposed areas like faces and ears, and can be removed easily (though it may be disfiguring). It’s clear that sun exposure is a risk factor for basal cell carcinoma and squamous cell carcinoma, and that sun avoidance can reduce this risk. The third cancer, melanoma, is rare (about 3% of all skin cancers) but frequently fatal, causing 75% of the deaths). When it comes to melanoma, the data on sun exposure are not as clear. There isn’t good evidence to demonstrate that reducing sun exposure has an effect, as chronic sun exposure seems to have a protective effect. However, there is good evidence linking sunburns, and particularly intermittent sun exposure to melanoma. The data with indoor tanning also seem to support a dose-response relationship. Overall, the data points to an association between intentional sun exposure and melanoma, non-intentional sun exposure with squamous cell carcinoma, and basal cell carcinoma likely related to both. (Source)
When it comes to the efficacy of sunscreen to reduce cancer risk, the data are less clear. Most sunscreens didn’t offer UVA protection until recently, confounding studies examining relationships between sunscreen use and cancer risk. Consequently, the evidence linking sunscreen use to reduced melanoma risk isn’t convincing. Studies are confounded by the long latency period for melanoma, the challenges with recall studies, and the changing formulations of sunscreens. One hypothesis for the lack of link is that sunscreen could confers a false sense of security, increasing overall exposure through more time in the sun, and possibly less use of protective clothing. Compounding this would be a relative lack of protection against UVA. Overall, however, there’s good evidence to demonstrate sunscreen use can reduce precursors to cancer, and the incidence of squamous cell cancer. On balance, the data suggest that sunscreens provide protective effects against cancer.
Pharmaceutical Elegance: The Importance of Formulation
One consideration I frequently discuss when counseling consumers about sunscreens are questions and concerns about aesthetics — particularly in products for children. If the product is greasy, opaque, or thick, it won’t be used properly, no matter how effective the product might be. Aesthetics are a function of the vehicle (what the active ingredients are mixed in) as well as the specific characteristics of the compound. Alcohol-based and “dry” versions are also available, but must rely on a smaller number of ingredients because of manufacturing issues.
A related problem is photostability — the ability of sunscreens to remain effective when irradiated by UV rays. Photostability is a function of the vehicle, and the type and concentrations of the different ingredients. Inorganic sunscreens don’t have this problem: not only are they photostable, they are also ideal for those with sensitive skin that may be allergic to organic chemicals.
In general, if the final product doesn’t have great aesthetics, it probably won’t be used properly. And this compromises the point of using sunscreens in the first place.
Sunscreen Risks
Acute side effects of sunscreens are rare and are generally limited to hypersensitivity reactions, such as skin rashes to the chemical (organic) sunscreens. Longer term effects can be categorized into two categories: long term toxicities from the constituents of the sunscreen (the bulk of the Environmental Working Groups’s concerns) and the potential for reduced vitamin D absorption.
While vitamin D production is blocked when UVB-blocking sunscreens are used, the real-world impact isn’t clear. Deficiency is plausible, but there’s little evidence to suggest meaningful deficiencies in vitamin D are related to typical use of sunscreens.
Is Retinyl Palmitate Causing Cancer?
The EWG report evaluates the different ingredients and formulations of sunscreens and uses its own ranking system to assign a score. Their scoring system is internally developed, and has not been validated, but the methodology is reasonably transparent.
Based on the coverage of the EWG’s report, you might get the impression that sunscreens containing retinyl palmitate are causing cancer. Retinyl palmitate is a form of vitamin A commonly used in cosmetic products to reduce wrinkles and fine lines. The EWG points to a 2009 study of retinyl palmitate on mice as their main cause for concern. Treated mice, and a control group were exposed to the equivalent of nine minutes of noontime Florida sun daily, for a year. Compared to the control group, the RP group developed more tumours. That’s adequate evidence to avoid the product says the EWG. But is this finding relevant? The mice were treated with retinyl palmitate — not sunscreen that contained retinyl palmitate. It’s known that retinyl palmitate can be a photosensitizer. When used as a single ingredient cream, as with other forms of vitamin A, you must wear sunscreen, or you’ll burn more easily. So how relevant is this mouse study to human subjects, wearing sunscreens containing retinyl palmitate? It’s difficult to say. Study completion and peer review is expected by 2011. What’s the best approach until then? Well, given that retinyl palmitate isn’t approved as a sunscreen, there’s no compelling rationale for it to be in these products. It’s not unreasonable to avoid it if desired, but there’s no persuasive evidence to suggest its presence is a sound reason to skip sunscreen.
Oxybenzone: Disrupting our Hormones?
Oxybenzone, or more properly, 2-hydroxy-4-methoxybenzophenone, is naturally found in flower pigments and is commercially synthesized as a sunscreen agent and UV stabilizer. Oxybenzone provides UVB and some UVA protection, and stabilizes avobenzone, an effective (but less chemically stable) UVA-sunscreen agent. It has been the target of criticism by those asking for more long-term safety assurances. The CDC recently reported that oxybenzone was detected in 97% of urine samples in a representative sampling of Americans. So it’s in our bodies and in our environment. Is it harmful?
EWG says yes, calling it a “potential hormone disrupter”. Yet oxybenzone hasn’t been linked conclusively to negative health effects. But absence of evidence isn’t evidence of absence, so do consumers have cause for concern? The CDC notes, “Human health effects from benzophenone-3 at low environmental doses or at biomonitored levels from low environmental exposures are unknown.” The European Union’s review is online [PDF], which asks for more information on dermal absorption, yet concludes that in vitro and in vivo data indicate oxybenzone does not possess photo-mutagenic or photo-genotoxic properties.
EWG recommends that oxybenzone should be avoided in sunscreens. However, evidence isn’t yet persuasive that meaningful hazards have been documented. It’s important to recognize that EWG takes a strict perspective on ingredients that is not shared by other organizations. Because something is in the environment at very low doses, it does not mean it is harmful. In addition, the ubiquity of oxybenzone in personal care products makes it very difficult to avoid, as the CDC sampling showed. As the American Cancer Society points out in its discussion of cosmetics,
It’s important to have a sense of the difference between the hazard an ingredient may pose and the risk a person faces from being exposed to it. Scientists use the term hazard to describe the potential of a chemical to cause unwanted health effects. Risk is used to describe the chances of an unwanted health effect in a person from normal use of the ingredient. A substance may be deemed to be potentially hazardous for some reason, but it may pose very little risk to people during normal use.
When it comes to oxybenzone and sunscreens, the myriad of alternatives available mean that it’s possible to avoid oxybenzone if desired, while still finding products that provide good UV protection.
Nano, Nano
If we want to avoid organic (chemical) sunscreens, the inorganic options, titanium and zinc are the attractive alternative. But EWG raises further concerns about new formulations of these products — those that contain nanoparticles. Nanoparticles are a new innovation to deal with the aesthetic drawbacks of the physical sunblocks: Make the particles small enough, and they become translucent and even transparent. Traditional titanium dioxide and zinc oxide have particle sizes of over 200 nm — large enough to reflect visible light, giving the traditional white appearance. Make the particles small enough, and they won’t scatter visible light. (This chart [pdf] nicely illustrates the effect.) EWG is concerned about the risk of absorption of nano-particles and is calling for more research. However, they note the following:
Although we expected to reach a different conclusion at the outset of our sunscreen investigation, when we balanced all factors important in sunscreen safety, our analysis shows that many zinc and titanium-based sunscreens are among the safest and most effective sunscreens on the market.
This statement is evidence-based. Measurable systemic absorption does not seem to occur with titanium and zinc nano-material sunscreens. EWG does flag sprays and powder forms of sunscreens as potentially problematic, particularly the nano-formulations, due to inhalation risks of sunscreen ingredients. While the risk of absorption is certainly greater with aerosols, compared with creams, this can be mitigated by selecting liquid sprays instead of dry powders, and avoiding spraying directly on the facial area. Probably the biggest drawback to nanomaterials is that as the particles get smaller, the UVA protection diminishes. Consequently, ultrafine particles may need to be combined with chemical sunscreens to provide complete (broad spectrum) protection. On balance, the inorganic sunscreens, whether they are nano-sized or not, are excellent sunscreens.
Conclusion
Sunscreen is not a panacea for skin protection. Sun avoidance and physical barriers remain the best approaches to minimizing the acute and long-term effects of UV radiation. The data on sunscreen use and cancer risk are complex, but on balance suggest that the short-term and long-terms benefits of sunscreens significantly outweigh their risks when used during periods of unavoidable exposure. There’s no evidence that vitamin D deficiency is a consequence of safe sun behaviours, and given there are safe and inexpensive methods of obtaining vitamin D (oral supplementation) the rationale for intentional, unprotected sun exposure remains unclear.
Sunscreens remain an important option to help avoid unwanted UV exposure. Overall, the EWG report makes it easy for consumers to differentiate between sunscreens, and make selections based on UV spectrum protection and ingredient preferences. While I’m personally not convinced about the hazards of the current FDA-approved products, I agree with the group’s overall recommendation that physical barriers, containing titanium and/or zinc, have superior risk/benefit profiles. When you look past the headlines, the Environmental Working Group’s analysis isn’t bad. It’s cautious but pragmatic. The bad probably isn’t as bad as they say, but they take a good perspective related to risk/benefit overall.

   Steven Fowkes (Part 1 of 2): How to Cure Alzheimer’s and Herpes
Harriet Hall
Link
A correspondent asked me to review a video presentation by Steven Fowkes, “Nutrients for Better Mental Performance,” one segment of a 9-part series on preventing and curing Alzheimer’s that was mentioned recently by an SBM commenter. Fowkes is an organic chemist without a PhD; he says this means:
I am not institutionalized [This begs for a joke, but I will refrain.] and see the world differently. Everything I know I learned outside the system.
He is associated with CERI, the Cognitive Enhancement Research Institute and has written extensively on nutrition and health. I’ll comment on his claims for Alzheimer’s and herpes first, and then return to the “Nutrients for Better Mental Performance” video next week.
Alzheimer’s
He says he can prevent Alzheimer’s disease and cure it in the early stages, although later damage will not be reversible. And yet he doesn’t actually specify the details of how he accomplishes that miracle: apparently it’s complicated (I would imagine so) and varies with the individual. Science doesn’t know what causes Alzheimer’s, but Fowkes does. The current thinking of scientists is that it is due to genetic factors interacting with environmental factors, and it might be a natural consequence of the aging process that would eventually affect anyone who lives long enough. Fowkes says it involves a complicated domino cascade of effects, but the cause boils down to loss of glutathione cycling and failure of sulfhydryl enzymes, which interferes with the detoxification of mercury in the brains of Alzheimer’s patients.
He says the brain is special and is more sensitive to thyroid imbalance, inflammation, and other factors. Aerobic metabolism is particularly important in the brain, since it is far more efficient than anaerobic metabolism and is needed to support multicellular life, the central nervous system, and consciousness. He goes into great detail about the energy production mechanisms in metabolic processes, discussing the Krebs cycle, phosphorylation, microtubules, antioxidant defenses, NADH, NADPH, recycling of glutathione, how sulfhydryl enzymes are poisoned by mercury, etc.
He assumes that Alzheimer’s patients have increased mercury levels in their brains. There are a couple of older studies that appeared to show that they do, but these are contradicted by studies done since showing that they don’t. If there is not extra mercury in the brains of Alzheimer’s patients, all the rest of his reasoning fails. He has built a huge house of cards on a tiny wobbly foundation. He assumes that removing the mercury or correcting an imbalance between mercury and glutathione ought to improve Alzheimer’s, but he has no clinical data.
The fact that Alzheimer’s is reversible should be front page news. He says the news has been suppressed because:
    • The breakthrough came through the back door (research done by a few dentists).
    • Mainstream dentists rejected the information because it showed that amalgams and root canal procedures were not safe.
    • The medical establishment rejected it because it undermines prescription options and points to supplements everyone can buy.
He tries to relate complicated biochemistry diagrams to clinical topics. Cardiovascular conditions impact cognitive function. Hypercoagulability is caused by inflammation. There are blood gas impairments in lung disease. pH disturbances alter O2 binding in the blood. Hiccups and tachycardia are examples of CO2 deficiency and are more common in people with senility and low energy metabolism.
Plaque can cause cognitive dysfunction by restricting blood flow. Plaque is sometimes caused by impaired collagen maturation which he says can be readily reversed by Mathias Rath’s vitamin C, lysine, and proline treatment and by more complex mixtures. (For readers who don’t recognize his name, Rath is an infamous quack who is notorious for causing thousands of deaths in South Africa by substituting vitamins for effective AIDS treatment). Soft tissue calcification in plaque can be reversed with magnesium, high dose vitamin D, strontium, and potassium, with or without adjunctive EDTA chelation therapy (Note: There is no evidence for this, and there is evidence against chelation therapy). Vasoconstriction occurs with deficiency of Mg or vitamin D and impaired NO. NO accounts for cognitive improvement with gingko, vinpocetine, arginine. (Note: there is no evidence of cognitive improvement to account for.)
Ketosis trains the brain to use body fat as a source of energy. Toxins are released when body fat is mobilized. Exercising in and out of ketosis makes the process more efficient.
Mercury is toxic to microtubules. He says amalgam fillings and root canal procedures must be avoided.
The genetic risk factors are due to the fact that apoE modulates mercury toxicity. Mercury toxicity causes Alzheimer’s but, paradoxically, fish consumption is protective. The anti-inflammatory effects of fish oil apparently outweigh the toxic effects of mercury.
He displays a tree of steroid effects, some good and some bad. The menstrual cycle postpones a wide range of anti-aging effects. Other factors are involved: allergies, the leaky gut syndrome, oxidative stress from heavy metals, nutritional deficiencies, chemical exposures, and alcoholism. The great variety of factors means treatment for Alzheimer’s must be individualized. To individualize treatment, patients can be tested in various ways before and after an intervention or a supplement to see what works best for them.
Cognitive testing can be done by an extensive, expensive battery of neuropsychological tests that assess cognitive, motor, balance, proprioception, and sensory functions. But these functions can be tested just as well at home by monitoring performance on:
    • Computer games like Tetris.
    • Concentration game with stopwatch.
    • Finger to nose and other tests.
    • Bridge, chess, juggling, handwriting, crossword puzzles.
Home self-testing allows constant feedback to improve compliance. Does he offer any evidence from controlled studies or peer-reviewed journals that Alzheimer’s patients have actually improved with this plan? Not a scrap.
How to Cure Herpes
In his books, one of which is available free on the CERI website, he also offers a “biologically sustainable solution to chronic viral diseases” via two options:
    • Taking BHT.
    • Using a natural combination of foods, nutrients, hormones, and lifestyle changes.
These cause a metabolic shift that some people will not perceive, but others will notice better sleep, improvement in skin quality, reduced asthma symptoms, decreased sensitivity to cold weather, and fewer migraine headaches. He says that his program has been successfully applied to recurring herpes, shingles, herpes encephalitis, “raging intestinal CMB,” and hepatitis C.
So he says. But there are no clinical studies. Of course, he knows lots of doctors who have prescribed BHT and gotten fantastic results, but they won’t let him release their names because they don’t want to get into trouble for using a nonstandard treatment. (I would think they’d want to publish case reports and case series and become famous!) His extensive writings on herpes amount to (1) complicated speculations based on biochemistry, (2) testimonials, and (3) bashing the medical establishment.
Conclusion
Fowkes is good at explaining complicated relationships in biochemistry, but he does not seem to understand medicine and the errors that occur when you jump from speculation to therapy without clinical trials. I am not impressed. I would love to be proven wrong, because we need effective treatments for these diseases; but I must provisionally conclude that he has not found the cure for Alzheimer’s or herpes. I will cover his ideas about nutrients for better mental performance next week.

   Milk Thistle and Mushroom Poisoning
David J Kroll
Link
If you’ve been fortunate to live in the parts of the US that were soggier than usually as of late – or unfortunate enough to have had flooding from hurricanes and tropical storms – then you’ve be noticing a tremendous burst of mushrooms.
For mycologists – mushroom enthusiasts – there are two classic chestnuts: “There are old mushroom collectors and bold mushrooms collectors, but there are no old, bold mushroom collectors.”
Or, in a more concise Croatian proverb, “All mushrooms are edible, but some only once.”
As such, this is the time of year that emergency rooms and regional poison centers begin to see a burst in poisonings from mushroom ingestion, due primarily to amateur misidentification of the fruiting bodies.
Just this past week, Jason McClure at Medscape Oncology News (free reg req’d) wrote about the unusual bloom of mushrooms in the northeastern US and the concomitant bloom of mushroom poisonings this fall.
But “mushroom poisoning” is an imprecise diagnosis for the ER physician. The constellation of symptoms caused by toxic mushrooms is as diverse as the colors and shapes of these wonders of nature. From another Medscape article on emergency management of mushroom poisoning by Dr. Rania Habal from the Emergency Medicine department of NYU:
Mushrooms are best classified by the physiologic and clinical effects of their poisons. The traditional time-based classification of mushrooms into an early/low toxicity group and a delayed/high toxicity group may be inadequate. Additionally, many mushroom syndromes develop soon after ingestion. For example, most of the neurotoxic syndromes, the Coprinus syndrome (ie, concomitant ingestion of alcohol and coprine), the immunoallergic and immunohemolytic syndromes, and most of the GI intoxications occur within the first 6 hours after ingestion.
Ingestions most likely to require intensive medical care involve mushrooms that contain cytotoxic substances such as amatoxin, gyromitrin, and orellanine. Mushrooms that contain involutin may cause a life-threatening immune-mediated hemolysis with hemoglobinuria and renal failure. Inhalation of spores of Lycoperdon species may result in bronchoalveolitis and respiratory failure that requires mechanical ventilation.
Mushrooms that contain the GI irritants psilocybin, ibotenic acid, muscimol, and muscarine may cause critical illness in specific groups of people (eg, young persons, elderly persons). Hallucinogenic mushrooms may also result in major trauma and require care in an intensive care setting. Lastly, coprine-containing mushrooms cause severe illness only when combined with alcohol (ie, Coprinus syndrome).
Among the poisonous mushrooms, Amanita phalloides is perhaps the most deadly. If you’ve spent any time in a biochemical laboratory you will have learned of the primary toxin of the mushroom, α-amanitin. This potency of this toxin comes from its remarkably high affinity for RNA polymerase II, the primary RNA polymerase for making messages that are converted into proteins.
The challenge in treating α-amanitin poisoning is that it has a relatively long half-life in the body because it is conjugated with glucuronic acid in the liver and secreted in the bile. But then microbes that normally inhabit our gut cleave the glucuronide sugar molecule off the toxin, released the toxic α-amanitin.
Throughout the history of folk medicine in the Middle East and Europe, extracts of the seeds of milk thistle (Silybum marianum) were determined to have protective effects against liver toxins. I’m still not terribly pleased with understanding the history of how this came about but answering this question is one of my liberal arts pursuits. As an aside, I should make the disclosure that my laboratory and colleagues have been investigating the anticancer effects of compounds from milk thistle and still receive NIH funding to do so; however, I do not (yet) study how milk thistle compounds prevent liver toxicity.
Nevertheless, milk thistle products are quite popular in Europe and the US for the general prevention of liver toxicity from statins, acetaminophen, and alcohol. Several of my friends have joked that one could make create a successful market for an alcoholic product containing milk thistle extract.
But one of the primary roadblocks in using milk thistle extracts or pure compounds for any indication is that the compounds have rather poor bioavailability. The seven major flavonolignans and one flavonoid in the typical extracts are very avidly conjugated by glucuronidation. In studies by collabortors at the University of Colorado, we now know that it takes daily doses of approximately 10-13 grams of milk thistle extract to achieve plasma concentrations consistent with known anticancer effects in vitro. It can be done, but it means taking much more than the typical 180 mg capsules you can buy at your local health food store.
However, an intravenous preparation of milk thistle extract has been available in Europe for over 20 years: Legalon SIL. This GMP-manufactured product is common to emergency rooms in Germany, France, and Belgium for the treatment of mushroom poisoning. The preparation is comprised of silybin A and silybin B – known collectively as silibinin – as a hemisuccinate that both improves the solubility and bioavailability of the compounds.
Two cases in the US – one in 2007 and another just this past month – have seen emergency IND approval of this European product. In 2007, Legalon was used to save four of five family members who had ingested Amanita phalloides while on a New Year’s Day picnic outside of Santa Cruz, California. And just last month, a team led by Dr. Jacqueline Laurin at Georgetown Medical Center successfully treated two men for accidental ingestion of Amanita. Georgetown is now an approved referral center for this IV prep of Legalon and their efforts were greatly assisted by the Santa Cruz team who handled the 2007 cases.
Less satisfying to me is the mechanism by which silybin A and silybin B protect the liver from the effects of RNA polymerase II inhibition by α-amanitin. The literature to date seems to converge on the inhibition of toxin uptake into hepatocytes by silibinin. A German group led by Herbert de Groot in Essen, Germany, published a highly-cited 1996 paper proposing that inhibition of inflammatory mediator release from Kupffer cells (the macrophage of the liver) might partly account for the hepatoprotective effects of silibinin. More recent work continues to address the modulation of inflammation.
Regardless, we are now seeing legitimate use of a medicine from a herbal tradition being used in clinical situations where emergency IRB approval and IND status have been given to such a product. Certainly, these stories may be used by marketers to promote use of their oral milk thistle products. But, as I mentioned earlier, such effects required ingestion of large doses of capsules. Instead, I present this story to SBM readers to illustrate that amidst the wooful promotion of herbal therapies, a few gems exist and are most worthy of our scientific investigation.

Red Yeast Rice and Cholesterol
Harriet Hall on July 24, 2012
Link
While much of CAM is ridiculous or implausible, herbal remedies are an exception. Plants produce pharmacologically active substances; in fact, the science of pharmacology grew out of herbalism. Some herbal remedies have not been scientifically tested, but others have been tested and are clearly effective. Nevertheless, these are seldom if ever the best choice for treatment.
One natural remedy stands out. Red yeast rice has been tested and has been shown to lower cholesterol as well as a statin drug. That’s hardly surprising when you realize that it contains the exact same ingredient as the pharmaceutical drug lovastatin.
Only it doesn’t any more.
Origin
Red yeast rice has been widely used in Asian cuisines as a coloring agent and taste enhancer. It has been used in traditional Chinese medicine for centuries for indigestion, diarrhea, blood circulation, and spleen and stomach health.
Preparation
It is prepared by fermenting rice with the yeast Monascus purpureus. It contains eight mevinic acids (statins), mainly lovastatin or monacolin K. It also contains sterols and other components. Its overall cholesterol-lowering effect may be due to a combination of several of its constituents. In manufacturing it for use as a supplement, temperature and growing conditions are carefully controlled to increase the concentration of mevinic acids. These products are not the same as the red yeast rice sold in Chinese grocery stores.
Safety concerns
The safety of red yeast rice has not been established. The Natural Medicines Comprehensive Database only gives it a “possibly safe” rating. Since it contains lovastatin, it can be expected to have the same side effects as the prescription drug. Patients on statins are monitored for liver, muscle, and kidney damage; sellers of red yeast rice do not usually inform their customers of those risks. There are also a number of interactions with other drugs and dietary supplements. And eating grapefruit can affect blood levels of lovastatin.
Regulatory actions
When does a food cross the line to become a drug? Red yeast rice was marketed in the US as a dietary supplement, Cholestin. The FDA banned it in 1998, saying that since it contained lovastatin it was an unapproved drug. In 1999, a federal judge overruled the FDA, saying it could be sold as a food supplement. In 2000 a Circuit Court of Appeals said that ruling was in error and restored the FDA’s ability to regulate Cholestin as a drug. The FDA then sent warning letters to several companies, and the product disappeared from the market for a few years.
The manufacturers’ response
Red yeast rice products gradually reappeared on the market. Around 30 brands are now available. Most of them got around the FDA restriction by eliminating the monacolin content and by careful labeling and advertising that does not claim to lower cholesterol. In 2007, the FDA sent warning letters to two companies whose products still contained monacolins; the products were withdrawn. Red yeast rice products are still widely sold in the US and products containing lovastatin are still readily available from other countries.
Pharmanex continues to sell a product under the name Cholestin, but it no longer contains lovastatin. They say:
Cholestin® is a breakthrough all-natural solution for individuals concerned with maintaining cholesterol levels already in the normal range.
Cholestin’s proprietary blend contains polymethoxylated flavones extracted from citrus fruits, geraniol and the essential fatty acids EPA and DHA found in marine lipids. Each individual constituent has been shown to control existing normal cholesterol levels in the body and promote overall cardiovascular health. Only Pharmanex’s new Cholestin® offers this unique blend of scientifically-tested constituents for effective cholesterol management.
Pharmanex sells Cholestin for around a dollar a pill. Theprice of lovastatin varies from 29 cents to $1.71 per pill 
CAM recommendations
Dr. Andrew Weil recommends red rice yeast extracts, saying they are by far the most effective natural supplement for lowering cholesterol and claiming that they are less likely to cause side effects than prescription statins. 
Dr. Oz says red yeast rice is a statin that will lower your cholesterol by 30 points.
Dr. Mercola says red yeast rice is a statin and all statins should be avoided.
Natural News recommends it but notes that supplements currently sold in the US don’t contain any of the active ingredient.
Many websites have outdated and false information.
Other herbal remedies
My general objections to herbal medicines are these:
    • When tested, isolated active ingredients tend to work at least as well as the whole plant derivative.
    • Although herbalists claim that the other components in their remedies act synergistically, that has seldom been substantiated, and the other ingredients might just as well be expected to do harm or to decrease the effect of the active ingredient. 
    • Most herbal products have not been adequately tested to ensure safety.
    • Herbal products on the market vary in dosage and purity. There is no guarantee that you will get what the label says.
    • Products may contain contaminants. Products have been found to contain everything from toxins to insect parts and even prescription drugs.
I see no good reason to prefer St. John’s wort to a prescription antidepressant. On a practical basis, I can understand that some people might prefer it because it is less expensive and can be acquired without a visit to a doctor with all the inconvenience and cost that entails. But I think their health would be better served by being diagnosed and regularly monitored by a medical doctor and by taking a pure antidepressant in a controlled dosage.
Conclusion
Red yeast rice containing lovastatin is effective in lowering cholesterol, but brands currently sold in the US contain no lovastatin. It’s ironic that one of the few proven CAM treatments was effective only because it contained a drug available by prescription. And that they continue to recommend it after the lovastatin was removed. Even if a lovastatin-containing red yeast product can be obtained, concerns remain about purity and safety. It would be hard to justify recommending it over a pharmaceutical statin.

Are “keto supplements” necessary?
A closer look at the science supporting beta hydroxybutyrate supplements
Scott Gavura on August 31, 2023
Link


A reader writes,
I searched the Science-Based Medicine website but can’t find an answer to this question that has been bugging me. As a primary care physician I am constantly asked about supplements, lately about “keto supplements” for weight loss. Those living the “keto lifestyle” monitor for ketosis via urine ketone test strips. One popular keto supplement is KetoCharge. Its active ingredient is 800mg of beta-hydroxybutyrate. Biochemistry was 20+ years ago, but my sense is that this is an unabashed scam. Sell people beta-hydroxybutyrate to ingest, then have them test their urine for … beta-hydroxybutyrate. The scam seems to be that people don’t realize the ketones showing up on their test strips are exogenous, not a result of any internal biochemical process other than excretion. Am I missing something, or is this just the supplement industry not even trying to be honest anymore?
What is a ketogenic diet aka going “keto”?
Normally, glucose is acquired through your diet by consuming carbohydrates, including sugars and starches. Once ingested, your body breaks down these carbohydrates into glucose, which serves as a source of energy. Surplus glucose is stored in the liver and is released when required. Carbohydrates are the usual base fuel for cells such as the brain and nervous system that depend on glucose.
A ketogenic diet is one that generally includes under 50 grams of carbohydrate. When carbohydrates are not available, the body begins to break down fat, putting your body in a state of “ketosis” and producing “ketones”.
Studies have indicated that ketosis may offer some health benefits. Some forms of epilepsy respond to keto diets. A more current reason for interest in the ketogenic diet is its potential for promoting weight loss. Being in ketosis seems to reduce appetite, potentially resulting in decreased food consumption. A “keto diet” is not inherently superior to other types of diet for weight loss, however. The benefit seems to be from the overall reduction in calories, rather than anything magical about ketosis itself. The jury is out on the long-term health effects of a keto diet.
Keto sounds straightforward! Why would I need a supplement?
Until this reader request, I had never heard of a keto supplement. Keto Charge is one of many supplements that contain beta-hydroxybutyrate (BHB). Beta-hydroxybutyrate (BHB) is the primary ketone utilized by the body for energy when glucose availability is restricted. Normally, BHB levels in the blood are low, but during periods of fasting (or low/no carbohydrate ingestion), the liver converts fatty acids to ketone bodies like BHB, which can be utilized by other organs and tissues as energy. BHB is also a signaling molecule that can influence various cellular processes, including metabolism and gene expression. This has led to interest in studying the potential therapeutic effects of BHB, such as its impact on exercise performance, cognitive function, and certain health conditions. Some of the natural questions about BHB might include formulation (is it well absorbed?) and the effect on different paramaters, particularly in those that are on a keto diet (who are already using ketone body as a primary fuel) and those that are not on a keto diet, and primarily using glucose as a primary fuel.
Has beta hydroxybutyrate been studied in clinical trials?
Unlike many other supplements, the answer is yes…but there is some digging we need to do to determine the relevance of these trials. Searching for BHB brings up pages of results, but when I searched for randomized controlled trials using BHB as a supplement, I found just nine results:
     1.  One trial looked at intravenous infusions of 3-hydroxybutyrate, so was irrelevant to a review of dietary supplements.
     2.  A 2021 trial randomized pre-diabetic adults to a BHB supplement to evaluate the effect on plasma glucose. It concluded “Ingestion of the KEβHB-supplemented drink acutely increased the blood βHB concentrations and lowered the plasma glucose concentrations in adults with prediabetes.”
     3.  A 2018 trial examined the effect of a BHB-containing beverage on cognition and anaerobic exercise performance measures, and found no effects.
     4.  A 2021 trial of BHB supplements on markers of iron metabolism in people with prediabetes. No meaningful effects (other than increased blood levels of BHB) were noted.
     5.  A 2019 trial of BHB supplementation to evaluate the effect on a regulator of inflammation.
     6.  A 2020 trial of a pre-workout supplement of BHB, caffeine and amino acids on high-intensity exercise, in people on ketosis diets and those that were on a non-keto diet. This was a non-blinded trial, and the supplement was found to benefit both groups.
     7.  A 2019 trial examining BHB supplementation (or placebo) on walking economy and measures of perceived exertion. It found no difference between groups.
     8.  A 2021 trial of 90 days of BHB supplementation in adolescents to evaluate safety, including ” fasting blood safety metrics, bone density, happiness, emotional intelligence, or blood pressure”. It concluded the supplement was safe and well tolerated. I am curious how this manufacturer-funded trial passed institutional review board review.
     9.  A 2019 evaluating ingestion of BHB on exercise in trained cyclists. It concluded “ingestion of βHB salts does not affect lactate appearance, perceived exertion, or muscular efficiency.”
I also found one paper in the Journal of Insulin Resistance which didn’t come up in a PubMed search because it seems that journal isn’t abstracted by the National Library of Medicine, which is a red flag for quality, but not a reason to ignore the findings. Regular readers may recall that Journal of Insulin Resistance is where Aseem Malhotra published two long articles filled with antivaccine misinformation – discussed at length by David Gorski in late 2022, an also by Health Feedback here. The journal seems to be erratically published (only six editions since 2016 and a two year gap from 2019-2022). While the main findings of that trial seemed uncontroversial (BHB supplementation raises BHB plasma levels), I’m not going to spend any further time on it.
So why take a BHB supplement?
Here’s what the manufacturer of one supplement says about the effect of supplementation:
I could find no credible published evidence to support any of these claims, with the possible exception of “instant ketones”, as there seems to be reasonable evidence that orally consumed BHB is absorbed. I could locate no published clinical trials to show that BHB consumption provides meaningful medical or health benefits to those in ketosis (on keto diets) or to those that are not in ketosis. If you’re “going keto” with the intent of burning ketones from fat, then I’m at a loss to understand why you would consume exogenous ketones, which simply provide a source of external fuel – like any other energy source. And measuring your urine for the presence of ketones when you deliberately consume BHB makes no sense to me whatsoever.
BHB looks like a supplement still in search of a purpose. Perhaps one will be identified someday. There is no convincing evidence to suggest that BHB supplementation is beneficial or necessary, regardless of your dietary choices.

Should Protein Powder Have a Warning Label?
The unfortunate death of a teen in London has some experts calling for new warning labels on products containing large amounts of protein. But would that work?
Clay Jones on August 4, 2023
Link
In late June, I came across an article from the BBC that raised the question posed in the title of this post. Protein powder consumed by a teenager in London in order to bulk up was believed to have contributed to his death, and medical professionals involved in the case were calling for labels to warn consumers of the risk in people unable to safely metabolize large amounts of protein. But is this reasonable? Would it have actually saved this child’s life?
The case of Rohan Godhalia
On August 16, 2020, 16-year-old Rohan began drinking protein shakes made from powder purchased at a grocery store in West London. Three days later, after suffering from altered mental status, seizures, cerebral edema, and ultimately irreversible brain damage, he died. At the time, and even after an autopsy ten days later, the cause of his death was unable to be determined.
Rohan’s family had made the heroic choice to donate his organs, in this case his liver and kidneys, in the hopes that some good would come from the tragic loss of their child. Because of this, and completely unbeknownst to them of course, the discovery of what happened to their son would be delayed for several months until the recipient of his liver required hospitalization for similar mysterious symptoms. A simple lab test, but one that unfortunately wasn’t ordered during Rohan’s hospitalization, was the break in the case that lead to the diagnosis.
Doctors caring for the patient with Rohan’s liver discovered that they were suffering from dangerously elevated levels of ammonia. Not only is this potentially treatable with dialysis to remove the offending chemical from the bloodstream, though not always in time to prevent permanent injury to the brain, it was an important clue that the patient’s liver was the root of the problem. The liver, among many other important functions, is the organ where this highly neurotoxic byproduct of protein metabolism is converted into urea. Urea is then safely excreted in the urine.
Most adults who present with elevated ammonia levels have cirrhosis, a chronic scarring of the liver that occurs after years of injury from a variety of potential conditions, but most commonly excessive alcohol intake, viral hepatitis, or non-alcoholic fatty liver disease. None of these common causes made sense in this case, so a biopsy was performed which revealed the problem and also answered the question of Rohan’s untimely demise. It turns out that he had a rare genetic disorder, specifically a urea cycle disorder known as ornithine transcarbamylase (OTC) deficiency, that impaired his liver’s ability to convert ammonia into urea.
OTC deficiency: a brief primer
OTC deficiency is a rare condition that is passed down genetically on the X chromosome. So-called “X-linked” conditions generally occur more frequently, or present with more severe disease, in people with only one X chromosome. The additional X chromosome carried by most people assigned female at birth is usually protective and they are rarely significantly affected by elevated levels of ammonia in the bloodstream, with only 10-20% of them ever developing any symptoms at all.
Patients with one X chromosome carrying a defective OTC gene and another that is fully functional are known as carriers of the disease, and there is a 50% chance that their biological child would receive the dysfunctional gene. If that child has another X chromosome, they are a carrier as well. If they don’t, with the vast majority of these cases being diagnosed in patients assigned male at birth, they are significantly more likely to have severe disease that presents in the newborn period. There are exceptions, of course, such as in the case of Rohan Godhalia. Had Rohan lived long enough to have children, he would have pass his one defective X chromosome to each of them.
Symptoms from OTC deficiency are most likely to present in the newborn period once feeds start to pick up after the typical sleepy first day. By a few days of age, patients with early-onset disease, which is seen in roughly 1 in every 14,000 to 77,000 infants, will develop feeding difficulty and become excessively sleepy. This is often accompanied by abnormal breathing and problems maintaining a normal body temperature, and as ammonia level continue to increase unabated the brain will begin to swell, leading to seizures, coma, and even death over a period of hours to days if not treated with emergent dialysis. Surviving infants are still at risk of developing intellectual impairments and cerebral palsy over time, particularly if there are multiple episodes of severe hyperammonemia in childhood.
Some patients have a partial OTC deficiency and present later in adolescence or young adulthood. This usually occurs in carriers of the disease and is mild, but can rarely occur in patients assigned male at birth and even result in severe or fatal disease. Rohan is an example of this. OTC deficiency occurs in roughly 1 in every 35,000 people, but this likely underestimates the true incidence given how it likely misdiagnosed or undiagnosed in many people with a partial deficiency.
The most common clue that an older patient has a urea cycle defect such as OTC deficiency is when unusual symptoms such as headaches, nausea, and confusion are linked to high protein meals. It is not uncommon for these patients to have learned to reduce meat consumption, or even to have become vegan/vegetarian in response to their symptoms for years prior to being diagnosed. Some patients will also develop symptoms unrelated to protein intake, such as during stressful periods like pregnancy, intense exercise, illness, etc.
In the United States, only 8 states and territories have included OTC deficiency in their standard newborn screening programs. This involves the detection of decreased levels of citrulline in a newborn’s blood, which is an amino acid that is produced early in the urea cycle from ornithine and carbamoyl phosphate with assistance from OTC. Deficiency can also be detected indirectly by newborn screening in three additional states. Many babies with the condition will develop symptoms days prior to screening results being available, however, so pediatricians and family doctors who care for newborns need to be up to speed and to know when to check an ammonia level. England does not screen universally for the condition.
The plot thickens…..
I don’t have access to Rohan’s full medical or family history, so I don’t know if he or any of his relatives had episodes of recurrent symptoms consistent with OTC deficiency. That isn’t required, however. Some patients will go years, even decades, in apparent good health before a significant protein load or physical stress tips them over. And clearly, as with poor Rohan, not all cases are mild.
I found one interesting case report involving a healthy 34-year-old man who had developed acute mental status changes at age 30 that was initially diagnosed as psychosis. He subsequently had seizures that were misdiagnosed as epilepsy as well, but that was ultimately found to have partial OTC deficiency. He had apparently started an intense exercise program and increased his protein intake just prior to the onset of his odd symptoms. The authors of this report mention at least 10 other similar cases found in their literature search.
So it makes sense that, although this is a very rare scenario, Rohan’s liver was unable to handle a large protein load that was perhaps accompanied by exercise. What doesn’t appear to make sense to Rohan’s family, and honestly to me as well, is why an ammonia level wasn’t checked when he presented to care suffering from altered mental status without a clear etiology. He may have survived had emergent dialysis been provided.
An inquiry is underway looking into this issue as well as the question of why his organs were approved for transplant. I’m not an expert in these things, but I think it’s pretty unusual to clear organs without a known cause of death. Finally, and more pertinent to Rohan’s potential for surviving his condition, his family is asking why he wasn’t seen by a neurologist or transferred to a tertiary care center. It turns out that he was essentially listed as an adult and his transfer to a pediatric facility was rejected.
About those warning labels…..
According to the articles written about Rohan’s case, the coroner and at least one pediatric specialist have called for new regulations:
Coroner Tom Osborne said: “Concerning these protein drinks, my preliminary view about them is that I ought to write to one of the regulatory authorities that some sort of warning ought to be put on the packaging of these drinks because, although OTC is a rare condition, it can have harmful effects if someone drinks [one] and it causes a protein spike.”
Finbar O’Callaghan, professor of paediatric neurology at the Institute of Child Health, University College London, agreed intervention was needed, describing it as “potentially life-saving” at the hearing.
I’m skeptical that warning labels would make a difference. People who have a sense that they don’t tolerate meat, because of an undiagnosed partial OTC deficiency for example, aren’t going to know that it’s the protein that is the problem. So they wouldn’t think that the label applies to them. And if they have made that connection, they aren’t going to buy protein powder. For Rohan, I just can’t imagine how a label would have prevented his deterioration because it doesn’t look like he or his family had any concerns regarding protein consumption.
Patients with a known urea cycle defect are educated extensively on adhering to a low protein diet. They just wouldn’t pick up protein powder or drink protein shakes, and it’s important to point out that lots of people buy protein shakes from dining establishments without ever looking at a jug of powder. Are these businesses supposed to put up warnings or screen customers as well?
Protein powders and drinks might deserve some kind of warning for other reasons, however. And in fact some do when sold in California thanks to Proposition 65, which is also known as the Safe Drinking Water and Toxic Enforcement Act of 1986. Because of Prop 65, California maintains a list of chemicals linked with cancer or reproductive toxicity and products containing levels of such chemicals above a certain threshold must be labeled with a warning.
What is that threshold? For chemicals believed to cause cancer, it is the level of exposure that would result in not more than one excess case of cancer in 100,000 individuals over a 70-year lifetime. For reproductive toxicity, it is 1/1000th of the “no observable effect level” deemed safe by most relevant organizations such as the FDA and WHO. I can’t help but assume that there is a large amount of alarm fatigue that occurs in California and that these labels do little to influence use of these products.
There are definitely reasons to avoid protein powders and drinks. There are serious concerns regarding the presence of toxins in protein powders, for example. One 2018 study found that many protein powders contain heavy metals like lead and arsenic, bisphenol-A, pesticides, and other potential contaminants.
In addition, they are dietary supplements and thus regulation is weak and largely left up to the foxes to guard the hen house when it comes to safety. Consumers should approach labels skeptically with these and similar products because they may not provide accurate information. (Check out Scott’s post from yesterday for a nice discussion on this very problem.) There are also often large amounts of added sugar and excessive calories in these products. Essentially, there are better and likely safer ways to increase protein intake, which isn’t even necessary for most people.

TikTok driving chlorophyll supplement fad
#chlorophyll is latest supplement trending on TikTok.
Scott Gavura on April 13, 2023
Link

Leave it to TikTok to take an otherwise healthy food product – green leafy vegetables – and invent something that’s not even healthy. A trend that has been circulating for some time on TikTok is that chlorophyll, extracted from plants, has near-magical properties. Acne, bloating, and body odour disappear, replaced with flat stomachs and clear skin. While claims related to chlorophyll have been circulating for years, these types of trends are massively influenced by virality on social media. And TikTok (for now, at least) is one of the biggest platforms out there. With stores reporting that they have completely sold out of chlorophyll supplements, perhaps it’s time to take a closer look at what your teenager might be asking you to buy.
What is chlorophyll, anyway?
Chlorophyll is a group of pigments that share remarkable properties, and are arguably critical to life on earth. Beyond giving plants their green colour, chlorophyll is a critical component of photosynthesis, allowing plants to capture light energy from the sun and convert it to chemical energy. If you’ve forgotten much of your grade 10 biology (like I have), chlorophyll absorbs light absorb light and create ATP and NADPH. Plants can then converts carbon dioxide and water into glucose, while producing oxygen. That glucose powers the cell.
There are five main types of chlorophylls, but two (chlorophyll a and chlorophyll b) are the main ones involved in photosynthesis. Structurally they have a long tail and a ring (surrounding an ion of magnesium) that absorbs the light.

The nutrition of chlorophyll
Let’s say you’ve decided to take chlorophyll supplements. These probably contain chlorophyllin, which is a semi-synthetic and more stable derivative of chlorophyll. With chlorphyllin, the magnesium ion (see above) is replaced with another cation, usually copper. Or, you’ve simply decided to eat a salad of leafy greens.
If you’re eating plant-based sources, the chlorophyll will be liberated from the plant cells and distributed in the gastrointestinal tract. Chlorophyll is not soluble in water, and from what I could find, it’s not clear that it is even absorbed intact from the gastrointestinal tract. While we do know a diet rich in green leafy vegetables is healthy, there is no evidence that attributes this benefit solely or even partially to chlorophyll. It could be the fibre, potassium, magnesium, vitamins, or other components in these foods.
If you’re taking supplements, chlorphyllin is water soluble and more easily absorbed, compared to chlorophyll. It’s not clear if the product is absorbed intact but there is evidence that components of the molecule (i.e., copper) are absorbed.
Is there a role for chlorophyll as a supplement?
So let’s take a closer at clinical trials that have looked at the benefits of consuming chlorophyll or chlorophyllin. This will be a short section. Despite the popularity, evidence is lacking and unconvincing. While chlorophyll has been touted as a treatment for acne, allergies, odours (colostomy, halitosis, body odour etc.) and skin conditions including wounds, non-melanoma cancer and herpes zoster, there is no evidence to demonstrate that chlorophyll is effective for any of these conditions. There are very few clinical trials published that have studied chlorophyll supplementation (as food or otherwise) for effects in humans.
There is even less data for chlorophyllin, which is what a supplement will likely contain. The best evidence for its use is as a colouring agent, when present in limited quantities in food. When used topically, for conditions like acne, the evidence is not convincing that chlorophyllin provides any meaningful benefits.
Possible health concerns
Chlorophyll, when consumed as a component of food products, is safe to eat. There is little to no safety information on the use of high dose isolated/purified forms of chlorophyll when consumed, injected or used topically. Chlorophyllin supplements may contain copper in concentration at about 4%. When used as a colouring agent, there are no health risks with use. There is insufficient data on the absorption of chlorophyllin supplements, but there is evidence that it can raise copper levels. Supplementation can cause green discoloration of the urine or stool, as well as tongue discolouration. Given long-term consumption of high levels of copper is associated with health risks, there may be risks with long-term use of chlorophyllin – especially in children. There is no safety information on the use of supplements while pregnant or when breastfeeding.
The best source of chlorophyll
If you’re adamant about boosting your chlorophyll intake, the most “natural” way of all would be to skip the supplements and go directly for its primary source: food. Chlorophyll supplements are not cheap, and given the evidence and potential for side effects, that money is better spent on food. A diet that is rich in chlorophyll-containing foods is likely going to be a healthy diet.

Ashwagandha – An Herbal TikTok Sensation
Ashwagandha is another dubious herbal products marketing with inadequate evidence and poor logic.
Steven Novella on April 26, 2023
Link

Ashwagandha, an herbal supplement commonly used in traditional Indian medicine, is the latest fad herb trending on social media. It is also an excelent example of everything that is wrong with the herbal supplement industry.
Herbs are Drugs
The biggest problem with the herbal supplement industry and the rhetoric used to promote it is that it ignores the primary reality of herbal products – herbs are drugs. That is it – they are nothing more or less than pharmacological agents. This means they can cause drug-drug interactions, and they can have all the usual side effects and risks that pharmaceutical can have. They also are not very good drugs, because they have multiple potentially active ingredients, we don’t always know what they are, and they vary considerably among various preparations and even crop to crop.
The fact that there are multiple active ingredients is often marketed as an advantage, with the notion that there is a positive synergistic effect among these ingredients. But why would that be? Plants evolve chemicals to be toxins, to keep animals from eating them. There are no evolutionary pressures to be useful as medicinals. Polypharmacy is also tricky business, and is far more likely to enhance toxicity than any beneficial effect. Often the alleged benefits of herbal polypharmacy are explicitly supernatural in explanation, having to do with chakras, life energy, and a spiritual origin of the plants themselves. Looked at scientifically, however, the messy and variable polypharmacy of herbs should be viewed with extreme caution.
The supplement industry is also famously poorly regulated. There are problems with substitution, contamination, and adulteration. This has significant risks to the consumer. But it also means that clinical trials performed with verified and measured extracts will not necessarily translate to any product on the shelf.
Herbal drugs also have the potential for drug toxicity, even without contamination. The safety of herbs is often falsely assumed, based on the appeal to nature fallacy, but also on the fact that we simply lack adequate evidence for safety and toxicity. Ashwagandha, for example, is associated with cases of liver injury, a common drug toxicity.
What we should do is isolate and purify specific active ingredients, study them in isolation, and if they have a medically safe and exploitable effect, they can be provided at a known dose with a known safety profile, pharmacokinetics, bioavailability, risks, and interactions. Of course then, they are a normal pharmaceutical, and not a magical herb that can be marketed as “natural”.
Hyping Preliminary Evidence
The herbal industry thrives on preliminary scientific results. We have spent years and thousands of articles explaining in careful detail why preliminary medical evidence is unreliable and a poor predictor of actual safety and efficacy. It is quite possible that any particular herbal product may have useful medical effects – again, they are drugs. There is a potential mechanism by which they may have an effect. Also, some effects are easy to observe, which is why most cultures have managed to find local plants that act as hallucinogens. But subtle subjective effects and long term risks and altered health outcomes require careful scientific study.
What we see with Ashwagandha is the same pattern. Studies go back decades, and yet we have not yet managed to definitely answer the question of safety and efficacy. Herbal products seem to be stuck in this preliminary phase of evidence, perhaps by design.
Recent systematic reviews show similar results:
The current systematic review and dose-response meta-analysis of RCTs revealed a beneficial effect in both stress and anxiety following Ashwagandha supplementation. However, further high-quality studies are needed to firmly establish the clinical efficacy of the plant.
The individual studies are mostly small studies, often with methodological issues, and often with subjective outcomes. Again, it’s quite possible there is one or more active ingredients in Ashwagandha that has anxiolytic properties. But as we know from studies looking at anti-anxiety medications, preliminary positive results are often false positives, and it takes large rigorous trials to determine if an effect is real. The studies I looked at generally don’t assess blinding, which is problematic with an herb which can have many active ingredients, some of which may have noticeable effects. Without using an active placebo to conceal who is getting the treatment, or assessing blinding, we have no way of knowing.
We are often therefore left with the “more studies are needed” conclusion, and that status never seems to change.
Extrapolating from Basic Science
This is the aspect of the herbal industry (and the CAM industry in general) that I find most frustrating. What happens is that the substance in question is given even to animals or to cells in a culture, and then stuff happens. Whatever happens can be interpreted as a potentially beneficial effect. Immune function is an almost ubiquitous target.
Immune activity, first of all, is highly reactive. It seems to change and react to almost any stimuli. Anything that increases any marker of immune activity can be spun as “boosting” the immune system. Anything that decreases any marker of immune activity can be spun as “anti-inflammatory”. Sometimes both of these things are claimed at the same time. Of course, we could just as easily present increasing immune activity as causing inflammation and decreasing immune activity as “suppressing” the immune system. These interpretations are just as valid, and in fact are always the case. Even beneficial anti-inflammatories suppress the immune system, and anything that “boosts” the immune system can have negative inflammatory effects.
This is because the immune system is a double-edged sword. It fights off invaders, infections, and cancers, but it causes inflammatory stress and damage. Just increasing or decreasing immune activity is not inherently beneficial or harmful, and can be either. It all depends on the details, the targeting and regulation of immune activity. Even experts in immunology, designing a treatment for an inflammatory disease, have made wrong predictions in the past about net effects (see alpha-interferon and MS).
The same is true of steroids. Reducing corticosteroid levels in the body may be a marker of reduced stress, but these steroids exist in the body for a reason. They are part of a delicately regulated system kept in careful homeostatic balance. Altering this system in any one direction is not inherently good or bad. The same is also true of oxidative stress and anti-oxidants. This is another good example of simplistic herbal thinking – oxygen is good, except when it’s bad.
Conclusion
Is Ashwagandha a useful herb or just another herbal snake oil? I don’t know, no one does, and I think that’s the point. As an herbal treatment Ashwagandha has some plausibility, because (say it with me) it’s a drug, or actually a combination of multiple drugs. I find the pre-clinical data completely unconvincing, for the reasons I stated above. Stuff happens, it could be useful, it could be harmful. It could also be inconsequential.
The clinical evidence is also unconvincing. Like most other herbs, Ashwagandha is living in the world of preliminary evidence, like being stuck in scientific purgatory. I believe that is a feature not a bug of the CAM/herbal world. There is just enough evidence to use for marketing and promotion, without ever having the kind of evidence that would confidently indicate whether or not the herb actually worked for a specific indication. When we do sometime get that level of evidence (from NIH studies, for example) the results are usually disappointing.
Reports of liver damage are also very concerning. This is not something that should be casually dismissed. Long term use is also not reassuring. Most over the counter use likely involves small doses or low bioavailability. Low doses are less likely to have toxicity, but also less likely to have a beneficial effect. When you ramp up the concentrations and dosage to get an effect, that is where the toxicity also comes in. What matters is – is there a safe dose range? We can only know this if we carefully measure dosage, which is impossible with messy and variable herbs.
Which brings me to the ultimate conclusion – the problem is inherent to the herbal supplement industry itself. Using herbs as drugs has inherent problems. There is simply no advantage to this approach (except for the companies selling dubious products with unsupported claims). Herbs should be treated as the drugs they are – purified, studied, and regulated. Otherwise the probability of harm vastly outweighs the probability of benefit for the health consuming public. Although the most likely outcome is simply wasting billions of dollars on useless products.

Balm of Gilead
Balm of Gilead was mentioned in the Bible, but we don’t know what was in it. It is supposed to relieve pain, but we don’t know if it is effective; there are no controlled studies.
Harriet Hall on December 6, 2022
Link

I have been watching the National Geographic series Life Below Zero which profiles people who live off the grid in Alaska, often alone, meeting challenges with ingenuity and supplying their own needs by hunting, fishing, gathering, and cutting down trees for firewood. One of the people it features is Sue Aikens, a grandmother who lives alone at Kavik River Camp on the North Slope. One episode showed her preparing a salve from natural ingredients to treat her pain; she called it Balm of Gilead. She’s not an authority; she doesn’t have a medical or scientific background and relies on hearsay, but I wondered if there was any scientific evidence that Balm of Gilead was effective for relieving pain. I soon learned that we don’t really know what plant it was derived from.
According to Wikipedia:
Balm of Gilead was a rare perfume used medicinally, that was mentioned in the Hebrew Bible, and named for the region of Gilead, where it was produced. The expression stems from William Tyndale’s language in the King James Bible of 1611, and has come to signify a universal cure in figurative speech. The tree or shrub producing the balm is commonly identified as Commiphora gileadensis. However, some botanical scholars have concluded that the actual source was a terebinth tree in the genus Pistacia.
The Wikipedia article describes the linguistic confusion of various translations and lists various species of plant proposed as ingredients of the balm. Most of them are indigenous to the Middle East and do not grow in Alaska. Aikens may have used resin from the balsam poplar, but there is no evidence that that was in the Balm of Gilead mentioned in the Bible.
BytheSeaApothecary sells a healing salve containing “Wildcrafted Balsam polpar [sic] buds”. They describe it as “An aromatically rich all-purpose healing salve. Used for skin conditions including; eczema, psoriasis, diaper rash and chapped or itchy skin. Also provides relief to sore muscles, aching joints and sunburns and is gentle enough to use on children… works effortlessly to heal a multitude of skin conditions. Favoured by bees to prevent microbes and decay in their hives…”
They don’t provide any evidence for these claims.
Balm of Gilead is also the name of a project on end-of-life care for safety-net populations. They do not use the salve with that name.
The Balm of Gilead is also the title of a book about an ethnobotanist’s experience in the Amazon. I haven’t read the book, but I would be surprised if he claimed to have found actual Balm of Gilead in the Amazon. I presume the title was metaphorical.
It’s also the title of a novel and the name of an anointing oil sold by the Judaica webstore. They say:
This aromatic blend of essential oils is scented with the heady, sweet fragrance of Rose of Sharon, and enriched with the gold-colored sap extracted from the bark of balsam trees. Native to the Gilead region (an eastern territory of ancient Israel, now in Jordan), balsam trees and their resin are known for their antiseptic and analgesic properties. Perked up with invigorating mint, this anointing oil smells good and feels wonderful on the skin.
I checked PubMed and didn’t find much. One study found that beta-caryophyllene, a compound they say they isolated from the Biblical Balm of Gilead (which they identified as Commiphora gileadensis), is a selective apoptosis inducer for tumor cell lines. There were articles about the history and identification of plants that might have been in the Biblical balm, and a few non-helpful studies of poplar buds, but no controlled clinical studies of pain relief in humans.
Did the salve Sue Aikens prepared work to relieve her pain? The documentary didn’t say. If she thought it helped, we would have no way of knowing if it was just a placebo response.
Using a medicine mentioned in the Bible may impress some people, but we have no way of even knowing what was in the original Balm of Gilead or if it was effective. And we have no way of knowing whether the modern product Balm of Gilead or Sue’s homemade salve is effective. Would it be worth doing controlled studies? We might learn something, but I’m not convinced it would be worth taking the time and money away from other research that is more likely to be productive. Was it worth all the time and effort Sue Aikens put in to gather the ingredients and prepare the salve? If she had a placebo response, she might think so. It might have been just as effective to take her own advice: her motto is “If it hurts, don’t think about it.” That approach may not be possible for everyone, but it was for her. According to a report on the internet, when she was severely mauled by a grizzly bear and her hips were dislocated, she dragged herself to shelter and even managed to go out and kill the bear before she was found 10 days after the attack.

Tag Away
Harriet Hall on June 18, 2013
Link

Skin tags (acrochordon) are benign growths, often raised on a pedicle with a tiny stem. 46% of the population has one or more of them. They are usually ignored, but some people think they are ugly and want to get rid of them, and sometimes the lesions rub on clothing and become irritated. Never fear! Tag Away is here!
I saw it advertised on TV. They said it is “not available in stores.” But they only meant their special TV offer is not available in stores. You can buy Tag Away on Amazon.com, at Walgreens, at Walmart, and elsewhere. Tag Away is an all-natural product that promises to remove unsightly skin tags painlessly. It comes in a 15 cc bottle and is applied with a cotton swab 3 times daily for 3-8 weeks. One website claims:
One of the secrets of this product’s amazing success rate is Thuka [sic] Occidentalis, which is world-renowned for its ability to eradicate even the largest, most unsightly skin tags.
That’s not true. It doesn’t have an amazing success rate, it’s not world-renowned, and there’s no evidence that it can actually remove skin tags of any size.
Evidence
There isn’t any. It has never been tested in controlled trials.
Testimonials
There are the usual testimonials saying that it works, but there are many more testimonials saying that it does not work. On the Amazon website, negative customer reviews far outnumber the positive reviews. “The only thing this product was capable of effectively removing was money from my wallet!” “Does nothing but smell funny.” Some said even if it does work, it takes too long and stinks.
It stinks
Customers report a horrible smell. Some called it nauseating. Some said bystanders had asked them “what the hell is that smell?” One compared it to deer urine. One couple reported “The smell is so bad that there is no way you could apply this and leave the house…gave us terrible headaches.”
What’s in it?
The active ingredient is Thuja occidentalis, an essential oil. Other (presumably inactive) ingredients are cedar leaf oil, Melaleuca alternifolia leaf oil, and Ricinus communis seed oil.
Thuja occidentalis is a small tree, also known as white cedar, yellow cedar, arborvitae, and numerous other names. Despite the names, it’s not part of the cedar family. It has had a number of traditional uses, including teas for constipation and headache and external application for warts, ringworm, thrush, osteoarthritis joint pain, muscle pain, skin diseases, and as an insect repellent. The Natural Medicines Comprehensive Database (NMCD) says there is insufficient reliable information to determine its effectiveness. It warns against use during lactation and lists reported adverse reactions from oral use including seizures and death.
Melaleuca alternifolia is tea tree oil. It has been used topically for nail fungus, athlete’s foot and acne and is rated “possibly effective.” Topical application can cause irritation and inflammation in some patients.
Cedar leaf oil = Thuja occidentalis. It’s just another name for the active ingredient, yet it is listed as an inactive additive.
Ricinus communis = castor. It has been used topically as an emollient and to dissolve cysts, growths, warts, for osteoarthritis, and to soften bunions and corns, but there is no scientific evidence that it is effective for these uses.
Tag Away is advertised as “homeopathic.” Lists of the homeopathic uses of Thuja are endless, but they don’t mention skin tags. Interesting. I tried to find out what homeopathic dilution they were using, and it took 3 inquiries to the company to get an answer. They eventually divulged that the active Thuja is a 6X dilution. That’s not one of the extreme dilutions where no molecules are left. 6X means there is one part of Thuja to a million parts of water. It seems unlikely that a one to a million dilution would have any therapeutic effect, especially since there’s no evidence that full-strength Thuja has any effect. They said the other 3 ingredients were not homeopathic dilutions but they had no information about the amounts. The company does not claim that these other ingredients are “active,” but could there be enough to have some kind of positive or negative effect? A concerned consumer would like to know how much was present. If Thuja is the active ingredient, what does it mean when one of the presumably inactive ingredients is also Thuja? Did they realize the homeopathic dilution was insufficient and decide they needed to add more Thuja? And why did they add the tea tree oil and castor? A plausible rationale does not readily come to mind.
Questionable business practices
There is a money-back guarantee but it doesn’t include the $9.95 shipping and handling charge, and it is only for 30 days. They say it takes up to 8 weeks to work. So if you try it for 8 weeks and still have your skin tag, it’s too late to ask for your money back. By buying the product, you automatically commit yourself to an arbitration agreement that requires dissatisfied customers to submit to binding arbitration rather than attempting to resolve disputes in a court of law. In other words, you give up your right to sue. Customers are only released from the arbitration agreement if they return the product within 14 days.
There have been many complaints about the company, describing questionable business practices. They sell customer information to telemarketers and customers are bombarded with phone calls. Unauthorized charges are made to credit cards. One customer said he was unable to get the recurrent credit card charges blocked and had to close that card number and get a new one.
What other treatments are available?
Skin tags can easily be removed by a dermatologist using excision, ligation, cauterization, or freezing with liquid nitrogen. If they are pedunculated, they can also be removed at home by tying a string (dental floss?) around the base of the stem to cut off blood supply: the dead tissue falls off after a few days. One dissatisfied Tag Away customer reported, “Dental floss worked in about 2 weeks.” Other home treatments mentioned online are vitamin E oil, Compound W, and duct tape, but there’s no evidence that they work.
Amazon.com also sells other products for skin tag removal containing the same ingredients: Tag Be Gone, Tag No More, Miracle of Aloe Miracle Skin Tag Remover, Naturasil, and Tea Tree Oil.
Bottom line
These lesions are easy to treat at home or in a doctor’s office, with results much more rapid than 3-8 weeks. There’s no evidence that Tag Away works, and there are testimonials galore saying it doesn’t work. In my opinion, this product stinks in more ways than one.

Tonaki Tinnitus Protocol
Todd Carson promises to cure tinnitus in 21 days with a 3-ingredient smoothie containing vegetables from Tonaki. Fanciful claim with not a shred of evidence. The webpage even admits it’s fiction.
Harriet Hall on November 5, 2019
Link


Last week I wrote about LipoFlavonoid for tinnitus. I said there is no cure for tinnitus. Then I got this email that seemed to indicate I was wrong:
Stop the presses! (if there is still such a thing.)
Breaking news… Tinnitus can now be cured with a simple, three ingredient smoothie.
Yes, boys and girls, moms and dads, ladies and gentlemen, it’s true. It has to be. I read it on the Internet.
bit.ly/2PznkWM
The friend who sent the email is a skeptic who wasn’t trying to convince me there was a cure; he thought that website would make me laugh, and it did.
The claim is worth quoting in its entirety to illustrate its absurdity:
“Your tinnitus has nothing to do with your ears at all. But is instead, all down to a special type of “NERVE FAT” which every tinnitus sufferer is in short supply of. And right now, is being rapidly and ruthlessly destroyed by your own body.
We are quickly approaching the day when people who suffer from the horrible tinnitus symptoms can kiss goodbye to the worthless and expensive drugs, the ear pain and ringing.
Watch how, Todd Carson, a retired military officer was able to successfully treat his wife’s Tinnitus with a simple 3 ingredients smoothie, and in the process discovered the real cause of tinnitus.
Obsessed to help his wife’s painful battle with Tinnitus, Todd conducted a massive research with the help of his friend, an Ivy League University medical researcher, and found 3 special ingredients found on a tiny, barely populated island, which treat the root cause of Tinnitus. Against all odds, they created the tinnitus-silencing smoothie which would eventually save his wife from Tinnitus.
There is an accompanying video that wouldn’t play for me, but I found reports that it was tedious, lasted an hour, and consisted of pseudoscience and irrelevant verbiage. And at the bottom of the page, there is a note that this website is an advertisement. It states the usual requisite FDA disclaimer that the information is not intended to diagnose, treat, cure, or prevent any disease. In addition, it has this astounding admission:
any page on the website, is based loosely off a true story, but has been modified in multiple ways including, but not limited to: the story, the photos, and the comments. Thus, this page, and any page on this website, are not to be taken literally or as a non-fiction story.
In other words, you can’t believe anything you read here.
My first thought was that this had to be a spoof. Unfortunately, it isn’t. There are numerous websites with reviews of Todd Carson’s Tonaki Tinnitus Protocol, and numerous reports from people who have tried it. There are positive testimonials but also many negative comments. Needless to say, there are no scientific studies. An answer to a query on Quora said “Their website reeks of b*******.” It does, indeed. The story hits all the usual CAM tropes: ancient Oriental wisdom, criticism of mainstream medicine, warnings to eschew prescription drugs, conspiracy, attempted suppression by Big Pharma, “natural,” limited supply, money back guarantee, a time-limited discount, etc.
Tonaki is a small island in Okinawa where an elderly woman supposedly told Todd Carson about the recipes. The Tonaki Tinnitus Protocol is described in Todd Carson’s e-book with a 21-day diet manual and a list of nutrients to take and foods to avoid. The 3-ingredient smoothie combines these three ingredients:
     1.  Imo, a sweet potato
     2.  Kombu, a seaweed
     3.  Natto, a fermented soy bean delicacy
But the Protocol mentions at least 12 ingredients, “herbal treasures used by Japanese people for ages,” that are supposedly clinically proven to regenerate the myelin sheath around nerves, including a bitter melon called goya, Okinawan tofu, a bright green sea lettuce called Asa, and a cucumber-like vegetable called Loofah.
Another website promises a different natural 100% cure with ingredients that do not match the Protocol, including green tea, juniper berries, uva ursi, hibiscus, hawthorn berries, and vitamin C. It has the dire warning that tinnitus is the first signal that your brain could be dying! It is actually a sales pitch for the dietary supplement Tinnitus 911TM. That product is advertised to not only cure tinnitus, but to prevent Alzheimer’s, Parkinson’s disease, and brain tumors. It also allegedly improves memory and raises IQ. Again, no evidence.
Conclusion: No reason to think smoothies will cure tinnitus
Sufferers with tinnitus are not likely to find relief in these smoothies from Okinawa. Or from any other dietary supplement, except inasmuch as they distract the patient and induce a placebo response. But the claims can provide entertainment and provoke laughter.

Rightful for Pain: Deceptive Advertising and a Dangerous Ingredient
Rightful is an herbal supplement mixture offering pain relief and much more. Its claims are deceptive and not backed by good science. Not only that, but one of its ingredients is contraindicated.
Harriet Hall on March 16, 2021
Link

Rightful is a mixture of herbal ingredients alleged to relieve pain, improve sleep, and “restore your body to its optimal state”. They say, “Pain-free days are rightfully yours”. They advertise that it was designed by integrative and conventional medical experts, has the best bio-availability on the market, and provides high, clinically effective, scientifically proven precise doses of each component. Tieraona Low Dog is listed as “Rightful co-founder, Chief Innovation Officer and Formulator”. Her name will be familiar to critics of alternative and integrative medicine. She says, “crafting an herbal supplement is an art form.” Maybe; it sure isn’t science. No conventional medical expert is identified in their advertising.
They claim to have tested their formula, but the “testing” was laughable; they gave it to people and recorded their subjective reports of improvement. No control group, no comparison to placebos. All their “testing” did was confirm the effect of suggestion and the placebo response.
They claim to have the best bioavailability, but bioavailability doesn’t necessarily translate to improved clinical outcomes.
“We have consulted the latest clinical research to determine the precise amount of every therapeutic ingredient that’s most effective”. They don’t tell us what research they consulted, and I couldn’t find any such research. After all, why would they need research when they claim to be relying on an art form rather than science?
The ingredients
    • Turmeric rhizome – to help reduce inflammation
    • Corydalis – promotes pain relief and healthy circulation
    • Curcumin – helps inhibit inflammatory responses to physiological stressors
    • Broad-spectrum hemp – promotes healthy function of the central nervous system
    • Ashwagandha – supports the body’s response to stress and inflammation
    • California poppy – promotes restful sleep, relaxation and mental calm
    • Black pepper – enhances the absorption and effectiveness of turmeric and hemp
The evidence for these effects is pretty sketchy. For instance, the Natural Medicines Comprehensive Database rates California Poppy as “Insufficient evidence to rate effectiveness” and it says there is insufficient evidence to establish an appropriate dose.
What happens when you mix ingredients?
It may seem logical that if you mix two ingredients, there will be an additive effect. But that may not be true. The effect may be additive (2 + 2 = 4), may be potentiated (0 + 2 > 2), may be antagonistic (6 + 4 < 10), or may be synergistic (2 + 2 = >>>4, maybe as much as 10 times greater). There’s no way to reliably predict what will happen, so each combination must be tested.
Serendipity
As I was writing this, I received the current issue of The Medical Letter with their evaluation of ashwagandha (volume 63, issue number 1619, dated March 8, 2021). It was a revelation. Rightful claims its ingredients have no serious side effects. While it is true that no major adverse effects have been reported in clinical trials of ashwagandha, there have been many case reports that are very concerning. It has been reported to cause severe diarrhea, skin burning and discoloration, sedation, severe liver injury, heavy metal poisoning, thyrotoxicosis, increased testosterone levels, and miscarriage. The Medical Letter didn’t mince words. Its conclusion reads:
There is no convincing evidence that ashwagandha supplements are effective or safe for any indication; patients should be advised not to take them. FDA-approved drugs are available for treatment of all the conditions for which these herbal supplements are being promoted.
In all the years I have subscribed to The Medical Letter, I don’t remember them ever issuing such a strong condemnation.
Conclusion: This product can’t be recommended
Despite the testimonials, there is no science to back up Rightful’s misleading claims. And considering The Medical Letter’s condemnation of ashgawandha, it should not be included in any herbal mixture.
Reading the advertising for Rightful was not a total loss. I did learn something: now I know how to spell ashgawandha!

NAD Therapy
NAD therapy is touted as a cure-all for addiction and several chronic diseases. Evidence supporting these claims is lacking.
Scott Gavura on December 9, 2021
Link

While acceptance of the COVID-19 vaccine has generally been high, hesitancy and even refusal remain issues for some. I’ve wondered if vaccines might be better received (by some of the refusers) if, instead of an intramuscular injection, they were offered via intravenous infusions in beautiful “wellness clinics”, perhaps with a few vitamins and electrolytes added for good measure. For some, all those preferences for “natural” methods are ignored when it comes to intravenous infusions. How else to explain the perennial popularity of intravenous infusions of vitamins among naturopaths? These treatments are very popular with celebrities and influencers, too. Even Dr. Oz called them “cutting edge” way back in 2013 (that video is sadly no longer available). Not only do advocates claim vitamin injections offer medical benefits for an array of medical conditions (from cancer to macular degeneration to fibromyalgia and more), they are touted as helpful for preventing illness, too. Despite the continued hype, there is no evidence that vitamin infusions are necessary if you have a functioning gastrointestinal tract and are able to eat food.
Nicotinamide adenine dinucleotide (NAD) and its hydrate (NADH) therapy are dietary supplements touted to support brain illnesses (Alzheimer’s disease, Parkinson’s disease, dementia, depression) as well as high blood pressure and high cholesterol. It’s also promoted conditions like jet lag and even improve athletic performance. Given intravenously it’s also promoted as a treatment for drug addiction. Addiction is a topic that deserves more treatment here at SBM owing to the sheer amount of misinformation and bad science and policy that exists. When a reader recently pointed me to an NPR program on the inappropriate promotion of NAD for addiction, I thought it was worth taking a closer look at this product.
What is NAD/NADH/NAD+?
Nicotinamide adenine dinucleotide is a molecule present in every cell. NAD exists in an oxidized form (NAD+) and a reduced form (NADH). A coenzyme, its activity was first observed in 1906 when biochemists observed that a yeast extract could accelerate alcohol fermentation. It was isolated in the 1930s and synthesized in the 1950s. The primary and most important function of NAD+ is in cellular metabolism – it is present in every cell in the body. NAD is formed in the mitochondria from reactions with niacin, nicotinamide, and tryptophan. Many cellular functions utilized NAD and NAD phosphate (NADP) including the metabolism of tissues, lipids, and carbohydrates. Because it is involved in so many cellular functions and because there is some evidence that NAD levels may decrease with aging and with certain diseases, there is interest in whether supplementation with NAD could provide medicinal and even anti-aging effects. Given the importance of NAD to cellular function, the body can synthesize it through a number of different biochemical pathways. For the same reason, NAD and its synthesis pathway are the target of research in the treatment of diseases. For example, isoniazid, an antibiotic used to treat tuberculosis, is activated by an enzyme in Mycobacterium tuberculosis that then binds to NADH to create a molecule that inhibits cell wall production.
Does NAD therapy have medicinal potential?
Given the crucial function of NAD to cellular activity, and the systems the body has in place to synthesize it, it would be surprising if cellular function was sensitive to dietary or other forms of administration. There seem to be very few clinical trials that give us any meaningful information.
Parkinson’s disease: what appears to be the sole randomized, double-blind, placebo controlled trial was conducted in the 1990s to follow-up on anecdotal reports of benefits. A small trial (9 patients) found no benefit of intravenous or intramuscular supplementation.
Chronic fatigue: Natural Medicines Database rates this as “possibly effective” noting some trials suggested NADH might reduce symptoms of CFS when used alone or in combination with coenzyme q10. In one trial, benefits waned, in another, measures of fatigue improved. A third small trial was felt to be promising with results warranting a larger trial (which hasn’t appeared, 20+ years later).
Dementia: NADH supplements appear to be ineffective. After 12 weeks of oral treatment, dementia patients had no improvement in memory, cognition, or behavior.
I should also point to a 2020 systematic review that found only 18 clinical trials of NAD or NAD precursors like nicotinamide. Only two of these trials were considered adequately powered: A trial evaluating the supplementation of nicotinamide on the progression to Type 1 diabetes, which was negative, and an open label trial in Parkinson’s disease, which was positive.
NAD for addiction treatment
There is considerable interest in making NAD available for the treatment of addiction, but there is a lack of published evidence showing that this therapy is effective.
One provider claims:
It has been determined that the excessive use of drugs and alcohol will deplete the body’s natural stores of NAD. Because of this, the brain cannot receive the same energy it usually would from breaking down food. NAD Therapy floods the brain with the co-enzyme to replenish its stores, providing 4 key effects.
    • It flushes out all of the drugs that are still in the user’s system.
    • It reduces withdrawal effects, which can be extremely difficult and uncomfortable to tolerate.
    • It curbs the cravings for alcohol and Opioids and lessens the pain of withdrawal, making recovery easier physically and mentally.
    • It allows the body to produce energy more naturally, without a crash or jitters like Caffeine and sugar or the negative effects that come with other substances.
From an investigation into NAD marketing conducted by NPR in 2019:
Cheryl had taken Jason to the clinic out of desperation. Jason, now in his late 30s, has struggled with addiction since he was a teenager. Cheryl saw his drug use escalate after he was prescribed a benzodiazepine for his anxiety, and he eventually began using heroin and meth. Over the years, Jason would try to get into recovery, but treatment programs didn’t help him for very long.
“I thought he was going to die,” Cheryl says. (Side Effects and NPR are using only first names because Jason worried he would lose his job if his employer found out about his addiction history.)
In late 2016, she saw a local TV news segment about a clinic called Emerald Neuro-Recover. The staff there treats addiction with something called NAD therapy, an IV infusion that can contain amino acids and other nutritional supplements, including nicotinamide adenine dinucleotide, a compound found in living cells.
The infusion, which is delivered over 10 to 15 days, cost $15,000, and it wasn’t covered by insurance. But the TV report said Emerald’s treatment was “proven to wipe drug cravings away.” Cheryl was intrigued.
There is no published evidence to show that NAD therapy has any benefit in the treatment of addiction. But that hasn’t stopped an industry from flourishing:
“I don’t know where those claims could come from, but it doesn’t seem realistic to me,” says Emily Zarse, an addiction psychiatrist in Indianapolis. She says there’s insufficient evidence to support using NAD therapy over other standard treatments: “There’s no actual data on any of these things.”
For an additional $400 fee, Emerald patients can have their brain scanned at a nearby clinic to document their progress with NAD therapy. An Emerald brochure shows a series of scans from a woman whose “brain is suffering from alcoholism.” Areas that glow red, orange and yellow — “HYPERACTIVE and OVERACTIVE” — totally disappear from the scans after 12 days of NAD therapy, according to the company.
“This is totally bogus,” says Leslie Hulvershorn, an addiction psychiatrist at the Indiana University School of Medicine with expertise in brain imaging, who reviewed the images via email. “We do not have research in our field that allows us to use EEG or any other brain imaging technique to document treatment response.”
After decades of research, still no benefits shown
        ◦ Despite decades of pre-clinical research and a number of clinical trials that are small and lacked rigorous controls, there is no persuasive or convincing evidence that supplementation with NAD or its precursors has any medicinal or health benefits for the treatment of addiction or any other medical condition. Regrettably there is no shortage of providers that are willing to sell access to this therapy at exorbitant cost. Evidence and ethics are no barrier to provision, it seems.

Nada for NADA: “acudetox” not effective in addiction treatment
Jann Bellamy on September 1, 2016
Link
The National Acupuncture Detoxification Association (NADA) teaches and promotes a standardized auricular acupuncture protocol, sometimes called “acudetox.” NADA claims acudetox
encourages community wellness . . . for behavioral health, including addictions, mental health, and disaster & emotional trauma.
I do not know what “community wellness” is or how one measures whether wellness has been successfully “encouraged.” In any event, in the NADA protocol, acupuncture needles are inserted bilaterally into the auricle (outer portion) of the ear at a depth of 1-3 mm at five specific points (sympathetic, shen men, lung, liver, and kidney) and left in place for 45 minutes.
And:
Beyond the actual needling treatment, a key element of the protocol specifies qualities of behavior and attitude on the part of the clinician, consistent with what is known as the Spirit of NADA.
NADA claims there is
strong evidence for the effect of the NADA protocol in improving patient outcomes [in addiction treatment] in terms of program retention, reductions in cravings, anxiety, sleep disturbance and need for pharmaceuticals.
In support of these claims, NADA offers research in the form of Evidence for the NADA Ear Acupuncture Protocol: A Review of the Literature, an unpublished monograph available on its website. According to the Review, the “evidence base for the adjunctive use of the NADA protocol for addictions continues to grow” and that two recent studies “demonstrate that the NADA protocol in addition to standard care is significantly better than standard addictions care alone.” We’ll return to these claims shortly.
According to its website, NADA has trained more than 10,000 counselors, social workers, nurses, MDs, psychologists, acupuncturists, chiropractors, corrections officers, and others to use its protocol and over 1,000 addictions programs in the U.S. and Canada “now use acupuncture.” Graduates of their 70-hour program earn certificates which, in a number of states, entitle them to practice auricular acupuncture for addiction treatment. NADA also claims that over 25,000 providers worldwide have been trained and that the protocol is offered in 40 countries.
The practice of auricular acupuncture is governed by a patchwork of state laws with inconsistent provisions. In some, there is no specific law governing the use of auricular acupuncture. In others, statutes spell out who can be trained in auricular acupuncture (e.g., nurses, social workers), what they are called (e.g., “acupuncture detoxification technician,” “acudetox specialist”), and who must supervise them (e.g., acupuncturist, medical doctor). Some states incorporate NADA’s training standards without mentioning NADA; others specify NADA training. NADA actively lobbies for laws permitting those who are not licensed acupuncturists to perform the NADA protocol.
One source mentions French neurologist Paul Nogier and his “discovery” of a fetal homunculus on the human ear in discussing the use of auricular acupuncture in addiction treatment. In an apparently independent “discovery” (whose relationship, if any, to Nogier is unclear), in the 1970s, a Dr. H.L. Wen was investigating electro-acupuncture for analgesia in Hong Kong. Patients reported that their desire for heroin was eliminated after the electro-acupuncture treatment. (Heroin abuse was rampant in Hong Kong, hence the number of users scheduled for surgery.) Case studies, but no trials, of the procedure were published.
Dr. Michael O. Smith, who worked at a methadone treatment program at Lincoln Hospital in the South Bronx in New York City, was looking for alternatives to methadone and heard about Dr. Wen’s work in the 1970s. He originally used electro-acupuncture, but switched to auricular acupuncture at some point, which he apparently used as a primary, and not just adjunctive, treatment. He chose the five points based on traditional Chinese acupuncture maps supposedly “known to give the best results in treatment of drug dependence.” Smith reported great success anecdotally, but no clinical trials were done. At Lincoln, Smith expanded the use of auricular acupuncture from heroin addiction to crack cocaine and alcohol dependency. In 1985, Smith (who is still on the Board of Directors) and others formed NADA.
In 1989, Dade County, Florida started the nation’s first “drug court,” that is, a program to divert those charged with certain drug crimes to treatment. It incorporated acupuncture detoxification into its program. Other jurisdictions followed suit and one source claims it is used in 40% of drug courts. Yet, in 1991, the National Institute of Drug Abuse (NIDA) conducted a technical review of acupuncture for opiate dependence, noting that “very little methodologically solid work” had been done in the 1970s and 1980s. In a criticism reminiscent of one we often make on SBM, NIDA chastised the premature adoption of acupuncture treatment:
[A]cupuncture procedures have been accepted and expanded over the same period of time and are now used in the treatment of cocaine and alcohol dependence. While some studies have emerged that were experimentally and clinically reasonable, the consensus was that much fundamental work remains to be done and that after two decades of contemporary use in the field of addiction, there is no compelling evidence for the efficacy of acupuncture in the treatment of either opiate or cocaine dependence.
Does NADA’s evidence support the protocol?
In the twenty-five years since, there is still no compelling evidence, but you’d never know that from reading NADA’s Evidence for the NADA Ear Acupuncture Protocol: A Review of the Literature. (The Review is undated, but another source dates it as 2013.) The author, a Doctor of Oriental Medicine and a NADA Registered Trainer, reaches his positive conclusions about the NADA protocol by cherry-picking the evidence. (Unfortunately, so does a Bureau of Justice Assistance Drug Court Technical Assistance Project on the subject.) That fact, unfortunately, is lost on public policy makers. Just last month, in yet another example of Legislative Alchemy, the Governor of Rhode Island signed legislation allowing chemical dependency professionals to use “auricular acudetox” in their practices “in accordance with the NADA protocol.”
The Review also says that evidence supports the NADA protocol as an adjunctive treatment for nicotine addiction, behavioral health (e.g., PTSD), and for cancer and blood disorders, topics this post will not address.
The Review makes two claims for use of the NADA protocol for addictions:
     1.  The prevalence and appropriateness of acupuncture for addictions is well established.
     2.  The evidence base for the adjunctive use of the NADA protocol for addictions continues to grow.
Prevalence, of course, is not indicative of effectiveness. As for “appropriateness,” the Review says the Center for Substance Abuse Treatment, the UN, New Mexico and the U.S. Department of Defense/Veterans Affairs all include best practice guidelines “that address the value of acupuncture for chemical dependency.” This statement is true – they do mention acupuncture. But, the Center for Substance Abuse Treatment actually says there is no conclusive data. The UN’s Drug Dependence Treatment: Interventions for drug users in prison cites only one pilot study published in Medical Acupuncture. New Mexico’s prison reform task force report claims acupuncture is “very effective” but cherry picks the evidence in its brief review. The VA Clinical Practice Guideline is for PTSD, not substance abuse. In any event, as we know, the VA has a weakness for unproven CAM treatments and this document is no exception. David Gorski recently deconstructed the VA’s promotion of acupuncture, including for PTSD.
A review of the Review
Let’s turn, then, to the Review‘s claim that the evidence base “continues to grow” for the NADA protocol in treatment of heroin, alcohol and cocaine addictions. In support of his conclusion, the author cites eleven journal articles. Five of the studies reported in these articles were pilot studies, which do not evaluate safety, efficacy or effectiveness. (Bullock, Culliton; Bullock, Ulmen; Chang; Russell; Santasiero – I could not locate this article based on the citation given, but the title says it is a pilot study.) Significantly, the author fails to mention that two of the pilot studies were followed by a large randomized controlled study of auricular acupuncture for alcohol dependence, carried out by some of the same researchers, that did not confirm their results:
In this study, we extended the work of our early pilot studies . . . utilizing a more powerful design in an effort to further delineate the role of acupuncture in the treatment of alcoholism. . . In summary, our findings do not support the addition of acupuncture to conventional treatment in the treatment of alcoholism.
Of the remaining citations in support of the NADA’s claims, one (Bergdahl) simply described 15 patients’ “experiences” of the NADA protocol during post-acute withdrawal. Another (Janssen) was a feasibility study.
The rest do little to make up for the lack of evidence of effectiveness presented so far:
Avants: Participants receiving NADA protocol had significantly fewer positive urine samples over 8 weeks than 2 controls. No significant differences between the 3 treatment conditions in ratings of satisfaction with sessions, duration of treatment effects, or willingness to pay for future sessions. Comparisons between the 2 needle-insertion conditions disclosed no significant differences on ratings of pain. Relaxation controls reported significantly more relaxation effects after sessions than did patients assigned to either type of needle insertion. Practitioners unblinded, participants partially blinded, high dropout rate.
Carter: Prospective trial in a self-selected population of nonrandomized patients. “NADA acupuncture may help facilitate significant reduction in cravings, depression, anxiety, anger, body aches/headaches, concentration, and decreased energy.”
Schwartz: “[O]ur study is of the value of outpatient detox programs that utilize acupuncture; it is not of the contribution that acupuncture makes to the outcomes associated with these programs.”
Washburn: “Attrition was high for both groups, but subjects assigned to the standard treatment attended the acupuncture clinic more days and stayed in treatment longer than those assigned to the sham condition.”
On the other hand . . .
In addition to the large RCT that refuted the results of earlier pilot studies of auricular acupuncture, the NADA’s research monograph fails to cite other studies and reviews of the evidence that do not support the NADA protocol for addiction, either as a primary or adjunct treatment. This is even more inexplicable in light of the fact that what is described as a “bibliography of research” on the NADA website does list some of the omitted journal articles, although the list does not give any information about their conclusions. Thus, the existence of the studies was known, but they were ignored in the Review. In fact, there are so many studies and systematic reviews concluding that acupuncture, auricular acupuncture and/or the NADA protocol are not effective in the treatment of addiction, you could well find the repetition boring, but here we go:
“Efficacy of acupuncture for cocaine dependence: a systematic review and meta-analysis ,” published in 2005, concluded that the research does not support the use of auricular acupuncture for cocaine dependence.
A systematic review of acupuncture for opiate addiction, including auricular acupuncture, published the next year in the Journal of Substance Abuse Treatment found that
acupuncture treatment does not demonstrate the type of qualitative and quantitative research needed to validate its efficacy in the treatment of opiate-addicted (or cocaine-addicted) patients . . . [W]hen well-run methodologically sound studies are painstakingly administered, the placebo effect become apparent and the minimal efficacy of acupuncture in opiate addiction can be demonstrated.
A Cochrane Database Systematic Review, also published in 2006, concluded there is no evidence that auricular acupuncture is effective for cocaine dependence and that
[t]he widespread use of acupuncture is not based on sound evidence.
A 2012 systematic review of acupuncture studies, including auricular acupuncture, for attendance rate, craving scale, and opiate withdrawal symptoms said that, after 35 years of research by both Asian and Western scientists, the efficacy of acupuncture in the treatment of opiate addiction had not been established.
A 2009 systematic review came to the same conclusion for alcohol dependence.
A 2004 systematic review of the efficacy of the NADA protocol itself “could not confirm” it was effective for cocaine abuse.
A 2002 randomized controlled trial studying the NADA protocol for cocaine addiction, published in JAMA, concluded it was no more effective than sham needle insertion or a relaxation control in reducing cocaine use as either a stand-alone treatment or where patients were receiving only minimal concurrent psychosocial treatment, nor did acupuncture improve retention rates in the treatment program.
Fortunately, later trials with similarly negative results have begun to question the NADA protocol’s continued use. In 2008, a study concluded that auricular acupuncture had no effect upon withdrawal severity or craving when provided as an adjunct to a standard methadone detoxification regimen.
The results are consistent with the findings of other studies that failed to find any effect of acupuncture in the treatment of drug dependence. The failure to find any clinical gains from the adjunctive use of auricular acupuncture during detoxification from opiates raises concerns about the widespread acceptance of this intervention.
Another, published in 2011, was, according to the authors, the first randomized controlled trial to use objective measures in evaluating the efficacy of the NADA protocol for reducing anxiety in patients withdrawing from psychoactive substances.
The authors noted that
despite a lack of research evidence, the NADA protocol remains in use in more than 700 treatment facilities in the United States, as well as in approximately 30 countries worldwide. To date, more than 15,000 individuals have received training in the NADA protocol.
Their own randomized controlled single-blinded clinical trial, they said, added to the body of evidence refuting the NADA protocol’s utility. Thus,
Collectively, these findings are leading many substance abuse treatment agencies to question the appropriateness of the therapy.
However, having made its excellent points about the lack of evidence and the sensible pushback against using the NADA protocol, the article ends on this unfortunate note:
Evidence-based decision making tells us that evidence is only one part of the decision-making process (Sackett, Richardson, Rosenberg, & Haynes, 1997). Equally important to the clinical decision-making process are conclusions from clinical observation and patient values and perspectives. As such, it would be inappropriate to conclude that he NADA protocol is without value based on only one aspect of the decision-making process.
No, it wouldn’t. Sackett, et al., didn’t say the clinician should ignore the evidence in favor of uncontrolled clinical observations and misinformed patient choices, which is what the authors appear to suggest. They actually said:
The practice of evidence based medicine means integrating individual clinical expertise with the best available external clinical evidence from systematic research.
The “best available external clinical evidence from systematic research” tells us that the NADA protocol is ineffective.
Finally, a panel of 75 addictions experts rated 65 addiction treatments to establish a professional consensus on discredited treatments, rating them on a 1 (“not at all discredited”) to 5 (“certainly discredited”) scale. The results, published in the Journal of Addiction Medicine in 2010, scored auricular acupuncture for cocaine addiction at 3.88, 4 being “probably discredited.” Acupuncture for alcohol dependence and cocaine dependence scored 3.5 and 3.7, respectively.
Conclusion: Acupuncture does not treat addiction
The NADA protocol was conceived and initially used based on pre-scientific myths about human functioning and anecdotal evidence. As is the case with acupuncture studies in general, more rigorous trials failed to support the initial weak evidence in its favor, either as a primary or adjunctive treatment for addiction itself or related symptoms. It is an elaborate placebo masquerading as an effective adjunct treatment for addiction. Yet, NADA continues to push its protocol by cherry-picking the evidence and continues to teach it to addiction treatment professionals and lobby for it in state legislatures. Via the magic of quackademic medicine, Yale has established a NADA training program for its psychiatry addictions fellows, despite its admitted lack of evidence, resulting in physicians “integrating acupuncture into their current practice.”
Not content with its unsupported claims for use as an adjunct to addiction treatment, NADA has been seized by a bad case of mission creep and branched out into promoting the protocol for behavioral disorders, such as PTSD, disaster relief/humanitarian aid, and “adjunctive care and self-help support” for cancer and blood disorders. That, of course, is the beauty of alternative/complementary/integrative medicine. Evidence doesn’t matter.

Khat and Muguka Use in East Africa
Steven Novella on May 29, 2024
Link

Many countries (such as Kenya’s recent regulatory changes regarding Muguka use) are struggling with the dilemma of how to regulate drug use by its citizens. There are many psychoactive drugs (we seem to be good at discovering them) with a variety of effects. Often there may be subjectively desirable effects in the short term, but long term addiction, the potential for withdrawal, and a host of physically and socially destructive effects.
Use of these drugs exists on a spectrum from medicinal to cultural, recreational, and addictive. There doesn’t seem to be a strong consensus about how best to regulate their use, and even if we should, but there is a clear social cost regardless of which approach is taken. It’s just a matter of which tradeoffs we are willing to accept.
But this debate is not the main focus of this article, just the background. The angle I do want to discuss, as it is central to the principles of SBM, is that whether or not psychoactive drugs with a potential for addiction and abuse are “natural” or synthetic is entirely irrelevant, at least directly. Synthetic versions tend to be more purified and potent, and therefore a much lower dose can often achieve the same effect.
We see the result of this with the Fentanyl crisis in the US. Fentanyl is a synthetic opioid that is 100 times as potent as morphine, and 50 times as potent as heroin. It was created for medical use but eventually the drug trade discovered how to make it in their own labs. The majority of fentanyl in the US is made in Mexico from chemicals sourced from China. It is then sold as is, or cut into other street drugs. Users can then unknowingly get an extremely high dose of this opioid, leading to overdoses.
Kenya is now facing their own drug crisis, in the form of Muguka. Muguka is a variety of the Khat plant, which has long been used as a stimulant. The young leaves or buds are chewed, causing a stimulant effect. The main active ingredients are cathine and cathinone, which are amphetamine analogues. Muguka is a more potent variety that is increasing the use, addiction, and withdrawal symptoms in users and is being blamed for increases in crime and mental illness.
The pharmacological effects of Khat use, and specifically cathine and cathinone, are well studied and documented. They are amphetamines with the same effects and other similar drugs. According to the NIH:
“The main toxic effects include increased blood pressure, tachycardia, insomnia, anorexia, constipation, general malaise, irritability, migraine and impaired sexual potency in men.”
In the US synthetic versions of cathinone, known on the street as “bath salts”, are a significant problem and are responsible for incidents of extreme violent and destructive behavior.
There was a push to ban Muguka in Kenya as its popularity grew. A 2019 study, looking at Khat use, found:
“The prevalence of current khat chewing in the region was at 36.8% (n = 306) with a male gender predominance (54.8%). At least one psychotic symptom was reported by 16.8% (n = 168) of the study population. Interestingly, psychotic symptoms in general were significantly prevalent in women (19.5%) compared to men (13.6%) (p = 0.023). Khat chewing was significantly associated with reported strange experiences (p = 0.024) and hallucinations (p = 0.0017), the two predominantly reported psychotic symptoms.”
In the last few years these numbers have grown with the introduction of the more potent Muguka, leading ultimately to a recent ban. However, Kenya’s president recently reversed the ban, mainly due to pressure from local farmers who rely on Muguka as a cash crop.
Another aspect of the phenomenon is that many farmers, including small scale farmers, are growing Muguka instead of food crops. This is exacerbating the food insecurity problem in the region, but the farmers cannot pass up the increased profit from selling the drug. They can make three times more selling Muguka than food crops.
And there the issue sits, without a clear resolution. But this is just one example of the many similar plants that contain significantly doses of psychoactive drugs. In the US we are also dealing with Kratom, which is again a “natural” plant that contains opioid like drugs with addiction and withdrawal potential. It is being marketed, however, as a “natural” alternative with resistance to regulation.
        ◦ Whatever decisions we ultimately make about the regulation of these substances, we need to remain clear-eyed that they are drugs, taken for their pharmacological effects. The fact that they are plants or “natural” is not relevant.

Mayim Bialik’s Neuriva Commercials Make Questionable Claims
Mayim Bialik is a neuroscientist. In her TV commercials for Neuriva Plus she asserts that it is backed by strong science. I don’t think so.
Harriet Hall on July 6, 2021
Link


I wrote about the brain supplement Neuriva over a year ago. I thought their claim to have proof from clinical studies was misleading. I won’t repeat here what I said there about the evidence: I urge you to click on the link and read what I wrote.
An article in Psychology Today reviewed the evidence and called it “Neuriva nonsense” and “just another snake oil.”
Now they are selling Neuriva Plus, which combines the ingredients in the original Neuriva with vitamins B6, B12, and folate. Do they have any evidence that adding these vitamins enhances the effectiveness of Neuriva? Of course not! Neither Neuriva nor Neuriva Plus has been clinically tested. They are relying on studies of individual ingredients, and those studies are questionable. The results have been mixed, and one study was in aged mice!
Now Mayim Bialik has embarked on a campaign as Neuriva’s science ambassador. You may have seen her commercials on TV where she says she “loves the science of Neuriva” and claims it supports six key indicators of brain health. You may remember her as Amy Farrah Fowler, Sheldon’s girlfriend in The Big Bang TV series.
Elsewhere she has said:
Neuriva Plus is backed by strong science — yes, I checked it myself — and it combines two clinically tested ingredients that help support six key indicators of brain health.
She holds a PhD in neuroscience, but I couldn’t find whether she ever actually worked as a neuroscientist. It’s obvious that her understanding of “strong science” doesn’t mean what she thinks it means. I doubt if she reads Science-Based Medicine or understands the principles we go by.
Conclusion: Bialik is a good actress
Does Neuriva Plus support brain health? Maybe. We have no way of knowing for sure until the product itself is clinically tested.

Procera AVH: A Pill to Restore Memory
Harriet Hall on September 18, 2012
Link
At the recent Amaz!ng (no, the ! is not a typo) Meeting in Las Vegas, Dr. Gorski, Dr. Novella, “Dr. Rachie” (Rachael Dunlop of Australia) and I participated in a workshop on “Dr. Google” about how to find reliable health information on the Internet. In my presentation, I described step by step how I researched a typical diet supplement product, Procera AVH. Later, one of our readers wrote to ask us about that very product, so I decided to convert part of my presentation into this blog post.
The Trigger
A half-page spread in my local newspaper proclaimed: “Memory Pill Does for the Brain What Prescription Glasses Do for the Eyes, Claims US Surgeon General Candidate.” It looked superficially like a news report, but it was actually an advertisement for the diet supplement Procera AVH. Closer inspection revealed the words “Paid advertisement” in tiny print, the required FDA disclaimer for diet supplements, a “Call Toll-Free” number and offers of a FREE Bonus Bottle, FREE book, and FREE supply of Rapid Detox Formula for First 500 Callers.
The Problem
The ad said we lose one-third of our brain power by the age of 40, and 50 percent by the age of 50. The decline is so gradual that we may not even notice how impaired we have become. Do you routinely lose your car keys, forget to call people back, or misplace your TV remote control? Help is on the way!
The Claims
    • Helps restore up to 15 years of lost memory power in s little as 30 days.
    • Unique, fast-acting process that pumps the brain full of more energy, improves blood circulation to the brain and increases the key neurotransmitters that are responsible for cognitive functioning.
    • 3 clinically validated brain energy nutrients in the formula have been shown to “light up aging brains like a Christmas tree.”
    • Revitalizes tired sluggish brain cells with a fresh supply of oxygen and key vital nutrients.
    • Clinically shown to quickly help improve memory, focus, concentration and mental energy!
    • Time Travel for Your Brain
The Testimonials
    • I felt like I did when I was younger. I had my mental edge back.
    • It helped me speak out more than I used to. I am growing more confident every day.
    • I feel so much more focused and with the new energy I’m now ready to tackle the things I’ve been putting off for years.
    • Even my husband was impressed with my improved memory.
“Claims US Surgeon General Candidate”
Who is this Surgeon General candidate? In the ad, he is identified as Dr. Paul Nemiroff. Who is this guy? Is he an expert whose word we should trust? An Internet search revealed that he is an MD and PhD with good credentials, but he is also a TV medical journalist and the inventor and seller of his own diet supplement product, Joint Formula 88. The Procera website says he has published “hundreds of articles,” but PubMed only lists eight. The website says he was “invited to the White House where he was considered for Surgeon General of the United States.” I couldn’t find any independent verification of that; but even if it’s true, who considered him, the President or the janitor? Even if a president had seriously considered appointing him to the post, that doesn’t carry much weight. Presidents are not exactly the best judges of a person’s scientific credibility: after all, one of our recent presidents followed the advice of an astrologer.
Similar Ads
A correspondent sent me an almost identical ad from his local paper. In that version, the Surgeon General candidate is mentioned in the headline but not in the body of the text. In that version, the picture of Dr. Nemiroff is replaced by a picture of Dr. Robert Heller. In that version, Dr. Heller is quoted as saying word for word what Dr. Nemiroff was quoted as saying in my version of the ad. That’s curious. Plagiarism? Great minds think (exactly) alike? Total fabrication?
The Website
I went to the company’s website to see if I could learn more. It features a video with the title “Breaking News” that is obviously intended to make you think it’s from an actual TV news program, with a reporter behind a news desk, but it’s really an infomercial featuring Dr. Nemiroff. The website features the usual testimonials and special offers. It also has a “Clinical Research” tab. I figured if they had any real evidence, that’s where I could find it. But it wasn’t very helpful. It said a study was done but it provided no links, details, or even information that would help locate the study.
The Study
I really wanted to read that study, and there were enough clues in the newspaper ad that I was able to locate it after a short detour. The ad said that a randomized, double-blind, placebo-controlled study was published in JANA, “A Leading Scientific Journal.” How many of you read that as JAMA? I’m sorry to say I did. When I googled “JAMA Procera” the first hit was a news story in a Tampa newspaper that pointed out it was not the JAMA but the JANA.
The JAMA is the prestigious Journal of the American Medical Association. JANA is the Journal of the American Nutraceutical Association, an obscure journal that was published erratically (1-4 issues a year) from 1996 to 2009. It’s not even listed in PubMed. The only way to access its articles is to purchase their CD containing all the back issues.
I was able to find a copy of the study online on another Procera website. I asked the four questions Bausell proposed in his book Snake Oil Science as a quick indication of study quality:
    • Was it randomized with a credible control? Hard to say. They don’t describe the placebo or the randomization process, and they didn’t do an exit poll to see if patients could guess which group they were in.
    • Were there over 50 subjects in each group? No, 43 and 31.
    • Was the dropout rate less than 25%? Yes, 18 percent.
    • Was it published in a high-quality journal? No.
The study found that compared to the placebo group, the Procera group showed significantly more improvement in 3 areas: working memory accuracy, long term memory consolidation, and one measure of mood. But there were no significant differences in several other measures of mood or in any of the other things they measured, like information processing speed, reaction time, etc. The magnitude of the statistically significant differences was small and probably not clinically significant. And of course, we can’t be very confident that the results are valid, because it was only one study, it was commissioned by the manufacturer of the product, and it has not been replicated.
How the Company Reported the Study
They claimed it showed improved mental clarity, focus, and concentration; improved ability to learn and recall information faster; sharpened thinking and mental quickness; boosted alertness and mental energy; elevated mood and self-confidence; reduced anxiety and stress. It didn’t.
What’s In It?
Procera AVH contains 3 ingredients. The A is Acetyl-L-carnitine, the V is vinpocetine and the H is Huperzine-A. How much of each? They’re not telling. All they disclose is that each pill contains 1515mg of “proprietary blend.” Have any of these ingredients been shown to improve memory? I looked in PubMed, Cochrane reviews, Wikipedia, and the Natural Medicines Comprehensive Database to try to determine what published evidence there was for each ingredient. The Natural Medicines Comprehensive Database gave the 3 components “possibly effective” ratings for dementia (not for memory enhancement in non-demented people). Its safety ratings varied from “possibly safe” to “likely safe;” it listed a number of adverse reactions and warned of interactions with drugs (one “major” warning and 5 “moderate” warnings).
Evidence for Efficacy
Vinpocetine. In a study of 12 healthy volunteers, memory improved with the 40 mg dose. A Cochrane Review found 3 studies in adults with dementia and said they were inconclusive.
Huperzine A. A small study of students in China showed improved memory and higher test scores. Some studies in adults with dementia were favorable, but a Cochrane review found inadequate evidence to draw any conclusions.
Acetyl-L-Carnitine. A Cochrane review found that the only studies were in Alzheimer’s disease, and while there was evidence of benefit on global clinical impression, there was no evidence using objective assessments.
A research section on the Brain Research Labs website lists more studies that supposedly support Procera AVH. They don’t. One study showed that huperzine A improved abnormal lipid peroxidation and superoxide dismutase in aged rats. Another showed an effect of vinpocetine on warfarin-induced inhibition of coagulation. Another study was on oxidative damage and mitochondrial decay in aging. Their list doesn’t contain a single study of Procera AVH — not even the JANA study.
The company’s website says Huperzine has been shown to improve learning and memory at all ages. It hasn’t.
Supplement Geek Digs Up Some Dirt
When I searched the Internet for criticism of Procera, I stumbled upon the very handy website of Supplement Geek, who reviews supplements with a critical eye. I like this guy; I will definitely be re-visiting his site.
He found that the company’s address was in a residential area, that there is no company website other than the Procera website, that the company is not accredited by the Better Business Bureau and that multiple complaints have led to a BBB alert, that money-back guarantees are not honored, that customers are enrolled in an automatic shipment program that continues to bill their credit card until the customer takes action to stop shipments, that Dr. Nemiroff has a financial interest in selling the product, and that there are safety concerns.
Supplement Geek reviewed a deceptive 30-minute TV infomercial for Procera. Its host is the same as the reporter on the pseudo-news website video, a woman billed as “an award winning investigative reporter.” Actually she was a former TV news anchor and guess what? She just happens to be Dr. Nemiroff’s wife!
He also looked for information about the product’s inventor Josh Reynolds, billed as a brain scientist researcher and author as well as a pioneer in the study and science of the brain and cognitive performance. He found evidence that Reynolds had attended college but no evidence that he had earned any college degrees or that he had any medical training or even any background in science.
Conclusion
The evidence for the individual ingredients and for the product is of low quality and inconclusive. Some of the company’s claims are clearly false; others are speculative hype. The advertising is highly deceptive and raises many of the red flags associated with quackery. Does Procera AVH work to improve memory? Maybe it does … if you can remember to take it! Maybe it does nothing. Maybe it does more harm than good. We have no way of knowing. I’m not buying.

Bad Documentary Review: The Great Culling
The Great Culling is a mess of an anti-fluoridation documentary trying to scare you into…something. I watched it so you don’t have to, and you shouldn’t.
Braden MacBeth on June 19, 2021
Link

Tap water fluoridation has been called one of the most successful public health interventions of all time by the CDC. It has all of the hallmarks of a good public health intervention; it’s cheap way to prevent tooth decay, it can benefit everyone regardless of access to healthcare, and best of all it doesn’t require any effort for people to take advantage of it. Unfortunately like all public health interventions, it sounds like you’re doing something bad when you take it out of context. Tap water fluoridation attracts no small amount of conspiracy theorists claiming public health advocates want to dump “toxic chemicals” in the water supply.
Which brings me to my most recent find from my hunting trip in the Amazon: The Great Culling: Our Water by Paul Wittenberger. The film is described as: “an investigation of the theory that adding fluoride to drinking water is not as beneficial to dental health as originally thought, and may in fact be one of the causes of a cornucopia of neurological diseases that have arisen over the past several decades in America”. Fluoride fear mongering is nothing new, and it’s been covered multiple times on SBM. Even the most poorly designed studies about potential health risks of fluoridated tap water are still able sneak their way into prestigious medical journals and get tons of attention from the media.
Tap water fluoridation is safe and it really works for preventing tooth decay. According to the American Dental Association, tap water fluoridation prevents about 25% of tooth decay cases. They also estimate for most cities, every dollar spent on tap water fluoridation saves 38 dollars in dental treatment costs. Unfortunately because of documentaries like The Great Culling, they can get people to protest at city council meetings when tap water fluoridation is on the agenda. These groups are highly active and can push legislators to make the wrong decision.
Let’s look at one example: the town of Windsor, Ontario. In 2013, the city council decided to stop fluoridating their tap water after a town hall debate. You’ll never guess what happened next. Public health agencies started urging the city council to start fluoridating the water again after it was found that the cases of tooth decay requiring urgent treatment in children increased by 51%. The number of such cases was double that of neighboring counties that did fluoridate their water. So documentaries like this can spur political action that leads to bad public health outcomes.
The Great Culling misrepresents the history of tap water fluoridation, chemistry, and the causes of serious fluorosis. It shouldn’t be taken seriously by anyone. Let’s look at why.
Revisionist history
In The Great Culling, Wittenberger’s argument is that key research used to push for tap water fluoridation was funded by the Mellon Institute. The problem with this is that as a direct result, Wittenberger argues that it’s all a conspiracy so Alcoa could get away with dumping fluoride pollutants into the water supply. The major problem with Wittenberger’s argument is that it assumes a relationship between the Mellon Institute and Alcoa. While Andrew Mellon was a major stockholder in Alcoa, he was also a major stockholder in lots of other companies: Westinghouse Electric, Gulf Oil, the Standard Steel Car, and the Pittsburgh Coal to name a few. Most historical records indicate that Mellon took little interest in the companies he invested in and I haven’t seen anything that would suggest otherwise. The Mellon Institute is distinct from Alcoa, but not from Andrew Mellon.
The finding that lead to Dr. Gerard Cox proposing we artificially fluoridate the water supply in some areas came from the Utensil Fellowship at the Mellon Institute. While the Utensil Fellowship was funded by Alcoa, the fellowship had nothing to do with fluoride. That’s a far more interesting story, that we don’t have time for. The short version is that the Fellowship was established in 1926 to investigate the health risks of aluminum cooking utensils. One piece of evidence used to suggest aluminum utensils might be toxic was the high incidence of mottled teeth of people who lived in bauxite mining towns.
So naturally Gerard Cox and his team at the Mellon Institute investigated. Their findings weren’t different from that of Dr. Frederick McKay, who investigated cases of what was called (at that time) “Colorado Brown Stain”. McKay observed that despite the appearance of their teeth, the children who had the “Colorado Brown Stain” (lol what a terrible name) had far fewer cavities than children who didn’t. Because of Dr. Gerard Cox’s work 21 years later, funded by the Mellon Institute, we now know that it was the fluoride ions in the water that were responsible for the staining and the protective effects. The discovery of the protective effects of fluoride really was the result of coincidence, not conspiracy.
But let’s assume for the sake of argument that Andrew Mellon had some reason to put together a giant scientific conspiracy with the help of the Mellon Institute. The question still remains, why? The film never makes any concrete argument as to why Mellon would have such an interest. However it is insinuated that Alcoa would want to do this to get away with dumping its “toxic pollutants” into the water supply. In order to get away with something, you have to have something to get away with. While there were laws against dumping stuff in the water supply, the risk of getting caught was low and the penalties were a joke. The EPA didn’t even exist until the 1970s. This argument is patently absurd.
Chemistry fails
The Great Culling features infinitely more interviews with holders of PhD’s in chemistry than any documentary I’ve previously reviewed. It should come as no surprise that The Great Culling misrepresents basic facts about chemistry at every turn. For instance:
When they started using fluoride, they used sodium fluoride that they were able to get from the aluminum industry. The fluoride that is being put in the water now, not back in the 1940s, now it’s a mineral that is coming from the phosphate industry. It is a byproduct that is a very toxic waste. It’s basically fluoride bound to silica, and its called fluorosillic acid. Extremely toxic.
While it’s true that fluorosilicic acid is toxic, the same is true of sodium fluoride. When fluorosillic acid is added to water at the concentrations used to fluoridate drinking water, it dissociates and releases fluoride ions. There’s no real difference between an atom of fluorine from sodium fluoride or fluorosillic acid once it is floating free in the water. Fluorosillic acid is used because it is cheaper compared to sodium fluoride, but from a safety standpoint they are the same. If they’re handled appropriately, they’re safe.
The latter half of The Great Culling almost becomes a war on fluorine. They actually argue that any medications that have fluorine in their composition that have side effects or are associated with something bad happening is because those drugs contained fluorine. While they provide multiple examples, they choose to go after Prozac. Which is just mind-boggling. So what is their beef with Prozac? One “expert” who has a PhD in Organic Chemistry states that the main ingredient in Prozac is fluoride. I have no idea how this person has a PhD in Organic Chemistry because the main ingredient in Prozac is Prozac.
Prozac has three fluorine molecules in its composition, however that doesn’t mean fluoride is the active ingredient. Prozac works because its chemical structure makes it good at competitively binding to enzymes that reuptake serotonin. Fluorine just happens to be part of that structure. In order for fluoride to be the active molecule in Prozac, the fluorine atoms would have to dissociate from the main structure as fluoride ions. However a cursory look at the Prozac page on Wikipedia will reveal that fluoxetine’s main active metabolite leaves the body with all three fluorine molecules attached. So if the fluorine keeps its electrons inside the ride at all times, how is fluoride supposed to be the active ingredient in Prozac? Right, that’s all nonsense.
This war on the third-most-prescribed antidepressant in the country seems to come from Mike Adams. Mike Adams is very deeply entrenched in the anti-psychiatry camp, and openly praises Scientology for their war on psychiatry. His knowledge of psychiatric medications is not based upon a place of understanding, which his apparent from his comments in the film, such as:
Prozac is made up almost entirely of fluoride molecules. SSRI drugs are similar molecularly to some of the elements in fluoride.
For the record, Prozac is not made up almost entirely of fluoride molecules. He goes on to argue that Prozac was responsible for the Columbine shooting. He believes this because both of the shooters had taken SSRI drugs and that these drugs “…make your mind think that you aren’t in the real world. That you’re just kind of experiencing a false reality and I think Fluoride has much the same effect”. This argument is ridiculous, and it’s obvious.
Fluorosis is not caused by fluoridated water
The Great Culling also tries to sell you the idea fluoridated tap water can actually harm your teeth by causing dental fluorosis. Dental fluorosis is a condition caused when fluoride intake is very high while the teeth are forming. This causes a change in the appearance of the tooth enamel – most commonly seen as opaque white patches. In severe (and very rare) cases it can cause a dark brownish stain or even deformities of the tooth. While some people may seek cosmetic treatment in severe cases, these cases are not the result of fluoridated-tap water.
Tap water fluoridation is only done in communities where the fluoride concentration in the water is below the optimal level (about 0.7-1 parts per million). If someone were to develop severe fluorosis, it would be because their water has a very high concentration of fluoride or they got too much fluoride from some other source. When it’s found that drinking water has too much fluoride, it is typically defluorinated to optimal levels. The documentary conveniently `leaves these facts out and tries to convince the viewer that the most severe presentation of dental fluorosis as the most common presentation.
Suppose one were to buy into this, the next logical question is: what other problems would too much fluoride cause? Well The Great Culling tries to sell you on the answer with the same false premise. They insinuate that tap water fluoridation could also cause skeletal fluorosis, the accumulation of fluoride in the bones, damaging both bones and joints. The issue is the same: it’s impossible for this to happen from tap water that is kept at safe levels of fluoride, and defluoridated if too high. In general, skeletal fluorosis is caused by inhalation of fluoride dust and fumes by industrial workers, or drinking water (generally from wells or untreated sources) that is known to have unsafe levels of fluoride. By an unsafe amount, I mean a truly absurd amount.
They use a very obscure example to try to demonstrate their point. One of the film’s experts explains that it took doctors 10 years to discover that a woman’s back pain was caused by skeletal fluorosis. They found that she was getting excess fluoride from drinking Lipton iced tea. The levels of fluoride in the tea mix far exceeding federal guidelines but I wouldn’t throw out your tea just yet. According to the NEJM report, the woman had habitually consumed a pitcher of tea made with 100 to 150 tea bags daily for 17 years. I’m not defending Lipton, I’m just saying there are some serious extenuating circumstances here. This isn’t something that anyone needs to be worried about (and it had nothing to do with her tap water).
Conclusion: Conspiracy weary
Tap water fluoridation is a safe and effective public health intervention that prevents tooth decay, that’s it. Nothing in The Great Culling should make you think otherwise, not that I’m suggesting you watch it. The film just kind of throws misinformation at you with the hopes that something will stick. The film left me confused more than anything. The film starts out with Wittenberger talking about the first commandment inscribed on the Georgia Guidestone: Maintain humanity under 500,000,000 in perpetual balance with nature”. The monument draws a lot of attention from conspiracy theorists because of its anonymous creators and ominous endorsement of eugenics and population control. Therefore, it doesn’t really come as a surprise when Wittenberger drops this bombshell in the first few minutes:
I have a question for you: how do you suppose [they] plan on eliminating over 90 percent of the population? Perhaps by using the oldest trick in the book by doing it right under our noses. Then cloak it in the phrase, “it’s all for your own good”.
Naturally your response is: “oh, this is one of those films”. But you’d be wrong, the rest of the film isn’t spent trying to prove some globalist eugenics conspiracy. If it were like that, it’d be a lot more interesting. Normally I would try and point out what the creators’ financial interests were in its message, but I genuinely don’t know. Mike Adams contributed significantly to the budget of this film, and that certainly explains why he gets so much screen time in it. But after that, I’m really coming up short. The film spends almost 5 minutes showing off their LaMotte Fluoride Tester. Does anyone featured in this documentary have any financial ties to LaMotte? Not that I’ve been able to find. It really seems like they just crammed all the footage they got with their budget, added commentary, and hoped it all worked out. It didn’t and this the result.
Tap water fluoridation is safe and not something you should be worried about. Tap water fluoridation is one of the most successful public health interventions available and is a cost effective way to prevent tooth decay. While The Great Culling is a grossly incompetent mess, films like can be incredibly dangerous. If films like this can convince you to question a basic aspect of your reality, like the safety of your drinking water, they can also leave you confused and incredibly prone to manipulation about other things. If you were wrong about your drinking water being safe, what else are you wrong about? That’s how Mike Adams sells you a book.
The Great Culling even shows how conspiracy theory documentaries can harm people financially if they adopt conspiracy theory beliefs and act on them. Let’s say someone chose to believe the documentary and believes that tap water fluoridation is a threat to their health. What actions are they going to take now that they’re convinced their local water company is poisoning them by putting fluoride in their tap water? According to Mike Adams you should either purchase a reverse osmosis filter for your house or spend the time to go get water that isn’t fluoridated from…somewhere. Other suggestions in the film included not eating food that has fluoride in it, like canned soups, and testing products for fluoride.
This sequence discussed above, lasting about five minute, demonstrates the harm beliefs in conspiracy theories can cause you if they’re acted upon. Purchasing a reverse osmosis system is expensive, they require changing filters, and they waste a lot of water. Purchasing all of your water unfluoridated isn’t logistically or financially practical because unfluoridated drinking water is possibly the most niche market possible. Testing everything for fluoride requires at a minimum a fluoride testing kit, and even if your food has fluoride in it… what then? Are you going to refuse to go out to eat with your friends because the food has fluoride in it?
It’s not just the financial harm, conspiracy theories can be emotionally harmful too. Even just doing one of the aforementioned things is adding a lot of new stressors for no benefit. It’s adding another step in your life that you have to do. Maybe you do find that store that sells unfluoridated drinking water, but now you have to go to that specific store and buy more anytime you need drinking water. Then you also have to keep a place in your fridge for your special unfluoridated drinking water. You see where I’m going with this? It’s a lot of things you now have to do, for no actual health benefits.
There’s a lot of money in being a conspiracy theory content creator, and Mike Adams of all people knows this. Conspiracy theories are driven by beliefs about the motives of others, then finding any facts that can be stretched to support those beliefs. A well-presented conspiracy theory can make it seem like there is a group of rogue actors working to push governments to subvert the public interest to their personal benefit. While it’s true that governments sometimes make decisions that aren’t in our best interest when analyzed in retrospect, it’s never a grand conspiracy. In the cases where this does happen, the reality always much more entertaining and boneheaded than a nefarious group of masterminds meeting in a shadowy room.
Conspiracy theories have on-occasion found a way to bleed into the mainstream, but it’s always felt like a sideshow more than anything else. But when conspiracy theory groups on social media are allowed to grow unchecked, they start to bleed into the mainstream. We’ve seen the consequences of this throughout the past year. People who believed that 5G towers are dangerous and spread COVID-19 ended up burning down dozens of 5G towers in the UK and Europe. Conspiracy theories have led to people refusing the wear masks, accelerating the spread of COVID-19. Conspiracy theories about the results of the 2020 presidential election caused a violent mob to attack the capitol, killing 5 people. Conspiracy theories, even potentially benign ones like tap water fluoridation, can become dangerous quickly when people act on their beliefs.
Documentaries like The Great Culling serve as a sort of hook into the conspiracy theory cyber sphere. They often appear alongside other sensationalist health documentaries like What The Health. While those documentaries are bad, conspiracy documentaries like The Great Culling are markedly worse. After watching The Great Culling you might visit Mike Adam’s site and read about COVID-19 vaccine conspiracy theories. You might watch similar fluoride conspiracy documentaries also on the Amazon’s store to further entrench conspiracy beliefs formed due to the movie. If you join a Facebook group about one of these “documentaries”, you’ll probably hear about other conspiracy documentaries, watch those, and maybe join their associated groups. The cycle continues until you’re the crazy conspiracist at Thanksgiving.
The Great Culling doesn’t belong on Amazon, but it seems that they have removed it from Amazon Prime videos so you can’t watch it for free. It’s better than nothing I suppose. Conspiracy theories are always going to be a problem on social media platforms, but platforms can’t hide behind the “it’s all online” defense anymore. It’s not all online, because clearly these online groups cause people to do stuff offline. The reach and impact of these online groups can be measured and reasoned about. The factual foundation of these conspiracy beliefs can also be evaluated and found to be shaky.
It’s safe to say given certain events over the past few years that there is a social media fueled-conspiracy problem. The bad news is I don’t think critical thinking classes are going to fix the problem. I don’t think beliefs in conspiracy theories are the result of a lack of critical thinking. I think people see a video that appeals to them, they get sucked into conspiracy groups where their newly formed beliefs are reinforced, and then it becomes impossible to talk them about even if it’s harming them. Sure, critical thinking skills can prevent things from getting to that stage, but nobody is immune to their lizard brain not liking to change what it believes in response to contrary evidence.
The best way to fight harmful conspiracy groups is to kick them off of platforms when it has been shown that they’re harmful. If there is some business risk to taking harmful conspiracy content off of your platform, I haven’t seen it yet. In 2019, Amazon removed conspiracy documentaries like Vaxxed and Cancer Can Be Killed. Their was no massive consumer backlash, Amazon is still Amazon. Facebook banned the President of the United States for tweeting conspiracy theories about the election that caused a violent insurrection. Of course this brazen act of censorship meant tons of people left the platform and…Facebook’s stock increased by five dollars. It’s genuinely puzzling to me that big tech companies don’t do more in this area, it’s a PR gimme of the highest order.
But at the end of the day, I don’t control that. Tap water fluoridation is safe and you definitely shouldn’t let The Great Culling change your mind. The Great Culling is a mess of a documentary even by my standards, I wouldn’t even recommend it as a hate watch. The good news is the intro implies that The Great Culling was going to be a multipart series. I’ve been unable to find a sequel. Let’s hope it stays that way.

Another In a Pattern of Really Stupid Marketing Videos, This One Claiming Tinnitus Has Nothing to Do with the Ear and Is 100% Curable.
This really stupid video was an insult to my intelligence. Nothing in it can be believed. They claim tinnitus has nothing to do with the ears and they sell a 100% effective dietary supplement mixture supposedly developed by MENSA with government funding. It has never been clinically tested. No, there is no cure for tinnitus.
Harriet Hall on April 27, 2021
Link

Recently I have written about several really stupid marketing videos for dietary supplements e.g. here. They suck you in by promising to reveal a secret, but you have to watch the entire video to learn the secret. One says “5 minutes” but lasts half an hour. They are not only deceptive, but their pattern is the same, almost as if they were following the same marketing script. One was for ReVision, promising to enable you to throw away your glasses, then there was SavageGrow Plus, for penis enlargement. Then one claiming you could lose 52 pounds in 28 days without diet or exercise. They are full of emotion and exaggeration but no evidence and no science. Now there’s another, perhaps the worst yet, claiming that brain scans have uncovered the real root cause of tinnitus, and they are selling a 100% effective cure. It could almost serve as a parody of the others.
It deserves a prize. We need something like a Pulitzer Prize for nonsense, or an IgNobel award for pseudoscience, or something like James Randi’s Pigasus award to expose frauds. SBM’s Silly Bogus Medicine prize? Readers are welcome to make suggestions.
The “evidence”
The video claims that brain scans have uncovered the real root cause of tinnitus. The speaker calls himself Gregory Peters. He says he is a medical librarian who suffered from tinnitus for seven years, and he claims that everything in the video is 100% true; but it can’t be, because Gregory Peters doesn’t even exist. The website tells us “Gregory Peters is a pen name used for marketing purposes and to protect the author’s identity. Any likeness to a real Gregory Peters living or dead is entirely coincidental”.
At his 53rd birthday party, when his family began to sing “Happy Birthday,” he “lost it”. His tinnitus became so unbearable that he went to the bedroom, got his Glock and tried to kill himself. But when he looked into his young son’s eyes, he just couldn’t pull the trigger. He started shaking and dropped the gun. The bullet passed only an inch from his wife’s cheek and lodged in the ceiling. This episode terrified him so badly that he started on a 2-year quest that ended in his finding an effective way to stop his tinnitus, a ground-breaking, inexpensive, natural cure. It allegedly “turned the medical establishment upside down” and saved thousands of lives. Big Pharma is willing to spill blood to keep this information hidden.
Nothing in this story rings true. Why would a suicidal man take the gun back into the presence of his family to let them watch him kill himself? The scenario of shaking, dropping the gun and having it go off is not just implausible; it’s impossible. The safety on a Glock is integrated into the trigger mechanism so that you have to pull back on the safety to release the safety and then pull back further to activate the trigger. The Glock was chosen for use by the police and military precisely because it was the top performer in reliability and safety tests. Testing showed that it was secure against accidental discharge from shock, strike, and even a drop from a height of 2 m onto a steel plate. If he was shaking or dropped the gun, the safety would have remained on, and the gun couldn’t possibly have fired. Another discrepancy: in the video, his son is shown as quite young, way too young to have children of his own; but later Peters mentions that he has grandchildren.
His description of his tinnitus symptoms is over-the-top. Many people with tinnitus don’t find it distressing at all (I am one of those), and it doesn’t always last; sometimes it can resolve spontaneously. Peters says it was “horrifying” and turned him into a vegetable. He describes dizziness, hearing loss, nausea, depression, sleepless nights, having to ask co-workers to repeat themselves, a ruined social life, and brain fog. His mind was deteriorating; his memory began to slip. Once he was so desperate, he stuffed onions in his ears (!?). He couldn’t focus. He couldn’t read because he couldn’t understand long sentences. He couldn’t carry on a conversation for more than 5 minutes. He would go into a room and not remember why he went there (That has happened to me, but it has nothing to do with my tinnitus). Once he forgot the way to his local supermarket.
After 4 weeks of suffering, he made an appointment with a noted ear specialist who ran a lot of useless, expensive tests. He says he pretty much had all his internal organs scanned. (That’s hard to believe. When a patient has tinnitus, there is no earthly reason to scan all the internal organs.) The specialist told him nothing was wrong with his ears. He couldn’t accept that, and it made him distrust the entire medical establishment.
His wife made him consult more doctors; they spent the money they had saved for a vacation. He tried everything: psychiatrists, acupuncture, herbal remedies, antidepressants, hearing aids, sound therapies, sleep drugs. After 7 years of torment, he was exhausted, had to drag himself to work, and was barely able to leave his bed. He didn’t know how much more he could stand. He was a burden to his family – they had to keep quiet and tiptoe around. He didn’t want to live any more. He looked into options like lethal powders from China and assisted suicide.
He then bought the Glock, which featured in his impossible-to-believe story.
What really causes tinnitus?
He tells us that tinnitus has absolutely nothing to do with the ears but reflects a life-threatening process that is occurring in your brain, taking it over and causing memory loss, amnesia, and other dangerous brain diseases.
He describes how he discovered this by doing an intensive search in the medical library. He almost gave up several times, but after only a week, he found two little-known studies that had him doing mental backflips. One was from Germany, where tinnitus researchers had done brain scans. The other was from the University of Iowa. It mapped tinnitus signals in the brain of a single patient during brain surgery. Other studies implicated damage to the auditory cortex, mixing the signals and creating a buzzing. One hypothesis was that cutting the auditory nerve would stop tinnitus as well as producing deafness; but after becoming deaf, patients continued to hear the ringing. The communication lines break down and eventually the brain shuts down. There is a failure of synapses, a failure of brain connectivity. Your brain is a ticking time bomb. He sent these two “unquestionable” studies to many specialists. They obviously didn’t agree that the studies were unquestionable; only one answered: Steven Campbell.
Peters thinks MENSA members are the most intelligent people on the planet and the most powerful He describes Campbell as a genius because he is a member of MENSA and his IQ was measured as 159, only one point lower than Einstein’s. (Einstein’s IQ was never tested, and it’s not clear where the estimate of 160 came from). Campbell said he had cured his tinnitus with a secret protocol only known to Mensa members and a select few others, including some government officials and heads of state (presumably the ones who are not shapeshifting lizards from Alpha Draconis!) :-). Campbell told him Mensa members were motivated to protect their valuable brains. He says MENSA got government funding to develop their secret protocol (Really? Where’s the evidence?). He says this was top-secret medical research that the public has no access to. Do you believe that? He says that according to Campbell many people get into MENSA just to have access to this treatment (I seriously doubt that!). 1 in 10 Americans has tinnitus, but only 3% of the population have access to this treatment. Why is it suppressed?
Why? Because Big Pharma makes Big Bucks from tinnitus treatments, brain boosters, headache pills, and supplements and they don’t want to reduce their profits. And if they did release the new treatment, it would be obscenely expensive.
He says the treatment has been “clinically proven to work regardless of your age”. Actually, no; it has never been clinically tested. The only testing he describes is informal, unpublished, and with no control group; he gave samples to 20 people he knew with tinnitus, and they all said it helped them. He says, “No more hearing aids or chemical-filled remedies, painful ear flushing, or risky surgeries”.
He claims it worked for 47,000 people, typically in 3 weeks. He says he couldn’t wait to try it, but then he says his daughter had to talk him into trying it. That doesn’t add up.
What are the ingredients?
Hibiscus. Hawthorn berry to wipe out panic attacks. Olive leaf strengthens brain networks so they are stronger than steel; it also prevents ear infections. Niacin repairs DNA and corrects years of deterioration. Garlic powers up your memory and fights off dementia. Vitamins B12, B6, and Buchu leaves are like steroids for the brain. They keep the brain from getting smaller with age. Green tea, juniper berry, uva ursi, and vitamin C work to clear toxins from your brain; vitamin C prevents tumors. Dr. Campbell was ready to retire and leave MENSA, so he was willing to reveal the secret formula and help the speaker re-create it. They knew it was incredibly risky and could have cost them their jobs and their lives. 97% of the ingredients on the market are bogus and are derived from chemicals, not from natural sources. They had to seek out only the purest, 100% effective ingredients. But effectiveness is not determined by purity; it requires controlled clinical studies. He mentions homeopathic remedies, seemingly confusing them with other natural ingredients. They did all their research in a “night lab”, testing until dawn. That’s not how legitimate research is done.
He promises to reveal how each ingredient works. But he does no such thing. He makes vague claims about improvements but offers no evidence.
It’s called Sonus Complete.
Do any of these statements sound familiar? They should. They’re taken straight from the standard script for stupid marketing videos.
    • A limited time discount reduces the price from $99 to $49 a bottle. Today only. Buy now. Price will go up. Money-back guarantee.
    • It prevents dementia, rejuvenates and protects brain cells, and can even increase IQ.
    • Everyone should take it.
    • Manufacture takes up to 3 months; quantities are limited. They may run out at any point.
    • 90 days treatment will completely regenerate your brain.
    • We don’t know how long we can hide from Big Pharma.
    • The page may be taken down at any time.
No side effects or allergic reactions?
He says there are no side effects. Not true. If you look up the ingredients, you will find extensive lists of reported side effects.
He claims the amounts of each ingredient are too low to trigger allergies. That shows a complete misunderstanding of how allergies work.
Healthy Supplement Reviews noticed that the marketing story appeared to be fake. They did a taste test which suggested that it only contains garlic.
Conclusion: There is nothing believable here
I don’t believe anything in this video. Watching it was a painful experience and an insult to my intelligence. I wish regulators could put a stop to this kind of false advertising. As for MENSA, my IQ qualifies me for membership; but I have never chosen to join, since I firmly believe that it’s more a matter of how you use your intelligence than of an arbitrary IQ number.
And there’s still no cure for tinnitus.

Gut Check. Probiotics and Metabiome.
Mark Crislip on January 23, 2015
Link


I always cringe when I see an acupuncture headline with ‘needle’ or ‘point’ in the title. Can’t the writer avoid the clichéd pun? I had an editor who commented that the titles of my essays are often obtuse. Probably true. In going back over my essays on SBM I often can’t tell from the title what I have written about until I read the article. It is a fine line between (what I think) is a clever title and obscurity. So gut check it is.
Time flies when you are having fun. I wrote about probiotics back in 2009.
My conclusion at the time:
Probiotics are useful for the prevention of antibiotic-associated diarrhea. Probiotics may be helpful in preventing other overgrowth syndromes or diseases associated, and perhaps with perturbations of the gut microbial flora such as IBS and colic.
Probiotics are foreign bacteria that are not a normal part of your GI tract; they do not enhance your immune system and, in normal people do not promote the nebulous bowel health.
If you are a normal human, with a normal diet, save your money. Probiotics have nothing to offer but an increased cost.
Medicine is not static and there have been interesting advances in the understanding of the human microbiome in health and disease since 2009, so for SBM and my own medical understanding, I thought it would be a good opportunity to review the topic. Although with over 12,000 references on the PubMeds, I will only touch on a smattering of the papers. My ID attending in medical school always referred to reading the medical literature as drinking from a fire hose. Indeed. 
Probiotics
The more I understand about normal GI flora, the more I suspect probiotics are the wrong answer to a wide variety of medical questions. We have a complex bacterial flora in and on us. We carry with us 10–100 times more bacteria than there are cells that make us up. We may think we are the pinnacle of evolution, but we are just sentient transport and feeding machines for bacteria.
The human GI tract is predominantly a bacterial ecosystem. Cell densities in the colon (1011–1012/ml contents) are the highest recorded for any known ecosystem. The vast majority belong to two divisions (superkingdoms) of Bacteria – the Bacteroidetes (48%) and the Firmicutes (51%).
There are over a 1,000 species in the GI tract with over 5 million genes. Most of these bacteria cannot be cultured but only identified by molecular techniques.
While they are often called “good” bacteria, the constituents of probiotics are not part of the normal GI tract in significant numbers if at all. The Lactobacilli, Bifidobacteria and Saccharomyces (a yeast) found in most of the products are better-classified as “less pathogenic organisms” rather than good.
As a treatment for C. difficile, protiotics have marginal benefits and the clinical trials have had difficulty definitively demonstrating efficacy although for prevention, the most recent meta-analysis suggests benefit:
Pooled analyses revealed significant reductions in the risks of AAD [antibiotic-associated diarrhea] (RR 0.61, 95% CI 0.47 to 0.79) and CDI [Clostridium difficile infection] (RR 0.37, 95% CI 0.22 to 0.61) among patients randomly assigned to co-administration of probiotics. The number needed to treat for benefit was 11 (95% CI 8 to 20) for AAD and 14 (95% CI 9 to 50) for CDI.
Even though well-conducted studies suggest otherwise:
We found no evidence that probiotic administration was effective in preventing AAD. Although there was a trend towards reduced [Clostridium difficile diarrhea] in the probiotic arm, on balance, the administration of this probiotic seems unlikely to benefit older patients exposed to antibiotics.
Like much of the medical literature when using an intervention of perhaps-uncertain biologic plausibility, you can read the literature as you see fit. I tend to see the preponderance of data suggesting ‘yes’ for prevention and ‘no ‘for treatment.
It is instructive to compare the efficacy of probiotics, uncertain, with the real deal, bacteria that actually belong in the GI tract.
Stool transplants cure 90% of people with C. difficile. That’s impressive. Even more impressive are frozen poo pills derived from humans, which lack the ick factor of a stool slurry.
Resolution of diarrhea was achieved in 14 patients (70%; 95% CI, 47%–85%) after a single capsule-based [fecal microbiota transplantation]. All 6 nonresponders were re-treated; 4 had resolution of diarrhea, resulting in an overall 90% (95% CI, 68%–98%) rate of clinical resolution of diarrhea (18/20).
And there is also synthetic stool, which is also effective and has the following recipe:
Thirty-three isolates, representing commensal species that were generally sensitive to a range of antimicrobials and were relatively straightforward to culture, were selected for the final stool substitute formulation.
So when I read the literature, I suspect we are seeing the beginning of the end of the stone knives and bear skins era of probiotics. Currently we are using organisms that are of low pathogenicity, but foreign and have the potential to generate an inflammatory response as well as the rare illness. As we gain more understanding of both the composition of the normal microbiome and its interactions with the immune and other systems, I suspect we will have more sophisticated and complex probiotics, made from the real “good bacteria”, those that belong in the GI tract.
Microbiome as treatment for other diseases
It is probably why the studies of probiotics for diseases besides diarrhea are less than compelling. Inflammatory bowel disease, bowel cancer and allergies all may have a link to the gut microbiome. The complexity of the ecosystem and the interactions of human genetics and diet will make this a complicated issue to tease out causality. This is an area with more speculation and intriguing hints than hard data. The identification and tracking of the gut microbiome is in its early days and definitive clinical trials are lacking. For instance:
To date, there is insufficient data to recommend probiotics for use in CD [Crohn’s disease]. There is evidence to support the use of probiotics for induction and maintenance of remission in UC [ulcerative colitis] and pouchitis. Future quality studies are needed to confirm whether probiotics, prebiotics, and synbiotics have a definite role in induction or maintenance of remission in CD, UC, and pouchitis.
Or allergies:
Many studies demonstrated that the administration of probiotics is able to prevent the onset of allergic sensitizations and improve the symptoms of atopic dermatitis and allergic rhinitis; however, studies were published, too, that achieved negative outcomes. The overall evaluation of results is, however, difficult, as the strains used and the study design are markedly heterogeneous.
If there is going to be benefit in probiotics, perhaps it will come from transplanting ecosystems of bacteria rather than the odd Lactobacillus.
Weight gain
It is fascinating that the microbiome is associated with weight gain. Have the wrong microbiome and you will gain weight. At least if you are a mouse. Transplant a fat-promoting microbiome into thin mice and they will gain weight. So if you are going to get a stool transplant, I suppose you should make sure you obtain the specimen from a thin person. But as the NEJM review points out:
Currently, however, there is no direct evidence for a causal relationship in humans. And the translation of findings from mouse to human is challenging.
Still, it has long been known that low concentrations of antibiotics in animal feed leads to fatter animals, perhaps by changing the microbiome. It is interesting that there is an association between otitis media and obesity in children and those children often get lots of antibiotics. The potential reasons for the association are probably many, of course, and the data to support early antibiotic use with subsequent weight gain are both pro and con.
In my world, some antibiotic regimens are more likely to result in weight gain. Vancomycin as well as doxycycline and hydroxychloroquine used for endocarditis have both been associated with weight gain, the latter with a documented change in the gut microbiome.
The information is preliminary but is pointing in one direction. It is a fun and fascinating topic, but it is far too early to use clinically. I do expect that in the future we will have a better understanding of what the ‘correct’ microbiome(s) should be, and it will likely not include the currently-touted products despite the numerous sites that offer probiotics, prebiotics, herbs and supplements to promote and support bowel health. I am also willing to bet that preliminary data will be hyped far out of proportion to clinical applicability in the SCAM community.
And there is always someone who will take preliminary information and make it a diet: The Microbiome Diet. It is “scientifically proven” so it must be good. Me? I am writing the Paleo-Microbiome diet, getting back to the microbiome of our ancestors, before we started farming. I’ll make a mint.
For 89 bucks you can even find out what your own microbiome is. I am half tempted to spend the money just out of curiosity. I would be doubly curious given my ability to pack on weight given my total colectomy. They look legit.
SIBO
A week or so ago I was asked a quick question outside the stairwell.
“How do you treat Archaea?”
“Huh? You mean the third domain of life, after Bacteria and Eukaryota?”
“Yep.”
“You don’t. They don’t cause disease in humans. They are extremeophiles. Why would you want to do that?”
“A naturopath has diagnosed bowel overgrowth and is treating a patient.”
Well, I had never heard of that and if you judge an idea by the company it keeps…
“That’s stupid. I don’t buy it.”
And I walked on up the stairs.
But as I walked up the steps I thought, is it? What do I really know about Archaea and human disease? Nothing. And purveyors of pseudo-medicines do love to wildly extrapolate from preliminary basic science or small clinical trials to develop grand diagnostic and treatment schemes for all diseases. So maybe there is a nugget of truth of which I am unaware.
So I went to Pubmed. Yep. I was ignorant on the topic.
For it turns out that Archaea are part of the human GI tract and are responsible for the production of methane:
Methanogenic archaea are known as human gut inhabitants since more than 30 years ago through the detection of methane in the breath and isolation of two methanogenic species belonging to the order Methanobacteriales, Methanobrevibacter smithii and Methanosphaera stadtmanae.
I suppose the colon qualifies as an extreme environment. I would not want to live in one. Archaea are found in about 50% of adults.
Methanogenic archaea are strict anaerobes that occur in a large range of environments, such as freshwater and marine sediments, soils and the gut of numerous animal species, including humans. Their physiology and ecology is widely studied for their intrinsic capacity to produce methane which is both an energy source (biogas) in bioreactor and a greenhouse gas emitted from natural and anthropic environments, including livestock. As a recurrent component of the human digestive tract, impact of archaea and more particularly methanogens on human health have been questioned for many years.
There are some intriguing associations between the presence of Archaea and colorectal cancer, obesity, IBD, IBS, diverticulosis, constipation (perhaps the most robust data), and periodontitis, remembering the mantra that association is not causation. The review has a nice pro/con table of the evidence.
One author notes:
It is important to consider the above findings using an evidence-based medicine approach. A recent meta-analysis evaluated the existing literature comparing the presence of methane and constipation. Although not all studies have confirmed these results, most do to support a significant association.
As the review notes:
Links with diseases/human health, if any, will therefore be established in the next years, considering the archaea as a diverse population, as it is for bacteria, with more discriminant methods than methane in breath for methanogens…Genomics has strongly helped in the determination of their putative roles in the [gastrointestinal tract], and indicated their unique metabolic properties before experimental proofs. This shows the potent physiological importance of the still poorly known domain Archaea in the human gut, and the role of its members, beneficial or deleterious, remaining to be determined.
And the ND connection? Evidently it is considered part of bacteria of SIBO, small intestine bacterial overgrowth, for which Portland has a specialty ND clinic. With the usual pseudo-medical ability of making a mountain range from a grain of sand, besides IBS, according to the ND site, SIBO is associated with:
Acne Roseacea, Acromegaly, Age: Elderly, Alcohol Consumption (moderate intake), Anemia, Atrophic Gastritis, Autism, Celiac Disease, Chronic Fatigue Syndrome, CLL (Chronic Lymphocytic Leukemia), Cystic Fibrosis, Diabetes, Diverticulitis, Dyspepsia, Erosive Esophagitis, Fibromyalgia, Gallstones, Gastroparesis, GERD (Gastroesophageal Reflux Disease) , Hepatic Encephalopathy (Minimal), Hepatic Steatosis, H pylori Infection, Hyprochlorhydria, Hypothyroid/ Hashimoto’s Thyroiditis, IBD (Inflammatory Bowel Disease), -Crohn’s, -Ulcerative Colitis, IBS (Irritable Bowel Syndrome), Interstitial Cystitis, Lactose Intolerance, Leaky Gut, Liver cirrhosis, Lyme, Medications: Proton Pump Inhibitors, Opiates, NSAIDS Myelomeningocele, Muscular Dystrophy (myotonic Type 1), NASH/NAFLD (non-alcoholic: steatohepatitis/fatty liver disease), Obesity, Pancreatitis, Parasites, Parkinson’s , Prostatitis (chronic), Radiation Enteropathy, Restless Leg Syndrome, Rheumatoid Arthritis, Scleroderma.
And more. Color me skeptical. Perhaps yet another one true cause of all disease. I got me a hammer, look, everything is a nail.
It is cool that as one branch of the tree of life, we carry around the other 3. Or is it 4?

The Species in the Feces: Probiotics and the Microbiome
Mark Crislip on March 23, 2012
Link
I do not understand the interest many appear to have in their bowels and the movement there of. But then, I pay little attention to most of my body functions as long they are functioning within reasonable parameters, and as I get older the definition of reasonable is increasingly flexible.
The elderly especially seem to obsess about their bowels. My theory is that since they have often lost taste, smell, hearing and are alone with little direct human touch, a good BM is the only remaining physical joy left, and when it is compromised they are understandably upset.
Still, the concept of colonics for ‘detoxification’ strikes me as more humorous than repellent, despite the lack of efficacy and documented complications of the procedure. Under normal circumstances, when it comes to the colon it is probably better to be removing substances than to be introducing them. 
I do not pretend to be expert in the human microbiome: the complex ecosystem of bacteria and other organisms that are in and on us. It is of interest but usually not a direct concern in the daily application of infectious diseases. I spend most of my days trying to kill the odd pathogen, most of whom are not usually part of the human bacterial ecosystem. There are 1000’s of species in and on us, and we can grow only a small fraction of them in the clinical microbiology lab. There are an estimated 10 to 100 times more bacterial cells in and on you than there are cells of you. Take your colon. Please.
…it has been estimated that the cumulative human lower intestinal microbiota contains at least 1800 genera and 15 000–36 000 species (depending on a conservative vs liberal classification).
I tend to think that the conservative approach has a larger quantity of lower intestinal material associated with it. You may think you are hot stuff, but really you are only a sentient transport and feeding mechanism for your bacteria.
A side effect of antibiotics is wiping out large swaths of the normal flora in and on us. Early in my career it was taught that the benefits of the microbiome were simple: competition for adherence sites and nutrition with a little vitamin K production thrown in for good measure. It turns out the interactions of the metabiome and the humans is much more complex than suspected. There probably is a core microbiome that we share, but the diversity of bacterial flora is greater than the similarities.
At the national meeting I last year I attended some lectures on the microbiome, and the two most interesting factoids from my notes were that microbiomes are more similar in people who are related. My microbiome resembles that of my parents and children more than that of my wife. And even more interesting is that the microbiology found on the left upper canine tooth resembles the right upper canine, rather than the tooth below it or the teeth next to it. Each tooth is a Galapagosian island of separate and sometimes parallel evolution. Neat.
I mess with the microbiome of others on a daily basis wiping out billions of bacteria and upsetting the human ecology. Not that I have much choice. Most of the patients I see would likely die from their infection without antibiotics, although if there is karma for causing the deaths of other creatures, given the huge number of microbial deaths for which I am responsible, I am destined to come back in the next life as a rabbit in a syphilis laboratory.
What little data exists suggests that the bacterial flora declines dramatically with antibiotics and is slow to recover, often taking months to return to pre-antibiotic diversity. Each course of antibiotics is, to the bowel bacteria, an almost K-T extinction event. There would be a less prolonged effect if we were more like mice and were coprophagic, but eating poo is not high on the human consumption list. Except for those of us that love hot dogs.
The best known and more reliable effect of messing with the bowel flora is diarrhea, which comes in two flavors: antibiotic associated and Clostridia diarrhea. Some antibiotics, like oral amoxicillin/clavulanic, are arguably better than most laxatives at cleaning out the gastrointestinal tract, and antibiotic associated diarrhea adds to discomfiture and cost of hospitalization, with the upside that you can get more reading done.
Probiotics are useful in prevention of antibiotic associated diarrhea, supported by reasonable studies in the literature. In my institutions when we instituted yogurt for all our patients on antibiotics our testing for causes of diarrhea fell by half, a reasonable surrogate that the product was effective.
I recommend the yogurt over probiotic pills if possible, despite how unpleasant yogurt can be. Yogurt has the advantage of a known quantity and distribution of bacteria since its production is overseen by regulatory agencies. I suggest yogurt that has the more diverse and highest quantities of bacteria, the yogurt closest to stool, a slogan not likely to be used by Dannon anytime soon: “The yogurt that most resembles stool. ”Probiotic pills are problematic, since their contents are not regulated and the organisms can be dead or be species of bacteria other than what is listed on the label.
It is wrong to consider the organisms in probiotics to be ‘good’ bacteria. They are not part of the normal flora and can incite an inflammatory response or invade the blood stream in rare circumstances. It is interesting, but not surprising, that probiotics can prevent URI’s in children.
Regarding the potential mechanisms through which the reductions in respiratory symptoms and antibiotic usage could be explained, an immune-enhancing effect is a likely explanation, because numerous studies with various probiotic bacteria have demonstrated their ability to modulate immune responses through interactions with toll-like receptor.
As I have mentioned before, “immune-enhancing” is what ID docs call an inflammatory response, which, if activated in advance of a pathogen, primes the immune response against subsequent infections. The inflammatory response, long term, is bad, being associated short term with increased vascular events (stroke, heart attack and pulmonary embolism) and long term with vascular disease. Being immune-enhanced may, for example, prevent TB at the price of the metabolic syndrome. As far as I can tell, the immune system is best left alone if not under acute microbial attack
Bacteria are neither good nor bad, but more or less likely to be pathogenic. Some are collaborators with the enemy, aiding and abetting pathogens in their invasion. The normal flora, the so called ‘good’ bacteria, may enhance infection from polio, some worms, and other bacteria. Not a surprise, for even as we were evolving in tandem with our flora, our pathogens were certainly evolving along us and our microbiome. Even the ‘good’ bacteria would be happy to consume you if given half an opportunity. As would some of our pets as I think about it.
The utility of probiotics in the prevention and treatment of probiotics for C. difficile diarrhea is problematic, and the literature can be read either way, I tend to think the glass is half full (of stool) and is of little utility. It is a problem as C. difficile can be a difficult disease to treat with antibiotics and has a high relapse rate. Some patients go through multiple courses of different antibiotics without resolution of their disease, each antibiotic more expensive than the last. The newest agent for C. difficile, fidaxomicin, has set a new record for price gouging with a 10 day course costing round $2800. Yep. Two thousand eight hundred.
The best therapy, best being the highest cure rate, for C. difficile is the stool transplant, and I get puky just writing about it. The stool of spouse (although it should be the parents or children) is pureed and given either down a nasogastric tube or as an enema. Efficacy is almost 100%. There are worries about disease transfer, as some infections are spread by the fecal-oral route. Ick. But most spouses, unlike other relatives, probably share most infections anyway. I have yet to send a patient for stool transplant, but my partner and the GI docs have done a handful with good results.
Imagine my surprise when the local weekly had an article on stool transplants being used by a naturopath as part of a 3000 to 7000 dollar treatment, depending on whether you want to do receive it at home or as part of a colon health retreat. According to the Willamette Week, the practitioner is self taught and the stool is obtained from a 13 year old who was chosen as he had never had prior antibiotics. The kid is paid for his donations. I had a paper route and it also was a …, no I’m not going there. Nope.
According to the web site,
FMT is over 90% effective at treating C. difficile infections, and is 50-90% effective at significantly decreasing or eliminating symptoms of ulcerative colitis and IBS-C.
The first number is legit, the second? At best I can find a half dozen case reports for ulcerative colitis and a similar number for irritable bower syndrome.
For non C. difficile bowel disease stool transplant is an intriguing idea, and given the interactions of the colonic microbiome and the gut, I would not dismiss the idea out of hand. How alterations in gut flora plays a role in IBS, UC, or even weight gain or loss are interesting concepts. The understanding of these interactions is in their infancy and may be a fruitful therapeutic option someday. I would be cautious since it is also reasonable that that giving someone a strangers poo could conceivably set them up for chronic inflammation with resultant stroke and heart attack, increase their risk for polio or even put them at long term risk for bowel cancer, given the curious association between toxigenic Bacteroides fragilis and colorectal cancer.
There are likely to be subtleties in different microbiomes and an individuals immune system’s interactions with that microbiome that will alter the risk or benefit of a random stool transplant. At least with a kidney they try and match it to the recipient. I would not be surprised if a similar process would optimize the benefits of a stool transplant, although a complication of organ rejection is infection, and how would you tell in a stool transplant. While it is medicine that is accused of not treating the individual, it is often the SCAM practitioners who have a one size fits all in their treatments with no consideration of the potential ramifications of the practice. In the practice of medicine you learn early that no good deed ever goes unpunished; everything has downsides.
I would be disinclined to recommend that a patient spend thousands of dollars based on an interesting idea. I would not have though someone could beat out Big Pharma and charge more than fidaxomicin for a 10 day course for bowel therapy, but evidently I lack the imagination. I also lack the insight to realize the importance of the colon for so many extra-colonic processes, except I will admit my health did improve markedly for the better when I had my colon removed.
…using fecal microbial transplantation for other health problems, including autoimmune disease, eczema, asthma, multiple sclerosis and depression… and detoxifies the body and improves mood.
Interesting. The comments write themselves. To say there is even biologic plausibility to treating MS or depression with stool transplants requires a biology I was never taught and cannot imagine. The opportunity for placebo effects to predominate with stool transplant would be enormous. But there are those who, well, like that sort of thing. To each their own.
I do not see why squirting another’s poo in your colon would not be, in the world of colonic detox, the equal to giving a toxin enema. If there is anyone with toxins in their colon, it would be a 13 year old boy. I have seen what mine will eat if given half a chance.
As for performing an unregulated procedure as unproven therapy, Davis says, “The FDA hasn’t said not to.”
The FDA also hasn’t said not to jump off a bridge, and damn I am getting old resorting to that trope. That’s how to choose interventions for patients: if the powers that be don’t say not to, it is OK. That is the approach to life of my teenage kids and I have found it to be a reliable technique for them to learn from really stupid decisions.
The practice of medicine is always in flux* and off the wall ideas today are tomorrows standard of care. For fecal transplant and some colonic diseases, it is an intervention that, outside of C. difficile, is still unproven, although a promising idea. For diseases outside the colon, biologic plausibility makes stool transplant unlikely to have any benefit with real potential downsides. Stool transplants are unlikely to be of widespread to benefit, but when all you have to offer is crap, everything is a toilet.
* an old term for diarrhea.

Probiotics Online
Probiotics still don’t live up to the hype, and online information is mostly misleading.
Steven Novella on January 15, 2020
Link

Dubious health products tend to fall into one of several familiar patterns. Some are invented out of whole cloth, for the purpose of marketing as the latest health craze. Others emerge out of medical pseudoscience. Perhaps the most insidious, however, are those that are based on legitimate science but are either going beyond what the science can support, and/or are exploiting premature hype. Probiotics fall into this latter category.
A recent study published in Frontiers in Medicine, “Online Information on Probiotics: Does It Match Scientific Evidence?” – quantifies this phenomenon. They assessed the accuracy, completeness, and reliability of the information found online about probiotics. Only 23% of the claims made for probiotics on the 150 websites reviewed were backed by scientific evidence. Another 20% had essentially no supportive evidence, while the rest had some evidence but not enough to justify the claims.
The only claims that were backed by evidence are for gastrointestinal symptoms, which were made by 88% of the sites. Even here, though, most sites did not give complete information, properly referencing potential side effects, which bacterial species are backed by evidence, and linking to supportive evidence. The reviewed sites also included claims for boosting the immune system and treating cancer, obesity, and respiratory disorders, for which there is insufficient or no scientific evidence.
The authors also categorized the websites by type. The most common was commercial sites, 43%, who also had the least reliable information. So the most common sites were the least reliable and most of the claims made were wrong or incomplete. This should not come as a surprise, and is consistent with other reviews of online health information.
The skinny on probiotics
Our own Mark Crislip wrote an excellent review of the state of probiotic science in 2015. His bottom line, which still applies today, was that there is reasonable evidence for the use of probiotics to prevent diarrhea resulting from antibiotic use, but not for treatment once it has occurred. The current study also adds (probably the only real update):
Cochrane reviews also support the use of probiotics in the prevention of necrotizing enterocolitis in preterm infants, but with insufficient data regarding the benefits and the potential adverse effects in the most at risk infants.
But that is about it. The use of probiotics to treat any disease or illness is not established. I did my own review to see what the latest systematic reviews are saying. This one for irritable bowel syndrome is typical:
Current evidence shows particular combinations, species or strains of probiotics are effective for overall IBS symptoms. However, it is hard to derive a definite conclusion due to high heterogeneity and unclear risk of bias of some trials. Large well-designed and rigorous trials are warranted.
The research is exploring the role of the gut microbiome in various conditions, finding some correlations, but we mostly do not yet understand the cause and effect. Clinical evidence has been either negative or preliminary. No disease treatments for probiotics have been established.
Mark notes, and I agree, that the probiotic technology is still in its infancy. He also notes that the use of stool transplants, either directly or by frozen pill, works much better than probiotics. The approach of introducing one or a few benign but often foreign bacteria into the gut microbiome may simply be a flawed approach. Giving existing ecosystems of bacteria seems to be the better approach.
Our understanding of the microbiome and the potential role of trying to alter it as a health intervention is still relatively early. We are in what I like to call the early hype phase of the science. We are discovering a lot of interesting information, with intriguing implications. But leveraging this information to improve health is proving to be horrifically complicated, and most of the early clinical trials are disappointing. With probiotics we are where using viral vectors for gene therapy was 30 years ago. It seems very promising, but the road ahead was more difficult than anticipated. Here we are three decades later and the technology is still struggling, but starting to finally make some advances.
It seems like we will still need decades of research and tinkering to appreciate the real potential of probiotics. Keep in mind, I am not saying that in 30 years or so probiotics will work, I am saying it will take that much time to understand if they will work. In the end they may turn out to be more hype than reality, with limited indications and benefits. Stool transplant technology may also eclipse probiotics for those indications for which they do offer some benefit.
Probiotics may also turn out to be surprisingly helpful, but may need to wait until they are helped by other technologies, such as genetic engineering. We won’t know until we can look back over the next few decades.
Meanwhile, the concept of probiotics is now firmly established as a marketing tool. Just like routine vitamins, superfoods, herbal products, and organics – the industry has successfully created a health halo around the term. Regardless of how the science evolves, we are likely to see probiotic products as a permanent fixture in the supplement industry.

Probiotics, revisited
New guidelines do not recommend probiotics for most gastrointestinal conditions.
Scott Gavura on July 9, 2020
Link

We are not one organism, we are many organisms. There is continued scientific interest in studying how our bodies interact with the organisms that we carry, on and in us. Probiotics, which are live bacteria given to treat or prevent illness, have been a subject of blog posts back to SBM’s early years. They’re an interesting subject, with scientific plausibility (and some real science) but layered with lots of myth and pseudoscience. The interaction between our gastrointestinal microbes and our own body can affect our wellbeing as well as illnesses like inflammatory bowel disease, Crohn’s disease, and ulcerative colitis. We can look to the evolving evidence for fecal transplantation as an illustration of how our microbiome matters. My favorite analogy is from former SBM blogger Mark Crislip who likened the gastrointestinal tract to a “metaphorical rainforest” giving a vivid mental image of the number of species (thousands) in our guts, and the complexity of that ecology. If the gastrointestinal tract is a rainforest, then can oral doses of “good” bacteria provide meaningful health benefits?
New practice guidelines
The American Gastroenterology Association (AGA) is the professional organization that represents gastroenterologists. Gastroenterologists are medical doctors that have taken postgraduate specialized training in gastrointestinal diseases. The AGA publishes guidelines on different conditions, which are said to represent clinical best practices and are intended to support medical practice. They state their guidelines follow best practices with respect to methodologic rigor, comprehensiveness, transparency, and conflict of interest. The AGA recently published a clinical practice guideline on probiotics in the journal Gastroenterology.
Probiotics are not drugs, and consequently the regulatory status can vary from country to country. In general, they are lightly regulated and do not require a prescription. Direct-to-consumer advertising is common, and the evidence behind efficacy claims is often unclear. Over time, the usage of probiotics has grown significantly, but that growth has not been accompanied by a solid evidence base to demonstrate that these products are beneficial. These new clinical practice guidelines are intended to help physicians and patients make decisions that are informed by the best evidence.
When it comes to assessing clinical practice guidelines, the fine print matters. In this case, funding for the work was provided by the AGA – not by any manufacturer, pharma, probiotic, or otherwise. The guidelines underwent independent peer review and was also open to public comment. Using methodologists, relevant questions were developed and the medical literature was searched systematically for high-quality evidence. In some cases, systematic reviews existed. In others, a Technical Review Panel completed the systematic review. Following the evidence search and retrieval, a Guideline Panel independently formulated the guideline recommendations. Considerations included evidence, risks/benefits, patient values, costs, and other factors. Here are the main recommendations and some comments:
In patients with Clostridioides difficile infection, we recommend the use of probiotics only in the context of a clinical trial.
C. difficile infections are very difficult to treat, often recur, and cause 29,000 deaths per year in the US. This is an infection that can be effectively treated with fecal transplantation. The evidence for probiotics is poor. Five trials with different products were identified, and because they were so different (in terms of patient populations and other considerations) the results couldn’t be combined. Due to high risk of bias (unpublished trials) and mixed results (one product appeared to increase C. difficile infection recurrence) there was little certainty that these products are effective.

In adults and children on antibiotic treatment, we suggest the use of S boulardii; or the 2-strain combination of L acidophilus CL1285 and Lactobacillus casei LBC80R; or the 3-strain combination of L acidophilus, Lactobacillus delbrueckii subsp bulgaricus, and Bifidobacterium bifidum; or the 4-strain combination of L acidophilus, L delbrueckii subsp bulgaricus, B bifidum, and Streptococcus salivarius subsp thermophilus over no or other probiotics for prevention of C difficile infection.
There is low quality evidence for some probiotics to prevent C. difficile infections. While there are many studies, the data is difficult to interpret owing to variations in patient type, antibiotic therapies, and the treatment setting (in-hospital vs. outpatient). Perhaps not surprisingly, the beneficial effects were seen mainly in patients already at high risk of a C. difficile infection. The guidelines note:
It should be pointed out that beneficial effect of probiotics was seen mainly in patients with very high risk of developing C difficile infection (>15% baseline risk) and that the analysis of most studies had a wide CI that includes the potential for some benefit, as well as for some harm. Thus, patients who place a high value on avoiding associated financial cost or potential harms (especially those immunocompromised patients) and who have low risk of developing C difficile infection (mainly outpatients in the community) may choose not to use any probiotics.

In adults and children with Crohn’s disease, the AGA recommends use of probiotics only in the context of a clinical trial.
Crohn’s disease is a chronic inflammatory bowel disease with no cure, and often requiring surgery. Given the interest in the microbiome and its relationship with Crohn’s disease, there has been significant interest in the potential for probiotics to help manage this debilitating disease. Given the evidence found it isn’t clear if probiotics have any potential value in Crohn’s disease.

In adults and children with ulcerative colitis, the AGA recommends the use of probiotics only in the context of a clinical trial.
Ulcerative colitis is another form of chronic inflammatory bowel disease. Like Crohn’s disease, the quality of evidence for probiotics was felt to be low.

In adults and children with pouchitis, the AGA suggests the use of the 8-strain combination of L paracasei subsp paracasei DSM 24733, L plantarum DSM 24730, L acidophilus DSM 24735, L delbrueckii subsp bulgaricus DSM 24734, B longum subsp longum DSM 24736, B breve DSM 24732, B longum subsp infantis DSM 24737, and S salivarius subsp thermophilus DSM 24731 over no or other probiotics.
When the large intestine and rectum is removed surgically to treat ulcerative colitis, the intestines can be operated on to formed a type of pocket which can hold waste before it is eliminated which eliminates the need for an external bag. Pouchitis is a common complication of this surgery and is an inflammation of the lining of the pouch. While the overall evidence was felt to be low there was weak evidence to support specific probiotics. The AGA supports the use under these circumstances, considering risk and benefit.

In symptomatic children and adults with irritable bowel syndrome, we recommend the use of probiotics only in the context of a clinical trial.
Irritable bowel syndrome is a disorder of the large intestines that can include cramping, pain, bloating, gas, and diarrhea or constipation. The causes of IBS are not known and may be multifactorial. Foods, medicines, and stress can trigger IBS. Given the difficulty in treating IBS there is a lot of interest in probiotics as a potential simple treatment. The evidence is lacking. Some studies use the same strain (S. boulardii) but found no overall difference in abdominal pain. An 8-strain combination found a reduction in abdominal pain but due to a number of methodologic problems, the overall significance is unclear. Single studies exist for other products but the overall quality of these trials was felt to be low. Additionally, publication bias due to registered-but-unpublished trials means that there is a lack of good data to inform decision-making.

In children with acute infectious gastroenteritis, we suggest against the use of probiotics.
Gastroenteritis is the infamous “stomach flu” that is common in children. It can be caused by bacteria and viruses, and causes diarrhea, cramping, nausea/vomiting, and sometimes a fever. Gastroenteritis is usually self-limiting and rehydration is typically all that is necessary. This is also an area where there have been dozens of trials but the number of high-quality trials is actually quite small. Most of the trials that show benefit were conducted outside of North America and were felt to be at high risk of bias. Two high-quality trials conducted in the US and Canada, conversely, showed no benefit. The guidelines note:
Given likely differences in host genetics, diet, sanitation, and endemic enteropathogens between North America and the other global regions, as well as different causes of acute infectious gastroenteritis in children, we do not feel that the studies conducted in other regions can be generalized to the population served by the AGA and thus suggest against the use of probiotics for acute infectious gastroenteritis in children.

In preterm (less than 37 weeks gestational age), low-birth-weight infants, we suggest using a combination of Lactobacillus spp and Bifidobacterium spp (L rhamnosus ATCC 53103 and B longum subsp infantis; or L casei and B breve; or L rhamnosus, L acidophilus, L casei, B longum subsp infantis, B bifidum, and B longum subsp longum; or L acidophilus and B longum subsp infantis; or L acidophilus and B bifidum; or L rhamnosus ATCC 53103 and B longum Reuter ATCC BAA-999; or L acidophilus, B bifidum, B animalis subsp lactis, and B longum subsp longum), or B animalis subsp lactis (including DSM 15954), or L reuteri (DSM 17938 or ATCC 55730), or L rhamnosus (ATCC 53103 or ATC A07FA or LCR 35) over no and other probiotics.
Necrotizing enterocolitis (NEC) is a very serious infection of the gastrointestinal tract that can affect preterm babies, often with devastating consequences. Preterm infants with NEC have different microbial flora compared with healthy infants, leading to the hypothesis that probiotics may be beneficial. And they are. There is moderate/high quality evidence that specific probiotics given to preterm infants can reduce the risk of death compared to placebo. They can also reduce the number of days of hospitalization, as well as the number of days for a preterm infant to reach full feeding.
Don’t believe (all) the hype
        ◦ There is a lack of evidence to support the use of probiotics for digestive conditions like C. difficile infection, Crohn’s disease, ulcerative colitis, and irritable bowel syndrome. The AGA recommends against probiotic use for these conditions. And importantly, there is moderate evidence that probiotics do not improve the treatment of acute infectious gastroenteritis in children. However, the AGA found that there is evidence to suggest that probiotics may be useful in other, very specific clinical circumstances. Given the variety of species, strains, and manufacturing methods, it’s not possible to extrapolate across different products to assume that one will provide the same benefits as another. While manufacturers and marketers continue to make vague and often unproven claims of effectiveness, the evidence for probiotics is far less impressive than the hype. An editorial that accompanies the guidelines comments that the emergence of better evidence is held back by a regulatory framework for probiotics that isn’t designed to give clinicians and patients products that have been carefully evaluated. Given the potential value of microbial therapeutics, it is discouraging that we face an ongoing situation of a lack of good information to inform personal decision-making.

The Trans Fat 51-Day Half-Life Myth
Various websites repeat the myth that trans fats are slowly metabolized, with a 51-day half-life. There is no evidence for that claim.
Harriet Hall on August 7, 2018
Link

There is good reason to limit trans fats in the diet, good enough reason that many countries have passed legislation to restrict trans fats in products and restaurants. The good reason is that dietary trans fats increase the risk of coronary artery disease and heart attacks. But there is also a bogus reason to avoid trans fats: the myth that trans fats are metabolized very slowly and have a half-life of 51 days.
In the book Dr. Bob’s Trans Fat Guide: Why No Fat, Low Fat, Trans Fat is Killing You, he explains:
Do you remember in science class when your teacher talked about Madame Curie’s discovery of the half-life of uranium? Well, trans fat has a half life as well. Through research and experience, I have learned that the half-life of trans fat is fifty-one days. That may or may not seem like a lot, but understand how half-life works. When you eat a bag of chips, a deep friend doughnut, cream-filled cookies or anything with hydrogenated fat, it takes your body 51 days to properly metabolize and eliminate HALF of it. In another 51 days, HALF of that, 25 percent, is still in your body. That’s 102 days, over 3 months, and you still haven’t processed all of the trans fat you just ate!! If you are eating trans fat every day – and you are if you eat snack foods, prepackaged foods and deep fried foods – imagine how much trans fat is congesting your body from years of this eating pattern. That’s a pretty nauseating thought. Take two breaths and read this again.
In the following paragraph, he proceeds to blame trans fats for ADHD, depression, and Alzheimer’s; and claims what people are eating is slowly killing them.
Another alarmist cites the half-life as 52 days and claims that the process used to create trans fats causes your body to view them as a foreign substance, not food.
Simply not true
Those claims are simply not true. The terms trans and cis refer to stereoisomers, different geometrical configurations of molecules with the same chemical formula. Cis means that the functional groups are on the same side of the carbon chain; trans means they are on opposite sides. Trans fats are produced commercially by the process of hydrogenation, but they are also found in animal products. The body can’t tell whether the molecule came from an animal or a factory. The idea that trans fats in processed foods are viewed by the body as foreign substances is ridiculous. The metabolism of trans and cis fatty acids is the same. The concept of half-life doesn’t apply to their metabolism. So where did the 51-day myth originate?
Dr. Bob said so
The 51-day story apparently was invented by Dr. Bob, the author of the book quoted above.
Who is Dr. Bob? Dr. Bob DeMaria is a chiropractor who calls himself the drugless doctor. He’s against drugs, but is very much in favor of dietary supplements, which he sells. He has written about how he came up with the 51-day story: “…through my research and experience…” He doesn’t offer any supporting references. I can’t help but wonder what he thinks “research” means, and how his “experience” came up with the 51-day figure.
This 51-day half-life claim has been disseminated widely on numerous chiropractic and other alternative medicine websites. Amazingly, no one seems to have challenged this absurd assertion. So I will be the first to say it is absolute nonsense.
Conclusion: trans fats don’t have a 51-day half-life
As Christopher Hitchens said, “What can be asserted without evidence can be dismissed without evidence“. This claim can be dismissed.
Of course, it is still a good idea to limit trans fats in the diet – for real reasons, not imaginary ones.

dōTERRA: Multilevel Marketing of Essential Oils
Harriet Hall on January 22, 2013
Link
A stay-at-home mom recently e-mailed me. She is a former CAM user who once treated her infant’s colic with homeopathy but has since seen the light and is now thinking skeptically. She asked that I look into the dōTERRA company, seller of essential oils: concentrated extracts distilled from plants, containing the “essence” or distinctive odor of the plant. She said:
…moms, well educated and seemingly rational moms, will believe anything. This isn’t a big deal if we are talking about sugar pills trying to cure crying that has no cause. However, I recently attended a dōTERRA “talk” (aka pressure to buy) about how essential oils can cure everything and anything, including one woman’s mother’s skin cancer. I didn’t want to offend this mom by calling her a quack, so I walked away spending 60 bucks on oils to be polite (this was the least amount I could spend and I used these oils to make my home smell nice, even though they were intended to solve all sorts of skin and digestive problems. I didn’t want to use them without knowing if they actually worked).
Instead of stressing the aromas, the focus was on the need to spend hundreds of dollars on these products to keep your family healthy. A handout showed how you could replace everything in your medicine cabinet with an essential oil alternative. She said:
The reps talked about how conventional medicine failed them and how they never go to the doctor anymore because the oils are a better cure.
dōTERRA’s Claims
The company’s website, www.doterra.com, doesn’t claim to cure cancer. It is rather vague. Instead of making specific claims for their products, they talk about the use of essential oils in history for anti-bacterial properties, to heal burns, and for “wellness.”
In addition to their intrinsic benefits to plants and being beautifully fragrant to people, essential oils have been used throughout history in many cultures for their medicinal and therapeutic benefits. Modern scientific study and trends towards more holistic approaches to wellness are driving a revival and new discovery of essential oil health applications.
They say modern science is validating “the numerous health and wellness benefits of essential oils” but they don’t identify those benefits or offer any evidence. No clinical studies are cited, and there is no research section on their website.
Their products are intended to be used in various ways: to smell, to apply to the skin, and to take internally. Claims for individual oils are vague: to soothe sore muscles and joints, to ease breathing, as a cooling agent for the skin, for calming, cleansing, mood-enhancing, to relieve menstrual discomfort, to supply antioxidants, digestive support, supporting a healthy insulin response, supporting localized blood flow, beautifying legs and hips, immune support, cleansing the air, regenerative properties, fighting off seasonal bugs, “calming the skin” (?). Any claim that begins to sound specific is asterisked to the usual FDA disclaimer. (“These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent disease.”)
Since so many of the oils are supposed to do the same things, how does a customer decide which to use? They conveniently offer mixtures of oils designed for specific purposes: to promote restful sleep, disinfect countertops, to apply to areas of the skin affected with blemishes, itchy scalp, unsightly nail beds and feet, etc. One mixture is a roll-on for troubled skin spots. Others are for achy joints and sore muscles, to calm, purify, relieve tension, eliminate and control pathogens, help manage hunger, cleanse the body’s organs, enhance focus and support healthy thought processes… there is even an anti-aging blend.
Rose Essential Oil: dōTERRA says rose essential oil has traditionally been used to help with skin problems, depression, stress, anxiety, and is supportive to the organs in the body. It supposedly works as an aphrodisiac, and has commonly been used for its antispasmodic, antimicrobial, anti-inflammatory, and sedative properties.
The Natural Medicines Comprehensive Database disagrees. It says “insufficient reliable evidence to rate” and lists a number of adverse reactions and interactions with drugs.
Jasmine Oil: Dabbing a little jasmine essential oil over your heart at bedtime will provide a deep sleep filled with positive dreams. It helped six White Sox players improve their batting average. The NMCD disagrees. It says “There is insufficient reliable information available about the effectiveness of jasmine.” Anyway, I can’t help but wonder how something that makes you sleep could improve batting prowess except in a dream.
There’s Hardly Any Science Behind Essential Oils
I first heard of essential oils years ago in connection with Gary Young, described on Quackwatch as “an uneducated huckster with a track record of arrests for health fraud.” Gary Young and his Essential Oils are still in business despite the devastating critique that has long been featured on Quackwatch. The record of misdeeds there makes for painful reading. Among other things, he practiced medicine without a license, was arrested repeatedly, did bogus lab tests, and contributed to the death of his own child by performing an underwater delivery and holding the newborn infant underwater for an hour. His judgment about medical matters is obviously not very trustworthy.
The published evidence is sparse to nonexistent. There are clinical studies to support a few of the recommended uses, but they are generally poorly designed, uncontrolled, and unconvincing. Research is difficult, because patients can’t be blinded to the odors, and mental associations and relaxation could account for most of the observed effects.
The claims for essential oils are handily summarized and debunked in articles like these:
    • “Essential oils and aromatherapy: A rebuttal to bunk science and the healing power of odors.”
    • Entry on aromatherapy by Robert Carroll in The Skeptics Dictionary
    • “Aromatherapy: Does It Pass the Smell Test?” (answer: no) by Paul DesOrmeaux for the Bay Area Skeptics
    • “What’s That I Smell? The Claims of Aromatherapy” by Lynn McCutcheon in Skeptical Inquirer 
Multilevel Marketing (MLM)
Multilevel marketing is a system of direct sales through a hierarchy of individual distributors, where sellers get a cut of the profits from sales by other distributors they have recruited. It’s also called network marketing. There is a whole website dedicated to critiquing it: MLM Watch, affiliated with Quackwatch. At the top levels, people who got in early have sometimes become millionaires, but the great majority of distributors lose money. In a typical company, Quixtar (formerly known as Amway), 99% of distributors made no profit, and 70% quit in the first year. Stephen Barrett’s article “The Mirage of Multilevel Marketing” concludes:
Consumers would be wise to avoid health-related multilevel products altogether. Those that have nutritional value (such as vitamins and low-cholesterol foods) are invariably overpriced and may be unnecessary as well. Those promoted as remedies are either unproven, bogus, or intended for conditions that are unsuitable for self-medication.
Why Does MLM Appeal to Manufacturers? It allows them to sell a product that could not compete in the open marketplace, at least not at those prices. It allows the big players to get filthy rich. It allows distributors to make claims the company can’t legally make in its advertising, such as: “It cured my mother’s skin cancer,” “It cured my child’s tonsillitis,” and “It keeps my kids from catching colds.” And that kind of testimonial from a friend is far more powerful than any advertising.
Why Does MLM Appeal to Distributors? It offers the promise of direct income from sales; the chance to piggyback on the sales of others; the dream of making it rich; the opportunity to sell a product they believe in; and a way to make money in a pleasant way, at home, with their own hours, with a lot of social contact, and no need to apply for a job.
Why Do Customers Buy? Imagine a typical customer experience. A friend or acquaintance invites you into her home, provides refreshments, a party atmosphere, and a social opportunity to visit with other old acquaintances and meet new friends and neighbors. You get free samples. People you know and trust tell you about their personal experiences, providing persuasive testimonials of apparently miraculous benefits. They vouch for the quality and manufacturing standards of the products. They offer discounts and the opportunity to join the community of distributors. It all sounds so good! The hostess has given you refreshments and goodies, so you feel a social obligation to reciprocate. There is the peer pressure of all the other attendees who are buying the products, and you don’t want to look like a Scrooge or an ungrateful oddball. You might end up, like the person who e-mailed me, spending $60 for something you didn’t want and don’t believe works.
Conclusion
There is no good evidence to support the use of essential oils for health purposes, and exposing yourself to deceptive MLM sales tactics is a bad idea. Lynn McCutcheon said it best:
All of this sounds as though I am strongly opposed to the use of essential oils. I’m not! If it pleases you to put some in your bath water or have a little rubbed on your back once in a while, by all means, go ahead. It is not the odor that arises from these fragrances that is troubling, it is the stench arising from the unwarranted claims made about them.

The Dr. Oz Red Palm Oil (non-) Miracle
Scott Gavura on January 10, 2013
Link
If there is an antithesis to the principles of science-based medicine, it’s probably the Dr. Oz show. In this daytime television parallel universe, anecdotes are evidence. There are no incremental advances in knowledge — only medical miracles. And every episode neatly offers up three or four takeaway health nuggets that, more often than not, seem to leave the audience more ill-informed about health and medicine than they were 30 minutes earlier.
After I completed my post on Dr. Oz’s prolonged embrace of the “miracle” that is green coffee bean extract, a number of readers brought me up to speed. Green coffee beans are yesterday’s miracle. The new weight loss miracle for 2013 is red palm oil. This constant drive for miracles must keep the producers in a perpetual panic. They need at least five miracles per week. Having now watched a few episodes, I’m reminded of the classic “That Mitchell and Webb Look” skit where two nutritionists pick a new superfood. It could be just a matter of time until we see white veal profiled as a superfood in a future Dr. Oz episode.
If there is a common characteristic of complementary and alternative medicine (CAM) proponents who believe themselves to be scientific (and I include Dr. Oz in this group), it is that they extrapolate from weak clinical evidence to grandiose claims by cherry picking the most supportive strands of evidence to give the impression of being evidence-based. They have the belief, and then they look for the supporting evidence to bolster the claim. In short, to paraphrase a quote attributed to Hahns Kuhn, they use scientific evidence like a drunkard uses a light post: for support, not for illumination. As I noted with green coffee bean extract, Dr. Oz extrapolated from ambiguous, preliminary data to recommendations to consume green coffee bean extract as a weight loss strategy. Frankly, the evidence isn’t there, so I didn’t have high expectations with the latest miracle. All I knew going in about palm oil is that it’s used in most industrial food production and the demand for it is linked to massive destruction of tropical rainforests. But who doesn’t want longevity? So I sat down and watched another episode.

Dr. Oz’s first miracle solution of 2013 is red palm oil, an amazing fat that helps stop the signs of aging inside and out!
— DoctorOz.com
Let’s look at the claims made on the show, and then consider the evidence supporting them. I’m quoting liberally from the show so it’s clear exactly what Dr. Oz said, but I recommend you watch both clips for the full effect. This show needs to be seen to be believed. Keep in mind that Dr. Oz is no ordinary daytime television host: he is an accomplished and still active cardiac surgeon, an academic, and a research scientist. He has hundreds of scientific publications to his name. His show has been broadcast since 2009 and he reaches millions every day. He is perceived as a credible authority, because he’s a real health professional. Unfortunately Dr. Oz has a persistent history of giving dubious health advice that doesn’t hold up when it’s checked against the evidence.
This episode is all about miracles for 2013 and the segment features Canadian homeopath Bryce Wylde, introduced by Dr. Oz as a “miracle worker and alternative medicine expert”). Oz introduces red palm oil with an argument from antiquity:
That red color is perfect because I think of it as a stop sign for aging, inside and out. Did you know that palm trees contain an ancient remedy that can slow down the aging process, fight belly fat, and combat heart disease?
There’s a secret inside the flesh of this fruit, extending the warranty of nearly every organ in your body. This mega-oil may very well be the most the most miraculous find of 2013.
The purported benefits Wylde mentions include carotene, described as a “a super-powerful antioxidant” and tocotrienols, “a special form of vitamin E, very, very cardioprotective”. Oz is impressed:
I think this will actually help protect us against Alzheimer’s…
Wylde continues from there, showing a sliced apple that has browned (emphasis added):
This apple is just like our brain. When…oxygen from the environment, stress hits it, it will ultimately denature, it will become rotten. We all know the culinary trick…of putting lemon juice juice or lime juice on our fruit salad or apple. That protects it, keeps it white. Well red palm oil does the exact same thing in our brains, protecting it….That special form of tocotrienols we’re talking about, that special form of vitamin E, is actually going to increase blood circulation, it’s going to reduce incidence of dementia and Alzheimer’s, so it’s going to protect our most important organ.
The “demo” then moves on to the heart. Dr. Oz asks Wylde to explain why saturated fats protect the heart. Two fake arteries (actually what appears to be sections of bisected PVC sewer pipe) are shown. Both are coated with clumps of white goo. Oz pours some liquid down one pipe. The liquid is viscous and sticks to the goo. Then he pours some red palm oil down the other pipe. It washes the pipe clean. This new biochemical model clearly impresses Dr. Oz:
Folks who were using this lowered their bad cholesterol by nearly 40% in one month! Drugs don’t even do this!
In a statement on the Dr. Oz website, Wylde elaborates:
Over the past two decades, researchers have intensely studied red palm oil’s effect on cardiovascular health and the preliminary results initially baffled scientists. At room temperature, this semi-solid oil seems as likely as lard to clog your arteries. But what might shock you to learn, as it has equally stunned researchers, is that although red palm fruit oil is indeed high in saturated fat, it actually protects against heart disease. Saturated fats behave like a thick molasses through the cardiovascular system, eventually contributing to plaque (atherosclerosis). But studies show that adding palm oil into the diet can remove plaque build-up in arteries and, therefore, reverse the process of plaque and prevent blockages.
The demonstration finally moves a piece of fat that Dr. Oz says is our omentum. Wylde notes:
Red palm fruit oil goes straight to the liver and gets used up as calories, and might help to reduce your fat tissue concentration, because you’re not storing it, your burning it.
Then Dr. Oz ignites a candle, which he likens to other fats, and a sparkler (which explodes) which he likens to red palm oil:
There was another study done of women who ate two tablespoons of an oil that was like palm oil. And it helped turn up their metabolism and whittled away this belly fat that so many of you are frustrated by.
So at the end of the segment we are left with three distinct, testable claims about red palm oil consumption and supplementation:
     1.  Red palm oil protects against dementia and Alzheimer’s.
     2.  Red palm oil reduces bad cholesterol, reduces atherosclerosis, and prevents new blood clots.
     3.  Red palm oil spot reduces belly fat.
Palm Oil
If you eat any packaged or prepared foods that contain “vegetable oil”, you’re probably eating palm oil. The palm tree is the source of one of the most widely used industrial oils in the world. Raw palm oil does contain a rich source of carotenoids and vitamin E. Red palm oil is a refined version of raw red palm oil which retains a significant amount of these ingredients. For industrial purposes, however, red palm oil is not ideal. It is described as having a bitter, pronounced flavor which some describe as unpalatable. The dark colour, a consequence of the carotenoids, can discolor prepared foods. Refining raw palm oil further, with bleaching, eliminates the carotenoids and tocoperols. Refined, palm oil is very versatile: it’s stable at high heat, largely tasteless, trans-fat free, and is low cost. With the exception of the carotenoids and vitamin E, red palm oil, and refined palm oil, are essentially the same product: saturated fatty acids palmitic acid (44%), stearic acid (5%) and myristic acid (1%), and the unsaturated fatty acids oleic acid (39%) and linoleic acid (11%).
It’s the vitamin content that has driven most of the research into uses for red palm oil. Vitamin A deficiency is a significant public health issue in developing countries [PDF], as major cause of blindness as well as overall mortality. Red palm oil has been studied as a supplement and as part of food fortification to boost vitamin A levels. It seems to be effective and could serve to help fortify the food supply in nations where widespread deficiency exists. Vitamin A deficiency, however is rare in developed countries, though it can still appear in some malabsorbtion-related disease states. When used as a supplement, red palm oil seems to be a good source of the vitamin E compounds as well. Compared to vitamin A, however, vitamin E deficiency is almost unheard of — even in developing countries.
Do consumers in developed countries need to routinely supplementation with carotenoids and vitamin E? Here we get into the complexity of diet. Dietary patterns have been examined in observational studies that have suggested that foods high in antioxidants like carotene may offer protection from cardiovascular disease, cancer, and other illnesses. Randomized trials with antioxidants have not borne out the touted benefits of supplements, however, so the most pragmatic advice seems to be that eating a diet of foods that contain these factors is a better approach than using supplements. Given red palm oil is not consumed routinely in populations that have been studied in supplement trials, the overall effect of a diet that includes regular consumption of red palm oil isn’t clear. Unlike the well-studied “Mediterranean Diet” that features olive oil as the primary oil consumed, there have been no similar studies of populations that consume red palm oil routinely as part of their diet.
The rationale for specific vitamin E supplementation is even more questionable. The idea for years was “oxidation bad, antioxidant good”. Eating foods that contain sources of vitamin E seems to be beneficial to health. Yet trials with supplements haven’t been shown to protect against heart disease or stroke, and at higher doses may increase the risk of cancer and of overall mortality. On balance the best evidence seems to suggest that diets rich in fruits and vegetables may be protective of different diseases, but specific supplementation may not. What this means if you decide to consume red palm oil isn’t clear — it may be influenced by whether you add it to your existing diet, or if you substitute it for something else.
The Evidence Check
Dr. Oz’s statements were unambigous and testable. Here is how they stack up against the evidence.
Claim 1: Red palm oil protects against dementia and Alzheimer’s
There is no direct evidence to substantiate this claim, either with refined palm oil or red palm oil. I couldn’t locate any trial that has prospectively examined this — and I’m not surprised, because studying treatments for the prevention of dementia are notoriously difficult to do, requiring hundreds of patients and years if not decades of follow-up.
Alzheimer’s disease is the most common form of dementia, but not the only cause. Antioxidants have been proposed as possible preventative treatments for dementia, given oxidative stress may be a component of the degenerative changes observed with the disease. Trials studying vitamin E supplementation for the prevention of Alzheimer’s disease have shown no effect, though it may have a role in the treatment of established disease. It’s been similarly disappointing with beta-carotene, where no clear benefit has been demonstrated.
If we look at the fatty acid components, there’s no evidence suggesting palm oil will have any meaningful effects. Rather what evidence exists suggests negative effects from saturated fats. In contrast to palm oil, the evidence is at least promising for the omega-3 fatty acids, particularly when consumed as fatty fish. The same can be said for the Mediterranean diet. But the usual biases in studying diet confound the results.
Overall, there is no convincing evidence to suggest that consuming red palm oil will have any meaningful effect at preventing dementia or Alzheimer’s disease. What limited evidence exists suggests either a neutral or possibly a negative effects from supplementation.
Claim 2: Red palm oil reduces bad cholesterol, reduces atherosclerosis, and prevents new clots
There is no convincing evidence with red palm oil to substantiate a recommendation to preferentially consume this oil. Studies with palm oil suggest that it can raise LDL and total cholesterol, but the effects are not consistently shown. None of the studies are large, nor do they clearly establish any role for red palm oil as a therapeutic treatment for reducing LDL cholesterol or preventing clots. (Edit: I was unable to find any trial showing a 40% reduction of LDL in one month, but Colby Vorland did in the comments, and the actual results are underwhelming.) Despite the impressive effects Dr. Oz showed with his sewer pipe, the effects in the real world, with real arteries, haven’t been established.
When it comes to the antioxidants in red palm oil, there is no convincing data from prospective trials that vitamin E or the carotenoids have any benefit for the primary prevention of cardiovascular disease. Again, the usual recommendations (lots of fruit and vegetables, using monounsaturated and polyunsaturated fats instead of trans fats and saturated fats, and eating omega-3 fatty acid-rich foods) have much better evidence behind them. Like claim 1, there is actually some promising evidence with other oils — particular fish oils and the consumption of fatty fish. And again, it’s really not clear that if you want to reduce bad cholesterol, that palm oil is your best choice. Some data suggests palm oil raises total cholesterol and LDL, compared to olive oils. It also may be inferior to sunflower oil. The data are preliminary and no clear effects on lipids have been established.
Claim 3: Red palm oil spot reduces belly fat
Finally, let’s look at the claim that red palm oil won’t cause belly fat gain and will “melt away” existing belly fat. Spot reduction of fat is a huge red flag for bogus claims. The idea comes from the thought that red palm oil-rich fatty acids are metabolized by the body, and not deposited as fat. Spot reduction is a persistent but unfounded dietary myth that can give unrealistic expectations about weight loss and what constitutes a healthy diet. While weight loss can result in fat loss in different areas of the body at different rates, this is due to genetic effects — not due to any specific treatment. Not surprisingly, there is no direct evidence suggesting red palm oil, or refined palm oil, contributes to a loss of belly fat. Oz may be extrapolating the idea the medium-chain triglyceride oil, when used instead of other oils, can cause weight loss. But MCT oil isn’t red palm oil. There’s been a trial in coconut oil that was unimpressive, showing a 1.4cm difference versus soy oil after 12 weeks. In aggregate, the evidence isn’t impressive, even when coconut oil is used as a substitute for other oils. Whether any of the studies with other oils are relevant to the consumption of red palm oil isn’t known — it hasn’t been directly studied. Certainly if net calorie intake goes up because of specific supplementation, all things being equal, we should not expect any meaningful changes in weight or waist size. On balance, supplementing with or switching oils probably has a trivial effect compared to the big drivers of obesity, like overall energy intake and expenditure. Calories clearly still matter. Substituting oils may not.
Other considerations
If environmental impact is a factor in your oil selection, palm oil may not be the best option. Orangutan protection advocates are outraged Dr. Oz has endorsed red palm oil, and have launched a campaign to shame him. Says Orangutan outreach:
Dr. Oz Declares war on OrangutansDr Oz and his staff should have done more research before recommending palm oil. In doing so, he has inadvertently declared war on orangutans– along with every other living creature in the jungles of Borneo and Sumatra.While originally from West Africa, today 90% of the global supply of palm oil actually comes from Indonesia & Malaysia. This has come at a tremendous environmental cost. Indonesian and Malaysian forests are being burned to the ground– releasing so much carbon into the atmosphere that Indonesia now ranks 3rd behind China and US in carbon emissions– and it is barely industrialized. The UNEP estimates that the forests of Indonesia are being cleared at a rate of 6 football fields per minute every minute of every day.
While this may be the case, it’s unlikely that even Dr. Oz-driven demand for red palm oil is meaningful compared to the current worldwide use of palm oil. With use predicted at 42.6 million tons this year, I’d be surprise if even the Dr. Oz effect will have a big effect on what appears to be a consequence of our already massive consumption of palm oil.
Conclusion
If there is one thing that really frustrates me about the Dr. Oz show is that he ignores the boring-but-factual and always hypes the gimmicks. Red palm oil is no exception. It’s foolish and short-sighted to declare red palm oil as healthy or beneficial based on the limited data that exists. The history of dietetics and nutrition is replete with cases of extrapolating preliminary data into supplement and dietary advice, only to see population-level data, and good clinical trials later refute it. There is no clearly established need for the routine supplementary consumption of the carotenoids and vitamin E in red palm oil. And you may already have palm oil as a routine part of your diet — perhaps unwittingly. The impact of red palm oil consumption on your health is likely to be insignificant, compared to the big drivers of health. But none of this matters on the Dr. Oz show. Because just as quickly as this post is published, Oz will have moved on to the next dietary fad, leaving consumers who watch his show more confused than ever about what constitutes good health and nutrition.

No Benefit from Fish Oil
A new systematic review of clinical trials shows no clear benefit to consuming omega-3 fatty acids in food or supplements.
Steven Novella on August 8, 2018
Link

One day I was cooking pasta when the kitchen started to fill with the odor of fish. I happen to hate fish, so this was not a pleasant experience. It was also a mystery, since I never cook fish. A little detective work discovered that the offensive odor was coming from the pasta. Apparently I didn’t notice the “Now with Omega 3” label on the box when I purchased it. My daughter and I still refer to this as the “fish pasta incident”.
Why would someone foul a perfectly good box of rotini with omega 3 oils? This is based on the belief that omega 3 fatty acids reduce heart disease and vascular risk, probably through reducing blood pressure and cholesterol. This is a plausible claim, but as we see over and over again in medicine, plausibility (while nice) is insufficient as a basis for clinical claims.
There have been numerous clinical trials looking mainly at death, stroke, and cardiac outcomes related to omega 3 consumption, either in food or in supplements. Now the Cochrane Library has published the largest systematic review of these studies to date. Unfortunately, the review shows little benefit from consuming omega 3 fatty acid. This is a fairly extensive review with good statistical power:
We included 79 RCTs (112,059 participants) in this review update and found that 25 were at low summary risk of bias. Trials were of 12 to 72 months’ duration and included adults at varying cardiovascular risk, mainly in high‐income countries. Most studies assessed LCn3 supplementation with capsules, but some used LCn3‐ or ALA‐rich or enriched foods or dietary advice compared to placebo or usual diet.
LCn3s are long chain fatty acids from fish, including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). ALA is plant-based omega 3-alpha‐linolenic acid. Fatty acids are essentially chains of carbon atoms with an OOH group at one end. The available binding sites on the carbon atoms are filled with hydrogen atoms. If every binding site is occupied with a hydrogen, that is a saturated fatty acid. If instead of hydrogen atoms there is a double bond between two adjacent carbon atoms, that is an unsaturated fatty acid. If there are multiple double bonds, that is polyunsaturated. Omega 3 fatty acids are unsaturated, with a double bond between the third and fourth carbon atoms from the end opposite the OOH group.
The number, location, and orientation of the double bonds determine the health effects of fatty acids on the body. One aspect of this is their effect on triglycerides and LDL and HDL types of cholesterol, which in turn affect how much cholesterol gets deposited on the inside of blood vessels. There are also subtypes of LDL and HDL which are also likely important to their health effects.
Consuming omega-3 fatty acids tends to decrease triglyceride levels, which have a positive health effect, but they also decrease HDL, which can have a negative health effect. So what is the net effect on balance? That is what the review sought to determine. They found:
Meta‐analysis and sensitivity analyses suggested little or no effect of increasing LCn3 on all‐cause mortality (RR 0.98, 95% CI 0.90 to 1.03, 92,653 participants; 8189 deaths in 39 trials, high‐quality evidence), cardiovascular mortality (RR 0.95, 95% CI 0.87 to 1.03, 67,772 participants; 4544 CVD deaths in 25 RCTs), cardiovascular events (RR 0.99, 95% CI 0.94 to 1.04, 90,378 participants; 14,737 people experienced events in 38 trials, high‐quality evidence), coronary heart disease (CHD) mortality (RR 0.93, 95% CI 0.79 to 1.09, 73,491 participants; 1596 CHD deaths in 21 RCTs), stroke (RR 1.06, 95% CI 0.96 to 1.16, 89,358 participants; 1822 strokes in 28 trials) or arrhythmia (RR 0.97, 95% CI 0.90 to 1.05, 53,796 participants; 3788 people experienced arrhythmia in 28 RCTs). There was a suggestion that LCn3 reduced CHD events (RR 0.93, 95% CI 0.88 to 0.97, 84,301 participants; 5469 people experienced CHD events in 28 RCTs); however, this was not maintained in sensitivity analyses – LCn3 probably makes little or no difference to CHD event risk. All evidence was of moderate GRADE quality, except as noted.
Increasing ALA intake probably makes little or no difference to all‐cause mortality (RR 1.01, 95% CI 0.84 to 1.20, 19,327 participants; 459 deaths, 5 RCTs),cardiovascular mortality (RR 0.96, 95% CI 0.74 to 1.25, 18,619 participants; 219 cardiovascular deaths, 4 RCTs), and it may make little or no difference to CHD events (RR 1.00, 95% CI 0.80 to 1.22, 19,061 participants, 397 CHD events, 4 RCTs, low‐quality evidence). However, increased ALA may slightly reduce risk of cardiovascular events (from 4.8% to 4.7%, RR 0.95, 95% CI 0.83 to 1.07, 19,327 participants; 884 CVD events, 5 RCTs, low‐quality evidence), and probably reduces risk of CHD mortality (1.1% to 1.0%, RR 0.95, 95% CI 0.72 to 1.26, 18,353 participants; 193 CHD deaths, 3 RCTs), and arrhythmia (3.3% to 2.6%, RR 0.79, 95% CI 0.57 to 1.10, 4,837 participants; 141 events, 1 RCT). Effects on stroke are unclear.
The bottom line of all that is that there was no clear health benefit from consuming omega-3 fatty acids in food or supplements. There was a suggestion of a possible benefit from LCn3 on cardiac events, but this did not hold up when they took into consideration the quality of the evidence. The better trials, with less risk of bias, tended to be negative.
As always with such trials, you can never prove zero benefit (or zero risk), but an essentially negative trial or meta-analysis sets statistical limits on the size of any remaining plausible effect. What we can now say with a fairly high degree of confidence is that any health benefit from consuming omega-3 fatty acids is tiny, probably too small to warrant supplementing (or adding it to pasta).
This is unfortunate. It would be desirable if we could reduce the leading cause of death in developed nations simply by taking a supplement or making small changes to our diet. To be clear, a healthy diet is still important to overall health and reducing vascular risk, but going out of your way to consume omega-3 is not necessary.

Fish Oil Doesn’t Help Dry Eyes
Dry eyes? Despite guidelines that recommend fish oil consumption, a new trial demonstrate that they are not effective.
Scott Gavura on September 20, 2018
Link

I visit my optometrist annually for a checkup, and several years ago she started recommending that I eat more fatty fish. She told me that I had dry eyes and that the glands that produce eye lubrication on the lid were clogging up – it’s called Meibomian Gland Dysfunction which is a common cause of dry eye. While for years I just assumed I wasn’t changing my contact lenses frequently enough, now I had a diagnosis and seemingly something I could do about it. Eating fatty fish twice weekly, in combination with warm compresses on my eyes periodically, might help relieve my symptoms and potential prevent longer-term damage. While the optometrist didn’t recommend fish oil supplements, she cited the omega-3 fatty acids in fatty fish as likely beneficial for this condition. So I added this to the list of possible benefits from substituting fish for meat, and try to eat salmon at least once per week.Now it turns out that that there’s one less reason to take fish oil supplements. A recent review has found that the supplements don’t appear to help dry eye conditions at all. So while there’s likely some health benefits from eating fatty fish, treating dry eyes isn’t one of them.
Dry eyes and fish oil
Fish oil supplement sales are big business, and the category is one of the more popular among supplements. Annual sales of fish-derived supplements amount to more than a $1-billion market in the United States, driven more by hype than good evidence. Many formulations are sold over-the-counter, while others require a prescription or are available for purchase from a health care provider (see, for example, Jann’s post on the prescription fish oil, Vascepa). The enthusiasm has been driven in part by observational studies of diets, noting a relationship between fatty fish consumption and cardiovascular disease. But in trials with fish oil capsules, those benefits haven’t been proven.
Dry eye is a very common condition (affecting about 14% of American adults) that can distort vision and affect quality of life. It’s a consequence of the dysfunction of tear-secreting glands, and can be made worse by medications and environmental conditions such as heating, drafts, and air conditioning. Allergens can worse dry eyes, but don’t cause it. In most cases, the condition isn’t serious, just bothersome – usually blurred vision and irritated eyes. Severe forms can cause scarring of the cornea and even ulceration. The condition isn’t considered curable, and treatment focuses on addressing symptoms. Usual treatments include eye drops (“artificial tears”), lid scrubbing, and frequently, omega-3 fatty acid supplements. There doesn’t seem to be clear evidence to suggest why omega-3 fatty acids would help dry eyes, beyond the thought that there might be some sort of anti-inflammatory effect. So a trial was developed to actually test the hypothesis.
The paper is entitled “n−3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease” and comes from the Dry Eye Assessment and Management Study Research Group, published in April in the New England Journal of Medicine. The study was funded by the National Eye Institute of the National Institutes of Health. (Thank you, America, for funding this study.)
This was a really well-designed study that is “generalizable” meaning that the results should be relevant for many people. This study took place at 27 centres and enrolled 535 community-dwelling people with a minimum 6-month history of moderate to severe dry eyes, as evaluated by the Ocular Surface Disease Index (ODSI). Patients were excluded if they couldn’t comply with the 5-day run-in of supplements, if they wore contact lenses recently, or if they had other ocular conditions recently. Participants were randomly assigned to a 3,000mg daily dose of fish-derived fatty acids, or to an olive oil placebo. Interestingly, patients could continue using treatments for dry eye, including fatty acid supplements, as long as the daily dose was below 1,200mg. This makes the findings even more interesting.
349 patients were randomized to the treatment arm, taking five capsules of fish oil per day, providing a total of 2,000 mg eicosapentaenoic acid (EPA) and 1000 mg docosahexaenoic acid (DHA). This dose of omega-3 is the highest ever tested for treating dry eye disease. 186 people received the placebo, which was 5 grams daily of olive oil (about 1 teaspoon) in identical capsules. Both patients and investigators were blinded to the treatment arm. There were no significant differences between the groups. Participants were followed for 12 months, and evaluated at the 6- and 12-month point. At 12 months, both groups were highly compliant with therapy (83%) taking five capsules daily. The primary endpoint measured in the trial was the change from the initial ODSI scale, as well as other signs of dry eye disease.
The results were not impressive. All Table 2 tells you is that there’s really no meaningful difference in terms of symptoms, despite significantly higher levels of EPA and DHA in the active treatment arm:
After 12 months, both groups improved significantly, but there was no meaningful difference between the fish oil group and the group that received a placebo. There was also no improvement in measures of dry eye that were conducted using standardized testing – so not only was there no subjective difference with the fish oil, there was no objective improvement, either. Finally, there were no significant differences between adverse events. Some may call this a “powerful placebo” but what this really tells us is that randomized trials, not anecdotes, are necessary to determine if something is actually “working”.
Don’t count on fish oils to help dry eye
This well conducted, high quality trial shows that there is no compelling reason to take fish oil supplements if you have moderate to severe dry eye. Fish oil supplements are no more effective than an equivalent placebo.

Fake News about Fish Oil
An ad for the dietary supplement Omega Rejuvenol is disguised as a news story in my local newspaper. It makes claims that are not supported by evidence.
Harriet Hall on June 5, 2018
Link


My local newspaper, The News Tribune of Tacoma, is a prolific source of fake news. On most days there are between one and three half-page ads for dietary supplements. They are thinly disguised as news stories, with “paid advertisement” in small print. One recent ad is a doozy. It’s for the omega-3 supplement Omega Rejuvenol. The same ad was published in various newspapers; you can see a copy of it here. In a way, it’s really quite amusing, because it repeats a story that essentially debunked what the ad is selling.
The headline shouts, “Washington Post Exposes $1.2 Billion Fish Oil Scam.” It did indeed. But the exposé is several years old and it didn’t say what the supplement manufacturer would like to think it said. In a 2015 article, it reported that Americans spend $1.2 Billion on fish oil supplements. It went on to say that the fish oil supplement industry was “built on empty promises.” The ad even quotes the Journal of the American Medical Association saying that fish oil supplements “lack efficacy across a range of health outcomes.”
Fish oil vs. krill oil
Then the ad subtly switches gears. First it warns that some fish are contaminated with mercury and other toxins, letting the reader assume that products sourced from those fish are toxic. They aren’t. Consumer Lab has tested fish oil supplements and found no mercury contaminants and only trace amounts of PCBs (which is unavoidable since water everywhere contains the same trace amounts).
Then they claim that other brands:
     1.  Fail to get into cells quickly enough.
     2.  Don’t deliver enough of the most important omega-3, DHA.
     3.  Can’t cross the blood/brain barrier, “so the brain is left wanting.”
     4.  Often don’t contain the amount specified on the label.
They say experts are throwing out fish oil and turning to new and better sources of omega-3’s. They claim their product contains “deep sea Omega-3s” from the pure, cold waters near the South Pole that are “virtually 100% free of contaminants.” That’s not true. Their product is made from squid and krill oil. They explain that krill oil DHA is bound to phospholipids, which may offer some advantages over DHA bound to triglycerides or ethyl esters. But other omega-3 supplements on the market contain krill oil, and absorption of EPA and DHA from krill has not definitively been shown to be better from fish oil. Other sources say deep sea fish are less nutritious and more likely to be contaminated with toxins.
Who sells it?
Dr. Al Sears is quoted in the ad and guess what? He sells the product on his website. It is one of many questionable supplements he sells under his Private Label Primal Force. He says “Omega Rejuvenol helps restore the stamina, strength and mental acuity that Nature intended by recreating the Primal conditions of our hunter-gatherer ancestors.” He calls it an anti-aging formula, but it is listed under his “Brain and memory” category.
What’s in it?
Its ingredients:
    • DHA and EPA from squid and krill oils
    • Natural astaxanthin complex
    • Tocotrienols/Tocopherols
    • Vitamins A, D3, and K2
Why that particular combination of ingredients? Sears doesn’t explain. Where is the evidence that those ingredients, either separately or in combination, have the effects that he claims for his product? The only references he offers are two articles. One is a rat study about krill oil’s effect on mitochondrial tricarboxylate carrier, the other is not a study but a review and opinion piece recommending lipids and antioxidants for metabolic syndrome patients who suffer to various degrees from fatigue.
What is it supposed to do?
He claims its unique combination of ingredients will
    • Support smoother skin, better vision and more flexible discomfort-free joints
    • Generate extra energy by promoting a powerful heart and lungs
    • Enhance confidence by fostering greater brainpower
    • Support blood-pressure and blood-vessel health
    • Encourage healthy levels of blood sugar and triglycerides
    • Protect, support and even lengthen your telomeres
How does he know this? Certainly not from clinical studies.
The Wikipedia article on omega-3s provides a handy compilation of studies on their health effects. For some conditions, no effect was found; for other conditions, there was preliminary and tentative evidence of benefit. Overall, the evidence is not very impressive, and it certainly doesn’t support the claims for Omega Rejuvenol.
Typical hype and advertising ploys
It has the usual features of these fake news ads. Meaningless testimonials (“Kerry gets compliments galore for her youthful looking skin.”) Special arrangements have been made for readers to get a risk-free trial with a money-back guarantee. Order today. And of course, the FDA disclaimer in small print at the bottom.
Conclusion: Unanswered questions
Should you take omega-3 supplements? Does this product provide more omega-3s than other sources? Does it have clinically significant benefits, and if so, are the benefits greater than with other products on the market? There’s no way to know. In the absence of controlled clinical trials, it’s a crap shoot. Buyer beware. And déjà vu all over again.
A half-page ad can’t be cheap. The fact that these fake news ads continue to appear so regularly must mean that a lot of naïve readers are being baffled with bullshit and are buying the products. Even if the only harms are false hope and a lighter wallet, it’s a shame. I wish the newspapers would take some responsibility and stop printing these misleading ads, but that’s not going to happen because these ads are a lucrative source of income for an industry in decline. The almighty dollar outweighs journalistic integrity.

Essential Oils in the Ambulance
Aromatherapy with essential oils is pseudoscience, backed only with low quality studies guaranteed to show a placebo effect. Their growing popularity warns that better science education is needed.
Steven Novella on May 9, 2018
Link

Tri-State Ambulance operating in the La Crosse, Wisconsin area has started using essential oils to treat minor pain. This is now a new front on the struggle against the infiltration of pseudoscience into medicine. Similar to acupuncture, it represents a fundamental failure of medical education.
The goal of any science-based system, which medicine should be, is to have clear and valid procedures for reliably answering basic questions – in the case of medicine, questions about safety, efficacy, and fundamental issues of biology and mechanism of action. In short we need to be able to adequately address the question – is this phenomenon real, and what exactly is it?
Promoters of snake oil (whether naïve or intentional) fail at this basic task. They have also discovered the weak points in the medical system where they can infiltrate. This is where the failure of medical education comes in, because it should be obvious to any trained health professional that these interventions are not scientific. We should be holding the line against pseudoscience, and then educating the public about what is legitimate and what isn’t. Instead, far too many health care providers become deceived themselves and then promote pseudoscience. Then the entire system starts to crumble as we see a proliferation of specialists, journals, products, and services in the mainstream based on bad science.
What Tri-state Ambulance is doing
David wrote earlier this year about acupuncture proponents exploiting the opioid crisis to promote their pseudoscience as an “alternative.” This strategy is now being replicated for essential oils:
Dr. Chris Eberlein, medical director for Tri-State, said he noticed paramedics were often giving small doses of narcotics like fentanyl to patients who ended up not needing a prescription for pain medication.
“We started reviewing ‘Why are they giving narcotics?’ and really it came down to the fact that they didn’t have many other things they could do in the ambulance ride,” Eberlein said.
That is a real issue, the overuse of narcotics for minor acute pain. Using a fake treatment, however, is not the answer. The last line of the report also states:
Tri-State paramedics will also have access to liquid Tylenol as another alternative to opioids.
Why not skip the snake oil and go right to the Tylenol? If you need something stronger but don’t want to use a narcotic, there is also tramadol. There is a range of options, but now it seems like the allure of doing something novel and “natural” is distracting from real medicine.
Eberlein also says that patients feel better because of the pleasant odor of the oils, and that ambulances otherwise smell very sterile. Allow me to introduce you to the concept of the air freshener.
Reading the comments to the article we find the now typical polarization from skeptics to true believers. The skeptics point out (correctly in my opinion) that pseudoscience has no place in modern medicine. The believers reply with the usual range of responses – keep an open mind, medicine is poison, and hey, there is lots of evidence if you just look.
OK – let’s take a look at the evidence.
Evidence for essential oils
Before I review the published evidence concerning the efficacy of essential oils, let me review what should be a reasonable standard of evidence. If we sincerely want to know if any particular essential oil is effective when applied in a specific way for a specific condition, then we need to conduct carefully-designed clinical trials.
The core of any well-designed scientific experiment is that it adequately controls for all possible variables and confounding factors. In medical trials we want to isolate the treatment itself from all other possible effects, and then objectively measure an appropriate outcome. So if we want to know if Rosa damascena Mill. is effective for reducing pain, we need to compare it to adequate controls in a double-blind study. Controls should include a group receiving only the carrier oil, another with a similarly pleasant odor but not Rosa damascena Mill., and perhaps a control group with no intervention.
Pain is challenging to measure in an objective way, so most studies resort to subjective patient report. That is why the studies have to be properly blinded and adequate controls are essential. You can use pseudo-objective measures, like the need for additional pain medication, functional ratings, and other markers of their health outcome as appropriate. And of course, studies need to be large enough and carried out for long enough to get adequate data, and executed to prevent p-hacking.
Especially when dealing with a treatment for a subjective symptom like pain, one that we know to be highly modifiable by non-specific interventions (like distraction, mood, the introduction of a novel treatment, physical contact, the environment, interaction with the practitioner, and other variables), adequate controls are essential (pun intended). You may be shocked to learn that such high quality studies are almost completely lacking in the published literature regarding essential oils.
Very similar to the acupuncture literature, most studies are designed (in effect, if not intent) to show a positive result. They rely heavily on unblinded comparisons (to a no-treatment or no-odor group, for example) and subjective outcomes. Such studies are almost guaranteed to be positive, which means they actually tell us absolutely nothing.
There are also many studies looking at the properties of specific essential oils in vitro. These are interesting basic science studies, which basically show that the oils are drugs (because they are) with pharmacological properties. None of these studies, however, can be used as a basis for clinical claims. We know from a century of experience that such basic science studies rarely translate to a clinical application.
One main reason is bioavailability. When you directly expose cells in a culture to a compound, what happens in that setting may say nothing about what happens when the same substance is taken by a living organism. Little or none of the compound may get absorbed or find its way to the target tissue. In the case of essential oils, they are often delivered by aromatherapy – smelling. Who knows what the bioavailability is of each of these compounds by this particular route of administration?
All the individual studies I found had serious methodological flaws. Few are double-blind, some are single-blind, and most are unblinded. The better designed studies tend to have mixed results, and reek of p-hacking.
There are several systematic reviews of specific essential oils for various types of pain. They also show the same kind of results as acupuncture reviews. The reviews are negative, meaning that no specific treatment has crossed the threshold of evidence where we can honestly say that it has been shown to work. Rather, all the reviews report that the evidence is not sufficient, and the precise spin depends on the reviewers and the journal. Cochrane reviews give the typical, “More and better quality research is needed.” Alternative medicine journals call the treatments, “promising” or similar.
Here are some examples – starting with a study of rose oil for pregnancy related low back pain:
A randomized controlled clinical trial was conducted on 120 women with pregnancy-related low back pain. Patients were allocated to 3 parallel groups to receive topical rose oil (in the carrier of almond oil), placebo (carrier oil), or no intervention. All groups were followed for 4 weeks. All participants were evaluated by Visual Analog Scale and the Roland-Morris Disability Questionnaires to assess the pain intensity and its impact on daily activities before and after the intervention. Significant decrease in pain intensity compared to carrier oil or no intervention was observed. The rose oil also improves the functional ability of these patients in contrast with no intervention, while its effect on function is not significant compared to carrier oil.
Notice that the study is not double-blinded. Further, we see a difference in the subjective measure, but in the more objective measure (functional ability) we only see a difference with the no-intervention group, and not with the carrier oil group. This is the exact pattern of results we would expect from a placebo-only intervention. Positive results are dependent upon subjective outcomes and unblinded comparisons, with interventions that should provoke more of a placebo effect showing more of an effect. The best comparison, between rose oil and carrier oil in the functional ability assessment, was negative.
Here is another study of lavender oil and osteoarthritis of the knee:
METHODS:In this single-blinded, randomized clinical trial, 90 patients with osteoarthritis of the knee who referred to the outpatient rheumatology clinics affiliated with Birjand University of Medical Sciences were selected through convenience sampling method. They were randomly assigned to three groups: intervention (aromatherapy massage with lavender essential oil), placebo (massage with almond oil) and control (without massage). The patients were evaluated at baseline, immediately after the intervention, 1 week, and 4 weeks after the intervention in terms of pain via visual analogue scale. The data were analyzed in SPSS (version 16) using the repeated measure ANOVA, one-way ANOVA, and chi-squared test.
RESULTS:Pain severity of the patients in the intervention group was significantly different immediately and 1 week after the intervention compared with their initial status (p < 0.001) and that of the control group (p < 0.001 and p = 0.009 respectively). However, at the third phase of follow-up (i.e., 4 weeks after the intervention), there was no significant difference between the groups according to the visual analogue scale (p = 0.67).
Subjects were not blinded and the outcome was subjective, so right there the results are mostly useless. Further, we see the same pattern as above. When compared to no intervention at all, there is a placebo effect (surprise). When comparing lavender oil to almond oil, there is no difference. They didn’t even bother stating this explicitly in the abstract.
This study also shows additional features of a typical placebo intervention. First, the results were short-lived, present at 1 week but not 4 weeks. Second, the researchers mixed variable by including massage. So essentially we can conclude from this study that massage has short term subjective effects on knee pain, but essential oils add nothing to the efficacy.
One more to show an additional feature, Rosa damascena Mill. for migraine headaches. This was one of the rare double-blind studies, but was small, with only 40 subjects. Here are the results:
Mean pain intensity of the patients’ migraine headache in the different time-points after R. damascena oil or placebo use, was not significantly different. Additionally, regarding mean scores of N/V, photophobia, and phonophobia severity of the patients, no significant differences between the two groups were observed. Finally, applying syndrome differentiation model, the mean score of migraine headache pain intensity turned out to be significantly lower in patients with “hot” type migraine syndrome at in 30, 45, 60, 90, and 120min after R. damascena oil application compared to “cold” types (P values: 0.001, 0.001, <0.001, <0.001, and 0.02; respectively).
See what’s happening here? First, we again see an inverse relationship between quality of study design and outcome. In this double-blind study, there was no difference at all between the treatment group and the placebo – so this is a negative study. But wait, they did a subgroup analysis and found a difference for “hot” type migraines vs “cold” type. What are hot vs cold migraines? That’s a new one on me, and nothing comes up when I search on it (except for this one study). In short – the whole thing has the strong aroma of p-hacking.
What about the systematic reviews? Here’s one of Rosa damascena Mill in pain relief:
There are promising evidences for the effectiveness and safety of Rosa damascena Mill in pain relief, but confirmatory studies with standardized products is suggested.
This was published in the journal Complementary Medicine Therapy. So they use the buzzwords “promising” and “confirmatory studies suggested” which is code for – the evidence is lacking.
Here is a Cochrane review of aromatherapy for symptoms of cancer:
There was a lack of evidence on the clinical effectiveness of massage for symptom relief in people with cancer. Most studies were too small to be reliable and key outcomes were not reported. Any further studies of aromatherapy and massage will need to address these concerns.
The Cochrane authors are more blunt – the evidence is crap.
This is now the standard of science for “alternative” treatments. Do a lot of basic studies showing that “stuff happens” in the petri dish. Then do worthless clinical trials with inadequate designs guaranteed to show a placebo effect, and use them to declare your treatment “evidence-based.” This will help your true-believers (and marketing team) who can point to all this evidence, and then call skeptics “closed-minded.”
Doctors should know enough science to see through all this, and many do, but unfortunately many cannot. They combine terrible science with personal anecdotes and then use their professional status to lend credence to pseudoscience, and become the gateway for the infiltration of this pseudoscience into our profession.

Activated charcoal, the wellness scam
Charcoal lemonade is yet another detox scam aimed at separating customers from their money.
Scott Gavura on August 8, 2019
Link

Summer days, SBMers. Scott is on vacation and here’s an old post from 2015. See you in two weeks!
Our diet is either the cause of, or solution to, all of life’s problems. I’m paraphrasing a great philosopher. We just can’t seem to let food be food. Today each ingredient we eat seems to be demonized or glorified. Is gluten still evil? It used to be fat. At some point in the past, it was MSG. Or it’s a superfood, preferably local, organic and GMO-free. Even on the healthiest diet, however, we’re apparently still ingesting too many harmful chemicals. After all, this is apparently a toxic environment we live in. Gwyneth Paltrow says so. So does the Food Babe. In an era of daily television quackery and loony internet health conspiracy websites, one might think that bizarre food ideas are a recent phenomena. But worries that we’re being poisoned from within are probably innate. One of the oldest surviving written documents is an Egyptian papyrus from the 16th century BCE that linked the cause of disease to digestive wastes in our colon. Since that time, our scientific knowledge about the cause of disease has advanced, but the underlying obsession with diet and elimination hasn’t waned. Anecdotally, it seems to be growing. The idea that our bodies need to “detox” is thriving, despite the fact that it has no scientific basis or validity. Part of the modern appeal of “detox” may be that detoxification is a legitimate medical term and treatment. However, in the alternative-to-health perspective, the word has been co-opted, but the science part has been ignored. Fake “detox” is easy. And now proponents of “detox” have taken it one step further. They’re using real medicine for a fake “detox”. That’s how activated charcoal has become the latest health fad. 
The popular use of charcoal got a big boost in 2014. After Gwyneth Paltrow’s magazine “Goop” named charcoal lemonade as one of the “best juice cleanses”, the idea of socially consuming charcoal really took off. If you spot someone drinking what looks like a bottle of ink, it could be “lemonade with activated charcoal“. All this for just $10 for 16oz, making this fad a pretty costly one.
Paraphrasing another philosopher, if you integrate fantasy with reality, you do not instantiate reality. And when you add charcoal to lemonade, it doesn’t make your lemonade tastier, or healthy. Nor does it give a beverage any magical properties. It gives you black, gritty, gag-inducing lemonade that is in all likelihood even less nutritious than plain lemonade. So how did someone arrive at the idea that adding charcoal to lemonade might be a good idea? It’s based on the popular, but baseless ideas about the toxins that are apparently harming us.
True poisoning can be very real, but “detox” is pure marketing
What’s popularly called a “detox” today has nothing to do with actual medical detoxification. In the setting of real medicine, detoxification means treatments for dangerous levels of drugs, alcohol, or poisons, like heavy metals. Real detoxification is a treatment for a medical emergency, when a poisoning may be life-threatening. Real detoxification isn’t something you contemplate based on a menu. You don’t order real detoxification treatments at juice bar, and it’s not delivered in smoothie format.
Fake detox, the kind you find in magazines, and sold in pharmacies, juice bars, and health food stores, is make-believe medicine. The use of the term “toxin” in this context is meaningless. There are no toxins named, because there’s no evidence that these treatments do anything at all, but it sounds just scientific enough to be plausible.
The fact is that we are constantly exposed to a huge variety of chemicals, both natural and synthetic. Given many naturally-derived substances can be exceptionally toxic, we evolved a remarkable set of defenses and mechanisms to remove unwanted substances. The skin, kidneys, lymphatic system, our gastrointestinal system, and most importantly, the liver make up this sophisticated system.
But there’s no question that those defences can be overwhelmed. In the setting of real poisonings, activated charcoal is one treatment that’s used to reduce the risk of harmful effect. Whether or not something is a “poison” depends on the dose. Acetaminophen is remarkably safe at appropriate doses yet causes almost-certain fatalities in overdoses.
Activated charcoal is a medicine and drug sponge. It’s not absorbed into the body, and is put into the gastrointestinal tract to reduce the absorption of drugs and other poisons after they have been ingested, but before they have been absorbed into the body (scientifically speaking, the contents of the mouth, throat, stomach, large and small intestine and rectum are considered “outside of” the body). While the overall effectiveness of charcoal isn’t well documented for all drugs and poisons, it has become a routine part of poisoning protocols. Huge doses of activated charcoal are given with the intent of clearing the harmful substance out of the gastrointestinal tract.
Activated charcoal is produced by heating wood (or another high-carbon product) to high temperatures, and then oxidizing it. The fine particles that remain are almost pure carbon, and the resulting structure has an enormous surface area. The preparation process gives the charcoal the ability to absorb various chemicals to its surface. This is why you’ll see charcoal as a routine ingredient as a filtering agent in commercial and household use, ranging from gas masks to water filters. Depending on the production process, its ability to absorb different chemicals can be made to vary.
Compared to real detoxification protocols, the amount of charcoal added to charcoal lemonade products is small. Given it’s more for aesthetics and marketing than any actual medicinal effects, ingesting charcoal should be well-tolerated with few side effects. It’s not entirely without potential negative consequences, especially when added to a regular diet (or even combined with juice). Activated charcoal doesn’t discriminate between the healthful chemical components of food, and any unwanted chemicals in the digestive system. Activated charcoal appears to bond vitamins like ascorbic acid (vitamin C), niacin, pyridoxine (vitamin B6), thiamine (vitamin B1) and biotin, so it has the potential to make food and drinks you consume actually less nutritious, not more.
Despite the marketing hype, activated charcoal has no ability to suck out the toxic chemicals from the rest of your body. Its effects are limited to the gastrointestinal tract only, and it’s been studied in poisoning situations only. There’s no evidence to demonstrate that the everyday consumption of activated charcoal is either beneficial or helpful in any way.
Charcoal lemonade does seem to have one profound effect though. At $10 per pint, the product does seem very effective at removing cash from the wallets of unsuspecting consumers. As I have noted before, if you hear the words “detox” uttered anywhere but an emergency room, keep in mind that you’re hearing a marketing pitch, not credible health advice.

Green Tea: Panacea or Poison?
Harriet Hall on June 9, 2015
Link

In the news: a woman in Fort Wayne, Indiana is suing the Arbonne International company in Allen Superior Court, claiming that its product contained toxic levels of green tea extracts, causing her to develop acute liver failure.
Green tea accounts for 20% of tea consumption worldwide. It has become more and more popular because of its many reported health benefits; the consumption of green tea in the US has risen by 40% just since 2000. A less-processed form of tea, green tea contains higher levels of antioxidants and polyphenols than other teas. It was traditionally used to control bleeding, heal wounds, aid digestion, improve heart and mental health and regulate body temperature. More recently, research has suggested that it has many health benefits.
The evidence for health benefits
The University of Maryland Medical Center has a helpful webpage that summarizes all the relevant research and provides a long list of references. Green tea may reduce the risk of heart disease (but the FDA prohibits that claim on labels; they concluded there was no credible evidence to support it). Green tea lowers total cholesterol and raises HDL. Population studies suggest that it may help protect against several kinds of cancer, but the evidence is mixed: other studies suggest that it may actually increase the risk of some cancers, and it may interfere with cancer chemotherapy. It may help in inflammatory bowel disease, diabetes, liver disease, and weight loss. There is even preliminary evidence that it might prevent dental cavities, might be useful in arthritis, might help treat genital warts, and might even prevent symptoms of colds and flu. Studies show that drinking green tea is associated with reduced risk of dying from any cause. At first glance, it might sound like a panacea, but the evidence is still questionable. Much of it is from small, preliminary studies that have not been replicated or that contradict each other.
The Natural Medicines Comprehensive Database does not rate green tea as “effective” for any indication. It rates green tea as “likely effective” only for genital warts, lyperlipidemia, and mental alertness (because it contains caffeine?). It rates it as “possibly effective” for cervical dysplasia, coronary artery disease, endometrial cancer, hypotension, oral leukoplakia, osteoporosis, ovarian cancer, and Parkinson’s disease. It concludes that there is insufficient reliable evidence to rate its effectiveness in acne, amyloidosis, athletic performance, bladder cancer, esophageal, cancer, pancreatic cancer, breast cancer, cardiovascular disease, colds and flu, colorectal cancer, diabetes, fertility, gastric cancer, hypertension, Japanese cedar pollinosis, leukemia, lung cancer, metabolic syndrome, obesity, oral cancer, periodontal disease, pneumonia, prostate cancer, stress, stroke, upper respiratory infection, or wrinkled skin.
Safety?
The Natural Medicines Comprehensive Database gives green tea a rating of “likely safe” when used as a beverage in moderate amounts, as “possibly safe” when used as an extract for up to 6 months, as “possibly unsafe” for long-term use in high doses due to its caffeine content, and as “likely unsafe” when used orally in very high doses. It reports a long list of adverse reactions including liver failure. It reports a long list of interactions with other supplements and with drugs, and warns that green tea may worsen symptoms of various diseases.
The Arbonne lawsuit
There is emerging evidence to suggest that green tea can cause liver damage. The woman who is suing Arbonne, Vicki Swanson, bought the company’s “30-Day Feeling Fit Kit,” because it promised to “take the guesswork out of getting fit.” After about 6 weeks, she developed lethargy and jaundice. She was hospitalized and diagnosed with acute liver failure caused by toxic levels of green tea extracts. She had no history of liver disease and no other source of green tea. Her lawsuit accuses Arbonne of selling a dangerous and defective product, breaching its warranties, and negligence.
Arbonne International is a multilevel marketing company that sells herbal-based skincare, beauty, and wellness products. The “30-Day Feeling Fit Kit” is also sold on the Amazon website. For $265.97 (marked down from list price $299) + $10.49 shipping, you get “protein shakes mixes, energy fizz sticks, fit chews, chocolate, herbal detox, and fiber boost.” I was unable to find out how much green tea is in the products.
Evidence for liver toxicity
Concerns about safety developed as early as 2003, when a green tea weight-loss supplement was withdrawn from the market in France after it was blamed for 13 cases of liver toxicity. In 2009 the FDA warned consumers to stop using Hydroxycut products because of the risk of liver injury.
An April, 2015 article in the Archives of Toxicology reviewed the evidence for the liver toxicity of green tea-based herbal supplements. The same authors had earlier written a review of the literature published between 1999 and 2008, identifying 34 cases of liver damage from green tea, with one death and with positive re-challenge tests confirming causation in 20% of cases. In this new study, they surveyed more recent evidence from studies published between 2008 and March 2015. They found a probable causal link in 8 cases of liver damage and a possible causal link in 11 other cases. They used stringent criteria to determine causation, ruling out other causes of liver damage such as viral hepatitis and alcohol abuse. 12 of the 19 reactions involved patients who took multicomponent (MC) preparations. All cases required hospitalization. The reactions from MC preparations had a quicker onset (mean: 44.7 days) and were more serious, requiring liver transplantation in four cases. Recovery occurred mainly between 20 and 90 days, but took as long as 540 days and sometimes treatment with corticosteroids was required to obtain resolution. MC preparations may contain other ingredients that enhance the risk, and it is difficult to ascribe the toxicity to one component. The patients who took only green tea consumed as little as two cups to as much as three liters daily. Considering the vast numbers of people who have used green tea supplements or who drink tea, the quantitative risk is very small.
A systematic review of the safety of green tea extracts by the U.S. Pharmacopeia (a nonprofit standards-setting organization) was published in Drug Safety in 2008.
They analyzed 216 case reports on green tea products and found 34 reports of liver damage. They categorized 27 of these as possible causality and 7 as probable. They were concerned that they might only be seeing the tip of the iceberg. An FDA-commissioned study showed that the FDA only receives <1% of all adverse event reports associated with dietary supplements. The authors of that study commented that (thanks to the DSHEA):
for dietary supplements, vital premarket information (which is available for drug products) is often missing so that possible public health concerns generated by the adverse event reporting system, such as limited clinical information, product identification, and information on consumer use, cannot be adequately assessed.
The benefits and risks of polyphenols
In a 2007 article in Chemical Research in Toxicology, the authors reviewed the evidence for benefits and risks of polyphenols, the major component of green tea. They concluded:
Although consumption of dietary phytochemicals such as flavonoids has been suggested to have beneficial biological effects including the prevention of cancer and heart disease, there is considerable evidence to suggest that such compounds are not without risk of adverse effects. The risk of adverse effects is likely increased by the use of pharmacological doses in prevention/treatment and supplement situations and genetic polymorphisms or drug−drug interactions that increase the bioavailability of test compounds. Such situations should be the subject of extensive future animal studies. A clear understanding of the potential adverse effects of dietary phytochemicals, including polyphenols, is necessary. Only when such data are compared to the evidence for beneficial health effects can a balanced judgment be made regarding the potential utility of these compounds for disease prevention and treatment.
Conclusion
So where do we stand? Even if Ms. Swanson wins her lawsuit, that wouldn’t constitute proof of causation. We don’t have any direct, incontrovertible evidence that green tea can cause liver failure, but we have good enough evidence to suspect that it can. On the other hand, neither do we have any really compelling evidence that it has the many health benefits claimed for it. Further research will be needed to better understand the risk/benefit ratio. In my opinion, a cautious approach to green tea supplements is indicated, but there is no reason to avoid drinking green tea as a beverage in moderate amounts if you enjoy the taste.

Chaga Tea
Chaga tea is made from a mushroom that rots birch trees. Health benefits are claimed on the basis of folk medicine, but there isn’t a shred of scientific evidence.
Harriet Hall on April 28, 2020
Link


A correspondent said he had looked for Chaga on the Science-Based Medicine website and found nothing. I decided to remedy that.
Chaga mushrooms, scientific name Inonotus obliquus, are parasites of trees in cold climates, from Alaska to Northern Europe to Siberia. They are most commonly found on birch trees, but also on alder, oak, beech, and poplar. On the outside, they look like a large amorphous lump of burnt charcoal, but the inside is soft and orange. The name in Canada is Sterile Conk Trunk Rot of Birch. They cause white heart rot and damage the trees, which often have to be destroyed.
Health benefits
It’s definitely not healthy for trees. What about for people?
Chaga tea is an infusion made by hot water extraction, alcohol extraction, or fermentation. Some people think it is medicinal. It is thought to boost immunity (which you can’t do) and improve overall health. It has also been used for cancer, diabetes, tuberculosis, digestive diseases, and heart disease. It is said to provide a boost of energy. A few studies in animals and test tubes have suggested it might have health benefits (for animals?). Those studies are conveniently collected here. It has been used in folk medicine for centuries, but there is little or no scientific evidence that it has any health benefits for humans, and there are safety concerns.
Risks
It is high in antioxidants, but that isn’t necessarily a good thing. It contains high levels of oxalates and is contraindicated in people with kidney disease or who are at risk of kidney stones. Its safety in pregnancy and breastfeeding is not known. It may interfere with blood clotting and should be used with caution in patients on blood thinners. It might cause hypoglycemia in patients who are being treated for diabetes. There is no standardization of dosage in Chaga products.
Dr. Oz recommends it (is there any fad he doesn’t recommend?). Integrative medicine guru Dr. Andrew Weil doesn’t (he lists other mushrooms that he does recommend).
It is readily available online and in health food stores, and it won’t break your wallet. You can buy it in the form of Magic Mushroom Mix, with chocolate and 6 organic superfoods. It works out to $1.16 per serving. Harney and Sons sells 50 sachets of Chaga mushroom for $49.99 with free shipping. You can buy it in the form of convenient bleach-free tea bags; each cup of tea will cost you as little as 44 cents. Amazon has an even lower price: it sells 18 bags of Buddha Tea for $6.99, or 38 cents per cup. But remember, it’s false economy to pay a low price for something that doesn’t work.
Customer reviews
It doesn’t even taste good. One source politely described it as “not unpleasant”. A disappointed Amazon customer said it is “nearly flavorless, and reminds you of chewing paper for spit wads”. Another said, “Horrible. Tasted like dirt”. Another commented, “No one ever asks me for a 2nd cup”.
There are plenty of testimonials, but nothing to suggest anything more than a placebo response or a coincidence. Here’s a sampling:
    • Helping our aches and pains. Seems like our high blood pressure is lower.
    • I can definitely tell a difference in the amount of discomfort in my joints. I also noticed that this tea tends to make me sleepy so only drink it in the late afternoon and at night.
    • Ancient, generations proven remedy. [The “ancient wisdom” fallacy?]
    • Great energy boost
    • I’ve been taking it in order to dacalcify [sic] my pineal glad [sic]
    • Not so long after I drink a cup of it, my body started working to expel what was in my nasal passage, throat and starting to move into my chest.
    • I can definitely feel a quiet calming effect after drinking my cup
Conclusion: No evidence that Chaga has health benefits
Definitely thumbs down on this one. I’m wondering who first thought of ingesting a tree disease. Were they brave or foolhardy?
Should properly controlled clinical studies be done to investigate its benefits and harms? IMHO, scarce research money would be better spent on something with more promise.

Lipo-Flavonoid for Tinnitus
Lipo-Flavonoid is sold to treat tinnitus. The claims are misleading, and the evidence isn’t there.
Harriet Hall on October 29, 2019
Link


The dietary supplement Lipo-Flavonoid is advertised as an effective treatment for tinnitus. They claim “More than 50 Years of Clinical Experience” and go on to explain:
Lipo-Flavonoid® Plus is a natural bioflavonoid product that has been used extensively for decades for the treatment of tinnitus. Lipo-Flavonoid has been used and evaluated in clinical settings for over 50 years, and continues to be the #1 recommendation of doctors for relief of ringing in the ears (Source: April 2018 survey).
With a little investigation, I soon learned that the “#1 recommendation” claim was bogus. The National Advertising Division (NAD) of the Better Business Bureau found the company’s claims unsubstantiated and found that the survey they cite did not ask ENTs the proper questions. The doctors surveyed did not recommend Lipo-Flavonoid for its effectiveness in treating tinnitus in general; they recommended it only as an adjunct therapy for tinnitus in patients with Meniere’s disease. The NAD recommended the company discontinue the advertising claims, but the claims continue unchanged.
I don’t know of any doctors who recommend it, and I know “used extensively” and “clinical experience” are no guarantee of effectiveness. I wanted to see the evidence.
What is tinnitus?
Tinnitus is a symptom, the perception of noise or ringing in the ears, usually a phantom noise that is not audible to an examining doctor. It can be a symptom of age-related hearing loss, exposure to loud noise, earwax blockage, otosclerosis, Meniere’s disease, TMJ disorders, head and neck injuries, acoustic neuroma, Eustachian tube dysfunction, muscle spasms, or blood vessel disorders. Various medications can cause tinnitus or worsen it, including certain antibiotics, aspirin, cancer medications, diuretics, and quinine. Underlying treatable causes must be ruled out, but in many cases an exact cause is never found. The good news is that it usually isn’t a sign of anything serious; it can be very annoying to some people but is otherwise harmless.
Up to 18% of people in industrialized societies are mildly affected by chronic tinnitus, and 0.5% report tinnitus having a severe effect on their daily life.
Tinnitus is the most frequent service-connected disability for U.S. military veterans, with nearly 1 million veterans receiving disability payments for tinnitus in 2012. I am one of them. I was exposed to flight line noise as a flight surgeon in the Air Force, and I am considered 10% disabled, so that 10% of my retirement pay comes from the VA and is tax-exempt.
Not all tinnitus is bothersome. I am a good example of that. When I think about it, my tinnitus is always there; but unless I happen to think about it, I am not aware of it – I tune it out, sometimes for days or weeks at a time. Normal brain mechanisms allow us to become habituated to a constant background noise and no longer notice it.
What are the ingredients in Lipo-Flavonoid?
    • Lemon bioflavonoid complex 300 mg (This is a proprietary blend that includes eriodictyol glycoside, a phytonutrient found in lemon peels.)
    • Ascorbic acid (Vitamin C) 300 mg
    • Choline bitartrate 334 mg
    • Inositol 334 mg
    • Thiamine (Vitamin B-1) 1 mg
    • Niacinamide (Vitamin B-3) 10 mg
    • Pyridoxine (Vitamin B-6) 1 mg
    • Cyanocobalamin (Vitamin B-12) 5 mcg
    • Pantothenate 5 mg
    • Riboflavin (Vitamin B-2) 1 mg
    • And Lipo-Flavonoid Night also contains melatonin (3 mg immediate-release and 2 mg time-release).
It has been tested and was found lacking. A small randomized controlled trial in 2016 did not find Lipoflavonoid Plus effective for tinnitus.
As for melatonin, an article on Healthline said:
Randomized-controlled studies have shown that the supplement improves tinnitus symptoms, but many of the studies were poorly designed, so it’s hard to draw any conclusions…Melatonin may be most effective for helping people with this condition sleep more soundly.
Money back guarantee
To their credit, they acknowledge that “Lipo-Flavonoid may not work for everyone”. They offer a money-back guarantee: “Try it for 60 days, and if you don’t find relief, just submit your cash register receipt and UPC code, and we will refund your purchase”.
But please use it correctly:
In order for Lipo-Flavonoid caplet products to work effectively, the recommended dosage is two (2) caplets, three (3) times a day for 60 days (a total of 360 caplets) before seeing results. This exact dosage is based on clinical experience and is recommended to maintain blood levels over time and reduce stomach upset. Taking the correct dosage of Lipo-Flavonoid caplet products is necessary to maintain inner ear health and reduce the symptoms of tinnitus.
What does the evidence say?
Many treatments have been used for tinnitus, but how many of them actually work? What does the evidence show? What do the experts say?
Clinical practice guidelines published by the American Academy of Otolaryngology offer this advice:
    • Clinicians should offer hearing aid evaluations, education, and counselling.
    • Sound Therapy – Clinicians may offer sound therapy to patients with persistent, bothersome tinnitus.
    • Cognitive Behavior Therapy – Clinicians should recommend cognitive behavior therapy to patients with persistent, bothersome tinnitus.
    • Medical Therapy – Clinicians should NOT routinely prescribe antidepressants, anticonvulsants, anxiolytics, or intratympanic medications.
    • Dietary Supplements – Clinicians should NOT recommend ginkgo biloba, melatonin, zinc, or other dietary supplements for treating patients with persistent, bothersome tinnitus.
    • Acupuncture – No recommendation can be made.
    • Transcranial Magnetic Stimulation – Clinicians should NOT recommend.
A Clinical Evidence Handbook published in American Family Physician reviewed the published evidence. They found insufficient evidence for most treatments including acupuncture, hypnosis, tinnitus masking devices, tinnitus retraining therapy, drugs, and dietary supplements. As for cognitive behavioral therapy, they said it “may be ineffective at reducing tinnitus loudness, but it may improve quality of life in persons with tinnitus.”
A review article in Audiology Online titled “Dietary Supplements for Tinnitus – Really? says “the promise of an easy fix for tinnitus is a false one.” There are over 50 products sold over the counter for tinnitus relief, but the ingredients:
are often selected based on folklore, anecdotes or traditional Chinese medicine, and routinely contain ingredients that have not been scientifically-evaluated for their efficacy or safety, or have been shown to be no better than a placebo.
ConsumerLab reported two studies of flavonoids and vitamin B6 for Meniere’s disease and vertigo and said:
Based on these reports, some have assumed that these ingredients would be beneficial for a variety of ear disorders including tinnitus and others. However, these reports are very preliminary. Neither Lipo-flavonoid Plus, nor its main ingredient, have been evaluated in reliable clinical studies for tinnitus or other ear-related conditions.
A survey of the effectiveness of dietary supplements to treat tinnitus was published in the American Journal of Audiology in 2016. 1,788 subjects in 53 different countries answered a questionnaire. 70.7% reported no effect, 19% reported improvement, and 10.3% reported worsening. 6% reported adverse effects including bleeding, diarrhea, headache, and others. The authors warned that the positive subjective reports should be interpreted with caution, since these subjects were committed to treatment and expected a benefit. They concluded:
The use of dietary supplements to treat tinnitus is common, particularly with Ginkgo biloba, lipoflavonoids, magnesium, melatonin, vitamin B12, and zinc. It is likely that some supplements will help with sleep for some patients. However, they are generally not effective, and many produced adverse effects. We concluded that dietary supplements should not be recommended to treat tinnitus but could have a positive outcome on tinnitus reactions in some people.
A review of over-the-counter tinnitus remedies was published in Laryngoscope in 2019. It found that all the remedies made unfounded claims, and some of them, including Lipo-Flavonoid, targeted otolaryngologists by advertising in their specialty journals, and featured supposed endorsements by ENT doctors in their marketing. They recommended that specialty organizations oppose such misrepresentations and that their journals not accept advertisements for dietary supplements that make unproven therapeutic claims.
Steven Novella wrote about alternative treatments for tinnitus in 2012, including gingko, the homeopathic remedy Quietus, and craniosacral therapy (CST, recommended by Andrew Weil). He pointed out that homeopathy and CST were both “rank pseudosciences” and that the best evidence showed gingko was ineffective. He concluded that alternative therapies had nothing to offer. Since he wrote that article, research has confirmed the gingko findings: a 2013 Cochrane review found that the limited evidence did not show that gingko biloba was effective for tinnitus, and a 2018 review of systematic reviews concluded that it didn’t work.
Conclusion: No cure, but distraction helps
Some people are bothered by tinnitus; some aren’t. I suspect there is a large psychological component. If you are worried that it could be a sign of something serious, it is likely to bother you more. If you think of it as only a harmless, minor annoyance, you are less likely to worry. There is no cure for tinnitus, but anything that helps distract attention from the noise is likely to reduce the suffering. It is unethical to prescribe untested treatments or placebos, but in this case, I’m almost tempted to recommend Lipo-Flavonoid, telling patients only “it may make you less aware of the tinnitus.” It probably won’t do any harm, and I think there’s a good chance it might serve as a distraction and elicit a placebo response.
They say laughter is the best medicine. It might help if patients could laugh about it; laughter can be a good distraction. There’s a website that features tinnitus cartoons. In one, the patient tells the doctor, “It’s a constant ringing in my ears. When I try to ignore it, they leave a message.” In another, the doctor tells the patient “Tinnitus? I think I can help”. The patient is a cow wearing a large cowbell.

On Guard, DōTERRA, Essential Oils, and a Lesson in Reading Research Studies
A study of On Guard™, a mixture of essential oils, showed that it reduced the infectivity of influenza virus in dog kidney cells in the lab; but that’s irrelevant to the question of whether the product has any clinical effect in humans.
Harriet Hall on June 13, 2017
Link


I got an e-mail inquiry about the product On Guard™. It is a blend of five essential oils (wild orange, clove, cinnamon, eucalyptus, and rosemary) sold by the multilevel marketing (MLM) company DōTERRA. My correspondent had read my article about that company and its products, and she was skeptical. She said “A pilot told me he has used On Guard™ for years and it seems to ward off colds/flus for him but that is only a personal testimonial and I wanted to do more research before I purchased/used.” She sent me a link to a published study of On Guard™. She was impressed that it seemed to take an objective research approach with no hidden agenda (not paid for by DōTERRA) but she didn’t feel qualified to evaluate it and she wanted to know what I thought about the study.
I read the study. I was not impressed. It was an in vitro study in dog kidney cells and had no relevance to human use of the product. As I reviewed it, I thought of some simple questions a layman could ask to decide whether a study supported use of a product like this.
The study
The full text of the study is available online. The title is “Protective essential oil attenuates influenza virus infection: An in vitro study in MDCK cells.” They grew influenza virus in cell cultures of dog kidney cells. One group was incubated with On Guard™ and a control group was incubated with canola oil. They did various tests to evaluate the effects, including fluorescent focus assay, cell viability analysis, hemagglutinin titration, flow cytometry analysis and confocal microscopy of IAV binding and internalization, relative end-point RT-PCR, and immunoblotting for viral NS1 protein. You don’t need to understand what all those mean; I don’t either. Essentially, they found that the number of particles of influenza virus was significantly reduced by incubation with On Guard™: by 40% for a 1:6000 dilution and by 90% for a 1:4000 dilution. After establishing that it worked to weaken the infectivity of the virus, they did more tests to try to understand how it worked.
Assuming their conclusions were valid, so what? On Guard™ works to reduce the number of viral particles released by infected dog kidney cells in the lab, but it is not marketed to make dog kidney cells less infectious, it is marketed for humans to use. The authors commented:
The lack of toxicity and potent specific viral inhibitory activity suggest essential oil may be helpful as a possible antiviral drug for control and treatment of influenza virus infection. It could potentially be used as a non-toxic way to cleanse surfaces, or dispersed to eliminate aerosolized virus particles in confined areas. Since the oil is currently used as a food supplement, oral administration, once the pharmacokinetics are determined, may provide therapeutic benefit during infection.
Please note the qualifiers “suggest,” “possible,” “potentially,” “may.” This is nothing but idle speculation. There is nothing in the study to show that any of these uses are feasible. The study didn’t attempt to investigate whether the product benefits humans in any way when used as intended by its marketers. The study is worthless except as a suggestion for further research.
The marketing
The DōTERRA website claims these primary benefits for On Guard™:
    • Supports healthy immune and respiratory function
    • Protects against environmental and seasonal threats
    • Supports the body’s natural antioxidant defenses
    • Promotes healthy circulation
    • Energizing and uplifting aroma
These claims are flagged with the usual FDA disclaimer that the product is not intended to diagnose, treat, cure, or prevent any disease. But it is clear from testimonials like that of my correspondent’s pilot friend that customers have been persuaded to believe it will protect them from infections like colds and flu. There is a video on the website that is strongly suggestive, and there is a statement that it is “an effective alternative to synthetic options.” They have to be careful not to make any statements that the FDA and the FTC might object to; but the multilevel distributors may very well be making more specific claims to potential customers in private, or at least persuading them with strong suggestions and personal testimonials.
It can be taken internally on a daily basis (diluting one drop in 4 ounces of liquid), added to water to use on surfaces in the home as a non-toxic cleaner, applied to the skin (1-2 drops to the desired area after diluting with a carrier oil to minimize skin sensitivity), and diffused (3-4 drops in a diffuser) to purify the air. I find it hard to imagine that such tiny amounts would have any significant effect.
They warn against contact with eyes, inner ears, and sensitive areas and against use during pregnancy. They recommend avoiding sunlight or UV rays for up to 12 hours after applying to the skin. The company charges $42.67 for a dropper bottle containing 15 cc. (That’s only one tablespoonful.) It’s no longer sold only by MLM. You can buy it directly from the company online and from other online sources. Amazon sells it for $36.16.
Essential oils: The evidence is skimpy
Many people find aromatherapy enjoyable. The good smells are reason enough to use essential oils for relaxation and enjoyment. But there is little justification for using them to improve health. There are many health claims for essential oils, for instance in Dr. Axe’s Essential Oils Guide. Dr. Axe is a naturopath/chiropractor who claims essential oils are useful for everything from healing broken bones to preventing brain tumors, and he claims there is scientific evidence. But the evidence from scientific studies is skimpy, preliminary, or non-existent. The Skeptoid website has criticized the exaggerated claims for these oils, citing DōTERRA as a bad example.
Questions anyone can ask
When someone not well-versed in scientific research is contemplating purchasing a product that is allegedly supported by a scientific study, here are some questions anyone can ask:
    • Was the study done on the actual product as sold, or just on one or more of its ingredients?
    • Was there a control group?
    • Was it a clinical study in humans, or just a study in animals or in cell cultures in a lab?
    • Did it show meaningful clinical benefits like reduced incidence of infections, or did it just show surrogate measures like changes in lab tests?
    • Did the study show that the product works for humans when used as you would use it if you bought it?
If my correspondent had read the abstract of the study with these questions in mind, I think she might have realized on her own that the study did not provide a reason for her to buy the product.

Neuriva: Clinically Proven?
Neuriva claims to have proof from clinical studies. That’s misleading.
Harriet Hall on May 5, 2020
Link


My TV is threatening to collapse under the onslaught of commercials for Neuriva. They say it has been clinically proven to improve five measures of brain performance: accuracy, performance, concentration, memory, and learning. I found that hard to believe, since I recently wrote an article for Skeptical Inquirer reviewing the claims for nootropics and performance and image enhancing drugs (PIED). I found the evidence for all of these drugs lacking. I warned readers not to follow the PIED piper.
Had I missed something? Have they found a new nootropic that really works? No such luck; they had merely recycled two old ones. Do they really have clinical proof that Neuriva is effective? They say, “Nature made it. Science proved it. Brains love it.” I looked for their “proof”. I soon found that “clinically proven” doesn’t mean what they would like us to believe it means.
In the first place, nature didn’t make it; a company did. A company that doesn’t inspire confidence, since it is the same company that sells Airborne, a bogus cold remedy. And science didn’t prove that Neuriva is effective; it hasn’t even tested Neuriva. Neuriva contains only two ingredients: phosphatidylserine and coffee cherry extract. Those two ingredients have been studied, but the combination has not. When they say “science has proven,” they only mean there is scientific evidence for each of the two ingredients. But what kind of evidence? I tried to ferret it out.
Coffee cherry extract
Coffee cherry extract, also known as cascara (not to be confused with that other cascara, cascara sagrada), is made from what is left after the coffee beans have been removed. Bloomberg reports that this coffee waste is selling for 480% more than coffee itself. Coffee cherry extract has been shown to increase brain-derived neurotrophic factor (BDNF) by 143%, but only in a single study with no control group that gave a one-time dose to participants and concluded that larger clinical studies were needed to evaluate its therapeutic potential. One study found that coffee cherry extract reduced reaction time in 71 adults with mild cognitive decline but did not significantly improve other measures. Reaction time is not one of the five benefits claimed for Neuriva.
BDNF has been studied, but its relationship to mild cognitive impairment is unclear. A study was done to “determine whether serum BDNF level might be a useful biomarker for assessing risk for mild cognitive impairment (MCI) in older people”. It found that low serum BDNF was associated with lower cognitive test scores and MCI. It said that future prospective studies should establish the discriminative value of serum BDNF for the risk of MCI. Bottom line: correlation, not causation; possibly useful but only as a biomarker; no evidence that raising serum BDNF levels would improve measures of cognition.
In a study about the effects of acute exercise, cognitive function scores improved after all exercise conditions, but they did not correlate with BDNF changes.
Phosphatidylserine
One study showed that phosphatidylserine improved memory in aged mice.
There are some positive studies in humans, for instance this one from Japan in which the improvement in memory was only significant in a subgroup and was attributed to one measure: delayed verbal recall.
And there were also negative studies like this one: It showed that phosphatidylserine does not affect memory or other cognitive functions in older individuals with memory complaints.
Research not convincing
In short, I didn’t find convincing evidence that either ingredient was an effective nootropic, and the combination in Neuriva has not been studied. I was underwhelmed and soon stopped looking. I admit I did not do an exhaustive search; perhaps one of our readers can point out something impressive that I missed. But I won’t hold my breath. There is a pattern here that I have seen over and over for dietary supplements. By “clinical proof” they do not mean what they would like us to believe they mean.
Customer reviews
People who tried it had mixed results. Even the positive reviews reported side effects. Interfered with sleep, helped with sleep, awesome, love it! Didn’t work. Really helps with memory. Doesn’t taste good. In short, pretty much what we would expect from placebo responses to an ineffective treatment.
Conclusion: claims not supported
Despite the advertising claims, Neuriva has not been properly tested in a controlled clinical study. So we have no way of knowing if it is safe and effective. My guess is probably not. I’d be happy to be proven wrong if well-designed clinical studies corroborate the claims.

“Healthy Directions” Is a Double Misnomer
Healthy Directions sells dietary supplements without scientific evidence. A better name would be Misdirections that Won’t Make You Healthy.
Harriet Hall on March 10, 2020
Link

The Healthy Directions website says it is “A Better Way to Better Health.” There’s no reason to believe it is any such thing! It is a sales site for dietary supplements. It offers only misdirection and it offers no evidence that its overpriced products will improve the customer’s health.
Instaflex spray
The home page prominently features a product called Instaflex spray, promising that it will spray away your toughest pains, providing extra strength relief with a 360 degree continuous spray that is perfect for hard-to-reach spots. It has two active ingredients: menthol 5% and methyl salicylate 10%.
Other menthol/methyl salicylate sprays or topical treatments are available at lower cost. Some examples are Tiger Balm, Salonpas, Bengay, and Icy Hot. They often contain higher amounts of active ingredient. Icy Hot contains 16% menthol. Bengay contains 30% methyl salicylate.
Are menthol/methylsalicylate sprays effective for pain?
According to Harvard Medical School”
Menthol used in topical pain relievers is a harmless substance that causes a pleasing sensation that counteracts pain, but it doesn’t influence the underlying cause or inflammation.
And
Products that contain methyl salicylate might provide some pain relief, but there’s no solid proof. Anyone with an aspirin allergy or who is taking blood thinners for cardiovascular disease should consult a doctor before regularly using topical medications that contain salicylates.
Other products for sale on Healthy Directions
You can search by doctor for the products the Healthy Directions doctors recommend. A typical example is “Complete Neurovascular Support” which contains Vitamin B6, B12, alpha lipoic acid, benfotiamine, and a proprietary blend of lychee extract and green tea extract. Nowhere is there any explanation of a rationale for the mixture, nor are there any scientific studies showing efficacy. They offer supplements for every imaginable purpose. Some of the top sellers are Omega Q Plus Max, Cholesterol Solutions (with a powerful citrus fruit extract), Heart Healthy Multivitamins, Magnesium Broad-Spectrum Complex, Heart Healthy Probiotic Solutions Extra, Eyedrate, and Gut Restore Advanced. Dr. Sinatra’s Omega Q Plus Max is advertised as revolutionizing heart health with one product that has many benefits. I urge you to browse the website and look at some of the mixtures offered. And take a gander at the prices! I can’t help wondering who is buying these products and how they decide which one or ones to order. And the customers are not all happy. There have been numerous complaints to the Better Business Bureau. And there are plenty of reviews on the Amazon website saying the products didn’t work or caused side effects.
The doctors
There are several doctors featured on the Healthy Directions website. Information about their training and practice is included, as well as the specific products they recommend. Are they science-based doctors whose advice we can trust? Judge for yourself.
Dr. Joseph Pergolizzi, Jr. is an MD with good credentials who has published studies, but few of them have anything to do with dietary supplements. He is an anesthesiologist who specializes in practical pain management. He endorses Instaflex.
The three Sinatras. Health Directions appears to be a family affair. Three Sinatras are listed:
     1.  Stephen Sinatra is an integrative cardiologist with impressive credentials, but with some questionable beliefs. He says cholesterol is not a serious risk factor for heart disease, and he says the best way to protect yourself is to reduce inflammation by such steps as eliminating sugar from the diet. He has called refined sugar “public enemy number one”. He says a CoQ10 deficiency is a common cause of lack of energy and fueling your body with CoQ10 is one of the most important things you can do for your heart. He was one of the first to warn about the health effects of electromagnetic fields (EMF) and he is working to keep WiFi out of the school system. He is a certified bioenergetic psychotherapist, whatever that means. He advocates grounding or earthing. He advocates nutritional supplementation that includes a high-potency multi-nutrient, fish oil, magnesium, vitamin C, and coenzyme Q10. He also advocates “detoxification,” one of the typical buzzwords of alternative medicine.
     2.  Drew Sinatra, Stephen Sinatra’s son, is a Bastyr-trained doctor of naturopathic medicine who claims to address the root cause of disease and focuses on the gut microbiome. He has his own line of digestive health products that are vegetarian, gluten free, and minimally processed without artificial sweeteners, artificial colors, artificial preservatives, and HFCS. They are also made without wheat, eggs, shellfish, fish, tree nuts, peanuts, and when at all possible, dairy and soy. He holds a Master’s of Science (Science??!!) in 5-Element Acupuncture.
     3.  Briana Sinatra is Drew’s wife, also a Bastyr graduate with an MS in Acupuncture. She focuses on women and families.
Dr. Aaron Tabor is an MD and “beauty expert” who specializes in anti-aging and skin care. He developed Gene Facelift, a biotech spin-off that “enhances damaged DNA growth factors to help heal wrinkles, wounds, and inherited skin diseases”. That claim raises some red flags, and I couldn’t find any supporting research.
David Williams presents himself as a doctor, but he is actually a chiropractor. ‘Nuff said. The website says, “Double-blind, placebo-controlled studies are one type of proof that Dr. Williams considers, but he is open to traditional use and other forms of scientific research as well”. He uses the Mom Test: would he give it to his Mom?
And last but not least (although arguably the worst):
Dr. Julian Whitaker. Where have I heard that name before? Oh, yes, he’s the anti-vaccine expert who debated Steven Novella at FreedomFest in Las Vegas in 2012. Steve was a last-minute replacement for the pulmonologist who was originally scheduled to present the pro-vaccine side. As David Gorski put it, Steven Novella “handily wiped the floor with Dr. Whitaker“. Gorski said, “he brought the stupid. Oh, man, did he bring the stupid… it’s been a long time since I’ve seen such a glaring example of mathematic, statistical, and scientific illiteracy”. Whitaker even projected a slide of this graph, which has to be the worst graph ever:
The y-axis for number of autistic spectrum disorder children per 100 goes up to 120, as if 120 out of 100 children could have ASD. It absurdly extrapolates from current data to predict that by 2038, 100% of US children in the general population will be autistic. As if that weren’t bad enough, the graph then shows that 100% of girls in the US will be autistic by 2041. Weren’t girls part of the general population that was already 100% autistic in 2038? I have never seen such a stupid graph. It says the graph is courtesy of Shawn Siegel: he deserves a booby prize. Whitaker not only accepted it but featured it in his newsletter and used it as an argument in the debate; he deserves prize for a degree of gullibility nearly impossible to imagine in a scientifically trained doctor. The teachers who awarded him his MD degree must be rolling over in their graves.
Whitaker testified at congressional hearings in support of the Dietary Supplement Health and Education Act (DSHEA). He is an activist who advocates freedom of choice in medical care. He was a cofounder of Linus Pauling’s California Orthomolecular Medical Society and he ran the Whitaker Wellness Institute from 1979 to 2018, when it closed. As David Gorski explained in his article about the debate, Whitaker has also claimed that metformin doesn’t work, antibiotics don’t work, and conventional medicine doesn’t work. He treats patients with diabetes and heart disease with acupuncture, nutritional supplements, diet, hyperbaric oxygen, chelation therapy, and a wide variety of other questionable therapies. To top it all off, he’s a big fan of the infamous Stanislaw Burzynski and was the primary pro-Burzynski medical expert in Burzynski: The Movie.
Do you trust these “experts”?
Since you are reading the Science-Based Medicine blog, you presumably value medicine based on good science and you want to see the evidence that supports health recommendations. It should be obvious that the Healthy Directions website is not a source of reliable information about science-based medicine. And you will have noticed numerous examples of treatments that have not been tested or that have been tested and shown not to work.
Bottom line: The Healthy Directions website is devoted to slick marketing but not to science. Not recommended.

Ellura: A Supplement Backed By Evidence
Ellura is a dietary supplement marketed to treat recurrent urinary tract infections. There is promising evidence and a credible mechanism of action, and using it instead of antibiotic prophylaxis could reduce antibiotic resistance.
Harriet Hall on December 24, 2019
Link


In October, I wrote about SuperMannan, a dietary supplement that is supposed to cure bladder infections. The “evidence” for that claim was a single study of 9 women who were family members and friends of the researchers. The research design was laughable; there was no control group, and there were many other flaws. Oh, and they vouched for SuperMannan’s safety because they had fed it to the family dog and the dog seemed OK! The research design was a recipe for disaster.
Now Facebook’s algorithm apparently thinks I want to buy supplements for UTIs (urinary tract infections), because my Facebook feed keeps sending me “sponsored” posts about Ellura, another dietary supplement for UTIs. I was expecting it to be just another over-hyped product with shoddy science behind it, but I was pleasantly surprised. The evidence indicates that Ellura is probably a safe and effective way to reduce the frequency of infections in patients with recurrent UTIs. Finally! A supplement that has been shown by science to really work.
The problem
Women are more susceptible to bladder infections than men. 40-60% of women will have a UTI during their lifetime, and most of those are bladder infections. In 25-30% of cases, the UTI will recur during the next 6 months, and sometimes recurrent infections are so frequent that daily antibiotics are prescribed for prevention. Antibiotics reliably prevent recurrent UTIs, but they may be expensive, may cause adverse reactions, and using them may contribute to the development of antibiotic resistance.
The ad
The ad starts with quotations from two urologists:
Ellura is an opportunity for my patients to use a product that is natural and is going to prevent a UTI without the use of antibiotics and all the side effects and expense that goes along with them.
Our patients are experiencing fewer UTIs, calling our office less and asking us for antibiotics less!
It goes on to say “85% of women report fewer UTIs.” And it links to a page on the Ellura website where you can buy a 3-month supply for $120. The website claims that Ellura “supports a clean urinary tract” and says “stop UTIs before they start” and “avoid antibiotic overuse.” Since it is marketed as a dietary supplement, they have the required disclaimer that the statements have not been evaluated by the FDA and the product is not intended to diagnose, treat, cure, or prevent any disease.” But they are clearly marketing it for prevention.
Patient comments
There are plenty of comments online from purchasers of Ellura. There are some negative ones (“didn’t work for me”) but many more positive ones (“changed my life”). One comment said the writer was hedging her bets by taking mannose along with Ellura. It’s apparent that some customers misunderstood the claims and took it to treat UTIs, which doesn’t work. The company clearly states Ellura should not be used to treat established infections. They advise patients to double up on the dose if they feel like a UTI might be coming on, and they advise that a urine culture is a must for diagnosing an infection.
What’s in Ellura?
Ellura is a cranberry derivative, but with a difference. To cause an infection, the bacteria must adhere to the cells lining the bladder. Cranberries contain A-type proanthocyanidins (PACs) that interfere with this adhesion. P fimbriae are appendages on the surface of E. coli bacteria that mediate adherence. Ellura does not protect against bacteria that don’t exhibit P-fimbriae, but it covers the bacteria that cause over 90% of UTIs. When adhesion is prevented, the bacteria get flushed out with urination, which is probably what the ads mean by the claim “supports a clean urinary tract”. If untreated, bladder infections can spread to the kidneys and lead to pyelonephritis, sepsis, kidney failure, and possibly even death.
Cranberry juice has long been recommended to prevent UTIs, but it doesn’t work. A Cochrane review concluded that cranberry products could not be recommended. And when our own Scott Gavura evaluated the evidence, he concluded:
Even taking the analysis at face value, cranberry is only modestly effective, expensive, and may come at a high dietary cost. And, it’s substantially less effective than conventional treatments.
Ellura is different. Each capsule contains 36 mg of type-A PAC derived from concentrated North American cranberry juice through a proprietary extraction process.
The research
The company’s website has a page for “Studies and clinical papers” that conveniently describes the research that has been done:
    • In a small uncontrolled trial of 36 mg PACs in 22 patients with indwelling catheters, no symptomatic UTIs occurred, and antibiotic resistances decreased by 28%.
    • In a randomized double-blind placebo-controlled study of 32 volunteers, 2 capsules of Ellura (72mg PACs) reduced bacterial adhesion in urine samples.
    • A review published in 2007 documented the beneficial effects of PACs for prevention of infections in vitro and in vivo.
    • A pilot study of Ellura in 15 bladder surgery patients found that it reduced asymptomatic bacteriuria by an estimated 93%.
    • A 2012 Cochrane review found that cranberry products had no significant effect, but said more research was needed with quantification of the active ingredient.
    • A syrup formulation of Ellura was tested in a study of 192 pediatric patients with recurrent UTIs in Spain. It was found to be noninferior to prophylaxis with the antibiotic trimethoprim for preventing recurrent UTIs in children.
The Ellura website says a dose of 36mg of PACs has been proven effective, but one study suggests that a dose of 72mg of PACs is preferable.
We still don’t have a gold standard randomized placebo-controlled study in women with recurrent UTIs who are currently taking antibiotics for prophylaxis and would be candidates for switching to Ellura. But the existing studies are very promising. In my opinion, the evidence is sufficient to warrant trying Ellura as a replacement for antibiotic prophylaxis in patients with recurrent UTIs, as long as proper precautions are taken. Patients who develop UTI-like symptoms while taking Ellura should be tested with urine cultures, and verified infections should be treated with an appropriate course of antibiotics.
Conclusion: the evidence is promising
We need to reduce the development of antibiotic-resistant bacteria. If Ellura can replace daily antibiotic prophylaxis for recurrent UTIs, that’s a good thing. Apparently, some urologists are already recommending it. If definitive studies showed it was safe and effective, it could be submitted to the FDA for approval as a drug. But we’re not likely to get the definitive studies we need, because they can continue to sell it as a dietary supplement. In the absence of more compelling evidence, I think it is reasonable to try it. Significant side effects have not been reported, so we can assume it is probably safe to try it; and if an infection occurs, patients can be treated. I don’t see any obvious downside other than the out-of-pocket expense, but antibiotics are often considerably more expensive.
It’s refreshing to see a dietary supplement with a good science-based rationale that can present evidence from studies that used the actual product rather than just a different preparation of an active ingredient, or a mixture of ingredients. After some of the supplements I’ve looked at, Ellura is a breath of fresh air. I didn’t notice any pseudoscience or mumbo-jumbo on their website.
A personal note: I have had recurrent UTIs but never often enough to warrant prophylaxis. I did finally persuade my doctor to give me a prescription for an antibiotic I could keep on hand to start taking the next time my symptoms recurred. That cured me 🙂 – the pill bottle sits untouched on a shelf in my medicine cabinet. No, I’m not going to give a testimonial that an unopened pill bottle is curative. But that does show how important it is to have a control group before concluding that a treatment has worked.

“SuperMannan Cures Bladder Infections!” Really?
The ads claim SuperMannan cures bladder infections. The science is a single uncontrolled study of 9 women; its design is a recipe for disaster.
Harriet Hall on October 22, 2019
Tweet

I was surprised to read that SuperMannan cures bladder infections. I’m a skeptic; I question and proportion my belief to the evidence. I wanted to know more. Who says that? How do they know? Why haven’t I heard about this before? What is it? How could it work? Have there been any controlled clinical studies? Where is the evidence? Have studies compared it to other treatments? Is it as effective as/more effective than other treatments? Are there any side effects? Is it wise to choose it over other options to treat a bladder infection?
I soon learned that the claim is based on an overly generous interpretation of very preliminary research. There may be something there, but the evidence doesn’t currently support recommending it as an effective option in clinical practice.
The claims
The SuperMannan website makes strong claims:
    • Groundbreaking discovery to promote urinary tract health!
    • Testimonial: “Cured forever.”
    • a food-based PATENTED discovery, tested for purity, efficacy, safety.
    • This isn’t D-Mannose; it isn’t just cranberry; this IS a one-time wonder!
Their website includes lots of testimonials and a tab titled “Read the Science“.
The study
The “Science” tab reports a single study. The lead author is an acupuncturist, which doesn’t inspire confidence. The title is “Yeast Mannan Oligosaccharide Dietary Supplement in the Treatment of Chronically Acute Urinary Tract Infections”. The title doesn’t inspire confidence either: infections are either acute or chronic, not “chronically acute”. I think they meant “recurrent”. The carelessly cited references don’t inspire confidence either: a reference that is supposedly about the complications of antibiotic treatment is actually about the effects of cranberry juice. It references a patent granted to Richard Katz for his discovery of a natural intervention for urinary tract infections in humans. The patent was only for a specific method of administering yeast mannan oligosaccharides; patents do not require and do not constitute evidence of efficacy.
The study design was a recipe for disaster. The subjects were a mere 9 women who were family members and friends of the investigators and who requested access to the product. They had all been diagnosed with recurrent episodes of culture-positive urinary tract infections (UTIs), and their urologists had given them an open prescription for antibiotics to use whenever they had recurrent symptoms of dysuria, frequency, and hematuria. There was no control group and no randomization. It was open-label: the subjects knew what they were taking. They were given SuperMannan, a mixture of three ingredients: two dried, autolyzed yeast products containing yeast mannan oligosaccharides (MOS) and cranberry (which is itself problematic). They were instructed to take 2 capsules followed by 2 additional capsules every 20 minutes for the next 2 hours, and then 2 capsules every 12 hours for the next 24 hours, for a total of 18 capsules in 24 hours.
The results consisted of self-reports by the subjects. All reported relief within an hour and a lower rate of recurrence after treatment (lower than what?). Three of the nine subjects reported “side effects” of urinary urgency without the other symptoms of UTI. They did have the grace to admit that “we do not know at this time whether mild symptoms in the weeks or months following the acute attack were related to E. coli or were irritations without E. coli present.” And they admitted that their results were “preliminary” and only “suggested” a role for SuperMannan, and that their hypotheses should be tested in follow-up randomized trials – they specified randomization but they failed to mention the need for a control group.
They describe (hypothesize) a mechanism by which MOS might act to reduce the ability of E. coli bacteria to infect bladder cells, but the best they can say is that it “likely” metabolizes complex mannosides and “likely” opsonizes the bacteria. This is purely speculation on their part. Their “safety testing” included administering it to a dog for 2 weeks; he experienced no adverse side effects and his digestion reportedly improved.
I won’t bother to list all the flaws that could have led to noise and false-positive results in this study design; I think most readers will be able to spot them for themselves.
Studies of D-mannose
An article in MedicalNewsToday reviewed the research on D-mannose and found it suggestive but insufficient and flawed. They said there is no way to know the appropriate form and dosage to use. And they reported side effects (diarrhea) and a concern that pregnant women or diabetics might experience complications. WebMD concluded “insufficient evidence“.
An article in Reviews in Urology was skeptical and raised concerns that D-mannose might be ineffective or even harmful:
Studies utilizing rodents and human urothelial cell lines have demonstrated that d-mannose-based inhibitors of FimH can block UPEC adhesion and invasion of uroepithelial cells. This basic science evidence has formed the basis for the promotion of d-mannose in human rUTI prevention. However, it is important to note that there are virtually no clinical studies in which d-mannose has been evaluated for rUTI prevention. In fact, there is in vitro evidence that mannose can inhibit macrophage activity, which could theoretically retard bacterial clearance from the urinary tract. Additionally, d- mannose may not be effective against certain strains of UPEC or other uropathogenic bacteria that do not express type 1 pili and FimH.
Effective treatments are available
Science has produced a lot of reliable data about effective treatments for acute UTIs and recurrent UTIs. That information is well summarized in an article in American Family Physician. Research results must be interpreted with caution, keeping in mind that up to one-third of UTIs resolve spontaneously in a week. Overuse of antibiotics is a concern because it can contribute to antibiotic resistance, but that doesn’t justify replacing proven effective treatments with unproven ones. SuperMannan and D-mannose are unproven.
Conclusion: Not convincing
The only evidence for SuperMannan is one very small, very flawed uncontrolled study. The evidence for D-mannose itself isn’t much better: it is preliminary and lacking in human clinical studies. Prudent patients with recurrent UTIs will get their medical advice from science-based health care providers, not from acupuncturists and supplement salesmen..

SeroVital: Dubious Anti-Aging Claims
SeroVital is marketed as an anti-aging remedy that works by raising human growth hormone (HGH) levels naturally with amino acids. The research consists of one preliminary study that measured HGH levels. There is no clinical evidence that it is effective for anything.
Harriet Hall on November 26, 2019
Link

I recently wrote about David Sinclair’s belief that aging is a preventable disease. Science has found intriguing evidence that certain treatments can slow the aging process in animals, but there’s no good evidence in humans so far. That didn’t stop him from devising his own hopeful anti-aging regimen based on the preclinical evidence. And it certainly hasn’t stopped dietary supplement companies from marketing a torrent of anti-aging remedies, some of which have a flimsy scientific rationale and others that are more fanciful. One websitec claims the following ingredients have been shown by science to have anti-aging effects: vitamins A, C, D, B3, B6, B9, curcumin, clove extract, ginger root extract, Indian gooseberry extract, L-carnitine, CoQ10, resveratrol, choline, glutathione, NAC, and alpha-lipoic acid. It combines all these in the Anti-Aging Topical Patch to be worn daily. Perhaps the most egregious offering is a product called SeroVital that claims to be a natural way to increase the body’s own production of human growth hormone (HGH).
Is raising HGH beneficial?
Human growth hormone has many essential actions in the body. Levels of HGH gradually decline after the age of 30. That’s not necessarily a bad thing, and raising levels may not be a good idea. Women with high levels of HGH are more likely to get breast cancer and men with high levels are more likely to develop prostate cancer, and individuals of both sexes are more apt to die at younger ages than those with naturally low HGH levels. Mice with very high levels of HGH have premature brain aging and reduced life spans. But some physicians cite studies indicating that the lower levels seen with aging are responsible for diminished energy, muscle loss, and decreased tissue repair, and they feel that bringing HGH levels up to the levels considered normal in young people will have health benefits that will make them feel younger. HGH is useful for some medical conditions, but according to the Mayo Clinic,
it is not intended to be used as an anti-aging medication. No evidence exists that shows HGH works against the effects of aging. In fact, taking HGH may be dangerous for some people.
Numerous other sources agree. An article on Quackwatch says that even HGH injections lack proven effectiveness and have significant side effects, and that so-called “growth-hormone releasers” should be regarded as fakes. It reports many enforcement actions that have been taken against doctors who promote HGH treatments. It reports harmful side effects including increased risk for cancer, cardiovascular disease, and behavior changes. It quotes an editorial in The New England Journal of Medicine that said the general use of HGH “now or in the immediate future” is not justified. And the American Association of Clinical Endocrinologists has warned that the clinical use of growth hormone as an anti-aging treatment or for obesity is not recommended. The pertinent research and concerns are conveniently covered here.
The claims for SeroVital
The SeroVital website features testimonials calling it “magic” and “a fountain of youth”. It is a mixture of ingredients that allegedly increases the body’s own production of HGH. The active ingredients are five amino acids (lysine, arginine oxo-proline, N-acetyl cysteine, and L-glutamine), and a powdered herb, Japanese catnip. The package says HGH is associated with increased energy, decreased body fat, reduced fine lines and wrinkles, and deeper, more restorative sleep. That “association”, if true, would be with HGH, not with the mixture of ingredients in the product. The company claims it raises HGH levels by a whopping 682%. It also claims it strengthens bones and improves sex drive and the testimonials suggest even more benefits. There is a 30-day money back guarantee.
Amino acids have been shown to raise HGH levels, but only in high doses and only in the short term. Japanese catnip has some anti-inflammatory effects. Some SeroVital users have reported significant side effects including swelling of hands and feet, bloating, acne, vertigo, headaches, achy joints, nausea, abdominal cramps, weight gain, heartburn, fatigue, and a possible exacerbation of breast cancer. It costs $99 a month (that’s $1,188 a year) and would have to be continued indefinitely. Customers are directed to take 4 capsules on an empty stomach and told not to eat for two hours before or after taking it. And of course, it carries the usual warning that it has not been evaluated by the FDA and is not intended to diagnose, prevent, cure, or treat any disease.
Dr. Oz praises HGH
Dr. Oz says HGH is the key to feeling decades younger. He uses the terms Fountain of Youth and miracle. He recommends amino acids as natural remedies that increase the body’s own production of HGH. He cites a single study showing that a special blend of amino acids can spike your HGH levels by 600%. He recommends taking a supplement that contains glycine, ornithine, arginine, and lysine (only two of which are in SeroVital), and says appropriate products can be purchased from your health foods store for less than $20. Note that amino acids are not listed as one of the many ingredients of the Anti-Aging Topical Patch I mentioned above (in the first paragraph), and do not feature in Dr. Sinclair’s regimen based on preclinical research.
The research
An extensive review of the claims, the evidence, and the facts can be found here.
There is only one study that evaluated the mixture of ingredients in SeroVital. It involved a mere 16 subjects, 12 men and 4 women, age 32 +/- 14 years. It supposedly found that two hours after taking SeroVital, the body’s production of HGH increased by 682% as measured by enzyme-linked immunosorbent assay. There was no attempt to measure anything else. No mention of any clinically significant effects. No replication. No other peer-reviewed studies.
Conclusion: No evidence of clinical efficacy, and potential side effects
It might work. Without proper controlled studies there is no way to know. But if I had to make an educated guess, I’d rate the probability of it having beneficial health effects or anti-aging effects as very low. I suspect there are better ways to spend your money. Or you might just save your money and follow standard mainstream evidence-based advice: exercise more, eat less, and don’t smoke.

The “Evidence” for Prodovite Is Junk Science
Prodovite is a liquid nutritional supplement marketed as “nutrition you can feel.” The claims are pseudoscientific nonsense and the single unblinded clinical study is junk science that relies on a bogus test: live cell microscopy.
Harriet Hall on March 12, 2019
Tweet

I recently got an email asking:
What are your thoughts on this supplement? It seems to be a very good one.Have you ever researched Prodovite, it does have a published IRB Clinical Study.
I immediately had questions: “Good compared to what? Good for what?” I couldn’t find any answers. They claim it is better absorbed; so what? They claim “Prodovite can help restore the ability to use oxygen and water to make energy, manage that energy, and then have enough strength to eliminate the garbage.” But there is no evidence that we lack that ability or need help to restore it, or that Prodovite can restore anything. Anyway, so what? Are there real-world clinical consequences? Does it affect the way people feel and perform? Does it change health outcomes? Are there measurable changes and if so, are they just changes in lab tests or is there Patient Oriented Evidence that Matters (POEMS)? It’s all very nebulous, and it carries the usual FDA disclaimer that it is not intended to diagnose, treat, cure or prevent any disease.
I read the “published IRB Clinical Study”. It is an appalling example of junk science.
What is Prodovite?
Prodovite is “a distinctively unique and superior liquid vitamin, mineral, and plant phytonutrient complex”. The scientific code is VMP35: Vitamin, Mineral, Phytonutrient, with “35 macro ingredients providing hundreds of microingredients.” It includes ingredients similar to those in other vitamin/mineral supplements plus things like inositol and white pine cone extract; but the essential ingredient is an herbal blend whose ingredients are listed here. They claim that “without micronutrients, or nutrients that isn’t [sic] processed on a macro level, we cannot function to our maximum capacity and will eventually end up shortening our life if we don’t get these essential micronutrients.” Says who? There’s no evidence for that claim.
They explain their technology: Only premium quality ingredients are used. They are predigested to get small uniform particle sizes that the body can utilize. They are put into a phospholipid capsule, forming a liposome, with clusters of up to 100 layers of liposomes inside other liposomes. They say all the tissues of the digestive system, from the mouth to the colon, LOVE phospholipids. (What?)
They say when you put it in your mouth and swish it around, it absorbs rapidly into the blood vessels under the tongue. What doesn’t get absorbed in the mouth passes on through the digestive tract and the particles adhere to the intestinal wall and begin to degrade and release nutrients and phospholipids into the blood stream so you get rapid and sustained absorption over a prolonged period of time. (How long? They mention 30 minutes, but what happens after that? Do you need to repeat the dose every 30 minutes?) They brag that their product is unlike any other product on the market
It is “nutrition you can feel”. It will change the quality of your life.
They have a Webinar on “Why You Need Prodovite”. It claims “the number one health malady in our culture is digestive problems.” (Really? I don’t think so!) It describes the published study, and demonstrates how Prodovite lights a 15 watt bulb. (What’s that supposed to prove?)
They say their phospholipids are treated with Energy Frequency Imprinting. (Energy Frequency Imprinting? What nonsense!) They describe a one of a kind exothermic reaction: the temperature rises to 98.6 and supposedly stops exactly at normal body temperature. (I find that hard to believe!)
They claim Prodovite is necessary for all of us because we have a reduced ability to use oxygen and water (and just how do they know this?). They provide a long list of resulting symptoms and diseases including restless legs, muscle twitches, bone spurs, osteoporosis, kidney stones, periodontal disease, depression, cardiovascular disease, diabetes, cancer, and much more. Of course, this is all nonsense. They say these are also signs of acidosis. (No, they aren’t!) They say, “We don’t treat diseases, we give the body the resources it needs to rejuvenate and revitalize cellular metabolism”.
Their rampant pseudoscientific bullshit made it painful for me to watch the videos and read the claims on their website. They even quote the Bible. They say a picture shows “dead rotting red blood cells that are poisoning the patient”. But then the follow-up picture supposedly shows them restored to life. They refer to a structure larger than a blood cell as a “molecule”. They provide testimonials: a legally blind man’s sight was restored to where he got his driver’s license back. A foot amputation for a diabetic ulcer was prevented, and the ulcer healed completely. A weight lifter increased his squat lifting performance from 395 to 575 pounds.
The published study
There is only one published study. You can read it for yourself. It is not listed in PubMed, but I found it through Google Scholar. It was published in the journal Functional Foods in Health & Diseasenearly four years ago, in September 2015. The title is “The effect of VMP35 supplement ingredients encapsulated in a novel Phospholipid Prodosome SK713 SLP nutrient delivery technology observed as a result of changes in properties of live human blood”.
38 subjects were recruited at random. They underwent live blood cell imaging before and 5 minutes after ingesting Prodovite. They served as their own controls, using bottled water for comparison. The “before” images were all abnormal (does that mean it’s normal to be abnormal?) There was no blinding. The authors interpreted changes in live blood cell observations before and after taking Prodovite as proof that the nutraceuticals were rapidly and effectively delivered into the blood. They called it “an important contribution towards increasing the potential benefits of dietary supplements”. These conclusions were not warranted by the data.
No blinding!? Blinding is essential to prevent bias. In this case, the subjects could tell whether they were getting Prodovite or bottled water, and the microscopists knew what they hoped to see and could deliberately or unconsciously manipulate their observations to produce the desired findings.
There were conflicts of interest: 3 of the authors had ownership interest in Victory Nutrition International, the manufacturer of Prodovite. Another author’s wife was an independent representative of Victory Nutrition.
They make a big deal of having gotten IRB approval for their study. They think it was an unprecedented accomplishment for a nutraceutical. Actually, everyclinical study must get IRB approval to protect human subjects. They describe the time and expense involved, and the steps involved in getting a study published (As if understanding their difficulties would persuade people to believe their results!). They pride themselves on establishing a formal protocol for live blood cell analysis but the protocol is useless because it doesn’t include blinding. They assumed it was a valid test. (It isn’t. See below.) They did nothing to evaluate its validity.
A video interprets the live cell microscopy findings in the study. It claims the red blood cells are aggregating because they have lost their negative charge and the white blood cells are a quarter the size they should be, “probably because of the cell aggregation somehow affecting circulation, directly or indirectly affecting immune [sic]”.
5 minutes after taking Prodovite, they say the negative charge has been restored, the red blood cells are flowing freely, no longer aggregated, and the white blood cells are 4 times bigger. (How on earth could circulating white blood cells get 4 times bigger in 5 minutes?!!)
Live blood cell analysis is sheer bunkum
According to Stephen Barrett’s analysis on Quackwatch the claims for live cell analysis are “sheer bunkum.” Naive observers misinterpret artifacts that occur as the blood sample dries, they fail to clean slides and interpret the residual dirt as blood components, and they fail to properly focus the microscope and misinterpret out-of-focus observations. The “improvements” they see are likely due to examining the slides differently. “Blood dries more quickly near the edges of the slide than near the center. Thus ‘improvement’ will be seen if the first specimen is examined near an edge and the second specimen is examined near its center.” Stephen Barrett tested it: he faked taking the pills they gave him; and sure enough, his second specimen showed the “improvement” that they predicted from the pills. Regulators have deemed live blood cell analysis fraudulent and of no discernable value. There is a good article debunking it on the Committee for Skeptical Inquirer website. Mark Crislip critiqued it on Science-Based Medicine in 2009. Wikipedia and Edzard Ernst explain that there is no evidence that it is reliable or effective; they call it fraudulent. Even Andrew Weil rejects it.
Conclusion: Prodovite is a good example of bad science
The claims for Prodovite are nothing but speculation, wishful thinking, self-deception, placebo responses, and junk science. The one published study is a travesty; live blood cell analysis is a bogus test that cannot provide “evidence”. Publishing the study was a mistake; doing the study in the first place was a mistake.
Selling Prodovite benefits the company, but I see no reason to think it benefits the health of customers.
There is no way to know whether it is safe and effective, because it has never been properly tested. Maybe it works to improve the health of at least some patients in some situations. I will be happy to follow the evidence wherever it leads, but the company will have to provide some real evidence, not just junk science. After perusing their website, I am not optimistic about their ability to do that, and I’m not going to hold my breath.

Herbalife or Herbadeath?
A case of fatal liver failure in India was attributed to Herbalife products, adding to many other reports from around the world. Analysis showed Herbalife products contain heavy metals and other contaminants. The products have not been scientifically tested, and in the absence of evidence of benefit to human health, they can’t be recommended.
Harriet Hall on September 10, 2019
Link

Herbalife is a multilevel marketing company that sells nutritional and weight loss supplements in 94 countries. After many complaints, the Federal Trade Commission (FTC) investigated the company. In 2016, they described Herbalife as a scam disguised as healthy living; the company was fined $200 million and ordered to restructure its business and issue refunds to 350,000 Herbalife distributors. Herbalife has also been sued in Belgium and Israel. There have been over 50 reports of liver toxicity attributed to Herbalife products in Spain, Israel, Latin America, Switzerland, Iceland, and the US. India is fast becoming the largest growing market for Herbalife products. A recent article “Slimming to the Death” is the first case report of fatal acute liver failure from the Asia-Pacific region. The researchers also found contamination of Herbalife products with heavy metals, toxins, psychotropic substances, and pathogenic bacteria.
Supplements are used by one-third to one-half of adults in the US. They are big business, with sales rising from $9.6 billion in 1994 to $36.7 billion in 2014. 20% of hepatotoxicity cases in the US are attributed to herbal and dietary supplements, the biggest culprit being multi-ingredient nutritional supplements. Identification of the responsible component in multi-ingredient supplements is a challenge due to lack of documentation about source, dosage, and purity; and some products are contaminated or mislabeled.
The LiverTox database on the NIH website categorizes Herbalife products as “a well-established cause of clinically apparent liver injury”. Not everyone would agree with the assessment of “well-established”. A study of 53 cases of suspected Herbalife toxicity evaluated 8 cases where the assumption of toxicity was reportedly confirmed by unintentional re-exposure. They found quality problems, missing data, confounding variables, and uncertainties. They concluded causality was probable in 1 of those 8 cases, unlikely in 4, and excluded in 3.
The Asian patient in question was a 24-year-old Indian woman with hypothyroidism (treated with thyroxine) and a BMI of 32.1 but no other health problems. She had been taking three Herbalife slimming products for 2 months when she developed loss of appetite, jaundice, and transient pruritus. Her liver enzymes had skyrocketed. Her condition worsened and she died while on the waiting list for liver transplant surgery. The researchers were unable to retrieve the actual Herbalife products she had taken but were able to source one product from the same seller that she had purchased her products from; it was a nutritional club functioning without a license, and it was eventually shut down by the government of Kerala. They obtained eight similar Herbalife products from the internet and had them analyzed. High levels of multiple heavy metals were found in all of the products. There were traces of psychotropic recreational agent in 75%, bacterial DNA in 63%, including highly pathogenic species, and other potential liver-toxic agents. The products and contaminants are listed in Table 1 in the article. They pointed out that this is a growing public health concern. They recommended better regulation, with preclinical and clinical scientific studies and post-marketing vigilance.
Conclusion: Cause for concern
This was a case report, not definitive proof of causation, but along with other reports of liver toxicity from many countries, it adds to the circumstantial evidence and is clearly a cause for concern. It highlights the possible dangers of dietary supplements and the lack of purity of products on the market. Until dietary supplements are better studied and better regulated, taking products like the ones sold by Herbalife is a gamble and cannot be recommended. There is no credible scientific evidence that they improve health, so the plausible risk must be balanced against zero evidence of benefit. In the absence of proven benefit, even a suspicion of possible risk is unacceptable.
Addendum
The article “Slimming to the Death” referred to in the first paragraph has been removed by Elsevier for legal reasons following a complaint from Herbalife. According to Elsevier, “The article, which was published in the March-April 2019 issue of the journal, has been removed for legal reasons. However the decision to remove the article does not imply admission of any allegation made about the article by any party.”

Reader’s Digest Promotes Prevagen
Reader’s Digest is advertising a memory aid, Prevagen, that has been tested and shown not to work. Shame on them!
Harriet Hall on December 4, 2018
Link

I am a long-time subscriber to Reader’s Digest. I enjoy the jokes and some of the human interest stories, but I have become increasingly disturbed by some of the questionable health information they present. The most recent issue carried a prominent ad for Prevagen on the back cover. In large print, it says “Healthier Brain. Better Life.” It shows pictures of the product’s box and bottle, both of which say “Improves Memory.” And on the box, you can clearly see the claims that it “supports healthy brain function, sharper mind, and clearer thinking.” The ad claims it is “America’s best-selling brain support supplement and has been clinically shown to help with mild memory problems associated with aging.” This statement has an asterisk leading to a small-print boxed FDA disclaimer: “These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
The editors of Reader’s Digest have obviously not been reading the Science-Based Medicine blog. In a 2015 article, Steven Novella wrote about the entire class of nootropics, or drugs that are designed to enhance cognitive function. He concluded that they are being abused and hyped without adequate evidence, and he deplored the fact that they are being sold as dietary supplements rather than as drugs. He said some manufacturers cheat by including a stimulant, which can benefit patients diagnosed with certain diseases, but “Current non-stimulant nootropics are likely useless in healthy individuals.”
And earlier this year, Jann Bellamy reviewed the evidence for Prevagen and the lawsuit filed against it by the FTC claiming that the company was making false and misleading statements in labeling and advertisements, that:
(1) there is not “competent and reliable scientific evidence” to support Prevagen’s claims, which is required of health care product advertising, and (2) the claim that Prevagen is “clinically proven” is false.
It was not “clinically proven”. The study they’re referring to found that it didn’t work, but the manufacturer relied on post hoc analyses of subgroups and p-hacking that found some apparently positive results. The FTC explained that:
post-hoc data-dredging is unreliable and can’t rule out ‘statistically significant difference’ as mere noise.
What is Prevagen? What does the evidence show?
It is a dietary supplement whose main ingredient, apoaequorin, is a calcium-binding compound first identified in jellyfish. The company website claims that it is safe and effective for improving memory and supporting brain function. It cites three safety studies and one randomized, double-blinded, placebo-controlled clinical trial in community-dwelling older adults who self-reported memory concerns, the Madison Memory Study. That study was negative: “no statistically significant results were observed over the entire study population.” But the company did some data mining and p-hacking and teased out statistically significant p results for two subgroups of individuals with either minimal or no cognitive impairment. Essentially, they tortured the data to make it confess. Then they used the p-hacked data to speculate that Prevagen would benefit their customers: it would “support people with mild memory loss associated with aging.” That conclusion is not supported by the data. Jann’s articledescribes some of the other problems with the study and with the company’s claims. They claim apoaequorin crosses the blood-brain barrier, but the only evidence they have is in dogs. The safety studies they cite were all in rats. They have no evidence that it crosses the human blood-brain barrier or that it is safe in humans. In fact, there are many consumer complaints and reports of side effects. They are not selling it for dogs or rats, but for humans.
In addition, the American Pharmacists Association website raises some other concerns. They say it “is unlikely to be absorbed to a significant degree; instead it degrades into amino acids.” And they say the tests used in the Madison Memory Study were not validated tests.
Conclusion: Prevagen claims not supported by evidence
There is no evidence that Prevagen is effective or safe in humans. We knew that. The FTC knew that. Mainstream scientific organizations knew that. Why didn’t Reader’s Digest know that? Shame on them! The magazine is widely read and respected, and this Prevagen ad, prominently featured in full color on the back cover, will probably persuade many readers to waste their money on this placebo under the mistaken belief that it will help with the memory problems associated with aging.

Nope, Quenepa Has No Health Benefits.
Is quenepa, a fruit found in the Caribbean, Central, and South America, a miracle superfood? Spoiler alert – no. No it’s not.
Abby Campbell on April 8, 2017
Link

[Editor’s note: We welcome back to the blog Abby Campbell, a practicing MD, Ph.D and contributor at HealthyButSmart.com, for her second post. If you haven’t already, have a look at her post on the non-wonder-drug phenibut!]

If we are to believe certain “natural health” authorities (not mentioning any names except Natural News), a weird fruit called quenepa ( Melicoccus bijugatus Jacq.) is the latest superfood.
Yet unsurprisingly, the claims about it don’t stand up to scrutiny.
Let’s take a look at the claims and the relevant research.
What is quenepa?
Quenepa is the fruit of a tree which is native to South America. It is also known as the Spanish lime, but not spinach lime as a recent blogger said!
Quenepa is related to other exotic fruits such as longans, lychees and rambutans.The quenepa fruit is made up of three distinct parts: green leathery skin, a pink colored fleshy pulp and a crustaceous seed coat which contains the embryo.Each part has its own characteristics and uses. The pulp of the fruit is used to make cold drinks, deserts and jams while the seeds can be roasted and eaten like chestnuts or made into flour.
According to published papers, it has an odd taste which is part sweet and part astringent and is not to everyone’s liking. (Full disclosure, I have no idea what quenepa tastes like. Being super diligent, I did call in to my exotic local fruit shop and asked for some quenepa. All I got was a raised eyebrow and ‘You gotta be kidding me’ from the owner!)
A handful of studies (linked in the next section) have looked at the composition of quenepa and all agree that the content of the quenepa varies from country to country. So, we can say that not all quenepas are created equal! But what does quenepa do?
Does quenepa help insomnia?
Some health bloggers have claimed that quenepa is a great cure for insomnia. FYI- these are the same bloggers who called it the spinach lime not the Spanish lime! Now here is the interesting thing. There are a grand total of three papers published on quenepa! Yes three!
Being somewhere on the spectrum between geekie and obsessive compulsive, I sat down to read all three papers. The papers were actually really interesting (for geeks with OCD types).
According to the papers, quenepa is used in traditional medicine for a wide range of medical conditions including diarrhea, intestinal parasites, asthma, and hypertension, but there was no mention of insomnia.
According to health bloggers, quenepa contains tryptophan which is supposed to account for the ‘sleep benefits’. The three published studies used a technology called mass spectrometry to determine the chemical composition of quenepa.
The studies mention all sorts of weird organic acids with really complicated names but they do not mention tryptophan. Not once. Not anywhere.
To satisfy my geekiness, I emailed the lead author on all three of the quenepa papers to ask about the tryptophan connection. Lori Bystrom wrote back to me and said that she too had seen the blog referring to insomnia and tryptophan but could find no evidence to support the claim.
To summarize, quenepa is not used in traditional medicine for sleep nor do the existing studies say that quenepa contains tryptophan. Quite frankly, there is no quenepa sleep connection at all. Forget for a moment the fact that there are lots of other sleep aids that taste better and are easier to find.
Does quenepa help cholesterol levels?
There is no research to back up the claim that quenepa helps lower cholesterol.
Quenepa belongs to the Sapindaceae family and contains saponins. From other work, we know that saponins may help lower cholesterol. But before you go out and eat a tree full of quenepa, beware. Saponins are toxic to fish and can be toxic to human red blood cells if taken in high enough quantities. You have to get the dose just right. From the published work, it would be difficult to strike a balance between having enough quenepa to make a clinically significant difference to cholesterol levels while not running the risk of toxicity. Not to mention the fact that the saponin level would vary among different cultivars.
I think I will stick to watching my diet and add in a little extra exercise to keep my cholesterol in check, thank you very much.
Does quenepa help kidney stones? Urinary tract infections?
There is some evidence to suggest that citrates play a role in preventing recurrent urinary tract infections and kidney stones.
Quenepa is a source of citric acid. But to use this and extrapolate that quenepa prevents kidney infections or kidney stones is beyond irresponsible.
Further, Lori Bystrom summarizes the not-at-all-proven-but-vaguely-possible health benefits of quenepa in one of her papers and kidney stones and kidney infections are not even on the list.
Does quenepa do anything?
So what does quenepa actually do? It is used in foods and drinks but has no proven health benefits.
And there is more. The one and only paper on the possible health benefits of quenepa warns that ‘the fruit pulp may have toxicological effects when consumed excessively or during periods of growth or high iron requirements’.
So let’s look at the unique selling proposition of the quenepa fruit. It has a bitter taste, no health benefits, possible side effects, and is not readily accessible in many countries. Need I say more?
Conclusion: Not worth the carbon
Even though I am pretty eco-friendly, I do love a few foods that come with an unreasonable number of food miles. Maybe the fact that fruits, herbs and spices come from the rainforest or other exotic places makes me feel better about living in concrete suburbia.
However, I have to agree with my greengrocer on this one. There is not a single good reason to leave a massive carbon footprint to make quenepa go global!

Liver cancer, naturally
Aristolochic acid, a highly toxic substance naturally found in some traditional herbal medicines, may be a significant cause of liver cancer.
Scott Gavura on November 2, 2017
Link
Not all cancers affect all populations equally. Liver cancer is the fifth-most common cancer worldwide, but the prevalence varies widely. Liver cancer cases skew heavily to less developed regions of the world, where 83% of cases are found – it’s over six times more common there than in Northern Europe, for example. In Asia, the high rates of liver cancer have been linked to hepatitis B and C, which is widespread, and a proven cause of cancer. And liver cancer continues to strike Asian American and Pacific Islanders more than any other American ethnic group as well, where hepatitis continues to circulate in the population. Now there’s new evidence to suggest that a substance found in some traditional Chinese medicines may also be causing liver cancer. They’re called aristolochic acids, and they illustrate, with a substantial body count, that what’s natural isn’t necessarily healthy or good.
What are Aristolochic acids?
In the early 1990’s a strange cluster of acute, end-stage renal disease appeared in women in Belgium. It was determined that all had been exposed to the chemical aristolochic acid (AA) at a weight loss clinic, due to the consumption of Chinese herbs which contained natural AA. Approximately one third of the more than 300 cases have subsequently required a kidney transplant, and cancers of the urothelial tract in this group have also been widespread. In the Balkans, low level exposure to AA via flour consumption that contains seeds from Aristolochia clematitis is believed to be responsible for what is now called Balkan-endemic nephropathy. Subsequent study that was initiated after the Belgian case identified that that AA is responsible for tumour development and for activating destructive fibrotic changes in the kidney. For over a decade now it has been well established that AA is a nephrotoxin and a powerful carcinogen with a short “latency period”, in that it causes permanently damage, quickly. What’s remarkable is that none of this was known until the 1990s despite “thousands of years” of use as a traditional medicine. As Steven Novella noted in a past post on aristolochic acid and urinary tract cancer:
This example just highlights the fact that widespread use of an herbal product, or any treatment, is not sufficient to ensure that it is safe, or even that it is effective. Common use may be enough to detect immediate or obvious effects, but not increased risk of developing disease over time. That requires careful epidemiology or specific clinical studies. We know about the risks of prescription drugs only because they are studied, and then tracked once they are on the market. Without similar study and tracking there is simply no way to know about the risks of herbal products. Relying upon “generally recognized as safe” is folly.
While herbal remedies that contain AA are now banned in many countries, AA-induced kidney damage and related cancers continues to appear worldwide. As AA’s cancer-causing effects have now been widely studied, the distinct way that they damage cells has been described as a sort of “signature” that is easily identifiable in tumour samples. This brings us to this new study of liver cancers attributed to AA, which have been less closely associated with AA. This study used that unique “signature” to look for AA exposure.
Aristolochic acids and liver cancers
There is good evidence to show that the consumption of AA-containing products in Taiwan has been widespread through the use of prescribed herbal medicines. The paper is entitled “Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia” and it’s from Alvin Ng and associates, published in Science Translational Medicine in October, 2017. This was a retrospective analysis of hepatocellular carcinomas (HCC, liver cancer in lay terms) and patients were included if they (1) had true HCC (2) there was sufficient DNA available from a sample of the tumour. 98 HCCs from Taiwan hospitals were studied based on whole-exome sequencing and mutation identification. They looked for the distinctive way in which AA causes mutations. The researchers subsequently examined 1,400 HCCs from other regions in the world. The final analysis was as follows:
Taiwan: 78% of tumours had evidence of AA exposure
China: 47% of tumours had evidence of AA exposure
Southeast Asia: 29% of tumours had evidence of AA exposure
Korea: 13% of tumours had evidence of AA exposure
Japan: 2.7% of tumours had evidence of AA exposure
North America: 4.8% of tumours (in one hospital, 22% of 87 patients, all of Asian ancestry, had evidence of AA exposure)
Europe: 1.7% of tumours had evidence of AA exposure
Here is the global breakdown, with the red portion illustrating the proportion of tumours that were linked to AA exposure:

Reducing your risk of kidney and liver cancer
Herbal remedies are popular worldwide. In China and other countries in Asia, there is strong support for, and belief in “traditional” Chinese medicine despite the fact that it is neither truly traditional (as it is now promoted), nor particularly effective. This new analysis shows that the use of (or exposure to) AA is widespread in some parts of the world, and appears to be be a cause in a substantial numbers of liver cancers. The authors noted that the presence of AA-associated cancer does not appear to be declining in Taiwan, despite the banning of some AA-containing herbs in 2003. This may be due to a lag effect (like cancer and smoking) but may also be due to continued exposure to, or consumption of, AA-containing products.
If you’re a user of traditional Chinese medicine, avoiding AA is easier said than done, unless you have impeccable knowledge of herbs, their origins, and the supply chains you’re getting your products from. I’ve blogged before about TCM, noting that contamination is common. Mislabelling of products also appears to be widespread, suggesting that rigorous and credible testing of final products may be the only way consumers can be assured they’re avoiding AA in the products they buy. The linkage of AA to kidney damage, and the evolving story of its cancer-causing potential illustrates that even widespread use of a product for hundreds (or thousands) of years give no automatic assurance of safety. If it were not for the Belgian weight loss clinic kidney failure cluster, the widespread toxicity of AA may not even be known today.

ASEA

ASEA: Another Expensive Way to Buy Water
ASEA is an expensive way to buy salt water, backed up by an enormous number of sciencey-sounding buzzwords and no meaningful evidence, all wrapped up in a multi-level marketing scheme designed to separate the credulous from their money. Don’t buy it.
Harriet Hall on August 7, 2012
Link
ASEA is a diet supplement described as a “life-changing” health aid that can benefit everyone:
ASEA is trillions of stable, perfectly balanced Redox Signaling Molecules suspended in a pristine saline solution—the same molecules that exist in the cells of the human body. Redox signaling is a function that is central to all life. Signaling molecules are created within every cell in the body. After the age of 12, our cells make fewer and fewer of these molecules. ASEA is the world’s only source for replenishing them.
ASEA allegedly:
    • Promotes enhanced immune function
    • Supports the vital activity of cellular communication
    • Provides superior “support” to athletes
    • Boosts efficiency of the body’s own antioxidants by 500%
    • Protects against free radical damage
ASEA doesn’t (can’t legally) claim to be effective for any disease, but since a number of diseases are related to immune function, free radical damage, etc., it’s only natural to assume that ASEA would benefit a host of conditions. The claims are deliberately vague, and there is the usual disclaimer that it has not been evaluated by the FDA and is not intended to treat or prevent any disease; but testimonials and innuendo suggest all kinds of specific benefits ranging from better sleep to cancer.
What’s in this miracle product? The ingredients are listed on the label: water and salt.
Pseudoscientific balderdash
But they explain:
ASEA is a mixture of 16 chemically recombined products of salt and water with completely new chemical properties. It is no longer salt or water just like table salt is no longer chlorine gas or sodium metal.
OK, so what exactly are these 16 chemically recombined products of salt and water with completely new chemical properties and how did they determine they are there? They don’t say. They only explain how ASEA is made:
ASEA is made in Utah from municipal water that is highly purified using both reverse osmosis and distillation. The pure water is then combined with pure salt and allowed to cure, before undergoing a patented process that oxidizes and reduces the saline solution into the final product. During processing most of the chloride ions are integrated into redox molecules. Sodium ions are not effected [sic] and help to maintain electrical neutrality. Hydrogen and oxygen also contribute to the formation of redox molecules, but most of the water forms a matrix of clusters around the active redox molecules and ions. This micro-clustering further contributes to the stability and electrical neutrality of the product. The final product is no longer a saline solution. It is not salt and water. It is a balanced buffet of redox molecules. The raw materials have been transformed into a new product. Ingredients: Some people ask why redox Molecules are not listed as an ingredient on each bottle of ASEA. By comparison, when we look at the ingredients on a loaf of bread, we find flour, water, eggs, sugar, oil, yeast, etc. Nowhere on the list does it say “bread”. The raw ingredients have been blended and heated and forever transformed. You can no longer locate the eggs or oil that we know went into the process. It’s the same with ASEA.
This is very creative, but it’s not science. It’s just an attempt to baffle you with bullshit.
The research
They have some scientific studies that they say “prove” the presence and effectiveness of those “chemically recombined products,” but they actually do no such thing. Their evidence is indirect and unconvincing. They say the product contains an equilibrium of several known reactive molecules that are stable in ASEA and measurable using standard analytic methods. But they never name any of those known molecules, and their analytic method is to use a fluorescent indicator as a probe for unspecified “highly reactive oxygen species.”
They tested antioxidant enhancement and oxidative stress reduction in cell cultures and found “large, well-defined effects .”
They tested 17 athletes and found a 3% increase in VO2max. They didn’t have a control group and either didn’t bother to calculate whether the observed changes were statistically significant or calculated that they were not statistically significant and chose not to mention that.
A small study of cyclists was done with a crossover control but with no placebo control. It measured a number of changes in metabolites that “may represent effects on inflammation, oxidative stress, and physiologic stress.”
Not a single placebo-controlled study. Worse, these studies were “in house” studies that were never published in a peer-reviewed journal. Steven Novella recently pointed out the unreliability of such studies.
Nothing listed in PubMed. Without replication, peer review, and better designed studies, this research does not constitute any credible evidence to support the claims for ASEA. They have made what Carl Sagan would have called extraordinary claims and they have not even provided any ordinary evidence, much less any extraordinary evidence.
Redox science
Redox refers to reduction/oxidation, the loss or gain of electrons. Redox signaling is a process whereby free radicals, reactive oxygen species, and other compounds act as biological messengers. Nitric oxide, hydrogen sulfide, and carbon monoxide can be classified as redox signaling molecules. Redox signaling is involved in a number of biological processes from inflammation to cancer. As one online commenter said:
The science may be valid, but that doesn’t mean this product is!
Safety
They claim it is proven to be completely safe, with zero toxicity, but:
    • “ASEA is not recommended for pregnant or nursing mothers.”
    • The webpage listing safety studies consists of cell culture and studies on mutant bacteria (!?) and animals (rabbits, mice, dogs, usually only 4 or 5 of each).
    • It is supposedly so effective that it might increase the efficiency of certain message carriers in the body, such as hormones, insulin, adrenaline, etc. Patients taking any of those medications are advised to carefully monitor themselves and make adjustments to compensate, with the aid of their doctor if needed.
Knowing that something appeared to be safe for a few mice and dogs over the short period of a study does not strike me as very reassuring. On the other hand, if the product contains only salt and water rather than the alleged 16 undefined “chemically recombined products” there’s no reason to worry about safety.
Marketing
ASEA is sold through a multilevel marketing scheme with “7 ways to get paid.” It is expensive. The cheapest way to try it is to order 64 oz for $75. It costs less if you choose the autoship option where they will continue to charge your credit card every month, and even less if you become an associate (but that requires an investment of $120 to $818). At a recommended dosage of 2-8 oz per day, that works out to between $2 and $9 a day.
A Google search yields an article headlined “ASEA Exposed – Learn the Truth about ASEA. 9 Things You Should Know Right Now.” It simply links to a promotional site. This is a devious ploy to capture both the credulous shopper and the “skeptical but curious” and also to divert traffic from genuinely skeptical pages.
Criticism in online forums
One commenter said:
This is bullshit. It’s salt water for $1 an ounce. The science-babble is meaningless. “Reactive molecule stabilization technology” is the kind of phrase that’s probably best translated as “it may just look like water, but it’s magic water that we’ve trained to do tricks!”
Another commenter, a chemist, said:
That’s just a load of nonsense. “Reactive molecule” isn’t an established term with some specific scientific meaning other than it’s literal meaning. And the literal meaning is so generic that it’s useless. (And if anything, a ‘reactive molecule’ is something that’s bad for you. Chemically reactive substances = toxic substances. And ‘reactive’ and ‘stabilization’ isn’t something you’d normally see in the same sentence. A reactive compound is by definition not very stable.)
“Redox signaling molecules” sounds like a scientific term as well, but isn’t. “Redox” means reduction/oxidation reactions, and signaling substances are anything that has a biochemical receptor of some kind that changes something else due to that molecule’s presence or absence. Again, it’s a couple of vague scientific-sounding terms strung together to sound like they’re talking about some established scientific concept, when they’re not. It’s not an established term and the literal meaning is too vague to say anything at all. Just because something sounds ‘sciency’ doesn’t make it science, or vice-versa: “sonic hedgehog” is a more established chemistry term than “redox signalling molecule”.
Other water scams
The list of water-related scams is long and is constantly getting longer. A retired chemist maintains a handy website critiquing them.
Here are three of my favorites:
Vitamin O is still for sale. I recently wrote about Vitamin O. The Rose Creek Company marketed oxygenated water that didn’t contain any oxygen. Their own advertising said it was tested in a lab and found not to contain any oxygen. They explained that the lab’s precision equipment couldn’t measure over 40 ppm of oxygen and there was so much oxygen in their product that it had registered as zero.
Sea Salt Colon Cleanse is an easy way to cleanse your colon. Their pseudoscience is just as imaginative as ASEA’s. I’ll quote it at length for your enjoyment, since it is rolling-on-the-floor hilarious:
A solution of sea salt and water has the same specific gravity as human blood. Due to this reason, it is not passed to the kidney for further purification like normal liquid solutions. Instead, the sea salt and water solution pass through the digestive tract almost wholly intact till the end, cleansing your stomach, small and large intestines. The components present in sea salt not only dislodge the waste particles sticking to your colon and hampering other digestive organs, they also effectively kill all parasites present in your digestive organs. A sea salt colon cleanse is almost like an oral enema because it is just as effective without being invasive at all.
Another major advantage that sea salt has over and above normal table salt is that it does not raise your blood pressure. This is because the sea salt and water solution, if mixed correctly, is not broken down into its components and is not made to pass into the blood stream. You also do not need to fear any water retention like you would have by consuming large amounts of normal sodium chloride… You cannot achieve the same or even similar results by using common table salt because it not only lacks certain essential minerals that are present in sea salt, but also contains iodine, which is not present in crude sea salt.
Hado Water is Masaru Emoto’s contribution: a geometrically perfect hexagonal water with a message imprinted in it that transfers vital energy to your body.
The bottom line
ASEA is salt water. You can make your own salt water at home for much less than a dollar an ounce. The only value of the product is the entertainment value that can be derived from reading the imaginative pseudoscientific explanations they have dreamed up to sell it.

Fan Mail from an ASEA Supporter
Harriet Hall on November 13, 2012
Link
We have an active comments section on our blog, but for some reason some people prefer not to comment there, but to send personal e-mails to authors when they disagree. Some of them make me laugh. Some of them make me despair. We can carry on our struggle better if we know what we are fighting; and in that spirit, I want to describe a recent e-mail exchange.
If an e-mail is filled with angry CAPITALS and abusive language, I know there is no point in responding. But I still get suckered in by the ones that start out sounding as if a productive dialog might be possible; unfortunately, discussions almost always degenerate. In this case, it started with a polite request for my opinion about a specific study.
Note: I have not corrected the many spelling/punctuation/grammar errors in my correspondent’s e-mails. Why is it that so many of scientific medicine’s critics can’t or won’t bother to write proper English? In case you are wondering, English is this woman’s native language and she is a college graduate.
Act 1
The initial e-mail was in response to the article I wrote about ASEA, a diet supplement described as a “life-changing” health aid. The email said:
Have you seen this?
Just was wondering if you think he is not telling the truth?
2. Summary of North Carolina Research Institute double blinded study plus significant new research results(17 min): http://vimeo.com/asea/review/50788371/b2d2c857e8
I very much appreciate your opinion.
The video was from an ASEA company meeting/pep rally; a researcher was describing his unpublished research.
I told her I wouldn’t waste my time on a video but would wait until he published his findings in a peer-reviewed journal. I said I would assume he was telling the truth as he sees it. I explained that even published findings are wrong about half the time, and that if ASEA is effective, it will take an accumulating body of well-designed research with replications to convince me and the scientific community.
Act 2
She responded:
I believe he is very well know guy and only does research as he is head of the Human Performance Laboratory at Appalachian State University.
http://www.ncresearchcampus.net/partners-and-research/latest-research/asu-peaking-human-performance
Do you think he can afford messing and lying???
Do you ?? he will lose his job. !
Where do you work?
I should have realized at this point that it would be a wasted effort, but I tried to answer her questions. I pointed out that I did not think he was “messing and lying.” I explained that even the best scientists do studies whose results are overturned by better studies by other researchers. I explained the collaborative process of peer review, replication, and eventual consensus. I pointed out that scientists who only report their results in videos are bypassing that process.
I told her I was a retired family physician and warned her against the appeal to authority fallacy. It doesn’t matter who a person is; what matters is what they say.
Act 3
Thanks again
However I feel that your site is very negative, and your commenst are based on no facts nor science either.
You do not acgnolage the fact that there is a good company with a good product which is trying to get all the necessary research they need to exactely get to that point . And as you pointed out below that will take time; but they will get there.
In the menatime the product is sold well as it obvioulsy helps, otherwise it would not sell so well and it does not need scinetific proove to work well does it? .
Getting back to your first email however I felt that your respons was ignorant and sarcastic.
And that’s why I did ask … where do you work. ? Simply to compare your excpertise with such from the head of the North Carolina Research Institute !
Simply as I did not see a response coming from a creditable source.
However your last response I can very well live with and I very much thank you for such.
I responded: How would you feel about a drug company selling a pharmaceutical before they had done any research? The FDA doesn’t allow that. Why should there be a double standard?
And the idea that the product “obviously helps” may well be a false conclusion — the history of medicine is full of things that seemed to help but really didn’t. For instance, for centuries people believed that bloodletting “obviously helped,” until testing showed that it did more harm than good. Paul Ingraham has a good list on PainScience.com of other strange and obviously harmful or useless medical treatments that were once popular — obvious to anyone now, and probably to some skeptics at the time.
Act 4
Her agenda became more clear with her next e-mail:
Dear Hariette [I was intrigued that she managed to insert three spelling errors into my name at one fell swoop, dropping an r and adding both a t and an e.]
Well how many of the so called medicine is harmful and is still being used? And not removed from the marked. How much was used and created damaged children in Mothers’ wombs.
However everything that comes out of a large Pharmaceutical company seems to be ok in the eyes of everyone. To me everything that is natural does help, plants are very intelligent and all we need is in front us even growing at our doorstep, but the big “guy “ want the money so they change it around.. Remember the case in south’s Africa where farmers where able to grow their own medicine for aids then the big guys come along and want to sell the expensive version made by them, they also arranged to forbid framers to keep growing the natural version. Would you support such behaviour?
Dr Nieman has found that ASEA is less toxic than water, what type of medicine can make that statement! In addition the bovis amount was measured and is also is very high.
Just look at GMo food
Click on the video or the link to watch http://geneticroulettemovie.com
+ microwaves its harmful to us and the environment but still on the market, so how can I trust the so called testing institutes?
In addition I have three doctors that have tested the ASEA well for me… that’s why I am taking it. With a method you would not approve but the only one I do accept. Called applied Kinesiology and a computer that works on your meridians. I am using my body to tell me what is good for me or my cat, as they can be trusted.
In Russian hospitals they heal people from cancer with Grabovoi and Petrov methods, but would your institute approve.?
Look at the vaccine, your institutes allow stuff in vaccines that are very harmful to children e.g. vaccine grows on cancer cells and GMO cells. How will the children’s children who got the GMO vaccines look after their birth ? As you know there is also Mercury in the vaccine does your institute take it out? No ? Why? Cause they are too scared going against the big guys. As they have the money..
Look at the vaccine study about mercury … the first study said its harmful, the pharmaceutical company said to the guy: no not good do it again. He changed it w, but as still not good enough and the third one which said Mercury is actually good for children was published. That doc was promoted to a high job in Brussels. In similar cases where the docs don’t do what they are told, they have lost jobs…. So you want to tell me I can trust your testing methods ?
And bloodletting can be good, its depending on the problem you have and what type of person you are again, again you need to ask your body computer for what’s best to you. .
Medicine is every person responsibility. Do not just trust some test manipulated you also need to trust your body.
Please excuse my long email but I feel you are taking this matter from a single point only which often is manipulated by the big guys.
Blessings
Act 5
At this point I knew there was no chance of reaching her with science or reason. She is obviously a true believer in several areas of nonsense and misinformation. Our readers will readily recognize the many things wrong with her thinking, but I’ll highlight just a few:
    • Paranoia and conspiracy theories
    • Wrong facts (for instance, vaccines don’t contain mercury and are not grown on GMO cells, and the statements about AIDS in Africa are blatant lies).
    • The natural fallacy (“plants are intelligent”?!)
    • She completely fails to understand the need for scientific studies. My example of bloodletting went right over her head.
    • She doesn’t trust “your testing methods” yet she cites ASEA tests done by those methods as trustworthy.
    • Her “doctors” have tested her response to ASEA with applied kinesiology and a computer that works on your meridians!
    • She believes it is already established that ASEA works and that it is OK to market it before scientific testing. She expects the research to prove to the satisfaction of others that it works; she sees no need for research to ask if it works. She didn’t respond to my point about the double standard. Would she accept a prescription drug on the basis of the kind of evidence available for ASEA? I suspect not.
This time I didn’t answer her. I would have had to write a book-length answer to address all her errors adequately, and even then she would probably not be able to understand — or would not want to understand. Her worldview is just too different from mine.
Then she sent me an “FYI” e-mail with a link to an article claiming that microwave cooking is killing people. It isn’t. And even if it were, that would hardly be any support for the effectiveness of ASEA.
People who are gullible enough to fall for applied kinesiology and meridians and electrodiagnosis with biofeedback machines are not likely to listen to any arguments from science or reason. ASEA is salt water, but she wants to believe it is something more. She is an educated woman, with a diploma in engineering; but she is hopelessly ignorant about medicine and science. We can’t hope to give people like her a complete education in science and critical thinking; we are not writing for the handicapped: the “true believers” who lack critical thinking skills. I can only hope she will keep reading SBM and eventually start to question some of her beliefs. I am not optimistic.
Science-based medicine is chipping away at a mountain of ignorance, misinformation, and misunderstanding. Like Sisyphus, we laboriously push the boulder of science and reason up the hill only to see it roll right back down again. It’s a tough job, but someone has to do it.

Accused of Lying about ASEA: Not Guilty
Harriet Hall on March 11, 2014
Link
I wrote about ASEA in August, 2012. To quote the company’s website, “ASEA is trillions of stable, perfectly balanced Redox Signaling Molecules suspended in a pristine saline solution—the same molecules that exist in the cells of the human body.” Molecules that supposedly have all kinds of antioxidant benefits for health and for athletic performance through “redox signalling.” They claim it is “a mixture of 16 chemically recombined products of salt and water with completely new chemical properties.” But they never specify exactly which molecules those are, what they mean by balanced, or how they can determine that they remain stable. The product label only lists salt and water. If those 16 recombined molecules are really in the product, the FDA can and should act against them for false labeling.
An ASEA distributor (part of the company’s multi-level marketing cadre) recently wrote an e-mail, not to me, and not to the editors of SBM, but to an assistant editor, to demand that my article be taken down, or that at least the comments for that article be re-opened. Since the e-mail was not sent to me, and I don’t have the writer’s permission, I won’t name him or quote him directly but will paraphrase what he said. He said my article had prevented thousands of people from benefitting from the health effects of ASEA. Thousands? I don’t think I’m that influential; I only wish I were! Anyway, it has not been established that ASEA offers any health benefits. He complains that I don’t have any evidence that ASEA doesn’t work, and of course I don’t. The burden of proof is not on me to prove it doesn’t work, but on those making the claims to prove it does.
He says there is real scientific evidence showing that it does work. My article said there was nothing about ASEA listed in PubMed, and he countered that there are 102 mentions. I was skeptical, so I checked for myself. What I found left me rolling on the floor in paroxysms of laughter.
There are indeed 102 citations on PubMed when you search for “ASEA”:
    • 84 of them were listed because they were written by an author whose last name was Asea!
    • 2 were about alfalfa extracts
    • 1 about acoustics
    • 1 about nuclear power plants
    • 1 about percutaneous coronary intervention for heart attacks
    • 1 about the response of Bacillus subtilis to metal ion stress
    • 1 about radiotherapy for glioma
    • 1 about coronary angiograms
    • 1 about training surgeons
    • 1 about ceramics to repair skull bone defects in a rabbit
    • 1 about another kind of “ASEA”: Alkaline soluble Trypanosoma cruzi epimastigote antigen
    • 1 about balancing corporate power
    • 1 about industrial robots
    • 1 about the driver’s cab in the Rc5 engine
    • 1 about electromyography
    • 1 about industrial robots
    • 1 about an enzyme in the white bloods cells of cattle
    • 1 about back disorders
    • 0 (that’s ZERO) about the product ASEA or even with any remote connection to redox signaling
And the dates of these articles go back to the 1950’s. According to the company’s website, ASEA wasn’t invented until 6 years ago.
I am still flabbergasted. What was he thinking? Did he even bother looking to see what the articles were about, or did he simply stop reading after he located the number of citations? Did he think we would take his word for it without looking? Does he think the number of citations for a search word means anything about the efficacy of his product? Apparently he does, since he goes on to cite the 11,121 mentions of “redox signaling” on PubMed. So what? There are 20,292 citations for homeopathy. There are 1,665,853 citations for “bacteria;” perhaps he imagines that citing those numbers would be sufficient to prove that any new antibiotic was effective.
One controlled human study
The company website brags about a 2012 study done in the Appalachian State Human Performance Laboratory in North Carolina. The e-mail writer emphasizes that the laboratory and the researchers were reputable, and that the company agreed to publish the results of the tests regardless of whether the findings were favorable. I don’t question any of that. I do question the results and significance.
It was a double blind crossover study of 20 cyclists. Athletes drank either 4 oz of ASEA or a placebo daily for a week. They measured VO2Max, body composition, and 43 metabolites before and after strenuous exercise. Compared to those on placebo, the group taking ASEA had higher levels of myristic acid, palmitic acid, oleic acid, stearic acid, palmitelaidic acid, capric acid, glycerol, lower levels of 7 amino acids, higher levels of fumarate, citrate, and malate, lower levels of ascorbic acid, fructose and threonic acid, and increases in aminomalonic acid, serum creatinine and urea. These are all reported as “least square mean area” (why?) and no measure of significance is provided (why not?).
They found that ASEA did not cause any changes in creatinine, BUN, bilirubin, alkaline phosphatase, AST and ALT; these are reported in mg/dl and “treatment x time p-values” are provided, ranging from 0.7717 to 0.9971. You will notice that creatinine is listed as both higher and as unchanged: it was higher by least square mean area but not by mg/dl.
The study was not published except in the form of slides and videos on the company website. I don’t know whether it was ever even submitted to a peer-reviewed journal for publication; but if it was, I think any reviewer worth his salt would have sent it back for significant revision. They said they knew they could not publish without first analyzing ASEA to see what was in it, and they said their analysis found “signaling molecules,” one of which was a superoxide. They don’t tell us which superoxide or what the other molecules were. I doubt if that would be enough to satisfy any journal editor. At any rate, before we can say anything about such a study it must be published so other experts can review it and offer comments and criticisms and can attempt to replicate the study if they are interested; that’s how science works. The information that they provide online is insufficient to judge the quality of the study. They don’t describe their methods in the detail expected for a published study, and we don’t know whether subjects could distinguish ASEA from placebo by taste, or what their previous experience and beliefs about ASEA were.
What does it mean?
What does all that data mean? I have no idea. The researchers themselves professed to be completely surprised by their results, which they did not expect from what they knew about the effects of the redox signaling molecules that they presumed were in the product. But of course that didn’t stop them from speculating about ASEA’s mechanism of action and its possible clinical benefits. When a study gives such unexpected results, it is prudent to question whether they might be spurious. There are any number of things that can go wrong in a study to generate false findings.
We need to hear from experts in the field who can comment on what these results might mean and whether the study methodology and statistical analyses were appropriate. This was an unpublished, small, preliminary “pilot” study; this kind of study is all too often followed by larger, better studies that reverse the findings. Studies like this are not sufficient to guide clinical practice; all we can do at this point is to suspend judgment and wait for further evidence. Customers who rely on this evidence might want to ask themselves whether they would want to take a prescription drug if the evidence from human trials consisted of a single trial with 20 patients.
I would want to ask those experts about some additional things. They found elevated levels of free fatty acids (FFAs). Is this a good thing? FFAs are elevated in obesity; they cause insulin resistance and may play a role in coronary atherosclerosis. Elevated levels suppress muscle glucose transport, leading to reduced muscle glycogen synthesis and glycolysis. Lowering FFAs should help treat obesity and type 2 diabetes. If this effect of ASEA is real, wouldn’t it be possibly harmful? How accurate are the measurements? I found one comment that “It is very easy to generate FFAs artefactually by faulty storage or extraction.”
Patents
My critic says they have “a boatload” of patents. I guess so, if you define a boatload as 4 (maybe it’s a small boat); but the existence of a patent says nothing about whether the product is effective. The company tells us that the foundational technology for ASEA is completely protected by US patents 5,507,932; 5,674,537; 6,007,686; and 6,117,285. It’s easy enough to look them up by number in the patent database. I did, and I found nothing about ASEA or about generating redox signaling molecules.
    • 5,507,932 This patent is for an apparatus for electrolyzing fluids, to produce disinfecting agents such as chlorine and ozone.
    • 5,674,537 Electrolyzed saline solution containing concentrated amounts of ozone and chlorine species for in vitro treatment of microbial infections.
    • 6,007,686 An apparatus for electrolyzing fluids to disinfect blood, dental drills, and other materials.
    • 6,117,285 A system for carrying out sterilization of equipment.
These patents say nothing about ASEA or about a unique proprietary method of producing redox signaling molecules. They simply show that the company has patents on a method of electrolysis that offers some advantages for the production of chlorine and ozone. Whoa! Those substances are toxic. There is no evidence to support their claims that the molecules in ASEA are the same ones as in the human body, that they have been somehow stabilized in solution (this would be very hard to do, since they are very reactive molecules), that the “clusters” described on their website exist, that the solution is “balanced” in any sense except in the trivial one that electrolysis necessarily produces equal numbers of positive and negative ions, that it produces “16 chemically recombined products of salt and water with completely new chemical properties,” or that it has any health benefits for humans.
Safety data
They claim that ASEA is “Safer than water” (?!) but they have no evidence to support that claim. They list the safety studies here. They are studies in cell culture of hamster ovary cells, bacterial cells, rabbits, several beagle dogs, and some mice. They have not studied safety in humans. If, as I suspect, ASEA amounts to nothing but salt water, adverse effects would not be expected unless large quantities were ingested. Again, I would ask customers if they would be willing to take a prescription drug that had not been shown toxic to animals but that had never been tested for safety in humans.
An analogy
This study attempted to show that there must be therapeutic molecules in ASEA because it “did something” to 43 metabolites. It reminded me of a study for Vitamin O. The product supposedly contained oxygen, but independent laboratory analysis found no oxygen in it. The company argued that there was so much oxygen in it that it didn’t register on the machines! So they did an experiment to show that there must be oxygen in vitamin O because vitamin O raised the abnormally low blood oxygen pressure (PaO2) of anemic patients (even though PaO2 is not abnormally low in anemia). The study was perhaps the most flawed one I have ever read. They got results that were not only “surprising” but impossible, given what we know about physiology.
More criticism
The e-mail writer goes on to use the fallacious argument from popularity (lots of happy customers) with no understanding of how people might come to believe an ineffective product is helping them. Apparently he doesn’t realize that water scams and quack remedies all have plenty of testimonials from grateful customers. He accuses SBM of being in the business of publishing lies, and he suggests we are doing it for the money (!?), which is pretty ironic given that he is the one selling ASEA to make money and SBM writers are not paid.
Conclusion
Did I lie? I don’t think so. I may have been guilty of a mis-statement in saying there were “no” placebo-controlled studies; but there certainly were no published placebo-controlled studies, which, for the purpose of scientific evidence, amounts to the same thing. I still have no reason to think ASEA is anything more than expensive water.
Now that I have written a new article, my critic and his fellow ASEA distributors and their customers are welcome to join in the comments. They may want to further demonstrate the level of ignorance that led him to cite the irrelevant 102 PubMed articles. I didn’t particularly want to write about ASEA again, but that was just too delicious not to share. I’m still laughing about it! It’s almost enough to make me wonder if ASEA causes brain damage…

ASEA, ORMUS, and Alchemy
Harriet Hall on July 28, 2015
Link


I got an e-mail from a woman who had read my article on ASEA, a multilevel marketing diet supplement that I characterized as an expensive way to buy water. She had not tried ASEA products but was applying for a position as an accountant with the company, and she chastised me for not doing my due diligence and researching the new science of ORMUS.
First she dismissed science, saying “science as we know it is no longer valid and quantum physics clearly shows this.” Then she claimed there was valid science that would support ASEA’s claims. She had personally done a sea salt cleanse with good results. If ASEA is only salt water, that doesn’t negate its validity, since ORMUS material is from sea salt and when minerals are rearranged they no longer register as the original element. Alchemy is not a myth, and the “quantum non-mainstream sciences” prove it is real. Quantum physics “explains that particles can interact without actually being on contact, this is a form or property of superconductivity.” She thinks ORMUS material is superconductive and constitutes a percentage of the human brain mass, allowing transmission of thoughts to others who tune in to these superconductive energy transmissions.
But wait, there’s more! She went on to tell me about an experiment where a dog’s entire blood volume was replaced by seawater. She shared her belief that the power of the mind can heal all disease, and she explained that she relies on a natural knowing within herself and only uses outside evidence to confirm her beliefs. She has been studying subjects like sacred geometry, Vedic mathematics, the golden ratio, quantum physics, and extraterrestrials.
Orbitally Rearranged Monoatomic Elements
This woman is obviously misguided and misinformed, but what is this ORMUS she’s talking about? I’d never heard of it, so I started with Rational Wiki:
ORMUS, also called ORMEs (Orbitally Rearranged Monoatomic Elements) and m-state materials, is a fictitious group of substances exhibiting many miraculous properties, such as healing powers and superconductivity at room temperature. They were supposedly discovered in 1975 by David Hudson, a cotton farmer from Arizona.
They are precious materials like gold and platinum in an exotic state of matter where they exist as single atoms. They are life-giving elements found in all living beings, and they can supposedly:
    • Cure all forms of disease, including cancer and AIDS
    • Correct errors in the DNA
    • Act as a superconductor
    • Emit gamma radiation
    • Partially levitate in the Earth’s magnetic field
    • Read a person’s mind
    • Have a “weigh-ability” different from mass, which probably means an inertial mass different from the gravitational mass
    • Be fused into a transparent glass
    • Act as a flash powder, causing “explosions of light”
    • Make severed cat tails grow back
The “discovery” of ORMUS
The notoriously unreliable Natural News website explains how ORMUS was discovered:
[An Arizona farmer named David Hudson] discovered some material in his soil that he had never seen before. He laid it out to dry in the hot Arizona sun so he could have it analyzed. What happened next was absolutely remarkable: the stuff exploded in a big flash of light and disappeared! But when he dried it without the use of sunlight it didn’t disappear.
A professor at Cornell analyzed it and found gold, silver, iron, and aluminum. These did not dissolve in acids as they should have, and after removal of the elements a staggering 98% of the material was left. Further analysis by a German expert who built special machinery and by a specialist at the University of Iowa revealed that:
    • It contained various precious metals
    • With heat treatment, precious elements were absent up to 69 seconds but appeared after 70 seconds
    • It changed into a white powder or glass depending on temperature
    • Elements spontaneously disappeared or morphed into other elements
    • It changed weight when exposed to air
He patented 12 elements that he called Orbitally Rearranged Monoatomic Elements or ORMEs, that exist both in a material and an immaterial, energetic form, are superconductors, dissolve in sunlight, and are exempt from gravity. By dissecting animal brains he showed that they contained ORMUS. We can increase the ORMUS content of our brains by taking in food and water with a high ORMUS content.
ORMUS conspiracy theories
The author of the Natural News article goes on to make conspiracy claims. ORMUS makes us more spiritual and corrects our DNA. The ancient Egyptians knew about it, but today knowledge is suppressed by dark and powerful sources that are trying to prevent our true evolution to a higher consciousness. Diseases are both caused and treated with war chemistry; chemotherapy is nothing more than a variation of mustard gas. GMOs make plants sick. In the slaughterhouse, animals are skinned alive.
ORMUS-based medicine
He recommends that we expose ourselves to as much ORMUS as possible by:
    • Growing food with diluted ocean water or sea salt
    • Taking supplements like Mountain Manna or Liquid Chi [You can look these up. The first is homeopathic, and both claim to have miraculous health results.]
    • Eating natural products grown with love
    • Gazing into the sun with eyes closed and palms outstretched
    • Breathing in as much forest air and sea air as possible
He says ORMUS is life energy, and we need it to counterbalance
the death energy we are exposed to daily through our food, our drinking water, our ‘medicines’, electromagnetic fields and radioactivity due to the use of depleted uranium by a flourishing war industry. This negative energy keeps us sick and dumb.
Many amazing claims are made for health benefits of ORMUS. Here are just a few:
    • Enhanced immune system functioning
    • Increased rate of healing
    • Slowing and reversing the aging process
    • Boosting strength and athletic conditioning
    • Mood enhancing and antidepressant
    • Improved sleep
    • Heightened energy and awareness
    • Increases electrolytes
    • Improves vision
    • Increases absorption of nutrients
    • Maintains healthy blood sugar level
    • Promotes healthy cellular pH balance
Another website makes specific disease claims for AIDS, Alzheimer’s, cancer, diabetes, emphysema, heart disease, MS, and several others.
Citing Hal Putoff
The Natural News article says Hudson consulted “one of the pioneers of quantum physics, Hal Putoff.” Putoff’s PhD is in electrical engineering and he is a parapsychologist. His name will be instantly recognized by many in the skeptic community as half of the gullible Targ/Putoff team that was fooled by Uri Geller into believing he had psychic powers. Putoff was a Scientologist who reached the top OT VII level and claimed he had developed remote viewing abilities.
Hudson’s errors
Rational Wiki says most of the time Hudson is “babbling incoherently and not even wrong or teaching a disfigured version of high school chemistry.” They provide a non-exhaustive list of his errors, showing his misunderstanding and distortion of basic chemical and physical principles.
The research
There is a lot of metaphysical mumbo-jumbo about ORMUS on the Internet, including claims that it is the philosopher’s stone long sought by alchemists, that it is the secret alchemy of Mary Magdalene, that the word Ormus was originally another name for the Zoroastrian deity Ahura Mazda. There are even instructions for making your own ORMUS at home.
But there is some scientific research. Here’s a list of scientific papers about ORMUS. In my opinion they don’t even begin to support the claims that have been made.
The dog experiments
Rene Quinton did experiments on abandoned dogs in 1897. In one experiment he completely removed a dog’s blood and replaced it with diluted seawater. The dog developed an infection and fever, but recovered and by the eighth day had become exaggeratedly exuberant and ran about wildly. Five years later the dog was still alive and well.
Based on this experiment, some people have suggested sea water could be used as a substitute for blood transfusions, which would be a great boon for Jehovah’s Witnesses if it worked.
Frankly, I don’t believe the story. There is a huge body of established scientific knowledge that would have to be overthrown before we could accept that an animal’s entire blood volume could be replaced with saline without resulting in death. Extraordinary claims require extraordinary evidence, and this century-old report doesn’t even meet the standards of ordinary peer-reviewed published evidence.
A tribute to the unlimited inventiveness of the human imagination
You are probably rolling on the floor laughing at this point. Indeed, there is an entry for David Hudson in the Encyclopedia of American Loons that describes the ORMUS people as belonging to the more extreme fringes of the lunacy movement. It says they serve as an illustration of how far into idiot land it is possible to fall without being committed to an institution.
ORMUS is a tribute to the unlimited inventiveness of the human imagination and the human capacity for self-deception, and it is great as humorous entertainment, but there is no reason to think it has anything to do with reality or science. If the claims were true, it would be Nobel Prize-worthy. Science doesn’t recognize ORMUS, and it won’t unless the proponents can come up with credible evidence. I’m not holding my breath.

ASEA – Still Selling Snake Oil
ASEAs marketing practices, in my opinion, are clearly deceptive. They use a lot of pseudoscientific claims representing the epitome of supplement industry misdirection and obfuscation. They use science as a marketing tool, not as a method for legitimately advancing our knowledge or answering questions about the efficacy of specific interventions.
Steven Novella on November 1, 2017
Link
We often examine the claims made by companies or individuals for their health products, especially those we feel are making dubious claims based on questionable science. In 2012 Harriet Hall wrote an excellent review of one multi-level marketing company, ASEA, who are basically selling salt water with a load of dubious pseudoscientific claims. ASEA is just about a perfect example of everything we try to warn consumers about when it comes to dubious supplements and the inadequacies of current regulations.
When we post such reviews it is not uncommon for the company to give us push back, and it is much more likely if that company sells through multi-level marketing (which is a scam unto itself). We recently received an e-mail from the “ASEA Team” who were not happy about Harriet’s review. They asked us to revisit our review (be careful what you wish for), concluding:
Bottom Line for our part:
The criticism of ASEA made by Mr. Hall [sic] is not constructive and Author’s points of view are not based on decent and verifiable facts. On the contrary, we have provided you with reliable information that is proven by the documentation. So, the article is misleading and deceives your website’s auditory and our potential and current customers. We are sure that after a deep consideration you will come to a conclusion and agree with us that it would be best to delete the article. Thank you.
Respectfully,
ASEA team.
After deep consideration, and re-review of the ASEA current website, I have come to the personal conclusion (and hope they will agree) that ASEA is selling quackery and nonsense with misleading claims designed to defraud both their customers and their sales agents (who often overlap). I suspect there is a combination of (financially) motivated reasoning and scientific illiteracy on their part, so I will explain again why I have come to this conclusion.
Let’s take their points in the ASEA team e-mail to SBM. They begin by objecting to Harriet’s (who they refer to as male throughout their letter) listing of the claims they were making on their website at the time:
ASEA allegedly:
    • Promotes enhanced immune function
    • Supports the vital activity of cellular communication
    • Provides superior “support” to athletes
    • Boosts efficiency of the body’s own antioxidants by 500%
    • Protects against free radical damage
Their “counterpoint”:
This information is out of date and does not correspond to reality, you can not even find these statements up on our website anymore. We have changed the formula, carefully tested it out and conducted several studies that proved that ASEA products have been shown to signal the activation of genetic pathways or affect genes that:
Improve immune system health;
Help maintain a healthy inflammatory response;
Help maintain cardiovascular health and support arterial elasticity;
Improve gut health and digestive enzyme production;
Modulate hormone balance to support vitality and wellness.
I see, they swapped out one list of dubious claims for a slightly tweaked list of dubious claims. “Promotes enhanced immune function” became “Improve immune system health.” And of course if you go to their website the old claims are still there, maybe not in the same location and jot list, but deeper in the copy or the linked “studies.” They are still claiming it improves cell signaling and increasing the body’s own anti-oxidants.
As a side point, we do not maintain and update every article. That is not standard or practical, nor is it expected, nor do we claim to. Articles are clearly dated, and it should be obvious they are only as current as the date they were posted. We will make corrections if they are pointed out to us or we discover them, and we use our own discretion in deciding whether or not to write an addendum or an updated article.
Their next point was so clueless it gave me the impression that we were dealing with low-level sales people who are not only scientifically illiterate, but had no backing from anyone with legal experience. In response to Harriet pointing out that ASEA is not making disease claims, because they can’t, they responded:
This statement doesn’t make any sense. As it was correctly noticed, we can’t legally and we actually don’t claim that ASEA is effective for any disease, so there is no point in writing more about this and even mentioning this. There is no information up on our website that says that ASEA would cure cancer or other diseases, however we do say that ASEA improves immune system health as well as has some other beneficial effects for a human being, and as we pinpointed that before, the effects have been verified by several laboratory tests. This statement made by Mr. Hall is far-fetched and offensive and shows that the Author tends to make things up and base his article on assumptions rather than on the facts.
Where do I begin? Here is the very salient point that Harriet was making, and that we make frequently on SBM. The current US regulations allow companies to make “structure-function” claims for their “supplements” without FDA oversight. Products with disease claims are, by definition, drugs and subject to FDA regulation. So what do many supplement companies do? They make structure-function claims that sound as if they may be beneficial for health, and combine those legally allowed claims with other statements about diseases, hoping their potential customers will connect the dots. They are skirting the spirit of the law in order to imply, without directly making, unsupported health claims.
On ASEA’s website they make the following claims:
    • Decline of cell signaling causes cellular breakdown, which in turn causes a long list of common diseases including autoimmune and cardiovascular disease.
    • ASEA improves cell-signaling which decreases cellular breakdown.
    • Here is some (not peer-reviewed) science showing that ASEA alters markers which we will choose to interpret as “improving” some aspect of cell signaling or function.
So they do not directly say that ASEA cures any disease, because they know that it is not legal under current regulation, but they do imply that it does through the above chain of claims. That is standard procedure in the dubious corners of the supplement industry (i.e. most of the supplement industry).
Let’s get to the scientific studies they use to support their claims. In response to Harriet’s review they wrote:
The studies that Mr. Hall is referring to are old and no longer available on the ASEA website. Instead, we have conducted other studies that proved the effect of the ASEA products as well as their safety.
So, were those previous studies not valid? Science is cumulative. We don’t just scrub “old” studies from the record and replace them with new studies. In my opinion that reveals the marketing mentality of the “ASEA team”. Studies are not used to determine if their product works, but to support their marketing claims that it does work.
As Harriet pointed out, their studies are not being performed by academic scientists and published in peer-reviewed journals. They are being outsourced to third party research companies for hire. There is no paper-trail of research that would lead an honest scientist to the conclusions that ASEA is now selling. They appear to have started with their product and are backfilling in essentially worthless studies (as far as clinical claims go) to support their marketing.
Perhaps the biggest problem with ASEA’s “research” is that they don’t actually address their implied clinical claims. In other words – there are no studies that directly show that ASEA will improve your health – let alone multiple independently replicated rigorous studies published in peer-reviewed journals.
Their current marketing focuses heavily on the claim that ASEA increases natural antioxidants in the body. Antioxidants are currently very popular, having been given a health halo by two decades of heavy marketing. However, the real science tells a different story. In their scientific summary they write:
Oxidative damage has been implicated in aging and agedependent diseases, including cardiovascular disease, cancer, neurodegenerative disorders, and other chronic conditions. If the generation of free radicals exceeds the protective effects of antioxidants and some co-factors, this can cause oxidative damage.
That is the simplistic story that the anti-oxidant industry is selling, but it is nonsense. Essentially they are assuming that increasing antioxidant activity (even assuming that ASEA does so, which I doubt) must be a good thing. This turns out to be a naive assumption. A homeostatic balance between oxygen free radicals and antioxidants evolved to optimality, unless adversely affected by a disease state such as a genetic mutation. There is no reason to think that artificially disrupting this natural homeostasis would be a good thing. In fact, the evidence has shown that actual antioxidants taken in large amounts are bad for your health. Our bodies use free radicals as part of the immune system, to kill invading cells, and as important signaling molecules. Blocking free radicals in a healthy person can actual cause harm.
The same is true of immune function, which naturally exists in a carefully-balanced state. ASEA marketing naively assumes that increasing any arbitrary marker of immune function equals “improving” immune function. If you have an auto-immune disease, increasing immune function would be a bad thing.
This is the core fallacy of the entire supplement industry, which assumes that you can “improve” the function of an evolved homeostatic system by simply pushing it in one direction. This often leads to contradictory claims, such as some supplements claiming to increase oxygen while others claim to be anti-oxidants.
Finally, Harriet appropriately asked what was in ASEA anyway. It appears to be just salt and water, and ASEA makes the pseudoscientific claim that the salt water molecules have been arranged somehow into these redox signaling molecules. They respond:
As for what the components are, this is a confidential information. We have spent a lot of time and resources coming up with the idea as well as setting it all in motion.
Sorry, but science requires transparency. You cannot pretend to be scientific and then simultaneously state that your core claim is a secret. This is especially true when that core claim makes no scientific sense. It is not an extrapolation of existing scientific research or established principles. In fact, their core claim sounds like utter nonsense, so simply saying that it is a secret does not inspire confidence.
Far from taking down Harriet’s original review of ASEA and their claims, her assessment deserves to be updated and amplified. ASEAs marketing practices, in my opinion, are clearly deceptive. They use a lot of pseudoscientific claims representing the epitome of supplement industry misdirection and obfuscation. They use science as a marketing tool, not as a method for legitimately advancing our knowledge or answering questions about the efficacy of specific interventions.
I am amused that they chose to e-mail us with their juvenile analysis and requests. That may suggest they are more naïve than calculating, but it really doesn’t matter. They are selling a product with health claims. They have the responsibility not to deceive their customers, and I do not feel as if they have met their burden for due diligence. They may have from a regulatory perspective, but only because current regulations are horrifically inadequate. But they certainly haven’t from a moral or scientific perspective.
        ◦ S

Protandim: Another Kind of Antioxidant
Harriet Hall on August 25, 2009
Link
Four years ago I received an e-mail inquiry about Protandim. I had never heard of it; but I looked it up and wrote a quick, informal, somewhat snarky answer that got posted on the Internet. It got a lot of attention. Googling for Protandim now brings up my critique right after the Protandim website itself: that can’t be good for sales. Over the years, several e-mails and blog comments have informed me that I was wrong (usually offering testimonials or calling me closed-minded), and recently I’ve been getting inquiries asking if I’ve changed my mind now that a clinical study has been published. I haven’t.
Instead of providing antioxidants directly, Protandim is supposed to stimulate the body to produce its own antioxidants. The website tells us it is “the only supplement clinically proven to reduce oxidative stress by 40%, slowing down the rate of cell aging to the level of a 20 year old.” It provides “thousands of times more antioxidant power than any food or conventional antioxidant supplement.” It signals the body’s genes to produce the enzymes SOD (superoxide dismutase) and CAT (catalase) that act as catalysts to neutralize free radicals and are not “used up” like ingested antioxidants are. It “creates a cascade of your body’s natural catalytic antioxidants that are able to destroy millions of free radicals per second.” It raises the level of glutathione by 300%. Glutathione is good, apparently.
What is Protandim? It’s a combination of Milk thistle, Bacopa extract, Ashwagandha, GreeLn tea extract, and Turmeric extract. I looked these up in the Natural Medicines Comprehensive Database. None of them is known to have any significant clinical benefit from antioxidant effects. Some of them are listed as “not enough information” to know if they are safe. One has estrogenic properties and more than one has known side effects and potential interactions with other drugs. The only one that even sounds remotely like it might have some pertinent data behind it is green tea. Green tea contains antioxidant catechins that are “thought to possibly have a protective effect against atherosclerosis and heart disease” and contains flavonoids that “might reduce lipoprotein oxidation; however benefits have not yet been described in humans.”
A Pubmed search for “Protandim” yielded only 3 studies: One in mice, one in cell cultures and one in humans. 
1. The mouse study. Protandim reduced the development of skin cancers in a mouse model.2. The cell culture study. Cells in cell culture produced more glutathione in the presence of Protandim. There was a synergistic effect of components in the induction of heme oxygenase-1.3. The human study. The only clinical study so far.
After 30 days of supplementation, TBARS declined by an average of 40% (p = 0.0001) and the age-dependent increase was eliminated. By 120 days, erythrocyte SOD increased by 30% (p < 0.01) and catalase by 54% (p < 0.002). We conclude that modest induction of the catalytic antioxidants SOD and catalase may be a much more effective approach than supplementation with antioxidants (such as vitamins C and E) that can, at best, stoichiometrically scavenge a very small fraction of total oxidant production.
The concept is intriguing, and it may have promise, but the current evidence is not sufficient to make clinical recommendations. There is only one study to date in humans, and it only measured markers in the blood. TBARS (thiobarbituric acid reactive substances) is a measurement that has not demonstrated clinical usefulness. I could only find one study suggesting that TBARS levels might be helpful in predicting outcome in patients who already have cardiovascular disease. This review article critiques TBARS and other measures of antioxidant activity and suggests that measuring isoprostanes might be more meaningful.
It’s all very well to show that a remedy changes blood test results or even a known marker for disease; but what we really need to know is whether it improves health, prevents cancer, prolongs life…We need POEMS: Patient Oriented Evidence that Matters. Avandia improves hemoglobin A1C levels in diabetics but increases mortality. Mortality matters a lot; Hgb A1C levels don’t matter so much. “The operation was a success but the patient died” is not good enough.
I went to Wikipedia not as a reliable source but because it often has links to more information from primary sources. For what it’s worth, the Wiki article on Protandim concurs with my assessment, stating “There is no acceptable evidence that it improves health.” Wiki links to a very useful “Protandim Watch” website that has gathered a lot of information in one place, including information about the company and its multilevel marketing. It is skeptical and recommends caution. Wikipedia also questions Protandim’s claim of life extension, listing several studies on animals suggesting that increasing production of those catalytic enzymes might not increase life span and possibly might shorten it.
From the Protandim Watch website I learned that a second patent was awarded to Protandim in 2008. In the patent application, they claimed that
The compositions of the present invention are useful to prevent or treat the following disorders and diseases: memory loss; Parkinson’s disease; aging; toxin-induced hepatotoxicity, inflammation; liver cirrhosis; chronic hepatitis; and diabetes due to cirrhosis; indigestion; fatigue; stress; cough; infertility; tissue inflammation; cancer; anxiety disorders; panic attacks; rheumatism; pain; manic depression; alcoholic paranoia; schizophrenia; fever; insomnia; infertility; aging; skin inflammations and disorders; alcoholism; anemia; carbuncles; convalescence; emaciation; HIV; AIDS; immune system problems; lumbago; multiple sclerosis; muscle energy loss; paralysis; swollen glands; ulcers; breathing difficulties; inflammation; psoriasis; cancer (e.g.; prostate cancer, lung cancer and breast cancer); pain; cardiovascular disease (e.g.; arteriosclerosis and atherosclerosis); ischemia/reperfusion injury; anxiety; attention deficit disorder; leprosy; arthritis (e.g., psoriatic arthritis; ankylosing spondylitis; and rheumatoid arthritis); hemorrhoids; tuberculosis; high blood pressure; congestive heart failure; venous insufficiency (pooling of blood in the veins; usually in the legs); sore throat; hepatitis; syphilis; stomach ulcers; epilepsy; diarrhea; asthma; burns; piles; sunburn; wrinkles; headache; insect bites; cuts; ulcers; sores; herpes; jaundice; bursitis; canker sores; sore gums; poison ivy; gastritis; high cholesterol; heart disease; bacterial infection; viral infection; acne; aging; immune disorders; dental caries; periodontitis; halitosis; dandruff; cardiovascular disease (e.g., hypertension; thrombosis; arteriosclerosis); migraine headaches; diabetes; elevated blood glucose; diseases of the alimentary canal and respiratory system; age-related physical and mental deterioration (e.g., Alzheimer’s Disease and age-related dementia); cardiovascular disease; cerebral vascular insufficiency and impaired cerebral performance; congestive symptoms of premenstrual syndrome; allergies; age-related vision loss; depression; Raynaud’s disease; peripheral vascular disease; intermittent claudication; vertigo; equilibrium disorder; prevention of altitude sickness; tinnitus (ringing in the ear); liver fibrosis; macular degeneration; asthma; graft rejection; and immune disorders that induce toxic shock; bronchpulmonary disease as cystic fibrosis; chronic bronchitis; gastritis; heart attack; angina pectoris; chronic obstructive pulmonary disease; kidney damage during coronary angiography; Unverricht-Lundborg disease; pseudoporphyria; pneumonia; and paracetamol hepatotoxicity.
Did they leave anything out?
Clearly, these claims can’t be substantiated, and they can’t legally list them on their website. LifeVantage Corporation’s website still states that it
does not market and sell Protandim® for the purposes of preventing, treating, curing, or mitigating any disease, including MS.
I guess we can assume they only market and sell it for the purposes of making money.
The second study listed above really intrigues me. They tested the individual components and apparently established that there was a marked synergism when the ingredients were combined. If this is true, it is unusual and deserves further investigation. In general, mixing natural medicines has produced additive but not synergistic effects, despite the claims of naturopaths that synergistic effects are common and are a basic principle of herbal medicine.
Some 20 studies in humans are said to be in progress. I’ll watch developments with great interest. Meanwhile, I can’t recommend taking Protandim. There has been a lot of hype about antioxidants. Most of the research indicates that eating fruits and vegetables is beneficial, but taking antioxidant supplements is either useless or counterproductive.
If you did want to raise your antioxidant levels, how could you rationally choose from all the products on the market? For instance, how about Seanol? – they say it has some of “the most powerful antioxidants on earth” and is responsible for the longevity of Okinawans.
I’m not buying.

Pursued by Protandim Proselytizers
Harriet Hall on October 11, 2011
Link
I’m fed up! In August 2009 I wrote about Protandim, pointing out that it’s not supported by good evidence. I thought I had made myself clear; but apparently I had only made myself a target. True believers have deluged the Internet with attacks on my article, calling it mere “opinion,” ignoring its main points, and denigrating me personally. I have ignored the Internet attacks, but I’m beginning to feel personally harassed: I have lost count of the e-mails I have received from Protandim enthusiasts trying to convince me that it works and that I should change my mind. I’ve spent hours trying to explain my reasoning in e-mails, and it’s becoming a repetitive chore, so I am writing this so that next time I get an e-mail inquiry I can simply forward this link.
What Is In It?
Protandim is a mixture of milk thistle, bacopa extract, ashwagandha, green tea extract, and turmeric extract (all of which, incidentally, can be purchased individually at much lower cost).
What Do They Claim It Does?
As described on Wikipedia:
The manufacturers of Protandim claim the product can indirectly increase antioxidant activity by up-regulating endogenous antioxidant factors such as the enzymes superoxide dismutase (SOD) and catalase, as well as the tripeptide glutathione, and by activation of theNrf2 pathway.
Nrf2 is a transcription factor that upregulates the expression of various genes that may regulate oxidative stress. Drugs to target that pathway might have benefits for diseases that are caused or exacerbated by oxidative stress. Such drugs are investigational at this point, but the makers of Protandim have skipped the investigational stage and are marketing a product that they think is effective for almost every ailment known to man and that they are promoting as an anti-aging supplement.
In the application for their second patent, awarded in 2008, they wrote:
The compositions of the present invention are useful to prevent or treat the following disorders and diseases: memory loss; Parkinson’s disease; aging; toxin-induced hepatotoxicity, inflammation; liver cirrhosis; chronic hepatitis; and diabetes due to cirrhosis; indigestion; fatigue; stress; cough; infertility; tissue inflammation; cancer; anxiety disorders; panic attacks; rheumatism; pain; manic depression; alcoholic paranoia; schizophrenia; fever; insomnia; infertility; aging; skin inflammations and disorders; alcoholism; anemia; carbuncles; convalescence; emaciation; HIV; AIDS; immune system problems; lumbago; multiple sclerosis; muscle energy loss; paralysis; swollen glands; ulcers; breathing difficulties; inflammation; psoriasis; cancer (e.g.; prostate cancer, lung cancer and breast cancer); pain; cardiovascular disease (e.g.; arteriosclerosis and atherosclerosis); ischemia/reperfusion injury; anxiety; attention deficit disorder; leprosy; arthritis (e.g., psoriatic arthritis; ankylosing spondylitis; and rheumatoid arthritis); hemorrhoids; tuberculosis; high blood pressure; congestive heart failure; venous insufficiency (pooling of blood in the veins; usually in the legs); sore throat; hepatitis; syphilis; stomach ulcers; epilepsy; diarrhea; asthma; burns; piles; sunburn; wrinkles; headache; insect bites; cuts; ulcers; sores; herpes; jaundice; bursitis; canker sores; sore gums; poison ivy; gastritis; high cholesterol; heart disease; bacterial infection; viral infection; acne; aging; immune disorders; dental caries; periodontitis; halitosis; dandruff; cardiovascular disease (e.g., hypertension; thrombosis; arteriosclerosis); migraine headaches; diabetes; elevated blood glucose; diseases of the alimentary canal and respiratory system; age-related physical and mental deterioration (e.g., Alzheimer’s Disease and age-related dementia); cardiovascular disease; cerebral vascular insufficiency and impaired cerebral performance; congestive symptoms of premenstrual syndrome; allergies; age-related vision loss; depression; Raynaud’s disease; peripheral vascular disease; intermittent claudication; vertigo; equilibrium disorder; prevention of altitude sickness; tinnitus (ringing in the ear); liver fibrosis; macular degeneration; asthma; graft rejection; and immune disorders that induce toxic shock; bronchpulmonary disease as cystic fibrosis; chronic bronchitis; gastritis; heart attack; angina pectoris; chronic obstructive pulmonary disease; kidney damage during coronary angiography; Unverricht-Lundborg disease; pseudoporphyria; pneumonia; and paracetamol hepatotoxicity.
Wow! Yet the website says it “does not market and sell Protandim® for the purposes of preventing, treating, curing, or mitigating any disease, including MS.”
So what purposes are we to think they do market and sell it for? Since oxidation is thought to be somehow involved in all the listed conditions, they are speculating that Protandim should prevent or treat those diseases by increasing the body’s production of antioxidants. They are promoting it for “anti-aging” because they are speculating that it will prevent or treat age-related diseases. They have no credible evidence to support their speculations.
An Update of Their Evidence
My original article only mentioned the 3 studies available at that time. As of this writing (October 2011), a query to PubMed brings up 8 published, peer-reviewed studies:
     1.  A human study showing changes in TBARS, SOD, and catalase.(2006)
     2.  A cell culture study showing increases in glutathione. (2009)
     3.  A mouse study showing an effect on skin tumor carcinogenesis. (2009)
     4.  A study in a mechanical animal model showing that chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. (2009)
     5.  Another mouse study showing that Protandim suppressed experimental carcinogenesis and suggesting that suppression of p53 and induction of MnSOD may play an important role.  (2010)
     6.  A study of muscular dystrophy mice showing that Protandim decreased plasma osteopontin and improved markers of oxidative stress. (2010)
     7.  An ex vivo (tissue culture) study of human saphenous veins, showing that Protandim attenuated intimal hyperplasia. (2011)
     8.  An evaluation of the role of manganese superoxide dismutase in decreasing tumor incidence in a two-stage skin carcinogenesis model in mice. (2011)
Note that there have been no human clinical studies since the one in 2006. The newer studies are just more animal and laboratory studies, so they do nothing to change my previous conclusion.  If I were a mouse being artificially induced to develop skin cancer in a lab study, I might seriously consider taking Protandim.  But so far, the only study in humans measured increased antioxidant levels by a blood test but did not even attempt to assess whether those increases corresponded to any measurable clinical benefit, for cancer or for anything else.
My Assessment of the Evidence
This sounds like a promising area of investigation, but many treatments look promising in animal and in vitro (test tube) studies in the lab and then fail to translate to any useful clinical applications in humans. Much has been said about the benefits of antioxidants, but giving antioxidants as supplements has generally resulted in no benefits and even sometimes in harm. Protandim is trying another approach: getting the body to produce more of its own antioxidants. Even if it does that, it still remains to be seen whether those higher levels will correspond to any meaningful clinical benefits. And the tests they are using for antioxidant levels may not mean what they would like to think they mean. Sometimes the same substance can show either anti-oxidant or pro-oxidant effects depending on which test is used. And adverse consequences haven’t been ruled out. Free radicals play important roles in human health: they are essential for killing bacteria, cell signaling, and other functions. Raising antioxidant levels might interfere with some of these essential functions. Human biochemistry is complex, and changing one factor often has unexpected effects elsewhere in the web.
Conclusion
We simply don’t know enough at this point to recommend Protandim for treatment or prevention of any disease, for anti-aging, for making people feel healthier or more energetic, or for anything else. We need good human studies showing that people who take Protandim have better clinical outcomes than people who don’t. For instance, fewer heart attacks or fewer cancers…not just higher levels on a TBARS test. What we need is POEMS: patient-oriented evidence that matters.
I Get Mail
I heard from doctors working with the company, from company employees, from distributors, from customers, from relatives of customers, and even from people who were none of the above. Most of my correspondents completely failed to understand what I meant by human studies with meaningful clinical outcomes. Some of them thought I was not aware of the published evidence. Some of them wanted to insult me and the whole medical profession. Some offered testimonials. One wanted to revise the Hippocratic Oath. Others wanted to inform me that Protandim had been awarded patents and that its shares were doing well on the stock market. Some were more coherent than others. Here’s a sampling (errors in the original):
    • My wife has stage 4 metastatic breast cancer, a friend was telling about a natural supplement called Protandim. I was thinking about buying it after he showed me a study from LSU that says is maybe helpful in fighting cancer. I just ran across your blog and you say it is a scam. I am wondering if you are familiar with the LSU study
    • Did LSU not just present evidence that TBAR reduction with Protandim led to a meaningful clinical outcome?.. Regarding glutathione’s potential efficacy: go to youtube and search Dr. David perlmutter. Check out the before and after videos of Parkinson’s patients being injected with glutathione… Protandim is unique in having extensive scientific validation published in our most well respected, peer reviewed journals..
    • How do you feel about Protandim now that it has a clinical study?
    • I was impressed that Dr Perlmutter and Dr Colker both endorse protandim. What about the recent peer reviews on Cancer and Heart disease as well as the one on Glutathione?
    • Purpose of the email is to entice, I hope, you into taking a closer look at Protandim… Publishing a negative opinion will impact these people and if you are wrong and Dr. McCord is correct, there are a number of people who will not benefit from what is considered by a growing number of scientists to be cutting edge science in ageing and disease prevention.  My opinion is that you would benefit from getting up to speed in this arena.
    • You quackbusted on a Protandim back in 2005.  I’m wondering if you still feel the same about Protandim and Dr Joe McCord now that it’s 5 years later???  I was just made aware of protandim and wanted to know more because everything I am seeing is pointing me in the direction of yes you should be taking the stuff!!
    • Obviously there are 2 sides to what is going on here and I’m quite disturbed with the medical community and the belief that it’s their way or the highway and that the human body isn’t capable of fixing itself as Gerson explains it!!  I have been on the Protandim for 3 weeks tomorrow just 1 supplement a day and I feel a difference in my knees and ankles with a little more kick when going up the stairs…I’m actually bouncing a lot better than I was 3 weeks ago…I’m still on a 12,000 ORAC Unit intake so nothing has changed except the protandim supplements…it appears I’m experiencing the same thing I am seeing/hearing from the others!!
    • you stille hold that opinion after the new studies ?How can you explain the fact that many universities fundind their own research ?Is dr Pearlmuter that endors protandim will risk his reputation if it is not the real deal
    • Protandim was up 10% yesterday on volume of 177,000.  Another step in the right direction.
    • (paraphrased) My friend’s lipid peroxidase levels rose; here’s his lab report to prove it.
    • proven by peer reviewed, published scientific research to reduce oxidative stress by an average of 40%, slowing down the cellular aging process to that of a 20 year-old!
    • I accept your views and beliefs for they are yours, and who am I to disagree?  I do have a couple points to voice which may offer some advice on confirming whether a product is legitimate or fake….I notice that you mentioned because something is not FDA approved that it must therefore be quackery.  Again, this is your belief, so ok…. Herbs have been used in medicines around the world, successfully, and for thousands of years…prior to Western medicine.  The FDA and many doctors here in the ‘West’ are unsure of these remedies and this causes fear.  Ego, a human trait, can also get in the way.  It’s just our nature.” (this was from someone who has yet to try the product but plans to do so soon)
    • that’s the problem with modern medicine.  they are challenged by something, so incredibly, that they would rather eliminate it than find perhaps a new direction for health and medicine.   Ego?  Fear?
    • btw, you know an underlying problem in medicine today?  the hippocratic oath.   “First, do no harm.”    The reason this needs to be improved is because that oath has the words:  ‘no’ and ‘harm’ in it.   Modern psychology today will confirm that our brains really only focus on the key words, rather than a ‘no’ or ‘dont’ that precedes a statement.
    • Harriet, have you ever challenged any modern medicine, Lipitor as an example? Or any so called modern medicine?
    • I am not against allopathic medicine, however, I feel that our bodies work better with organic natural medicine.
    •  while I share some of your concerns, I feel that the house is burning and something must be done for our poorly aging population.
    • Just wanted to make you aware that Protandim received its 4th patent.”Compositions for alleviating inflammation and oxidative stress in a mammal
    • I have tons of them [clinical studies] , I have MD ‘s by the tons getting involved . I have clients getting of MEDs , cholesterol , Bp’s. Insulin cut in half , sleep apnea gone, chronic fatigue gone. Should I listen to results and MD’s and Using Godly wisdom or your bashing and other people see a nutritionist’s opinion as important. Thanks any way ms. Hall”
    • “It more than establish’s things when people’s lives have been changed. I didn’t see your name on the winners of the Elliot Cresant award hince , Joe McCord . Last time I checked all my clients were humans . All of them have been on for 4 months or more so there is no placebo affect. Oh and I trust the holy spirit more than all the above things. Thanks
    •  I have read some of your older write-ups about Protandim… it seems many are dated 2005.  Surely by now you have changed your mind about Protandim. The proof it works is now everywhere. I have seen many benefits myself and my wife has finally got her sugar levels under control by doing nothing other than take Protandim.  I do not sell this nor own stock in the company but I try to get as many people on this as I can… because it works. Are you on board or are you still against Protandim?
One Skeptical Message
I did get one message (only one) that was skeptical about Protandim. It pointed out further problems with the research:
Both Protandim and Mona Vie site numerous peer reviewed, published studies that support their claims. Upon basic investigation you will see that all the peer review studies are lead by the same shareholder / researcher (One for Mona Vie and One for Protandim). Shouldn’t this obvious conflict be a red flag for the peers that are reviewing? In addition for Protandim products most of the papers were published in one journal of which that lead researcher is also an editor. The only other journal they were published in is Plos One which appears to be an open access online journal with a very high publish rate per submission (I read 98%).
A message to Protandim supporters
I am not “against” Protandim. I would be very pleased if it turns out to improve people’s health. I await clinical research with great interest. I would not take it myself or recommend it at this time because I have seen too many initially promising treatments turn out not to work or even to cause harm.  I understand why some people are enthusiastic about Protandim and want to take it now rather than wait for better evidence, and I have no objection to their taking it. I am not “quackbusting;” I am only asking for the same kind of evidence that the scientific community requires before it accepts any new treatment. Please try to understand what I mean by clinical studies with meaningful outcomes and contact me again when such studies are available… and not before.

Update on ASEA, Protandim, and dōTERRA
Multilevel marketing distributors of dietary supplements and essential oils point to studies that they think constitute evidence that their products work. They don’t understand why those studies are inadequate.
Harriet Hall on November 7, 2017
Link

I have written critiques of several dietary supplements sold through multilevel marketing (MLM) schemes, and they keep coming back to haunt me. I get testimonials from users who believe they have been cured of every ailment under the sun; and every time another study is done, I get e-mails from distributors who apparently think the new “evidence” will change my mind. Recently I received three more emails about ASEA, one about Protandim, and three about dōTERRA essential oils, asking me to reconsider. I thought this would be a good opportunity to explain why I have not changed my mind and to explain once again what constitutes evidence in science-based medicine.
ASEA
Recently an email from “The ASEA Team” asked us to delete the article I wrote about ASEA in 2012, based on their opinion that it “was not constructive” and “was not based on decent and verifiable facts.” They did not mention two other followup articles I wrote here and here. And they did not directly try to refute most of the points I made in my critique; I think they failed to understand what I was saying. They provided six attachments with studies they said were “made to prove the effectiveness of ASEA” but those studies didn’t prove any such thing.
Last week Steven Novella answered them very effectively, calling ASEA snake oil and pointing out the deceptive marketing practices of the company, the pseudoscientific nature of their claims, and the worthlessness of the studies they cite.
The claims
The ASEA website currently makes these claims:
As we age, and as stress and environmental toxins inundate our lives and weaken our defenses, normal cellular function declines, and with it, the body’s ability to produce and maintain a proper balance of redox signaling molecules. ASEA has developed the only technology that can create and stabilize active redox signaling molecules in a consumable form. No matter what your health concern may be, ASEA Redox Supplement can bring your cellular communication to optimal levels, improving the health of every system of your body.
Questions
This brings up several questions:
    • How exactly does normal cellular function decline? How would improved cellular communication reverse the decline?
    • What is a proper balance of redox signaling molecules? How do they know? How is it measured?
    • What active redox molecules are in the product? (They won’t tell us. The label just lists salt and water. In my opinion, if there are redox molecules in ASEA, listing only salt and water constitutes false labeling.)
    • What evidence do they have that the product improves health?
What redox molecules?
All they have is a statement from a lab, BioAgilytix, that indirectly measures “biomarkers” of redox levels in ASEA using a fluorescent indicator as a probe for unspecified highly reactive oxygen species. I don’t know what that means. There is no direct evidence that redox molecules are present. No other lab has analyzed the product.
Safety
Their claim that the product is safe is based on a brief description of two unpublished studies. In the first study, 106 overweight women took ASEA or placebo for 12 weeks; they reported no adverse effects, (None?! In most studies, even the placebo group typically reports some symptoms.) and there were no changes in liver or kidney function tests or complete blood counts. In the second study, an in vitro study of cultured eukaryotic cells, the cells “did not register a significant toxic response as measured by a visual assessment of green dye that indicated “nuclear translocation.” Based only on this flimsy subjective and in vitro evidence, they claimed “ASEA Redox Supplement, orally administered, does not manifest a toxic response or inflammation to exposed tissue.” Such thin gruel does not constitute convincing evidence that the safety of the product has been established.
Studies
Before I accept that a treatment works, I want to see human studies published in peer reviewed journals. There are none on their website, but I was able to locate two articles in the FASEB Journal here and here.
It quickly became obvious why these are not featured on the company website: they are not full articles, but abstracts from a meeting that were published in a supplement to the journal. One is a human study, the other is in mice (the poor mice were gavaged with ASEA and then run to exhaustion). One of my correspondents claimed that these are peer-reviewed studies, but peer review is not possible when all that is available is an abstract.
As far as I could determine, there have been three studies in humans. One, a small study of 17 cyclists, has been deleted from the web. It was not placebo-controlled. There is an abstract of a similar study of 20 cyclists that did use a placebo control and was double-blinded. It was essentially negative: ASEA did not improve time trial performance. They found that it caused a significant shift (good or bad?) in 43 metabolites, but had no apparent influence on traditional biomarkers of inflammation, oxidative stress, or immunity.
The third, most recent human study is the one my true believer correspondents are currently crowing about. They refer to it as a “genetic” study. One of them snarkily commented “It’s called science, u should look into it sometime.” I did look into it, and I was not impressed. The title is “Initial Gene Study Showed ASEA REDOX Affected Important Signaling Pathway Genes.” The company paid Tauret Labs to do the study. It has not been published in a peer-reviewed journal. It was an 8-week double-blind randomized placebo controlled study with 60 participants that measured changes in expression of 5 genes and found statistically significant changes of 20-31% with ASEA. They claim that “These genes are key in the health of the individual and play a vital role in five human health areas and dozens of pathways.” Maybe, but they have not demonstrated that human health benefits in any way from these changes in gene expression. Their summary of results states “Effects are non-specific to race, sex or age, and were observed in all populations tested.” This conclusion is not supported by their data. The only population tested was 60 individuals, 41% male, 92% Caucasian, average age 35 with age distribution not reported.
Conclusion
The evidence for their claims is indirect and inadequate. Half of all research studies turn out to be wrong. Changes in blood tests might be spurious; they have not been independently replicated. Changes may be statistically significant but not clinically significant. If they want us to believe ASEA causes objective, meaningful improvements in human health, they’ll have to do better. They’ll have to test directly for meaningful clinical outcomes. And if they want us to believe ASEA contains all those redox signaling molecules, they’ll have to prove it with a direct analysis by an independent lab and name those molecules.
As Steven Novella put it,
Asea, however, is still a fantastical and unbelievable claim supported by nothing but hype, sales copy, and empty promises. It is salt water. The hand-waving nonsense about redox reactions is incoherent technobabble – the very essence of pseudoscience. What would be convincing is published, peer-reviewed, independent, rigorous scientific studies with clear results. These don’t exist. No amount of distraction will change that fact.
Protandim
I have written about Protandim four times, here, here, here, and here.
What is it?
It is a mixture of five dietary supplements (Milk thistle, Bacopa extract, Ashwagandha, green tea extract, and turmeric extract) that allegedly stimulates the body to produce its own antioxidants. They claim it is “the only supplement clinically proven to reduce oxidative stress by 40%, slowing down the rate of cell aging to the level of a 20 year old [and they measured this how?].”
An email from a reader
You really need to up date your studies on this product! There are thousands of people with improved health because of PROTANDIM. For example, my son in law with high blood pressure was able to cut his BP medication in half after only two months on it and after three months, he is off meds completely with normal blood pressure; my daughter suffered for a year with a horrible rash under her arm that looked like tree bark. After several visits to her doctor where he prescribed cortisone and antibiotics nothing worked. She finally went to a dermatologist who was shocked to see that she had Granular Parakeratosis a rare skin disease. My daughters case was only the second time she has seen it, and at a follow up visit was told that there is no cure, only palliative care. Three days later the crud came off in her washcloth in the shower, and she had been on PROTANDIM for about two months. See photos. On the after picture you can see a round sore which is from the biopsy. In addition, my husband who has cOPD and had bypass surgery last year, and myself have great, new energy. In addition, my nerve damaged feet and numbness in my right foot have improved by at least 80 per cent after only 5 weeks! For the first time in 15 years or so, I can now feel my right big toe and it is no longer cold, like a piece of granite, and our bad backs have greatly improved. I could go on and on and I don’t need someone like you to tell me and thousands of others that it does not work! We are walking human studies for this amazing product! Check out the human studies for liver disease! I am proof it works so you should take another look: in fact go to You Tube PROTANDIM testimonials and see for yourself what this product does when it reduces oxidative stress!
My most recent article was in May 2017, and I’m not aware of any new studies requiring me to “update my studies” in the last six months. The evidence on the website is mainly about Nrf2 protein messengers in general, and studies of Protandim in cell culture (in vitro) and in mice. One 2006 human study found changes in lab tests such as TBARS but did not even attempt to look for any clinically meaningful improvement in health outcomes. A second human study in 2016 was negative: It concluded “Protandim® did not (1) alter 5-km running time, (2) lower TBARS at rest (3) raise antioxidant enzyme concentrations compared to placebo (with exception of SOD in those ≥ 35 years old) or, (4) affect quality of life compared to placebo.” And another study of patients with alcohol use disorders was also negative. Not only negative but laughable.
Conclusion
Increasing levels of antioxidants could be beneficial or harmful. The only way to know if Protandim improves human health is to do properly designed, placebo-controlled human studies looking for meaningful clinical outcomes.
dōTERRA essential oils
I have written about dōTERRA twice before: here and here.
An email asked me to “Check with Johns Hopkins and the research published about dōTERRA oils. Dr. Nicole Parrish claims that dōTERRA oils have killed three super bugs that synthetics cannot. It is published and the medical world is learning more about essential oils in September.” I asked her for links to that research; she never responded.
Another email chastised me for having a “complete scientific mindset.” (I thought that was a good thing!) She said, “It really is worth looking further into to help people stay healthy.” She provided all kinds of testimonials: her dentist and her real estate agent use it, her son and stepson carry the beadlets with them during allergy season, and when her husband got cancer, they used essential oils for diabetes, neuropathy, infections, and asthma. She also chastised me for not mentioning what the Bible says about oils and plants! She believes “science is here to prove God’s existence and the Bible can be used for medicinal research.” I didn’t try to answer her.
An in vitro study was done on dog kidney cells infected with influenza virus. Based on their results, they speculated that essential oils might be useful in treating humans with influenza (or might not). In my article critiquing that study, I provided some guidelines on how to read research studies that claim to support a product.
A third email said I needed to visit the website again and review the 17 studies published in peer-reviewed journals. I found an in vitro study of frankincense and an in vitro study of Deep Blue, a mixture of essential oils. There was also an extensive bibliography which included a lot of irrelevant articles along with in vitro and animal studies. There were a lot of scattershot preliminary studies on individual oils, but these were seldom if ever followed by replications or confirmations. My own PubMed search found a few studies supporting the use of an essential-oil-containing mouthrinse, reports of adverse effects of essential oils, some negative studies, and a couple of Cochrane reviews that pointed out the poor methodology of the few studies they found. A 2012 systematic review of aromatherapy concluded “the evidence is not sufficiently convincing that aromatherapy is an effective therapy for any condition.”
My correspondent said, “In my opinion, there are too many confirmed reports of improved health & well-being (when using essential oils) to chalk it all up to “hysteria” or “ignorance” or even chance.” Her opinion is misguided. The plural of anecdote is not data. Confirmed reports of improved health and well-being, no matter how numerous, are meaningless without a control group. Reports of failures are not systematically collected. Patients may improve for reasons other than the oils: suggestion, placebo effect, social factors, the natural course of the disease, regression to the mean, etc.
Essential oils can be very pleasant to use, and I have no problem with using them as “comfort” measures. And the company website is careful not to make any egregious disease-prevention or -treatment claims. But at their in-home presentations, the distributors feel free to claim that the oils can cure anything and everything, including cancer. These claims are not backed by any science but are illustrated by persuasive anecdotes, touching and heartwarming stories, testimonials from users that the attendees may know personally. Attendees are easily influenced to believe and to buy.
The published evidence for each of dōTERRA’s many products is sparse to nonexistent. There are clinical studies to support a few of the recommended uses, but they are generally poorly designed, uncontrolled, unreplicated, and unconvincing. Research is difficult, because patients can’t be blinded to the odors, and mental associations and relaxation could account for most of the observed effects. I remain skeptical of the claims for objective benefits in treating diseases.
Conclusion: No reason to change my mind
Testimonials are notoriously unreliable. These products are not supported by acceptable scientific evidence. I’m not saying they don’t work. No one knows whether they work or not, because they have not been properly tested. I am simply asking for a single standard of evidence, the kind of evidence required to achieve a scientific consensus that any treatment is effective and safe. If they want us to buy their products, they should test them against placebo controls in human studies looking for objective, meaningful improvements in health; and they should get those studies published in reputable peer reviewed journals. In the pharmaceutical industry, only a small percentage of promising candidates survive testing. Considering the huge number of dietary supplement products like these on the market, the chance that any one of them will prove to be truly effective is vanishingly small.

I Was Wrong about Protandim
A seriously flawed Protandim study seemed to show that side effects were no more common than with placebo. Actually, they were almost twice as common. The researchers were looking at the wrong numbers and didn’t even add correctly.
Harriet Hall on December 5, 2017
Link

I have written about Protandim several times. In May, 2017, I said that while there was no evidence from human studies that it improved meaningful clinical health outcomes, Protandim was probably safe to try. I based my opinion about its safety on a human trial in athletes. That trial was negative, but I relied on its report of signs/symptoms to conclude that side effects were not significantly more likely with Protandim than with placebo. That was unwise of me. A research scientist who wishes to remain anonymous recently emailed me to point out some serious flaws in that study. The authors fudged or carelessly miscalculated the data, which actually show that side effects are almost twice as common with Protandim as with placebo. And there were a number of other irregularities.
What is Protandim?
Protandim is a mixture of milk thistle, Bacopa extract, Ashwagandha, green tea extract, and turmeric extract. It is supposed to indirectly increase antioxidant activity. But there have now been three double-blind, randomized, placebo-controlled trials in humans, all showing that it did not increase antioxidant activity.
Why do people use it?
I don’t get it. Why are people taking a supplement that has been shown not to work? I guess it’s a matter of preferring hope to evidence. Apparently customers are willing to disregard the negative evidence from human trials and prefer to rely on animal studies, in vitro studies, and one non-randomized, non-controlled human trial carried out by the company in 2006 that found that TBARS (thiobarbituric acid-reacting substances) declined by 40% with Protandim. They are assuming that those findings are valid, although they have never been replicated. They are further assuming that decreased TBARS means they will enjoy better health, longer life, weight loss, less chronic disease, or some other unproven benefit. There is no evidence for any of that, and the company recently was warned by the FDA that it must stop suggesting that Protandim could prevent cancer, diabetes, cardiovascular disease, and Alzheimer’s disease. Numerous statements on the company website constituted misbranding.
Side effects
The company website says they don’t expect any side effects for the typical consumer, but some individuals may have natural allergic responses to one or more of the ingredients, manifested as stomach ache, diarrhea, vomiting, headache, or rash on the hands and feet. This does not describe a typical allergic response to a medication, which is manifested by hives, itching, generalized rashes not restricted to hands and feet, fever, swelling, wheezing, etc. The Natural Medicines Comprehensive Database reports non-allergic side effects, notably gastrointestinal, for each of the ingredients in Protandim. The only human study to look at side effects was the one I cited, and the company has no basis for its claim that any side effects are merely allergic responses.
The most recent human study “suggested that Protandim may enhance proteostatic mechanisms of skeletal muscle contractile proteins after 6 weeks of milk protein feeding in older adults.” It was a small study that only looked at lab tests and did not report any kind of clinical improvement and did not mention side effects at all.
Another concern is contamination. There has already been one recall due to metal contamination.
Data presentation and analysis were faulty
Table 4, from the study, is reproduced here with corrections. It is interesting in several respects:
    • Errors in addition:
        ◦ They listed 232 events in the Protandim group. There were 231.
        ◦ They listed 220 events in the placebo group. There were 209.
        ◦ They listed 453 total events; there were 440
    • Two signs/symptoms listed in the table (rash, low blood pressure) didn’t occur in either group. There is no reason for them to be listed.
    • The column on the right lists the total number of events in both groups. That information is meaningless.
    • Only one subject in the Protandim group experienced gas, but reported it a total of 51 times, which would tend to skew the results.
    • No patients in the placebo group reported vomiting, but 2 vomiting events are listed (!?)
    • The 19 patients in the Protandim group reported 40 signs and symptoms, nearly twice as many as the 19 patients in the placebo group (23). I would guess that is a statistically significant difference, but they made no attempt at statistical analysis and didn’t even mention the difference in their write-up.
    • There were roughly twice as many reports in the Protandim group for stomach ache (5 vs 2), diarrhea (5 vs 2), vomiting (2 vs 0), headache (6 vs 3), nausea (5 vs 2), dizziness (5 vs 2), and low blood sugar (2 vs 0).
    • There were many more events reported in the Protandim group for stomach ache (19 vs 2), headache (40 vs 12), constipation (17 vs 8), nausea (17 vs 7), dizziness (33 vs 5), itching (8 vs 0), joint pain (12 vs 6), and low blood sugar (18 vs 0).
    • There is no attempt at statistical analysis.
    • The total number of events is not as meaningful as the number of patients reporting side effects. This is not the way side effects are usually tabulated in research studies.
    • We could calculate averages from the data: 23 side effects were reported in the placebo group of 19 subjects, for an average of 1.2; 40 were reported in the Protandim group of 19 subjects, for an average of 2.1. But averages can obscure details. It would be more interesting to know how many side effects were reported by each individual. What if there was an outlier in the Protandim group who was a hypochondriac and who reported all 15 side effects? That would drastically skew the results. And it would be interesting to know if any side effects were reported by the principal investigator who was also a subject.
    • The numbers from such a small study (19 subjects in each group) are insufficient to determine the actual incidence of side effects attributable to Protandim, but it certainly suggests that they are more common than the company website indicates.
Other irregularities
    • Protocol violation. In the Funding Statement, the authors indicate that when the trial failed its primary endpoint, they included data from a post-hoc analysis on superoxide dismutase (SOD) that was not part of the original trial design and therefore was a protocol violation.
    • P-hacking. They analyzed SOD in a subset of male patients over the age of 35, which amounted to 8 subjects age 35-46. This is an example of p-hacking/fishing/cherry-picking at its worst.
    • The principal investigator was also a subject.
    • Safety signals were ignored. Basing an analysis of adverse events solely on a comparison of the total number of all events is unheard of. My correspondent said, “Imagine if a study used an analysis like that where the raw data showed a 10-fold higher rate of lymphoma vs placebo but it got washed out because of a higher rate of some trivial adverse event like constipation in the placebo group.”
    • The norm is to call attention to any adverse events that occur in the treatment group at a rate that exceeds a certain threshold (often as low as 10-15%) or exceeds that of the placebo group by a certain ratio (double for example). The authors failed to do that.
Conclusion: reason for concern
Is there a risk of side effects with Protandim? The only study that has attempted to answer that question was carelessly done, full of flaws, and can’t be trusted. I was wrong to opine that Protandim would probably be safe to try based on that one flawed study: we can’t really know that it is safe, and there is certainly reason to be concerned about possible adverse effects. Most of the reported events were not serious, but it’s always possible that a larger, longer study might find more serious problems. There are herbal remedies that were widely used for centuries before we realized they were killing people; Aristolochia is a prime example. And since Protandim is not known to have any clinical benefits, and has been shown not to even fulfill its stated purpose of increasing antioxidant levels, it would be hard to justify trying it.
I’m happy to admit it when I am wrong, because it means I have learned something. In this case, there were several lessons: don’t assume that tables are correct or that researchers know how to add, don’t assume that peer reviewers and editors will identify obvious errors.

Vital Stem: Affordable Stem Cell Treatments for Everyone? Anti-Aging Breakthrough?
Vital Stem is a dietary supplement mixture that supposedly reverses the changes of normal aging by increasing the body’s production of stem cells. We can’t know if it works, because it hasn’t been tested.
Harriet Hall on April 18, 2017
Link


Stem cell treatments are very promising. Bone marrow transplants are already widely used, and researchers are investigating stem cell treatments for a variety of conditions; but as yet there are few proven practical applications. I recently wrote about one stem cell treatment for age-related macular degeneration that stabilized the disease in a single patient and another that went awry and left three women blind (and see also David Weinberg’s discussion).
Enter Dr. Rand McClain. Forget about expensive surgeries and injections. Forget about finding and enrolling in clinical trials. He says you can boost your body’s own stem cell levels by taking his dietary supplement Vital Stem. He says it will improve cognitive function, enhance joint and muscle strength, increase longevity, and reverse the pesky changes of normal aging. He has testimonials. In a slick marketing video, he explains his remarkable new antiaging product. He says it takes old worn-out cells and replaces them with new ones, with astonishing results. He says thousands are already using this product to turn back the clock. He uses the product himself, and provides his own enthusiastic testimonial.
Who is Rand McClain?
When I hear about a new breakthrough in stem cell or anti-aging treatment (or, for that matter, any new medical breakthrough), one of my first questions is who is making the claim? Is he an expert in the field? Has he published clinical research? Is he a credible source of information?
Rand McClain is a DO who runs a Regenerative Medicine clinic in California. The video claims he is one of the world’s top physicians, featured on talk shows and in magazines. It says people wait months to get an appointment with him. His clients include top athletes and some of the richest people in America. Good for him. But that says nothing about his credibility as a source of scientific information.
He says he has studied the causes of aging for over a decade, not just in the lab, but with thousands of his patients (elsewhere in the video he says hundreds). According to his Bio, his research experience consists only of a two-year (2001-3) stint as a research assistant where his job was to “collect and maintain data” related to a potential treatment for osteoporosis. He gave two presentations at an Epilepsy Foundation Conference in 2002 related to epilepsy treatment: one on Traditional Chinese Medicine and one on exercise and nutrition. I searched PubMed and found no articles by McClain R or McClain RS on any subject relating to stem cells or aging.
I am not convinced that he is an expert we can trust to provide credible information about stem cells or anti-aging. But that doesn’t mean we can dismiss his claims.
What is he claiming?
McClain says “stem cell tourists” have to travel to other countries for “secret” expensive experimental stem cell treatments because stem cell research was banned in the US. (Demonstrably not true. Federal funding for embryonic stem cell research was banned, but not private funding, and not research on non-embryonic stem cells, which is thriving). He says people are being denied these treatments in the US; only millionaires can afford to go to other countries for treatment at some of the most expensive clinics in the world. So he developed an alternative: a product that he makes available at affordable cost to everyone. Recounting two success stories, he implies that the experimental stem cell injections and surgeries those patients got are established, effective treatments. They are not. Their effectiveness has not been established, and there are associated risks. He describes stem cell research for various conditions and vastly over-represents the results of what are actually just preliminary studies. He claims that “stem cells have already been used to heal thousands and thousands of people with serious illness.” That is true, but almost all of those were hematopoietic stem cell transplants to re-constitute bone marrow in patients with leukemia and multiple myeloma after the patient’s own bone marrow had been destroyed by radiation and chemotherapy. He claims that treatments involving adult stem cells are perfectly safe; they are clearly not. There are many examples of harm, including the three women who were recently left blind.
He describes how a cut on the skin heals: the injured cells are replaced by new, healthy cells. He says his product can increase healing processes ten times in all parts of the body (!?). But most of the people he treats are not even sick; they’re regular people in good health who want to optimize their health. Some are pro athletes.
He says drug companies are “terrified” by the prospect of competition. He admonishes viewers of his video to share the information quickly, because he is “told this video may soon be taken down by the major search engines [because] corporate lobbyists will do everything in their power to keep you from seeing it.” Really?
He says our body’s own stem cells circulate in the body and know to go to wherever they are needed to repair cells damaged by trauma, illness, or aging. That’s a combination of oversimplification and falsehood. Then he contradicts himself by quoting a researcher who says, “The ability to direct stem cells to differentiate into rare cell types means that potentially any cell type in the body can now be replaced.” Potentially. We don’t yet have that ability to direct.
He says the American lifestyle destroys stem cells. As supporting evidence, he cites a study about how toxins in cigarette smoke prevent stem cells from becoming cartilage.
He claims that a decrease in stem cells is one of the primary causes of aging. Maybe, but that’s far from established, and is not even mentioned in most discussions of aging. He tells us we begin life with between 6 and 7 trillion stem cells. The numbers decrease as we get older; he blames this on nutritional and lifestyle factors.
What’s in Vital Stem?
Vitamin D, 2000 IU (500% DV)
L-leucine
Blueberry fruit
Green tea leaf extract
L-carnosine
The amounts of the last four ingredients are not individually specified. They are in a proprietary blend that contains 1,400 mg total.
It comes as a powder: mix one scoop into a 12-oz. glass of water. Only 10 calories a serving. Use once daily. Container lasts 30 days. Money-back guarantee (less S&H). It will cost $89.95 when they have the volume to offer it in stores. Savings of $40 or more if you respond to the video in 24 hours and if supplies last. It could cost you as little as $2 a day. Buy more at once to get a better price.
Has Vital Stem been scientifically tested?
No. Neither Vital Stem nor the particular combination of five nutrients has been tested to see if it produces clinically significant effects.
There is some evidence for benefits from individual components of this mixture. For instance, a randomized controlled trial of L-carnosine in Gulf War Illness found an increase in IQ but not in other parameters. The evidence is preliminary and it has not been established that the benefit is related to an increase in stem cells.
There is some evidence that nutrients can increase the number of stem cells and can act synergistically. For instance, this study found that a combination of blueberry, green tea, catechin, carnosine, and vitamin D3 promoted proliferation of hematopoietic stem cells in vitro. Most of the supporting research is in mice and cell cultures; there is little evidence from clinical studies in humans.
McClain describes a study, presumably an unpublished study of his own patients, where a group of volunteers between the ages of 40 and 75 used Vital Stem for 6 months. After only 2 weeks,
93% said their bodies felt stronger.
73% had less joint pain.
80% had less muscle pain.
93% reported having more energy.
87% reported having more motivation.
87% were thinking more clearly.
67% said their memory had significantly improved.
93% had much less fatigue.
73% said their skin looked smoother.
87% said they wanted to exercise more.
93% said they felt Vital Stem would help them live healthier and longer.
This is not credible evidence. What’s wrong with it?
No control group! We don’t know whether they might have reported the same improvements after taking a sugar pill.
No objective results, only subjective reports from patients, the kind of reports that might be expected from patients experiencing a placebo response and motivated to please a charismatic doctor. It’s more like a collection of testimonials.
He doesn’t tell us how long these reported improvements lasted. It was a six-month study and he only describes the results at two weeks.
Methodology not described. Were the patients prompted by questions like “have you noticed more energy?”
Not published in a peer-reviewed journal where other researchers could critique it.
Conclusion: Questions remain
If you take Vital Stem, will you feel better? Probably. But then people who take placebos or use any charlatan’s snake oil are likely to feel better, especially if they believe they will work.
Does it work better than a sugar pill? We don’t know, and there is only one way to find out: test it against placebo in a blinded, randomized, controlled trial.
Does the product as formulated significantly increase the body’s production of stem cells? Again, we can’t know until it has been properly tested.
If it increases stem cell production, does that translate to clinically significant improvement in objective measures of health? Again, no way to know without testing.
Does it reverse the signs and symptoms of normal aging? Will it make you live longer? Maybe, but I will remain skeptical until I see some credible evidence.

Turpentine, the Fountain of Youth According to Dr. Jennifer Daniels
Jennifer Daniels says turpentine is the Fountain of Youth, able to cure many ailments, both real and imaginary. It isn’t; it’s a poison with no recognized benefits for human health.
Harriet Hall on November 14, 2017
Link


Turpentine is a solvent and a poison, but some people are drinking it as a medicine. Scott Gavura wrote about it 2 years ago and concluded, “There’s no reason to consume turpentine and multiple reasons to avoid it completely, with the primary reason being that it’s a poison.”
Scott’s article mentioned an MD who advocates turpentine to cure the fake illness chronic Candida, and who had been stripped of her license. That MD was Jennifer Daniels. It would be bad enough if she only recommended it for Candida, but she also claims to have discovered that turpentine is the Fountain of Youth, a miracle cure that reverses disease and aging and is good for pretty much whatever ails you. That’s ludicrous.
The facts
The Natural Medicines Comprehensive Database (which I consider to be the most reliable source) says, “There is insufficient reliable information” to evaluate its effectiveness for any medical use. It rates turpentine as “possibly safe” when used topically and appropriately, “possibly unsafe” when applied to large areas of skin, and “likely unsafe” when used orally for medicinal purposes; 2 ml/kg is toxic, and 120-180 ml is potentially lethal in adults.
The NMCD goes on to explain that turpentine is a central nervous system depressant, a pulmonary aspiration hazard, a skin irritant, and might cause abortions. It can have a decongestant effect when inhaled. Many adverse reactions are reported from ingestion, including headache, insomnia, coughing, vomiting, hematuria, albuminuria, urinary tract inflammation, coma, and death. Inhalation can cause inflammation and bronchial spasms. Applying it to the skin can lead to kidney and central nervous system damage.
A drug information website has an extensive monograph on turpentine. It says, “Turpentine has been used experimentally in a bath for the treatment of disseminated sclerosis and sexual dysfunction. It also has been studied for its antibacterial activity and inhibition of osteoclast activity. Turpentine is utilized in experimental models of inflammation to induce a systemic inflammatory immune response in animals.” It warns against using it during pregnancy and lactation, stresses that it is highly toxic (fatal poisonings have occurred with ingestion of as little as 15 mL, just 3 teaspoonsful) and has caused skin tumors in animals. It provides a bibliography with pertinent citations.
The discovery
Jennifer Daniels tells the story of her discovery in a radio interview. She asked her African-American patients if their slave ancestors had a miracle cure that cured everything and was cheap; several of them mentioned turpentine and sugar. So she tried it for herself. She put turpentine on 3 sugar cubes and washed them down. Right after ingesting it, she says:
I think my IQ went up like 50 points, I could just feel it, all this mental energy and understanding and clarity, just like when I was 10 years old, everything was very clear and focused. I said WOW what a feeling. I did some math problems, I said this is pretty good.
She had heard that turpentine could cause seizures, so she figured out the maximum safe dose by stopping at a dose where she felt a little twitch, “even softer than a twitch.” Then she gave it to her mother, who began to feel better in less than a minute (!). It relieved pains that her mother had had for 30 years. Other family members served as guinea pigs and appeared to benefit. So with no further ado, Daniels started using it on all her patients.
The published evidence she relies on
In that same interview, Daniels talks about a review article from France with 100 references that supposedly support the use of turpentine for parasites, cancer cells, pathogenic bacteria, fungus, yeast, rheumatism, MRSA, sciatica, nephritis, constipation, increasing membrane permeability, etc. It doesn’t say what she thinks it says.
Using turpentine: The treatment plan
First you have to hydrate. Then you have to have three bowel movements a day, which you can supposedly achieve by taking her Vitality Capsules, which (unlike everything else on earth) contain “no chemicals.” If you don’t have three bowel movements a day, the Candida can’t get out of your body and will “shift through your left hip to your right hip, your right hip to your stomach, and your stomach to your shoulder. It’s gonna play musical chairs all over your body.” Then you have to follow her diet instructions (organic, no GMOs, no “dead food,” and many more restrictions). Only then can you do the Candida Cleanse.
She says you must avoid steroids, antibiotics, and chemotherapy, because they prevent cell repair and yeast will move in to eat up the dead cells. She advises patients to stop all their medications if they can (potentially dangerous advice).
She says in the last days of her practice, she stopped using antibiotics. She would not admit seriously ill patients with pneumonia to the hospital, but would dose them with turpentine and send them home. She thinks children with high fevers will recover in less than 24 hours if given turpentine. When her daughter badly injured her ankle, she gave her a teaspoon of turpentine and ¼ cup of castor oil. “She drank it, she pooped, all the pain was gone.”
More strange and unsupported claims
    • “Liver time is 1-3 AM; lung time is 3-5 AM.”
    • “Vitality Capsules clean out the bile ducts and the gall bladder system as well as the small intestine, large intestine, and it also promotes circulation.”
    • Children should start getting turpentine in castor oil when they reach 30 pounds, to prevent Candida and parasites.
    • You should keep taking turpentine at least once a month for the rest of your life.
    • Turpentine improves eyesight; users were able to throw away their reading glasses.
    • “if I want thicker hair and less gray hair, then I’m gonna use minerals, small willow flower, and shou wu.”
    • Turpentine improves diabetes by healing the pancreas. It will allow Type I diabetics to lower their insulin dose.
    • It resolves tinnitus.
To her credit, she does get a few things right; for instance, she realizes that “rope worms” are not actually worms. On the other hand, she is anti-vaccine: “There is no vaccine or injection Dr. Daniels recommends.”
A spy troll is shocked
David McAfee infiltrated the closed 640-member Facebook group “Parasites cause all disease – turpentine cure” and was appalled at what he found. People were seeking support for the horrible side effects they were experiencing from turpentine. They were hoping to cure everything from scabies to herpes to “electromagnetic hypersensitivity.”
One woman who was using turpentine and castor oil complained that when she did enemas a lot of red liquid came out. Another list member told her not to worry because it was probably just old and damaged intestine wall coming out!
Some of the comments following McAfee’s exposé article were amusing:
    • “Sometimes you just roll your eyes, mutter darwinism to yourself and move on.”
    • “I’m a believer in alternative medicine-trust me, these people aren’t into alternative, they are idiots. Anyone with half a brain knows not to ingest a solvent. Dear god, where does this stupidity come from?”
    • “There is in my family a story about the medical use of turpentine. It dates from the time of my grand-father or great-grand-father. It was suggested as a topical treatment for hemorrhoids. It was not suggested in good faith. Folks could have a very crude sense of humor in those days too.”
What about science?
Daniels is a graduate of Harvard and of the University of Pennsylvania School of Medicine. Surely she learned about science at those prestigious Ivy League schools. One can only wonder how she came to disregard science and go her own way. She says she reads research studies but does not believe them: “I’m not much of a fan of research because every research project I’ve been involved with, I’ve been asked to falsify data.” That certainly is an unusual experience, and I can’t help but wonder if she reported the fraud/misconduct. She could have had a great career as a whistleblower.
Her words and actions show that she does not think like a scientist. Here are just a few revelations from her Confidential Underground Report: Top Secret; The Candida Cleanser.
    • She assumed the existence of some folk remedy that was a miracle cure that would cure everything. Considering all the many different causes of different illnesses, this is not a reasonable assumption.
    • She experimented on herself and assumed that the dose that seemed to work for her would work for everyone. If that were true, drug companies could dispense with phase 2 trials and just give the drug to one person.
    • She describes immediate results, too soon for a medication to be absorbed and have any effect; she doesn’t recognize that this is almost certainly a placebo response.
    • She doesn’t put her belief that turpentine is effective to any kind of test.
    • She wonders how long you could take it every day without experiencing side effects. So she takes it daily for a week, notices no adverse effects, and says “I decided that was long enough for the purposes of science.” Wow! Wouldn’t Big Pharma love to hear that all they needed to do to demonstrate the safety of their drugs to the FDA was to have one person take a drug for a week and say they hadn’t noticed any symptoms?
    • Without any further testing, she immediately moves on to treating other people with turpentine.
    • She makes all kinds of claims unsupported by any evidence, for instance:
        ◦ Breads, meats and dairy are all full of parasites.
        ◦ “Trail mix is an abomination and has destroyed the health of many a health nut.”
        ◦ “It has been my observation [emphasis added] that one should be having at least three bowel movements a day.”
        ◦ “There is no medication that turpentine interacts with.”
        ◦ “Censorship is so severe that it is difficult to find information on turpentine in print.”
    • She makes dangerous recommendations: laxatives and daily enemas, stopping prescription medications, avoiding immunizations, and many more.
No longer practicing, but…
On her website, it says “Dr. Daniels is a former medical doctor who had her medical license suspended due to not prescribing enough drugs and truly healing her patients.” I don’t believe that; no medical board has ever suspended a doctor’s license for healing their patients or for “not prescribing enough drugs.” According to the New York medical board website, she surrendered her license less than 6 years after it was granted. Apparently she was uncooperative, refusing to share her patient records with the board, and from her comments online it seems she was deliberately trying to hide her many questionable treatment methods from the authorities. By voluntarily surrendering her license, she avoided any further investigation or board actions.
No longer able to practice medicine, Daniels has moved to Panama, where she is making a living producing books, radio shows, CDs, and videos; selling supplements; and advising clients as a health coach. She is available for “Holistic Mentoring Consultations;” you can schedule a consultation online and will be able to speak to the doctor directly. What she is doing may not be illegal, but she is still in a position to harm people with bad advice.
Conclusion: not recommended
Not only is turpentine not the Fountain of Youth, it has not been proven effective for any health condition. Jennifer Daniels is not a reliable source of health information. She fails to understand the need for scientific testing, relies on testimonials and beliefs instead of facts, and demonstrates poor judgment. She makes claims that are bald assertions not supported by any evidence. She is offering dangerous advice, not just about turpentine but about vaccines and other things.

Elderberry (What is it good for)
Accumulated evidence does not demonstrate that elderberry has meaningful beneficial effects.
Scott Gavura on October 10, 2024
Link
Elderberry is a popular natural product and remedy used to treat viral infections like influenza (the flu), colds and in recent years, COVID-19. Touted for its immune-boosting properties, and seemingly available in every dosage form from syrups to gummies, elderberry has many enthusiasts, and the billion-dollar market is forecast to continue to grow. With cold and flu season (in the northern hemisphere) approaching quickly, I wanted to refresh my understanding of the evidence supporting this widely marketed remedy. New trials continue to be published – but are the compelling enough to warrant a recommendation?
Elderberry is the dark purple fruit of the European or Black elder, a deciduous tree native to Europe, but also found in North America. The tree produces both elderberries and elderflowers, used in food, beverages, and traditional medicine. Historically, elderberries have been used as folk remedies to treat colds and flu, but they are also used as a diuretic, laxative, and for “stimulating the immune system”. There are a number of potentially active ingredients in elderberry, so it is plausible that elderberry may have biological and medicinal effects. For this review, I focused on evidence for treatments of respiratory infections.
Elderberry extract may inhibit the replication of certain viruses, which fuels much of the marketing. Of course, inhibiting viral replication is not difficult to do in a test tube. Supportive trials published to date have had mixed results. Taking elderberry extract syrup (Sambucol)) 15 mL four times daily for 5 days may improve symptoms such as aches, cough, and nasal congestion about 4 days earlier than control groups, and reduce the need for additional medications. However, in a study involving children and adults aged 5 and older, including those with high-risk conditions, taking Sambucol for 5 days did not significantly shorten the time to complete symptom resolution compared to placebo.
A randomized, double-blind, placebo-controlled trial conducted from January 2018 to April 2019 and published in 2020 aimed to determine if elderberry extract reduces the duration and severity of influenza. The study included 87 patients aged 5 and older with confirmed influenza, who were treated with either elderberry extract or placebo for 5 days. Patients were permitted to choose to also receive oseltamivir (Tamiflu). The primary outcome was the number of days until symptoms were mild or none, and secondary outcomes included total symptom resolution. The results: no significant difference in symptom improvement between the elderberry and placebo groups, with elderberry showing no benefit in reducing flu duration or severity. In fact, post hoc analysis suggested that elderberry alone (i.e., without oseltamivir) may have prolonged symptoms compared to placebo by about two days.
In colds, a 2016 randomized, double-blind, placebo-controlled trial looked at air travel overseas using a standardized elderberry extract. While the number of cold episodes between the placebo and elderberry groups was similar between the two groups participants in the placebo group experienced significantly longer cold durations and more severe symptoms. The authors conclude that elderberry extract may reduce the duration and severity of colds during air travel. As this is a single trial and not replicated, it’s not terribly convincing.
There is no evidence to suggest that elderberry is effective against COVID-19 infections. The FDA and FTC and Federal Trade Commission have taken action against companies that marketed products with claims of effectiveness for COVID-19.
Safety Summary
Elderberry is rated by the Natural Database as likely safe when consumed orally, in amounts typically found in foods, and it holds Generally Recognized As Safe (GRAS) status in the US. It is considered possibly safe when elderberry fruit extract is used short-term. Specific products like Sambucol and BerryPharma have been used safely for up to 5 and 15 days, respectively, while ViraBLOC lozenges are safe for up to 2 days. Consuming unripe or uncooked elderberries, leaves, or stems is considered possibly unsafe due to cyanide-producing chemicals, which can cause serious toxicity. Cooking eliminates this toxin. In children, elderberry is likely safe in food amounts and possibly safe for up to 3 days, but unripe or uncooked elderberries should be avoided. During pregnancy and lactation, elderberry is likely safe in food amounts, but there is insufficient data to ensure its safety when used as a dietary supplement or medicinally. Larger doses should be avoided. There is also the ongoing concern about accuracy of supplement labels (and product contents) which increases the risk to the pregnant/breast feeding.
Don’t skip your flu or COVID-19 shot this fall
Very weak data suggest that elderberry may offer some benefit for colds and flu, but it’s also refuted with conflicting evidence that is more compelling. I don’t recommend elderberry, but it has a reasonable safety profile for most adults. If people really want to self-medicate with something, I warn them that it may not be helpful and there’s a suggestion it could actually be harmful.

Plavinol and Other Natural Remedies for Diabetes: “Condimentary Medicine”?
Harriet Hall on October 4, 2016
Link


We don’t yet have a cure for diabetes, but we have insulin; it controls the disease and allows Type 1 diabetics to lead a relatively normal life instead of suffering and quickly dying as they all did in the pre-insulin era. We know to counsel Type 2 diabetics about weight loss, diet, and exercise; and when those measures are not enough, we have prescription medications that work very well to control symptoms and help prevent complications.
For some people, that’s not good enough. They want to find “natural” remedies to supplement or replace conventional treatments. In a recent article on SBM, Scott Gavura quoted a pharmacy customer who said “I don’t want to take any drugs. Do you have something natural I can use to cut my blood sugar?” Scott went on to cover the questionable evidence for cinnamon in that article. Many other “natural” remedies have been proposed. Here’s an alphabetical list: acetyl L-carnitine, aloe, alpha-lipoic acid, banaba leaf (not banana!), basil, berberine, bilberry, biotin, bitter melon, cinnamon, chromium, coQ10, crepe myrtle, fenugreek, fish oil, fructo-oligosaccharides, green tea, ginseng, glucomannan, gymnema, hibiscus, Indian kino tree extract, magnesium, mistletoe, olive leaf, onion, psyllium, purslane, resveratrol, starch blockers, thiamine, vanadium, and vitamins. I compiled that list from just three websites; I’m sure there are many more natural remedies that I missed. These natural remedies have been recommended on the basis of rather shaky preliminary evidence that they lower blood sugar, usually by only a small amount. Even the CAM-friendly National Center for Complementary and Integrative Health (NCCIH) concluded:
There is not enough scientific evidence to suggest that any dietary supplements can help prevent or manage type 2 diabetes.
They also warn that “Some dietary supplements may have side effects, including interacting with your diabetes treatment or increasing your risk of kidney problems.”
Plavinol
Marketers are eager to sell these natural remedies to diabetics, and they often mix several ingredients together; but they never bother to test whether the product itself is effective. The latest candidate was advertised in my local newspaper (a reliable source of unreliable health claims). It’s called Plavinol.
From their website:
Plavinol is a breakthrough formula that works with your body to fight the effects of unhealthy blood sugar. With it’s [sic] active ingredient ‘Morus Alba’ along with 4 supporting nutrients, Plavinol is effective in promoting healthy insulin response and weight loss including:
    • Post meal blood sugar
    • Healthy weight
    • Improved A1C levels
    • Supports metabolism
The ingredients and daily doses are:
    • Mulberry leaf extract (1% deoxynojirimycin) 500 mg
    • Gymnema sylvestre leaf extract 400 mg
    • Ashgawandha root and leaf extract 250 mg
    • Banaba leaf extract (1% corosilic acid) 48 mg
    • Vanadium 100 mcg
A month’s supply costs $78.85.
Active ingredient: Morus alba (white mulberry)
There are a number of positive mouse studies of Morus alba alone or in combination with other herbal remedies. But mice are not people.
There has been little research on humans. One study used mulberry leaf extract with enriched 1-deoxynojirimycin (DNJ) content (approximately 1.5%, half again as much as in Plavinol). It was a two-part study. The first part was a double blind crossover trial in 12 subjects. It found that a single dose decreased the rise of blood sugar after a glucose challenge; but insulin levels did not change. The second part was a 12-week randomized controlled trial (RCT) of 76 subjects. 1,5‐anhydroglucitol levels increased gradually and were higher than controls at the 8 and 12 week points, but not earlier. There were no significant differences in fasting plasma glucose, insulin, hemoglobin A1C, or glycated albumin.
An uncontrolled human study from Romania in 1989 found that a mixture of Morus alba with two other herbs (not the ones in Plavinol) lowered blood sugar levels in 74 out of 82 patients.
The Natural Medicines Comprehensive Database (NMCD) which I consider the most reliable source of information about natural medicines, rated it as only “possibly safe” and “possibly effective” and noted that the studies failed to show a decrease in HbA1C, which is the most reliable measure of the effect on diabetes over a period of time.
The 4 “supporting nutrients”
The other ingredients in Plavinol are said to be “supporting nutrients,” but there is no evidence that they improve the effects of mulberry. And there is no explanation of the rationale by which they were chosen. The evidence for them is scanty.
Gymnema silvestre leaf extract: NMCD effectiveness rating: “Insufficient reliable evidence to rate.” Safety rating: “Possibly” safe.
Ashgawandha root and leaf extract: NMCD effectiveness rating: “Insufficient reliable evidence to rate.” Safety rating: “Possibly” safe.
Banaba leaf extract: NMCD effectiveness rating: “Insufficient reliable evidence to rate.” Safety rating: “Possibly” safe.
Vanadium: NMCD effectiveness rating: “Insufficient reliable evidence to rate.” Safety rating: “Likely safe.”
Studies of vanadium for diabetes typically used doses of 30-150 mg daily, orders of magnitude greater than the amount in Plavinol. Even at those higher doses, the evidence was unconvincing. A 2008 review concluded “There is no rigorous evidence that oral vanadium supplementation improves glycemic control in type 2 diabetes. The routine use of vanadium for this purpose cannot be recommended. A large-scale randomized controlled trial is needed to address this clinical question.” A 2016 review concluded “vanadium administration for the treatment of human diabetes is misplaced.”
Conclusion: Condimentary medicine?
As a Healthline article warns: “Supplements should not replace standard diabetes treatment…Some supplements have shown promise in animal studies. However, there is currently only limited evidence that they have the above mentioned benefits in humans.”
Richard Rawlins, an orthopedic surgeon in the UK, coined the term “condimentary medicine.” It “adds spice and flavor but has no actual effect on the course of treatment.” Until they have been properly tested against a placebo, we can’t really know whether products like Plavinol are mere condiments, or whether they are safe and effective additions to the therapeutic armamentarium for diabetes. 

Natural Remedies for Diabetes: Plavinol, Glucopure
There is not enough evidence to support using dietary supplements in the treatment of diabetes. There is preliminary evidence that some herbs lower blood sugar by a modest amount, but it would be foolish to think they could replace conventional treatment of diabetes.
Harriet Hall on February 14, 2017
Link


There is good news for diabetics; unfortunately, it is fake news based on “alternative facts.” I monitor my local newspaper, the Tacoma News Tribune, for health-related advertisements, and I have yet to find an advertised product or service that is supported by credible scientific evidence. Within the space of two weeks, they published half-page advertisements masquerading as news stories about two miraculous natural remedies for diabetes: Plavinol and Glucopure.
Plavinol
I have written about Plavinol before. Plavinol’s active ingredient is Morus alba (white mulberry). That ingredient is supported by mouse studies but not by human studies. A systematic review of clinical studies of Morus alba for diabetes found inconsistent results and concluded “Products derived from M. alba can effectively contribute [emphasis added] to the reduction in PPG [post-prandial glucose] levels, but large-scale RCTs would be informative.” Plavinol contains four additional “supporting nutrients” without any good rationale. The product itself has not been tested, so there is really no way to know whether it is safe and effective as marketed.
Glucopure
The new kid on the block is Glucopure. The headline reads “Diabetics in A Frenzy Over Newly-Released Blood Sugar Pill.”
It offers the usual sales pitches: a shortage is expected, get free bottles if you call right away, free shipping if you subscribe, and a double-your-money money-back guarantee (with a few strings attached).
The claims are impressive:
    • Key ingredient reduces blood sugar 25%, cholesterol 23% and A1c 2.2% in University Study.
    • Studies on other ingredients showed reduced sugar levels.
    • In one study, a key Glucopure ingredient was shown to work better than a major Big Pharma drug.
    • It can stop hunger pangs and lead to steady weight loss.
    • Must-have ingredients: Diabetes is a nutritional wasting disease, so elevated glucose causes substantial loss of minerals through the urine and this results in diabetic complications like nerve pain, high blood pressure, damage to eyes and kidneys, and insulin resistance. Glucopure replaces the lost minerals with essentials like Vitamins C and E, magnesium, and biotin. [Note: the only one of these that is a mineral is magnesium. And scientists do not recognize mineral loss as the cause of diabetic complications.]
    • It’s natural and prescription-free.
    • It destroys sugar and recreates pancreatic cells. [What? I don’t think so!]
    • Doctors are lining up for bulk supplies. [Why? Are they going to sell them to patients at a markup?]
    • Indisputable proof: in the 10-day test. 90% of people had “healthy blood sugar spikes” before (!?) and after meals, fewer cravings, weight loss, and more energy, all without changing their lifestyle.
What’s in it?
    • Glucopure Healthy Sugar Blend: Banaba, Guggul, Bitter Melon, Licorice Extract, Cinnamon Bark, Gymnema sylvestre.
    • Vitamin C
    • Vitamin E
    • Magnesium
    • Biotin
    • Zinc
    • Manganese
    • Chromium
    • Yarrow Flowers
    • Cayenne
    • Juniper Berries
    • White Mulberry Leaf
    • “Vandium” (perhaps vanadium?)
    • Alpha Lipoic Acid
    • L-taurine
Where is the evidence?
The company website offers testimonials, but its “Research” tab only says “Coming Soon.”
I don’t have the patience to look up the evidence behind each of Glucopure’s 20 ingredients. Several experts have already done that and more.
“A systematic review of herbs and dietary supplements for glycemic control in diabetes” published in Diabetes Care concluded:
There is still insufficient evidence to draw definitive conclusions about the efficacy of individual herbs and supplements for diabetes; however, they appear to be generally safe. The available data suggest that several supplements may warrant further study. The best evidence for efficacy from adequately designed randomized controlled trials (RCTs) is available for Coccinia indica and American ginseng. Chromium has been the most widely studied supplement. Other supplements with positive preliminary results include Gymnema sylvestre, Aloe vera, vanadium, Momordica charantia, and nopal.
Note that only 3 of these “best evidence” ingredients are included in Glucopure. Why not the rest? Why all the other stuff?
The American Diabetes Association warns about side effects and drug interactions.
An article onWebMD says “So far there is not enough research to support specific recommendations for diabetes and dietary supplements” and they warn that some supplements can hinder diabetic control.
Even the usually supplement-friendly NCCIH says:
There is not enough scientific evidence to suggest that any dietary supplements can help prevent or manage type 2 diabetes.
They describe the published evidence for several of the ingredients in Glucopure.
Does it work?
There is some evidence that some of the ingredients in Glucopure might lower blood sugar levels to a modest degree; but the evidence is preliminary, inconsistent, and far from compelling. There is no way to know if the combination of 20 ingredients in Glucopure is safe or effective, because neither the combination of ingredients nor the product as formulated has ever been tested.
Dangerous advice
They can’t legally advertise Glucopure as an effective treatment for diabetes, but they are strongly suggesting that it is. They make statements like these:
    • “This may signal the end of expensive prescriptions and daily injections for millions struggling with their blood sugar.”
    • “While diet and exercise are important, most sufferers tell you they would prefer healthy sugar and A1c levels without changing their daily routine.”
    • “All but eliminates the need for pricey drugs and injections.”
    • “Could be the nail in the coffin for low-carbohydrate diets.”
They may have skated past the legalities, but they are on thin ice; there is no question that they are misleading customers.
Diabetes is a serious disease with life-threatening complications. It can’t be cured but it can be treated effectively. While certain dietary supplements might help reduce blood sugar levels to a modest degree and could be considered as possible adjuncts to conventional treatment, it would be foolish to think they could replace diabetes drugs or insulin, or for that matter, diet and exercise.
Note: I am highlighting Plavinol and Glucopure only because their advertisements appeared in my local newspaper. There are many similar natural remedies for diabetes on the market. They all make similar claims and are similarly unsupported by evidence.

AllerVarx: A Questionable Remedy for Allergic Rhinitis
AllerVarx, a new dietary supplement, claims to relieve nasal allergy symptoms, but the only “evidence” is a single disreputable clinical trial with no control group. There is no reason to try this unproven remedy when there are so many effective remedies offered by mainstream medicine.
Harriet Hall on July 25, 2017
Link


A newspaper ad alerted me to a new dietary supplement, AllerVarx, a remedy for seasonal allergy symptoms. It describes AllerVarx as an all-natural, clinically proven blend of three ingredients: Perilla, Quercetin, and Vitamin D3. It promises instant relief, a 70% reduction in allergy symptoms, and no side effects.
The ad gave me déjà vu. I’ve seen the same kind of ad over and over, but usually for things like memory loss, urinary symptoms, diabetes, arthritis, weight loss, etc. This surprised me because it was the first I’d seen for seasonal allergies. One of the theories about why people turn to alternative medicine is that it fills an unmet need, treating conditions that mainstream medicine does not deal with satisfactorily. But mainstream medicine has a whole armamentarium of treatments for seasonal allergies that have been tested and proven effective. Is there any reason to prefer an alternative remedy?
The ad distorts the truth about conventional treatments
The ad claims that conventional treatments are problematic. It distorts the truth, saying the leading over-the-counter brands are “not an option.” Why?
    • Antihistamines make you drowsy. [This is a bit misleading. The newer antihistamines are much less likely to cause drowsiness, and most people tolerate them well.]
    • Decongestants have a “horrifying” effect on blood pressure, sending it “skyrocketing” and they can’t be taken every day or with most medications. [This is demonstrably wrong: the truth is that they only raise the systolic blood pressure by an average of 1.2 mm and most patients with high blood pressure can take decongestants.]
It fails to mention that there are other effective treatments, both prescription and over-the-counter. And nowhere does it compare the effectiveness of Allervarx to any other treatment.
According to a review article in American Family Physician, the first-line treatment for allergic rhinitis is a corticosteroid nasal spray. If this doesn’t control symptoms, second-line therapies are indicated: antihistamines, decongestants, cromolyn, leukotriene receptor antagonists, and nonpharmacological therapies such as nasal irrigation. Immunotherapy is also available for severe cases.
Their claims for the ingredients
Perilla “immediately blocks the release of histamines.”
Quercetin “makes sure that your histamines stay blocked: and delivers fast action!”
Vitamin D3 “acts as a natural anti-inflammatory and supports normal function of immune systems, improving that ‘blocked up’ feeling.”
Checking their claims on the Natural Medicines Comprehensive Database
The Natural Medicines Comprehensive Database is an independent source of information about natural medicines: it rates them for safety and effectiveness, includes all kinds of information, and provides references. I refer to it frequently and consider it the most reliable source of information about dietary supplements. Here’s what it has to say about the ingredients in AllerVarx:
Perilla: There is insufficient reliable evidence to rate its effectiveness; there is only preliminary evidence of a possible effect in allergic rhinitis. It gives Perilla a safety rating of “Possibly safe” and recommends against using it during pregnancy and lactation because of insufficient reliable evidence.
Quercetin: Rated as possibly effective for prostatitis. No rating of effectiveness for allergic rhinitis, but does mention that there is preliminary evidence that it might work similarly to cromolyn, inhibiting antigen-stimulated histamine release from mast cells of patients with allergic rhinitis. Rated as “possibly safe;” avoid using in pregnancy and lactation.
Vitamin D3: Does not rate effectiveness for allergic rhinitis because there is no evidence for that. Mentions that administering it during the first year of life could potentially increase the risk of allergic rhinitis later in life.
Clinically proven?
They refer to a clinical trial that showed the product reduced allergy symptoms by 70%. There is actually no clinical trial of AllerVarx; they are referring to a trial of the supplement Lertal, which appears to be the same product sold under a different brand name in Europe. It is the only study in humans. It was an open-label observational study with only 23 subjects. It compared patient-reported symptoms at baseline and one month, grading them by number of episodes per day:
    • 0=absence
    • 1= 1-5 episodes a day
    • 2= 6-10 episodes
    • 3 = 11 or more episodes
They found a 70% reduction in sneezing, rhinorrhea, nasal obstruction, ocular itching, lacrimation and congestion of the conjunctiva. And they found a 73% reduction of use of anti-allergic drugs.
This was a useless study, the kind of junk science that is designed to practically guarantee a positive result. There was no control group. The number of patients was small. Open label means the subjects knew they were taking AllerVarx, and presumably were led to expect it would reduce their symptoms. Subjective symptoms were reported using an awkward measure: “episodes per day” divided into 4 groups by frequency. No objective parameters were measured.
Checking their claims on PubMed
The company website lists 18 references, but they are all basic science and animal studies. The one whose title sounds possibly relevant is an incomplete reference that lists only the authors and title but gives no information about where the study can be found. One reference is a market report about allergy drug sales, and one is a patent! There has been only the one human study.
Pubmed lists a single systematic review of herbal medicines for allergic rhinitis that does not even mention perilla or quercetin.
Individual studies:
    • Perilla inhibits histamine release in vitro and in mouse models.
    • A study of the effect of perilla and rosmarinic acid on allergic inflammatory reactions in mice and in tissue culture.
Further concerns
An online review of AllerVarx pointed out:
Neither AllerVarx’s website nor the study itself referenced clinical evidence regarding “stabilized mast cells,” a reduction in histamines and inflammation, or a reduction in the expression of interleukins (IL-6 and TNF-alpha), as claimed on the supplement’s site.
They also don’t provide evidence that their patented bi-layer “fast slow” technology necessarily allows controlled ingredient release, or that this technology delivered measurably better results in their clinical study.
That same review says the company, Innovus Pharmaceuticals, has an F rating with the Better Business Bureau. And apparently they don’t manufacture AllerVarx, but are selling the European product Lertal under an in-license, merely changing the brand name. It was launched as Allervarx in May of 2017.
Marketing techniques
As I said, I have seen this kind of ad many times before. It is a half-page newspaper ad thinly disguised as a news report. It uses the buzz word “natural.” It makes unsupported claims. It refers to a clinical study but fails to provide references. It offers a money-back guarantee. It says supplies are limited, so call now! They have established a special hotline to deal with the demand. A special introductory discount is available. An accompanying photo of a doctor in a white coat with a stethoscope around his neck is intended to inspire confidence. Long on hype but short on substance.
These deceptive marketing techniques are red flags that suggest to me that the seller is only out to make a buck and the information is not to be trusted.
At the bottom, in small print, there is the required FDA disclaimer that this product that they are selling to treat allergic rhinitis is not intended to treat any disease! The company website claims the product will “provide relief during the allergy season.” In my opinion, this goes beyond the “structure and function” claims allowed for dietary supplements and constitutes an illegal claim that it is effective in treating a disease. A 30-day supply sells for $49.99. There is a 30-day refund policy, but it doesn’t refund S&H, and they subtract a $10 restocking fee. And customers would have to make a quick decision to apply for a refund within the time limit.
Why would anyone choose this product?
An article on WebMD lists 30 supplements that are used to treat allergic rhinitis. Perilla is listed; quercetin is not. Perilla and 18 more of the listed items are rated as “insufficient evidence.” Seven are listed as “possibly effective” and four are listed as “possibly ineffective.”
With all the conventional treatments that have been proven effective and all those other dietary supplements (that have not been proven effective) to choose from, why would anyone choose AllerVarx? Cost is not a reason: it is more expensive than many of the proven treatments. The fact that it doesn’t require a prescription is not a reason: many of the effective conventional remedies are available over-the-counter. The lack of side effects might be a reason, but absence of side effects is no advantage if there is also an absence of effects.
I don’t think there is any valid reason to choose AllerVarx, but if a patient wanted to ignore reason in favor of hope and the attraction of “trying something new,” I couldn’t object. There is no evidence that it is unsafe. If a patient tries it and thinks it helps, OK. (But experience tells us there’s a good possibility the perceived relief won’t last and the patient will soon be trying another unproven remedy.) If it doesn’t help, they will only have their allergy symptoms a bit longer and will be out a few bucks.

BrainPlus IQ: Lying with Advertising
Harriet Hall on November 29, 2016
Link


I got an email urging me to check out a wonderful new product that boosts brain performance: it “doubles IQ, skyrockets energy levels, and connects areas of the brain not previously connected.” It is BrainPlus IQ, a dietary supplement that falls into the category of nootropics, substances that enhance cognition and memory. After looking into it, my first thought was that if it doubles your IQ you might become smart enough to realize you have been scammed. The advertising for this product is as reprehensible as anything I have seen (and I have seen a lot).
The link in the email was to a “Discovery” website article titled “Anderson Cooper: Stephen Hawking Predicts, “This Pill Will Change Humanity” and It’s What I Credit My $20 Million Net Worth To.” According to the article, Stephen Hawking said his brain is sharper than ever because he uses BrainPlus IQ. It quotes Denzel Washington, saying he gave a speech at a science convention (unnamed) in New York City, saying BrainPlus IQ enabled him to memorize movie lines after reading them just once. He brought to the stage MIT scientist Peter Molnar, who said he had tested BrainPlus IQ against Adderall in 1,000 patients and found it was 600% more effective and subjects doubled their IQ in 10 days. It has “absolutely no harmful ingredients, it’s non-addictive, and 79% of participants double their IQ within 24 hours.” It was supposedly described as “Viagra for the brain” in Forbes magazine.
Men benefit more because of the ingredients’ reaction to a specific gene in the male brain. It helps men “effortlessly attract and seduce beautiful women with their new found quick wit and charm.”
Fact-checking
The most elementary fact-checking readily demolishes the claims in the article. In the first place, the name of the website is designed to deceive. It is not Discovery Channel or Discover magazine. It is “Discovery News Journal.” There is no such journal. A Google search for “Discovery News Journal” brings up only one hit: the article in question.
There is a link to a Dr. Oz show with a picture of a bottle of BrainPlus IQ. I watched the video. Nowhere does Dr. Oz mention any specific product. He talks about nootropics in general and shows how they work with a silly, irrelevant demonstration showing that a single audience member’s speed in solving a simple jigsaw puzzle is enhanced when two other audience members help her. Duh!
An image of a Forbes article is a doctored image replacing the words “Brain Storm Elite” with BrainPlus IQ, and the original Brain Storm Elite article was exposed by Forbes as a fake. They reference “over 2,000 trials” at the Nottingham Clinical Trials Unit. Those trials are not mentioned anywhere else. There is nothing in PubMed about them, and there is nothing in PubMed about Peter Molnar’s test where he allegedly compared BrainPlus IQ to Adderall. I couldn’t find any evidence that the product had ever actually been tested.
Sidebar fabrications
In a sidebar there is a doctored image of a National Geographic cover, with the title “Your Brain on Brain Boosters: Works 600% Better.” The original cover has the title “Your Brain: 100 things you never knew.”
There is an altered Time magazine cover with Tiger Woods quoting his alleged testimonial for the product. The real Time cover can be seen here.
There is a “CNN Breaking News” screenshot that says “GOVERNMENT IN FRENZY OVER PILL THAT DOUBLES IQ” and says it’s only a matter of time before the government bans it. It is a complete fake.
Buy now! Verified real testimonials
And of course there is a link where you can purchase it. The article warns that stocks are running out and you should purchase some right away. At the bottom of the page there are 21 testimonials, each with the odd notation “Verified Real.”
What’s in it?
Steven Novella has written about “The PIED Piper of Nootropics” showing that brain enhancing drugs are being abused and hyped without adequate evidence. The ingredients of BrainPlus IQ are acetyl-L-Carnitine, Ginkgo Biloba, Phosphatidylserine, St John’s Wort, Bacopa Monnier, Glutamine, DMAE, and Vinpocetine. As the Supplementcritique website succinctly explains, “There isn’t a whole lot of credible research on most of these supplements,” the company doesn’t disclose the amounts of each ingredient, and it’s highly unlikely that they’re using clinically tested amounts. Curiously, the BioTrim company’s own website doesn’t even list it among its six top products, which include Cambogia, Nitric Max Muscle, Pure Life Cleanse, Acai Ultra, Anabolic RX24 testosterone booster, and pure green coffee extract.
Conclusion: you would be smarter not to buy it
There is little evidence that any of the ingredients boost cognitive abilities, and there is no evidence that this particular combination of ingredients does anything. It has not been tested. They are deliberately lying, fabricating images, making up fake news stories, and attributing to celebrities things they never said. This goes far beyond hype to intentional deception. It is truly despicable.

“Glyconutrients,” Mannatech, and Ambrotose: Marketing, Not Science
Harriet Hall on September 13, 2016
Tweet

It has been a long time since I first became aware of Mannatech, the multilevel marketing company that sells “glyconutrient” dietary supplements. After its claims were debunked and it lost a court case, it had dropped off my radar; but last month it came roaring back in the form of an email from a reader in South Africa. He said his in-laws had recently become Mannatech Sales Associates. Although the company can’t legally claim that their products cure any ailments, they continue to imply that their products give your body the tools it needs to cure itself. Company representatives and other advocates continue to claim in seminars and on the Internet that Ambrotose helps with a variety of conditions including MS, AIDS, cancer, lupus, colitis, diabetes, fibromyalgia, cystic fibrosis, ADHD, neuralgia, wound healing, and much more. There are even claims that it “cures” Down syndrome and even changes its characteristic facial features. My correspondent had done his own research and had concluded that Mannatech was marketing modern day snake oil with outrageous claims. But he was shocked that there was so little impartial information available about “glyconutrients.”
He is right: much of the available information about “glyconutrients” is from people who are trying to sell products; there isn’t much unbiased information available. Science-Based Medicine has not previously addressed “glyconutrients” or Mannatech except when Dr. Gorski recently wrote about presidential candidate Ben Carson, MD, shilling for Mannatech and claiming that Mannatech products had cured his prostate cancer. Let’s take a closer look at the science behind the claims for “glyconutrients.”
The science of “glyconutrients”
The very term “glyconutrients” is questionable. There is no accepted scientific definition. It is a marketing term coined by Mannatech to refer to eight sugars that they say are needed at the cellular level for optimum wellness: fucose, galactose, glucose, mannose, N-acetylgalactosamine, N-acetylglucosamine, N-acetylneuraminic acid, and xylose. They say you may not be receiving these beneficial sugars in the right amounts from the food you eat, so you will benefit from their supplement products. The Society for Glycobiology does not accept the term “glyconutrients.” It has this disclaimer on its website:
The Society for Glycobiology is a scholarly society devoted to furthering knowledge of the functions of sugar molecules in biology and medicine. As world leaders in academic glycobiology, the Society’s members may receive requests for information about health benefits of nutritional supplements, including but not limited to so-called glyconutrients, glyconutritionals, or other similarly named products.
The Society does not endorse use of these or other nutritional supplements, and is not associated with any manufacturer or supplier of “glyconutrients”. The Society urges persons having questions regarding nutritional supplements to consult a physician before initiating use of any nutritional supplement claiming to enhance health or treat disease.
A PubMed clinical query search for “glyconutrients” brings up a scant 5 articles, the most pertinent being a devastating critique titled “A ‘Glyconutrient Sham'” by Schnaar and Freeze in the journal Glycobiology. The full text is available online. They deplore the perversion of glycobiology science for commercial purposes, citing the false claims of Mannatech. They are concerned that these commercial claims may adversely impact respect for legitimate research in glycobiology. They point out that three Nobel laureates have taken action to stop Mannatech from using their names to promote “glyconutrient” sales.
They say:
we hope to maintain a bright line between legitimate glycobiology research, including research into the potential of dietary glycans to be of health benefit, and what has become a vigorous marketing campaign to sell certain mixtures of plant polysaccharides as health products in the absence of controlled clinical studies to support their efficacy.
They point out that humans biosynthesize the different monosaccharides the body needs from common dietary precursors. They question whether dietary glycans are required for or significantly enhance glycosylation. They suggest that the components of Ambrotose can’t even be effectively digested, since the body lacks the necessary enzymes.
They reference the patent for Ambrotose, which includes a long list of disorders and diseases “… treated by administration of glyconutrients… (alone or in combination with other nutraceuticals).” The list of treated diseases is breathtaking: aging, stroke, multiple sclerosis, ALS, muscular dystrophy, cerebral palsy, macular degeneration, Down syndrome, immune deficiency, Tay–Sachs, Huntington’s, Alzheimer’s, Parkinson’s, spinal cord injury, Crohn’s, Tourette’s, lupus, rheumatoid arthritis, alcoholism, atherosclerosis, asthma, allergy, silicon breast implant, agent orange, Gulf War syndrome, hepatitis, influenza, common cold, AIDS, cancer, and poor athletic performance (among others).
They point out that the claims allowed by the patent office do not establish that the product works. The patent applicant is claiming that the product can be used to treat those disorders, not that it has been proven to have a therapeutic effect.
They review the evidence for “the value to human health of ingesting glycans – particularly the plant polysaccharides larch bark arabinogalactan, aloe vera glucomannan, and plant gums” and find “no convincing support for human therapeutic or health claims of Ambrotose® Complex or its components.”
They show how “Those who claim to speak for the glyconutrient industry often challenge the basic principles of scientific inquiry.” They say, “As scientists, it is also our mandate to impress on the public the importance of rigorous unbiased studies to distinguish biomedical facts from marketing schemes.”
The scientific evidence for Ambrotose
Whatever the basic science says about the biochemical role of these sugars, what potential customers need to know is whether there is any scientific evidence that the product Ambrotose has clinical benefits. A PubMed search for “Ambrotose” yields these 6 articles that are far from convincing:
     1.  A small placebo-controlled study reported a statistically significant improvement in recognition and working memory performance in middle-aged adults under conditions of mental fatigue.
     2.  An open-label study found significant changes in serum protein N-glycosylation in healthy adults but noted that biological significance remains to be determined.
     3.  A double-blind crossover study found increased resting blood antioxidant capacity and “may enhance post exercise antioxidant capacity. However, no statistically detected difference is observed in resting or exercise-induced oxidative stress biomarkers, in quality of life, or in GXT time to exhaustion.” They measured antioxidant capacity by ORAC, a measure that was rejected by the USDA because of mounting evidence that it had no relevance to the effects of specific bioactive compounds, including polyphenols, on human health.
     4.  A forced titration open label study was designed to determine the optimal dose; it also depended on ORAC scores and the authors warned that their results should not be over-interpreted, that it was a preliminary phase 1 and 2 trial, subject to limitations and potential bias, and that potential benefits would have to be confirmed by a phase 3 randomized controlled trial.
     5.  A study on rats with induced colitis. ‘Nuff said.
     6.  An opinion piece asking “Doctor, should I supplement my diet with Ambrotose?” that states there’s no good evidence to back any of its therapeutic claims.
The company’s own magazine even admitted that there were no double-blind, placebo-controlled studies of the type used by drug companies establishing that its products work.
Mannatech products
The company website offers a multitude of products for integrative health, targeted health, weight, fitness, skincare, and home living; but their flagship product is Ambrotose. Here are the claims for Ambrotose:
    • May enhance recall and recognition memory.
    • May improve mood and decrease irritability.
    • Supports your immune system as well as proper organ function.
    • Helps support proper digestive system function.
    • Promotes gastrointestinal health.
    • Supports cell-to-cell communication through a blend of specific plant saccharides called Glyconutrients.
The website includes the required FDA disclaimer (aka the Quack Miranda Warning). Mannatech can’t legally claim to treat or cure any disease, but they manage to do so indirectly. YouTube abounds with testimonials.
Testimonials
One typical YouTube video reports miraculous cures of cancer, autoimmune disease, allergies (symptoms resolved in 3 hours!), hormone disorders, arthritis, bursitis, plantar fasciitis, autism, rashes, diarrhea, constipation, seizures, atopic dermatitis, lymphangioma, diabetic neuropathy. Birthmarks resolve, patients report improved sleep, improved hair growth, etc.
Other videos make claims for a variety of other conditions. There are even videos claiming that glyconutrients “completely healed” people with Down syndrome.
Legal actions
In 2009 Mannatech and its founder agreed to pay $7 million to resolve a complaint by the Attorney General of Texas. It agreed to monitor sales associates’ statements about its products and to not advertise or otherwise claim that its products can cure, treat, mitigate or prevent disease.
Mannatech has also been sued by its investors.
An Australian doctor lost his license for selling up to $250 a month of Mannatech products to patients with hemochromatosis, cancer, infertility, and seizures and misrepresenting the products as effective for those conditions.
Conclusion: Marketing, not science
There is no credible evidence behind the claims for “glyconutrients.” “Glyconutrients” is not even an accepted scientific category. Mannatech is marketing a myth.

Diatomaceous Earth? No Thank You!
Harriet Hall on July 12, 2016
Link


Diatoms are unicellular algae, one of the two major classes of the phytoplankton that constitute the bottom of the food chain in oceans and freshwater. Diatomaceous earth is a soft, siliceous sedimentary rock containing the fossilized skeletal remains of diatoms. It has been used as a bug killer: it is hypothesized that the sharp particles physically cut up the insects and also damage their waxy protective layer, causing dehydration. It is also used as an abrasive, a filter, an anticaking agent, and in various other industrial and agricultural applications. It contains silica, mainly in the form of amorphous silicon dioxide but with some crystalline silica. Silica is dangerous when inhaled, causing lung disease in workers exposed to silica dust. Silicosis is the most common occupational disease worldwide.
Those are the indisputable facts. So far, so good. Now for the unsupported claims. Diatomaceous earth is being sold as a dietary supplement and is being promoted as “one of the cheapest and most versatile health products on the market.” One of the red flags for quack remedies is the claim that the remedy works for a long list of disparate ailments. Another is that the claims are supported only by testimonials, not by scientific studies. Another is the claim that it “detoxifies.” And most of those who claim it works just happen to have their own brand that they want to sell you. Diatomaceous earth fits the bill, on all counts. But just because it walks like a duck doesn’t mean we can summarily dismiss it. To be fair, we must examine the claims and the evidence.
The health claims
Taken internally, it is said to help promote healthier hair, skin, nails, gums, bones, and joints; support healthy digestion, improve absorption of nutrients, regularize bowel movements, and detoxify the digestive system; strengthen cartilage and reduce joint pain; assist in weight loss; promote healthy cholesterol levels and blood pressure; and increase energy. It is said that it either does, “can,” or “might” have many other benefits: it functions like a medicine against cough; reduces inflammation in bronchitis; reduces the side effects of menopause; preserves youthfulness and delays aging; safeguards against radiation; acts as a diuretic; can prevent both diarrhea and constipation; can help normalize hemorrhoidal tissue; may alleviate back discomfort; can stimulate defense mechanisms; can decrease vertigo, headache, tinnitus and insomnia; might help prevent TB; might help with Alzheimer disease; can stimulate the cell metabolic process and division; and it “prolongs and slows down facial aging lines.”
It must be good, because it’s “natural” and it’s “organic.” I guess they justify calling it “organic” because it was derived from an organism, the diatom; but silicon dioxide is a mineral. It’s a rock, folks, a kind of sand.
Some of the language of the claims is incoherent. It “proves to be effective with female discharge, abscesses and stomach problems within the vagina and cervix, in addition to mastitis (specifically for breastfeeding moms).” Really? Where is that proof? And how can you have stomach problems within the vagina? It “might help diabetes by marketing synthesis of elastase inhibitor through the pancreas.” It “might help arterial disease by strengthening the bloodstream ships.” Hmmm…
On one website they claim that diatomaceous earth has a strong negative charge and that pathogens and toxins have a positive charge; I question that. They claim that it attracts, traps, and absorbs fungi, protozoa, viruses, endotoxins, pesticides, drug residues, E.coli, and heavy metals. Apparently it’s pretty smart; somehow it knows to only attract things that are bad for you. They say the sharp particles scrub the walls of the intestines. They say the colon is coated with mucus and molds and that removing the coating allows better absorption of nutrients. Really? I would think sharp particles would injure the delicate lining of the bowel; mucus is normal and has a protective function; molds are not a problem except in the imagination of those who believe in Candida overgrowth syndrome; and if anything, I would think diatomaceous earth would be more likely to absorb nutrients and decrease their availability.
On another page of that same website they claim “life can’t exist without silica,” “silica is the most important trace element in human health,” and “most people are silica deficient” and they make extravagant claims for its health benefits. Their evidence is from testimonials, and they make excuses:
Of course, most actual in depth health related studies are initiated and controlled by the pharmaceutical industry, and why should those companies study the value of health remedies found in nature that could actually hurt their bottom line?
And they protest that they are not allowed to make specific medical claims, and are required to use the term “may help.” This is a deceptive ploy to make customers think their product is truly effective and it is only unfair censorship that prevents them from saying so.
The scientific evidence
Natural medicine websites claim that silicon is an essential trace mineral, that our diet fails to provide the amount we need, that there is a deficiency syndrome, that our soils have been depleted of silicon, and that supplementation has significant health benefits. More reliable science-based sources indicate that it has not been established that silicon has any metabolic function, and it is not considered to be an essential trace element.
Silicon is readily available from foods, and “neither silicon deficiency nor a silicon-responsive condition have yet been identified in humans.” There is some preliminary evidence suggesting that silicon might have a role in bone health, but that has not been confirmed.
PubMed lists 92 articles on diatomaceous earth, but none of them support the health claims that have been made. A PubMed search for the health benefits of silicon was equally unrewarding. One article found a decrease in litter pH when silicon was added to the feed of turkeys; nice to know! One review article said “compelling data [compelling to whom?] suggest that silica is essential for health although no RDI has been established.”
Another review found a positive relationship between dietary silicon intake and bone regeneration. A review of the skeletal effects of nutrients concluded, “Data are very limited for the role of nutritional levels of boron, strontium, silicon and phosphorus in bone health. A nutrient rich diet with adequate fruits and vegetables will generally meet skeletal needs in healthy individuals.” As far as I was able to determine, there have never been ANY controlled clinical trials in humans to test the effects of supplementing the diet with silicon or diatomaceous earth.
One evidence-based nutrition website concluded that the “claims of health benefits are theoretical and anecdotal” and that “while some supplements can definitely help, there is absolutely no evidence that diatomaceous earth is one of them.”
The Natural Medicines Comprehensive Database doesn’t take diatomaceous earth seriously enough to even list it. It does list silica, which it rates as “likely safe” but recommends against using it during pregnancy and lactation. It rates silica as “possibly effective for osteoporosis.” It found some evidence that men and premenopausal women who have higher dietary intake of silicon seem to have higher bone mineral density, which could reduce the risk of osteoporosis. But higher silicon intake does not seem to benefit postmenopausal women; bone loss in postmenopausal women is primarily due to bone resorption, and silicon seems to affect only bone formation. They found insufficient reliable evidence to rate the effectiveness of silicon for any of its other proposed uses. They stated that “an essential biological role for it has not been identified.”
No thank you!
Is it worth trying? I can’t rule out the possibility that it might work for some indications, but without proper controlled clinical studies we have no way of knowing. I can’t prove that it doesn’t work or that it is unsafe, but in my opinion there is no credible basis for recommending dietary supplementation with diatomaceous earth. Taking it would amount to offering yourself as a guinea pig in an uncontrolled experiment and sandpapering your intestines with an industrial abrasive on the strength of testimonials. I’ll pass.

Is there a natural treatment for tinnitus?
Scott Gavura on August 27, 2015
Link


“Why do you bother blogging?” asked a colleague. “You take hours of your personal time to write, and you do it for free. You’re not even getting any citations for all that work.” I admit I found the questions a bit surprising. True, you won’t find SBM posts abstracted in PubMed. But I’m writing for an entirely different audience. I blog for the same reason that I became a pharmacist: to help people use medicines more effectively. Practicing as a pharmacist is one way to do that. In that setting, you’re helping one patient at a time. And seeing how your advice and support can enhance someone’s care is tremendously gratifying.
I see blogging as another form of pharmacy practice, hopefully with similar effects. Yes I do get regular hate mail, and the occasional legal threat, but there’s also gratitude for a post that resonated with someone, or helped them make better decisions about their health. When Google searches don’t give answers, I get questions — too many to answer. Today’s post is based on a request for help from someone seeking advice on natural supplements to treat ringing in their ears. They have tinnitus, and they’re frustrated at the limits of what their physician (and medicine) can do. They sent me an advertisement for a supplement called Ear Tone, a natural health product which is advertised (and approved) to provide tinnitus relief. Can natural supplements do what conventional medicine cannot? 
When buying supplements, the deck is stacked against consumers
One of my recurring (and favourite) blog topics is evaluating the evidence supporting dietary supplements. Not only is it an opportunity to look at a specific medical condition, it’s a tool to illustrate how to use a science-based approach to answer medical questions. Supplements are also the perfect subject to illustrate the consequences of weak, ineffective health regulation, and how this approach harms consumers. Nowhere else in medicine is there an area that’s in such need of consumer advocacy and patient protection. While regulations will differ between countries, supplements tend to get a “pass” by most governments. This pass (which is usually in the form of special regulations), usually excludes supplements from the licensing requirements (and evidence standards) that applies to conventional drug products. It will vary somewhat depending on what country you live in, but in countries like the USA and Canada, this is what you’ll find:
There are few limits on what can be legally sold as a supplement or natural health product.
There are few limits on the health claims that can be made about these products.
There are few, if any, requirements to directly test supplements for safety.
There are often no requirements to test supplements for actual effectiveness.
Pharmacies and other retailers sell supplements alongside regular drug products, without distinguishing them.
The result is a marketplace that is a boon to supplement makers, but puts consumers at a considerable disadvantage. Worse, many health professionals also give supplements a pass, failing to hold them to the same evidence standards as drug products. Pharmacy shelves are becoming the “Wild West” of healthcare, where evidence-supported products are sold alongside those that are either unproven, or even worse, completely ineffective (e.g. homeopathy).
Supplement manufacturers exploit difficult-to-treat conditions, like tinnitus
When medicine can’t deliver an obvious cure, or where a medical condition is poorly understood, you create the breeding ground for alternative medicine remedies. Steven Novella described their characteristics in a past post:
conditions that have subjective symptoms (think fake diseases, like adrenal fatigue)
conditions that may vary naturally, over time (e.g. supplements to treat fertility concerns; or pain)
illnesses with a substantial psychological condition (e.g. anxiety)
Tinnitus is one of those conditions.
Tinnitus is not just a ringing in the ears
Tinnitus is the perception of noise when there is no external cause. While it’s typically thought of as ringing, it can also be perceived as buzzing or hissing. Tinnitus is common, affecting up to 15% of individuals, depending on your age. While rarely serious, tinnitus can significantly interfere with quality of life. Tinnitus can be caused by age, loud noise (from construction equipment to loud music), ear wax blockage, and ear bone changes. (Sixties rock icon Pete Townsend is a famous tinnitus sufferer, which he attributes to years of listening to headphones.) Many medications are associated with tinnitus, as can other medical conditions, such as cardiovascular disease. Consequently, every tinnitus case needs to be medically evaluated, to search for any underlying causes and to rule out more serious medical conditions. In some cases a clear cause for tinnitus cannot be found, and it becomes a chronic condition. Reducing the impact and effects becomes the treatment goal.
The management of tinnitus focuses first on any underlying causes or conditions. While there is no cure, there are medical treatments that can be effective, including:
addressing hearing loss with products like hearing aids
treating depression or anxiety which may be identified in patients with tinnitus
using behavioral therapies such as tinnitus retraining (reducing awareness of the noise), cognitive behavioural therapy, or masking (low-level noise) to drown out the sound
Overall, these therapies are only modestly effective. There is no magic bullet. While numerous vitamins, minerals and supplements have also been tested, there are no studies that suggest that any supplement provides a meaningful improvement.
What is Ear Tone?
Ear Tone is a combination herbal remedy that’s advertised widely and sold in many pharmacies for the treatment of tinnitus. It’s manufactured by New Nordic, a Swedish supplement manufacturer that has been criticized in the past for making misleading claims about its product. The manufacturer makes the following claim:
Ear Tone is a new product that is based on new research, showing significant results in treating tinnitus naturally. Ear Tone works by supplying the ear with the right nutrients while promoting peripheral blood circulation.
According to the manufacturer’s website, each Ear Tone tablet contains:
Ginkgo biloba leaf: [50:1]: 100 mg
24 % Flavonoid glycosides
6 % Terpene lactones
Magnesium (as magnesium oxide): 532 mg
Pinus pinaster (Maritime pine bark): 50 mg
labelled as 95 % Proanthocyanidins
The recommended dose is two tablets per day, which gives a monthly cost of about $30.
Do the ingredients in Ear Tone help tinnitus?
The first ingredient, ginkgo, has a long history of use as a natural medicine, but there’s no clear evidence that ginkgo is effective for any medical condition. Presumably included here to enhance blood circulation in the area, studies have shown mixed results for the treatment of vascular disease and while it has been studied specifically for tinnitus, results have been mixed. Overall, there’s no convincing evidence it actually has any meaningful benefit with tinnitus. A Cochrane review concluded the same, noting:
The limited evidence does not demonstrate that Ginkgo biloba is effective for tinnitus when this is the primary complaint.
The second ingredient is magnesium, supplied as magnesium oxide, and according to the manufacturer is included because it “protects the nerves in the inner ear and promotes an electrolyte balance in its hair cells.” While magnesium is an abundant ion in the body, there is no published evidence with magnesium supplements to suggest it protects nerves or promotes electrolyte balance in hair cells. I found a single open-label study of magnesium supplementation and tinnitus published in 2011 that suggested a modest beneficial effect. Given it was neither randomized nor blinded, it’s hard to see this as evidence as efficacy.
The third ingredient is literally the bark from a pine tree, in this case, the Maritime pine. There’s one study with a branded version of pine bark (“Pycnogenol”) that was evaluated in a pilot study for effectiveness against tinnitus. Over four weeks, patients on the supplement were noted to experience an improvement in symptoms as well as cochlear blood flow. It’s not clear if the study was blinded or randomized, however, and the authors note:
More studies should be planned to better evaluate the pathology and potential applications of Pycnogenol in a larger number of patients who are currently without a real therapeutic solution.
There’s also a 2014 study with Pycnogenol which was a registry — a real-world evaluation that concluded the product may offer benefit in Meniere’s disease and tinnitus. This is nonrandomized, uncontrolled, and therefore unconvincing data. Before we can conclude this product offers actual benefits, it needs to be evaluated in prospective, blinded, and controlled trials.
So there’s little evidence Ear Tone works.
What are the risks of gingko and pine bark?
What about risks? There are few case reports of serious harms with ginkgo or with pine bark, but that’s complicated by poor data collection — since there are few trials and only limited real-world surveillance, the long-term safety is unclear. There is the risk that this combination of products could magnify or interfere with the action of drugs that affect blood coagulation. Its possible effects on other drugs are not well understood.
I don’t see enough evidence of effectiveness here to recommend Ear Tone, but ultimately this is a personal decision. Given what we know (and don’t know) about the efficacy and safety, some may decide it’s worth a try, especially if they’re experiencing poor quality of life from tinnitus. If that was my patient’s choice, I’d want to ensure that their other medications had been reviewed for any possible interactions. I’d also encourage any user to try to objectively measure whether or not they experience any relief. From reports online, many have not found it helpful.
Health Canada’s recommendations aren’t based on evidence
Despite the limited evidence suggesting that Ear Tone has any beneficial effects, Health Canada has approved Ear Tone with the following wording:
Recommended Use or Purpose:Helps to reduce the perception of tinnitus in the ears. Helps to support peripheral circulation.
Health Canada has concluded the product is effective despite the fact that there is no published evidence suggesting this particular combination of ingredients has even been formally tested. This is the double-standard for supplements at work — approval from the regulator without the requirement to actually test your product for safety or effectiveness.
What’s the bottom line for consumers with tinnitus?
Tinnitus is an often-chronic condition for which we lack a good understanding of the causes and treatments. While there are some therapies that can help minimize symptoms, there are no cures.
Despite the hype, the anecdotes, and the marketing, there are no supplements for tinnitus that have been shown to offer any meaningful benefit. It would be wonderful if there really were a magic herb (or combination of herbs and minerals, like Ear Tone) that you could grind up, put in capsules or tablets, and expect relief. But that’s not realistic. This doesn’t stop manufacturers from making claims, or regulators like Health Canada from agreeing, that products like Ear Tone are “effective” because they’ve squeaked over a lowered evidence bar for natural health products.
Learning there are no easy solutions or cures for tinnitus can be difficult to accept, especially when tinnitus significantly impairs your quality of life. Supplement marketers know this all too well, and will likely continue to market unproven supplements for tinnitus that lack good evidence of efficacy.

Not natural, not safe: Grapefruit Seed Extract
Grapefruit-seed extract is claimed to be a cure-all for nearly every type of infection. But there’s a dangerous problem with GSE that supplement manufacturers haven’t fixed.
Scott Gavura on March 10, 2016
Link


Where do you draw the line between “supplement” and “drug”? And how much processing of a “natural” substance can occur before it’s no longer “natural”? These seemingly-philosophical questions are very real when it comes to the supplement industry. In many countries, regulators have implemented weaker safety, effectiveness and quality standards for anything branded a supplement or natural health product. The result has been a boon and boom for manufacturers, with thousands of products flooding the market. This same boom has challenged consumers and health professionals who are seeking products that are safe, effective, and manufactured to high quality standards (and in the bottle you are buying). Nowhere is this challenge better illustrated than a supplement that I’ve seen for sale for some time. Grapefruit seed extract (GSE), according to promoters, is a panacea that destroy bacteria, viruses and fungi anywhere in the body, without any risk of harm. But the actual science is quite telling. Grapefruit seed is a supplement that’s of such poor quality that even herbal medicine boosters recommend against its use.
Grapefruit seed extract is claimed to treat virtually every infection
GSE is claimed to be produced from the seeds of the grapefruit (Citrus x paradisi). The production method isn’t clearly described but different manufacturers say they grind the seeds and pulp in water, and then process this chemically to yield an extract. The methodology of production doesn’t appear standardized, nor is it disclosed in sufficient details to given consumers any assurance that the product is consistent (in content) or safe to consume.
GSE is primarily promoted to treat or prevent infections. It is believed to be simultaneously antibacterial, antiviral, and antifungal. As a liquid, it can be applied topically to surfaces as a disinfectant, or to skin as an antiseptic. It is also consumed orally based on claims that it can treat infections of the gastrointestinal tract (or elsewhere in the body). It is particularly popular for the alternative medicine treatment of what’s called “chronic candida” infection. Chronic candida is not a real condition, but is a fake disease created out of thin air as an explanation for often non-specific gastrointestinal symptoms. In the “treatment” of chronic candida, it’s claimed that GSE selectively kills fungi but leaves normal gastrointestinal species intact. In addition to being consumed in the belief that it can treat candida infections, it’s also claimed that GSE can treat toenail fungus, restore normal blood lipids, heal wounds, “alkalize” the body, is an effective douche, cures warts, treat “dysbiosis”, and more.
There’s no evidence grapefruit seed extract has any meaningful effectiveness
Does grapefruit seed extract actually work? Before looking at the evidence, it is important to distinguish between in vitro use (i.e. in glass dishes on lab benches) and in vivo use (i.e. in an actual human or animal). What kills bacteria, viruses and fungi in a test tube or on an agar plate isn’t necessarily going to be effective when you swallow the same ingredient. Consider the following scenario: Tequila, based on its alcohol content, is going to be an effective disinfectant on surfaces. You can probably disinfect your hands with it, just like you would with an alcohol gel. But no matter how many margaritas you may drink, tequila will not cure your cold or any other infection in body. To be effective after it’s consumed, an ingredient must be absorbed into the body, distributed via the bloodstream to the appropriate location at a minimum concentration, and be present long enough at that location to have an antiviral, antibacterial, or antifungal effect. At the same time it has to do so without causing you or your body more harm than good. Tequila fails spectacularly on all counts. It’s not effective because it’s not possible to have enough in your body to have an effect without killing you. The bottom line is that the only way GSE can truly be evaluated is through actual clinical trials. Test tube or any other in vitro studies are irrelevant when looking at any internal use. GSE, or any supplement or drug for that matter, isn’t exempted from basic efficacy requirements; the only true measure of efficacy is rigorous testing against a specific infection.
Perhaps not surprisingly, there is a lack of evidence showing that GSE has any effectiveness for any condition. A search for clinical trials with grapefruit seed extract reveals no results.
Commercial grapefruit seed extract products may be adulterated with synthetic disinfectants and antibacterials
There is a serious problem with commercially available GSE products sold on the market. There’s an over 20-year history of adulteration of GSE products with synthetic antibacterial disinfectants and cleansers. The first report appeared in the 1990s when testing of a commercially-available GSE product found benzalkonium chloride and triclosan, which were not found in an extract of the seeds themselves. A 1999 study tested six products. Five were effective inhibitors of bacteria and fungus in test tubes. In all five products, the synthetic preservative benzethonium chloride was detected. Three extracts also contained triclosan and methylparaben. The one GSE product with no additives also had no efficacy. The investigators also tested their own seed extract, as well as pulp. No antibacterial or antifungal properties were noted. In their own words:
Thus, it is concluded that the potent as well as nearly universal antimicrobial activity being attributed to grapefruit seed extract is merely due to the synthetic preservative agents contained within. Natural products with antimicrobial activity do not appear to be present.
A 2001 paper drew similar conclusions:
This work has conclusively demonstrated that benzethonium chloride is present in commercial GSE samples. Higher amounts of benzethonium chloride were present in powder GSE samples than in liquid GSE samples, although though we did not determine the exact concentration. This research confirms an earlier study that found benzethonium chloride in commercial GSE samples. It seems unlikely that benzethonium chloride is formed during any extraction and/or processing of grapefruit seeds and pulp.
There have been several other studies conducted. All point to the same conclusion. GSE products that are commercially available are regularly adulterated with synthetic antibacterial and antifungal disinfectants. GSE products that are not adulterated have no efficacy, because GSE has no intrinsic efficacy at all.
The American Botanical council summed this up nicely in a 2012 paper:
A significant amount, and possibly a majority, of ingredients, dietary supplements and/or cosmetics labeled as or containing grapefruit seed extract (GFSE) is adulterated, and any observed antimicrobial activity is due to synthetic additives, not the grapefruit seed extract itself. Tests conducted in multiple laboratories over almost 20 years indicated that all commercial GFSE preparations that exhibited antimicrobial activity contained one or more synthetic microbicides/disinfectants, while freshly-prepared extracts of grapefruit seeds made with a variety of extraction solvents neither exhibited antimicrobial activity nor contained the antimicrobial synthetic compounds found in the commercial ingredient materials. Furthermore, over the course of the 18 years covered by the various analyses, the actual antimicrobial compounds found in the putative grapefruit seed extracts changed from triclosan and methyl p-hydroxybenzoate in early samples to benzethonium chloride in the middle years to mixtures of benzalkonium and/or alkonium chlorides in more recent years. The suggestion on a commercial website that these antimicrobial compounds are formed from the phenolic compounds naturally occurring in grapefruit seed and pulp by heating them with water, ammonium chloride, and hydrochloric acid is not supported by chemical evidence, or any known organic chemistry pathway. None of these compounds could be formed from flavonoids like naringenin, the most abundant flavonoid in grapefruit seeds, pulp, and peel, or other grapefruit seed constituents (e.g., limonoids) and ammonium chloride; the alkyl chains and substituent arrays found in the antimicrobial adulterants are not naturally present in grapefruit seed and cannot be prepared from those materials. The fact that the antimicrobial components found in GFSE changed from 1991 to 2008 not only argues against such in situ synthesis (i.e., occurring naturally or synthesized in the processing of grapefruit seed material itself), but is suggestive of efforts by manufacturers of these commercial materials to stay one step ahead of analytical methods to detect adulteration.
Grapefruit seed extract products may cause unpredictable effects with prescription drugs
GSE products have the potential to cause significant drug interactions. One case report notes that a GSE product significantly increased the levels of warfarin (Coumadin), which means a significantly increased risk of bleeding for patients taking the drug. Upon further examination of the product it was determined that the active ingredient was actually benzethonium chloride. Benzethonium is an antiseptic that is for surface disinfection and is also in consumer products like mouthwash.
The Natural Medicines Database says that GSE is possibly safe based on this paper. The paper describes the open-label use of an extract and provides no data or statistical analysis, yet concludes the product is effective and safe. I am not convinced that these conclusions are appropriate given the methodological quality of this paper and the widespread adulteration issues documented above. Given the risk of potentially harmful drug interactions, and the unknown ingredients that may be used to adulterate commercially available supplies, GSE products have the potential to cause significant harm when combined with medications like anticoagulants.
What’s the bottom line with GSE?
There is no evidence suggesting that actual grapefruit seed extract has any meaningful antibacterial, antifungal, or antiviral effects. Repeated testing over the past 20 years has demonstrated that any GSE efficacy is due to product adulteration with one or more synthetic chemical disinfectants. Adulterated or not, there is no reason to take GSE at all. The fact that it continues to be widely sold is testament to the ineffectiveness of regulations that should put consumer safety ahead of a manufacturer’s right to sell a dodgy product.

The THRIVE Experience: Masterful Marketing, Short on Substance
Harriet Hall on June 28, 2016
Link


My daughter told me about the latest health fad among her group of acquaintances. She knows people who are spending $300 a month on the THRIVE program and claiming miraculous results. With a skeptic for a mother, my daughter knew enough to question the claims and do her own research; she was not impressed. She concluded that THRIVE was essentially selling caffeine and vitamins at exorbitant prices.
Claims on the website
THRIVE is offered by Le-Vel Brands, LLC. A slick video on the website asks:
Are you ready to hear about the hottest weight loss, nutrition and fitness plan sweeping North America? It’s called the THRIVE 8-week experience. The only premium lifestyle transformation plan. People from all walks of life are accomplishing their physical goals with THRIVE, and many are also accomplishing their financial goals by choosing to promote the experience.
    • Weight management
    • Joint support
    • Pain management
    • Antioxidant support
    • Cognitive performance
    • Lean muscle support
    • Anti-aging
    • Digestive and immune support
    • Calms general discomfort
“You’re going to live, look, and feel Ultra Premium like never before.”
Testimonials: yes. Hype: yes. Evidence: no.
What are they selling?
The THRIVE experience involves setting and committing to an 8-week goal (anything from weight loss to looking better and having more energy) and taking supplement products: a combination of THRIVE Premium Lifestyle Capsules, THRIVE Ultra Micronized Lifestyle Shake Mix, and a skin patch with their patent pending Premium Lifestyle DFT (Dermafusion Technology). You can choose one of four THRIVE Premium Lifestyle Capsules: for men, for women, for premium lifestyle, and for premium lifestyle DFT.
The products are “naturopathic, gender specific and synergistic.” They contain mixtures of vitamins, minerals, plant extracts, anti-oxidants, enzymes, probiotics and amino acids: a little of everything. For example, the women’s formula includes vitamins A, B1, B2, B3, B5, B6, B12, D3, folic acid, chromium, selenium, vanadium, and a “Proprietary Blend” of B. lactis, L. acidophilus, L. casei, l. helviticus, L. salvarius, L. plantarum, L rhamnosus, guarana caffeine, green tea caffeine, glucosamine, white willow ext., glutamine, green coffee bean, PEA, kelp, Irvingia extract, BCAA blend, theobromine, ginger ext, Citrus aurantium ext, aspartic acid, L-serine, grape seed ext, CoQ10, white tea ext.
There is no rationale for mixing all these ingredients, and no reason to think the effects are synergistic. The products contain caffeine in several forms: guarana, green coffee bean, green tea, white tea; these are listed as part of a proprietary blend, and the total amount of caffeine is not divulged. If this mixture actually has any effect beyond producing expensive urine, I would guess it might be similar to the effect of drinking a couple of cups of coffee.
And of course, “These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease”
Then there are THRIVE PLUS products for even GREATER RESULTS! Some examples: BOOST, a berry-flavored premium greens beverage designed to alkalize and energize your system, ACTIVATE, designed to activate your core (?!), while supporting clean healthy energy, clarity and performance, and BLACK LABEL, offering “mood support and of course, plenty of attitude.”
The newest product is FORM, “the world’s first sequentially absorbed collagen protein gel… a hybrid dietary supplement that delivers broad-based support to the body, including firm and healthy skin, weight management, lean muscle mass, post-exercise recovery and repair, and strong bones and joints.”
How are they selling it?
You can buy it online, and you can essentially get the products for free if you recruit others. It’s a multilevel marketing scheme that has reached over 3.5 million customers and $500 million annual revenue. It boasts the number one industry ranked car bonus. If you sell enough and recruit enough other promoters, you can also qualify for a lifestyle getaway for two with airfare to New Orleans. But we know from long, sad experience that only a few people at the top of an MLM hierarchy make any money, and the great majority of MLM distributors lose money. There is a Quackwatch-affiliated website, MLM Watch, that dispels the myths surrounding this marketing approach.
They offer lots of testimonials: “within 2-3 hours it completely changed my life.” “I’m the best version of me that’s ever existed. You have nothing to lose and so much to gain.”
The plural of “anecdote” is not “data.” As the “Red Flags of Quackery” chart points out, you can stack manure up to the sky, but it’s still a pile of crap. On Science-Based Medicine, we know to question testimonials and ask for reliable evidence. What evidence does the Le-Vel company offer? Not even a shadow of a whisper of a suggestion of a thread.
Similar products
All this gives me a sense of déjà vu. THRIVE is just another in a long line of similar supplement offerings. I have written about several of them, including Protandim, Isagenix, and Shred360.
And there are other supplement products involving caffeine where you can at least taste the coffee: Healthy Habits coffee and Genius Java. Most products like these have never been tested, and even when they have been clinically tested in a scientific trial, the results have been far from convincing.
Is there any reason to think that the supplement mixture in THRIVE is superior to any other? There is no rational basis to choose one of these products over the others.
Bottom line: does it work?
Maybe. How could we know? The only way to tell is with controlled scientific testing. But I’ll offer my educated guess that it doesn’t accomplish anything a healthy diet, exercise, and a couple of cups of coffee couldn’t accomplish at far less expense. And the idea of setting an 8-week goal for weight loss or self-improvement is undoubtedly a good one, but you don’t have to buy THRIVE products to do that. I’m not buying.

Medicine doesn’t come from the hardware store: Don’t drink turpentine
Scott Gavura on June 4, 2015
Link


I enjoy feedback from readers. Yes, there’s the regular hate mail accusing me of being a Big Pharma Shill. But there’s the occasional appreciative comment from someone that found a post helpful or informative. The most gratifying feedback is when someone tells me that something I wrote led to a more informed health decision. Often it’s because I was able to answer a question that they couldn’t find a science-based answer to. I’ve answered thousands of questions in my pharmacy career, and have only blogged a handful of them (so far). One of my most fascinating experiences was a stint working evenings in a pharmacy that happened to have a large “natural” health focus. It’s there I began to scrutinize alternative medicine more closely, because it was virtually all the store sold. Homeopathy, ear candles, copper bracelets and salt lamps were all for sale. If it was unproven, proven ineffective, or defied some law of physics or chemistry, this pharmacy probably sold it. But the customers loved these products. I was dumbfounded. Some would buy dozens of supplements, costing hundreds dollars per month, on the advice of their naturopath, treating some vague or non-specific complaints. Others swore by homeopathic remedies, for themselves and their pets. It was common to meet people who were treating conditions that either didn’t exist, or hadn’t been properly diagnosed, like naturopath-diagnosed “food intolerances” or “hormone imbalances”. There were also the occasional “pH balancing” advocates that insisted I was misguided and uneducated for reassuring them that their body’s pH was just fine, despite what their urine test strips were telling them.
I eventually stopped being surprised at the recommendations and practices I was seeing, and started becoming concerned and sometimes even appalled. Much of my time was spent (often unsuccessfully) trying to correct misinformation and beliefs that these individuals not only felt were true, but strongly and personally identified with. If you reassure someone that they don’t have an infection that requires antibiotics, they’re generally pretty happy. But when you explain that “detox” is a marketing term, and there is no need to waste money on a “detox” kit, sometimes it only seemed to reinforce the belief that supplements were useful. Several times I was presented with a prescription, and a simultaneous request for a supplement recommendation as a substitute for the drug, based on the belief that supplements are as effective as and safer than prescription drugs. I’d explain that following a heart attack, and considering quality, safety, and efficacy, that red yeast rice was a poor substitute for a statin. Some would feel otherwise. Many had a very negative perception about the risk and benefits of prescription drugs, with the opposite perception about the merits of various “alternative” remedies.
Every time I think I’ve heard it all in the world of alternative medicine, I can still be surprised. But there will be no natural limit of alternative medicine remedies and treatments for the same reason that there are an infinite number of wrong answers for every right one. A reader writes:
A friend has been taking turpentine orally as ordered by her naturopath to remove candida from her body. She claims she has been transformed – more energy, losing her fat, etc. Would like your comments on this. Do you have any info about it?
There are a couple of questions to sort out here. The first is the safety and efficacy of the oral consumption of turpentine. The second is scientific evidence supporting naturopatic beliefs about “candida” infections.
Turpentine: Natural, perhaps. Safe? No
You may have used turpentine to thin paints and clean brushes, which is its most typical use. Turpentine is an essential oil distilled from pine tree sap – so it does have “natural” origins. The major active ingredients in turpentine are aromatic hydrocarbons called terpenes, natural chemicals widely found in essential oils that provide the aroma and flavour of many everyday products – like the hint of pine resin you taste in your IPA. As you might expect from the poison label on a bottle of turpentine, consuming turpentine can cause hydrocarbon poisoning. At little as a single tablespoon of turpentine can be fatal to a child. Fatalities appear to be rare in adults from consumption, but turpentine can cause severe and even fatal lung inflammation if inhaled, in addition to heart arrhythmias. The CDC says turpentine is “Immediately Dangerous to Life or Health Concentrations.” Even the vapour can irritate mucous membranes in the mouth, eyes and nose.
It’s amazing the pace at which medicine has advanced since we started using evidence to determine what works. One need only look back at pre-scientific practices to see therapies based solely on folklore and belief. Turpentine is one such remedy that has moved from the pharmacy to the hardware store as a result. Turpentine used to be a folk remedy for all kinds of ailments. Given its toxicity, it remained part of evidence-based medicine only in a few topical products: Vicks Vapo-Rub is probably the most well-known product that still contains turpentine. There are no credible scientific or medical reasons for consuming turpentine orally, but you can find those that advocate consuming it orally, as if the past hundred years’ of scientific understanding were irrelevant. A physician stripped of her New York medical license espouses the consumption of turpentine as a “candida cleaner”. There are also various internet threads describing how to consume it (on a sugar cube, apparently). It’s widely believed to treat candida infections. Why candida? Because candida is a fake disease.
Treating a fake disease: Candida
Candida infections or colonizations that alternative medicine providers describe are not the same fungal infections that are diagnosed by medical doctors and treated with antifungal drugs. In the alternative medicine world, nonspecific complaints (e.g., fatigue) are often attributed to Candida infections. These types of “infections” are invisible to medical professionals, but seem universal in the CAM belief system. To be clear, Candida is a real fungus, and Candida infections can be real. But in these cases, there’s no evidence that Candida is causing any infection. It’s a made-up diagnosis with no objective evidence to back it up. Given the Candida infection isn’t even real, there’s a huge variety of “cures” available. Candida “kits” don’t usually include turpentine however. These remedies are usually laxatives and purgatives, which are believed to “mop up” Candida, and restore “balance” to the body. It’s all a charade, designed to give the consumer the illusion that they’re doing something beneficial. Would turpentine actually kill Candida? Perhaps – in a petri dish. But if you take enough to kill any Candida in your body, it may kill you in the process. Could you feel better after consuming turpentine, if it were taken in small amounts? Possibly, but it would have nothing to do with the turpentine. Given the symptoms attributed to candida are nonspecific, it’s normal to expect that they will wax and wane over time. There’s no evidence to suggest that consuming turpentine will provide any health benefits at all.
Becoming an informed consumer
Candida is a fake disease invented to sell fake treatments. The worst that could usually be said for most candida “treatments” was that they were probably not harmful. That changes when proponents advocate consuming paint thinner as a supposed natural remedy. There’s no reason to consume turpentine and multiple reasons to avoid it completely, with the primary reason being that it’s a poison. If someone tells you that you may have a Candida infection, then brace yourself, as you’re not getting health advice, but being marketed to.

Beetroots Don’t Cure Cancer
Steven Novella on April 13, 2016
Link
https://sciencebasedmedicine.org/beetroots-dont-cure-cancer/Alternative medicine, like all good marketing, is largely about creating a narrative. Once you have sold people on the narrative, products essentially market themselves. That narrative has been evolving for literally centuries, although it seems to have accelerated with the advent of mass media and now the internet. It is optimized to push emotional buttons in order to sell products.
There are countless examples available on the internet, with many peaking above the crowd for their 15 minutes of fame. In my feed this morning came this typical example: “Cancer Cells Die In 42 Days: This Famous Austrian’s Juice Cured Over 45,000 People From Cancer And Other Incurable Diseases!”
The story has many of the typical alternative medicine narrative talking points: natural is good, a healthful diet can cure anything, anti-inflammatory, anti-oxidants, and detoxification are all good.
The narrative is so well established, especially within the target audience, that many components don’t have to be stated outright, they are just implied. The story is of a lone individual working for years to find a natural cure for cancer, and then finding it. The idea is simple – just starve tumors of the protein they need to live. His special organic raw vegetable juice (of mostly beetroot) will keep you healthy while you starve the cancer, while providing detoxing antioxidants to boot.
What’s wrong with this story?
The scientific narrative is very different from this alternative. Scientists want to know what is actually real, and in order to do so they have to painstakingly construct a picture from rigorous evidence filtered through critical analysis and logic. This is tedious, and often does not give us the answers we want, but they have the virtue of being more likely to be true.
First, there are problems with the big picture of this and similar claims. The most glaring is that cancer is not one disease, but a category containing many diseases. For this reason there will likely never be one cure for all cancer (at least not with any extrapolation of current technology). Right there any “cure for cancer” claims are highly suspect.
Further, cancer is complicated. Scientists around the world have been investing a great deal of resources trying to understand and treat cancer for decades. They have made a lot of progress, but also have discovered how complex and tricky cancer is as a phenomenon.
For this reason any significant new treatment for cancer would have a paper trail of supporting research behind it. By the time we are doing clinical trials there is a mountain of pre-clinical and preliminary clinical studies supporting a potential treatment.
The article claims, for example, that solid tumors require protein to survive, and therefore starving them of protein is the key to killing the tumor cells. OK, where is the evidence for that? That claim contradicts actual studies which show, if anything, cancer cells rely on sugar to maintain their rapid metabolism (though unsurprisingly, it’s a little more complicated than that).
Even still, starving tumors of sugar in the diet does not kill them off. Cancer cells are cancerous partly because they are versatile – if they are starved of sugar they switch to a different energy source. Mutations in cancer cells turn off the usual restraints that limit healthy cells from growing without limit.
In short, the 42-day juice diet is unlikely to starve cancer cells.
Another major problem with this kind of narrative is that, if there were such a treatment and it were as successful as claimed (they claim 100% success – itself suspect), then there would be no way to keep that treatment contained. If it were possible to cure any cancer in 42 days, everyone would be using by now. The effects would be undeniable. Such a homerun would be easy to demonstrate in even a simple clinical trial.
A dramatic cure for cancer would be like aliens landing on the White House lawn – everyone would know about it. Knowledge of the cure or aliens would not be hiding in the dark recesses of the internet.
When confronted with this argument, the narrative (like many cancer cells) adapts. It just invokes the grand conspiracy – the evil medical establishment is clearly hiding the cure. This, of course, is impossible. No institution has that reach or power.
Even when unstated, an establishment conspiracy is implicit in the narrative. That’s why doctors aren’t prescribing beetroot juice diets for all cancers.
Detox and anti-oxidants
There are also some specific problems with this particular narrative, invoking anti-inflammatory, anti-oxidant, boosting the immune system, and detoxification as further mechanisms for the alleged benefits of beetroot juice. These are the alternative narrative buzzwords of the day. Marketing has created a health halo around these terms, and all you have to do is sprinkle them on top of any product claim.
Detoxification is not even a legitimate concept. There are no products that generally detoxify the body. There are, of course, specific treatments for some specific toxins, but that is very different than general detoxification. This is just a vague term that sounds good but does not really mean anything.
“Boosting the immune system” is similar – it’s not really a thing. It has no coherent scientific meaning.
Interestingly, anti-inflammatory and antioxidant effects are the opposite of “boosting” the immune system. The immune system uses inflammation and oxidative stress as part of its defense against things like cancer cells.
Metabolism creates reactive oxygen species, which require antioxidants to keep them in check. Cancer cells require increased antioxidants to handle their increased metabolism. So, putting more antioxidants into the system would help cancer cells survive, if anything.
Beetroot extract does, in fact, contain betanin, which is an antioxidant. It also has some anti-tumor effect in vitro, but only 8.6% as effective as similar compounds already in use. This also does not say much about its activity when consumed because then bioavailability needs to be considered. Bioavailability is one of those things that scientists worry about, but is not part of the alternative narrative at all.
Conclusion: The narrative collapses
If you dig even slightly below the surface of the narrative, it starts to fall completely apart. There is no cure for all cancer. No treatment is 100% effective. Cancer is too complex for a lone researcher to find a cure, without a mountain of research leading the way – research that would require collaboration, resources, and create a paper trail.
There is no such thing as detox or boosting the immune system. Inflammatory and antioxidant effects are part of a complex homeostatic system within the body, and when you alter them the effects will be complex and just as likely to be harmful as beneficial. In this case, anti-inflammatory and antioxidant effects would very likely be counterproductive by helping tumor cells survive and suppressing the immune system’s ability to fight them.
The scientific narrative, in my opinion, is also very compelling, much more so than the simplistic marketing narrative purveyors of dubious treatments would have you believe. The scientific narrative, however, takes more activation energy.

DMAA: Efficacious but is it Safe?
Andrey Pavlov on June 7, 2013
Link

by Igor I. Bussel & Drey A. Pavlov
Jann Bellamy has recently authored an excellent piece on the limitations of the FDA and how the DSHEA actually protects the profits of supplement manufacturers rather than the health and well-being of consumers. Bellamy used the very poignant and currently “controversial” example of DMAA (methylhexanamine or 1,3-dimethylamylamine) to illustrate her point regarding the loopholes and lack of enforcement power of the FDA. The authors of this piece had been considering writing about DMAA and felt this would be an excellent time to further expound on Bellamy’s work. The goal of this article will be twofold: 1) to discuss the known history and pharmacology of DMAA, especially in regards to the basic methodology for evaluating novel substances or novel uses of substances in the context of lacking randomized, controlled trial-level evidence (i.e. the concept of science vs. evidence based medicine) and 2) how the DMAA story clearly and unequivocally demonstrates how the DSHEA allows for unscrupulous profiteers to game the system with little, if any, consequence and nothing but profit until the cost in lives forces the issue.
History
DMAA was originally developed by Eli-Lilly in 1948 and then later trademarked as Forthane to be used as a nasal decongestant (there are varying accounts but it seems that Eli Lilly patented the molecule in the early 1940s, trademarked and marketed it as Forthane in 1971 for allergic rhinitis, and then voluntarily withdrew it in 1983). The mechanism of action was vasoconstriction – the blood vessels in the nose would constrict so that less blood flow would lead to less nasal discharge. This is a mechanism used by common OTC nasal sprays like oxymetazoline (Afrin) and is indeed quite effective. However, Forthane was later withdrawn from the market because of significant side effects including headaches, tremors, and increased blood pressure. These effects likely occur because DMAA is structurally similar to amphetamine and as a result, the compound is not only a vasoconstricting agent but is also a central nervous system (CNS) stimulant.
Pharmacology
A 2011 study looked at the physiological effects of DMAA and claimed that “[t]o our knowledge, no data are available concerning the effects of oral geranamine intake on heart rate (HR) and blood pressure in individuals.”  Literature searches for any of a number of variations of DMAA including various equivalent chemical names, trade names, and geranium derivatives also revealed no studies on the physiological effects of DMAA (except for one article in JAMA from 1950 which has no text available entitled “NEW and nonofficial remedies: methylhexamine; forthane.”) prior to the 2011 study. Since then, there have only been a few studies, many of them done this year. The only data available on the compound is from chemical safety manuals like the Merck Index, and an Encyclopedia of Chemicals, Drugs, and Biologicals from 1989 listing toxicological data of the compound in animals. The toxicology report is rather telling:
    • TYPE OF TEST: LDLo — Lowest published lethal dose
    • ROUTE OF EXPOSURE: Unreported
    • SPECIES OBSERVED: Rodent — mouse
    • DOSE/DURATION: 20 mg/kg
    • TOXIC EFFECTS:
        ◦ Behavioral — convulsions or effect on seizure threshold
        ◦ Behavioral — ataxia
        ◦ Lungs, Thorax, or Respiration — other changes
Based on this limited report, it is difficult to determine clinical safety and efficacy effects of the compound. As with all vague things in the biomedical world, unsubstantiated declarations can be fabricated as long as they don’t make specific disease claims.
But do we really have no idea what this compound could or would do? Is there truly an absence of evidence? From the strictest interpretation of the hierarchy of evidence in EBM there is so little evidence as to be akin to no evidence. This is where science-based medicine steps in. Here at SBM we often talk about prior probability in the context of most CAM modalities having none, thus a p-value can indeed be spurious and safely disregarded in the proper context, regardless of “how significant” it is. But prior probability also works the other way and is indeed the basis physicians use for off-label prescription of medications, amongst other things. So in the case of DMAA we can look at the chemical structure, the side effects that led to the withdrawal of Forthane decades ago, the known vasoconstrictive effects that Eli Lilly exploited as the mechanism for their drug, the Merck toxicology data, and especially the fact that DMAA interferes with immunoassays for amphetamines, to draw a conclusion that in the absence of better evidence it is quite reasonable to conclude that the primary and side effects, as well as dangers of DMAA, would be very close to those of amphetamine – a compound we have studied extensively. A little bit of intellectual honesty would then lead someone to realize quite rapidly that unless we felt comfortable putting amphetamines out on the open market for anyone of any age to buy and consume, we shouldn’t do the same for DMAA. This is regardless of the source since coming from a plant won’t magically make the compound any safer or have different effects. Unless of course you believe in magic.
In a recent Google search, many websites devoted to bodybuilding and health supplementation have made the claim that DMAA is safe or at least is safe in “appropriate” doses while recognizing that taking too much can have adverse effects. Yet what can this possibly be based on? We have no idea what the elimination route actually is, what the half life is, if it builds up in tissues over time, if it causes damage to particular organs (like the liver or kidneys), or what the long term effects would be at any dosage. Many of these sites use anecdotal data – individuals using it didn’t die or have horrible effects and felt great whilst taking it. Yet this cannot possibly take into account the previously-mentioned considerations. Some sites even list recommended dosages and frequencies of administration. Once again, based on what? Nobody has any idea if the compound accumulates in the body or what the half-life is to make such a claim. But, such claims are perfectly legal and reasonable in the world of the DSHEA.
How to game the system using the DSHEA
So now that we have established that DMAA is a synthetically derived amphetamine-like molecule, how did we go from a drug that was discarded from medical use decades ago to a “natural” and “safe” dietary “supplement?”
It seems to have started in 1996 with an article out of China called “A study on the chemical constituents of geranium oil” (Ping et al. Journal of Guizhou Institute of Technology). Despite our best search efforts, we could not find that actual article, merely hundreds of references to it. We attempted to go directly to the journal website, but none exists. Despite this, it is the most commonly cited reference for the “natural” origins of DMAA as it claimed that this study found evidence of DMAA in geranium extracts.
That’s it. Really. That is all that was needed, despite all of the long synthetic history of the compound, to make it legal to market under the DSHEA. The Human Performance Resource Center has a pretty comprehensive list of all the companies and products that sell DMAA-containing compounds (PDF) under the protection of the DSHEA. There are 79 different products with almost as many companies. And that is just the list of products still currently marketed. There is a much longer list of products that are no more or no longer use DMAA. Sure makes that FDA warning to 10 companies seem even more pitiful, doesn’t it?
Since the unfindable Ping et al. study there have been a few more that have used extremely sensitive techniques and not been able to find any DMAA in geranium extracts. USPLabs rebuts by claiming that these studies didn’t look at the correct (and incredibly specific) geranium plant and states that “critics are uninformed”. Interestingly enough, in that same article “[a USPLabs spokesperson] did not clarify whether the DMAA contained in Jack3d and OxyElite Pro was actually sourced from geranium…” Thankfully, we have science to help us answer that question.
A recent study did actually find some DMAA in geranium extracts. However this was in the 0.6 to 1.4 ng/g range. That’s nanograms – as in one billionth of a gram, or 1/10^-9 grams of active substance per gram of geranium. The amount of DMAA in Jack3d by USPLabs appears to be a secret. Reading that thread from the USPLabs official blog is quite telling in and of itself, with comments from USPLabs claiming it has been studied and determined safe, citing their own in-house studies and press releases as evidence of this (as well as one actual peer reviewed study). However, in perusing the various sources and recommendations on the web anything ranging from 20 mg-75 mg is the recommended dosage with 50 mg being most commonly mentioned. That means USPLabs would have to be processing 50,000 kg of geranium to produce one dose of their product. What was that about prior plausibility again? If that weren’t enough, yet another study demonstrated that:
the enantiomeric and diastereomeric ratios of two different known synthetic DMAA compounds, as well as the total concentrations of DMAA and its stereoisomeric ratios in 13 different supplements, were determined by gas chromatography. The stereoisomeric ratios of DMAA in the synthetic standards and in all the commercial supplements were indistinguishable.
In organic chemistry, molecules that have the exact same number and type of atoms can have different configurations in three dimensions. Even if they have the same exact number and type of bonds this can occur. This is biologically very important since most of our enzymes have evolved to process one particular configuration of compounds that have multiple configurations. In synthetic chemistry, making a compound that has exactly the three dimensional shape that you want is often rather tricky and is called “controlling” the stereogenic or chiral centers. So when you do a synthetic reaction, you often get a mixture of these various configurations and the ratios are determined by the initial conditions and the reaction conditions. What this paper is telling us is that an actual sample of products that contain DMAA has ratios that are identical to what you would get from the standard laboratory synthesis of the compound. Of course, it is possible that this could be entirely coincidental and the geranium plant just happens to have the exact same ratios as well. However, for reasons that would go well beyond the scope of this article, that is almost as likely as homeopathy working. For a more in-depth discussion of how incredibly implausible the claims are, there is an excellent article dissecting every claim and every molecule as well.
Since there is a potential profit, USPLabs has created an entire website devoted to trying to prove many of these studies to be false accusations. They only address a handful of the criticisms above and none of them actually demonstrate the safety of DMAA. So why even bother? Because if DMAA is not a “natural” compound used for “hundreds” of years and generally recognized as safe (GRAS) then DMAA would be considered a novel drug and USPLabs would actually have to demonstrate safety and efficacy data in order to stay on the market. By asserting it is a “natural geranium extract” it can be shielded by the DSHEA and make all the burden of proof lay with the FDA while selling their product. Some consumers clearly know it is an amphetamine and use it as such for performance enhancement. At least they are (marginally) informed consumers. But many do not realize this and believe the marketing hype that this is a safe and an all-natural product, and have paid with their health and their lives.
Conclusion
Despite USPLabs protestations, there is no reasonable way that DMAA can be considered a natural or safe product for sale as a supplement under the DSHEA. And even if it did meet DSHEA requirements, this is an excellent example of the dangers of the law in the first place that allows so-called natural compounds to be marketed without prior safety and efficacy testing. The authors recognize that in the vast majority of cases such compounds have no effect at all, whether positive or negative, and the primary harm is in wasting people’s money with claims that are tantamount to fraud. However, there are clearly cases where that is not the case and harm is established about as clearly as one could expect without people dropping like flies. And that doesn’t take into account the less severe or acute harms experienced by vast numbers of people taking untested supplements.
But even more alarming to us is the fact that this DMAA saga exposes quite clearly how unscrupulous companies driven by nothing more than profit can game the system using the DSHEA as a shield, with such incredibly paltry evidence as a single article that can’t even be found as anything but a reference to support their claim for exemption under the DSHEA. While it is not established to any legal certainty, it seems quite clear to these authors that there is a preponderance of evidence demonstrating USPLabs and potentially other DMAA product manufacturers are knowingly selling a synthetically-derived drug and using the popular notion of the fallacy of the appeal to nature to market it for significant profits.

Amish Farmer Jailed for Selling Snakeoil
An Amish farmer is convicted of selling a caustic poison as patent medicine (and of witness tampering) and yet is defended by “alternative medicine” proponents who apparently want the freedom to be defrauded and harmed.
Steven Novella on July 5, 2017
Link
If you strip away the political controversy, the core story here is rather straightforward. Samuel A. Girod was selling a patent medicine he called “TO-MOR-GONE” with claims that it could cure skin disorders, sinus infections, and cancer. What he was doing was identical to the patent-medicine sellers of the 19th century – putting together some concoction of chemicals and making completely unsubstantiated medical claims. This is the kind of specific behavior that the FDA was created to regulate.
In this case Girod’s patent medicine contained an extract of bloodroot (Sanguinaria canadensis). Bloodroot contains benzylisoquinoline alkaloids, which are toxic and highly caustic substances. It destroys animal cells on contact. There are a number of “alternative” or herbal salves that are similarly highly caustic substances (with bloodroot being a common ingredient) that are sold as treatments for skin cancer and other conditions. The idea is to burn away the cancer.
Another example is black salve. Sometimes it is claimed that such treatments will kill cancer or abnormal cells, but leave healthy cells unaffected. This is untrue and actually quite absurd. These substances are simply caustic – they kill everything. They are similar in effect to pouring acid on your skin. Using these products is likely to cause disfiguring lesions (warning – the images in this link are gruesome), and is also unlikely to completely remove a cancer.
What this shows is how ideologically flexible so-called “alternative” medicine can be. On the one hand proponents rail against the “cut, burn, and poison” approach of standard cancer treatment. This is an unfair characterization of evidence-based anti-cancer treatments, which are targeted as much as they can be, and are only used when they show benefit in excess of risk. Alternative treatments are supposed to be kinder and gentler. But then they also promote as “alternative” a caustic poison that non-specifically burns away tissue leaving behind often horrific scars.
This is justified because the caustic poison is “natural” – an appeal to nature, one of the most deceptively harmful concepts in our culture. The notion of “natural” is used to justify all sorts of false dichotomies, and “greenwash” over a meaningful analysis of mechanism and risks vs benefits. It is a marketing term used, as marketing terms often are, to encourage people to trust their manipulated gut feelings rather than to think reasonably or scientifically about a claim.
Healthcare freedom
Many countries, including the US, sensibly have a system in place for evaluating medical products to protect the public from fraud, waste, or harm. Evaluating medical products is complicated and can even be risky, and it is unrealistic to expect that individuals will be able to parse the dense medical literature to evaluate claims on their own. People tend to rely on their personal anecdotes or word-of-mouth, which are fantastically unreliable when it comes to medical treatments. Plus, once an herbal salve burns a disfiguring hole in your arm or face you cannot be remedied simply by asking for your money back.
The notion that the market can sort out medical products is, in my opinion, naïve and ill-considered. Essentially the choice is between two systems of evaluating medical products. We can do carefully designed and executed clinical trials that are intended to minimize risk and arrive at the most objective and reliable answers possible. Or we can do uncontrolled trials with real-world use, which will produce ambiguous and mostly worthless results and cause a great deal of harm in the process.
In fact most Americans assume that if they go to the pharmacy and buy a health product, that product has been tested and approved, that the claims made are reasonable, and the product is basically safe to use as directed. This is similar to assuming that if you drive over a bridge, the design, construction, and maintenance of that bridge has been inspected and it is not up to you to decide if the bridge is safe or if it’s likely to collapse underneath you. I also think most people would be unsatisfied with the notion that if the bridge collapses you, or your estate, can always sue the engineer for damages.
And yet proponents of worthless, potentially harmful, and scientifically implausible treatments (i.e. “alternative”) often appeal to freedom in order to fend off regulations intended to protect the public from snake oil. The case of “TO-MOR-GONE” is no different. In this case the fact that the harmful product is being sold by a folksy Amish farmer just adds to the optics.
Girod has taken this strategy farther than most. He claims that the federal government has no jurisdiction over him. According to reports:
“I am not a creation of state/government, as such I am not within its jurisdiction,” Girod wrote. He added later: “The proceedings of the ‘United States District Court’ cannot be applied within the jurisdiction of the ‘State of Kentucky.’”
It’s odd that he, on the one hand, says he has no connection to any state, then invokes the sovereignty of the “State of Kentucky” for protection. He may have missed the fact that we fought an entire war over this very question with a very definitive outcome.
Girod was convicted and sentenced to six years in prison. I think that is a reasonable sentence for selling an unapproved caustic substance to the public with instructions to put it on your skin. However, much of that sentence is likely due to Girod’s direct resistance to the federal government. He did not allow FDA agents to inspect his manufacturing process. Also, and likely most damning, he threatened a potential witness and was therefore convicted of tampering with a federal witness.
And yet the alternative medicine community came out to support Girod, buying into the “natural” and “health freedom” narratives that they have been using to sell fraudulent medical products and services.
On close inspection it becomes clear that, at its root, the alternative medicine movement is anti-consumer. Their goal is to erode the regulations that protect the public from bad medicine, so that they will be free to sell products and services that were once considered “health fraud.” It is disheartening, the extent to which they have already been successful.

Oregano Snake Oil
Steven NovellaonJune 25, 2025
Tweet
Shares
Oregano oil is being marketed with a variety of health claims, including as a treatment for various infections, inflammatory disorders, and skin conditions. This TikTok video by an “Ayervedic specialist” is typical of the claims made for this product.
The claims suffer all the usual problems of the supplement industry, which we can go through them in some detail. But here is the executive summary – claims for oregano oil are based partly on traditional use and partly on pre-clinical data. There is almost no scientific data involving people. Proponents are extrapolating from the basic science to clinical claims, which is not valid and has proven extremely unreliable. They justify this with the usual appeal-to-nature fallacious arguments.
What does the basic science say? Here is one of the better studies. It shows that oregano oil in vitro has bactericidal activity, likely through disruption of the bacterial cell membrane. They also demonstrate potential activity as a topical treatment for burn infections. However, I note that they did not use a proper control comparison. The two treatment arms contained different concentrations of oregano oil mixed with grape seed oil. For some reason they did not include a treatment arm with grape seed oil only (a pretty obvious control).
Other research shows potential anti-inflammatory properties. These, however, are all biomarker-based studies. There is no research demonstrating a clinically relevant effect in humans. Showing changes in biomarkers of inflammation is not very compelling on it’s own. I would also note that anti-inflammatory effects are not generally what you want when trying to fight off an infection. So claiming anti-infection and anti-inflammatory effects at the same time is a bit of a contradiction.
And of course there is the almost ubiquitous claim for supplements of antioxidant activity. However, there are no proven health benefits to eating antioxidants. And again, oxidative compounds are actually used by the immune system to kill invaders, to a genuinely potent antioxidant could impair your immunity.
Even if we stipulate a probable anti-microbial effect of oregano oil at a high enough concentration, dose, and delivery mechanism, there is still a long way to go before making clinical claims. Topical use is a much easier bar to clear, because we don’t have to deal with bioavailability, metabolism, distribution in the body, pharmacodynamics and pharmacokinetics. As a topical antimicrobial oregano oil has promise, but it can also cause skin irritation and rashes, even without an allergic reaction. We therefore need human clinical trials looking at specific formulations and doses.
For internal use there are a host of factors that we simply do not know, because of the utter lack of human clinical trials. Do the active ingredients get absorbed, how are they metabolized, how are the metabolites distributed in the body, how quickly are they eliminated, and what are the net clinical risks and effects? Is it safe in pregnancy and breast feeding? What are the interactions with other drugs?
Oregano oil has a host of potentially serious side effects and interactions with medications. It can increase blood thinning, resulting in a risk of bleeding. It can also interact with blood sugar lowering agents, and can therefore be dangerous in anyone taking medication for diabetes.
In the world of scientific medicine, we may begin with a promising agent, like oregano oil, but then we need to study is in vitro, then in animals, and finally in a series of clinical trials in humans for every potential clinical use and in special populations. Only then can we make clinical claims of safety and efficacy, know the proper dose and treatment regimen, and make informed decisions about risk vs benefit.
What you absolutely cannot legitimately do it leap over a decade or more of necessary clinical research and go directly from preliminary in vitro data to clinical claims. But that is exactly what proponents of oregano oil are doing. The video by the Ayurvedic specialist make very clear the process they use – just make up magical thinking about the product based on mystical appeal-to-nature nonsense.
She claims that oregano oil just knows what is bad in your body and it magically flushes it away. The universe simply does not work that way. At the very least, this should be considered a faith-based claim, not a science-based or reason-based claim, and it is certainly not evidence-based.


Creatine Supplements for Brain Function
Steven Novella onN ovember 19, 2025
Link

There is a long history of supplements marketed to enhance memory, focus, overall cognitive function, and brain health. None of them are backed by quality scientific evidence, and they seem to go through the typical conveyor belt of claims – by the time one claim is collapsing, such as ginkgo biloba, the industry is happy to move on to the next.
The latest in this brain supplement story is creatine (specifically creatine monohydrate). The story here is a bit more complex than the typical supplement slop. The putative mechanism is reasonably plausible – creatine is converted into phosphocreatine and stored in neurons, which can be broken down into ATP to use as energy. The idea is that when the brain is stressed it can tap into this extra source of energy. At least there is no quantum vibrations or chi energy involved.
With these types of potential mechanisms, however, it is difficult to know if the effect is clinically significant. First, is the availability of ATP a rate-limiting step in brain function? Second, is the amount of ATP made available through phosphocreatine significant enough to affect function? To answer these questions we need clinical research.
A 2024 systematic review goes over all the relevant clinical studies – “Sixteen RCTs involving 492 participants aged 20.8-76.4 years.” That is a modest amount of data, but enough to get a preliminary idea of whether there is any potential here. The review found:
“Creatine supplementation showed significant positive effects on memory (SMD = 0.31, 95% CI: 0.18-0.44, Hedges’s g = 0.3003, 95% CI: 0.1778-0.4228) and attention time (SMD = -0.31, 95% CI: -0.58 to -0.03, Hedges’s g = -0.3004, 95% CI: -0.5719 to -0.0289), as well as significantly improving processing speed time (SMD = -0.51, 95% CI: -1.01 to -0.01, Hedges’s g = -0.4916, 95% CI: -0.7852 to -0.1980). However, no significant improvements were found on overall cognitive function or executive function. Subgroup analyses revealed that creatine supplementation was more beneficial in individuals with diseases, those aged 18-60 years, and females.”
I would characterize these findings as mixed. It seems to help memory, attention, and processing speed, but not overall cognitive function (that seems important) or executive function. Also, the effect was greater in women, those <60, and those with chronic illness. Generally, when we see mixed results like this with preliminary studies, that’s not a good sign.
The authors conclude that there is low to moderate confidence for a beneficial effect which requires “larger robust clinical trials” to validate. That is code for ‘not ready for prime time.’
There is also some evidence that creatine may be helpful for sleep deprivation specifically. This makes sense since a brain under stress, such as sleep deprivation, may make the availability of ATP a rate-limiting step.
Studies generally use a dose of 3-5 grams per day, or even 5-10 grams. For some applications, like sleep deprivation, a loading dose of 20 grams per day for a week is used. These doses are generally safe, but they can stress out the kidneys and should not be used in people with kidney disease. They can also worsen mania in bipolar disorder and worsen Parkinson’s disease when combined with caffeine.
What does all this mean for current recommendations for creatine for brain function? There are currently no published official recommendations from any medical body – so here’s my SBM-orientated take.
The claims for creatine are semi-plausible, and low-dose supplementation is likely safe (with the caveats above). But the clinical evidence is mixed and preliminary. I am especially concerned that the evidence shows no effect for “overall cognitive performance”. Given the overall false positive bias in the medical literature, especially for preliminary studies, the probability that creatine will turn out to be significantly effective is somewhat low, but non-zero.
Clearly, we need larger and more rigorous clinical research to provide more confident answers. There may also be a sub-population or specific indication where it is reasonably effective. That would be similar to melatonin – it is not really an effective general sleep aid, but it can be effective in treating jet lag. Perhaps creatine will turn out to only be effective for acute sleep deprivation.
I would not be surprised either way, but a more confident answer awaits larger clinical trials.

    • 

The peptide craze sweeping America has a fan in RFK Jr
This could lead to less FDA oversight just when more is needed
Paul Knoepfler on February 9, 2026
Link

So-called “peptides” are a fad that rivals some of the riskiest past health crazes I’ve seen, including unproven stem cells, but the peptide mania poses unique risks.
For context, more than 100 peptides have been FDA approved for legitimate purposes since the introduction of insulin in 1923, all the way up to and including GLP-1 drugs. These scientifically-proven peptide drugs are currently prescribed for conditions including diabetes, osteoporosis, chronic pain, and rare genetic disorders. But those peptides and uses are not what this post is about.
Instead, I’m covering the unproven and non-FDA-approved peptides that seem to be everywhere now. This fad also has become wrapped up in politics related to HHS Secretary RFK Jr, who apparently is a peptide enthusiast. There are notable parallels between marketing of unproven stem cells and peptides, including Kennedy’s interest in both.
The peptide craze took off in the US around 2020 when a constellation of physicians, wellness influencers, and firms like compounding pharmacies started making these unproven snippets of amino acids available to Americans. Many of those cashing in on the half-dozen or so most popular peptides like BPC-157, GHK-Cu, TB-500, and others (I’ll loosely call these “pop peptides”) claim without any solid evidence that these substances can do many good things in people ranging from increasing muscle to regenerating tissues to making you live longer.
Prescription not always required
As compounders and others started preparing pop peptides for customers, you’d think that a prescription would be required, but I’m not sure that always happened. I also wonder if some firms were producing peptides in bulk for dubious suppliers, who then sold them to influencers or directly to consumers. In the summer of 2022, a compounding industry newsletter rightly urged caution on pop peptides. It noted, “Wise prescribers will stay away from any entity that prepares or distributes peptide products for individual patients without a prescription. They’re not compounding pharmacies, and they’re likely violating state and/or federal law.”
Whatever the source, Americans either popped the peptides orally or got them injected. Some laypeople were even self-injecting. For a few years the FDA wasn’t carefully overseeing this space or maybe trying to play catch up, and these peptides floated in a regulatory gray area. The same kind of thing happened with unproven stem cells, where eventually more than one thousand stem cell clinics had spread around the country before the FDA did much of anything, such as seeking injunctions.
FDA action
Fortunately, in 2023, the agency put most of the pop peptides off limits to compounding by reclassifying them as Category 2, effectively barring compounding pharmacies from making them due to safety concerns, lack of data, or impurities. As a result, BPC-157, GHK-Cu (for injectable routes of administration), and most of the other pop peptides could no longer legally be compounded. This law firm webpage cautions potential suppliers on the legality of such peptide use now that they have been placed in Category 2. Note that the FDA seems to allow topical use of the peptide GHK-Cu, an application that is not considered Category 2. However, to be clear, no pop peptide has FDA approval for any supposed wellness application.
The Category 2 classification of most pop peptides was a positive public safety move by the FDA. To my knowledge, there hasn’t been even one medium-sized, well-controlled clinical trial of injection of BPC-157 or similar peptides in humans for a specific condition. Most of the studies on the pop peptides were done in rodents or in cell cultures in plastic dishes in the lab.
What does the research tell us?
I found only one vague listing on Clinicaltrials.gov for a phase 1 study of BPC-157 where the results were submitted but then cancelled before quality control took place. Yet somehow there are 207 articles on PubMed. They report a hodge-podge of animal and cell culture studies, along with opinion pieces sometimes touting the peptide. Other peptides like GHK have also been the subject of many animal and cell culture studies. Here too, the publication record contains little data on human use including especially by injection.
A review on BPC-157 published this past December rightly noted the lack of human data and the uncertainties arising from that. While this review also noted encouraging pre-clinical animal data on BPC-157, that doesn’t prove anything for humans and the authors cautioned about possible publication bias. I also wonder about potential conflicts of interest of authors of many of the publications that seem so upbeat about peptides. For instance, how many have no financial ties to BPC-157?
Backlash to peptide restrictions
The 2023 FDA action prompted a strong reaction. Some compounders, wellness influencers, and other companies profiting from peptides objected. There was at least one peptide-related lawsuit against the FDA, a case that was ultimately settled in a way that, to the best of my knowledge, did not open the door to resuming compounding.
Despite the grumpiness from those in the peptide world (there’s even a ‘save the peptides’ website), the FDA wasn’t somehow acting unreasonably on peptides. The US and world anti-doping agencies have also banned BPC-157. The US Anti-Doping Agency even has a BPC-157 doping webpage. If anything, overall the FDA had been too tolerant of unapproved peptide drugs.
It’s also important to consider the route of peptide use. While supposed wellness influencers largely promote peptide injection, there is also a vast array of oral supplements containing pop peptides. Although some synthetic peptides may be resistant to destruction in the GI tract, I suspect that many taken orally are quickly digested and then have no chance for meaningful activity in humans, if they even had any to begin with, which remains unclear. Even though many pop peptide formulations are often marketed as supplements, it’s unclear whether that allows them to escape drug classification.
Prohibition, gray markets, and risks
You might think the peptide problem would have eased since the FDA prohibited their compounding, but instead it appears to have worsened, and the scope of potentially dangerous peptide use in the US is astounding. Perhaps a million or more Americans have gotten non-FDA-approved peptide drugs at least once. There are peptide parties, peptide stacks (taking two or more peptides together), conferences and businesses that give free peptides as perks, and “peptide guys” who supply them for personal use.
Since American compounding pharmacies for now can no longer legally market these peptide drugs (although perhaps a few still do under the radar), where are people getting all these peptides lately? There has been a big shift to a gray market. Research-grade peptides are flooding the U.S., often coming from other countries, including Chinese suppliers. A recent New York Times piece on Chinese peptides in the US is a sobering read. Remarkably, users are often now instructed to DIY reconstitute the peptide powder with sterile water and then inject themselves. Not only does this risk infection, but also there’s often no medical provider around should something go wrong.
Of course, using research-grade pop peptides comes with all kinds of other risks. They can contain contaminants, including chemical residues related to their synthesis, and may come with incomplete peptides that might have even more unpredictable activities. The gray market vials may also contain the wrong peptide, an incorrect amount, no peptide, or who knows what.
The huge popularity of GLP-1 drugs, which are also peptides, may also be feeding into the pop peptide excitement. Perhaps it’s not surprising then that the overall peptide trend goes beyond BPC-157 and the other supposed wellness peptides to also include unproven and non-FDA-approved GLP-1-related peptides too.
Taken together, this is a major public health problem. Two women at a longevity meeting were hospitalized right after peptide infusions, but there are no details as to which peptides may have made them so ill. There was another recent report of necrotizing pancreatitis after peptide use. Such reports may just be the tip of the iceberg.
Since good clinical trial data are lacking, there is no way to know what any particular peptide injection might do to the body. There is also no solid information on dosage, potential interactions with other peptides or drugs, or longer-term risks. Given the lack of clinical trial data, it’s very possible that those who regularly take these peptides could have elevated risks of diseases that will only become apparent years down the road. I’m thinking of things like kidney or liver damage, immune issues, and elevated cancer risk.
Regulatory cop out coming?
Despite the risks and the fact that these are unapproved drugs, I’m hearing that an announcement could come as soon as within a month that the FDA will exercise what’s called enforcement discretion on the most popular group of these peptides. In other words, the agency would look the other way and allow compounding pharmacies to market pop peptides again, even though there’s been no clear change in the data on these substances.
Enforcement discretion in this case would be a political and regulatory shortcut (and I say a cop out) since changing actual relevant laws or regulations related to peptide compounding would be a lengthy, complex process.
Say what?
In a recent podcast, Tenille Davis, Chief Advocacy Officer for the Alliance for Pharmacy Compounding (which put out the 2022 newsletter I mentioned earlier), advocated for FDA enforcement discretion for certain peptide compounding (start listening around the 20-minute mark for the most relevant comments). Compounders argue that if there are no data proving these peptides are unsafe, they should be allowed to sell the peptides, even if there is also no evidence of efficacy in humans. That argument makes no sense, as all drugs—including peptides—must have strong data supporting safety and efficacy before marketing or the public is put at great risk.
Yet such arguments could win the day soon. HHS Secretary RFK Jr. seems quite interested in these peptides. GOP lawmakers have also asked him to weaken FDA oversight of peptides specifically through enforcement discretion. Note that one of the politicians who reached out to Kennedy co-owns a compounding pharmacy. Here, the arguments more generally are that consumers really want these peptides and, if compounding continues to be blocked, risky overseas peptide use poses ongoing dangers that justify allowing American compounders to be the suppliers. I don’t buy either of these rationales even if gray-market peptides do pose additional risks. In the frenzy over these peptides, we should keep reminding ourselves that these pop peptides are unproven and unapproved drugs.
The drumbeat for less FDA oversight here definitely has a right-to-try (RTT) feel to it. RTT is also often invoked for unproven stem cell drugs as well, which has led to a slew of state legislation legalizing use of non-FDA-approved stem cell drugs, with the latest being the so-called Stem Cell Freedom Act of Wyoming. Some of the “stem cells” covered by these laws are not even real stem cells. How long until we see federal or state laws legalizing pop peptides? Maybe a Peptide Freedom Act? To a great extent it will depend on whether the FDA ties its own hands behind its back on compounding of these peptides via enforcement discretion, which is what the compounders seem to be anticipating.
The role of influencers
What has driven this continuing peptide craze even after the compounding was blocked?
In large part wellness influencers have maintained the fad. One name that keeps coming up is an influencer named Gary Brecka, who is linked to Kennedy. It was on Brecka’s podcast that Kennedy disclosed getting unproven stem cells. The podcast also promotes pop peptide use and Brecka offers forms of BPC-157 and other peptides.
Many other influencers also engage in such promotion, either directly or indirectly, such as by enthusiastically stating they take the peptides. Eric Topol has a helpful post on the peptide craze that lists influencers and associated peptides. For example, remarkably, Topol indicates that Stanford professor and podcaster Andrew Huberman has in some way advocated for nine different unproven peptides. Joe Rogan promotes BPC-157 and influencer Dave Asprey is listed as advocating for “various peptides.”
Reply hazy, try again
It’s possible the FDA will take dual actions on peptides. It may crack down on gray market peptide import, while allowing American compounders to make and provide the products again. By the way, it’s doubtful that unproven peptide drug import into the US is remotely legal. That’s probably why the packages reportedly can be falsely labelled as though they are something else and “for research use.” What’s really in the little glass vials of white powder that show up at your house? There are now new firms sprouting up that will analyze the peptides you’ve gotten, including for purity, before you take them.
Admittedly, the US compounders seem to have made far better products, but the peptides are still unproven. Still, the compounders have major sway now. There was an entire session on compounding at Kennedy’s MAHA meeting last November. One of the panelists was Brigham Buhler of Ways2Well, which has marketed peptides. Asprey was also a panel moderator at the MAHA meeting.
Within the FDA, I had originally thought that its biologics branch CBER would oversee these pop peptides, but it turns out that the drug branch CDER is responsible for what are officially considered “peptides”, defined as chains of 40 amino acids or less. Anything longer than that is considered a protein instead, meaning a biological drug overseen by CBER.
CDER Director Tracy Beth Høeg seems likely to do whatever Kennedy and FDA Commissioner Marty Makary want on peptides. I don’t find it reassuring that Høeg previously had offered unproven stem cells. With an anticipated new Kennedy-friendly composition to the Pharmacy Compounding Advisory Committee (PCAC) related to its likely renewal as a committee by this April, PCAC may also facilitate softening of FDA oversight of pop peptide compounding.
A curious paradox
There’s a paradox with MAHA excitement about peptides. Many of the same folks who claim to be against food additives and proven vaccines will nonetheless inject themselves with risky peptides because some guru (who in many cases likely profits from the peptides) tells them it’ll do wonders
The FDA has a critical role in both properly overseeing pop peptides and educating the public about the risks of such products, but it seems the agency is soon more likely to make things worse than better on this front.

   Law and Regulation

The Congressional Dietary Supplement Caucus
The Congressional Dietary Supplement Caucus, an officially-recognized Congressional Membership Organization, operates as an in-house mouthpiece for the dietary supplement industry. Both the caucus and the rules allowing it should be reformed to prohibit this.
Jann Bellamy on August 17, 2017
Link


If you were thinking from the title that this might be another facetious SBM post (a la Clay Jones) in which I fabricate an officially-recognized organization within the U.S. Congress devoted to the dietary supplement industry, you would be wrong. There really is an official organization of the U.S. Congress, called the Congressional Dietary Supplement Caucus, and it is devoted, in every sense of the word, to the dietary supplement industry. Its job is feeding your elected representatives a steady diet of industry-friendly talking points and protecting the industry from meaningful regulation, all skillfully orchestrated by the industry itself.
I am not particularly sanguine about the U.S. Congress to begin with, but I must admit that, despite over a decade of dealing with quackery and its many deceits, even I was taken aback to find what is essentially a lobbying arm of the dietary supplement industry imbedded in the institution itself. To be fair, there are other special interests with their own caucuses (beef, bourbon, and cement, for example). I have not investigated the extent to which those and other industries with dedicated caucuses have the same degree of industry control over their message as the Congressional Dietary Supplement Caucus. If they do, don’t expect the beef, bourbon or cement industries to be reformed anytime soon.
Before we put the two together, let’s take a brief look at dietary supplements and caucuses separately.
Just yesterday, Steve Novella’s post reviewed yet another article in the press decrying the lack of effective regulation of dietary supplements and the unfortunate misconception in the public’s mind that supplements are safe and effective, when, in fact, the evidence is to the contrary. (You can find other articles here, here and here.) As he pointed out,
Routine supplementation with vitamins and minerals (sometimes sold in dosages far exceeding the recommended daily allowance) is unnecessary for the vast majority of the public.
Herbal remedies are essentially unpurified drugs with unfavorable risk-benefit ratios and are not intended to supplement the diet in any event (which is how “dietary supplement” is legally defined).
To this list, I’d add desiccated animal glands, another category of dietary supplement also used as drugs (also here), but (like herbal remedies), without the pre-market testing and post-market level of surveillance pharmaceutical drugs must undergo.
The root cause of the supplement con, as Steve correctly names it, is the Dietary Supplement Health and Education Act of 1994 (DSHEA), which eschews premarket testing for product safety and efficacy in favor of a post-market catch-the-bad-guys-if-you-can regulatory scheme enforced by a severely understaffed and underfunded FDA: 26 government employees and a $5 million budget versus a $41 billion-a-year dietary supplement industry, of which Big Pharma owns a large chunk.
In addition to its own profits, the dietary supplement industry is an economic engine of the vast pseudoscience market. Naturopaths derive significant income from selling patients dietary supplements they prescribe. Gwyneth Paltrow and her apologist, Dr. Aviva Romm, “functional medicine” guru Dr. Mark Hyman, “integrative medicine” inventor Andrew Weil, right wing conspiracy theorist Alex Jones, and President Donald Trump all have (or, in the case of Trump, had) their own branded dietary supplements they want to sell you.
None of these will easily give up their profits. And, if their pals in Congressional Dietary Supplement Caucus have their way, they won’t have to.
A “caucus” is formally known as a Congressional Member Organization (CMO), formed by members of Congress “to pursue common legislative objectives.” CMOs must register with the House Committee on Administration and are governed by its rules. They are not publicly funded per se, although caucus members can use certain publicly-funded resources to carry out the legislative objectives of the caucus, including staff help, communications resources, space on an official website, and preparation of materials for dissemination. Representatives and Senators can use their personal funds to support caucus activities, but the Administration Committee’s rules provide that:
Neither CMOs nor individual Members may accept goods, funds, or services from private organizations or individuals to support the CMO.
As of 2014, according to an article in The Atlantic, there were almost 700 CMOs, up from about 100 in the early 1990s. You can find the current list here. (I didn’t count them, but feel free.)
The Dietary Supplement Caucus
With that background, let’s turn to the Congressional Dietary Supplement Caucus. According to the United Natural Products Alliance (UNPA), an industry trade association, the Dietary Supplement Caucus (DSC) was formed in 2006 and:
serves as a bipartisan congressional group of legislators, who promote discussions among lawmakers about the benefits of dietary supplements; provide tips and insights for better health and wellness; and promote research about the health care savings these products provide. In a recent letter confirming the DSC to the Committee on House Administration, the DSC writes, ‘The caucus seeks to enhance Congressional attention to the role of supplements in health promotion, disease prevention and address the regulation of the supplement industry.’ The DSC sponsors regularly scheduled luncheon briefings on Capitol Hill for members of Congress, their staffers, the media and the public.
Apparently, any consideration of meaningful industry reform via legislation to protect the public from the deleterious health and financial effects of dietary supplements is not on the agenda. Other industry reps were even more blunt in their assessment of the DSC’s purpose. In congratulating Rep. Mia Love (R-UT) on her ascension to co-chair of the DSC following Rep. Jason Chaffetz’s (R-UT) resignation from Congress, here’s what the President of the American Herbal Products Association had to say:
‘We greatly appreciate Rep. Love volunteering her valuable time and expertise to lead this Caucus in representing the regulated dietary supplement industry on Capitol Hill,’ said Michael McGuffin, president of the American Herbal Products Association. ‘Rep. Love’s leadership will help the Caucus continue to educate policymakers about this growing industry’s significant and positive impact on consumer health and the U.S. economy.’
Yep. That’s Job #1 of the DSC: “representing the dietary supplement industry on Capitol Hill.”
And this from the head of the Council for Responsible Nutrition, another industry trade group:
As more than 170 million Americans take dietary supplements each year, the Dietary Supplement Caucus serves as an important resource to ensure legislators and their staff learn more about the wellness benefits of dietary supplements and the regulatory complexities of our booming industry . . .
Of course, as mentioned, the “wellness benefits” of dietary supplements overall are extraordinarily modest compared to their risks, so much so that major health institutions advise against their use. The actual research demonstrates that:
Most supplements do not prevent chronic disease or death, their use is not justified, and they should be avoided. This message is especially true for the general population with no clear evidence of micronutrient deficiencies, who represent most supplement users in the United States and in other countries.
Yet, according to a rep from the UNPA, the DSC has its work cut out for it: making sure Americans take even more unnecessary and potentially dangerous dietary supplements.
Loren Israelsen, president of the United Natural Products Alliance, which is based in Salt Lake City, said, ‘UNPA is thrilled that Rep. Love is taking on this important new leadership role. We look forward to working with her to help grow the $41 billion national dietary supplement industry, which includes more than $13 billion in supplement business activity in Utah. The dietary supplement industry is a positive and powerful economic engine that creates thousands of jobs while helping Americans support their healthy lifestyles.’
Rep. Love, for her part, is all in:
‘I’m excited to begin work on behalf of the more 68 percent of Americans who take dietary supplements every year, ‘ Love said. ‘The industry is also a crucial part of Utah’s economy. Not only do dietary supplement companies provide jobs and opportunities in my state, they give consumers the opportunity to make educated choices to fill critical nutrient gaps and achieve better health.’
(Once again, no, they don’t.)
In fact, when the DSC reauthorized itself with the House Committee on Administration this year, a Senior VP of the Council for Responsible Nutrition, Mike Greene, made it clear just who was behind the effort:
In the past, it used to take us months to reform the caucus, which has to be done each two years. This year was relatively quick.
And:
Normally at the beginning of every Congress we refile the caucus. It used to be that we had to reach out to each individual to see if they wanted to continue to be a member; now we tell participants they will continue to be carried as members unless they affirmatively opt out.
“Us?” “We?” In other words, the supplement industry isn’t just getting its messaging out via the DSC, it’s dictating the terms of membership in the caucus and taking a proprietary role in its administration.
The Dietary Supplement Caucus seems to have taken a liberal view of the rule against accepting “goods, funds, or services from private organizations or individuals.” An announcement imploring other members of Congress to join the DSC, sent out by the Council for Responsible Nutrition, conveniently provides the names and contact information of Congressional staffers for those wanting more information. Or, your elected representative was told, he or she could just contact the CRN’s own “DSC industry liaison” for more information on joining the DSC. That seems a bit cozy, as well as a clear indication that the industry has no reason to fear that the DSC might present anything other than pro-supplement fodder to its members. (Current members of the Dietary Supplement Caucus are listed on the announcement. If you see one of your elected officials there, you might want to contact him or her and give them your thoughts on belonging to this group.)
The DSC has co-hosted a number of luncheons and briefings for members of Congress and their staffs “in cooperation with” (also here, here, here, here, here, and here) the four major industry associations: the American Herbal Products Association, the Council for Responsible Nutrition, the Natural Products Association and the United Natural Products Alliance. One can guess who picked up the tab.
In fact, Daniel Fabricant, executive director of the Natural Products Association (and former director of the FDA’s Division of Dietary Supplement Programs), has been remarkably frank about the industry’s role in running the show:
If you look at the history of the caucus, it has been the best way to educate Congress about dietary supplement issues. At these meetings, we can bring in speakers . . .
Yes, “we” can and “we” do.
You’ll not be surprised, by the way, to learn that Sen. Orrin Hatch (R-UT) is a member of the Dietary Supplement Caucus, nor that he is again sponsoring a bill to permit people with Health Savings Accounts to purchase dietary supplements and homeopathic remedies with their triply-tax-exempt funds. (A companion bill has been filed in the House.) We at SBM have criticized Sen. Hatch for blocking needed reforms in dietary supplement regulation. Perhaps we have been remiss in giving him too much credit. Looks like he’s got plenty of help from his fellow DSC members.
Any organization that is essentially part of Congress and operated with taxpayer-funded resources should not function as the in-house lobbying arm of an industry special interest group, nor should Congressional rules allow this to happen. As presently constituted, the Congressional Dietary Supplement Office is simply a shill for Big Supp. Both the caucus and the rules should be reformed to prevent this.

Supplements, Lies, and a Lengthy Transcript
Jann Bellamy on May 26, 2016
Link

On October 21, 1993, there was a hearing before the U.S. Senate Committee for Labor and Human Resources, with the long-winded title:
Examining How the Federal Government Should Regulate the Marketing and Use of Dietary Supplements and Related Measures, Including S. 784, To Strengthen Federal Standards with Respect To Dietary Supplements.
S. 784, sponsored by Sen. Orrin Hatch, would eventually be enacted as the Dietary Supplement Health and Education Act of 1994 (DSHEA).
I discovered this bit of Congressional theater when doing research for my recent talk at NECSS. Scott Gavura and I joined forces to present “Natural Disaster: Dietary Supplements.” Scott focused on pharmacology, while I talked about FDA regulation of dietary supplements (or lack thereof). Thanks to him, I now have a rudimentary knowledge of pharmacokinetics, the science behind how a drug or supplement works (or doesn’t) in the body. If you haven’t read his post from last week explaining this, and more, you should.
Reading the lengthy hearing transcript (well, ok, a lot of it) confirmed my suspicions that the fix was in even before the gavel went down to begin the hearing. What I had not realized was, at least according to some proponents of DSHEA, part of the deal was that consumers would have access to accurate information backing efficacy claims made for supplements and their safety. Nor had I realized that the weaknesses of DSHEA, which have become painfully obvious in the 20-plus years since the law was passed, were anticipated from the get-go and that Congress was well-informed of what they were. Finally, I was not previously aware of the provenance (shall we say) of the “experts” asked to testify at the behest of Sen. Hatch.
First, let’s set the stage on which this drama plays out, according to two excellent books on dietary supplements, Natural Causes and Vitamania. In 1991, Congress passed the Nutrition Education and Labeling Act (NELA). Most famously, NELA, for the first time, required that all foods bear the now-familiar nutrition label. It also required that any health claims made for foods be backed by “significant scientific agreement.” Rep. Henry Waxman and others wanted the same standard applied to dietary supplement health claims. After all, if food companies had to meet a certain standard to make health claims for, say, calcium in their products, why shouldn’t claims for the health benefits of calcium in dietary supplement form be held to the same standard? But the supplement industry knew it couldn’t survive under such stringent rules and Sen. Hatch made sure it didn’t happen. All parties agreed to let the FDA decide what standard should be required of supplement health claims and left it at that.
Lo and behold, the FDA turned right around proposed a regulation that dietary supplement health claims would be held to the same “significant scientific agreement” standard. This could be met in one of two ways. The supplement company could submit the evidence to the FDA for review or show that the claim was backed by a statement from a recognized scientific authority, like the National Academy of Sciences. (Actually, this is still the standard for health claims, but DSHEA did away with the necessity of making health claims. The nebulous “structure/function” claim and the “substantiation” standard for evidence obviated the need go to all the trouble.)
Sen. Hatch and the industry were not amused. The industry started an absolutely false rumor that the FDA was out to “ban” or “take away” consumers’ supplements. Thus riled up, hundreds of thousands of people wrote and called Congress demanding that something be done. With that, let’s turn to the hearing itself.
Where’s the evidence?
Rep. Bill Richardson (D-NM), who sponsored the House version of S. 784, led off the testimony. Rep. Richardson framed the issue as one of “freedom of choice.” If consumers could “choose dietary supplements that will help them prevent illness and disease,” the “safe use of supplements could save this country billions of dollars in health care costs each year.” How? By giving consumers “adequate information” using labels and “pamphlets.” (This is before the age of Google U and widespread use of internet sales.) And,
I also believe that health claims must be truthful, nonmisleading, and based upon the totality of scientific evidence . . . [M]anufacturers of supplements must be allowed to make truthful and nonmisleading claims when there is scientific evidence to back those claims. Let’s allow science to be the determining factor for the validity of health claims for supplements and any questions involving safety. This should be our goal as we move forward. [Emphasis added.]
The importance of consumer access to the evidence was emphasized by the Commission on Dietary Supplement Labels, which was created by DSHEA. The largely-forgotten Commission, which included industry representatives, was charged with making recommendations for
the regulation of label claims and statements for dietary supplements . . . [T]he Commission shall evaluate how best to provide truthful, scientifically valid, and not misleading information to consumers so that [they] may make informed and appropriate health care choices.
The Commission’s 1997 Report said that the supplement industry has a responsibility to provide a synopsis of the scientific evidence regarding statements of nutritional support and product safety to potential buyers and health professionals. These synopses should indicate how health professionals can obtain access to the studies and evidence that support these statements, which would facilitate the ability of health professionals and consumers to evaluate them.
Later in the hearing, Sen. Tom Harkin, of NCCAM/NCCIH fame, steps up to the bat, teeing off (badly scrambled sports metaphor noted) with his infamous story about how bee pollen cured his allergies. To that he added an anecdote about how someone gave him a traditional Native American substance (never identified) to chew on and it cured his sore throat, practically instantaneously. He then wanted to know why supplement companies shouldn’t be able to tell consumers that some people have been “cured of allergies,” for example, by a dietary supplement. However, to his credit, Sen. Harkin ends up agreeing with David Kessler, then head of the FDA and a witness at the hearing, that “significant scientific agreement” would be an appropriate standard.
Science and the Senator
As might be expected, the supplement industry’s protector-in-chief, Sen. Orrin Hatch, who dominated the mic, spent most of his time lambasting the FDA, including a downright abusive confrontation with Dr. Kessler. (Fortunately, Sen. Katzenbaum, for the record, stepped in and established that the rumors about the FDA “banning” supplements were encouraged by the industry and absolutely false.)
For their part, Dr. Kessler and other FDA officials present at the hearing tried to warn the committee about the dangers of supplements and the lack of evidence of their efficacy. Their points:
    • Many products sold as dietary supplements – amino acids, herbs and botanicals, and other non-vitamin and non-mineral products, have no established role in nutrition, have been associated with serious adverse reactions, and frequently bear unsubstantiated claims to prevent or treat disease.
    • If no scientific standard is imposed, the market will be filled with unsubstantiated claims, putting the public’s health at risk, including diverting people from proven medical treatments.
    • The lack of reported adverse events doesn’t mean they don’t happen, because there is no system for reporting them.
    • Although some botanicals are derived from well-known culinary herbs, most are not and have no known nutritional value or history of use as foods. Dietary supplements containing herbs and botanicals are not standardized, making testing them for efficacy or safety problematic. The FDA’s testimony specifically discussed the risks of germander, comfrey, chapparal, yohimbe, lobelia, Jin Bu Huan, Stephania/Magnolia, Ma Huang (ephedra), and willow bark.
And, finally, in Dr. Kessler’s own words,
The proposed legislation would permit companies to make the initial judgment. A claim could be made as long as it accurately described the state of the scientific evidence, which under the bill as written could include a complete lack of evidence. Thus, a claim could be based on mere belief or on one small preliminary study that in no way established the nutrient-disease relationship, as long as the label statements accurately portray the state of the evidence.
[I am not sure what he is referring to by “accurately portray the state of the evidence” as there is no such requirement in DSHEA.]
In yet another session of lambasting Dr. Kessler and the FDA, Sen. Hatch makes two statements confirming my initial impression that either Sen. Hatch does not, or does not want to, understand science-based, or even evidence-based, medicine. First, he asks, in essence, “what’s the harm?” If a supplement doesn’t hurt someone, why not let it remain on the market, even without evidence of efficacy:
The fact of the matter is that many people get well because they take placebos because in a large sense they believe they are doing something that helps them, and psychosomatically it does.
And,
[what] you have been advocating for . . . is basically that they [the supplement companies] have got to prove every claim that they make before they can put the claims out there. And, if they do not, they cannot do it. Therefore, a lot of products that basically are helping people like Senator Harkin . . .
Sen. Hatch then trails off into the “bee pollen anecdote” but his message is clear: anecdotal evidence is sufficient and supplement companies should not have to have any valid evidence before making claims.
He also said, in questioning a representative of the Center for Science in the Public Interest,
I have seen estimates where just if people would take Vitamin E that we would save about $25 billion a year in health care costs on the reduction of cardiovascular disease. You could just extrapolate that out with Vitamin C, beta carotene, Vitamin A. You could just go right through it. The American people would be much better off.
He does not explain exactly how one can “extrapolate” the alleged evidence for the efficacy of one vitamin to prove the efficacy of other vitamins, but such is the scientific prowess of our elected representatives in Congress.
Sen. Hatch’s “experts”
Sen. Hatch’s remarks were not without humor, although that certainly wasn’t his intent. The good Senator thanked a number of luminaries from the alternative medicine industry “who have worked closely with us during our consideration of this issue.” These included “Citizens for Health,” now run by James Turner, “neutraceutical” litigator and lobbyist, and supported by the Weston A. Price Foundation and the National Health Freedom Coalition, on whose board the late homeopathy enthusiast Rustum Roy sat.
Also recognized were a number of “helpers” with obvious ties to the supplement industry. And:
Another individual who has been a great help to me is Dr. Julian Whitaker, a noted physician, author of the monthly newsletter, “Health and Healing,” President of the American Preventive Medical Association.
I laughed out loud when I came to this point in the transcript. We’ll all have to agree that Dr. Whitaker is “noted,” just not in the way Sen. Hatch had in mind. He is an anti-vaccinationist who debated our very own Steve Novella. And, if that weren’t enough, he is a supporter of cancer quack Stanislaw Burzynski, claims he can cure diabetes “naturally,” thinks antibiotics don’t work, and prescribes chelation therapy for this patients. The American Preventive Medical Association, now the American Association for Health Freedom, was described by SBM’s Kimball Atwood as part of “what is probably the largest and most insidious family of organizations hyping implausible practices and the ‘freedom’ to peddle them.”
Dr. Whitaker did not personally appear, but submitted written testimony touting the benefits of saw palmetto, calling it more effective than Proscar. Apparently, Dr. Whitaker was the source of Sen. Hatch’s claim that we could save “billions” by taking Vitamin E. He extrapolated from two observational studies that by taking Vitamin E there would be a 23% reduction in the U.S. heart disease rate.
Another of Sen. Hatch’s experts at the hearing was Michael Janson, MD, who, according to his website, is past president of both the American Preventive Medicine Association and the American College for Advancement in Medicine, another pseudomedical pseudoprofessional organization. Quackwatch, which lists the ACAM among “Questionable Organizations,” complained to a website about it’s referring readers to ACAM for advice on “alternative medicine” that
referring readers to ACAM members is like referring people who want to borrow money to Mafia loan sharks.
Dr. Janson also described himself in his testimony as a charter member of yet another pseudomedical professional organization, the American Holistic Medical Association, whose members include such luminaries as Christiane Northrup, MD.
Dr. Janson seemed to enjoy his position as medical advisor to Sen. Hatch, a position of authority one doubts comes his way all that often. He refers to the “vast medical literature” substantiating the use of dietary supplements for health. He describes supplements as “safer than water.” His claimed that saw palmetto reduces enlarged prostates, heart attacks are preventable by taking vitamin C, and that antioxidant supplements are beneficial. He also sets up a giant straw man by displaying, in a chart, adverse reactions to drugs. He used the opportunity to promote one of his books by handing out free copies.
Although he didn’t personally testify, a letter from Linus Pauling to President Bill Clinton was included in the record. He opined that “vitamin C can help prevent the common cold” (it can’t) and that “a whole range of vitamins, known as antioxidants, can also prevent chronic illnesses including the nation’s two largest killers, heart disease and cancer.” (Vitamin supplementation may increase cancer mortality.)
Of course, if you’re pushing for a law like DSHEA, these are just the sort of “experts” one would want as advisors.
On the other hand, Bruce Silverglade, from the Center for Science in the Public Interest, presented the views of that organization and the American Cancer Society, American Heart Association, American Association of Retired Persons, American College of Physicians, American Institute for Cancer Research, American Nurses Association, Association of State and Territorial Public Health and Nutrition Directors, Citizens for Public Action on Cholesterol, Consumer Federation of America, Public Voice for Food and Health Policy, and the Society for Nutrition Education. With all due respect to Mr. Silverglade and his excellent testimony, having one person present the opinion of so many different organizations was a tactical error. Given the influence of the supplement industry and its powerful protector, I doubt it would have made any difference in the outcome, but it would have at least made the outcome look worse.
Mr. Silverglade said, in a statement overly generous in its interpretation of S. 784, that the bill would allow health claims “so long as manufacturer disclosed the state of the evidence supporting the claim, even if it was minimal.” This concerned him because
Manufacturers could hype products on the basis of preliminary, shaky, and inconclusive scientific evidence that would preclude consumers from making an informed choice, and a [sic] uninformed choice is tantamount to no choice at all.
He also warned against making health policy based on the “sole assumption that because a product has been used for many years that it is safe.” As well, he thought the level of proof required for removing products from the market – “substantial and unreasonable risk of injury or illness” – was too stringent and that the “amount and type of evidence needed by a supplement manufacturer to substantiate safety is insufficient.”
So, who was right?
How has DSHEA worked out? Splendidly, for the dietary supplement industry. Sales of dietary supplements were at $4 billion annually in 1994. In 2014, they were just under $37 billion.
For the rest of us, not so much. Over 20 years later, we know that some of the testimony at the hearing was prescient. Some of it proved dead wrong.
    • Consumers and health care professionals have never received the promised evidence for safety and efficacy. In fact, the industry fought legislation which would make them tell us what evidence they have backing their claims, even though they are required to have substantiation. And when the Department of Health and Human Services Office of Inspector General looked into whether a sample of the industry was complying with the “substantiation” requirement, they were not. The prediction that supplements would be put on the market with flimsy evidence behind them came true.
    • Placebos have yet to make anyone “get well.” But, as we know, there are dangers of thinking you are better because you feel better. For example, choosing alternative medicine over effective asthma treatment because placebo responses lead to feeling better without altering the underlying illness, could very well lead to preventable asthma deaths.
    • The supplements touted by Julian Whitaker and others at the hearing have not held up to further scrutiny, for Vitamin E and cardiovascular disease, for saw palmetto and prostate problems, for Vitamin C and colds or heart disease, or for antioxidant supplements. In fact, a 2012 systematic review of randomized, placebo-controlled clinical trials led the authors to conclude
With the possible exceptions of Vitamin D and omega-3 fatty acids there is no data to support the widespread use of dietary supplements in Westernized populations; indeed, many of these supplements may be harmful.
    • The evidence that the health care system has saved “billions” of dollars annually due to the public’s taking dietary supplements never materialized.
    • The standard for getting supplements off the market has proven problematic. Only one ingredient, ephedrine alkaloids, has been banned by the FDA, and that took a decade to accomplish. The other supplements Dr. Kessler and the FDA warned the committee about are still available and still have serious adverse effects: germander, chapparal, comfrey, Jin Bu Huan, yohimbe, lobelia, stephania, magnolia, and willow bark. Yet, because DSHEA does not require warning labels, consumers may not know of the risks.
    • Anecdotes weren’t evidence then, and they still aren’t.
    • Not knowing about adverse events doesn’t mean they aren’t happening. Through investigation of one manufacturer, we learned that the company withheld over 13,000 adverse events from the government. It was not until 2008 that a reporting system was imposed, although it is only for serious adverse events.
    • Recently, as Dr. Kessler predicted, the disturbing possibility that use of dietary supplements might actually result in rejecting an effective medical intervention was raised when researchers discovered a correlation between CAM use, including supplements, and chemotherapy refusal among breast cancer patients.
Conclusion: DSHEA is still a terrible law that harms consumers
The real experts, those who hew to the standards of evidence-based medicine, are vocal in their condemnation of DSHEA and the profligate use of dietary supplements. (For example, here, here, here, here, here, here and here.) But as long as Orrin Hatch remains in the Senate and the dietary supplement industry continues to rake in billions, regulatory reform is unlikely.

US Department of Justice Goes After Supplements
Steven Novella on November 18, 2015
Link

It is shaping up to be a good year for those of us advocating more effective regulation of supplements and unproven therapies in the US. The Food and Drug Administration (FDA) is reviewing its regulation of homeopathy, and recently also announced it is taking public comment on its regulation of the term “natural.” The Federal Trade Commission (FTC) is also reviewing the claims made by the homeopathy industry, and even gave a nudge to the FDA to fix its regulation.
Now the US Department of Justice (DOJ) is getting in on the fun:
USPlabs, which sold the best-selling workout supplement Jack3d, and six of its executives face criminal charges for the unlawful sale of nutritional supplements, the U.S. Justice Department said Tuesday in announcing a larger probe by federal agencies aimed at stemming the sale of unproven products.
This action by the DOJ raises the stakes to a new level – criminal charges. While the FDA and FTC do the best they can, they often lack teeth when it comes to supplements. The FDA might issue a polite request and then escalate to a stern warning when companies step out of line. The FTC can issue fines which amount to little more than a slap on the wrist – the cost of doing business. Both agencies are playing whack-a-mole and losing.
As an aside, homeopathy is different because legally it is regulated as a drug, meaning the FDA has much more regulatory power and could effectively shut down the industry if they wanted. All they have to do is require evidence of efficacy for any homeopathic product and the entire industry would evaporate.
Some background on supplements
Supplements are regulated under DSHEA – the Dietary Supplement Health and Education Act of 1996. This was essentially a gift to the supplement industry, effectively removing it from FDA regulation by creating massive loopholes. The legislation (thanks to senators Orin Hatch and Tom Harkin) is blatantly pro-industry and anti-consumer, even though it was sold to the public as being pro-consumer freedom.
The predictable result was that the supplement industry exploded. We now no longer need to speculate about what an ineffectively regulated health care product industry would look like – we have almost 20 years of the supplement industry as an example.
The idea of DSHEA is that market forces and consumer choice will lead to better products, with the FDA and FTC looking over industry’s shoulder and helping them self-regulate. That’s not what happened.
What did happen was that the supplements industry realized it could put almost anything in a bottle (as long as it didn’t contain an actual drug), and make whatever claims they wanted for it. They didn’t have to do any research or provide any evidence, just put a small disclaimer at the bottom saying the FDA has not reviewed the claims, a disclaimer the public was certain to ignore.
Even though the lax regulations created a formula for essentially making millions off of the placebo effect, the supplement industry pushed the limits even further. It has recently come to light that many supplements on the market don’t contain what’s on the label, and contain undisclosed fillers, substitutions, and contaminants.
Sometimes they even contain banned drugs – put a little Viagra in your male enhancement supplement, or a stimulant in your weight loss supplement, to get an edge on the competition. The FDA issues warning letters to companies who do this, but most fail to comply.
All of this is justified by those making millions off supplements, and those in the public who have been receptive to their advertising, by the assumption that supplements are “natural” and therefore magically safe and effective. This is not true. Herbs are drugs and can have drug side effects, toxicity, and interactions. This is why the FDA is now targeting regulation of the term “natural.”
Now the DOJ is involved
While the FDA and FTC struggle to contain this avalanche of what are essentially fake products defrauding the public, without really having the teeth or resources to do so effectively, now they are getting some help from the justice sector.
At the state level, earlier this year New York State attorney general’s office, after an investigation, filed a cease-and-desist order against GNC, Target, Walgreens, and Wal-Mart, ordering them to stop selling a number of herbal supplements that were found not to contain the ingredients on the label, and some of which contained unlisted fillers that were potential allergens.
Now at the federal level, the DOJ is getting involved, and with good reason. Here is perhaps the worst offense alleged in the indictment:
The indictment also said there were a rash of liver injuries associated with the product OxyElite Pro Advanced Formula in late 2013, and several users needed liver transplants.
USPlabs, when told of this, informed the U.S. Food and Drug Administration that it would stop marketing the supplement but instead tried to sell off inventories as quickly as possible even as executives ordered that two offending substances be removed from the formula, the indictment said.
Let that sink in – the executives were apparently told that their product was causing liver failure, so they sold off their inventory as fast as they could.
Conclusion: What will happen to the supplements industry?
We can think of the regulation and behavior of the supplement industry on three levels. The first level is where the supplement industry fully complies with current regulations. Even then, the industry is allowed to essentially sell unregulated drugs (herbs) with “structure function” health claims, testimonials, and endorsements without any burden of proof to back up their claims.
We now have a two-decade experiment on this regulation, and it is the utter failure that its critics said it would be. The net result was the public wasting billions of dollars a year on worthless supplements – and this is the best case scenario.
Level two is where the industry violates even these lax regulations, with poor quality control, inaccurate labeling, adulteration with regulated drugs, contamination, and making prohibited claims.
Now we are seeing level three – criminal corporate malfeasance. No one should be surprised that when lax regulations allow an industry to be dishonest, it attracts dishonest people.
What we need now is a complete overhaul of how the supplement industry is regulated. DSHEA should be repealed, or at least updated to fix its myriad problems (effectively repealed).
I have nothing against the free market, it can be a powerful tool to drive innovation and quality. In our current economic system companies can invest in research and product development, and then make a huge profit off of that development.
But the free market is a construct of regulations – there have to be rules or else you don’t have a free market, you have chaos. Especially with a vital industry like health care, thoughtful regulations are necessary to allow innovation while protecting the public health.
There is also a unique challenge for health care products in the free market – it is very difficult for consumers to evaluate long term effects of products and services. All product effects are obscured by placebo effects. Consumers cannot reasonably rely on their own anecdotal experience – they need to be informed by scientific evidence. That evidence will not be created and evaluated unless regulations demand it. Private consumer information companies also don’t have the resources to do this.
What we need is a system in which drugs are regulated as drugs, not food or vitamins. All health claims should be backed by adequate evidence. The industry needs to be carefully regulated for quality control, transparency, and accuracy in labeling.
Ironically, the public thinks this is what they already have. Most people have no idea that they are at the mercy of the supplement industry’s self-regulation.
Perhaps, however, we are reaching a tipping point where the political will exists to make some effective changes. Let’s hope so.

Don’t supplement users deserve consumer protection, too?
Scott Gavura on June 5, 2014
Link

The Canadian Parliament, hypothetically protecting consumers since Confederation.
One of the most pervasive yet appealing health myths is the idea that natural equals safe. It’s a statement that’s repeated constantly by manufacturers of supplements and “natural” health products. It’s been the primary argument used, with considerable success, to give these products completely different regulatory structures than exist for drug products. Weaker regulation of supplements and natural health products has been a boon to manufacturers, but the same can’t be said for consumer protection. It’s effectively a buyer-beware marketplace in most parts of the world, with little accurate information available to consumers. But supplement manufacturers aren’t content with the minimal regulation that’s currently in place – they want health “freedom”. In this case, “freedom” means the right to sell any product, while being exempted from safety and regulatory requirements. New Canadian legislation is poised to raise safety standards for drugs and enhance the ability of regulators to recall dangerous products, yet consumers of natural health products are left behind. The legislation proposes to exempt anything considered a “natural health product”. This is not only bad public policy, but it has the potential to cause avoidable harm. After all, shouldn’t users of supplements and natural health products be entitled to the same safety and quality standards as those that use prescription drugs? If the supplement industry gets its way, the answer will be “no”. (There is an opportunity until June 10 for you to provide feedback on this legislation – see below.)
In late 2013 the Canadian government introduced Bill C-17, the Protecting Canadians from Unsafe Drugs Act. Also called “Vanessa’s Law”, the bill is named after the daughter of Terence Young, a Canadian Member of Parliament whose daughter died of an adverse drug reaction. The Act has been written to enhance and strengthen Canadian food and drug regulations, and is expected to bring Canadian regulations in line with international best practices for drug regulation. The Act will do the following:
give government the authority to recall drugs from the market (it currently must ask the manufacturer’s permission, and the decision is at the manufacturer’s discretion)
increase fines to manufacturers from $5,000 to $5,000,000 per day for companies that do not comply with the Food and Drugs Act
the ability to require companies to undertake post-marketing (real-world) research
the ability to force a manufacturer to change a drug’s label because of new harms or risks to health
make adverse event reporting mandatory for hospitals.
These changes are overdue in Canada, and welcome. There is an interesting exemption. The act applies to “therapeutic products” which is defined as:
a drug or device or any combination of drugs and devices, but does not include a natural health product within the meaning of the Natural Health Products Regulations
Even the preamble makes it clear – there are apparently no issues with natural health products:
And whereas new measures are required to further protect Canadians from the risks related to drugs and medical devices, other than natural health products
What are the consequences of excluding natural health products? Tainted drugs can be recalled, but not contaminated or mislabelled supplements (which have been documented with Canadian products). Adverse event reporting becomes mandatory for drugs and even “medical devices” (e.g., bandages) but reporting on herbal products and other supplements is not. And oddly, even some drug products are considered “natural health products” (e.g., some decongestants). The result of this legislation, if passed intact, will mean the extent to which consumers will be protected from unsafe products will vary.
Drug safety disasters like thalidomide led to the pharmaceutical regulatory framework that is generally in place around the world today. Amazingly, manufacturers of supplements and other “alternative” medicine products have been largely successful in circumventing these safety rules, convincing regulators that “natural” equals “safe”, and therefore, should be exempted from regulation. In the USA, the framework is DSHEA, which removed the onus of demonstrating safety and efficacy from the manufacturer and put the requirement to demonstrate harm on the FDA – exactly the same scenario as drugs in the early 1900′s. In Canada, the Natural Health Product regulations had a similar effect, and implemented a lowered bar for non-drug supplements. Today even homeopathic remedies in Canada are deemed safe and effective and approved with unique recommended uses.
Is there any rationale that would exempt natural health products from stronger regulatory oversight? Some (particularly the industry) point to the lack of evidence of harms. And from one perspective, that is true. Despite their widespread use, surveillance of supplements (the limited amount that occurs) reveals generally few adverse events. It could be that many products lack meaningful pharmacologic activity — either positive or negative. An adverse event is probably less likely in placebos that have no beneficial effects. But beyond efficacy, there are several other factors, unique to supplement use, that may contribute to the perception (and under-reporting) of harms from supplements. I’ve mentioned several reasons before, which include:
Consumers believing natural products are safe may be less likely to associate adverse events with supplement use.
Supplements don’t require a prescription. No health professional may be involved in measuring the response to therapy, who might be able to identify adverse events as part of a monitoring plan.
Side effects and harms may not be reported, as some are reluctant to share concerns with health professionals.
Consumers may not know how to manage an adverse event, and to whom they should report an adverse event. They may be unwilling to describe health consequences to the vendor of a product, or report in a setting like a natural foods store.
Users may have a distrust of “conventional” medicine which drove their initial use of the product. When adverse events were identified, they may be reluctant to consult “conventional” health care providers for assistance.
Some fear of losing access to supplements, which may drive a reluctance to report adverse events.
Supplements are commonly used for short intervals for self-limiting conditions, and long-term harms may not appear (or be detectable).
If you don’t look for it, you won’t find it. And if you set the system up to minimize even the potential of reporting, it should be no surprise that supplements are not associated with a lot of safety concerns or reports. And that’s exactly what the bill’s exemption of natural health products will do – reinforce a weak regulatory structure and make no meaningful improvements in transparency or accountability from supplement manufacturers.
Taking action
The Canadian advocacy organization Bad Science Watch has organized a campaign to press for changes in Bill C-17. It is proposing two amendments:
Removing the natural health products exemption.
Requiring companies to disclose all clinical trials data that exists for a product in an “all trials” clinical trials database.
The bill has been referred to a Standing Committee on Health which will meet on Tuesday June 10. There is a draft letter at Bad Science Watch, with the email address of the Members of Parliament that will be considering the bill. There is also a draft letter prepared by AllTrials, which elaborates on the rationale for a registry (yet does not address the NHP exemption.) If you want to provide comments that will be considered, you must do so by Tuesday, June 10.
Conclusion
Canadian consumers deserve equal protection from unsafe health products, no matter how they are categorized. In light of the questionable efficacy, safety, and product quality standards of natural health products in Canada, there is no clear rationale why Natural Health Products should be exempted from newly proposed safety enhancements. In addition, Bill C-17 represents an important opportunity to bring greater transparency to clinical trial data – a move with the potential to improve health care not just for Canadians, but for patients worldwide.

The Amarin case: off-label promotion and a double standard for prescription drugs vs. dietary supplements
Jann Bellamy on October 15, 2015
Link
A recent court decision enjoined the FDA from threatening prosecution against a drug manufacturer for off-label promotion of a prescription drug. Based on this and an earlier decision by an appellate court, it appears that the FDA can no longer prosecute a pharmaceutical manufacturer for a truthful and non-misleading off-label promotion to health care professionals, at least within the jurisdiction of the United States Court of Appeal for the Second Circuit, which covers Connecticut, New York and Vermont.
For this reason, the case, Amarin Pharma, Inc. v. FDA (Amarin), received a good deal of attention in the world of drug regulation. (Here is an excellent analysis by two attorneys who practice in the area of drug regulation.) First, we’ll take a look at the issue of off-label promotion. Then we’ll look at an issue that really didn’t engender much comment, but that I find fascinating: how the same substance can be subject to very different regulatory treatment, depending on whether it is sold as a dietary supplement or prescription drug.
Background: Initial approval of Vascepa and subsequent research
In 2012, the pharmaceutical manufacturer Amarin received FDA approval for a new drug, Vascepa, as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia (triglycerides ≥ 500mg/dL). Approval was based on a single phase 3 clinical trial.
Following that approval, Amarin designed a second single phase 3 clinical trial to look at the effect of Vascepa on triglyceride levels among statin-treated patients with persistently high triglycerides (≥ 200 and ≤ 500 mg/dL). Pursuant to an agreement with the FDA that, if it met certain conditions, Vascepa would obtain approval for this use, Amarin proceeded with an FDA-approved protocol. As a further condition of the agreement, it also began enrolling patients in a third trial to see if Vascepa actually reduced major cardiac events.
The second trial showed that Vascepa did decrease triglyceride levels, and Amarin thought it had fulfilled the agreement’s requirements for approval. However, the FDA convened an advisory panel and called into question the clinical validity of the reduction in triglycerides achieved in the second trial. That is, the FDA questioned whether that result would translate into an actual reduction in cardiac events. This was based on other research indicating, according to the FDA, that indeed it did not. This research did not include the third trial’s results, designed to answer this very question, because that trial won’t be completed until 2017.
The FDA rescinded its agreement, did not approve Vascepa’s use for patients with persistently high triglycerides, and notified Amarin that any effort to market Vascepa for this unapproved use could constitute misbranding under the Food, Drug, and Cosmetic Act (FDCA).
I’ll see you in court
What happened next gives one the impression that the FDA’s actions really frosted Amarin. Instead of waiting for the FDA to come after it for promoting off-label use, it hauled the FDA into court and asked the judge for a preliminary injunction preventing the agency from taking any action against the company for truthful, non-misleading promotion of Vascepa to health care professionals for patients with persistently high triglycerides. And it won.
By now you might be wondering: what, exactly, is in this Vascepa? It’s fish oil. Or, if you’re a stickler for details, it is, according to the FDA:
icosapent ethyl or ethyl-eicosapentaenoic acid (EPA). . . The drug substance, icosapent ethyl, is a long-chain, polyunsaturated omega-3 fatty acid ester derived from fish oil.
The recommended daily dose for treatment of severe hypertriglyceridemia is 4 grams daily.
Off-label prescribing is not per se illegal, although a physician can get into trouble if he falls below the standard of care. And, because the FDA doesn’t regulate doctors (the states do that), it can’t prevent it. Actually, the FDA doesn’t disapprove of what it sees as responsible off-label use. The FDA’s concern is with off-label promotion by pharmaceutical companies, and it has taken the position that such promotion violates the Food, Drug and Cosmetic Act, even though there is no such proscription in the Act itself. It does so by reasoning that off-label promotion amounts to “misbranding” the drug.
The FDA has backed off this absolute position in the last decade, and issued draft guidance on the circumstances under which truthful information about an off-label use can be distributed. This includes, for example, distribution of journal articles and medical texts that include information on unapproved uses. As with all draft guidance, it is not binding on the FDA or anyone else.
The court’s opinion has some interesting statistics on the ubiquity of off-label prescribing:
    • The most comprehensive study on off-label prescriptions in the United States, conducted in 2001, found that approximately 21% of prescriptions were for off-label purposes.
    • According to a 2000-2006 study, more than 90% of antidepressants prescribed to children and adolescents in an outpatient care setting were for off-label purposes.
    • Based on review of Veterans Affairs databases, more than 60% of prescriptions of antipsychotic drugs in 2007 were for off-label use.
    • A study of medication orders for 414 patients in 37 intensive care units across nation showed that more than 35% were for an off-label purpose and that 97% of patients received at least one off-label medication.
Not included was the fact that the vast majority of prescriptions for fish-oil drugs are off-label, including an estimated 75% of a competitor’s prescriptions.
In ruling on Amarin’s request for a preliminary injunction, the district court had to decide whether it was likely Amarin could ultimately succeed on the merits of its case. This, in turn, required the court to address whether the FDA could prevent Amarin from promoting off-label use of Vascepa for patients with persistently high triglycerides, even when the information was truthful and not misleading. Relying heavily on a decision of Second Circuit Court of Appeals, United States v. Coronia, the court held that the FDA could not constitutionally prevent Amarin from:
engag[ing] in truthful and non-misleading speech promoting the off-label use of Vascepa, i.e., to treat patients with persistently high triglycerides, and under Coronia, such speech may not form the basis of a prosecution for misbranding.
In Coronia, the government criminally prosecuted a drug rep for off-label promotion but the appellate court overturned his conviction. The Second Circuit first decided that:
‘[s]peech in aid of pharmaceutical marketing . . . is a form of expression protected by the . . . First Amendment’ . . . It then applied to such speech truthfully promoting off-label drug use the four-prong test of [the U.S. Supreme Court’s decision in] Central Hudson, used to determine a restriction upon commercial speech violates the First Amendment.
We won’t go through the entire Central Hudson analysis here, but it’s worth noting that while the court recognized that the FDA has a legitimate interest in protecting the integrity of the FDCA drug approval process, it had chosen means (a criminal prosecution) that was broader than necessary to achieve that goal, that off-label promotion is not per se illegal, and the FDA’s ban:
‘paternalistically’ interferes with the ability of physicians and patients to receive potentially relevant treatment information.
Although the FDA tried to distinguish Coronia, the district court didn’t buy it. If anything, the FDA’s position in Amarin was even weaker than in Coronia. It was threatening to go after Amarin for telling physicians the results of a clinical trial that the FDA itself had approved and whose results the FDA didn’t dispute. And, as the court pointed out, if the FDA didn’t like the Coronia decision, it should have sought rehearing or review by the U.S. Supreme Court. Now, it is stuck with the decision, like it or not.
At some point in this imbroglio, the FDA backed off a bit, and the parties tried to reach an agreement on what representations about off-label use of Vascepa could, and could not, make. (Actually, at the end, they weren’t that far apart.) Having decided the FDA could not constitutionally prohibit truthful promotion, the court proceeded to settle this dispute for them.
Which brings us to dietary supplements
As you may recall, unlike drugs, there is no pre-market approval of dietary supplements by the FDA. Supplement manufacturers are supposed to have evidence backing up their “structure and function” claims, but they don’t have to show their evidence to the FDA or the public. However, under the Nutrition Labeling and Education Act of 1990, dietary supplements can also make “qualified health claims” if the FDA:
determines based on the totality of the publicly available evidence (including evidence from well-designed studies conducted in a manner which is consistent with generally recognized scientific procedures and principles), that there is significant scientific agreement among experts qualified by scientific training and experience to evaluate such claims, that the claim is supported by such evidence.
Fish oil is sold as a dietary supplement and, like Vascepa, is promoted for its ability to reduce triglycerides. But the connection between high triglycerides and cardiovascular risk is not yet fully understood. (The full document is behind a paywall, but Scott Gavura helpfully provided me with some of its information on fish oil.)
Although the contribution of triglycerides to cardiovascular risk has been debated in the past, it now seems clear that elevated triglyceride levels are independently associated with cardiovascular risk, particularly coronary risk. It remains uncertain, however, whether this association is causal, such that hypertriglyceridemia, independent of associated lipoprotein, inflammatory and hemostatic abnormalities, causes atherosclerosis. It is also uncertain whether lowering triglyceride levels reduces risk.
This is the very concern that, according to the FDA, led it to renege on its agreement with Amarin.
Yet, the FDA permits fish oil dietary supplements to make the following “qualified health claim”:
Supportive but not conclusive research shows that consumption of EPA and DHA omega-3 fatty acids may reduce the risk of coronary heart disease.
Which is, as noted above, true. But:
Active omega-3 fatty acids constitute only 30 to 50 percent of many fish oil supplements. In comparison, a commercial preparation (Lovaza in the United States and Omacor elsewhere) is 85 percent omega-3 fatty acids. In patients with severe hypertriglyceridemia, Lovaza (4 g/day) reduced triglyceride levels by 45 percent, but raised LDL-C levels by 31 percent. Another commercial preparation, Vascepa, is more than 95 percent icosapent-ethyl, the ethyl ester of EPA. Icosapent-ethyl (4 g/day) also reduced triglyceride levels by up to 45 percent, but did not significantly affect LDL-C levels. [References in original deleted.]
In fact, Amarin is using this difference between Vascepa and fish oil dietary supplements to promote its product. According to its website, you’d have to take 10 capsules of fish oil supplements a day to reduce triglycerides, and this could mean the supplement is actually more expensive than the prescription drugs. Plus, it says, low dose omega-3 fatty acids can raise “bad” cholesterol levels.
Amarin actually proposed to the FDA that it be allowed to make the same statement in its off-label promotion that the dietary supplement can make. Sounds reasonable.
The FDA said “no.” Why? Because, the statement:
would be potentially harmful to the public health, and [the FDA] would consider such conduct to be potentially misleading or potential evidence of intended use.
Further, according to the court, the FDA argued that the coronary heart disease claim could cause a physician to prescribe Vascepa in lieu of promoting health, dietary and lifestyle changes, or prescribing statin therapy.
However, the FDA stated that, if Amarin repackaged Vascepa as a dietary supplement, the FDA would not object to including the coronary heart disease claim, on certain conditions. That’s right. The company couldn’t promote it to doctors by making truthful coronary heart disease claims but selling it directly to consumers on that basis would be just fine.
In response, Amarin proposed adding the following information to the statement the dietary supplement manufacturers are allowed to use:
Vascepa should not be taken in place of a healthy diet and lifestyle or statin therapy.
The court agreed that, so qualified, Amarin could make this claim without exposing itself to liability for misbranding.
This result makes no sense whatsoever. True, it is an accurate reflection of the different statutory requirements for prescription drugs versus dietary supplements, and no one could find fault with the court for its decision permitting Amarin to make this qualified statement about Vascepa’s benefits. But, logically, it makes no sense. The law allows a claim to be made for a dietary supplement that cannot be made for a prescription drug, even though:
    • It’s essentially the same ingredient (derived from fish oil) although it is of pharmaceutical grade quality in Vascepa,
    • which can be taken at the same dose (it just takes more of the dietary supplement),
    • for the same purpose.
Yet, the prescription drug had to jump through all the hoops of a supplemental new drug approval, conduct a clinical trial, and, despite the favorable results, was denied approval. On the other hand, the dietary supplement companies, although they did have to meet the FDA’s standard for a qualified health claim, avoided all of this expense and didn’t have to go to court to protect their right to make this same statement to consumers without the further disclosure required of Amigen when promoting its product to doctors. And this is in spite of research showing that consumers don’t fully understand the level of evidence conveyed by a “qualified health claim.” (If you want to see how complicated the drug process actually was for Vascepa’s approved use, take a look at the FDA’s Approval Package for the drug.)
The side effects of Amarin
In addition to the salutary effect of providing an excellent example of why the regulation of dietary supplements should be reformed, what else does the Amarin decision portend? As one commentator noted, the Amarin case is different than the dozens of cases where pharmaceutical companies have paid billions of dollars in settling off-label promotion enforcement actions:
‘I don’t think it’s going to open the floodgates to irresponsible off-label promotion,’ said Dr. Daniel Carlat, a drug marketing expert and associate clinical professor of psychiatry at the Tufts University School of Medicine. ‘Companies are still going to have to be really cautious about what their sales reps say.’
Still, the case may raise questions about what constitutes truthful off-label marketing. Small clinical studies that are not well controlled that show a drug is effective for treating a particular condition or patient population may be held up as scientific data that is truthful and is not misleading. ‘That may be more likely to happen with a decision like this,’ Carlat said.
As a preventative against the FDA’s taking action, the court itself gave some sensible advice. It recommended that all manufacturers take advantage of the FDA’s guidance that a pharmaceutical manufacturer vet and script in advance statements about a drug’s off-label use. It warned that leaving drug reps “at liberty to converse unscripted with doctors about off-label use,” invites a misbranding action if false or misleading representations are made, adding that Caronia “leaves the FDA free to act against such lapses.”
After the decision, the parties jointly requested that the proceedings be stayed until October 30 to explore settlement of the matter. Even though a decision granting a preliminary injunction doesn’t preclude a finding in the FDA’s favor after a full adjudication on the merits, I think the FDA sees the handwriting on the wall.
Amarin has already inspired at least one other lawsuit. On September 8, pharmaceutical manufacturer Pacira filed a complaint in the U.S. District Court for the Southern District of New York seeking to prevent FDA from bringing an enforcement action against the company for what it claims is truthful and non-misleading speech concerning its product, Exparel.

FDA poised to reshape the cold remedy aisle
The FDA is proposing to order the removal of phenylephrine from oral cough and cold remedies.
Scott Gavura on November 21, 2024
Link
Is phenylephrine destined for the history books?
On November 7, 2024, the FDA announced that it is proposing to remove oral phenylephrine as a drug that is permitted for use in over-the-counter (OTC) drug products. This is a good decision for consumers, because phenylephrine is ineffective as an ingredient, and should never have been authorized as a cold remedy.
In today’s post I want to review the long path to reconsider the FDA’s approval phenylephrine, and I will quote extensively from some of my past posts.
Colds are ubiquitous. Surprisingly, while there are literally dozens of cough and cold remedies on pharmacy shelves, they all use combinations of the same core handful of ingredients. And the evidence supporting some of these products is very, very weak.
In 1976, the FDA concluded that three medicines were safe and effective for the treatment of nasal congestion caused by colds, allergies, and sinusitis: phenylpropanolamine, pseudoephedrine, and phenylephrine. Almost 25 years later, phenylpropanolamine was withdrawn from the market after use was associated with strokes. Pseudoephedrine is an effective decongestant that is chemically very similar to methamphetamine, a addictive and controlled drug that is subject to abuse. Pseudoephedrine does not share the same stimulant properties as methamphetamine, though it can cause jitteriness, mild tremors, and insomnia. However, because pseudoephedrine can be used to manufacture methamphetamine, the over-the-counter sale of cough and cold products that contain this ingredient are not permitted. Sales were moved “behind the counter” in the US (it is more widely available in other countries), with the requirement for the customer to produce photo identification and the requirement for the pharmacy to maintain a log of all sales, tracked by customer name and address. Not surprisingly, this put a damper on sales.
When pseudoephedrine was moved behind the counter, manufacturers of cough and cold products either had to accept a much smaller market for their pseudoephedrine-containing product, or reformulate.
Some companies reformulated their products to contain phenylephrine instead, which was the last remaining non-prescription ingredient that the FDA permitted for use to treat congestion. Phenylephrine is from a category of drugs called alpha-1 agonists: they stimulate alpha-1 receptors that are present throughout the body, including the nasal passages. It is used as a nasal spray, but more commonly in the United States as a oral product taken to treat nasal congestion. There was a problem with FDA’s historical approval, however. There was little convincing evidence phenylephrine, when taken orally, was actually effective at reducing congestion.
The case against phenylephrine
Phenylephrine is a poorly-absorbed drug (i.e., it has low bioavailability). Most of the drug is broken down during the absorption process, after passing through the liver. So there have been persistent questions if the drug was actually effective.
In clinical trials, oral phenylephrine was compared to other decongestants in a randomized controlled trial of 20 patients (way back in 1971) and found to be no more effective than placebo in reducing lung airway resistance. Another trial compared single doses of four different decongestants against placebo in 88 patients with congestion. It also found that phenylephrine was no more effective than placebo. In a review of the data that the FDA had considered, that review noted that for the 10mg dose, 4 studies showed efficacy and seven showed no difference from placebo. The authors concluded that a systematic review did not support the FDA’s decision. Other trials conducted since that time (like this one in 2009) are supportive of the conclusion that the 10mg dose is ineffective.
The fact that we are relying on trials conducted in the 1970’s pretty much tells us what we need to know about phenylephrine. Given how poorly it is absorbed, there is the question of whether simply giving bigger doses will work – and it turns out it may. However, the 10mg dose is what’s available in US cough and cold products – and the best evidence shows that this drug is effectively a placebo at that dose. I will point out that the manufacturers of the consumer products that contain this ingredient continue to write their own papers suggesting that there is evidence of efficacy. However, despite the large sales of these products, they have not produced any new randomized controlled trials to show that they are effective.
The FDA’s re-review of the evidence
In March 2023 I blogged about how the FDA had committed to re-review the evidence for phenylephrine. The Non-Prescription Drug Advisory Committee met in September 2023. The committee concluded that the evidence does not support that phenylephrine is effective as a nasal decongestant. Here are a few of the key slides and conclusions from that review:
Phenylephrine has action against alpha receptors – not its metabolites.  Less than 1% of the drug is actually absorbed as the “active” drug. The maximum effective blood concentration (Cmax) is lower than the EC50, which is half maximal effective concentration. Finally, the drug is quickly eliminated from the body. All of this suggests that the drug will not be clinically effective. And here is their bottom line on the clinical data, which won’t be surprising based on the pharmacology of the drug in the body:
The agency commented that the data available today refutes some of the assumptions made back in the 1970’s (pg. 55):
Finally, the science has changed in the interim, and a full understanding of the clinical pharmacology of PE [phenylephrine] when administered orally was not appreciated at the time that the Panel issued its recommendations. We now know that in addition to PE having less than 1% systemic bioavailability, the half-life is also significantly shorter than the original 4-hour dosing interval. These data were not available to the Panel, nor was the technology to fully assess oral bioavailability available until around the turn of this century. Therefore, is it not surprising that the Panel considered the equivocal findings in the original studies as sufficient to support a finding of efficacy (and safety) of PE 10 mg administered orally every 4 hours.
and, interestingly (pg. 60),
After careful review, we note that there were many methodological and statistical issues with these studies. We believe that these issues significantly limit any judgement of a statistical “win”, and more importantly a clinical “win”, for any of these studies. In fact, if these studies were submitted to the Agency today all would at most be considered Phase 1 studies at best. As a result, we believe that these studies do not stand up to the new data that are now available with regard to the efficacy of orally administered PE as a nasal decongestant.
Ultimately, the committee unanimously concluded that the evidence does not support that the recommended dosage of orally administered phenylephrine is effective as a nasal decongestant. Importantly, no safety issues with use of oral phenylephrine at the recommended dose were identified.
Your chance to comment
The FDA is currently inviting comments on this proposed order. Options available to the FDA include a final order removing oral phenylephrine from the “OTC monograph” which means that cough and cold products would no longer be permitted to contain oral phenylephrine. The FDA says it would provide manufacturers with time to come up with new formulations, or remove these products from.
Does this restricts consumer choice? Yes, but only from being marketed products that do not work as labelled. Having oral phenylephrine available with the FDA’s apparent approval, when it’s ineffective, offers a false choice that preys on consumer ignorance. And a regulatory standard that ensures approved product are both safe and effective is ultimately a win for consumers. While overdue, it’s to the FDA’s credit that it is willing to scrutinize, reflect, and act on the evidence, even for a decision with a large, but positive, consumer impact.

FDA v. Jack3d: Round 2
Jann Bellamy on May 16, 2013
Link
Jack3d is a dietary supplement manufactured by USPlabs and promoted by the giant supplement retailer GNC as producing “ultra-intense muscle-gorging strength, energy, power and endurance.” A key ingredient is DMAA, which the FDA doesn’t think is a proper dietary supplement ingredient at all and wants Jack3d and other products containing it removed from the shelves and the web. The FDA also questions its safety.
As discussed in a previous post on the subject, both USPlabs and GNC maintain Jack3d (pronounced “jacked”) is safe when properly used. Apparently few agree with them on this point: not the FDA, not the U.S. military, not the countries and athletic associations which have banned DMAA. And certainly not the parents of Michael Lee Sparling, a 22-year-old Army private. The Sparlings filed a lawsuit alleging Jack3d caused the death of their son, who went into cardiac arrest and died after using it.
Here is where we left off the last time we looked at DMAA:
Last April [2012], the FDA sent warning letters to several supplement manufacturers saying it had no evidence DMAA is a legitimate dietary ingredient and citing its risks. (Health regulators in other countries, such as Sweden and Denmark, have actually banned DMAA-containing supplements.) Heart attacks, heart failure, kidney failure and liver failure were among the health problems reported to the FDA, as well as 5 deaths. GNC responded that it was “completely opposed to this unilateral, factually and legally unfounded action by the FDA.”
Now to Round 2.
Ding!
The FDA has a separate web page devoted exclusively to DMAA, its dangers, and efforts to get it off the market. A sense of the agency’s frustration at the limitations imposed by the Dietary Supplement Health and Education Act (DSHEA) on its power to police the dietary supplement market comes through in a description of these efforts:
Unlike drugs, dietary supplements do not have pre-market approval for safety or effectiveness. If a safety issue arises post-market, FDA can investigate and take steps to remove products that may be unsafe from the market. However, in order for FDA to ban a compound in a dietary supplement, FDA is required under the statute to undertake a series of lengthy scientific and legal steps. In the interim, FDA can take direct action by issuing warning letters to industry to obtain removal of ingredients in dietary supplements and protect the public from potentially harmful products. FDA can also bring a seizure action to remove products from the market or obtain an injunction against a company to prevent it from manufacturing and distributing illegal products.
Note that the FDA must initiate a federal court proceeding and meet the applicable burden of proof before getting a court order permitting seizure or granting an injunction.
The FDA sent warning letters to 11 supplement manufacturers, accounting for “most of” the manufacturers using DMAA. As you may recall, the FDA does not have a complete list of all manufacturers or distributors of dietary supplements or know what supplements are out there because there is no requirement in the DSHEA that companies register themselves or their products with the agency. The letters raised the following issues:
    • Because DMAA had not been marketed as a dietary supplement ingredient prior to 1994 it was considered a “new dietary ingredient” (“NDI”). Manufacturers are required to notify the FDA of evidence supporting their conclusion that their use of NDIs is safe. The companies failed to do this.
    • The FDA was not aware of any evidence or history of use that indicated DMAA is safe. In fact, DMAA is known to narrow blood vessels and arteries which can elevate blood pressure and lead to cardiovascular events. Serious adverse events had been reported, including cardiac disorders, nervous system disorders, psychiatric disorders, and death.
    • Synthetically-produced DMAA is not a “dietary ingredient” and therefore cannot be used as an active ingredient in a supplement.
Eventually 10 of the 11 complied and agreed to stop making supplements containing DMAA; the remaining supplier is still in the market. The lone holdout was USPlabs. In fact, USPlabs seems to think the safety issue is cause for a bit of fun. The company puts a faux “Black Box Warning” on the Jack3d label:
This product produces an intense sensation of drive, focus, energy, motivation & awareness. In addition, it allows for rapid increases in strength, speed, power & endurance. Therefore, extreme caution must be exercised & should not be used by novice athletes. Use with caution under strict dosing products.
Such marketing cleverness!
USPlabs plays defense
USPlabs wrote the FDA back, defending its claim that DMAA is a dietary ingredient by arguing it is a constituent of a type of Chinese geranium. The FDA was having none of it. It notified the company on April 10 of this year that it found the information insufficient, with an official warning letter to follow. USPlabs was still defending its product in an April 12 New York Times story. However, on April 16, USPlabs announced it would phase out products containing DMAA.
The formal warning letter was issued nevertheless, on April 18. In a Gorski-style takedown of studies relied upon by USPlabs in its attempt to convince the FDA that DMAA is a dietary ingredient, the agency shredded the studies cited. Because the details of these studies would interest only those familiar with such things as “gas chromatography (GC)–mass spectrometry (MS) analysis” and methods of authenticating the source of plant materials (which is way more complicated than you might imagine), I will spare you the details. (You’re welcome.)
Actually, I couldn’t begin to understand what they are talking about, but I will share this amusing (to me) bit of comeback to USPlabs’ claim that DMAA is a dietary ingredient because it is “a dietary substance for use by man to supplement the diet by increasing total dietary intake.” The FDA retorted:
. . . the possibility that geraniums may have been consumed as a food or drink by humans does not demonstrate that DMAA is a dietary substance because, as explained above, the totality of the scientific evidence does not demonstrate the presence of DMAA as a constituent of geraniums.
Somehow the thought of people eating and drinking geraniums struck me as funny, although that possibility shouldn’t be at all surprising considering what I’ve learned about “complementary and alternative” medicine.
Because the FDA determined DMAA is not a legitimate dietary ingredient the agency found it unnecessary to address USPlabs’ contention that DMAA is safe.
During this controversy, USPlabs sued a retailer in Nevada for defamation. The complaint alleges that a Max Muscle retail outlet franchisee said Jack3d is “the equivalent of rat poison” in a radio interview.
NEW! IMPROVED!
Although the remaining stock of Jack3d is still available from some retailers, including GNC, USPlabs has reformulated the product, now sold as “Jack3d Micro” and promises to deliver another new Jack3d product in the future, although it does not say whether this product will contain the same ingredients as the Micro version. (It is, in addition, reformulating OxyElite Pro, which also contains DMAA.) The only common ingredient between the new and old versions is caffeine. Interestingly, a sales pitch for Jack3d Micro on the company’s website is presented as a comparison with the original DMAA-containing formula:There is no mention of the controversy about DMAA, although it does not appear that the original Jack3d is still sold on its website, unlike other internet outlets. The website still touts the safety and effectiveness of DMAA-containing products.
The faux Black Box warning is gone but the label does advise the purchaser to consult with a physician before using, especially if he is taking prescription medications or has certain pre-existing medical conditions, and to discontinue prior to surgery. It also advises the purchaser not to use the product if taking certain named medications as well as warning against using it in combination with other stimulants, such as caffeine-containing products, or alcohol. The label tells the purchaser to “consult your health care professional if you experience any adverse reaction to this product.” What it does not do is warn the purchaser of what those adverse reactions might be.
The FDA requires dietary supplement labels to list ingredients. Here is the ingredient list for Jack3d Micro.Assuming the role of a diligent consumer, but one with no background in medicine or science (in other words, me) I tried to locate reliable information about the safety and effectiveness of these ingredients. None of this information is available to the consumer on the USPlabs website as far as I could determine, although I only searched the website using specific ingredient names listed on the label. WebMD does have an easy-to-use way to search for information about dietary supplement ingredients, but not all of those found in Jack3d Micro were on their website. Of course, WebMD’s analysis must compete with the tremendous amount of hype about supplement ingredients from supplement sellers and other sources available on the internet.
Here’s the information not mentioned on the warning label that I thought a consumer should be concerned about, all from WebMD unless otherwise indicated. (Some ingredients have more than one name.)
3,4-Dihydroxycinnamic acid, caffeic acid (stimulant, ingredient in many foods, such as coffee)
    • Effects when taken by people unknown.
    • No information available on interactions with other supplements or drugs.
    • Insufficient evidence for use to enhance athletic performance and for exercise-related fatigue.
    • Not enough evidence to know if safe when taken as a supplement or to determine appropriate range of doses.
Higenamine, Norcoclaurine (stimulant)
    • Insufficient evidence for use to enhance athletic performance.
    • Possibly unsafe when taken orally. Not studied in people therefore safety unclear.
    • Aconite (a plant) shown to cause serious heart-related side effects including arrhythmias and death; effects may be caused in part by higenamine in aconite. Warning about irregular heartbeat repeated in information, although it’s not clear whether this is based on additional evidence.
    • Not enough evidence to determine appropriate range of doses.
L-citrulline (amino acid)
    • Possibly safe.
    • Insufficient evidence for exercise performance. May not be effective for improving exercise performance. In one test, did not improve performance on treadmill and people taking it actually became exhausted more quickly than those who did not take it.
    • No information available on interactions with other supplements or drugs.
    • Not enough evidence to determine appropriate range of doses.
Grape seed extract 
    • Headache, abdominal pain, sore throat, nausea, and diarrhea may occur.
    • Very serious allergic reaction to this product rare, but warning to seek immediate medical attention if any of the following symptoms of a serious allergic reaction appear: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.
Arginine nitrate and Agmatine sulfate
These ingredients are not listed on WebMD. Best I can tell, arginine nitrate is L-arginine bonded to nitrate. It is all the rage now in bodybuilding products and a supposed improvement over L-arginine, an amino acid. Agmatine sulfate is the decarboxylation product of arginine. (And good for you if you know what that means.) I could not find any information on the safety and effectiveness of either of these ingredients, when used in a dietary supplement for Jack3d Micro’s intended purpose, from any source I considered reliable and unbiased. I do not know if these new forms of L-arginine would retain the safety issues of that substance. According to WebMD, L-arginine is possibly safe for most people when taken appropriately by mouth in the short term, but it can have unpleasant gastrointestinal side effects and can cause swelling of the airways. There is concern that it may increase the risk of death after a heart attack and has known moderate interactions with high blood pressure drugs and sildenafil (Viagra). It has not been studied for athletic performance.
The Score
I suppose if I were scoring Round 2, I would count it even. The FDA will eventually see most, if not all, of the dietary supplements containing DMAA off the market. Of course, since DMAA is not a dietary ingredient, it should never have been on the market in the first place. And, because DSHEA allows it, supplements containing DMAA were sold without manufacturers having to demonstrate their safety and effectiveness to the FDA. As it turns out, the FDA concluded DMAA was not safe.
USPlabs has reformulated Jack3d, but, again, DSHEA allows it to go on sale without the company having to provide all the information a consumer should consider before taking it or proving its safety and effectiveness to the FDA. The consumer can do this research on his own but information about all of the ingredients is not readily available. Some of the ingredients have a potential for causing harm and there is no adequate research showing they are effective for their intended use. And apparently there is no research on the safety and effectiveness of using these ingredients in this combination and at this dose. In other words:
Safety and effectiveness unknown. Use at your own risk.

FDA issues new CBD safety warnings, calls for more research to guide regulation
The FDA recently warned the public about CBD health risks and urged further research. Meanwhile, special interest groups are pressing Congress and the FDA for quick action to allow CBD in dietary supplements and other consumer products.
Jann Bellamy on April 23, 2020
Link

Ever since the Agriculture Improvement Act of 2018 removed hemp with very low levels of THC from the definition of marijuana in the Controlled Substances Act, cannabidiol (CBD) products are, as the FDA recently noted,
available almost everywhere, and marketed as a variety of products including drugs, food, dietary supplements, cosmetics, and animal health products.
Yet, as the agency reminds the public, the only product legally approved to make therapeutic claims for CBD is one prescription drug (Epidiolex), used to treat two very rare, severe forms of epilepsy.
This disconnect between the ubiquity of CBD products and the evidence of safety and effectiveness for those products is one focus of a recent FDA Consumer Update and FDA Statement warning about the risks of taking CBD-containing products, summarizing the current evidence, and calling for more research. The agency also issued a Congressionally-required report on its progress in evaluating potential regulatory pathways for consumer products containing CBD.
Before we get into the weeds of the FDA’s latest pronouncements, a brief refresher on CBD and its current legal status. The Agricultural Improvement Act defines legal hemp as cannabis plants and derivatives containing no more 0.3 percent THC. In addition to THC, there are dozens of biologically active compounds in cannabis, CBD among them. But, although legal hemp may contain CBD, that does not mean that CBD in any form, from any source, is also legal.
Depending on the form in which it is marketed, CBD is subject to the Food, Drug, and Cosmetic Act of 1938 and FDA regulations. At present, CBD is not a legal ingredient in any product marketed as
    • a prescription or over-the-counter drug (except Epidiolex);
    • a dietary supplement; or
    • a human or animal food, if the food is introduced into interstate commerce (leaving to state regulation your CBD-containing brownies and dog biscuits from the local bakery).
Currently, federal law does not prohibit the use of CBD in cosmetics, which do not require FDA pre-market approval (except for color additives), as long as the cosmetic otherwise complies with the law, including refraining from making drug claims (that is, claims that the product prevents, diagnoses, mitigates, or treats disease) or false advertising, and as long as it doesn’t pose a safety risk.
With that background, let’s turn to the FDA’s most recent statements on CBD: it’s safety concerns, call for research, and development of a risk-based enforcement policy.
Safety of CBD
In its Statement, “FDA Advances Work Related to Cannabidiol Products with Focus on Protecting Public Health, Providing Market Clarity”, the agency says it is concerned that the public wrongly thinks the myriad of CBD products on the market — such as oil drops, capsules, syrups, food products (e.g., chocolate bars and teas), cosmetics, topical lotions, creams, and pet products – have been evaluated by the FDA and determined to be safe or that using CBD “can’t hurt”.
To disabuse people of those notions, the agency provides a long list of potential harms and side effects in the Consumer Update, including
    • liver injury
    • affecting how other drugs you are taking work, potentially causing serious side effects
    • use of CBD with alcohol or other drugs that slow brain activity (e.g., anxiety drugs), increasing the risk of sedation
    • male reproductive toxicity, or damage to fertility in males or male offspring of women who have been exposed, as reported in animal studies
    • changes in alertness and mood
    • gastrointestinal distress.
Among the many unknowns, according to the FDA, are
    • effects of taking CBD daily for an extended time
    • what intake level triggers known risks of taking CBD
    • how the method of consumption (e.g., oral, topical) affects level of intake
    • effects on the developing brain, the developing fetus, and breastfed babies
    • interaction with herbs and other plants.
In addition to inherent safety risks, the FDA is also concerned with the lack of appropriate processing controls: it has tested the chemical content of cannabinoid compounds in some products, finding that many did not contain the levels of CBD claimed. It is also investigating reports of CBD products containing contaminants like pesticides, heavy metals, and THC.
Finally, there is the danger of unproven claims of benefit, like those made by companies, warned by the FDA, that their products prevent, diagnose, treat, or cure serious diseases, such as cancer, Alzheimer’s disease, psychiatric disorders, and diabetes.
Research and regulation of CBD
While legalizing some cannabis and cannabis derivatives actually opened up new opportunities for research, the FDA told Congress that “outside groups have not provided the robust data and information needed to fully inform potential paths forward”. The agency itself has initiated a couple of research projects – on CBD exposure during pregnancy and to assess sensitization and dermal penetration of THC and CBD applied topically. As mandated by Congress, it is performing a sampling study of the CBD marketplace to determine the extent to which products are mislabeled or adulterated, although that report is several months out. It is also relying on “engagement” with other federal, state, and international agencies to further its understanding of issues related to CBD, including safety.
Other than that, the FDA has reopened a public docket to “enable responsible industry participants, academic researchers, and other stakeholders to share relevant information with the FDA – including information about specific products”. It is “particularly interested in data that may help to address uncertainties and data gaps related to the safety of cannabidiol (CBD)”. Unlike most public dockets, which limit the time for submitting comments on a particular issue, this one will remain open indefinitely.
The lack of safety and efficacy data complicates the FDA’s constructing a regulatory path forward. The agency believes the drug approval process is currently
the best way to ensure that safe and effective new medicines, including any drugs derived from cannabis, are in need of appropriate medical therapy.
Of course, given the time, expense, and uncertainty involved in that process, it would be much easier to make a bundle selling CBD as a dietary supplement, either alone or in combination with other supplement ingredients. The fuzzy line between the “structure/function” claims allowed for dietary supplements and the claims allowed for FDA-approved drugs – that they can prevent, diagnose, mitigate, or treat disease – as well as the public’s misperception that dietary supplements are evaluated for safety and effectiveness by the FDA, make the advantages of going the dietary supplement route obvious.
The prospect of a vast market has put pressure on the FDA from the dietary supplement industry and its friends in Congress to allow CBD in supplements. The FDA could accomplish this via rulemaking, although the agency told Congress it would take three to five years. This prompted four dietary supplement industry associations to write Congress last fall urging it to pass legislation making CBD derived from hemp a legal dietary supplement ingredient, obviating the need for a new rule. One of the industry groups, the Consumer Healthcare Products Association, also filed a Citizen Petition with the FDA advocating ways to shortcut the time-consuming rulemaking process.
Members of Congress wrote the FDA as well, urging it to “act quickly to provide legal clarity” in light of “growing consumer demand and the expected surge in hemp farming in the near future”.
Regulatory certainty will allow the legal hemp industry to flourish while opening up exciting new economic opportunities for farmers and entrepreneurs in a way that protects the public.
In response, the FDA pointed out, in its latest report to Congress, that the (woefully inadequate) Dietary Supplement Health and Education Act posed a number of challenges to successfully introducing CBD into the dietary supplement market. These include lack of authority to require supplement companies to tell the FDA what products they are making and selling to consumers and the limited authority to identify and address products that violate the law and put the public at risk. The agency also noted the drain on its very limited resources for policing the supplement market that would be caused by introducing a large number of new CBD products into the market.
As for now, the FDA is considering issuing a “risk-based enforcement policy” clarifying what factors it will take into account in prioritizing enforcement decisions until it can figure out a final regulatory policy on CBD. During this interim, it will continue to take action “to address violations we identify that put the public at risk.” As the FDA Law Blog pointed out in a November, 2019, post, although FDA maintains its position that the use of CBD in food and dietary supplements is illegal, FDA enforcement has been relatively minimal. Given the agency’s current, and understandable, consumption by the COVID-19 pandemic, except for the most egregious violations, I imagine CBD marketers have little to fear.

FDA: No CBD in dietary supplements or foods for now, but let’s talk
The FDA reminds everyone that (no matter what your state says) CBD is not a legal ingredient in dietary supplements and foods. The agency is willing to explore changes to the law but unproven claims for CBD health benefits, such cancer cures, will not be tolerated.
Jann BellamyonMay 9, 2019
Link

The FDA is slowly clearing the fog of confusion surrounding consumer products under its jurisdiction containing cannabis or cannabis derivatives, including drugs, dietary supplements, foods, and cosmetics. As one of his final acts before leaving the FDA on April 5, Commissioner Scott Gottlieb, M.D., announced new steps
to advance [the] agency’s continued evaluation of potential regulatory pathways for cannabis-containing and cannabis-derived products
with a particular focus on cannabidiol (CBD).
CBD is one of more than 100 biologically active chemical compounds in the cannabis plant and one of the most commonly known. Unlike THC, another well-known compound found in cannabis, CBD is not intoxicating. It is marketed in a variety of forms, such as oil, drops, capsules, syrups, teas, and topical lotions, often sold online, not necessarily legally.
Some confusion surrounding CBD’s legal status was generated by the Agricultural Improvement Act of 2018, which legalized hemp, basically defined as cannabis plants and derivatives containing no more than 0.3 percent THC (dry weight). Although legal hemp may contain CBD, that does not mean that CBD in any form, from any source, is also legal, contrary to popular misconception. Hemp-derived CBD is legal, according to this Brookings Institution publication,
if and only if that hemp is produced in a manner consistent with the [Agricultural Improvement Act], associated federal regulations, associated state regulations, and by a licensed grower. All other cannabinoids [including CBD] produced in any other setting, remain a Schedule I substance under federal law and are thus illegal.
“Associated federal regulations” include the Food, Drug & Cosmetics (FD&C) Act and the rules enacted by the FDA under the authority conferred on the agency by the FD&C Act, a subject we explore in more detail below.
(In this post, we’ll look at federal law only. State laws on CBD are all over the map. Over the past few decades, many states have legalized cannabis for medical purposes and some for adult recreational use. All of those uses remain illegal under federal law.)
Like other cannabis products, CBD is being promoted for near-miracle health benefits, which remain unproven. (SBM’s own Dr. David Gorski has done a good job of evaluating such claims in a series of posts, finding them wanting.) Right now, in Florida, where I live, yet another sad case of parents vying with the state to choose “natural” remedies over chemotherapy for their child is proceeding through the courts. A three-year-old boy who was diagnosed last month with acute lymphoblastic leukemia has been temporarily removed from the custody of his parents by the state, which is seeking permission from the court to re-start his chemotherapy, offering a cure rate of over 90% after a full 2 ½ year-regimen. His parents’ attorney told reporters that they want to start the child on medical marijuana (legalized by the Florida legislature) which “is a far superior treatment to chemotherapy” and that he will present studies to the court that “show cannabis causes ‘cell death of cancer’ without harmful side effects.” These are exactly the type of claims that are getting companies who make them in trouble with the FDA.
When (if ever) are CBD products legal?
While hinting that there may be an avenue forward for CBD-containing dietary supplements and foods, the FDA is making clear it will not tolerate companies illegally selling CBD products that claim to prevent, diagnose, treat, or cure disease, claims that can legally be made only by FDA-approved drugs (sometimes referred to as “drug claims”). To bring home the point, the FDA, in conjunction with the FTC, recently issued warning letters to three companies – Advanced Spine and Pain (headed by an M.D.), Nutra Pure, and PotNetwork Holdings – making what Dr. Gottlieb said were “unfounded, egregious claims” that their products containing CBD could treat cancer, neurodegenerative conditions, autoimmune diseases, opioid use disorder, and other serious diseases, putting consumers at risk. As he pointed out, when products make unproven claims to treat serious or life-threatening diseases
patients may be misled to forgo otherwise effective, available therapy and opt instead for a product that has no proven value or may cause them serious harm.
Examples include:
CBD successfully stopped cancer cells in multiple different cervical cancer varieties.
CBD also decreased human glioma cell growth and invasion, thus suggesting a possible role of CBD as an antitumor agent.
For Alzheimer’s patients, CBD is one treatment option that is slowing the progression of that disease.
CBD has demonstrated the ability to block spinal, peripheral and gastrointestinal mechanisms responsible for the pain associated with migraines, fibromyalgia, IBS and other related disorders.
Cannabidiol May Be Effective for Treating Substance Use Disorders.
Obviously, making claims that are legally limited to FDA-approved drugs will put you in the crosshairs of the agency as well as the FTC, and rightly so. How, then, might a company legally sell CBD-containing products, in the FDA’s view? For the answer to that question, we turn to a new agency webpage: “FDA Regulation of Cannabis and Cannabis-Derived Products,” and other recent FDA statements on the subject.*
Can I sell CBD at all?
According to the FDA,
It depends, among other things, on the intended use of the product and how it is labeled and marketed.
As noted, the Agriculture Improvement Act legalized hemp, which may contain CBD. However, as the FDA has taken pains to point out, Congress explicitly preserved the agency’s authority to regulate products containing cannabis or cannabis-derived compounds, including CBD. Thus, the fact that hemp is legal doesn’t automatically mean you can use it in an FDA-regulated product (e.g., dietary supplements), as we shall see below. And, whether it’s legal hemp-derived CBD or not, it’s important to remember that a seller can never legally (under federal law) market a CBD product for the prevention, cure or mitigation of a disease.
Can CBD be used in dietary supplements?
No, regardless of whether the CBD is hemp-derived or not. Under the Dietary Supplement Health and Education Act (DSHEA), dietary supplements can’t contain substances that are active ingredients in an FDA-approved drug or authorized for investigation as a new drug. In June, 2018, the FDA approved a new drug, Epidiolex, which contains cannabis-derived CBD, for the treatment of seizures associated with two rare and severe forms of epilepsy. (Prior to approval, the FDA had taken the position that supplements couldn’t contain CBD because Epidiolex was the subject of a new drug investigation [NDI]).
There would be an exception to this rule if CBD had been marketed as a dietary supplement prior to the NDI or FDA approval of Epidiolex, but the FDA says there’s no evidence this is the case. It is, however, willing to revisit this conclusion based on new evidence, a possible path forward for CBD-containing supplements. (There are two other possible exceptions to the ban on CBD in supplements and foods, although much harder to come by, which we’ll get to in a minute.)
Can CBD be added to foods, including animal foods?
No again, if the food is introduced, or delivered for introduction, into interstate commerce, for the same reason that CBD cannot be an ingredient in dietary supplements – because it’s an active ingredient in an FDA-approved drug. However, since the FDA’s authority over foods in this case is based on Congress’s constitutional authority to regulate interstate commerce, the FDA apparently does not claim jurisdiction over your locally-made, locally-sold CBD-laced brownies, cookies, gummies, and the like, as long as the sellers aren’t shipping them out-of-state. They may still be illegal under federal law, however, depending on the CBD’s source
Can CBD be an ingredient in cosmetics?
Currently, there is no FDA regulation prohibiting the use of CBD in cosmetics, which do not require pre-market approval (except for color additives), as long as the cosmetic otherwise complies with the law, including refraining from making drug claims or false advertising. The FDA can take action if any ingredient, including CBD, proves unsafe to consumers. Again, no matter the FDA’s position, the CBD in cosmetics may still be illegal under federal law.
Can CBD be used in drug compounding?
This is one question the FDA does not address: Whether and under what circumstances pharmaceutical-grade CBD can be used in traditionally compounded drugs. While components of FDA-approved drugs can legally be used in compounding, other restrictions may prevent CBD’s use in compounded drugs. (It’s complicated.) If that is not the case, we should worry about doctors, including naturopaths with prescription privileges, prescribing compounded CBD for unproven uses.
Prohibitions aside, Dr. Gottlieb’s recent FDA Statement also announced
a number of important new steps and actions to advance our consideration of a framework for the lawful marketing of appropriate cannabis and cannabis-derived products under our existing authorities.
Toward this end, the FDA will
hold a public hearing on May 31, giving “stakeholders” the opportunity to provide the FDA with information relevant to the its current regulation of cannabis products and possible “lawful pathways” for marketing these products. Presumably this will include an opportunity to argue with the FDA about whether CBD was already being marketed as a dietary supplement ingredient prior to Epidiolex’s approval.
take written public comments “to share . . . experiences and challenges with these products, including information and views related to product safety.”
form a “high-level agency working group to explore potential pathways for dietary supplements and/or conventional foods containing CBD to be lawfully marketed.”
There are apparently two potential “lawful pathways” in the FDA’s thinking. One, obviously, would be for Congress to change the law (as it did with hemp), allowing dietary supplements and foods to contain CBD within a framework, in Dr. Gottlieb’s view, that defines permitted concentration levels.
The other is the FDA’s enacting a regulation, through notice-and-comment rulemaking, which can take years, permitting CBD in supplements and food. However, the FDA thinks it is critical to answer “open questions . . . regarding the safety conditions raised by their widespread use.” For example, during its review of Epidiolex, the FDA identified safety risks, including potential liver injury. As Dr. Gottlieb points out, these risks can be managed with medical supervision, but it is not clear how to address them when CBD is used with no medical oversight and without the labeling requirements for prescription drugs. He says there are also questions regarding cumulative exposure if consumers access CBD across a broad range of consumer products as well as questions of CBD’s “intended functionality” in these products.
Either way, it is clear to Dr. Gottlieb that Congress wants action on CBD:
Every meeting I go into on Capitol Hill, almost every meeting, I get asked about this.
Given the current disarray in Congress and the FDA’s lack of resources, it’s likely that we’ll continue to muddle along with conflicting federal and state laws, outlandish claims of health benefits, and confused sellers and consumers for the time being.

*While I am a lawyer, I am not your lawyer. This post is my interpretation of the FDA’s position on CBD, not legal advice to you, and you should not rely on it as such. If you want legal advice on CBD, including, but not limited to, whether and in what form you might sell it or any other cannabis product, consult a licensed attorney who specializes in this area of the law.

FDA promises industry-friendly “modernization” of dietary supplement regulation
The FDA promises the “most significant modernization of dietary supplement regulation” in 25 years while maintaining its industry-friendly regulatory scheme.
Jann Bellamy on February 14, 2019
Link

On Monday, FDA Commissioner Scott Gottlieb, MD, announced
a new plan for policy advancements with the goal of implementing one of the most significant modernizations of dietary supplement regulation and oversight in more than 25 years.
Depending on who you ask, this is either mostly unnecessary (the dietary supplement industry); a welcome development, albeit with insufficient resources (some consumer advocates); a meaningless PR move (another consumer advocate); or wholly insufficient (me).
Dr. Gottlieb begins with some interesting statistics: three out of four Americans regularly take a dietary supplement. For older Americans, that rate rises four in five; for children, it’s one in three. Since Congress passed the Dietary Supplement Health and Education Act (DSHEA) in 1994, the dietary supplement market has grown ten-fold, from a $4 billion to a $40 billion industry, and from 4,000 unique products to “more than 50,000 – and possibly as many as 80,000 or even more,” a tacit admission that the FDA doesn’t even know what dietary supplements are on the market because DSHEA has no requirement that the industry let the FDA know what products it’s selling to consumers.
According to Dr. Gottlieb, the FDA will focus on collaring the “bad actors”, those who market potentially dangerous products and make unproven or misleading claims about their products’ health benefits. While this is laudable, by narrowly defining the terms “potentially dangerous” and “unproven or misleading claims” in a manner suitable to the dietary supplement industry, the FDA fails to address the legally authorized health dangers and misleading claims baked into the dietary supplement regulatory scheme by DSHEA.
To Dr. Gottlieb, “potentially dangerous” means one of three things: (1) the supplement contains unlawful ingredients, including drugs like sildenafil or tadalafil; (2) the supplement is not manufactured in compliance with current good manufacturing practice regulations; or (3) the supplement has obviously inherently dangerous ingredients, like kratom or highly concentrated caffeine.
“Potentially dangerous” apparently does not include, however, products sold to consumers as beneficial to health but which are, in fact, not tested for safety or efficacy prior to their going on the market, a deficiency that necessarily eliminates any real risk/benefit calculation. That is because DSHEA does not require such testing. (The law does require submission of some safety, but not efficacy, information on new dietary ingredients, a topic we’ll return to in a moment.) Although manufacturers are supposed to have substantiation backing claims that their products benefit a structure (like the skeleton) or function (like digestion) of the body, the FDA is not permitted to see their evidence. (When a few dietary supplement manufacturers did agree to share their evidence with the government, a GAO report found it less than adequate.)
Dr. Gottlieb carefully elides the issue of efficacy in his statement. He says he has “personally benefitted from the use of dietary supplements” and recognizes the benefits of “certain” supplements in a comprehensive health plan. He says that it is “clear” to him that supplements “play an important role” as we “strive to stay healthy.” What he doesn’t do is quantify that role or identify which of the “certain” supplements actually have benefits. In fact, according to the best available evidence, with the possible exception of specific groups like pregnant women or those with verified nutritional deficiencies, the role of dietary supplements in health is miniscule to none and any health benefit remains unproven for the vast majority of supplements on the market
“Unproven or misleading claims”, are apparently limited, in Dr. Gottlieb’s view, to claims that a dietary supplement can prevent, treat, or cure disease. As he rightly points out, only drugs can legally claim they treat disease and must gain FDA approval before they are sold in order to help ensure they are safe and effective for their intended medical use. To bring home that message, the same day as Dr. Gottlieb’s statement appeared, the FDA sent warning and advisory letters to 17 companies whose products, including dietary supplements, are being illegally marketed to prevent, treat, or cure Alzheimer’s disease and other serious diseases, like diabetes and cancer.
What he does not mention, however, is that consumers cannot necessarily distinguish between the impermissible “prevent, treat, or cure” and the permissible, under DSHEA, structure/ function claims. Indeed, even the FDA itself has trouble telling the difference. To an older individual worried whether memory loss is the first sign of dementia, a dietary supplement’s claim that it “enhances memory” or “improves cognition” could well be read as “prevents dementia”. As a recent “Viewpoint” article in JAMA Network lamented, even though no known dietary supplement prevents cognitive decline or dementia, the promotion of supplements to improve cognition and brain health is itself a $3.2 billion industry that benefits from high-penetration consumer advertising.
Thus, in the schema of Dr. Gottlieb, the FDA’s job is to ratchet up its pursuit of the “bad actors” who “exploit the halo created by quality work of legitimate manufacturers” and other players in the industry “most of whom act responsibly”. In his view, all consumers need to “make healthy choices” is available, for the most part, within the current framework of DSHEA via access to “safe [meaning, basically, unadulterated], well-manufactured, and appropriately labeled products,” even if the information on those labels isn’t backed by solid scientific evidence and safety warnings (except for supplements containing iron) are not required. (Labels must, however, include the ineffective Quack Miranda Warning.)
Lest the supplement industry be alarmed by this newly energized FDA, Dr. Gottlieb’s statement contains assurances that the FDA will be “flexible enough” in evaluating product safety so as not to discourage “innovation,” a word he uses five times (plus one “innovate”) in a statement less than four pages long, mostly in the context of “promoting” this innovation and protecting innovation from “barriers.” He does not explain what innovation he is expecting. As it currently stands, “innovation” in the dietary supplement industry seems to me to consist of figuring out how to combine the same ingredients in different ways and sell the results as a new product.
Other than stepped-up enforcement actions against the bad actors, details about how the FDA is going to accomplish this modernizing and reforming are sketchy. Plans include the “Botanical Safety Consortium”, a “public-private partnership” to evaluate the safety of botanical ingredients and mixtures in dietary supplements to “promote the goals of safety and effectiveness”. That’s good news. According to the American Botanical Council, an industry group, herbal supplement sales increased 8.5% in 2017, topping $8 billion, the strongest sales growth in 15 years “and there appears to be no slowing in sight”.
Dr. Gottlieb also promises “communicating to the public as soon as possible when there is a concern about dietary supplement.” While admirable, this may not be effective. A small study, recently published, found that supplements still contained prohibited ingredients even after public notices targeting those ingredients had been issued, providing further evidence, according to the authors, that a post-market regulatory system is insufficient to ensure the safety of supplements.
In what The Washington Post described as “a nod to industry,” Dr. Gottlieb also says the FDA will review its regulations on new dietary ingredients “to make sure they are flexible enough to ensure product improvement”. If a supplement incorporates an ingredient not in use when DSHEA was passed in 1994, what the law calls a “new dietary ingredient” (NDI), its manufacturer must notify the FDA and include the NDI’s history of use or other evidence of safety. (I’m not equating “history of use” with “evidence of safety”, but the law does.) The industry has been miffed by the FDA’s interpretation of this requirement ever since the agency issued new draft guidance on NDIs in 2016. Apparently, Dr. Gottlieb took their complaints to heart.
Interestingly, Dr. Gottlieb hints that amendments to DSHEA might be part of the solution, although not one he or the FDA will commit to, at least for now. At this time, all he will admit to is that “there may be value in a broader public conversation about whether changes to the law might be helpful” while at the same time “preserving the law’s essential balance,” this balance apparently consisting of “preserving consumer access to lawful supplements,” (i.e., the current system of pro-industry regulation mandated by DSHEA) and fulfilling the FDA’s duty to protect the public from unsafe supplements. In fact, he maintains that none of this must impose “any significant new burdens on responsible firms”, which is, as you will recall, the majority of the supplement industry in his view.
One of the DSHEA amendments could be, he suggests, a list of products on the market and their ingredients. Right now, all manufacturers have to do is register their facilities with the FDA, although we don’t know how many are complying because we don’t know how many are out there or where they are. And we have no idea what they’re selling.
The industry is not universally warm to the idea of a mandatory registry. They are all for the “bad actor” initiative, which eliminates the most egregious offenders and the bad publicity for dietary supplements accompanying publication of their scandalous behavior. But, quarrels with NDI guidance aside, they very much like the current scheme, which guarantees, in their view, that “Americans have continued access to safe, natural, and affordable supplements.” Or at least they want some quid pro quo for cooperating with any tinkering with DSHEA. According to the American Herbal Products Association, this would include measures to
appropriately reduce burdens on the industry or create new opportunities for it and the consumers it serves, for example in the context of nutrient content claims.
Consumer advocates are generally positive, but at least one wonders where the authority, and resources, will come from to implement all of this. According to Peter Lurie, MD, MPH, former FDA official and president of The Center for Science in the Public Interest:
The FDA is hampered by a terrible law and drastically limited resources. Within that there’s only so much you can do.
He’s right on both counts. DSHEA is a terrible law, or, as we like to say here at SBM, it’s a travesty of a mockery of a sham. In 2017, an FDA official told a reporter that the agency patrolled the multi-billion dollar supplement industry and its tens of thousands of products with 26 people and a $5 million budget.
Pieter Cohen, MD, JD, who frequently exposes the dangers of dietary supplements in the medical literature, thinks Dr. Gottlieb is overselling the idea that the FDA is moving forward, characterizing this instead as “restating things they have been doing for years” and “a big PR push.”
In my view, while increased enforcement of DSHEA’s weak consumer protections is not a bad thing, this is lipstick on a pig. DSHEA needs to be tossed out and replaced with a new law, one that protects consumers and not the dietary supplement industry. That’s what Dr. Gottlieb should be saying, but won’t. Prior to his confirmation, he assured former Sen. Orrin Hatch, the industry’s protector-in-chief,
“As someone who uses dietary supplements every day, I believe they serve an important role in health promotion for millions of Americans, and I support consumer access to these products.” He also wrote that FDA’s current regulatory framework under DSHEA provides adequate enforcement tools to remove unsafe dietary supplements from the market and “if confirmed, I would commit to enforcing DSHEA, as intended by Congress.”

The FDA under MAHA control: Weakening the quack Miranda warning on supplements
The FDA sent a letter to the supplement industry assuring that it would make it easier for them to hide disclaimers (which we like to call “quack Miranda warnings”) about unproven health claims for supplements. What does this tell us about MAHA?
David Gorski on December 15, 2025
Link

Ever since life events made it impossible for me to maintain two blogs (this one and my not-so-super-secret other blog, which other than a handful of original posts has been mostly fallow for several months), one frustration that I’ve found with once-a-week blogging in the age of President Donald Trump and his Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr.‘s “make America healthy again” (MAHA) is that there’s just too damned much material. Every week, since January I have a truly difficult time choosing between multiple horrors to write about. Sometimes the choice is obvious, such as when the CDC Advisory Committee on Immunization Practices (ACIP) meeting led to last week’s post about how RFK Jr. and the Trump administration will invoke a distorted version of “best practices” of other countries that don’t recommend vaccination against as many diseases as the US does to justify rolling back as many vaccine requirements as possible or my post from the week before writing about the director of the FDA Center for Biologics Evaluation and Research (CBER), Dr. Vinay Prasad, sending an email memo blaming ten pediatric deaths on COVID-19 vaccines without actually showing the work that led to that conclusion or citing the evidence, all while telling anyone who disagrees with his approach that they should resign. This time around, the choice was less obvious, with multiple horrors continuing to best science-based medicine and health policy, but one post on X, the hellsite formerly known as Twitter, led me to revisit a longtime topic that we at SBM haven’t written much about in a while. Does anyone remember the Dietary Supplement Health Education Act (DSHEA) of 1994?
MAHA does:
Deeply predictable. So on-brand. Still maddening.

RFK Jr & his anti-science crew plan to:

1) Lessen labelling requirement for grifters pushing bunk & unproven supplements

2) Put warning labels on highly studied, safe & monitored COVID vaccines

Holy mental gymnastics, Batman! pic.twitter.com/Jibmd9k9kO
— Timothy Caulfield (@CaulfieldTim) December 13, 2025
The DSHEA disclaimer, by the way, is something that, back in the day, we used to refer to as the “quack Miranda warning,” as I couldn’t resist taking to the same hellsite to mention:
So @SecKennedy is weakening the Quack Miranda warning. Quelle surprise! https://t.co/XbeibODlxd
— David Gorski, MD, PhD (@gorskon) December 12, 2025
I could have discussed more about the MAHA war on vaccines, but then I would neglect another RFK Jr. action that, in addition to being consistent with MAHA, is also consistent with the Trump administration’s deregulatory agenda and therefore much more likely to slide in under the radar, unlike RFK Jr.’s war on vaccines. I realize that some of this might come across as too much “inside baseball” to some of our readers, but it’s totally been in our wheelhouse here at SBM since the very beginning 18 years ago. Moreover, there are plenty of others writing about RFK Jr.’s latest attacks on vaccines, but I haven’t seen much written (yet) about this. (Indeed, a search of X only finds two posts about it.)
To return to the topic at hand, the quack Miranda warning is our term for the DSHEA disclaimer, which generally reads, “This/these statement/statements has/have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.” Often there will be other optional flourishes, such as saying that these statements are for “informational purposes only” and/or “not intended as medical advice,” all with a “see your doctor” finale. If there’s one thing we’ve discussed here again and again over the years, it’s how the DSHEA weakened supplement regulation and how a quack Miranda warning on a website is a major red flag that it is likely selling quackery.
I always knew that, sooner or later, RFK Jr. and his MAHA minions whom he’s placed in key positions in the regulatory agencies of HHS would get around to dietary supplements, because of course they would. After all, just look at key MAHA allies. One great example is Dr. Peter McCullough, cardiologist turned COVID grifter during the pandemic and now the “chief scientific officer” for The Wellness Company, which, in addition to selling ivermectin to treat and prevent COVID-19, also sells various supplements to treat COVID-19 “vaccine injury.” Indeed, the wellness influencers who got their start during the pandemic have now become indistinguishable from the quacks of old who used to sell all manner of unproven (and disproven) supplements.
So what is the FDA doing about the quack Miranda warning? Before I discuss how the above proposal will weaken the already weak DSHEA labeling requirement, most likely as a first step towards weakening dietary supplement regulation further, let’s discuss what the DSHEA is (and is not) and how it set the stage for the proliferation of unproven supplements sold as medicine with a not-so-subtle, “wink-wink, nudge-nudge.” (It also provide a mechanism for huge revenue streams for quacks like Joe Mercola and right wing conspiracy theorist influencers, like Alex Jones.)
The DSHEA and the Quack Miranda warning
I’ve known that the quack Miranda warning would be on RFK Jr.’s target list ever since late summer of 2024, when, after having abandoned his independent campaign for President and bent the knee to Donald Trump in return for the position of HHS Secretary if Trump won, he published what I called a “MAHA manifesto” in the Wall Street Journal and then, a week before the election, declared MAHA war on the FDA thusly:
Of course, peptides and “nutraceuticals” are often sold as dietary supplements, complete with marketing claiming health benefits and the treatment of some diseases, as are some chelating compounds. It was at this point that it became clear to me that RFK Jr. had pivoted from being primarily antivaccine to embracing a more general “health freedom” orientation frequently associated with the antivaccine movement that paints the Food and Drug Administration as the pharma-serving villain suppressing “natural” treatments, low cost medications, and “miracle cures.” I also realized that I shouldn’t have been surprised by this open attack on the FDA, given that it’s long been a goal of the “health freedom” movement to dismantle the FDA and return it at least to a pre-thalidomide state if not to eliminate the FDA entirely. Recall that, before the thalidomide scandal, drug manufacturers were only required to submit evidence of safety, not efficacy, to win approval to market their products. After the thalidomide scandal, Congress passed the Kefauver-Harris Amendments in 1962. These Amendments to the federal Food, Drug, and Cosmetic Act tasked the FDA with additional requirements and responsibilities:
    • Efficacy requirement: Manufacturers must provide substantial evidence that a drug is effective for its intended use before it can be sold.
    • Retroactive review: The FDA was required to review the effectiveness of drugs approved between 1938 and 1962, a review that by the early 1970s had categorized approximately 600 medicines as “ineffective” and forced their removal from the market.
    • Informed consent: The amendment mandated that subjects provide informed consent before participating in clinical trials.
    • Good manufacturing practices: The amendments established rules for drug manufacturing and required routine inspections of production facilities.
    • Adverse event reporting: Manufacturers were for the first time required to report serious side effects to the FDA.
    • Advertising regulation: The amendments transferred the regulation of prescription drug advertising from the Federal Trade Commission (FTC) to the FDA and required more truthful and informative advertisements. Drug manufacturers were required to inform consumers of side effects and contraindications in their advertising.
You can see why the “health freedom” movement that ultimately spawned MAHA over six decades later did not like these amendments. But where does the DSHEA fit in? Basically, it’s a law that, by intent, made it difficult for the FDA, even when it wanted to, to act on dubious health claims for unproven, disproven, and sometimes even outright harmful supplements. As one of our former bloggers here at SBM, Dr. Peter Lipson, once described it long ago, the DSHEA is a “travesty of a mockery of a sham.”
According to the FDA‘s discussion of the DSHEA of 1994:
A dietary supplement is a product intended for ingestion that, among other requirements, contains a “dietary ingredient” intended to supplement the diet. The term “dietary ingredient” includes vitamins and minerals; herbs and other botanicals; amino acids; “dietary substances” that are part of the food supply, such as enzymes and live microbials (commonly referred to as “probiotics”); and concentrates, metabolites, constituents, extracts, or combinations of any dietary ingredient from the preceding categories.
There are two types of ingredients that may be used in dietary supplements: “dietary ingredients,” discussed above, and “other ingredients.” These “other ingredients” include substances such as fillers, binders, excipients, preservatives, sweeteners, and flavorings.
As you can see, one thing that the DSHEA does is to make a distinction between food and medicine. It also requires that dietary supplements be ingested and not injected or breathed in, which also makes sense. While on its surface distinguishing between food and medicine would seem to be quite reasonable (after all, it wouldn’t make a lot of sense to hold food to the same standards to which drugs are held), as implemented by the DSHEA this distinction has a pernicious effect in that in practice it allows manufacturers to label all sorts of botanicals, many of which with pharmacological activity, as “supplements,” and supplements, being defined as food and not medicine, do not require prior approval by the FDA before marketing:
FDA regulates both finished dietary supplement products and dietary ingredients. FDA regulates dietary supplements under a different set of regulations than those covering “conventional” foods and drug products. Under the Dietary Supplement Health and Education Act of 1994 (DSHEA):
    • Manufacturers and distributors of dietary supplements and dietary ingredients are prohibited from marketing products that are adulterated or misbranded. That means that these firms are responsible for evaluating the safety and labeling of their products before marketing to ensure that they meet all the requirements of the Federal Food, Drug, and Cosmetic Act as amended by DSHEA and FDA regulations.
    • FDA has the authority to take action against any adulterated or misbranded dietary supplement product after it reaches the market.
In other words, when a supplement is marketed it’s more or less the honor system. No registration with the FDA is required. After all, supplements are food, not medicine! (Just like “fish are friends, not food”?) Even though there are exceptions that require manufacturers to notify the FDA if they add a new ingredient to a supplement, in effect, the government can’t really do much of anything unless problems are reported after the supplement is marketed. Even worse, the definition of “supplement” has become very broad, as Quackwatch pointed out:
The Food, Drug, and Cosmetic Act defines “drug” as any article (except devices) “intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease” and “articles (other than food) intended to affect the structure or function of the body.” These words permit the FDA to stop the marketing of products with unsubstantiated “drug” claims on their labels.
To evade the law’s intent, the supplement industry is organized to ensure that the public learns of “medicinal” uses that are not stated on product labels. This is done mainly by promoting the ingredients of the products through books, magazines, newsletters, booklets, lectures, radio and television broadcasts, oral claims made by retailers, and the Internet.
DSHEA worsened this situation by increasing the amount of misinformation that can be directly transmitted to prospective customers. It also expanded the types of products that could be marketed as “supplements.” The most logical definition of “dietary supplement” would be something that supplies one or more essential nutrients missing from the diet. DSHEA went far beyond this to include vitamins; minerals; herbs or other botanicals; amino acids; other dietary substances to supplement the diet by increasing dietary intake; and any concentrate, metabolite, constituent, extract, or combination of any such ingredients. Although many such products (particularly herbs) are marketed for their alleged preventive or therapeutic effects, the 1994 law has made it difficult or impossible for the FDA to regulate them as drugs. Since its passage, even hormones, such as DHEA and melatonin, are being hawked as supplements.
In other words, under the DSHEA, substances that are clearly not foods can be marketed as supplements, including herbs and other botanicals (the vast majority of which are marketed as having a beneficial medicinal effect and some of which contain chemicals that do act as drugs).As long as the manufacturer is careful not to make specific health claims, it’s all good. In other words, a “nutritional support” statement claimed for a supplement must not be a “drug” claim; i.e., it must not claim that the supplement can be used for the treatment or prevention of a disease. Supplement manufacturers easily evade this requirement by making vaguer claims related to organs or systems, such as claiming that a product “boosts the immune system,” “supports heart health,” or something similar, often accompanied by what Dr. Lipson has sarcastically referred to as the “quack Miranda warning.“
Arguably, the DSHEA was the greatest boon to supplement manufacturers ever. In its wake, the supplement industry exploded, racking up huge increases in sales. Indeed, by 2007 a GAO report estimated that the supplement industry had grown to a $23.7 billion industry, and, in 2025, Grand View Research estimated that the size of the dietary supplement industry has reached $112.6 billion and also forecast it to grow at a compound annual growth rate (CAGR) of 4.9% from 2025 to 2030. Moreover, so lax was the regulation of supplements even before RFK Jr, and MAHA took over HHS, that it took a very extreme and egregious act, namely the marketing of an industrial chelator as an “antioxidant” supplement for the treatment of autism, before the FDA finally acted, and the FDA has seldom acted forcefully even over the one aspect of supplement regulation that the DSHEA does give it, to recall products due to “adulteration.”
Over the years, supporters of science-based medicine and sound public policy have made efforts in Congress to alter or repeal the DSHEA, such as the Dietary Supplement Safety Act of 2010, which would, among other things, have mandated reporting of all adverse events due to supplements to the FDA and given the FDA mandatory recall power over supplements that cause harm. All have failed to pass, as the DSHEA has had powerful patrons, such as its co-sponsors Sen. Tom Harkin (D-Iowa) and Sen. Orrin Hatch (R-Utah), and Utah is home to many supplement manufacturers. Sens. Harkin and Hatch might have retired from the Senate years ago, but they have many successors in Congress. With MAHA ascendant, supplement manufacturers in their stans are more powerful than ever, as is the Congressional Dietary Supplement Caucus. Yes, that’s a real thing, and, although Republicans do outnumber Democrats in the caucus, the caucus is currently pretty bipartisan, with a ratio of Republicans to Democrats of roughly 3:2.
Next, let’s look at what the FDA plans to do.
Too many quack Miranda warnings?
Let’s take a look at the text of the FDA letter to supplement manufacturers from Kyle Diamantas, Deputy Commissioner for Human Foods. The letter is dated December 11, and entitled Letter to the Dietary Supplement Industry on the DSHEA Disclaimer. The first thing I noted is that the letter starts out by stating that the FDA has “received several requests to amend our labeling regulation at 21 CFR 101.93(d),1 which governs the placement of the disclaimer required under section 403(r)(6)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act).” Specifically, the FDA has required that the DSHEA disclaimer (a.k.a. the quack Miranda warning) be placed on every panel in supplement documentation in which a health claim is made.
According to the letter, currently the requirement mandates:
This regulation states the DSHEA disclaimer shall be placed adjacent to the statement with no intervening material or linked to the statement with a symbol (e.g., an asterisk) at the end of each statement described in section 403(r)(6) of the FD&C Act, such as a structure/function claim, (i.e., a “403(r)(6) claim”). The regulation goes on to state “the disclaimer shall appear on each panel” of a product label where there is a 403(r)(6) claim.
A “structure-function” claim is another way that the DSHEA allows supplement manufacturers to bypass the requirement that they cannot claim to treat or prevent any diseases. You’ve seen these sorts of structure-function claims before. Examples include:
    • “Supports [specific organ] health.” Examples include: “supports prostate health”; “supports brain health”; “supports immune health”; “helps maintain a healthy heart.”
    • The ever-popular “boosts the immune system” or “supports immunity”
    • “Builds strong bones”
A study from several years ago found that 87% of advertisements for supplements contain structure-function claims, with an average of 2.5 claims per ad. There is a great PowerPoint presentation from Venable, LLP outlining the differences between permissible and impermissible structure-function claims based on eleven (!) FDA criteria. If you peruse the list, you’ll find that some of these are truly splitting hairs, like, for example, these two (click to embiggen):
Examples of permissible and impermissible structure-function claims
In any event, regardless of the structure-function claim, there has to be at least an asterisk leading to a quack Miranda warning for every instance, at least under current FDA regulations.
So what does the FDA now want to do? Back to the letter:
Based on FDA’s initial review, we expect that revising this regulation to remove the requirement for the DSHEA disclaimer to appear on each panel of a product label where there is a 403(r)(6) claim would be consistent with section 403(r)(6)(C) of the FD&C Act while reducing label clutter and unnecessary costs. Further, FDA recognizes that we have rarely, if ever, enforced this requirement. If FDA does not identify significant concerns as we continue our review of the available data and information regarding this request, we are likely to propose a rule to amend this requirement.
I like how Diamantas basically admits that the FDA wasn’t really enforcing this requirement very much anyway and the goes on to say that the FDA will exercise “enforcement discretion regarding the requirement for the DSHEA disclaimer to appear on each panel of a product label where a 403(r)(6) claim appears,” while still requiring that the DSHEA disclaimer appear at least once.
Why, you might ask, would the supplement manufacturers want this regulation changed so badly? One obvious answer, of course, is that if the quack Miranda appears only once in the product’s labeling it will be very easy for consumers to overlook it, as opposed to when it is required to appear on every panel in which a structure-function claim is made. There’s another reason, though, that was revealed in the congratulatory messages posted by supplement manufacturing groups, such as the Council for Responsible Nutrition (CRN), which “applauded FDA clarification on DSHEA disclaimer after years of industry advocacy“:
For nearly 30 years, FDA practice has allowed the use of an asterisk to direct consumers to the full DSHEA disclaimer elsewhere on the label, consistent with section 403(r)(6)(C) of the Food, Drug & Cosmetic Act and 21 C.F.R. § 101.93(d). However, a recent uptick in class-action lawsuits has relied on an alternative interpretation, arguing that the full disclaimer must be placed on every panel where a structure/function claim is used on a product label. These legal challenges have created confusion, prompted unnecessary litigation, and imposed costly and disproportionate burdens on responsible manufacturers—without improving consumer understanding.
Earlier this year, CRN called on FDA [starting on page 23] to revise section 101.93(d) to clarify that the law does not require duplicative use of the DSHEA disclaimer on multiple panels of the same product. CRN offered then that making the change “would maintain adequate levels of consumer protection while reducing unnecessary, redundant regulatory burdens on companies,” and argued that a single disclaimer on a dietary supplement product’s label linked by an asterisk or other symbol to structure/function claims adequately informs consumers of the existence of additional information and satisfies the legislative intent to have a structure/function statement “contain” the disclaimer. Separately, CRN made clear to the agency that it was prepared to file a citizen petition to formally escalate the matter if needed.
Those pesky citizen activists and their class-action suits, getting in the way of supplement industry obfuscation about its products! Make no mistake, the supplement industry sees this as a big win and a harbinger of things to come. Here’s the American Herbal Products Association’s take:
This significant action comes directly in response to sustained advocacy from AHPA dating back to and continuing since 2021. AHPA and others have argued that the existing “every panel” requirement (found in 21 C.F.R. § 101.93(d)) is overly prescriptive and exceeds the demands of DSHEA. AHPA has long advocated for FDA to update the regulation to reflect historical industry practice: prominently displaying the disclaimer once on the product label or labeling, not necessarily on every panel, and connecting each claim to the disclaimer via symbols (e.g., asterisks). The contemplated revision would also accord the technical requirements of the regulation with FDA’s historical enforcement approach; as conceded in the letter, and consistent with AHPA’s analysis of agency documents, FDA has “rarely, if ever, enforced this requirement.”
“This news is a major win for the dietary supplement industry,” said AHPA President & CEO Graham Rigby. “AHPA has long led the charge for this sensible regulatory reform, and we thank FDA for taking action on an unenforced provision that has fueled opportunistic litigation. This is a strong, positive signal of the agency’s commitment to modernizing regulations, and AHPA looks forward to continued engagement in shaping a rational and modern regulatory environment for this vital category of products.”
Again, I realize that this might strike some readers as too much “inside baseball,” but there are real consequences. Some readers might reasonably wonder why it matters if the quack Miranda warning appears on every panel where disease treatment claims barely disguised as “structure-function” claims or not. I found the most succinct explanation here:
Moreover:
yeah the DSHEA disclaimer was expressly provided by Congress in the statute, they can’t (lawfully) get rid of it, they’re just trying to let companies hide it more than the current version of the implanting reg allowswww.ecfr.gov/current/titl…
— ❀°。Der Siebenschläfer *.ﾟ✿ ⋆ (@sababausa.bsky.social) 2025-12-13T07:15:28.218Z
The current relevant regulations state:
The disclaimer shall be placed adjacent to the statement with no intervening material or linked to the statement with a symbol (e.g., an asterisk) at the end of each such statement that refers to the same symbol placed adjacent to the disclaimer specified in paragraphs (c)(1) or (c)(2) of this section. On product labels and in labeling (e.g., pamphlets, catalogs), the disclaimer shall appear on each panel or page where there such is a statement. The disclaimer shall be set off in a box where it is not adjacent to the statement in question.
Getting rid of the requirement for the DSHEA on each panel will make it a lot easier for supplement manufacturers to hide the “prominent” disclaimer, to bury it somewhere else and then refer to it by an asterisk.
What does this mean, and does it matter?
As I mentioned before, I realize that to many people this change seems minor. Indeed, one can argue if DSHEA disclaimers (or, as we prefer to call them, quack Miranda warnings) even matter that much to consumers, if they dissuade them from purchasing a product. After all, Cheerios claims to help maintain a healthy cholesterol in its ads, along with a quack Miranda warning. This is about more than just supplement manufacturers. Many food manufacturers use the DSHEA as well to justify structure-function health claims for their products.
Nonetheless, given RFK Jr.’s declaration of MAHA war on the FDA, I nonetheless believe that this proposed change is important for a number of reasons. First, it signals to the supplement industry that RFK Jr. is on its side now and that the FDA will be far more compliant in terms of doing the industry’s bidding than ever before. Second, this step is clearly meant as a first step in deregulating supplements using the most industry-friendly interpretation of the DSHEA that RFK Jr. and his cronies can come up with. The next steps, I predict, will be to loosen the restrictions on what is considered a “structure-function” claim, so that supplement manufacturers can make more explicit disease treatment and prevention claims without the evidence that would be required for a manufacturer of a drug to make a similar claim.
Finally, as Tim Caulfield, whose X post was quoted above notes, one only has to look at the regulatory double standard in terms of evidence required between supplements, for which RFK Jr. clearly plans to lower the bar as much as possible, and vaccines to see what MAHA is really about. News reports now indicate that, based on a non-transparent “analysis” of pediatric deaths linked with COVID vaccines that has only been referred to thus far in a leaked memo and blames the vaccines for killing at least ten children without explaining how the FDA came to the conclusion of causation, the FDA plans on adding a black box warning to COVID vaccines. A “black box” warning is the FDA’s strongest warning included in the package insert for a drug, medical device, vaccine or biological. Usually such warnings are about a significant risk of death or serious injury due to a product that must be weighed against the product’s benefit. Sometimes such warnings are targeted to certain groups most at risk, for example the warning for Accutane of potential birth defects when used during pregnancy. It’s also interesting to note how the FDA is going through the standard regulatory process to change the requirements for how a quack Miranda warning must be displayed but is, according to news reports, not doing so with its changes to the package insert for COVID vaccines:
“I guess my concern is that in this case, there’s not a process,” said Kesselheim, who has studied the impact of black box warnings on drug labels. “There isn’t that same opportunity for discussion and good-faith review of the data on which this decision is being made.
“My concern is that this will be seen as yet another in the long line of decisions that this FDA is making based on its own political goals, rather than after a dutiful and thoughtful and public review of the science.”
When I first noted that RFK Jr. is coming for your vaccines, I outlined six strategies that he would use. Strategy #6 read: Co-opt the FDA to make approval of new vaccines more difficult and issue black-box warnings based on antivax fear mongering for existing vaccines. (I hate to say I told you so, but…) I further noted that RFK Jr. would, through his minions, cherry pick and misrepresent evidence to portray vaccines as dangerous in order to accomplish this.
This double-standard is inherent in MAHA: Massively lower standards for unproven treatments that “health freedom” and wellness influencers like and profit from, such as supplements, quack treatments, unproven stem cell treatments, and the like, while increasing the regulatory bar for vaccines and certain pharmaceuticals to impossible levels, with the goal being to ultimately remove them from the market. Adding a black box warning to COVID vaccines is just one step.
I hate to end without a bit of hope. As we all know, the Trump administration is all about deconstructing the administrative state and deregulating favored industries, using Project 2025 as a playbook, the better to turn staffing the government back to the spoils system, one manifestation of which is how MAHA wants to turn the criteria for NIH funding of research away from pure scientific merit and towards patronage and political loyalty, the better to make it a tool to enforce ideological conformity. There is one area in which this deregulatory drive is running afoul of MAHA activists, specifically the dismantling of the Environmental Protection Agency, which is angering “MAHA moms,” as reported in the New York Times over the weekend, to the point that EPA Administrator Lee Zeldin recently met with a group of very unhappy MAHA moms who are accusing the agency of prioritizing chemical industry interests over public health through its efforts to loosen restrictions on harmful chemicals, and approve new pesticides, loosen pollution regulations, not to mention Trump’s having appointed several former chemical industry executives and lobbyists to senior roles overseeing pesticides and toxic chemicals.
Of course, as I pointed out last week, this was always part of the Faustian bargain RFK Jr. made when he bent the knee to Donald Trump: Abandon the environmentalist activism for which he was primarily known before turning antivax activist in return for a chance at getting rid of as many vaccines as he can. When it comes to loosening restrictions on supplements while ratcheting up restrictions on vaccines to untenable levels, there is no conflict. The same might not be true when it comes to being complicit in the extreme deregulatory agenda being promoted at the EPA. I suspect that not even RFK Jr. can square that circle indefinitely. At least I hope not.
Unfortunately, in the meantime, massive damage has already been done to the vaccine program and the regulatory apparatus that assures safe and effective drugs, with over three years for this administration to do worse.
    • 

Consumer and public health groups push for cancer warning on alcoholic beverages
A coalition of consumer and public health groups, citing scientific consensus, is pushing for a government-required warning that alcohol consumption causes cancer on alcoholic beverage containers. Despite the evidence, we can expect alcohol industry opposition.
Jann Bellamy on January 28, 2021
Link

A coalition of consumer and public health groups is pushing for a government-required warning that alcohol consumption causes cancer on labels of liquor bottles and other alcoholic beverage containers.
Currently, federal law requires a “health statement” on the label of all alcoholic beverage containers warning that alcohol consumption “may cause health problems” — specifically, that it impairs the ability to drive or operate machinery and, during pregnancy, risks birth defects. That warning has not changed since 1988, when Congress enacted the law mandating the health statement. The law also directs the Alcohol and Tobacco Tax and Trade Bureau (“TTB”, part of the Department of the Treasury), in consultation with the Surgeon General, to “promptly” notify Congress of the need to update the health statement if “available scientific information would justify a change” and to make “specific recommendations” TTB determines “to be appropriate and in the public interest”.
According to the American Public Health Association, the American Society for Clinical Oncology, the Consumer Federation of America, a coalition of breast cancer organizations, and similarly-minded groups, the “available scientific information, accrued over more than three decades, shows that alcohol causes cancer”, yet the TTB has taken no action. Thus, the organizations (eight in all) filed a Citizen Petition (per federal regulations) with the Department of the Treasury requesting that the TTB report this scientific consensus to Congress and recommend that Congress amend the current health disclosure to state:
WARNING: According to the Surgeon General, consumption of alcoholic beverages can cause cancer, including breast and colon cancer.
The petition asks that this warning be put in rotation with the two existing health statements, citing increased consumer awareness of information that is new or different.
In support, the petition summarizes the evidence on the association between alcohol consumption and cancer, the public’s lack of awareness of that association (we’ll look at industry efforts to keep it that way in a moment), and the drinking habits of Americans.
According to the petition, quoting the National Cancer Institute, “there is a strong scientific consensus that alcohol drinking can cause several types of cancer”. American Cancer Society (ACS) researchers estimate that, in 2014, alcohol consumption was associated with an estimated 6.4% of all cancer cases in women (50,110 cases) and 4.8% of all cancers in men (37,410 cases). The largest burden “by far” was for female breast cancer (39,060 cases), per the ACS, which says that in the U.S.,
alcohol consumption represents the third largest contributor to cancer in women (behind smoking and obesity) and the fourth largest contributor to cancer in men (behind smoking, obesity, and UV radiation).
The World Health Organization’s International Agency for Research on Cancer (IARC), in 2012, considered the data on alcohol’s contribution to cancer and concluded that there is sufficient evidence in humans for the carcinogenicity of alcohol consumption causing cancers of the oral cavity, pharynx, larynx, esophagus, colorectum, liver, and female breast. The IARC also concluded that even low levels of consumption (“up to 1 drink/day”) increases the risks of some cancers. The 2016 report, Facing Addiction in America: The Surgeon General’s Report on Alcohol, Drugs, and Health, agrees, reporting that “[e]ven one drink per day may increase the risk of breast cancer” and “light” drinking (up to one drink per day) is associated with an increased risk of cancer of the oral cavity, pharynx, and esophagus.
To top this off, the petition references research from several other organizations.
    • World Cancer Research Fund and American Institute for Cancer Research: “strong evidence that consuming alcoholic drinks increases the risk of cancers” of the mouth, pharynx, larynx, esophagus, breast, stomach, liver, and colorectum.
    • American Society of Clinical Oncology: “the relationship between drinking alcohol and cancer risk has been evaluated extensively in epidemiologic case-control and cohort studies” and “[e]ven the modest use of alcohol may increase cancer risk.”
    • American Cancer Society: “it is best not to drink alcohol” but those who do choose to drink should limit their consumption to no more than one drink per day for women and two drinks per day for men.
    • National Toxicology Program of the U.S. Department of Health and Human Services: alcohol is a known human carcinogen, a conclusion reached in 2000.
    • 2020 Dietary Guidelines Advisory Committee: Do not drink alcohol “because you think it will make you healthier”; recommends limits of one drink per day for both men and women. [Somewhat controversially, the Trump Administration rejected this recommendation, along with the Committee’s recommendation for further limiting sugar consumption.]
In addition to taking on the notion that moderate drinking does not have adverse health effects, the petition rejected the claim that there is an association between moderate drinking and health benefits, quoting the CDC:
Although past studies have indicated that moderate alcohol consumption has protective human benefits (e.g., reducing risk of heart disease), recent studies show this may not be true. While some studies have found improved health outcomes among moderate drinkers, it’s impossible to conclude whether these improved outcomes are due to moderate alcohol consumption or other differences in behaviors or genetics between people who drink moderately and people who don’t.
Despite this sobering news, according to the petition, while the evidence is limited, it indicates that few consumers are aware of the link between alcohol and cancer. A 2019 American Institute for Cancer Research survey showed that just 45% of adults identify alcohol as a cancer risk. A National Cancer Institute survey, also in 2019, found 32% of respondents identified cancer as a health condition that can result from alcohol consumption.
(Personally, based solely my own experience in over a decade of blogging at SBM, this is a refreshingly high level of knowledge about any health subject, considering the plethora of misinformation and lack of critical thinking that abounds in healthcare. But that’s just me.)
Given the fact that alcohol consumption is a totally preventable risk factor for cancer, based on our current drinking habits, the petition finds much room for improvement in Americans’ health, citing data showing:
    • More than half of the population aged 12 (!) or older reports drinking alcohol within the last 30 days.
    • Excessive drinking, associated with the greatest cancer risk, increased over the last decade.
    • In 2015, 22% of men and 10% of women reported consuming more than 7 drinks per week; 11% of men and 5% of women reported more than 14 drinks per week. (Not to minimize the gravity of these statistics, and maybe I’m just in with the wrong crowd, but I would expect these percentages to be higher.)
    • In 2018, 26.45% of people aged 18 or older reported they engaged in “binge drinking” (5 or more drinks for men, 4 or more for women, on one occasion), and close to 7% engaged in binge drinking on five or more days per month, considered “heavy drinking”.
Big Booze fights back
According to the director of food policy at the Consumer Federation of America, the petition was inspired in part by a Canadian study using an identical warning. That study both produced useful data on increased consumer awareness after warnings appeared and previewed for the petitioners how the alcohol industry will fight such warnings tooth and nail.
In 2017, Canadian researchers planned to place three different types of information labels on tens of thousands of containers of booze sold in the city of Whitehorse, Yukon. One warned of cancer risks; two others had information related to Canada’s low-risk drinking guidelines. The messages were to have been evaluated through analysis of alcohol sales data and surveys of liquor store customers in Whitehorse and in Yellowknife, Northwest Territories, which was used as a control. Unfortunately, and predictably, the alcohol industry successfully intervened and the labelling research was halted by the government a few months in. One industry strategy was to claim this research was unlawful, a claim experts later termed “groundless”, part of a game plan the industry has employed successfully in other jurisdictions.
Unfortunately for the industry, even the truncated study provided useful data: Shoppers in Whitehorse were significantly more likely to know about alcohol’s cancer risk than control groups and total alcohol sales decreased by more than 6%. The industry’s attempts to sabotage the research also produced something of a Streisand effect, garnering unflattering Canadian and international media attention.
In addition to making dubious legal claims, the alcohol industry, in fact, has a long history of misleading the public regarding connections between health and drinking, according to a 2017 Mother Jones exposé. Seemingly taking a page from the tobacco playbook, the industry has emphasized the (debunked) health benefits of alcohol (especially wine), sponsored popular sporting events like the Super Bowl and NASCAR, funded studies casting alcohol in a favorable light and doubt on unfavorable research, wined and dined researchers, contributed to political campaigns of sympathetic legislators, and participated in the revolving door between government regulators and industry employment.
A 2017 study examining alcohol industry communications with the public opined that the industry “appears to be engaged in the extensive misrepresentation of evidence about the alcohol-related risk of cancer”.
Three main industry strategies were identified: (i) denial/omission: denying, omitting or disputing the evidence that alcohol consumption increases cancer risk; (ii) distortion: mentioning cancer, but misrepresenting the risk; and (iii) distraction: focusing discussion away from the independent effects of alcohol on common cancers. Breast cancer and colorectal cancer appeared to be a particular focus for this misrepresentation.
Another study documented “pinkwashing”: alcohol products promoted with pink ribbons, partnerships with breast cancer charities, and general terms such as “breast cancer research” or “cure”.
Australian researchers examining alcohol industry trade publications found three “primary themes” evident in the articles reviewed indicating a denial of the risks associated with drinking by the industry: (1) the legitimization of alcohol as an important social and economic product, (2) the portrayal of the industry as trustworthy and benign, and (3) the strategic embedding of alcohol in various facets of everyday life.
This led the researchers to conclude that:
additional regulation of the industry and its tactics will need to proceed without industry acceptance. Clear resistance to increasing consumer protections also points to the futility of inviting industry members to the policy table.
The risks of alcohol consumption are probably not high on the new administration’s health issues “to do” list, and understandably so. Perhaps when things return to normal, if that happens and whatever “normal” may look like then, this effort might gain traction, especially considering the heavy hitters among the petitioners. On the other hand, I’d not bet against the alcohol industry drowning this one before it even reaches the Capitol.

   Utah Senator Orrin Hatch: A pit bull in defense of the supplement industry
Published by David Gorski 
Link
The weakness and ineffectiveness of the law in the U.S. regulating dietary supplements has been a frequent topic here on Science-Based Medicine, including the continued failure of efforts to address the serious shortcomings of current law and the illogic at its very heart. Indeed, over the last decade or so that I’ve paid attention to relevant issues regarding supplements continually amazed at how much supplement manufacturers can get away with and for how long. For example, one of the most recent atrocities against science occurred when Boyd Haley, disgraced chemistry professor at the University of Kentucky and prominent member of the mercury militia wing of the anti-vaccine movement, tried to sell an industrial chelator as a dietary supplement to treat autistic children. True, that was too much even for the underfunded, undermanned FDA to ignore, but it was amazing how long he got away with it. Apparently it takes someone trying to market a chemical compound that can’t by any stretch of the imagination be characterized as a “nutrient” or “food” to be so obviously against even the travesty of a mockery of a sham of a law regulating supplements (the Dietary Supplement Health and Education Act of 1994, or the DSHEA) that the FDA could take action.
Of course, here at SBM, we’ve written numerous posts on the shortcomings of the DSHEA. Basically, this law created a new class of regulated entities known as dietary supplements and liberalized the sorts of information that supplement manufacturers could transmit to the public. The result has been this:
It [the DSHEA] also expanded the types of products that could be marketed as “supplements.” The most logical definition of “dietary supplement” would be something that supplies one or more essential nutrients missing from the diet. DSHEA went far beyond this to include vitamins; minerals; herbs or other botanicals; amino acids; other dietary substances to supplement the diet by increasing dietary intake; and any concentrate, metabolite, constituent, extract, or combination of any such ingredients. Although many such products (particularly herbs) are marketed for their alleged preventive or therapeutic effects, the 1994 law has made it difficult or impossible for the FDA to regulate them as drugs. Since its passage, even hormones, such as DHEA and melatonin, are being hawked as supplements.
One might wonder how such a bad law could survive for so long (seventeen years now), but it has its defenders. One man, in particular, defends the DSHEA against all regulatory threats, foreign and domestic. His name is Senator Orrin Hatch (R-UT), and he was just the subject of a writeup in the New York Times last week referring to him as a “natural ally” of the supplement industry:
A drive along mountain-lined Interstate 15 here shows why Senator Orrin G. Hatch is considered a hero in this region nicknamed the Silicon Valley of the nutritional supplement industry.
In the town of Lehi is the sprawling headquarters of Xango, where company officials praised Mr. Hatch, a Utah Republican, late last year for helping their exotic fruit juice business “operate without excessive intrusion” from Washington.
Up in Sandy, Utah, is 4 Life Research, whose top executives donated to Mr. Hatch’s last re-election campaign after federal regulators charged the company with making exaggerated claims about pills that it says helps the immune system.
And nearby in West Salem, assembly-line workers at Neways fill thousands of bottles a day for a product line that includes Youthinol, a steroid-based hormone that professional sports leagues pushed to ban until Mr. Hatch blocked them.
And, as the article goes on to mention, Hatch was the principal author of the DSHEA. Fast forward seventeen years, and these days any time the Obama Administration tries to write rules to regulate supplements more strictly, Orrin Hatch is there to do his damnedest to block them. Because Hatch is a very senior (and therefore powerful) Senator, he nearly always succeeds. Indeed, as the NYT article points out, the relationship between Hatch and Utah’s massive supplement industry been a hugely mutually beneficial one, and the article also describes just how incestuous it has been as well. First of all, there’s an enormous amount of campaign contributions that Hatch garners every election cycle from supplement manufacturers, but the relationship goes so much more deeply than that:
His [Hatch's] family and friends have benefited, too, from links to the supplement industry. His son Scott Hatch, is a longtime industry lobbyist in Washington, as are at least five of the senator’s former aides. Mr. Hatch’s grandson and son-in-law increase revenue at their chiropractic clinic near here by selling herbal and nutritional treatments, including $35 “thyroid dysfunction” injections and a weight-loss product, “Slim and Sassy Metabolic Blend.” And Mr. Hatch’s former law partner owns Pharmics, a small nutritional supplement company in Salt Lake City.
But many public health experts argue that in his advocacy, Mr. Hatch has hindered regulators from preventing dangerous products from being put on the market, including supplements that are illegally spiked with steroids or other unapproved drugs. They also say he is the person in Washington most responsible for the proliferation of products that make exaggerated claims about health benefits.
Many are the times that I’ve complained about a different Senator, namely Senator Tom Harkin (D-IA) for his advocacy of pseudoscience that led hm to foist the atrocity that is the National Center for Complementary and Alternative Medicine (NCCAM) upon an unsuspecting nation. However, as bad as Tom Harkin is, he is nonetheless also widely appreciated as a staunch advocate of the National Institutes of Health and other funding for legitimate medical research. This has been true for decades, and he has been honored as such more than once. The problem is that, along with all that advocacy for the NIH, Harkin has a very hard time distinguishing worthwhile medical research from quackery. Even so, arguably he has supported enough good medical research that his unwavering support of NCCAM can almost be forgiven. Almost. Hatch, on the other hand, has no such redeeming quality to counterbalance his support for quackery and his defense of supplement manufacturers against any government law or regulation, no matter how reasonable, that might jeopardize their profits. Not surprisingly, he denies that this is true in the NYT article. He even has the gall to claim that he’s been a champion of regulating supplements, a claim that is so risible that it’s hard to believe he could make it with a straight face. I guess that’s why he’s a politician.
I am gratified, though, that the NYT didn’t forget to point out that there’s a new Republican quackery supporter in town, and he’s out to unseat Hatch by–you guessed it–sucking up to the supplement industry even more than Hatch does. His name is Jason Chaffetz, and he’s a former supplement company executive turned U.S. Representative and co-chair of the Dietary Supplement Caucus. (Yes, there really is such a thing.) I wrote about him not too long ago because of his support for what I then termed the “wonderfully Orwellian” Free Speech About Science Act of 2011 (FSAS). Boiled down to its essence, the FSAS would weaken even more the already desperately weak DSHEA. Basically, under the auspices of allowing “more free speech about food,” it would neuter the FDA with respect to claims about supplements, and it would do it through a very clever turnabout regarding the use of peer-reviewed research in that it places the burden of proof on the FDA to demonstrate that scientific studies used to bolster health claims for food and supplements are not good research. One can see the obvious problem with that. Supplement manufacturers could claim anything they wanted, as long as they could pull out a scientific paper or two, and it would be up to the FDA to have to refute them. Like the case for quacks, it wouldn’t be too difficult for supplement manufacturers to produce a constant stream of dubious research to point to, allowing the to make almost any claims they want to with impunity.
Fortunately, that law appears not to be going anywhere right now, and I hope it doesn’t. However, it was only a year ago that Hatch demonstrated why he is the master when it comes to protecting his supplement industry backers. That was when John McCain tried to pass legislation to tighten the regulation of supplements, Orrin Hatch and the supplement industry slapped him down in no uncertain terms. Basically, McCain ended up groveling before Orrin Hatch seeking absolution for his sins against the free market. The story is actually mentioned in the NYT article, as is Hatch’s attempts to intimidate the Obama Administration’s nominee for commissioner of the FDA, Dr. Margaret A. Hamburg.
So long standing and blatant has Hatch’s advocacy been that ten years ago Stephanie Mencimer wrote a devastating article for The Washington Monthly entitled Scorin’ with Orrin, an accurate description of Hatch’s activities then and now. To this day, Hatch remains in the pockets of the supplement manufacturers, and he has served them well, passing the DSHEA, a law that has been exploited by Utah companies like Xango:
But Xango’s record illustrates how companies eager to exploit the law can go too far.
In 2006, federal regulators warned Xango that brochures improperly promoted mangosteen juice as a disease cure, not just a healthy option. Xango is among more than a dozen Utah companies cited by federal regulators over the last decade for apparent violations of the law.
Xango, whose executives are the single biggest Utah-based contributors to Mr. Hatch’s political campaigns and have drawn Mr. Hatch to its headquarters to down shot glasses of their juice, blamed a marketing company that had printed the brochures. The company also insisted that it was closely monitoring distributors to make sure they did not make inappropriate claims.
But in his talk at Xango in March, Dr. Johnson — who lectures across the country at other company events — used some of the same language the F.D.A. had cited in its 2006 warning letter, and he referred the sales agents to a nearby company that still sold brochures making the improper claims.
Amusingly, this NYT article also includes a truly mind-numbingly idiotic statement justifying the activities of certain supplement companies from Dr. Johnson, so much so that even our very own Steve Novella labeled it the “Dumb Statement of the Week.” I think it has a real shot of winning far more than that:
One night in March, Dr. Vaughn T. Johnson, a Xango distributor, delivered part pep talk, part medical seminar, in describing extraordinary powers attributed to mangosteen. Studies showed, Dr. Johnson said, it was “anti-tumor,” “anti-obesity,” “anti-aging,” “anti-fatigue,” “antiviral,” “antibiotic” and “antidepressant.”
“How do I know this isn’t just snake oil?” Dr. Johnson, an osteopathic physician, asked. “It’s a really simple answer. A company that is selling snake oil is not going to stay in business for almost 11 years and grow as fast as this company is growing.”
In other words, because his supplements sell well, they must work. Anyone familiar with evidence- and science-based medicine knows that this is utter nonsense on steroids (which adulterate quite a few supplements, by the way). Placebo effects, confirmation bias, expectancy effects, and a number of other nontherapeutic effects can lead to the success of a product. Before the FDA existed, there were countless useless patent medicine products sold in this country that were quite popular. Heck, homeopathy is still popular in some parts of the world, and it’s just water!
It is with great irony that, having read this NYT article, I note how advocates of unscientific modalities frequently love to bash big pharma and insinuate that legislators are in the pocket of the drug companies. While it is true that pharmaceutical companies are heavy contributors to a number of legislators and wield considerable influence, pro-CAM apologists frequently contrast what they paint as big, soulless, corporations with local, mom & pop “natural medicine” businesses that big pharma is supposedly trying to crush, all in a nefarious plot to protect its obscene profits. However, as Orrin Hatch demonstrates, in the wake of the DSHEA of 1994, in the U.S. supplement manufacturers have themselves become quite a force to be reckoned with themselves. In states like Utah, supplement manufacturers can become far more powerful than pharmaceutical companies. One reason is that there isn’t much in the way of a pharma presence, big or otherwise, in Utah. There are, however, lots and lots of supplement manufacturers pushing all manner of poorly supported health claims to sell their products. Because these supplement manufacturers are very profitable and have a lot of money to throw around, it’s not surprising that they now also have a very powerful patron, too, in Orrin Hatch. As long as Hatch is in office, you can be quite sure that the DSHEA will stand, and, if Hatch has his way, sooner or later its remaining tooth will be pulled.
The question then becomes: What will happen after Hatch retires? He is, after all, in his late 70s. Clearly, it’s likely (although not a lock) that Jason Chaffetz will succeed him. If that happens, he will be even more in the pocket of the supplement manufacturers than Hatch has been over the years. Chaffetz will, of course, not have the seniority and long years of having built up political power and capital that Hatch has right now; so at first he is unlikely to be nearly as effective a protector of the supplement industry as Hatch has been. Still, that might offer a window of opportunity. The only time supporters of more science-based regulations of supplements will have a chance to do away with the DSHEA will be in the immediate wake of Hatch’s retirement or death, before his successor can accumulate clout.
Even at that time, I’m not optimistic that the DSHEA will ever be repealed.

   The Dietary Supplement Safety Act of 2010: A long overdue correction to the DSHEA of 1994?
David Gorski
Link
BACKGROUND: A BAD, BAD LAW
One of the themes of this blog has been how, over the last couple of decades, the law has been coopted by forces supporting “complementary and alternative” medicine (CAM) in order to lend legitimacy to unscientific and even pseudoscientific medical nonsense. Whether it be $120 million a year being spent for the National Center for Complementary and Alternative Medicine (NCCAM) or attempts to insert provisions mandating that insurers in the government health care co-ops that would have been created by President Obama’s recent health care reform initiative (which at the moment seems to be pining for the fjords, so to speak), the forces who do not want pesky things like regulation to interfere with their selling of pseudoscience have been very successful. Arguably the crown jewel of their legislative victories came in 1994, when the Dietary Supplement Health and Education Act (DSHEA) was passed. Demonstrating that pseudoscience is a bipartisan affair, the DSHEA was passed, thanks to a big push from the man who is arguably the most powerful supporter of quackery in government and the man most responsible for the creation of the abomination that is NCCAM, Senator Tom Harkin (D-IA), along with his partner in woo, Senator Orrin Hatch (R-UT). It should be noted that Harkin happens to be the recipient of large contributions from supplement manufacturer Herbalife, demonstrating that big pharma isn’t the only industry that can buy legislation related to health.
Dr. Lipson has discussed the DSHEA before (calling it, in his own inimitable fashion, a “travesty of a mockery of a sham“) as has a certain friend of mine. Suffice it to say that the DSHEA of 1994 is a very bad law. One thing it does is to make a distinction between food and medicine. While on its surface this is a reasonable distinction (after all, it wouldn’t make a lot of sense to hold food to the same sorts of standards to which drugs are held), as implemented by the DSHEA this distinction has a pernicious effect in that it allows manufacturers to label all sorts of botanicals, many of which with pharmacological activity, as “supplements,” and supplements, being defined as food and not medicine, do not require prior approval by the FDA before marketing:
Under the Dietary Supplement Health and Education Act of 1994 (DSHEA), the dietary supplement manufacturer is responsible for ensuring that a dietary supplement is safe before it is marketed. FDA is responsible for taking action against any unsafe dietary supplement product after it reaches the market. Generally, manufacturers do not need to register their products with FDA nor get FDA approval before producing or selling dietary supplements.* Manufacturers must make sure that product label information is truthful and not misleading.
In other words, when a supplement is marketed it’s more or less the honor system. No registration with the FDA is required. After all, supplements are food, not medicine! In effect, the government can’t really do anything unless problems are reported after the supplement is marketed. Even worse, the definition of “supplement” has become very broad, as Quackwatch points out:
DSHEA worsened this situation by increasing the amount of misinformation that can be directly transmitted to prospective customers. It also expanded the types of products that could be marketed as “supplements.” The most logical definition of “dietary supplement” would be something that supplies one or more essential nutrients missing from the diet. DSHEA went far beyond this to include vitamins; minerals; herbs or other botanicals; amino acids; other dietary substances to supplement the diet by increasing dietary intake; and any concentrate, metabolite, constituent, extract, or combination of any such ingredients. Although many such products (particularly herbs) are marketed for their alleged preventive or therapeutic effects, the 1994 law has made it difficult or impossible for the FDA to regulate them as drugs. Since its passage, even hormones, such as DHEA and melatonin, are being hawked as supplements.
In other words, under the DSHEA, substances that are clearly not foods can be marketed as supplements, including herbs and other botanicals (the vast majority of which are marketed as having a beneficial medicinal effect and some of which contain chemicals that do act as drugs). As long as the manufacturer is careful not to make specific health claims, it’s all good. In other words, a “nutritional support” statement claimed for a supplement must not be a “drug” claim; i.e., it must not claim that the supplement can be used for the treatment or prevention of a disease. Supplement manufacturers easily evade this requirement by making vaguer claims related to organs or systems, such as claiming that a product “boosts the immune system,” “supports heart health,” or something similar, often accompanied by what Dr. Lipson has sarcastically referred to as the “quack Miranda warning“:
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
It doesn’t take too much searching to find supplement advertising that does claim to treat, cure, or prevent disease.
The DSHEA was the greatest boon to supplement manufacturers ever. In its wake, the supplement industry exploded, racking up huge increases in sales. Indeed, a recent GAO report estimated that the supplement industry has grown to a $23.7 billion industry in 2007. Moreover, so lax is the regulation of supplements that it took a very extreme and egregious act, namely the marketing of an industrial chelator as an “antioxidant” supplement for the treatment of autism, before the FDA finally acted. Over the years, supporters of science-based medicine and sound public policy have made efforts to alter or repeal the DSHEA. All have failed. Tom Harkin and Orrin Hatch are powerful patrons, and Utah is home to many supplement manufacturers, whose interests Hatch zealously defends. Indeed, when adulterated supplements manufactured in Utah caused Olympic athletes to test positive for banned drugs and the International Olympic Committee warned athletes to avoid banned supplements, particularly those manufactured in Utah, Hatch leapt to the defense of the supplement manufacturers:
…he [Hatch] has been unapologetic in his support for the supplement industry, having battled the FDA and other federal agencies over the regulation of vitamins, herbals, and other natural medicines for more than a decade…Hatch considers his 1994 law, DSHEA, a triumph on behalf of consumer health freedom. But a close look suggests that if anything, DSHEA (or the Hatch Act, as body builders call it) has left Americans “free” to serve as guinea pigs for a multibillion-dollar industry, much of which is built on a foundation of fraudulent claims, pyramid schemes, and lousy manufacturing practices.
We here at Science-Based Medicine have said much the same thing multiple times. Last week, I learned that yet another effort is being made to strengthen the DSHEA and close some of its loopholes. This effort comes in the form of a law under consideration, the Dietary Supplement Safety Act of 2010. It is a law proposed by, of all legislators, John McCain.
Can the Dietary Supplement Safety Act of 2010 fix the DSHEA?
On February 3, 2010 Senator John McCain (R-AZ) gave a speech announcing new legislation that he was introducing, the Dietary Supplement Safety Act of 2010:
Like many of you, I am looking forward to watching the Super Bowl this Sunday and the Winter Olympics later this month. However, a little over a year ago the NFL suspended six players, including two players from one of the teams competing this Sunday, for violating the league’s anti-doping policy. Several of the players were surprised that they tested positive for a banned substance because they used a dietary supplement they believed to be safe and legal.
It is for precisely this reason that today Senators Dorgan and I are proud to introduce the Dietary Supplement Safety Act of 2010. All Americans should know the exact ingredients of any dietary supplement they use and the FDA must have the tools necessary to ensure the safety of dietary supplements.
This legislation would require dietary supplement manufactures to register with the FDA and fully disclose the ingredients contained in the supplement. Surveys have found that a majority of dietary supplement users believe the FDA approves the safety of dietary supplements prior to market introduction. However, that is not the case. In fact, dietary supplement manufacturers’ advertised claims of safety and effectiveness are not reviewed or approved by the FDA.
The complete text of the bill can be found here. Perhaps the most promising aspect of the McCain-Dorgan Bill is that it provides the FDA with mandatory recall authority if a supplement is found to be unsafe or harmful. Part of the reason that the government could do little about, for example, ephedra, which it took the FDA over a decade to be able to ban, despite multiple deaths linked to supplements containing it. Perhaps the most notorious death attributed to ephedra-containing supplements was that of Steve Bechler, a pitcher for the Baltimore Orioles, who died of heat strokefollowing a spring training workout in 2003. The medical examiner found that ephedra toxicity played a “significant role” in Bechler’s sudden death. Sad to say that cleaning up sports seems to be the primary motivation behind Senator McCain’s decision to take on the DSHEA, rather than protecting the public at large, but, whatever his motivation, it is good to see a legislator trying to make some corrections to the abomination of a travesty that is the DSEA of 1994. Indeed, as long as 6 years ago, McCain appeared to get it:
McCain voted for DSHEA, the 1994 law that gutted the federal government’s authority to oversee supplements — and that triggered the explosive growth in the sale of everything from horny goat weed to bee feces. But he says: “I’m not satisfied at all. The bill I voted for, frankly, I was not as aware of it as I should have been.”
Now McCain would like to force makers of supplements or any substance that affects the human body to test their products before bringing them to market. Given that the supplement manufacturers have huge political influence in Congress — they can mobilize millions of loyal customers, and they have a powerful patron in Sen. Orrin Hatch, R-Utah — that’s not likely to happen.
The bill has a number of good features. One part that I like is that the DSSA mandates that all adverse events be reported to the FDA, including non-serious ones. As mentioned by Senator McCain, it also includes expanded power for the FDA to issue cease distribution and notification order requiring that the manufacturer cease sales and marketing of the supplement in question. It also provides a mechanism for a hearing within ten days for the manufacturer to defend itself against the charges. After the hearing, the FDA may then issue a formal recall if it finds adequate evidence that the supplement is unsafe. While it is true that the DSHEA does currently allow the FDA to ban supplements, it does not, as I understand it, give the FDA the power to issue a rapid order to cease distribution or to mandate a recall this quickly, nor does it require supplement manufacturers to register with the FDA. All in all, it is a welcome modification of a very bad law. Although it does not go far enough, it is a bill that supporters of science-based medicine should support.
Not surprisingly, the supplement industry is very much opposed to this bill. For example, the Council for Responsible Nutrition (CRN) was fast to respond to Senator McCain’s press conference. In a bit of denialist double-speak that would make tobacco manufacturers blush, the CRN had the audacity to claim that requiring the reporting of all adverse events, not just serious ones, would not do anything to protect consumers. Even more Orwellian, the CRN actually claimed with (apparently) a straight face that the supplement industry had lobbied to “increase the regulation under which the supplement industry operates” and to “increase funding for the FDA’s enforcement efforts.” It supports a different bill, the Senate Food and Drug Administration Food Safety and Modernization Act (S.510), sponsored by Senator Richard Durbin (D-IL).
My reading of Durbin’s bill is that, although it too has a number of good features, it does not really address the supplement industry, at least not directly. Rather, it concentrates primarily on sanitation, and adulteration, the inspection of food manufacturing facilities, and regulation of imported food. Indeed, it appears to be primarily an agricultural bill to regulate food safety, and it says nothing about supplements explicitly. Of course, given that the law considers supplements food, supplements would fall under the law, but the law doesn’t really look as though it would actually do much about supplements. Certainly, it would not require supplement manufacturers to report all adverse events. No wonder the supplement industry likes it better than the McCain bill. S.510 would do little or nothing to reform the DSHEA, and that’s how the supplement industry likes it. Indeed, founder executive director of the American Botanical Council, Mark Blumenthal, essentially said as much when he argued that a new law isn’t necessary, claiming that all that is necessary is “robust enforcement” of the DSHEA. That is, of course, laughable, because even if the DSHEA were enforced to the letter, the problem would remain, namely that the FDA can do nothing about harmful supplements until after the fact and or about deceptive health claims made by supplement manufacturers–again, which is just the way the supplement industry likes it. Indeed, the record of the supplement industry has been to push for the passage of the DSHEA, which weakened the FDA’s authority to protect the public against dangerous supplements, and to fight every substantive effort to fix that travesty of a law.
In fact, if you want the attitude of supplement manufacturers encapsulated, just look at the reaction of attorney Jonathan W. Emord, a flack for the supplement industry:
Emord said a requirement to report non-serious adverse events was “laughable”.
“If it is not serious why bother?” he wondered, noting ‘seriousness’ had not been defined. “Is it when the vitamin bottle drops to the floor and the cat eats every one?”
Of course, I could point out that the FDA does define serious adverse events. Basically an SAE is a complication that is either life-threatening or require hospitalization and requires mandatory reporting. Even then, there was no guarantee that an adverse event due to a supplement would be reported because often such events are not linked to various supplements that people take. However, there are quite a few adverse events that might not fall under the FDA’s definition of “serious” that are significant, and there is currently no requirement that these be reported.
I’m not a politician, nor am I a political blogger. I don’t know what the chances are that the DSSA will pass congress. I’m not very optimistic, though. For one thing, it’s being introduced by a Senator from the minority party, although Senator Byron Dorgan (D-ND) is a Democrat. More importantly, it’s likely to run into a buzzsaw of opposition, thanks to Senators Hatch and Harkin. On the other hand, the publicity of the Winter Olympics may help get this bill some traction, and the emphasis of athletes who have either been harmed or tested positive for banned substances, thanks to adulterated supplements. Still, my guess is that the bipartisan tag-team of woo, Senators Harkin and Hatch, will guarantee that the DSSA dies a quiet death. Hatch will do it for his campaign contributors in the supplement industry; Harkin will do it because he’s a true believer.
I’d love to be proven wrong, but doubt that I will be. After all, Senator McCain has been trying to tighten regulation of the supplement industry since 2004. For all the features it shares with the DSSA, I don’t think Durbin’s bill goes far enough because it doesn’t directly address supplements in a manner in which they need to be addressed to fix the DSHEA, and that is why I prefer the McCain bill at present. In fact, even the McCain bill doesn’t appear to go far enough in that it seems to leave the DSHEA largely intact in terms of what supplement manufacturers are allowed to say in their advertisements. Even so, the McCain-Dorgan bill strikes me as unlikely to pass unless there is a groundswell of public support for it, which is why I hope you will contact your Senators and tell them you support the bill and hope that they will support it too.
Whatever bill passes, the McCain or Durbin bill, as has been true for 16 years now, something needs to be done to fix the the DSHEA, or, as I like to call it, the Supplement Manufacturer’s Protection Act. As long as the DSHEA remains intact, it’s more or less the honors system for supplement manufacturers, and I don’t trust supplement manufacturers any more than many trust big pharma. In fact, in many cases, they are becoming one and the same. Big pharma recognizes profit potential when it sees it, and supplements can be marketed without all that pesky and expensive testing that are required for new drugs.

   The GAO Report on Supplement Regulation
Steven Novella
Link
We advocate for Science-Based Medicine partly because science incorporates various generic intellectual virtues to which everyone should aspire. These include logical and clear thinking, unambiguous definitions, and internal consistency. In fact it is demonstrably true that opposing science often equates to promoting muddied and sloppy thinking, ambiguous language, and self-contradiction.
Last week I wrote about that latter virtue – consistency – and its lack when dealing with regulating physicians vs regulating so-called complementary and alternative medicine (CAM). In fact CAM exists, in my opinion, specifically to create a double-standard to disguise contradictory standards. It is institutionalized compartmentalization to minimize public cognitive dissonance.
This week, as promised, I will discuss how the same double standard has been made to apply to the regulation of supplements vs pharmaceuticals. The recently published Government Accountability Office (GAO) report on supplement regulation by the FDA brings this to light.
DSHEA
In the US, supplement regulation is primarily determined by the Dietary Supplement Health and Education Act of 1994 (DSHEA), which is an amendment of the Federal Food, Drug and Cosmetic Act. The purpose of DSHEA was to limit FDA power to regulate supplements and to expand the definition of “supplement.” Here we see the first internal contradiction. The GAO report states:
DSHEA defines dietary supplements as products that, among other things, are intended for ingestion to supplement the diet, labeled as a dietary supplement, and not represented as a conventional food or as a sole item of a meal or diet. They must also contain one or more dietary ingredients.
DSHEA also states that herbs and other botanical are to be considered supplements. Botanicals, however, are not dietary supplements. They are taken not for their nutritional value but for their pharmacological effects. Herbs and botanicals are simply one form of drugs. Vitamins and minerals are nutritional supplements; echinacea is a collection of chemicals, some of which may be pharmacologically active, but with no or trivial nutritional value.
The GRAS Is Always Greener
The justification for regulating herbal drugs as nutritional supplements derives, it seems, from the concept of GRAS – which stands for “generally recognized as safe.” FDA regulations state that for supplements and food additives companies do not have to prove safety if the ingredient is GRAS and if it was in use prior to 1994. Any totally new ingredient must be studied for safety (which makes sense as a new ingredient has not been around long enough to be considered GRAS).
The argument is that herbs that have been around for a long time are generally recognized as safe and therefore should not suffer the burden of having to prove safety prior to marketing. However, it is not always true that herbal supplements have been in use for very long, especially not as they are currently marketed. And even for those that have been around for centuries, subtle risks and toxicity would not be necessarily generally recognized without controlled trials.
The example I think is very relevant is that of VIOXX, which was pulled from the market because studies showed that it significantly increased heart attacks in those at risk. This was enough to generate a scandal. And yet, without large post-marketing clinical trials this increased statistical risk would never have come to light. We cannot say with any confidence that any herbal supplement does not carry a similar risk – the GRAS standard is simply not sufficient for this.
GRAS is reasonable when it comes to food and true supplements. Companies should not have to conduct clinical trials prior to adding salt, corn oil, chocolate, or other common ingredients to their food products. The GRAS standard is sufficient for this. But I do not think it properly applies to taking an botanical drug for a medical condition.
The GAO report also noted that companies are responsible for determining whether or not an ingredient falls under GRAS, and they are under no obligation to report this to the FDA (although some do voluntarily). This means the FDA may not even hear about food or supplement ingredients if the companies themselves felt they were GRAS.
Safety, Efficacy, and the GAO Report
The GAO report looks at current FDA effectiveness in regulating the safety and educating the public about the science of supplements under DSHEA. It is interesting to note that the GAO report does not question a central fact of DSHEA – that the FDA has no role in regulating the claims made for supplement products. This, in my opinion, is a major failure of DSHEA. Regulating marketing claims has been left entirely to regulatory agencies like the Federal Trade Commision (FTC), which can go after supplement marketers for commercial fraud. However, FTC fines have been little more than a slap on the wrist, and they have no authority to pull products themselves from the market.
FDA regulation of claims was reduced with another double-standard contradiction – so-called structure/function claims. Under DSHEA companies are free to make whatever structure/function claims they wish. These are claims that a supplement or ingredient improves a structure or function of the body. Companies are not allowed to claim that their product treats or cures a disease. However, it did not take long for companies to figure out that they could restate disease claims as structure/function claims to skirt the FDA. For example, a company may claim that their product promotes a positive mood, but they cannot say it treats depression. Or they may say it boosts the immune system (which is important for fighting cancer -wink, wink, nod, nod), but they may not say it cures cancer.
The result has been an explosion of unregulated supplement claims, and a growing supplement market. The GAO report says the supplement industry grew to 23.7 billion dollars in 2007.
The GAO report does not question or recommend changes to this basic structure, which I think is fatally flawed. Rather their recommended solution is to increase FDA efforts to educate the public about the science of supplements. I am very much in support of efforts to educate the public. However, I do not hold out much hope that such efforts will have a significant effect. The supplement industry has billions of dollars with which to market their claims. The FDA is not likely to significantly impact upon this. It is also much easier to make claims that people want to believe rather than patiently explain that science does not support those claims.
Regarding safety the GAO report makes a number of observations and conclusions. At present companies are required to report to the FDA severe adverse reactions to their products. They are not required to report mild or moderate adverse reactions, which are voluntary.
The FDA cannot require safety testing prior to marketing. The FDA primarily uses after-marketing monitoring for safety, and the burden of proof is on them to show that a product is unsafe before they can pull it from the market. The only product so removed was ephedra, and that was 10 years after the FDA issued it first warning about the product and after thousands of people were harmed.
Conclusion
The GAO report brings to light many of the current shortcomings of FDA regulations of supplements. The FDA is underfunded and does not have the authority to properly regulate supplements and as a result, the GAO concludes, the public is insufficiently protected.
In order to improve safety regulation they recommend:
1. To improve the information available to FDA for identifying safety concerns and better enable FDA to meet its responsibility to protect the public health, we recommend that the Secretary of the Department of Health and Human Services direct the Commissioner of FDA to request authority to require dietary supplement companies to
Recommendations for Executive Action
• identify themselves as a dietary supplement company as part of the existing registration requirements and update this information annually,
• provide a list of all dietary supplement products they sell and a copy of the labels and update this information annually, and
• report all adverse events related to dietary supplements.
2. To better enable FDA to meet its responsibility to regulate dietary supplements that contain new dietary ingredients, we recommend that the Secretary of the Department of Health and Human Services direct the Commissioner of FDA to issue guidance to clarify when an ingredient is considered a new dietary ingredient, the evidence needed to document the safety of new dietary ingredients, and appropriate methods for establishing ingredient identity.
3. To help ensure that companies follow the appropriate laws and regulations and to renew a recommendation we made in July 2000, we recommend that the Secretary of the Department of Health and Human Services direct the Commissioner of FDA to provide guidance to industry to clarify when products should be marketed as either dietary supplements or conventional foods formulated with added dietary ingredients.
To better regulate claims of efficacy for supplements they recommend:
4. To improve consumer understanding about dietary supplements and better leverage existing resources, we recommend that the Secretary of the Department of Health and Human Services direct the Commissioner of FDA to coordinate with stakeholder groups involved in consumer outreach to (1) identify additional mechanisms—such as the recent WebMD partnership—for educating consumers about the safety, efficacy, and labeling of dietary supplements; (2) implement these mechanisms; and (3) assess their effectiveness.
While I think these are all reasonable measures, my sense is that they do not go nearly far enough. Perhaps they consider this a baby-step, making the best of the current regulations. However, there are core problems with DSHEA that need to be addressed.
Structure/function claims are a fiction – a manufactured loop-hole for supplement marketers. It should be done away with. Instead, any health claims made for supplements or food ingredients should be subjected to some form of FDA review prior to allowing the claims. Opponents of this typically appeal to a false dichotomy – pharmaceutical level regulation or no regulation. However, a middle-level of regulation is also an option. Existing scientific evidence can be reviewed and only claims that are sufficiently backed by evidence should be allowed in the marketplace.
In terms of safety, I do not think the GRAS standard should apply to herbals and botanicals. They should, in fact, not be categorized as supplements at all. This would eliminate the problem of having companies classify their food additives as supplements to evade regulation. Rather, it makes more sense to create another category for botanical drugs. Evidence of both safety and efficacy should be required, but the same level of procedures for pharmaceuticals is not realistic. An appropriate level of evidence can be mandated, but perhaps, for example, the FDA can allow use of prior research to establish their claims.
Further, even though DSHEA and the GAO report do not deal with this issue, while I am making recommendations to alter FDA regulation, I would eliminate approval for homeopathic substances. Their inclusion under FDA approval is anachronistic (not that it was ever justified) and is another glaring contradiction. Homeopathic substances are not supplements or drugs – they are nothing but water, lies, and pseudoscience. It is time FDA regulations reflected this demonstrable scientific fact.
While the GAO recommendations would be a few baby steps in the right direction, much more substantive changes to FDA regulations are required to bring them into line with science-based medicine.

   CAM and the Law Part 4: Regulation of Supplements and Homeopathic Remedies
Brennen McKenzie
Link
Another major set of legal standards that apply to alternative medicine are the laws and regulations that govern the manufacturing and availability of homeopathic and herbal remedies and dietary supplements. Although there is less ambiguity in these standards than in some of the areas I’ve covered previously, there are certainly loopholes aplenty available to avoid the need for any truly scientific standards of evaluating safety and efficacy. This is perhaps the area in which the triumph of politics over science is most vivid.
Regulation of Homeopathic Remedies
The Food and Drug Administration was constituted as the agency responsible for regulating medicines and most foods by the Food, Drug, and Cosmetic Act (FDCA) of 1938. The FDCA has been updated and amended in various ways since then, but it is still the primary law governing the regulation of prescription and non-prescription substances used to treat illness. The law identifies substances acceptable for sale as medicines as those listed in its official compendia, the United States Pharmacopeia-National Formulary (USP-NF) and the Homeopathic Pharmacopeia of the United States (HPUS). The HPUS was a list of homeopathic remedies first published by the American Institute of Homeopathy, a professional body for homeopaths, in 1897 and now published and maintained by the Homeopathic Pharmacopoeia Convention of the United States (HPCUS), an independent organization of homeopathic “experts.” The inclusion of homeopathic remedies as accepted drugs in the original legislation was primarily due to the efforts of Senator Royal Copeland, a physician trained in homeopathy and one of the principle authors of the FDCA.1
Most homeopathic remedies are available as over-the-counter products, though at least theoretically some homeopathic drugs do require a prescription. The distinction between ordinary drugs that can be sold over-the-counter and those available only by prescription is made by the FDA based on the history of use of the particular ingredients, the nature of the complaint for which they are used and, in the case of new OTC drugs, the scientific evidence concerning safety and efficacy. However, with respect to homeopathic products, the distinction seems to depend solely on the intended use of the remedy. If a complaint is expected to be easily recognized by a lay person and self-limiting or not life-threatening, then a homeopathic remedy for such a complaint can be sold without a prescription. However, remedies intended for use in conditions that are serious, not self-limiting, and not easily diagnosed by laypeople require a prescription. 
The HPCUS has promulgated detailed guidelines for approving new homeopathic drugs. According to one review:
The clinical benefits of the new drug must be established in one of the following ways: through clinical verification acceptable to HPCUS, after which there is a period of clinical verification; through published documentation that the substance was in use prior to 1962; through use established by at least two adequately controlled double-blind clinical studies using the drug as the single intervention; or through use established by data gathered from clinical experience encompassing the symptom picture before and after treatment, including subjective and any available objective symptoms.[citation omitted]
The criterion of clinical use prior to 1962 was used to grandfather many drugs during the 1970s and 1980s into acceptance. This criterion is now rarely, if ever, used, and HPCUS is rereviewing [sic] many monographs accepted under this approach. HPCUS reports that the criterion of clinical experience has never been used. Consequently, only the criteria of homeopathic drug “proving” and establishment by two adequate clinical studies are currently in actual use [citation omitted].1
This sounds very impressive and scientific if we ignore the fact that the vast majority of the “drugs” we are talking about are identical and contain nothing but water. It is a testament to the power of cognitive dissonance and faith that a complex set of laws and regulations as well as scores of dedicated professionals in government and the private sector are devoted to regulating the use of over 1200 differently labeled preparations of water. It is also a reminder that scientific facts are not as persuasive in the legal and political arenas as we might hope.
The FDA guidelines for marketing of homeopathic drugs specifies the labeling and manufacturing requirements for homeopathic remedies, but it is most interesting for the inclusion of a definition of Health Fraud:
The deceptive promotion, advertisement, distribution or sale of articles, intended for human or animal use, that are represented as being effective to diagnose, prevent, cure, treat, or mitigate disease (or other conditions), or provide a beneficial effect on health, but which have not been scientifically proven safe and effective for such purposes. Such practices may be deliberate, or done without adequate knowledge or understanding of the article.
The inclusion of this definition without any apparent acknowledgement of its clear application to the practice of homeopathy being regulated by the document is as fine an example of the disconnect between scientific and legal reasoning.
Regulation of Herbal Remedies and Other “Therapeutic” Dietary Supplements
Much has previously been written here at Science-Based Medicine on the subject of the Dietary Supplement and Health Education Act of 1994 (DSHEA) (e.g. 1, 2, 3, 4), and I don’t have a great deal to add. In brief, the supplement industry and sympathetic lawmakers created this law to pretend to regulate herbal remedies and other dietary supplements while effectively stripping the FDA of the ability to control the sale of these products for the prevention or treatment of disease. This was accomplished by classifying all such products as foods and codifying the principle that they must be assumed to be safe unless the government can generate substantial evidence to the contrary. There are some restrictions on the medical claims manufacturers can make on the labels of these remedies, but they are routinely ignored and the resources and will behind enforcement of them are manifestly inadequate.
It is instructive to look at some of the judicial opinions that have been rendered in cases where the FDA did attempt to restrict the use of supplements that had clear potential to be harmful or to challenge unsupported label claims. When the FDA banned the sale of the supplement Ephedra in 2004, for example, due to strong evidence of adverse effects and deaths due to use of the supplement, the company sued and the district court ruled in the manufacturer’s favor. The argument made by the company, and accepted by the district court, was that “by injecting a risk-benefit analysis, the FDA required [the manufacturer] to make a showing of the benefits of its product.” This would be inappropriate because in passing DSHEA “Congress expressly placed the burden of proof on the government to determine whether a dietary supplement” is unsafe.2 
The Tenth Circuit court agreed with the interpretation that the law requires no burden of proof be placed on supplement manufacturers to demonstrate the safety or efficacy of their products. However, it upheld the FDA ban on the basis that because the agency gathered all the data and conducted the analysis at its own expense and without requiring the company to prove any benefit to justify the risks identified, no inappropriate burden was placed on the manufacturer.2 At the risk of injuring myself, I have tried to imagine the public reaction to such a one-sided, industry-friendly regulatory system applied to the pharmaceutical companies, but the image of the resulting rhetorical conflagration is simply too horrible to contemplate.
In another case, a supplement manufacturer was denied permission to market their products with certain health claims on the label, due to a lack of sufficient scientific evidence to support the claims. The company sued the FDA, and the court of appeals found that denying the claims violated the company’s First Amendment commercial speech rights because the alternative of allowing the unproven claims accompanied by a disclaimer was not offered. The court did not challenge, or even address, the quality of the evidence for or against the specific claims. It simply ruled that not allowing them to be made, with appropriate disclaimers indicating the weakness of the evidence or the lack of FDA approval, was unduly restrictive of the company’s speech rights and represented a “simplistic view of human nature or market behavior” that did not give adequate credit to the ability of consumers to judge the merit of such claims for themselves.3
These cases illustrate, yet again, the priorities and concerns of justices and lawmakers with regard to the use of alternative medicine, which are often quite different from those of scientists and healthcare providers.
Where Do We Go From Here?
This series has been a relatively superficial survey of a complex subject, but hopefully I have been able to illustrate a few key issues. First, the scientific facts of claims made about alternative therapies, and the importance of using appropriate and effective epistemological methods to establish those facts, must be the foundation of a rational public policy concerning these therapies. Whether an intervention helps or harms or both is vital to the process of determining how government should approach regulating that intervention. However, the lawmakers and justices who shape public policy towards medicine are seldom themselves experts in scientific methods and the information they generate. To effectively argue the case for science-based medicine, we must understand the way the processes and data of science appear to smart, educated non-scientists, and we must be effective in communicating about science to such people. 
While I don’t want to wade too far into the debates surrounding science communication, I would recommend looking at the work of Michael Nisbet, Randy Olson, and Chris Mooney, all somewhat controversial figures who make a variety of interesting arguments about the most effective ways to communicate about science to the general public. If nothing else, these arguments are good for stimulating a healthy debate about how to promote science and science-based medicine in a culture not as friendly to science as it once was.
In addition to not necessarily understanding the nuances of scientific evidence, policy makers also have other agendas and sometimes have to serve their constituencies even when that means promoting policies based on unscientific or even irrational foundations. There are legitimate philosophical questions about the rights of the individual versus the power of the government, the most effective way to organize and run healthcare delivery systems, and other issues that are not primarily scientific but which influence law and policy concerning science and medicine. In promoting science-based and rational policies, we must take these other issues into account. And the plain political reality remains that if enough people, or people with enough influence, support an idea, it is unlikely to be effectively combated through law and regulation even if it is inherently unscientific and not in the best interest of the public health. Such ideas are better addressed through education and lobbying to alter public opinion rather than through legal or regulatory avenues.
I’ve tried in these posts to provide a rudimentary familiarity with the basics of how the laws that govern medicine in this country relate to the practices of alternative medicine. Hopefully, this will be useful in informing our efforts to advocate for science-based medicine and further marginalize unsafe and ineffective medical approaches.
References
     1.  Borneman JP, Field RI. Regulation of homeopathic drug products. Amerian Journal of Health-System Pharmacy 2006;63:p. 86-91. 
     2.  Nutraceutical Corporation v Von Eschenbach, Tenth Circuit Court of Appeals, 459 F.3d 1033 (2006). Cited in: Jesson LE, Tovino SA. Complementary and alternative medicine and the law. Durham (NC), USA: Carolina Academic Press, 2010. p. 208-10. 
     3.  Pearson v. Donna Shalala, Secretary, United States Department of Health and Human Services United States Court of Appeals for the District of Columbia 164 F.3d 650 (1999). Cited in: Jesson LE, Tovino SA. Complementary and alternative medicine and the law. Durham (NC), USA: Carolina Academic Press, 2010. p. 214-17. 

Supplements are the Wild West of health. One Attorney General is out to change that.
Scott Gavura on April 9, 2015
Link

Bold moves from the New York State attorney general’s (AG) office are shaking up the supplement industry. In February, the AG accused four retailers (GNC, Target, Walmart, and Walgreens) of selling supplements that failed to contain their labelled ingredients. Using a testing method called “DNA barcoding“, the AG’s office concluded that few of the products it tested actually contained the labelled ingredient, and some contained undisclosed ingredients. It demanded that they stop the sale of those products. All four retailers complied.
When the recall occurred, I noted that the AG may not have had an airtight case: manufacturers and other critics challenged the AG’s methodology, claiming that DNA barcoding was unvalidated, inappropriate, and insufficient. They also stated that the DNA may not survive processing, so the absence of DNA didn’t imply a lack of the original product. Some claimed that the “contaminants” that AG found could have been acceptable fillers. The Attorney General refused to release further information about the testing methods it used, raising further questions about its validity.
Before describing what happened next, it’s important to understand how we got here. While the US Food and Drug Administration (FDA) is respected worldwide for ensuring the quality of the pharmaceuticals it regulates, the same cannot be said for its regulation of supplements. Today, the overall quality of supplements sold in the United States is unclear. Audits and recalls suggest that there is a small but persistent trend of poor manufacturing standards. Adulteration, virtually unheard of with drug products, seems to be a regular complaint with supplements. This shouldn’t surprise, as it’s likely a consequence of legislation deliberately designed to weaken the FDA from regulating and providing oversight of supplements. The Dietary Supplement Health and Education Act of 1994 (DSHEA) was an amendment to the U.S. Federal Food, Drug and Cosmetic Act that established the American regulatory framework for dietary supplements. It effectively excludes manufacturers of these products from many of the requirements that are in place for prescription and over-the-counter drugs. Amazingly, it puts the requirement to demonstrate harm on the FDA, rather than the onus on the manufacturer to show a product is safe and effective. A weak regulatory framework, which doesn’t require pre-sale testing of product quality and finished product specifications, might be expected to result in a weaker commitment to quality. And that might result in more erratic product quality. And that’s exactly what we find when you look at supplement sales today.
There’s an additional twist with herbal remedies, which gets to the criticism of the AG’s analysis and claims. This problem isn’t exclusive to the FDA, but is a challenge to manufacturers and regulators alike. With a herb, what should we be testing for? With a pharmaceutical product, there’s an active ingredient that is manufactured into a tablet or capsule to be predictably and consistently absorbed. We can easily measure the tablet’s contents by assay, or measure how completely it is absorbed by drawing blood levels after ingestion. The same cannot be said for herbal remedies, which are essentially unpurified, unstandardized, drugs. A single plant species may have dozens, or even hundreds of biologically-active compounds. The relative proportions of all of these ingredients may vary based on growth, harvesting, and storage conditions. Now add in the fact that there’s little evidence to demonstrate that herbal products have any meaningful, beneficial effects. If there was a positive effect, we could try to determine what ingredient (or ingredients) were the cause. With that in mind, we could test for it in supplements for sale. But because there’s a lack of evidence to establish that herbal remedies have any useful effects, we don’t even know what we should test for. Without knowing if there is an “active” chemical component, we can’t test for it. So the AG’s test of DNA barcoding represented a minimum testing standard of sorts. It was simply a test to see if the labelled herb was in the tablet or capsule. And the testing showed that even that basic assumption about herbal quality may have been premature.
Supplement vendors, industry backers, and even some industry critics were quick to point out that DNA barcoding wouldn’t detect any herb present if the herb had been processed so extensively that DNA traces had been destroyed or removed. This could be expected with herbal extracts, which are not raw herbs but rather the result of combining a herb with a solvent, in a process where some components of the herb are removed or “extracted”. The process of extraction brings with it a huge number of variables that can affect the finished product’s chemical composition.
Rather than responding to criticisms about the herbal testing the AG conducted, the AG decided to double down. In mid-February, it issued subpoenas to GNC, Walgreens, Target and Walmart, demanding that they substantiate their “structure/function claims” for their supplements. Manufacturers of supplements cannot claim that their product can prevent or treat a disease. But they are allowed to make claims that describe how their product can benefit the structure of the body, or some aspect of how it functions. A structure/function claim might be “calcium builds strong bones,” or “antioxidants maintain cell integrity” which tell you nothing about the effectiveness of the product in question. Structure-function claims don’t give consumers adequate information to determine if supplements are useful or effective, but they do allow manufacturer to imply efficacy without the requirement to provide any proof. The FDA notes:
These three types of claims are not pre-approved by FDA, but the manufacturer must have substantiation that the claim is truthful and not misleading and must submit a notification with the text of the claim to FDA no later than 30 days after marketing the dietary supplement with the claim. If a dietary supplement label includes such a claim, it must state in a “disclaimer” that FDA has not evaluated the claim. The disclaimer must also state that the dietary supplement product is not intended to “diagnose, treat, cure or prevent any disease,” because only a drug can legally make such a claim.
The disclaimer is the infamous Quack Miranda warning that in a few sentences tells you that what you’re holding is a product that hasn’t been tested or evaluated for effectiveness by the FDA.
The AG didn’t stop there, either. It subsequently demanded that four supplement manufacturers, Nature’s Way, NBTY (Sundown Naturals, Nature’s Bounty, Met-Rx, Solgar, Vitamin World and other brands), Nutraceutical Corp (Herbs for Kids brand), and Pharmavite (Nature Made brand), provide detailed information on their manufacturing and quality control practices. The AG noted:
The scientific community, public health officials, and others have raised serious doubt about the steps taken to ensure the safety and efficacy of the herbal dietary supplements taken daily by millions of Americans. As part of a broader investigation, NYAG is reviewing the sufficiency of the measures manufacturers and retailers are taking to independently assess the validity of their representations and advertising in connection with the sale of herbal supplements. We seek your company’s cooperation as an herbal dietary supplement manufacturer to address these issues and, ultimately, to resolve any deficiencies.
As you may know, NYAG recently commissioned an analysis that used DNA barcoding technology to test several popular herbal dietary supplements sold at four retailers in New York State. The results were shocking to many consumers and raise troubling legal questions. In addition to the frequent absence of genetic material associated with the plant depicted on the label from the tested supplements, more than one in three samples tested positive for the DNA of an unlisted plant species, potentially constituting a contaminated or substituted product. The contamination, substitution, or false labeling of herbal products would constitute a deceptive business practice and, even more troublingly, could expose consumers to unacceptable health risks. Of particular concern, companies selling herbal products may have inadequate proof that the substances come from the plant species they claim, not be able to easily identify the source of the ingredients, or have failed to put proper controls in place or conduct proper testing or measurement to prevent contamination.
The decision by the AG to go directly after manufacturers has brought considerable criticism from the supplement industry, with most of the criticism being centred on the fact that regulation of supplements was felt to be a matter for the FDA, and not for local (state) action. In other words, they prefer the FDA’s light touch. The president of the United Natural Products Alliance complained:
This is a massive fishing expedition and highly disruptive to these companies’ daily operations that are all part of the clearly defined federal regulatory structure for dietary supplements. We continue to be mystified as to why the NY AG has chosen to do FDA’s job. We regret to see this misplaced use of the AG’s time, taxpayer money and red tape for reputable supplement companies that are simply trying to do the right thing.
Perhaps not unexpectedly, one of the supplement’s industry’s biggest supporters has weighed in as well. Senator Orin Hatch and Senator Martin Heinrich have written a letter [PDF] to the FDA Commissioner, asking the FDA to comment on the AG’s methodology and the appropriateness of the AG’s demands. They note:
Attorney General Schneiderman has refused to make the test results and the details of the study methodology public, and questions about the appropriateness of DNA testing for herbal extracts have been raised that merit consideration. The question at the heart of this matter is whether DNA barcoding methodology is fit for the purpose of identifying DNA in botanical extracts found in dietary supplements. It is our understanding that the process of extracting an herb’s phytochemicals for use in finished products can either damage, destroy or simply leave behind the DNA this testing protocol is designed to find, which has left many scientists – both inside and outside the industry – to question whether DNA barcoding technology is an appropriate or validated method for determining the presence of herbal ingredients in finished botanical products.
Hatch and Heinrich’s letter raises questions in four areas:
     1.  Does the FDA require testing of incoming material as well as tests of finished product quality?
     2.  Does the FDA recognize DNA barcoding for the identification of botanical materials in finished extract dietary supplements? Without additional testing, is this satisfactory?
     3.  Does the FDA recommend DNA barcoding for herbal extracts? Is the current technology adequate to permit use?
     4.  Do federal laws and regulations require food labeling (including dietary supplements) to identify all ingredients? Are trace amounts of materials allowed without labelling? Can plant materials be used as excipients if they are labelled?
The AG’s prosecution has already had an effect that’s disrupting and angering the industry. GNC and the AG have already reached an agreement to put GNC’s products back on the shelves in New York stores. While noting that the products that were pulled do in fact meet FDA requirement for sale, GNC has agreed to implement additional testing of their products that go beyond FDA requirements and will be implemented nation-wide. As per the AG:
Under today’s agreement, GNC will perform DNA barcoding on the “active” plant ingredients used in its products; implement testing for contamination with allergens, both before and after production; and post prominent signage advising consumers of the processed, chemical nature of extracts. GNC will be required to implement these new procedures in all of its more than 6,000 stores nationwide, making this agreement the first in the nation to require testing standards for herbal supplements that exceed current FDA requirements.
The supplement industry seems to have mixed feelings. While this deal may have been necessary for GNC to allow its sales to resume, it raises the expectations of quality for all manufacturers, a move that is being likened to California’s move to tighten crash standards and emissions standards for vehicles. Moreover, it seems to reinforce what the AG’s message has been all along – that supplement product quality is dubious, and the AG is getting results. One industry magazine noted:
The agreement also serves to make the case in the mainstream media and the world of social media that Schneiderman was right: The marketers of dietary supplements and the companies that make the products don’t have their customers’ best interests at heart and can’t be trusted to mind their own store.
“The extensive media coverage of the NY AG’s actions has caused a profound shift in consumer attitudes, far beyond anything I’ve observed before. I’ve closely monitored reader comments to negative media coverage for years, and what I am seeing now indicates an overwhelming loss of confidence in all dietary supplements, not just herbs. Comments in the past could be summed up as ‘I don’t believe this article: I’m healthier and feel better when I take my supplements.’ Now I’m seeing, ‘Those people should be in jail, those products are useless / dangerous so I will never buy them again.’ ” Shelton said.
The story doesn’t stop there. Now the AG has teamed up with 13 other state AGs asking Congress to launch an inquiry into the herbal supplements industry. The letter notes:
The current investigation in New York and subsequent interest by other states, and the outstanding request to FDA, represent only the most recent indication of serious problems in the herbal supplements industry. The scientific community and the media have issued a series of troubling reports that suggest broader problems. Researchers, for example, measured high levels of heavy metals like lead, mercury, and arsenic in certain supplements. Products falsely identified as black cohosh—an herb commonly taken to reduce menopause symptoms—may have caused severe liver damage in certain women. And media reports have uncovered over-the-counter supplements, including those purporting to build muscle, aid weight loss, and reduce anxiety, that were secretly laced with dangerous prescription medications.
Additionally, if the producers of herbal supplements fail to identify all the ingredients on a product’s label, a consumer with food allergies, or who is taking medication for an unrelated illness, is taking a potentially serious health risk every time a contaminated herbal supplement is ingested.
The FDA has long been aware of problems in the dietary and herbal supplement supply chain, from dubious ingredient sourcing to a failure to carry out proper testing on finished products. In FY 2013, FDA inspectors cited two out of every three supplement manufacturers for allegedly violating current good manufacturing practices or “cGMPs.” More than one in five of those citations—called Form 483s—observed that the manufacturer failed to verify that a finished supplements batch met product specifications as to identity, purity, strength, or composition. A similar proportion was cited for failing to employ an appropriate test or examination to verify the identity of a dietary ingredient before incorporating it in the final product.
Specifically they want Congress, with the FDA, to address the following:
    • The adequacy and effectiveness of existing quality assurance measures for verifying the source, identity, purity, potency, and quality of ingredients and fillers;
    • The adequacy and effectiveness of existing regimes for verifying the identity, composition, purity, potency, and quality of the finished products sold by domestic manufacturers and retailers;
    • The degree to which product labels and marketing, including the use of the terms ‘natural,’ ‘herbal,’ and ‘extract,’ mislead consumers about the contents of herbal and dietary supplements, and whether the FDA should develop standards and restrictions governing their use;
    • The extent to which Congress should mandate, or direct the FDA to develop enhanced, uniform, industry-wide quality assurance and verification regimes to guarantee the source, identity, purity, and potency of materials incorporated into herbal and dietary supplements; and,
    • The extent to which Congress should mandate, or direct the FDA to develop, enhanced manufacturing and supply chain management requirements for the industry to guarantee the safety and efficacy of the finished herbal and dietary supplements.
Conclusion
It’s good to see the New York AG recognizing the serious concerns that have been identified with the supplement industry in the United States. However, for its actions to be truly effective, it needs to build a careful case. In the interests of transparency, the AG should be releasing the results of its own testing – just as it is asking manufacturers to do. And it needs to address the criticisms of its testing methods. On balance, however, these moves should be seen as beneficial to consumers, particularly if the FDA’s role is re-evaluated. Until consumers and health professionals alike have confidence that supplements are of uniform and consistent quality, it’s not possible to use them safely, or to expect that they will deliver any predictable effects. The marketplace has been overly friendly to manufacturers for years. Now it seems the tide has a chance of turning, with the focus on consumer protection. If we want to avoid playing health roulette when we shop the supplement aisle, we should strongly support efforts to strengthen the quality and safety of herbal supplements.

   Supplement Regulation: Be Careful What You Wish For
Scott Gavura
Link
A recurring theme at SBM is the regulation of supplements, and the impact and consequences of the Dietary Supplement Health and Education Act of 1994 (DSHEA). As one of SBM’s international contributors, I thought it might be helpful to look at how the DSHEA stacks up against the equivalent regulations of its neighbor to the north, Canada. Given the multiple calls for overhauls and changes to DSHEA, an international comparison may help focus the discussion around what a more science-based framework could look like.
Briefly, the DSHEA is an amendment to the U.S. Federal Food, Drug and Cosmetic Act that establishes a regulatory framework for dietary supplements. It effectively excludes manufacturers of these products from virtually all regulations that are in place for prescription and over-the-counter drugs. The FDA notes:
Generally, manufacturers do not need to register their products with FDA nor get FDA approval before producing or selling dietary supplements. Manufacturers must make sure that product label information is truthful and not misleading. FDA’s post-marketing responsibilities include monitoring safety, e.g. voluntary dietary supplement adverse event reporting, and product information, such as labeling, claims, package inserts, and accompanying literature. The Federal Trade Commission regulates dietary supplement advertising.
Quackwatch has excellent resources on the DSHEA, and SBM bloggers have brought up specific criticisms of the Act at posts like this, this and this. The main concerns with the Act can be summarized as:
DSHEA draws a crude distinction between food and drugs, even defining therapeutic and pharmacologically-active products (e.g., herbs, botanicals, some hormones) to be categorized as foods, and therefore eligible for DSHEA exemptions from the FDA’s drug regulations.
Manufacturers can put virtually any claim on a supplement, without any requirement to provide persuasive clinical evidence, as long as it’s accompanied by the Quack Miranda Warning: “These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.” Disease treatment claims are not permitted, but are typically restated as permissible “structure/function” claims, implying an ability to improve the structure or function of the body only. (Colloidal silver is one example)
There is a lack of regulatory oversight of manufacturing practices.
In multi-chemical products such as herbals, there is no standardization of active ingredient(s), nor are there mandatory purity guarantees.
There are essentially no pre-marketing requirements before selling products. Once available for sale, there is little ability for the FDA to issue cease-sale orders and recalls. Regulators can block the sale of products only after significant problems have been identified (i.e., ephedra)
The regulation of marketing claims is effectively left to the Federal Trade Commission (FTC), which can prosecute manufacturers for fraud.
The Canadian Regulatory Framework
Until several years ago, Canadian natural health products fell into a regulatory grey zone. Products were treated either as drugs, or as foods. Consultation began in the late 1990′s on a new framework to provide regulation and oversight to these products. In 2004, the Natural Health Product (NHP) Regulations, under Canada’s Food and Drugs Act, became a reality. The NHP Regulations cover nutritional supplements, probiotics, traditional Chinese medicine, vitamins, herbal products, and homeopathy – many of the same products that would be considered “dietary supplements” under DSHEA. Rather than fully regulating these products as drugs, or leaving them virtually unregulated, the NHP regulations were a regulatory compromise: implementing manufacturing quality and safety standards, while significantly relaxing the standards for product efficacy claims. The Natural Health Products Directorate is the unit of Health Canada (Canada’s version of the FDA) that administers the NHP Regulations. Health Canada assures Canadians of the following:
Through the Natural Health Products Directorate, Health Canada ensures that all Canadians have ready access to natural health products that are safe, effective and of high quality, while respecting freedom of choice and philosophical and cultural diversity.
Let’s look at the DSHEA through the Canadian regulatory framework lens. Does it set a science-based example?
Lowering the Efficacy Bar
One of the biggest problems with DSHEA is that it facilitates unsubstantiated efficacy claims. While DSHEA doesn’t apply to homeopathy, the NHP regulations do. Health Canada says that regulated products are “effective,” so what’s the evidence standard being applied?
Health Canada’s Evidence for Homeopathic Medicines: Guidance Document states that applications for licenses for homeopathic products must include evidence to support the “safety, efficacy, and quality” of a homeopathic medication. All “homeopathic medicine” must be from substances referred to in homeopathic pharmacopias, such as the Homeopathic Pharmacopeia of the United States (HPUS), or other references.
Under the NHP Regulations, if randomized, double-blind, placebo-controlled trials are not conducted, manufacturers can make efficacy claims based on “traditional uses”, i.e., anecdotal evidence of use and efficacy. The two most common types of traditional use claims are provings, and references to homeopathic materia medica, which are essentially compilations of provings. There is no objective evaluation of efficacy in provings or in materia medica. Health Canada offers a list of 59 references it will accept at “evidence”, with publication dates as old as 1834 — dating back before the germ theory of disease was proposed.
Consider the popular remedy Oscilliococcinum, sold as an influenza treatment. It’s prepared by decapitating a duck, taking 35 grams of its liver and 15 grams of its heart and fermenting it for 40 days. The solution then undergoes serial dilutions (1 part in 100) 200 times in a row, (in homeopathy lexicon, “200C”) and is dried on lactose/sucrose tablets. (Wikipedia notes that that in order to obtain even a single molecule of the original fermented duck, a volume of tablets greater that the mass of the entire universe would need to be consumed.) Consulting Health Canada’s NHP database (Search NPN 80014156 here) Health Canada has registered the product, with the labelled medicinal ingredient as “Extract of the liver and heart of Annas barbariae: 200C” and approved the following recommended use (translated from French):
Homeopathic medicine to relieve flu symptoms: fever, chills, body aches, headaches.
This is one consequence of Canadian regulation: the efficacy standard has been lowered so far, it’s meaningless. The Canadian regulatory process assigns distinct registration numbers, dosages, and specific “recommended uses” to hundreds of physically indistinguishable brands of sugar pills.
Shifting categories, let’s consider an herbal product. Ginkgo biloba was discussed back in December in the SBM post Ginkgo Biloba-No Effect. Yet the product Dr. Andrew Weil, M.D. Ginkgo Biloba is approved by Health Canada (Search NPN 80003088 here) with the following recommended use:
helps to improve memory. helps to improve attention. consult a health care practitioner for use beyond 6 weeks. [sic]
Again, the evidence bar is far lower than a critical appraisal of the evidence would suggest is accurate. The result? Arguably worse than under the DSHEA. Statements based on questionable evidence gain a regulatory stamp of approval.
Manufacturing Oversight
The NHP Directorate establishes manufacturing standards and issues site licenses. Good Manufacturing Practices (GMP) must be followed. Setting aside the labelling accuracy of homeopathic remedies, the licensure should provide consumers and health professionals with more assurance that what is on the label is actually in the product. Health Canada’s FAQs include a question on DSHEA and it states:
In the United States, dietary supplements are considered as food products under the Dietary Supplements Health Education Act (DSHEA) and, as such, claims may not be made about the use of a dietary supplement to diagnose, prevent, mitigate, treat, or cure a specific disease. These products are not subject to mandatory review, approval or quality requirements, including appropriate testing for identity, purity or potency of active ingredients.
However, GMP standards also exist for supplements sold under DSHEA, so it’s not clear if the NHP regulations impose more strict requirements for Canadian products.
Standardization
The NHP Directorate has created a series of monographs about dozens of single-ingredient products which are intended to provide more standardization of product labeling, dosing and constituents. All of this is worthwhile. Unfortunately a quick scan reveals some significant discrepancies between the current state of the evidence and what’s in the monographs. Harriet Hall’s recent SBM post on glucosamine points out there’s little persuasive data to suggest it has any meaningful effects. In contrast, the current Health Canada-approved monograph for glucosamine selectively cites the positive trials, and labels it effective for osteoarthritis pain. So while the Regulations may be supporting improvements in the consistency of the the finished products, the evidence standards may be compromising their real-world utility.
Marketing and Post-Marketing Surveillance
One of most important elements of the NHP regulations is the implementation of pre-marketing registration requirements. That is, only products reviewed and deemed to meet minimal standards of product quality, safety, and the (relaxed) standard for efficacy claims are permitted to be sold. Unfortunately, even after after six years, thousands of products remain unregistered due to a backlog at Health Canada. Until then, these products continue to be sold. Despite the published standards for consumer advertising of natural health products, there seems to be little enforcement of these requirements. As noted by Tom Blackwell in the National Post,
Recent ads, for instance, tout unapproved natural remedies as being able to prevent diabetes, heart and eye disease, treat menopause and Parkinson’s and help melt away excess weight. By contrast, makers of prescription drugs are essentially barred from promoting their products directly to consumers at all.
Federal law says even natural products — considered generally safer — must be approved under the natural health regulatory system before they can publish or air any kind of ad, and even then must stick closely to the claims allowed in the licence. Many companies that are waiting for word on their applications have chosen to ignore that rule, however, while others have not even attempted to get approval, observers say.
This regulatory backlog seems to have complicated the enforcement of marketing claims, and advertising standards for both approved and unapproved products don’t seem to be facing any serious scrutiny. In Canada, the Competition Bureau is the agency most comparable to the FTC, but it doesn’t seem to have the same focus on actively and publicly prosecuting fraudulent claims. While it has on occasion required companies to change their messaging, it’s rare, and only when the company has gone beyond the already over-generous efficacy claims allowed through the regulations. Perhaps this situation will change when the registration backlog is eliminated.
With respect to product withdrawals, the Minister of Health has the authority under the NHP regulations to direct the stop sale of a product or to cancel licenses of products to prevent injury. Licenses can also be suspended for regulation contravention, or if a product does not appear to meet safety criteria. It’s difficult to directly compare the FDA to Health Canada in this regard, as most Canadian warnings echo FDA advisories for products that may or may not be sold in Canada.
A Science-Based Regulatory Framework for Supplements
Given the regulatory approaches of Canada and the USA, what might a science-based framework look like? I see at least four different perspectives towards supplements/NHPs. I’m sure more will emerge in the comments.
Consumers want products that are safe, and labeled accurately. They may consult health professionals, or make their own decisions about whether products are effective.
Science-based health advocates, like the contributors at this blog, argue that that product safety and quality are paramount, and efficacy statements must be based on good science. They argue against a different approval standard for products just because they’re deemed a “supplement.”
Free market advocates, and those that call for health “freedom” question the value of most regulation that inhibits choice, emphasizing personal responsibility over government-legislated consumer protection measures.
Supplement manufacturers generally seek a market where they face as few regulatory restrictions as possible, whether it be safety, efficacy, or quality.
Certainly, there is some common ground here. Many will likely be agreeable to a regulatory framework that give consumer and health professionals assurance that they’re being protected from health fraud and dangerous products. Even free market advocates generally accept that markets operate less effectively when consumers cannot evaluate benefits and consequences (risks). With respect to health “freedom” claims, I question if anyone anyone wants the “freedom” to be sold products that don’t contain what is claimed, or have not been evaluated to be safe. Turning to manufacturers, some may welcome more rigorous regulatory verification of their own quality processes, especially if it helps with market acceptance.
One approach to to a new framework could be to unbundle the various types of supplements and treat each according to the science. Herbal products and botanicals stands out as the most likely to benefit from some elements of the Canadian regulations. Without quality manufacturing and standardization of active ingredients, it is impossible to infer anything about a particular herb. However, with respect to homeopathy, it’s questionable if anyone benefits from the regulation of sugar pills.
The biggest differences in opinion will clearly be the standards for efficacy and safety claims. Supplements/NHPs will rarely be be supported by the rigorous data we require for prescription and over-the-counter drugs. Through the NHP regulation process, Canada effectively eliminated any meaningful efficacy requirements, to accommodate products like homeopathy. Yet if all treatment and efficacy statements are forbidden, the information will emerge elsewhere. It’s an issue that other regulators are grappling with, too. Ben Goldacre, writing in The Guardian, points out the European Union’s process, evaluating health claims for similar products, has rejected 80% of claims submitted for formal approval. Ben’s solution is unorthodox, but one that I’m starting to warm up to:
You’ll never stop companies making these claims. You’ll never stop people enjoying their claims. This game is at least 200 years old. The best solution I can foresee is an EU-mandated bullshit box, where people can say whatever they want about their product, where consumers can join in, but the game at last is clearly labelled.
Conclusion
Canada has implemented a supplement registration and regulation framework with the goal of assuring Canadians that natural health products are safe, effective, and of high quality. While its approach to manufacturing quality is laudable, there are significant shortcomings with respect to product efficacy standards, and the regulation of marketing. The DSHEA at least informs consumers that the labelled statements on supplements haven’t been evaluated by the FDA. In Canada, with approved products, such as homeopathy, recommended use statements have been both evaluated and approved.
Yet if we want to incorporate dietary supplements into science-based practices, consumers and health professionals need quality products, but also objective and transparent evaluations of efficacy. As a health professional that advises consumers on natural health products, I welcome any regulation assures me, and my patients, that what’s on label is actually in the bottle. Without this information, I can’t make evidence-based recommendations. Yet if a regulatory system doesn’t also properly inform consumers about product effectiveness and safety, how can they be expected to make rational decisions about their own health? Canada’s approach offers some lessons, but also some cautions, for those calling for supplement regulation.

Holding the supplement industry to account: Can we learn from tobacco regulation?
A new paper compares the supplement industry to Big Tobacco and argues that states should use the same tactics to improve consumer safety and protection.
Scott Gavura on December 3, 2015
Link


The idea that “natural” products are safe and effective has been so effectively marketed to us that many don’t recognize it as a fallacy. Much of the supplement industry is built around an appeal to nature. Supplements are described as natural, gentle, and “holistic”. Medicine, especially prescription drugs, is the opposite. They’re “chemicals”. They’re risky and dangerous – just look at that list of side effects! Supplements are packaged beautifully, have impressive claims, and are for sale at Whole Foods. Drugs are hazardous: They may come in a plain vial, with warning labels, detailed information sheets, and cautious statements about their effectiveness. Is it any wonder that many consumers, when faced with health concerns or medical issues, instinctively think of supplements as a safer alternative? Purveyors of supplements and alternative medicine have leveraged this fallacy so effectively that it’s even guided the regulations that allow their sale. Regrettably, the result is a marketplace that puts consumers’ interests last. The supplement industry has completely stacked the odds against the consumer, challenging their ability to make informed decisions about their health. Most supplements on the market have never been properly tested for safety or effectiveness. And those that have been tested have largely been shown to be ineffective – or in the case of products like vitamins, often unnecessary. And while there are undoubtedly some ethical companies out there, the industry is regularly revealed to resemble a wretched hive of scum and villainy. Despite this, the industry has gone from success to success – in terms of sales, at least. In 1994 supplement sales were about $4 billion in the US. It’s now a $37 billion industry that is remains only lightly regulated – or largely unregulated. With recent action taken against fraudulent products, there are more questions than ever about how to force the supplement industry to make consumer protection a priority. A new paper in Drug Testing and Analysis makes a provocative suggestion: Local and state governments already regulate another hazardous product: tobacco. Can lessons learned from the tobacco wars improve the safety of supplements?
Whether you’re a supplement user or not, one thing we can probably all agree on is that these products should be manufactured to high quality standards. Setting aside any efficacy questions, consumers should get what they pay for, and be able to trust that what’s on the label is actually in the bottle. Adulterated supplements, or supplements that contain undeclared ingredients (from potential allergens to houseplants) are fraudulent and prohibited – yet they continue to appear on the market. Why this occurs isn’t unexpected. Current regulation doesn’t require manufacturers to demonstrate quality before products are sold, nor does it to hold manufacturers to account when things go wrong. That’s the reality with supplements today. And we can trace the cause (in the United States, at least) to a pivotal piece of legislation.
Supplement regulation: A travesty of a mockery of a sham of a mockery of a travesty of two mockeries of a sham
While the US Food and Drug Administration (FDA) effectively sets the worldwide standard for pharmaceutical regulation, the same cannot be said for its regulation of supplements. The overall quality of supplements sold in the United States is unclear. Adulteration, virtually unheard of with drug products, is a regular complaint with supplements. This shouldn’t surprise, as the FDA is at the mercy of legislation deliberately designed to prevent effective oversight. The Dietary Supplement Health and Education Act of 1994 (DSHEA) was an amendment to the U.S. Federal Food, Drug and Cosmetic Act that established the American regulatory framework for dietary supplements. It effectively excludes manufacturers of these products from many of the requirements that are in place for prescription and over-the-counter drugs. Amazingly, it puts the requirement to demonstrate harm on the FDA, rather than the onus on the manufacturer to show a product is safe and effective. A weak regulatory framework, which doesn’t require pre-sale testing of product quality and finished product specifications, might be expected to result in a weaker commitment to quality. Yet consumers are not aware of this. After two decades of DSHEA, many consumers believe that supplements are approved by the FDA, that supplements are tested for product quality, and that adverse events are disclosed to consumers. DSHEA does not require this, and there is no assurance to consumers it is occurring.
Herbals and botanicals: Crude drugs of vegetable origins
One of the bizarre aspects of DSHEA (and similar regulation, such as what you can find in Canada) is that what regulations consider “supplements” is a disparate mix of products that vary in their risk to consumers. Some supplements are completely synthetically manufactured, such as certain vitamins. These products are probably the closest to drug products (and in some cases, are considered drugs). They can have specific and genuine, established uses (e.g., folic acid in prenatal vitamins for preventing neural tube defects). These supplements can be assayed and tested, and can be easily manufactured to the same standard as conventional drug products.
But the category of “supplement” also includes herbal remedies – which I would argue shouldn’t be “supplements” at all, as there is no established role for herbs to be “supplementary” to our diet (and some, like DMAA , are classified as “herbal supplements” despite almost certainly not being extracted from plants). Herbal remedies are effectively crude, unpurified drugs – possibly with hundreds of ingredients, and unclear product standards. And when they have a medicinal effect, they are effectively drugs. Many drugs sold today have botanical origins. Acetylsalicylic acid (aspirin) is derived from salicin, found in the bark of the willow tree. Atropine was found in nightshade, and digitalis (digoxin) makes the foxglove plant toxic. Drugs have an edge over herbs because their effects are predictable and reproducible. It starts with identifying, isolating and purifying the active ingredient – and sometimes enhancing it, to reduce side effects or improve its efficacy. Next, you develop a dosage form (e.g., a tablet) that dissolves completely and consistently, and is absorbed reliably. Clinical trials establish if the drug has meaningful effects. None of this is certain or predictable with herbal remedies. Herbals and botanicals are concoctions of chemicals which are rarely “standardized” to contain a predictable amount of an active ingredient, because in most cases, there’s no clear evidence of efficacy. So consumers are completely at the mercy of the manufacturer’s own quality assurance process for a product that may not even have the same ingredients, batch-to-batch.
Botanical and herbal safety: Here be dragons?
Claims made about the efficacy of herbal remedies are typically based on “history of use” claims but often fall short in terms of anything that’s convincing, whether it’s small trials, bad study design – or the fact that it’s not even clear what chemical constituent is having an effect – and if it’s in the dose at all. Without close evaluation, and a standardized product, it’s very difficult to determine if herbal remedies are effective or harmful. The story of Aristolochia is cautionary and telling. Aristolochia is a plant that has been considered to have medicinal properties for hundreds, perhaps thousands of years. Owing to its resemblance to a uterus it has been thought to be effective for childbirth (that’s herbalism “evidence” for you) and has been used as part of traditional Chinese medicine for a number of conditions, none of which were supported by any evidence. The harms of this botanical weren’t identified until recently; when a cluster of Belgian women developed kidney disease and urinary cancers after taking Aristolochia-containing diet pills, the catastrophic harms were revealed. Aristolochia promotes cancer formation through DNA mutations. It’s now classified as a type 1 carcinogen, alongside asbestos and solar radiation. Are other herbals and botanicals causing cancer, or other harms? There’s no routine data collection, so it’s impossible to say for sure. And even if there was, drawing associations is exceptionally difficult: The appearance of an effect like cancer may lag for years, or decades. The harms of a product like Aristolochia are so widespread and diffuse that it’s notable that it took a cluster of cases in Belgium to finally bring this toxicity to light. We may see elevated number of urinary cancer cases in some Asian countries, possibly for decades. Aristolochia is an example of the challenge we face in identifying and monitoring for adverse effects from herbal products. We simply have no clear understanding of the potential for harms, and DSHEA makes it very difficult for anything to change.
Can states learn from tobacco regulation?
Given the likelihood of robust federal consumer protection regulation is remote, the focus has shifted to the potential for state-level action to improve patient safety. It’s worth noting that this is already occurring. Earlier this year the New York State Attorney General issued letters to several retailers demanding that sales cease of mislabelled store-brand supplements. While this inspection was justifiably criticized in part because of its methodology, the state eventually reached an agreement with GNC to implement DNA barcoding nationwide – thereby pushing one manufacturer to adopt standards that are more rigorous than established by DSHEA. Another example was the state of Oregon which, this past April, reached an agreement with Vitamin Shoppe to stop selling supplements containing BMPEA (a stimulant) nationwide.
What else can states do? This is the focus of Rajani Starr’s interesting paper entitled “Should states and local governments regulate dietary supplements?” in Drug Testing and Analysis. The paper is currently open access, so I will touch on the highlights only. Starr points out that states are entitled to create laws to protect health and safety. Tobacco licensing is one example, alcohol is another. States are entitled to impose restrictions on activities like retail sales, and this is an approach that might be desirable from a public health perspective. Not only would it ensure that states knew which retailers were selling products, it could impose signage and marketing requirements – just like you see today with tobacco and alcohol. States could mandate or conduct their own quality assurance testing of supplements, expanding and extending the New York AG’s actions. The risk of licence revocation could ensure more consistent communication about risks, and support any product recall requirements. Starr argues that a one-ingredient-at-a-time approach is insufficient, and states must take broader actions to ensure supplements are of high quality, and that they are used safely. Prohibiting the sale of weight loss and bodybuilding supplements to minors, an approach currently being considered by Massachusetts, is an example of such an approach. Not surprisingly, the natural products industry is fighting it:
If the FDA deemed these supplements (which millions of Americans rely on for their health and fitness) unsafe then they would not be on the shelves in the first place. Also, if they were in fact unsafe then why would it be okay for someone over the age of 18 to purchase them?
Denying those under the age of 18 access to these supplements will likely drive them to purchase them on the internet where they cannot talk to a store salesperson and ask safety questions. Alternatively those under 18 could easily drive across state lines to somewhere they can buy them freely. This action ultimately drives a huge amount of business out of Massachusetts.
By placing the supplements behind the counter for those over the age of 18, you deny them the ability to make the informed decision that they would be able to come to by picking up and comparing multiple supplement containers side by side, looking at the warning and ingredient labels of each.
An appeal to consumer “freedom” for minors to buy potentially adulterated products.
What are the limitations on state action? There are several. Legislation may be limited by “pre-emption” whereby the laws of one level of government (e.g., state) can be overruled by a higher level of government (e.g., federal). The tobacco industry successfully used pre-emption to reverse state-level tobacco control for years. Starr argues that the supplement industry understands pre-emption well, and has successfully argued that DSHEA was written to enable access to supplements. The second barrier to state regulation is the Commerce Clause of the US Constitution. In short, any burden on interstate commerce must be assessed against the benefits they bring. Finally, there is the First Amendment protection of commercial free speech: The tobacco industry used this argument to fight package warnings. The supplement industry has used the same argument in its fight to make treatment-related claims on product packages. What you see today is a product of that battle: “Structure/function” claims that are accompanied by a quack Miranda disclaimer that “These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.”
Conclusion: An encouraging zephyr of change
Just like the gradual public health push for tobacco legislation, recent actions at the federal and state level are encouraging – legislators are recognizing the fallacy of supplement safety, and are finally moving to put consumer protection ahead of industry interests. The industry’s inability to keep adulterated products off the market does itself no favours, and public support may dwindle if it’s recognized that the industry, to date, really hasn’t taken product quality seriously. What we argue for here at SBM is a consistent approach to quality and safety, where claims of effectiveness are backed by good evidence, and health professionals and consumers can use these products in science-based ways. The challenge we face is that the supplement industry will fight this tooth and nail. It took decades for tobacco. Comparing supplements to tobacco is definitely provocative. But given what we don’t know about supplement quality and safety, the comparison may be more apt than it appears.
References and additional reading
Starr R. “Should states and local governments regulate dietary supplements?” doi: 10.1002/dta.1926
There are several other new articles in Drug Testing and Analysis that relate to this topic, and are recommended:
    • The history of efforts to regulate dietary supplements in the USA
    • Breaking the gridlock: Regulation of dietary supplements in the United States
    • Hepatotoxicity associated with the dietary supplement OxyELITE Pro™ — Hawaii, 2013
    • Adulterated dietary supplements threaten the health and sporting career of up-and-coming young athletes
    • Consumers’ perceptions of the dietary supplement health and education act: implications and recommendations
    • Self-reported side-effects associated with use of dietary supplements in an armed forces population
    • Dietary supplements: What’s in a name? What’s in the bottle?

CAM Docket: Kardashian Diet Products Klass Action
Jann Bellamy on June 13, 2013
Link
Kim, Khloe and Kourtney Kardashian permit the use of their names and images of their curvaceous bodies to promote “QuickTrim” diet products, a line of dietary supplements making overblown claims typical of the weight loss supplement industry. Their personal testimonies and formidable publicity machine (Kim alone has over 13 million followers on Twitter), “has reportedly generated $45 million in revenue since they struck the deal with New Jersey-based Windmill Health Products in 2009,” according to the N.Y. Post. Naturally, the sisters are paid for their efforts, although how that amount is calculated or how much they receive apparently is not a matter of public record.
Some Quick Trim consumers who are not as enthused about the products as the Kardashians filed two class action lawsuits last year alleging violation of consumer protection and other state and federal laws. One is pending in New York and the other in California. The judge in the California suit issued a preliminary approval of a settlement in March, a subject we’ll get to in a minute.
Keeping up with the Kardashians
For those of you lucky enough to live in a corner of the planet where news of every Kardashian family spat, marriage, divorce, pregnancy, baby and assorted other details of their extensively chronicled lives are not forced upon you via every popular media delivery device available, a bit of background is in order. Kim, Khloe and Kourtney Kardashian are sisters and stars of their own popular American TV reality show, Keeping Up With the Kardashians. The sole premise of the show appears to be that there are a lot of people extremely interested in keeping up with the Kardashians and that premise appears to be correct.
The show, which also features their mother, Kris Jenner, wife of Olympic gold medalist Bruce Jenner (who is not the sisters’ father) and various Kardashian husbands, ex-husbands, boyfriends . . . well, you get the idea. The show generated several reality show spinoffs, Kourtney and Khloe Take Miami, Kourtney and Kim Take New York, and Khloe & Lamar, Lamar being Khloe’s husband, NBA player Lamar Odom. These shows, as well as product endorsements and other commercial activities, have made the sisters multi-millionaires. Apparently these folks employ an army of publicists who ensure that the media, and you, are kept well informed of pretty much everything they want you to know about themselves, which is an awful lot. In short, the Kardashians are famous for being famous.
The New York Lawsuit
Several people who purchased QuickTrim in a number of different states brought suit in New York federal district court seeking compensatory and punitive damages in an amount greater than $5,0000,000 (but not otherwise specified), as well as injunctive relief, on behalf of themselves and a class of other QuickTrim product purchasers. Cowan et al. v. Windmill Health Products, LLC et al., Case No. 1:12-cv-01541-VM-AJP (S.D.N.Y.) has not yet been certified as a class action by the court. The Kardashian sisters, as well as companies involved in the manufacture and sale of QuickTrim products, including GNC, the retail and on-line dietary supplement seller, are named as defendants.
The suit alleges statements made by the Kardashians in advertising and the products’ labels are false and misleading, in violation of various state and federal consumer protection laws. In addition, the suit alleges that QuickTrim’s individual product weight loss and appetite suppression claims and the whole QuickTrim system, which is touted as working “synergistically” to promote weight loss and weight control, are actually drug claims within the meaning of the Food, Drug and Cosmetic Act. Because the products do not have FDA approval, plaintiffs claim their distribution also violates the Act.
The “Quick Trim Weight Loss System” includes:
    • QuickTrim Extreme Burn
    • QuickTrim Fast Cleanse
    • QuickTrim Burn & Cleanse
    • QuickTrim Hot Stix (“an antioxidant rich, delicious berry drink mix”)
    • QuickTrim Sugar & Carb Cheater
    • QuickTrim Fast Shake
    • QuickTrim Satisfy (a “chocolate fudge soft chew” to “help satisfy between meal cravings”)
    • QuickTrim Celluslim (a “body sculpting gel” to fight cellulite, smooth tone and firm, and spot-treat problem areas)
QuickTrim’s claims of easy weight loss and “detoxification” sound depressingly familiar. With apologies for the lengthy quote, the complaint alleges the following product misrepresentations, lifting language directly from product labels and ads:
QuickTrim’s labeling and advertising represents that QuickTrim products (a) are effective for “weight loss,” (b) use “research proven ingredients,” (c) “safely work to help burn calories [and] curb cravings,” (d) that the “sustained release formula allows for greater absorption and controlled release of nutrients providing optimum calorie burning,” (e) are “synergistically designed to work together” with other QuickTrim formulas,(f) “Help Cleanse and Detoxify,” (g) “Help Jump-Start Weight Loss,” (h) “Help Reduce Belly Bloating,” (i) “Help Jump Start Your Weight Loss,” (j) “Help Burn More Calories by Day,” (k) will “Flush Out [your] System Overnight,” (l) “stimulate metabolism to burn more calories and fat through the day,” (m) “help to release and burn stored fat,” (n) “help to remove toxins and impurities out of your system,” (o) “help remove excess water from under the skin,” (p) “Help Block Excess Sugar & Carbs,” (q) “Help Curb Carbohydrate Cravings,” (r) “increase the body’s ability to burn stored fats and decrease the appearance of cellulite while helping increase firmness and elasticity,” (s) “Increase lipolytic effect by 630%,” (t) “Release stored lipids at adipocytes 1064%,” (u) “Reduce indentation by 9.5%,” (v) “Reduce roughness by 32.4%,” (w) “Decrease fat deposits by 33%,” (x) “Help increase circulation to problem areas,” (y) “Help tone, smooth and firm skin,” (z) “attack cellulite by breaking down excess fat stored in the cells,” (aa) “[are] scientifically designed and clinically shown to work with your body naturally to help increase your ability to burn calories,” and also to “reduce carbohydrate cravings,” (bb) “ha[ve] been clinically tested and shown to increase metabolism by burning 278 calories (on average) per day”.
(I’ve removed some of the attorney’s editing, which is necessary for quotations in a document filed with the court but which also makes the quote harder to read.)
I searched the FDA website and could not find that the agency has issued a warning letter to any of the defendants or taken any other regulatory action regarding the QuickTrim products.
Interestingly, according to the complaint, the Kardashian sisters represented that they personally formulated and tested QuickTrim products “to make sure that this was something that really works.” I guess they are scientists in addition to being reality TV stars.
These products are not cheap. You can buy them online for between $12 to $30 a package, depending on the product and the amount supplied, but there is a hefty shipping and handling charge for most sellers, up to $14 per product. A package will last you, again depending on the product, up to 30 days.
The defendants deny any wrongdoing in their answers to the complaint. Specifically, the Kardashian sisters state in their answer
. . .that they have used QuickTrim products, and that they base their statements about QuickTrim products (including on Twitter and Facebook) on their honest opinions, experiences and beliefs about the products.
In a U.S. News & World Report article about QuickTrim and the New York lawsuit, registered dietitian Keri Gans and Adriane Fugh-Berman, a physician and associate professor in the complementary and alternative medicine master’s degree program at Georgetown University Medical Center (sigh), criticized several QuickTrim products and their unproven ingredients. (The reporters said QuickTrim did not respond to repeated requests for comment.)
According to the article, the “Burn and Cleanse 14 Day Diet System” contains products for both morning and evening which provide a total of 400 milligrams of caffeine per day, the equivalent of about 4 cups of coffee, as well as piperine (black pepper) and white willow bark extract, both of which can increase the potency of caffeine.
‘It irritates me that they’re not saying how much caffeine is in these pills,’ Fugh-Berman says. ‘Too much caffeine can make you jittery and increase your blood pressure and pulse. If you pop a couple of these pills with your Starbucks coffee, that’s not good; you could get caffeine poisoning, which can cause heart arrhythmias.’
“IsoCleanse and Flush Herbal Complex,” the evening product, is a combination of “natural” stimulants and bulk laxatives, designed to increase the movement of food and liquid through the body. This is fine, said Fugh-Berman, if you are constipated. If you’re not, “you’ll get diarrhea.” In addition, “stimulant laxatives, of which IsoCleanse is chock-full, can cause your intestines to become dependent on them for stimulation, causing constipation if you stop.”
“Fast Cleanse,” a “48-hour Super Diet Detox,” is a drink rich in fiber ingested four times a day between meals of clear soups, gelatin, fruits and vegetables. This may cause you to drop of few pounds, but Fugh-Berman says you’ll be “putting them right back on.” “Sugar & Carb Cheater” is designed for dieters concerned “that their sugar and carbohydrate intake is keeping them heavy.” I suppose a sensible solution would be to reduce one’s sugar and carb intake, but that’s just me. For those seeking a less taxing solution, the “Cheater” contains chromium, fenugreek seed, bilberry fruit, and vanadyl sulfate and is touted to keep carbs from turning into fat by blocking the enzyme that causes the conversion. To Gans, the registered dietician, “scientifically, it doesn’t make sense . . . It’s offering people false hope.”
Fugh-Berman doesn’t think anyone should take these products. Healther Mangieri, a spokeswoman for the American Dietetic Association added, “The good news is that these products are absolutely not necessary for weight loss. My suggestion is to leave them on the shelf.” Good advice all around.
In March, the judge stayed the New York suit pending the outcome of a proposed settlement in the California case. If the settlement gets final approval, the plaintiffs in the New York suit would be included in the class of QuickTrim product purchasers in the California suit, because its scope is nationwide, unless they opt out of the class, which they say they will do. However, unless their suit covers a different time period than the California action (product purchases made between August 14, 2009 and March 1, 2013), the New York plaintiffs will be able to pursue their claims only as individuals, not as representatives of a class of purchasers, barring some highly unlikely circumstances.
The California Lawsuit
So let us move from the East Coast to the West and to Anaya v. Quick Trim, LLC, et al., Case No. CIV VS 1201177, pending before the Superior Court of the State of California, County of San Bernardino. The same defendants are named, plus Kris Jenner, Jenner Communications, Inc., and additional sellers of QuickTrim products, the CVS pharmacy chain, Walmart, Amazon.com, and Drugstore.com. Also named is Vitaquest International, a New Jersey company that formulates, develops and manufactures dietary supplements for its clients. (I can just imagine the Kardashian sisters in their crisp white lab coats formulating and testing QuickTrim products in the Vitaquest laboratories.) Finally, three corporations with the cutie-pie names Kimsaprincess, Inc., Khlomoney, Inc. and 2Die4Kourt, Inc., are named as defendants.
(And here I will switch, for reasons of economy, from the actual documents filed in the New York action, which can be viewed as they appear in the court’s files for a reasonable charge, to the information available on a website set up by the California settlement administrator, which can be viewed for free. Viewing the actual documents from the California court’s files costs up to $50 per document.)
Like its New York counterpart, this suit seeks certification as a class action on behalf of purchasers of the same eight QuickTrim products. The California state court has issued a preliminary approval of a class action settlement, the details of which can be found on the website, although not nearly as much information as is available in the New York case.
The plaintiff alleges that improper statements were contained on the product labels and in advertisements, and that these statements violate state consumer protection laws and various other state and federal laws. She seeks, among other remedies, damages and injunctive relief. As is usual in such settlements, the defendants deny any wrongdoing.
If the settlement is approved, plaintiff’s counsel will get $250,000 in fees and costs and the named plaintiff, Teresa Anaya, will get $2,500. QuickTrim will have to “redesign its labeling and packaging to restate the nature of its products and its benefits.” Members of the class who file a claim (other than those who opt out of the settlement) receive different amounts depending on where they bought the product and whether they have proof of purchase. Basically, they can get either a refund or a coupon good towards purchase of another QuickTrim product. In other words, the defendants have managed to turn the settlement into a product promotion event.
We’ll have to wait until August, when the settlement proposal will have a final hearing, to find out what happens.
Conclusion
This is yet another tale of outlandish dietary supplement claims, testimonial “evidence” of effectiveness and the failure of the DSHEA to adequately protect consumers by preventing this sort of thing from happening in the first place. As I have said before, lawsuits are not the ideal way of bringing supplement companies and their enablers to justice. But until the federal law is amended, these suits remain the best way to apply some brakes to the runaway dietary supplement industry.

   European Union “Ban” On Herbal Products
Published by Steven Novella 
Link
Regulations have just gone into effect in the EU regarding the sale of herbal products. The regulations seem reasonable, but they have sparked near hysteria on the part of herbal sellers and advocates of “natural” medicine. They are calling the regulation a “ban” on herbal products, which much of the media has parroted, but it is not a true ban, just a requirement for registration.
The law was sparked by cases of toxicity from over-the-counter herbal products. For example, aristolochia is a toxic plant species that is either used deliberately or can be accidentally or carelessly substituted for other plant species. It is known to cause kidney damage – even leading to kidney failure is some cases. Another herb, kava, has been linked to liver damage.
The new EU law, which went into effect May 1, 2011, will require herbal products to be licensed, or prescribed by a licensed herbal practitioner. In order to be licensed evidence for safety of the product must be presented. It is estimated that it will cost between 80,000 and 120,000 British pounds to get an individual herbal product licensed.
I find it interesting, and completely predictable, that sellers of herbal products are wailing that this is all a conspiracy by “Big Pharma” to crush the little guy and steal all the herbal profits for themselves, or to ban herbal products to protect their drug profits. But this is a straw man. The real question here is the balance between marketing freedom and quality control – but those who want to defend their right to sell herbs don’t want to discuss the real issues, apparently.
Dr Rob Verkerk from a trade organization, the ANH, is quoted as saying:
“Thousands of people across Europe rely on herbal medicines to improve their quality of life. They don’t take them because they are sick – they take them to keep healthy. If these medicines are taken off the market, people will try and find them elsewhere, such as from the internet, where there is a genuine risk they will get low quality products, that either don’t work or are adulterated.”
First, he begs the question that the use of herbs improves anyone’s quality of life. That is, in fact, the entire question – are the risks worth the alleged benefits. The legislation is simply an attempt to provide a better risk/benefit for the consumer by putting into play better assurances of safety.
His next point if the same point that is always made against regulation – if you make X illegal then people will just obtain X illegally or from less regulated sources. This is not specific to herbal products. There is a point there – regulation is not easy, especially with a global market and the internet. But that does not mean we should abandon all efforts at quality control and honesty in marketing.
He concludes with an assumption that herbal products under the current scheme work for anything and have adequate quality control – but again, that is the very issue. In fact regulations are generally not adequate to assure quality control in terms of dose and purity. And there is virtually no regulation about the claims that can be made for herbal products.
In the US the 1994 DSHEA essentially allows herbal manufacturers to make a host of pseudo-health claims without any oversight. The same is and will continue to be true in the EU. One could argue that this legislation does not go far enough to protect the public against false claims and useless products.
Others argue that this legislation will put the small producers out of business. This is exactly what patent medicine sellers complained about when the FDA was proposed. In fact all of the objections are identical to those raised against regulation of drugs. Of course, the point of the FDA was to put the mom and pop patent medicine sellers out of business – because they were largely selling snake oil and did not have the resources to perform proper safety and efficacy testing.
Here the claims are even less relevant – because herbal remedies are a multi-billion dollar industry, and the relative cost to get licensing is much less than getting a drug through the FDA.
What we really have here is an industry that wants to continue selling poorly regulated products with health claims and without any burden of having to prove that their products are safe or that their health claims are based upon science.
I acknowledge that there is a real political debate here, and that some people might want to favor freedom and risk over government regulation. But I object to the way the debate is often framed by opponents to regulation. Even for those who would prefer to have a free market for herbal products would likely agree that the consumer deserves accurate information in order to make informed decisions. Right now, in most markets, the consumer does not have that.
Most people I talk to about this assume that herbs are more regulated than they currently are. People want both freedom and protection, and are not always aware of the degree to which the two are at cross purposes. So if you ask them if they want freedom in the market, they say yes. And if you ask them if they want assurance of safety and honesty, they also say yes. They want the freedom to choose, but only among products that are safe and effective.
With respect to herbal remedies, however, the evidence is largely against the efficacy that is being claimed for many products. If you look at the big sellers, like echinacea and Gingko biloba, the large well-controlled studies are largely negative – they don’t appear to work for the indications for which they are commonly marketed.
The industry has largely failed to self-regulate, and to use their profits to generate good science to back up their claims. And they consistently fight against regulation to force them to do so, and try to make it seem like they are on the side of the little guy against big corporate interests. But this is just spin – they are just another big industry protecting their interests. If they really cared about the little guy or the consumer they would be producing good science, and keeping their claims within the evidence, rather than fighting against attempts to make them do just that.
Under most current regulatory schemes, there is a disincentive to conduct good efficacy research. Such research is a lose-lose proposition for industry. They have to spend the money to do the research. If it’s positive, it is unclear how that will benefit them since they already can make health claims (or pseudo-health claims, like the so-called “structure function” claims under DSHEA). But if it’s negative, then they risk losing market share. The risk/benefit of doing efficacy research is simply not there, and that is probably why there is so little such industry-sponsored research into supplements. The only way to get the industry to spend some of their profits doing quality research is to make such research a requirement for entry into the marketplace.
In the end we should remember that herbs are drugs – they have pharmacological activity, they have toxicity, an they have drug-drug interactions. How much regulation and quality assurance do we want for our drug industries (no matter what they are called)?

FDA Decision on Oleandra
FDA rejects the application for oleandrin as a new dietary ingredient, but flaws in the regulations remain.
Steven Novella on September 9, 2020
Link

Last month I wrote about a proposed treatment for COVID-19 – an extract (oleandrin) from a plant known to be highly poisonous, Oleandra. This was news because the CEO of MyPillow (Mike Lindell) was pushing this new snake oil to President Trump through HUD secretary Ben Carson. Trump assured him that “We will look into it”. This is a perfect representation of what is wrong with supplement regulation in this country, I argued, because Lindell was simultaneously asking for approval as an investigational drug and, failing that, as a dietary supplement. It brazenly revealed how our lax supplement regulation is used to essentially market untested drugs, without any assurance of safety or efficacy.
Phoenix Biotechnology, the company that produces oleandrin (and in which Lindell now has a stake) recently received a letter from the FDA (clicking on this link will automatically download a PDF of the letter) on their decision regarding their disclosure of a potential new ingredient. For dietary supplements, manufacturers only need to inform the FDA at least 75 days before putting the new ingredient on the market. The FDA reviews the new ingredient on two criteria – does it meet the definition of a dietary supplement, and can it be generally regarded as safe (GRAS) based on prior use. Dietary supplements, in other words, are treated as if they were food.
However the regulations also allow companies to make pseudo-medical claims for their supplement ingredients, so-called structure-function claims. As long as they don’t mention a disease by name, they can make or imply claims that the supplement can be used to improve certain health conditions or symptoms. Of course, outside of direct company marketing, people (who may or may not be connected to the company) can make direct medical claims, creating a market for the supplement with health claims that have not been reviewed by the FDA.
The FDA letter to Phoenix Biotechnology has rejected their filing of oleandrin as a new dietary ingredient. The primary reason they cite is that oleandrin does not meet the definition of a dietary ingredient, because it contains:
…an article authorized for investigation as a new drug, antibiotic, or biological for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public
This is where the Phoenix Biotechnology strategy of hedging their bets has bit them in the backside. Because they are also asking to investigate oleandrin as an FDA approved drug, this excludes the substance from being considered a dietary supplement. That is the one thing you can’t put into your nutritional supplement – an actual drug. The FDA considers such products as “adulterated”. This is still a common occurrence. The FDA’s response when it discovers that a product is adulterated with a drug is to send them a strongly worded warning letter.
For example, a recent review found:
The authors found that between 2007 and 2016 the FDA identified 746 brands of supplements adulterated with pharmaceutical agents. The adulterants included prescription medications such as sildenafil and fluoxetine, withdrawn medications including sibutramine and phenolphthalein, and unapproved drugs including dapoxetine and designer steroids. Twenty percent of the adulterated supplements contained 2 or more undeclared drugs, for example, weight loss supplements containing both an anorectic and a laxative.
The FDA essentially asks the company for a voluntary recall. However:
Despite their limited effectiveness, voluntary recalls are the most common approach used by the FDA to remove adulterated supplements from commerce. In the current study, the agency discovered 746 distinct supplements to be adulterated but announced voluntary recalls for only 360. Only 360 of 746 (48%) were recalled, leaving the majority of adulterated supplements, more than 350 products, available for sale.
In the case of oleandrin, however, the FDA is preemptively rejecting approval as a new dietary ingredient on the grounds that it meets the definition of a drug.
FDA has concluded that the “Oleandrin” has been authorized for investigation as a new drug for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public. Further, FDA has carefully reviewed the information provided in your submission and other available information and has not identified any evidence to demonstrate that “Oleandrin” was marketed as a dietary supplement or as a food prior to such authorization.
This implies that if oleandrin were marketed as a supplement prior to being studied as a drug, it would be OK. Again this shows the blurry distinction between the two, and how the regulations are essentially just a way to market drugs without having to prove safety or efficacy.
Not only is oleandrin being tested as a potential drug, it is failing so far. The U.S. Army Institute of Infectious Diseases halted a neutralization test of oleandrin against COVID-19 because the results were “inconclusive”. So it did not even look promising on a preliminary study of potential effectiveness, and was abandoned to focus on other potential agents.
Finally, the FDA points out in the letter that, even if oleandrin could be considered a dietary ingredient:
…the agency has significant concerns about the evidence included in your submission as a basis for concluding that a dietary supplement containing “Oleandrin” will reasonably be expected to be safe under the conditions of use described in your notification.
They could not even meet the low bar of showing that the ingredient is probably safe, based on prior usage (as opposed to controlled clinical trials).
While this is a good decision from the FDA, it does also reflect the weakness of our current regulatory scheme. A company could, for example register as a new ingredient a substance that is not toxic and is not already being studied as a potential drug. If approved as a dietary ingredient (even though it is actually a pharmacological agent), the company could then market it as a way to help fight off COVID-19, by “boosting the immune system” or some other vague language. This is not the FDA’s fault, it’s Congress’s. They passed DSHEA, and have failed to revise it despite its blatant problems.

   Airborne Settles Case On False Advertising
Steven Novella
Link
The story of Airborne – a popular supplement marketed as an “herbal health formula that boosts your immune system to help your body combat germs” – is representative of what is wrong with the supplement industry and how it is regulated in the US. Recently the company that sells Airborne – Airborne Health, Inc – agreed to pay $23.3 million to refund consumers who purchased the product (if they have proof of purchase). This was to settle a class-action law suit brought by the Center for Science in the Public Interest (CSPI) and others claiming false advertising. In the settlement the company did not admit any wrongdoing. While this can be viewed as a minor victory for science-based medicine, it actually highlights the many deficiencies in the system.
For background, Airborne was launched in 1999 as a supplement designed to ward off the common cold. It has been extremely successful, due largely to its slick packaging, a clever slogan that it was developed by a school teacher, and promotion by Oprah Winfrey. The Airborne brand of products has expanded, including pixie powder for children, Airborne seasonal, Airborne Jr., Airborne on-the-go, and others. Advertising urged users to take Airborne at the first sign of a cold or as a preventive treatment if about to enter a germ-filled area, like an airplane. They also cited a “scientific” study that demonstrated Airborne is effective.
What is in Airborne is nothing more than common vitamins and herbs. There is no reason to believe that this particular concoction has any health benefit (beyond the basic nutritional value of the vitamins) or specifically that it enhances immune function or helps fight off infections. David Schardt from CSPI is quoted as saying:
There’s no credible evidence that what’s in Airborne can prevent colds or protect you from a germy environment. Airborne is basically an overpriced, run-of-the-mill vitamin pill that’s been cleverly, but deceptively, marketed.
It should also be noted that Airborne is not without risk because it is a supplement. Airborne contains too much vitamin A. Two pills contains 10,000 IU, which is the maximum safe limit, but the instructions say to take three pills per day. So taken as directed Airborne contains more than the safe limit of vitamin A. This would also have to be added to vitamin A consumed in food, and of course many consumers may also be taking a multivitamin without realizing that Airborne is essentially just another vitamin pill itself.
Airborne is marketed as a supplement – in the US this means it falls under the Dietary Supplement Health and Education Act of 1994 (DSHEA). Under DSHEA a health product can be marketed as a supplement and make “structure/function” claims for the product without any FDA oversight, as long as they place a disclaimer on their label and advertising stating that the claims have not been reviewed by the FDA and that they do not make “disease” claims for the product.
What this means is that any company can put together an essentially random combination of vitamins and herbs and make any structure/function claim they choose (boosts the immune system, gives energy, improves sleep, aids mental focus -whatever) as long as they don’t mention a specific disease by name. There is no FDA oversight to make sure their claims have been validated scientifically.
Companies are still responsible for the claims that they make, but accountability is entirely post-marketing. The Federal Trade Commission (FTC) can take action for false advertising – just as it can with toasters, vacuum cleaners, or any product. And, of course, the civil courts can always be used to seek compensation for any deception or wrong-doing by the company. But there is no pre-marketing oversight – no hurdle to get over before getting to market with specific claims.
In the case of Airborne there was no FTC action – a grass roots watchdog group, CSPI, brought a class action suit for false claims. Specifically they were able to document that there is no scientific evidence to support the claims made for Airborne. In addition, Airborne Health cited a “clinical study” to back its claim that Airborne is effective at preventing colds. But an ABC news investigation reported:
Airborne said that a double-blind, placebo-controlled study was conducted with “care and professionalism” by a company specializing in clinical trial management, GNG Pharmaceutical Services.
GNG is actually a two-man operation started up just to do the Airborne study. There was no clinic, no scientists and no doctors. The man who ran things said he had lots of clinical trial experience. He added that he had a degree from Indiana University, but the school says he never graduated.
In response to these critical news reports (and likely fear of legal ramifications) references to the clinical trial have now been removed from Airborne packaging. Elise Donahue, Airborne CEO, explained: “”We found that it confused consumers. Consumers are really not scientifically minded enough to be able to understand a clinical study.” The packaging has also been changed to remove the claim that Victoria Knight-McDowell (the school teacher) developed Airborne because she was “sick of catching colds,” and replace it with the claim that she created Airborne because she “needed help supporting her immune system.”
What we see here is the evolution of the packaging and marketing of Airborne to conform to DSHEA, which effectively shields them from legal repercussions. Scientific evidence is not needed – so why bother going through the motions of doing a “clinical study.” You are not allowed to claim that you can treat a cold, but you can “support the immune system.” Yet, the public still understands what the product is supposed to do. Airborne has created a market using deceptive claims and now they are allowed to benefit from that market.
The class action suit resulted in a settlement of $23.3 million, but the company has estimated revenue of over $150 million in 2006 alone. Such settlements are little more than the cost of doing business. The FTC is looking into also investigating the company as well, so fines may be forthcoming. While the FTC has taken up some of the slack since DSHEA, and appears sincere about wanting to crack down on fraudulent supplement claims, they are also overwhelmed and understaffed. In addition their fines are often little more than slaps on the wrist – again the cost of doing business.
This situation is not the same as otherwise legitimate companies that behave badly and need to be punished or to compensate wronged consumers. The entire existence and marketing of Airborne is based upon a deception of the consumer. Allowing such companies to continue to do business, with some tweaks to their claims and fines that are a minor inconvenience, has not been an effective protection for the consumer.
Given that Airborne is nothing more than an overpriced (and potentially unsafe) vitamin pill, and that there is no reason (either theoretically or based upon clinical evidence) to conclude that this product is of any use in fighting off germs, as is claimed, Airborne seems to be of no practical use to the consumer. It is a waste of health resources, and may serve as a source of false confidence and therefore distract consumers from effective means of avoiding infectious disease – like simple hand washing. Our current regulations have not prevented such products from getting to the marketplace, nor removed them from the market once the facts come to light.

   FDA Zicam Warning
Steven Novella
Link
On June 16th the FDA issued a warning advising consumers not to use Zicam Nasal Gel or Nasal Swabs because of reports that it can damage the sense of smell, a condition called anosmia. This event highlights some problems with current regulations of health products.
There have been 130 cases reported to the FDA of decreased sense of smell following the use of one of these Zicam products – sometimes after a single use, sometimes after repeated use. All of these cases were reported by patients or their doctors; none were reported by the company, Matrixx Initiatives. According to reports, the FDA has asked Matrixx to turn over 800 consumer complaints regarding to Zicam. There is a 2007 law that requires company to report such complaints to the FDA, although the FDA has not said whether Matrixx violated this law.
Anosmia is a serious medical condition. The senses of smell is one of those things we take for granted until it is gone. People who lack a sense of smell cannot tell if milk has gone sour or if their food is bad. They cannot smell smoke to warn of a fire, nor can they smell a gas leak. The FDA fears that some of the cases of anosmia associated with Zicam use may be permanent.
Correlation does not prove causation, but there is reason to think that the anosmia in some of these cases may have been caused by the zinc in these Zicam products. As the FDA reports, viral upper airway infections can also cause anosmia, but the anosmia that results from zinc is associated with burning and is much more rapid in onset. Apparently some of these cases had features suggestive of zinc-caused anosmia.
Further, it has already been described in the literature that decreased smell (hyposmia) or loss of smell (anosmia) can result from the intranasal use of zinc.
There is some evidence that zinc preparations may reduce the severity or duration of the common cold if used within 24 hours of onset. This review of the literature concludes:
Clinical trial data support the value of zinc in reducing the duration and severity of symptoms of the common cold when administered within 24 hours of the onset of common cold symptoms. Additional clinical and laboratory evaluations are warranted to further define the role of ionic zinc for the prevention and treatment of the common cold and to elucidate the biochemical mechanisms through which zinc exerts its symptom-relieving effects.
Therefore, intranasal zinc products may have a modest effect in reducing the symptoms of a cold, but come with the risk of permanent damage to the sense of smell. Since the common cold is a self-limited illness that typically lasts about 7 days, this would not seem to be a favorable risk vs benefit ratio.
How, then, did these Zicam products make it onto the market in the first place?
The FDA regulates, among other things, drugs. They require adequate evidence for both safety and effectiveness before a drug can be placed on the market and sold to consumers. They also determine the level of regulation for each drug – can it be sold over the counter, with prescription only, and it is a controlled substance, like a narcotic.
There are two important exceptions to this general rule. The first is an exception that was carved out for homeopathic products in 1938. The FDA states:
The Federal Food, Drug, and Cosmetic Act (the Act) recognizes as official the drugs and standards in the Homeopathic Pharmacopeia of the United States and its supplements (Sections 201 (g)(1) and 501 (b), respectively). Until recently, homeopathic drugs have been marketed on a limited scale by a few manufacturers who have been in business for many years and have predominantly served the needs of a limited number of licensed practitioners. In conjunction with this, homeopathic drug products historically have borne little or no labeling for the consumer.
Homeopathy was much more popular early in the 20th century in the US, and the homeopathic lobby was sufficient to gain legitimacy under the FDA. Specifically, Senator Royal Copeland of New York, a physician trained in homeopathy and a principal author of the FDCA, pushed for the inclusion of homeopathy as approved drugs. Homeopathic remedies are classified as “drugs” by the FDA, which means they fall under FDA oversight, but at the same time they are granted automatic approval as long as they appear in the Homeopathic Pharmacopeia.
What this means is that the Homeopathic Pharmacopoeia Convention of the United State, the non-governmental agency that writes the homeopathic pharmacopoeia, only has to add an agent to their list and it is granted automatic FDA approval.
Homeopathic remedies are typically diluted beyond the point where any active ingredient remains. Therefore, in practice there is no difference between any one homeopathic preparation and any other – or just plain water. (Here is a recent overview I wrote about homeopathy.)
The biggest problem with this regulation is that it amounts to official government recognition of pseudoscience. The FDCA should be amended to remove homeopathy completely.
But there is also a problem with definition. While most homeopathic remedies are diluted to the point that they are indistinguishable from water, that is not a requirement. Lesser dilutions may contain small amounts of active ingredient. If a “homeopathic remedy” contains a biological active amount of a drug as an active ingredient, is it not a regular drug?
This is relevant to Zicam because these products are regulated as homeopathic drugs – which means they were allowed on the market without having to provide any evidence for safety or efficacy.The homeopathic exception allowed the manufacturer to simply bypass the usual requirements, even though Zicam is not really homeopathic but contains biologically active levels of zinc.
But because homeopathic remedies do fall under FDA regulation the FDA has the power to decide that a product poses a safety risk to the public and therefore can demand evidence for safety. In this case the FDA has requested that Matrixx Initiatives “submit a new drug application to demonstrate safety and efficacy.” (I confirmed this over e-mail with the FDA.)
The second exception to the FDA regulation of drugs was created by the Dietary Supplement Health and Education Act of 1994 (DSHEA). This law allows botanical drugs to be sold as supplements, with no requirement to prove safety or efficacy. While with products marketed as homeopathic “drugs” the FDA can step in if they feel there is a safety concern, with supplements under DSHEA the FDA bears a high burden of proof to show that a product is harmful before it can take action. So far it has only done this for one ingredient – ephedra.
Here, too, we see a significant problem with definition. Why is a botanical drug or herb regulated like food rather than a drug?
A more science-based regulatory system would eliminate homeopathic agents altogether. They are a relic from the past. Further, any substance meant to be consumed or taken internally for its pharmacological activity is a drug and should be regulated like a drug. This could still leave room for subcategories of drugs, as we have now (for example, over the counter vs prescription only). But regulating herbal drugs as food has only opened the flood-gates for dubious products with even more dubious claims.

   What does a new drug cost?
Scott Gavura
Link
Despite the variety of health systems across hundreds of different countries, one feature is near-universal: We all depend on private industry to commercialize and market drug products. And because drugs are such an integral part of our health care system, that industry is generally heavily regulated. Yet despite this regulation, little is publicly known about drug development costs. But aggregate research and development (R&D) data are available, and the pharmaceutical industry spends billions per year.
A huge challenge facing consumers, insurers, and governments worldwide are the acquisition costs of drugs. On this point, the pharmaceutical industry makes a consistent argument: This is a risky business, and it costs a lot to bring a new drug to market. According to PhRMA, the U.S. pharmaceutical industry’s advocacy group, it cost $1.3 billion (in 2005 dollars) to bring a new drug to market. The industry argues that high acquisition costs are necessary to support the multi-year R&D investment, and considerable risks, in to meet the regulatory requirements demanded for new drugs.
But what goes into this $1.3 billion figure? To understand the cost of a new drug, we need to consider both the cost of drugs that were marketed, but also factor in the costs of the failures – those discontinued during development. While most pharmaceutical companies are publicly held, no company produces detailed breakdowns of “per marketed drug” R&D costs, or the specific amounts spent on drugs that were later abandoned. Yet there have been attempts to estimate these values. The most detailed and perhaps controversial paper is a 2003 paper from DiMasi et al, entitled, The Price of Innovation: New Estimates of Drug Development Costs.[PDF] DiMasi’s estimates has been subject to considerable criticism, most recently in a paper by Light and Warburton, entitled Demythologizing the high costs of pharmaceutical research. They claim the median R&D cost is a fraction of DiMasi’s estimate: Just $43.4 million. “Big Pharma lies about R&D to justify illicit profits” shouted Natural News. Who’s right?
Drug Development
Drugs can be developed in different ways, but the usual model used describes a series of phases. The pre-clinical development stage constitutes preliminary studies of chemicals that have been synthesized or isolated, and are then screened. This process can take years: Identifying promising leads, validating them, tweaking with their chemical structures, and conducting endless in vitro studies. Only a fraction of drugs that show promise in pre-clinical studies will every progress to clinical trials. Clinical trials are generally grouped into three stages, each one representing an important milestone in a drug’s development. Phase I studies are small studies in healthy volunteers designed to help understand the basic pharmacology and pharmacokinetics in humans: how a drug is absorbed, distributed, metabolized, and eliminated. It’s in Phase II that the drug is tested in groups with the condition of interest. These trials are larger, and may be randomized, with multiple arms, possibly evaluating different dosing regimens. Endpoints are usually related to basic efficacy and safety parameters. Phase III studies are the largest studies, that may be randomized and double-blind, in order to establish a drug’s efficacy against a given condition. Regulators like the FDA will usually require one or more Phase III trials to support an approval to market a drug. In cases where real outcomes need to be measured (like mortality or morbidity), phase III studies can be massive. (Like this one, with over 18,000 participants!).
While the trial pathway is usually illustrated as a straight-line path, that’s a post hoc view: A tree may be a more appropriate model. Clinical trials may be conducted in different doses, treating different patient groups, using different protocols, in order to understand a drug’s effectiveness.
At any one time, multiple drugs may be in development, so only the most promising products may move forward in the development pathway, as subsequent phases of development mean a significant increase in costs. A drug’s development can be discontinued at any point along the path. Developers may identify toxicity issues, or lack of effectiveness issues. Or clinical practice may change, and all of a sudden, the clinical trials are measuring the wrong endpoints in the wrong patients. Decisions are always made in the face of uncertain evidence about efficacy and toxicity, and for every drug that moves forward that is eventually found to fail, it could be that there is an effective drug that didn’t reveal itself as promising, and went back on the shelf.
The development process is laborious and typically takes several years from discovery to clinical trials. The pharmaceutical industry estimates that it takes 10,000 molecules developed to bring a single drug to market. Without validating that number (a whole other post), it’s fair to say that the number of drugs that make it to market is a tiny fraction of the number of products identified or synthesized that enter initial screening. So there will be a substantial investment into drugs that never make it to market. Without including the cost of abandoned drugs into the costs of drugs that are marketed, we’d be underestimating the investment incurred. So any analysis needs to consider this cost, too.
The DiMasi Paper
The DiMasi paper, from the Tufts Center for the Study of Drug Development is the most widely cited paper on drug development costs. While the methodology they use is described in detail, some essential information is unfortunately (though perhaps understandably) opaque. The authors used a sample of drug costs drawn from ten companies that volunteered (out of 24 that were asked) that were willing to provide R&D data on a per-chemical basis. Data were collected, and stratified by development phase. Only the costs of self-originated drugs (i.e., they developed the drug themselves) were included. In total, data on 68 products were collected, and the sample consisted of mostly small-molecule drugs, but also included four recombinant proteins, two monoclonal antibodies, and one vaccine. No further information is provided, so there’s no way to know just how representative this sample is.
The methodology for the different calculations is fairly well detailed, but as I noted, the underlying data are not provided. Whether this basket of drugs studied represents a fair measure of the market is impossible to determine. The authors compiled actual costs wherever possible, broken down by development phase. A notable exception is the “preclinical” development period where it’s difficult to draw a direct link between expenditures and a specific drug that ends up being commercialized. For this segment, they inferred, using their own database, costs of $121 million per approved new drug.
To account for the costs of drugs that were abandoned (for any reason) during development, the authors used their own database of investigational drugs to estimate the odds any given new drug would reach a particular development milestone. Setting aside a detailed analysis of the methodology, let’s look at the two biggest cost drivers of the final that have been subject to repeated criticism: Tax issues, and the cost of capital.
Tax Issues
A major criticism of the DiMasi paper has been that the preferential taxation provisions for R&D expenses have not been factored into the analysis. Essentially, if R&D costs are given preferential tax treatment, this should reduce the net cost of R&D to the company. I have no particular insight into this issue other than to flag it as one that has caused controversy. Given preferential treatment of R&D expenses isn’t unique to the pharmaceutical sector, the extent to which this biases the validity of this particular analysis isn’t clear to me. But I’m a pharmacist, not a tax expert.
The Cost of Capital
Probably the biggest criticism of the DiMasi paper is that the authors factor in what’s called the cost of capital into the development cost. Looking at the calculations, DiMasi estimated the out-of-pocket costs per new drug at $403 million (2000 dollars). But this is then capitalized, based on the opportunity cost of that investment – at 11%, bringing the “total” cost up to $802 million. Adjusting this cost to 2005 dollars, and we’re at the $1.3 billion that PhRMA is calling “the average cost to develop one new drug.
The cost of capital can be a bit baffling to understand. If I’m going to invest my money in something now, with a possible payoff down the road, I need to factor in the opportunity cost of something else I could have invested in – but decided not to. It is a true cost, because by choosing to invest in one thing, you’re forgoing the investment in another.
DiMasi uses a cost of capital of 11% – that is, they assumed that the drug developers, by moving forward with the development of a drug, where forgoing investments which would be expected to yield 11%. Is 11% valid? From a personal investment perspective, 11% seems rich. But the cost of capital that companies use is dependent on the risk involved. Different industries have different business risks. The DiMasi paper bases the 11% estimate based (in part) on historic returns in the industry. Given that half of the reported “cost” of a new drug is based on the cost of capital, the value we use use has a massive influence on what the final “cost” of a new drug will be. But is 11% appropriate? Many argue no – that current returns don’t match past returns, and therefore the CoC should be lower. I took a look at a cost of capital table created by Aswath Damodaran, a Professor of Finance at the Stern School of Business at New York University. He calculates that pharma’s cost of capital is 8.59%. But there is no single “right” answer here. It’s an assumption that goes into our calculation.
Other Reviews
Other authors have made their own attempt at estimating the cost of a new drug. Paul Adams of the Federal Trade Commission, writing in Health Economics estimates that the DiMasi estimate is low, and the 2003 cost is closer to $1 billion per new drug, but noted there is significant variation between products. A 2006 Congressional Budget Office report on drug development [PDF] largely supports the DiMasi estimates. Most recently, Light and Warburton argued that, “based on independent sources and reasonable arguments, R&D costs companies a median of $43.4 million per new drug, just as company supported analysts can conclude they are over 18 times larger, or $802 million.” This figure seems implausibly small, given a single clinical trial can involve hundreds to thousands of patients. (For a more detailed critique of the Light and Warburton paper, I’ll refer the interested reader to Derek Lowe’s excellent In the Pipeline blog (and its comments) where it was dissected in detail here and here.) One of the best ways to contemplate the costs and calculations is to manipulate the numbers yourself: There’s a model developed by venture capitalist Bruce Booth, where you can enter your own estimates and see what cost it spits out. I tried working with the model for a while, and I couldn’t get it anywhere near $43 million – it was always in the hundreds of millions.
Other considerations
One important factor that isn’t considered in any of these analyses (from what I can see) are the costs of new indications for existing chemical entities. Consider the case of cancer drugs, where drugs are often approved for the treatment of metastatic disease, and only after efficacy is demonstrated, is it studied as a potential “adjuvant” treatment for early stages of disease. Additionally, the DiMasi analysis only looked at drugs developed solely in-house. Given the growing role of smaller biotech companies that develop, and then sell, promising drugs to pharmaceutical companies, the impact on costs isn’t clear. In contrast, the cost of the “me-too” drugs that seem to fill the pharmaceutical marketplace aren’t discussed explicitly, either. When your new drug is a variation on a competitor’s (or your own) product, how does this influence overall R&D expense? Again, it’s not clear.
Conclusion
Is the $1.3 billion new drug a myth? New drugs could be hitting, or even exceeding this mark – it depends on what your assumptions are. When we try to summarize all the variables of drug development into a single number, accounting for the hits and the misses, we can end up with a number that sounds impressive. But is it meaningful? Without transparency, only the manufacturer will know what it cost for their own drugs. It’s probably more important to understand the key drivers of R&D costs, noting that there are a huge number of variables that may influence the final cost of bringing a new drug to market.

   Chelation: Compounding Pharmacy’s Problems
Scott Gavura
Link
Chelation is the provision of a substance to increase the body’s excretion of heavy metals. In poisoning situations (lead, aluminum, iron, etc.), chelation is medically necessary, objectively effective, and approved for use. But the same term has a completely different meaning in the alternative medicine universe, where proponents often believe heavy metal toxicity is the “one true cause” of disease, and chelation can undo microvascular inflammation, atherosclerosis, and even aging itself. From early days as an unproven treatment of coronary artery disease, its use has expanded to include autism, Alzheimer’s disease, cancer, and dozens of other diseases. Today, chelation is widely available. Regrettably, my own profession, pharmacy, facilitates this pseudoscience by manufacturing and selling chelation products.
Provoked urine tests are a common entry point to chelation therapy. Patients are given a product to provoke heavy metal excretion. The urine is tested and the patient is informed that they’re “toxic” and require chelation. Unfortunately, these results are meaningless and provide no evidence that chelation is medically necessary. But that’s the justification used for advocating a treatment regimen that will be useless at best and fatal at worst. A recent Medical Letter review concluded:
Medical Letter consultants believe that the use of chelation therapy in non-standard protocols for unsubstantiated indications should be discouraged. The results of provoked urine testing are not an acceptable basis for such treatment.
Providing chelation to patients isn’t a straightforward matter. It’s typically an intravenous infusion (though there are some oral products). Unless you’re part of the dubious TACT trial, which has administration centres across the United States and Canada, there are few products commercially available. For example, edetate calcium disodium (EDTA) is approved for sale in the United States but not Canada. Edetate disodium (also called EDTA) is not approved for sale in either country. But these products are widely available: they’re manufactured by pharmacists in pharmacies.
Not that many decades ago, almost all prescriptions were custom manufactured, or compounded. The pharmacist combined raw chemicals into dosage forms like capsules, tablets, liquids and creams. Compounding allows complete customization of a prescription — from a new strength of a capsule, to a liquid form of a tablet, to creams with combinations of ingredients that can be completely individualized. With the proper equipment, even sterile injectables can be made.
These days, commercial manufacturers supply most drug products, and the need for in-pharmacy compounding has dwindled. At the same time, regulatory oversight, by agencies like Health Canada and the FDA, ensure product uniformity, purity, potency, efficacy, and safety standards for consumers. However, any pharmacy is still capable of providing compounded prescriptions, and some specialize, calling themselves “compounding pharmacies” and aggressively promoting the service. In compounding pharmacies, the same level of regulatory oversight and scrutiny does not exist. Professional Compounding Centers of America, provides training, formulations (recipes), and raw ingredients to compounding pharmacies. To pharmacies and pharmacists, compounding is a business opportunity, and an ideal way for independent pharmacies to compete against large chain stores, which typically do not offer these services.
The relationship between compounding pharmacies that prepare chelation treatments, and the practitioners that prescribe these products, is a symbiotic one — each group needs the other to offer these treatments. Consider this article in a pharmacy publication, entitled, Chelation for Antiaging: The Pharmacist’s Role, which touts the benefits of chelation:
Removing toxic metals from the body is one of the most important antiaging therapies available. The results from many scientific studies indicate that an increased accumulation (body burden) of toxic metals—such as mercury, lead, cadmium, and arsenic—increases the risk for common diseases, including cancer, cardiovascular disease, diabetes, Alzheimer’s disease, and attention-deficit/ hyperactivity disorder.
And:
Serious toxic-metal problems must be managed by an experienced physician. It is becoming increasingly recognized, however, that virtually everyone has a chronic accumulation of toxic metals in the body, which contributes to health problems and accelerates the aging process. Pharmacists who take the time to become knowledgeable about the correct use of OTC detoxification products can provide a much-needed service. At the same time, guiding customers on detoxification protocols also can become a new source of income for pharmacists who charge for their consultation time.
It’s a huge, burgeoning, evidence-free marketplace that pharmacies have stepped in to fill. College Pharmacy in Colorado has a “Hot List” of chelation protocols including the DAN! protocol — all of which can be ordered. Dallas-based ApothéCure offers a huge list of intravenous chelation options. Quantum Pharmacy in San Francisco touts a long list of benefits from EDTA infusions. Smith’s Pharmacy in Toronto offers chelation among a number of biomedical treatments for autism.
If there’s no evidence to support its use, why the persistent interest in chelation? Despite anecdotal evidence of success, my sense is chelation is simply another manifestation of sympathetic magic: specifically, contagious magic. Patients remove these non-existent “toxins” and become “cleansed” through a sciencey-looking purification ritual that is repeated dozens of times. With no objective measurement of efficacy, protocols and treatment measurements vary widely, but typically lack a defined endpoint. According to the Medical Letter, regimens of 20-50 infusions are common, at costs of $100-$300 per treatment.
Regulators have had difficulty finding a balance between allowing the legitimate practice of individualized compounding of products to meet unique patient needs, and the desire to limit pharmacy compounding as a workaround to prepare products that are pointedly not approved for use, or are used as a means of commercially selling products that require FDA evaluation and approval for sale. The FDA has taken action against a number of pharmacies who have been alleged to contravene federal food and drug regulations. There’s been little action from pharmacy regulators themselves against these practices.
Unfortunately for patients, a network of pharmacies continues to facilitate the provision of compounded chelation therapies, in the absence of any persuasive evidence to support their use. That state and provincial pharmacy regulators ignore these activities is an embarrassment to the profession of pharmacy, and consumers quite literally are paying the price.

The Truth vs. Alex Jones: How the DSHEA of 1994 gave conspiracy mongers the means to fund their empires
As the HBO documentary The Truth vs. Alex Jones shows, Alex Jones promoted the conspiracy theory that the Sandy Hook massacre was a hoax to sell his supplement line. It’s a model that many Internet conspiracy theorists use, like Mike Adams. Did the DSHEA help create Alex Jones and the modern conspiracy industry?
David Gorski on April 1, 2024
Link

Last week, HBO released a rather intense documentary, The Truth vs. Alex Jones, that documents how the king of conspiracy theorists Alex Jones promoted the lie that the mass shooting at Sandy Hook Elementary School was a hoax, a false flag operation designed to provide a pretext for liberals and the government to take away Americans’ guns. Jones’ decade-long promotion of this conspiracy theory, which involved attacking parents whose children had been gunned down as “actors” and “fake” while claiming that their children never died, ended up in his losing two defamation suits, the judgment against him from one of them being the largest single defamation judgment in American history. You might wonder why I would be writing about this documentary and Alex Jones, given that the main topic of the film is a conspiracy theory not related to medicine. However, I suspect that a lot of you know that one of the major ways that Jones funds his online empire is through the sale of supplements, as was so clearly demonstrated by the filmmaker.
As I watched in horror, anger, frustration, and some relief when the parents finally won their defamation judgments, an odd thought popped to mind: The Dietary Health and Supplement Education Act of 1994 (DSHEA of 1994, which we’ve written about many times) was one thing in addition to the Internet that had made Alex Jones possible. Indeed, it made a whole online ecosystem of misinformation, disinformation, and conspiracy theories possible by providing a revenue stream that conspiracy mongers like Jones could use to fund their activities and then business empire. Let me explain.
The Truth vs. Alex Jones: One of the best documentaries I’ve ever seen
Before I discuss supplements, however, let me just say one thing. If you have HBO or Max, watch The Truth vs. Alex Jones. It is one of the best documentaries that I have ever seen. I will concede, however, that it is at times a very hard watch. It is, however, a necessary watch, at least in my opinion. For example, only 15 minutes into the film there is a segment in which Daniel Jewess, a now-retired Connecticut State Police detective who served as lead investigator for the shooting, spends six agonizing minutes of screen time explaining over photos of relevant parts of the school and interspersed with 911 calls exactly what, as far as the investigation could piece together, happened and when. He presented a detailed reconstructed timeline of how the shooter went from one classroom (Room 10) to another (Room 8) killing teachers and students (26 in all, 20 children and six adult teachers and staff), finishing with a massacre in a small restroom packed with children, where one class’s substitute teacher had told them, after which he committed suicide—all in around six minutes. Particularly moving is how Jewess says the name of each and every child and staff member killed. This segment was preceded by interviews with parents, who related what they did with their children that morning before dropping them off at school, all noting that that was the last time they had seen their children alive. Remember, these children were all between six and seven years old.
So, yes. It’s a very hard watch.
Contributing to this are segments showing the parents describing their experiences after the shooting, how the brutal murder of their child had affected their lives, and how Alex Jones’s decade-long promotion of conspiracy theories that the Sandy Hook shooting had never really happened, that it was a false flag designed to be used as a pretext to allow the government to take away the guns of patriotic Americans, and how the parents were crisis actors lying about what happened and their children either never existed or had not died had upended their lives with threats and intermittent terror. It was a campaign that began, as one lawyer for the parents who brought defamation suits against Jones, noted, “before the bodies were even cold,” less than three hours after the massacre, with Jones ramping up over the next few days:
The parents sob and whimper as they quietly talk about seeing their children, who are riddled with gunshots, cold, and distorted, and with fragments from their teachers’ body parts, who attempted to shield the kids from being shot. There’s around 20 minutes of heart-wrenching recollection of the tragedy, undercut directly after by Jones, who begins to claim that the shooting was “staged” the same day as those 26 souls’ lives were cut short. Robbie Parker, the father of slain six-year-old Emilie Parker, says he just wanted to be left alone by the media and particularly Jones, so he assembled a press conference. “I had just wanted to share something about who my daughter was,” Parker says in an interview. But as soon as the press conference wrapped, Jones and his team labeled Parker a crisis actor. This resulted in dozens and dozens of threats on Emilie’s memorial page on Facebook, calling the child a “whore” and claiming she was still alive.
Why did Jones label Parker a “crisis actor”? As Parker also explains in the interview, he was incredibly nervous right before the press conference and, as a result, had laughed nervously right before approaching the microphone. Throughout the rest of the movie, it’s shown how Jones keeps cutting to that nervous laugh, after which Parker became somber, mocking him viciously time and time again with those exaggerated fake sobs that he likes to employ for being an “actor” who, noticing the camera, had suddenly gotten back “into character.” This vile mockery pops up time and time again, as Jones repeated this mockery many times over the next decade.
In another harrowing narrative, Neil Heslin describes how he had cradled the cold body of his son Jesse Lewis one final time and seen the gunshot wound to the forehead that had killed him. Almost immediately after the original press interview in which Heslin had described this, Jones pounced, claiming that, according to the timeline he had assembled, this was not possible, demanding that Heslin explain himself and/or admit that he was lying.
As this review of the documentary notes:
This went on for 10 years. It’s still going on. Every time Jones aired another hoaxer theory, these grieving families would be hit with a fresh wave of vicious harassment: rape threats, death threats, people confronting them on the street. In the film, another mother, Jacqueline Barden, testifies in court that she and her husband received letters from people who said they’d peed on their son Daniel’s grave, or promised to dig it up, because they were convinced no one was in it. Yet another, Francine Wheeler, tells of how she was in an elevator at a conference for mothers who’d lost their children to gun violence when a woman told her that the mass shooting that killed her son Ben never happened.
“It’s just a drip, drip, drip of constant undermining of your feeling of safety and security while you’re trying to grieve for your 6-year-old child who was murdered unexpectedly in the classroom,” says director Dan Reed. “The cumulative harm is really I hope what comes out of the film.”
One of the parents noted in the film that he could always tell when Jones had aired a new Sandy Hook segment, because they would notice a large uptick in harassment and threats by Jones’ fans.
Nor does the film spare Jones’ conspirators, people whom he used as “sources” for his conspiracy theory. For example, the filmmakers include an interview with Wolfgang Halbig, one of Jones’ go-to “experts,” who kept claiming that the shooting had been staged based on anomaly hunting. For instance, one version of a video interview with one of the parents by Anderson Cooper had a moment where his nose seemed to disappear, which Halving and Jones claimed to have been due to the use of green screen. (The film notes that the copy on the CNN website does not have that video glitch.) One of Halvig’s other reasons was particularly bizarre, namely that they had not brought in helicopters to airlift the wounded out. He seemed blissfully unaware that it very rapidly appeared that there were no survivors. In fact, it turned out that there was only one survivor in the bathroom who, miraculously, had not been hit when Lanza sprayed bullets into the enclosed space, and had survived by playing dead. He also wondered why paramedics didn’t go inside the school, when in fact they had just as soon as the police had determined that Lanza was dead and there were no other shooters. (Jewess mentions talking to the chief paramedic on the scene.) Halbig is quite the nasty bit of work, too, having been arrested for possessing someone else’s identification information after he had repeatedly emailed several people and law enforcement agencies the Social Security number, birth date and other information of Leonard Pozner, whose 6-year-old son, Noah, died at Sandy Hook.
I could go on, but watch the film. I’ll just add that the difficulty in watching some of the segments is more than made up for by the deposition and courtroom footage of Alex Jones’ testimony, where, not controlling the venue and not being on his show, he alternately lied, raged, and conspiracy mongered, obviously very uncomfortable and distressed. There’s one particularly satisfying scene in which the plaintiff’s attorney confronts him on the witness stand with text messages erroneously sent by the defense attorneys that demonstrated quite clearly that Jones had lied about being bankrupt, about the revenue stream to his company, and about not having discussed Sandy Hook. Through it all, clips of Jones ranting about how both trials were “show trials” by a “kangaroo court” and how the whole thing had been scripted from the beginning play, even as both judges for the two cases end up making a summary judgment against Jones and his company, because he had failed to cooperate with discovery, even, as they characterized it, making a mockery of the process. Less satisfying was watching the final huge verdict being read down, because Jones live streamed the proceedings with him in a side box mocking the verdict and claiming he wouldn’t pay because he didn’t have any money. Worse, Jones might be right, as the final black screen included text saying how, as of March 2024, Jones had not yet paid any of the nearly $1.5 billion awarded by juries in the two states (Texas and Connecticut) to the families and was still doing his show. Also particularly disturbing was the oft-cited statistic that nearly one-quarter of Americans either deny or doubt that Sandy Hook happened, largely thanks to Alex Jones.
If there’s one thing that The Truth vs. Alex Jones demonstrates, unfortunately, it’s that the hopes of the parents for their verdict to usher in an “era of truth” was incredibly naive. I wish it were otherwise.
The DSHEA as a mechanism for funding disinformation
Regular longtime readers will likely know that we have been describing how bad a law the DSHEA is dating back to 2008, with guest contributor Dr. Peter Lipson once describing it as a “travesty of a mockery of a sham.” The DSHEA is, after all, a law pushed through by a bipartisan group of quack-friendly legislators, including Democratic Senator Tom Harkin (who was responsible for getting the National Center for Complementary and Alternative Medicine, now known as the National Center for Complementary and Integrative Health, created and funded as part of the NIH) and Republican Sen. Orrin Hatch, whose home state of Utah has become the supplement manufacturing capital of the US and who was through his entire career before his retirement a pit bull in defense of his home state supplement industry.
Because it’s been a while since we’ve discussed the DSHEA, I’ll just remind you what it does and why it’s such a bad law. Basically, as Peter Lipson described back in 2009:
DSHEA has a couple of very important consequences (aside from filling the pockets of supplement makers).
What does the FDA require of “supplements”?
Under the Dietary Supplement Health and Education Act of 1994 (DSHEA), the dietary supplement manufacturer is responsible for ensuring that a dietary supplement is safe before it is marketed. FDA is responsible for taking action against any unsafe dietary supplement product after it reaches the market. Generally, manufacturers do not need to register their products with FDA nor get FDA approval before producing or selling dietary supplements.* Manufacturers must make sure that product label information is truthful and not misleading.
To paraphrase: “sell whatever you want, just don’t let us catch you.”
What’s more frightening than this inexcusable lack of oversight is that many of the products marketed under DSHEA aren’t just vitamins and such, but products that claim to do the same things as real medicines. How do they get away with that?
There is a bit of a loophole. Supplement sellers can’t make specific claims that the supplement being sold can treat or prevent any disease. Moreover, when a supplement is marketed it’s more or less the honor system. No registration with the FDA is required. After all, supplements are food, not medicine! In effect, the government can’t really do anything unless problems are reported after the supplement is marketed. Even worse, the definition of “supplement” has become very broad, as Quackwatch points out:
DSHEA worsened this situation by increasing the amount of misinformation that can be directlytransmitted to prospective customers. It also expanded the types of products that could be marketed as “supplements.” The most logical definition of “dietary supplement” would be something that supplies one or more essential nutrients missing from the diet. DSHEA went far beyond this to include vitamins; minerals; herbs or other botanicals; amino acids; other dietary substances to supplement the diet by increasing dietary intake; and any concentrate, metabolite, constituent, extract, or combination of any such ingredients. Although many such products (particularly herbs) are marketed for their alleged preventive or therapeutic effects, the 1994 law has made it difficult or impossible for the FDA to regulate them as drugs. Since its passage, even hormones, such as DHEA and melatonin, are being hawked as supplements.
In other words, under the DSHEA, substances that are clearly not foods can be marketed as supplements, including herbs and other botanicals (the vast majority of which are marketed as having a beneficial medicinal effect and some of which contain chemicals that do act as drugs). As long as the manufacturer is careful not to make specific health claims, it’s all good. In other words, a “nutritional support” statement claimed for a supplement must not be a “drug” claim; i.e., it must not claim that the supplement can be used for the treatment or prevention of a disease. Supplement manufacturers easily evade this requirement by making vaguer claims related to organs or systems, such as claiming that a product “boosts the immune system,” “supports heart health,” or something similar, often accompanied by what Dr. Lipson has sarcastically referred to as the “quack Miranda warning“:
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
At the bottom of the landing page of the InfoWars Store:
* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. If you are pregnant, nursing, taking medication, or have a medical condition, consult your physician before using this product.
* The products sold on this site are not intended for use in the cure, treatment, prevention, or mitigation of any disease, including the novel coronavirus. Any suggestion to the contrary is false and is expressly disavowed.
Sure thing, Alex. Your double Quack Miranda Warning is noted.
Color me unsurprised.
In general, it doesn’t take too much searching to find supplement advertising that does claim to treat, cure, or prevent disease. That’s why I’ve argued before that the DSHEA was the greatest boon to supplement manufacturers ever. In its wake, the supplement industry exploded, racking up huge increases in sales. Moreover, so lax is the regulation of supplements that I like to point to one example of an extreme and egregious act, namely the marketing of an industrial chelator as an “antioxidant” supplement for the treatment of autism, that went on for quite some time before the FDA finally acted. Over the years, supporters of science-based medicine and sound public policy have made efforts to repeal the DSHEA or, failing that, to reform it to make it less of an enabler of grifting quacks. All have failed.
Which brings us back to Alex Jones.
I know that I’ve argued that all antivaccine misinformation (which Alex Jones also spreads but was not discussed in the film) and quackery (again, also promoted by Alex Jones but not discussed in the film much) are, like all science denial, at their core conspiracy theories. I’ve discussed, for example, the central conspiracy theory of the antivaccine movement, which posits that vaccines are dangerous and promoted for nefarious reasons (e.g., profit, control), but that “they” (the CDC, doctors, big pharma) are covering up the evidence. Similarly, all science denial takes the same form, namely that the science being denied (e.g., evolution, oncology) is accepted for nefarious reasons and all evidence showing it to be bogus is being “covered up” by powerful forces. Sandy Hook is very much the same, but what the film shows is just how integral the sale of bogus supplements was to the motivation for spreading increasingly outrageous conspiracy theories, to being the funding source for people like Alex Jones.
For example, “stories” like this:
Hook ’em with the outrageous headline and wild conspiracy story lying about how the FBI had concluded that “no one” had been killed at Sandy Hook…
And then:
Sell ’em the supplements! (Both are screenshots from The Truth vs. Alex Jones.)
InfoWars sells lots of supplements, too. One particularly effective passage involved the gang that couldn’t shoot straight, namely Jones’ defense team, again. In explaining the significance of the story above, the filmmaker notes that Jones’ lawyers had accidentally sent them attachments to emails with daily sales and revenue data. At one point, Jones is grilled on his business model, which, it had become obvious, was to sell supplements and to gin up outrage to draw viewers, some of whom would be receptive to the pitch for Jones’ line of supplements that inevitably peppered his broadcast and appeared after many segments. Indeed, after the story in the screenshot above above ran, according to the sales figures mistakenly sent to the plaintiffs’ attorneys, sales from the InfoWars supplement store immediately more than quadrupled. (See screenshot below.) One lawyer even asked, “InfoWars is actually an infomercial, right?”
The story ran on September 24, 2014. Notice how supplement sales nearly quintupled on September 25, 2014.
Make no mistake, Alex Jones sells a lot of supplements. Indeed, at one point on the stand, Jones is shown bragging about how he has the best supplements, the purest supplements, all made in Japan by experts and branded with his company. In fact, I laughed out loud when I saw that he was selling colloidal silver, of all things! There are also shots of him hawking iodine supplements after the Fukushima nuclear power plant disaster in Japan and promoting his DNA Force supplements. Just for yucks, I checked out the InfoWars Store yesterday, and, no surprise, Jones is selling lots and lots of supplements, ranging from Turbo Force Plus (which contains vitamin C, thiamine, green tea extract, and a number of other common supplements) to Brain Force Ultra (which contains a proprietary mix of ingredients including green tea leaves, ginkgo, and other herbs), and, perhaps my favorite, DNA Force Plus, which claims to “boost your body’s cellular engines” and contains CoQ10, rhodiola root extract, and a number of other ingredients. There’s a whole line of supplements under the names InfoWars Life, InfoWars MD, InfoWars Platinum, Emric’s Essentials, Dr. Jones’ Naturals (it’s not clear to me who Dr. Jones is, unless it’s referring to Alex), Summit News, and, of course, a line of cannabis products under the name Rebel Zen CBD. Unsurprisingly, he also sells prepper supplies, books, and videos.
All of this led me to wonder: Without the DSHEA, would there be an Alex Jones? Maybe, but I have my doubts. It is certainly possible that a grifting pathological liar as skillful as Jones is would be able to identify something else to sell as profitable as supplements to support his online media empire, but I doubt it. The attraction to conspiracy theories among those predisposed to purchase colloidal silver, for instance, is strong, and Jones knows that by supplying all manner of conspiracy theories, be they Sandy Hook, antivaccine, COVID-19-related, or about the “failure” of conventional medicine and how quackery works, he will attract such people, some of whom will be predisposed to his sales pitches for his supplements.
Worse, he is not the only—or even first—one to use supplements to become rich promoting conspiracy theories. Mike Adams, whom I sometimes think of a protege turned competitor of Alex Jones’ given his past work for Jones, also sells supplements and prepper supplies. I sometimes think that Adams has surpassed the master as well, in that he has weaponized a mass spectrometer to study his competitors’ products and proclaim them full of heavy metal contaminants, using his results to persuade you to buy his line of supplements. He also uses the same mass spectrometer to fear monger about vaccines by finding trace amounts of mercury in influenza vaccines, for example. Back in the late 1990s, well before Adams and Jones (and when Adams was grifting on the Y2K scare), Joe Mercola started a supplement store to fund his server charges running his website, a business that ballooned over the following two decades to turn him into a quack tycoon, with a net worth now north of $100 million.
Unfortunately, in the age of COVID-19, conspiracists like Adams, Mercola, and Jones now have many who emulate their business model, such as Dr. Peter McCullough and those running The Wellness Company, which promotes COVID-19 conspiracy theories and sells quackery to treat both COVID-19 and “vaccine injury” due to spike protein from the mRNA vaccines. A prime example includes Drs. Pierre Kory and Paul Marik, among the co-founders of the Frontline COVID-19 Critical Care (FLCCC) Alliance, which uses COVID-19 misinformation and conspiracy theories to sell ivermectin and various supplements claiming to prevent or treat COVID-19 or COVID-19 vaccine injury—and now even cancer. (Do you sense a theme yet?) The list goes on and on. Let’s put it this way. Whenever I see a new conspiracy site, I look for the supplement story. It’s usually there, and if it isn’t I can usually count on seeing one before too long, with the only major exception that I’ve found thus far being Robert F. Kennedy, Jr.’s Children’s Health Defense, which sells mainly branded T-shirts, hats, and other clothing. Maybe it’s because he’s running for President.
I’ll conclude by revisiting my question: Did the DSHEA create Alex Jones and the whole infrastructure of conspiracy theories, disinformation, and lies, an ecosystem in which he is still probably the biggest, baddest conspiracy theorist out there? In answering the question, I have to conceded that “create” is likely too strong a word. However, certainly “facilitate” is not. That’s why I feel comfortable concluding that, absent the massive supplement industry fueled by pseudoscience and conspiracy theories, Alex Jones and his ilk almost certainly would have had a much more difficult time funding their activities, much less growing to the behemoths of misinformation that threaten science-based medicine and even democracy itself. In that, the damage from the DSHEA goes beyond just its damage to medicine and the harms that it allows supplement manufacturers to cause its users to encompass damage of the sort to the parents and relatives of those killed at Sandy Hook by the conspiracy theories spread by Alex Jones.

Pandemic drives huge surge in herbal remedy sales
The COVID-19 pandemic has fueled a boom in herbal supplement sales.
Scott Gavura on November 11, 2021
Link

You may or may not have noticed that I stepped away from blogging a few months back, though it feels like longer to me. I want to express my appreciation to the David Gorski and Steven Novella for their understanding, and to Dr. Jonathan Howard for stepping in while I was away. I’ve learned a lot from Dr. Howard’s posts, and I hope you’ve appreciated his writing, too. They’ve been saying blogging is dead or dying for over a decade, but I’m thrilled to be back making my modest contribution to SBM’s Sisyphean mission and keeping science and medicine blogging alive.
– Scott
For more than a year, I felt like it was inappropriate or irrelevant to write about anything other than the pandemic, given how quickly the science was emerging and how it totally dominated all aspects of our lives. I wasn’t thinking of much else. But I’m increasingly optimistic that we are on our way out. Notwithstanding new variants, breakthrough infections, and the inevitable antivaxxer tears, it’s the effectiveness of the vaccines and now the emergence of effective antivirals that makes it look like the worst of the pandemic may be behind us.
With that cautious optimism in mind, maybe it’s time to look at some of our recurring topics, such as the popularity of complementary and alternative medicine. Pre-pandemic, I probably would have guessed a global pandemic that kills millions might turn people away from unsubstantiated, unproven supplements that have limited roles in actually promoting health. I would have been terribly wrong. The pandemic created the conditions for a huge surge in demand for herbal remedies, as detailed in the 2020 American Herbal Council annual report. They recently reported that supplements made up of herbal and/or fungal ingredients had sales that exceeded $10 billion in 2020, a 17.3% increase over 2019, crushing the previous record increase of 9.4% in 2018. Let’s take a closer look at some of the highlights.
Elderberries sales surge amidst pandemic
Elderberries make me think of Monty Python, not supplements. But elder berry (or elderberry, if you prefer) was the top selling “mainstream” (food/grocery/pharmacy) supplement in 2020, with a sales surge of a whopping 150% over 2019. This ingredient has been growing in popularity for past few years, moving from 25th top selling herbal ingredient in 2015, to first place in 2020. The fruit of the European or Black elder tree, it has a long history of use in food, beverages and for medicinal purposes, where berries are used as a laxative, diuretic, and to treat respiratory infections. It is an active ingredient in supplements like Sambucol and is manufactured into a variety of lozenges and other products. The Natural Medicines Database rates elder berry as “possibly effective” for influenza but notes that a small clinical trial with adults and children showed it did not reduce the duration of symptoms. Harriet Hall blogged about it in 2019 and was perhaps a bit more optimistic than I am now. In 2020, the largest double-blind, randomized, placebo controlled study of elder berry on influenza (87 patients) was published and found no meaningful effects. The National Center for Complementary and Integrative Health says, “There’s not enough information to show whether elderberry is helpful for any other health purposes”. Perhaps not surprisingly, there is also no published evidence to suggest it is effective to prevent or treat COVD-19 infections. The Herbal Gram report notes:
Google searches for “elderberry” peaked in late March 2020, shortly after the World Health Organization declared the COVID-19 outbreak a pandemic,6 and the fifth most-common search with “elderberry” in 2020 was “elderberry coronavirus.”7 According to the US National Center for Complementary and Integrative Health (NCCIH), there were no published human clinical trials related to elder berry and COVID-19 as of July 2021,8 and the FDA sent warning letters to at least five companies in 2020 for marketing products with unsubstantiated claims involving elder berry and COVID-19.9
It is understandable that “immune health” would be a frequent reason for seeking dietary supplements in 2020, perhaps demonstrating the triumph of marketing over evidence. There are no dietary supplements that can actually boost immunity or improve resistance to, or the consequences of, COVID-19 infections. The report notes that other products that were popular in 2020 for “immune health” included echinacea, garlic, and turmeric, with all of these products experiencing sales increases.
Ashwagandha
Ashwagandha sales had a large increase (185%) in mainstream channels with $31 million in sales, putting it as the 12th best selling herb in 2020. Popularity has grown quickly over the past few years as more consumers in North America have become familiar with this product. Ashwagandha is used in the Ayurveda medical system and is touted to be an “adaptogen”, a product said to help one resist or adapt to stress. The name of the plant is Withania somnifera, which is a small shrubbery from which the roots are dried and used for medicinal purposes. Oral consumption of ashwagandha seems to be safe, and there is evidence that it does have medicinal effects. The Natural Medicines Database rates it as “possibly effective” to reduce stress and stress-related weight gain. Harriet Hall discussed ashwagandha in March 2021, and noted The Medical Letter‘s warning about the risk serious adverse events:
There is no convincing evidence that ashwagandha supplements are effective or safe for any indication; patients should be advised not to take them. FDA-approved drugs are available for treatment of all the conditions for which these herbal supplements are being promoted.
The paper quotes a survey conduced by the “Council for Responsible Nutrition” which represents dietary supplement manufacturers, with some insight into how and why consumers changed their supplement habits:
According to CRN’s 2020 COVID-19 Consumer Survey, 43% of supplement users changed their supplement routines since the beginning of the pandemic, and of those, 91% increased their supplement intake. When asked why these consumers increased their supplement intake, nearly a quarter cited mental health reasons, including stress and anxiety.
There’s no question that the pandemic has affected mental health. It’s not surprising that people sought out therapies and tried to self-medicate with supplements, particularly when health professionals may have been harder to access.
Apple cider vinegar
This supplement has admittedly always puzzled me. It’s vinegar, not magic! Yet the pandemic was the backdrop to a 100% surge in mainstream market sales over 2019, leading to an amazing $80 million in sales. ACV has been recommended as a cure-all for decades, for everything from weight loss to digestive issues (especially the ubiquitous “detox”) to the belief that it can affect blood sugars and insulin sensitivity. New to me, you can apparently get ACV in tablets, capsules and even “gummies” now. Personally, I use ACV occasionally in a salad dressing. For that purpose, it seems to be highly effective. For any medicinal or health-oriented use, research and evidence is lacking.
On the decline
Harriet Hall discussed garcinia back in 2013 when it was featured on The Dr. Oz Show. Sales through mainstream channels skyrocketed through 2015, hitting $54 million, based on his promotion of the fruit as a “magic weight loss cure”. Following multiple lawsuits, Senate hearings, and an FTC settlement with a garcinia manufacturer, sales have been steadily declining.
Another product which probably deserves its own blog post is ivy leaf supplement, which is manufactured into cold and influenza remedies. Sales of these products dropped significantly in 2020, possibly owning to the dramatic decrease in colds and influenza due the public health measures enacted to control the spread of the novel coronavirus.
Finally, another product with significant decline in sales is CBD oil, down from a peak in 2019. While it was the top selling product in the “natural” sales channel (meaning specialty supplement retailers, like GNC), sales dropped 36% over 2019, to $57 million. The report speculates on possible factors for the decline, ranging from isolation at home, the prioritization of immune health, and the quality issues with CBD in the United States market place, where many products advertised as containing CBD actually have no CBD in them. (If you’re looking for regulated, quality-controlled CBD then I invite you to come to Canada when cannabis products are not only legal, the number of retail shops seemingly has no upper limit. Just don’t try crossing the border with it.)
The pandemic affected everything, even supplement buying behavior
        ◦ The pandemic disrupted industries and forced businesses to adapt – and the herbal supplement industry is no exception. What surprised me was how much the pandemic has turned out to be a net positive for this industry. Clearly, the decades of marketing herbal remedies and dietary supplements as safe and effective has paid off, driving sales increases and demand for products with little to no evidence of efficacy. But given what we’ve seen in the pandemic in terms of demand for products like hydroxychloroquine and later ivermectin, a lack of effectiveness is no barrier to sales success.

Facebook promoting dangerous and even banned supplements
A Consumer Reports analysis found little oversight of supplements marketed by Facebook.
Scott GavuraonNovember 10, 2022
Link

I abandoned Facebook several years ago, realizing the value it offered me had gone from tolerable to terrible. While I no longer see updates from some of my childhood friends, I found it was quickly becoming a hellsite, so I deleted everything and quit. (Is anyone maintaining the Science-Based Medicine page there anymore?) Now as I watch the accelerating decline of Twitter, I’m wondering what social media is going to look like in a decade. Much as I’d like to see a blogging resurgence, the appetite for long form writing seems to have been replaced by media like TikTok. While I’m not sure what Facebook is like for users anymore, I always found the advertising was, at best, sort of sketchy. I recently found an interesting investigation into Facebook’s advertising standards. Consumer Reports examined dietary supplement advertisements appearing on the platform. Perhaps not surprisingly, it found advertisements for implausible, unproven, and even prohibited supplements. 
Facebook’s Ad Library is readily accessible and that’s where Consumer Reports started. The Library is accurately named: It’s a searchable database of every ad on Facebook. The library includes information on who created the ad, when it was published, and the ad itself. Type in a few key words and depending on where you’re located, you’ll see advertisements for diets, diabetes supplements, and more. When I tried “long COVID” I was presented with ads for cognition supplements, Ayurveda, and hyperbaric oxygen. Searching “weight loss” brings up dozens and dozens of ads.
Consumer Reports also used a tool called Citizen Browser. This is a desktop application that captures and analyzes advertisements as they are being presented to actual Facebook users. While it’s got limitations, it does give more detail on the user experience. Consumer Reports found the following products advertised:
    • Comfrey is advertised even though it’s illegal to sell in the USA owing to the potential for causing liver damage and even death.
    • Kratom is an herbal extract sold as a stimulant and pain reliever and was sold on Facebook Marketplace. There are numerous reports of death following ingestion. Following inquiries by Consumer Reports, most advertisements disappeared from Facebook.
    • Something called “Focus + Recall” promoted as a brain supplement was targeted at users as young as 18 years old, as well as “women in STEM fields” (science, technology, engineering, and math).
    • A “Reverse Diabetes Package” appeared to be marketed to those interested in the topic of diabetes. The ad copy read, “This diabetes type 2 patient just ate a Walmart pie without headaches or a spike in his sugar levels. 🤯” (With emoji):

Few supplements are known to have any medicinal effects on the management of diabetes, and none are effective as medication.
While Facebook’s policies do not allow the sale of “unsafe” substances, most of these ads remained on the platform until Consumer Reports notified Facebook of its findings.
Supplements are a “Buyer Beware” market
There are many reasons why someone may choose to buy a dietary supplement. Many believe them to be more “natural” and possibly less risky than pharmaceutical drugs. It’s been covered in depth before, but is worth repeating, that the American regulatory framework for dietary supplements effectively excludes manufacturers of these products from most of the regulations that are in place for prescription and over-the-counter drugs, and puts the requirement to demonstrate harm on the FDA, rather than the onus on the manufacturer to show a product is safe and effective. Because there is no routine pre-market or post-market product testing in place, the FDA relies on other forms of monitoring in an attempt to ensure that supplements are safe. This includes collecting adverse event reports and consumer complaints, inspecting manufacturing facilities, and monitoring imported ingredients. In exceptional circumstances, the FDA can take supplements off the market by issuing a recall. The regulation of marketing claims is effectively left to the Federal Trade Commission (FTC), which can prosecute manufacturers for fraud.
In a small paper published this past August and cited by Consumer Reports, researchers conducted an analysis of 30 dietary supplements marketed to “support” or “boost” the immune system that were sold on Amazon. Using liquid chromatography-mass spectrometry, they found that of 30 products purchased, 17 had inaccurate labels, 13 were misbranded, and 9 contained additional ingredients not disclosed on the label. The authors noted:
Claims made on the labels of most dietary supplement products seem to stretch what would be considered as allowable claims, which can by statute and/or FDA regulations be made for dietary supplements.
Conclusion: Be skeptical of products hosted on Facebook ads
An investigative analysis by Consumer Reports found that Facebook is being used to market unapproved and even prohibited supplements. Despite its policies against marketing unsafe products, there appears to be little enforcement of this policy. Given the general state of quality control and marketing standards observed for dietary standards, it is highly likely that consumers are not only being misled but are possibly purchasing products that are ineffective and may even have health risks. Given social media platforms like Facebook have little incentive to prevent the marketing of these products consumers should be vigilant and skeptical of supplements sold or promoted online.
